PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Schirmbeck, R; Kwissa, M; Fissolo, N; ElKholy, S; Riedl, P; Reimann, J				Schirmbeck, R; Kwissa, M; Fissolo, N; ElKholy, S; Riedl, P; Reimann, J			Priming polyvalent immunity by DNA vaccines expressing chimeric antigens with a stress protein-capturing, viral J-domain	FASEB JOURNAL			English	Article						stress protein; antigen expression; DNA-based vaccines	HEAT-SHOCK-PROTEIN; LARGE T-ANTIGEN; IN-VIVO; MOLECULAR CHAPERONES; FUSION PROTEINS; PEPTIDE; CELLS; GP96; HSP70; VIRUS	The N-terminal domain of large tumor antigens (T-Ag) of polyomaviruses forms a DnaJ-like structure with a conserved J domain that associates with constitutively expressed stress protein heat shock protein (hsp)73. Mutant (but not wild-type) SV40 T-Ag show stable, ATP-dependent binding to the stress protein hsp73 when expressed in cells from different vertebrate tissues. Intracellular T/hsp73 complexes accumulate to high steady-state levels. From this observation, we designed a vector system that supports stable expression of a large variety of hsp73-capturing, chimeric antigens containing an N-terminal, T-Ag-derived domain, and different C-terminal antigenic domains from unrelated antigens. Most antigenic domains tested could be stably expressed only in eukaryotic cells as fusion protein/hsp73 complexes. The N-terminal 77 residues representing the J domain of T-Ag were required for stable hsp73 binding and efficient expression of chimeric antigens. Hsp73-bound chimeric antigens expressed by DNA vaccines showed strikingly enhanced immunogenicity evident in humoral (antibody) and cellular cytolytic T lymphocytes (CTL) responses. The described system supports efficient expression of chimeric, polyvalent antigens and their codelivery with hsp73 as a "natural adjuvant" for enhanced immunogenicity for T and B cells.	Univ Ulm, Inst Med Microbiol & Immunol, D-89081 Ulm, Germany	Ulm University	Schirmbeck, R (corresponding author), Univ Ulm, Inst Med Microbiol & Immunol, Albert Einstein Allee 11, D-89081 Ulm, Germany.	reinhold.schirmbeck@medizin.uni-ulm.de	Fissolo, Nicolas/J-3067-2012	Fissolo, Nicolas/0000-0002-7701-9346; F. Elkholy, Dr. Shereen/0000-0002-2582-9021				ARNOLD D, 1995, J EXP MED, V182, P885, DOI 10.1084/jem.182.3.885; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Birk OS, 1999, P NATL ACAD SCI USA, V96, P5159, DOI 10.1073/pnas.96.9.5159; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Breloer M, 1999, J IMMUNOL, V162, P3141; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; Chen CH, 2000, CANCER RES, V60, P1035; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; Cho BK, 2000, IMMUNITY, V12, P263, DOI 10.1016/S1074-7613(00)80179-X; Ciupitu AMT, 1998, J EXP MED, V187, P685, DOI 10.1084/jem.187.5.685; FELDWEG AM, 1995, INT J CANCER, V63, P310, DOI 10.1002/ijc.2910630227; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; Heikema A, 1997, IMMUNOL LETT, V57, P69, DOI 10.1016/S0165-2478(97)00048-5; Huang Q, 2000, J EXP MED, V191, P403, DOI 10.1084/jem.191.2.403; Ishii T, 1999, J IMMUNOL, V162, P1303; Kammerer R, 2002, J IMMUNOL, V168, P108, DOI 10.4049/jimmunol.168.1.108; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; Kuhrober A, 1997, INT IMMUNOL, V9, P1203, DOI 10.1093/intimm/9.8.1203; KUHROBER A, 1996, J IMMUNOL, V156, P3687; Kwissa M, 2000, J MOL MED-JMM, V78, P495, DOI 10.1007/s001090000135; Kwissa M, 2000, VACCINE, V18, P2337, DOI 10.1016/S0264-410X(00)00030-X; Lammert E, 1996, EUR J IMMUNOL, V26, P875, DOI 10.1002/eji.1830260423; Liu DW, 2000, J VIROL, V74, P2888, DOI 10.1128/JVI.74.6.2888-2894.2000; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; Paul AGA, 2000, J IMMUNOL, V165, P7270, DOI 10.4049/jimmunol.165.12.7270; Pumpens P, 1999, FEBS LETT, V442, P1, DOI 10.1016/S0014-5793(98)01599-3; Roman E, 1997, IMMUNOLOGY, V90, P52, DOI 10.1046/j.1365-2567.1997.00136.x; Roman RC, 1996, DANCE MAG, V70, P88; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Schild H, 1999, CURR OPIN IMMUNOL, V11, P109, DOI 10.1016/S0952-7915(99)80019-3; Schirmbeck R, 1999, EUR J IMMUNOL, V29, P1740, DOI 10.1002/(SICI)1521-4141(199905)29:05<1740::AID-IMMU1740>3.3.CO;2-O; SCHIRMBECK R, 1993, EUR J IMMUNOL, V23, P1528, DOI 10.1002/eji.1830230720; SCHIRMBECK R, 1994, EUR J IMMUNOL, V24, P1478, DOI 10.1002/eji.1830240704; Schirmbeck R, 1996, J IMMUNOL, V157, P3550; Schirmbeck R, 1997, EUR J IMMUNOL, V27, P2016, DOI 10.1002/eji.1830270828; Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Sondermann H, 2000, BIOL CHEM, V381, P1165, DOI 10.1515/BC.2000.144; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Sullivan CS, 2001, VIROLOGY, V287, P1, DOI 10.1006/viro.2001.1038; Suzue K, 1996, J IMMUNOL, V156, P873; Todryk S, 1999, J IMMUNOL, V163, P1398; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; Vanhove M, 2001, IMMUNITY, V15, P105, DOI 10.1016/S1074-7613(01)00163-7; VONHOYNINGENHUENE V, 1992, VIROLOGY, V190, P155, DOI 10.1016/0042-6822(92)91201-5; Yoo CG, 2000, J IMMUNOL, V164, P5416, DOI 10.4049/jimmunol.164.10.5416; YOUNG RA, 1989, CELL, V59, P5, DOI 10.1016/0092-8674(89)90861-1	56	26	30	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7					1108	+		10.1096/fj.01-0993fje	http://dx.doi.org/10.1096/fj.01-0993fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039856				2022-12-28	WOS:000175973900008
J	Guerini, D; Guidi, F; Carafoli, E				Guerini, D; Guidi, F; Carafoli, E			Differential membrane targeting of the SERCA and PMCA calcium pumps: experiments with recombinant chimeras	FASEB JOURNAL			English	Article						plasma membrane Ca2+ pump; chimeric proteins; ER/SR Ca2+ pump	PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; CA2+ PUMP; SARCOPLASMIC-RETICULUM; GOLGI RETENTION; TRANSMEMBRANE SEGMENT; CA-2+ PUMP; PROTEINS; EXPRESSION; DOMAIN	Structural features underlying retention of the SERCA pump in intracellular compartments and the sorting of the PMCA pump to the plasma membrane are not known. The biochemical properties of the two pumps suggest that their differential localization may respond to specific functional demands. The two pumps may control Ca2+ gradients of different magnitude and dynamic properties. For instance, it has recently become clear that the Ca2+ gradient across the endoplasmic reticulum (ER) membrane is smaller than that across the plasma membrane. Previous experiments with chimerical constructs of the SERCA and PMCA pumps had suggested a role for the amino-terminal domain in the ER retention of the SERCA pump. Experiments aimed at narrowing down the region responsible for the retention now indicate that the first 28 amino acids of the SERCA pump may play a role in membrane localization. Results also suggest that the formation of oligomers (possibly through the first 28 amino acids) might be critical to the retention mechanism.	Univ Padua, Dept Biochem, I-35121 Padua, Italy; Univ Padua, Venetian Inst Mol Med, I-35121 Padua, Italy; Novartis Pharma AG, CH-4002 Basel, Switzerland; Swiss Fed Inst Technol, Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland	University of Padua; University of Padua; Veneto Institute Molecular Medicine; Novartis; ETH Zurich	Carafoli, E (corresponding author), Univ Padua, Dept Biochem, Viale G Colombo 3, I-35121 Padua, Italy.	carafoli@civ.bio.unipd.it	Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ADAMO HP, 1992, J BIOL CHEM, V267, P14244; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; Carafoli E, 1996, EXPERIENTIA, V52, P1091, DOI 10.1007/BF01952107; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; FOLETTI D, 1995, FASEB J, V9, P670, DOI 10.1096/fasebj.9.8.7768360; Grimaldi ME, 1996, J BIOL CHEM, V271, P26995, DOI 10.1074/jbc.271.43.26995; Guerini D, 1998, ACTA PHYSIOL SCAND, V163, P265; Guerini D, 2000, J BIOL CHEM, V275, P31361, DOI 10.1074/jbc.M003474200; HEIM R, 1992, J BIOL CHEM, V267, P24476; HOFMANN F, 1993, J BIOL CHEM, V268, P10252; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; Preiano BS, 1996, BIOCHEMISTRY-US, V35, P7946; Robert V, 1998, J BIOL CHEM, V273, P30372, DOI 10.1074/jbc.273.46.30372; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VERMA AK, 1988, J BIOL CHEM, V263, P14152; ZVARITCH E, 1995, J BIOL CHEM, V270, P2679, DOI 10.1074/jbc.270.6.2679; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	37	8	8	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					519	528		10.1096/fj.01-0362com	http://dx.doi.org/10.1096/fj.01-0362com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919154				2022-12-28	WOS:000175425900005
J	Permanne, B; Adessi, C; Saborio, GP; Fraga, S; Frossard, MJ; Van Dorpe, J; Dewachter, I; Banks, WA; Van Leuven, F; Soto, C				Permanne, B; Adessi, C; Saborio, GP; Fraga, S; Frossard, MJ; Van Dorpe, J; Dewachter, I; Banks, WA; Van Leuven, F; Soto, C			Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide	FASEB JOURNAL			English	Article						therapy; protein; conformational disorders; neuronal loss; brain inflammation; senile plaques	BLOOD-BRAIN-BARRIER; FIBRIL FORMATION; NERVOUS-SYSTEM; AMINO-ACIDS; RAT-BRAIN; PROTEIN; INHIBITION; PATHOLOGY; MICE; IMMUNIZATION	Genetic, neuropathological, and biochemical studies have provided strong evidence for a central role of amyloid in the pathogenesis of Alzheimer's disease (AD). We have proposed previously that peptides designed as beta-sheet breakers may be useful in preventing the formation of amyloid plaques. In this study, we describe a modified beta-sheet breaker peptide with improved pharmacological properties, a high rate of penetration across the blood-brain barrier, and the ability to induce a dramatic reduction in amyloid deposition in two different transgenic AD models. In addition, we report for the first time a significant increase in neuronal survival and a decrease in brain inflammation associated with the reduction of amyloid plaques. These results demonstrate that the process of amyloid deposition is one of the causes of neurodegeneration in AD. Moreover, our findings indicate that beta-sheet breaker peptides provide a valuable tool for evaluating further the importance of amyloid in the etiology of AD and suggest that these peptides or some of their derivatives might be good candidates for AD treatment.	Serono Pharmaceut Res Inst, Geneva, Switzerland; Katholieke Univ Leuven, Expt Genet Grp, B-3000 Louvain, Belgium; VA Med Ctr St Louis, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Internal Med, Div Geriatr, St Louis, MO 63104 USA	KU Leuven; Saint Louis University	Soto, C (corresponding author), Serono Pharmaceut Res Inst, 14 Chemin Aulx,1228 Plan Ouates, Geneva, Switzerland.	Claudio.Soto@serono.com	Banks, William A/K-1330-2017	Banks, William A/0000-0002-0496-3619; , Ilse Dewachter/0000-0001-7202-515X				Banks WA, 1996, LIFE SCI, V59, P1923, DOI 10.1016/S0024-3205(96)00380-3; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Blanchard Barbara J., 2000, Journal of Alzheimer's Disease, V2, P137; Bronfman FC, 1996, NEUROSCI LETT, V218, P201, DOI 10.1016/S0304-3940(96)13147-5; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; CHREST FJ, 1993, CYTOCHEM, V8, P883; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; Dewachter I, 2000, J NEUROSCI, V20, P6452, DOI 10.1523/JNEUROSCI.20-17-06452.2000; Dewachter I, 2000, EXP GERONTOL, V35, P831, DOI 10.1016/S0531-5565(00)00149-2; Duff K, 1999, TRENDS NEUROSCI, V22, P485, DOI 10.1016/S0166-2236(99)01489-7; FAUCHERE JL, 1992, ADV DRUG RES, V23, P127; Findeis MA, 1999, BIOCHEMISTRY-US, V38, P6791, DOI 10.1021/bi982824n; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Ghanta J, 1996, J BIOL CHEM, V271, P29525, DOI 10.1074/jbc.271.47.29525; Gordon DJ, 2001, BIOCHEMISTRY-US, V40, P8237, DOI 10.1021/bi002416v; GUTIERREZ EG, 1993, J NEUROIMMUNOL, V47, P169, DOI 10.1016/0165-5728(93)90027-V; Halliday G, 2000, CLIN EXP PHARMACOL P, V27, P1, DOI 10.1046/j.1440-1681.2000.03200.x; Hardy J, 1998, NAT NEUROSCI, V1, P355, DOI 10.1038/1565; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; Howlett DR, 1999, BIOCHEM J, V343, P419, DOI 10.1042/0264-6021:3430419; Hyman BT, 2001, ANN NEUROL, V49, P808, DOI 10.1002/ana.1061; JANCIAUSKIENE S, 1995, J BIOL CHEM, V270, P26041, DOI 10.1074/jbc.270.44.26041; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kastin AJ, 1999, BRAIN RES, V848, P96, DOI 10.1016/S0006-8993(99)01961-7; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; Kuner P, 2000, J BIOL CHEM, V275, P1673, DOI 10.1074/jbc.275.3.1673; Lee VMY, 2001, P NATL ACAD SCI USA, V98, P8931, DOI 10.1073/pnas.171311798; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Matsubara E, 1996, BIOCHEM J, V316, P671, DOI 10.1042/bj3160671; McGeer EG, 1999, CURR PHARM DESIGN, V5, P821; MCGEER PL, 1994, NEUROPATH APPL NEURO, V20, P191; MERLINI G, 1995, P NATL ACAD SCI USA, V92, P2959, DOI 10.1073/pnas.92.7.2959; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Pachter JS, 1997, MOL PSYCHIATR, V2, P91, DOI 10.1038/sj.mp.4000212; Pappolla M, 1998, J BIOL CHEM, V273, P7185, DOI 10.1074/jbc.273.13.7185; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Ray I, 2000, BRAIN RES, V853, P344, DOI 10.1016/S0006-8993(99)02315-X; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; Salomon AR, 1996, BIOCHEMISTRY-US, V35, P13568, DOI 10.1021/bi9617264; Sarnat HB, 1998, BRAIN DEV-JPN, V20, P88, DOI 10.1016/S0387-7604(97)00111-3; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SCHWARZMAN AL, 1994, P NATL ACAD SCI USA, V91, P8368, DOI 10.1073/pnas.91.18.8368; Selkoe DJ, 2000, JAMA-J AM MED ASSOC, V283, P1615, DOI 10.1001/jama.283.12.1615; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Sigurdsson EM, 2000, J NEUROPATH EXP NEUR, V59, P11, DOI 10.1093/jnen/59.1.11; Sigurdsson EM, 2001, AM J PATHOL, V159, P439, DOI 10.1016/S0002-9440(10)61715-4; Small D H, 1998, Amyloid, V5, P301, DOI 10.3109/13506129809007304; Solomon B, 1996, P NATL ACAD SCI USA, V93, P452, DOI 10.1073/pnas.93.1.452; Soto C, 1999, J MOL MED-JMM, V77, P412, DOI 10.1007/s001090050371; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Soto C, 1999, MOL MED TODAY, V5, P343, DOI 10.1016/S1357-4310(99)01508-7; Soto C, 2000, ACTA NEUROL SCAND, V102, P90, DOI 10.1034/j.1600-0404.2000.00313.x; Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3; St George-Hyslop PH, 1999, NATURE, V400, P116; Terry RD, 1996, J NEUROPATH EXP NEUR, V55, P1023, DOI 10.1097/00005072-199655100-00001; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tomiyama T, 1996, J BIOL CHEM, V271, P6839, DOI 10.1074/jbc.271.12.6839; Tran PB, 1999, TRENDS NEUROSCI, V22, P194, DOI 10.1016/S0166-2236(99)01409-5; TRIGUERO D, 1990, J NEUROCHEM, V54, P1882, DOI 10.1111/j.1471-4159.1990.tb04886.x; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Wood SJ, 1996, J BIOL CHEM, V271, P4086; Yankner BA, 2000, ANN NY ACAD SCI, V924, P26	72	184	196	1	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					860	+		10.1096/fj.01-0841fje	http://dx.doi.org/10.1096/fj.01-0841fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967228				2022-12-28	WOS:000175425900019
J	Vernersson, M; Ledin, A; Johansson, J; Hellman, L				Vernersson, M; Ledin, A; Johansson, J; Hellman, L			Generation of therapeutic antibody responses against IgE through vaccination	FASEB JOURNAL			English	Article						allergy; C epsilon 3; allergen-specific IgE	FC-EPSILON-RI; SEASONAL ALLERGIC RHINITIS; HIGH-AFFINITY RECEPTOR; HUMAN-IMMUNOGLOBULIN-E; MONOCLONAL-ANTIBODY; BINDING-SITE; DEFICIENT MICE; ALPHA; CHAIN; PHARMACOKINETICS	IgE is the central mediator in atopic allergies such as hay fever, eczema, and asthma; therefore, it is a prime target in the development of allergen-independent preventive treatments. We describe an active immunization strategy that has the potential to reduce IgE to a clinically significant extent. The active vaccine component is a chimeric IgE molecule, Cepsilon2-Cepsilon3-Cepsilon4. The receptor-binding target domain, Cepsilon3, is derived from the recipient species, whereas the flanking domains, Cepsilon2 and Cepsilon4, are derived from an evolutionarily distant mammal. The flanking domains have dual functions, acting both as structural support for the Cepsilon3 domain and to break T cell tolerance by providing foreign T cell epitopes. The efficacy of the vaccine was studied in an ovalbumin-sensitized rat model. Vaccination resulted in antibody responses against IgE in all rats and in a substantial reduction in serum IgE levels in three out of four strains. The skin reactivity upon allergen challenge was significantly reduced in vaccinated animals. The vaccine appears to be safe to use as an antigen. No cross-linking activity was observed in sera of vaccinated animals, and the response to vaccination was reversible with time. Our results suggest that active immunization against IgE has the potential to become a therapeutic method for humans.	Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden; Resistentia Pharmaceut AB, S-75323 Uppsala, Sweden	Uppsala University	Hellman, L (corresponding author), Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, Box 596, S-75124 Uppsala, Sweden.	Lars.Hellman@icm.uu.se						Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Aveskogh M, 1998, EUR J IMMUNOL, V28, P2738, DOI 10.1002/(SICI)1521-4141(199809)28:09<2738::AID-IMMU2738>3.0.CO;2-I; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; Chackerian B, 2001, J CLIN INVEST, V108, P415, DOI 10.1172/JCI11849; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Cook JPD, 1997, BIOCHEMISTRY-US, V36, P15579, DOI 10.1021/bi9713005; Corne J, 1997, J CLIN INVEST, V99, P879, DOI 10.1172/JCI119252; Dalum I, 1999, NAT BIOTECHNOL, V17, P666, DOI 10.1038/10878; DAVIS FM, 1993, SPRINGER SEMIN IMMUN, V15, P51; DIAZSANCHEZ D, 1991, IMMUNOLOGY, V72, P297; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; HELLMAN L, 1994, EUR J IMMUNOL, V24, P415, DOI 10.1002/eji.1830240222; HELLMAN L, 1982, NUCLEIC ACIDS RES, V10, P6041, DOI 10.1093/nar/10.19.6041; Hellman L, 1999, HANDB EXP PHARMACOL, V133, P499; Hellman L, 1996, ADV EXP MED BIOL, V409, P337; HELLMAN L, 1995, CLIN IMMUNOTHER, V2, P130; HELM B, 1989, P NATL ACAD SCI USA, V86, P9465, DOI 10.1073/pnas.86.23.9465; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; Heusser C, 1997, CURR OPIN IMMUNOL, V9, P805, DOI 10.1016/S0952-7915(97)80182-3; ISHIDA N, 1982, EMBO J, V1, P1117, DOI 10.1002/j.1460-2075.1982.tb01306.x; KARLSSON T, 1979, SCAND J IMMUNOL, V9, P217, DOI 10.1111/j.1365-3083.1979.tb02725.x; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KOLBINGER F, 1993, PROTEIN ENG, V6, P971, DOI 10.1093/protein/6.8.971; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEVY DA, 1970, NEW ENGL J MED, V283, P541; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; PRESTA L, 1994, J BIOL CHEM, V269, P26368; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Racine-Poon A, 1997, CLIN PHARMACOL THER, V62, P675, DOI 10.1016/S0009-9236(97)90087-4; Talwar GP, 1999, IMMUNOL REV, V171, P173; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; Vernersson M, 1997, IMMUNOGENETICS, V46, P461, DOI 10.1007/s002510050306; Wurzburg BA, 2000, IMMUNITY, V13, P375, DOI 10.1016/S1074-7613(00)00037-6	38	61	69	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					875	+		10.1096/fj.01-0879fje	http://dx.doi.org/10.1096/fj.01-0879fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967231				2022-12-28	WOS:000175425900016
J	Brigotti, M; Alfieri, R; Sestili, P; Bonelli, M; Petronini, PG; Guidarelli, A; Barbieri, L; Stirpe, F; Sperti, S				Brigotti, M; Alfieri, R; Sestili, P; Bonelli, M; Petronini, PG; Guidarelli, A; Barbieri, L; Stirpe, F; Sperti, S			Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells	FASEB JOURNAL			English	Article						ribosome-inactivating proteins; alkaline-halo assay; AP sites; cytotoxins	RIBOSOME-INACTIVATING PROTEINS; POLYNUCLEOTIDE-ADENOSINE GLYCOSIDASE; ESCHERICHIA-COLI O157-H7; SINGLE-STRANDED-DNA; EUKARYOTIC RIBOSOMES; SENSITIVE METHOD; KINASE-C; APOPTOSIS; RNA; DEATH	Ribosome-inactivating proteins (RIPs) remove a specific adenine from 28S rRNA leading to inactivation of ribosomes and arrest of translation. Great interest as to a possible second physiological substrate for RIPs came from the observation that in vitro RIPs remove adenine from DNA. This paper addresses the problem of nuclear lesions induced by RIPs in human endothelial cells susceptible to the bacterial RIP Shiga toxin 1 and the plant RIP ricin. With both toxins, nuclear DNA damage as evaluated by two independent techniques (alkaline-halo assay and alkaline filter elution) appears early, concomitant with (ricin) or after (Shiga toxin 1) the inhibition of protein synthesis. At this time, the annexin V binding assay, caspase 3 activity, the formation of typical less than or equal to 50 Kb DNA fragments, and changes in morphology associated with apoptosis were negative. Furthermore, a block of translation comparable to that induced by RIPs, but obtained with cycloheximide, did not induce nuclear damage. Such damage is consistent with the enzymatic activity (removal of adenine) of RIPs acting in vitro on RNA-free chromatin and DNA. The results unequivocally indicate that RIPs can damage nuclear DNA in whole cells by means that are not secondary to ribosome inactivation or apoptosis.	Univ Bologna, Dipartimento Patol Sperimentale, I-40126 Bologna, Italy; Univ Parma, Dipartimento Med Sperimentale, Sez Patol Mol & Immunol, I-43100 Parma, Italy; Univ Urbino, Fac Sci Motorie, Catedra Farmacol, I-61029 Urbino, Italy; Univ Urbino, Ist Farmacol & Farmacognosia, I-61029 Urbino, Italy	University of Bologna; University of Parma; University of Urbino; University of Urbino	Brigotti, M (corresponding author), Univ Bologna, Dipartimento Patol Sperimentale, Via S Giacomo 14, I-40126 Bologna, Italy.	brigotti@alma.unibo.it	Alfieri, Roberta R/G-6350-2012; Brigotti, Maurizio/AAB-9007-2022	Brigotti, Maurizio/0000-0001-7429-744X; Sestili, Piero/0000-0001-9412-1660				Alfieri R, 1996, BIOCHEM J, V319, P601, DOI 10.1042/bj3190601; ARAKI S, 1990, BIOCHEM BIOPH RES CO, V172, P1081, DOI 10.1016/0006-291X(90)91557-9; Barbieri L, 1998, MOL MICROBIOL, V29, P661, DOI 10.1046/j.1365-2958.1998.00911.x; Barbieri L, 2000, BBA-PROTEIN STRUCT M, V1480, P258, DOI 10.1016/S0167-4838(00)00077-7; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; BARBIERI L, 1994, NATURE, V372, P624, DOI 10.1038/372624a0; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Barbieri L, 2000, J BIOCHEM-TOKYO, V128, P883, DOI 10.1093/oxfordjournals.jbchem.a022827; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brigotti M, 2001, TOXICON, V39, P341, DOI 10.1016/S0041-0101(00)00135-5; Brigotti M, 1998, NUCLEIC ACIDS RES, V26, P4306, DOI 10.1093/nar/26.18.4306; Brigotti M, 2000, NUCLEIC ACIDS RES, V28, P2383, DOI 10.1093/nar/28.12.2383; CANTONI O, 1984, CARCINOGENESIS, V5, P1207, DOI 10.1093/carcin/5.9.1207; CORCORAN GB, 1994, TOXICOL APPL PHARM, V128, P169, DOI 10.1006/taap.1994.1195; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DONOHUEROLFE A, 1988, METHOD ENZYMOL, V165, P231; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; FERRERAS JM, 1993, BIOCHIM BIOPHYS ACTA, V1216, P31, DOI 10.1016/0167-4781(93)90034-B; GRIFFITHS GD, 1987, J PATHOL, V151, P221, DOI 10.1002/path.1711510310; Hamuro T, 1998, FEBS LETT, V421, P197, DOI 10.1016/S0014-5793(97)01559-7; Hu RG, 2001, J CELL BIOCHEM, V81, P583, DOI 10.1002/jcb.1076; HUANG RCC, 1969, J MOL BIOL, V39, P365, DOI 10.1016/0022-2836(69)90323-4; Hughes JN, 1996, HUM EXP TOXICOL, V15, P443, DOI 10.1177/096032719601500513; Kiyokawa N, 2001, J CELL BIOCHEM, V81, P128, DOI 10.1002/1097-4644(20010401)81:1<128::AID-JCB1029>3.0.CO;2-G; KOHN KW, 1991, PHARMACOL THERAPEUT, V49, P55, DOI 10.1016/0163-7258(91)90022-E; KOHN KW, 1981, DNA REPAIR LAB MAN B, V1, P397; Komatsu N, 1998, J BIOCHEM-TOKYO, V124, P1038, DOI 10.1093/oxfordjournals.jbchem.a022197; LOUISE CB, 1995, INFECT IMMUN, V63, P2766, DOI 10.1128/IAI.63.7.2766-2769.1995; Louise CB, 1997, INFECT IMMUN, V65, P3337, DOI 10.1128/IAI.65.8.3337-3344.1997; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MANGENEY M, 1993, CANCER RES, V53, P5314; Marini M, 1996, BIOCHEM BIOPH RES CO, V229, P910, DOI 10.1006/bbrc.1996.1901; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Nakagawa I, 1999, MOL MICROBIOL, V33, P1190, DOI 10.1046/j.1365-2958.1999.01564.x; Nakao H, 2000, J NAT TOXINS, V9, P299; Nicolas E, 2000, J BIOL CHEM, V275, P31399, DOI 10.1074/jbc.M004505200; NICOLSON GL, 1974, BIOCHEMISTRY-US, V13, P196, DOI 10.1021/bi00698a029; OBRIG TG, 1988, INFECT IMMUN, V56, P2373, DOI 10.1128/IAI.56.9.2373-2378.1988; Olmo N, 2001, EUR J BIOCHEM, V268, P2113, DOI 10.1046/j.1432-1327.2001.02086.x; Paton JC, 1998, CLIN MICROBIOL REV, V11, P450, DOI 10.1128/CMR.11.3.450; PETRONINI PG, 1987, EXP CELL RES, V172, P450, DOI 10.1016/0014-4827(87)90403-4; Petronini PG, 1996, J CELL PHYSIOL, V169, P175, DOI 10.1002/(SICI)1097-4652(199610)169:1<175::AID-JCP18>3.0.CO;2-C; Peumans WJ, 2001, FASEB J, V15, P1493, DOI 10.1096/fj.00-0751rev; Ramirez CD, 2000, CELL DEATH DIFFER, V7, P548, DOI 10.1038/sj.cdd.4400686; RYD M, 1989, FEBS LETT, V258, P320, DOI 10.1016/0014-5793(89)81684-9; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; Sestili P, 1999, FREE RADICAL BIO MED, V26, P1019, DOI 10.1016/S0891-5849(98)00290-1; SESTILI P, 1995, CARCINOGENESIS, V16, P703, DOI 10.1093/carcin/16.4.703; Sestili P, 1996, FEBS LETT, V396, P337, DOI 10.1016/0014-5793(96)01130-1; SPERTI S, 1986, BIOSCIENCE REP, V6, P1035, DOI 10.1007/BF01141024; Suzuki A, 2000, GENE DEV, V14, P1734; TESH VL, 1991, J INFECT DIS, V164, P344, DOI 10.1093/infdis/164.2.344; URBANI S, 1996, FUND CLIN IMMUNOL, V4, P27; Williams JM, 1997, TOXICOL LETT, V91, P121, DOI 10.1016/S0378-4274(97)03879-4; Yamasaki C, 1999, FEBS LETT, V442, P231, DOI 10.1016/S0014-5793(98)01667-6	56	119	124	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0365	10.1096/fj.01-0521com	http://dx.doi.org/10.1096/fj.01-0521com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874985	Green Submitted			2022-12-28	WOS:000174755900028
J	Davies, SS; Amarnath, V; Montine, KS; Bernoud-Hubac, N; Boutaud, O; Montine, TJ; Roberts, LJ				Davies, SS; Amarnath, V; Montine, KS; Bernoud-Hubac, N; Boutaud, O; Montine, TJ; Roberts, LJ			Effects of reactive gamma-ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function	FASEB JOURNAL			English	Article						isoketal; free radical; neurodegenerative	20 S PROTEASOME; MULTICATALYTIC PROTEINASE COMPLEX; AMYLOID-BETA-PROTEIN; HUMAN BJ FIBROBLASTS; FACTOR-KAPPA-B; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; LIPID-PEROXIDATION; MAMMALIAN-CELLS; PROSTAGLANDIN ENDOPEROXIDES	Oxidative stress can impair proteasome function, both of which are features of neurodegenerative diseases. Inhibition of proteasome function leads to protein accumulation and cell death. We discovered recently the formation of highly reactive gamma-ketoaldehydes, isoketals (IsoKs), and neuroketals (NeuroKs) as products of the isoprostane and neuroprostane pathways of free radical-induced lipid peroxidation that are analogous to cyclooxygenase-derived levuglandins (LGs). Because aldehydes that are much less reactive than IsoKs have been shown to inhibit proteasome function, we explored the ability of the proteasome to degrade IsoK-adducted proteins/peptides and the effect of IsoK and IsoK-adducted proteins/peptides on proteasome function. Adduction of IsoK to model proteasome substrates significantly reduced their rate of degradation by the 20S proteasome. The ability of IsoK to inhibit proteasome function directly was observed only at very high concentrations. However, at much lower concentrations, an IsoK-adducted protein (ovalbumin) and peptide (Abeta(1-40)) significantly inhibited chymotrypsin-like activity of the 20S proteasome. Moreover, incubation of IsoK with P19 neuroglial cultures dose-dependently inhibited proteasome activity (IC50 = 330 nM) and induced cell death (LC50 = 670 nM). These findings suggest that IsoKs/NeuroKs/LGs can inhibit proteasome activity and, if overproduced, may have relevance to the pathogenesis of neurodegenerative diseases.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Roberts, LJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 522 RRB, Nashville, TN USA.	jack.roberts@mcmail.vanderbilt.edu		Davies, Sean/0000-0001-9879-8062; Montine, Kathleen/0000-0003-2110-8363				Bernoud-Hubac N, 2001, J BIOL CHEM, V276, P30964, DOI 10.1074/jbc.M103768200; Boutaud O, 1999, BIOCHEMISTRY-US, V38, P9389, DOI 10.1021/bi990470+; Brame CJ, 1999, J BIOL CHEM, V274, P13139, DOI 10.1074/jbc.274.19.13139; Breitner JCS, 1996, ANNU REV MED, V47, P401; Bulteau AL, 2001, J BIOL CHEM, V276, P30057, DOI 10.1074/jbc.M100142200; Calingasan NY, 1999, J NEUROCHEM, V72, P751, DOI 10.1046/j.1471-4159.1999.0720751.x; DAVIES KJA, 1993, BIOCHEM SOC T, V21, P346, DOI 10.1042/bst0210346; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Fataccioli V, 1999, HEPATOLOGY, V29, P14, DOI 10.1002/hep.510290106; Ferrington DA, 2001, J BIOL CHEM, V276, P937, DOI 10.1074/jbc.M005356200; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; GREGORI L, 1995, J BIOL CHEM, V270, P19702, DOI 10.1074/jbc.270.34.19702; Gregori L, 1997, J BIOL CHEM, V272, P58; Grune T, 1997, BIOFACTORS, V6, P165, DOI 10.1002/biof.5520060210; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Ho L, 2001, ARCH NEUROL-CHICAGO, V58, P487, DOI 10.1001/archneur.58.3.487; Ho L, 1999, J NEUROSCI RES, V57, P295; Hoozemans JJM, 2001, ACTA NEUROPATHOL, V101, P2, DOI 10.1007/s004010000251; IYER RS, 1994, J ORG CHEM, V59, P6038, DOI 10.1021/jo00099a039; IYER RS, 1989, PROSTAGLANDINS, V37, P471, DOI 10.1016/0090-6980(89)90096-8; JIROUSEK MR, 1990, PROSTAGLANDINS, V40, P187, DOI 10.1016/0090-6980(90)90083-8; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Keller JN, 2000, MECH AGEING DEV, V113, P61, DOI 10.1016/S0047-6374(99)00101-3; Kitamura Y, 1999, BIOCHEM BIOPH RES CO, V254, P582, DOI 10.1006/bbrc.1998.9981; KOJIMA S, 1992, FEBS LETT, V304, P57, DOI 10.1016/0014-5793(92)80588-8; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Lukiw WJ, 1997, J NEUROSCI RES, V50, P937, DOI 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Masaki R, 2000, J NEUROSCI RES, V62, P75, DOI 10.1002/1097-4547(20001001)62:1<75::AID-JNR8>3.0.CO;2-V; MILLER DB, 1990, J ORG CHEM, V55, P3164, DOI 10.1021/jo00297a036; Montaldo PG, 1997, CELL DEATH DIFFER, V4, P150, DOI 10.1038/sj.cdd.4400215; Montine KS, 1997, J NEUROPATH EXP NEUR, V56, P866, DOI 10.1097/00005072-199708000-00004; Montine TJ, 1996, AM J PATHOL, V148, P89; Montine TJ, 1999, AM J PATHOL, V155, P863, DOI 10.1016/S0002-9440(10)65185-1; Montine TJ, 1999, NEUROLOGY, V52, P1104, DOI 10.1212/WNL.52.5.1104; Montine TJ, 1998, ANN NEUROL, V44, P410, DOI 10.1002/ana.410440322; Montine TJ, 1999, NEUROLOGY, V52, P562, DOI 10.1212/WNL.52.3.562; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; Morris MC, 1998, ALZ DIS ASSOC DIS, V12, P121, DOI 10.1097/00002093-199809000-00001; MURTHI KK, 1993, BIOCHEMISTRY-US, V32, P4090, DOI 10.1021/bi00066a034; Niu CS, 1996, J ORG CHEM, V61, P1014, DOI 10.1021/jo951651u; Ohtani-Kaneko R, 1998, NEUROCHEM RES, V23, P1435, DOI 10.1023/A:1020763009488; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; Orlowski M, 2000, ARCH BIOCHEM BIOPHYS, V383, P1, DOI 10.1006/abbi.2000.2036; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777; Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9; Reich EE, 2001, AM J PATHOL, V158, P293, DOI 10.1016/S0002-9440(10)63968-5; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Salomon R G, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P323; Salomon RG, 1999, J BIOL CHEM, V274, P20271, DOI 10.1074/jbc.274.29.20271; Salomon RG, 1997, CHEM RES TOXICOL, V10, P750, DOI 10.1021/tx970016b; SALOMON RG, 1984, J AM CHEM SOC, V106, P6049, DOI 10.1021/ja00332a049; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Sayre LM, 1997, J NEUROCHEM, V68, P2092; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SEGEL IH, 1993, ENZYME KINETICS BEHA, P208; Shringarpure R, 2000, CELL MOL LIFE SCI, V57, P1802, DOI 10.1007/PL00000660; Sitte N, 2000, FASEB J, V14, P1490, DOI 10.1096/fj.14.11.1490; Sitte N, 2000, FASEB J, V14, P2503, DOI 10.1096/fj.00-0210com; Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com; Stein RL, 1996, BIOCHEMISTRY-US, V35, P3899, DOI 10.1021/bi952262x; Subbanagounder G, 1997, J ORG CHEM, V62, P7658, DOI 10.1021/jo970858f; Taglialatela G, 1998, NEUROREPORT, V9, P489, DOI 10.1097/00001756-199802160-00024; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X; Yermakova AV, 1999, J NEUROPATH EXP NEUR, V58, P1135, DOI 10.1097/00005072-199911000-00003	71	85	89	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					715	+		10.1096/fj.01-0696fje	http://dx.doi.org/10.1096/fj.01-0696fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11978738				2022-12-28	WOS:000174755900014
J	Patlak, M				Patlak, M			Targeting leukemia	FASEB JOURNAL			English	Editorial Material																			0	5	5	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/-1897/0016-0273	10.1096/fj.02-0029bkt	http://dx.doi.org/10.1096/fj.02-0029bkt			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874976				2022-12-28	WOS:000174755900019
J	Ragone, R				Ragone, R			Homocystine solubility and vascular disease	FASEB JOURNAL			English	Article						homocysteine; cystine solubility; redox thiol status	PLASMA HOMOCYSTEINE; PROTEIN-BINDING; REDOX STATUS; AMINOTHIOLS; HOMOCYST(E)INE	There is evidence that mild elevations of tHcy are associated with an increased risk for occlusive vascular disease, thrombosis, and stroke. It is hypothesized here that cellular toxicity could indirectly result from auto-oxidation of homocysteine to homocystine. Elevated levels of total plasma homocysteine could be the primary cause of increased vascular risk, causing endothelial damage through a mechanism similar to that of cystine precipitation, which is known to cause stone formation in cystinosis and cystinuria. In fact, only traces of homocysteine circulate in plasma as the free thiol; the remainder is present as oxidation products. Of these, the symmetric disulfide homocystine is scarcely soluble at neutral pH. Its saturation limit is so close to the concentration of homocysteine in normal plasma that a transient increase of homocysteine levels could lead to precipitation of homocystine microcrystals in the bloodstream. These could damage endothelial tissue, acting as a mechanic primer for subsequent prothrombotic blood vessel alterations.	Univ Naples 2, Dept Biochem & Biophys, CRISCEB, I-80138 Naples, Italy	Universita della Campania Vanvitelli	Ragone, R (corresponding author), Univ Naples 2, Dept Biochem & Biophys, CRISCEB, Via Costantinopoli 16, I-80138 Naples, Italy.	ragone@unina2.it						Borsook H, 1937, J BIOL CHEM, V117, P281; BRENTON DP, 1965, J PEDIATR-US, V67, P58, DOI 10.1016/S0022-3476(65)80304-3; DAngelo A, 1997, BLOOD, V90, P1; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; GUTTORMSEN AB, 1993, CLIN CHEM, V39, P1390; GUTTORMSEN AB, 1994, J NUTR, V124, P1934, DOI 10.1093/jn/124.10.1934; Hankey GJ, 1999, LANCET, V354, P407, DOI 10.1016/S0140-6736(98)11058-9; Jacobsen DW, 1998, CLIN CHEM, V44, P1833; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; LIDE DR, 1999, HDB CHEM PHYSICS; MANSOOR MA, 1993, CLIN CHEM, V39, P980; MANSOOR MA, 1993, METABOLISM, V42, P1481, DOI 10.1016/0026-0495(93)90202-Y; MANSOOR MA, 1992, CLIN CHEM, V38, P1316; MCCULLY KS, 1975, ATHEROSCLEROSIS, V22, P215, DOI 10.1016/0021-9150(75)90004-0; MUDD SH, 1995, NEW ENGL J MED, V333, P325; Schwarzenbach R., 1993, ENV ORGANIC CHEM; Ueland PM, 1996, J NUTR, V126, pS1281, DOI 10.1093/jn/126.suppl_4.1281S	18	21	21	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0401	10.1096/fj.01-0682hyp	http://dx.doi.org/10.1096/fj.01-0682hyp			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874989				2022-12-28	WOS:000174755900032
J	Van Den Steen, PE; Proost, P; Grillet, B; Brand, DD; Kang, AH; Van Damme, J; Opdenakker, G				Van Den Steen, PE; Proost, P; Grillet, B; Brand, DD; Kang, AH; Van Damme, J; Opdenakker, G			Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis	FASEB JOURNAL			English	Article						autoimmunity; gelatinase B; neutrophil; rheumatoid arthritis; glycosylation	T-CELL RECOGNITION; MHC CLASS-II; DENDRITIC CELLS; SYNOVIAL-FLUIDS; IV COLLAGENASE; IDENTIFICATION; INTERLEUKIN-8; PROTEIN; METALLOPROTEINASE; RECRUITMENT	During acute inflammation, leukocytes release proteolytic enzymes including matrix metalloproteinases (MMPs), but the physiopathological mechanisms and consequences of this process are not yet fully understood. Neutrophils, the predominant leukocyte type, produce neutrophil collagenase (MMP-8) and gelatinase B (MMP-9) but not the tissue inhibitors of MMPs. After stimulation, these cells also activate MMPs chemically. In arthritic diseases, neutrophils undergo great chemoattraction to the synovium, are activated by interleukin-8, and are stimulated to release gelatinase B in vivo. Production levels and net activities of gelatinase B were found to be absent in degenerative osteoarthritis but significantly increased in rheumatoid arthritis. The cleavage sites in cartilage type II collagen by gelatinase B were determined by a combination of reverse phase high-performance liquid chromatography, Edman degradation, and mass spectrometry analysis. The analysis revealed the site specificity of proline and lysine hydroxylations and O-linked glycosylation, the cleavage specificities by gelatinase B, and the preferential absence and presence of post-translational modifications at P2' and P5', respectively. Furthermore, gelatinase B leaves the immunodominant peptides intact, which are known from studies with (autoreactive) T cells. Lysine hydroxylation was detected at a critical position for T-cell activation. These data lend support to the thesis that extracellular proteolysis and other post-translational modifications of antigenic peptides may be critical in the establishment and perpetuation of autoimmune processes.	Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium; Univ Tennessee, Res Serv, Vet Affairs Med Ctr, Memphis, TN 38104 USA	KU Leuven; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Opdenakker, G (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, Minderbroedersstr 10, B-3000 Louvain, Belgium.	Ghislain.Opdenakker@rega.kuleuven.ac.be	Van den Steen, Philippe E/K-5132-2012; Proost, Paul/V-3052-2017; Opdenakker, Ghislain/Q-3130-2017; Opdenakker, Ghislain/V-8562-2019	Van den Steen, Philippe E/0000-0002-7334-9145; Proost, Paul/0000-0002-0133-5545; Opdenakker, Ghislain/0000-0003-1714-2294; Opdenakker, Ghislain/0000-0003-1714-2294; Van Damme, Jo/0000-0002-6707-1167; Brand, David/0000-0002-9260-7963				Ahrens D, 1996, ARTHRITIS RHEUM, V39, P1576, DOI 10.1002/art.1780390919; AKAHOSHI T, 1994, LYMPHOKINE CYTOK RES, V13, P113; Andersson EC, 1998, P NATL ACAD SCI USA, V95, P7574, DOI 10.1073/pnas.95.13.7574; Arndt SO, 2000, EMBO J, V19, P1241, DOI 10.1093/emboj/19.6.1241; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bartholome EJ, 2001, J INTERF CYTOK RES, V21, P495, DOI 10.1089/10799900152434367; BRAND DD, 1994, J IMMUNOL, V152, P3088; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CLAGUE RB, 1991, ANN RHEUM DIS, V50, P769, DOI 10.1136/ard.50.11.769; D'Haese A, 2000, J INTERF CYTOK RES, V20, P667, DOI 10.1089/107999000414853; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; Gruber BL, 1996, CLIN IMMUNOL IMMUNOP, V78, P161, DOI 10.1006/clin.1996.0025; HAURUM JS, 1994, J EXP MED, V180, P739, DOI 10.1084/jem.180.2.739; Inaba K, 2000, J EXP MED, V191, P927, DOI 10.1084/jem.191.6.927; ISHIOKA GY, 1992, J IMMUNOL, V148, P2446; Kleifeld O, 2000, J BIOL CHEM, V275, P34335, DOI 10.1074/jbc.M005714200; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; Martinez ON, 2001, AM J GASTROENTEROL, V96, P1665; MASURE S, 1990, BIOCHIM BIOPHYS ACTA, V1054, P317, DOI 10.1016/0167-4889(90)90103-K; MASURE S, 1991, EUR J BIOCHEM, V198, P391, DOI 10.1111/j.1432-1033.1991.tb16027.x; MICHAELSSON E, 1994, J EXP MED, V180, P745, DOI 10.1084/jem.180.2.745; MILLER EJ, 1972, BIOCHEMISTRY-US, V11, P4903, DOI 10.1021/bi00776a005; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; MYERS LK, 1995, IMMUNOLOGY, V84, P509; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; OPDENAKKER G, 1991, LYMPHOKINE CYTOK RES, V10, P317; Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851; OPDENAKKER G, 1994, IMMUNOL TODAY, V15, P103, DOI 10.1016/0167-5699(94)90151-1; PEICHL P, 1991, SCAND J IMMUNOL, V34, P333, DOI 10.1111/j.1365-3083.1991.tb01554.x; PEPPIN GJ, 1986, P NATL ACAD SCI USA, V83, P4322, DOI 10.1073/pnas.83.12.4322; RAMPART M, 1992, LAB INVEST, V66, P512; Rosloniec EF, 1996, CELL IMMUNOL, V172, P21, DOI 10.1006/cimm.1996.0210; ROSLONIEC EF, 1997, CURRENT PROTOCOLS IM; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; Santambrogio L, 1999, P NATL ACAD SCI USA, V96, P15056, DOI 10.1073/pnas.96.26.15056; SEITZ M, 1992, RHEUMATOL INT, V12, P159, DOI 10.1007/BF00274936; SELTZER JL, 1990, J BIOL CHEM, V265, P20409; SHIKHMAN AR, 1994, J IMMUNOL, V152, P4375; SOPATA I, 1995, RHEUMATOL INT, V15, P9, DOI 10.1007/BF00286763; StPierre Y, 1996, CYTOMETRY, V25, P374, DOI 10.1002/(SICI)1097-0320(19961201)25:4<374::AID-CYTO9>3.0.CO;2-D; SUN JP, 1991, EUR J IMMUNOL, V21, P1461, DOI 10.1002/eji.1830210620; Taylor PC, 2000, ARTHRITIS RHEUM-US, V43, P38, DOI 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L; Van Damme J, 1990, Cytokine, V2, P106, DOI 10.1016/1043-4666(90)90004-D; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Vergelli M, 1997, EUR J IMMUNOL, V27, P941, DOI 10.1002/eji.1830270421	48	134	137	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0379	10.1096/fj.01-0688com	http://dx.doi.org/10.1096/fj.01-0688com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874987				2022-12-28	WOS:000174755900030
J	Cho, JH; Park, IY; Kim, HS; Lee, WT; Kim, MS; Kim, SC				Cho, JH; Park, IY; Kim, HS; Lee, WT; Kim, MS; Kim, SC			Cathepsin D produces antimicrobial peptide parasin I from histone H2A in the skin mucosa of fish	FASEB JOURNAL			English	Article						innate immunity; metalloprotease; Parasilurus asotus; teleost	MONOCLONAL-ANTIBODIES; PROCATHEPSIN-D; RAINBOW-TROUT; PROTEINS; CATFISH; ANTIBIOTICS; INHIBITORS; IMMUNITY; SEQUENCE; DEFENSE	Parasin I is a potent 19-residue antimicrobial peptide isolated from the skin mucus of wounded catfish (Parasilurus asotus). Here we describe the mechanism of parasin I production from histone H2A in catfish skin mucosa on epidermal injury. Cathepsin D is found to exist in the mucus as an inactive proenzyme (procathepsin D), and a metalloprotease, induced on injury, cleaves procathepsin D to generate active cathepsin D. This activated form of cathepsin D then cleaves the Ser(19)-Arg(20) bond of histone H2A to produce parasin I. Immunohistochemical analysis reveals that unacetylated histone H2A, a precursor of parasin I, and procathepsin D are present in the cytoplasm of epithelial mucous cells and that parasin I is produced on the mucosal surface on epidermal injury. Western blot analysis shows that parasin I is also present in the skin mucus of other fish species. Furthermore, parasin I shows good antimicrobial activity against fish-specific bacterial pathogens. Taken together, these results indicate that cathepsin D and a metalloprotease participate in the production of parasin I from histone H2A and that parasin I contributes to the innate host defense of the fish against invading microorganisms.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Yonsei Univ, Coll Med, Dept Anat, Seoul 120752, South Korea; Korea Inst Energy Res, Biomass Team, Taejon 305343, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Yonsei University; Yonsei University Health System; Korea Institute of Energy Research (KIER)	Kim, SC (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Kusong Dong Yusong Gu, Taejon 305701, South Korea.	sckim@mail.kaist.ac.kr	Kim, Sun/GSN-4867-2022; Kim, Sun Chang/C-2026-2011	Lee, Won Taek/0000-0001-7348-9562				Alexander John B., 1992, Annual Review of Fish Diseases, V2, P249, DOI 10.1016/0959-8030(92)90066-7; ALHASSAN JM, 1990, INT J TISSUE REACT, V12, P121; BLY JE, 1991, VET IMMUNOL IMMUNOP, V28, P365, DOI 10.1016/0165-2427(91)90127-X; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Brooks S, 1997, GENE, V201, P45, DOI 10.1016/S0378-1119(97)00426-5; Brun NT, 2000, J INVERTEBR PATHOL, V75, P163, DOI 10.1006/jipa.1999.4917; Capasso C, 1999, BBA-PROTEIN STRUCT M, V1431, P64, DOI 10.1016/S0167-4838(99)00039-4; Cole AM, 1997, J BIOL CHEM, V272, P12008, DOI 10.1074/jbc.272.18.12008; CONNER GE, 1998, HDB PROTEOLYTIC ENZY, P828; CONNOR W, 1984, J MOL EVOL, V20, P236, DOI 10.1007/BF02104730; Ellis A. E., 1982, MICROBIAL DISEASES F, P1; ERICKSON AH, 1989, J CELL BIOCHEM, V40, P31, DOI 10.1002/jcb.240400104; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Garcia M, 1996, STEM CELLS, V14, P642, DOI 10.1002/stem.140642; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; HARVIMA RJ, 1988, BIOCHEM J, V250, P859, DOI 10.1042/bj2500859; HIEMSTRA PS, 1993, INFECT IMMUN, V61, P3038, DOI 10.1128/IAI.61.7.3038-3046.1993; HIRSCH JG, 1958, J EXP MED, V108, P925, DOI 10.1084/jem.108.6.925; Huang HJ, 1997, J LEUKOCYTE BIOL, V61, P624, DOI 10.1002/jlb.61.5.624; HUNTER K, 1999, PEDIATR RES, V45, P785; Kim HS, 2000, J IMMUNOL, V165, P3268, DOI 10.4049/jimmunol.165.6.3268; LARSEN LB, 1993, FEBS LETT, V319, P54, DOI 10.1016/0014-5793(93)80036-T; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Lemaitre C, 1996, EUR J BIOCHEM, V240, P143, DOI 10.1111/j.1432-1033.1996.0143h.x; MONESTIER M, 1993, MOL IMMUNOL, V30, P1069, DOI 10.1016/0161-5890(93)90153-3; Monestier M, 2000, J BIOL CHEM, V275, P13558, DOI 10.1074/jbc.275.18.13558; MURPHY CJ, 1993, J CELL PHYSIOL, V155, P408, DOI 10.1002/jcp.1041550223; Park CB, 2000, P NATL ACAD SCI USA, V97, P8245, DOI 10.1073/pnas.150518097; Park IY, 1998, FEBS LETT, V437, P258, DOI 10.1016/S0014-5793(98)01238-1; Patrzykat A, 2001, ANTIMICROB AGENTS CH, V45, P1337, DOI 10.1128/AAC.45.5.1337-1342.2001; PILLAI S, 1986, J BIOL CHEM, V261, P4919; Riggio M, 2000, GENE, V260, P67, DOI 10.1016/S0378-1119(00)00469-8; Rose FRAJ, 1998, INFECT IMMUN, V66, P3255, DOI 10.1128/IAI.66.7.3255-3263.1998; SAMAREL AM, 1989, AM J PHYSIOL, V257, pC1069, DOI 10.1152/ajpcell.1989.257.6.C1069; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Skin Suzuki Y, 1995, ATLAS FISH HISTOLOGY, P8; VETVICKA V, 1993, BIOCHEM MOL BIOL INT, V30, P921; Westley BR, 1996, EUR J CANCER, V32A, P15, DOI 10.1016/0959-8049(95)00530-7; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yano Tomoki, 1996, Fish Physiology, V15, P105; YEOMAN LC, 1972, J BIOL CHEM, V247, P6018; ZUHLSDORF M, 1983, BIOCHEM J, V213, P733	45	136	145	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					429	+		10.1096/fj.01-0736fje	http://dx.doi.org/10.1096/fj.01-0736fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11821259				2022-12-28	WOS:000173656600015
J	Polontchouk, L; Ebelt, B; Jackels, M; Dhein, S				Polontchouk, L; Ebelt, B; Jackels, M; Dhein, S			Chronic effects of endothelin-1 and angiotensin-II on gap junctions and intercellular communication in cardiac cells	FASEB JOURNAL			English	Article						connexin; endothelin; angiotensin; MAPKs	CONDUCTANCE; SYSTEM; EXPRESSION; CONNEXIN43; RECEPTOR; PROTEIN	Endothelin-1 (ET-1) and angiotensin-II (AT-II) participate in the pathophysiology of cardiovascular diseases. Regulation of gap junctional intercellular communication may influence heart function and its response to cardiac injury. In this study, we examined the effects of ET-1 and AT-II on connexin43 (Cx43) and connexin40 (Cx40) in cultured neonatal rat ventricular cardiomyocytes (NRCs) and the role of mitogen-activated protein kinase signaling in the ET-1-and AT-II-induced responses. NRCs were incubated for 24 h with either ET-1 or AT-II (each at concentrations ranging from 10 to 1000 nM), and Cx43 expression and phosphorylation increased with increasing concentrations of both. ET-1 effects were significantly blocked by ETA (BQ123), but not by ETB (BQ788), receptor antagonists. AT-II-induced Cx43 induction could be completely inhibited by the AT(1) receptor antagonist losartan. In contrast to Cx43, Cx40 expression did not change in either ET-1- or in AT-II-treated NRCs. Thus, these two connexins were differentially regulated. ET-1 and AT-II increased the gap junctional conductance between the cardiomyocytes in culture as measured using a dual-cell voltage clamp. Mitogen-activated protein kinase inhibition revealed that ERK1/2 was critical for up-regulation of Cx43 in response to ET-1, whereas both ERK and p38 signal pathways were involved in the regulation of Cx43 by AT-II. Thus, stimulation of the ERK and p38 signal pathways via ETA and AT1 receptors may partcipate in the regulation of cardiac gap junctions under (patho) physiological conditions.	Univ Halle Wittenberg, Inst Pharmacol, D-06097 Halle An Der Saale, Germany	Martin Luther University Halle Wittenberg	Dhein, S (corresponding author), Univ Leipzig, Herzzentrum, Clin Cardiac Surg, Russenstr 19, D-04289 Leipzig, Germany.	dhes@medizin.uni-leipzig.de						ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; DEGASPARO M, 1994, EUR HEART J, V15, P98, DOI 10.1093/eurheartj/15.suppl_D.98; Dietz R., 1999, Thrombosis and Haemostasis, V82, P73; Dodge SM, 1998, J AM COLL CARDIOL, V32, P800, DOI 10.1016/S0735-1097(98)00317-9; FIREK L, 1995, J MOL CELL CARDIOL, V27, P1633, DOI 10.1016/S0022-2828(95)90623-1; Gros DB, 1996, BIOESSAYS, V18, P719, DOI 10.1002/bies.950180907; Haefliger JA, 2001, KIDNEY INT, V60, P190, DOI 10.1046/j.1523-1755.2001.00786.x; Hollenberg NK, 2000, HYPERTENSION, V35, P150, DOI 10.1161/01.HYP.35.1.150; Kobayashi T, 1999, AM J PHYSIOL-HEART C, V276, pH1197, DOI 10.1152/ajpheart.1999.276.4.H1197; KWAK BR, 1995, EXP CELL RES, V220, P456, DOI 10.1006/excr.1995.1337; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maki S, 1998, J CARDIOVASC PHARM, V31, pS412, DOI 10.1097/00005344-199800001-00118; McEwan PE, 2000, J CARDIOVASC PHARM, V36, pS144, DOI 10.1097/00005344-200036051-00045; Miyauchi T, 1999, ANNU REV PHYSIOL, V61, P391, DOI 10.1146/annurev.physiol.61.1.391; Muller A, 1999, AM J PHYSIOL-CELL PH, V276, pC980, DOI 10.1152/ajpcell.1999.276.4.C980; Nagy JI, 1997, EXP CELL RES, V236, P127, DOI 10.1006/excr.1997.3716; Poenicke Klaus, 1997, British Journal of Pharmacology, V121, P118; Rossi GP, 1999, CARDIOVASC RES, V43, P300, DOI 10.1016/S0008-6363(99)00110-8; Shyu KG, 2001, J MOL CELL CARDIOL, V33, P691, DOI 10.1006/jmcc.2000.1333; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; Yamazaki T, 1999, ANN NY ACAD SCI, V874, P38, DOI 10.1111/j.1749-6632.1999.tb09223.x	21	103	106	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					87	+		10.1096/fj.01-0381fje	http://dx.doi.org/10.1096/fj.01-0381fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11709493				2022-12-28	WOS:000172420500033
J	Yoon, SO; Kim, MM; Park, SJ; Kim, D; Chung, J; Chung, AS				Yoon, SO; Kim, MM; Park, SJ; Kim, D; Chung, J; Chung, AS			Selenite suppresses hydrogen peroxide-induced cell apoptosis through inhibition of ASK1/JNK and activation of PI3-K/Akt pathways	FASEB JOURNAL			English	Article						survival signal; mitochondria membrane potential; cell proliferation	SIGNAL-REGULATING KINASE; CYTOCHROME-C; DEATH; AKT; MITOCHONDRIA; THIOREDOXIN; MECHANISMS; CASPASE-3; RELEASE	The relationship between selenium and signal molecules has not been well elucidated. It was found that physiological concentration of selenite, <3 <mu>M, reduced ASK1 activity and induced PI3-kinase (PI3-K)/Akt pathways in HT1080 cells. Duration of these signal molecules by selenite was much longer than that by growth factors and other stresses. The longer duration time of these signal molecules may be important to maintain normal functions against stresses. Selenite increased cell proliferation through up-regulation of Bcl-2 expression, mitochondrial membrane potential, adenosine triphosphate (ATP) generation, and glucose uptake mediated by PI3-K pathway. High concentration of H2O2 increased an apoptotic signal molecule, ASK1, which resulted in Bcl-2 down-regulation, membrane potential disruption, decreased ATP and glucose uptake, and activation of caspases. However, an antiapoptotic signal molecule, Akt, was activated also by H2O2, but duration of its activation was much shorter. Selenite blocked apoptosis induced by H2O2, which was related to blocking ASK1 and further stimulating PI3-kinase/Akt activities. Selenite blocked mitochondrial membrane potential disruption by 400 muM H2O2. Selenite also blocked caspase-9 and -3 activities and apoptosis induced by 500 muM H2O2, even after mitochondrial membrane potential disruption. These observations demonstrate that selenite increases cell proliferation and maintains cell survival by activating the antiapoptotic signal and blocking the apoptotic signal.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Chung, AS (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	aschung@mail.kaist.ac.kr						Baum MK, 1997, J ACQ IMMUN DEF SYND, V15, P370, DOI 10.1097/00042560-199708150-00007; Beck MA, 2001, FASEB J, V15, P1481, DOI 10.1096/fj.00-0721fje; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Coffer PJ, 1998, BIOCHEM J, V335, P1; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Ghosh R, 1994, Diabetes Res, V25, P165; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gupta S, 2000, MOL CELL BIOL, V20, P9294, DOI 10.1128/MCB.20.24.9294-9306.2000; Hajduch E, 2001, FEBS LETT, V492, P199, DOI 10.1016/S0014-5793(01)02242-6; HASUNUMA R, 1982, ANAL BIOCHEM, V126, P242, DOI 10.1016/0003-2697(82)90510-3; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jo DG, 2001, FASEB J, V15, P589; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim S, 2000, J BIOL CHEM, V275, P25979, DOI 10.1074/jbc.M001975200; Mackerness SAH, 2001, FEBS LETT, V489, P237, DOI 10.1016/S0014-5793(01)02103-2; Mandlekar S, 2000, CANCER RES, V60, P5995; Moley KH, 2000, APOPTOSIS, V5, P99, DOI 10.1023/A:1009697908332; Park HS, 2000, J BIOL CHEM, V275, P8487, DOI 10.1074/jbc.275.12.8487; Park HS, 2000, J BIOL CHEM, V275, P2527, DOI 10.1074/jbc.275.4.2527; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Reed JC, 1999, P NATL ACAD SCI USA, V96, P7614, DOI 10.1073/pnas.96.14.7614; RODEN M, 1995, HEPATOLOGY, V22, P169, DOI 10.1016/0270-9139(95)90370-4; Roshal M, 2001, APOPTOSIS, V6, P103, DOI 10.1023/A:1009636530839; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shisler JL, 1998, SCIENCE, V279, P102, DOI 10.1126/science.279.5347.102; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wu WH, 2000, J BIOL CHEM, V275, P40113, DOI 10.1074/jbc.M004108200; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	44	110	117	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					111	+		10.1096/fj.01-0398fje	http://dx.doi.org/10.1096/fj.01-0398fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11709494				2022-12-28	WOS:000172420500039
J	Lim, D; Kyozuka, K; Gragnaniello, G; Carafoli, E; Santella, L				Lim, D; Kyozuka, K; Gragnaniello, G; Carafoli, E; Santella, L			NAADP(+) initiates the Ca2+ response during fertilization of starfish oocytes	FASEB JOURNAL			English	Article						Ca2+ response at fertilization; nicotinic acid adenine nucleotide phosphate; inositol 1,4,5-trisphosphate; starfish oocytes	SEA-URCHIN EGGS; ADENINE-DINUCLEOTIDE PHOSPHATE; CYCLIC ADP-RIBOSE; INDUCED CALCIUM OSCILLATIONS; GTP-BINDING PROTEIN; BETA-GAMMA-SUBUNIT; INOSITOL TRISPHOSPHATE; ASCIDIAN OOCYTES; 1-METHYLADENINE-INDUCED MATURATION; MEIOSIS REINITIATION	We have explored the role of the recently discovered second messenger nicotinic acid adenine nucleotide phosphate (NAADP(+)) in Ca2+ swings that accompany the fertilization process in starfish oocytes. The injection of NAADP(+) deep into the cytoplasm of oocytes matured by the hormone 1-methyladenine (1-MA), mobilized Ca2+ exclusively in the cortical layer, showing that the NAADP(+)-sensitive Ca2+ pool is restricted to the subplasma membrane region of the cell. At variance with this, InsP(3) initiated the liberation of Ca2+ next to the point of injection in the center of the cell. The initial cortical Ca2+ liberation induced by NAADP(+) was followed by a spreading of the Ca2+ wave to the remainder of the cell and by a massive cortical granule exocytosis similar to that routinely observed on injection of InsP(3). A striking difference in the responses to NAADP(+) and InsP(3) was revealed by the removal of the nucleus from immature oocytes, i.e., from oocytes not treated with 1-MA. Whereas the Ca2+ response and the cortical granule exocytosis induced by NAADP(+) were unaffected by the removal of the nucleus, the Ca2+ response promoted by InsP(3) was significantly slowed. In addition, the cortical granule exocytosis was completely abolished. When enucleated oocytes were fertilized, the spermatozoon still promoted the Ca2+ wave and normal cortical exocytosis, strongly suggesting that the Ca2+ response was mediated by NAADP(+) and not by InsP(3). InsP(3)-sensitive Ca2+ stores may mediate the propagation of the wave initiated by NAADP(+) since its spreading was strongly affected by removal of the nucleus.	Staz Zool Anton Dohrn, Cell Biol Lab, I-80121 Naples, Italy; Asamushi Marine Biol Stn, Asamushi, Aomori 0393501, Japan; Univ Padua, Dept Biochem, I-35121 Padua, Italy	Stazione Zoologica Anton Dohrn di Napoli; University of Padua	Santella, L (corresponding author), Staz Zool Anton Dohrn, Cell Biol Lab, Villa Comunale, I-80121 Naples, Italy.	santella@alpha.szn.it	Lim, Dmitry/H-9101-2012; Carafoli, Ernesto/K-5192-2016; Santella, Luigia/AAM-3524-2020	Carafoli, Ernesto/0000-0002-7826-0094; Santella, Luigia/0000-0001-7159-0499				Albrieux M, 1998, J BIOL CHEM, V273, P14566, DOI 10.1074/jbc.273.23.14566; Auld A, 2000, BBA-MOL CELL RES, V1497, P11, DOI 10.1016/S0167-4889(00)00045-8; Calakos N, 1996, PHYSIOL REV, V76, P1; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; CHIBA K, 1989, DEV GROWTH DIFFER, V31, P447; CHIBA K, 1990, DEV BIOL, V140, P300, DOI 10.1016/0012-1606(90)90080-3; CHIBA K, 1993, MOL BIOL CELL, V4, P1027, DOI 10.1091/mbc.4.10.1027; Ciapa B, 2000, BIOL CELL, V92, P215, DOI 10.1016/S0248-4900(00)01065-0; CRETON R, 1995, DEV GROWTH DIFFER, V37, P703; DALE B, 1991, EXP CELL RES, V192, P302, DOI 10.1016/0014-4827(91)90190-6; Deguchi R, 1996, DEVELOPMENT, V122, P3651; Deng MQ, 2000, BIOL REPROD, V62, P873, DOI 10.1095/biolreprod62.4.873; Flament S, 2000, ZYGOTE, V8, P3, DOI 10.1017/S0967199400000770; Galione A, 2000, BIOL CELL, V92, P197, DOI 10.1016/S0248-4900(00)01070-4; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; Genazzani AA, 1997, TRENDS PHARMACOL SCI, V18, P108, DOI 10.1016/S0165-6147(96)01036-X; Genazzani AA, 1997, BRIT J PHARMACOL, V121, P1489, DOI 10.1038/sj.bjp.0701295; Gillo B, 1996, J PHOTOCH PHOTOBIO B, V35, P77, DOI 10.1016/1011-1344(96)07303-4; Giusti AF, 1999, DEV BIOL, V208, P189, DOI 10.1006/dbio.1998.9187; HAGIWARA S, 1975, J GEN PHYSIOL, V65, P617, DOI 10.1085/jgp.65.5.617; Halabisky B, 2000, J NEUROSCI, V20, P5124; HIRAI S, 1971, EXP CELL RES, V68, P137, DOI 10.1016/0014-4827(71)90595-7; JAFFE LA, 1993, J CELL BIOL, V121, P775, DOI 10.1083/jcb.121.4.775; JAFFE LA, 1993, DEV BIOL, V156, P556; JAFFE LF, 1990, MECH FERTILIZATION, V3, P127; Jones KT, 1998, INT J DEV BIOL, V42, P1; KANATANI H, 1969, NATURE, V221, P273, DOI 10.1038/221273a0; KINOSITA K JR, 1977, Proceedings of the National Academy of Sciences of the United States of America, V74, P1923, DOI 10.1073/pnas.74.5.1923; Kishimoto T, 1999, DEV BIOL, V214, P1, DOI 10.1006/dbio.1999.9393; Kyozuka K, 1998, DEVELOPMENT, V125, P4099; Leclerc C, 2000, BIOL CELL, V92, P285, DOI 10.1016/S0248-4900(00)01069-8; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 2000, J CELL SCI, V113, P4413; Levasseur M, 2000, DEVELOPMENT, V127, P631; Leveque C, 2000, J NEUROCHEM, V74, P367, DOI 10.1046/j.1471-4159.2000.0740367.x; LONGO FJ, 1995, ZYGOTE, V3, P225, DOI 10.1017/S0967199400002628; MCDOUGALL A, 1995, CURR BIOL, V5, P318, DOI 10.1016/S0960-9822(95)00062-5; McDougall A, 1998, DEVELOPMENT, V125, P4451; McDougall Alex, 1993, Zygote, V1, P35; McGuinness OM, 1996, DEVELOPMENT, V122, P2199; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MIYAZAKI S, 1979, DEV BIOL, V70, P327, DOI 10.1016/0012-1606(79)90031-9; MOHRI T, 1995, DEV BIOL, V172, P139, DOI 10.1006/dbio.1995.0011; PAREKH AB, 1995, PFLUG ARCH EUR J PHY, V430, P954, DOI 10.1007/BF01837409; PerezTerzic CM, 1995, BIOCHEM J, V312, P955, DOI 10.1042/bj3120955; PETERSEN CC, 1996, BIOCHEM J, V307, P663; RIDGWAY EB, 1977, P NATL ACAD SCI USA, V74, P623, DOI 10.1073/pnas.74.2.623; ROSSIGNOL DP, 1983, BIOCHIM BIOPHYS ACTA, V763, P346, DOI 10.1016/0167-4889(83)90096-4; Runft LL, 2000, DEVELOPMENT, V127, P3227; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; Santella L, 1997, CELL CALCIUM, V22, P11, DOI 10.1016/S0143-4160(97)90085-3; Santella L, 1999, EXP CELL RES, V248, P567, DOI 10.1006/excr.1999.4425; SCHMIDT T, 1982, DEV BIOL, V90, P284, DOI 10.1016/0012-1606(82)90377-3; SHILLING F, 1989, DEV BIOL, V133, P605, DOI 10.1016/0012-1606(89)90063-8; STEINHARDT R, 1977, DEV BIOL, V58, P185, DOI 10.1016/0012-1606(77)90084-7; STEVENS M, 1970, EXP CELL RES, V59, P482, DOI 10.1016/0014-4827(70)90658-0; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; Stricker SA, 1999, MICROSC RES TECHNIQ, V46, P356, DOI 10.1002/(SICI)1097-0029(19990915)46:6<356::AID-JEMT4>3.0.CO;2-6; Stricker SA, 1998, DEV BIOL, V203, P305, DOI 10.1006/dbio.1998.9058; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TURNER PR, 1986, J CELL BIOL, V102, P70, DOI 10.1083/jcb.102.1.70; Vogel SS, 1999, P NATL ACAD SCI USA, V96, P5019, DOI 10.1073/pnas.96.9.5019; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0	64	84	85	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2257	2267		10.1096/fj.01-0157com	http://dx.doi.org/10.1096/fj.01-0157com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641253				2022-12-28	WOS:000171920400038
J	Kim, WH; Hong, F; Jaruga, B; Hu, ZY; Fan, SJ; Liang, TJ; Gao, B				Kim, WH; Hong, F; Jaruga, B; Hu, ZY; Fan, SJ; Liang, TJ; Gao, B			Additive activation of hepatic NF-kappa B by ethanol and HBX or HCV core protein: involvement of TNF-alpha receptor I-independent and -dependent mechanisms	FASEB JOURNAL			English	Article						CYP2E1; ethanol metabolism; hepatitis; nuclear factor-kappa B; liver	C VIRUS-INFECTION; NECROSIS-FACTOR-ALPHA; SIGNAL-TRANSDUCTION PATHWAY; ALCOHOLIC LIVER-DISEASE; TRANSCRIPTION FACTORS; INTERFERON THERAPY; X PROTEIN; DNA-BINDING; ACETALDEHYDE; EXPRESSION	Alcohol consumption and viral hepatitis infection synergistically accelerate liver injury, but the underlying mechanism is not fully understood. Here we have examined the effects of ethanol on hepatitis B protein X (HBX)- or hepatitis C core protein (HCV core protein)- mediated activation of NF-kappaB, a critical signal in hepatic injury, regeneration, and tumor transformation. Acute ethanol or acetaldehyde exposure potentiates HBX or HCV core protein activation of NF-kappaB in primary mouse hepatocytes. Such potentiation can be abolished by blocking ethanol metabolism or overexpression of dominant negative NF-kappaB inducing kinase (NIK), I kappaB kinase (IKK), or I kappaB. Moreover, pertussis toxin attenuates NF-kappaB activation induced by acetaldehyde but not by HBX or HCV core protein, whereas HBX or HCV core protein-mediated activation of NF-kappaB is abolished completely in tumor necrosis factor receptor 1 (TNFR1) (-/-) hepatocytes. Finally, chronic ethanol consumption induces hepatic CYP2E1 protein expression and potentiates HBX or HCV core protein activation of NF-kappaB in the liver. These findings suggest that ethanol activates hepatic NF-kappaB via its metabolism and that HBX or HCV core protein activates hepatic NF-kappaB via TNFR1. With the essential role of TNFR1 in alcoholic liver injury, targeting TNFR1 by hepatitis viral proteins could contribute to cooperative effects of alcohol consumption and viral hepatitis on liver disease.	NIAAA, Sect Liver Biol, Lab Physiol Studies, NIH, Bethesda, MD 20892 USA; NIDDKD, Liver Dis Sect, NIH, Bethesda, MD 20892 USA; Long Isl Jewish Med Ctr, Albert Einstein Coll Med, New Hyde Pk, NY 11042 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Northwell Health; Yeshiva University	Gao, B (corresponding author), NIAAA, Sect Liver Biol, Lab Physiol Studies, NIH, Pk Bldg,Room 120,12420 Parklawn Dr,MSC 8115, Bethesda, MD 20892 USA.	bgao@mail.nih.gov		Kim, Won-Ho/0000-0002-4849-472X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054501, ZIADK054500, Z01DK054500, Z01DK054502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000367] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Anania FA, 1999, ALCOHOL CLIN EXP RES, V23, P279; Andrisani OM, 1999, INT J ONCOL, V15, P373; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Banerjee R, 2000, HEPATOLOGY, V32, P367, DOI 10.1053/jhep.2000.9197; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BRECHOT C, 1982, NEW ENGL J MED, V306, P1384, DOI 10.1056/NEJM198206103062302; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CLEMENS DL, 1995, ARCH BIOCHEM BIOPHYS, V321, P311, DOI 10.1006/abbi.1995.1400; Cook RT, 1998, ALCOHOL CLIN EXP RES, V22, P1927, DOI 10.1097/00000374-199812000-00007; Corrao G, 1998, HEPATOLOGY, V27, P914, DOI 10.1002/hep.510270404; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; Dai Y, 1995, J PHARMACOL EXP THER, V275, P1614; Di Bisceglie AM, 1998, LANCET, V351, P351, DOI 10.1016/S0140-6736(97)07361-3; DIEHL AM, 1990, GASTROENTEROLOGY, V99, P1105, DOI 10.1016/0016-5085(90)90631-A; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; FORKERT PG, 1991, CARCINOGENESIS, V12, P2259, DOI 10.1093/carcin/12.12.2259; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GAO B, 1995, J BIOL CHEM, V270, P5614, DOI 10.1074/jbc.270.10.5614; Gao B, 1996, MOL CELL BIOL, V16, P5997; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Henkler F, 1996, J VIRAL HEPATITIS, V3, P109, DOI 10.1111/j.1365-2893.1996.tb00001.x; Hoek JB, 1999, HEPATOLOGY, V29, P1602, DOI 10.1002/hep.510290536; Hong F, 2001, FASEB J, V15, P1595, DOI 10.1096/fj.00-0908fje; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Iimuro Y, 1997, HEPATOLOGY, V26, P1530; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; Kawamura T, 1997, HEPATOLOGY, V25, P1014, DOI 10.1002/hep.510250437; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KEKULE AS, 1992, ARCH VIROL, P63; Khan KN, 2000, ALCOHOL ALCOHOLISM, V35, P286, DOI 10.1093/alcalc/35.3.286; Kondili LA, 1998, EPIDEMIOL INFECT, V121, P391, DOI 10.1017/S0950268898001216; Lai MMC, 2000, HEPATOLOGY, V32, P427, DOI 10.1053/jhep.2000.9856; LAUER U, 1994, HEPATOLOGY, V19, P23, DOI 10.1002/hep.1840190106; LOBOALFONSO J, 1997, FOCUS, V17, P6; MAUCH TJ, 1986, HEPATOLOGY, V6, P263, DOI 10.1002/hep.1840060218; MENDENHALL CL, 1993, AM J GASTROENTEROL, V88, P1022; Mochida S, 1996, ALCOHOL CLIN EXP RES, V20, pA371, DOI 10.1111/j.1530-0277.1996.tb01811.x; Nalpas B, 1998, ALCOHOL ALCOHOLISM, V33, P202; Nanji AA, 1999, HEPATOLOGY, V30, P934, DOI 10.1002/hep.510300402; Nevins CL, 1999, DIGEST DIS SCI, V44, P1236, DOI 10.1023/A:1026605130185; Nguyen VAT, 2000, BIOCHEM J, V349, P427, DOI 10.1042/0264-6021:3490427; NICHOLLS RM, 1994, ALCOHOL ALCOHOLISM, V29, P149; NIEMELA O, 1991, J CLIN INVEST, V87, P1367, DOI 10.1172/JCI115141; Niemela O, 1998, ALCOHOL CLIN EXP RES, V22, P2118, DOI 10.1111/j.1530-0277.1998.tb05925.x; NIEMELA O, 1994, LAB INVEST, V70, P537; Ohnishi K, 1996, AM J GASTROENTEROL, V91, P1374; Ohta S, 1998, PREV MED, V27, P461, DOI 10.1006/pmed.1998.0298; OKAZAKI T, 1994, SCAND J GASTROENTERO, V29, P1039, DOI 10.3109/00365529409094883; OSHITA M, 1994, HEPATOLOGY, V20, P1115; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Regev A, 1999, ALCOHOL CLIN EXP RES, V23, P1543, DOI 10.1111/j.1530-0277.1999.tb04679.x; Roman J, 1999, HEPATOLOGY, V30, P1473, DOI 10.1002/hep.510300623; Roman J, 2000, J BIOL CHEM, V275, P14684, DOI 10.1074/jbc.275.19.14684; Rosman AS, 1996, AM J GASTROENTEROL, V91, P498; SAWADA M, 1993, ALCOHOL ALCOHOLISM, V28, P85, DOI 10.1093/alcalc/28.Supplement_1B.85; SCHENKER S, 1995, ALCOHOL CLIN EXP RES, V19, P1364, DOI 10.1111/j.1530-0277.1995.tb01626.x; Schiff Eugene R., 1999, American Journal of Medicine, V107, p95S; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; WATSON RR, 1994, ALCOHOL ALCOHOLISM, V29, P131; Weil R, 1999, MOL CELL BIOL, V19, P6345; Wheeler MD, 2000, HEPATOLOGY, V32, P1050, DOI 10.1053/jhep.2000.19339; Wiley TE, 1998, HEPATOLOGY, V28, P805, DOI 10.1002/hep.510280330; Wu Jian, 1999, Frontiers in Bioscience, V4, pd520; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9; You LR, 1999, J VIROL, V73, P1672, DOI 10.1128/JVI.73.2.1672-1681.1999; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	76	66	70	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2551	+		10.1096/fj.01-0217	http://dx.doi.org/10.1096/fj.01-0217			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641261	Bronze			2022-12-28	WOS:000171372700023
J	Tracey, KJ; Czura, CJ; Ivanova, S				Tracey, KJ; Czura, CJ; Ivanova, S			Mind over immunity	FASEB JOURNAL			English	Article						macrophage; TNF-alpha; HMG-1; vagus nerve; acetylcholine; placebo effect	SUBDIAPHRAGMATIC VAGOTOMY; BRAIN COMMUNICATION; VAGUS NERVE; ENDOTOXIN; ALPHA	The central nervous system regulates the innate immune system by elaborating anti-inflammatory hormone cascades in response to bacterial products and immune mediators. We recently discovered that the central nervous system also responds via acetylcholine-mediated efferent signals carried through the vagus nerve. Nicotinic cholinergic receptors expressed on macrophages detect these signals and respond with a dampened cytokine response. Vagus nerve stimulators can mimic this response and can prevent lethal endotoxemia. This newly appreciated cholinergic anti-inflammatory pathway provides a neural substrate to study brain-immune interactions and might be harnessed for therapy of cytokine-mediated disease.	NYU, N Shore Univ Hosp, Lab Biomed Sci, Manhasset, NY 11030 USA	New York University; Northwell Health; North Shore University Hospital	Tracey, KJ (corresponding author), NYU, N Shore Univ Hosp, Lab Biomed Sci, 350 Community Dr, Manhasset, NY 11030 USA.	kjtracey@sprynet.com	Czura, Christopher/E-1862-2012	Czura, Christopher/0000-0002-1347-6986; Tracey, Kevin J/0000-0003-1884-6314				Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Borovikova LV, 2000, AUTON NEUROSCI-BASIC, V85, P141, DOI 10.1016/S1566-0702(00)00233-2; Chiao H, 1996, J CLIN INVEST, V97, P2038, DOI 10.1172/JCI118639; Fleshner M, 1998, J NEUROIMMUNOL, V86, P134, DOI 10.1016/S0165-5728(98)00026-5; Maier SF, 1998, ANN NY ACAD SCI, V840, P289, DOI 10.1111/j.1749-6632.1998.tb09569.x; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P2374, DOI 10.1073/pnas.86.7.2374; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; WATKINS LR, 1995, NEUROSCI LETT, V183, P27, DOI 10.1016/0304-3940(94)11105-R	9	58	95	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2001	15	9					1575	1576		10.1096/fj.01-0148hyp	http://dx.doi.org/10.1096/fj.01-0148hyp			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427490				2022-12-28	WOS:000170318500010
J	Peluso, G; Petillo, O; Barbarisi, A; Melone, MAB; Reda, E; Nicolai, R; Calvani, M				Peluso, G; Petillo, O; Barbarisi, A; Melone, MAB; Reda, E; Nicolai, R; Calvani, M			Carnitine protects the molecular chaperone activity of lens alpha-crystallin and decreases the posttranslational protein modifications induced by oxidative stress	FASEB JOURNAL			English	Article						alpha-crystallin; carnitine; cataract; lens proteins; oxidative stress	NON-ENZYMIC GLYCOSYLATION; A-CRYSTALLIN; POSSIBLE MECHANISM; CATARACT FORMATION; ASPIRIN PREVENTS; CROSS-LINKING; IN-VITRO; E-DOMAIN; TRANSGLUTAMINASE; EYE	alpha-Crystallin prevents heat-induced lens protein aggregation by acting as a molecular chaperone. We investigated whether oxidative stress in an in vitro model of cataract increases the posttranslational modifications to lens proteins induced by transglutaminase (TGase). We also investigated whether carnitine safeguards the chaperone activity of alpha-crystallin and inhibits the TGase-mediated aggregation of lens proteins and lens opacification. One lens of each pair of rat lenses was cultured without H2O2 (controls), and the controlateral lens was exposed to 500 muM H2O2, an as oxidizing agent, in the presence and absence of 300 muM L-carnitine. Lenses treated with H2O2 alone became opaque, whereas the L-carnitine-treated lenses remained clear. Incubation with 500 muM H2O2 significantly increased the level of TGase-mediated cross-links of lens protein and decreased the ability of a-crystallin to prevent heat-induced aggregation of beta(L)-crystallin, L-carnitine prevented both these negative effects. After H2O2, glutathione and free carnitine levels dropped dramatically. L-carnitine did not prevent the loss of glutathione, but it did prevent carnitine from falling below control values. In conclusion, carnitine safeguards the chaperone activity of alpha-crystallin that prevents protein aggregation in the lens, and it decreases the protein posttranslational modifications induced by oxidative stress. This process is not mediated by glutathione.	CNR, Inst Prot Biochem & Enzymol, I-80072 Naples, Italy; Natl Canc Inst, Dept Expt Oncol, Naples, Italy; Univ Naples 2, Sch Med, Inst Clin Surg, Naples, Italy; Univ Naples 2, Sch Med, Div Neurol 2, Naples, Italy; Sigma Tau Pharmaceut Co, Dept Sci, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); IRCCS Fondazione Pascale; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Italfarmaco; Leadiant Biosciences	Peluso, G (corresponding author), CNR, Inst Prot Biochem & Enzymol, Via Toiano 6, I-80072 Naples, Italy.	peluso@daffne.ibpe.na.cnr.it	Melone, Mariarosa Anna Beatrice/N-6788-2015; terracciano, chiara/C-2955-2018	Melone, Mariarosa Anna Beatrice/0000-0002-7213-9277; terracciano, chiara/0000-0002-1853-5578; Barbarisi, Alfonso/0000-0003-2357-1132				AJIBOYE R, 1989, EXP EYE RES, V49, P31, DOI 10.1016/0014-4835(89)90073-0; Andley UP, 1998, J BIOL CHEM, V273, P31252, DOI 10.1074/jbc.273.47.31252; ANDLEY UP, 1987, PHOTOCHEM PHOTOBIOL, V46, P1057, DOI 10.1111/j.1751-1097.1987.tb04893.x; ARDUINI A, 1992, AM HEART J, V123, P1726, DOI 10.1016/0002-8703(92)90850-U; ARDUINI A, 1992, J BIOL CHEM, V267, P12673; Augusteyn R., 1981, MECH CATARACT FORMAT, P72; Bettelheim F. A., 1985, OCULAR LENS STRUCTUR, P265; BLAKYTNY R, 1992, EXP EYE RES, V54, P509; BLOEMENDAL H, 1982, CRC CR REV BIOCH MOL, V12, P1, DOI 10.3109/10409238209105849; CARVER JA, 1994, BBA-PROTEIN STRUCT M, V1204, P195, DOI 10.1016/0167-4838(94)90009-4; CHERIAN M, 1993, LIFE SCI, V52, P1699, DOI 10.1016/0024-3205(93)90478-L; CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V212, P184, DOI 10.1006/bbrc.1995.1954; CROMPTON M, 1985, EXP EYE RES, V40, P297, DOI 10.1016/0014-4835(85)90014-4; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; de Jong W W, 1974, Eur J Biochem, V48, P271; DILLON J, 1985, OCULAR LENS STRUCTUR, P349; Francis PJ, 1999, TRENDS GENET, V15, P191, DOI 10.1016/S0168-9525(99)01738-2; Gibala MJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE235; GROENEN PJTA, 1993, BIOCHEM J, V295, P399, DOI 10.1042/bj2950399; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Harding J.J., 1981, MOL CELLULAR BIOL EY, P327; HASAN A, 1993, EXP EYE RES, V57, P29, DOI 10.1006/exer.1993.1095; HOHL D, 1991, J BIOL CHEM, V266, P6626; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; HUBY R, 1988, EXP EYE RES, V47, P53, DOI 10.1016/0014-4835(88)90023-1; JONES RHV, 1993, EXP EYE RES, V57, P783, DOI 10.1006/exer.1993.1186; JONES RHV, 1999, EXP EYE RES, V69, P291; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KONIGSBERG WH, 1983, P NATL ACAD SCI-BIOL, V80, P2467, DOI 10.1073/pnas.80.9.2467; KRAMPS JA, 1978, BIOCHIM BIOPHYS ACTA, V533, P487, DOI 10.1016/0005-2795(78)90394-X; Kreis R, 1999, NMR BIOMED, V12, P471, DOI 10.1002/(SICI)1099-1492(199911)12:7<471::AID-NBM591>3.0.CO;2-A; Lee JS, 1997, J PROTEIN CHEM, V16, P283, DOI 10.1023/A:1026305025816; Lorand L, 1998, P NATL ACAD SCI USA, V95, P537, DOI 10.1073/pnas.95.2.537; LORAND L, 1992, P NATL ACAD SCI USA, V89, P11161, DOI 10.1073/pnas.89.23.11161; LORAND L, 1981, P NATL ACAD SCI-BIOL, V78, P1356, DOI 10.1073/pnas.78.3.1356; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MOCKROS LF, 1974, BIOPHYS CHEM, V2, P164, DOI 10.1016/0301-4622(74)80037-2; Murthy SNP, 1998, EXP EYE RES, V67, P273; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Peluso C, 2000, J CELL BIOCHEM, V80, P1; Perng MD, 1999, J CELL SCI, V112, P2099; PERNG MD, 1999, J BIOL CHEM, V47, P33235; PESSOTTO P, 1994, J OCUL PHARMACOL, V10, P643, DOI 10.1089/jop.1994.10.643; Pessotto P, 1997, EXP EYE RES, V64, P195, DOI 10.1006/exer.1996.0188; RAO GN, 1988, BIOCHEM BIOPH RES CO, V151, P991, DOI 10.1016/S0006-291X(88)80463-7; RAO GN, 1985, BIOCHEM BIOPH RES CO, V128, P1125, DOI 10.1016/0006-291X(85)91057-5; Rasmussen BB, 1999, ANNU REV NUTR, V19, P463, DOI 10.1146/annurev.nutr.19.1.463; RICHARD RC, 1998, P SOC EXP BIOL MED, V217, P397; Robertson JD, 1997, TOXICOLOGY, V124, P11, DOI 10.1016/S0300-483X(97)00126-1; SAMOKHIN GP, 1995, J BIOL CHEM, V270, P21827, DOI 10.1074/jbc.270.37.21827; Sims NR, 2000, MOL BRAIN RES, V77, P176, DOI 10.1016/S0169-328X(00)00049-8; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; Swamy-Mruthinti S, 1999, EXP EYE RES, V69, P109, DOI 10.1006/exer.1999.0680; TAKEMOTO L, 1992, CURR EYE RES, V11, P651, DOI 10.3109/02713689209000738; TARDIEU A, 1988, ANNU REV BIOPHYS BIO, V17, P47; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; vandenIjssel PRLA, 1996, OPHTHALMIC RES, V28, P39, DOI 10.1159/000267941; VANKLEEF FSM, 1976, EUR J BIOCHEM, V66, P477; VARMA SD, 1984, CURR EYE RES, V3, P35, DOI 10.3109/02713688408997186; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; Wuensch SA, 1997, COMP BIOCHEM PHYS B, V118, P599, DOI 10.1016/S0305-0491(97)00242-3; ZIGLER JS, 1989, FREE RADICAL BIO MED, V7, P499; Zigman S., 1981, MECHANISMS CATARACT, P117; Zigman S., 1985, OCULAR LENS STRUCTUR, P301	68	24	28	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1604	+		10.1096/fj.00-0727fje	http://dx.doi.org/10.1096/fj.00-0727fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427500				2022-12-28	WOS:000173707700025
J	Quan, N; Ho, E; Lai, WM; Tsai, YH; Bray, T				Quan, N; Ho, E; Lai, WM; Tsai, YH; Bray, T			Administration of NF-kappa B decoy inhibits pancreatic activation of NF-kappa B and prevents diabetogenesis by alloxan in mice	FASEB JOURNAL			English	Article						hyperglycemia; insulin; oxidative stress; pancreas	IN-VIVO TRANSFECTION; INSULIN	Many risk factors can trigger the development of insulin-dependent diabetes mellitus (IDDM). The induction of IDDM in vivo is strongly associated not only with the generation of reactive oxygen species but also with the activation of the transcription factor nuclear factor-kappaB (NF-kappaB). The purpose of this study was to determine the role of NF-kappaB activation in diabetogenesis. Alloxan, a diabetogenic compound that causes diabetic conditions by selectively killing the insulin-producing pancreatic beta-cells, was used as a model chemical compound to induce diabetes. We show here that the injection of alloxan in mice rapidly and specifically induced the activation of NF-kappaB in the pancreas. Intravenous administration of synthetic oligodeoxynucleotides, which are exact copies of the DNA binding site of NF-kappaB (NF-kappaB decoy), given before the alloxan injection, effectively blocked pancreatic NF-kappaB activation in mice and subsequently prevented pancreatic cell death, restored insulin secretion, and abolished hyperglycemia. Injection of scrambled NF-kappaB decoy oligodeoxynucleotides to mice had no effect on alloxan-induced diabetic conditions, These results demonstrate that NF-kappaB activation in the pancreas is required for the induction of chemically induced diabetes by alloxan.	Ohio State Univ, Dept Human Nutr, Columbus, OH 43210 USA; Ohio State Univ, Dept Oral Biol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Bray, T (corresponding author), Ohio State Univ, Dept Human Nutr, 350 E Campbell Hall,1787 Neil Ave, Columbus, OH 43210 USA.	bray.21@osu.edu						Abdel-Mageed AB, 1998, J UROLOGY, V160, P2000, DOI 10.1016/S0022-5347(01)62224-9; Arnush M, 1998, J CLIN INVEST, V102, P516, DOI 10.1172/JCI844; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; Gill JS, 2000, NEUROBIOL DIS, V7, P448, DOI 10.1006/nbdi.2000.0312; Ho E, 1999, P SOC EXP BIOL MED, V222, P205, DOI 10.1046/j.1525-1373.1999.d01-137.x; Ho E, 1999, FASEB J, V13, P1845, DOI 10.1096/fasebj.13.13.1845; Hofmann MA, 1998, DIABETES CARE, V21, P1310, DOI 10.2337/diacare.21.8.1310; Kawamura I, 1999, GENE THER, V6, P91, DOI 10.1038/sj.gt.3300819; Li JF, 1997, J BIOL CHEM, V272, P16498, DOI 10.1074/jbc.272.26.16498; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Ono S, 1999, HUM GENE THER, V10, P335; Ono S, 1998, HUM GENE THER, V9, P1003, DOI 10.1089/hum.1998.9.7-1003; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; REDDY S, 1985, AUST J BIOL SCI, V38, P59, DOI 10.1071/BI9850059; Schmitt R, 2000, EDN, V45, P77; Sharma HW, 1996, ANTICANCER RES, V16, P61; Tomita T, 1999, ARTHRITIS RHEUM, V42, P2532, DOI 10.1002/1529-0131(199912)42:12<2532::AID-ANR5>3.0.CO;2-2; West IC, 2000, DIABETIC MED, V17, P171, DOI 10.1046/j.1464-5491.2000.00259.x	21	22	23	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1616	+		10.1096/fj.00-0855fje	http://dx.doi.org/10.1096/fj.00-0855fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427504				2022-12-28	WOS:000173707700015
J	Panigone, S; Bergomas, R; Fontanella, E; Prinetti, A; Sandhoff, K; Grabowski, GA; Delia, D				Panigone, S; Bergomas, R; Fontanella, E; Prinetti, A; Sandhoff, K; Grabowski, GA; Delia, D			Up-regulation of prosaposin by the retinoid HPR and the effect on ceramide production and integrin receptors	FASEB JOURNAL			English	Article						fenretinide; retinoic acid; reactive oxygen species; adhesion molecules; c-DNA; differential display	CELL-ADHESION; N-(4-HYDROXYPHENYL) RETINAMIDE; CARCINOMA-CELLS; APOPTOSIS; PROTEIN; GENE; INDUCTION; ACTIVATOR; IDENTIFICATION; NEUROBLASTOMA	N-(4-hydroxyphenyl)retinamide (HPR) is a synthetic retinoid of clinical use in breast cancer chemoprevention. Its in vitro effects on tumor cell lines include growth inhibition and apoptosis and are, to a large extent, independent of the activation of retinoic acid receptors. We have performed a cDNA differential display analysis to identify genes potentially relevant for understanding the mechanism of action of HPR. We report that prosaposin (PSAP), a gene encoding for the common precursor protein of saposins (cofactors involved in the metabolism of various sphingolipids), was significantly up-regulated, both at transcriptional and protein level, in MCF7 and T47D breast cancer cell lines after treatment with HPR, but not with all trans retinoic acid (ATRA). Remarkably, this response was also induced by oxidants, whereas it was abrogated by antioxidants in cells treated with HPR, which implies a direct role of free radicals generated by HPR in prosaposin up-regulation. Stable transfectants of T47D cells overexpressing prosaposin (T47D-PSAP) exhibited morphological changes, reduced proliferation, and impaired attachment to culture plates, which correlated with down-regulation of alpha6, beta1, and beta4 subunits of the integrin family of adhesion receptors. Concordant with a role of prosaposin in ceramide generation, increased amounts of this lipid were found in T47D-PSAP and in HPR-treated T47D cells. Moreover, treatment of T47D with C2-ceramide resulted in the up-regulation of prosaposin and down-regulation of integrin receptors. Altogether, these findings establish a link between prosaposin, ceramide, and integrin receptor regulation. In view of the association between integrin down-regulation and suppression of metastatic capacity, our data raise the possibility that the cancer chemopreventive activity of HPR may rely, at least in part, on its capacity to regulate integrin receptors through prosaposin.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Milan, Sch Med, Dept Med Chem & Biochem, I-20122 Milan, Italy; Gerhard Domagk Strl, Inst Organ Chem & Biochem, D-53121 Bonn, Germany; Childrens Hosp Res Fdn, Div Human Genet, Cincinnati, OH 45229 USA; Childrens Hosp Res Fdn, Program Human Genet, Cincinnati, OH 45229 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan; University of Bonn; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Delia, D (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	delia@istitutotumori.mi.it	Prinetti, Alessandro/R-4206-2017; Sonnino, Sandro/R-4154-2017	Prinetti, Alessandro/0000-0003-0252-2593; Sonnino, Sandro/0000-0001-8180-5908				Alonso DF, 1998, ANTICANCER RES, V18, P4499; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; BHATNAGAR R, 1991, BIOCHEM PHARMACOL, V41, P1471, DOI 10.1016/0006-2952(91)90563-K; Bierfreund U, 2000, METHOD ENZYMOL, V311, P255; BOTTINI C, 1993, INT J CANCER, V54, P261, DOI 10.1002/ijc.2910540217; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; Campana WM, 1999, BBA-GEN SUBJECTS, V1427, P392, DOI 10.1016/S0304-4165(99)00036-7; Campana WM, 1998, FASEB J, V12, P307, DOI 10.1096/fasebj.12.3.307; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chigorno V, 1997, EUR J BIOCHEM, V250, P661, DOI 10.1111/j.1432-1033.1997.00661.x; Debernardi S, 1997, GENOMICS, V42, P67, DOI 10.1006/geno.1997.4720; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; DELIA D, 1993, CANCER RES, V53, P6036; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Erdreich-Epstein A, 2000, CANCER RES, V60, P712; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; Henseler M, 1996, AM J HUM GENET, V58, P65; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Kazmi SMI, 1996, CANCER RES, V56, P1056; Kitareewan S, 1999, ONCOGENE, V18, P5747, DOI 10.1038/sj.onc.1202981; KONDOH K, 1991, BIOCHEM BIOPH RES CO, V181, P286, DOI 10.1016/S0006-291X(05)81415-9; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Leonova T, 1996, J BIOL CHEM, V271, P17312, DOI 10.1074/jbc.271.29.17312; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; McCormick DL, 1996, CARCINOGENESIS, V17, P2513, DOI 10.1093/carcin/17.11.2513; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Moon Richard C., 1994, P573; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; PELLEGRINI R, 1992, TUMORI, V78, P1; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Prinetti A, 2000, J BIOL CHEM, V275, P11658, DOI 10.1074/jbc.275.16.11658; RIBONI L, 1992, FEBS LETT, V300, P188, DOI 10.1016/0014-5793(92)80193-K; Sandhoff K, 1997, CLIN CHIM ACTA, V266, P51, DOI 10.1016/S0009-8981(97)00166-6; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; Sun SY, 1999, MOL PHARMACOL, V55, P403; TOYOKUNI T, 1991, J LABELLED COMPD RAD, V29, P567, DOI 10.1002/jlcr.2580290508; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Webber MM, 1999, CLIN EXP METASTAS, V17, P255, DOI 10.1023/A:1006665616932; Zhao Q, 2000, J BIOL CHEM, V275, P24829, DOI 10.1074/jbc.M003497200	46	15	21	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1475	+		10.1096/fj.00-0531fje	http://dx.doi.org/10.1096/fj.00-0531fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387262				2022-12-28	WOS:000173705800005
J	Tilghman, RW; Hoover, RL				Tilghman, RW; Hoover, RL			The Src-cortactin pathway is required for clustering of E-selectin and ICAM-1 in endothelial cells	FASEB JOURNAL			English	Article						adhesion; tyrosine phosphorylation; inflammation; leukocyte; cytoskeleton	TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; LYMPHOCYTE MIGRATION; ADHESION MOLECULES; FOCAL ADHESIONS; ARP2/3 COMPLEX; ACTIN; CYTOSKELETON; ACTIVATION	Adhesion molecules such as E-selectin and intercellular adhesion molecule-1 (ICAM-1) expressed on endothelial cells (ECs) at sites of inflammation play an important role in the recruitment of leukocytes from the bloodstream into extravascular tissue. However, little is known about the signaling pathways that are initiated in ECs following adhesion molecule engagement. Here, we report that an 85-kDa protein becomes tyrosine phosphorylated in human ECs following leukocyte adhesion or upon antibody-induced clustering of E-selectin or ICAM-1. Through immunoprecipitation experiments, this protein was identified as cortactin, a cytoskeleton-binding molecule and prominent src substrate involved in cell adhesion. Following adhesion molecule clustering, cortactin phosphorylation was inhibited by the src family kinase inhibitor PP2. Both src and tyrosine-phosphorylated cortactin were found to be associated with E-selectin and ICAM-1 following adhesion of antibody-coated beads to ECs. PP2 did not inhibit the association of cortactin with E-selectin and ICAM-1; however, PP2 inhibited adhesion between paraformaldehyde-fixed THP-1 cells and ECs. This decrease in adhesion correlated with inhibition of adhesion molecule clustering on PP2-treated ECs at sites of THP-1 attachment. These findings implicate src and cortactin as mediators of leukocyte/EC interactions at sites of inflammation by regulating adhesion molecule clustering on ECs.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University	Hoover, RL (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, U4202 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.	richard.hoover@mcmail.vanderbilt.edu						Adamson P, 1999, J IMMUNOL, V162, P2964; Aplin AE, 1998, PHARMACOL REV, V50, P197; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; Gilmore AP, 1996, STRUCTURE, V4, P647, DOI 10.1016/S0969-2126(96)00069-X; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hu YY, 2000, J IMMUNOL, V165, P2142, DOI 10.4049/jimmunol.165.4.2142; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Ley K, 1996, CARDIOVASC RES, V32, P733, DOI 10.1016/0008-6363(96)00066-1; MAA MC, 1992, ONCOGENE, V7, P2429; MACIAG T, 1982, J BIOL CHEM, V257, P5333; Malik AB, 1996, PHARMACOL REV, V48, P213; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; PATCH LA, 1995, J CELL SCI, V108, P1371; ROMER LH, 1992, COLD SPRING HARB SYM, V57, P193, DOI 10.1101/SQB.1992.057.01.024; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Vuori K, 1998, J MEMBRANE BIOL, V165, P191, DOI 10.1007/s002329900433; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yoshida M, 1998, J IMMUNOL, V161, P933; Yoshida M, 1996, J CELL BIOL, V133, P445, DOI 10.1083/jcb.133.2.445; ZHAN X, 1993, J BIOL CHEM, V268, P24427	33	71	73	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1257	+		10.1096/fj.01-0969fje	http://dx.doi.org/10.1096/fj.01-0969fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060669				2022-12-28	WOS:000176683900034
J	Zingarelli, B; Hake, PW; Yang, ZQ; O'Connor, M; Denenberg, A; Wong, HR				Zingarelli, B; Hake, PW; Yang, ZQ; O'Connor, M; Denenberg, A; Wong, HR			Absence of inducible nitric oxide synthase modulates early reperfusion-induced NF-kappa B and AP-1 activation and enhances myocardial damage	FASEB JOURNAL			English	Article						apoptosis; nuclear factor kappa B; activator protein 1; heat shock protein 70; nitrotyrosine	INTERCELLULAR-ADHESION MOLECULE-1; PROGRAMMED CELL-DEATH; INFARCT SIZE; ISCHEMIA-REPERFUSION; ISCHEMIA/REPERFUSION INJURY; KINASE IKK; LATE-PHASE; IN-SITU; APOPTOSIS; HEART	The role of nitric oxide (NO) generated by the inducible NO synthase (iNOS) during myocardial ischemia and reperfusion is not understood. We investigated the role of iNOS during early reperfusion damage induced in genetically deficient iNOS (iNOS(-/-)) mice and wild-type littermates. In wild-type mice, ischemia (60 min) and reperfusion (60 min) induced an elevation in serum levels of creatine phosphokinase and myocardial injury characterized by the presence of scattered apoptotic myocytes and mild neutrophil infiltration. Northern blot analysis showed increased expression of iNOS, whose activity was markedly elevated after reperfusion. Immunohistochemistry showed staining for nitrotyrosine; Western blot analysis showed elevated expression of heat shock protein 70 (HSP70), a putative cardioprotective mediator. Plasma levels of nitrite and nitrate, tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), and IL-10 were also increased. These events were preceded by degradation of inhibitor kappaBalpha (IkappaBalpha), activation of IkappaB kinase complex (IKK) and c-Jun-NH2-terminal kinase (JNK), and subsequently activation of nuclear factor-kappaB (NF-kappaB) and activator protein 1 (AP-1) as early as 15 min after reperfusion. In contrast, iNOS(-/-) mice experienced 35% mortality after reperfusion. The extensive myocardial injury was associated with marked apoptosis and infiltration of neutrophils whereas expression of HSP70 was less pronounced. Nitrotyrosine formation and plasma levels of nitrite and nitrate were undetectable. TNF-alpha and IL-6 were increased and IL-10 was reduced in earlier stages of reperfusion. Activation of IKK and JNK and binding activity of NF-kappaB and AP-1 were significantly reduced. Thus, we conclude that iNOS plays a beneficial role in modulating the early defensive inflammatory response against reperfusion injury through regulation of signal transduction.	Childrens Hosp, Med Ctr, Div Crit Care, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Zingarelli, B (corresponding author), Childrens Hosp, Med Ctr, Div Crit Care Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	bzingarelli@chmcc.org	, Basilia/AAV-7582-2021		NHLBI NIH HHS [R01 HL-60730] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060730] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; BAIS R, 1982, CRC CR REV CL LAB SC, V16, P291, DOI 10.3109/10408368209107030; Chandrasekar B, 1997, FEBS LETT, V401, P30, DOI 10.1016/S0014-5793(96)01426-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; Colucci WS, 1996, NEW ENGL J MED, V335, P1224, DOI 10.1056/NEJM199610173351610; Connelly L, 2001, J IMMUNOL, V166, P3873, DOI 10.4049/jimmunol.166.6.3873; DarleyUsmar V, 1996, PHARM RES-DORDR, V13, P649, DOI 10.1023/A:1016079012214; Das DK, 1998, ANN NY ACAD SCI, V865, P297, DOI 10.1111/j.1749-6632.1998.tb11190.x; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DeMeester SL, 2001, FASEB J, V15, P270, DOI 10.1096/fj.00-0170hyp; Ferrari R, 1998, EUR HEART J, V19, pB2; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Grisham MB, 1998, FREE RADICAL BIO MED, V25, P404, DOI 10.1016/S0891-5849(98)00094-X; Guo Y, 1999, P NATL ACAD SCI USA, V96, P11507, DOI 10.1073/pnas.96.20.11507; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Halliwell B, 1997, FEBS LETT, V411, P157, DOI 10.1016/S0014-5793(97)00469-9; Imagawa J, 1999, BRIT J PHARMACOL, V126, P701, DOI 10.1038/sj.bjp.0702368; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; JOHNSON G, 1991, CRIT CARE MED, V19, P244, DOI 10.1097/00003246-199102000-00021; Jones SP, 1999, AM J PHYSIOL-HEART C, V276, pH1567, DOI 10.1152/ajpheart.1999.276.5.H1567; Kanno S, 2000, CIRCULATION, V101, P2742, DOI 10.1161/01.CIR.101.23.2742; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; LEFER DJ, 1993, CIRCULATION, V88, P2337, DOI 10.1161/01.CIR.88.5.2337; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; Ma XL, 1999, P NATL ACAD SCI USA, V96, P14617, DOI 10.1073/pnas.96.25.14617; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; Maulik N, 1999, FEBS LETT, V443, P331, DOI 10.1016/S0014-5793(98)01719-0; Mesri M, 1999, J BIOL CHEM, V274, P23111, DOI 10.1074/jbc.274.33.23111; Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657; Mizuno T, 1998, J THORAC CARDIOV SUR, V115, P931, DOI 10.1016/S0022-5223(98)70376-9; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Mustapha S, 2000, AM J PHYSIOL-HEART C, V279, pH939, DOI 10.1152/ajpheart.2000.279.3.H939; Nossuli TO, 1997, CIRCULATION, V96, P2317; Nossuli TO, 2000, AM J PHYSIOL-HEART C, V278, pH1049, DOI 10.1152/ajpheart.2000.278.4.H1049; Onishi I, 1999, TRANSPLANT P, V31, P1077, DOI 10.1016/S0041-1345(98)01912-5; Pabla R, 1996, CIRC RES, V78, P65, DOI 10.1161/01.RES.78.1.65; PATEL VC, 1993, BIOCHEM BIOPH RES CO, V194, P234, DOI 10.1006/bbrc.1993.1809; ROEBUCK KA, 1995, J BIOL CHEM, V270, P18966, DOI 10.1074/jbc.270.32.18966; Shimizu N, 1998, CARDIOVASC RES, V38, P116, DOI 10.1016/S0008-6363(97)00327-1; Song JS, 1999, J IMMUNOL, V163, P802; Szabo C, 1996, BRIT J PHARMACOL, V118, P1659, DOI 10.1111/j.1476-5381.1996.tb15589.x; Takano H, 1998, CIRCULATION, V98, P441, DOI 10.1161/01.CIR.98.5.441; Vadlamani L, 2000, Curr Cardiol Rep, V2, P120, DOI 10.1007/s11886-000-0008-3; Valen G, 2000, CARDIOVASC RES, V47, P49, DOI 10.1016/S0008-6363(00)00071-7; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Wildhirt SM, 1999, CARDIOVASC RES, V43, P698, DOI 10.1016/S0008-6363(99)00080-2; WOOLFSON RG, 1995, CIRCULATION, V91, P1545, DOI 10.1161/01.CIR.91.5.1545; Xi L, 1999, CIRCULATION, V99, P2157, DOI 10.1161/01.CIR.99.16.2157; Yang ZQ, 2000, CIRCULATION, V101, P1019, DOI 10.1161/01.CIR.101.9.1019; Zingarelli B, 1997, CARDIOVASC RES, V36, P205, DOI 10.1016/S0008-6363(97)00137-5; Zingarelli B, 1996, J IMMUNOL, V156, P350; Zingarelli B, 2001, GUT, V48, P610, DOI 10.1136/gut.48.5.610; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85; ZINGARELLI B, 2001, IN PRESS SHOCK; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	62	106	112	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0327	10.1096/fj.01-0533com	http://dx.doi.org/10.1096/fj.01-0533com			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874982				2022-12-28	WOS:000174755900025
J	Cipolla, MJ; Gokina, NI; Osol, G				Cipolla, MJ; Gokina, NI; Osol, G			Pressure-induced actin polymerization in vascular smooth muscle as a mechanism underlying myogenic behavior	FASEB JOURNAL			English	Article						myogenic reactivity; mechanotransduction; cytoskeletal rearrangement	FOCAL ADHESIONS; CONTRACTION; CELLS	We hypothesize that actin polymerization within vascular smooth muscle (VSM) in response to increased intravascular pressure is a novel and previously unrecognized mechanism underlying arterial myogenic behavior. This hypothesis is based on the following observations. 1) Unlike skeletal or cardiac muscle, VSM contains a substantial pool of unpolymerized globular (G) actin whose function is not known. 2) The cytosolic concentration of G-actin is significantly reduced by an elevation in intravascular pressure, demonstrating the dynamic nature of actin within VSM and implying a shift in the F: G equilibrium in favor of F-actin. 3) Agents that inhibit actin polymerization and stabilize the cytoskeleton (cytochalasins and latrunculin) inhibit the development of myogenic tone and decrease the effectiveness of myogenic reactivity. 4) Depolymerization of F-actin with cytochalasin D causes VSM relaxation and increased G-actin content, whereas polymerization of F-actin with jasplakinolide causes VSM contraction and decreased G-actin content. These results are consistent with observations in other cell types in which actin dynamics have been implicated in contractility and/or motility. Actin filament formation in VSM may therefore underlie mechanotransduction and, by providing additional sites for interaction with myosin, enhance force production in response to pressure. Although the mechanism by which actin polymerization is stimulated by pressure is not known, it likely occurs via integrin-mediated activation of signal transduction pathways previously associated with VSM contraction (e. g., PKC activation, Rho A, and tyrosine phosphorylation).	Univ Vermont, Coll Med, Dept Obstet Gynecol, Burlington, VT 05405 USA	University of Vermont	Cipolla, MJ (corresponding author), Univ Vermont, Coll Med, Dept Obstet Gynecol, Given C454, Burlington, VT 05405 USA.	mcipolla@zoo.uvm.edu	Cipolla, Marilyn J./B-7098-2009		PHS HHS [R0I 59406] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CAMBELL GR, 1987, VASCULAR SMOOTH MUSC, P39; CHRANOWSKAWODNI.M, 1996, J CELL BIOL, V133, P1403; Cipolla MJ, 1998, STROKE, V29, P1223, DOI 10.1161/01.STR.29.6.1223; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; HAEBERLE JR, 1994, CAN J PHYSIOL PHARM, V72, P1400, DOI 10.1139/y94-202; JAMNEY PA, 1994, ANNU REV PHYSIOL, V56, P169; JOHANSSON B, 1989, J HYPERTENS, V7, pS5; KNOWLES GC, 1992, J HISTOCHEM CYTOCHEM, V40, P1605, DOI 10.1177/40.10.1527379; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; Ku D. N., 1993, HEMODYNAMIC FORCES V, P1; LOW RB, 1984, AM REV RESPIR DIS, V129, P311; MAUSS S, 1989, N-S ARCH PHARMACOL, V340, P345; Mehta D, 1999, J PHYSIOL-LONDON, V519, P829, DOI 10.1111/j.1469-7793.1999.0829n.x; MELLANDER S, 1989, J HYPERTENS, V7, pS21; OBARA K, 1994, EUR J PHARMACOL, V255, P139, DOI 10.1016/0014-2999(94)90092-2; OSOL G, 1995, J VASC RES, V32, P275, DOI 10.1159/000159102; OSOL G, 1991, CIRC RES, V68, P359, DOI 10.1161/01.RES.68.2.359; PENDER N, 1991, J CELL SCI, V100, P187; PETROLL WM, 1993, J CELL SCI, V104, P353; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Schmidt C, 1998, J BIOL CHEM, V273, P5081, DOI 10.1074/jbc.273.9.5081; SEIDEL CL, 1981, PHYSIOLOGIST, V4, P120; SINGER HA, 1996, BIOCH SMOOTH MUSCLE, P143; Smith PG, 2000, J APPL PHYSIOL, V89, P2092, DOI 10.1152/jappl.2000.89.5.2092	26	182	182	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					72	76		10.1096/cj.01-0104hyp	http://dx.doi.org/10.1096/cj.01-0104hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11772938				2022-12-28	WOS:000173656600009
J	Gazit, E				Gazit, E			A possible role for pi-stacking in the self-assembly of amyloid fibrils	FASEB JOURNAL			English	Article						Alzheimer's disease; aromatic residue; amyloid related proteins	POLYPEPTIDE IAPP; ABNORMAL PROPERTIES; PRION PROTEIN; IN-VITRO; BETA; PEPTIDES; DISEASE; 4'-IODO-4'-DEOXYDOXORUBICIN; POLYMERIZATION; PENTAPEPTIDE	Amyloid fibril formation is assumed to be the molecular basis for a variety of diseases of unrelated origin. Despite its fundamental clinical importance, the mechanism of amyloid formation is not fully understood. When we analyzed a variety of short functional fragments from unrelated amyloid-forming proteins, a remarkable occurrence of aromatic residues was observed. The finding of aromatic residues in diverse fragments raises the possibility that pi-pi interactions may play a significant role in the molecular recognition and self-assembly processes that lead to amyloid formation. This is in line with the well-known central role of pi-stacking interactions in self-assembly processes in the fields of chemistry and biochemistry. We speculate that the stacking interactions may provide energetic contribution as well as order and directionality in the self-assembly of amyloid structures. Experimental data regarding amyloid formation and inhibition by short peptide analogs also support our hypothesis. The pi-stacking hypothesis suggests a new approach to understanding the self-assembly mechanism that governs amyloid formation and indicates possible ways to control this process.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Gazit, E (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel.	ehudg@post.tau.ac.il	Gazit, Ehud/C-3715-2011; Gazit, Ehud/M-8026-2019; Gazit, Ehud/AHE-9332-2022	Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720; 				ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; Azriel R, 2001, J BIOL CHEM, V276, P34156, DOI 10.1074/jbc.M102883200; Balbach JJ, 2000, BIOCHEMISTRY-US, V39, P13748, DOI 10.1021/bi0011330; Balbirnie M, 2001, P NATL ACAD SCI USA, V98, P2375, DOI 10.1073/pnas.041617698; BENVENGA S, 1994, J ENDOCRINOL INVEST, V17, P119, DOI 10.1007/BF03347697; BERGER G, 1988, VIRCHOWS ARCH A, V412, P543, DOI 10.1007/BF00844290; Claessens CG, 1997, J PHYS ORG CHEM, V10, P254, DOI 10.1002/(SICI)1099-1395(199705)10:5<254::AID-POC875>3.0.CO;2-3; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Findeis MA, 1999, BIOCHEMISTRY-US, V38, P6791, DOI 10.1021/bi982824n; GAZIT E, 2001, IN PRESS ANGEW CHEM; Gillard RE, 1997, CHEM-EUR J, V3, P1933, DOI 10.1002/chem.19970031208; Haggqvist B, 1999, P NATL ACAD SCI USA, V96, P8669, DOI 10.1073/pnas.96.15.8669; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Higham CE, 2000, FEBS LETT, V470, P55, DOI 10.1016/S0014-5793(00)01287-4; HUNTER CA, 1993, ANGEW CHEM INT EDIT, V32, P1584, DOI 10.1002/anie.199315841; Jaikaran ETAS, 2001, J MOL BIOL, V308, P515, DOI 10.1006/jmbi.2001.4593; Kahn SE, 1999, DIABETES, V48, P241, DOI 10.2337/diabetes.48.2.241; Kayed R, 1999, J MOL BIOL, V287, P781, DOI 10.1006/jmbi.1999.2646; KEIZMAN IK, 1976, ISRAEL J MED SCI, V12, P1137; Kuner P, 2000, J BIOL CHEM, V275, P1673, DOI 10.1074/jbc.275.3.1673; Li LM, 2000, SCIENCE, V287, P661, DOI 10.1126/science.287.5453.661; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MAURY CPJ, 1992, BIOCHEM BIOPH RES CO, V183, P227, DOI 10.1016/0006-291X(92)91632-Z; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; MERLINI G, 1995, P NATL ACAD SCI USA, V92, P2959, DOI 10.1073/pnas.92.7.2959; Merlini G, 1999, BLOOD, V93, P1112, DOI 10.1182/blood.V93.3.1112; MUCCHIANO G, 1992, AM J PATHOL, V140, P871; Nilsson MR, 1999, J MOL BIOL, V294, P1375, DOI 10.1006/jmbi.1999.3286; Palha JA, 2000, AM J PATHOL, V156, P1919, DOI 10.1016/S0002-9440(10)65065-1; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Priola SA, 1998, J BIOL CHEM, V273, P11980, DOI 10.1074/jbc.273.19.11980; PRUSINER SB, 1995, AMYLOID, V2, P39, DOI 10.3109/13506129509031887; Shetty AS, 1996, J AM CHEM SOC, V118, P1019, DOI 10.1021/ja9528893; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Sun S, 1996, J PHYS CHEM-US, V100, P13348, DOI 10.1021/jp960739o; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Tagliavini F, 2000, J MOL BIOL, V300, P1309, DOI 10.1006/jmbi.2000.3840; Taubes G, 1996, SCIENCE, V271, P1493, DOI 10.1126/science.271.5255.1493; Tenidis K, 2000, J MOL BIOL, V295, P1055, DOI 10.1006/jmbi.1999.3422; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tuite MF, 2000, CELL, V100, P289, DOI 10.1016/S0092-8674(00)80663-7; Twyman LJ, 1999, TETRAHEDRON LETT, V40, P9383, DOI 10.1016/S0040-4039(99)02030-4; Vidal R, 1999, NATURE, V399, P776; WESTERMARK GT, 1992, BIOCHEM BIOPH RES CO, V182, P27, DOI 10.1016/S0006-291X(05)80107-X; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036	47	898	923	5	163	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					77	83		10.1096/fj.01-0442hyp	http://dx.doi.org/10.1096/fj.01-0442hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11772939				2022-12-28	WOS:000173656600010
J	Scheid, A; Wenger, RH; Schaffer, L; Camenisch, I; Distler, O; Ferenc, A; Cristina, H; Ryan, HE; Johnson, RS; Wagner, KF; Stauffer, UG; Bauer, C; Gassmann, M; Meuli, M				Scheid, A; Wenger, RH; Schaffer, L; Camenisch, I; Distler, O; Ferenc, A; Cristina, H; Ryan, HE; Johnson, RS; Wagner, KF; Stauffer, UG; Bauer, C; Gassmann, M; Meuli, M			Physiologically low oxygen concentrations determined in fetal skin regulate hypoxia-inducible factor 1 and transforming growth factor beta 3	FASEB JOURNAL			English	Article						fetal wound healing; migration; scar formation; hypoxia; cytokine expression	FACTOR 1-ALPHA; FACTOR-I; DEGRADATION DOMAIN; O-2 HOMEOSTASIS; GENE-EXPRESSION; OWN EXPRESSION; SCAR FORMATION; WOUNDS; ALPHA; CELL	In the first-trimester mammalian fetus, skin wounds heal with perfect reconstitution of the dermal architecture without scar formation. Understanding environmental molecular regulation in fetal wound healing may reveal scar-limiting therapeutical strategies for the prevention of postnatal scarring wound repair. Therefore, we performed studies on fetal skin oxygenation and skin and wound expression of hypoxia-inducible factor 1alpha (HIF-1alpha) in the sheep model in vivo and performed studies on the potential relevance of HIF-1alpha during wound healing in vitro. Skin oxygen partial pressure levels were hypoxic throughout normal development. In nonscarring fetal skin at gestation day (GD)60, HIF-1alpha could be detected neither in healthy nor in wounded tissue. At GD100, in wounds with minimal scar formation, HIF-1alpha was expressed in fibroblasts and was markedly up-regulated at the wound edge. In scarring fetal wounds at GD120, HIF-1alpha was predominantly expressed in inflammatory cells. Expression of transforming growth factor beta3 (TGF-beta3), a potent antiscarring cytokine, overlapped with HIF-1alpha expression at GD100. HIF-1alpha-deficient mouse embryonic fibroblasts showed impaired migratory capabilities and demonstrated that TGF-beta3, but not proscarring TGF-beta1, manifests hypoxia- and HIF-1alpha-dependent regulation. In conclusion, HIF-1-dependent regulation of a potent antiscarring cytokine may provide new strategies for antiscarring manipulation of wound healing.	Univ Childrens Hosp, Dept Surg, CH-8032 Zurich, Switzerland; Univ Zurich Irchel, Inst Physiol, CH-8057 Zurich, Switzerland; Med Univ Lubeck, Dept Anesthesiol, D-23538 Lubeck, Germany; Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany; Univ Zurich Hosp, Dept Obstet & Gynecol, CH-8096 Zurich, Switzerland; Univ Zurich Hosp, Ctr Expt Rheumatol, CH-8096 Zurich, Switzerland; Univ Zurich Hosp, Inst Lab Anim Sci, CH-8096 Zurich, Switzerland; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University Children's Hospital Zurich; University of Zurich; University of Lubeck; University of Lubeck; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of California System; University of California San Diego	Scheid, A (corresponding author), Univ Childrens Hosp, Dept Surg, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	ascheid@physiol.unizh.ch; mmeuli@kispi.unizh.ch	Wenger, Roland H./B-7953-2009; Johnson, Randall/AAM-1189-2021; Distler, Oliver/AAE-6225-2019	Wenger, Roland H./0000-0001-7592-4839; Johnson, Randall/0000-0002-4084-6639; Distler, Oliver/0000-0002-0546-8310; Gassmann, Max/0000-0003-2750-8878				Adam MF, 1999, INT J RADIAT ONCOL, V45, P171, DOI 10.1016/S0360-3016(99)00157-1; ADZICK NS, 1991, J SURG RES, V51, P216, DOI 10.1016/0022-4804(91)90097-6; Adzick NS, 2000, NEW ENGL J MED, V342, P1726, DOI 10.1056/NEJM200006083422307; Bichet S, 1999, FASEB J, V13, P285, DOI 10.1096/fasebj.13.2.285; Brockes JP, 1997, SCIENCE, V276, P81, DOI 10.1126/science.276.5309.81; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; BURRINGTON JD, 1971, J PEDIATR SURG, V6, P523, DOI 10.1016/0022-3468(71)90373-3; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Caniggia I, 2000, J CLIN INVEST, V105, P577, DOI 10.1172/JCI8316; Chen EY, 1999, TERATOLOGY, V60, P215; CHEN WYJ, 1989, J CELL SCI, V94, P577; Elson DA, 2000, CANCER RES, V60, P6189; Feldser D, 1999, CANCER RES, V59, P3915; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; Grimshaw MJ, 2001, EUR J IMMUNOL, V31, P480, DOI 10.1002/1521-4141(200102)31:2<480::AID-IMMU480>3.0.CO;2-L; Harlow E., 1999, USING ANTIBODIES LAB; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; LIN RY, 1995, ANN SURG, V222, P146, DOI 10.1097/00000658-199508000-00006; LONGAKER MT, 1990, J PEDIATR SURG, V25, P63, DOI 10.1016/S0022-3468(05)80165-4; LONGAKER MT, 1991, PLAST RECONSTR SURG, V87, P788, DOI 10.1097/00006534-199104000-00032; LORENZ HP, 1995, PLAST RECONSTR SURG, V96, P1251, DOI 10.1097/00006534-199511000-00001; MARTIN P, 1993, DEV GENET, V14, P225, DOI 10.1002/dvg.1020140309; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MEULI M, 1995, NAT MED, V1, P342, DOI 10.1038/nm0495-342; NATH RK, 1994, J PEDIATR SURG, V29, P855, DOI 10.1016/0022-3468(94)90002-7; NICOLAIDES KH, 1989, AM J OBSTET GYNECOL, V161, P996, DOI 10.1016/0002-9378(89)90770-9; Pugh CW, 1997, J BIOL CHEM, V272, P11205; RUDOLPH AM, 1970, CIRC RES, V26, P289, DOI 10.1161/01.RES.26.3.289; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; SCHOR SL, 1985, J CELL SCI, V73, P221; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SHAH M, 1995, J CELL SCI, V108, P985; SHEFFIELD P, 1988, TISSUE OXYGEN MEASUR; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Stelnicki E J, 1999, Semin Pediatr Surg, V8, P124; Turner L, 1999, EUR J IMMUNOL, V29, P2280, DOI 10.1002/(SICI)1521-4141(199907)29:07<2280::AID-IMMU2280>3.0.CO;2-C; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2000, J EXP BIOL, V203, P1253; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845; Wenger RH, 1996, BLOOD, V87, P756, DOI 10.1182/blood.V87.2.756.bloodjournal872756; West DC, 1997, INT J BIOCHEM CELL B, V29, P201, DOI 10.1016/S1357-2725(96)00133-1; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1; Xiong M, 1998, AM J PATHOL, V153, P587, DOI 10.1016/S0002-9440(10)65601-5	58	53	58	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					411	+		10.1096/fj.01-0496fje	http://dx.doi.org/10.1096/fj.01-0496fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11790723				2022-12-28	WOS:000173656600018
J	Goto, S; Ihara, Y; Urata, Y; Izumi, S; Abe, K; Koji, T; Kondo, T				Goto, S; Ihara, Y; Urata, Y; Izumi, S; Abe, K; Koji, T; Kondo, T			Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi	FASEB JOURNAL			English	Article						Glutathione S-transferase pi; doxorubicin; cisplatin; nuclear transfer; DNA damage	BREAST-CANCER-CELLS; RESISTANCE-ASSOCIATED PROTEIN; WHEAT-GERM AGGLUTININ; ATP-DEPENDENT EFFLUX; DRUG-RESISTANCE; PEROXIDASE-ACTIVITY; CONFERS RESISTANCE; ANTITUMOR DRUGS; LEUKOTRIENE C-4; EXPRESSION	Glutathione S-transferase (GST) functions in xenobiotic biotransformation and drug metabolism. Increased expression of GST pi, an isozyme of GST, has been found in cancer cells resistant to doxorubicin hydrochloride (DOX) or cis-diamminedichloroplatinum (II) (CDDP), and this increase was believed to be correlated with drug resistance of cancer cells. GST is mainly expressed in the cytoplasm; GST pi in the nucleus has been reported in cancer cells, but the meaning of this result is not known. Here, we studied changes in the amount of nuclear GST pi after exposure of cancer cells to anticancer drugs, and role of the nuclear GST pi in drug resistance. We found nuclear GST pi in cancer cells resistant to DOX, and the amount of nuclear GST pi was enhanced by treatment of the cancer cells with DOX or CDDP. We also found that a mushroom lectin, an inhibitor of nuclear transport, inhibited the nuclear transfer of GST pi, suggesting the existence of a specific transport system for the nuclear transfer of GST pi. Nuclear GST pi protected DNA against damage by anticancer drugs. These results suggest a possible role of GST pi in the acquisition of resistance to anticancer drugs by cancer cells.	Nagasaki Univ, Sch Med, Dept Biochem & Mol Biol Dis, Atom Bomb Dis Inst, Nagasaki 8528523, Japan; Nagasaki Univ, Sch Med, Dept Histol & Cell Biol, Nagasaki 8528523, Japan	Nagasaki University; Nagasaki University	Kondo, T (corresponding author), Nagasaki Univ, Sch Med, Dept Biochem & Mol Biol Dis, Atom Bomb Dis Inst, Nagasaki 8528523, Japan.	kondo@net.nagasaki-u.ac.jp						Ali-Osman F, 1997, CLIN CANCER RES, V3, P2253; Awasthi S, 1996, INT J CANCER, V68, P333; Bai F, 1996, CANCER, V78, P416; BATIST G, 1986, J BIOL CHEM, V261, P5544; Beutler E, 1984, RED CELL METABOLISM, P77; BLACK SM, 1990, BIOCHEM J, V268, P309, DOI 10.1042/bj2680309; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; Chen ZS, 1999, MOL PHARMACOL, V55, P921; CHU G, 1994, J BIOL CHEM, V269, P787; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GOTO S, 1995, CANCER RES, V55, P4297; Goto S, 1999, FREE RADICAL RES, V31, P549, DOI 10.1080/10715769900301121; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; HAMILTON TC, 1985, BIOCHEM PHARMACOL, V34, P2583, DOI 10.1016/0006-2952(85)90551-9; He Q, 2000, P NATL ACAD SCI USA, V97, P5768, DOI 10.1073/pnas.100108697; HIRATA S, 1992, CANCER, V70, P2381, DOI 10.1002/1097-0142(19921115)70:10<2381::AID-CNCR2820701002>3.0.CO;2-9; HOWIE AF, 1990, CARCINOGENESIS, V11, P451, DOI 10.1093/carcin/11.3.451; ISHIHARA T, 1994, J LUMIN, V60-1, P269, DOI 10.1016/0022-2313(94)90145-7; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; KANO T, 1987, CANCER RES, V47, P5626; Karni O, 1998, FEBS LETT, V429, P421, DOI 10.1016/S0014-5793(98)00645-0; Kawabe T, 1999, FEBS LETT, V456, P327, DOI 10.1016/S0014-5793(99)00979-5; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; MAEDA O, 1993, CANCER RES, V53, P2051; MANNERVIK B, 1987, CARCINOGENESIS, V8, P1929, DOI 10.1093/carcin/8.12.1929; MEIJER C, 1990, BRIT J CANCER, V62, P72, DOI 10.1038/bjc.1990.232; MEYER DJ, 1985, FEBS LETT, V184, P139, DOI 10.1016/0014-5793(85)80670-0; MIYAZAKI M, 1990, BIOCHEM BIOPH RES CO, V166, P1358, DOI 10.1016/0006-291X(90)91016-L; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; NAKAGAWA K, 1990, J BIOL CHEM, V265, P4296; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Priebe W, 1998, BIOCHEM BIOPH RES CO, V247, P859, DOI 10.1006/bbrc.1998.8887; PROHASKA JR, 1977, BIOCHEM BIOPH RES CO, V76, P437, DOI 10.1016/0006-291X(77)90744-6; PRUSCHY M, 1994, J CELL BIOL, V127, P1527, DOI 10.1083/jcb.127.6.1527; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; SABURI Y, 1989, CANCER RES, V49, P7020; SATOH K, 1985, P NATL ACAD SCI USA, V82, P3964, DOI 10.1073/pnas.82.12.3964; Serafino A, 1998, ANTICANCER RES, V18, P1159; SHIRATORI Y, 1987, CANCER RES, V47, P6806; SINHA BK, 1990, FREE RADICAL BIO MED, V8, P567, DOI 10.1016/0891-5849(90)90155-C; TAN KH, 1986, FEBS LETT, V207, P231, DOI 10.1016/0014-5793(86)81494-6; TOWNSEND AJ, 1992, MOL PHARMACOL, V41, P230; UJIHARA M, 1988, ARCH BIOCHEM BIOPHYS, V264, P428, DOI 10.1016/0003-9861(88)90308-6; Urata Y, 1996, J BIOL CHEM, V271, P15146, DOI 10.1074/jbc.271.25.15146; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; WANG YY, 1989, CANCER RES, V49, P6185; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; Yu LG, 1999, J BIOL CHEM, V274, P4890, DOI 10.1074/jbc.274.8.4890; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690	57	95	101	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					2702	2714		10.1096/fj.01-0376com	http://dx.doi.org/10.1096/fj.01-0376com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726546				2022-12-28	WOS:000172964800040
J	Madani, S; Hichami, A; Legrand, A; Belleville, J; Khan, NA				Madani, S; Hichami, A; Legrand, A; Belleville, J; Khan, NA			Implication of acyl chain of diacylglycerols in activation of different isoforms of protein kinase C	FASEB JOURNAL			English	Article						DAG; omega-3/omega-6 fatty acids; PKC isoenzymes	FATTY-ACID COMPOSITION; FISH OIL SUPPLEMENTATION; EICOSAPENTAENOIC ACID; PHORBOL ESTERS; EPITHELIAL-CELLS; PHOSPHOLIPASE-D; RAT-BRAIN; IN-VITRO; N-3; PHOSPHATIDYLSERINE	We synthesized diacylglycerols (DAGs) containing omega -6 or omega -3 polyunsaturated fatty acids [i.e., 1-stearoyl-2-arachidonoyl-sn-glycerol (SAG), 1-stearoyl-2-docosahexaenoyl-sn-glycerol (SDG), and 1-stearoyl-2-eicosapentaenoyl-sn-glycerol (SEG)] and assessed their efficiency on activation of conventional (alpha, betaI, gamma) and novel (epsilon, delta) protein kinase C (PKC). SAG exerted significantly higher stimulatory effects than SDG and SEG on activation of PKC alpha and PKC delta. Activation of PKC betaI by SEG and SDG was higher than that by SAG. Activation of PKC gamma did not differ significantly among DAG molecular species. Addition of SAG to assays containing SEG and SDG exerted additive effects on activation of alpha and epsilon, but not on betaI and gamma, isoforms of PKC. SDG- and SEG-induced activation of PKC delta was significantly curtailed by the addition of SAG. Three DAG species significantly curtailed the PMA-induced activation of betaI, gamma, and delta, but not of alpha and epsilon, isoforms of PKC. Our study demonstrates for the first time that in vitro activation of different PKC isoenzymes vary in response to different DAG species, and one can envisage that this differential regulation may be responsible for their in vivo effects on target organs.	Univ Bourgogne, Fac Sci, UPRES Lipides & Nutr, EA 2422, F-21000 Dijon, France; Univ Rennes 1, Fac Pharm, Mol Pharmacol Lab, F-35014 Rennes, France	Universite de Bourgogne; Universite de Rennes	Khan, NA (corresponding author), Univ Bourgogne, Fac Sci, UPRES Lipides & Nutr, EA 2422, F-21000 Dijon, France.	naim.khan@u-bourgogne.fr		hichami, aziz/0000-0003-4331-5152				Alpert SE, 1999, AM J PHYSIOL-LUNG C, V277, pL457, DOI 10.1152/ajplung.1999.277.3.L457; BELL MV, 1987, COMP BIOCHEM PHYS B, V86, P227, DOI 10.1016/0305-0491(87)90282-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bordoni A, 1992, Cardiologia, V37, P631; GALLOWAY JH, 1985, CLIN SCI, V68, P449, DOI 10.1042/cs0680449; GOLDBERG EM, 1995, BIOPHYS J, V69, P965, DOI 10.1016/S0006-3495(95)79970-2; GOLDBERG EM, 1994, BIOPHYS J, V66, P382, DOI 10.1016/S0006-3495(94)80788-X; Harbige LS, 1998, P NUTR SOC, V57, P555, DOI 10.1079/PNS19980081; HARDY SJ, 1994, J NEUROCHEM, V62, P1546; HOLIAN O, 1992, ANTICANCER RES, V12, P975; Huang MC, 1996, J NUTR, V126, P2199, DOI 10.1093/jn/126.9.2199; KHAN NA, 1990, BIOCHEM PHARMACOL, V40, pR1, DOI 10.1016/0006-2952(90)90340-Q; KHAN NA, 1991, EXP CELL RES, V194, P248, DOI 10.1016/0014-4827(91)90361-W; Khan NA, 1999, BIOCHEM J, V344, P199, DOI 10.1042/0264-6021:3440199; KHAN NA, 2001, IN PRESS RECENT ADV; Kuroki T, 1998, BIOCHEM BIOPH RES CO, V247, P473, DOI 10.1006/bbrc.1998.8814; LEGRAND AB, 1991, J BIOL CHEM, V266, P7570; Mantzioris E, 2000, AM J CLIN NUTR, V72, P42; Marignani PA, 1996, J NUTR, V126, P2738; Marignani PA, 1996, BIOCHEM BIOPH RES CO, V225, P469, DOI 10.1006/bbrc.1996.1196; McMurray DN, 2000, J INFECT DIS, V182, pS103, DOI 10.1086/315909; MORI TA, 1987, LIPIDS, V22, P744, DOI 10.1007/BF02533975; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; PHILBRICK DJ, 1987, J NUTR, V117, P1663, DOI 10.1093/jn/117.10.1663; RANDO RR, 1984, BIOCHEM BIOPH RES CO, V122, P818, DOI 10.1016/S0006-291X(84)80107-2; Rise P, 1999, PROSTAG LEUKOTR ESS, V60, P367, DOI 10.1016/S0952-3278(99)80014-3; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; Sebaldt RJ, 1997, ADV EXP MED BIOL, V400, P937; SEBALDT RJ, 1992, BIOCHEM J, V284, P367, DOI 10.1042/bj2840367; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; Slater SJ, 1996, J BIOL CHEM, V271, P4627; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; TERANO T, 1996, LIPIDS, V31, P301; Vernhet L, 1996, J LIPID MEDIAT CELL, V13, P233, DOI 10.1016/0929-7855(95)00050-X; VONSCHACKY C, 1985, J LIPID RES, V26, P457; Ziboh VA, 2000, AM J CLIN NUTR, V71, p361S, DOI 10.1093/ajcn/71.1.361s	39	82	83	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					2595	2601		10.1096/fj.01-0753int	http://dx.doi.org/10.1096/fj.01-0753int			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726535				2022-12-28	WOS:000172964800029
J	Henaff, M; Antoine, S; Mercadier, JJ; Coulombe, A; Hatem, SN				Henaff, M; Antoine, S; Mercadier, JJ; Coulombe, A; Hatem, SN			The voltage-independent B-type Ca2+ channel modulates the apoptosis of cardiac myocytes	FASEB JOURNAL			English	Article						myocyte apoptosis; calcium channels; mitochondria	RAT VENTRICULAR MYOCYTES; MITOCHONDRIAL PERMEABILITY TRANSITION; CELL-DEATH; T-LYMPHOCYTES; CALCIUM; CERAMIDE; ACTIVATION; MEMBRANE; RELEASE; DEPOLARIZATION	In cardiac myocytes, Ca2+ is the second messenger of various physiological processes, including the excitation-contraction coupling phenomenon. Here, we examined how Ca2+ regulates cardiac myocyte apoptosis. Using an adult rat ventricular myocyte culture model, we found that ceramide (Cer) induces an apoptotic process that is highly sensitive to calcium: it is inhibited by the Ca2+ buffer BAPTA-AM and is potentiated by the Ca2+ ionophore ionomycin. Cer-treated myocytes maintained their Ca2+ homeostasis and normal activity of their voltage-dependent sarcolemmal Ca2+ entry pathways but showed enhanced activity of B-type Ca2+ channels that were stimulated by Cer in the inside-out patch clamp configuration. Pharmacological modulations of B-type Ca2+ channels modulated Cer-induced apoptosis. Mitochondria were involved in Cer-induced apoptosis, as indicated by the inhibitory effect of cyclosporine A and caspase-9 inhibitor. Both the loss of mitochondrial membrane potential and the caspase-9 activation in Cer-treated myocytes were attenuated by blocking B-type Ca2+ channels. The mitochondrial Ca2+ content was evaluated as changes in [Ca2+](i) after a short application of a mitochondrial uncoupler, FCCP, was increased in Cer-treated cells. Together, these results show that Ca2+ modulates Cer-induced cardiac myocyte apoptosis through the coupling of B-type Ca2+ channels with mitochondria.	Univ Paris 07, INSERM, U460, F-75018 Paris, France; Hop Marie Lannelongue, CNRS, ESA 8078, F-92350 Le Plessis Robinson, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Hopital Marie Lannelongue	Hatem, SN (corresponding author), Univ Paris 07, INSERM, U460, 16 Rue Henri Huchard, F-75018 Paris, France.	hatem@bichat.inserm.fr	Hatem, Stephane/D-1016-2017	hatem, stephane/0000-0002-9790-0755				Aime-Sempe C, 1999, J AM COLL CARDIOL, V34, P1577, DOI 10.1016/S0735-1097(99)00382-4; Andrieu-Abadie N, 1999, FASEB J, V13, P1501, DOI 10.1096/fasebj.13.12.1501; Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; Antoine S, 1998, J MOL CELL CARDIOL, V30, P2623, DOI 10.1006/jmcc.1998.0818; Antoine S, 2001, J MEMBRANE BIOL, V179, P37, DOI 10.1007/s002320010035; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Bielawska AE, 1997, AM J PATHOL, V151, P1257; Chossat N, 2001, CARDIOVASC RES, V49, P288, DOI 10.1016/S0008-6363(00)00234-0; COULOMBE A, 1989, J MEMBRANE BIOL, V111, P57, DOI 10.1007/BF01869209; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Delpy E, 1999, CARDIOVASC RES, V43, P398, DOI 10.1016/S0008-6363(99)00142-X; Duchen MR, 1998, J CELL BIOL, V142, P975, DOI 10.1083/jcb.142.4.975; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; Gutierrez AA, 1999, J PHYSIOL-LONDON, V517, P95, DOI 10.1111/j.1469-7793.1999.0095z.x; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; Hernandez OM, 2000, CIRC RES, V86, P198, DOI 10.1161/01.RES.86.2.198; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; Hoyt KR, 1997, BRIT J PHARMACOL, V122, P803, DOI 10.1038/sj.bjp.0701442; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; LEFEVRE T, 1995, J MEMBRANE BIOL, V147, P147; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; Manion MK, 2000, FASEB J, V14, P1297, DOI 10.1096/fj.14.10.1297; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; Olivetti G, 1996, J MOL CELL CARDIOL, V28, P2005, DOI 10.1006/jmcc.1996.0193; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Richter C, 1999, BIOCHEM SOC SYMP, V66, P27, DOI 10.1042/bss0660027; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Schinder AF, 1996, J NEUROSCI, V16, P6125; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Teiger E, 1996, J CLIN INVEST, V97, P2891, DOI 10.1172/JCI118747; WANG SY, 1995, J MOL CELL CARDIOL, V27, P211, DOI 10.1016/S0022-2828(08)80020-X; White RJ, 1996, J NEUROSCI, V16, P5688; Zhu LP, 2000, CELL CALCIUM, V28, P107, DOI 10.1054/ceca.2000.0138; Zhu LP, 1999, J BIOL CHEM, V274, P33267, DOI 10.1074/jbc.274.47.33267	43	18	18	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					99	+		10.1096/fj.01-0389fje	http://dx.doi.org/10.1096/fj.01-0389fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11772941				2022-12-28	WOS:000172420500030
J	Botchkarev, VA; Botchkareva, NV; Nakamura, M; Huber, O; Funa, K; Lauster, R; Paus, R; Gilchrest, BA				Botchkarev, VA; Botchkareva, NV; Nakamura, M; Huber, O; Funa, K; Lauster, R; Paus, R; Gilchrest, BA			Noggin is required for induction of the hair follicle growth phase in postnatal skin	FASEB JOURNAL			English	Article						hair cycle; bone morphogenetic protein; telogen; anagen; sonic hedgehog	BASAL-CELL CARCINOMAS; NEUROTROPHIC FACTOR; SIGNALING PATHWAYS; SONIC-HEDGEHOG; BETA-CATENIN; STEM-CELLS; ANAGEN; EXPRESSION; MORPHOGENESIS; INVOLVEMENT	During postnatal development, the hair follicle (HF) shows cyclic activity with periods of relative resting, active growth (anagen), and regression. We demonstrate that similar to the HF induction in embryonic skin, initiation of a new hair growth phase in postnatal skin requires neutralization of the inhibitory activity of bone morphogenetic protein 4 (BMP4) by the BMP antagonist noggin. In the resting HF, BMP4 mRNA predominates over noggin in the epithelium and mesenchyme, and the BMP receptor IA is prominently expressed in the follicular germ. Anagen development is accompanied by down-regulation of the BMP4 and increased noggin mRNA in the HF. Furthermore, administration of noggin protein induces new hair growth phase in postnatal telogen skin in vivo. In contrast, BMP4 induces selective arrest of anagen development in the non-tylotrich (secondary) HF. As a hair growth inducer, noggin increases Shh mRNA in the HF whereas BMP4 down-regulates Shh. This suggests that modulation of BMP4 signaling by noggin is essential for hair growth phase induction in postnatal skin and that the hair growth-inducing effect of noggin is mediated, at least in part, by Shh.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA; Univ Hamburg, Univ Hosp Eppendorf, Dept Dermatol, Hamburg, Germany; Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Clin Chem & Pathobiochem, D-1000 Berlin, Germany; Univ Gothenburg, Dept Anat & Cell Biol, Gothenburg, Sweden; Deutsch Rheumaforschungszentrum, Berlin, Germany	Boston University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Gothenburg; Deutsches Rheuma-Forschungszentrum (DRFZ)	Botchkarev, VA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA.	vladbotc@bu.edu	Huber, Otmar/AAA-4548-2021; Paus, Ralf/F-6243-2011	Huber, Otmar/0000-0003-4359-1747; Botchkarev, Vladimir/0000-0002-5212-5353	NIAMS NIH HHS [1RO3 AR47414-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR047414] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Botchkarev V. A., 2000, Journal of Investigative Dermatology, V114, P754; Botchkarev VA, 2000, CANCER RES, V60, P5002; Botchkarev VA, 2000, FASEB J, V14, P1931, DOI 10.1096/fj.99-0930com; Botchkarev VA, 1999, NAT CELL BIOL, V1, P158, DOI 10.1038/11078; Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Botchkarev VA, 1999, FASEB J, V13, P395, DOI 10.1096/fasebj.13.2.395; Botchkarev VA, 1999, LAB INVEST, V79, P557; Botchkareva NV, 2001, FASEB J, V15, P645, DOI 10.1096/fj.00-0368com; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; Chiang C, 1999, DEV BIOL, V205, P1, DOI 10.1006/dbio.1998.9103; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Cotsarelis G, 1999, EXP DERMATOL, V8, P80, DOI 10.1111/j.1600-0625.1999.tb00351.x; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; HANDJISKI BK, 1994, BRIT J DERMATOL, V131, P303, DOI 10.1111/j.1365-2133.1994.tb08515.x; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Jung HS, 1998, DEV BIOL, V196, P11, DOI 10.1006/dbio.1998.8850; Koch PJ, 1998, J CELL SCI, V111, P2529; Kulessa H, 2000, EMBO J, V19, P6664, DOI 10.1093/emboj/19.24.6664; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LAVKER RM, 1999, DERMATOLOGY GEN MED, P230; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Mecklenburg L, 2000, J INVEST DERMATOL, V114, P909, DOI 10.1046/j.1523-1747.2000.00954.x; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; NAGORCKA BN, 1985, J THEOR BIOL, V114, P243, DOI 10.1016/S0022-5193(85)80106-5; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; Nifuji A, 1999, J CELL BIOCHEM, V73, P437, DOI 10.1002/(SICI)1097-4644(19990615)73:4<437::AID-JCB2>3.3.CO;2-2; Noramly S, 1998, DEVELOPMENT, V125, P3775; Oh HS, 1996, P NATL ACAD SCI USA, V93, P12525, DOI 10.1073/pnas.93.22.12525; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; PAUS R, 1989, LAB INVEST, V60, P365; PAUS R, 1994, DEV BIOL, V163, P230, DOI 10.1006/dbio.1994.1139; PAUS R, 1994, LAB INVEST, V71, P134; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; Philpott M, 1998, MOL BASIS EPITHELIAL, P75; Price VH, 1999, NEW ENGL J MED, V341, P964, DOI 10.1056/NEJM199909233411307; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; Sano S, 2000, P NATL ACAD SCI USA, V97, P13824, DOI 10.1073/pnas.240303097; Sato N, 1999, J CLIN INVEST, V104, P855, DOI 10.1172/JCI7691; SLOMINSKI A, 1994, J INVEST DERMATOL, V102, P862, DOI 10.1111/1523-1747.ep12382606; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; SLOMINSKI A, 1991, J INVEST DERMATOL, V96, P172, DOI 10.1111/1523-1747.ep12460956; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Stenn K., 1998, MOL BASIS EPITHELIAL, P111; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Tobin DJ, 1999, J INVEST DERM SYMP P, V4, P323, DOI 10.1038/sj.jidsp.5640239; Tucker AS, 2000, DEVELOPMENT, V127, P4691; Vielkind U, 1996, ACTA ANAT, V157, P183; Wang LC, 2000, J INVEST DERMATOL, V114, P901, DOI 10.1046/j.1523-1747.2000.00951.x; WILSON C, 1994, DIFFERENTIATION, V55, P127, DOI 10.1046/j.1432-0436.1994.5520127.x; Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317; Zhang YD, 2000, DEVELOPMENT, V127, P1431; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	68	164	181	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2205	2214		10.1096/fj.01-0207com	http://dx.doi.org/10.1096/fj.01-0207com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641247				2022-12-28	WOS:000171920400032
J	Qiu, FH; Devchand, PR; Wada, K; Serhan, CN				Qiu, FH; Devchand, PR; Wada, K; Serhan, CN			Aspirin-triggered lipoxin A(4) and lipoxin A(4) up-regulate transcriptional corepressor NAB1 in human neutrophils	FASEB JOURNAL			English	Article						eicosanoids; LXA(4) receptor; glucocorticoids; leukocytes; anti-inflammation; differential display	STABLE ANALOGS; A EGR-1; RECRUITMENT; RESPONSES; RECEPTORS; GROWTH; DIFFERENTIATION; INFLAMMATION; SPECIFICITY; REPERFUSION	Aspirin-triggered 15-epi-lipoxin A(4) (ATL) is an endogenous lipid mediator that mimics the actions of native lipoxin A4, a putative "stop signal" involved in regulating resolution of inflammation. A metabolically more stable analog of ATL, 15-epi-16-(para-fluoro)-phenoxylipoxin A(4) analog (ATLa), inhibits neutrophil recruitment in vitro and in vivo and displays potent anti-inflammatory actions. ATLa binds with high affinity to the lipoxin A(4) receptor, a G protein-coupled receptor on the surface of leukocytes. In this study, we used freshly isolated human neutrophils to examine ATLa's potential for initiating rapid nuclear responses. Using differential display reverse transcription polymerase chain reaction, we identified a subset of genes that was selectively up-regulated upon short exposure of polymorphonuclear leukocytes to ATLa but not to the chemoattractant leukotriene B-4 or vehicle alone. We further investigated ATLa regulation of one of the genes, NAB1, a transcriptional corepressor identified previously as a glucocorticoid-responsive gene in hamster smooth muscle cells. Treatment of human neutrophils with pertussis toxin blocked ATLa up-regulation of NAB1. In addition, ATLa stimulated NAB1 gene expression in murine lung vascular smooth muscle in vivo. These findings provide evidence for rapid transcriptional induction of a cassette of genes via an ATLa-stimulated G protein-coupled receptor pathway that is potentially protective and overlaps with the anti-inflammatory glucocorticoid regulatory circuit.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Serhan, CN (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St,Thorn Bldg Med Res, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu						Bandeira-Melo C, 2000, J IMMUNOL, V164, P1029, DOI 10.4049/jimmunol.164.2.1029; BOUMPAS DT, 2001, ARTHRITIS ALLIED CON, P827; Chavis C, 1996, J EXP MED, V183, P1633, DOI 10.1084/jem.183.4.1633; Chertov O, 2000, IMMUNOL REV, V177, P68, DOI 10.1034/j.1600-065X.2000.17702.x; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Chiang N, 1999, J CLIN INVEST, V104, P309, DOI 10.1172/JCI7016; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Fan WM, 1997, MOL ENDOCRINOL, V11, P1342, DOI 10.1210/me.11.9.1342; Gewirtz AT, 1998, J CLIN INVEST, V101, P1860, DOI 10.1172/JCI1339; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Levy BD, 1999, FASEB J, V13, P903, DOI 10.1096/fasebj.13.8.903; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Madara J. L., 1999, Prostaglandins and Other Lipid Mediators, V59, P74, DOI 10.1016/S0090-6980(99)90309-X; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; McMahon B, 2001, TRENDS PHARMACOL SCI, V22, P391, DOI 10.1016/S0165-6147(00)01771-5; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Qiu FH, 2000, P NATL ACAD SCI USA, V97, P4267, DOI 10.1073/pnas.97.8.4267; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Scalia R, 1997, P NATL ACAD SCI USA, V94, P9967, DOI 10.1073/pnas.94.18.9967; Schaldach CM, 1999, BIOCHEMISTRY-US, V38, P7594, DOI 10.1021/bi982861e; Serhan CN, 2000, AM J RESP CRIT CARE, V161, pS95, DOI 10.1164/ajrccm.161.supplement_1.ltta-19; Sodin-Semrl S, 2000, J IMMUNOL, V164, P2660, DOI 10.4049/jimmunol.164.5.2660; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Titos E, 2000, GASTROENTEROLOGY, V119, P794, DOI 10.1053/gast.2000.17831; Vane J, 2000, THORAX, V55, pS3, DOI 10.1136/thorax.55.suppl_2.S3; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873; Yan SF, 2000, J CLIN INVEST, V105, P553, DOI 10.1172/JCI9513; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168	36	55	56	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2736	+		10.1096/fj.01-0576fje	http://dx.doi.org/10.1096/fj.01-0576fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11687510				2022-12-28	WOS:000171920400004
J	Ganglberger, E; Sponer, B; Scholl, I; Wiedermann, U; Baumann, S; Hafner, C; Breiteneder, H; Suter, M; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E				Ganglberger, E; Sponer, B; Scholl, I; Wiedermann, U; Baumann, S; Hafner, C; Breiteneder, H; Suter, M; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E			Monovalent fusion proteins of immunoglobulin E mimotopes are safe for therapy of type I allergy	FASEB JOURNAL			English	Article						Bet v 1; IgE epitope; ABP-fusion protein; blocking IgG	BIRCH POLLEN ALLERGEN; BET V 1; IGG MONOCLONAL-ANTIBODIES; PHAGE-DISPLAYED PEPTIDES; B-CELL EPITOPES; MOLECULAR CHARACTERIZATION; DISCONTINUOUS EPITOPES; IMMUNE-RESPONSE; BINDING; SELECTION	By screening phage display random peptide libraries with purified immunoglobulin E (IgE) from birch pollen-allergic patients, we previously defined peptides mimicking natural IgE epitopes (mimotopes) of the major birch pollen allergen Bet v 1. The present study aimed to define a monovalent carrier for the IgE mimotopes to induce protective antibodies directed to the IgE epitopes, suitable for mimotope-specific therapy. We expressed the selected mimotopes as fusion proteins together with streptococcal albumin binding protein (ABP). The fusion proteins were recognized specifically by anti-Bet v 1 human IgE, which demonstrated that the mimotopes fused to ABP resemble the natural IgE epitope. Bet v 1-specific IgG was induced by immunization of BALB/c mice with fusion proteins. These IgG antibodies could inhibit IgE binding to Bet v 1. Skin testing of Bet v 1 allergic mice showed that the ABP mimotope constructs did not elicit type I skin reactions, although they possess IgE binding structures. Our data suggest that IgE mimotopes are safe for epitope-specific immunotherapy of sensitized individuals, when presented in a monovalent form. Therefore, ABP-fused mimotopes are promising candidates for a new type of immunotherapy based on the precise induction of blocking antibodies.	Univ Vienna, Sch Med, Dept Pathophysiol, A-1090 Vienna, Austria; Univ Zurich, Dept Virol, CH-8057 Zurich, Switzerland	University of Vienna; University of Zurich	Jensen-Jarolim, E (corresponding author), Univ Vienna, Sch Med, Dept Pathophysiol, AKH-3Q,Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	erika.jensen-jarolim@akh-wien.ac.at	Jensen-Jarolim, Erika/C-5120-2018	Jensen-Jarolim, Erika/0000-0003-4019-5765; Wiedermann, Ursula/0000-0002-1302-3223				Ball T, 1999, FASEB J, V13, P1277, DOI 10.1096/fasebj.13.11.1277; BARBAS CF, 1991, METHODS COMPANION ME, V2, P119; Bauer L, 1997, CLIN EXP IMMUNOL, V107, P536, DOI 10.1046/j.1365-2249.1997.d01-953.x; Baumann S, 1998, J IMMUNOL METHODS, V221, P95, DOI 10.1016/S0022-1759(98)00168-9; Denepoux S, 2000, FEBS LETT, V465, P39, DOI 10.1016/S0014-5793(99)01703-2; FELICI F, 1993, GENE, V128, P21, DOI 10.1016/0378-1119(93)90148-V; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; Focke M, 2001, INT ARCH ALLERGY IMM, V124, P398, DOI 10.1159/000053769; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Ganglberger E, 2000, FASEB J, V14, P2177, DOI 10.1096/fj.99-1000com; Grabowska AM, 2000, VIROLOGY, V269, P47, DOI 10.1006/viro.2000.0185; Helm BA, 1997, ALLERGY, V52, P1155, DOI 10.1111/j.1398-9995.1997.tb02518.x; JAROLIM E, 1990, J ALLERGY CLIN IMMUN, V85, P996, DOI 10.1016/0091-6749(90)90043-4; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; Jensen-Jarolim E, 1999, FASEB J, V13, P1586, DOI 10.1096/fasebj.13.12.1586; Jensen-Jarolim E, 1998, FASEB J, V12, P1635, DOI 10.1096/fasebj.12.15.1635; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; Laffer S, 1996, J IMMUNOL, V157, P4953; Lebecque S, 1997, J ALLERGY CLIN IMMUN, V99, P374, DOI 10.1016/S0091-6749(97)70056-3; Leitner A, 1998, EUR J IMMUNOL, V28, P2921, DOI 10.1002/(SICI)1521-4141(199809)28:09<2921::AID-IMMU2921>3.0.CO;2-D; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; MEOLA A, 1995, J IMMUNOL, V154, P3162; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Simon Gary L., 1995, P53; Srivastava N, 2000, HYBRIDOMA, V19, P23, DOI 10.1089/027245700315761; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Visco V, 1996, J IMMUNOL, V157, P956; VOGEL M, 1994, EUR J IMMUNOL, V24, P1200, DOI 10.1002/eji.1830240529; Wiedermann U, 1998, CLIN EXP IMMUNOL, V111, P144; Zuercher AW, 2000, EUR J IMMUNOL, V30, P128, DOI 10.1002/1521-4141(200001)30:1<128::AID-IMMU128>3.3.CO;2-O; ZURCHER AW, 1995, IMMUNOL LETT, V46, P49, DOI 10.1016/0165-2478(95)00014-V	34	25	28	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2524	+		10.1096/fj.00-0888fje	http://dx.doi.org/10.1096/fj.00-0888fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641259				2022-12-28	WOS:000171372700016
J	Shahin, V; Danker, T; Enss, K; Ossig, R; Oberleithner, H				Shahin, V; Danker, T; Enss, K; Ossig, R; Oberleithner, H			Evidence for Ca2+- and ATP-sensitive peripheral channels in nuclear pore complexes	FASEB JOURNAL			English	Article						nuclear hourglass technique; Ca2+ stores; nuclear envelope; atomic force microscopy	IONIC PERMEABILITY; DEPLETION; ENVELOPE; CALCIUM; CA2+; ALDOSTERONE; DIFFUSION; MYOSIN; ACTIN	In eukaryotic cells the nuclear envelope (NE) serves as a functional barrier between cytosol and nucleoplasm perforated by nuclear pore complexes (NPCs). Both active and passive transport of ions and macromolecules are thought to be mediated by the centrally located large NPC channel. However, 3-dimensional imaging of NPCs based on electron microscopy indicates the existence of additional small channels of unknown function located in the NPC periphery. By means of the recently developed nuclear hourglass technique that measures NE electrical conductance, we evaluated passive electrically driven transport through NPCs. In isolated Xenopus laevis oocyte nuclei, we varied ambient Ca2+ and ATP in the cytosolic solution and/or chelated Ca2+ in the perinuclear stores in order to assess the role of Ca2+ in regulating passive ion transport. We noticed that NE electrical conductance is large under conditions where macromolecule permeability is known to be low. In addition, atomic force microscopy applied to native NPCs detects multiple small pores in the NPC periphery consistent with channel openings. Peripheral pores were detectable only in the presence of ATP. We conclude that NPC transport of ions and macromolecules occurs through different routes. We present a model in which NE ion flux does not occur through the central NPC channel but rather through Ca2+ - and ATP-activated peripheral channels of individual NPCs.	Univ Munster, Dept Physiol, D-48149 Munster, Germany	University of Munster	Oberleithner, H (corresponding author), Univ Munster, Dept Physiol, Robert Koch Str 27A, D-48149 Munster, Germany.	oberlei@uni-muenster.de						Aebi U, 1992, VERH DTSCH ZOOL GES, V85, P285; Assandri R, 1997, J MEMBRANE BIOL, V157, P301, DOI 10.1007/s002329900237; BERRIOS M, 1986, J CELL BIOL, V103, P711, DOI 10.1083/jcb.103.3.711; Bustamante JO, 2000, PFLUG ARCH EUR J PHY, V439, P433, DOI 10.1007/s004240050960; BUSTAMANTE JO, 1995, J MEMBRANE BIOL, V146, P239; CALLAN HG, 1949, NATURE, V163, P280, DOI 10.1038/163280a0; Danker T, 1999, P NATL ACAD SCI USA, V96, P13530, DOI 10.1073/pnas.96.23.13530; Danker T, 1997, CELL BIOL INT, V21, P747, DOI 10.1006/cbir.1997.0219; Draguhn A, 1997, J MEMBRANE BIOL, V158, P159, DOI 10.1007/s002329900253; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GREBER UF, 1992, J CELL BIOL, V116, P15, DOI 10.1083/jcb.116.1.15; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; Keminer O, 1999, BIOPHYS J, V77, P217, DOI 10.1016/S0006-3495(99)76883-9; LOEWENSTEIN WR, 1962, NATURE, V195, P462, DOI 10.1038/195462a0; LOEWENSTEIN WR, 1964, PROTOPLASMATOLOGIA, V5, P26; MAK DOD, 1994, J BIOL CHEM, V269, P29375; MAZZANTI M, 1990, NATURE, V343, P764, DOI 10.1038/343764a0; Mazzanti M, 2001, PHYSIOL REV, V81, P1, DOI 10.1152/physrev.2001.81.1.1; MAZZANTI M, 1994, FASEB J, V8, P231, DOI 10.1096/fasebj.8.2.7509760; Oberleithner H, 1999, STEROIDS, V64, P42, DOI 10.1016/S0039-128X(98)00090-7; OBERLEITHNER H, 1994, P NATL ACAD SCI USA, V91, P9784, DOI 10.1073/pnas.91.21.9784; Pante N, 1996, CRIT REV BIOCHEM MOL, V31, P153, DOI 10.3109/10409239609106583; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; Petersen OH, 1998, CELL CALCIUM, V23, P87, DOI 10.1016/S0143-4160(98)90106-3; Prat AG, 1996, AM J PHYSIOL-CELL PH, V270, pC1532, DOI 10.1152/ajpcell.1996.270.5.C1532; Rakowska A, 1998, J MEMBRANE BIOL, V163, P129, DOI 10.1007/s002329900377; SCHINDLER M, 1986, J CELL BIOL, V102, P859, DOI 10.1083/jcb.102.3.859; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; TABARES L, 1991, J MEMBRANE BIOL, V123, P49, DOI 10.1007/BF01993962; Wang HW, 1999, BIOPHYS J, V77, P241, DOI 10.1016/S0006-3495(99)76885-2	33	55	58	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					1895	1901		10.1096/fj.00-0838com	http://dx.doi.org/10.1096/fj.00-0838com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532969				2022-12-28	WOS:000171372700004
J	Buyse, M; Viengchareun, S; Bado, A; Lombes, M				Buyse, M; Viengchareun, S; Bado, A; Lombes, M			Insulin and glucocorticoids differentially regulate leptin transcription and secretion in brown adipocytes	FASEB JOURNAL			English	Article						cell line; uncoupling protein; ob gene; signaling pathway; obesity	OB GENE-EXPRESSION; BINDING-PROTEIN-ALPHA; WHITE ADIPOSE-TISSUE; MOUSE OBESE GENE; UNCOUPLING PROTEIN; MESSENGER-RNA; 3T3-L1 ADIPOCYTES; PLASMA LEPTIN; RAT; PROMOTER	Leptin, the ob gene product, is produced by adipose tissue and is submitted to a complex hormonal and metabolic regulation. Leptin plays a critical role in the balance of body weight. Here we report on secretion and hormonal regulation of leptin by brown adipocytes. Using the recently established T37i cell line, we show that leptin expression and secretion occurred as a function of cell differentiation. In differentiated T37i cells, insulin induced leptin release (similar to0.25 ng/10(6) cells/h) in a concentration-dependent manner (EC50=0.1 nM), and this was totally suppressed by beta3 -adrenergic ligand, thiazolidinedione, cycloheximide, or actinomycin D. Insulin induced a strong, rapid (within 2 h) but transient fivefold increase in leptin mRNA levels. This transcriptional control of ob gene expression by insulin involved both phosphatidylinositol 3-kinase- and MAP kinase-dependent pathways. Glucocorticoids inhibited both insulin-stimulated leptin secretion and ob gene expression without affecting leptin mRNA stability (t(1/2)=3h05). Altogether, our results demonstrate that brown adipocytes express and secrete leptin, whose hormonal regulation clearly differs from that described in white adipose tissue. These findings point to tissue-specific molecular mechanisms and suggest that leptin might exert direct effects on energy homeostasis through an autocrine mechanism.	Univ Paris 07, Inst Federatif Rech Cellules Epitheliales, INSERM, U478, F-75870 Paris 18, France; Univ Paris 07, Inst Federatif Rech Cellules Epitheliales, INSERM, U410, F-75870 Paris 18, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Lombes, M (corresponding author), Univ Paris 07, Inst Federatif Rech Cellules Epitheliales, INSERM, U478, IFR2,16 Rue Henri Huchard, F-75870 Paris 18, France.	mlombes@bichat.inserm.fr	Lombes, Marc/L-5933-2018; BADO, Andre/G-3408-2013; Viengchareun, Say/M-6612-2017; Buyse, Marc/J-4658-2013; Viengchareun, Say/GOV-6812-2022	Lombes, Marc/0000-0003-3189-023X; BADO, Andre/0000-0002-8007-1460; viengchareun, say/0000-0003-4280-3250				Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Barr VA, 1997, ENDOCRINOLOGY, V138, P4463, DOI 10.1210/en.138.10.4463; Bradley RL, 1999, DIABETES, V48, P272, DOI 10.2337/diabetes.48.2.272; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Cinti S, 1997, ENDOCRINOLOGY, V138, P797, DOI 10.1210/en.138.2.797; Coleman RA, 1999, DIABETOLOGIA, V42, P639, DOI 10.1007/s001250051210; Considine RV, 1997, J CELL BIOCHEM, V65, P254, DOI 10.1002/(SICI)1097-4644(199705)65:2<254::AID-JCB10>3.0.CO;2-I; De Vos P, 1998, EUR J BIOCHEM, V253, P619, DOI 10.1046/j.1432-1327.1998.2530619.x; delaBrousse FC, 1996, P NATL ACAD SCI USA, V93, P4096, DOI 10.1073/pnas.93.9.4096; Deng CJ, 1997, ENDOCRINOLOGY, V138, P548, DOI 10.1210/en.138.2.548; Dessolin S, 1997, FASEB J, V11, P382, DOI 10.1096/fasebj.11.5.9141506; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; Donahoo WT, 1997, J CLIN ENDOCR METAB, V82, P4139, DOI 10.1210/jc.82.12.4139; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; Fukuda H, 1999, FEBS LETT, V455, P165, DOI 10.1016/S0014-5793(99)00877-7; Gettys TW, 1996, ENDOCRINOLOGY, V137, P4054, DOI 10.1210/en.137.9.4054; Gong DW, 1996, J BIOL CHEM, V271, P3971; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hardie LJ, 1996, HORM METAB RES, V28, P685, DOI 10.1055/s-2007-979878; HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; HIMMSHAGEN J, 1995, P SOC EXP BIOL MED, V208, P159, DOI 10.3181/00379727-208-43847A; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; Jain R, 1999, BIOCHEM J, V338, P737, DOI 10.1042/0264-6021:3380737; Jin L, 2000, ENDOCRINOLOGY, V141, P333, DOI 10.1210/en.141.1.333; Kaabache T, 1995, ANAL BIOCHEM, V232, P225, DOI 10.1006/abio.1995.0011; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kirchgessner TG, 1997, J CLIN INVEST, V100, P2777, DOI 10.1172/JCI119824; Kosaki A, 1996, DIABETES, V45, P1744, DOI 10.2337/diabetes.45.12.1744; Larsson H, 1996, J CLIN ENDOCR METAB, V81, P4428, DOI 10.1210/jc.81.12.4428; Leroy P, 1996, J BIOL CHEM, V271, P2365, DOI 10.1074/jbc.271.5.2365; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; Mason MM, 1998, ENDOCRINOLOGY, V139, P1013, DOI 10.1210/en.139.3.1013; Masuzaki H, 1997, NAT MED, V3, P1029, DOI 10.1038/nm0997-1029; Miller SG, 1996, P NATL ACAD SCI USA, V93, P5507, DOI 10.1073/pnas.93.11.5507; Morash B, 2000, MOL CELL ENDOCRINOL, V165, P97, DOI 10.1016/S0303-7207(00)00259-8; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Penfornis P, 2000, AM J PHYSIOL-ENDOC M, V279, pE386, DOI 10.1152/ajpendo.2000.279.2.E386; Rentsch J, 1996, FEBS LETT, V379, P55, DOI 10.1016/0014-5793(95)01485-3; Reul BA, 1997, BIOCHEM J, V324, P605, DOI 10.1042/bj3240605; Ricci MR, 1999, OBES RES, V7, P233, DOI 10.1002/j.1550-8528.1999.tb00401.x; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Scarpace PJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259; Scarpace PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE226, DOI 10.1152/ajpendo.1997.273.1.E226; Serradeil-Le Gal C, 2000, FEBS LETT, V475, P150, DOI 10.1016/S0014-5793(00)01649-5; Siegrist-Kaiser CA, 1997, J CLIN INVEST, V100, P2858, DOI 10.1172/JCI119834; Sinha MK, 1996, J CLIN INVEST, V97, P1344, DOI 10.1172/JCI118551; Slieker LJ, 1996, J BIOL CHEM, V271, P5301, DOI 10.1074/jbc.271.10.5301; TRAYHURN P, 1995, FEBS LETT, V368, P488, DOI 10.1016/0014-5793(95)00719-P; Uchida Y, 1999, N-S ARCH PHARMACOL, V360, P691, DOI 10.1007/s002109900134; VIENGCHAREUN S, 2001, IN PRESS AM J PHYSL; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Webster JC, 1999, TRENDS ENDOCRIN MET, V10, P396, DOI 10.1016/S1043-2760(99)00186-1; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Yoshida T, 1996, EUR J ENDOCRINOL, V135, P619, DOI 10.1530/eje.0.1350619; Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zilberfarb V, 1997, J CELL SCI, V110, P801	63	37	39	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1357	1366		10.1096/fj.00-0669com	http://dx.doi.org/10.1096/fj.00-0669com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11387233				2022-12-28	WOS:000169261200003
J	Picard, F; Kapur, S; Perreault, M; Marette, A; Deshaies, Y				Picard, F; Kapur, S; Perreault, M; Marette, A; Deshaies, Y			Nitric oxide mediates endotoxin-induced hypertriglyceridemia through its action on skeletal muscle lipoprotein lipase	FASEB JOURNAL			English	Article						endotoxemia; inducible nitric oxide synthase; triglycerides	TUMOR-NECROSIS-FACTOR; TISSUE-SPECIFIC EXPRESSION; ADIPOSE-TISSUE; LIPID-METABOLISM; FACTOR-ALPHA; BROWN ADIPOCYTES; PPAR-GAMMA; SYNTHASE; INSULIN; RAT	Hypertriglyceridemia (hyperTG) is a common characteristic of endotoxemia. At high doses of endotoxin, hyperTG is caused by a reduction in the activity of lipoprotein lipase (LPL), the enzyme responsible for TG intravascular clearance. The present studies were aimed at evaluating the role of nitric oxide (NO), overproduced in endotoxemia through the activation of inducible NO synthase (iNOS), in the decrease in tissue LPL activity brought about by lipopolysaccharide (LPS, 15 mg/kg). In rats, the specific iNOS inhibitor aminoguanidine (AGN, 100 mg/kg) prevented the LPS-induced threefold elevation in plasma TG concentration, through actions that were not related to changes in hepatic TG secretion. AGN administration abrogated the LPS-induced reduction in LPL activity in skeletal muscle but not that in white adipose tissue (WAT). Quantification of LPL mRNA revealed that AGN prevented LPS-mediated alterations in muscle LPL activity through posttranscriptional mechanisms. The above findings were confirmed in iNOS (-/-) knockout mice injected with endotoxin. LPS increased plasma TG concentration in wild-type mice by 75%, whereas hyperTG did not occur in knockout mice. Skeletal muscle LPL activity decreased by 40% in wild-type mice but remained unchanged in knockout mice 6 h after LPS injection, whereas WAT LPL activity decreased to one-third of control levels in both genotypes. These findings demonstrate that, after LPS administration, reduced muscle LPL activity and the resulting hyperTG are caused by the overproduction of NO via the induction of iNOS. The findings further provide evidence for a central role of muscle LPL in the response of TG metabolism to acute endotoxemia.	Univ Laval, Sch Med, Dept Anat & Physiol, Ctr Res Energy Metab, Quebec City, PQ G1K 7P4, Canada; Univ Laval, CHUQ, Lipid Res Unit, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University	Deshaies, Y (corresponding author), Univ Laval, Sch Med, Dept Anat & Physiol, Ctr Res Energy Metab, Quebec City, PQ G1K 7P4, Canada.	yves.deshaies@phs.ulaval.ca	Marette, Andre/E-9342-2013; Deshaies, Yves/E-9858-2013	Deshaies, Yves/0000-0002-6242-4592				AMIN AR, 1995, P NATL ACAD SCI USA, V92, P7926, DOI 10.1073/pnas.92.17.7926; BAGBY GJ, 1987, AM J PHYSIOL, V253, pE59, DOI 10.1152/ajpendo.1987.253.1.E59; BAGBY GJ, 1987, LIPOPROTEIN LIPASE, P247; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; Bedard S, 1997, BIOCHEM J, V325, P487, DOI 10.1042/bj3250487; Bennett MJ, 2000, AM J PHYSIOL-ENDOC M, V278, pE802, DOI 10.1152/ajpendo.2000.278.5.E802; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; FEINGOLD KR, 1992, J LIPID RES, V33, P1765; FEINGOLD KR, 1994, ARTERIOSCLER THROMB, V14, P1866, DOI 10.1161/01.ATV.14.11.1866; GOUNI I, 1993, J LIPID RES, V34, P139; GRUNFELD C, 1992, P SOC EXP BIOL MED, V200, P224; Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008; HARRIS HW, 1993, J CLIN INVEST, V91, P1028, DOI 10.1172/JCI116259; Hill MR, 1997, ENDOCRINOLOGY, V138, P3073, DOI 10.1210/en.138.7.3073; Kapur S, 1997, DIABETES, V46, P1691, DOI 10.2337/diabetes.46.11.1691; Kapur S, 1999, AM J PHYSIOL-ENDOC M, V276, pE635, DOI 10.1152/ajpendo.1999.276.4.E635; KRAEGEN EW, 1983, AM J PHYSIOL, V245, pE1, DOI 10.1152/ajpendo.1983.245.1.E1; Lanza-Jacoby S, 1998, SHOCK, V9, P46, DOI 10.1097/00024382-199801000-00007; LanzaJacoby S, 1997, J LIPID RES, V38, P701; LANZAJACOBY S, 1992, BIOCHIM BIOPHYS ACTA, V1124, P233, DOI 10.1016/0005-2760(92)90134-H; Liaudet L, 2000, CRIT CARE MED, V28, pN37, DOI 10.1097/00003246-200004001-00005; LopezSoriano J, 1997, MOL CELL ENDOCRINOL, V132, P93, DOI 10.1016/S0303-7207(97)00125-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEMON RA, 1993, ENDOCRINOLOGY, V132, P2246, DOI 10.1210/en.132.5.2246; Moldawer LL, 1997, CANCER-AM CANCER SOC, V79, P1828; Murad F, 1999, BIOSCIENCE REP, V19, P133, DOI 10.1023/A:1020265417394; NILSSONEHLE P, 1987, LIPOPROTEIN LIPASE, P59; Nishida K, 1997, BIOCHEM BIOPH RES CO, V236, P275, DOI 10.1006/bbrc.1997.6972; Picard F, 1999, DIABETES, V48, P452, DOI 10.2337/diabetes.48.3.452; Picard F, 2000, DIABETOLOGIA, V43, P866, DOI 10.1007/s001250051463; Pilon G, 2000, HORM METAB RES, V32, P480, DOI 10.1055/s-2007-978674; Reid MB, 2001, J APPL PHYSIOL, V90, P724, DOI 10.1152/jappl.2001.90.2.724; Reid MB, 1996, NEWS PHYSIOL SCI, V11, P114, DOI 10.1152/physiologyonline.1996.11.3.114; Rosato EF, 1997, J SURG RES, V73, P73, DOI 10.1006/jsre.1997.5199; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; STEFANOVICRACIC M, 1994, ARTHRITIS RHEUM, V37, P1062, DOI 10.1002/art.1780370712; Stoclet JC, 1999, EUR J PHARMACOL, V375, P139, DOI 10.1016/S0014-2999(99)00221-6; Uchida Y, 1997, ANN NY ACAD SCI, V813, P369, DOI 10.1111/j.1749-6632.1997.tb51720.x; Uchida Y, 1997, EUR J PHARMACOL, V335, P235, DOI 10.1016/S0014-2999(97)01181-3; VERDON CP, 1995, ANAL BIOCHEM, V224, P502, DOI 10.1006/abio.1995.1079; WARREN HS, 1988, INFECT IMMUN, V56, P204, DOI 10.1128/IAI.56.1.204-212.1988; WILLIAMS G, 1994, AM J PHYSIOL-REG I, V267, pR1020, DOI 10.1152/ajpregu.1994.267.4.R1020; ZECHNER R, 1988, MOL CELL BIOL, V8, P2394, DOI 10.1128/MCB.8.6.2394; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005	47	23	23	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1828	+		10.1096/fj.00-0830fje	http://dx.doi.org/10.1096/fj.00-0830fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481244				2022-12-28	WOS:000169261200008
J	Tsukamoto, H; Lu, SC				Tsukamoto, H; Lu, SC			Current concepts in the pathogenesis of alcoholic liver injury	FASEB JOURNAL			English	Review						mitochondria; ALD; ethanol; antioxidants	TUMOR-NECROSIS-FACTOR; S-ADENOSYLMETHIONINE SYNTHETASE; ADENOSYL-L-METHIONINE; HEPATIC STELLATE CELLS; ETHANOL-FED RATS; ALDEHYDE DEHYDROGENASE GENOTYPES; ADHESION MOLECULE-1 EXPRESSION; VASCULAR SMOOTH-MUSCLE; ALPHA MESSENGER-RNA; KAPPA-B ACTIVATION	Alcoholic liver disease (ALD) develops as a consequence of priming and sensitizing mechanisms rendered by cross-interactions of primary mechanistic factors and secondary risk factors. This concept, albeit not novel, is becoming widely accepted by the field, and more research is directed toward identifying and characterizing the interfaces of the cross-interactions to help understand individual predisposition to the disease. Another pivotal development is the beginning of cell type-specific research to elucidate specific contributions not only of hepatocytes, but also of hepatic macrophages, liver-associated lymphocytes, sinusoidal endothelial cells, and hepatic stellate cells to sensitizing and priming mechanisms. In particular, the critical role of hepatic macrophages has been highlighted and the priming mechanisms concerning this paracrine effect have been proposed. Glutathione depletion in hepatocyte mitochondria is considered the most important sensitizing mechanism. One of the contributing factors is decreased methionine metabolism. Remaining key questions include how altered methionine metabolism contribute to the pathogenesis of ALD; how cross-talk among nonparenchymal liver cells or between nonparenchymal cells and hepatocytes leads to ALD; how dysfunctional mitochondria determine the type of cell death in ALD; and what secondary factors are critical for the development of advanced ALD such as alcoholic hepatitis and cirrhosis.	Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Div Gastrointestinal & Liver Dis, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA; Univ So Calif, UCLA Res Ctr Alcohol Liver & Pancreat Dis, USC Res Ctr Liver Dis, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California	Tsukamoto, H (corresponding author), Univ So Calif, Keck Sch Med, Dept Pathol, 1333 San Pablo St,MMR-412, Los Angeles, CA 90033 USA.	htsukamo@hsc.usc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051719, P30DK048522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA011999, R37AA006603, R01AA012677] Funding Source: NIH RePORTER; NIAAA NIH HHS [P50 AA11999, R01 AA12677, R37-AA006603] Funding Source: Medline; NIDDK NIH HHS [DK48522, R01 DK51719] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI Y, 1994, HEPATOLOGY, V20, P453, DOI 10.1002/hep.1840200227; ADACHI Y, 1995, GASTROENTEROLOGY, V108, P218, DOI 10.1016/0016-5085(95)90027-6; Aleynik MK, 1999, ALCOHOL CLIN EXP RES, V23, P96, DOI 10.1111/j.1530-0277.1999.tb04028.x; ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; ARDIES CM, 1987, BIOCHEM PHARMACOL, V36, P3613, DOI 10.1016/0006-2952(87)90010-4; Avila MA, 1997, HEPATOLOGY, V25, P391; AVILA MA, 2000, IN PRESS J HEPATOL; BARAK AJ, 1993, ALCOHOL CLIN EXP RES, V17, P552, DOI 10.1111/j.1530-0277.1993.tb00798.x; BARAK AJ, 1971, J NUTR, V101, P533, DOI 10.1093/jn/101.4.533; Bautista AP, 1997, HEPATOLOGY, V25, P335, DOI 10.1002/hep.510250214; Baylin SB, 1998, ADV CANCER RES, V72, P141; Brady LM, 1998, BIOCHEM BIOPH RES CO, V248, P174, DOI 10.1006/bbrc.1998.8935; CABRERO C, 1988, HEPATOLOGY, V8, P1530, DOI 10.1002/hep.1840080610; Cahill A, 1999, HEPATOLOGY, V30, P881, DOI 10.1002/hep.510300434; Cai JX, 1998, CANCER RES, V58, P1444; Cai JX, 1996, HEPATOLOGY, V24, P1090; Cao Q, 1998, ALCOHOL CLIN EXP RES, V22, P723, DOI 10.1097/00000374-199805000-00026; Cao Q, 1999, ALCOHOL CLIN EXP RES, V23, P1660, DOI 10.1111/j.1530-0277.1999.tb04058.x; CARR LG, 1995, ALCOHOL CLIN EXP RES, V19, P182, DOI 10.1111/j.1530-0277.1995.tb01489.x; CASTILLO T, 1992, HEPATOLOGY, V16, P992, DOI 10.1002/hep.1840160423; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Chawla RK, 1998, AM J PHYSIOL-GASTR L, V275, pG125, DOI 10.1152/ajpgi.1998.275.1.G125; CHRISTENSEN B, 1991, J CELL PHYSIOL, V146, P52, DOI 10.1002/jcp.1041460108; Colell A, 1997, HEPATOLOGY, V26, P699, DOI 10.1053/jhep.1997.v26.pm0009303501; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; Colell A., 1997, Journal of Hepatology, V26, P127; CORRALES F, 1991, HEPATOLOGY, V14, P528, DOI 10.1002/hep.1840140320; CORRALES F, 1992, HEPATOLOGY, V16, P1022, DOI 10.1002/hep.1840160427; Cortez-Pinto H, 1998, BIOCHEM BIOPH RES CO, V251, P313, DOI 10.1006/bbrc.1998.9473; Cravo ML, 1996, AM J CLIN NUTR, V63, P220, DOI 10.1093/ajcn/63.2.220; Deaciuc IV, 1996, ALCOHOL CLIN EXP RES, V20, P607, DOI 10.1111/j.1530-0277.1996.tb01662.x; DIEHL AM, 1995, HEPATOLOGY, V22, P252, DOI 10.1016/0270-9139(95)90379-8; DUCE AM, 1988, HEPATOLOGY, V8, P65, DOI 10.1002/hep.1840080113; Eastin CE, 1997, ALCOHOL CLIN EXP RES, V21, P1037, DOI 10.1111/j.1530-0277.1997.tb04250.x; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; FERNANDEZCHECA JC, 1991, J CLIN INVEST, V87, P397, DOI 10.1172/JCI115010; FERNANDEZCHECA JC, 1989, J CLIN INVEST, V83, P1247, DOI 10.1172/JCI114008; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FINKELSTEIN JD, 1986, J BIOL CHEM, V261, P1582; FINKELSTEIN JD, 1974, BIOCHEM BIOPH RES CO, V61, P525, DOI 10.1016/0006-291X(74)90988-7; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FRENCH SW, 1984, HEPATOLOGY, V4, P912, DOI 10.1002/hep.1840040521; FRENCH SW, 1966, J NUTR, V88, P291, DOI 10.1093/jn/88.3.291; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GARCIARUIZ C, 1995, HEPATOLOGY, V21, P207, DOI 10.1016/0270-9139(95)90430-1; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gasso M, 1996, J HEPATOL, V25, P200, DOI 10.1016/S0168-8278(96)80074-2; Gil B, 1996, HEPATOLOGY, V24, P876; GOMEZDUMM CL, 1968, LAB INVEST, V18, P365; Grove J, 1997, HEPATOLOGY, V26, P143, DOI 10.1002/hep.510260119; Grove J, 2000, GUT, V46, P540, DOI 10.1136/gut.46.4.540; Halim AB, 1999, J BIOL CHEM, V274, P29720, DOI 10.1074/jbc.274.42.29720; Halsted CH, 1996, HEPATOLOGY, V23, P497, DOI 10.1002/hep.510230314; HARTROFT WS, 1968, CAN J PHYSIOL PHARM, V46, P463, DOI 10.1139/y68-069; HIGUCHI S, 1994, LANCET, V343, P741, DOI 10.1016/S0140-6736(94)91629-2; Hill DB, 1999, CLIN BIOCHEM, V32, P563, DOI 10.1016/S0009-9120(99)00056-9; HOFFMAN DR, 1980, J BIOL CHEM, V255, P822; HORIKAWA S, 1993, FEBS LETT, V330, P307, DOI 10.1016/0014-5793(93)80894-Z; HOROWITZ JH, 1981, GASTROENTEROLOGY, V81, P668; HRUBEC Z, 1984, ALCOHOL CLIN EXP RES, V9, P306; Huang ZZ, 1999, HEPATOLOGY, V29, P1471, DOI 10.1002/hep.510290525; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; HULTBERG B, 1993, ALCOHOL CLIN EXP RES, V17, P687, DOI 10.1111/j.1530-0277.1993.tb00820.x; Iimuro Y, 1997, HEPATOLOGY, V26, P1530; INGELMANSUNDBERG M, 1984, J BIOL CHEM, V259, P6447; IWAHASHI K, 1995, ALCOHOL CLIN EXP RES, V19, P564, DOI 10.1111/j.1530-0277.1995.tb01549.x; KAMIMURA S, 1992, HEPATOLOGY, V16, P448, DOI 10.1002/hep.1840160225; KINSELL LW, 1947, SCIENCE, V106, P589, DOI 10.1126/science.106.2763.589; KLATSKIN G, 1954, J EXP MED, V100, P605, DOI 10.1084/jem.100.6.605; KONO H, 1999, AM J PHYSIOL, V277, P1259; Koop DR, 1997, MOL PHARMACOL, V51, P944, DOI 10.1124/mol.51.6.944; KOOP DR, 1985, P NATL ACAD SCI USA, V82, P4065, DOI 10.1073/pnas.82.12.4065; KOTB M, 1985, J BIOL CHEM, V260, P3923; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; KUKIELKA E, 1994, ARCH BIOCHEM BIOPHYS, V309, P377, DOI 10.1006/abbi.1994.1127; Lee FYJ, 1999, AM J PHYSIOL-CELL PH, V276, pC386, DOI 10.1152/ajpcell.1999.276.2.C386; LEMOINE O, 1995, HEPATOLOGY, V22, P1436, DOI 10.1016/0270-9139(95)90149-3; Lentz SR, 1997, LIFE SCI, V61, P1205, DOI 10.1016/S0024-3205(97)00392-5; LI JJ, 1992, HEPATOLOGY, V15, P373, DOI 10.1002/hep.1840150303; LI JJ, 1993, HEPATOLOGY, V17, P174; LIEBER CS, 1963, T ASSOC AM PHYSICIAN, V76, P289; LIEBER CS, 1975, P NATL ACAD SCI USA, V72, P437, DOI 10.1073/pnas.72.2.437; LIEBER CS, 1994, ALCOHOL CLIN EXP RES, V18, P592, DOI 10.1111/j.1530-0277.1994.tb00915.x; LIEBER CS, 1990, HEPATOLOGY, V11, P165, DOI 10.1002/hep.1840110203; Lieber CS, 1997, ALCOHOL CLIN EXP RES, V21, P375, DOI 10.1097/00000374-199704000-00029; LIEBER CS, 1994, GASTROENTEROLOGY, V106, P152, DOI 10.1016/S0016-5085(94)95023-7; Lin HZ, 2000, NAT MED, V6, P998, DOI 10.1038/79697; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; Loffreda S, 1997, GASTROENTEROLOGY, V112, P2089, DOI 10.1053/gast.1997.v112.pm9178702; Lu SC, 2000, AM J PHYSIOL-GASTR L, V279, pG178, DOI 10.1152/ajpgi.2000.279.1.G178; Lu SC, 2000, INT J BIOCHEM CELL B, V32, P391, DOI 10.1016/S1357-2725(99)00139-9; Lu SC, 1998, SEMIN LIVER DIS, V18, P331, DOI 10.1055/s-2007-1007168; Maher JJ, 1997, HEPATOLOGY, V26, P618, DOI 10.1002/hep.510260313; Majors A, 1997, ARTERIOSCL THROM VAS, V17, P2074, DOI 10.1161/01.ATV.17.10.2074; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; Mato JM, 1999, J HEPATOL, V30, P1081, DOI 10.1016/S0168-8278(99)80263-3; Mato Jose M., 1994, P461; MATSUOKA M, 1990, HEPATOLOGY, V11, P173, DOI 10.1002/hep.1840110204; MCCLAIN C, 1993, SEMIN LIVER DIS, V13, P170, DOI 10.1055/s-2007-1007347; McClain CJ, 1998, ALCOHOL CLIN EXP RES, V22, p248S, DOI 10.1111/j.1530-0277.1998.tb04011.x; McCullough AJ, 1998, GASTROENTEROLOGY, V115, P947, DOI 10.1016/S0016-5085(98)70267-7; MCCUSKEY RS, 1995, J GASTROEN HEPATOL, V10, pS18, DOI 10.1111/j.1440-1746.1995.tb01790.x; MENDENHALL CL, 1984, AM J MED, V76, P211, DOI 10.1016/0002-9343(84)90776-9; Mingorance J, 1996, BIOCHEM J, V315, P761, DOI 10.1042/bj3150761; MORIMOTO M, 1995, HEPATOLOGY, V21, P1610, DOI 10.1016/0270-9139(95)90466-2; MUDD SH, 1995, METABOLIC BASIS INHE, P693; NANJI AA, 1994, ALCOHOL CLIN EXP RES, V18, P902, DOI 10.1111/j.1530-0277.1994.tb00058.x; NANJI AA, 1995, J LIPID RES, V36, P736; NANJI AA, 1994, P SOC EXP BIOL MED, V205, P243; NANJI AA, 1995, EXP MOL PATHOL, V62, P42, DOI 10.1006/exmp.1995.1005; Neuman MG, 1999, CLIN BIOCHEM, V32, P547, DOI 10.1016/S0009-9120(99)00054-5; Nicolaou A, 1996, EUR J CLIN INVEST, V26, P167, DOI 10.1046/j.1365-2362.1996.122254.x; Nieto N, 1999, HEPATOLOGY, V30, P987, DOI 10.1002/hep.510300433; PAJARES MA, 1992, J BIOL CHEM, V267, P17598; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; PASCALE RM, 1992, CANCER RES, V52, P4979; Pastorino JG, 1999, BIOCHEM BIOPH RES CO, V265, P405, DOI 10.1006/bbrc.1999.1696; POGRIBNY IP, 1995, CANCER RES, V55, P1894; POGRIBNY IP, 1995, CANCER RES, V15, P2711; PORTA EA, 1967, FED PROC, V62, P1449; Rai RM, 1997, HEPATOLOGY, V25, P889, DOI 10.1002/hep.510250417; Rashid A, 1999, HEPATOLOGY, V29, P1131, DOI 10.1002/hep.510290428; Reed T, 1996, ALCOHOL CLIN EXP RES, V20, P1528, DOI 10.1111/j.1530-0277.1996.tb01695.x; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Roman J, 1999, HEPATOLOGY, V30, P1473, DOI 10.1002/hep.510300623; Ruiz F, 1998, HEPATOLOGY, V28, P1051, DOI 10.1002/hep.510280420; SanchezGongora E, 1997, FASEB J, V11, P1013, DOI 10.1096/fasebj.11.12.9337154; Sarphie TG, 1996, ALCOHOL CLIN EXP RES, V20, P973, DOI 10.1111/j.1530-0277.1996.tb01933.x; Saso K, 1996, ALCOHOL CLIN EXP RES, V20, pA330; SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; ShimizuSaito K, 1997, HEPATOLOGY, V26, P424, DOI 10.1002/hep.510260224; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; Stickel F, 2000, ALCOHOL CLIN EXP RES, V24, P259, DOI 10.1111/j.1530-0277.2000.tb04606.x; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017; Tahara M, 1999, J CLIN INVEST, V103, P313, DOI 10.1172/JCI4433; TAKEUCHI J, 1968, LAB INVEST, V19, P211; Tang LL, 1998, ATHEROSCLEROSIS, V136, P169, DOI 10.1016/S0021-9150(97)00208-6; Thiele GM, 1999, HEPATOLOGY, V29, P1511, DOI 10.1002/hep.510290517; Thiele GM, 1998, ALCOHOL CLIN EXP RES, V22, P1731, DOI 10.1111/j.1530-0277.1998.tb03973.x; THOMASSON HR, 1991, AM J HUM GENET, V48, P677; Torres L, 1999, BBA-MOL BASIS DIS, V1455, P12, DOI 10.1016/S0925-4439(99)00049-6; TRIMBLE KC, 1993, HEPATOLOGY, V18, P984, DOI 10.1002/hep.1840180433; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; TSUKAMOTO H, 1986, HEPATOLOGY, V6, P814, DOI 10.1002/hep.1840060503; TSUKAMOTO H, 1995, J CLIN INVEST, V96, P620, DOI 10.1172/JCI118077; Tsukamoto H, 1999, AM J PHYSIOL-GASTR L, V277, pG1240, DOI 10.1152/ajpgi.1999.277.6.G1240; Tsukamoto H, 1996, AM J PHYSIOL-GASTR L, V270, pG581, DOI 10.1152/ajpgi.1996.270.4.G581; Tuma DJ, 1998, ALCOHOL, V15, P233, DOI 10.1016/S0741-8329(97)00127-4; TUMA DJ, 1987, ALCOHOL CLIN EXP RES, V11, P579, DOI 10.1111/j.1530-0277.1987.tb00178.x; Tuma DJ, 1996, HEPATOLOGY, V23, P872, DOI 10.1002/hep.510230431; Tworek BL, 1996, J BIOL CHEM, V271, P2531, DOI 10.1074/jbc.271.5.2531; Tyagi SC, 1998, AM J PHYSIOL-CELL PH, V274, pC396, DOI 10.1152/ajpcell.1998.274.2.C396; VARELAMOREIRAS G, 1995, HEPATOLOGY, V22, P1310, DOI 10.1016/0270-9139(95)90644-4; VENDEMIALE G, 1989, SCAND J GASTROENTERO, V24, P407, DOI 10.3109/00365528909093067; WAHL DG, 1992, ALCOHOL CLIN EXP RES, V16, P971, DOI 10.1111/j.1530-0277.1992.tb01903.x; Watson WH, 1999, BIOCHEM J, V342, P21, DOI 10.1042/0264-6021:3420021; Wu DF, 1996, J BIOL CHEM, V271, P23914, DOI 10.1074/jbc.271.39.23914; Xu DS, 1998, GASTROENTEROLOGY, V115, P686, DOI 10.1016/S0016-5085(98)70148-9; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; Yang SQ, 1998, AM J PHYSIOL-GASTR L, V275, pG696, DOI 10.1152/ajpgi.1998.275.4.G696; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9	162	279	300	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1335	1349		10.1096/fj.00-0650rev	http://dx.doi.org/10.1096/fj.00-0650rev			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11387231				2022-12-28	WOS:000169261200001
J	Legler, DF; Doucey, MA; Cerottini, JC; Bron, C; Luescher, IF				Legler, DF; Doucey, MA; Cerottini, JC; Bron, C; Luescher, IF			Selective inhibition of CTL activation by a dipalmitoyl-phospholipid that prevents the recruitment of signaling molecules to lipid rafts	FASEB JOURNAL			English	Article						signal transduction; dipalmitoyl-phosphatidylethanolamine; TCR	T-CELL ACTIVATION; GPI-ANCHORED PROTEINS; POLYUNSATURATED FATTY-ACIDS; INSOLUBLE MEMBRANE DOMAINS; ANTIGEN RECEPTOR; LIGAND INTERACTIONS; PALMITOYLATION; MICRODOMAINS; LYMPHOCYTES; LOCALIZATION	Antigen-specific T-cell activation implicates a redistribution of plasma membrane-bound molecules in lipid rafts, such as the coreceptors CD8 and CD4, the Src kinases Lek and Fyn, and the linker for activation of T cells (LAT), that results in the formation of signaling complexes. These molecules partition in lipid rafts because of palmitoylation of cytoplasmic, membrane proximal cysteines, which is essential for their functional integrity in T-cell activation. Here, we show that exogenous dipalmitoyl-phosphatidylethanolamine (DPPE), but not the related unsaturated dioleoyl-phosphatidylethanolamine (DOPE), partitions in lipid rafts. DPPE inhibits activation of CD8(+) T lymphocytes by sensitized syngeneic antigen-presenting cells or specific major histocompatibility complex (MHC) peptide tetramers, as indicated by esterase release and intracellular calcium mobilization. Cytotoxic, T lymphocyte (CTL)-target cell conjugate formation is not affected by DPPE, indicating that engagement of the T-cell receptor by its cognate ligand is intact in lipid-treated cells. In contrast to other agents known to block raft-dependent signaling, DPPE efficiently inhibits the MHC peptide-induced recruitment of palmitoylated signaling molecules to lipid rafts and CTL activation without affecting cell viability or lipid raft integrity.	Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, CH-1066 Epalinges, Switzerland; Univ Lausanne, BIL Biomed Res Ctr, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland	University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne	Legler, DF (corresponding author), Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	daniel.legler@ib.unil.ch		Legler, Daniel F./0000-0001-8610-4764				Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; Arcaro A, 2000, J IMMUNOL, V165, P2068, DOI 10.4049/jimmunol.165.4.2068; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CRISE B, 1992, J BIOL CHEM, V267, P13593; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; DOUCEY MA, 2001, IN PRESS EUR J IMMUN; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; KWONG J, 1995, BIOCHEM BIOPH RES CO, V207, P868, DOI 10.1006/bbrc.1995.1266; Lanzavecchia A, 1999, CELL, V96, P1, DOI 10.1016/S0092-8674(00)80952-6; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; LUESCHER IF, 1995, IMMUNITY, V3, P51, DOI 10.1016/1074-7613(95)90158-2; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; Millan J, 1999, TISSUE ANTIGENS, V53, P33, DOI 10.1034/j.1399-0039.1999.530104.x; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; OFFNER H, 1987, J IMMUNOL, V139, P3295; PASTERNACK MS, 1986, NATURE, V322, P740, DOI 10.1038/322740a0; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; Stulnig TM, 2000, FASEB J, V14, P939, DOI 10.1096/fasebj.14.7.939; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	40	19	20	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1601	+		10.1096/fj.00-0841fje	http://dx.doi.org/10.1096/fj.00-0841fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427499				2022-12-28	WOS:000173707700019
J	Simonitsch, I; Polgar, D; Hajek, M; Duchek, P; Skrzypek, B; Fassl, S; Lamprecht, A; Schmidt, G; Krupitza, G; Cerni, C				Simonitsch, I; Polgar, D; Hajek, M; Duchek, P; Skrzypek, B; Fassl, S; Lamprecht, A; Schmidt, G; Krupitza, G; Cerni, C			The cytoplasmic truncated receptor tyrosine kinase ALK-homodimer immortalizes and cooperates with ras in cellular transformation	FASEB JOURNAL			English	Article						NPM/ALK; NTM/ALK constructs; primary rat embryo cells; immortalization; transformation; tumor formation	ANAPLASTIC LYMPHOMA KINASE; NON-HODGKINS-LYMPHOMA; CHROMOSOMAL TRANSLOCATION; MALIGNANT-TRANSFORMATION; TUMORIGENIC CONVERSION; POSITIVE LYMPHOMA; FUSION PROTEIN; GENE FUSION; NPM-ALK; C-MYC	Anaplastic large-cell lymphomas are highly associated with a chromosomal translocation t(2;5). This condition results in a chimeric protein NPM/ALK (nucleophosmin/anaplastic lymphoma kinase), in which the shuttle protein NPM is fused to the catalytic domain of the tyrosine receptor kinase ALK. Because the oncogenic potential of NPM/ALK is not well understood, we analyzed the effects of NPM/ALK and the specific contribution of ALK in a standardized cell culture system by using primary rat embryo cells (REC) as cellular targets. We demonstrate by several biological parameters that NPM/ALK is an immortalizing oncogene that provides unlimited, yet normal, growth potential to REC and, with cooperation with a c-H-ras oncogene, induces cellular transformation. Targeting NPM/ALK to the nucleus diminishes its oncogenicity, which indicates that the fusion protein exerts its action mainly in the cytoplasm. Expression of the mere catalytic domain of ALK is insufficient with regard to immortalization and transformation. However, reestablishing the potential of ALK to homodimerize by fusing the bacterial dimerization domain of the tetracycline repressor to ALK reenforces the immortalizing function. Collaboration of dimeric ALK with c-H-ras converted primary REC into aggressively growing tumor cell lines. These studies identify ALK as a new member of immortalizing oncoproteins that exerts its function within the cytoplasm.	Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria; Univ Vienna, Inst Clin Pathol, A-1090 Vienna, Austria	University of Vienna; University of Vienna	Cerni, C (corresponding author), Univ Vienna, Inst Canc Res, Borschkegasse 8A, A-1090 Vienna, Austria.	Christa.Cerni@.univie.ac.at		Krupitza, Georg/0000-0003-2949-7906				Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Benharroch D, 1998, BLOOD, V91, P2076, DOI 10.1182/blood.V91.6.2076; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Cerni C, 2000, MUTAT RES-REV MUTAT, V462, P31, DOI 10.1016/S1383-5742(99)00091-5; CERNI C, 1995, ONCOGENE, V11, P587; CERNI C, 1990, VIROLOGY, V177, P427, DOI 10.1016/0042-6822(90)90506-M; CERNI C, 1989, P NATL ACAD SCI USA, V86, P3266, DOI 10.1073/pnas.86.9.3266; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Colleoni GWB, 2000, AM J PATHOL, V156, P781, DOI 10.1016/S0002-9440(10)64945-0; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; Drexler HG, 2000, LEUKEMIA, V14, P1533, DOI 10.1038/sj.leu.2401878; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hernandez L, 1999, BLOOD, V94, P3265; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KNECHT H, 1993, BRIT J HAEMATOL, V83, P655, DOI 10.1111/j.1365-2141.1993.tb04706.x; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lamant L, 1999, BLOOD, V93, P3088; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOPATEGUI JR, 1995, AM J PATHOL, V146, P323; Mason DY, 1998, CANCER RES, V58, P1057; MERZAK A, 1992, ONCOGENE, V7, P2031; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; MOUGNEAU E, 1988, ONCOGENE RES, V2, P177; Ott G, 1998, GENE CHROMOSOME CANC, V22, P114, DOI 10.1002/(SICI)1098-2264(199806)22:2<114::AID-GCC5>3.0.CO;2-#; Pileri SA, 1997, AM J PATHOL, V150, P1207; Pittaluga S, 1997, AM J PATHOL, V151, P343; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; PORIES SE, 1993, GASTROENTEROLOGY, V104, P1346, DOI 10.1016/0016-5085(93)90343-B; Pospelova TV, 1999, GENE EXPRESSION, V8, P19; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; Pulford K, 1999, AM J PATHOL, V154, P1657, DOI 10.1016/S0002-9440(10)65421-1; Sandlund JT, 1996, NEW ENGL J MED, V334, P1238, DOI 10.1056/NEJM199605093341906; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHIOTA M, 1994, ONCOGENE, V9, P1567; Shiota Mami, 1997, Leukemia (Basingstoke), V11, P538; Simonitsch I, 1996, BRIT J HAEMATOL, V92, P866, DOI 10.1046/j.1365-2141.1996.402944.x; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Weisenburger DD, 1996, BLOOD, V87, P3860, DOI 10.1182/blood.V87.9.3860.bloodjournal8793860; ZERLIN M, 1987, ONCOGENE, V1, P19; ZHANG LS, 1995, CANCER RES, V55, P3890	60	17	18	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1416	+		10.1096/fj.00-0678fje	http://dx.doi.org/10.1096/fj.00-0678fje			32	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387242				2022-12-28	WOS:000173705800026
J	Tiwari, A; Salacinski, HJ; Punshon, G; Hamilton, G; Seifalian, AM				Tiwari, A; Salacinski, HJ; Punshon, G; Hamilton, G; Seifalian, AM			Development of a hybrid cardiovascular graft using a tissue engineering approach	FASEB JOURNAL			English	Article						hybrid graft; anticoagulant peptide; endothelial cells; spacer arm; covalent bonding; x-ray photoelectron spectroscopy	VASCULAR BYPASS GRAFTS; EXPANDED POLYTETRAFLUOROETHYLENE; CELL ATTACHMENT; EPTFE GRAFTS; IN-VITRO; ENDOTHELIALIZATION; ADHESION; SEQUENCE; DACRON; PTFE	Tissue engineering of endothelial cells (EC) and chemical engineering with anticoagulant moieties has been undertaken in order to improve prosthetic graft patency and thrombogenicity. This was done by covalently bonding a compliant poly(carbonate-urea) urethane graft (MyoLink(TM)) with arginine-glycine-aspartate (RGD) or/and heparin (Hep) to ascertain whether EC retention could be improved. The retention of these moieties and EC was assessed after exposure to pulsatile flow. We covalently bonded RGD, Hep, and RGD/Hep onto the luminal surface of MyoLink using spacer arm technology. Narrow-beam X-ray photoelectron spectroscopy was carried out to check the efficiency of the bonding. EC were radiolabeled and seeded onto native MyoLink and with 1) RGD-, 2) Hep-, and 3) RGD/Hep-bonded grafts and exposed to shear stress in a physiological flow circuit for 6 h, which reproduces femoral artery flow waveforms and pulsatility. Results were recorded on a gamma camera imaging system. Viability of cells was tested with a modified Alamar Blue assay (ABA) and scanning electron microscopy for morphological appearance of seeded cells. Experiments were repeated (n=6). RGD, Hep, and RGD/Hep were bonded together in a uniform distribution on the luminal surface of each graft type, and bioactivity of each moiety covalently bonded was very high. In the flow circuit, there was exponential cell retention for the first 60 min of flow for all the grafts, but after 6 h of exposure to pulsatile flow the RGD/Hep-bonded graft had a significantly better cell retention rate than native MyoLink (75.7%+/-2.3 vs. 60.5+/-10.1, P<0.05). ABA test showed that all the seeded cells postexposure to flow were viable, and significantly higher metabolic activity was recorded on a RGD/Hep-bonded graft than with MyoLink-seeded graft (P<0.01). Using RGD/Hep covalently bonded onto graft surfaces improves cell retention and provides an antithrombogenic surface for initial blood flow in vivo until full EC activity develops postseeding. This would allow the development and further improvement of hybrid grafts.	Royal Free Hosp, Univ Coll London, Royal Free & Univ Coll Med Sch, Univ Dept Surg, London NW3 2QG, England; UCL, Royal Free & Univ Coll Med Sch, Univ Dept Surg, Tissue Engn Ctr, London, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London	Seifalian, AM (corresponding author), Royal Free Hosp, Univ Coll London, Royal Free & Univ Coll Med Sch, Univ Dept Surg, Pond St, London NW3 2QG, England.	A.Seifalian@RFC.UCL.AC.UK	hamilton, george/K-4764-2013; Seifalian, Alexander M/I-6028-2013; Punshon, Geoffrey/K-5352-2013	Seifalian, Alexander M/0000-0002-1180-3322; Punshon, Geoffrey/0000-0001-9247-9546				ABBOTT WM, 1987, J VASC SURG, V5, P376, DOI 10.1067/mva.1987.avs0050376; BRANDLEY BK, 1988, ANAL BIOCHEM, V172, P270, DOI 10.1016/0003-2697(88)90442-3; Deutsch M, 1999, SURGERY, V126, P847, DOI 10.1016/S0039-6060(99)70025-5; Devine C, 2001, J VASC SURG, V33, P533, DOI 10.1067/mva.2001.113578; Giudiceandrea A, 1998, EUR J VASC ENDOVASC, V15, P147, DOI 10.1016/S1078-5884(98)80136-6; Giudiceandrea A, 2000, J ARTIF ORGANS, V3, P16; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; Hynes RO, 1999, GUIDEBOOK EXTRACELLU, P422; HYNES RO, 1990, FIBRONECTIONS; JOHNSON WC, 1988, ARCH SURG-CHICAGO, V123, P434; KRIJGSMAN B, 2002, IN PRESS TISSUE ENG; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; LIN HB, 1992, J BIOMAT SCI-POLYM E, V3, P217, DOI 10.1163/156856292X00132; LIN HB, 1994, J BIOMED MATER RES, V28, P329, DOI 10.1002/jbm.820280307; Netelenbos T, 2001, EXP HEMATOL, V29, P884, DOI 10.1016/S0301-472X(01)00653-1; Robinson BI, 1999, CARDIOVASC SURG, V7, P214, DOI 10.1016/S0967-2109(98)00126-4; RUBIN BG, 1992, J VASC SURG, V15, P683, DOI 10.1016/0741-5214(92)90016-2; Salacinski HJ, 2001, ARTIF ORGANS, V25, P974, DOI 10.1046/j.1525-1594.2001.06716.x; Salacinski HJ, 2001, MED BIOL ENG COMPUT, V39, P609, DOI 10.1007/BF02345431; Salacinski HJ, 2002, J BIOMED MATER RES, V59, P207; Salacinski HJ, 2000, EUR J VASC ENDOVASC, V20, P342, DOI 10.1053/ejvs.2000.1185; Seifalian AM, 2001, J BIOMED MATER RES, V55, P637, DOI 10.1002/1097-4636(20010615)55:4<637::AID-JBM1058>3.0.CO;2-Z; SEIFALIAN AM, 1999, TISSUE ENG PROSTHETI, V2, P45; Tai NR, 2000, BRIT J SURG, V87, P1516, DOI 10.1046/j.1365-2168.2000.01566.x; Tiwari A, 2001, EUR J VASC ENDOVASC, V21, P193, DOI 10.1053/ejvs.2001.1316; TIWARI A, 2002, IN PRESS CARDIOVASC; VOHRA RK, 1990, ARTIF ORGANS, V14, P41; Walluscheck KP, 1996, EUR J VASC ENDOVASC, V12, P321, DOI 10.1016/S1078-5884(96)80251-6; Walpoth BH, 1998, CIRCULATION, V98, pII319; ZILLA P, 1989, SURGERY, V105, P515	30	100	106	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6682/02/0016-0791	10.1096/fj.01-0826com	http://dx.doi.org/10.1096/fj.01-0826com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039860				2022-12-28	WOS:000176683900004
J	Thomas, LL; Xu, W; Ardon, TT				Thomas, LL; Xu, W; Ardon, TT			Immobilized lactoferrin (Lf) stimulates eosinophil superoxide (O-2) production and release of eosinophil-derived neurotoxin (EDN).	FASEB JOURNAL			English	Meeting Abstract									Rush Univ, Chicago, IL 60612 USA; Beloit Coll, Beloit, WI 53511 USA	Rush University; Beloit College				xu, weiming/0000-0002-7085-7814					0	45	58	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 22	2002	16	5	2				A1238	A1239		10.1096/fj.01-0590fje	http://dx.doi.org/10.1096/fj.01-0590fje			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	534PC	11772948				2022-12-28	WOS:000174593902841
J	Gu, YC; Gorelik, J; Spohr, HA; Shevchuk, A; Lab, MJ; Harding, SE; Vodyanoy, I; Klenerman, D; Korchev, YE				Gu, YC; Gorelik, J; Spohr, HA; Shevchuk, A; Lab, MJ; Harding, SE; Vodyanoy, I; Klenerman, D; Korchev, YE			High-resolution scanning patch-clamp: new insights into cell function	FASEB JOURNAL			English	Article						calcium channels; chloride channels; potassium channels; cardiomyocyte; neuron; sperm; patch-clamp; scanning probe microscopy	ION CONDUCTANCE MICROSCOPY; RAT VENTRICULAR MYOCYTES; CHLORIDE CHANNELS; CARDIAC MYOCYTES; CA2+ CHANNELS; POTASSIUM CHANNELS; SKELETAL-MUSCLE; SODIUM-CHANNELS; LIVING CELLS; CL CHANNELS	Cell specialization is often governed by the spatial distribution of ion channels and receptors on the cell surface. So far, little is known about functional ion channel localization. This is due to a lack of satisfactory methods for investigating ion channels in an intact cell and simultaneously determining the channels' positions accurately. We have developed a novel high-resolution scanning patch-clamp technique that enables the study of ion channels, not only in small cells, such as sperm, but in submicrometer cellular structures, such as epithelial microvilli, fine neuronal dendrites, and, particularly, T-tubule openings of cardiac myocytes. In cardiac myocytes, as in most excitable cells, action potential propagation depends essentially on the properties of ion channels that are functionally and spatially coupled. We found that the L-type calcium and chloride channels are distributed and colocalized in the region of T-tubule openings, but not in other regions of the myocyte. In addition, chloride channels were found in narrowly defined regions of Z-grooves. This finding suggests a new synergism between these types of channels that may be relevant for action potential propagation along the T-tubule system and excitation-contraction coupling.	Univ London Imperial Coll Sci Technol & Med, Div Med, MRC Clin Sci Ctr, Fac Med, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; Off Naval Res, Arlington, VA 22217 USA; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	Imperial College London; Imperial College London; United States Department of Defense; United States Navy; University of Cambridge	Korchev, YE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Med, MRC Clin Sci Ctr, Fac Med, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	y.korchev@ic.ac.uk	Korchev, Yuri/D-2498-2009; Harding, Sophie/HCH-8711-2022	Korchev, Yuri/0000-0002-4872-8696; Gorelik, Julia/0000-0003-1148-9158; Klenerman, David/0000-0001-7116-6954; gu, yuchun/0000-0002-7558-0447				Abrami L, 1997, EUR J CELL BIOL, V73, P215; Ahmed N, 2000, BIOCHEM J, V352, P789, DOI 10.1042/0264-6021:3520789; Alkondon M, 1996, J PHARMACOL EXP THER, V279, P1491; ALMERS W, 1983, J PHYSIOL-LONDON, V336, P261, DOI 10.1113/jphysiol.1983.sp014580; Alonso G, 1997, NEUROSCIENCE, V77, P617; ANGELIDES KJ, 1986, NATURE, V321, P63, DOI 10.1038/321063a0; Banke TG, 1997, J NEUROSCI RES, V49, P176, DOI 10.1002/(SICI)1097-4547(19970715)49:2<176::AID-JNR6>3.0.CO;2-6; Britton FC, 2000, AM J PHYSIOL-HEART C, V279, pH2225, DOI 10.1152/ajpheart.2000.279.5.H2225; CHENG H, 1994, PFLUG ARCH EUR J PHY, V428, P415, DOI 10.1007/BF00724526; COHEN MW, 1991, J NEUROSCI, V11, P1032; Curtis Michael J., 1994, Journal of Basic and Clinical Physiology and Pharmacology, V5, P19; Duan D, 2000, CIRC RES, V86, pE63, DOI 10.1161/01.RES.86.4.e63; Duan D, 1997, CIRC RES, V80, P103, DOI 10.1161/01.RES.80.1.103; EHARA T, 1990, NATURE, V347, P284, DOI 10.1038/347284a0; FROSCH MP, 1992, NEUROSCI LETT, V138, P59, DOI 10.1016/0304-3940(92)90472-J; Gathercole DV, 2000, J MOL CELL CARDIOL, V32, P1981, DOI 10.1006/jmcc.2000.1230; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSMA PK, 1989, SCIENCE, V243, P641, DOI 10.1126/science.2464851; HARDING SE, 1988, J MOL CELL CARDIOL, V20, P635, DOI 10.1016/S0022-2828(88)80121-4; HAUSSLER U, 1994, PFLUG ARCH EUR J PHY, V428, P323, DOI 10.1007/BF00724514; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; JOE EH, 1992, NATURE, V356, P333, DOI 10.1038/356333a0; KARPEN JW, 1992, J PHYSIOL-LONDON, V448, P257, DOI 10.1113/jphysiol.1992.sp019040; KINNAMON SC, 1988, P NATL ACAD SCI USA, V85, P7023, DOI 10.1073/pnas.85.18.7023; Korchev YE, 2000, NAT CELL BIOL, V2, P616, DOI 10.1038/35023563; Korchev YE, 1997, BIOPHYS J, V73, P653, DOI 10.1016/S0006-3495(97)78100-1; Korchev YE, 2000, BIOPHYS J, V78, P451, DOI 10.1016/S0006-3495(00)76607-0; Lopatin AN, 1998, TRENDS PHARMACOL SCI, V19, P395, DOI 10.1016/S0165-6147(98)01238-3; Maduke M, 2000, ANNU REV BIOPH BIOM, V29, P411, DOI 10.1146/annurev.biophys.29.1.411; Marrion NV, 1998, NATURE, V395, P900, DOI 10.1038/27674; Pascarel C, 1999, EXP PHYSIOL, V84, P1043, DOI 10.1111/j.1469-445X.1999.01876.x; Premkumar LS, 1999, MOL PHARMACOL, V56, P1138, DOI 10.1124/mol.56.6.1138; Reinhardt J, 1998, P NATL ACAD SCI USA, V95, P5378, DOI 10.1073/pnas.95.9.5378; SARIBANSOHRABY S, 1984, J BIOL CHEM, V259, P1221; Saviane C, 1999, J GEN PHYSIOL, V113, P457, DOI 10.1085/jgp.113.3.457; Scriven DRL, 2000, BIOPHYS J, V79, P2682, DOI 10.1016/S0006-3495(00)76506-4; Sorota S, 1999, CARDIOVASC RES, V42, P361, DOI 10.1016/S0008-6363(99)00039-5; Spencer CI, 2000, BRIT J PHARMACOL, V129, P235, DOI 10.1038/sj.bjp.0703074; SUN XH, 1995, J CELL BIOL, V129, P659, DOI 10.1083/jcb.129.3.659; TOUSSON A, 1989, J CELL SCI, V93, P349	41	65	68	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					748	+		10.1096/fj.01-1024fje	http://dx.doi.org/10.1096/fj.01-1024fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923226				2022-12-28	WOS:000174755900002
J	Schliess, F; Gorg, B; Fischer, R; Desjardins, P; Bidmon, HJ; Herrmann, A; Butterworth, RF; Zilles, K; Haussinger, D				Schliess, F; Gorg, B; Fischer, R; Desjardins, P; Bidmon, HJ; Herrmann, A; Butterworth, RF; Zilles, K; Haussinger, D			Ammonia induces MK-801-sensitive nitration and phosphorylation of protein tyrosine residues in rat astrocytes	FASEB JOURNAL			English	Article						MAP kinases; calcium; hepatic; encephalopathy; nitric oxide; NMDA receptor; glutamine synthetase; liver	NITRIC-OXIDE SYNTHASE; D-ASPARTATE RECEPTORS; BRAIN IN-VIVO; HEPATIC-ENCEPHALOPATHY; PORTACAVAL ANASTOMOSIS; GLUTAMINE-SYNTHETASE; CULTURED ASTROCYTES; HYPO-OSMOLARITY; CEREBRAL EDEMA; NMDA RECEPTORS	Astrocytes play a key role in the pathogenesis of ammonia-induced neurotoxicity and hepatic encephalopathy. As shown here, ammonia induces protein tyrosine nitration in cultured rat astrocytes, which is sensitive to the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801. A similar pattern of nitrated proteins is produced by NMDA. Ammonia-induced tyrosine nitration depends on a rise in [Ca2+](i), IkappaB degradation, and NO synthase (iNOS) induction, which are prevented by MK-801 and the intracellular Ca2+ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA-AM). Moreover, the increase in tyrosine nitration is blunted by L-NMMA, 1400W, uric acid, Cu, Zn-superoxide dismutase/catalase treatment, and methionine-sulfoximine, which indicate the involvement of reactive nitrogen intermediates and intracellular glutamine accumulation. Such reactive nitrogen intermediates additionally mediate ammonia-induced phosphorylation of the MAP-kinases Erk-1/Erk-2 and p38(MAPK). Among the proteins, which are tyrosine-nitrated by ammonia, glyceraldehyde-3-phosphate dehydrogenase, the peripheral-type benzodiazepine receptor, Erk-1, and glutamine synthetase are identified. Ammonia-induced nitration of glutamine synthetase is associated with a loss of enzymatic activity. Astroglial protein tyrosine nitration is found in brains from rats after acute ammonia-intoxication or after portacaval anastomosis, indicating the in vivo relevance of the present findings. The production of reactive nitrogen intermediates and protein tyrosine nitration may alter astrocyte function and contribute to ammonia neurotoxicity.	Univ Dusseldorf, Med Einrichtungen, Klin Gastroenterol Hepatol & Infektiol, D-40225 Dusseldorf, Germany; Univ Montreal, Hop St Luc, Neurosci Res Unit, Montreal, PQ H3C 3J7, Canada; Univ Dusseldorf, C&O Vogt Inst Brain Res, D-40225 Dusseldorf, Germany; Cardion AG, Erkrath, Germany; Res Ctr Julich, Inst Internal Med, Julich, Germany	Heinrich Heine University Dusseldorf; Universite de Montreal; Heinrich Heine University Dusseldorf; Helmholtz Association; Research Center Julich	Haussinger, D (corresponding author), Univ Dusseldorf, Med Einrichtungen, Klin Gastroenterol Hepatol & Infektiol, Moorenstr 5, D-40225 Dusseldorf, Germany.	Haeussin@uni-duesseldorf.de	Zilles, Karl/Y-3784-2019; Zilles, Karl/J-9704-2013	Zilles, Karl/0000-0002-4705-4175; Zilles, Karl/0000-0001-9296-9959; Gorg, Boris/0000-0002-4630-9420				Allert N, 1998, BRAIN RES, V782, P261, DOI 10.1016/S0006-8993(97)01288-2; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Bidmon HJ, 2001, EXP NEUROL, V168, P1, DOI 10.1006/exnr.2000.7456; Blei AT, 1999, J HEPATOL, V31, P771, DOI 10.1016/S0168-8278(99)80361-4; Braissant O, 1999, NEUROSCI LETT, V266, P89, DOI 10.1016/S0304-3940(99)00274-8; Brunelli L, 2001, FREE RADICAL BIO MED, V30, P709, DOI 10.1016/S0891-5849(00)00512-8; Buchczyk DP, 2000, BIOL CHEM, V381, P121, DOI 10.1515/BC.2000.017; BUTTERWORTH RF, 1987, NEUROCHEM PATHOL, V6, P1, DOI 10.1007/BF02833598; BUTTERWORTH RF, 1988, J NEUROCHEM, V51, P486, DOI 10.1111/j.1471-4159.1988.tb01064.x; Chamuleau RAFM, 1996, SEMIN LIVER DIS, V16, P265, DOI 10.1055/s-2007-1007239; Desjardins P, 1999, METAB BRAIN DIS, V14, P273, DOI 10.1023/A:1020741226752; Fischer R, 1997, GLIA, V20, P51; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; GIGUERE JF, 1992, BRAIN RES, V585, P295, DOI 10.1016/0006-8993(92)91222-Z; HAUSSINGER D, 1994, GASTROENTEROLOGY, V107, P1475; Haussinger D, 2000, J HEPATOL, V32, P1035, DOI 10.1016/S0168-8278(00)80110-5; Hazell AS, 1999, P SOC EXP BIOL MED, V222, P99, DOI 10.1046/j.1525-1373.1999.d01-120.x; Hazell AS, 1998, NEUROCHEM RES, V23, P869, DOI 10.1023/A:1022411012512; Hermenegildo C, 2000, HEPATOLOGY, V31, P709, DOI 10.1002/hep.510310322; HIDAKA H, 1983, METHOD ENZYMOL, P94; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; Isaacks RE, 1999, NEUROCHEM RES, V24, P51, DOI 10.1023/A:1020928029845; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Klotz LO, 2000, BIOCHEM J, V352, P219, DOI 10.1042/0264-6021:3520219; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kosenko E, 1999, FREE RADICAL BIO MED, V26, P1369, DOI 10.1016/S0891-5849(98)00339-6; Kosenko E, 2000, BRAIN RES, V880, P139, DOI 10.1016/S0006-8993(00)02785-2; Kosenko E, 1998, METAB BRAIN DIS, V13, P29, DOI 10.1023/A:1020626928259; Larsen FS, 2001, J HEPATOL, V34, P548, DOI 10.1016/S0168-8278(00)00069-6; Lin KI, 1998, CELL DEATH DIFFER, V5, P577, DOI 10.1038/sj.cdd.4400384; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; Master S, 1999, HEPATOLOGY, V30, P876, DOI 10.1002/hep.510300428; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; NORENBERG MD, 1991, NEUROCHEM RES, V16, P833, DOI 10.1007/BF00965694; Norenberg MD, 1998, METAB BRAIN DIS, V13, P319, DOI 10.1023/A:1020688925901; OCONNOR ER, 1993, J NEUROSCI, V13, P2638, DOI 10.1523/JNEUROSCI.13-06-02638.1993; Peng TI, 1998, MOL PHARMACOL, V53, P974; Schliess F, 2001, J HEPATOL, V34, P610, DOI 10.1016/S0168-8278(01)00051-4; Schliess F, 1996, BIOCHEM J, V320, P167, DOI 10.1042/bj3200167; Stewart VC, 2000, J NEUROCHEM, V75, P694, DOI 10.1046/j.1471-4159.2000.0750694.x; Vogels BAPM, 1997, HEPATOLOGY, V25, P820, DOI 10.1002/hep.510250406; WARD HK, 1979, J NEUROCHEM, V33, P339, DOI 10.1111/j.1471-4159.1979.tb11737.x; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104	44	238	244	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					739	+		10.1096/fj.01-0862fje	http://dx.doi.org/10.1096/fj.01-0862fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923223				2022-12-28	WOS:000174755900012
J	Urbich, C; Reissner, A; Chavakis, E; Dernbach, E; Haendeler, J; Fleming, I; Zeiher, AM; Kaszkin, M; Dimmeler, S				Urbich, C; Reissner, A; Chavakis, E; Dernbach, E; Haendeler, J; Fleming, I; Zeiher, AM; Kaszkin, M; Dimmeler, S			Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin	FASEB JOURNAL			English	Article						angiogenesis; Akt; migration; VEGF signaling; PP2A	GROWTH-FACTOR; CELL MIGRATION; AKT; PHOSPHORYLATION; VEGF; ANGIOSTATIN; INHIBITORS; SURVIVAL; SUPPRESSION; ACTIVATION	Endostatin is an anti-angiogenic factor that inhibits endothelial cell (EC) migration and induces EC apoptosis. Because nitric oxide (NO) plays a key role in vascular endothelial growth factor (VEGF)-induced angiogenesis, we hypothesized that endostatin interferes with the activation of the endothelial NO synthase (eNOS). Human recombinant endostatin significantly reduced VEGF-induced NO-release, which suggests that endostatin inhibits eNOS activation. Because the activation of eNOS by VEGF is associated with the Akt-dependent phosphorylation of eNOS at Ser1177, we investigated whether endostatin interferes with phosphorylation of eNOS. Endostatin reduced VEGF-induced phosphorylation of eNOS at Ser1177, whereas Akt phosphorylation was not affected. Coinciding with the inhibition of eNOS phosphorylation, endostatin completely blocked VEGF-induced EC migration. The NO-donor SNAP reversed the inhibitory effect of endostatin on EC migration. In addition, endostatin significantly inhibited VEGF-induced tube formation, whereas endostatin did not affect tube formation induced by NO. Finally, a non-dephosphorylatable constitutive active eNOS construct (S1177D), but not constitutive active Akt, abolished the inhibitory effect of endostatin on EC migration. Endostatin activated PP2A, which is known to directly dephosphorylate eNOS at Ser1177. Inhibition of PP2A prevented the inhibitory effect of endostatin. Thus, endostatin inhibits VEGF-induced EC migration and angiogenesis upstream of NO-synthesis via dephosphorylation of eNOS at Ser1177.	Goethe Univ Frankfurt, Dept Internal Med 4, Div Mol Cardiol, D-60590 Frankfurt, Germany; Goethe Univ Frankfurt, Inst Cardiovasc Physiol, D-60590 Frankfurt, Germany; Goethe Univ Frankfurt, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt	Dimmeler, S (corresponding author), Goethe Univ Frankfurt, Dept Internal Med 4, Div Mol Cardiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Dimmeler@em.uni-frankfurt.de	Fleming, Ingrid/L-1225-2014; Fleming, Ingrid/AAB-6123-2022	Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635; Dimmeler, Stefanie/0000-0002-1045-2436; Haendeler, Judith/0000-0001-8507-4540				Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bishop E T, 1999, Angiogenesis, V3, P335, DOI 10.1023/A:1026546219962; Boehm T, 1998, BIOCHEM BIOPH RES CO, V252, P190, DOI 10.1006/bbrc.1998.9617; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Chavakis E, 2001, CIRCULATION, V103, P2102; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; Clauss M, 2000, CIRC RES, V86, P251, DOI 10.1161/01.RES.86.3.251; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Ding YH, 1998, P NATL ACAD SCI USA, V95, P10443, DOI 10.1073/pnas.95.18.10443; Evans DRH, 1999, J BIOL CHEM, V274, P24038, DOI 10.1074/jbc.274.34.24038; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Isner JM, 1999, NAT MED, V5, P491, DOI 10.1038/8374; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kuhlencordt PJ, 2001, CIRCULATION, V104, P448, DOI 10.1161/hc2901.091399; Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1; Ma L, 2001, P NATL ACAD SCI USA, V98, P6470, DOI 10.1073/pnas.111150798; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; Muller JM, 1997, CIRC RES, V80, P320, DOI 10.1161/01.RES.80.3.320; Murohara T, 1999, ARTERIOSCL THROM VAS, V19, P1156, DOI 10.1161/01.ATV.19.5.1156; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pages G, 2000, ANN NY ACAD SCI, V902, P187; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ryan CJ, 2000, DRUG AGING, V17, P249, DOI 10.2165/00002512-200017040-00001; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Sim BKL, 2000, CANCER METAST REV, V19, P181, DOI 10.1023/A:1026551202548; Soff GA, 2000, CANCER METAST REV, V19, P97, DOI 10.1023/A:1026525121027; Thomsen LL, 1998, CANCER METAST REV, V17, P107, DOI 10.1023/A:1005912906436; Urbich C, 2000, CIRC RES, V87, P683, DOI 10.1161/01.RES.87.8.683; Urbich C, 2002, ARTERIOSCL THROM VAS, V22, P69, DOI 10.1161/hq0102.101518; Webb CP, 2000, J NEURO-ONCOL, V50, P71, DOI 10.1023/A:1006466605356; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Ziche M, 2000, J NEURO-ONCOL, V50, P139, DOI 10.1023/A:1006431309841	57	113	127	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					706	+		10.1096/fj.01-0637fje	http://dx.doi.org/10.1096/fj.01-0637fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11978735				2022-12-28	WOS:000174755900015
J	Jones, DR; Sanjuan, MA; Stone, JC; Merida, I				Jones, DR; Sanjuan, MA; Stone, JC; Merida, I			Expression of a catalytically inactive form of diacylglycerol kinase induces sustained signaling through RasGRP	FASEB JOURNAL			English	Article						GFP; Ras signaling; Erk; lymphocytes; T cell activation	T-CELL ACTIVATION; CALCIUM-BINDING; PROTEIN; ALPHA; LYMPHOCYTES; RECEPTOR; TRANSLOCATION; STIMULATION; ANTIGEN; P21RAS	Regulating the generation and clearance of lipid second messengers, such as diacylglycerol (DAG), is critical for the correct propagation of intracellular signaling pathways. DAGK type alpha acts as a negative modulator of the DAG levels generated during T cell activation, which is initiated by triggering of the endogenous T cell receptor (TCR), as well as by stimulation of an ectopically expressed human muscarinic type 1 receptor. Here we show that stimulation of either of these receptors causes rapid, transient membrane translocation of the recently discovered Ras guanyl nucleotide release protein (RasGRP), followed by activation of mitogen-activated protein kinase (MAPK). When cells expressing a catalytically inactive form of DAGKalpha were analyzed, however, similar agonist stimulation resulted in sustained signaling through RasGRP and MAPK. Biochemical analysis showed that expression of kinase-dead diacylglycerol kinase alpha (DGKalpha) led to a greater, more sustained, DAG accumulation following receptor stimulation. These results suggest that, in T cells, agonist-stimulated DAG generation is the key factor controlling activation of the Ras/MAPK signaling pathway through membrane translocation of RasGRP. Moreover, we demonstrate that through the modulation of the intracellular level of agonist-stimulated DAG, DGKalpha alters Ras activation and downstream signaling dramatically, a process of utmost importance for sound immunological function.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Univ Alberta, Dept Biochem, Edmonton, AB, Canada	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); University of Alberta	Merida, I (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Plaza Murillo 2, E-28049 Madrid, Spain.	imerida@cnb.uam.es	Merida, Isabel/A-9713-2014; Sanjuán, Miguel AF/B-7709-2011	Merida, Isabel/0000-0003-2762-6241; Sanjuán, Miguel AF/0000-0003-3515-0837				Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; Flores I, 1999, J IMMUNOL, V163, P708; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; Genot E, 2000, CURR OPIN IMMUNOL, V12, P289, DOI 10.1016/S0952-7915(00)00089-3; Genot E, 1998, ONCOGENE, V17, P1731, DOI 10.1038/sj.onc.1202101; Izquierdo M, 1996, J IMMUNOL, V157, P21; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; Jiang Y, 2000, J BIOL CHEM, V275, P34092, DOI 10.1074/jbc.M004914200; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; Jones DR, 1998, FEBS LETT, V433, P23, DOI 10.1016/S0014-5793(98)00875-8; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Pierret P, 2000, J NEUROCYTOL, V29, P485, DOI 10.1023/A:1007245728751; REIF K, 1994, J BIOL CHEM, V269, P14081; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SAKANE F, 1991, J BIOL CHEM, V266, P7096; Sakane F, 1996, BIOCHEM J, V318, P583, DOI 10.1042/bj3180583; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Wada I, 1996, FEBS LETT, V393, P48, DOI 10.1016/0014-5793(96)00857-5; YAMADA K, 1989, FEBS LETT, V244, P402, DOI 10.1016/0014-5793(89)80572-1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	34	57	60	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					595	+		10.1096/fj.01-0762fje	http://dx.doi.org/10.1096/fj.01-0762fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919165				2022-12-28	WOS:000174203700012
J	Birbes, H; El Bawab, S; Hannun, YA; Obeid, LM				Birbes, H; El Bawab, S; Hannun, YA; Obeid, LM			Selective hydrolysis of a mitochondrial pool of sphingomyelin induces apoptosis	FASEB JOURNAL			English	Article						targeting; ceramide; mitochondria; apoptosis; Bcl-2; cytochrome c	PERMEABILITY TRANSITION PORE; CERAMIDE-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; CYTOCHROME-C RELEASE; DISTINCT POOL; CELL-SURFACE; BCL-2; ACTIVATION; MEMBRANES; DEATH	Our previous results have indicated that the major cellular pool of sphingomyelin present on the outer leaflet of the plasma membrane is not involved in the ceramide pathway of apoptosis. Thus, in this study we aimed at defining which intracellular pools of sphingomyelin and ceramide are involved in cell death. The bacterial sphingomyelinase (SMase) gene fused with green fluorescent protein was subcloned into mammalian vectors containing sequences that target the fusion proteins to cytoplasm, plasma membrane, mitochondria, Golgi apparatus, endoplasmic reticulum, or nucleus. Transfection of MCF7 breast cancer cells showed for all constructs an increase in SMase activity ranging from 2- to 60-fold, concomitant with an increase in total cellular ceramide levels (10-100%) as compared with vector-transfected cells. Next, the effect of overexpression of the SMase on cell death was examined. Results demonstrate that only when bacterial SMase was targeted to mitochondria did cells undergo apoptosis; its targeting to the other intracellular compartments was ineffective. Further, the results show that apoptosis induced by mitochondrial targeting of bacterial SMase requires SMase catalytic activity, is prevented by the overexpression of Bcl-2, and is mediated by inducing cytochrome c release. These results demonstrate that ceramide induces cell death specifically when generated in mitochondria. The results highlight the significance of compartment-specific lipid-mediated cell regulation, and they offer a novel general approach for these studies.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Adm, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 114 Doughty St,Strom Thurmond Bldg,Room 605, Charleston, SC 29425 USA.	obeidl@musc.edu		obeid, lina/0000-0002-0734-0847	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER; NIA NIH HHS [AG16583] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE A, 1995, J LIPID RES, V36, P611; Andrieu N, 1996, EUR J BIOCHEM, V236, P738, DOI 10.1111/j.1432-1033.1996.00738.x; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Bielawska AE, 1997, AM J PATHOL, V151, P1257; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; COLLEY CM, 1973, BIOCHIM BIOPHYS ACTA, V307, P74, DOI 10.1016/0005-2736(73)90026-6; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FISCHERFANTUZZI L, 1988, MOL CELL BIOL, V8, P5495, DOI 10.1128/MCB.8.12.5495; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jarvis WD, 1997, MOL PHARMACOL, V52, P935, DOI 10.1124/mol.52.6.935; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Luberto C, 2000, J BIOL CHEM, V275, P14760, DOI 10.1074/jbc.275.19.14760; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RAWYLER AJ, 1983, BIOCHIM BIOPHYS ACTA, V730, P130, DOI 10.1016/0005-2736(83)90325-5; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; TAMURA H, 1995, BIOCHEM J, V309, P757, DOI 10.1042/bj3090757; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Veldman RJ, 1998, BIOCHEM J, V331, P563, DOI 10.1042/bj3310563; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; VENIEN C, 1988, BIOCHIM BIOPHYS ACTA, V942, P159, DOI 10.1016/0005-2736(88)90285-4; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhang P, 1997, J BIOL CHEM, V272, P9609; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000; ZWAAL RFA, 1975, BIOCHIM BIOPHYS ACTA, V406, P83, DOI 10.1016/0005-2736(75)90044-9	60	205	212	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2669	2679		10.1096/fj.01-0539com	http://dx.doi.org/10.1096/fj.01-0539com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726543				2022-12-28	WOS:000172964800037
J	Butler, PJ; Tsou, TC; Li, JYS; Usami, S; Chien, S				Butler, PJ; Tsou, TC; Li, JYS; Usami, S; Chien, S			Rate sensitivity of shear-induced changes in the lateral diffusion of endothelial cell membrane lipids: a role for membrane perturbation in shear-induced MAPK activation	FASEB JOURNAL			English	Article						membrane fluidity; force; gene expression; FRAP; confocal	STRESS; KINASE; CHOLESTEROL; MODULATION; PROTEINS	Vascular endothelium transduces the temporal gradients in shear stress (tau) originating from unsteady blood flow into functional responses. We measured the effects of step-tau and ramp-tau (i.e., with different temporal shear gradients) on the lipid lateral diffusion coefficient (D) in the apical membranes of confluent cultured bovine aortic endothelial cells by using fluorescence recovery after photobleaching. A step-tau of 10 dynes/cm(2) elicited a rapid (5 s) increase of D in the portion of the cell upstream of the nucleus and a concomitant decrease in the downstream portion. A ramp-tau with a rate of 20 dynes/cm(2) per min elicited a rapid (5 s) decrease of D in both the upstream and the downstream portions. The mitogen-activated protein kinases (MAPKs) ERK and JNK were activated by step-tau but not by ramping to the same tau level. Benzyl alcohol, which increases D, enhanced the activities of both MAPKs; cholesterol, which reduces D, diminished these activities. We conclude that the lipid bilayer can sense the temporal features of the applied tau with spatial discrimination and that the tau -induced membrane perturbations can be transduced into MAPK activation. These results have implications for understanding the role of tau in modulating vascular functions in health and disease.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Univ Calif San Diego, Whitaker Inst Biomed Engn, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Chien, S (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr,MC 0427, La Jolla, CA 92093 USA.	shuchien@ucsd.edu	Tsou, Tsui-Chun/C-1366-2010; Butler, Peter/P-2209-2017	Tsou, Tsui-Chun/0000-0003-3546-9901				AXELROD D, 1983, J MEMBRANE BIOL, V75, P1, DOI 10.1007/BF01870794; Bao XP, 2000, AM J PHYSIOL-HEART C, V278, pH1598, DOI 10.1152/ajpheart.2000.278.5.H1598; BARBEE KA, 1995, AM J PHYSIOL-HEART C, V268, pH1765, DOI 10.1152/ajpheart.1995.268.4.H1765; Blackman BR, 2000, J BIOMECH ENG-T ASME, V122, P274, DOI 10.1115/1.429660; Butler PJ, 2000, MICROCIRCULATION, V7, P53, DOI 10.1038/sj.mn.7300093; Butler PJ, 2001, AM J PHYSIOL-CELL PH, V280, pC962, DOI 10.1152/ajpcell.2001.280.4.C962; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DEPAOLA N, 1992, ARTERIOSCLER THROMB, V12, P1254, DOI 10.1161/01.ATV.12.11.1254; Frangos JA, 1996, BIOCHEM BIOPH RES CO, V224, P660, DOI 10.1006/bbrc.1996.1081; Gopalakrishna P, 2000, J CELL BIOCHEM, V77, P517, DOI 10.1002/(SICI)1097-4644(20000615)77:4<517::AID-JCB1>3.3.CO;2-Y; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Gudi S, 1998, P NATL ACAD SCI USA, V95, P2515, DOI 10.1073/pnas.95.5.2515; Haidekker MA, 2000, AM J PHYSIOL-HEART C, V278, pH1401, DOI 10.1152/ajpheart.2000.278.4.H1401; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; HECKER M, 1993, AM J PHYSIOL, V265, pH828, DOI 10.1152/ajpheart.1993.265.3.H828; Hu YL, 1999, AM J PHYSIOL-HEART C, V277, pH1593, DOI 10.1152/ajpheart.1999.277.4.H1593; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Kano Y, 1996, CIRC RES, V79, P1000, DOI 10.1161/01.RES.79.5.1000; Knudsen HL, 1997, AM J PHYSIOL-HEART C, V273, pH347, DOI 10.1152/ajpheart.1997.273.1.H347; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Mitchell DC, 1996, J BIOL CHEM, V271, P19033, DOI 10.1074/jbc.271.32.19033; Satoh A, 2000, FEBS LETT, V477, P249, DOI 10.1016/S0014-5793(00)01746-4; WOLF DE, 1985, BIOCHEMISTRY-US, V24, P582, DOI 10.1021/bi00324a006	24	68	73	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					216	+		10.1096/fj.01-0434fje	http://dx.doi.org/10.1096/fj.01-0434fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11744620				2022-12-28	WOS:000172964800019
J	Hwang, D				Hwang, D			Modulation of the expression of cyclooxygenase-2 by fatty acids mediated through Toll-like receptor 4-derived signaling pathways	FASEB JOURNAL			English	Review						proinflammatory markers; NF-kappa B; lipopolysaccharide	NF-KAPPA-B; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; PROLIFERATOR-ACTIVATED RECEPTORS; CONFERS LIPOPOLYSACCHARIDE RESPONSIVENESS; MITOGEN-INDUCIBLE CYCLOOXYGENASE; CELL WALL COMPONENTS; HUMAN COLON-CANCER; MESSENGER-RNA; EPITHELIAL-CELLS; TERMINAL KINASE	Genetic evidence that Toll-like receptor 4 (Tlr4) is the lipopolysaccharide (LPS) receptor and biochemical evidence that Tlr4 confers LPS responsiveness as determined by activation of NF-kappaB and expression of inducible cyclooxygenase 2 have been demonstrated. Saturated fatty acids (SFAs) acylated in lipid A moiety of LPS are essential for biological activities of LPS. It is now demonstrated that SFAs, but not unsaturated fatty acids (UFAs), induce NF-kappaB activation and expression of COX-2 and other inflammatory markers in macrophages. UFAs inhibit COX-2 expression induced by SFAs and LPS. Additional evidence suggests that both SFA-induced COX-2 expression and its inhibition by UFAs are mediated through a common signaling pathway derived from Tlr4. These results represent a novel mechanism by which fatty acids modulate signaling pathways and target gene expression. Whether fatty acids also modulate signaling pathways and target gene expression derived from the activation of other Tlrs remains to be determined.-Hwang, D. Modulation of the expression of cyclooxygenase 2 by fatty acids mediated through Toll-like receptor 4-derived signaling pathways.	Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Hwang, D (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	hwangdh@pbrc.edu			NCI NIH HHS [CA-75613] Funding Source: Medline; NIDDK NIH HHS [DK-41868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Greene C, 1999, BBA-MOL CELL RES, V1451, P109, DOI 10.1016/S0167-4889(99)00079-8; HAMASAKI Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P226, DOI 10.1006/abbi.1993.1343; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HAN JH, 1993, J BIOL CHEM, V268, P25009; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Hwang D, 1999, AM J CLIN NUTR, V70, P545; Ingalls RR, 1999, INFECT DIS CLIN N AM, V13, P341, DOI 10.1016/S0891-5520(05)70078-7; JONES DA, 1993, J BIOL CHEM, V268, P9049; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LEE JY, 2001, J BIOL CHEM, V2, P2; LEE SH, 1992, J BIOL CHEM, V267, P25934; LIN AH, 1989, J BIOL CHEM, V264, P17379; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; OBANION MK, 1991, J BIOL CHEM, V266, P23261; Paik JH, 2000, J BIOL CHEM, V275, P28173; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, TRENDS GENET, V15, P291, DOI 10.1016/S0168-9525(99)01782-5; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; SANO H, 1995, CANCER RES, V55, P3785; SCHUPBACH T, 1989, GENETICS, V121, P101; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; Yoshimura A, 1999, J IMMUNOL, V163, P1; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	74	121	128	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					2556	2564		10.1096/fj.01-0432com	http://dx.doi.org/10.1096/fj.01-0432com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726530				2022-12-28	WOS:000172964800024
J	Arck, PC; Handjiski, B; Hagen, E; Joachim, R; Klapp, BF; Paus, R				Arck, PC; Handjiski, B; Hagen, E; Joachim, R; Klapp, BF; Paus, R			Indications for a brain-hair follicle axis: inhibition of keratinocyte proliferation and up-regulation of keratinocyte apoptosis in telogen hair follicles by stress and substance P	FASEB JOURNAL			English	Article						sonic stress; activated macrophages; apoptosis; hair follicle; mast cells	CORTICOTROPIN-RELEASING HORMONE; MAST-CELL DEGRANULATION; MURINE SKIN; MODULATION; RECEPTOR; INVOLVEMENT; NEUROPEPTIDES; MACROPHAGES; ENDOCRINE; BIOLOGY	It has long been suspected that stress can cause hair loss, although convincing evidence of this has been unavailable. Here, we show that in mice sonic stress significantly increased the number of hair follicles containing apoptotic cells and inhibited intrafollicular keratinocyte proliferation in situ. Sonic stress also significantly increased the number of activated perifollicular macrophage clusters and the number of degranulated mast cells, whereas it down-regulated the number of intraepithelial gamma delta T lymphocytes. These stress-induced immune changes could be mimicked by injection of the neuropeptide substance P in nonstressed mice and were abrogated by a selective substance P receptor antagonist in stressed mice. We conclude that stress can indeed inhibit hair growth in vivo, probably via a substance P-dependent activation of macrophages and/or mast cells in the context of a brain-hair follicle axis.	Humboldt Univ, Dept Internal Med, Charite, Berlin, Germany; Univ Hamburg, Univ Hosp eppendorf, Dept Dermatol, Hamburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf	Arck, PC (corresponding author), Biomed Forschungszentrum, Med Klin, Charite, Campus Virchow Klinikum,Raum 2-0549,Augustenburge, D-13353 Berlin, Germany.	petra.arck@charite.de	Paus, Ralf/F-6243-2011; Arck, Petra C/D-7094-2013	Arck, Petra/0000-0002-2932-926X				ADER R, 1995, LANCET, V345, P99, DOI 10.1016/S0140-6736(95)90066-7; ARCK PC, 1995, BIOL REPROD, V53, P814, DOI 10.1095/biolreprod53.4.814; Arck PC, 1997, AM J REPROD IMMUNOL, V37, P87; Berman AS, 1996, NEUROIMMUNOMODULAT, V3, P141, DOI 10.1159/000097239; BIENENSTOCK J, 1988, MONOGR ALLERGY, V24, P134; BLALOCK JE, 1994, IMMUNOL TODAY, V15, P504, DOI 10.1016/0167-5699(94)90205-4; Botchkarev VA, 1999, J INVEST DERMATOL, V113, P878, DOI 10.1046/j.1523-1747.1999.00791.x; CAMACHO F, 1997, TRICHOLOGY; ChancellorFreeland C, 1995, ANN NY ACAD SCI, V771, P472, DOI 10.1111/j.1749-6632.1995.tb44703.x; CHASE HB, 1953, BIOL HAIR GROWTH, P435; Chrousos GP, 1998, ANN NY ACAD SCI, V851, P311, DOI 10.1111/j.1749-6632.1998.tb09006.x; Conti B, 2000, NEUROIMMUNOMODULAT, V8, P1, DOI 10.1159/000026445; Csermely P, 1998, CELL STRESS CHAPERON, V3, P1, DOI 10.1379/1466-1268(1998)003<0001:MBOSRI>2.3.CO;2; Dawber R., 1997, DIS HAIR SCALP; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; Eichmuller S, 1998, J HISTOCHEM CYTOCHEM, V46, P361, DOI 10.1177/002215549804600310; Ericson M, 1999, Exp Dermatol, V8, P344; Farooqi IS, 2000, J CLIN ENDOCR METAB, V85, P2644, DOI 10.1210/jc.85.8.2644; Farrell AM, 1997, BRIT J DERMATOL, V136, P802, DOI 10.1111/j.1365-2133.1997.tb03685.x; Foitzik K, 2000, FASEB J, V14, P752, DOI 10.1096/fasebj.14.5.752; Garcia-Hernandez Maria Jose, 1999, Journal of Dermatology (Tokyo), V26, P625; GARRET C, 1991, P NATL ACAD SCI USA, V88, P10208, DOI 10.1073/pnas.88.22.10208; GERDES J, 1984, J IMMUNOL, V133, P1710; Hordinsky M K, 1999, Exp Dermatol, V8, P314; Jessop D S, 2000, Stress, V3, P209, DOI 10.3109/10253890009001125; JOACHIM RA, IN PRESS AM J REPROD; KAWATE R, 1994, PHYSIOL BEHAV, V55, P921, DOI 10.1016/0031-9384(94)90080-9; KOBLENZER CS, 1983, ARCH DERMATOL, V119, P501, DOI 10.1001/archderm.119.6.501; Lindner G, 1997, AM J PATHOL, V151, P1601; Maurer M, 1997, LAB INVEST, V77, P319; Maurer M, 1995, Exp Dermatol, V4, P266, DOI 10.1111/j.1600-0625.1995.tb00256.x; MAZELIS AG, 1987, DIABETES RES CLIN EX, V6, P195; McCann BS, 1999, ANN BEHAV MED, V21, P103, DOI 10.1007/BF02908290; McCormack RJ, 1996, NEUROIMMUNOMODULAT, V3, P35, DOI 10.1159/000097225; McEwen BS, 1997, BRAIN RES REV, V23, P79, DOI 10.1016/S0165-0173(96)00012-4; NAKAMURA K, 1990, J NEUROIMMUNOL, V30, P23, DOI 10.1016/0165-5728(90)90049-S; NIO DA, 1993, J IMMUNOL, V150, P5281; Paus R, 1999, ANN NY ACAD SCI, V885, P350; PAUS R, 1995, ARCH DERMATOL RES, V287, P500, DOI 10.1007/BF00373436; PAUS R, 1994, DEV BIOL, V163, P230, DOI 10.1006/dbio.1994.1139; PAUS R, 1994, LAB INVEST, V71, P134; PAUS R, 1994, BRIT J DERMATOL, V130, P281, DOI 10.1111/j.1365-2133.1994.tb02922.x; Paus R, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P61, DOI 10.1038/jidsymp.1997.13; Paus R, 1999, J INVEST DERM SYMP P, V4, P226, DOI 10.1038/sj.jidsp.5640217; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, IN PRESS J ALLERGY; QUI BS, 1999, NAT MED, V5, P1178; RUCKERT R, IN PRESS BR J DERMAT; Rupniak NMJ, 1999, TRENDS PHARMACOL SCI, V20, P485, DOI 10.1016/S0165-6147(99)01396-6; RYDER M. L., 1958, BIOLOGY HAIR GROWTH, P305; SCHMIDT JB, 1994, SKIN PHARMACOL, V7, P61; Sheridan JF, 1998, ANN NY ACAD SCI, V840, P803, DOI 10.1111/j.1749-6632.1998.tb09618.x; Sinclair R, 1999, INT J DERMATOL, V38, P8, DOI 10.1046/j.1365-4362.1999.00003.x; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; STENN KS, 1994, J DERMATOL SCI, V14, P109; STENN KS, IN PRESS PHYSL REV; Suzuki R, 1999, J IMMUNOL, V163, P2410; Suzuki S, 1998, J INVEST DERMATOL, V111, P963, DOI 10.1046/j.1523-1747.1998.00427.x; Takashima A, 1996, Semin Immunol, V8, P333, DOI 10.1006/smim.1996.0044; Theoharides TC, 1998, ENDOCRINOLOGY, V139, P403, DOI 10.1210/en.139.1.403; Venencie PY, 1999, BRIT J DERMATOL, V141, P438; Webster EL, 1998, ANN NY ACAD SCI, V840, P21, DOI 10.1111/j.1749-6632.1998.tb09545.x; WHITE SE, 1976, ARCTIC ALPINE RES, V8, P1; WILLIAMS RM, 1995, CHEM IMMUNOL, V61, P208; York J, 1998, PSYCHOL REP, V82, P1044; Zhu GF, 1996, J NEUROSCI, V16, P3745	67	95	100	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2536	+		10.1096/fj.00-0699fje	http://dx.doi.org/10.1096/fj.00-0699fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641256				2022-12-28	WOS:000171372700019
J	Dominguez-Jimenez, C; Yanez-Mo, M; Carreira, A; Tejedor, R; Gonzalez-Amaro, R; Alvarez, V; Sanchez-Madrid, F				Dominguez-Jimenez, C; Yanez-Mo, M; Carreira, A; Tejedor, R; Gonzalez-Amaro, R; Alvarez, V; Sanchez-Madrid, F			Involvement of alpha 3 integrin/tetraspanins complexes in the angiogenic response induced by angiotensin II	FASEB JOURNAL			English	Article						endothelium; lateral junctions; angiogenesis; adhesion molecules; vasoactive peptide	ENDOTHELIAL GROWTH-FACTOR; JUNCTIONAL ADHESION MOLECULE; CELL-ADHESION; STIMULATES ANGIOGENESIS; CLINICAL-APPLICATIONS; INTEGRIN RECEPTOR; BETA-1 INTEGRIN; TNF-ALPHA; IFN-GAMMA; IN-VIVO	The effect of angiotensin II (Ang II) on endothelial cell (EC) function has important potential implications, both under physiological conditions and in the pathogenesis of different cardiovascular diseases. We studied the effect of Ang II on EC junctions and its possible functional consequences. We found that Ang II induced a remarkable change on human umbilical vein endothelial cells (HUVEC) in the distribution of alpha3beta1 integrin and CD151, CD9 tetraspanins on cell membrane, with an important decrease of these molecular complexes at intercellular contacts. However, the morphology of EC, the integrins located at cell-substratum contact areas, the components of adherens and tight-junctions, as well as the barrier functions of EC monolayers, remained unchanged after Ang II exposure. The Ang II effect on alpha3beta 1/tetraspanins complexes was associated with a significant induction of angiotube formation by HUVEC in an in vitro model of capillary formation on Matrigel. The effect of Ang II was mediated through the angiotensin II receptor 1 AT1 receptor and was inhibited with antibodies specific for the alpha3 integrin chain, which indicates the critical role of this integrin in the angiogenic effect of Ang II. These results show that Ang II exerts a direct and very specific effect on EC lateral junctions that is selectively associated with the induction of angiogenesis by this peptide.	Univ Autonoma Madrid, Hosp Univ Princesa, Serv Inmunol, Madrid 28006, Spain; Univ Autonoma Madrid, Hosp Univ Princesa, Serv Nefrol, Madrid 28006, Spain	Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Hospital de La Princesa	Sanchez-Madrid, F (corresponding author), Univ Autonoma Madrid, Hosp Univ Princesa, Serv Inmunol, C Diego de Leon S-N 62, Madrid 28006, Spain.	fsanchez@hlpr.insalud.es	Yáñez-Mó, María/K-8577-2014; Gonzalez-Amaro, Roberto/AAZ-1504-2020; Sanchez-Madrid, Francisco/M-7889-2016; YÃÃez-MÃ, Maria/AAI-4544-2020	Yáñez-Mó, María/0000-0001-7484-2866; Sanchez-Madrid, Francisco/0000-0001-5303-0762; YÃÃez-MÃ, Maria/0000-0001-7484-2866				ARIZA A, 1988, AM J CLIN PATHOL, V90, P437, DOI 10.1093/ajcp/90.4.437; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; Bazzoni G, 1999, CURR OPIN CELL BIOL, V11, P573, DOI 10.1016/S0955-0674(99)00023-X; Bazzoni G, 1999, TRENDS CARDIOVAS MED, V9, P147, DOI 10.1016/S1050-1738(99)00022-5; BELL L, 1990, AM J PATHOL, V137, P7; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Bischoff J, 1997, J CLIN INVEST, V99, P373, DOI 10.1172/JCI119168; Bujan J, 1999, J VASC RES, V36, P106, DOI 10.1159/000025632; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chua CC, 1998, BBA-MOL CELL RES, V1401, P187, DOI 10.1016/S0167-4889(97)00129-8; DEDHAR S, 1992, J BIOL CHEM, V267, P18908; Dimmeler S, 1997, CIRC RES, V81, P970; Fabre JE, 1999, CIRCULATION, V99, P3043, DOI 10.1161/01.CIR.99.23.3043; FERNANDEZ LA, 1985, J LAB CLIN MED, V105, P141; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; JAFFE EA, 1972, CIRCULATION, V46, P211; Kim S, 2000, PHARMACOL REV, V52, P11; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; Lampugnani MG, 1997, CURR OPIN CELL BIOL, V9, P674, DOI 10.1016/S0955-0674(97)80121-4; leNoble FAC, 1996, J VASC RES, V33, P480, DOI 10.1159/000159187; LENOBLE FAC, 1991, EUR J PHARMACOL, V195, P305, DOI 10.1016/0014-2999(91)90552-2; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Munzenmaier DH, 1996, HYPERTENSION, V27, P760, DOI 10.1161/01.HYP.27.3.760; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; Noria S, 1999, CIRC RES, V85, P504, DOI 10.1161/01.RES.85.6.504; Otani A, 1998, CIRC RES, V82, P619, DOI 10.1161/01.RES.82.5.619; Ozaki H, 1999, J IMMUNOL, V163, P553; Penas PF, 2000, J INVEST DERMATOL, V114, P1126, DOI 10.1046/j.1523-1747.2000.00998.x; Pratt RE, 1999, J AM SOC NEPHROL, V10, pS120; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; Rival Y, 1996, J IMMUNOL, V157, P1233; ROMEO G, 1995, EUR J HUM GENET, V3, P1; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Sincock PM, 1999, J CELL SCI, V112, P833; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; Stoll M, 1995, J HYPERTENS, V13, P1529; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; van Rijen HVM, 1998, CYTOKINE, V10, P258, DOI 10.1006/cyto.1997.0287; Volpert OV, 1996, J CLIN INVEST, V98, P671, DOI 10.1172/JCI118838; Williams B, 1998, LANCET, V351, P837, DOI 10.1016/S0140-6736(05)78974-1; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751	54	15	16	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1457	+		10.1096/fj.00-0651fje	http://dx.doi.org/10.1096/fj.00-0651fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387256				2022-12-28	WOS:000173705800014
J	Tran, MH; Yamada, K; Olariu, A; Mizuno, M; Ren, XH; Nabeshima, T				Tran, MH; Yamada, K; Olariu, A; Mizuno, M; Ren, XH; Nabeshima, T			Amyloid beta-peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors	FASEB JOURNAL			English	Article						amyloid beta-peptide; nitric oxide synthase; Alzheimer's disease; acetylcholine; learning and memory	NECROSIS-FACTOR-ALPHA; ALZHEIMERS-DISEASE; INTERFERON-GAMMA; IN-VIVO; MICROGLIAL CELLS; MEMORY FORMATION; BRAIN; PROTEIN; INDUCTION; PEROXYNITRITE	Amyloid beta-peptide (Abeta) plays a critical role in the development of Alzheimer's disease. However, the molecular mechanisms of Abeta-induced brain damage in vivo remain to be elucidated. Here, we investigated whether overproduction of nitric oxide (NO) catalyzed by inducible NO synthase (iNOS) is involved in Abeta-induced brain dysfunction. Chronic intracerebroventricular infusion of Abeta1-40 induced iNOS mRNA expression in the hippocampus on days 3 and 5 after the infusion. An accumulation of NO metabolites was observed, and the peak correlated with expression of iNOS mRNA. Measurement of NOS activities revealed an increase in Ca2+-independent, but not Ca2+-dependent, activity. Immunohistochemistry identified numerous iNOS-immunoreactive microglia and astrocytes in the dentate gyrus and to a lesser extent in the CA1 subfield of the hippocampus. Daily treatment with the iNOS inhibitor aminoguanidine (AG, 100 mg/kg/day, i.p.) or S-methylisothiourea (10 mg/kg/day, i.p.) during Abeta infusion prevented an impairment of nicotine-evoked acetylcholine release induced by Abeta, whereas the neuronal NOS inhibitor 7-nitroindazole (30 mg/kg/day, i.p.) had no effect. Daily treatment with AG also ameliorated the impairment of spatial learning of Abeta-infused rats in a radial arm maze. Our findings suggest that overproduction of NO catalyzed by iNOS is responsible for Abeta-induced brain dysfunction.	Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Nagoya, Aichi 4668560, Japan	Nagoya University	Nabeshima, T (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Nagoya, Aichi 4668560, Japan.	tnabeshi@med.nagoya-u.ac.jp	Yamada, Kiyofumi/I-7487-2014; Sokabe, Masahiro/I-1565-2012	Yamada, Kiyofumi/0000-0002-5280-5180; 				ADACHI H, 1993, EUR J BIOCHEM, V217, P37, DOI 10.1111/j.1432-1033.1993.tb18215.x; Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1994, ANN NY ACAD SCI, V738, P69; BOHME GA, 1993, P NATL ACAD SCI USA, V90, P9191, DOI 10.1073/pnas.90.19.9191; Braak H, 1991, BRAIN PATHOL, V1, P213, DOI 10.1111/j.1750-3639.1991.tb00661.x; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; DAWSON TM, 1994, ANN NY ACAD SCI, V738, P76; Dawson VL, 1998, PROG BRAIN RES, V118, P215; Di Stasi AMM, 1999, J NEUROCHEM, V73, P727; Galimberti D, 1999, BIOCHEM BIOPH RES CO, V263, P251, DOI 10.1006/bbrc.1999.1276; GLENNER GG, 1988, CELL, V52, P307, DOI 10.1016/S0092-8674(88)80021-7; GRIFFITHS MJD, 1993, BRIT J PHARMACOL, V110, P963, DOI 10.1111/j.1476-5381.1993.tb13907.x; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Han D, 2000, J NEUROCHEM, V74, P792, DOI 10.1046/j.1471-4159.2000.740792.x; HASEGAWA M, 1993, NEUROSCI LETT, V150, P53, DOI 10.1016/0304-3940(93)90106-U; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286, DOI 10.1152/ajpregu.1995.268.1.R286; Itoh A, 1996, J NEUROCHEM, V66, P1113; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kendrick KM, 1997, NATURE, V388, P670, DOI 10.1038/41765; Kitamura Y, 1996, GLIA, V18, P233, DOI 10.1002/(SICI)1098-1136(199611)18:3<233::AID-GLIA7>3.0.CO;2-#; Lee SC, 1999, J NEUROPATH EXP NEUR, V58, P1163, DOI 10.1097/00005072-199911000-00006; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mackenzie GM, 1997, SYNAPSE, V26, P301, DOI 10.1002/(SICI)1098-2396(199707)26:3<301::AID-SYN11>3.0.CO;2-Y; MACKENZIE GM, 1994, NEUROREPORT, V5, P1993, DOI 10.1097/00001756-199410000-00039; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Minghetti L, 1997, GLIA, V19, P152, DOI 10.1002/(SICI)1098-1136(199702)19:2<152::AID-GLIA6>3.0.CO;2-2; Nabeshima T, 1997, ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, P623; NITTA A, 1994, NEUROSCI LETT, V170, P63, DOI 10.1016/0304-3940(94)90239-9; Olariu A., 1999, Society for Neuroscience Abstracts, V25, P2118; PARK SK, 1994, BIOCHEM BIOPH RES CO, V201, P762, DOI 10.1006/bbrc.1994.1766; Park SK, 1996, J NEUROCHEM, V67, P1766; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; Smith MA, 1997, J NEUROSCI, V17, P2653; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; SZABO C, 1994, P NATL ACAD SCI USA, V91, P12472, DOI 10.1073/pnas.91.26.12472; Vodovotz Y, 1996, J EXP MED, V184, P1425, DOI 10.1084/jem.184.4.1425; Weldon DT, 1998, J NEUROSCI, V18, P2161; Yamada K, 1996, NEUROSCIENCE, V74, P365, DOI 10.1016/0306-4522(96)00161-3; Yamada K, 1999, EUR J NEUROSCI, V11, P83, DOI 10.1046/j.1460-9568.1999.00408.x; Yamada K, 1999, NEUROSCIENCE, V88, P281, DOI 10.1016/S0306-4522(98)00237-1; YAMADA K, 1995, BRIT J PHARMACOL, V115, P852, DOI 10.1111/j.1476-5381.1995.tb15011.x; Yamada K, 1997, J NEUROCHEM, V68, P1234; YAMADA K, 2000, IN PRESS PHARM THER; Yates SL, 2000, J NEUROCHEM, V74, P1017, DOI 10.1046/j.1471-4159.2000.0741017.x; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317; Zou LB, 1998, NEUROPHARMACOLOGY, V37, P323, DOI 10.1016/S0028-3908(98)00042-2; Zou LB, 1999, NEUROSCIENCE, V92, P819, DOI 10.1016/S0306-4522(99)00029-9	53	88	91	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1407	+		10.1096/fj.00-0719fje	http://dx.doi.org/10.1096/fj.00-0719fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387239				2022-12-28	WOS:000173705800029
J	Huang, STJ; Cidlowski, JA				Huang, STJ; Cidlowski, JA			Phosphorylation status modulates Bcl-2 function during glucocorticoid-induced apoptosis in T lymphocytes	FASEB JOURNAL			English	Article						Bcl-2 expression; glucocorticoids; cell shrinkage	PERMEABILITY TRANSITION PORE; MITOTIC CHROMOSOMAL BCL-2; PROTEIN-KINASE; CELL-DEATH; DEPENDENT DEGRADATION; SIGNALING PATHWAY; FAMILY PROTEINS; CYTOCHROME-C; BAX; SUPPRESSION	Glucocorticoids are known to induce apoptosis in lymphoid cells, and Bcl-2 overexpression can block the apoptosis-inducing action of glucocorticoids. Since phosphorylation of Bcl-2 is implicated in regulating Bcl-2 function, we considered the role of Bcl-2 phosphorylation in protecting lymphoid cells from glucocorticoid-induced cell death. Five stably transfected cell lines of WEHI 7.1 cells expressing either wild-type Bcl-2 or alanine mutants of Bcl-2 at amino acids threonine 56, serine 70, threonine 74, or serine 87 were created. Expression of the mutant Bcl-2 proteins was documented by flow cytometry and Western blot analysis. Mutation of Bcl-2 on T56 and S87 eliminated the ability of Bcl-2 to inhibit glucocorticoid-induced cell shrinkage, mitochondrial depolarization, DNA fragmentation, and cell death. Mutation of T74 only partially impaired the ability of Bcl-2 to block glucocorticoid-induced apoptosis whereas mutation of S70 in Bcl-2 did not alter its ability to block glucocorticoid-induced apoptosis.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), 111 TW Alexander Dr,Bldg 101,MD F3-07, Res Triangle Pk, NC 27709 USA.	cidlowski@niehs.nih.gov	Cidlowski, John A/G-2548-2019; Huang, Se-Te/F-6881-2013	Cidlowski, John A/0000-0003-1420-0516; 				Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Blagosklonny MV, 1997, CANCER RES, V57, P130; Bortner CD, 1998, BIOCHEM PHARMACOL, V56, P1549, DOI 10.1016/S0006-2952(98)00225-1; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; CARONLESLIE LAM, 1994, FASEB J, V8, P639, DOI 10.1096/fasebj.8.9.8005391; Castano E, 1998, J STEROID BIOCHEM, V65, P101, DOI 10.1016/S0960-0760(97)00179-9; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; COSSON P, 1993, RACHIS, V5, P5; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Fang GF, 1998, CANCER RES, V58, P3202; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; Huang STJ, 1999, FASEB J, V13, P467, DOI 10.1096/fasebj.13.3.467; Iida N, 1998, CARCINOGENESIS, V19, P1191, DOI 10.1093/carcin/19.7.1191; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; IWATA M, 1994, INT IMMUNOL, V6, P431, DOI 10.1093/intimm/6.3.431; JOHNSSON N, 1986, EMBO J, V5, P3455, DOI 10.1002/j.1460-2075.1986.tb04669.x; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYASHITA T, 1992, CANCER RES, V52, P5407; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murata M, 1997, CELL MOL LIFE SCI, V53, P737, DOI 10.1007/s000180050093; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; ORTI E, 1993, J BIOL CHEM, V268, P7779; PEZZELLA F, 1992, BRIT J CANCER, V65, P87, DOI 10.1038/bjc.1992.16; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Schandl CA, 1999, J HISTOCHEM CYTOCHEM, V47, P139, DOI 10.1177/002215549904700203; Schandl CA, 1999, J HISTOCHEM CYTOCHEM, V47, P151, DOI 10.1177/002215549904700204; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Wang ZH, 1999, ANTICANCER RES, V19, P5445; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zer H, 1999, P NATL ACAD SCI USA, V96, P8277, DOI 10.1073/pnas.96.14.8277	46	33	35	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0825	10.1096/fj.01-0852com	http://dx.doi.org/10.1096/fj.01-0852com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039864				2022-12-28	WOS:000176683900008
J	Hubberstey, AV; Mottillo, EP				Hubberstey, AV; Mottillo, EP			Cyclase-associated proteins: CAPacity for linking signal transduction and actin polymerization	FASEB JOURNAL			English	Review						CAPs; actin cytoskeleton; cell signaling; endocytosis; development	YEAST ADENYLYL-CYCLASE; ABL TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; REGULATES ACTIN; BINDING-PROTEIN; ARP2/3 COMPLEX; SCHIZOSACCHAROMYCES-POMBE; DICTYOSTELIUM-DISCOIDEUM; POLARITY DEVELOPMENT; BIOCHEMICAL-ANALYSIS	Many extracellular signals elicit changes in the actin cytoskeleton, which are mediated through an array of signaling proteins and pathways. One family of proteins that plays a role in regulating actin remodeling in response to cellular signals are the cyclase-associated proteins (CAPs). CAPs are highly conserved monomeric actin binding proteins present in a wide range of organisms including yeast, fly, plants, and mammals. The original CAP was isolated as a component of the Saccharomyces cerevisiae adenylyl cyclase complex that serves as an effector of Ras during nutritional signaling. CAPs are multifunctional molecules that contain domains involved in actin binding, adenylyl cyclase association in yeast, SH3 binding, and oligomerization. Genetic studies in yeast have implicated CAPs in vesicle trafficking and endocytosis. CAPs play a developmental role in multicellular organisms, and studies of Drosophila have illuminated the importance of the actin cytoskeleton during eye development and in establishing oocyte polarity. This review will highlight the critical structural and functional domains of CAPs, describe recent studies that have implied important roles for these proteins in linking cell signaling with actin polymerization, and highlight their roles in vesicle trafficking and development.	Univ Windsor, Dept Biol Sci, Windsor, ON N9B 3P4, Canada	University of Windsor	Hubberstey, AV (corresponding author), Univ Windsor, Dept Biol Sci, Windsor, ON N9B 3P4, Canada.	ahubber@uwindsor.ca						AMBERG DC, 1995, NAT STRUCT BIOL, V2, P28, DOI 10.1038/nsb0195-28; Ayscough KR, 1996, ANNU REV CELL DEV BI, V12, P129, DOI 10.1146/annurev.cellbio.12.1.129; Bahn YS, 2001, J BACTERIOL, V183, P3211, DOI 10.1128/JB.183.10.3211-3223.2001; Baum B, 2000, CURR BIOL, V10, P964, DOI 10.1016/S0960-9822(00)00640-0; Baum B, 2001, NAT CELL BIOL, V3, P883, DOI 10.1038/ncb1001-883; Benlali A, 2000, CELL, V101, P271, DOI 10.1016/S0092-8674(00)80837-5; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Carlsen KH, 1994, EUR RESPIR REV, V4, P5; Condeelis J, 2001, TRENDS CELL BIOL, V11, P288, DOI 10.1016/S0962-8924(01)02008-6; Domke T, 1997, FEBS LETT, V411, P291, DOI 10.1016/S0014-5793(97)00719-9; Drees BL, 2001, J CELL BIOL, V154, P549, DOI 10.1083/jcb.200104057; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FENGER U, 1994, MECH DEVELOP, V47, P115, DOI 10.1016/0925-4773(94)90084-1; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FREEMAN NL, 1995, J BIOL CHEM, V270, P5680, DOI 10.1074/jbc.270.10.5680; Freeman NL, 1996, MOL CELL BIOL, V16, P548; Freeman NL, 2000, CELL MOTIL CYTOSKEL, V45, P106, DOI 10.1002/(SICI)1097-0169(200002)45:2<106::AID-CM3>3.0.CO;2-3; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; Geli MI, 1998, J CELL SCI, V111, P1031; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GIESELMANN R, 1992, FEBS LETT, V298, P149, DOI 10.1016/0014-5793(92)80043-G; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; Gottwald U, 1996, MOL BIOL CELL, V7, P261, DOI 10.1091/mbc.7.2.261; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Ho J, 2001, MOL BIOL CELL, V12, P1541, DOI 10.1091/mbc.12.6.1541; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Hubberstey A, 1996, J CELL BIOCHEM, V61, P459, DOI 10.1002/(SICI)1097-4644(19960601)61:3<459::AID-JCB13>3.0.CO;2-E; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; Kawai M, 1998, PLANT CELL PHYSIOL, V39, P1380, DOI 10.1093/oxfordjournals.pcp.a029346; KAWAMUKAI M, 1991, CELL REGUL, V2, P155, DOI 10.1091/mbc.2.2.155; KAWAMUKAI M, 1992, MOL BIOL CELL, V3, P167, DOI 10.1091/mbc.3.2.167; Kessels MM, 2000, MOL BIOL CELL, V11, P393, DOI 10.1091/mbc.11.1.393; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; MATVIW H, 1992, MOL CELL BIOL, V12, P5033, DOI 10.1128/MCB.12.11.5033; MEINERT MC, 1977, PLANT PHYSIOL, V59, P1088, DOI 10.1104/pp.59.6.1088; NAO SQ, 1995, J BIOL CHEM, V270, P6815, DOI 10.1074/jbc.270.12.6815; NEFSKY B, 1992, EUR J BIOCHEM, V206, P949, DOI 10.1111/j.1432-1033.1992.tb17005.x; Nishida Y, 1998, J BIOL CHEM, V273, P28019, DOI 10.1074/jbc.273.43.28019; Noegel AA, 1999, J CELL SCI, V112, P3195; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Scaife RM, 2000, J CELL SCI, V113, P215; Shima F, 1997, MOL CELL BIOL, V17, P1057, DOI 10.1128/MCB.17.3.1057; Shima F, 2000, MOL CELL BIOL, V20, P26, DOI 10.1128/MCB.20.1.26-33.2000; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; Stevenson VA, 2000, CURR BIOL, V10, pR695, DOI 10.1016/S0960-9822(00)00712-0; SWISTON J, 1995, GENE, V165, P273, DOI 10.1016/0378-1119(95)00522-8; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Theriot Julie A., 1994, Seminars in Cell Biology, V5, P193, DOI 10.1006/scel.1994.1024; Vaduva G, 1997, J CELL BIOL, V139, P1821, DOI 10.1083/jcb.139.7.1821; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; VOJTEK AB, 1993, J CELL SCI, V105, P777; WANG J, 1993, MOL CELL BIOL, V13, P4087, DOI 10.1128/MCB.13.7.4087; Wear MA, 2000, CURR BIOL, V10, pR891, DOI 10.1016/S0960-9822(00)00845-9; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Yang S, 1999, MOL BIOL CELL, V10, P2265, DOI 10.1091/mbc.10.7.2265; YU G, 1994, J CELL SCI, V107, P1671; Yu J, 1999, J BIOL CHEM, V274, P19985, DOI 10.1074/jbc.274.28.19985; Zelicof A, 1996, J BIOL CHEM, V271, P18243, DOI 10.1074/jbc.271.30.18243; ZELICOF A, 1993, J BIOL CHEM, V268, P13448; Zhou GL, 1998, MICROBIOL-UK, V144, P1085, DOI 10.1099/00221287-144-4-1085; Zhou GL, 2000, BIOSCI BIOTECH BIOCH, V64, P149, DOI 10.1271/bbb.64.149; Zigmond SH, 2000, J CELL BIOL, V150, pF117, DOI 10.1083/jcb.150.6.F117	82	160	168	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					487	499		10.1096/fj.01-0659rev	http://dx.doi.org/10.1096/fj.01-0659rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919151				2022-12-28	WOS:000175425900002
J	Ozaki, M; Suzuki, S; Irani, K				Ozaki, M; Suzuki, S; Irani, K			Redox factor-1/APE suppresses oxidative stress by inhibiting activity of the rac1 GTPase	FASEB JOURNAL			English	Article						NA(D)PH oxidase; NF-kappa B; apoptosis; reactive oxygen species rac1	DNA-BINDING ACTIVITY; NF-KAPPA-B; APURINIC/APYRIMIDINIC ENDONUCLEASE; REPAIR ENZYME; FREE-RADICALS; IN-VIVO; EXPRESSION; ACTIVATION; APOPTOSIS; PROTEIN	Oxidative stress triggered by many environmental and clinical insults results in cellular injury and death. The small GTPase rac1 promotes oxidative stress via the production of reactive oxygen species (ROS). In turn, the homeostatic response to such stress includes up-regulation of the dual function reducing protein/DNA repair enzyme APE/redox factor-1(ref-1). In this report we explore the function and relationship between ref-1 and rac1 in the setting of oxidative stress triggered by re-oxygenation/reperfusion. In a model of mouse hepatic ischemia/reperfusion (I/R), recombinant adenoviral overexpression of ref-1 resulted in suppression of reperfusion-stimulated oxidative stress, NF-kappaB induction, apoptosis, and acute injury, whereas down-regulation of endogenous ref-1 by adenoviral expression of antisense ref-1 led to an increase in these reperfusion-induced parameters. Ref-1 also mitigated ROS production induced by adenoviral expression of an active form of rac1. Finally, overexpression of ref-1 in primary hepatocytes suppressed reoxygenation-stimulated rac1 activity. This work demonstrates a novel function of ref-1 in inhibition of rac1 activity, and rac1-mediated oxidative stress and injury.	Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Natl Childrens Med Res Ctr, Div Expt Surg, Tokyo 154, Japan	Johns Hopkins University; National Center for Child Health & Development - Japan	Irani, K (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Ross 1023,720 Rutland Ave, Baltimore, MD 21205 USA.	Kirani@jhmi.edu	Ozaki, Michitaka/A-4549-2012	Irani, Kaikobad/0000-0001-9194-7387				Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; DUGUID JR, 1995, CANCER RES, V55, P6097; Embade N, 2000, MOL BIOL CELL, V11, P4347, DOI 10.1091/mbc.11.12.4347; Fung H, 1998, CANCER RES, V58, P189; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; GYLLENHAMMAR H, 1987, J IMMUNOL METHODS, V97, P209, DOI 10.1016/0022-1759(87)90461-3; HASSELGREN PO, 1984, J SURG RES, V37, P409, DOI 10.1016/0022-4804(84)90207-5; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; HUANG Y, 1993, TOUGHENED PLASTICS, V1, P1; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kakolyris S, 1998, HISTOPATHOLOGY, V33, P561; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Meira LB, 2001, CANCER RES, V61, P5552; MITOMO K, 1994, GENE, V145, P197; Monick MM, 1999, J BIOL CHEM, V274, P18075, DOI 10.1074/jbc.274.25.18075; NAKAGAWARA A, 1981, J CLIN INVEST, V68, P1243, DOI 10.1172/JCI110370; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Ozaki M, 2000, FASEB J, V14, P418, DOI 10.1096/fasebj.14.2.418; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Schlossberg H, 1996, HEPATOLOGY, V23, P1546, DOI 10.1053/jhep.1996.v23.pm0008675176; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Walton M, 1997, MOL BRAIN RES, V44, P167, DOI 10.1016/S0169-328X(96)00291-4; Webster KA, 1999, J CLIN INVEST, V104, P239; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	28	73	79	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					889	+		10.1096/fj.01-0664fje	http://dx.doi.org/10.1096/fj.01-0664fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039869				2022-12-28	WOS:000175425900031
J	Fisher, MC; Zeisel, SH; Mar, MH; Sadler, TW				Fisher, MC; Zeisel, SH; Mar, MH; Sadler, TW			Perturbations in choline metabolism cause neural tube defects in mouse embryos in vitro	FASEB JOURNAL			English	Article						neurulation; dimethylaminoethanol; ET-18-OCH3; embryo culture	HUMAN LEUKEMIC-CELLS; PROTEIN-KINASE-C; LIQUID-CHROMATOGRAPHY; PARENTERAL-NUTRITION; HEPATIC STEATOSIS; CHICK-EMBRYO; FOLIC-ACID; RAT-LIVER; APOPTOSIS; CERAMIDE	A role for choline during early stages of mammalian embryogenesis has not been established, although recent studies show that inhibitors of choline uptake and metabolism, 2-dimethylaminoethanol (DMAE), and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3), produce neural tube defects in mouse embryos grown in vitro. To determine potential mechanisms responsible for these abnormalities, choline metabolism in the presence or absence of these inhibitors was evaluated in cultured, neurulating mouse embryos by using chromatographic techniques. Results showed that 90%-95% of C-14-choline was incorporated into phosphocholine and phosphatidylcholine (PtdCho), which was metabolized to sphingomyelin. Choline was oxidized to betaine, and betaine homocysteine methyltransferase was expressed. Acetylcholine was synthesized in yolk sacs, but 70 kDa choline acetyltransferase was undetectable by immunoblot. DMAE reduced embryonic choline uptake and inhibited phosphocholine, PtdCho, phosphatidylethanolamine (PtdEtn), and sphingomyelin synthesis. ET-18-OCH3 also inhibited PtdCho synthesis. In embryos and yolk sacs incubated with H-3-ethanolamine, 95% of recovered label was PtdEtn, but PtdEtn was not converted to PtdCho, which suggested that phosphatidylethanolamine methyltransferase (PeMT) activity was absent. In ET-18-OCH3 treated yolk sacs, PtdEtn was increased, but PtdCho was still not generated through PeMT. Results suggest that endogenous PtdCho synthesis is important during neurulation and that perturbed choline metabolism contributes to neural tube defects produced by DMAE and ET-18-OCH3.	Univ N Carolina, Dept Cell Biol & Anat, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Sadler, TW (corresponding author), Univ N Carolina, Dept Cell Biol & Anat, Sch Med, CB 7090, Chapel Hill, NC 27599 USA.	tsadler@med.unc.edu						Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; Arthur G, 1998, BBA-LIPID LIPID MET, V1390, P85, DOI 10.1016/S0005-2760(97)00163-X; AUGUSTINSSON KB, 1949, J CELL COMPAR PHYSL, V34, P311, DOI 10.1002/jcp.1030340208; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boggs K, 1998, BBA-LIPID LIPID MET, V1389, P1, DOI 10.1016/S0005-2760(97)00145-8; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; BUCHMAN AL, 1995, HEPATOLOGY, V22, P1399, DOI 10.1002/hep.1840220510; BUCHMAN AL, 1992, GASTROENTEROLOGY, V102, P1363; Buznikov GA, 1996, CELL MOL NEUROBIOL, V16, P533, DOI 10.1007/BF02152056; CHANDAR N, 1988, CARCINOGENESIS, V9, P259, DOI 10.1093/carcin/9.2.259; COPELAND DH, 1946, AM J PATHOL, V22, P1059; Cui Z, 1997, BBA-LIPID LIPID MET, V1346, P10, DOI 10.1016/S0005-2760(97)00012-X; CZEIZEL AE, 1995, J PEDIATR GASTR NUTR, V20, P4, DOI 10.1097/00005176-199501000-00003; DACOSTA KA, 1993, J BIOL CHEM, V268, P2100; DANIEL LW, 1993, CANCER CHEMOTHERAPY, P146; DEAN W, 1990, SMART DRUGS NUTR IMP, P99; DIOMEDE L, 1993, INT J CANCER, V53, P124, DOI 10.1002/ijc.2910530123; Eskes TKAB, 1998, EUR J PEDIATR, V157, pS139, DOI 10.1007/PL00014299; ESSIEN FB, 1992, TERATOLOGY, V45, P205, DOI 10.1002/tera.1420450214; FALUGI C, 1993, EUR J HISTOCHEM, V37, P287; Fisher MC, 2001, TERATOLOGY, V64, P114, DOI 10.1002/tera.1053; GROSMAN DD, 1995, J NEUROCHEM, V65, P484; GUSTAFSON T, 1970, EXP CELL RES, V62, P102, DOI 10.1016/0014-4827(79)90512-3; GWEE MCE, 1978, CLIN EXP PHARMACOL P, V5, P649, DOI 10.1111/j.1440-1681.1978.tb00721.x; HAUBRICH DR, 1981, BIOCHEM PHARMACOL, V30, P2993, DOI 10.1016/0006-2952(81)90265-3; HAUBRICH DR, 1975, LIFE SCI, V17, P975, DOI 10.1016/0024-3205(75)90451-8; HAUBRICH DR, 1981, J NEUROCHEM, V37, P476, DOI 10.1111/j.1471-4159.1981.tb00480.x; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; HUEMER RP, 1999, J ADV MED, V12, P119; Johnston R B Jr, 1997, Adv Pediatr, V44, P231; Klein NW, 1997, INT J DEV BIOL, V41, P267; LAASBERG T, 1987, COMP BIOCHEM PHYS C, V86, P313, DOI 10.1016/0742-8413(87)90085-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLOYD JB, 1990, TERATOLOGY, V41, P383, DOI 10.1002/tera.1420410404; LOCKER J, 1986, CARCINOGENESIS, V7, P1309, DOI 10.1093/carcin/7.8.1309; LOHR J, 1990, J PHARMACOL EXP THER, V252, P154; LORENZI MV, 1992, DNA CELL BIOL, V11, P593, DOI 10.1089/dna.1992.11.593; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1999, DEV BRAIN RES, V118, P51, DOI 10.1016/S0165-3806(99)00105-4; MISAWA H, 1992, J BIOL CHEM, V267, P20392; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; MODOLELL M, 1979, CANCER RES, V39, P4681; MOLLINEDO F, 1993, BIOCHEM BIOPH RES CO, V192, P603, DOI 10.1006/bbrc.1993.1458; Moon EA, 1997, J REPROD FERTIL, V110, P213, DOI 10.1530/jrf.0.1100213; *NAT AC SCI I MED, 1998, DIET REF INT THIAM R, P255; National Toxicology Program, 1999, NIH PUBL; NOSEL PG, 1992, TERATOLOGY, V46, P499, DOI 10.1002/tera.1420460514; Oakley GP, 1996, J NUTR, V126, pS751, DOI 10.1093/jn/126.suppl_3.751S; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; PELECH SL, 1983, CAN J BIOCHEM CELL B, V61, P1147, DOI 10.1139/o83-147; PFEIFFER CC, 1957, SCIENCE, V126, P610, DOI 10.1126/science.126.3274.610; POMFRET EA, 1989, ANAL BIOCHEM, V180, P85, DOI 10.1016/0003-2697(89)90091-2; PRATT HPM, 1980, J REPROD FERTIL, V58, P237, DOI 10.1530/jrf.0.0580237; Previati M, 1996, ANAL BIOCHEM, V233, P108, DOI 10.1006/abio.1996.0014; SADLER TW, 1979, J EMBRYOL EXP MORPH, V49, P17; Shaw GM, 1997, TERATOLOGY, V56, P295, DOI 10.1002/(SICI)1096-9926(199711)56:5<295::AID-TERA1>3.0.CO;2-X; STEELE CE, 1974, J EMBRYOL EXP MORPH, V31, P707; Stott WT, 2000, TOXICOL LETT, V114, P67, DOI 10.1016/S0378-4274(99)00197-6; SWEIRY JH, 1985, J PHYSIOL-LONDON, V366, P251, DOI 10.1113/jphysiol.1985.sp015795; Tooyama I, 2000, J CHEM NEUROANAT, V17, P217, DOI 10.1016/S0891-0618(99)00043-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALINSKY JE, 1984, CELL DIFFER DEV, V14, P287, DOI 10.1016/0045-6039(84)90017-4; Vrablic AS, 2001, FASEB J, V15, P1739, DOI 10.1096/fj.00-0300com; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; WELLS IC, 1954, J BIOL CHEM, V207, P575; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Yen CLE, 2001, FASEB J, V15, P1704, DOI 10.1096/fj.00-0800com; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; ZEISEL SH, 1995, J NUTR, V125, P3049; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061; ZEISEL SH, 1981, ANNU REV NUTR, V1, P95, DOI 10.1146/annurev.nu.01.070181.000523	76	91	95	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					619	+		10.1096/fj.01-0564fje	http://dx.doi.org/10.1096/fj.01-0564fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919173				2022-12-28	WOS:000174203700001
J	Song, GJ; Harding, SE; Duchen, MR; Tunwell, R; O'Gara, P; Hawkins, TE; Moss, SE				Song, GJ; Harding, SE; Duchen, MR; Tunwell, R; O'Gara, P; Hawkins, TE; Moss, SE			Altered mechanical properties and intracellular calcium signaling in cardiomyocytes from annexin 6 null-mutant mice	FASEB JOURNAL			English	Article						heart failure; homeostasis; knockout; stimulus-response coupling	SARCOPLASMIC-RETICULUM; CARDIAC-MUSCLE; VI; HEART; RAT; IDENTIFICATION; MYOCYTES; NEURONS	Annexin 6 is one of a widely expressed family of calcium-binding proteins found in most mammalian tissues, including the heart. Several studies have implicated annexin 6 in the regulation of intracellular Ca(2+) signaling, and it has been shown in vitro to act as a modulator of the sarcoplasmic reticulum Ca(2+)-release channel, cardiac L-type calcium channel, and Na(+)/Ca(2+) exchanger. To investigate the role of annexin 6 in intact cardiomyocytes, we used mice containing a targeted disruption of the annexin 6 gene. Compared with controls, the myocytes of annexin 6 null-mutant mice demonstrated a significant increase in the rates of shortening and relengthening. Intracellular Ca(2+) transients in fura-2-loaded cardiomyocytes induced by caffeine showed a normal baseline and amplitude, whereas the rate of decay was doubled in annexin 6(-/-) myocytes compared with control mice. These results show that annexin 6 knockout in the mouse leads to an increase in myocyte contractility and faster diastolic Ca(2+) removal from the cytoplasm. In light of published findings showing annexin 6 to be down-regulated in end-stage heart failure, these results are consistent with a role for annexin 6 as a negative inotropic factor in the regulation of cardiomyocyte mechanics.	UCL, Inst Ophthalmol, Div Cell Biol, London EC1V 9EL, England; Natl Heart & Lung Inst, Imperial Coll Sch Med, London SW3 6LY, England; UCL, Dept Physiol, London WC1E 6BT, England	University of London; University College London; Imperial College London; University of London; University College London	Moss, SE (corresponding author), UCL, Inst Ophthalmol, Div Cell Biol, 11-43 Bath St, London EC1V 9EL, England.	s.moss@ucl.ac.uk	duchen, michael/A-2116-2009	duchen, michael/0000-0003-2548-4294; Harding, Sian/0000-0002-3651-6354				Benz J, 1996, J MOL BIOL, V260, P638, DOI 10.1006/jmbi.1996.0426; DIAZMUNOZ M, 1990, J BIOL CHEM, V265, P15894; DOUBELL AF, 1993, CARDIOVASC RES, V27, P1359, DOI 10.1093/cvr/27.7.1359; DOUBELL AF, 1991, HYPERTENSION, V18, P648, DOI 10.1161/01.HYP.18.5.648; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; GunteskiHamblin AM, 1996, AM J PHYSIOL-HEART C, V270, pH1091, DOI 10.1152/ajpheart.1996.270.3.H1091; HARDING SE, 1988, J MOL CELL CARDIOL, V20, P635, DOI 10.1016/S0022-2828(88)80121-4; Hawkins TE, 2000, CELL BIOCHEM BIOPHYS, V33, P275, DOI 10.1385/CBB:33:3:275; Hawkins TE, 1999, MOL CELL BIOL, V19, P8028; HAZARIKA P, 1991, J CELL BIOCHEM, V46, P78, DOI 10.1002/jcb.240460112; HAZARIKA P, 1991, J CELL BIOCHEM, V46, P86, DOI 10.1002/jcb.240460113; Heubach JF, 1999, CARDIOVASC RES, V42, P173, DOI 10.1016/S0008-6363(98)00262-4; IWASAKI A, 1989, J BIOCHEM-TOKYO, V106, P43, DOI 10.1093/oxfordjournals.jbchem.a122816; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; Naciff JM, 1996, AM J PHYSIOL-CELL PH, V271, pC2004; Nowicky AV, 1998, J PHYSIOL-LONDON, V507, P131, DOI 10.1111/j.1469-7793.1998.131bu.x; Ortega D, 1998, J CELL SCI, V111, P261; PULA G, 1990, FEBS LETT, V277, P53, DOI 10.1016/0014-5793(90)80808-V; SHIBATA S, 1992, J BIOCHEM-TOKYO, V112, P552, DOI 10.1093/oxfordjournals.jbchem.a123937; SMYTHE E, 1994, J CELL BIOL, V124, P301, DOI 10.1083/jcb.124.3.301; SOBOTA A, 1990, BIOCHEM BIOPH RES CO, V172, P1067, DOI 10.1016/0006-291X(90)91555-7; SONG G, 1995, CIRCULATION S, V92, P697; Song GJ, 1998, J MOL CELL CARDIOL, V30, P443, DOI 10.1006/jmcc.1997.0608; Tunwell REA, 1996, BIOCHEM J, V318, P477, DOI 10.1042/bj3180477; TUNWELL REA, 1991, BIOCHEM J, V279, P203, DOI 10.1042/bj2790203	25	41	42	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					622	+		10.1096/fj.01-0892fje	http://dx.doi.org/10.1096/fj.01-0892fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919174				2022-12-28	WOS:000174203700009
J	Brauer, AU; Savaskan, NE; Kole, MHP; Plaschke, M; Monteggia, LM; Nestler, EJ; Simburger, E; Deisz, RA; Ninnemann, O; Nitsch, R				Brauer, AU; Savaskan, NE; Kole, MHP; Plaschke, M; Monteggia, LM; Nestler, EJ; Simburger, E; Deisz, RA; Ninnemann, O; Nitsch, R			Molecular and functional analysis of hyperpolarization-activated pacemaker channels in the hippocampus after entorhinal cortex lesion	FASEB JOURNAL			English	Article						DDRT-PCR/ECL; HCN; hippocampus; I-h	RAT DENTATE GYRUS; THALAMIC RELAY NEURONS; FASCIA-DENTATA; COMMISSURAL FIBERS; CATION CURRENT; I-H; INDUCED SYNAPTOGENESIS; HISTOCHEMICAL EVIDENCE; ALTERED DEVELOPMENT; CHOLINERGIC FIBERS	Differential display of hippocampal tissue after entorhinal cortex lesion (ECL) revealed decreases in mRNA encoding the neuronal hyperpolarization-activated, cyclic nucleotide-gated channel HCN1. In situ hybridization confirmed that hippocampal transcripts of HCN1, but not HCN2/3/4, are down-regulated after ECL. Expression recovered at similar to 21 days after lesion (dal). Immunohistochemistry demonstrated a corresponding regulation of HCN1 protein expression in CA1-CA3 dendrites, hilar mossy cells and interneurons, and granule cells. Patch-clamp recordings in the early phase after lesion from mossy cells and hilar interneurons revealed an increase in the fast time constant of current activation and a profound negative shift in voltage activation of I-h. Whereas current activation recovered at 30 dal, the voltage activation remained hyperpolarized in mossy cells and hilar interneurons. Granule cells, however, were devoid of any detectable somatic I-h currents. Hence, denervation of the hippocampus decreases HCN1 and concomitantly the I-h activity in hilar neurons, and the recovery of h-current activation kinetics occurs parallel to postlesion sprouting.	Humboldt Univ Hosp Charite, Dept Cell & Neurobiol, Inst Anat, D-10098 Berlin, Germany; Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX USA; German Primate Ctr, Dept Neurobiol, D-37077 Gottingen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Deutsches Primatenzentrum (DPZ)	Nitsch, R (corresponding author), Humboldt Univ Hosp Charite, Dept Cell & Neurobiol, Inst Anat, Philippstr 12, D-10098 Berlin, Germany.	robert.nitsch@charite.de	Bräuer, Anja/N-3692-2019; Nitsch, Robert/AAI-9129-2021; Braeuer, Anja/K-8339-2013; Savaskan, Nicolai/D-2923-2018	Savaskan, Nicolai/0000-0003-1348-094X; Kole, Maarten/0000-0002-3883-5682				ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P608, DOI 10.1152/jn.1964.27.4.608; Bendotti C, 1996, NEUROREPORT, V7, P2539, DOI 10.1097/00001756-199611040-00027; BLACKSTAD TW, 1956, J COMP NEUROL, V105, P417, DOI 10.1002/cne.901050305; BRAGIN A, 1995, J NEUROPHYSIOL, V73, P1691, DOI 10.1152/jn.1995.73.4.1691; Brauer AU, 2001, NEUROSCIENCE, V102, P515, DOI 10.1016/S0306-4522(00)00471-1; BUCKMASTER PS, 1994, HIPPOCAMPUS, V4, P393, DOI 10.1002/hipo.450040402; BUCKMASTER PS, 1995, J NEUROSCI, V15, P774; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLUSMANN H, 1994, NEUROSCIENCE, V61, P805, DOI 10.1016/0306-4522(94)90403-0; COTMAN CW, 1985, ANN NY ACAD SCI, V457, P83, DOI 10.1111/j.1749-6632.1985.tb20800.x; DASHEIFF RM, 1982, BRAIN RES, V231, P444, DOI 10.1016/0006-8993(82)90381-X; Deller T, 1999, HIPPOCAMPUS, V9, P314, DOI 10.1002/(SICI)1098-1063(1999)9:3<314::AID-HIPO10>3.3.CO;2-Z; Deller T, 1996, NEUROSCIENCE, V71, P651, DOI 10.1016/0306-4522(95)00475-0; DELLER T, 1995, J COMP NEUROL, V352, P55, DOI 10.1002/cne.903520105; DELLER T, 1995, J NEUROSCI, V15, P6868; Dickson CT, 2000, J NEUROPHYSIOL, V83, P2562, DOI 10.1152/jn.2000.83.5.2562; Franz O, 2000, EUR J NEUROSCI, V12, P2685, DOI 10.1046/j.1460-9568.2000.00151.x; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Frotscher M, 1997, TRENDS NEUROSCI, V20, P218, DOI 10.1016/S0166-2236(96)01018-1; FROTSCHER M, 1994, SYNAPSE, V16, P148, DOI 10.1002/syn.890160208; Gasparini S, 1997, PFLUG ARCH EUR J PHY, V435, P99, DOI 10.1007/s004240050488; GOLDEN GT, 1991, NEUROREPORT, V2, P141, DOI 10.1097/00001756-199103000-00008; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harris NC, 1995, J NEUROPHYSIOL, V74, P2366, DOI 10.1152/jn.1995.74.6.2366; Kelley MS, 1997, REV NEUROSCIENCE, V8, P147; KOSAKA T, 1985, J COMP NEUROL, V239, P420, DOI 10.1002/cne.902390408; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIVSEY CT, 1992, NEURON, V8, P745, DOI 10.1016/0896-6273(92)90095-U; Lubke J, 1998, J NEUROPHYSIOL, V79, P1518, DOI 10.1152/jn.1998.79.3.1518; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Luthi A, 1998, NEURON, V21, P9, DOI 10.1016/S0896-6273(00)80509-7; MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130; Magee JC, 1999, NAT NEUROSCI, V2, P508, DOI 10.1038/9158; MATTHEWS DA, 1976, BRAIN RES, V115, P23, DOI 10.1016/0006-8993(76)90820-9; MATTHEWS DA, 1976, BRAIN RES, V115, P1, DOI 10.1016/0006-8993(76)90819-2; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; MESULAM MM, 1987, ANN NEUROL, V22, P683, DOI 10.1002/ana.410220603; Monteggia LM, 2000, MOL BRAIN RES, V81, P129, DOI 10.1016/S0169-328X(00)00155-8; Moosmang S, 1999, BIOL CHEM, V380, P975, DOI 10.1515/BC.1999.121; Moosmang S, 2001, EUR J BIOCHEM, V268, P1646, DOI 10.1046/j.1432-1327.2001.02036.x; Munsch T, 1999, J PHYSIOL-LONDON, V519, P505, DOI 10.1111/j.1469-7793.1999.0505m.x; NADLER JV, 1977, J COMP NEUROL, V171, P561, DOI 10.1002/cne.901710409; NADLER JV, 1977, J COMP NEUROL, V171, P589, DOI 10.1002/cne.901710410; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; NOLAN MF, 2000, SOC NEUR ABSTR, V26, P8032; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; PARNAVELAS JG, 1974, NATURE, V248, P71, DOI 10.1038/248071a0; Penttonen M, 1997, HIPPOCAMPUS, V7, P437, DOI 10.1002/(SICI)1098-1063(1997)7:4<437::AID-HIPO9>3.0.CO;2-F; REEVES TM, 1988, EXP NEUROL, V102, P37, DOI 10.1016/0014-4886(88)90076-3; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Savaskan NE, 2000, BRAIN RES, V864, P44, DOI 10.1016/S0006-8993(00)02148-X; SCHARFMAN HE, 1988, J NEUROSCI, V8, P3812; SCHARFMAN HE, 1990, NEUROSCIENCE, V37, P693, DOI 10.1016/0306-4522(90)90100-I; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Sciancalepore M, 1998, BRAIN RES, V814, P133, DOI 10.1016/S0006-8993(98)01067-1; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SOMOGYI P, 1983, J NEUROSCI, V3, P1450; SORIANO E, 1989, BRAIN RES, V503, P170, DOI 10.1016/0006-8993(89)91722-8; STEWARD O, 1978, BRAIN RES, V149, P216, DOI 10.1016/0006-8993(78)90601-7; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; STEWARD O, 1976, SCIENCE, V194, P426, DOI 10.1126/science.982024; Strata F, 1997, J NEUROSCI, V17, P1435; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200	70	48	51	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2689	2701		10.1096/fj.01-0235com	http://dx.doi.org/10.1096/fj.01-0235com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726545				2022-12-28	WOS:000172964800039
J	Moghadasian, MH; McManus, BM; Nguyen, LB; Shefer, S; Nadji, M; Godin, DV; Green, TJ; Hill, J; Yang, YY; Scudamore, CH; Frohlich, JJ				Moghadasian, MH; McManus, BM; Nguyen, LB; Shefer, S; Nadji, M; Godin, DV; Green, TJ; Hill, J; Yang, YY; Scudamore, CH; Frohlich, JJ			Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans	FASEB JOURNAL			English	Article						apo E; brain; antioxidants; atherosclerosis; xanthomatosis; lipids	HIGH-DENSITY-LIPOPROTEIN; CORONARY-ARTERY DISEASE; E KNOCKOUT MICE; ALZHEIMERS-DISEASE; CHOLESTEROL 7-ALPHA-HYDROXYLASE; III HYPERLIPOPROTEINEMIA; E GENOTYPE; PLASMA; LESIONS; HYPERCHOLESTEROLEMIA	Apolipoprotein E (apo E) deficiency (or its abnormalities in humans) is associated with a series of pathological conditions including dyslipidemia, atherosclerosis, Alzheimer's disease, and shorter life span. The purpose of this study was to characterize these conditions in apo E-deficient C57BL/6J mice and relate them to human disorders. Deletion of apo E gene in mice is associated with changes in lipoprotein metabolism [plasma total cholesterol (TC) (>+400%), HDL cholesterol (-80%), HDL/TC, and HDL/LDL ratios (-93% and -96%, respectively), esterification rate in apo B-depleted plasma (+100%), plasma triglyceride (+200%), hepatic HMG-CoA reductase activity (-50%), hepatic cholesterol content (+30%)], decreased plasma homocyst(e) ine and glucose levels, and severe atherosclerosis and cutaneous xanthomatosis. Hepatic and lipoprotein lipase activities, hepatic LDL receptor function, and organ antioxidant capacity remain unchanged. Several histological/immunohistological stainings failed to detect potential markers for neurodegenerative disease in the brain of 37-wk-old male apo E-KO mice. Apo E-KO mice may have normal growth and development, but advanced atherosclerosis and xanthomatosis may indirectly reduce their life span. Apo E plays a crucial role in regulation of lipid metabolism and atherogenesis without affecting lipase activities, endogenous antioxidant capacity, or appearance of neurodegenerative markers in 37-wk-old male mice.	Univ British Columbia, Dept Pathol & Lab Med, Healthy Heart Program, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Pathol & Lab Med, iCAPTUR4E Ctr, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Pharmacol, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Surg, Vancouver, BC V6T 1W5, Canada; Univ Med & Dent New Jersey, Dept Med, New Brunswick, NJ 08901 USA; Univ Miami, Dept Pathol, Miami, FL 33101 USA	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Miami	Moghadasian, MH (corresponding author), St Pauls Hosp, Healthy Heart Program, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	mhmoghad@interchange.ubc.ca						Bales KR, 2000, NEUROBIOL AGING, V21, P427, DOI 10.1016/S0197-4580(00)00143-3; Davignon J, 1999, CLIN CHIM ACTA, V286, P115, DOI 10.1016/S0009-8981(99)00097-2; DOBIASOVA M, 1991, ARTERIOSCLER THROMB, V11, P64, DOI 10.1161/01.ATV.11.1.64; Dobiasova M, 1996, PHYSIOL RES, V45, P65; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Feussner G, 1996, J CLIN PATHOL, V49, P985, DOI 10.1136/jcp.49.12.985; GHISELLI G, 1981, SCIENCE, V214, P1239, DOI 10.1126/science.6795720; GOLDEN JA, 1995, ARCH NEUROL-CHICAGO, V52, P209, DOI 10.1001/archneur.1995.00540260115030; Gordon I, 1996, MOL CHEM NEUROPATHOL, V28, P97, DOI 10.1007/BF02815210; GORDON I, 1995, NEUROSCI LETT, V199, P1, DOI 10.1016/0304-3940(95)12006-P; Haan MN, 1999, JAMA-J AM MED ASSOC, V282, P40, DOI 10.1001/jama.282.1.40; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; Keller JN, 2000, J NEUROCHEM, V74, P1579, DOI 10.1046/j.1471-4159.2000.0741579.x; Khaleeli E, 2001, AM HEART J, V141, P637, DOI 10.1067/mhj.2001.113224; Kokubo Y, 1999, ARCH NEUROL-CHICAGO, V56, P1506, DOI 10.1001/archneur.56.12.1506; Krugers HJ, 1997, NEUROREPORT, V8, P2505, DOI 10.1097/00001756-199707280-00018; Lomnitski L, 1999, J NEUROSCI RES, V58, P586; Mahley RW, 1999, J LIPID RES, V40, P1; Maldonado TA, 2000, BRAIN RES, V858, P237, DOI 10.1016/S0006-8993(99)02328-8; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Moghadasian MH, 1999, CIRCULATION, V99, P1733, DOI 10.1161/01.CIR.99.13.1733; Moghadasian MH, 1997, ARCH INTERN MED, V157, P2299, DOI 10.1001/archinte.157.20.2299; Moghadasian MH, 2001, METABOLISM, V50, P708, DOI 10.1053/meta.2001.23303; Moghadasian MH, 1999, LAB INVEST, V79, P355; NADJI M, 1997, PRINCIPLES PRACTICE, P63; Oitzl MS, 1997, BRAIN RES, V752, P189, DOI 10.1016/S0006-8993(96)01448-5; Olichney JM, 2000, ANN NY ACAD SCI, V903, P138, DOI 10.1111/j.1749-6632.2000.tb06360.x; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; Riddell DR, 1997, J BIOL CHEM, V272, P89; Robertson TA, 1998, NEUROSCIENCE, V82, P171; Saku K, 1999, J AM COLL CARDIOL, V33, P436, DOI 10.1016/S0735-1097(98)00560-9; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SE A, 2000, NEUROBIOL AGING, V21, P913; SHEFER S, 1994, HEPATOLOGY, V20, P213; SHEFER S, 1988, J CLIN INVEST, V82, P1833, DOI 10.1172/JCI113799; SHORE VG, 1973, BIOCHEMISTRY-US, V12, P502, DOI 10.1021/bi00727a022; Smith JD, 2000, ANN MED, V32, P118, DOI 10.3109/07853890009011761; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Veinbergs I, 1998, NEUROSCI LETT, V249, P71, DOI 10.1016/S0304-3940(98)00399-1; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; ZANNIS VI, 1980, J BIOL CHEM, V255, P1759; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhou XH, 1998, J CLIN INVEST, V101, P1717, DOI 10.1172/JCI1216	46	116	119	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2623	2630		10.1096/fj.01-0463com	http://dx.doi.org/10.1096/fj.01-0463com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726538				2022-12-28	WOS:000172964800032
J	Walev, I; Hombach, M; Bobkiewicz, W; Fenske, D; Bhakdi, S; Husmann, M				Walev, I; Hombach, M; Bobkiewicz, W; Fenske, D; Bhakdi, S; Husmann, M			Resealing of large transmembrane pores produced by streptolysin O in nucleated cells is accompanied by NF-kappa B activation and downstream events	FASEB JOURNAL			English	Article						membrane repair; IL-6; IL-8; bacterial toxin	MEMBRANE ATTACK COMPLEX; STAPHYLOCOCCAL ALPHA-TOXIN; ESCHERICHIA-COLI HEMOLYSIN; ENDOTHELIAL-CELLS; BINDING; OLIGOMERIZATION; INTERLEUKIN-1; KERATINOCYTES; INFECTION; MONOCYTES	Streptolysin O (SLO), archetype of a cholesterol-binding bacterial cytolysin, forms large pores in the plasma membrane of mammalian cells. We have recently reported that when a limited number of pores are generated in a cell, they can be sealed in a Ca++-dependent process. Here, we show that resealing is followed by the release of IL-6 and IL-8 from keratinocytes and from endothelial cells, both relevant targets for SLO attack. Production of cytokines by these cells was preceded by activation of transcription factor nuclear factor kappaB, which thus emerges as a common denominator of stress responses to various pore-forming agents, including alpha -toxin of Staphylococcus aureus and complement. Furthermore, we show that activation and cytokine release in response to an agent that forms a pore in the plasma membrane do not depend on paracrine effects, because supernatants of cells perforated by SLO did not activate bystander cells. The study provides definitive evidence that a transient transmembrane pore suffices to trigger productive transcriptional activation in a target cell.	Univ Mainz, Inst Med Microbiol, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz	Husmann, M (corresponding author), Inst Med Microbiol & Hyg, Obere Zahlbacher Str 67, D-55101 Mainz, Germany.	walev@mail.uni-mainz.de; MattHusmann@web.de						Alouf JE, 1991, SOURCEBOOK BACTERIAL, P147; Avirutnan P, 1998, J IMMUNOL, V161, P6338; Bhakdi S, 1996, ARCH MICROBIOL, V165, P73, DOI 10.1007/s002030050300; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BHAKDI S, 1990, J CLIN INVEST, V85, P1746, DOI 10.1172/JCI114631; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dragneva Y, 2001, INFECT IMMUN, V69, P2630, DOI 10.1128/IAI.69.4.2630-2635.2001; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Ghani EA, 1999, BIOCHEMISTRY-US, V38, P15204, DOI 10.1021/bi991678y; HACKETT SP, 1992, J INFECT DIS, V165, P879, DOI 10.1093/infdis/165.5.879; Husmann M, 1996, EUR J IMMUNOL, V26, P3008, DOI 10.1002/eji.1830261228; JONES J, 1990, BIOCHEM J, V267, P303, DOI 10.1042/bj2670303; Kayal S, 1999, MOL MICROBIOL, V31, P1709, DOI 10.1046/j.1365-2958.1999.01305.x; Kilgore KS, 1997, AM J PATHOL, V150, P2019; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; MORGAN BP, 1987, J IMMUNOL, V138, P246; MORGAN BP, 1992, CURR TOP MICROBIOL, V178, P115; Ruiz N, 1998, MOL MICROBIOL, V27, P337, DOI 10.1046/j.1365-2958.1998.00681.x; Valeva A, 2000, MOL MICROBIOL, V36, P467, DOI 10.1046/j.1365-2958.2000.01865.x; WALEV I, 1995, INFECT IMMUN, V63, P1188, DOI 10.1128/IAI.63.4.1188-1194.1995; WALEV I, 1994, MICROB PATHOGENESIS, V17, P187, DOI 10.1006/mpat.1994.1065; Walev I, 2001, P NATL ACAD SCI USA, V98, P3185, DOI 10.1073/pnas.051429498; Weller U, 1996, EUR J BIOCHEM, V236, P34, DOI 10.1111/j.1432-1033.1996.00034.x	23	49	49	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					237	+		10.1096/fj.01-0572fje	http://dx.doi.org/10.1096/fj.01-0572fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11744625				2022-12-28	WOS:000172964800014
J	Deng, WG; Ruan, KH; Du, M; Saunders, MA; Wu, KK				Deng, WG; Ruan, KH; Du, M; Saunders, MA; Wu, KK			Aspirin and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its ATPase activity in human fibroblasts	FASEB JOURNAL			English	Article						salicylate binding protein; SA; COX-2; acetylsalicylic acid	SYSTEMIC ACQUIRED-RESISTANCE; NF-KAPPA-B; SODIUM-SALICYLATE; CHAPERONE BIP; ACID; SPECIFICITY; KINASE; CYCLOOXYGENASE-2; TRANSCRIPTION; INFLAMMATION	Salicylic acid (SA), an endogenous signaling molecule of plants, possesses anti-inflammatory and anti-neoplastic actions in human. Its derivative, aspirin, is the most commonly used anti-inflammatory and analgesic drug. Aspirin and sodium salicylate (salicylates) have been reported to have multiple pharmacological actions. However, it is unclear whether they bind to a cellular protein. Here, we report for the first time the purification from human fibroblasts of a similar to 78 kDa salicylate binding protein with sequence identity to immunoglobulin heavy chain binding protein (BiP). The K-d values of SA binding to crude extract and to recombinant BiP were 45.2 and 54.6 muM, respectively. BiP is a chaperone protein containing a polypeptide binding site recognizing specific heptapeptide sequence and an ATP binding site. A heptapeptide with the specific sequence displaced SA binding in a concentration-dependent manner whereas a control heptapeptide did not. Salicylates inhibited ATPase activity stimulated by this specific heptapeptide but did not block ATP binding or induce BiP expression. These results indicate that salicylates bind specifically to the polypeptide binding site of BiP in human cells that may interfere with folding and transport of proteins important in inflammation.	Univ Texas, Sch Med, Dept Internal Med, Vasc Biol Res Ctr, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Internal Med, Div Hematol, Houston, TX 77030 USA	University of Texas System; University of Texas System	Wu, KK (corresponding author), Univ Texas, Sch Med, Dept Internal Med, Vasc Biol Res Ctr, 6431 Fannin MSB 5-016, Houston, TX 77030 USA.	Kenneth.K.Wu.@uth.tmc.edu	Wu, Kenneth Kun-Yu/B-1070-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50675] Funding Source: Medline; NINDS NIH HHS [NS-23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SB, 1991, BIOCHEM PHARMACOL, V41, P1567, DOI 10.1016/0006-2952(91)90155-X; AMIN AR, 1995, P NATL ACAD SCI USA, V92, P7626; Bellosillo B, 1998, BLOOD, V92, P1406, DOI 10.1182/blood.V92.4.1406.416k17_1406_1414; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BROT N, 1994, P NATL ACAD SCI USA, V91, P12120, DOI 10.1073/pnas.91.25.12120; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CHEN ZX, 1991, P NATL ACAD SCI USA, V88, P8179, DOI 10.1073/pnas.88.18.8179; CHEN ZX, 1993, P NATL ACAD SCI USA, V90, P9533, DOI 10.1073/pnas.90.20.9533; Cronstein BN, 1999, P NATL ACAD SCI USA, V96, P6377, DOI 10.1073/pnas.96.11.6377; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; HIGGS GA, 1987, P NATL ACAD SCI USA, V84, P1417, DOI 10.1073/pnas.84.5.1417; Klampfer L, 1999, BLOOD, V93, P2386, DOI 10.1182/blood.V93.7.2386.407k15_2386_2394; Knarr G, 1999, J BIOL CHEM, V274, P29850, DOI 10.1074/jbc.274.42.29850; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Law BK, 2000, J BIOL CHEM, V275, P38261, DOI 10.1074/jbc.M005545200; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; Mitchell JA, 1997, MOL PHARMACOL, V51, P907, DOI 10.1124/mol.51.6.907; Ruffer M, 1995, FEBS LETT, V377, P175, DOI 10.1016/0014-5793(95)01334-2; SAUNDERS MA, IN PRESS J BIOL CHEM; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SPOHN M, 1980, BIOCHIM BIOPHYS ACTA, V608, P409, DOI 10.1016/0005-2787(80)90186-0; THUN MJ, 1993, CANCER RES, V53, P122; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670; Xu XM, 1999, P NATL ACAD SCI USA, V96, P5292, DOI 10.1073/pnas.96.9.5292; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	36	30	35	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2463	2470		10.1096/fj.01-0259com	http://dx.doi.org/10.1096/fj.01-0259com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689471				2022-12-28	WOS:000172420500016
J	Toyofuku, K; Wada, I; Valencia, JC; Kushimoto, T; Ferrans, VJ; Hearing, VJ				Toyofuku, K; Wada, I; Valencia, JC; Kushimoto, T; Ferrans, VJ; Hearing, VJ			Oculocutaneous albinism types 1 and 3 are ER retention diseases: mutation of tyrosinase or Tyrp1 can affect the processing of both mutant and wild-type proteins	FASEB JOURNAL			English	Article						albinism; chaperones; pigmentation; melanogenesis	DHICA OXIDASE ACTIVITY; ENDOPLASMIC-RETICULUM; MAMMALIAN TYROSINASE; ULTRASTRUCTURAL-LOCALIZATION; BINDING-SPECIFICITY; MELANOGENIC COMPLEX; MEMBRANE-PROTEINS; MELANIN FORMATION; MOLECULAR-BASIS; B-16 MELANOMA	Various types of oculocutaneous albinism (OCA) are associated with reduced pigmentation in the skin, hair, and eyes that results from mutations in genes involved in melanin synthesis. Immortal mouse melanocyte lines (melan-a, melan-b, and melan-c) provide opportune models with which to investigate the etiology of two different types of OCA (types I and III), which arise from mutations in Tyr and Tyrp1, respectively. We compared intracellular processing, sorting, and degradation of tyrosinase and Tyrp1, and the effects on their catalytic function and melanin synthesis, in these wild-type and mutant melanocytes. A mutation in either Tyr or Tyrp1 increased the time of association of tyrosinase and Tyrp1 with calnexin and Bip, which in turn resulted in the retention of these mutant products in the ER. A mutation in either gene selectively enhanced the duration and efficiency of chaperone interactions (even with the wild-type protein in the mutant melanocytes) and markedly slowed their transport to melanosomes. These results show that OCA1 and OCA3 are (in some cases, at least) ER retention diseases wherein a mutation in one melanogenic protein affects the maturation and stability of the other in the melanogenic pathway.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Sapporo Med Univ, Dept Biochem, Sapporo, Hokkaido, Japan; NHLBI, Pathol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Sapporo Medical University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Room 1B25, Bethesda, MD 20892 USA.	hearingv@nih.gov		Wada, Ikuo/0000-0001-5668-6994				Allen S, 2000, BLOOD, V96, P560; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Boissy RE, 1996, AM J HUM GENET, V58, P1145; Boissy RE, 1998, EXP DERMATOL, V7, P198, DOI 10.1111/j.1600-0625.1998.tb00324.x; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; Branza-Nichita N, 1999, BIOCHEM BIOPH RES CO, V261, P720, DOI 10.1006/bbrc.1999.1030; DAKOUR J, 1993, EXP CELL RES, V209, P288, DOI 10.1006/excr.1993.1313; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; DOOLITTLE DP, 1996, GENETIC VARIANTS STR, P17; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Furumura M, 1998, BIOCHEM BIOPH RES CO, V242, P579, DOI 10.1006/bbrc.1997.8007; GIEBEL LB, 1991, J CLIN INVEST, V87, P1119, DOI 10.1172/JCI115075; GIEBEL LB, 1991, AM J HUM GENET, V48, P1159; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; HEARING VJ, 1978, BIOCHIM BIOPHYS ACTA, V522, P327, DOI 10.1016/0005-2744(78)90067-0; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; Jackson IJ, 1997, HUM MOL GENET, V6, P1613, DOI 10.1093/hmg/6.10.1613; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; Jimenez-Cervantes C, 1998, BIOCHEM BIOPH RES CO, V253, P761, DOI 10.1006/bbrc.1998.9817; JIMENEZCERVANTES C, 1994, J BIOL CHEM, V269, P17993; JOHNSON R, 1992, NAT GENET, V1, P226, DOI 10.1038/ng0692-226; Kikuchi A, 1996, BRIT J DERMATOL, V135, P400, DOI 10.1111/j.1365-2133.1996.tb01503.x; KING RA, 1991, J CLIN INVEST, V87, P1046, DOI 10.1172/JCI115064; KOBAYASHI T, 1994, EMBO J, V13, P5818, DOI 10.1002/j.1460-2075.1994.tb06925.x; KOBAYASHI T, 1994, PIGM CELL RES, V7, P227, DOI 10.1111/j.1600-0749.1994.tb00054.x; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; Kobayashi T, 1998, J BIOL CHEM, V273, P31801, DOI 10.1074/jbc.273.48.31801; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LEUSTEK T, 1992, CELL MOL BIOL, V38, P1; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Manga P, 1997, AM J HUM GENET, V61, P1095, DOI 10.1086/301603; Manga P, 2001, EXP EYE RES, V72, P695, DOI 10.1006/exer.2001.1006; Negroiu G, 2000, J BIOL CHEM, V275, P32200, DOI 10.1074/jbc.M005186200; Oetting WS, 2000, PIGM CELL RES, V13, P320, DOI 10.1034/j.1600-0749.2000.130503.x; Oetting WS, 1999, HUM MUTAT, V13, P99, DOI 10.1002/(SICI)1098-1004(1999)13:2<99::AID-HUMU2>3.3.CO;2-3; OETTING WS, 1994, J INVEST DERMATOL, V103, pS131, DOI 10.1111/1523-1747.ep12399447; OETTING WS, 1994, PIGM CELL RES, V7, P285, DOI 10.1111/j.1600-0749.1994.tb00629.x; ORLOW SJ, 1994, J INVEST DERMATOL, V103, P196, DOI 10.1111/1523-1747.ep12392743; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; SCHAUMBURGLEVER G, 1991, J CUTAN PATHOL, V18, P432, DOI 10.1111/j.1600-0560.1991.tb01380.x; Setaluri V, 2000, PIGM CELL RES, V13, P128, DOI 10.1034/j.1600-0749.2000.130302.x; SIEGRIST W, 1986, ANAL BIOCHEM, V159, P191, DOI 10.1016/0003-2697(86)90327-1; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; SPRITZ RA, 1994, ADV HUM GENET, V22, P1; Spritz RA, 1997, J INVEST DERMATOL, V109, P207, DOI 10.1111/1523-1747.ep12319351; SPRITZ RA, 1990, NEW ENGL J MED, V322, P1724, DOI 10.1056/NEJM199006143222407; SPRITZ RA, 1994, HUM MOL GENET, V3, P1469, DOI 10.1093/hmg/3.suppl_1.1469; Spritz RA, 1997, HUM MUTAT, V10, P171, DOI 10.1002/(SICI)1098-1004(1997)10:2<171::AID-HUMU11>3.3.CO;2-9; Tomita Y, 1999, J BIOCHEM-TOKYO, V126, P1090, DOI 10.1093/oxfordjournals.jbchem.a022554; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; Toyofuku K, 2001, BIOCHEM J, V355, P259, DOI 10.1042/0264-6021:3550259; TRIPATHI RK, 1991, GENE EXPRESSION, V1, P103; TRIPATHI RK, 1992, J BIOL CHEM, V267, P23707; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; URABE K, 1994, BBA-MOL CELL RES, V1221, P272, DOI 10.1016/0167-4889(94)90250-X; Wang Y, 2000, BIOCHEM BIOPH RES CO, V271, P22, DOI 10.1006/bbrc.2000.2577; WINDER A, 1994, CELL MOL BIOL RES, V40, P613	66	111	117	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2149	2161		10.1096/fj.01-0216com	http://dx.doi.org/10.1096/fj.01-0216com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641241				2022-12-28	WOS:000171920400026
J	Bessede, G; Miguet, C; Gambert, P; Neel, D; Lizard, G				Bessede, G; Miguet, C; Gambert, P; Neel, D; Lizard, G			Efficiency of homocysteine plus copper in inducing apoptosis is inversely proportional to gamma-glutamyl transpeptidase activity	FASEB JOURNAL			English	Article						HUVECs; ECV304 cells; Hcy; gamma-GT	ENDOTHELIAL-CELL INJURY; SMOOTH-MUSCLE-CELLS; RISK-FACTOR; LYMPHOBLASTOID-CELLS; THROMBOGENIC AGENT; VASCULAR-DISEASE; REDOX STATUS; ACTIVATION; PROTEIN; GLUTATHIONE	Hyperhomocysteinemia represents an independent risk factor for atherosclerosis, but the mechanisms leading to cellular dysfunctions remain unknown. Using ECV304 cells, we found that homocysteine (Hcy) plus copper (Cu2+) induced cytotoxic effects: loss of cell adhesion, increased permeability to PI, and the occurrence of morphologically apoptotic cells. This form of apoptosis, inhibited by Z-VAD-fmk, was associated with a loss of mitochondrial potential, a cytosolic release of cytochrome c, activation of caspase-3, degradation of poly( ADP-ribose) polymerase, and internucleosomal DNA fragmentation. However, the ability of Hcy plus Cu2+ to induce apoptosis decreased when the pretreatment culture time increased. As a positive correlation was found between the length of time of culture before treatment and the enhancement of gamma -glutamyl transpeptidase (gamma -GT) activity, we asked whether gamma -GT was involved in the control of Hcy plus Cu2+-induced apoptosis. Therefore, ECV304 cells were treated with either acivicin or dexamethasone, inhibiting and stimulating gamma -GT, respectively. In ECV304 cells and human umbilical venous endothelial cells, acivicin favored Hcy plus Cu2+-induced apoptosis whereas dexamethasone counteracted the apoptotic process. As acivicin and dexamethasone were also capable of modulating cell death in ECV304 cells treated with antitumoral drugs, our data emphasize that the involvement of gamma -GT in the control of apoptosis is not restricted to Hcy but also concerns other chemical compounds.	CHU, Hop Bocage, INSERM, U498,Lab Biochim Med, F-21034 Dijon, France	CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm)	Lizard, G (corresponding author), CHU, Hop Bocage, INSERM, U498,Lab Biochim Med, BP 1542,2 Bd Marechal de Lattre de Tassigny, F-21034 Dijon, France.	Gerard.Lizard@u-bourgogne.fr	Lizard, Gerard/B-2439-2012	Carole, MIGUET-ALFONSI/0000-0002-3317-6454				AHMAD S, 1987, J CELL PHYSIOL, V131, P240, DOI 10.1002/jcp.1041310214; AUBELSADRON G, 1984, BIOCHIMIE, V66, P333, DOI 10.1016/0300-9084(84)90018-X; Causse E, 1998, J CHROMATOGR A, V817, P181, DOI 10.1016/S0021-9673(98)00363-X; Chango A, 1999, ANN BIOL CLIN-PARIS, V57, P37; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; DIMANCHEBOITREL MT, 1992, INT J CANCER, V50, P677, DOI 10.1002/ijc.2910500502; Dirks WG, 1999, IN VITRO CELL DEV-AN, V35, P558; DOROSZ P, 1995, GUIDE PRATIQUE MED, P1512; DUDMAN NPB, 1993, ARTERIOSCLER THROMB, V13, P1253, DOI 10.1161/01.ATV.13.9.1253; Duell PB, 1997, CURR OPIN LIPIDOL, V8, P28, DOI 10.1097/00041433-199702000-00007; FAU D, 1988, J NUTR, V118, P128, DOI 10.1093/jn/118.1.128; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; GRABER R, 1995, INT J CANCER, V62, P443, DOI 10.1002/ijc.2910620414; GRABER R, 1995, ANAL CELL PATHOL, V8, P159; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; Halvorsen B, 1996, J LIPID RES, V37, P1591; Harada K, 1997, ATHEROSCLEROSIS, V135, P235, DOI 10.1016/S0021-9150(97)00167-6; HARKER LA, 1983, CIRC RES, V53, P731, DOI 10.1161/01.RES.53.6.731; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; Harrington EO, 2000, AM J PHYSIOL-LUNG C, V279, pL733, DOI 10.1152/ajplung.2000.279.4.L733; Hasdai D, 1999, ATHEROSCLEROSIS, V142, P317, DOI 10.1016/S0021-9150(98)00249-4; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HUGHES H, 1994, ARTERIOSCLER THROMB, V14, P1177, DOI 10.1161/01.ATV.14.7.1177; Hughes SE, 1996, EXP CELL RES, V225, P171, DOI 10.1006/excr.1996.0168; HULTBERG B, 1995, BBA-MOL CELL RES, V1269, P6, DOI 10.1016/0167-4889(95)00094-9; Hultberg B, 1997, CLIN CHIM ACTA, V262, P39, DOI 10.1016/S0009-8981(97)06531-5; Hultberg B, 2000, TOXICOLOGY, V147, P69, DOI 10.1016/S0300-483X(00)00189-X; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Karp DR, 2001, J BIOL CHEM, V276, P3798, DOI 10.1074/jbc.M008484200; Kiessling F, 1999, CELL TISSUE RES, V297, P131, DOI 10.1007/s004410051340; Kinscherf R, 1999, ATHEROSCLEROSIS, V144, P33, DOI 10.1016/S0021-9150(99)00037-4; Klein-Nulend J, 1998, BIOCHEM BIOPH RES CO, V250, P108, DOI 10.1006/bbrc.1998.9270; Kluijtmans LAJ, 1996, AM J HUM GENET, V58, P35; Koch HG, 1998, EUR J PEDIATR, V157, pS102, DOI 10.1007/PL00014294; Kockx MM, 2000, J PATHOL, V190, P267, DOI 10.1002/(SICI)1096-9896(200002)190:3<267::AID-PATH523>3.0.CO;2-A; Konecky N, 1997, AM HEART J, V133, P534, DOI 10.1016/S0002-8703(97)70148-0; KRISHNASWAMY K, 1977, ATHEROSCLEROSIS, V27, P253, DOI 10.1016/0021-9150(77)90033-8; Kullo IJ, 2000, MAYO CLIN PROC, V75, P369, DOI 10.4065/75.4.369; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; Leveque D, 1996, B CANCER, V83, P176; Lidington EA, 1999, TRANSPL IMMUNOL, V7, P239, DOI 10.1016/S0966-3274(99)80008-2; LIZARD G, 1995, CYTOMETRY, V21, P275, DOI 10.1002/cyto.990210308; Lizard G, 1998, FASEB J, V12, P1651, DOI 10.1096/fasebj.12.15.1651; MAJNO G, 1995, AM J PATHOL, V146, P3; MALINOW MR, 1990, CIRCULATION, V81, P2004, DOI 10.1161/01.CIR.81.6.2004; Matthias D, 1996, ATHEROSCLEROSIS, V122, P201, DOI 10.1016/0021-9150(95)05740-4; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; MCDONALD L, 1964, LANCET, V1, P745; MUDD SH, 1964, SCIENCE, V143, P1443, DOI 10.1126/science.143.3613.1443; Negri C, 1995, BIOCHIMIE, V77, P893, DOI 10.1016/0300-9084(95)90009-8; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; Nishio E, 1997, BRIT J PHARMACOL, V122, P269, DOI 10.1038/sj.bjp.0701391; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; REDDY GSR, 1982, METABOLISM, V31, P778, DOI 10.1016/0026-0495(82)90075-0; REED CJ, 1989, BIOCHEM BIOPH RES CO, V162, P1111, DOI 10.1016/0006-291X(89)90788-2; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH TK, 1994, FASEB J, V8, P661, DOI 10.1096/fasebj.8.9.7911768; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; Stehouwer CDA, 1998, EUR J PEDIATR, V157, pS107, DOI 10.1007/PL00014293; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; UELAND PM, 1989, J LAB CLIN MED, V114, P473; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; Wills PW, 2000, CANCER CHEMOTH PHARM, V46, P193, DOI 10.1007/s002800000119; Xu D, 2000, FEBS LETT, V470, P20, DOI 10.1016/S0014-5793(00)01278-3; XUN L, 2000, EXP CELL RES, V257, P290; YEH CJG, 1981, J IMMUNOL METHODS, V43, P269, DOI 10.1016/0022-1759(81)90174-5	82	23	23	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					1927	1940		10.1096/fj.00-0848com	http://dx.doi.org/10.1096/fj.00-0848com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532973				2022-12-28	WOS:000171372700008
J	Soler, C; Garcia-Manteiga, J; Valdes, R; Xaus, J; Comalda, M; Casado, FJ; Pastor-Anglada, M; Celada, A; Felipe, A				Soler, C; Garcia-Manteiga, J; Valdes, R; Xaus, J; Comalda, M; Casado, FJ; Pastor-Anglada, M; Celada, A; Felipe, A			Macrophages require different nucleoside transport systems for proliferation and activation	FASEB JOURNAL			English	Article						nucleoside uptake; interferon gamma; macrophage colony-stimulating factor	PROTEIN-KINASE PHOSPHATASE-1; RAT-LIVER; MOLECULAR-BIOLOGY; INTERFERON-GAMMA; B-LYMPHOCYTES; CELLS; EXPRESSION; RECEPTOR; MOUSE; LIPOPOLYSACCHARIDE	proliferation and activation, we studied the regulation of the nucleoside transport systems. In murine bone marrow-derived macrophages, the nucleosides required for DNA and RNA synthesis are recruited from the extracellular medium. M-CSF induced macrophage proliferation and DNA and RNA synthesis, whereas interferon gamma (IFN-gamma) led to activation, blocked proliferation, and induced only RNA synthesis. Macrophages express at least the concentrative systems N1 and N2 (CNT2 and CNT1 genes, respectively) and the equilibrative systems es and ei (ENT1 and ENT2 genes, respectively). Incubation with M-CSF only up-regulated the equilibrative system es. Inhibition of this transport system blocked M-CSF-dependent proliferation. Treatment with IFN-gamma only induced the concentrative N1 and N2 systems. IFN-gamma also down-regulated the increased expression of the es equilibrative system induced by M-CSF. Thus, macrophage proliferation and activation require selective regulation of nucleoside transporters and may respond to specific requirements for DNA and RNA synthesis. This report also shows that the nucleoside transporters are critical for macrophage proliferation and activation.	Univ Barcelona, Dept Bioquim & Biol Mol, Lab Fisiol Mol, E-08028 Barcelona, Spain; Univ Barcelona, Dept Fisiol Biol Macrofag, E-08028 Barcelona, Spain; Univ Barcelona, Fdn August Pi I Sunyer, E-08028 Barcelona, Spain	University of Barcelona; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Felipe, A (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Lab Fisiol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.	afelipe@porthos.bio.ub.es	Soler, Concepció/L-1185-2014; Celada, Antonio/I-1714-2016; Felipe, Antonio/M-8297-2015; Manteiga, Jose Manuel Garcia/AAN-1954-2020	Soler, Concepció/0000-0001-6502-5012; Felipe, Antonio/0000-0002-7294-6431; Manteiga, Jose Manuel Garcia/0000-0002-5481-040X; Casado Merediz, Francisco Javier/0000-0003-0192-841X; Celada, Antonio/0000-0003-3883-2171				Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BAER HP, 1990, BIOCHIM BIOPHYS ACTA, V1026, P241, DOI 10.1016/0005-2736(90)90070-5; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; Bellingan GJ, 1996, J IMMUNOL, V157, P2577; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cass CE, 1998, BIOCHEM CELL BIOL, V76, P761, DOI 10.1139/bcb-76-5-761; CELADA A, 1992, J IMMUNOL, V148, P1102; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; del Santo B, 1998, HEPATOLOGY, V28, P1504, DOI 10.1002/hep.510280609; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Felipe A, 1998, BIOCHEM J, V330, P997, DOI 10.1042/bj3300997; FELIPE A, 1994, J BIOL CHEM, V269, P30125; Felipe A, 1997, BIOCHEM BIOPH RES CO, V233, P572, DOI 10.1006/bbrc.1997.6498; FELIPE A, 1992, BIOCHEM J, V284, P577, DOI 10.1042/bj2840577; Flanagan SA, 1997, J BIOL CHEM, V272, P18026, DOI 10.1074/jbc.272.29.18026; GASSER T, 1981, SCIENCE, V213, P777, DOI 10.1126/science.7256279; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; GUTIERREZ MM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P202, DOI 10.1016/0005-2736(93)90202-B; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; MECKLINGGILL KA, 1993, J CELL PHYSIOL, V155, P530, DOI 10.1002/jcp.1041550311; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Pastor-Anglada M, 1998, BIOCHEM CELL BIOL, V76, P771, DOI 10.1139/bcb-76-5-771; Pastor-Anglada M, 1998, TRENDS PHARMACOL SCI, V19, P424, DOI 10.1016/S0165-6147(98)01253-X; PLAGEMANN PGW, 1991, BIOCHEM PHARMACOL, V42, P247, DOI 10.1016/0006-2952(91)90710-M; RAYNAL F, 1984, FEBS LETT, V167, P263, DOI 10.1016/0014-5793(84)80139-8; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Soler C, 1998, J BIOL CHEM, V273, P26939, DOI 10.1074/jbc.273.41.26939; Soler C, 2000, J LEUKOCYTE BIOL, V67, P345, DOI 10.1002/jlb.67.3.345; Thomas R, 1998, SPRINGER SEMIN IMMUN, V20, P53, DOI 10.1007/BF00831999; Valledor AF, 1999, J IMMUNOL, V163, P2452; Valledor AF, 2000, J IMMUNOL, V164, P29, DOI 10.4049/jimmunol.164.1.29; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; VANFURTH R, 1992, PRODUCTION MIGRATION, P3; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Xaus J, 2000, BLOOD, V95, P3823; Xu YJ, 1999, MOL CELL BIOCHEM, V195, P183, DOI 10.1023/A:1006961330375	39	86	90	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					1979	1988		10.1096/fj.01-0022com	http://dx.doi.org/10.1096/fj.01-0022com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532978				2022-12-28	WOS:000171372700013
J	Yang, SN; Yu, J; Mayr, GW; Hofmann, F; Larsson, O; Berggren, PO				Yang, SN; Yu, J; Mayr, GW; Hofmann, F; Larsson, O; Berggren, PO			Inositol hexakisphosphate increases L-type Ca2+ channel activity by stimulation of adenylyl cyclase	FASEB JOURNAL			English	Article						adenylyl cyclase; calcium channel; hippocampus; inositol polyphosphate; protein kinase A	DEPENDENT PROTEIN-KINASE; RAT HIPPOCAMPAL-NEURONS; CALCIUM CHANNELS; SYNAPTIC TRANSMISSION; CREB PHOSPHORYLATION; TRANSMITTER RELEASE; BINDING-PROTEINS; C ACTIVATORS; N-TYPE; CELL	Inositol hexakisphosphate (InsP(6))is a most abundant inositol polyphosphate that changes simultaneously with inositol 1,4,5- trisphosphate in depolarized neurons. However, the role of InsP6 in neuronal signaling is unknown. Mass assay reveals that the basal levels of InsP6 in several brain regions tested are similar. InsP6 mass is significantly elevated in activated brain neurons and lowered by inhibition of neuronal activity. Furthermore, the hippocampus is most sensitive to electrical challenge with regard to percentage accumulation of InsP6. In hippocampal neurons, InsP6 stimulates adenylyl cyclase (AC) without influencing cAMP phosphodiesterases, resulting in activation of protein kinase A (PKA) and thereby selective enhancement of voltage-gated L- type Ca2+ channel activity. This enhancement was abolished by preincubation with PKA and AC inhibitors. These data suggest that InsP6 increases L- type Ca2+ channel activity by facilitating phosphorylation of PKA phosphorylation sites. Thus, in hippocampal neurons, InsP6 serves as an important signal in modulation of voltage-gated L-type Ca2+ channel activity.	Karolinska Hosp, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res L3, S-17176 Stockholm, Sweden; Univ Hamburg, Krankenhaus Eppendorf, Inst Med Biochem & Mol Biol, D-20246 Hamburg, Germany; Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	Karolinska Institutet; Karolinska University Hospital; University of Hamburg; University of Freiburg	Yang, SN (corresponding author), Karolinska Hosp, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res L3, S-17176 Stockholm, Sweden.	yang.shaonian@enk.ks.se	Tuluc, Petronel/C-2527-2011	Berggren, Per-Olof/0000-0001-8991-413X				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURON A, 1994, PFLUG ARCH EUR J PHY, V427, P510, DOI 10.1007/BF00374268; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; DOERNER D, 1988, J NEUROSCI, V8, P4069; DOERNER D, 1988, NEURON, V1, P693, DOI 10.1016/0896-6273(88)90168-7; Efanov AM, 1997, P NATL ACAD SCI USA, V94, P4435, DOI 10.1073/pnas.94.9.4435; FISHMAN RA, 2000, CEREBROSPINAL FLUID; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Guillou JL, 1999, J NEUROSCI, V19, P6183, DOI 10.1523/JNEUROSCI.19-14-06183.1999; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; HELL JW, 1995, EMBO J, V14, P3036, DOI 10.1002/j.1460-2075.1995.tb07306.x; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; JACKSON TR, 1987, EMBO J, V6, P49, DOI 10.1002/j.1460-2075.1987.tb04717.x; Kavalali ET, 1997, J NEUROSCI, V17, P5334; Kavalali ET, 1997, NEURON, V18, P651, DOI 10.1016/S0896-6273(00)80305-0; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; Larsson O, 1997, SCIENCE, V278, P471, DOI 10.1126/science.278.5337.471; MAYR GW, 1991, BIOCHEM J, V280, P631, DOI 10.1042/bj2800631; MAYR GW, 1988, BIOCHEM J, V254, P585, DOI 10.1042/bj2540585; MEYERS DER, 1989, J NEUROPHYSIOL, V61, P467, DOI 10.1152/jn.1989.61.3.467; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MIRONOV SL, 1991, NEUROSCI LETT, V133, P175, DOI 10.1016/0304-3940(91)90563-9; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; PARENT A, 1994, EUR J NEUROSCI, V6, P67, DOI 10.1111/j.1460-9568.1994.tb00248.x; Reid CA, 1998, J NEUROSCI, V18, P2849; SASAKAWA N, 1994, MOL PHARMACOL, V46, P380; SASAKAWA N, 1993, BRAIN RES, V623, P155, DOI 10.1016/0006-8993(93)90023-G; SCULIER JP, 1993, SUPPORT CARE CANCER, V1, P135, DOI 10.1007/BF00366059; SCULPTOREANU A, 1995, AM J PHYSIOL-CELL PH, V269, pC725, DOI 10.1152/ajpcell.1995.269.3.C725; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; Shears S B, 1996, Subcell Biochem, V26, P187; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; Talley EM, 1999, J NEUROSCI, V19, P1895; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; THEIBERT AB, 1992, J BIOL CHEM, V267, P9071; Thibault O, 1996, SCIENCE, V272, P1017, DOI 10.1126/science.272.5264.1017; Tsien RW, 1998, NATURE, V391, P839, DOI 10.1038/35981; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; Wu LG, 1998, P NATL ACAD SCI USA, V95, P4720, DOI 10.1073/pnas.95.8.4720; Yang SN, 1999, J NEUROPHYSIOL, V81, P781, DOI 10.1152/jn.1999.81.2.781; Zhang KH, 1999, DEV BRAIN RES, V112, P11, DOI 10.1016/S0165-3806(98)00150-3	45	36	37	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2001	15	10					1753	1763		10.1096/fj.00-0799com	http://dx.doi.org/10.1096/fj.00-0799com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481223				2022-12-28	WOS:000170809900011
J	Ricci, JE; Lang, V; Luciano, F; Belhacene, N; Giordanengo, V; Michel, F; Bismuth, G; Auberger, P				Ricci, JE; Lang, V; Luciano, F; Belhacene, N; Giordanengo, V; Michel, F; Bismuth, G; Auberger, P			An absolute requirement for Fyn in T cell receptor-induced caspase activation and apoptosis	FASEB JOURNAL			English	Article						TCR-mediated apoptosis; Fyn knockout mice	PROTEIN-TYROSINE KINASES; LYMPHOCYTE STIMULATION; ANTIGEN RECEPTOR; B-CELLS; CLEAVAGE; PHOSPHORYLATION; DEGRADATION; INHIBITION; MICE; DNA	The mechanisms by which caspases are stimulated following T cell receptor engagement are presently unknown. We show here that TCR cross-linking induces caspase activation, annexin V binding, loss of cell viability, Fyn cleavage, and apoptosis in a T cell hybridoma. All these events are increased in T cells overexpressing wild-type Fyn and are inhibited in cells expressing a kinase dead mutant or a soluble form of Fyn. Moreover, DNA fragmentation mediated by various proapoptotic stimuli and anti-CD3-induced caspase activation and DNA fragmentation are reduced significantly in mouse embryo fibroblasts and thymocytes from Fyn knockout mice respectively. These results indicate that an active and membrane-anchored Fyn is required for T cell receptor-induced caspase activation and apoptosis in T lymphocytes and point out a specific role of Fyn in caspase activation and apoptosis in T cells.	LNC Label, INSERM, U526, IFR 50, F-06107 Nice 2, France; Ctr Hosp Pitie Salpetriere, Cellular Immunol Lab, CNRS, UMR 7627, F-75013 Paris, France; Inst Pasteur, Dept Immunol, Lab Mol Immunol, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Auberger, P (corresponding author), LNC Label, INSERM, U526, IFR 50, Av Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	RICCI, Jean Ehrland/AAS-4379-2020; AUBERGER, Patrick/G-1491-2013; luciano, frederic/P-6264-2016; Ricci, Jean Ehrland/I-7117-2016	RICCI, Jean Ehrland/0000-0003-1585-8117; AUBERGER, Patrick/0000-0002-2481-8275; luciano, frederic/0000-0001-9253-4998; Ricci, Jean Ehrland/0000-0003-1585-8117; Michel, Frederique/0000-0002-3524-2232; giordanengo, valerie/0000-0002-5114-1124				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; BLANK U, 1993, EUR J IMMUNOL, V23, P3057, DOI 10.1002/eji.1830231203; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Denny MF, 2000, MOL CELL BIOL, V20, P1426, DOI 10.1128/MCB.20.4.1426-1435.2000; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fusaki N, 1996, J IMMUNOL, V156, P1369; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; Guerin S, 1997, FASEB J, V11, P1003, DOI 10.1096/fasebj.11.12.9337153; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jiang D, 1999, CELL DEATH DIFFER, V6, P402, DOI 10.1038/sj.cdd.4400513; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; KATAGIRI T, 1990, P NATL ACAD SCI USA, V87, P2865; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Lang V, 1999, J IMMUNOL, V162, P7224; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; Maruo A, 1999, INT IMMUNOL, V11, P1371, DOI 10.1093/intimm/11.9.1371; Michel F, 1998, J BIOL CHEM, V273, P31932, DOI 10.1074/jbc.273.48.31932; MIGITA K, 1995, IMMUNOLOGY, V85, P550; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Paget WJ, 1999, SOZ PRAVENTIV MED, V44, P1, DOI 10.1007/BF01624804; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; QUILL H, 1992, J IMMUNOL, V149, P2887; Ricci JE, 1999, ONCOGENE, V18, P3963, DOI 10.1038/sj.onc.1202782; RON D, 1999, J BIOL CHEM, V274, P19203; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096	37	22	22	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1777	+		10.1096/fj.00-0665fje	http://dx.doi.org/10.1096/fj.00-0665fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481227				2022-12-28	WOS:000169261200016
J	Kagedal, K; Johansson, U; Ollinger, K				Kagedal, K; Johansson, U; Ollinger, K			The lysosomal protease cathepsin D mediates apoptosis induced by oxidative stress	FASEB JOURNAL			English	Article						caspases; cell death; naphthazarin p53; pepstatin A	PROGRAMMED CELL-DEATH; T-CELLS; ACTIVATION; RELEASE; DEGRADATION; SUPPRESSION; RELOCATION; CASPASE-3; TAU	It has been suggested that lysosomes and the lysosomal proteases cathepsin D and B act as proapoptotic mediators of apoptosis, in addition to mitochondrial release of cytochrome c and the activation of the caspase family of proteases. We found that cathepsin D was implicated in the onset of apoptosis in fibroblasts exposed to oxidative stress generated by redox cycling of naphthazarin (NZ)(5,8-dihydroxy-1,4-naphthoquinon). At the start of NZ treatment, the intracellular reduced glutathione concentration was diminished and cathepsins D, B, and L were all translocated from lysosomes to the cytosol before any biochemical or morphological signs of apoptosis were detected. Increase in cathepsin D activity and in the level of p53 protein, a transcription factor for cathepsin D, was observed before activation of caspase-3. Moreover, pretreatment with the cathepsin D inhibitor pepstatin A or the caspase-3 inhibitor Ac-DEVD-CHO prevented apoptosis, although the increase of cathepsin D activity was still detected when caspase-3 was inhibited. Cathepsin B activity decreased following oxidative stress, and inhibition of the protease did not affect the apoptotic process. We suggest that translocation of lysosomal proteases is an early event in NZ-induced apoptosis and that the release and increased activity of cathepsin D allow this protease to exert an apoptosis-mediating effect upstream of the caspase cascade.	Linkoping Univ, Fac Hlth Sci, Div Pathol 2, Linkoping, Sweden	Linkoping University	Kagedal, K (corresponding author), Linkoping Univ Hosp, Div Pathol 2, S-58185 Linkoping, Sweden.	katka@inr.liu.se						BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; Barrett A, 1977, PROTEINASES MAMMALIA, P209; BARRETT AJ, 1994, METHOD ENZYMOL, V244, P536; Bednarski E, 1996, J NEUROCHEM, V67, P1846, DOI 10.1046/j.1471-4159.1996.67051846.x; Brunk UT, 1999, REDOX REP, V4, P3, DOI 10.1179/135100099101534675; Brunk UT, 1997, FREE RADICAL BIO MED, V23, P616, DOI 10.1016/S0891-5849(97)00007-5; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; HONEGGER CG, 1989, J CHROMATOGR-BIOMED, V487, P463, DOI 10.1016/S0378-4347(00)83056-X; Isahara K, 1999, NEUROSCIENCE, V91, P233, DOI 10.1016/S0306-4522(98)00566-1; Kagedal K, 1999, FREE RADICAL RES, V31, P419, DOI 10.1080/10715769900300981; Kenessey A, 1997, J NEUROCHEM, V69, P2026; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATUS A, 1987, BIOCHEMISTRY-US, V26, P8083, DOI 10.1021/bi00399a010; McIlroy D, 2000, GENE DEV, V14, P549; Monney L, 1998, EUR J BIOCHEM, V251, P295, DOI 10.1046/j.1432-1327.1998.2510295.x; MORIYAMA A, 1980, J BIOCHEM, V88, P619, DOI 10.1093/oxfordjournals.jbchem.a133013; Neuzil J, 1999, FEBS LETT, V445, P295, DOI 10.1016/S0014-5793(99)00141-6; Ollinger K, 2000, ARCH BIOCHEM BIOPHYS, V373, P346, DOI 10.1006/abbi.1999.1567; OLLINGER K, 1995, FREE RADICAL BIO MED, V19, P565, DOI 10.1016/0891-5849(95)00062-3; Roberg K, 1998, J HISTOCHEM CYTOCHEM, V46, P411, DOI 10.1177/002215549804600316; Roberg K, 1998, AM J PATHOL, V152, P1151; Roberg K, 1999, FREE RADICAL BIO MED, V27, P1228, DOI 10.1016/S0891-5849(99)00146-X; Roberts Lewis R., 1999, Cell Biochemistry and Biophysics, V30, P71, DOI 10.1007/BF02737885; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; SENSIBAR JA, 1990, PROSTATE, V16, P263, DOI 10.1002/pros.2990160310; Shibata M, 1998, BIOCHEM BIOPH RES CO, V251, P199, DOI 10.1006/bbrc.1998.9422; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Wu YC, 2000, GENE DEV, V14, P536	37	220	228	1	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1592	+		10.1096/fj.00-0708fje	http://dx.doi.org/10.1096/fj.00-0708fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427496				2022-12-28	WOS:000173707700021
J	Tufan, AC; Tuan, RS				Tufan, AC; Tuan, RS			Wnt regulation of limb mesenchymal chondrogenesis is accompanied by altered N-cadherin-related functions	FASEB JOURNAL			English	Article						Wnt-5a; Wnt-7a; limb chondrogenesis; cellular condensation; N-cadherin; beta-catenin; collagen type II	BETA-CATENIN; CELL-ADHESION; TYROSINE PHOSPHORYLATION; IN-VITRO; MICROMASS CULTURES; CARTILAGE DIFFERENTIATION; PATTERN-FORMATION; GENE-EXPRESSION; LECTIN BINDING; MESSENGER-RNA	It has been suggested that Wnt proteins play essential roles in the regulation of limb development and morphogenesis. We have analyzed the effects of RCAS retroviral-mediated misexpression of Wnt-5a and Wnt-7a, two Wnt genes expressed during normal limb development, on chondrogenesis in high-density micromass cultures of chick limb bud mesenchymal cells. Wnt-7a misexpression inhibited chondrogenesis in vitro, whereas Wnt-5a did not. Analysis of cellular condensation and precartilage aggregate formation revealed that the inhibitory effect of Wnt-7a is unlikely to act at the cellular condensation step but, instead, influences the actual chondrogenic differentiation process. During early condensation, N-cadherin expression within the cellular aggregates in Wnt-7a cultures was slightly delayed, whereas Wnt-5a cultures appeared similar to control cultures. With the initiation of differentiation, Wnt-5a and control cultures showed down-regulation of N-cadherin and up-regulation of collagen type II expression, whereas Wnt-7a cultures showed persistent, high levels of N-cadherin expression both at the mRNA and protein levels, up to 72 h, and nearly no collagen type 11 expression. Wnt-7a misexpression was also accompanied by an initial increase in the serine/threonine phosphorylation of beta-catenin and N-cadherin, events known to affect N-cadherin turnover and stabilization of beta-catenin/N-cadherin cell adhesion complex, during chondrogenic differentiation. Writ regulation of limb mesenchymal chondrogenesis is thus likely to involve modulation of N-cadherin expression and function. In addition, Wnt-7a misexpression stimulates the proliferation of limb mesenchymal cells in vitro, possibly contributing to its chondro-inhibitory effect. Finally, the differences between Wnt-5a and Wnt-7a effects suggest functional diversity within the Wnt family.	Thomas Jefferson Univ, Dept Orthopaed Surg, Orthopaed Res Lab, Philadelphia, PA 19107 USA	Jefferson University	Tuan, RS (corresponding author), Thomas Jefferson Univ, Dept Orthopaed Surg, Orthopaed Res Lab, 1015 Walnut St,Room 501, Philadelphia, PA 19107 USA.	Rocky.S.Tuan@mail.tju.edu		Tufan, A. Cevik/0000-0002-5920-0475				AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; ANTONIO JDS, 1986, DEV BIOL, V115, P313, DOI 10.1016/0012-1606(86)90252-6; AULTHOUSE AL, 1987, DEV BIOL, V120, P377, DOI 10.1016/0012-1606(87)90240-5; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; BOSKEY AL, 1992, BONE MINER, V16, P11, DOI 10.1016/0169-6009(92)90819-Y; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dale TC, 1998, BIOCHEM J, V329, P209; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; DELISE AM, 2000, DEV BIOL PROTOCOLS, V3, P359; DELISE AM, 2000, DEV BIOL PROTOCOLS, V3, P377; DENKER AE, 1995, DIFFERENTIATION, V59, P25, DOI 10.1046/j.1432-0436.1995.5910025.x; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; FAGOTTO F, 1994, DEVELOPMENT, V120, P3667; FERRARI D, 1994, BIOCHEM BIOPH RES CO, V205, P429, DOI 10.1006/bbrc.1994.2683; Giarre M, 1998, ANN NY ACAD SCI, V857, P43, DOI 10.1111/j.1749-6632.1998.tb10106.x; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521-1878(200002)22:2<138::AID-BIES5>3.3.CO;2-W; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; Harlow E., 1988, ANTIBODIES LAB MANUA, P298; Hartmann C, 2000, DEVELOPMENT, V127, P3141; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; Hickok NJ, 1998, MICROSC RES TECHNIQ, V43, P174, DOI 10.1002/(SICI)1097-0029(19981015)43:2<174::AID-JEMT9>3.0.CO;2-P; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Kawakami Y, 1999, DEV GROWTH DIFFER, V41, P29; Kengaku M, 1997, COLD SPRING HARB SYM, V62, P421; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Knudson CB, 1999, BIOCHEM SOC T, V27, P142, DOI 10.1042/bst0270142; Kulyk WM, 2000, EXP CELL RES, V255, P327, DOI 10.1006/excr.1999.4784; LANGILLE RM, 1994, MICROSC RES TECHNIQ, V28, P455, DOI 10.1002/jemt.1070280602; Lee MM, 1997, DEV GENET, V20, P224; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LEV R, 1964, J HISTOCHEM CYTOCHEM, V12, P309, DOI 10.1177/12.4.309; Liu XX, 1999, P NATL ACAD SCI USA, V96, P14383, DOI 10.1073/pnas.96.25.14383; MAINI PK, 1991, INT REV CYTOL, V129, P91; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Mello MA, 1999, IN VITRO CELL DEV-AN, V35, P262; Meyer RA, 1997, DEV GENET, V21, P290; MILAIRE J, 1991, ANAT EMBRYOL, V184, P479, DOI 10.1007/BF01236054; Molenaar M, 1998, MECH DEVELOP, V75, P151, DOI 10.1016/S0925-4773(98)00085-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Murray D, 2000, J BIOL CHEM, V275, P3610, DOI 10.1074/jbc.275.5.3610; Niswander L, 1997, CURR OPIN GENET DEV, V7, P530, DOI 10.1016/S0959-437X(97)80082-2; OBERLENDER SA, 1994, CELL ADHES COMMUN, V2, P521, DOI 10.3109/15419069409014216; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; OLESEN CEM, 1997, RECOMBINANT PROTEIN, P61; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; PARADIES NE, 1993, J NEUROSCI RES, V36, P33, DOI 10.1002/jnr.490360105; PARR BA, 1993, DEVELOPMENT, V119, P247; ROARK EF, 1992, DEVELOPMENT, V114, P973; ROARK EF, 1994, DEV DYNAM, V200, P103, DOI 10.1002/aja.1002000203; Rudnicki JA, 1997, DEV BIOL, V185, P104, DOI 10.1006/dbio.1997.8536; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Stott NS, 1999, J CELL PHYSIOL, V180, P314, DOI 10.1002/(SICI)1097-4652(199909)180:3<314::AID-JCP2>3.3.CO;2-P; Stringa E, 1997, EXP CELL RES, V232, P287, DOI 10.1006/excr.1997.3532; Stringa E, 1996, ANAT EMBRYOL, V194, P427; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WIDELITZ RB, 1993, J CELL PHYSIOL, V156, P399, DOI 10.1002/jcp.1041560224; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; WONG MY, 1993, IN VITRO CELL DEV-AN, V29A, P917; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZAKANY J, 1993, NATURE, V362, P546, DOI 10.1038/362546a0; ZIMMERMANN B, 1984, HISTOCHEMISTRY, V81, P353, DOI 10.1007/BF00514329	80	67	67	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1436	+		10.1096/fj.00-0784fje	http://dx.doi.org/10.1096/fj.00-0784fje			31	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387249				2022-12-28	WOS:000173705800019
J	Hwang, DY; Chae, KR; Kang, TS; Hwang, JH; Lim, CH; Kang, HK; Goo, JS; Lee, MR; Lim, HJ; Min, SH; Cho, JY; Hong, JT; Song, CW; Paik, SG; Cho, JS; Kim, YK				Hwang, DY; Chae, KR; Kang, TS; Hwang, JH; Lim, CH; Kang, HK; Goo, JS; Lee, MR; Lim, HJ; Min, SH; Cho, JY; Hong, JT; Song, CW; Paik, SG; Cho, JS; Kim, YK			Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						AD; PS2; A beta-42; amyloid precursor protein	PRESENILIN-2 MUTATION N141I; PRECURSOR PROTEIN; APOLIPOPROTEIN-E; GENE; EXPRESSION; BRAIN; CYCLOOXYGENASE-2; LOCALIZATION; APOPTOSIS; CLEAVAGE	Alzheimer's disease (AD) occurs when neurons in the memory and cognition regions of the brain are accompanied by an accumulation of the long amyloid beta-proteins of the 39 to 43 amino acids derived from the amyloid precursor protein (APP) by cleavage with beta- and gamma-secretase. An increased production of Abeta-42 by mutation of PS2 genes promotes caspase expression and is associated with the Cox-2 found in the brain of AD patients. To address this question in vivo, we expressed the human mutant PS2 (hPS2m) (N141I) as well as wild PS2 (hPS2w) as a control in transgenic (Tg) mice under control of the neuron-specific enolase (NSE) promoter. Water maze tests were used to demonstrate the behavioral defect; dot blot, Western blot, and immunohistochemical analyses were performed on the brain with the hPS2, Abeta-42, caspase- 3, and Cox-2 antibody. We concluded that 1) Tg mice showed a behavioral dysfunction in the water maze test, 2) levels of hPS2, Abeta-42, caspase-3, and Cox-2 expression were modulated in the brains of both Tg mice, 3) dense staining with antibody to hPS2, Abeta-42, caspase- 3, and Cox-2 was visible in the brains of Tg mice compared with age-matched control mice, and 4) distinguishable AD phenotypes between hPS2w- and hPS2m-Tg mice did not appear. These results suggest that an elevation of Abeta-42 by overexpression of hPS2 and mutation of hPS2m might induce the behavioral deficit and caspase- 3 and Cox-2 induction, which could be useful in the therapeutic testing of compounds to have considerable clinical effects.	Natl Inst Toxicol Res, Korea FDA, Div Lab Anim Resources, Seoul 122704, South Korea; Natl Inst Toxicol Res, Korea FDA, Div Neurotoxicol, Seoul 122704, South Korea; Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, South Korea; Chungnam Natl Univ, Dept Biol, Taejon 305704, South Korea	Chungbuk National University; Chungnam National University	Kim, YK (corresponding author), Natl Inst Toxicol Res, Korea FDA, Div Lab Anim Resources, 5 Nokbun Dong Eunpyng Ku, Seoul 122704, South Korea.	kimyongkyu@hanmail.net						Arnold SE, 1991, CEREB CORTEX, V1, P103, DOI 10.1093/cercor/1.1.103; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Guenette SY, 1999, NEUROBIOL AGING, V20, P201, DOI 10.1016/S0197-4580(99)00042-1; Janicki S, 1997, J CELL BIOL, V139, P485, DOI 10.1083/jcb.139.2.485; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LETSCHER H, 1997, J BIOL CHEM, V272, P20655; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LI YM, 2000, NATURE, V405, P685; Oka A, 1997, NEUROREPORT, V8, P1161, DOI 10.1097/00001756-199703240-00020; OYANA F, 1999, J NEUROCHEM, V71, P313; Pasinetti GM, 1998, NEUROSCIENCE, V87, P319, DOI 10.1016/S0306-4522(98)00218-8; PerezTur J, 1995, NEUROREPORT, V7, P297; ROGAEV E, 1996, NATURE, V376, P775; Sawamura N, 2000, J BIOL CHEM, V275, P27901; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; van de Craen M, 1999, FEBS LETT, V445, P149, DOI 10.1016/S0014-5793(99)00108-8; VOGT BA, 1992, CEREB CORTEX, V2, P526, DOI 10.1093/cercor/2.6.526; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a; WEST MJ, 1994, LANCET, V344, P526; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	35	107	112	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0805	10.1096/fj.01-0732com	http://dx.doi.org/10.1096/fj.01-0732com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039862				2022-12-28	WOS:000176683900006
J	Poot, M; Gollahon, KA; Emond, MJ; Silber, JR; Rabinovitch, PS				Poot, M; Gollahon, KA; Emond, MJ; Silber, JR; Rabinovitch, PS			Werner syndrome diploid fibroblasts are sensitive to 4-nitroquinoline-N-oxide and 8-methoxypsoralen: implications for the disease phenotype	FASEB JOURNAL			English	Article						WRN helicase/exonuclease; DNA crosslinks; apoptosis; S-phase; aging	LYMPHOBLASTOID CELL-LINES; S-PHASE; SYNDROME PROTEIN; SYNDROME GENE; DNA; APOPTOSIS; MUTATIONS; HELICASE; EXONUCLEASE; CYCLE	The clinical phenotype of Werner Syndrome (WRN) includes features reminiscent of accelerated aging and an increased incidence of sarcomas and other tumors of mesenchymal origin. This syndrome results from mutations in the WRN DNA helicase/exonuclease gene. We found that WRN deficient primary fibroblasts, as well as lymphoblastoid cell lines (LCLs), show reduced proliferative survival in response to 4-nitroquinoline-N-oxide (4NQO) and 8-methoxypsoralen (8MOP), compared with WRN-proficient cells. This is the first demonstration of drug hypersensitivity in primary cells of mesenchymal origin from WRN patients. Notably, 8MOP-induced DNA interstrand crosslinks, but not 8MOP mono-adducts, produced S-phase apoptosis in WRN-deficient LCLs. In contrast, 8MOP did not induce S-phase apoptosis in WRN-deficient diploid fibroblasts, in which drug hypersensitivity was entirely due to reduced cell proliferation. Such reduced proliferation of damaged mesenchymal cells in WRN patients may lead to earlier proliferative senescence. In addition, failure of WRN-deficient mesenchymal cells to undergo apoptosis in response to DNA damage in S-phase may promote genomic instability and could help clarify the increased risk of sarcoma in WRN patients. Because interstrand crosslinks are believed to be repaired through homologous recombination, these results suggest an important role for WRN in recombinational resolution of stalled replication forks.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Poot, M (corresponding author), Univ Washington, Dept Pathol, Box 357705, Seattle, WA 98195 USA.	MartinP@medicine.washington.edu	Poot, Martin/F-9427-2010					CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GALIEGUEZOUITINA S, 1985, CANCER RES, V45, P520; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; HOEHN H, 1975, CYTOGENET CELL GENET, V15, P282, DOI 10.1159/000130526; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; MARTIN GM, 1970, LAB INVEST, V23, P86; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Melcher R, 2000, CYTOGENET CELL GENET, V91, P180, DOI 10.1159/000056841; NORWOOD TH, 1979, EXP CELL RES, V119, P15, DOI 10.1016/0014-4827(79)90330-6; NUNOSHIBA T, 1993, CANCER RES, V53, P3250; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Okada M, 1998, BIOL PHARM BULL, V21, P235; Oshima J, 1996, HUM MOL GENET, V5, P1909, DOI 10.1093/hmg/5.12.1909; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Poot M, 1999, HUM GENET, V104, P10, DOI 10.1007/s004390050903; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; POOT M, 1997, CYTOMETRY, V27, P1; RABINOVITCH PS, 1988, EXP CELL RES, V174, P309, DOI 10.1016/0014-4827(88)90302-3; RPINCE PR, 2001, GENE DEV, V15, P933; Seluanov A, 2001, MOL CELL BIOL, V21, P1552, DOI 10.1128/MCB.21.5.1552-1564.2001; Shen JC, 2000, NUCLEIC ACIDS RES, V28, P3260, DOI 10.1093/nar/28.17.3260; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; TAKEUCHI F, 1982, EXP GERONTOL, V17, P473, DOI 10.1016/S0531-5565(82)80009-0; Yu CE, 1997, AM J HUM GENET, V60, P330; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	31	80	85	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					757	+		10.1096/fj.01-0906fje	http://dx.doi.org/10.1096/fj.01-0906fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11978740				2022-12-28	WOS:000174755900013
J	Comerford, KM; Lawrence, DW; Synnestvedt, K; Levi, BP; Colgan, SP				Comerford, KM; Lawrence, DW; Synnestvedt, K; Levi, BP; Colgan, SP			Role of vasodilator-stimulated phosphoprotein in protein kinase A-induced changes in endothelial junctional permeability	FASEB JOURNAL			English	Article						cytoskeleton; neutrophil; adenosine; inflammation; cyclic AMP	CELL GAP FORMATION; FOCAL-ADHESION; BARRIER FUNCTION; LISTERIA-MONOCYTOGENES; HUMAN PLATELETS; SERINE-239 PHOSPHORYLATION; BINDING PROPERTIES; ENA/VASP PROTEINS; TIGHT JUNCTIONS; ACTIN-BINDING	At sites of ongoing inflammation, polymorphonuclear leukocytes (PMN, neutrophils) migrate across vascular endothelia, and such transmigration has the potential to disturb barrier properties and can result in intravascular fluid loss and edema. It was recently appreciated that endogenous pathways exist to dampen barrier disruption during such episodes and may provide an important anti-inflammatory link. For example, during transmigration, PMN-derived adenosine activates endothelial adenosine receptors and induces a cAMP-dependent resealing of endothelial barrier function. In our study reported here, we sought to understand the link between cyclic nucleotide elevation and increased endothelial barrier function. Initial studies revealed that adenosine-induced barrier function is tightly linked to activation of protein kinase A (PKA). Because PKA selectively phosphorylates serine and threonine residues, we screened zonula occludens-1 (ZO-1) immunoprecipitates for the existence of such phosphorylated proteins as targets for barrier regulation. This analysis revealed a dominantly phosphorylated band at 50 kDa. Microsequencing identified this protein as vasodilator-stimulated phosphoprotein (VASP), an actin binding protein with multiple serine/threonine phosphorylation sites. Immunofluorescent microscopy revealed that VASP localizes to endothelial junctional complexes and colocalizes with ZO-1, occludin, and junctional adhesion molecule-1 (JAM-1). To address the role of phospho-VASP in regulation of barrier function, we generated a phosphospecific VASP antibody targeting the Ser157 residue phosphorylation site, the site preferred by PKA. Immunolocalization studies with this antibody revealed that upon PKA activation, phospho-VASP appears at cell-cell junctions. Transient transfection of truncated VASP fragments revealed a parallel increase in barrier function. Taken together, these studies reveal a central role for phospho-VASP in the coordination of PKA-regulated barrier function, such as occurs during episodes of inflammation.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Colgan, SP (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Thorn Bldg 704,75 Francis St, Boston, MA 02115 USA.	colgan@zeus.bwh.harvard.edu	Colgan, Sean P./B-4573-2009	Lawrence, Donald/0000-0001-5912-6992				ADKINS WK, 1992, J APPL PHYSIOL, V72, P492, DOI 10.1152/jappl.1992.72.2.492; Ahern-Djamali SM, 1999, P NATL ACAD SCI USA, V96, P4977, DOI 10.1073/pnas.96.9.4977; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; BALUK P, 1994, AM J PHYSIOL, V266, pL461, DOI 10.1152/ajplung.1994.266.4.L461; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; BUTT E, 1994, J BIOL CHEM, V269, P14509; CASNOCHA SA, 1989, J APPL PHYSIOL, V67, P1997, DOI 10.1152/jappl.1989.67.5.1997; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Cohen CR, 1997, EXP CELL RES, V231, P184, DOI 10.1006/excr.1996.3450; Colgan SP, 1996, J EXP MED, V184, P1003, DOI 10.1084/jem.184.3.1003; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; DANCEY JT, 1976, J CLIN INVEST, V58, P705, DOI 10.1172/JCI108517; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; DRAIJER R, 1995, CIRC RES, V77, P897, DOI 10.1161/01.RES.77.5.897; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Friedman GB, 1998, J CELL PHYSIOL, V176, P76, DOI 10.1002/(SICI)1097-4652(199807)176:1<76::AID-JCP9>3.0.CO;2-5; GARCIA JGN, 1995, J INVEST MED, V43, P117; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HALBRUGGE M, 1992, CELL SIGNAL, V4, P189, DOI 10.1016/0898-6568(92)90082-J; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; HUANG AJ, 1988, J CELL PHYSIOL, V135, P355, DOI 10.1002/jcp.1041350302; HUBER AR, 1989, J CLIN INVEST, V83, P1122, DOI 10.1172/JCI113992; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Lehr HA, 2000, J PATHOL, V190, P373, DOI 10.1002/(SICI)1096-9896(200002)190:3&lt;373::AID-PATH593&gt;3.0.CO;2-3; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; LEWIS RE, 1988, MICROVASC RES, V35, P27, DOI 10.1016/0026-2862(88)90048-9; LOFTON CE, 1990, BIOCHEM BIOPH RES CO, V172, P793, DOI 10.1016/0006-291X(90)90744-8; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; Machesky LM, 2000, CELL, V101, P685, DOI 10.1016/S0092-8674(00)80879-X; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; MARCHESI V. T., 1960, QUART JOUR EXPTL PHYSIOL, V45, P343; MEYRICK B, 1984, TISSUE CELL, V16, P1, DOI 10.1016/0040-8166(84)90014-4; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL203, DOI 10.1152/ajplung.1998.275.2.L203; Narravula S, 2000, J IMMUNOL, V165, P5262, DOI 10.4049/jimmunol.165.9.5262; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; NOLTE C, 1991, J BIOL CHEM, V266, P14808; Nusrat A, 2000, J CELL SCI, V113, P1771; Nusrat A, 2000, AM J PHYSIOL-GASTR L, V279, pG851, DOI 10.1152/ajpgi.2000.279.5.G851; Oelze M, 2000, CIRC RES, V87, P999, DOI 10.1161/01.RES.87.11.999; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; Price CJ, 2000, ARTERIOSCL THROM VAS, V20, P2051, DOI 10.1161/01.ATV.20.9.2051; REINECKER HC, 1995, P NATL ACAD SCI USA, V92, P8353, DOI 10.1073/pnas.92.18.8353; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; Riley MV, 1998, INVEST OPHTH VIS SCI, V39, P2076; SHASBY DM, 1982, CIRC RES, V51, P657, DOI 10.1161/01.RES.51.5.657; SHAW JO, 1982, AM J PATHOL, V108, P17; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stevens T, 1999, AM J PHYSIOL-LUNG C, V277, pL119, DOI 10.1152/ajplung.1999.277.1.L119; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Zund G, 1996, P NATL ACAD SCI USA, V93, P7075, DOI 10.1073/pnas.93.14.7075	66	143	148	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					583	+		10.1096/fj.01-0739fje	http://dx.doi.org/10.1096/fj.01-0739fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919161				2022-12-28	WOS:000174203700016
J	Weiss, RG; Chatham, JC; Charron, MJ; Georgakopolous, D; Wallimann, T; Kay, L; Walzel, B; Wang, YB; Kass, DA; Gerstenblith, G; Chacko, VP				Weiss, RG; Chatham, JC; Charron, MJ; Georgakopolous, D; Wallimann, T; Kay, L; Walzel, B; Wang, YB; Kass, DA; Gerstenblith, G; Chacko, VP			An increase in the myocardial PCr/ATP ratio in GLUT4 null mice	FASEB JOURNAL			English	Article						phosphocreatine; glucose; left ventricular hypertrophy; P-31 NMR spectroscopy; magnetic resonance imaging	CORONARY-ARTERY DISEASE; LEFT-VENTRICULAR HYPERTROPHY; ACTIVATED PROTEIN-KINASE; DECREASED ENERGY RESERVE; P-31 NMR-SPECTROSCOPY; SKELETAL-MUSCLE; CREATINE-KINASE; DILATED CARDIOMYOPATHY; HEART-FAILURE; IN-VIVO	ATP and creatine phosphate (PCr) are prime myocardial high-energy phosphates. Their relative concentrations are conserved among mammalian species and across a range of physiologic cardiac workloads. The cardiac PCr/ATP ratio is decreased with several pathologic conditions, such as ischemia and heart failure, but there are no reports of an increase in the cardiac PCr/ATP ratio in any species or with interventions. We studied the in vivo energetics in transgenic mice lacking expression of the glucose transport protein GLUT4 (G4N) and observed a significant 60% increase in the myocardial PCr/ATP ratio in G4N that was confirmed in three different experimental settings including intact animals. The higher PCr/ATP in G4N is cardiac-specific and is due to higher total cardiac creatine (CR) concentrations in G4N than in wild-type (WT). However, [ATP], [ADP], and -DeltaG(similar toATP) did not differ between the strains. Expression of the creatine transport protein (CreaT) that is responsible for creatine uptake in myocytes was preserved in G4N cardiac tissue. These observations demonstrate, for the first time to our knowledge, that G4N manifest a unique increase in the cardiac PCr/ATP ratio, which suggests a novel genetic strategy for increasing myocardial creatine levels.	Johns Hopkins Univ, Sch Med, Dept Radiol, NMR Res Div, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10467 USA; ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins University; Yeshiva University; Albert Einstein College of Medicine; Swiss Federal Institutes of Technology Domain; ETH Zurich; University System of Maryland; University of Maryland Baltimore	Weiss, RG (corresponding author), Johns Hopkins Univ Hosp, Carnegie 584,600 N Wolfe St, Baltimore, MD 21287 USA.	rgweiss@rad.jhu.edu	Wallimann, Theo/C-6047-2008	Wallimann, Theo/0000-0003-4957-5836; Wang, Yibin/0000-0003-0852-0767				Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; BALABAN RS, 1986, SCIENCE, V232, P1121, DOI 10.1126/science.3704638; BARKER PB, 1990, SOC MAGN RES MED, V9, P1089; BOTTOLEY PA, 1989, NMR BIOMED, V20, P284; BOTTOMLEY PA, 1991, J MAGN RESON, V95, P341, DOI 10.1016/0022-2364(91)90223-G; BOTTOMLEY PA, 1993, J MAGN RESON SER A, V103, P242, DOI 10.1006/jmra.1993.1162; Bottomley PA, 1996, MAGNET RESON MED, V35, P664, DOI 10.1002/mrm.1910350507; BROOKER HR, 1987, MAGNET RESON MED, V5, P417, DOI 10.1002/mrm.1910050503; Chacko VP, 2000, AM J PHYSIOL-HEART C, V279, pH2218, DOI 10.1152/ajpheart.2000.279.5.H2218; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; FLAHERTY JT, 1982, CIRCULATION, V65, P561, DOI 10.1161/01.CIR.65.3.561; FROM AHL, 1986, FEBS LETT, V206, P257, DOI 10.1016/0014-5793(86)80992-9; Gamcsik MP, 1996, BIOTECHNOL BIOENG, V49, P348, DOI 10.1002/bit.260490302; Georgakopoulos D, 1998, AM J PHYSIOL-HEART C, V274, pH1416, DOI 10.1152/ajpheart.1998.274.4.H1416; GIBBS C, 1985, J MOL CELL CARDIOL, V17, P727, DOI 10.1016/S0022-2828(85)80034-1; Green AL, 1996, AM J PHYSIOL-ENDOC M, V271, pE821, DOI 10.1152/ajpendo.1996.271.5.E821; Gross WL, 1996, P NATL ACAD SCI USA, V93, P5604, DOI 10.1073/pnas.93.11.5604; Guerrero-Ontiveros ML, 1998, MOL CELL BIOCHEM, V184, P427, DOI 10.1023/A:1006895414925; HARDY CJ, 1991, AM HEART J, V122, P795, DOI 10.1016/0002-8703(91)90527-O; HETHERINGTON HP, 1995, MAGNET RESON MED, V33, P427, DOI 10.1002/mrm.1910330318; Horn M, 1999, CARDIOVASC RES, V43, P117, DOI 10.1016/S0008-6363(99)00075-9; INGWALL JS, 1993, CIRCULATION, V87, P58; INGWALL JS, 1994, INOTROPIC DRUGS BASI; Jung WI, 1998, CIRCULATION, V97, P2536, DOI 10.1161/01.CIR.97.25.2536; Kass DA, 1998, CIRC RES, V82, P519, DOI 10.1161/01.RES.82.4.519; Katz Arnold M., 1998, Cardiology Clinics, V16, P633, DOI 10.1016/S0733-8651(05)70040-0; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KINGSLEYHICKMAN PB, 1990, J BIOL CHEM, V265, P1545; Liao RL, 1996, CIRC RES, V78, P893, DOI 10.1161/01.RES.78.5.893; MCDONALD KM, 1994, J AM COLL CARDIOL, V23, P786, DOI 10.1016/0735-1097(94)90769-2; MENON RS, 1992, MAGNET RESON MED, V26, P368, DOI 10.1002/mrm.1910260216; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Nascimben L, 1996, CIRCULATION, V94, P1894, DOI 10.1161/01.CIR.94.8.1894; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; Neubauer S, 1999, CIRCULATION, V100, P1847, DOI 10.1161/01.CIR.100.18.1847; NEUBAUER S, 1992, CIRCULATION, V86, P1810, DOI 10.1161/01.CIR.86.6.1810; Neubauer S, 1997, CIRCULATION, V96, P2190; Odoom JE, 1996, MOL CELL BIOCHEM, V158, P179; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Omerovic E, 2000, BIOCHEM BIOPH RES CO, V271, P222, DOI 10.1006/bbrc.2000.2518; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; POOL PE, 1967, CIRC RES, V21, P365, DOI 10.1161/01.RES.21.3.365; REN JM, 1993, AM J PHYSIOL, V264, pC146, DOI 10.1152/ajpcell.1993.264.1.C146; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; Saupe KW, 1998, CIRC RES, V82, P898; Steenge GR, 1998, AM J PHYSIOL-ENDOC M, V275, pE974, DOI 10.1152/ajpendo.1998.275.6.E974; Stenbit AE, 1996, J CLIN INVEST, V98, P629, DOI 10.1172/JCI118833; Stenbit AE, 2000, AM J PHYSIOL-HEART C, V279, pH313, DOI 10.1152/ajpheart.2000.279.1.H313; SUN DQ, 1994, CIRCULATION, V89, P793, DOI 10.1161/01.CIR.89.2.793; SWAIN JL, 1982, P NATL ACAD SCI-BIOL, V79, P655, DOI 10.1073/pnas.79.2.655; Taegtmeyer H, 1994, Curr Probl Cardiol, V19, P59; Tian R, 2001, CIRCULATION, V103, P2961, DOI 10.1161/01.CIR.103.24.2961; Tian R, 1996, J MOL CELL CARDIOL, V28, P755, DOI 10.1006/jmcc.1996.0070; Tian R, 1996, AM J PHYSIOL-HEART C, V270, pH1207, DOI 10.1152/ajpheart.1996.270.4.H1207; Tsao TS, 1997, J CLIN INVEST, V100, P671, DOI 10.1172/JCI119579; WEISS RG, 1990, NEW ENGL J MED, V323, P1593, DOI 10.1056/NEJM199012063232304; WEISS RG, 1989, J MOL CELL CARDIOL, V21, P469, DOI 10.1016/0022-2828(89)90787-6; ZHANG JY, 1993, J CLIN INVEST, V92, P993, DOI 10.1172/JCI116676; ZHANG JY, 1995, AM J PHYSIOL-HEART C, V268, pH1891, DOI 10.1152/ajpheart.1995.268.5.H1891; Zierath JR, 1998, J BIOL CHEM, V273, P20910, DOI 10.1074/jbc.273.33.20910; Zorzano A, 2000, BIOCHEM J, V349, P667, DOI 10.1042/bj3490667; Zorzano A, 1997, AM J CARDIOL, V80, pA65, DOI 10.1016/S0002-9149(97)00459-1	62	41	42	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					613	+		10.1096/fj.01-0462fje	http://dx.doi.org/10.1096/fj.01-0462fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919171				2022-12-28	WOS:000174203700006
J	Cotgreave, IA; Goldschmidt, L; Tonkonogi, M; Svensson, M				Cotgreave, IA; Goldschmidt, L; Tonkonogi, M; Svensson, M			Differentiation-specific alterations to glutathione synthesis in hormonally stimulated release from human skeletal muscle cells	FASEB JOURNAL			English	Article						human skeletal muscle myoblasts; sulfur precursors; stress hormones; glutathione release	GAMMA-GLUTAMYL-TRANSPEPTIDASE; PERFUSED-RAT-LIVER; AMINO-ACIDS; HEPATIC GLUTATHIONE; BIOLOGICAL-SYSTEMS; MEMBRANE-VESICLES; N-ACETYLCYSTEINE; TRANSPORT; CYSTINE; EFFLUX	Muscle atrophy and cachexia are associated with many human diseases. These catabolic states are often associated with the loss of glutathione (GSH), which is thought to contribute to the induction of oxidative stress within the muscle. Glutathione synthesis and secretary characteristics were studied in human skeletal muscle myoblasts and myotube-like cells derived from the myoblasts by growth factor restriction. Differentiation was associated with a shift in the sulfur amino acid precursor specificity for synthesis of GSH from cystine to cysteine, as well as loss in ability to use extracellular glutathione and activation of methionine use. The thiol drug N-acetylcysteine was also shown to be an effective precursor irrespective of the state of differentiation. Additionally, myoblasts and myotube cultures were shown to secrete GSH continually, but only the differentiated cells responded to stress hormones such as glucagon, vasopressin, and phenylephrine, by increased secretion of the tripeptide. The data suggest that the skeletal muscle cells may provide an important hormonally regulated extra-hepatic source of systemic GSH and also shed light on the mechanisms of accelerated turnover of GSH operating during strenuous muscle activity and trauma. The data may also provide biochemical rationales for the nutritional and/or pharmacological manipulation of GSH with sulfur amino acid precursors during the treatment of muscle-specific oxidative stress and atrophy.	Karolinska Inst, Inst Environm Med, Div Biochem Toxicol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, S-11486 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Cotgreave, IA (corresponding author), Karolinska Inst, Inst Environm Med, Div Biochem Toxicol, Box 210, S-17177 Stockholm, Sweden.	ian.cotgreave@imm.ki.se		Svensson, Michael/0000-0003-4972-4416				ALP PR, 1976, BIOCHEM J, V154, P689, DOI 10.1042/bj1540689; Atalay M, 1996, ACTA PHYSIOL SCAND, V158, P129, DOI 10.1046/j.1365-201X.1996.540305000.x; BANNAI S, 1984, BIOCHIM BIOPHYS ACTA, V779, P289, DOI 10.1016/0304-4157(84)90014-5; BERGGREN M, 1984, FEBS LETT, V176, P189, DOI 10.1016/0014-5793(84)80938-2; COOPER AJL, 1983, ANNU REV BIOCHEM, V52, P187, DOI 10.1146/annurev.bi.52.070183.001155; COTGREAVE IA, 1986, J BIOCHEM BIOPH METH, V13, P231, DOI 10.1016/0165-022X(86)90102-8; COTGREAVE IA, 1988, ANNU REV PHARMACOL, V28, P189; COTGREAVE IA, 1991, J APPL PHYSIOL, V70, P1220, DOI 10.1152/jappl.1991.70.3.1220; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; COTGREAVE IA, 1994, BBA-MOL CELL RES, V1222, P375, DOI 10.1016/0167-4889(94)90043-4; COTGREAVE IA, 1987, BIOPHARM DRUG DISPOS, V8, P365, DOI 10.1002/bdd.2510080407; Fei YJ, 2000, J BIOL CHEM, V275, P23707, DOI 10.1074/jbc.M002282200; GARCIARUIZ C, 1992, J BIOL CHEM, V267, P22256; Hammarqvist F, 1997, CRIT CARE MED, V25, P78, DOI 10.1097/00003246-199701000-00016; JAESCHKE H, 1992, AM J PHYSIOL, V263, pG60, DOI 10.1152/ajpgi.1992.263.1.G60; LAUTERBURG BH, 1984, HEPATOLOGY, V4, P586, DOI 10.1002/hep.1840040402; LIU J, 1995, RES COMMUN MOL PATH, V87, P307; LU SC, J BIOL CHEM, V265, P16088; Luo JL, 1996, ANN SURG, V223, P420, DOI 10.1097/00000658-199604000-00011; MAKOWSKE M, 1982, J BIOL CHEM, V257, P5663; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MOLDEUS P, 1986, RESPIRATION, V50, P31, DOI 10.1159/000195086; NINA J, 1978, BIOCHEM J, V170, P627; OOKHTENS M, 1985, J CLIN INVEST, V75, P258, DOI 10.1172/JCI111682; ORMSTAD K, 1980, J BIOL CHEM, V255, P175; ORRENIUS S, 1983, FED PROC, V42, P3177; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RAIFORD DS, 1991, AM J PHYSIOL, V261, pG578, DOI 10.1152/ajpgi.1991.261.4.G578; REED DJ, 1977, BIOCHEM BIOPH RES CO, V77, P1257, DOI 10.1016/S0006-291X(77)80115-0; REED DJ, 1983, FUNCTIONS GLUTATHION, P39; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; SEGAL S, 1977, SCIENCE, V197, P169, DOI 10.1126/science.877548; SEN CK, 1992, J APPL PHYSIOL, V73, P1265, DOI 10.1152/jappl.1992.73.4.1265; SIES H, 1985, BIOCHEM J, V226, P545, DOI 10.1042/bj2260545; SMITH TK, 1991, ADV EXP MED BIOL, V289, P165; Soriano-Garcia JF, 1998, J PHYSIOL-LONDON, V509, P527, DOI 10.1111/j.1469-7793.1998.527bn.x; SVENSSON M, 2002, IN PRESS ACTA PHYSL; SZAASZ G, 1976, CLIN CHEM, V22, P650; THOMPSON GA, 1975, P NATL ACAD SCI USA, V72, P1985, DOI 10.1073/pnas.72.6.1985; Voskoboinik I, 1998, AM J PHYSIOL-CELL PH, V275, pC1031, DOI 10.1152/ajpcell.1998.275.4.C1031; WADE LA, 1981, J NEUROCHEM, V37, P730	41	23	23	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					435	+		10.1096/fj.01-0685fje	http://dx.doi.org/10.1096/fj.01-0685fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11821257				2022-12-28	WOS:000173656600013
J	Inoh, H; Ishiguro, N; Sawazaki, SI; Amma, H; Miyazu, M; Iwata, H; Sokabe, M; Naruse, K				Inoh, H; Ishiguro, N; Sawazaki, SI; Amma, H; Miyazu, M; Iwata, H; Sokabe, M; Naruse, K			Uni-axial cyclic stretch induces the activation of transcription factor nuclear factor B in human fibroblast cells	FASEB JOURNAL			English	Article						stretch-activated channel; gadolinium; calcium; fibroblast	NF-KAPPA-B; HUMAN IMMUNODEFICIENCY VIRUS; TUMOR-NECROSIS-FACTOR; VASCULAR ENDOTHELIAL-CELLS; GROWTH-FACTOR-BETA; BINDING-PROTEIN; SKELETAL-MUSCLE; CYCLOOXYGENASE ACTIVITY; MECHANICAL STIMULATION; PULSATILE STRETCH	The effect of uni-axial cyclic mechanical stretch on the activation of the transcription factor nuclear factor kappaB (NF-kappaB) was investigated in a human fibroblast cell line (TIG-1). In response to uni-axial cyclic stretch, NF-kappaB was found to be translocated into the nucleus. The NF-kappaB was first detectable 2 min after the onset of stretch and then peaked at 4 min and returned to the basal level within 10 min. To investigate whether NF-kappaB is activated following the translocation into the nucleus, we measured the luciferase activity in the cells transfected with pNF-kappaB-luciferase. The activity of luciferase increased 4 min after the initiation of cyclic stretch, peaked at 15 min (6.4-fold increase), and decreased gradually. We examined the involvement of the stretch-activated (SA) channel in the stretch-induced NF-kappaB activation. The application of Gd3+, a blocker of the SA channel, or the removal of extracellular Ca2+ inhibited both the translocation into the nucleus and the activation of NF-kappaB, which suggests that NF-kappaB is activated by uni-axial cyclic stretch via SA channel activation in human lung fibroblasts.	Nagoya Univ, Grad Sch Med, Cell Mechano Sensing Project,ICOPR,JST, Dept Physiol,Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Cell Mechano Sensing Project,ICOPR,JST, Dept Orthoped Surg,Showa Ku, Nagoya, Aichi 4668550, Japan	Japan Science & Technology Agency (JST); Nagoya University; Japan Science & Technology Agency (JST); Nagoya University	Naruse, K (corresponding author), Nagoya Univ, Sch Med, Dept Physiol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	knaruse@med.nagoya-u.ac.jp	NARUSE, Keiji/B-1620-2011; Sokabe, Masahiro/I-1565-2012; Ishiguro, Naoki/I-1563-2012	naruse, keiji/0000-0003-4100-6444				Aikawa K, 2001, LIFE SCI, V69, P1717, DOI 10.1016/S0024-3205(01)01256-5; ALMEKINDERS LC, 1993, MED SCI SPORT EXER, V25, P603; AWOLESI MA, 1995, J CLIN INVEST, V96, P1449, DOI 10.1172/JCI118181; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DESROSIERS EA, 1995, ANN CHIR, V49, P768; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DOLMETSCH RE, 1997, NATURE, V386, P759; Du W, 1995, J BIOMECH, V28, P1485, DOI 10.1016/0021-9290(95)00096-8; EMORINE L, 1983, NATURE, V304, P447, DOI 10.1038/304447a0; FREIMUTH WW, 1989, J IMMUNOL, V143, P3064; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; Hishikawa K, 1997, CIRC RES, V81, P797; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; JACKSON BA, 1993, BIOCHEM BIOPH RES CO, V197, P1465, DOI 10.1006/bbrc.1993.2642; KANDA K, 1993, CELL TRANSPLANT, V2, P475, DOI 10.1177/096368979300200606; Kato T, 1998, BIOCHEM BIOPH RES CO, V244, P615, DOI 10.1006/bbrc.1998.8335; Kurokouchi K, 1998, J BONE MINER RES, V13, P1290, DOI 10.1359/jbmr.1998.13.8.1290; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MITCHELL JA, 1995, BIOCHEM PHARMACOL, V50, P1535, DOI 10.1016/0006-2952(95)00212-X; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nagel T, 1999, ARTERIOSCL THROM VAS, V19, P1825, DOI 10.1161/01.ATV.19.8.1825; Naruse K, 1998, AM J PHYSIOL-HEART C, V274, pH1532; Naruse K, 1998, ONCOGENE, V17, P455, DOI 10.1038/sj.onc.1201950; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; Naruse K, 1998, FEBS LETT, V441, P111, DOI 10.1016/S0014-5793(98)01528-2; NARUSE K, 1992, AM J PHYSIOL, V262, pC453, DOI 10.1152/ajpcell.1992.262.2.C453; NGAN PW, 1988, ARCH ORAL BIOL, V33, P163, DOI 10.1016/0003-9969(88)90041-6; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; REGNAULT V, 1988, J CHROMATOGR-BIOMED, V432, P93, DOI 10.1016/S0378-4347(00)80636-2; Resnick N, 1997, ADV EXP MED BIOL, V430, P155; Roy R, 1996, J CELL BIOCHEM, V62, P411, DOI 10.1002/(SICI)1097-4644(199609)62:3<411::AID-JCB11>3.0.CO;2-L; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Stein B., 1989, J COGNITIVE NEUROSCI, V1, P12; SUMITANI K, 1989, ARCH BIOCHEM BIOPHYS, V270, P588, DOI 10.1016/0003-9861(89)90541-9; SUMPIO BE, 1990, SURGERY, V108, P277; Suzuki N, 1997, BIOCHEM BIOPH RES CO, V239, P372, DOI 10.1006/bbrc.1997.7364; VANDENBURGH HH, 1995, J CELL PHYSIOL, V163, P285, DOI 10.1002/jcp.1041630209; VANDENBURGH HH, 1990, AM J PHYSIOL, V259, pC232, DOI 10.1152/ajpcell.1990.259.2.C232; VANDENBURGH HH, 1982, J BIOL CHEM, V257, P13448; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yang XH, 1997, BBA-GENE STRUCT EXPR, V1350, P287, DOI 10.1016/S0167-4781(96)00225-4	50	67	71	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					405	+		10.1096/fj.01-0354fje	http://dx.doi.org/10.1096/fj.01-0354fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11790721				2022-12-28	WOS:000173656600016
J	Lemonnier, L; Prevarskaya, N; Shuba, Y; Vanden Abeele, F; Nilius, B; Mazurier, J; Skryma, R				Lemonnier, L; Prevarskaya, N; Shuba, Y; Vanden Abeele, F; Nilius, B; Mazurier, J; Skryma, R			Ca2+ modulation of volume-regulated anion channels: evidence for colocalization with store-operated channels	FASEB JOURNAL			English	Article						calcium; capacitative entry; chloride channels; regulatory volume decrease	HUMAN EPITHELIAL-CELLS; ACTIVATED CALCIUM CURRENT; JURKAT T-LYMPHOCYTES; PROTEIN-KINASE-C; POTASSIUM CHANNELS; TRANSPORT PATHWAYS; CHLORIDE CURRENTS; RELEASE; LINE; PERMEABILITY	Ca2+ regulation of Cl- current induced by cell swelling (I-Cl,I-swell) in response to hypotonicity was studied in human prostate cancer epithelial cells (LNCaP) by using the patch-clamp technique. Increase of global intracellular Ca2+ ([Ca2+](in)) to 1 muM as well as variations of the extracellular Ca2+ ([Ca2+](out)) in the 0 to 10 mM range did not affect time course of the development, maximal amplitude, rectification properties, and kinetics of I-Cl,I-swell. However, the presence of 0.1 muM thapsigargin (TG), an inhibitor of endoplasmic reticulum (ER) Ca2+ pump, resulted in a more than 50% inhibition of I-Cl,I-swell. The blockade of plasma membrane store-operated channels (SOCs), activated in the presence of TG, by 2 mM Ni2+ prevented TG-conferred I-Cl,I-swell inhibition by extracellular Ca2+. In the presence of TG and Ca2+, the cells failed to exhibit regulatory volume decrease. We conclude that interaction between volume-regulated anion channels (VRACs) carrying I-Cl,I-swell and Ca2+ occurs in the microdomains from the inner surface of the membrane that are not accessible to the changes in [Ca2+](in), but can be readily reached by Ca2+ entering the cell via plasma membrane, especially through SOCs. Preferred access of SOC-transported Ca2+ to VRAC suggests colocalization of these channels in the cell membrane.	Univ Sci & Technol Lille, Lab Physiol Cellulaire, INSERM, EPI 9938, F-59655 Villeneuve Dascq, France; Bogomoletz Inst Physiol, UA-01024 Kiev 24, Ukraine; Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; National Academy of Sciences Ukraine; A.A. Bogomoletz Institute of Physiology; KU Leuven	Skryma, R (corresponding author), Univ Sci & Technol Lille, Lab Physiol Cellulaire, INSERM, EPI 9938, Batiment SN3, F-59655 Villeneuve Dascq, France.	phycel@univ-lille1.fr	Vanden Abeele, Fabien/O-6012-2017; Shuba, Yaroslav/AAT-6758-2021; Lemonnier, Loic/L-7289-2018	Lemonnier, Loic/0000-0001-6200-5382; Vanden Abeele, Fabien/0000-0001-7111-7220; Prevarskaya, natacha/0000-0003-0316-197X				AdachiAkahane S, 1996, J GEN PHYSIOL, V108, P435, DOI 10.1085/jgp.108.5.435; ANDERSON JW, 1995, J PHYSIOL-LONDON, V483, P549, DOI 10.1113/jphysiol.1995.sp020605; BASAVAPPA S, 1995, J NEUROSCI, V15, P3662; Bratosin D, 1997, CYTOMETRY, V30, P269; Braun AP, 1996, J PHYSIOL-LONDON, V495, P743, DOI 10.1113/jphysiol.1996.sp021630; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CHOU CY, 1998, J PHYSL, V15, P435; Duan D, 1999, J GEN PHYSIOL, V113, P57, DOI 10.1085/jgp.113.1.57; DUBOIS JM, 1993, PROG BIOPHYS MOL BIO, V59, P1, DOI 10.1016/0079-6107(93)90005-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAUSSLER U, 1994, PFLUG ARCH EUR J PHY, V428, P323, DOI 10.1007/BF00724514; HAZAMA A, 1988, J PHYSIOL-LONDON, V402, P687, DOI 10.1113/jphysiol.1988.sp017229; HAZAMA A, 1990, BIOCHEM BIOPH RES CO, V167, P287, DOI 10.1016/0006-291X(90)91763-I; HOFFMANN EK, 1986, J MEMBRANE BIOL, V91, P227, DOI 10.1007/BF01868816; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; Jackson PS, 1996, KIDNEY INT, V49, P1695, DOI 10.1038/ki.1996.250; Kerschbaum HH, 1998, J GEN PHYSIOL, V111, P521, DOI 10.1085/jgp.111.4.521; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Lang F, 2000, CELL PHYSIOL BIOCHEM, V10, P417, DOI 10.1159/000016367; LLINAS R, 1995, NEUROPHARMACOLOGY, V34, P1443, DOI 10.1016/0028-3908(95)00150-5; MACLEOD RJ, 1991, AM J PHYSIOL, V260, pG26, DOI 10.1152/ajpgi.1991.260.1.G26; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; Meyer K, 1996, J GEN PHYSIOL, V108, P177, DOI 10.1085/jgp.108.3.177; Nilius B, 1997, PROG BIOPHYS MOL BIO, V68, P69, DOI 10.1016/S0079-6107(97)00021-7; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; Okada Y, 1997, AM J PHYSIOL-CELL PH, V273, pC755, DOI 10.1152/ajpcell.1997.273.3.C755; Okada Y, 1998, CONTRIB NEPHROL, V123, P21; Pasantes-Morales H, 2000, NEPHRON, V86, P414, DOI 10.1159/000045829; Peng JB, 2001, BIOCHEM BIOPH RES CO, V282, P729, DOI 10.1006/bbrc.2001.4638; Perlman DF, 1999, J EXP ZOOL, V283, P725, DOI 10.1002/(SICI)1097-010X(19990601)283:7<725::AID-JEZ10>3.3.CO;2-R; ROBSON L, 1994, J PHYSIOL-LONDON, V480, P1; Roman RM, 1998, HEPATOLOGY, V28, P1073, DOI 10.1002/hep.510280423; Sakai H, 1999, J PHYSIOL-LONDON, V515, P157, DOI 10.1111/j.1469-7793.1999.157ad.x; SARKADI B, 1985, AM J PHYSIOL, V248, pC480, DOI 10.1152/ajpcell.1985.248.5.C480; Shi CJ, 1999, J PHYSIOL-LONDON, V521, P57, DOI 10.1111/j.1469-7793.1999.00057.x; Shimizu T, 2000, J PHYSIOL-LONDON, V528, P457, DOI 10.1111/j.1469-7793.2000.00457.x; Shuba YM, 2000, AM J PHYSIOL-CELL PH, V279, pC1144, DOI 10.1152/ajpcell.2000.279.4.C1144; Skryma R, 1999, RECEPTOR CHANNEL, V6, P241; Skryma RN, 1997, PROSTATE, V33, P112, DOI 10.1002/(SICI)1097-0045(19971001)33:2<112::AID-PROS5>3.0.CO;2-M; SKRYMA RN, 2000, J PHYSL, V527, P73; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; Szucs G, 1996, PFLUG ARCH EUR J PHY, V431, P467, DOI 10.1007/s004240050023; VERDON B, 1995, J MEMBRANE BIOL, V147, P173; VOETS T, 1995, PFLUG ARCH EUR J PHY, V431, P132, DOI 10.1007/BF00374387; Voets T, 1997, AM J PHYSIOL-CELL PH, V272, pC667, DOI 10.1152/ajpcell.1997.272.2.C667; Wu JQ, 1996, J PHYSIOL-LONDON, V491, P743, DOI 10.1113/jphysiol.1996.sp021254; Wu X, 1997, J MEMBRANE BIOL, V158, P127, DOI 10.1007/s002329900250; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596	50	36	39	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					222	+		10.1096/fj.01-0383fje	http://dx.doi.org/10.1096/fj.01-0383fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11744619				2022-12-28	WOS:000172964800015
J	Seifalian, AM; El-Desoky, EH; Delpy, DT; Davidson, BR				Seifalian, AM; El-Desoky, EH; Delpy, DT; Davidson, BR			Effect of graded hypoxia on the rat hepatic tissue oxygenation and energy metabolism monitored by near-infrared and P-31 nuclear magnetic resonance spectroscopy	FASEB JOURNAL			English	Article						NIMR; liver hypoxia; beta nucleoside triphosphate	PERFUSED MOUSE-LIVER; CYTOCHROME-OXIDASE; HEMORRHAGIC-SHOCK; BLOOD-FLOW; IN-SITU; ATP; PHOSPHORYLATION; INVIVO; STATE; NMR	Alteration in hepatic cellular adenosine triphosphate (ATP) levels has been shown to be a sensitive index for hypoxic damage. Hepatic ATP metabolism can be monitored by P-31 nuclear magnetic resonance (NMR). Near-infrared spectroscopy (NIRS) can measure tissue oxyhemoglobin (HbO(2)), deoxyhemoglobin (Hb), and cytochrome oxidase (Cyt Ox), which reflect ATP production. In this study, hepatic oxygenation parameters have been correlated with ATP metabolism under graded hypoxia. Sprague-Dawley rats underwent laparotomy for liver exposure. NIRS probes and an NMR coil were placed on the liver and the animal was positioned in the NMR magnet. Graded hypoxia was achieved by a stepwise reduction of the fraction of inspired oxygen (FiO(2)) from 15 to 4%. Recovery between the hypoxic periods was achieved using 30% oxygen. Hepatic tissue oxygenation parameters were measured continuously by NIRS; P-31-NMR spectra obtained at 1 min intervals from energy metabolites and intracellular pH were calculated. All the hypoxic grades produced an immediate reduction in HbO(2) with a simultaneous increase in Hb. Cyt Ox was reduced significantly only with FiO(2) of less than or equal to 10%. P-31-NMR spectra showed a significant decrease in cellular beta nucleoside triphosphate (beta -NTP) only with FiO(2) of less than or equal to 10%. Significant correlation was seen between beta -NTP and HbO(2) (r=0.85), Hb (r=-0.74), and Cyt Ox (r=0.81). Cyt Ox was reduced with intracellular hypoxia and correlated temporally with the reduction of cellular beta -NTP, and therefore could be used as an index for the changes in beta -NTP with hypoxia.	UCL, Royal Free & Univ Coll Med Sch, Dept Surg, Hepat Haemodynam Lab, London NW3 2QG, England; UCL, Dept Med Phys & Bioengn, London, England	University of London; University College London; University of London; University College London	Seifalian, AM (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Surg, Hepat Haemodynam Lab, Pond St, London NW3 2QG, England.	a.seifalian@rfc.ucl.ac.uk	Seifalian, Alexander M/I-6028-2013	Seifalian, Alexander M/0000-0002-1180-3322				BOWERS JL, 1992, AM J PHYSIOL, V262, pG636, DOI 10.1152/ajpgi.1992.262.4.G636; BRADFORD BU, 1986, J PHARMACOL EXP THER, V236, P263; Brauer M, 1997, J STUD ALCOHOL, V58, P119, DOI 10.15288/jsa.1997.58.119; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CARINI R, 1995, BIOCHEM BIOPH RES CO, V206, P180, DOI 10.1006/bbrc.1995.1025; Chant C, 1997, ANN PHARMACOTHER, V31, P290, DOI 10.1177/106002809703100303; CHAPMAN AG, 1981, J NEUROCHEM, V36, P179, DOI 10.1111/j.1471-4159.1981.tb02393.x; CHAUDRY IH, 1976, CAN J PHYSIOL PHARM, V54, P750, DOI 10.1139/y76-104; CLAVIEN PA, 1992, TRANSPLANTATION, V53, P957, DOI 10.1097/00007890-199205000-00001; COOPER CE, 1994, BIOCHEM SOC T, V22, P974, DOI 10.1042/bst0220974; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DEGROOT H, 1985, ANESTHESIOLOGY, V62, P44, DOI 10.1097/00000542-198501000-00009; DESMOULIN F, 1987, EUR J BIOCHEM, V162, P151, DOI 10.1111/j.1432-1033.1987.tb10555.x; El-Desoky AE, 2001, LIVER, V21, P37; El-Desoky AEH, 1999, J HEPATOL, V31, P71, DOI 10.1016/S0168-8278(99)80165-2; El-Desoky AEH, 1999, LIVER TRANSPLANT SUR, V5, P219, DOI 10.1002/lt.500050316; El-Desoky AEH, 2000, EUR SURG RES, V32, P207, DOI 10.1159/000008766; ELDESOKY A, 2000, THESIS U LONDON, P70; EVANOCHKO WT, 1984, BIOCHIM BIOPHYS ACTA, V805, P104, DOI 10.1016/0167-4889(84)90042-9; FARBER JL, 1981, AM J PATHOL, V102, P271; Guyton ACHJ., 1999, TXB MED PHYSL; HIGASHI H, 1989, EUR SURG RES, V21, P76, DOI 10.1159/000129006; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; HUGHES RL, 1979, PFLUG ARCH EUR J PHY, V381, P151, DOI 10.1007/BF00582346; ILES RA, 1985, BIOCHEM J, V229, P141, DOI 10.1042/bj2290141; ILES RA, 1982, BIOSCIENCE REP, V2, P735, DOI 10.1007/BF01114837; Jobsis FF, 1992, QUANTITATIVE SPECTRO, P47; JONES DP, 1982, AM J PHYSIOL, V243, pC247, DOI 10.1152/ajpcell.1982.243.5.C247; KAMIIKE W, 1982, J BIOCHEM-TOKYO, V91, P1349, DOI 10.1093/oxfordjournals.jbchem.a133822; LARSEN JA, 1976, ACTA PHYSIOL SCAND, V98, P257, DOI 10.1111/j.1748-1716.1976.tb00244.x; LUTZ J, 1975, PFLUG ARCH EUR J PHY, V360, P7, DOI 10.1007/BF00584322; MALLIKA C, 1986, ELECTROCHIM ACTA, V31, P885, DOI 10.1016/0013-4686(86)85022-8; Matsunaga A, 1998, AM J PHYSIOL-CELL PH, V275, pC1022, DOI 10.1152/ajpcell.1998.275.4.C1022; MCLAUGHLIN AC, 1979, P NATL ACAD SCI USA, V76, P5445, DOI 10.1073/pnas.76.11.5445; NAKAJIMA Y, 1990, J SURG RES, V48, P111, DOI 10.1016/0022-4804(90)90201-C; NICHOLLS DG, 1982, BIOENERGETICS, P107; OSHINO N, 1974, BIOCHIM BIOPHYS ACTA, V368, P298, DOI 10.1016/0005-2728(74)90176-5; PASS LJ, 1982, J TRAUMA, V22, P730, DOI 10.1097/00005373-198209000-00002; Rolfe P, 2000, ANNU REV BIOMED ENG, V2, P715, DOI 10.1146/annurev.bioeng.2.1.715; SNOWDOWNE KW, 1985, J BIOL CHEM, V260, P1619; SUMIMOTO K, 1988, TRANSPLANTATION, V46, P506, DOI 10.1097/00007890-198810000-00007; Trautschold I., 1963, METHODS ENZYMATIC AN, P543; WILLIAMS SR, 1986, Q J EXP PHYSIOL CMS, V71, P335, DOI 10.1113/expphysiol.1986.sp002994; WILSON DF, 1979, ARCH BIOCHEM BIOPHYS, V195, P485, DOI 10.1016/0003-9861(79)90375-8; WILSON DF, 1977, AM J PHYSIOL, V233, pC135, DOI 10.1152/ajpcell.1977.233.5.C135; WILSON DF, 1979, ARCH BIOCHEM BIOPHYS, V195, P494, DOI 10.1016/0003-9861(79)90376-X; WINKLER K, 1986, EUR J CLIN INVEST, V16, P106, DOI 10.1111/j.1365-2362.1986.tb01316.x	47	29	31	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2642	2648		10.1096/fj.01-0308com	http://dx.doi.org/10.1096/fj.01-0308com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726540				2022-12-28	WOS:000172964800034
J	Pugliese, G; Pricci, F; Iacobini, C; Leto, G; Amadio, L; Barsotti, P; Frigeri, L; Hsu, DK; Vlassara, H; Liu, FT; Di Mario, U				Pugliese, G; Pricci, F; Iacobini, C; Leto, G; Amadio, L; Barsotti, P; Frigeri, L; Hsu, DK; Vlassara, H; Liu, FT; Di Mario, U			Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice	FASEB JOURNAL			English	Article						diabetic nephropathy; advanced glycation end products; advanced glycation end product receptors extracellular matrix	GLYCATION END-PRODUCTS; GENE-EXPRESSION; BINDING-PROTEIN; COMPETITIVE PCR; GROWTH-FACTOR; MATRIX; AGE; ACTIVATION; CELLS; IDENTIFICATION	Several molecules were shown to bind advanced glycation end products (AGEs) in vitro, but it is not known whether they all serve as AGE receptors and which functional role they play in vivo. We investigated the role of galectin-3, a multifunctional lectin with (anti) adhesive and growth-regulating properties, as an AGE receptor and its contribution to the development of diabetic glomerular disease, using a knockout mouse model. Galectin-3 knockout mice obtained by gene ablation and the corresponding wild-type mice were rendered diabetic with streptozotocin and killed 4 months later, together with age-matched nondiabetic controls. Despite a comparable degree of metabolic derangement, galectin-3-deficient mice developed accelerated glomerulopathy vs. the wild-type animals, as evidenced by the more pronounced increase in proteinuria, extracellular matrix gene expression, and mesangial expansion. This was associated with a more marked renal/glomerular AGE accumulation, indicating it was attributable to the lack of galectin-3 AGE receptor function. The galectin-3-deficient genotype was associated with reduced expression of receptors implicated in AGE removal (macrophage scavenger receptor A and AGE-R1) and increased expression of those mediating cell activation (RAGE and AGE-R2). These results show that the galectin-3-regulated AGE receptor pathway is operating in vivo and protects toward AGE-induced tissue injury in contrast to that through RAGE.	Univ Roma La Sapienza, Dept Clin Sci, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Ist Super Sanita, Lab Metab & Biochem Pathol, I-00161 Rome, Italy; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA	Sapienza University Rome; Sapienza University Rome; Istituto Superiore di Sanita (ISS); Scripps Research Institute; La Jolla Institute for Immunology; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Pugliese, G (corresponding author), Dipartimento Sci Clin Endocrinol, Viale Policlin 155, I-00161 Rome, Italy.	giuseppe.pugliese@uniroma1.it	Pugliese, Giuseppe/G-8776-2012; Liu, FU-TONG/A-5749-2019; Pricci, Flavia/K-7739-2016	Liu, FU-TONG/0000-0002-3354-1001; Pricci, Flavia/0000-0002-1877-4376; Pugliese, Giuseppe/0000-0003-1574-0397	Telethon [D.066] Funding Source: Medline	Telethon(Fondazione Telethon)		Bierhaus A, 1997, DIABETES, V46, P1481, DOI 10.2337/diabetes.46.9.1481; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; FUKUI M, 1992, DIABETES, V41, P1520, DOI 10.2337/diabetes.41.12.1520; GAMBARO G, 1994, KIDNEY INT, V46, P797, DOI 10.1038/ki.1994.335; He CJ, 2000, KIDNEY INT, V58, P1931, DOI 10.1046/j.1523-1755.2000.00365.x; HORIUCHI S, 1996, DIABETES S3, V45, P73; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; HSU DK, 1992, J BIOL CHEM, V267, P14167; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; KOTHS K, 1993, J BIOL CHEM, V268, P14245; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; Lougheed M, 1997, J BIOL CHEM, V272, P12938, DOI 10.1074/jbc.272.20.12938; Mazzucco G, 1997, CONTRIB NEPHROL, V122, P129; Mitsuhashi T, 1997, J IMMUNOL METHODS, V207, P79, DOI 10.1016/S0022-1759(97)00110-5; Mitsuhashi T, 1997, J CLIN INVEST, V100, P847, DOI 10.1172/JCI119600; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Ochieng J, 1998, BIOCHEM BIOPH RES CO, V246, P788, DOI 10.1006/bbrc.1998.8708; PETEN EP, 1993, KIDNEY INT, V43, pS55; PETEN EP, 1992, AM J PHYSIOL, V263, pF951, DOI 10.1152/ajprenal.1992.263.5.F951; Pricci F, 2000, KIDNEY INT, V58, pS31, DOI 10.1046/j.1523-1755.2000.07706.x; Pugliese G, 1997, DIABETES, V46, P1881, DOI 10.2337/diabetes.46.11.1881; Pugliese G, 1997, DIABETES, V46, P1198, DOI 10.2337/diabetes.46.7.1198; Pugliese G, 2000, DIABETES, V49, P1249, DOI 10.2337/diabetes.49.7.1249; Sasaki N, 2001, BRAIN RES, V888, P256, DOI 10.1016/S0006-8993(00)03075-4; STEFFES MW, 1989, DIABETES, V38, P1077, DOI 10.2337/diabetes.38.9.1077; Stitt AW, 2000, FASEB J, V14, P2390; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604; VLASSARA H, 1996, KIDNEY INT, V49, P1785; YANG CW, 1994, P NATL ACAD SCI USA, V91, P9436, DOI 10.1073/pnas.91.20.9436; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Zhang WP, 1997, BIOCHEM MOL MED, V61, P58, DOI 10.1006/bmme.1997.2592; Zhu WQ, 2001, BIOCHEM BIOPH RES CO, V280, P1183, DOI 10.1006/bbrc.2001.4256	35	151	153	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2471	2479		10.1096/fj.01-0006com	http://dx.doi.org/10.1096/fj.01-0006com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689472	Green Submitted			2022-12-28	WOS:000172420500017
J	Condorelli, G; Aycock, JK; Frati, G; Napoli, C				Condorelli, G; Aycock, JK; Frati, G; Napoli, C			Mutated p21/WAF/CIP transgene overexpression reduces smooth muscle cell proliferation, macrophage deposition, oxidation-sensitive mechanisms, and restenosis in hypercholesterolemic apolipoprotein E knockout mice	FASEB JOURNAL			English	Article						gene therapy; apoptosis; cell cycle; apo E knockout	E-DEFICIENT MICE; MEDIATED GENE-TRANSFER; HERITABLE HYPERLIPIDEMIC RABBITS; EXPERIMENTAL BALLOON ANGIOPLASTY; DEPENDENT KINASE INHIBITOR; ARTERIAL INJURY; CAROTID ARTERIES; VESSEL WALL; NEOINTIMAL HYPERPLASIA; CORONARY ANGIOPLASTY	We have investigated whether by introducing a mutated p21 cyclin-dependent kinase inhibitor through a standard type 5 adenovirus (Ad), it would be possible to interfere with restenosis in hypercholesterolemic apolipoprotein E knockout mice. Restenosis is a clinically relevant, undesired effect of percutaneous transluminal coronary angioplasty (PTCA). A critical event underlying restenosis is smooth muscle cell (SMC) proliferation leading to neointimal formation and vessel reocclusion. Recent data demonstrated that it is possible to reduce restenosis by introducing various genes blocking the cell cycle through Ad vectors. Nonetheless, most experiments were conducted in the healthy carotid artery of rat, which is far from the condition of human disease. Therefore, we investigated whether antiproliferative or proapoptotic genes affect restenosis in a model of atherosclerosis closer to clinical settings. Ad-mutated(m)-p21WAF/CIP1 transgene overexpression induces a significant reduction of restenosis in hypercholesterolemic apolipoprotein E knockout mice subjected to injury of common carotid artery. This was associated with reduced SMC density and proliferation, macrophage deposition, and oxidation-sensitive mechanisms. Treatment with p21/WAF also enhanced TUNEL positivity of arterial cells. We show that in an experimental model of atherosclerosis, braking the cell proliferation through increased vascular apoptosis and reduced oxidation-sensitive signal transduction and macrophage accumulation can significantly ameliorate the deleterious effects of vascular injuries similar to those that occur during PTCA and related procedures.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Roma La Sapienza, IRCCS Neuromed, Fac Med 2, Rome, Italy; Univ Naples Federico II, Dept Med, Naples, Italy; Univ Calif San Diego, Dept Med 0682, La Jolla, CA 92093 USA	Jefferson University; IRCCS Neuromed; Sapienza University Rome; University of Naples Federico II; University of California System; University of California San Diego	Condorelli, G (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, TJU 233 S 10th St, Philadelphia, PA 19107 USA.	gianluigi.condorelli@mail.tju.edu	Frati, Giacomo/ABI-7410-2020; Condorelli, Gianluigi/Q-6736-2017	Napoli, Claudio/0000-0002-5455-555X; Condorelli, Gianluigi/0000-0003-0481-6843; Frati, Giacomo/0000-0003-2703-3761				AMELI S, 1994, CIRCULATION, V90, P1935, DOI 10.1161/01.CIR.90.4.1935; Bauriedel G, 1998, ARTERIOSCL THROM VAS, V18, P1132, DOI 10.1161/01.ATV.18.7.1132; Bult H, 2000, TRENDS PHARMACOL SCI, V21, P274, DOI 10.1016/S0165-6147(00)01505-4; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; Claudio PP, 1999, CIRC RES, V85, P1032; Condorelli G, 1999, CIRCULATION, V99, P3071, DOI 10.1161/01.CIR.99.23.3071; de Nigris F, 2000, CIRCULATION, V102, P2111, DOI 10.1161/01.CIR.102.17.2111; Feldman MD, 2000, J LONG-TERM EFF MED, V10, P47; Gurlek A, 1995, J Cardiovasc Risk, V2, P51; HANKE H, 1994, EUR HEART J, V15, P691, DOI 10.1093/oxfordjournals.eurheartj.a060569; Johnson GJ, 1999, THROMB HAEMOSTASIS, V81, P835; Kanemitsu S, 1998, Ther Apher, V2, P65, DOI 10.1111/j.1744-9987.1998.tb00075.x; Kibbe MR, 2000, CIRC RES, V86, P829, DOI 10.1161/01.RES.86.8.829; Komatsu R, 1998, CIRCULATION, V98, P224, DOI 10.1161/01.CIR.98.3.224; LAFONT AM, 1995, J CLIN INVEST, V95, P1018, DOI 10.1172/JCI117746; Laitinen M, 2000, HUM GENE THER, V11, P263, DOI 10.1089/10430340050016003; Laitinen M, 1998, HUM GENE THER, V9, P1481, DOI 10.1089/hum.1998.9.10-1481; Le Tourneau T, 1999, J AM COLL CARDIOL, V33, P876, DOI 10.1016/S0735-1097(98)00621-4; Lee DP, 1999, VASC MED, V4, P257; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Lund DD, 1999, STROKE, V30, P120, DOI 10.1161/01.STR.30.1.120; Lundgren C, 1996, JPN HEART J, V37, P119; Manka DR, 2000, J MAGN RESON IMAGING, V12, P790, DOI 10.1002/1522-2586(200011)12:5<790::AID-JMRI19>3.0.CO;2-6; Manka DR, 1999, J VASC RES, V36, P372, DOI 10.1159/000025676; Marra DE, 2000, CIRCULATION, V102, P2124, DOI 10.1161/01.CIR.102.17.2124; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Monahan PE, 2000, GENE THER, V7, P24, DOI 10.1038/sj.gt.3301109; Moreno PR, 1999, AM J CARDIOL, V84, P462, DOI 10.1016/S0002-9149(99)00334-3; Moreno PR, 1996, CIRCULATION, V94, P3098, DOI 10.1161/01.CIR.94.12.3098; Morsy MA, 1998, P NATL ACAD SCI USA, V95, P7866, DOI 10.1073/pnas.95.14.7866; Napoli C, 1999, CIRCULATION, V99, P2003, DOI 10.1161/01.CIR.99.15.2003; Napoli C, 2000, P NATL ACAD SCI USA, V97, P3678, DOI 10.1073/pnas.97.7.3678; Napoli C, 2001, P NATL ACAD SCI USA, V98, P2860, DOI 10.1073/pnas.041602898; Niebauer J, 1999, CIRCULATION, V100, P1830, DOI 10.1161/01.CIR.100.17.1830; Ooboshi H, 1997, ARTERIOSCL THROM VAS, V17, P1786, DOI 10.1161/01.ATV.17.9.1786; Palasis M, 2000, HUM GENE THER, V11, P237, DOI 10.1089/10430340050015987; PALINSKI W, 2000, CONT CARDIOLOGY VASC, P149; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; RAPP JH, 1987, SURGERY, V101, P277; Reis ED, 2000, P NATL ACAD SCI USA, V97, P12764, DOI 10.1073/pnas.210394497; Rekhter MD, 1998, CIRC RES, V82, P1243, DOI 10.1161/01.RES.82.12.1243; Rouis M, 1999, CIRCULATION, V100, P533, DOI 10.1161/01.CIR.100.5.533; Sakai A, 1996, HEART VESSELS, V11, P255, DOI 10.1007/BF01746206; Sata M, 2000, J MOL CELL CARDIOL, V32, P2097, DOI 10.1006/jmcc.2000.1238; SCHULICK AH, 1995, CIRCULATION, V91, P2407, DOI 10.1161/01.CIR.91.9.2407; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smith RC, 1997, CIRCULATION, V96, P1899, DOI 10.1161/01.CIR.96.6.1899; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; VIOLARIS AG, 1994, CIRCULATION, V90, P2267, DOI 10.1161/01.CIR.90.5.2267; Walsh K, 2000, CARDIOVASC RES, V45, P756, DOI 10.1016/S0008-6363(99)00270-9; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; YHAHERTTUALA S, 2000, LANCET, V355, P213	53	49	50	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2162	2170		10.1096/fj.01-0032com	http://dx.doi.org/10.1096/fj.01-0032com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641242				2022-12-28	WOS:000171920400027
J	Abid, MR; Tsai, JC; Spokes, KC; Deshpande, SS; Irani, K; Aird, WC				Abid, MR; Tsai, JC; Spokes, KC; Deshpande, SS; Irani, K; Aird, WC			Vascular endothelial growth factor induces manganese-superoxide dismutase expression in endothelial cells by a Rac1-regulated NADPH oxidase-dependent mechanism	FASEB JOURNAL			English	Article						gene regulation; cell signaling; endothelial cell migration; reactive oxygen species; vascular endothelial growth factor	SMOOTH-MUSCLE CELLS; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; NITRIC-OXIDE; ANGIOTENSIN-II; SIGNAL-TRANSDUCTION; IN-VIVO; CRITICAL COMPONENT; OXIDATIVE STRESS; NAD(P)H OXIDASE	Vascular endothelial growth factor (VEGF) is a potent vascular endothelial cell-specific mitogen that modulates endothelial cell function. In the present study, we show that VEGF induces manganese-superoxide dismutase (MnSOD) mRNA and protein in human coronary artery endothelial cells (HCAEC) and pulmonary artery endothelial cells. VEGF-mediated induction of MnSOD mRNA was inhibited by pretreatment with the NADPH oxidase inhibitors, diphenyleneiodonium (DPI), and 4-(2-aminoethyl)-benzenesulfonyl fluoride, but not with the nitric oxide synthase inhibitor L-NAME (N-monomethyl-L-arginine) or the xanthine oxidase inhibitor allopurinol. VEGF stimulation of MnSOD was also inhibited by adenoviral-mediated overexpression of catalase Cu, Zn-SOD and a dominant-negative form of the small GTPase component of NADPH oxidase Rac1 (Rac1N17). Treatment of HCAEC with VEGF resulted in a transient increase in ROS production at 20 min, as measured by 2',7'-dichlorodihydrofluorescein oxidation. This effect was abrogated by expression of Rac1N17. Taken together, these findings suggest that VEGF induces MnSOD by an NADPH oxidase-dependent mechanism and that VEGF signaling in the endothelium is coupled to the redox state of the cell.	Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Mol Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Johns Hopkins University	Aird, WC (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, RW-663,330 Brookline Ave, Boston, MA 02215 USA.	waird@caregroup.harvard.edu		Irani, Kaikobad/0000-0001-9194-7387				Abid MR, 2000, FEBS LETT, V486, P252, DOI 10.1016/S0014-5793(00)02305-X; AKASHI M, 1995, J BIOL CHEM, V270, P15864, DOI 10.1074/jbc.270.26.15864; Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960; Bates DO, 1999, MICROCIRCULATION, V6, P83, DOI 10.1038/sj.mn.7300054; Bauersachs J, 1999, CIRCULATION, V100, P292, DOI 10.1161/01.CIR.100.3.292; Bayraktutan U, 1998, CARDIOVASC RES, V38, P256, DOI 10.1016/S0008-6363(98)00003-0; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; Cominacini L, 2000, J BIOL CHEM, V275, P12633, DOI 10.1074/jbc.275.17.12633; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; Deng L, 2001, J BIOL CHEM, V276, P413, DOI 10.1074/jbc.M004551200; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054; Howard AB, 1997, AM J PHYSIOL-CELL PH, V272, pC421, DOI 10.1152/ajpcell.1997.272.2.C421; Huang TT, 1999, ANN NY ACAD SCI, V893, P95, DOI 10.1111/j.1749-6632.1999.tb07820.x; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; Kiningham KK, 1999, FASEB J, V13, P1601, DOI 10.1096/fasebj.13.12.1601; Kunsch C, 1999, CIRC RES, V85, P753, DOI 10.1161/01.RES.85.8.753; Kuroda M, 2000, ANTICANCER RES, V20, P7; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LAURINDO FRM, 1994, CIRC RES, V74, P700, DOI 10.1161/01.RES.74.4.700; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MALTERUD KE, 1993, PHARMACOLOGY, V47, P77, DOI 10.1159/000139846; Marumo T, 1997, CIRCULATION, V96, P2361; Marumo T, 1999, J VASC RES, V36, P510, DOI 10.1159/000025694; Meeson AP, 1999, DEVELOPMENT, V126, P1407; Mitchell J, 1996, J CELL PHYSIOL, V169, P333, DOI 10.1002/(SICI)1097-4652(199611)169:2<333::AID-JCP12>3.0.CO;2-A; MOHAZZABH KM, 1994, AM J PHYSIOL, V266, pH2568, DOI 10.1152/ajpheart.1994.266.6.H2568; MUGGE A, 1991, AM J PHYSIOL, V260, P219; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; NIU XF, 1994, CIRC RES, V74, P1133, DOI 10.1161/01.RES.74.6.1133; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Rahman A, 1998, AM J PHYSIOL-LUNG C, V275, pL533, DOI 10.1152/ajplung.1998.275.3.L533; Robinson BH, 1998, J INHERIT METAB DIS, V21, P598, DOI 10.1023/A:1005427323835; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tsai JC, 2000, AM J PHYSIOL-CELL PH, V279, pC1414, DOI 10.1152/ajpcell.2000.279.5.C1414; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Van Gelder CM, 1999, J TRAUMA, V47, P885, DOI 10.1097/00005373-199911000-00012; Veikkola T, 2000, CANCER RES, V60, P203; VISNER GA, 1990, J BIOL CHEM, V265, P2856; Vlahopoulos S, 1999, BLOOD, V94, P1878, DOI 10.1182/blood.V94.6.1878; Warner BB, 1996, AM J PHYSIOL-LUNG C, V271, pL150, DOI 10.1152/ajplung.1996.271.1.L150; WEBER C, 1994, ARTERIOSCLER THROMB, V14, P1665, DOI 10.1161/01.ATV.14.10.1665; Wei ZH, 1999, CIRC RES, V85, P682, DOI 10.1161/01.RES.85.8.682; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Xie YW, 1998, CIRC RES, V82, P891; Yeh LH, 1999, AM J PHYSIOL-CELL PH, V276, pC838, DOI 10.1152/ajpcell.1999.276.4.C838; Zachary I, 1998, EXP NEPHROL, V6, P480; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488; Zhao GC, 1997, AM J PHYSIOL-LUNG C, V273, pL1112, DOI 10.1152/ajplung.1997.273.6.L1112; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	73	133	135	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					2548	+		10.1096/fj.01-0338fje	http://dx.doi.org/10.1096/fj.01-0338fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641265				2022-12-28	WOS:000171372700026
J	Krynetskaia, NF; Feng, JY; Krynetski, EY; Garcia, JV; Panetta, JC; Anderson, KS; Evans, WE				Krynetskaia, NF; Feng, JY; Krynetski, EY; Garcia, JV; Panetta, JC; Anderson, KS; Evans, WE			Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug	FASEB JOURNAL			English	Article						thiopurines; thioguanylated DNA; viral RNase H	HUMAN-IMMUNODEFICIENCY-VIRUS; GENE-TRANSFER VECTORS; REVERSE-TRANSCRIPTASE; RNASE-H; LYMPHOBLASTIC-LEUKEMIA; DNA-POLYMERASES; 6-THIOGUANINE; CLEAVAGE; CHEMOTHERAPY; RESISTANCE	Inhibition of HIV-1 reverse transcriptase (RT) and HIV protease are effective mechanisms for anti-retroviral agents, and the combined use of mechanistically different medications has markedly improved the treatment of HIV infected patients. The active metabolite of mercaptopurine and thioguanine (TG), deoxythioguanosine triphosphate, was shown to be incorporated into DNA by the polymerase function of HIV-1 RT and then to abrogate RNA cleavage by HIV-1 RNaseH. Treatment of human lymphocyte cultures with thioguanine produced substantial inhibition of HIV replication (IC50 = 0.035 muM, IC95 = 515.4 muM), with minimal toxicity to host lymphocytes (<10% at 15.4 <mu>M TG, P<0.000005). Furthermore, low concentrations of TG and zidovudine were synergistic in inhibiting HIV replication in human lymphocytes (synergy volume=9 <mu>M-2 %), without additive cytotoxicity to host lymphocytes. Thus, thiopurines are novel anti-retroviral agents that alter the DNA-RNA substrates for HIV RNaseH, thereby abrogating early stages of HIV replication.	St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Yale Univ, Sch Med, New Haven, CT USA; Univ Texas, SW Med Ctr, Dallas, TX USA	St Jude Children's Research Hospital; Yale University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Evans, WE (corresponding author), St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.	william.evans@stjude.org	Evans, William E./C-2069-2012; Panetta, John/AAY-3850-2021	Evans, William E./0000-0002-9333-5322; Panetta, John/0000-0003-1308-7208	NATIONAL CANCER INSTITUTE [R37CA036401, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049551] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, R37 CA36401] Funding Source: Medline; NIAID NIH HHS [AI39416] Funding Source: Medline; NIGMS NIH HHS [GM49551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Archer RH, 2000, J VIROL, V74, P8390, DOI 10.1128/JVI.74.18.8390-8401.2000; BUCKHEIT RW, 1991, AIDS RES HUM RETROV, V7, P295, DOI 10.1089/aid.1991.7.295; BUCKHEIT RW, 1994, ANTIVIR CHEM CHEMOTH, V5, P35, DOI 10.1177/095632029400500105; Budavari S., 1989, MERCK INDEX; CAMPISI J, 1981, J CELL PHYSIOL, V109, P469, DOI 10.1002/jcp.1041090313; D'Argenio DZ, 1997, ADAPT 2 USERS GUIDE; DeClercq E, 1997, CLIN MICROBIOL REV, V10, P674, DOI 10.1128/CMR.10.4.674; Douglas J, 1999, HUM GENE THER, V10, P935, DOI 10.1089/10430349950018337; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; Evans JT, 1999, HUM GENE THER, V10, P1479, DOI 10.1089/10430349950017815; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Gerondelis P, 1999, J VIROL, V73, P5803, DOI 10.1128/JVI.73.7.5803-5813.1999; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JacqzAigrain E, 1997, EUR J CLIN PHARMACOL, V53, P71, DOI 10.1007/s002280050339; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14056, DOI 10.1021/bi971385+; Krynetskaia NF, 1999, MOL PHARMACOL, V56, P841; Krynetskaia NF, 2000, FASEB J, V14, P2339, DOI 10.1096/fj.00-0089com; LEPAGE GA, 1963, CANCER RES, V23, P1202; LING YH, 1991, MOL PHARMACOL, V40, P508; LING YH, 1992, MOL PHARMACOL, V42, P802; LUDWIG J, 1989, J ORG CHEM, V54, P631, DOI 10.1021/jo00264a024; MAYBAUM J, 1987, MOL PHARMACOL, V32, P606; MAYBAUM J, 1983, CANCER RES, V43, P3852; METELEV VG, 1988, FEBS LETT, V226, P232, DOI 10.1016/0014-5793(88)81429-7; PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166-3542(90)90001-N; Rausch JW, 1997, J BIOL CHEM, V272, P8602, DOI 10.1074/jbc.272.13.8602; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; Skoog D.A, 1985, PRINCIPLE INSTRUMENT, Vthird, P7; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; Waters TR, 1997, BIOCHEMISTRY-US, V36, P2501, DOI 10.1021/bi9621573; Wodarz D, 2000, P NATL ACAD SCI USA, V97, P8193, DOI 10.1073/pnas.97.15.8193; XU YZ, 1992, TETRAHEDRON, V48, P1729, DOI 10.1016/S0040-4020(01)88731-7; YAMAMOTO K, 1988, ACTA VIROL, V32, P386; ZIMM S, 1983, NEW ENGL J MED, V308, P1005, DOI 10.1056/NEJM198304283081705	36	13	13	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					1902	1908		10.1096/fj.01-0124com	http://dx.doi.org/10.1096/fj.01-0124com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532970				2022-12-28	WOS:000171372700005
J	Slominski, A; Wortsman, J; Pisarchik, A; Zbytek, B; Linton, EA; Mazurkiewicz, JE; Wei, ET				Slominski, A; Wortsman, J; Pisarchik, A; Zbytek, B; Linton, EA; Mazurkiewicz, JE; Wei, ET			Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors	FASEB JOURNAL			English	Review						skin; PKA; CRH gene; stress	MAST-CELL DEGRANULATION; TISSUE-SPECIFIC EXPRESSION; ACTIVATED PROTEIN-KINASE; FETAL MEMBRANES EXPRESS; POMC-DERIVED PEPTIDES; HUMAN-PLACENTA; PROSTAGLANDIN SYNTHESIS; HUMAN MELANOCYTES; STRESS-RESPONSE; MESSENGER-RNA	Studies in mammalian skin have shown expression of the genes for corticotropin-releasing hormone (CRH) and the related urocortin peptide, with subsequent production of the respective peptides. Recent molecular and biochemical analyses have further revealed the presence of CRH receptors (CRHRs). These CRH-Rs are functional, responding to CRH and urocortin peptides (exogenous or produced locally) through activation of receptor(s)-mediated pathways to modify skin cell phenotype. Thus, when taken together with the previous findings of cutaneous expression of POMC and its receptors, these observations extend the range of regulatory elements of the hypothalamic-pituitary-adrenal axis expressed in mammalian skin. Overall, the cutaneous CRH/POMC expression is highly reactive to common stressors such as immune cytokines, ultraviolet radiation, cutaneous pathology, or even the physiological changes associated with the hair cycle phase. Therefore, similar to its central analog, the local expression and action of CRH/POMC elements appear to be highly organized and entrained, representing general mechanism of cutaneous response to stressful stimuli. In such a CRH/POMC system, the CRH-Rs may be a central element.	Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA; So Illinois Univ, Dept Internal Med, Springfield, IL 62701 USA; Med Univ Gdansk, Dept Histol & Immunol, Gdansk, Poland; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England; Albany Med Coll, Ctr Neuropharmacol & Neurosci, Albany, NY 12208 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of Tennessee System; University of Tennessee Health Science Center; Southern Illinois University System; Southern Illinois University; Fahrenheit Universities; Medical University Gdansk; University of Oxford; Albany Medical College; University of California System; University of California Berkeley	Slominski, A (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol, 899 Madison Ave,Room 576M-BMH,899 Madison Ave, Memphis, TN 38163 USA.	aslominski@utmem.edu		Pisarchik, Alexander/0000-0002-8991-919X; Slominski, Andrzej/0000-0001-8963-3995				Aguilera G, 1998, TRENDS ENDOCRIN MET, V9, P329, DOI 10.1016/S1043-2760(98)00079-4; Ahmed I, 2000, J CLIN ENDOCR METAB, V85, P755, DOI 10.1210/jc.85.2.755; Arai M, 2001, ENDOCRINOLOGY, V142, P446, DOI 10.1210/en.142.1.446; Arbiser JL, 1999, J INVEST DERMATOL, V113, P838, DOI 10.1046/j.1523-1747.1999.00760.x; Bamberger CM, 1998, J CLIN ENDOCR METAB, V83, P708, DOI 10.1210/jc.83.2.708; Barker DM, 1999, BRIT J PHARMACOL, V126, P317, DOI 10.1038/sj.bjp.0702261; Borrelli E, 1998, NAT GENET, V19, P108, DOI 10.1038/452; Brar B, 1997, J ENDOCRINOL, V154, P431, DOI 10.1677/joe.0.1540431; Brar BK, 2000, J BIOL CHEM, V275, P8508, DOI 10.1074/jbc.275.12.8508; CARLSON KW, 2001, IN PRESS ANTICANCER; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; Chalmers DT, 1996, TRENDS PHARMACOL SCI, V17, P166, DOI 10.1016/0165-6147(96)81594-X; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Crofford LJ, 1995, ANN NY ACAD SCI, V771, P459, DOI 10.1111/j.1749-6632.1995.tb44702.x; Donaldson CJ, 1996, ENDOCRINOLOGY, V137, P2167, DOI 10.1210/en.137.5.2167; Eckart K, 1999, CURR MED CHEM, V6, P1035; Ehrhart-Bornstein M, 1998, ENDOCR REV, V19, P101, DOI 10.1210/er.19.2.101; Emanuel RL, 2000, PEPTIDES, V21, P1819, DOI 10.1016/S0196-9781(00)00343-0; Fazal N, 1998, FEBS LETT, V435, P187, DOI 10.1016/S0014-5793(98)01067-9; Fleisher-Berkovich S, 1998, REGUL PEPTIDES, V77, P121, DOI 10.1016/S0167-0115(98)00107-4; Fleisher-Berkovich S, 1999, CYTOKINE, V11, P239, DOI 10.1006/cyto.1998.0417; FLEISHERBERKOVICH S, 1995, ENDOCRINOLOGY, V136, P4068, DOI 10.1210/en.136.9.4068; Funasaka Y, 1999, J INVEST DERM SYMP P, V4, P105, DOI 10.1038/sj.jidsp.5640192; GAO GC, 1991, PEPTIDES, V12, P639, DOI 10.1016/0196-9781(91)90113-4; Gjerde EAB, 1998, EUR J PHARMACOL, V352, P99, DOI 10.1016/S0014-2999(98)00403-8; Grammatopoulos D, 1998, J CLIN ENDOCR METAB, V83, P2539, DOI 10.1210/jc.83.7.2539; Grammatopoulos D, 1998, MOL CELL ENDOCRINOL, V138, P185, DOI 10.1016/S0303-7207(97)00238-4; Grammatopoulos DK, 1999, LANCET, V354, P1546, DOI 10.1016/S0140-6736(99)03418-2; Grammatopoulos DK, 1999, MOL ENDOCRINOL, V13, P2189, DOI 10.1210/me.13.12.2189; Grammatopoulos DK, 2000, MOL ENDOCRINOL, V14, P2076, DOI 10.1210/me.14.12.2076; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; Heinrich N, 1998, ENDOCRINOLOGY, V139, P651, DOI 10.1210/en.139.2.651; Iino K, 1997, J CLIN ENDOCR METAB, V82, P3842, DOI 10.1210/jc.82.11.3842; Inui A, 1999, TRENDS NEUROSCI, V22, P62, DOI 10.1016/S0166-2236(98)01292-2; Itoi K, 1998, ENDOCR J, V45, P13, DOI 10.1507/endocrj.45.13; JOYNER W L, 1989, FASEB Journal, V3, pA272; JOYNER WL, 1990, FASEB J, V4, P1125; Kageyama K, 1999, ENDOCRINOLOGY, V140, P5651, DOI 10.1210/en.140.12.5651; Karalis K, 1997, J NEUROIMMUNOL, V72, P131, DOI 10.1016/S0165-5728(96)00178-6; KARALIS K, 1991, SCIENCE, V254, P421, DOI 10.1126/science.1925600; Karalis KP, 1999, P NATL ACAD SCI USA, V96, P7093, DOI 10.1073/pnas.96.12.7093; Karteris E, 1998, J CLIN ENDOCR METAB, V83, P1376, DOI 10.1210/jc.83.4.1376; KAVELAARS A, 1990, ENDOCRINOLOGY, V126, P759, DOI 10.1210/endo-126-2-759; Kiang J G, 1987, Proc West Pharmacol Soc, V30, P63; KIANG JG, 1995, EUR J PHARM-MOLEC PH, V291, P107, DOI 10.1016/0922-4106(95)90131-0; KIANG JG, 1994, EUR J PHARM-MOLEC PH, V267, P135, DOI 10.1016/0922-4106(94)90164-3; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; Kishimoto T, 2000, NAT GENET, V24, P415, DOI 10.1038/74271; KONO M, 2000, P 11 INT C HIST CYT, P32; Kostich WA, 1998, MOL ENDOCRINOL, V12, P1077, DOI 10.1210/me.12.8.1077; Kozicz T, 1998, J COMP NEUROL, V391, P1, DOI 10.1002/(SICI)1096-9861(19980202)391:1<1::AID-CNE1>3.0.CO;2-6; KRAVCHENCO IV, 1994, BIOCHEM BIOPH RES CO, V204, P828, DOI 10.1006/bbrc.1994.2534; Kuryshev YA, 1996, ENDOCRINOLOGY, V137, P2269, DOI 10.1210/en.137.6.2269; LAVRIVIERE WR, 2000, PAIN, V84, P1; Lee AK, 1997, J PHYSIOL-LONDON, V504, P367, DOI 10.1111/j.1469-7793.1997.367be.x; Li H, 1998, INT J BIOCHEM CELL B, V30, P1389, DOI 10.1016/S1357-2725(98)00093-4; Liaw CW, 1996, ENDOCRINOLOGY, V137, P72, DOI 10.1210/en.137.1.72; LINTON EA, 2001, IN PRESS EXP PHYSL, V86; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; Maillot C, 2000, GASTROENTEROLOGY, V119, P1569, DOI 10.1053/gast.2000.20251; Malkoski SP, 1999, MOL ENDOCRINOL, V13, P1629, DOI 10.1210/me.13.10.1629; Mastorakos G, 1996, J CLIN ENDOCR METAB, V81, P1046, DOI 10.1210/jc.81.3.1046; MASTORAKOS G, 1995, ENDOCRINOLOGY, V136, P4650, DOI 10.1210/en.136.10.4650; Mazurkiewicz JE, 2000, J HISTOCHEM CYTOCHEM, V48, P905, DOI 10.1177/002215540004800703; McLoon LK, 1997, INVEST OPHTH VIS SCI, V38, P834; MELZIG MF, 1994, IN VITRO CELL DEV-AN, V30A, P741; Mimmack ML, 1998, J ANIM SCI, V76, P2205; Miyata I, 1999, BIOCHEM BIOPH RES CO, V256, P692, DOI 10.1006/bbrc.1999.0392; Muramatsu Y, 2000, PEPTIDES, V21, P1799, DOI 10.1016/S0196-9781(00)00335-1; Myers DA, 1998, MOL CELL ENDOCRINOL, V144, P21, DOI 10.1016/S0303-7207(98)00157-9; Navarra P, 2001, J CLIN ENDOCR METAB, V86, P317, DOI 10.1210/jc.86.1.317; Nishikimi T, 2000, AM J PHYSIOL-HEART C, V279, pH3031, DOI 10.1152/ajpheart.2000.279.6.H3031; Oki Y, 1998, LIFE SCI, V62, P807, DOI 10.1016/S0024-3205(97)01182-X; Okosi A, 1998, NEUROPEPTIDES, V32, P167, DOI 10.1016/S0143-4179(98)90033-6; ORTH DN, 1992, ENDOCR REV, V13, P164, DOI 10.1210/er.13.2.164; OWENS MJ, 1991, PHARMACOL REV, V43, P425; Palchaudhuri MR, 1999, J NEUROENDOCRINOL, V11, P419; Park JH, 2000, NEUROSCI LETT, V292, P45, DOI 10.1016/S0304-3940(00)01434-8; Parker CR, 1999, MOL CELL ENDOCRINOL, V155, P19; PEREDA MP, 1995, ENDOCRINOLOGY, V136, P5504; Perone MJ, 1998, MOL CELL ENDOCRINOL, V142, P191, DOI 10.1016/S0303-7207(98)00104-X; Perrin MH, 1999, ANN NY ACAD SCI, V885, P312, DOI 10.1111/j.1749-6632.1999.tb08687.x; PETRAGLIA F, 1987, NATURE, V328, P717, DOI 10.1038/328717a0; Petraglia F, 1999, J CLIN ENDOCR METAB, V84, P1420, DOI 10.1210/jc.84.4.1420; Petraglia F, 1996, ENDOCR REV, V17, P156, DOI 10.1210/er.17.2.156; Petraglia F, 1996, J CLIN ENDOCR METAB, V81, P3807, DOI 10.1210/jc.81.10.3807; Petraglia F, 1998, J REPROD IMMUNOL, V39, P221, DOI 10.1016/S0165-0378(98)00024-2; Quevedo ME, 2001, IN VITRO CELL DEV-AN, V37, P50; Radulovic M, 1999, J IMMUNOL, V162, P3013; Ramkumar T, 1999, MOL ENDOCRINOL, V13, P1237, DOI 10.1210/me.13.8.1237; Robinson BM, 1999, PEPTIDES, V20, P1177, DOI 10.1016/S0196-9781(99)00121-7; Rodriguez-Linares B, 1998, J ENDOCRINOL, V156, P15, DOI 10.1677/joe.0.1560015; Rohde E, 1996, BIOCHEM PHARMACOL, V52, P829, DOI 10.1016/0006-2952(96)00300-0; Roloff B, 1998, FASEB J, V12, P287, DOI 10.1096/fasebj.12.3.287; ROSS PC, 1994, BIOCHEM BIOPH RES CO, V205, P1836, DOI 10.1006/bbrc.1994.2884; Rossant CJ, 1999, ENDOCRINOLOGY, V140, P1525, DOI 10.1210/en.140.4.1525; SAKAI RR, 1998, PERSPECT ANTISEN SCI, V1, P125; Schafer M, 1997, EUR J PHARMACOL, V323, P1, DOI 10.1016/S0014-2999(97)00057-5; Schilling L, 1998, BRIT J PHARMACOL, V125, P1164, DOI 10.1038/sj.bjp.0702182; SEASHOLTZ A F, 1991, Molecular and Cellular Neuroscience, V2, P266, DOI 10.1016/1044-7431(91)90054-R; SHIBAHARA S, 1983, EMBO J, V2, P775, DOI 10.1002/j.1460-2075.1983.tb01499.x; Singh LK, 1999, J PHARMACOL EXP THER, V288, P1349; Slominski A, 2000, J CLIN ENDOCR METAB, V85, P815, DOI 10.1210/jc.85.2.815; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 1996, BBA-GEN SUBJECTS, V1289, P247, DOI 10.1016/0304-4165(95)00159-X; Slominski A, 1998, J CLIN ENDOCR METAB, V83, P1020, DOI 10.1210/jc.83.3.1020; Slominski A, 1996, INT J DERMATOL, V35, P849, DOI 10.1111/j.1365-4362.1996.tb05049.x; SLOMINSKI A, 1995, FEBS LETT, V374, P113, DOI 10.1016/0014-5793(95)01090-2; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 1996, FEBS LETT, V399, P175, DOI 10.1016/S0014-5793(96)01315-4; Slominski A, 2000, J CLIN ENDOCR METAB, V85, P3582, DOI 10.1210/jc.85.10.3582; Slominski AT, 2000, IN VITRO CELL DEV-AN, V36, P211; Slominski AT, 1999, ANN NY ACAD SCI, V885, P287; Spiess J, 1998, TRENDS ENDOCRIN MET, V9, P140, DOI 10.1016/S1043-2760(98)00037-X; STAIRNAWY S, 2000, THESIS U CALIFORNIA; STENZEL P, 1995, MOL ENDOCRINOL, V9, P637, DOI 10.1210/me.9.5.637; Stephanou A, 1997, MOL CELL ENDOCRINOL, V134, P41, DOI 10.1016/S0303-7207(97)00170-6; Takahashi K, 1998, PEPTIDES, V19, P643, DOI 10.1016/S0196-9781(98)00012-6; Theoharides TC, 1998, ENDOCRINOLOGY, V139, P403, DOI 10.1210/en.139.1.403; THEOHARIDES TC, 1995, ENDOCRINOLOGY, V136, P5745, DOI 10.1210/en.136.12.5745; THOMPSON RC, 1987, MOL ENDOCRINOL, V1, P363, DOI 10.1210/mend-1-5-363; Tjuvajev J, 1998, IN VIVO, V12, P1; Torpy DJ, 1999, NEUROIMMUNOMODULAT, V6, P182, DOI 10.1159/000026380; TsaiMorris CH, 1996, J BIOL CHEM, V271, P14519, DOI 10.1074/jbc.271.24.14519; Valdenaire O, 1997, BBA-GENE STRUCT EXPR, V1352, P129, DOI 10.1016/S0167-4781(97)00047-X; VAMVAKOPOULOS NC, 1994, ENDOCR REV, V15, P409, DOI 10.1210/er.15.4.409; VANWIJK PA, 1995, MOL CELL ENDOCRINOL, V111, P13, DOI 10.1016/0303-7207(95)03541-E; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; WEI ET, 1993, CIBA F SYMP, V172, P258; WEI ET, 1994, EUR J PHARMACOL, V263, P319, DOI 10.1016/0014-2999(94)90729-3; Wei ET, 1998, PEPTIDES, V19, P1183, DOI 10.1016/S0196-9781(98)00085-0; Yamamoto H, 1998, NEUROSCI LETT, V243, P21, DOI 10.1016/S0304-3940(98)00071-8; Zbytek B., 2000, Immunology Letters, V73, P273; Zhao LY, 1998, GENOMICS, V50, P23, DOI 10.1006/geno.1998.5292; Zoumakis E, 1997, J ENDOCRINOL INVEST, V20, P158, DOI 10.1007/BF03346896	137	224	226	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2001	15	10					1678	1693		10.1096/fj.00-0850rev	http://dx.doi.org/10.1096/fj.00-0850rev			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481215				2022-12-28	WOS:000170809900003
J	Danialou, G; Comtois, AS; Dudley, R; Karpati, G; Vincent, GV; Des Rosiers, C; Petrof, BJ				Danialou, G; Comtois, AS; Dudley, R; Karpati, G; Vincent, GV; Des Rosiers, C; Petrof, BJ			Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury	FASEB JOURNAL			English	Article						Duchenne/Becker muscular dystrophies cardiomyopathy; mdx mouse; cytoskeleton; amyocardial injury	FIBROBLAST-GROWTH-FACTOR; MUSCULAR-DYSTROPHY; MDX MOUSE; IN-VIVO; DILATED CARDIOMYOPATHY; MUSCLE; HEART; SKELETAL; MYOPATHY; SARCOGLYCANS	Although absence of the cytoskeletal protein dystrophin leads to dilated cardiomyopathy in humans, the functional role of dystrophin in cardiac muscle remains undefined. We have addressed the hypothesis that dystrophin could help protect the heart against injury and contractile dysfunction induced by mechanical stress. In normal and dystrophin-deficient (mdx) mice, cardiac mechanical stress was first manipulated ex vivo in a perfused working heart preparation. Despite an afterload level in the normal physiologic range, ex vivo perfused mdx hearts developed severe contractile dysfunction and nonischemic tissue damage, as is shown by excessive LDH release without a rise in coronary lactate. Injury to dystrophin-deficient hearts was significantly correlated with cardiac work, and reducing the afterload level improved contractility and prevented injury in mdx hearts studied ex vivo. The response to mechanical stress in vivo was also assessed by using the vital dye Evans blue, which penetrates into cardiomyocytes with a disrupted sarcolemma. In the mdx group only, cardiomyocyte injury was increased markedly by acute elevations of mechanical stress induced by isoproterenol or brief aortic occlusion. Strikingly accelerated mortality and cardiac necrosis were also observed in the mdx group subjected to chronically increased cardiac mechanical stress via subtotal aortic constriction. Taken together, our results provide the first direct evidence that dystrophin serves to protect cardiomyocytes from mechanical stress and workload-induced damage. Accordingly, reducing cardiac work in patients with dystrophin deficiency could be beneficial not only in treating established cardiomyopathy, but also in preventing the onset of cardiac disease.	McGill Univ, Dept Med, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; McGill Univ, Meakins Christie Labs, Montreal, PQ H3A 1A1, Canada; Univ Montreal, CHUM, Ctr Rech, Physiol Resp Lab, Montreal, PQ H2L 4M1, Canada; McGill Univ, Montreal Neurol Inst, Neuromuscular Res Grp, Montreal, PQ H3A 2B4, Canada; Univ Montreal, Dept Biochim, Lab Metab Intermediaire, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Nutr, Montreal, PQ H2L 4M1, Canada	McGill University; McGill University; Universite de Montreal; McGill University; Universite de Montreal; Universite de Montreal	Petrof, BJ (corresponding author), Royal Victoria Hosp, Room L4-11,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	basil.petrof@muhc.mcgill.ca	Rosiers, Christine Des/O-6285-2014					ANDERSON JE, 1994, MUSCLE NERVE, V17, P64, DOI 10.1002/mus.880170109; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; BANERJEE A, 1991, AM J PHYSIOL, V261, pH590, DOI 10.1152/ajpheart.1991.261.2.H590; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BRIDGES LR, 1986, J NEUROL SCI, V72, P147, DOI 10.1016/0022-510X(86)90003-1; BRUNET J, 1995, FREE RADICAL BIO MED, V19, P627, DOI 10.1016/0891-5849(95)00077-B; CLARKE MSF, 1995, CIRC RES, V76, P927, DOI 10.1161/01.RES.76.6.927; CLARKE MSF, 1993, J CELL SCI, V106, P121; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Cox GF, 1997, CURR OPIN CARDIOL, V12, P329; Dalakas MC, 2000, NEW ENGL J MED, V342, P770, DOI 10.1056/NEJM200003163421104; DILISA F, 1995, BIOCHEM J, V308, P57, DOI 10.1042/bj3080057; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FONG P, 1990, SCIENCE, V250, P673, DOI 10.1126/science.2173137; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; GRUPP IL, 1984, METHOD PHARMACOL, P111; Hack AA, 2000, J CELL SCI, V113, P2535; Hack AA, 1999, P NATL ACAD SCI USA, V96, P10723, DOI 10.1073/pnas.96.19.10723; Hayes A, 1997, J APPL PHYSIOL, V82, P435, DOI 10.1152/jappl.1997.82.2.435; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Larsen TS, 1999, PFLUG ARCH EUR J PHY, V437, P979, DOI 10.1007/s004240050870; Lu S, 2000, J MOL CELL CARDIOL, V32, P143, DOI 10.1006/jmcc.1999.1063; Maeda M, 1997, CIRCULATION, V95, P17, DOI 10.1161/01.CIR.95.1.17; MCNEIL PL, 1992, AM J PATHOL, V140, P1097; McNeil PL, 1997, J CELL BIOL, V137, P1, DOI 10.1083/jcb.137.1.1; Megeney LA, 1999, P NATL ACAD SCI USA, V96, P220, DOI 10.1073/pnas.96.1.220; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PETROF BJ, 1993, AM J PHYSIOL, V265, pC834; PONS F, 1994, CIRCULATION, V90, P369, DOI 10.1161/01.CIR.90.1.369; PORTER GA, 1992, J CELL BIOL, V117, P997, DOI 10.1083/jcb.117.5.997; ROCKMAN HA, 1993, CIRCULATION, V87, P14; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Stevenson S, 1997, CIRC RES, V80, P269, DOI 10.1161/01.RES.80.2.269; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; Towbin JA, 1998, CURR OPIN CELL BIOL, V10, P131, DOI 10.1016/S0955-0674(98)80096-3; Vilquin JT, 1998, MUSCLE NERVE, V21, P567, DOI 10.1002/(SICI)1097-4598(199805)21:5<567::AID-MUS2>3.0.CO;2-6; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; Yoshida T, 1998, J BIOL CHEM, V273, P1583, DOI 10.1074/jbc.273.3.1583; YUNGE L, 1989, AM J PATHOL, V134, P171	46	139	141	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1655	+		10.1096/fj.01-0030fje	http://dx.doi.org/10.1096/fj.01-0030fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427517				2022-12-28	WOS:000173707700005
J	Genever, PG; Skerry, TM				Genever, PG; Skerry, TM			Regulation of spontaneous glutamate release activity in osteoblastic cells and its role in differentiation and survival: evidence for intrinsic glutamatergic signaling in bone	FASEB JOURNAL			English	Article						intercellular communication; osteoblasts; osteoclasts	SODIUM-CHANNEL EXPRESSION; NITRIC-OXIDE; IN-VITRO; RECEPTORS; RESORPTION; RILUZOLE; DEATH; NEUROTOXICITY; INHIBITION; APOPTOSIS	Maintenance of bone mass depends on numerous osteoblast-derived autocrine and paracrine signaling factors that ensure the coupled resorptive and formative activity of osteoclasts and osteoblasts. Here, we provide the first evidence that osteoblasts actively secrete glutamate, an amino acid neurotransmitter found at excitatory synapses in the central nervous system, complementing previous reports of functional glutamate receptor expression by bone cells, Several osteoblastic cell-types spontaneously released between 2-7 nmoles glutamate per mg protein, equivalent to or greater than reported levels of glutamate release from depolarized neurons. Osteoblastic glutamate exocytosis appeared dependent on an AMPA-type glutamate autoreceptor, and addition of depolarizing concentrations of KCl caused significant calcium-dependent inhibition of glutamate release. Levels of exocytosed and intracellular free glutamate, and susceptibility to depolarization-induced inhibition of glutamate release, increased during osteoblastic differentiation of MC3T3-E1 cells. Pharmacological inhibition of glutamate release with riluzole (1-25 muM) significantly inhibited differentiation and induced morphological and biochemical characteristics of apoptosis in osteoblastic cells. Exogenous glutamate application increased survival rates of osteoblasts grown in serum-free medium, and proinflammatory cytokines (tumor necrosis factor-alpha and interferon-gamma) significantly inhibited osteoblastic glutamate release. These findings provide evidence for an intrinsic synaptic-like glutamatergic signaling network in bone that is essential for in vitro osteoblast differentiation and survival.	Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England	University of York - UK	Genever, PG (corresponding author), Univ York, Dept Biol, POB 373, York YO10 5YW, N Yorkshire, England.	pg5@york.ac.uk		Genever, Paul/0000-0002-5730-8976; Skerry, Timothy/0000-0003-1319-5575				BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; BHANGU PS, 2001, IN PRESS BONE; Black JA, 1996, DEV NEUROSCI-BASEL, V18, P139, DOI 10.1159/000111403; BLACK JA, 1995, MOL BRAIN RES, V34, P89, DOI 10.1016/0169-328X(95)00141-E; Breukel AIM, 1998, EUR J NEUROSCI, V10, P106, DOI 10.1046/j.1460-9568.1998.00008.x; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; Damoulis PD, 1997, J BONE MINER RES, V12, P412, DOI 10.1359/jbmr.1997.12.3.412; Duncan RL, 1998, SEMIN NEPHROL, V18, P178; Espinosa L, 1999, J PHYSIOL-LONDON, V518, P47, DOI 10.1111/j.1469-7793.1999.0047r.x; ESTEVEZ AG, 1995, EUR J PHARMACOL, V280, P47, DOI 10.1016/0014-2999(95)00186-O; GOWEN M, 1986, J BONE MINER RES, V1, P469; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Itzstein C, 2000, BIOCHEM BIOPH RES CO, V268, P201, DOI 10.1006/bbrc.2000.2097; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; Kizer N, 1997, P NATL ACAD SCI USA, V94, P1013, DOI 10.1073/pnas.94.3.1013; Laketic-Ljubojevic I, 1999, BONE, V25, P631, DOI 10.1016/S8756-3282(99)00224-0; Ludolph AC, 1999, J NEURAL TRANSM-SUPP, P79; Lynch MP, 1998, J CELL BIOCHEM, V68, P31; MacDermott AB, 1999, ANNU REV NEUROSCI, V22, P443, DOI 10.1146/annurev.neuro.22.1.443; MALAVAL L, 1994, J CELL PHYSIOL, V158, P555, DOI 10.1002/jcp.1041580322; MALGOURIS C, 1994, NEUROSCI LETT, V177, P95, DOI 10.1016/0304-3940(94)90053-1; Mason DJ, 1997, BONE, V20, P199, DOI 10.1016/S8756-3282(96)00386-9; Mogi M, 1999, BIOCHEM PHARMACOL, V58, P649, DOI 10.1016/S0006-2952(99)00131-8; Moreau R, 1997, J BONE MINER RES, V12, P1984, DOI 10.1359/jbmr.1997.12.12.1984; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; Patel DR, 1997, EUR J PHARMACOL, V332, P143, DOI 10.1016/S0014-2999(97)01077-7; Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1; Peet NM, 1999, FASEB J, V13, P2179, DOI 10.1096/fasebj.13.15.2179; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; SanchezPrieto J, 1996, TRENDS NEUROSCI, V19, P235, DOI 10.1016/0166-2236(96)10031-X; Spencer GJ, 1999, J BONE MINER RES, V14, P1033; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Zona C, 1998, NEUROSCIENCE, V85, P931, DOI 10.1016/S0306-4522(97)00604-0	40	64	67	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1586	+		10.1096/fj.00-0594fje	http://dx.doi.org/10.1096/fj.00-0594fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427494				2022-12-28	WOS:000173707700028
J	Murdoch, B; Gallacher, L; Awaraji, C; Hess, DA; Keeney, M; Jay, K; Chadwick, K; Foley, SR; Howson-Jan, K; Chin, YI; Wu, DM; Srour, E; Fellows, F; Bhatia, M				Murdoch, B; Gallacher, L; Awaraji, C; Hess, DA; Keeney, M; Jay, K; Chadwick, K; Foley, SR; Howson-Jan, K; Chin, YI; Wu, DM; Srour, E; Fellows, F; Bhatia, M			Circulating hematopoietic stem cells serve as novel targets for in utero gene therapy	FASEB JOURNAL			English	Article						fetal; gene therapy; xenotransplantation	HUMAN-IMMUNODEFICIENCY-VIRUS; REPOPULATING CELLS; RETROVIRAL VECTORS; NOD/SCID MICE; ASSAY; BLOOD; TRANSPLANTATION; IDENTIFICATION; LEUKEMIA; MARROW	In utero gene therapy has been proposed as a method for permanent correction of somatic disorders that affect the hematopoietic system before disease initiation (1, 2). However, clinical trials using transplantation of allogenic fetal liver, bone marrow, or adult stem cells have been unsuccessful, largely due to the failure of sustained hematopoietic reconstitution in fetal recipients (3). Here, we reveal that retroviral transduction of unique repopulating stem cells found in the human fetal circulation is superior to full-gestation cord blood or adult sources. In contrast to postnatal human stem cells, the fetal circulation is highly enriched for actively cycling blood stem cells, thereby forming the basis for enhanced transduction. Our findings indicate that active, transducible hematopoietic reconstituting cells are present in the circulation of the human fetus and that they represent novel target cells for future in utero gene therapy trials using autologous transplantation.	John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, London, ON, Canada; St Josephs Hosp, Fetal Med Div, London, ON N6A 4V2, Canada; London Hlth Sci Ctr, Dept Med & Hematol, London, ON, Canada; Hamilton Civ Hosp, Dept Hematol, Hamilton, ON, Canada; Indiana Univ, Sch Med, Dept Med & Pediat, Bloomington, IN 47405 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); McGill University; Western University (University of Western Ontario); London Health Sciences Centre; McMaster University; Indiana University System; Indiana University Bloomington	Bhatia, M (corresponding author), John P Robarts Res Inst, 100 Perth Dr, London, ON N6A 5K8, Canada.	mbhatia@rri.on.ca	Chin-Yee, Ian/G-3286-2011; Hess, David A/M-2828-2013					ALONSO K, 1995, ARCH PATHOL LAB MED, V119, P179; Bernstein I M, 1996, J Matern Fetal Med, V5, P124; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Bhatia M, 1997, J EXP MED, V186, P619, DOI 10.1084/jem.186.4.619; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; Dick JE, 1997, STEM CELLS, V15, P204; Dick JE, 2000, NAT MED, V6, P624, DOI 10.1038/76188; Dick JE, 1997, STEM CELLS, V15, P199, DOI 10.1002/stem.5530150826; Douar AM, 1996, MOL HUM REPROD, V2, P633, DOI 10.1093/molehr/2.9.633; Drager AM, 1998, BRAZ J MED BIOL RES, V31, P49; Flake AW, 1999, BLOOD, V94, P2179, DOI 10.1182/blood.V94.7.2179.419k43_2179_2191; Gallacher L, 2000, BLOOD, V96, P1740, DOI 10.1182/blood.V96.5.1740.h8001740_1740_1747; Gallacher L, 2000, BLOOD, V95, P2813, DOI 10.1182/blood.V95.9.2813.009k20_2813_2820; Giannina G, 1998, FETAL DIAGN THER, V13, P94, DOI 10.1159/000020813; Gordon DF, 1996, DNA CELL BIOL, V15, P531, DOI 10.1089/dna.1996.15.531; Gothot A, 1997, BLOOD, V90, P4384, DOI 10.1182/blood.V90.11.4384.4384_4384_4393; Herrero RL, 1999, J REPROD MED, V44, P674; Kiem HP, 1997, BLOOD, V90, P4638; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Leung BL, 1999, J IMMUNOL, V163, P1334; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Mielcarek M, 1997, Curr Opin Hematol, V4, P176; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; Rowley JD, 1998, NAT MED, V4, P150, DOI 10.1038/nm0298-150; Schneider H, 1999, NAT MED, V5, P256, DOI 10.1038/6458; Wagner JE, 1998, LEUKEMIA, V12, pS30; WILLIAMS DA, 1994, BLOOD CELLS, V20, P504; Zanjani ED, 1999, SCIENCE, V285, P2084, DOI 10.1126/science.285.5436.2084	31	19	21	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1628	+		10.1096/fj.00-0654fje	http://dx.doi.org/10.1096/fj.00-0654fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427508				2022-12-28	WOS:000173707700014
J	Lee, SL; Wang, WW; Fanburg, BL				Lee, SL; Wang, WW; Fanburg, BL			Dexfenfluramine as a mitogen signal via the formation of superoxide anion	FASEB JOURNAL			English	Article									Tufts Univ, Sch Med, New England Med Ctr, Dept Med,Tupper Res Inst,Pulm & Crit Care Div, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Fanburg, BL (corresponding author), Tufts Univ, Sch Med, New England Med Ctr, Dept Med,Tupper Res Inst,Pulm & Crit Care Div, 750 Washington St,257, Boston, MA 02111 USA.								0	28	30	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1324	1325		10.1096/fj.00-0431fje	http://dx.doi.org/10.1096/fj.00-0431fje			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344128				2022-12-28	WOS:000168655200050
J	Salven, P; Anttonen, K; Repo, H; Joensuu, H; Orpana, A				Salven, P; Anttonen, K; Repo, H; Joensuu, H; Orpana, A			Endotoxins induce and interferon alpha suppresses vascular endothelial growth factor (VEGF) production in human peripheral blood mononuclear cells	FASEB JOURNAL			English	Article									NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Univ Helsinki, Cent Hosp, Dept Clin Chem, FIN-00290 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Med Genet, FIN-00290 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Med, Infect Dis Unit, FIN-00290 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00290 Helsinki, Finland; Haartman Inst, Dept Bacteriol & Immunol, Helsinki 00290, Finland	New York University; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	Salven, P (corresponding author), Cornell Univ, Weill Med Coll, Div Hematol Oncol, 1300 York Ave, New York, NY 10021 USA.			Joensuu, Heikki/0000-0003-0281-2507					0	17	19	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1318	1320		10.1096/fj.00-0627fje	http://dx.doi.org/10.1096/fj.00-0627fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344126				2022-12-28	WOS:000168655200048
J	Huff, T; Otto, AM; Muller, CSG; Meier, M; Hannappel, E				Huff, T; Otto, AM; Muller, CSG; Meier, M; Hannappel, E			Thymosin beta(4) is released from human blood platelets and attached by factor XIIIa (transglutaminase) to fibrin and collagen	FASEB JOURNAL			English	Article						beta-thymosins; cross-linking; actin	ACTIN-SEQUESTERING PEPTIDE; ENDOTHELIAL-CELLS; BETA-4; INHIBITION; CANCER; SPLEEN; GENE	The beta-thymosins constitute a family of highly conserved and extremely water-soluble 5 kDa polypeptides. Thymosin beta(4) is the most abundant member; it is expressed in most cell types and is regarded as the main intracellular G-actin sequestering peptide. There is increasing evidence for extracellular functions of thymosin beta(4). For example, thymosin beta(4) increases the rate of attachment and spreading of endothelial cells on matrix components and stimulates the migration of human umbilical vein endothelial cells. Here we show that thymosin beta(4) can be cross-linked to proteins such as fibrin and collagen by tissue transglutaminase. Thymosin beta(4) is not cross-linked to many other proteins and its cross-linking to fibrin is competed by another family member, thymosin beta(10). After activation of human platelets with thrombin, thymosin beta(4) is released and crosslinked to fibrin in a time- and calcium-dependent manner. We suggest that thymosin beta(4) cross-linking is mediated by factor XIIIa, a transglutaminase that is coreleased from stimulated platelets. This provides a mechanism to increase the local concentration of thymosin beta(4) near sites of clots and tissue damage, where it may contribute to wound healing, angiogenesis and inflammatory responses.	Univ Erlangen Nurnberg, Fac Med, Inst Biochem, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Huff, T (corresponding author), Univ Erlangen Nurnberg, Fac Med, Inst Biochem, Fahrstr 17, D-91054 Erlangen, Germany.	thymosin@biochem.uni-erlangen.de						Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; GRANT DS, 1995, J CELL SCI, V108, P3685; HANNAPPEL E, 1985, ARCH BIOCHEM BIOPHYS, V240, P236, DOI 10.1016/0003-9861(85)90028-1; HANNAPPEL E, 1993, BIOL CHEM H-S, V374, P117, DOI 10.1515/bchm3.1993.374.1-6.117; HANNAPPEL E, 1989, ARCH BIOCHEM BIOPHYS, V273, P396, DOI 10.1016/0003-9861(89)90498-0; HANNAPPEL E, 1987, J CHROMATOGR, V397, P279, DOI 10.1016/S0021-9673(01)85010-X; HANNAPPEL E, 1988, ARCH BIOCHEM BIOPHYS, V260, P546, DOI 10.1016/0003-9861(88)90480-8; HEINTZ D, 1993, FEBS LETT, V329, P9, DOI 10.1016/0014-5793(93)80181-S; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; HUFF T, 1995, EUR J BIOCHEM, V230, P650; Huff T, 1999, FEBS LETT, V464, P14, DOI 10.1016/S0014-5793(99)01670-1; Huff T, 1997, ANAL CHIM ACTA, V352, P239, DOI 10.1016/S0003-2670(97)00133-5; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; Malinda KM, 1999, J INVEST DERMATOL, V113, P364, DOI 10.1046/j.1523-1747.1999.00708.x; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; SAFER D, 1991, J BIOL CHEM, V266, P4029; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; Sosne G, 2001, EXP EYE RES, V72, P605, DOI 10.1006/exer.2000.0985; VergheseNikolakaki S, 1996, BRIT J CANCER, V74, P1441, DOI 10.1038/bjc.1996.562; XU GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4006, DOI 10.1073/pnas.79.13.4006; Young JD, 1999, NAT MED, V5, P1424; YU FX, 1993, J BIOL CHEM, V268, P502	25	81	90	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7							UNSP 0892-6638/02/0016-0691	10.1096/fj.01-0713com	http://dx.doi.org/10.1096/fj.01-0713com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	11978733				2022-12-28	WOS:000175973900023
J	Zou, W; Schwartz, H; Endres, S; Hartmann, G; Bar-Shavit, Z				Zou, W; Schwartz, H; Endres, S; Hartmann, G; Bar-Shavit, Z			CpG oligonucleotides: novel regulators of osteoclast differentiation	FASEB JOURNAL			English	Article						RANKL; TNF-alpha; M-CSF; bone; immunostimulatory oligodexynucleotide	COLONY-STIMULATING FACTOR; MARROW-DERIVED MACROPHAGES; NF-KAPPA-B; BACTERIAL-DNA; BONE-MARROW; OSTEOPROTEGERIN LIGAND; OP/OP MICE; IN-VITRO; ACTIVATION; OSTEOPETROSIS	The macrophage capability to recognize bacterial DNA is mimicked by oligodeoxynucleotides containing unmethylated CG dinucleotides (CpG' motifs) in specific sequence contexts (CpG ODN). CpG ODN stimulates NF-kappaB activation in murine macrophages. In light of the pivotal role played by NF-kappaB in osteoclast differentiation, we examined the ability of CpG ODN to modulate osteoclastogenesis. CpG ODN alone induced TRAP- positive cells in bone marrow macrophage (BMM) cultures, but not multinucleation or calcitonin receptor expression. CpG ODN inhibited RANKL- induced osteoclastogenesis when present from the beginning of BMM culture, but strongly increased RANKL- induced osteoclastogenesis in RANKL- pretreated BMMs. CpG ODN enhanced the expression of interleukin 1beta (IL-1beta) and tumor necrosis factor alpha (TNF-alpha). Antibodies to TNF-alpha and the TNF type 1 receptor, but not the addition of IL- 1 receptor antagonist, blocked CpG ODN- induced osteoclastogenesis in RANKL- pretreated cultures. On the other hand, CpG ODN reduced expression of the M- CSF receptor, which is critical during the initiation of osteoclast differentiation. These results suggest that CpG ODN, via the induction of TNF-alpha, support osteoclastogenesis in cells that are committed to the osteoclast differentiation pathway but, due to down- modulation of M- CSF receptor, inhibit early steps of osteoclast differentiation. Thus, CpG ODN represents a potential therapeutic tool for treating bone diseases.	Hebrew Univ Jerusalem, Fac Med, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91120 Jerusalem, Israel; Univ Munich, Dept Med, Div Clin Pharmacol, D-80336 Munich, Germany	Hebrew University of Jerusalem; University of Munich	Bar-Shavit, Z (corresponding author), Hebrew Univ Jerusalem, Fac Med, Hubert H Humphrey Ctr Expt Med & Canc Res, POB 12272, IL-91120 Jerusalem, Israel.	barsha@cc.huji.ac.il	Hartmann, Gunther/P-7492-2017	Hartmann, Gunther/0000-0003-1021-2018; Zou, Wei/0000-0001-8081-268X				Abboud SL, 1998, J CELL PHYSIOL, V176, P323, DOI 10.1002/(SICI)1097-4652(199808)176:2<323::AID-JCP10>3.0.CO;2-4; ABUAMER Y, 1994, J CELL BIOCHEM, V55, P435, DOI 10.1002/jcb.240550404; BARON R, 1986, AM J PATHOL, V122, P363; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; GOLDMAN R, 1979, J NATL CANCER I, V63, P1009; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Kahn A J, 1982, Prog Clin Biol Res, V110 Pt B, P239; Kawata T, 1999, ARCH ORAL BIOL, V44, P81, DOI 10.1016/S0003-9969(98)00082-X; KITAZAWA R, 1994, J CLIN INVEST, V94, P2397, DOI 10.1172/JCI117606; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2001, TRENDS MICROBIOL, V9, P249, DOI 10.1016/S0966-842X(01)02039-X; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Macfarlane DE, 1998, J IMMUNOL, V160, P1122; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371-2380.1996; Pisetsky DS, 1996, IMMUNITY, V5, P303, DOI 10.1016/S1074-7613(00)80256-3; Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331; Reddy SV, 1998, CRIT REV EUKAR GENE, V8, P1; RODAN GA, 1992, BONE, V13, pS3, DOI 10.1016/S8756-3282(09)80003-3; Sambrook J., 1989, MOL CLONING, pA1; Sester DP, 1999, J IMMUNOL, V163, P6541; Sparwasser T, 1997, EUR J IMMUNOL, V27, P1671, DOI 10.1002/eji.1830270712; Suda Tatsuo, 1996, P87; Takatsuka H, 1998, J SUBMICR CYTOL PATH, V30, P239; Umeda S, 1996, J SUBMICR CYTOL PATH, V28, P13; Weiner GJ, 2000, J LEUKOCYTE BIOL, V68, P455; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200; Zou W, 2001, J CELL BIOCHEM, V83, P70, DOI 10.1002/jcb.1202	38	48	52	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					274	282	UNSP 0892-6638/02/0016-0283	10.1096/fj.01-0586com	http://dx.doi.org/10.1096/fj.01-0586com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874977				2022-12-28	WOS:000174755900020
J	Kallmann, BA; Wagner, S; Hummel V; Buttmann, M; Bayas, A; Tonn, JC; Rieckmann, P				Kallmann, BA; Wagner, S; Hummel, V; Buttmann, M; Bayas, A; Tonn, JC; Rieckmann, P			Characteristic gene expression profile of primary human cerebral endothelial cells	FASEB JOURNAL			English	Article						cDNA array analysis; blood brain barrier	BLOOD-BRAIN-BARRIER; GROWTH-FACTOR-BETA; CXC-CHEMOKINES; ONCOSTATIN-M; ANGIOGENESIS; RECEPTORS; INTERLEUKIN-6; MICROVESSELS; INFLAMMATION; ACTIVATION	Endothelial cells of blood vessels forming the interphase between systemic circulation and tissues are crucial for maintenance of homeostasis and organ-related functions. Recent experiments support organ-specific endothelial differentiation and suggest differential gene expression patterns in endothelial cells. Here, we compared gene expression in primary human cerebral endothelial cells (HCEC), which are major constituents of the blood brain barrier (BBB), with human umbilical vein endothelial cells (HUVEC) by using cDNA array analysis of 375 genes. Under basal culture conditions, 35 genes were expressed only in HCEC, whereas 20 gene transcripts were detected only in HUVEC. A total of 78 genes were expressed in both endothelial cell types partly with distinct expression levels. Genes expressed by cerebral endothelial cells are important in vasculo- and angiogenesis (VEGF, erbB1) and immunoregulation (OSM-R, decorin, IL-6) or have growth-supporting properties (brain-derived neurotrophic factor, stem cell factor, transforming growth factor-). The differential gene expression profiles were confirmed at the protein level of cell cultures (ELISA, immunoblotting) and human tissues (immunohistochemistry). Identification and further functional characterization of genes specifically expressed by cerebral endothelial cells will have important impact on our understanding of endothelial function at the BBB.	Univ Wurzburg, Dept Neurol, Clin Res Unit Multiple Sclerosis & Neuroimmunol, D-97080 Wurzburg, Germany; Univ Wurzburg, Dept Neurosurg, D-97080 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Kallmann, BA (corresponding author), Univ Wurzburg, Dept Neurol, Clin Res Unit Multiple Sclerosis & Neuroimmunol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.	b.kallmann@mail.uni-wuerzburg.de	Buttmann, Mathias/AAD-7488-2021; Buttmann, Mathias/R-7301-2019; Tonn, Joerg/AAK-8509-2021	Buttmann, Mathias/0000-0001-8309-7685; Buttmann, Mathias/0000-0001-8309-7685; 				Abumiya T, 1999, J CEREBR BLOOD F MET, V19, P1038, DOI 10.1097/00004647-199909000-00012; AHUJA SS, 1993, J IMMUNOL, V150, P3109; Althaus HH, 2000, INT REV CYTOL, V197, P203, DOI 10.1016/S0074-7696(00)97005-0; Beck GC, 1999, CLIN EXP IMMUNOL, V118, P298; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Fee D, 2000, CYTOKINE, V12, P655, DOI 10.1006/cyto.1999.0599; Glabinski AR, 1999, J NEUROVIROL, V5, P623, DOI 10.3109/13550289909021291; JOO F, 1992, J NEUROCHEM, V58, P1, DOI 10.1111/j.1471-4159.1992.tb09272.x; Kallmann BA, 2000, BRAIN, V123, P687, DOI 10.1093/brain/123.4.687; Kozian DH, 1997, LAB INVEST, V76, P267; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; Li JY, 2001, J CEREBR BLOOD F MET, V21, P61, DOI 10.1097/00004647-200101000-00008; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; MATSUMOTO K, 1994, DEV BRAIN RES, V79, P229, DOI 10.1016/0165-3806(94)90127-9; Nelimarkka L, 2001, AM J PATHOL, V158, P345, DOI 10.1016/S0002-9440(10)63975-2; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Persidsky Y, 1999, J NEUROVIROL, V5, P579, DOI 10.3109/13550289909021287; Ruprecht K, 2001, J NEUROPATH EXP NEUR, V60, P1087, DOI 10.1093/jnen/60.11.1087; Russell KS, 1999, AM J PHYSIOL-HEART C, V277, pH2205, DOI 10.1152/ajpheart.1999.277.6.H2205; Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com; St Croix B, 2000, SCIENCE, V289, P1197; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Tomoda T, 1996, DEV BIOL, V179, P79, DOI 10.1006/dbio.1996.0242; Vasse M, 1999, ARTERIOSCL THROM VAS, V19, P1835, DOI 10.1161/01.ATV.19.8.1835; VOSS B, 1986, J HISTOCHEM CYTOCHEM, V34, P1013, DOI 10.1177/34.8.2426331; Whitney LW, 1999, ANN NEUROL, V46, P425	30	79	89	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					589	+		10.1096/fj.01-0594fje	http://dx.doi.org/10.1096/fj.01-0594fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919163				2022-12-28	WOS:000174203700017
J	Wellejus, A; Loft, S				Wellejus, A; Loft, S			Receptor-mediated ethinylestradiol-induced oxidative DNA damage in rat testicular cells	FASEB JOURNAL			English	Article						7,8-dihydro-8-oxo-2 '-deoxyguanosine glutathione; 17 alpha-ethinylestradiol	FUNCTIONAL ESTROGEN-RECEPTOR; HUMAN SPERM MEMBRANE; GERM-CELLS; BREAST-CANCER; FREE-RADICALS; ESCHERICHIA-COLI; P450 AROMATASE; SEA-URCHIN; TESTIS; DIETHYLSTILBESTROL	Estrogenic chemicals are suspected of affecting cancer risk and male reproduction, possibly involving oxidative DNA damage. In this study, formation of 7,8-dihydro-8-oxo-2'-deoxyguanosine (8-oxodG), was measured in testicular cells from rats after 17 alpha-ethinylestradiol (EE) exposure in vivo and in vitro after incubation with EE with or without an antiestrogen. In vivo, preadult (30-35 days) and adult (110-120 days) Wistar rats received 0, 2.8, or 56 mg EE/kg body weight as intraperitoneal injections (n=6). After 1 or 4 h, the 8-oxodG/10(6) dG ratio was measured in the liver, kidneys, and testes. Testes DNA analysis revealed an age-related effect (adult animals had a higher ratio than the young animals) and a concentration effect in preadult rats (increased EE-concentration caused increased ratio), but no time effect. No differences were found in the liver or kidneys. In vitro, testicular cells were isolated and incubated with EE concentrations ranging from 0.1 to 1000 nM. The results indicated an increase in 8-oxodG/10(6) dG from 0 to 10 nM estrogen. At 1000 nM, the level was close to control level. Coincubation of 10 nM EE (maximum damage) with an estrogen antagonist, ICI 182.780, abolished the effect at 10 nM, indicating that the damaging effect is estrogen receptor mediated.	Univ Copenhagen, Inst Publ Hlth, Copenhagen, Denmark	University of Copenhagen	Loft, S (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Bldg 18-5,Blegdamsvej 3, DK-2200 Copenhagen, Denmark.	s.loft@pubhealth.ku.dk		Wellejus, Anja/0000-0003-4350-6063; Loft, Steffen/0000-0001-9552-8518				Andersen HR, 1999, ENVIRON HEALTH PERSP, V107, P89, DOI 10.2307/3434476; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; BACK DJ, 1980, CONTRACEPTION, V21, P145, DOI 10.1016/0010-7824(80)90126-2; Baldi E, 2000, MOL CELL ENDOCRINOL, V161, P31, DOI 10.1016/S0303-7207(99)00220-8; BARRETT JC, 1983, MUTAT RES, V107, P427; Behl C, 2000, J NEUROCYTOL, V29, P351, DOI 10.1023/A:1007109222673; BELLOMO G, 1992, P NATL ACAD SCI USA, V89, P4412, DOI 10.1073/pnas.89.10.4412; BRADLEY MO, 1985, CELL BIOL TOXICOL, V1, P181, DOI 10.1007/BF00120163; BROKAW CJ, 1984, ANN NY ACAD SCI, V438, P132, DOI 10.1111/j.1749-6632.1984.tb38282.x; BROKAW CJ, 1974, BIOCHEM BIOPH RES CO, V58, P795, DOI 10.1016/S0006-291X(74)80487-0; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; Chen YM, 2000, CHEM RES TOXICOL, V13, P342, DOI 10.1021/tx990186j; Collins AR, 2000, FREE RADICAL RES, V32, P333, DOI 10.1080/10715760000300331; DREVON C, 1981, MUTAT RES, V89, P83, DOI 10.1016/0165-1218(81)90134-8; Durkee TJ, 1998, AM J OBSTET GYNECOL, V178, P1288, DOI 10.1016/S0002-9378(98)70335-7; EWERTZ M, 1989, INT J CANCER, V43, P27, DOI 10.1002/ijc.2910430107; FACEMIRE CF, 1995, ENVIRON HEALTH PERSP, V103, P79, DOI 10.2307/3432416; Fisher JS, 1997, J ENDOCRINOL, V153, P485, DOI 10.1677/joe.0.1530485; Floreani M, 1997, FREE RADICAL RES, V26, P449, DOI 10.3109/10715769709084481; FORMAN D, 1994, CANCER SURV, V20, P323; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; FREE MJ, 1979, BIOL REPROD, V20, P269, DOI 10.1095/biolreprod20.2.269; GANJAM VK, 1976, ENDOCRINOLOGY, V99, P1618, DOI 10.1210/endo-99-6-1618; GILL WB, 1979, J UROLOGY, V122, P36, DOI 10.1016/S0022-5347(17)56240-0; GLATT HR, 1979, MUTAT RES, V67, P113, DOI 10.1016/0165-1218(79)90122-8; GUENGERICH FP, 1988, MOL PHARMACOL, V33, P500; Guillette LJ, 1999, ARCH ENVIRON CON TOX, V36, P447, DOI 10.1007/PL00006617; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HAN XL, 1994, CANCER RES, V54, P5515; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Hudson CE, 1998, CHEM-BIOL INTERACT, V112, P343, DOI 10.1016/S0009-2797(97)00171-3; Hudson EK, 1998, FREE RADICAL RES, V29, P573, DOI 10.1080/10715769800300611; *IARC WORK GROUP, 1999, IARC MON EV CARC RIS, P49; IDAOMAR M, 1989, ARCH ANDROLOGY, V22, P197, DOI 10.3109/01485018908986772; Jorgensen M, 1999, ELECTROPHORESIS, V20, P230, DOI 10.1002/1522-2683(19990201)20:2<230::AID-ELPS230>3.0.CO;2-I; Kacsoh B., 2000, ENDOCRINE PHYSL; Kuczyk MA, 1996, CANCER, V78, P1958, DOI 10.1002/(SICI)1097-0142(19961101)78:9<1958::AID-CNCR17>3.0.CO;2-X; KWON S, 1995, BIOL REPROD, V53, P1259, DOI 10.1095/biolreprod53.6.1259; LANG R, 1979, MUTAT RES, V67, P361, DOI 10.1016/0165-1218(79)90033-8; Liehr J G, 1998, Methods Mol Biol, V108, P425; LIEHR JG, 1990, FREE RADICAL BIO MED, V8, P415, DOI 10.1016/0891-5849(90)90108-U; LOBO RA, 1994, FERTIL STERIL, V61, P592; Loomis AK, 2000, BIOL REPROD, V62, P995, DOI 10.1095/biolreprod62.4.995; Luconi M, 1999, J CLIN ENDOCR METAB, V84, P1670, DOI 10.1210/jc.84.5.1670; Lunec J, 1998, FREE RADICAL RES, V29, P601, DOI 10.1080/10715769800300651; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MALINS DC, 1993, CANCER-AM CANCER SOC, V71, P3036, DOI 10.1002/1097-0142(19930515)71:10<3036::AID-CNCR2820711025>3.0.CO;2-P; McDougal A, 1998, ENVIRON HEALTH PERSP, V106, P203; Nathan L, 1998, SEMIN REPROD ENDOCR, V16, P309, DOI 10.1055/s-2007-1016289; NITTA H, 1993, ENDOCRINOLOGY, V132, P1396, DOI 10.1210/en.132.3.1396; OGAWA T, 1995, CARCINOGENESIS, V16, P831, DOI 10.1093/carcin/16.4.831; Roy D, 1999, MUTAT RES-FUND MOL M, V424, P107, DOI 10.1016/S0027-5107(99)00012-3; ROY D, 1991, CANCER RES, V51, P3882; SAI K, 1992, Journal of Environmental Pathology Toxicology and Oncology, V11, P139; Satoh T, 2000, ANAL BIOCHEM, V286, P179, DOI 10.1006/abio.1999.4775; Saunders PTK, 1998, J ENDOCRINOL, V156, pR13, DOI 10.1677/joe.0.156R013; Seacat AM, 1997, ARCH BIOCHEM BIOPHYS, V347, P45, DOI 10.1006/abbi.1997.0323; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Shen HM, 2000, FREE RADICAL BIO MED, V28, P529, DOI 10.1016/S0891-5849(99)00234-8; SHUIN T, 1994, CANCER, V73, P1721, DOI 10.1002/1097-0142(19940315)73:6<1721::AID-CNCR2820730628>3.0.CO;2-W; STAMPFER M, 1994, BRIT MED J, V309, P808, DOI 10.1136/bmj.309.6957.808b; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WANG YJ, 1995, CHEM-BIOL INTERACT, V94, P135, DOI 10.1016/0009-2797(94)03327-5; Westlind A, 2001, BIOCHEM BIOPH RES CO, V281, P1349, DOI 10.1006/bbrc.2001.4505; Yan ZJ, 1995, BIOCHEM MOL BIOL INT, V37, P175	66	34	35	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					195	201		10.1096/fj.01-0385com	http://dx.doi.org/10.1096/fj.01-0385com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11818367				2022-12-28	WOS:000174203700024
J	Altman, GH; Horan, RL; Martin I; Farhadi, J; Stark, PRH; Volloch V; Richmond, JC; Vunjak-Novakovic, G; Kaplan, DL				Altman, GH; Horan, RL; Martin, I; Farhadi, J; Stark, PRH; Volloch, V; Richmond, JC; Vunjak-Novakovic, G; Kaplan, DL			Cell differentiation by mechanical stress	FASEB JOURNAL			English	Article						mechanical stimulation; bone marrow stem cells; ligament	ANTERIOR CRUCIATE LIGAMENT; PATELLAR TENDON; EXPRESSION; RECONSTRUCTION; CARTILAGE; TENASCIN; TISSUE; LOAD	Growth factors, hormones, and other regulatory molecules are traditionally required in tissue engineering studies to direct the differentiation of progenitor cells along specific lineages. We demonstrate that mechanical stimulation in vitro, without ligament-selective exogenous growth and differentiation factors, induces the differentiation of mesenchymal progenitor cells from the bone marrow into a ligament cell lineage in preference to alternative paths (i.e., bone or cartilage cell lineages). A bioreactor was designed to permit the controlled application of ligament-like multidimensional mechanical strains (translational and rotational strain) to the undifferentiated cells embedded in a collagen gel. The application of mechanical stress over a period of 21 days up-regulated ligament fibroblast markers, including collagen types I and III and tenascin-C, fostered statistically significant cell alignment and density and resulted in the formation of oriented collagen fibers, all features characteristic of ligament cells. At the same time, no upregulation of bone or cartilage-specific cell markers was observed.	Tufts Univ, Dept Biol & Chem Engn, Ctr Bioengn, Medford, MA 02155 USA; Univ Basel Hosp, Dept Surg, Div Res, CH-4031 Basel, Switzerland; Tufts Univ New England Med Ctr, Dept Orthopaed, Boston, MA 02111 USA; MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Ctr Technol & Engn, Boston, MA USA	Tufts University; University of Basel; Tufts Medical Center; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	Kaplan, DL (corresponding author), Tufts Univ, Dept Biol & Chem Engn, Ctr Bioengn, 4 Colby St, Medford, MA 02155 USA.	david.kaplan@tufts.edu	stark, peter/G-4977-2013; Martin, Ivan/K-9286-2016	Martin, Ivan/0000-0001-6493-0432; Vunjak-Novakovic, Gordana/0000-0002-9382-1574				Aaron RK, 1996, J ORTHOP RES, V14, P582, DOI 10.1002/jor.1100140412; AMIEL D, 1986, J ORTHOPAED RES, V4, P162, DOI 10.1002/jor.1100040204; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; CHIQUETEHRISMANN R, 1994, J CELL BIOL, V127, P2093, DOI 10.1083/jcb.127.6.2093; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JM, 1990, J ORTHOPAED RES, V8, P180, DOI 10.1002/jor.1100080205; Freed L. E., 2000, PRINCIPLES TISSUE EN, P143; Goulet F, 1997, PRINCIPLES TISSUE EN, P633; JACKSON DW, 1993, AM J SPORT MED, V21, P176, DOI 10.1177/036354659302100203; Kim BS, 1999, NAT BIOTECHNOL, V17, P979, DOI 10.1038/13671; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Mackie EJ, 1996, J ANAT, V188, P157; Martin I, 2001, OSTEOARTHR CARTILAGE, V9, P112, DOI 10.1053/joca.2000.0366; Naruse K, 2000, BIOCHEM BIOPH RES CO, V268, P216, DOI 10.1006/bbrc.2000.2094; SAH RLY, 1989, J ORTHOPAED RES, V7, P619, DOI 10.1002/jor.1100070502; Sussman M, 2001, NATURE, V410, P640, DOI 10.1038/35070687; Thomas GP, 1996, CALCIFIED TISSUE INT, V58, P101, DOI 10.1007/s002239900018; Toyoda T, 1998, CLIN ORTHOP RELAT R, P247; WOO SLY, 1990, KNEE LIGAMENTS STRUC, P115	19	491	527	7	67	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					270	+		10.1096/fj.01-0656fje	http://dx.doi.org/10.1096/fj.01-0656fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11772952				2022-12-28	WOS:000172964800005
J	Diviacco, S; Rapozzi, V; Xodo, L; Helene, C; Quadrifoglio, F; Giovannangeli, C				Diviacco, S; Rapozzi, V; Xodo, L; Helene, C; Quadrifoglio, F; Giovannangeli, C			Site-directed inhibition of DNA replication by triple helix formation	FASEB JOURNAL			English	Article						peptide nucleic acid; triplex; PPT/HIV-1	NUCLEIC-ACID PNA; FORMING OLIGONUCLEOTIDES; TRANSCRIPTION ELONGATION; GENE-EXPRESSION; CROSS-LINKING; IN-VITRO; BINDING; CELLS; POLYMERASE	Sequence-specific DNA recognition can be achieved by the use of triplex-forming molecules, namely, oligonucleotides (TFO) and peptide nucleic acids (PNAs). They have been used to regulate transcription or induce genomic DNA modifications at a selected site in cells and, recently, in vivo. We have determined the conditions under which a triplex structure can inhibit DNA replication in cells. An oligopyrimidine.oligopurine sequence suitable for triplex formation was inserted in a plasmid on both sides of the SV40 origin of replication. This insert-containing plasmid was replicated in COS-1 cells together with the parent plasmid, and the ratio between the corresponding replicated DNAs was quantitated. Selective inhibition of replication of the insert-containing plasmid can be ascribed to ligand binding to the oligopyrimidine.oligopurine sequence. Inhibition of DNA replication was observed using triplex-forming molecules that induce either covalent binding at the double-stranded target sequence (with TFO-psoralen conjugate and irradiation) or noncovalent triplex formation after strand displacement (with bis-PNA). In contrast, in the absence of covalent cross-linking, TFOs (which have been shown to arrest transcription elongation) did not act on replication. These results open new perspectives for future design and use of specific inhibitors of intracellular DNA information processing.	Museum Natl Hist Nat, Biophys Lab, INSERM, U201,CNRS,UMR 8646, F-75231 Paris 05, France; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Giovannangeli, C (corresponding author), Museum Natl Hist Nat, Biophys Lab, INSERM, U201,CNRS,UMR 8646, 43 Rue Cuvier, F-75231 Paris 05, France.	giovanna@mnhn.fr	Xodo, Luigi/W-6350-2019	Xodo, Luigi/0000-0003-3344-7207; RAPOZZI, Valentina/0000-0001-7619-5252				Bailey C, 2000, NUCLEIC ACIDS RES, V28, P1154, DOI 10.1093/nar/28.5.1154; Bastide L, 1999, NUCLEIC ACIDS RES, V27, P551, DOI 10.1093/nar/27.2.551; Bentin T, 1996, BIOCHEMISTRY-US, V35, P8863, DOI 10.1021/bi960436k; BIRG F, 1990, NUCLEIC ACIDS RES, V18, P2901, DOI 10.1093/nar/18.10.2901; COGOI S, 2000, IN PRESS ANTISENSE N; Cutrona G, 2000, NAT BIOTECHNOL, V18, P300, DOI 10.1038/73745; DIVIACCO S, 1992, GENE, V122, P313, DOI 10.1016/0378-1119(92)90220-J; EGHOLM M, 1995, NUCLEIC ACIDS RES, V23, P217, DOI 10.1093/nar/23.2.217; Faria M, 2000, P NATL ACAD SCI USA, V97, P3862, DOI 10.1073/pnas.97.8.3862; Faria M, 2001, J MOL BIOL, V306, P15, DOI 10.1006/jmbi.2000.4386; Faruqi AF, 2000, MOL CELL BIOL, V20, P990, DOI 10.1128/MCB.20.3.990-1000.2000; Faruqi AF, 1997, NUCLEIC ACIDS RES, V25, P633, DOI 10.1093/nar/25.3.633; Faruqi AF, 1998, P NATL ACAD SCI USA, V95, P1398, DOI 10.1073/pnas.95.4.1398; Giovannangeli C, 2000, CURR OPIN MOL THER, V2, P288; Giovannangeli C, 1996, J MOL BIOL, V261, P386, DOI 10.1006/jmbi.1996.0471; GIOVANNANGELI C, 1992, NUCLEIC ACIDS RES, V20, P4275, DOI 10.1093/nar/20.16.4275; Giovannangeli C, 1997, P NATL ACAD SCI USA, V94, P79, DOI 10.1073/pnas.94.1.79; GIOVANNANGELI C, 1993, P NATL ACAD SCI USA, V90, P10013, DOI 10.1073/pnas.90.21.10013; GIOVANNANGELI C, 1992, P NATL ACAD SCI USA, V89, P8631, DOI 10.1073/pnas.89.18.8631; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; GUIEYSSE AL, 1995, BIOCHEM BIOPH RES CO, V217, P186, DOI 10.1006/bbrc.1995.2762; HACIA JG, 1994, BIOCHEMISTRY-US, V33, P6192, DOI 10.1021/bi00186a019; Kopel V, 1996, NUCLEIC ACIDS RES, V24, P330, DOI 10.1093/nar/24.2.330; Krasilnikov AS, 1997, NUCLEIC ACIDS RES, V25, P1339, DOI 10.1093/nar/25.7.1339; Kuhn H, 1999, J MOL BIOL, V286, P1337, DOI 10.1006/jmbi.1998.2578; Larsen HJ, 1996, NUCLEIC ACIDS RES, V24, P458, DOI 10.1093/nar/24.3.458; Luo ZJ, 2000, P NATL ACAD SCI USA, V97, P9003, DOI 10.1073/pnas.160004997; MAINE IP, 1994, BIOCHEM BIOPH RES CO, V204, P1119, DOI 10.1006/bbrc.1994.2578; Majumdar A, 1998, NAT GENET, V20, P212, DOI 10.1038/2530; NEURATH MF, 1995, P NATL ACAD SCI USA, V92, P5336, DOI 10.1073/pnas.92.12.5336; NIELSEN PE, 1993, NUCLEIC ACIDS RES, V21, P197, DOI 10.1093/nar/21.2.197; Nielsen PE, 1999, CURR OPIN STRUC BIOL, V9, P353, DOI 10.1016/S0959-440X(99)80047-5; PELEG M, 1995, NUCLEIC ACIDS RES, V23, P1292, DOI 10.1093/nar/23.8.1292; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; Porumb H, 1996, CANCER RES, V56, P515; Praseuth D, 1999, BBA-GENE STRUCT EXPR, V1489, P181, DOI 10.1016/S0167-4781(99)00149-9; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; SAMADASHWILY GM, 1994, GENE, V149, P127, DOI 10.1016/0378-1119(94)90421-9; SCAGGIANTE B, 1994, FEBS LETT, V352, P380, DOI 10.1016/0014-5793(94)00995-3; Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212; Vasquez KM, 1999, NUCLEIC ACIDS RES, V27, P1176, DOI 10.1093/nar/27.4.1176; Vasquez KM, 2000, SCIENCE, V290, P530, DOI 10.1126/science.290.5491.530; VASQUEZ KM, 1999, PERSPECT ANTISEN SCI, P167; Wang G, 1999, NUCLEIC ACIDS RES, V27, P2806, DOI 10.1093/nar/27.13.2806	44	50	55	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2660	2668		10.1096/fj.01-0440com	http://dx.doi.org/10.1096/fj.01-0440com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726542				2022-12-28	WOS:000172964800036
J	Faggioni, R; Feingold, KR; Grunfeld, C				Faggioni, R; Feingold, KR; Grunfeld, C			Leptin regulation of the immune response and the immunodeficiency of malnutrition	FASEB JOURNAL			English	Review						starvation; macrophages; lymphocytes; pleiotropic molecule	TUMOR-NECROSIS-FACTOR; CELL-MEDIATED-IMMUNITY; SERUM LEPTIN; PLASMA LEPTIN; OB/OB MICE; FACTOR-ALPHA; OBESE GENE; RECOMBINANT LEPTIN; CIRCULATING LEPTIN; PHYSIOLOGICAL-ROLE	Leptin is a 16 kDa protein mainly produced by adipose tissue in proportion to adipose tissue mass. Originally thought to be a satiety factor, leptin is a pleiotropic molecule. In addition to playing a role in energy regulation, leptin also regulates endocrine and immune functions. Both the structure of leptin and that of its receptor suggest that leptin might be classified as a cytokine. The secondary structure of leptin has similarities to the long-chain helical cytokines family, which includes interleukin 6 (IL-6), IL-11, CNTF, and LIF, and the leptin receptor is homologous to the gp-130 signal-transducing subunit of the IL-6-type cytokine receptors. Leptin plays a role in innate and acquired immunity. Leptin levels increase acutely during infection and inflammation, and may represent a protective component of the host response to inflammation. More important, leptin deficiency increases susceptibility to infectious and inflammatory stimuli and is associated with dysregulation of cytokine production. Leptin deficiency also causes a defect in hematopoiesis. Leptin regulates T cells responses, polarizing Th cells toward a Th1 phenotype. Low leptin levels occurring during starvation mediate the neuroendocrine and immune dysfunction of starvation.	Univ Calif San Francisco, Dept Vet Affairs Med Ctr, San Francisco, CA 94121 USA	University of California System; University of California San Francisco	Faggioni, R (corresponding author), Amgen Inc, 1 Amgen Ctr Dr,MS 15-2B, Newbury Pk, CA 91320 USA.	faggioni@amgen.com			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040990, R01DK049448] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-49448, R01-DK-40990] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agnello D, 1998, AM J PHYSIOL-REG I, V275, pR913, DOI 10.1152/ajpregu.1998.275.3.R913; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Ahima RS, 1998, J CLIN INVEST, V101, P1020, DOI 10.1172/JCI1176; Anders HJ, 1999, METABOLISM, V48, P745, DOI 10.1016/S0026-0495(99)90174-9; Arnalich F, 1999, J INFECT DIS, V180, P908, DOI 10.1086/314963; Barbier M, 1998, GUT, V43, P783, DOI 10.1136/gut.43.6.783; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bornstein SR, 1998, J CLIN ENDOCR METAB, V83, P280, DOI 10.1210/jc.83.1.280; Caldefie-Chezet F, 2001, J LEUKOCYTE BIOL, V69, P414; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Carlson GL, 1999, AM J PHYSIOL-ENDOC M, V276, pE658, DOI 10.1152/ajpendo.1999.276.4.E658; CASON J, 1986, CLIN EXP IMMUNOL, V64, P370; Chan J, 1996, P NATL ACAD SCI USA, V93, P14857, DOI 10.1073/pnas.93.25.14857; Chandra RK, 1996, P NATL ACAD SCI USA, V93, P14304, DOI 10.1073/pnas.93.25.14304; CHANDRA RK, 1980, FED PROC, V39, P3088; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; Faggioni R, 2000, P NATL ACAD SCI USA, V97, P2367, DOI 10.1073/pnas.040561297; Faggioni R, 2000, AM J PATHOL, V156, P1781, DOI 10.1016/S0002-9440(10)65049-3; Faggioni R, 1999, AM J PHYSIOL-REG I, V276, pR136, DOI 10.1152/ajpregu.1999.276.1.R136; Faggioni R, 1997, AM J PHYSIOL-REG I, V273, pR181, DOI 10.1152/ajpregu.1997.273.1.R181; Faggioni R, 1998, AM J PHYSIOL-REG I, V274, pR204, DOI 10.1152/ajpregu.1998.274.1.R204; Fantuzzi C, 2001, FASEB J, V15, pA1067; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Fleet JC, 2000, NUTR REV, V58, P209, DOI 10.1111/j.1753-4887.2000.tb01864.x; Flier JS, 1998, J CLIN ENDOCR METAB, V83, P1407, DOI 10.1210/jc.83.5.1407; Francis J, 1999, ENDOCRINE, V10, P291, DOI 10.1007/BF02738628; Frank S, 2000, J CLIN INVEST, V106, P501, DOI 10.1172/JCI9148; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gabay C, 2001, J CLIN ENDOCR METAB, V86, P783, DOI 10.1210/jc.86.2.783; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; GARTHWAITE TL, 1980, ENDOCRINOLOGY, V107, P671, DOI 10.1210/endo-107-3-671; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Granowitz EV, 1999, J INFECT DIS, V179, P1313, DOI 10.1086/314740; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Grunfeld C, 1996, J CLIN ENDOCR METAB, V81, P4342, DOI 10.1210/jc.81.12.4342; Gualillo O, 2000, LIFE SCI, V67, P2433, DOI 10.1016/S0024-3205(00)00827-4; Guebre-Xabier M, 2000, HEPATOLOGY, V31, P633, DOI 10.1002/hep.510310313; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Heiman ML, 1997, ENDOCRINOLOGY, V138, P3859, DOI 10.1210/en.138.9.3859; Hoppin AG, 1998, J PEDIATR GASTR NUTR, V26, P500, DOI 10.1097/00005176-199805000-00003; Howard JK, 1999, J CLIN INVEST, V104, P1051, DOI 10.1172/JCI6762; Huang L, 2001, J BIOL CHEM, V276, P6343, DOI 10.1074/jbc.M009795200; Janik JE, 1997, J CLIN ENDOCR METAB, V82, P3084, DOI 10.1210/jc.82.9.3084; Kaibara A, 1998, AM J PHYSIOL-REG I, V274, pR1518, DOI 10.1152/ajpregu.1998.274.6.R1518; Kastin AJ, 1999, PEPTIDES, V20, P1449, DOI 10.1016/S0196-9781(99)00156-4; Kher A S, 1990, J Postgrad Med, V36, P48; Konopleva M, 1999, BLOOD, V93, P1668, DOI 10.1182/blood.V93.5.1668.405a15_1668_1676; Lammert A, 2001, BIOCHEM BIOPH RES CO, V283, P982, DOI 10.1006/bbrc.2001.4885; Ledru E, 2000, BLOOD, V95, P3191, DOI 10.1182/blood.V95.10.3191.010k10_3191_3198; Lee FYJ, 1999, AM J PHYSIOL-CELL PH, V276, pC386, DOI 10.1152/ajpcell.1999.276.2.C386; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Moshyedi AK, 1998, INFECT IMMUN, V66, P1800, DOI 10.1128/IAI.66.4.1800-1802.1998; Ozata M, 1999, J CLIN ENDOCR METAB, V84, P3686, DOI 10.1210/jc.84.10.3686; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; QUI J, 2001, ENDOCRINOLOGY, V142, P348; Ring BD, 2000, ENDOCRINOLOGY, V141, P446, DOI 10.1210/en.141.1.446; Safrin S, 1999, AIDS, V13, P2493, DOI 10.1097/00002030-199912240-00002; Sarraf P, 1997, J EXP MED, V185, P171, DOI 10.1084/jem.185.1.171; Schwartz MW, 1997, NEW ENGL J MED, V336, P1802, DOI 10.1056/NEJM199706193362507; Seip M, 1996, ACTA PAEDIATR, V85, P2, DOI 10.1111/j.1651-2227.1996.tb14262.x; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Sinha MK, 1996, J CLIN INVEST, V98, P1277, DOI 10.1172/JCI118913; Spinedi E, 1998, ENDOCRINOLOGY, V139, P4016, DOI 10.1210/en.139.9.4016; Takahashi N, 1999, J EXP MED, V189, P207, DOI 10.1084/jem.189.1.207; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Torpy DJ, 1998, HORM METAB RES, V30, P726, DOI 10.1055/s-2007-978967; Tsuchiya T, 1999, EUR J PHARMACOL, V365, P273, DOI 10.1016/S0014-2999(98)00884-X; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Wallace AM, 2000, CYTOKINE, V12, P1042, DOI 10.1006/cyto.2000.0674; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zumbach MS, 1997, J CLIN ENDOCR METAB, V82, P4080, DOI 10.1210/jc.82.12.4080	90	377	401	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2565	2571		10.1096/fj.01-0431rev	http://dx.doi.org/10.1096/fj.01-0431rev			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726531				2022-12-28	WOS:000172964800025
J	Ricciarelli, R; Zingg, JM; Azzi, A				Ricciarelli, R; Zingg, JM; Azzi, A			Vitamin E: protective role of a Janus molecule	FASEB JOURNAL			English	Review						tocopherol; antioxidant; atherosclerosis; intervention trials	TOCOPHEROL TRANSFER PROTEIN; LOW-DENSITY-LIPOPROTEIN; D-ALPHA-TOCOPHEROL; INTIMA-MEDIA THICKNESS; SMOOTH-MUSCLE-CELL; KINASE-C; GAMMA-TOCOPHEROL; E-DEFICIENCY; MYOCARDIAL-INFARCTION; PLATELET-AGGREGATION	Since the discovery of vitamin E in 1922, its deficiency has been associated with various disorders, particularly atherosclerosis, ischemic heart disease, and the development of different types of cancer. A neurological syndrome associated with vitamin E deficiency resembling Friedreich ataxia has also been described. Whereas epidemiological studies have indicated the role of vitamin E in preventing the progression of atherosclerosis and cancer, intervention trials have produced contradictory results, indicating strong protection in some cases and no significant effect in others. Although it is commonly believed that phenolic compounds like vitamin E exert only a protective role against free radical damage, antioxidant molecules can exert other biological functions. For instance, the antioxidant activity of 17-beta -estradiol is not related to its role in determining secondary sexual characters, and the antioxidant capacity of all-trans-retinal is distinguished from its role in rhodopsin and vision. Thus, it is not unusual that alpha -tocopherol (the most active form of vitamin E) has properties independent of its antioxidant/radical scavenging ability. The Roman god Janus, shown in ancient coins as having two faces in one body, inspired the designation of 'Janus molecules' for these substances. The new biochemical face of vitamin E was first described in 1991, with an inhibitory effect on cell proliferation and protein kinase C activity. After a decade, this nonantioxidant role of vitamin E is well established, as confirmed by authoritative studies of signal transduction and gene regulation. More recently, a tocopherol binding protein with possible receptor function has been discovered. Despite such important developments in understanding the molecular mechanism and the targets of vitamin E, its new Janus face is not fully elucidated. Greater knowledge of the molecular events related to vitamin E will help in selecting the parameters for clinical intervention studies such as population type, dose response effects, and possible synergism with other compounds.	Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland	University of Bern	Azzi, A (corresponding author), Univ Bern, Inst Biochem & Mol Biol, Buhlstr 28, CH-3012 Bern, Switzerland.	angelo.azzi@mci.unibe.ch	Zingg, Jean-Marc/H-6960-2019; Ricciarelli, Roberta/AAE-8063-2019	Ricciarelli, Roberta/0000-0002-2053-2501	Fondazione Telethon Funding Source: Custom; Telethon [360/B] Funding Source: Medline	Fondazione Telethon(Fondazione Telethon); Telethon(Fondazione Telethon)		Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; Aratri E, 1999, FEBS LETT, V447, P91, DOI 10.1016/S0014-5793(99)00277-X; Azen SP, 1996, CIRCULATION, V94, P2369, DOI 10.1161/01.CIR.94.10.2369; Azzi A, 1998, Z ERNAHRUNGSWISS, V37, P21; Bauernfeind J., 1980, Vitamin E, P99; BAUERNFEIND JC, 1970, INT Z VITAMINFORSCH, V40, P391; BEHRENS WA, 1982, AM J CLIN NUTR, V35, P691, DOI 10.1093/ajcn/35.4.691; BENHAMIDA C, 1993, NAT GENET, V5, P195, DOI 10.1038/ng1093-195; Benomar A, 1999, J NEUROL SCI, V162, P97, DOI 10.1016/S0022-510X(98)00284-6; Benson GM, 1998, ATHEROSCLEROSIS, V141, P237, DOI 10.1016/S0021-9150(98)00177-4; Bird DA, 1998, J LIPID RES, V39, P1079; BLANKENHORN DH, 1987, CONTROL CLIN TRIALS, V8, P354, DOI 10.1016/0197-2456(87)90156-5; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; Boaz M, 2000, LANCET, V356, P1213, DOI 10.1016/S0140-6736(00)02783-5; BonithonKopp C, 1997, AM J CLIN NUTR, V65, P121, DOI 10.1093/ajcn/65.1.121; BOSCOBOINIK D, 1991, J BIOL CHEM, V266, P6188; BOWRY VW, 1992, BIOCHEM J, V288, P341, DOI 10.1042/bj2880341; Brigelius-Flohe R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145; Brown M, 1999, LANCET, V354, P441, DOI 10.1016/S0140-6736(99)00253-6; Cachia O, 1998, ATHEROSCLEROSIS, V138, P263, DOI 10.1016/S0021-9150(98)00028-8; Cachia O, 1998, J BIOL CHEM, V273, P32801, DOI 10.1074/jbc.273.49.32801; Cattin L, 1997, ARTERIOSCL THROM VAS, V17, P91, DOI 10.1161/01.ATV.17.1.91; Cavalier L, 1998, AM J HUM GENET, V62, P301, DOI 10.1086/301699; Chojkier M, 1998, AM J PHYSIOL-GASTR L, V275, pG1480, DOI 10.1152/ajpgi.1998.275.6.G1480; Christen S, 1997, P NATL ACAD SCI USA, V94, P3217, DOI 10.1073/pnas.94.7.3217; Clement S, 1997, EUR J BIOCHEM, V246, P745, DOI 10.1111/j.1432-1033.1997.t01-2-00745.x; Copp RP, 1999, BRAIN RES, V822, P80, DOI 10.1016/S0006-8993(99)01090-2; Devaraj S, 2001, J LIPID RES, V42, P521; Devaraj S, 1996, J CLIN INVEST, V98, P756, DOI 10.1172/JCI118848; Devaraj S, 1997, ARTERIOSCL THROM VAS, V17, P2273, DOI 10.1161/01.ATV.17.10.2273; Devaraj S, 1999, ARTERIOSCL THROM VAS, V19, P1125, DOI 10.1161/01.ATV.19.4.1125; Dutta-Roy AK, 1999, FOOD CHEM TOXICOL, V37, P967, DOI 10.1016/S0278-6915(99)00081-2; DUTTAROY AK, 1993, BIOCHEM BIOPH RES CO, V196, P1108, DOI 10.1006/bbrc.1993.2365; Esterbauer H, 1997, Adv Pharmacol, V38, P425; Evans HM, 1922, SCIENCE, V56, P650, DOI 10.1126/science.56.1458.650; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Freedman JE, 1996, CIRCULATION, V94, P2434, DOI 10.1161/01.CIR.94.10.2434; GEY KF, 1990, BIOCHEM SOC T, V18, P1041, DOI 10.1042/bst0181041; GEY KF, 1993, EPIDEMIOLOGICAL BASI; Goss SPA, 1999, ARCH BIOCHEM BIOPHYS, V363, P333, DOI 10.1006/abbi.1998.1094; Goti D, 1998, BIOCHEM J, V332, P57, DOI 10.1042/bj3320057; Goti D, 2001, J NEUROCHEM, V76, P498, DOI 10.1046/j.1471-4159.2001.00100.x; GOTODA T, 1995, NEW ENGL J MED, V333, P1313, DOI 10.1056/NEJM199511163332003; Halliwell B, 2000, LANCET, V355, P1179, DOI 10.1016/S0140-6736(00)02075-4; Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440; HENSE HW, 1993, ATHEROSCLEROSIS, V103, P21, DOI 10.1016/0021-9150(93)90036-T; Hodis HN, 1996, CIRCULATION, V94, P2311; Hosomi A, 1997, FEBS LETT, V409, P105, DOI 10.1016/S0014-5793(97)00499-7; Ilveskoski E, 2000, ATHEROSCLEROSIS, V153, P155, DOI 10.1016/S0021-9150(00)00388-9; Islam KN, 1998, CIRCULATION, V98, P2255, DOI 10.1161/01.CIR.98.21.2255; Iuliano L, 2000, CIRCULATION, V101, P1249, DOI 10.1161/01.CIR.101.11.1249; Jialal I, 2001, J NUTR, V131, p389S, DOI 10.1093/jn/131.2.389S; Jialal I, 1999, LANCET, V354, P1554, DOI 10.1016/S0140-6736(99)90191-5; Jishage K, 2001, J BIOL CHEM, V276, P1669, DOI 10.1074/jbc.C000676200; Jorge PAR, 1998, ATHEROSCLEROSIS, V140, P333, DOI 10.1016/S0021-9150(98)00137-3; KARDINAAL AFM, 1993, LANCET, V342, P1379, DOI 10.1016/0140-6736(93)92751-E; KAYDEN HJ, 1993, J LIPID RES, V34, P343; KEANEY JF, 1994, J CLIN INVEST, V93, P844, DOI 10.1172/JCI117039; Keaney JF, 1999, FASEB J, V13, P965, DOI 10.1096/fasebj.13.9.965; Kolleck I, 1999, FREE RADICAL BIO MED, V27, P882, DOI 10.1016/S0891-5849(99)00139-2; KOSTNER GM, 1995, BIOCHEM J, V305, P659, DOI 10.1042/bj3050659; Koya D, 1997, J AM SOC NEPHROL, V8, P426; Labauge P, 1998, REV NEUROL-FRANCE, V154, P339; Lee IK, 1999, DIABETES RES CLIN PR, V45, P183, DOI 10.1016/S0168-8227(99)00048-0; Lonn EM, 2001, CIRCULATION, V103, P919; Mabile L, 1999, ATHEROSCLEROSIS, V147, P177, DOI 10.1016/S0021-9150(99)00169-0; Martin A, 1997, ARTERIOSCL THROM VAS, V17, P429, DOI 10.1161/01.ATV.17.3.429; Martin-Nizard F, 1998, J Cardiovasc Risk, V5, P339, DOI 10.1097/00043798-199810000-00010; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; Neuzil J, 2001, FASEB J, V15, P403, DOI 10.1096/fj.00-0251com; Ng W, 1999, LANCET, V354, P1555, DOI 10.1016/S0140-6736(05)76584-3; Ozer NK, 1998, FREE RADICAL BIO MED, V24, P226, DOI 10.1016/S0891-5849(97)00136-6; Packer L, 2001, J NUTR, V131, p369S, DOI 10.1093/jn/131.2.369S; Perugini C, 2000, PHARMACOL RES, V41, P55; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Pryor WA, 2000, FREE RADICAL BIO MED, V28, P141, DOI 10.1016/S0891-5849(99)00224-5; PRYOR WA, 1993, J ORG CHEM, V58, P3521, DOI 10.1021/jo00065a013; Rexrode K M, 1996, J Cardiovasc Risk, V3, P363; Ricciarelli R, 2000, CIRCULATION, V102, P82, DOI 10.1161/01.CIR.102.1.82; Ricciarelli R, 1998, BIOCHEM J, V334, P243, DOI 10.1042/bj3340243; Ricciarelli R, 1999, FREE RADICAL BIO MED, V27, P729, DOI 10.1016/S0891-5849(99)00007-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Saldeen T, 1999, J AM COLL CARDIOL, V34, P1208, DOI 10.1016/S0735-1097(99)00333-2; Salen P, 1999, LANCET, V354, P1555, DOI 10.1016/S0140-6736(05)76583-1; Salonen JT, 2000, J INTERN MED, V248, P377, DOI 10.1046/j.1365-2796.2000.00752.x; SALONEN JT, 1993, CIRCULATION, V87, P56; Sattler W, 1996, BIOCHEM J, V318, P15, DOI 10.1042/bj3180015; SELZER RH, 1994, ATHEROSCLEROSIS, V111, P1, DOI 10.1016/0021-9150(94)90186-4; Shaw HM, 1998, J NUTR, V128, P2348, DOI 10.1093/jn/128.12.2348; Shwaery GT, 1997, CIRCULATION, V95, P1378; Sigounas G, 1997, NUTR CANCER, V28, P30, DOI 10.1080/01635589709514549; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Steiner M, 1997, J CELL PHYSIOL, V172, P351; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Stocker R, 1999, TRENDS BIOCHEM SCI, V24, P219, DOI 10.1016/S0968-0004(99)01404-8; Tada H, 1997, METABOLISM, V46, P779, DOI 10.1016/S0026-0495(97)90122-0; Tamaru Y, 1997, NEUROLOGY, V49, P584, DOI 10.1212/WNL.49.2.584; Tasinato A, 1995, P NATL ACAD SCI USA, V92, P12190, DOI 10.1073/pnas.92.26.12190; Terasawa Y, 2000, P NATL ACAD SCI USA, V97, P13830, DOI 10.1073/pnas.240462697; Tesoriere L, 1997, ARCH BIOCHEM BIOPHYS, V343, P13, DOI 10.1006/abbi.1997.0128; Teupser D, 1999, ATHEROSCLEROSIS, V144, P109, DOI 10.1016/S0021-9150(99)00040-4; TRABER MG, 1989, AM J CLIN NUTR, V49, P517, DOI 10.1093/ajcn/49.3.517; TRABER MG, 1992, J LIPID RES, V33, P1171; Upston JM, 1999, FASEB J, V13, P977, DOI 10.1096/fasebj.13.9.977; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; VERLANGIERI AJ, 1992, J AM COLL NUTR, V11, P131; Virtamo J, 1998, ARCH INTERN MED, V158, P668, DOI 10.1001/archinte.158.6.668; Williams JC, 1997, INT J EXP PATHOL, V78, P259, DOI 10.1046/j.1365-2613.1997.260359.x; WILLIAMS RJ, 1992, ATHEROSCLEROSIS, V94, P153, DOI 10.1016/0021-9150(92)90240-H; Witting P, 1999, J CLIN INVEST, V104, P213, DOI 10.1172/JCI6391; Wolf G, 1997, NUTR REV, V55, P376, DOI 10.1111/j.1753-4887.1997.tb01566.x; Wu CG, 1997, INT J CANCER, V71, P686, DOI 10.1002/(SICI)1097-0215(19970516)71:4<686::AID-IJC28>3.0.CO;2-8; Wu DY, 2001, J NUTR, V131, p382S, DOI 10.1093/jn/131.2.382S; Wu DY, 1999, ATHEROSCLEROSIS, V147, P297, DOI 10.1016/S0021-9150(99)00199-9; Yokota T, 1997, ANN NEUROL, V41, P826, DOI 10.1002/ana.410410621; Yokota T, 2000, J NEUROL NEUROSUR PS, V68, P521, DOI 10.1136/jnnp.68.4.521; Yoshida N, 1999, J LEUKOCYTE BIOL, V65, P757, DOI 10.1002/jlb.65.6.757; Yoshikawa T, 1998, BIOFACTORS, V7, P15, DOI 10.1002/biof.5520070103; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; Zimmer S, 2000, J BIOL CHEM, V275, P25672, DOI 10.1074/jbc.M000851200	121	222	228	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2314	2325		10.1096/fj.01-0258rev	http://dx.doi.org/10.1096/fj.01-0258rev			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689457				2022-12-28	WOS:000172420500002
J	Hartlapp, I; Abe, R; Saeed, RW; Peng, T; Voelter, W; Bucala, R; Metz, CN				Hartlapp, I; Abe, R; Saeed, RW; Peng, T; Voelter, W; Bucala, R; Metz, CN			Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo	FASEB JOURNAL			English	Article						fibroblast; antigen; MMP-9; wound healing; neovascularization	FIBROBLAST-GROWTH-FACTOR; PERIPHERAL-BLOOD FIBROCYTES; MATRIX METALLOPROTEINASES; TUMOR ANGIOGENESIS; BASEMENT-MEMBRANE; DOWN-REGULATION; IN-VITRO; EXPRESSION; INTERFERON; INVITRO	Angiogenesis is an ordered process requiring the inter-play of numerous cellular and humoral factors. Studies over the past 20 years have identified several growth factors, cytokines, and enzymes that promote blood vessel formation. Most have revealed how individual factors promote an angiogenic phenotype in endothelial cells in vitro or contribute to blood vessel formation in vivo. However, the fundamental question that remains unanswered is how the cellular microenvironment contributes to angiogenesis. Fibrocytes are a recently characterized mesenchymal cell type isolated from peripheral blood that rapidly enter subcutaneously implanted wound chambers and sites of tissue injury. Here we describe the induction of an angiogenic phenotype in microvascular endothelial cells in vitro and promotion of angiogenesis in vivo by cultured fibrocytes. Fibrocytes constitutively secrete extracellular matrix-degrading enzymes, primarily matrix metalloproteinase 9, which promotes endothelial cell invasion. In addition, fibrocytes secrete several proangiogenic factors including VEGF, bFGF, IL-8, PDGF, and hematopoietic growth factors that promote endothelial cell migration, proliferation, and/or tube formation. By contrast, they do not produce representative antiangiogenic factors. Finally, both autologous fibrocytes and fibrocyte-conditioned media were found to induce blood vessel formation in vivo using the Matrigel angiogenesis model.	Picower Inst Med Res, Lab Vasc Biol, Manhasset, NY 11030 USA; Univ Tubingen, Tubingen, Germany	Northwell Health; Eberhard Karls University of Tubingen	Metz, CN (corresponding author), Picower Inst Med Res, Lab Vasc Biol, 350 Community Dr, Manhasset, NY 11030 USA.	cmetz@picower.edu	Abe, Riichiro/A-5450-2012	Christine, Metz/0000-0002-1013-1691				Abe R, 2001, J IMMUNOL, V166, P7556, DOI 10.4049/jimmunol.166.12.7556; AGREN MS, 1994, BRIT J DERMATOL, V131, P634, DOI 10.1111/j.1365-2133.1994.tb04974.x; Baatout S, 1996, Rom J Intern Med, V34, P263; Baatout S, 1997, ANTICANCER RES, V17, P451; Brown KJ, 1996, LAB INVEST, V75, P539; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; BUSSOLINO F, 1991, J CLIN INVEST, V87, P986, DOI 10.1172/JCI115107; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; Chesney J, 1997, P NATL ACAD SCI USA, V94, P6307, DOI 10.1073/pnas.94.12.6307; Chesney J, 1998, J IMMUNOL, V160, P419; DAVIDSON JM, 1992, INFLAMMATION BASIC P, P809; Dentelli P, 1999, J IMMUNOL, V163, P2151; Dinney CPN, 1998, CANCER RES, V58, P808; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Gebauer G, 1998, ANTICANCER RES, V18, P1191; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; Goke M, 1998, AM J PHYSIOL-GASTR L, V274, pG809, DOI 10.1152/ajpgi.1998.274.5.G809; Grab DJ, 1999, MOL MED, V5, P46, DOI 10.1007/BF03402138; Harris SR, 1998, IN VIVO, V12, P563; HEYNS AD, 1985, EXP CELL RES, V161, P297, DOI 10.1016/0014-4827(85)90087-4; Ito Y, 1996, INT J CANCER, V67, P148, DOI 10.1002/(SICI)1097-0215(19960703)67:1<148::AID-IJC24>3.3.CO;2-6; Kahari VM, 1997, EXP DERMATOL, V6, P199, DOI 10.1111/j.1600-0625.1997.tb00164.x; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; Kumar R, 1998, INT J ONCOL, V12, P749; Madlener M, 1998, ARCH DERMATOL RES, V290, pS24, DOI 10.1007/PL00007450; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; Nilsen EM, 1998, GUT, V42, P635, DOI 10.1136/gut.42.5.635; PASSANITI A, 1992, LAB INVEST, V67, P519; PETZELBAUER P, 1995, CYTOKINE, V7, P267, DOI 10.1006/cyto.1995.0031; Riedel F, 2000, HEAD NECK-J SCI SPEC, V22, P183, DOI 10.1002/(SICI)1097-0347(200003)22:2<183::AID-HED11>3.0.CO;2-R; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; SALO T, 1994, LAB INVEST, V70, P176; SATO N, 1990, J INVEST DERMATOL, V95, pS85, DOI 10.1111/1523-1747.ep12874809; Sigounas G, 1997, ANGIOLOGY, V48, P141, DOI 10.1177/000331979704800207; Slaton JW, 1999, CLIN CANCER RES, V5, P2726; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410	36	204	228	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2215	2224		10.1096/fj.01-0049com	http://dx.doi.org/10.1096/fj.01-0049com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641248				2022-12-28	WOS:000171920400033
J	Im, SH; Barchan, D; Maiti, PK; Raveh, L; Souroujon, MC; Fuchs, S				Im, SH; Barchan, D; Maiti, PK; Raveh, L; Souroujon, MC; Fuchs, S			Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18	FASEB JOURNAL			English	Article						autoimmunity; interleukin 18; cytokines and costimulatory factors; immunotherapy; MG	INTERLEUKIN-1-BETA CONVERTING-ENZYME; ALKALINE-PHOSPHATASE ACTIVITY; ACETYLCHOLINE-RECEPTOR; IFN-GAMMA; CD40 LIGAND; INTERFERON-GAMMA; MONOCLONAL-ANTIBODIES; RECOMBINANT FRAGMENT; NASAL TOLERANCE; EXPRESSION	Interleukin-18 (IL-18) is a pleiotropic proinflammatory cytokine that plays an important role in interferon gamma (IFN-gamma) production and IL-12-driven Th1 phenotype polarization. Increased expression of IL-18 has been observed in several autoimmune diseases. In this study we have analyzed the role of IL-18 in an antibody-mediated autoimmune disease and elucidated the mechanisms involved in disease suppression mediated by blockade of IL-18, using experimental autoimmune myasthenia gravis (EAMG) as a model. EAMG is a T cell-regulated, antibody-mediated autoimmune disease in which the nicotinic acetylcholine receptor (AChR) is the major autoantigen. Th1- and Th2-type responses are both implicated in EAMG development. We show that treatment by anti-IL-18 during ongoing EAMG suppresses disease progression. The protective effect can be adoptively transferred to naive recipients and is mediated by increased levels of the immunosuppressive Th3-type cytokine TGF-beta and decreased AChR-specific Th1-type cellular responses. Suppression of EAMG is accompanied by down-regulation of the costimulatory factor CD40L and up-regulation of CTLA-4, a key negative immunomodulator. Our results suggest that IL-18 blockade may potentially be applied for immunointervention in myasthenia gravis.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Open Univ, IL-61392 Tel Aviv, Israel; Israel Inst Biol Res, IL-74100 Ness Ziona, Israel	Weizmann Institute of Science; Open University Israel	Fuchs, S (corresponding author), Weizmann Inst Sci, Dept Immunol, Wolfson Bldg,Room 404, IL-76100 Rehovot, Israel.	sara.fuchs@weizmann.ac.il	Im, Sin-Hyeog/E-6811-2013; Im, Sin-Hyeog/AAM-9586-2021	Im, Sin-Hyeog/0000-0002-3173-1856; Im, Sin-Hyeog/0000-0002-3173-1856				AHARONOV A, 1977, IMMUNOCHEMISTRY, V14, P129, DOI 10.1016/0019-2791(77)90291-9; Andre-Schmutz I, 1999, EUR J IMMUNOL, V29, P245, DOI 10.1002/(SICI)1521-4141(199901)29:01<245::AID-IMMU245>3.3.CO;2-F; Balasa B, 1997, J EXP MED, V186, P385, DOI 10.1084/jem.186.3.385; Barchan D, 1999, P NATL ACAD SCI USA, V96, P8086, DOI 10.1073/pnas.96.14.8086; Bright JJ, 1998, J IMMUNOL, V161, P1772; Christadoss P, 2000, CLIN IMMUNOL, V94, P75, DOI 10.1006/clim.1999.4807; Dinarello CA, 1999, METHODS, V19, P121, DOI 10.1006/meth.1999.0837; Grewal IS, 1996, IMMUNOL REV, V153, P85, DOI 10.1111/j.1600-065X.1996.tb00921.x; GU DL, 1995, J EXP MED, V181, P547, DOI 10.1084/jem.181.2.547; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; HASHIMOTO N, 1986, J IMMUNOL METHODS, V90, P97; Im SH, 2000, J NEUROIMMUNOL, V111, P161, DOI 10.1016/S0165-5728(00)00395-7; Im SH, 2000, J IMMUNOL, V165, P3599, DOI 10.4049/jimmunol.165.7.3599; Im SH, 1999, J CLIN INVEST, V104, P1723, DOI 10.1172/JCI8121; Im SH, 2001, J IMMUNOL, V166, P6893, DOI 10.4049/jimmunol.166.11.6893; Jander S, 1998, J NEUROIMMUNOL, V91, P93, DOI 10.1016/S0165-5728(98)00162-3; Karachunski PI, 2000, J IMMUNOL, V164, P5236, DOI 10.4049/jimmunol.164.10.5236; KASYAPA CS, 1992, IMMUNOL LETT, V33, P3151; KASYAPA CSS, 1992, IMMUNOL LETT, V31, P111, DOI 10.1016/0165-2478(92)90136-C; King C, 1998, IMMUNITY, V8, P601, DOI 10.1016/S1074-7613(00)80565-8; Kohka H, 1998, J LEUKOCYTE BIOL, V64, P519, DOI 10.1002/jlb.64.4.519; Lebel-Binay S, 2000, EUR CYTOKINE NETW, V11, P15; Moller B, 2001, RHEUMATOLOGY, V40, P302, DOI 10.1093/rheumatology/40.3.302; Monteleone G, 1999, J IMMUNOL, V163, P143; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; Perez VL, 1997, IMMUNITY, V6, P411, DOI 10.1016/S1074-7613(00)80284-8; Schultze JL, 1999, J EXP MED, V189, P1, DOI 10.1084/jem.189.1.1; Shi FD, 2000, NAT IMMUNOL, V1, P245, DOI 10.1038/79792; Shi FD, 1998, EUR J IMMUNOL, V28, P3587, DOI 10.1002/(SICI)1521-4141(199811)28:11<3587::AID-IMMU3587>3.3.CO;2-P; Shi FD, 1998, CLIN EXP IMMUNOL, V111, P506; SOUROUJON MC, 1983, MUSCLE NERVE, V6, P303, DOI 10.1002/mus.880060410; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Taniguchi M, 1997, J IMMUNOL METHODS, V206, P107, DOI 10.1016/S0022-1759(97)00094-X; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wildbaum G, 1998, J IMMUNOL, V161, P6368; Yin DL, 1999, J IMMUNOL, V163, P4328; Yoshimoto T, 1998, J IMMUNOL, V161, P3400; Zhang GX, 1999, J IMMUNOL, V162, P3775	40	41	51	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2140	2148		10.1096/fj.01-0072com	http://dx.doi.org/10.1096/fj.01-0072com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641240				2022-12-28	WOS:000171920400025
J	Johnson, AJ; Upshaw, J; Pavelko, KD; Rodriguez, M; Pease, LR				Johnson, AJ; Upshaw, J; Pavelko, KD; Rodriguez, M; Pease, LR			Preservation of motor function by inhibition of CD8+virus peptide-specific T cells in Theiler's virus infection	FASEB JOURNAL			English	Article						class I molecules; multiple sclerosis; immunodominant peptide; neurological deficit; central nervous system	CENTRAL-NERVOUS-SYSTEM; PERFORIN-DEFICIENT MICE; INDUCED DEMYELINATION; MULTIPLE-SCLEROSIS; LYMPHOCYTIC CHORIOMENINGITIS; INTERFERON-ALPHA/BETA; PERSISTENT INFECTION; MURINE MODEL; VIRAL MODEL; EPITOPE	Central nervous system-infiltrating CD8+ T cells are potential mediators of neuropathology in models of multiple sclerosis induced by Theiler's murine encephalomyelitis virus (TMEV) infection. C57BL/6 mice mount a vigorous cytotoxic T lymphocyte (CTL) response against the immunodominant virus peptide VP2(121-130) and clear TMEV infection. Interferon-gamma (IFN-gamma )R-/- mice also mount a strong CTL response against the VP2(121-130) epitope, but because of genetic deficiencies in critical IFN-gamma signaling pathways, they do not clear TMEV infection and develop prominent neurological deficits within 6 wk. This pronounced disease process, coupled with a defined CTL response, provides an ideal model for evaluating the importance of antiviral CTL activity in the development of severe demyelination and loss of motor neuron function. By administering the VP2(121-130) peptide before and during TMEV infection, 99% of the VP2(121-130)-specific CD8+ T cell response was inhibited. No decrease in virus infection was observed. Peptide treatment did result in significantly less motor dysfunction, even when no differences in levels of demyelination were observed. Although most investigators focus on the role of CD4+ T cells in demyelinating disease, these studies are the first to demonstrate a clear contribution of antiviral CD8+ T cells in neurological injury in a chronic-progressive model of multiple sclerosis.	Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Pease, LR (corresponding author), Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.	pease.larry@mayo.edu	Pavelko, Kevin D/K-7072-2019	Pavelko, Kevin D/0000-0001-7555-1315; Rodriguez, Moses/0000-0001-6328-6497				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ATLINTAS A, 1993, J IMMUNOL, V151, P2803; Aubagnac S, 1999, J VIROL, V73, P7965, DOI 10.1128/JVI.73.10.7965-7971.1999; Borson ND, 1997, J VIROL, V71, P5244, DOI 10.1128/JVI.71.7.5244-5250.1997; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; Carter RJ, 1999, J NEUROSCI, V19, P3248; CASTRO RF, 1995, J VIROL, V69, P8127, DOI 10.1128/JVI.69.12.8127-8131.1995; DOHERTY PC, 1974, TRANSPLANT REV-DENMA, V19, P89; DOHERTY PC, 1988, CELL IMMUNOL, V116, P475, DOI 10.1016/0008-8749(88)90246-8; FIETTE L, 1995, J EXP MED, V181, P2069, DOI 10.1084/jem.181.6.2069; FIETTE L, 1993, J VIROL, V67, P589, DOI 10.1128/JVI.67.1.589-592.1993; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Johnson AJ, 1999, J VIROL, V73, P3702, DOI 10.1128/JVI.73.5.3702-3708.1999; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Katz-Levy Y, 1999, J CLIN INVEST, V104, P599, DOI 10.1172/JCI7292; LarssonSciard EL, 1997, J VIROL, V71, P797, DOI 10.1128/JVI.71.1.797-799.1997; LECH K, 1987, CURRENT PROTOCOLS MO; LINDSLEY MD, 1989, J IMMUNOL, V142, P2677; LINDSLEY MD, 1992, MAYO CLIN PROC, V67, P829, DOI 10.1016/S0025-6196(12)60820-9; Magee CC, 1997, CURR OPIN IMMUNOL, V9, P669, DOI 10.1016/S0952-7915(97)80047-7; McGavern DB, 1999, EXP NEUROL, V158, P171, DOI 10.1006/exnr.1999.7082; Melero I, 1997, J VIROL, V71, P3998, DOI 10.1128/JVI.71.5.3998-4004.1997; Miller DJ, 1995, J NEUROSCI, V15, P8345; Miller SD, 1997, NAT MED, V3, P1133, DOI 10.1038/nm1097-1133; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Murray PD, 1998, J NEUROSCI, V18, P7306; Murray PD, 1998, J VIROL, V72, P7320, DOI 10.1128/JVI.72.9.7320-7329.1998; Njenga MK, 1997, LAB INVEST, V77, P71; Njenga MK, 1997, J VIROL, V71, P8592, DOI 10.1128/JVI.71.11.8592-8601.1997; PEWE L, 1996, IMMUNITY, V5, P352; PIERCE M, 1989, J HISTOTECHNOL, V12, P35; PULLEN LC, 1993, EUR J IMMUNOL, V23, P2287, DOI 10.1002/eji.1830230935; Rivera-Quinones C, 1998, NAT MED, V4, P187, DOI 10.1038/nm0298-187; RODRIGUEZ M, 1993, J IMMUNOL, V151, P266; RODRIGUEZ M, 1988, J IMMUNOL, V140, P2950; RODRIGUEZ M, 1991, J IMMUNOL, V146, P2596; RODRIGUEZ M, 1985, J IMMUNOL, V135, P2145; RODRIGUEZ M, 1983, ANN NEUROL, V13, P426, DOI 10.1002/ana.410130409; Rodriguez M, 1996, J IMMUNOL, V157, P5699; RODRIGUEZ M, 1986, IMMUNOL TODAY, V7, P9; Rolland J, 1998, CURR OPIN IMMUNOL, V10, P640, DOI 10.1016/S0952-7915(98)80082-4; Rossi CP, 1998, J VIROL, V72, P4515; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Vanderlugt CL, 1998, IMMUNOL REV, V164, P63, DOI 10.1111/j.1600-065X.1998.tb01208.x; Velders MP, 1998, CRIT REV IMMUNOL, V18, P7, DOI 10.1615/CritRevImmunol.v18.i1-2.30; Wu GF, 2000, J IMMUNOL, V165, P2278, DOI 10.4049/jimmunol.165.4.2278	47	58	60	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2760	+		10.1096/fj.01-0373fje	http://dx.doi.org/10.1096/fj.01-0373fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606479				2022-12-28	WOS:000171920400014
J	Tucker, PC; Sack, GH				Tucker, PC; Sack, GH			Expression of serum amyloid A genes in mouse brain: unprecedented response to inflammatory mediators	FASEB JOURNAL			English	Article						inflammation; neuroimmunology; acute-phase reactants; gene regulation; SAA	ACUTE-PHASE RESPONSE; ALZHEIMERS-DISEASE BRAIN; CEREBROSPINAL-FLUID; PROTEIN; CELLS; INTERLEUKIN-1; INDUCTION; MICROGLIA; SAA; IMMUNOREACTIVITY	Serum amyloid A (SAA) proteins were originally identified as prominent acute-phase serum proteins synthesized predominantly by hepatocytes. These small proteins are remarkably lipophilic, and we have sought evidence for their synthesis in mouse brain. RT-PCR showed constitutive expression of the murine SAA(1) gene in the brains of normal BALB/cJ mice. After intracerebral inoculation with Sindbis virus, these mice predictably increase brain expression of tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1 beta), and IL-6. However, brain SAA(1) expression fell after injecting either virus or control saline and remained low despite increases in TNF-alpha and IL-6, which are known to induce its expression in hepatocytes. Our data thus show that expression of the murine SAA(1) gene has different, unprecedented control in mouse brain, suggesting that the protein itself may have a different physiological role there.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Sack, GH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	gsack@jhmi.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029234] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01070-02] Funding Source: Medline; NINDS NIH HHS [NS29234] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AISEN PS, 1994, AM J PSYCHIAT, V151, P1105; Artl A, 2000, ARTERIOSCL THROM VAS, V20, P763, DOI 10.1161/01.ATV.20.3.763; Bartolak-Suki E, 2000, AMYLOID, V7, P111, DOI 10.3109/13506120009146247; BAUSSERMAN LL, 1983, J BIOL CHEM, V258, P681; BENDITT EP, 1971, FEBS LETT, V19, P169, DOI 10.1016/0014-5793(71)80506-9; BENDITT EP, 1977, P NATL ACAD SCI USA, V74, P4025, DOI 10.1073/pnas.74.9.4025; BETTS JC, 1993, J BIOL CHEM, V268, P25624; BRINCKERHOFF CE, 1989, SCIENCE, V243, P655, DOI 10.1126/science.2536953; Cabana VG, 1999, J LIPID RES, V40, P1090; Chung TF, 2000, AMYLOID, V7, P105, DOI 10.3109/13506120009146246; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; Finch CE, 1996, NEUROBIOL AGING, V17, P809; GANAPATHI MK, 1988, BIOCHEM BIOPH RES CO, V157, P271, DOI 10.1016/S0006-291X(88)80043-3; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GRIFFIN DE, 1986, J IMMUNOL, V136, P1841; GRIFFIN DE, 1994, ARCH VIROL, P31; GRIFFIN WST, 1995, J NEUROPATH EXP NEUR, V54, P276; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Hardardottir I, 1997, BBA-LIPID LIPID MET, V1344, P210, DOI 10.1016/S0005-2760(96)00143-9; HUSBY G, 1994, AMYLOID, V1, P119, DOI 10.3109/13506129409148635; HUSBY G, 1974, J CLIN INVEST, V53, P1054, DOI 10.1172/JCI107642; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; IWAMOTO N, 1994, NEUROSCI LETT, V177, P23, DOI 10.1016/0304-3940(94)90035-3; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; Liang JS, 1997, NEUROSCI LETT, V225, P73, DOI 10.1016/S0304-3940(97)00196-1; LIANG JS, 1995, J LIPID RES, V36, P37; Liang JS, 1996, J LIPID RES, V37, P2109; LOWELL CA, 1986, J BIOL CHEM, V261, P8442; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; MACKENZIE IRA, 1995, NEUROBIOL AGING, V16, P797, DOI 10.1016/0197-4580(95)00092-S; MCGEER PL, 1992, RES IMMUNOL, V143, P621, DOI 10.1016/0923-2494(92)80045-M; Meeker AK, 1998, PROTEINS, V30, P381, DOI 10.1002/(SICI)1097-0134(19980301)30:4<381::AID-PROT5>3.0.CO;2-M; MOENCH TR, 1984, J EXP MED, V159, P77, DOI 10.1084/jem.159.1.77; MORROW JF, 1981, P NATL ACAD SCI-BIOL, V78, P4718, DOI 10.1073/pnas.78.8.4718; RAYNES JG, 1991, CLIN EXP IMMUNOL, V83, P488; RIENHOFF HY, 1990, MOL BIOL MED, V7, P287; SACK GH, 1992, AM J PATHOL, V141, P525; SACK GH, 1989, GENE, V84, P509, DOI 10.1016/0378-1119(89)90528-3; SEGREST JP, 1976, BIOCHEMISTRY-US, V15, P3187, DOI 10.1021/bi00660a005; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Urieli-Shoval S, 1998, J HISTOCHEM CYTOCHEM, V46, P1377, DOI 10.1177/002215549804601206; WESSELINGH SL, 1994, J IMMUNOL, V152, P1289	43	11	11	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2241	2246		10.1096/fj.01-0133com	http://dx.doi.org/10.1096/fj.01-0133com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641251				2022-12-28	WOS:000171920400036
J	Sata, M; Nishimatsu, H; Suzuki, E; Sugiura, S; Yoshizumi, M; Ouchi, Y; Hirata, Y; Nagai, R				Sata, M; Nishimatsu, H; Suzuki, E; Sugiura, S; Yoshizumi, M; Ouchi, Y; Hirata, Y; Nagai, R			Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia	FASEB JOURNAL			English	Article						angiogenesis; cholesterol; statins; vasodilatation	THERAPEUTIC ANGIOGENESIS; GENE-TRANSFER; UP-REGULATION; PRAVASTATIN; SIMVASTATIN; AKT; ADRENOMEDULLIN; MYOCARDIUM; ACTIVATION; CELLS	HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors, or statins, are prescribed widely to lower cholesterol. Accumulating evidence indicates that statins have various effects on vascular cells, which are independent of their lipid-lowering effect. Here, we tested the hypothesis that statins may augment collateral flow to ischemic tissues. We induced hind-limb ischemia in wild-type mice and treated them with either saline or cerivastatin. Cerivastatin enhanced the blood flow recovery dramatically as determined by Laser Doppler imaging. The mice treated with saline displayed frequent autoamputation of the ischemic toe, which was prevented completely by cerivastatin. Anti-CD31 immunostaining revealed that cerivastatin significantly increased the capillary density. Endothelial nitric oxide synthase (eNOS) activity was enhanced markedly in the mice treated with cerivastatin. The angiogenic effect of cerivastatin was abrogated in eNOS deficient (eNOS-/-) mice. These results indicate that eNOS is essential for cerivastatin to promote collateral growth in response to ischemia.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Nephrol & Endocrinol, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Tokyo 1138655, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo	Sata, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	sata-2im@h.u-tokyo.ac.jp						Aikawa M, 2001, CIRCULATION, V103, P276; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Davignon J, 1999, CURR OPIN LIPIDOL, V10, P543, DOI 10.1097/00041433-199912000-00010; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Freedman SB, 2001, J MOL CELL CARDIOL, V33, P379, DOI 10.1006/jmcc.2000.1329; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Hayakawa H, 1999, HYPERTENSION, V33, P689, DOI 10.1161/01.HYP.33.2.689; Hernandez-Perera O, 1998, J CLIN INVEST, V101, P2711, DOI 10.1172/JCI1500; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Isner JM, 1999, CIRCULATION, V99, P1653, DOI 10.1161/01.CIR.99.13.1653; Kawata S, 2001, BRIT J CANCER, V84, P886, DOI 10.1054/bjoc.2000.1716; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Lee RJ, 2000, CIRCULATION, V102, P898; Lefer AM, 1999, CIRCULATION, V100, P178, DOI 10.1161/01.CIR.100.2.178; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Maron DJ, 2000, CIRCULATION, V101, P207, DOI 10.1161/01.CIR.101.2.207; Matoba T, 2000, J CLIN INVEST, V106, P1521, DOI 10.1172/JCI10506; Murohara T, 1999, ARTERIOSCL THROM VAS, V19, P1156, DOI 10.1161/01.ATV.19.5.1156; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Parenti A, 2001, FASEB J, V15, P1487, DOI 10.1096/fj.00-0503fje; PEDERSEN TR, 1994, LANCET, V344, P1383; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Sata M, 2000, HYPERTENSION, V36, P83, DOI 10.1161/01.HYP.36.1.83; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Simons M, 2000, NAT MED, V6, P965, DOI 10.1038/79646; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Ueda Y, 1999, J AM COLL CARDIOL, V34, P2120, DOI 10.1016/S0735-1097(99)00440-4; Vale PR, 2000, CIRCULATION, V102, P965, DOI 10.1161/01.CIR.102.9.965; Vale PR, 2001, CIRCULATION, V103, P2138; van Royen N, 2001, CARDIOVASC RES, V49, P543, DOI 10.1016/S0008-6363(00)00206-6; Vasa M, 2001, CIRCULATION, V103, P2885, DOI 10.1161/hc2401.092816; Vincent L, 2001, FEBS LETT, V495, P159, DOI 10.1016/S0014-5793(01)02337-7; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; Ziche M, 2000, J NEURO-ONCOL, V50, P139, DOI 10.1023/A:1006431309841	42	95	111	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2530	+		10.1096/fj.01-0415fje	http://dx.doi.org/10.1096/fj.01-0415fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641268				2022-12-28	WOS:000171372700017
J	Elmore, SP; Qian, T; Grissom, SF; Lemasters, JJ				Elmore, SP; Qian, T; Grissom, SF; Lemasters, JJ			The mitochondrial permeability transition initiates autophagy in rat hepatocytes	FASEB JOURNAL			English	Article						cyclosporin A; glucagon; tacrolimus	CELL-DEATH; AMINO-ACID; CONDUCTANCE CHANNEL; PROTEIN-DEGRADATION; INDUCED APOPTOSIS; INNER MEMBRANE; LIVER; CYCLOSPORINE; INHIBITION; NECROSIS	Cells degrade excess and effete organelles by the process of autophagy. Autophagic stimulation of rat hepatocytes by serum deprivation and glucagon (1 muM) caused a fivefold increase of spontaneously depolarizing mitochondria to about 1.5% of total mitochondria after 90 min. Cyclosporin A (CsA, 5 muM), an immunosuppressant that blocks the mitochondrial permeability transition (MPT), prevented this depolarization. Depolarized mitochondria moved into acidic vacuoles labeled by LysoTracker Red. These autophagosomes also increased several-fold after autophagic stimulation. CsA blocked autophagosomal proliferation, whereas tacrolimus, an immunosuppressant that does not block the MPT, did not. In conclusion, the MPT initiates mitochondrial depolarization after autophagic stimulation and the subsequent sequestration of mitochondria into autophagosomes.	Univ N Carolina, Sch Med, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC 27599 USA; Vrije Univ Amsterdam, Physiol Lab, NL-1081 BT Amsterdam, Netherlands	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Vrije Universiteit Amsterdam	Lemasters, JJ (corresponding author), Univ N Carolina, Sch Med, Dept Cell Biol & Anat, CB 7090,236 Taylor Hall, Chapel Hill, NC 27599 USA.	lemaster@med.unc.edu						ALTSCHULD RA, 1992, AM J PHYSIOL, V262, pH1699, DOI 10.1152/ajpheart.1992.262.6.H1699; ARSTILA AU, 1972, LAB INVEST, V27, P317; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Christensen ST, 1998, CELL BIOL INT, V22, P591, DOI 10.1006/cbir.1998.0320; CROMPTON M, 1988, BIOCHEM J, V255, P357; Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; ELMORE SP, 1998, TOXICOL SCI, V42, P370; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GRIFFITHS EJ, 1991, BIOCHEM J, V274, P611, DOI 10.1042/bj2740611; GRINDE B, 1983, BIOCHEM J, V216, P529, DOI 10.1042/bj2160529; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401; Jia L, 1997, BRIT J HAEMATOL, V98, P673, DOI 10.1046/j.1365-2141.1997.2623081.x; KASS GEN, 1992, BIOCHEM PHARMACOL, V44, P1995, DOI 10.1016/0006-2952(92)90102-O; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kushnareva YE, 2000, ARCH BIOCHEM BIOPHYS, V376, P377, DOI 10.1006/abbi.2000.1730; LARDEUX BR, 1987, J BIOL CHEM, V262, P14514; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; Lemasters JJ, 1999, METHOD ENZYMOL, V302, P341, DOI 10.1016/S0076-6879(99)02031-5; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; MENZIES RA, 1971, J BIOL CHEM, V246, P2425; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; NIEMINEN AL, 1994, AM J PHYSIOL, V267, pC67, DOI 10.1152/ajpcell.1994.267.1.C67; Ohsawa Y, 1998, ARCH HISTOL CYTOL, V61, P395, DOI 10.1679/aohc.61.395; PFEIFER U, 1978, J CELL BIOL, V78, P152, DOI 10.1083/jcb.78.1.152; Prins JB, 1998, BIOSCIENCE REP, V18, P329, DOI 10.1023/A:1020261316486; SANDVIG K, 1992, EXP CELL RES, V200, P253, DOI 10.1016/0014-4827(92)90171-4; SchulteHermann R, 1997, TOXICOL PATHOL, V25, P89, DOI 10.1177/019262339702500117; SCHWORER CM, 1981, J BIOL CHEM, V256, P7652; SEGLEN PO, 1984, J CELL BIOL, V99, P435, DOI 10.1083/jcb.99.2.435; SHELBURNE JD, 1973, AM J PATHOL, V72, P521; Trollinger DR, 1997, BIOCHEM BIOPH RES CO, V236, P738, DOI 10.1006/bbrc.1997.7042; VARGAS JL, 1987, FEBS LETT, V224, P182, DOI 10.1016/0014-5793(87)80444-1; Vittorini S, 1999, J GERONTOL A-BIOL, V54, pB318, DOI 10.1093/gerona/54.8.B318; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; YU QC, 1988, LAB INVEST, V58, P643; Zhang Y.-Z., 1994, Molecular Biology of the Cell, V5, p113A	48	522	551	1	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					2286	+		10.1096/fj.01-0206fje	http://dx.doi.org/10.1096/fj.01-0206fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11511528				2022-12-28	WOS:000170809900016
J	Vohradsky, J; Ramsden, JJ				Vohradsky, J; Ramsden, JJ			Genome resource utilization during prokaryotic development	FASEB JOURNAL			English	Article						gene expression; proteome	STATISTICAL-ANALYSES	The distributions of synthesis rates of expressed proteins in a liquid batch culture of the prokaryote S. coelicolor during 3 days' growth have been analyzed by using a law governing the relation between the synthesis rates and the corresponding ranks in a list of rates (the so-called simplified canonical law, scl), which we have found previously to characterize the distribution of prokaryotic protein expression. The scl remains valid throughout development and the two parameters of the distribution, theta and rho, evolve in a highly characteristic and revealing way. theta is a measure of the degree to which available genomic resources are used, in the sense of exploiting their potential diversity. The passage from one developmental phase to another is marked by a sharp peak in theta, as these resources are fully mobilized to deal with a crisis (i.e., exhaustion of the habitual food supply). This is followed by an even more pronounced trough, as the organism briefly focuses its resources on synthesizing just those proteins most essential for survival, especially those hitherto unavailable and needed for metabolizing the new nutrient source. The parameter rho indicates redundancy among the most abundantly expressed proteins: higher rho corresponds to more diversity; i.e., less duplication of function, hence less robustness. This parameter is relatively steady throughout the development of the culture, except for a pronounced peak during the developmental phase transition. This corresponds to the "emergency mode" characterized by extremely low theta, during which a minimum repertoire of proteins is expressed.	Univ Basel, Biozentrum, Dept Microbiol, Basel, Switzerland; Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague, Czech Republic; Univ Basel, Biozentrum, Dept Biophys Chem, Basel, Switzerland; Inst Adv Study, Collegium Basilea, Basel, Switzerland	University of Basel; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of Basel	Ramsden, JJ (corresponding author), Hochstr 51, CH-4053 Basel, Switzerland.	J.Ramsden@unibas.ch						GARRELS JI, 1989, J BIOL CHEM, V264, P5269; HOLT TG, 1992, MOL MICROBIOL, V6, P969, DOI 10.1111/j.1365-2958.1992.tb02163.x; Jollife I. T., 1986, PRINCIPAL COMPONENT; Mandelbrot B.B., 1952, PUBL I STAT U PARIS, V2, P1; Mandelbrot B, 1954, WORD, V10, P1; Neumann T, 1996, MICROBIOL-UK, V142, P1953, DOI 10.1099/13500872-142-8-1953; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PUGLIA AM, 1995, MOL MICROBIOL, V17, P737, DOI 10.1111/j.1365-2958.1995.mmi_17040737.x; Ramsden JJ, 1998, PHYS REV E, V58, P7777, DOI 10.1103/PhysRevE.58.7777; Ramsden JJ, 2000, PHYSICA A, V277, P220, DOI 10.1016/S0378-4371(99)00572-5; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; VanBogelen R A, 1995, Biotechnol Annu Rev, V1, P69, DOI 10.1016/S1387-2656(08)70048-6; Vohradsky J, 1997, ELECTROPHORESIS, V18, P1418, DOI 10.1002/elps.1150180817; Vohradsky J, 2000, J BACTERIOL, V182, P4979, DOI 10.1128/JB.182.17.4979-4986.2000; Wilkins M. R., 1997, PROTEOME RES NEW FRO	15	13	14	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2054	+		10.1096/fj.00-0889fje	http://dx.doi.org/10.1096/fj.00-0889fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511523				2022-12-28	WOS:000170318500011
J	Von Eckardstein, A; Langer, C; Engel, T; Schaukal, I; Cignarella, A; Reinhardt, R; Lorkowski, S; Li, ZC; Zhou, XQ; Cullen, P; Assmann, G				Von Eckardstein, A; Langer, C; Engel, T; Schaukal, I; Cignarella, A; Reinhardt, R; Lorkowski, S; Li, ZC; Zhou, XQ; Cullen, P; Assmann, G			ATP binding cassette transporter ABCA1 modulates the secretion of apolipoprotein E from human monocyte-derived macrophages	FASEB JOURNAL			English	Article						ABCA1; Tangier disease; apoE	CHOLESTEROL EFFLUX; TANGIER-DISEASE; APOPTOTIC CELLS; PLASMA-MEMBRANE; MICE; GENE; ATHEROSCLEROSIS; LIPOPROTEINS; EXPRESSION; HYPERCHOLESTEROLEMIA	Apolipoprotein E (apoE) produced by macrophages in the arterial wall protects against atherosclerosis, but the regulation of its secretion by these cells is poorly understood. Here we investigated the contribution of the adenosine triphosphate binding cassette transporters ABCA1 and ABC8 to the secretion of apoE from either primary human monocyte-derived macrophages (HMDM) or human THP1 macrophages. During incubations of up to 6 h, apoE secretion from both THP1 macrophages and HMDM was stimulated by 8-Br-cAMP, which activates ABCA1 expression. The putative ABCA1 inhibitor glyburide and antisense oligonucleotides directed against ABCA1 mRNA significantly reduced apoE secretion from THP1 macrophages and HMDM. Antisense oligonucleotides directed against ABC8 mRNA also inhibited apoE secretion, although this inhibition was less pronounced and consistent than in the case of ABCA1. ApoE secretion from HMDM of ABCA1-deficient patients with Tangier disease was also decreased. ApoE mRNA expression was not affected by inhibition of ABCA1 or ABC8 in normal HMDM or the lack of functional ABCA1 in HMDM from Tangier disease patients. Inhibition of ABCA1 in HMDM prevented the occurrence of anti-apoE-immunoreactive granular structures in the plasma membrane. We conclude that ABCA1 and, to a lesser extent, ABC8 both promote secretion of apoE from human macrophages.	Univ Munster, Cent Lab, Inst Clin Chem & Lab Med, D-48129 Munster, Germany; Inst Arteriosclerosis Res, D-48149 Munster, Germany; Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy; Univ Munster, Inst Physiol, D-48129 Munster, Germany	University of Munster; University of Milan; University of Munster	Von Eckardstein, A (corresponding author), Univ Munster, Cent Lab, Inst Clin Chem & Lab Med, Albert Schweitzer Str 33, D-48129 Munster, Germany.	vonecka@uni-muenster.de	Lorkowski, Stefan/B-9689-2008	Lorkowski, Stefan/0000-0002-9649-840X				Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; Assmann G, 2001, METABOLIC MOL BASES, P2937; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; Bielicki JK, 1999, J LIPID RES, V40, P85; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; BRAND K, 1993, J CLIN INVEST, V91, P2031, DOI 10.1172/JCI116425; BROWN MS, 1980, J BIOL CHEM, V255, P9344; Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; Daum U, 1999, J MOL MED, V77, P614, DOI 10.1007/s001099900034; DENG JT, 1995, J LIPID RES, V36, P2129; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Feussner G, 1996, AM J HUM GENET, V58, P281; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Heeren J, 1999, J CELL SCI, V112, P349; Huang YD, 1995, J CLIN INVEST, V96, P2693, DOI 10.1172/JCI118336; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lin CY, 1999, J LIPID RES, V40, P1618; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1984, J LIPID RES, V25, P1277; Mazzone T, 1996, CURR OPIN LIPIDOL, V7, P303, DOI 10.1097/00041433-199610000-00008; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 1996, J LIPID RES, V37, P2473; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Panousis CG, 2000, ARTERIOSCL THROM VAS, V20, P1565, DOI 10.1161/01.ATV.20.6.1565; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Rees D, 1999, J BIOL CHEM, V274, P27925, DOI 10.1074/jbc.274.39.27925; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schmitz G, 2000, CURR OPIN LIPIDOL, V11, P493, DOI 10.1097/00041433-200010000-00007; SCHMITZ G, 1985, P NATL ACAD SCI USA, V82, P6305, DOI 10.1073/pnas.82.18.6305; Schwede F, 2000, PHARMACOL THERAPEUT, V87, P199, DOI 10.1016/S0163-7258(00)00051-6; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Stannard AK, 1999, ATHEROSCLEROSIS, V144, P86, DOI 10.1016/S0021-9150(99)80328-1; Takahashi Y, 2000, BBA-GENE STRUCT EXPR, V1492, P385, DOI 10.1016/S0167-4781(00)00133-0; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wenner C, 2001, BIOCHEM BIOPH RES CO, V282, P608, DOI 10.1006/bbrc.2001.4611; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhao YW, 2000, J BIOL CHEM, V275, P4759, DOI 10.1074/jbc.275.7.4759	49	88	89	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					1555	1561		10.1096/fj.00-0798com	http://dx.doi.org/10.1096/fj.00-0798com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427487				2022-12-28	WOS:000170318500007
J	Claud, EC; Walker, WA				Claud, EC; Walker, WA			Hypothesis: inappropriate colonization of the premature intestine can cause neonatal necrotizing enterocolitis	FASEB JOURNAL			English	Article						necrotizing enterocolitis; prematurity; intestinal inflammation	PLATELET-ACTIVATING-FACTOR; RAT SMALL-INTESTINE; ISCHEMIC BOWEL NECROSIS; BREAST-FED INFANTS; NF-KAPPA-B; BACTERIAL-COLONIZATION; EPITHELIAL-CELLS; HUMAN-MILK; SALMONELLA-TYPHIMURIUM; FACTOR ACETYLHYDROLASE	Neonatal necrotizing enterocolitis (NEC) is a major cause of morbidity in preterm infants. We hypothesize that the intestinal injury in this disease is a consequence of synergy among three of the major risk factors for NEC: prematurity, enteral feeding, and bacterial colonization. Together these factors result in an exaggerated inflammatory response, leading to ischemic bowel necrosis. Human milk may decrease the incidence of NEC by decreasing pathogenic bacterial colonization, promoting growth of nonpathogenic flora, promoting maturation of the intestinal barrier, and ameliorating the proinflammatory response.	Harvard Univ, Massachusetts Gen Hosp, Sch Med,Combined Program Pediat Gastroenterol & N, Dev Gastroenterol Lab, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Walker, WA (corresponding author), Massachusetts Gen Hosp, Dev Gastroenterol Lab, 149 13th St, Charlestown, MA 02129 USA.	walker@helix.mgh.harvard.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012437, R01HD031852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033506] Funding Source: NIH RePORTER; NICHD NIH HHS [R37-HD12437, R01-HD31852] Funding Source: Medline; NIDDK NIH HHS [P01-DK33506] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYNSLEYGREEN A, 1990, J PEDIATR-US, V117, pS24, DOI 10.1016/S0022-3476(05)81127-8; BALLANCE WA, 1990, J PEDIATR-US, V117, pS6, DOI 10.1016/S0022-3476(05)81124-2; BARNESS LA, 1994, J NUTR, V124, pS128, DOI 10.1093/jn/124.suppl_1.128S; BEEBY PJ, 1992, ARCH DIS CHILD-FETAL, V67, P432, DOI 10.1136/adc.67.4_Spec_No.432; BENNET R, 1992, ACTA PAEDIATR, V81, P784, DOI 10.1111/j.1651-2227.1992.tb12103.x; Bernt KM, 1999, ACTA PAEDIATR, V88, P27; CAPLAN M, 1990, PROSTAGLANDINS, V39, P705, DOI 10.1016/0090-6980(90)90030-Y; CAPLAN MS, 1993, PEDIATR PATHOL, V13, P357, DOI 10.3109/15513819309048223; CAPLAN MS, 1990, J PEDIATR-US, V117, pS47, DOI 10.1016/S0022-3476(05)81130-8; CAPLAN MS, 1990, J PEDIATR-US, V116, P960, DOI 10.1016/S0022-3476(05)80661-4; CAPLAN MS, 1994, CLIN PERINATOL, V21, P235, DOI 10.1016/S0095-5108(18)30343-9; Caplan MS, 1997, J PEDIATR GASTR NUTR, V24, P296, DOI 10.1097/00005176-199703000-00012; CAPLAN MS, 1992, PEDIATR RES, V31, P428, DOI 10.1203/00006450-199205000-00002; Caplan MS, 2000, J PEDIATR GASTR NUTR, V30, pS18, DOI 10.1097/00005176-200000002-00004; CARBONARO CA, 1988, MICROB PATHOGENESIS, V5, P427, DOI 10.1016/0882-4010(88)90004-6; CHU SHW, 1986, BIOCHIM BIOPHYS ACTA, V883, P496, DOI 10.1016/0304-4165(86)90289-8; CLARK DA, 1990, J PEDIATR-US, V117, pS64, DOI 10.1016/S0022-3476(05)81133-3; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; Dai DW, 2000, J PEDIATR GASTR NUTR, V30, pS23, DOI 10.1097/00005176-200003002-00005; Elewaut D, 1999, J IMMUNOL, V163, P1457; Faix R G, 1994, Adv Pediatr Infect Dis, V9, P1; FURUKAWA M, 1993, PEDIATR RES, V34, P237, DOI 10.1203/00006450-199308000-00027; Fusunyan RD, 1998, PEDIATR RES, V43, P84, DOI 10.1203/00006450-199801000-00013; Gewirtz AT, 2000, J CLIN INVEST, V105, P79, DOI 10.1172/JCI8066; GONZALEZCRUSSI F, 1983, AM J PATHOL, V112, P127; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; HALAC E, 1990, J PEDIATR-US, V117, P132, DOI 10.1016/S0022-3476(05)72461-6; Harmsen HJM, 2000, J PEDIATR GASTR NUTR, V30, P61, DOI 10.1097/00005176-200001000-00019; HARRIS MC, 1994, J PEDIATR-US, V124, P105, DOI 10.1016/S0022-3476(94)70264-0; Hobbie S, 1997, J IMMUNOL, V159, P5550; HOY C, 1990, ARCH DIS CHILD-FETAL, V65, P1057, DOI 10.1136/adc.65.10_Spec_No.1057; Hoyos A B, 1999, Int J Infect Dis, V3, P197, DOI 10.1016/S1201-9712(99)90024-3; HSUEH W, 1987, FASEB J, V1, P403, DOI 10.1096/fasebj.1.5.3678700; ISRAEL EJ, 1990, GASTROENTEROLOGY, V99, P1333, DOI 10.1016/0016-5085(90)91158-3; KIEN CL, 1990, J PEDIATR-US, V117, pS52, DOI 10.1016/S0022-3476(05)81131-X; Kinugasa T, 2000, GASTROENTEROLOGY, V118, P1001, DOI 10.1016/S0016-5085(00)70351-9; KOSLOSKE A, 1994, ACTA PAEDIATR, V83, P2, DOI 10.1111/j.1651-2227.1994.tb13232.x; LARI AR, 1990, BIOL NEONATE, V58, P73; LODINOVAZADNIKOVA R, 1991, PEDIATR RES, V29, P396, DOI 10.1203/00006450-199104000-00013; LodinovaZadnikova R, 1997, BIOL NEONATE, V71, P224, DOI 10.1159/000244421; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; MACKENDRICK W, 1993, BIOL NEONATE, V64, P89, DOI 10.1159/000243976; MADARA JL, 1990, AM J PATHOL, V137, P1273; MOYA FR, 1994, J PEDIATR GASTR NUTR, V19, P236, DOI 10.1097/00005176-199408000-00015; MURRAY RD, 1990, J PEDIATR-US, V117, pS59, DOI 10.1016/S0022-3476(05)81132-1; Nanthakumar NN, 2000, P NATL ACAD SCI USA, V97, P6043, DOI 10.1073/pnas.97.11.6043; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; NEU J, 1986, PEDIATR RES, V20, P79, DOI 10.1203/00006450-198601000-00022; Newburg DS, 2000, J PEDIATR GASTR NUTR, V30, pS8, DOI 10.1097/00005176-200000002-00003; Orrhage K, 1999, ACTA PAEDIATR, V88, P47; OZAKI CK, 1989, BIOCHIM BIOPHYS ACTA, V991, P243; PANIGRAHI P, 1994, PEDIATR RES, V36, P115, DOI 10.1203/00006450-199407001-00021; Petschow BW, 1999, J MED MICROBIOL, V48, P541, DOI 10.1099/00222615-48-6-541; SANDERSON IR, 1994, J NUTR, V124, pS131, DOI 10.1093/jn/124.suppl_1.131S; SCHIFFRIN EJ, 1993, J PEDIATR GASTR NUTR, V17, P271; Tanaka M, 1996, J NUTR, V126, P424, DOI 10.1093/jn/126.2.424; UDALL JN, 1990, J PEDIATR-US, V117, pS33, DOI 10.1016/S0022-3476(05)81128-X; Walker WA, 1996, TRANSPLANT P, V28, P2438; WALLACE JL, 1987, GASTROENTEROLOGY, V93, P765, DOI 10.1016/0016-5085(87)90438-0; Yeh TF, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.5.e7	60	284	336	3	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1398	1403		10.1096/fj.00-0833hyp	http://dx.doi.org/10.1096/fj.00-0833hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11387237				2022-12-28	WOS:000169261200007
J	Guidotti, JE; Mallet, VO; Mitchell, C; Fabre, M; Schoevaert, D; Opolon, P; Parlier, D; Lambert, M; Kahn, A; Gilgenkrantz, H				Guidotti, JE; Mallet, VO; Mitchell, C; Fabre, M; Schoevaert, D; Opolon, P; Parlier, D; Lambert, M; Kahn, A; Gilgenkrantz, H			Selection of in vivo retrovirally transduced hepatocytes leads to efficient and predictable mouse liver repopulation	FASEB JOURNAL			English	Article						liver repopulation; molecular therapy; retrovirus; apoptosis	MEDIATED GENE-TRANSFER; IN-VIVO; LONG-TERM; THERAPY; MICE; TRANSPLANTATION; INTEGRATION; EXPRESSION; HEMOPHILIA; HEPATITIS	Stable liver gene transfer is generally limited by the low efficiency of commonly used vectors. One way to circumvent this difficulty is to confer a selective advantage on transduced hepatocytes, allowing them to progressively repopulate the liver. We have used a strategy for in vivo selection and controlled amplification of a small percentage of retrovirally engineered hepatocytes. Using a bicistronic retroviral vector encoding a reporter gene and Bcl2, which confers on liver cells a survival advantage against the Fas apoptotic pathway, we demonstrate that 1.5% of initially transduced hepatocytes repopulate up to 85% of the liver after 10 injections of a Fas agonist antibody. Moreover, we show that the kinetics of liver repopulation is highly predictable. This system provides a general means of expanding at will engineered hepatocytes in vivo and offering the possibility to obtain a genetically modified liver expressing a gene of interest in a desired proportion of hepatocytes.	Inst Cochin Genet Mol, INSERM, U129, F-75014 Paris, France; Hop Cochin, Serv Reanimat Polyvalente, F-75014 Paris, France; Hop Bicetre, Anat Pathol Lab, F-94275 Le Kremlin Bicetre, France; Inst Gustave Roussy, CNRS IGR Aventis, UMR 1582, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Gilgenkrantz, H (corresponding author), Inst Cochin Genet Mol, INSERM, U129, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	gilgenkrantz@cochin.inserm.fr	Gilgenkrantz, Helene/G-5534-2017; Guidotti, Jacques-Emmanuel/M-9014-2018; Mallet, Vincent/G-4623-2011	guidotti, jacques-emmanuel/0000-0001-9285-8167; gilgenkrantz, helene/0000-0001-6770-4561; Mallet, Vincent/0000-0003-2219-9201				Aurisicchio L, 2000, J VIROL, V74, P4816, DOI 10.1128/JVI.74.10.4816-4823.2000; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FERRY N, 1991, P NATL ACAD SCI USA, V88, P8377, DOI 10.1073/pnas.88.19.8377; Guha C, 1999, CANCER RES, V59, P5871; Guidotti JE, 2001, HEPATOLOGY, V33, P10, DOI 10.1053/jhep.2001.20678; Ji W, 1997, J VIRAL HEPATITIS, V4, P167, DOI 10.1046/j.1365-2893.1997.00144.x; Jin LQ, 2000, NAT GENET, V26, P64, DOI 10.1038/79194; Kaufman RJ, 1999, HUM GENE THER, V10, P2091, DOI 10.1089/10430349950017095; Kay MA, 1998, HAEMOPHILIA, V4, P389, DOI 10.1046/j.1365-2516.1998.440389.x; Kitten O, 1997, HUM GENE THER, V8, P1491, DOI 10.1089/hum.1997.8.12-1491; Laconi E, 1998, AM J PATHOL, V153, P319, DOI 10.1016/S0002-9440(10)65574-5; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Miao CH, 1998, NAT GENET, V19, P13, DOI 10.1038/ng0598-13; Mignon A, 1998, NAT MED, V4, P1185, DOI 10.1038/2681; Mitchell C, 2000, HUM MOL GENET, V9, P1597, DOI 10.1093/hmg/9.11.1597; Nakai H, 1998, BLOOD, V91, P4600, DOI 10.1182/blood.V91.12.4600.412k22_4600_4607; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; Park F, 2000, NAT GENET, V24, P49, DOI 10.1038/71673; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; Tangirala RK, 1999, CIRCULATION, V100, P1816, DOI 10.1161/01.CIR.100.17.1816; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568	22	20	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1849	+		10.1096/fj.00-0892fje	http://dx.doi.org/10.1096/fj.00-0892fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481251				2022-12-28	WOS:000169261200036
J	Koudinov, AR; Koudinova, NV				Koudinov, AR; Koudinova, NV			Essential role for cholesterol in synaptic plasticity and neuronal degeneration	FASEB JOURNAL			English	Article						amyloid beta protein; Alzheimer's disease; Down's syndrome; cholesterol and phospholipid efflux and synthesis; hippocampal slices; Niemann-Pick type C disease; tau phosphorylation; lipoprotein LDL LRP VLDL receptor	DENSITY-LIPOPROTEIN RECEPTOR; AMYLOID-BETA-PROTEIN; CEREBROSPINAL-FLUID LIPOPROTEINS; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; NORMAL HUMAN PLASMA; APOLIPOPROTEIN-E; MEMBRANE CHOLESTEROL; TRANSMITTER RELEASE; GENE-EXPRESSION	There is no understanding of the role of cholesterol and phospholipids in the mechanisms of synaptic function and neurodegeneration. Here we report that cholesterol disbalance is critical for synaptic transmission and plasticity as investigated by a study of paired pulse facilitation and long-term potentiation (LTP). Extracellular recording of field-evoked postsynaptic potentials showed enhanced PPF ratio and an impairment of LTP in CA1 subfield of adult rat ex-vivo hippocampal slices subjected to cyclodextrin- or normal human CSF-HDL3-mediated cholesterol efflux. Immunofluorescence with antibodies against neurofilament and tau revealed that cholesterol and phospholipids depletion causes alteration of normal hippocampal neurites and the appearance of PHF-tau in the mossy fibers. We further find that LTP and amyloid beta protein increase [C-14] acetate label incorporation into newly synthesized hippocampal membrane lipids. Our results indicate the importance of neuronal cholesterol redistribution and synthesis for synaptic plasticity and neurodegeneration.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Russian Acad Med Sci, Inst Biomed Chem, Moscow 121359, Russia; Russian Acad Med Sci, Natl Mental Hlth Res Ctr, Moscow 121359, Russia	Weizmann Institute of Science; Russian Academy of Medical Sciences; Institute of Biomedical Chemistry; Russian Academy of Medical Sciences	Koudinov, AR (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Candiotti Bldg, IL-76100 Rehovot, Israel.	koudin@imb.ac.ru						Albert AD, 1996, BBA-BIOMEMBRANES, V1285, P47, DOI 10.1016/S0005-2736(96)00145-9; ARENDT T, 1995, NEUROSCIENCE, V69, P691, DOI 10.1016/0306-4522(95)00347-L; AUER IA, 1995, ACTA NEUROPATHOL, V90, P547; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Berretta N, 2000, NEUROPHARMACOLOGY, V39, P2288, DOI 10.1016/S0028-3908(00)00076-9; BINDER LI, 1986, DYNAMIC ASPECTS MICR, P145; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; CHAMPAGNE D, 2000, SOC NEUR ABSTR, V26, P1546; CORNELIUS F, 1995, BBA-BIOMEMBRANES, V1235, P205, DOI 10.1016/0005-2736(95)80006-2; CREWS FT, 1983, BRAIN RES, V261, P155, DOI 10.1016/0006-8993(83)91296-9; Demeester N, 2000, J LIPID RES, V41, P963; DISTL R, 2000, NEUROBIOL AGING, V21, pS21; EISENSAMER B, 2000, SOC NEUR ABSTR, V26, P2159; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Fagan AM, 2000, ANN NEUROL, V48, P201, DOI 10.1002/1531-8249(200008)48:2<201::AID-ANA10>3.0.CO;2-X; Fan QW, 2001, J NEUROCHEM, V76, P391, DOI 10.1046/j.1471-4159.2001.00063.x; Friedman LK, 1999, J NEUROSCI, V19, P9412; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; Gong C.-X., 1996, Neurobiology of Aging, V17, pS133, DOI 10.1016/S0197-4580(96)80536-7; Goussakov IV, 2000, J NEUROSCI, V20, P3434, DOI 10.1523/JNEUROSCI.20-09-03434.2000; Hall GF, 2000, CELL MOTIL CYTOSKEL, V46, P166, DOI 10.1002/1097-0169(200007)46:3<166::AID-CM2>3.0.CO;2-8; Hanaka S, 2000, BRAIN DEV-JPN, V22, P321, DOI 10.1016/S0387-7604(00)00129-7; Heicklen-Klein A, 2000, BRAIN RES, V874, P1, DOI 10.1016/S0006-8993(00)02539-7; Henze DA, 2000, NEUROSCIENCE, V98, P407, DOI 10.1016/S0306-4522(00)00146-9; Igbavboa U, 1997, J NEUROCHEM, V69, P1661; IGBAVBOA U, 2000, NEUROSCI LETT S, V55, pS25; ISHIGURO M, 1995, MOL BRAIN RES, V33, P37, DOI 10.1016/0169-328X(95)00104-Z; Kaplan B, 1999, CLIN CHIM ACTA, V280, P147, DOI 10.1016/S0009-8981(98)00190-9; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Korkotian E, 1997, J NEUROSCI, V17, P1670; Koudinov A.R., 2000, SOC NEUR ABSTR, V26, P497; Koudinov AR, 1996, BIOCHEM MOL BIOL INT, V38, P747; Koudinov AR, 1996, BIOCHEM BIOPH RES CO, V223, P592, DOI 10.1006/bbrc.1996.0940; Koudinov AR, 1998, CLIN CHIM ACTA, V270, P75, DOI 10.1016/S0009-8981(97)00207-6; Koudinov AR, 1997, CELL BIOL INT, V21, P265, DOI 10.1006/cbir.1996.0126; KOUDINOV AR, 2000, NEUROSCI LETT S, V55, pS30; Koudinova NV, 1996, VOP MED KHIM, V42, P253; Koudinova NV, 2000, NEUROCHEM RES, V25, P653, DOI 10.1023/A:1007511120099; Krucker T, 2000, P NATL ACAD SCI USA, V97, P6856, DOI 10.1073/pnas.100139797; Kuchel GA, 1997, NEUROREPORT, V8, P799, DOI 10.1097/00001756-199702100-00044; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; LASALDE JA, 1995, BBA-BIOMEMBRANES, V1235, P361, DOI 10.1016/0005-2736(95)80025-B; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Liu YB, 1998, P NATL ACAD SCI USA, V95, P13266, DOI 10.1073/pnas.95.22.13266; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; Matthies H, 1997, NEUROSCIENCE, V79, P341, DOI 10.1016/S0306-4522(96)00703-8; MATTSON MP, 1990, NEURON, V4, P105, DOI 10.1016/0896-6273(90)90447-N; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; Morell P, 1997, NUTR METAB CARDIOVAS, V7, P187; Muller WE, 1997, NUTR METAB CARDIOVAS, V7, P210; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Nilova N S, 1996, Neurosci Behav Physiol, V26, P23, DOI 10.1007/BF02391152; NORTH P, 1983, J BIOL CHEM, V258, P1242; OKUIZUMI K, 1995, NAT GENET, V11, P207, DOI 10.1038/ng1095-207; Oleskevich S, 2000, J PHYSIOL-LONDON, V526, P349, DOI 10.1111/j.1469-7793.2000.t01-1-00349.x; Page KJ, 1998, NEUROSCIENCE, V85, P1161, DOI 10.1016/S0306-4522(97)00661-1; Paris D, 2000, NEUROBIOL AGING, V21, P183, DOI 10.1016/S0197-4580(99)00111-6; PERRY G, 1991, J NEUROSCI, V11, P1748; PITAS RE, 1987, J BIOL CHEM, V262, P14352; PITHA J, 1994, J PHARM SCI, V83, P833, DOI 10.1002/jps.2600830615; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; QIU Z, 2000, SOC NEUR ABSTR, V26, P2289; QUINTERO EM, 2000, SOC NEUR ABSTR, V26, P2059; Rebeck GW, 1998, EXP NEUROL, V149, P175, DOI 10.1006/exnr.1997.6710; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Rioult-Pedotti MS, 2000, SCIENCE, V290, P533, DOI 10.1126/science.290.5491.533; Roses AD, 1997, ANN NY ACAD SCI, V826, P200, DOI 10.1111/j.1749-6632.1997.tb48471.x; RUNZ H, 2000, NEUROBIOL AGING, V21, pS189; Scharnagl H, 1999, LAB INVEST, V79, P1271; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Sooksawate T, 2001, NEUROPHARMACOLOGY, V40, P178, DOI 10.1016/S0028-3908(00)00159-3; Sparks DL, 1996, NEUROBIOL AGING, V17, P291, DOI 10.1016/0197-4580(95)02067-5; SU JH, 1993, BRAIN RES, V625, P228, DOI 10.1016/0006-8993(93)91063-X; Swanson L. W, 1998, BRAIN MAPS STRUCTURE; Takei Y, 2000, J CELL BIOL, V150, P989, DOI 10.1083/jcb.150.5.989; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; TOVEY S, 1995, BIOCHEM SOC T, V23, pS429, DOI 10.1042/bst023429s; Turley SD, 1996, J LIPID RES, V37, P1953; Volgushev M, 2000, NEUROSCIENCE, V98, P9, DOI 10.1016/S0306-4522(00)00109-3; Wegiel J, 1998, BRAIN RES, V802, P259, DOI 10.1016/S0006-8993(98)00542-3; WHETTON AD, 1983, BIOCHEM J, V212, P331, DOI 10.1042/bj2120331; Wood WG, 1999, LIPIDS, V34, P225, DOI 10.1007/s11745-999-0357-9; Yamazaki T, 2001, J BIOL CHEM, V276, P4454, DOI 10.1074/jbc.M009598200; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	88	218	227	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1858	+		10.1096/fj.00-0815fje	http://dx.doi.org/10.1096/fj.00-0815fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481254				2022-12-28	WOS:000169261200017
J	Kretzler, M; Teixeira, VPC; Unschuld, PG; Cohen, CD; Wanke, R; Edenhofer, I; Mundel, P; Schlondorff, D; Holthofer, H				Kretzler, M; Teixeira, VPC; Unschuld, PG; Cohen, CD; Wanke, R; Edenhofer, I; Mundel, P; Schlondorff, D; Holthofer, H			Integrin linked kinase as a candidate downstream effector in proteinuria	FASEB JOURNAL			English	Article						glomerulus; nephrotic syndrome; actin; actinin; extracellular matrix	CONGENITAL NEPHROTIC SYNDROME; GLOMERULAR EPITHELIAL-CELL; RAT NEPHRIN; RAPID COMMUNICATION; MESSENGER-RNA; EXPRESSION; MOUSE; RECEPTORS; KIDNEY; GLOMERULOSCLEROSIS	The kidney glomerulus is responsible for the generation of a protein-free ultrafiltrate. After injury, it shows a characteristic, uniform response leading to progressive renal failure. Recent studies of hereditary proteinuric diseases have revealed mutations in molecules involved in podocyte cell-cell and cell-matrix interaction. Associated cellular signaling events activated in proteinuria have not been analyzed so far. To identify proteinuria-induced molecules, we used mRNA differential display in glomeruli from children with congenital nephrotic syndrome of the Finnish type. An increase in integrin linked kinase (ILK) mRNA, beta (1)-integrin coupled serine threonine kinase, was identified. Observations suggest a role for ILK in glomerular failure. An up-regulation of glomerular and Single-podocyte ILK mRNA was found in two murine models of proteinuria. In cultured podocytes, integrin attachment to matrix inhibited ILK activity and podocyte damage with puromycin activated ILK. Stable overexpression of ILK in murine podocytes caused reduced matrix adhesion and led to considerable phenotype alteration compared with expression of a kinase-defective ILK, paralleling aspects of in vivo podocyte damage. These results are consistent with ILK as a relevant player in the orchestration of podocyte matrix interaction and a candidate downstream regulator of podocyte permselectivity in glomerular diseases.	Univ Munich, Med Poliklin, D-80336 Munich, Germany; Univ Munich, Inst Vet Pathol, D-80336 Munich, Germany; Albert Einstein Coll Med, Dept Anat & Cell Biol, New York, NY USA; Univ Helsinki, Dept Immunol, FIN-00014 Helsinki, Finland	University of Munich; University of Munich; Yeshiva University; University of Helsinki	Kretzler, M (corresponding author), Univ Munich, Med Poliklin, Schillerstr 42, D-80336 Munich, Germany.	kretzler@medpoli.med.uni-muenchen.de	Unschuld, Paul G/N-7294-2013	Unschuld, Paul G/0000-0002-6116-3386; Wanke, Rudiger/0000-0002-0153-224X				Adler S, 1996, AM J PATHOL, V149, P987; ADLER S, 1992, AM J PATHOL, V141, P571; ADLER S, 1994, KIDNEY INT S, V45, P86; Ahola H, 1999, AM J PATHOL, V155, P907, DOI 10.1016/S0002-9440(10)65190-5; Barisoni L, 2000, KIDNEY INT, V58, P137, DOI 10.1046/j.1523-1755.2000.00149.x; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Haltia A, 1999, EXP NEPHROL, V7, P52; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Holthofer H, 1999, AM J PATHOL, V155, P1681, DOI 10.1016/S0002-9440(10)65483-1; Holzman LB, 1999, KIDNEY INT, V56, P1481, DOI 10.1046/j.1523-1755.1999.00719.x; HUTTUNEN NP, 1976, NEPHRON, V16, P401, DOI 10.1159/000180664; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kawachi H, 2000, KIDNEY INT, V57, P1949, DOI 10.1046/j.1523-1755.2000.00044.x; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; Kretzler M, 1996, AM J PHYSIOL-RENAL, V271, pF770; Kriz W, 1996, KIDNEY INT, V49, P1570, DOI 10.1038/ki.1996.227; Kriz W, 1996, KIDNEY BLOOD PRESS R, V19, P245, DOI 10.1159/000174083; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; NEUGARTEN J, 1995, J AM SOC NEPHROL, V5, P1903; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OMEARA YM, 1992, AM J PHYSIOL, V262, pF1083, DOI 10.1152/ajprenal.1992.262.6.F1083; Putaala H, 2000, J AM SOC NEPHROL, V11, P991, DOI 10.1681/ASN.V116991; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Reiser J, 2000, J AM SOC NEPHROL, V11, P1, DOI 10.1681/ASN.V1111; Reiser J, 2000, KIDNEY INT, V57, P2035, DOI 10.1046/j.1523-1755.2000.00070.x; Schadde E, 2000, NEPHROL DIAL TRANSPL, V15, P1046, DOI 10.1093/ndt/15.7.1046; Schroppel B, 1998, KIDNEY INT, V53, P119, DOI 10.1046/j.1523-1755.1998.00742.x; Shankland SJ, 2000, KIDNEY INT, V58, P674, DOI 10.1046/j.1523-1755.2000.00213.x; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Smoyer WE, 1997, AM J PHYSIOL-RENAL, V273, pF150, DOI 10.1152/ajprenal.1997.273.1.F150; WANKE R, 1991, PEDIATR NEPHROL, V5, P513, DOI 10.1007/BF01453693; WHITESIDE CI, 1993, AM J PATHOL, V142, P1641; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528	36	92	106	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1843	+		10.1096/fj.00-0832fje	http://dx.doi.org/10.1096/fj.00-0832fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481249				2022-12-28	WOS:000169261200025
J	Dolznig, H; Boulme, F; Stangl, K; Deiner, EM; Mikulits, W; Beug, H; Mullner, EW				Dolznig, H; Boulme, F; Stangl, K; Deiner, EM; Mikulits, W; Beug, H; Mullner, EW			Establishment of normal, terminally differentiating mouse erythroid progenitors: molecular characterization by cDNA arrays	FASEB JOURNAL			English	Review						erythropoiesis; expression profiling; signal transduction	MAMMARY EPITHELIAL-CELLS; SELF-ORGANIZING MAPS; FACTOR CHOP GADD153; C-SRC ACTIVITY; TRANSCRIPTION FACTOR; GENE-EXPRESSION; HEMATOPOIETIC-CELLS; IN-VITRO; ERYTHROPOIETIN RECEPTOR; GLUCOCORTICOID RECEPTOR	Expression profiling with cDNA arrays is an excellent tool for molecular analysis of complex processes such as terminal erythroid differentiation. The shortcomings of the currently available erythroid in vitro differentiation models, however, severely impaired the usefulness of this approach to study erythropoiesis. Here, we describe a novel, murine erythroid cell system closely corresponding to in vivo erythroid progenitors. Mortal, long-term proliferating erythroid progenitors of fetal liver or immortal strains of p53-deficient erythroblasts were established in culture. Both cell types proliferated in serum-free medium and were strictly dependent on physiologically relevant cytokines and hormones, stably retaining a diploid set of chromosomes. If exposed to physiological differentiation factors (erythropoietin plus insulin), cells synchronously recapitulated the normal in vivo differentiation program to mature terminally into enucleated erythrocytes and expressed stage-specific erythroid transcription factors in the expected temporal order. Using cDNA arrays, we found a large number of genes differentially expressed at time points during differentiation. Already 6 h after differentiation induction, 17% of the expressed genes showed significant alterations in mRNA abundance, increasing to 53% (12% up-regulated, 41% down-regulated genes) by 48 h. Cluster analysis of mRNA expression kinetics during differentiation identified six distinct expression patterns. All genes on the array with a known function in erythropoiesis showed the expected variations in expression. The genes identified also allowed first insights into the sequence of events within the regulatory network responsible for erythroid maturation. In mortal wild-type as well as immortal p53(-/-) erythroblasts, changes in mRNA abundance of several well-regulated gene products was verified at the protein level. Taken together, this novel hematopoietic cell system faithfully executes essential steps of normal erythropoiesis and allows us to dissect and characterize molecular mechanisms involved in erythropoiesis.	Vienna Bioctr, Inst Med Biochem, Div Mol Biol, A-1030 Vienna, Austria; Vienna Bioctr, Inst Mol Pathol, A-1030 Vienna, Austria; Inst Canc Res, A-1090 Vienna, Austria	Vienna Biocenter (VBC); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Mullner, EW (corresponding author), Vienna Bioctr, Inst Med Biochem, Div Mol Biol, Dr Bohr Gasse 9, A-1030 Vienna, Austria.	em@mol.univie.ac.at	Dolznig, Helmut/L-7005-2015; Mikulits, Wolfgang/AAH-4043-2021	Dolznig, Helmut/0000-0002-6063-3585; Mikulits, Wolfgang/0000-0003-4612-7106				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; ALTER BP, 1994, ANN NY ACAD SCI, V731, P36, DOI 10.1111/j.1749-6632.1994.tb55746.x; Anderson KP, 2000, BLOOD, V95, P1652, DOI 10.1182/blood.V95.5.1652.005k23_1652_1655; ANDERSON SM, 1985, MOL CELL BIOL, V5, P3369, DOI 10.1128/MCB.5.12.3369; Andrews NC, 1998, INT J BIOCHEM CELL B, V30, P429, DOI 10.1016/S1357-2725(97)00135-0; Athanasiou M, 2000, LEUKEMIA, V14, P439, DOI 10.1038/sj.leu.2401689; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BAUER A, 2001, IN PRESS HEMATOPOIES; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; Beug H, 1996, CURR TOP MICROBIOL, V211, P29; BEUG H, 1995, METHOD ENZYMOL, V254, P41; Broudy VC, 1996, BLOOD, V88, P75; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; CONSCIENCE JF, 1982, DIFFERENTIATION, V22, P100, DOI 10.1111/j.1432-0436.1982.tb01232.x; Coutts M, 1999, BLOOD, V93, P3369, DOI 10.1182/blood.V93.10.3369.410k11_3369_3378; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Cui KY, 2000, J BIOL CHEM, V275, P7591, DOI 10.1074/jbc.275.11.7591; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; De Maria R, 1999, BLOOD, V93, P796, DOI 10.1182/blood.V93.3.796.403k23_796_803; DEAN A, 1981, SCIENCE, V212, P459, DOI 10.1126/science.6163216; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONOHUE DM, 1958, J CLIN INVEST, V37, P1571, DOI 10.1172/JCI103750; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Elefanty AG, 1997, BLOOD, V90, P1435, DOI 10.1182/blood.V90.4.1435.1435_1435_1447; Elwood NJ, 1998, BLOOD, V91, P3756; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fibach E, 1998, HEMOGLOBIN, V22, P445, DOI 10.3109/03630269809071542; Forsberg EC, 2000, BLOOD, V96, P334, DOI 10.1182/blood.V96.1.334.013k17_334_339; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; Gubin AN, 1999, GENOMICS, V59, P168, DOI 10.1006/geno.1999.5855; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; Heyer LJ, 1999, GENOME RES, V9, P1106, DOI 10.1101/gr.9.11.1106; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOFFMAN R, 1991, HEMATOLOGY BASIC PRI; HROMAS R, 1994, INT J HEMATOL, V59, P257; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jansen MWJC, 1999, PRENATAL DIAG, V19, P323, DOI 10.1002/(SICI)1097-0223(199904)19:4<323::AID-PD534>3.3.CO;2-1; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; KABAT D, 1975, CELL, V5, P331, DOI 10.1016/0092-8674(75)90109-9; KAHN P, 1984, P NATL ACAD SCI-BIOL, V81, P7122, DOI 10.1073/pnas.81.22.7122; KENNEDY M, 1992, BLOOD, V79, P180; KILLISCH I, 1992, J CELL SCI, V103, P211; Kina T, 2000, BRIT J HAEMATOL, V109, P280, DOI 10.1046/j.1365-2141.2000.02037.x; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Lander ES, 1999, NAT GENET, V21, P3, DOI 10.1038/4427; LISTER J, 1995, J BIOL CHEM, V270, P17939, DOI 10.1074/jbc.270.30.17939; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; LUETHY JD, 1992, CANCER RES, V52, P5; MEAGHER RC, 1989, EXP HEMATOL, V17, P374; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Mikulits W, 1999, BIOTECHNIQUES, V26, P846, DOI 10.2144/99265bm09; Mikulits W, 2000, FASEB J, V14, P1641, DOI 10.1096/fj.14.11.1641; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; Nguyen MT, 1997, NATURE, V390, P78, DOI 10.1038/36342; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Orkin SH, 1997, ANNU REV GENET, V31, P33, DOI 10.1146/annurev.genet.31.1.33; Oshevski S, 1999, BIOCHEM BIOPH RES CO, V263, P603, DOI 10.1006/bbrc.1999.1425; OZBUN MA, 1993, CANCER RES, V53, P1646; PALMIERI S, 1985, VIROLOGY, V140, P269, DOI 10.1016/0042-6822(85)90365-4; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; PERKINS AC, 1995, NATURE, V375, P318; Perkins AC, 2000, BLOOD, V95, P1827, DOI 10.1182/blood.V95.5.1827.004k10_1827_1833; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; PINCUS SM, 1984, BIOCHEM BIOPH RES CO, V125, P491, DOI 10.1016/0006-291X(84)90567-9; Pollack MA, 2000, WASH QUART, V23, P41, DOI 10.1162/016366000561330; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rivero JA, 1998, BIOCHEM BIOPH RES CO, V248, P664, DOI 10.1006/bbrc.1998.9041; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SASE S, 1982, BIOCHIM BIOPHYS ACTA, V693, P253, DOI 10.1016/0005-2736(82)90493-X; SAWADA K, 1989, J CLIN INVEST, V83, P1701, DOI 10.1172/JCI114070; SAWADA K, 1988, J CELL PHYSIOL, V137, P337, DOI 10.1002/jcp.1041370218; SAWADA K, 1991, J CELL PHYSIOL, V149, P1, DOI 10.1002/jcp.1041490102; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; SAWADA K, 1987, J CLIN INVEST, V80, P35766; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shigematsu H, 1997, J BIOL CHEM, V272, P14334, DOI 10.1074/jbc.272.22.14334; Sitar G, 1999, CYTOMETRY, V35, P337, DOI 10.1002/(SICI)1097-0320(19990401)35:4<337::AID-CYTO6>3.0.CO;2-U; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; Toronen P, 1999, FEBS LETT, V451, P142, DOI 10.1016/S0014-5793(99)00524-4; UDUPA KB, 1988, BRIT J HAEMATOL, V69, P157, DOI 10.1111/j.1365-2141.1988.tb07617.x; UDUPA KB, 1986, BRIT J HAEMATOL, V62, P705, DOI 10.1111/j.1365-2141.1986.tb04094.x; UOSHIMA N, 1995, BRIT J HAEMATOL, V91, P30, DOI 10.1111/j.1365-2141.1995.tb05240.x; von Lindern M, 2000, J BIOL CHEM, V275, P34719, DOI 10.1074/jbc.M007042200; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; Wang RX, 1998, J IMMUNOL, V161, P2201; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wessely O, 1999, BIOL CHEM, V380, P187, DOI 10.1515/BC.1999.027; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; Yamamoto M, 1997, GENES CELLS, V2, P107, DOI 10.1046/j.1365-2443.1997.1080305.x	118	88	91	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1442	+		10.1096/fj.00-0705fje	http://dx.doi.org/10.1096/fj.00-0705fje			39	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387251				2022-12-28	WOS:000173705800011
J	Li, YP; Schwartz, RJ				Li, YP; Schwartz, RJ			TNF-alpha regulates early differentiation of C2C12 myoblasts in an autocrine fashion	FASEB JOURNAL			English	Article						cytokine; myogenesis; NF-kappa B; SRF; MHCf; alpha-actin	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; SERUM RESPONSE FACTOR; NITRIC-OXIDE SYNTHASE; C-FOS GENE; SKELETAL-MUSCLE; ACTIN GENE; BINDING-SITE; TRANSCRIPTIONAL REGULATION; MYOGENIC DIFFERENTIATION	Tumor necrosis factor-alpha (TNF-alpha) has long been known to mediate skeletal muscle protein catabolism as a humoral factor. However, recent findings that muscle normally synthesizes TNF-alpha and that strenuous exercise increases circulating TNF-alpha in healthy individuals raised the possibility that this cytokine may also have a physiological role in skeletal muscle. In this study, we observed a basal level of TNF-alpha expression in C2C12 myoblasts that was markedly up-regulated by serum restriction. Serum restriction also increased nuclear factor-kappaB (NF-kappaB) activity, which could be blocked by a TNF-alpha-neutralizing antibody. This antibody also inhibited the expression of a differentiation marker, adult fast myosin heavy chain, during the initial 24 h of serum restriction. Conversely, fast myosin heavy chain expression was stimulated by exogenous TNF-alpha during the same time period, which could be blocked by a dominant negative inhibitor of NF-kappaB activation. TNF-alpha rapidly stimulated the binding activity of serum response factor (SRF), a transcription factor required for myoblast differentiation, and expression of the SRF-dependent skeletal muscle alpha-actin gene. These results demonstrate for the first time that TNT-alpha is an endogenous muscle factor that promotes the early phase of differentiation by stimulating NF-kappaB and SRF activity.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Li, YP (corresponding author), Baylor Coll Med, Dept Med, Suite 520B,1 Baylor Plaza, Houston, TX 77030 USA.	yiping@bcm.tmc.edu						BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CAMPION DR, 1984, INT REV CYTOL, V87, P225, DOI 10.1016/S0074-7696(08)62444-4; Camus G, 1998, EUR J APPL PHYSIOL O, V79, P62, DOI 10.1007/s004210050474; Chambers R L, 1996, Can J Appl Physiol, V21, P155; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; ERNST H, 1991, MOL CELL BIOL, V11, P3735, DOI 10.1128/MCB.11.7.3735; ESPAT NJ, 1994, SURG ONCOL, V3, P255, DOI 10.1016/0960-7404(94)90027-2; Fahey T J 3rd, 1990, Cytokine, V2, P92, DOI 10.1016/1043-4666(90)90002-B; GARCIAMARTINEZ C, 1993, FEBS LETT, V323, P211, DOI 10.1016/0014-5793(93)81341-V; GarciaMartinez C, 1995, BIOCHEM BIOPH RES CO, V217, P839, DOI 10.1006/bbrc.1995.2848; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; GILGENKRANTZ H, 1992, J BIOL CHEM, V267, P10823; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU MCT, 1986, MOL CELL BIOL, V6, P15, DOI 10.1128/MCB.6.1.15; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Kim SS, 1998, FEBS LETT, V433, P47, DOI 10.1016/S0014-5793(98)00883-7; Layne MD, 1999, EXP CELL RES, V249, P177, DOI 10.1006/excr.1999.4465; Lee KH, 1997, BIOCHEM J, V324, P237, DOI 10.1042/bj3240237; Li YP, 1999, ANTIOXID REDOX SIGN, V1, P97, DOI 10.1089/ars.1999.1.1-97; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165, DOI 10.1152/ajpregu.2000.279.4.R1165; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; LIN JX, 1987, J BIOL CHEM, V262, P11908; LIU YC, 1990, BIOTECHNIQUES, V9, P558; Llovera M, 1997, BIOCHEM BIOPH RES CO, V230, P238, DOI 10.1006/bbrc.1996.5827; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P461, DOI 10.1002/(SICI)1097-4644(19981215)71:4<461::AID-JCB1>3.0.CO;2-0; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; Munoz C, 1996, BLOOD, V88, P3482, DOI 10.1182/blood.V88.9.3482.bloodjournal8893482; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NAKASHIMA J, 1995, CANCER RES, V55, P4881; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Ostrowski K, 1999, J PHYSIOL-LONDON, V515, P287, DOI 10.1111/j.1469-7793.1999.287ad.x; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904; SCHUTZE S, 1988, J IMMUNOL, V140, P3000; Sen CK, 1997, BIOCHEM BIOPH RES CO, V237, P645, DOI 10.1006/bbrc.1997.7206; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; Soulez M, 1996, MOL CELL BIOL, V16, P6065; SPRIGGS DRD, 1992, TUMOR NECROSIS FACTO; Thaloor D, 1999, AM J PHYSIOL-CELL PH, V277, pC320, DOI 10.1152/ajpcell.1999.277.2.C320; TRACEY KJ, 1989, LANCET, V1, P1122; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VREUGDENHIL G, 1992, EUR J CLIN INVEST, V22, P488, DOI 10.1111/j.1365-2362.1992.tb01495.x; Yokoyama T, 1997, CIRCULATION, V95, P1247	63	78	83	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1413	+		10.1096/fj.00-0632fje	http://dx.doi.org/10.1096/fj.00-0632fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387241				2022-12-28	WOS:000173705800027
J	Lindquist, JA; Hammerling, GJ; Trowsdale, J				Lindquist, JA; Hammerling, GJ; Trowsdale, J			ER60/ERp57 forms disulfide-bonded intermediates with MHC class I heavy chain	FASEB JOURNAL			English	Article						antigen presentation; chaperones; disulfide bond formation; endoplasmic reticulum; protein assembly	MAJOR HISTOCOMPATIBILITY COMPLEX; THIOL-DEPENDENT REDUCTASE; LIVER ENDOPLASMIC-RETICULUM; NEWLY SYNTHESIZED PROTEINS; PHOSPHOLIPASE-C-ALPHA; NEGATIVE CELL-LINE; PEPTIDE-BINDING; ER-60 PROTEASE; GLYCOPROTEIN GLUCOSYLTRANSFERASE; ANTIGEN PRESENTATION	We demonstrated previously that ER60/ERp57 is recruited into early folding intermediates in the MHC class I assembly pathway (1). ER60 binding preceded the binding of beta-2-microglobulin and was dependent on the presence of properly trimmed oligosaccharide moieties on the class I heavy chain (HC). Hence, this interaction could not be temporally differentiated from that of calnexin. Here, we show that calnexin is required for the recruitment of ER60 into early folding complexes with the HC and that in the absence of calnexin, ER60 is replaced by another member of the thiol-reductase family, ERp72. We demonstrate that once recruited, ER60 associates covalently with HC via a disulfide bond. The ER60/HC complexes were also found in late assembly complexes, noncovalently bound to the transporter associated with antigen processing and accounted for approximately one-third of the ER60 associated with the transporter associated with antigen processing. These results demonstrate that ER60 assists in the creation of conserved disulfide bonds within the class I HC through the formation of a mixed disulfide intermediate.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; German Canc Res Ctr, Dept Mol Immunol, D-69120 Heidelberg, Germany	University of Cambridge; Helmholtz Association; German Cancer Research Center (DKFZ)	Lindquist, JA (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	JL255@mole.bio.cam.ac.uk	Lindquist, Jonathan/AAB-8526-2021	Lindquist, Jonathan/0000-0001-6846-5056				Allen RL, 1999, J IMMUNOL, V162, P5045; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; Barnden MJ, 2000, J IMMUNOL, V165, P322, DOI 10.4049/jimmunol.165.1.322; BJORKMAN PJ, 1985, J MOL BIOL, V186, P205, DOI 10.1016/0022-2836(85)90271-2; BUSHKIN Y, 1986, P NATL ACAD SCI USA, V83, P432, DOI 10.1073/pnas.83.2.432; CARRENO BM, 1995, J IMMUNOL, V154, P5173; CELIS JE, 1993, ELECTROPHORESIS, V14, pU1091, DOI 10.1002/elps.11501401178; Coligan JKA, 1991, CURRENT PROTOCOLS IM; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Cresswell P, 1999, IMMUNOL RES, V19, P191, DOI 10.1007/BF02786487; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; Edwards JCW, 2000, IMMUNOL TODAY, V21, P256, DOI 10.1016/S0167-5699(00)01625-X; Farmery MR, 2000, J BIOL CHEM, V275, P14933, DOI 10.1074/jbc.275.20.14933; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; GARBI N, 2000, IN PRESS NATURE IMMU; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; Halaby DM, 1999, PROTEIN ENG, V12, P563, DOI 10.1093/protein/12.7.563; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; Hughes EA, 1998, CURR BIOL, V8, P709, DOI 10.1016/S0960-9822(98)70278-7; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Huppa JB, 1998, CELL, V92, P145, DOI 10.1016/S0092-8674(00)80907-1; KOOPMANN JO, UNPUB; LAEMLLI VK, 1970, NATURE, V227, P68; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Lewis JW, 1998, EUR J IMMUNOL, V28, P3214, DOI 10.1002/(SICI)1521-4141(199810)28:10<3214::AID-IMMU3214>3.3.CO;2-3; Lewis JW, 1998, CURR BIOL, V8, P717, DOI 10.1016/S0960-9822(98)70280-5; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; Lobigs M, 2000, EUR J IMMUNOL, V30, P1496, DOI 10.1002/(SICI)1521-4141(200005)30:5<1496::AID-IMMU1496>3.0.CO;2-6; MERRICK BA, 1993, BIOCHEM ARCH, V9, P335; MIYAZAKI JI, 1986, P NATL ACAD SCI USA, V83, P757, DOI 10.1073/pnas.83.3.757; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Morrice NA, 1998, CURR BIOL, V8, P713, DOI 10.1016/S0960-9822(98)70279-9; MURTHY MSR, 1994, BIOCHEM J, V304, P31, DOI 10.1042/bj3040031; NEEFJES JJ, 1986, IMMUNOGENETICS, V23, P164, DOI 10.1007/BF00373817; Neisig A, 1996, J IMMUNOL, V156, P3196; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; RIBAUDO RK, 1992, J IMMUNOL, V149, P2935; Rigney E, 1998, J BIOL CHEM, V273, P14200, DOI 10.1074/jbc.273.23.14200; Ritter C, 2000, NAT STRUCT BIOL, V7, P278; ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Sadasivan BK, 1995, COLD SPRING HARB SYM, V60, P267, DOI 10.1101/SQB.1995.060.01.031; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; Schoenhals GJ, 1999, EMBO J, V18, P743, DOI 10.1093/emboj/18.3.743; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SCOTT JE, 1995, J IMMUNOL, V155, P143; SMITH JD, 1995, MOL IMMUNOL, V32, P531, DOI 10.1016/0161-5890(95)00013-5; SNYDER HL, 1994, J EXP MED, V180, P2389, DOI 10.1084/jem.180.6.2389; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Spee P, 1999, BIOCHEMISTRY-US, V38, P10559, DOI 10.1021/bi990321r; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; STAM NJ, 1986, J IMMUNOL, V137, P2299; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; TECTOR M, 1995, J BIOL CHEM, V270, P19638, DOI 10.1074/jbc.270.33.19638; Tector M, 1997, MOL IMMUNOL, V34, P401, DOI 10.1016/S0161-5890(97)00045-X; Tortorella D, 1998, J CELL BIOL, V142, P365, DOI 10.1083/jcb.142.2.365; URADE R, 1992, J BIOL CHEM, V267, P15152; URADE R, 1992, FEBS LETT, V312, P83, DOI 10.1016/0014-5793(92)81415-I; URADE R, 1993, J BIOL CHEM, V268, P22004; Urade R, 1997, J BIOCHEM-TOKYO, V122, P834; WARBURTON RJ, 1994, HUM IMMUNOL, V39, P261, DOI 10.1016/0198-8859(94)90269-0; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang Q, 1998, J IMMUNOL, V160, P831; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	73	62	64	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1448	+		10.1096/fj.00-0720fje	http://dx.doi.org/10.1096/fj.00-0720fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387253				2022-12-28	WOS:000173705800016
J	Hickey, MJ; Sihota, E; Amrani, A; Santamaria, P; Zbytnuik, LD; Ng, ESM; Ho, W; Sharkey, KA; Kubes, P				Hickey, MJ; Sihota, E; Amrani, A; Santamaria, P; Zbytnuik, LD; Ng, ESM; Ho, W; Sharkey, KA; Kubes, P			Inducible nitric oxide synthase (iNOS) in endotoxemia: chimeric mice reveal different cellular sources in various tissues	FASEB JOURNAL			English	Article						leukocytes; chimera; lipopolysaccharide	DEFICIENT MICE; MESSENGER-RNA; SEPTIC SHOCK; L-ARGININE; LACKING; INFLAMMATION; MODULATION; EXPRESSION; INJURY; VIVO	The aim of these experiments was to determine the contribution of leukocyte-derived iNOS to total iNOS expression induced by lipopolysaccharide (LPS). By transferring bone marrow between iNOS(+/+) and iNOS(-/-) mice, we created chimeric mice in which iNOS expression was limited to either circulating leukocytes (leukocyte-iNOS mice) or parenchymal cells (parenchyma-iNOS mice). Analysis of congenic markers demonstrated that >95% of thymocytes in chimeric mice were of donor origin. Also, following LPS treatment, iNOS mRNA was detectable in blood from leukocyte-iNOS mice but not parenchyma-iNOS mice. Together these findings indicated that the host marrow had been replaced entirely by donor cells. In the lung, at least 50% of the LPS-induced iNOS mRNA was derived from leukocytes, and immunohistochemical analysis indicated that leukocytes were the main source of iNOS protein. In contrast in the liver, colon, and muscle, iNOS expression was derived predominantly from parenchymal cells. This divergence is potentially explained by the high level of leukocyte recruitment to the lung, relative to the other tissues. Plasma levels of NOS byproducts indicated that parenchymal iNOS was the dominant source of systemic iNOS activity. These findings indicate that in tissues other than the lung, parenchymal cells are the principal source of iNOS during endotoxemia.	Monash Univ, Monash Med Ctr, Dept Med, Ctr Inflammatory Dis, Clayton, Vic 3168, Australia; Univ Calgary, Immunol Grp, Calgary, AB, Canada; Univ Calgary, Neurosci Res Grp, Calgary, AB, Canada	Monash University; University of Calgary; University of Calgary	Hickey, MJ (corresponding author), Monash Univ, Monash Med Ctr, Dept Med, Ctr Inflammatory Dis, 246 Clayton Rd, Clayton, Vic 3168, Australia.	michael.hickey@med.monash.edu.au	Santamaria, Pere/ABF-6823-2021; Hickey, Michael J./A-5429-2012	Hickey, Michael J./0000-0003-2354-357X; Sharkey, Keith/0000-0001-9560-1711				BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BILLIAR TR, 1990, BIOCHEM BIOPH RES CO, V168, P1034, DOI 10.1016/0006-291X(90)91133-D; BILLIAR TR, 1990, J LEUKOCYTE BIOL, V48, P565, DOI 10.1002/jlb.48.6.565; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Comtois AS, 1999, AM J RESP CRIT CARE, V159, P1975, DOI 10.1164/ajrccm.159.6.9809020; Fenyk-Melody JE, 1998, J IMMUNOL, V160, P2940; Fierro IM, 1999, J LEUKOCYTE BIOL, V65, P508, DOI 10.1002/jlb.65.4.508; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; HOUSE SD, 1987, MICROVASC RES, V34, P363, DOI 10.1016/0026-2862(87)90068-9; KOLLS J, 1994, P SOC EXP BIOL MED, V205, P220; Laubach VE, 1998, AM J PHYSIOL-HEART C, V275, pH2211, DOI 10.1152/ajpheart.1998.275.6.H2211; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; McCafferty DM, 2000, AM J PHYSIOL-GASTR L, V279, pG90, DOI 10.1152/ajpgi.2000.279.1.G90; McCafferty DM, 1997, GASTROENTEROLOGY, V112, P1022, DOI 10.1053/gast.1997.v112.pm9041266; McCaffery DM, 1999, GUT, V45, P864, DOI 10.1136/gut.45.6.864; MILES AM, 1995, J LEUKOCYTE BIOL, V58, P616, DOI 10.1002/jlb.58.5.616; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; Nicholson SC, 1999, SHOCK, V11, P253, DOI 10.1097/00024382-199904000-00005; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Peng HB, 1998, J IMMUNOL, V161, P1970; Rai RM, 1998, P NATL ACAD SCI USA, V95, P13829, DOI 10.1073/pnas.95.23.13829; RIDINGS PC, 1995, AM J RESP CRIT CARE, V152, P247, DOI 10.1164/ajrccm.152.1.7541277; SATO K, 1995, J LEUKOCYTE BIOL, V57, P36, DOI 10.1002/jlb.57.1.36; Schmidt D, 1999, J IMMUNOL, V162, P4627; Shears LL, 1997, J CLIN INVEST, V100, P2035, DOI 10.1172/JCI119736; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Tsukahara Y, 1998, WORLD J SURG, V22, P771, DOI 10.1007/s002689900468; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Wong J M, 1995, Adv Pharmacol, V34, P155	38	41	41	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7					1141	+		10.1096/fj.01-0764fje	http://dx.doi.org/10.1096/fj.01-0764fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039841				2022-12-28	WOS:000175973900005
J	Nguyen, QD; Faivre, S; Bruyneel, E; Rivat, C; Seto, M; Endo, T; Mareel, M; Emami, S; Gespach, C				Nguyen, QD; Faivre, S; Bruyneel, E; Rivat, C; Seto, M; Endo, T; Mareel, M; Emami, S; Gespach, C			RhoA- and RhoD-dependent regulatory switch of G alpha subunit signaling by PAR-1 receptors in cellular invasion	FASEB JOURNAL			English	Article						colon cancer progression; metastatic potential; guanylate cyclases; src; rac; myosin light chain kinase; guanylin; cGMP	NUCLEOTIDE EXCHANGE FACTOR; SMOOTH-MUSCLE CONTRACTION; COLONIC EPITHELIAL-CELLS; TUMOR-CELLS; ACTIN CYTOSKELETON; THROMBIN RECEPTOR; STRESS FIBERS; CYCLIC-GMP; ALPHA-6-BETA-4 INTEGRIN; NEOPLASTIC PROGRESSION	Thrombin and proteinase-activated receptors (PAR) specifically regulate several functions that markedly enhance the transformation phenotype such as inflammation, cell proliferation, tumor growth, and metastasis. We recently reported that thrombin inhibits cellular invasion induced by src, hepatocyte growth factor (HGF), and leptin in kidney and colonic epithelial cells via predominant activation of the pertussis toxin (PTx) -sensitive G-proteins Galphao/Galphai. We provide pharmacological and biochemical evidence that in the presence of PTx, PAR-1 induced cellular invasion through Galpha12/Galpha13- and RhoA/Rho kinase (ROCK)-dependent signaling. However, inhibition of the endogenous small GTPase RhoA by the C3 exoenzyme, dominant-negative N19-RhoA, activated G26V-RhoD, and activators of the nitric oxide/cGMP pathways conferred invasive activity to PAR-1 via a signaling cascade using Galphaq, phospholipase C (PLC), Ca2+ / calmodulin myosin light chain kinase (CaM-MLCK), and phosphorylation of MLC. We found that cellular invasion induced by the src oncogene is abrogated by inhibitors of the RhoA/ROCK pathway and is independent of PLC/CaM-MLCK signaling. Our data demonstrate that the RhoA and RhoD small GTPases are acting as a molecular switch of cellular invasion and reveal a novel critical mechanism by which PAR-1 bypass Galphao/i and RhoA inhibition via differential coupling to heterotrimeric G-proteins linked to divergent or convergent biological responses. Our data also indicate that Rho GTPases and ROCK mediate a src-dependent invasion signal in kidney and colonic cancer cells. We conclude that dynamic regulation of Rho GTPases activation and inactivation by oncogenes, growth factors, cGMP-inducing agents, and adhesion molecules can initiate convergent invasion signals controlled by the thrombin PAR-1 in cancer cells.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; State Univ Ghent Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Chiba Univ, Dept Biol, Inage Ku, Chiba 2638522, Japan; Asahi Chem Ind Co Ltd, Shizuoka 4160934, Japan	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Chiba University	Gespach, C (corresponding author), Hop St Antoine, INSERM, U482, F-75571 Paris 12, France.	gespach@st-antoine.inserm.fr		Faivre, Sandrine/0000-0002-1590-485X				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Fiorentini C, 1997, J BIOL CHEM, V272, P19532, DOI 10.1074/jbc.272.31.19532; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; Furman MI, 1998, P NATL ACAD SCI USA, V95, P3082, DOI 10.1073/pnas.95.6.3082; Gilchrist A, 2001, J BIOL CHEM, V276, P25672, DOI 10.1074/jbc.M100914200; Grosheva I, 2001, J CELL SCI, V114, P695; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kamath L, 2001, CANCER RES, V61, P5933; Katoh K, 2001, J CELL BIOL, V153, P569, DOI 10.1083/jcb.153.3.569; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LAUNAY JM, 1994, AM J PHYSIOL, V35, pR526; Lucas KA, 2000, PHARMACOL REV, V52, P375; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; MACKIE EJ, 1987, P NATL ACAD SCI USA, V84, P4621, DOI 10.1073/pnas.84.13.4621; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Ridley A, 2000, J CELL BIOL, V150, pF107, DOI 10.1083/jcb.150.4.F107; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; Sagi SA, 2001, J BIOL CHEM, V276, P15445, DOI 10.1074/jbc.M008961200; Sakurada K, 1998, AM J PHYSIOL-CELL PH, V274, pC1563, DOI 10.1152/ajpcell.1998.274.6.C1563; Santagata S, 2001, SCIENCE, V292, P2041, DOI 10.1126/science.1061233; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Tanaka M, 2000, INT J MOL MED, V5, P505; Tsubakimoto K, 1999, ONCOGENE, V18, P2431, DOI 10.1038/sj.onc.1202604; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; WOJTUKIEWICZ MZ, 1995, CANCER RES, V55, P698; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	67	51	52	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					565	576		10.1096/fj.01-0525com	http://dx.doi.org/10.1096/fj.01-0525com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919159				2022-12-28	WOS:000175425900010
J	Ogura, T; Furukawa, T; Toyozaki, T; Yamada, K; Zheng, YJ; Katayama, Y; Nakaya, H; Inagaki, N				Ogura, T; Furukawa, T; Toyozaki, T; Yamada, K; Zheng, YJ; Katayama, Y; Nakaya, H; Inagaki, N			ClC-3B, a novel ClC-3 splicing variant that interacts with EBP50 and facilitates expression of CFTR-regulated ORCC	FASEB JOURNAL			English	Article						chloride channel; epithelium; PDZ domain; cystic fibrosis	RECTIFYING CHLORIDE CHANNELS; CYSTIC-FIBROSIS GENE; TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDENT PROTEIN-KINASE; CL CHANNELS; IDENTIFICATION; CELLS; CURRENTS; CLONING; FAMILY	We have cloned ClC-3B, a novel alternative splicing variant of ClC-3 (ClC-3A) that is expressed predominantly in epithelial cells. ClC-3B has a different, slightly longer C-terminal end than ClC-3A and contains a consensus motif for binding to the second PDZ (PSD95/Dlg/ZO-1) domain of the epithelium-specific scaffolding protein EBP50. Both in vitro and in vivo binding assays demonstrate interaction between ClC-3B and EBP50. C127 mouse mammary epithelial cells transfected with ClC-3B alone showed diffuse immunoreactivity for ClC-3B in the cytoplasmic region. In contrast, when EBP50 was cotransfected with ClC-3B, strong immunoreactivity for ClC-3B appeared at the leading edges of membrane ruffles. Patch-clamp experiments revealed that cotransfection of ClC-3B and EBP50 resulted in a remarkable increase in outwardly rectifying Cl- channel (ORCC) activities at the leading edges of membrane ruffles in C127 cells. The electrophysiological properties of the ClC-3B-induced ORCCs are similar to those of ORCCs described in native epithelial cells. When cystic fibrosis transmembrane conductance regulator (CFTR) was cotransfected with ClC-3B and EBP50, ClC-3B-dependent ORCCs were activated via the protein kinase A-dependent pathway. These findings indicate that ClC-3B is itself a CFTR-regulated ORCC molecule or its activator.	Akita Univ, Sch Med, Dept Physiol, Akita 0108543, Japan; Chiba Univ, Grad Sch Med, Dept Pharmacol, Chiba, Japan; Chiba Univ, Grad Sch Med, Dept Basic Pathol, Chiba, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Autonom Physiol, Tokyo, Japan; Japan Sci & Technol Corp, CREST, Akita, Japan	Akita University; Chiba University; Chiba University; Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST)	Furukawa, T (corresponding author), Akita Univ, Sch Med, Dept Physiol, Akita 0108543, Japan.	tfuru@med.akita-u.ac.jp	furukawa, tetsushi/ABD-3178-2020	Inagaki, Nobuya/0000-0001-8261-2593				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; Begenisich T, 1998, J MEMBRANE BIOL, V163, P77, DOI 10.1007/s002329900372; BORSANI G, 1995, GENOMICS, V27, P131, DOI 10.1006/geno.1995.1015; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; KAWAMURA K, 1995, IEEE T REHABIL ENG, V3, P14, DOI 10.1109/86.372888; KAWASAKI M, 1994, NEURON, V12, P597, DOI 10.1016/0896-6273(94)90215-1; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; KRICK W, 1991, PFLUG ARCH EUR J PHY, V418, P491, DOI 10.1007/BF00497777; KUNZELMANN K, 1991, PFLUG ARCH EUR J PHY, V418, P479, DOI 10.1007/BF00497776; Lepple-Wienhues A, 2001, FASEB J, V15, P927, DOI 10.1096/fj.00-0264com; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Shimada K, 2000, AM J PHYSIOL-GASTR L, V279, pG268, DOI 10.1152/ajpgi.2000.279.2.G268; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Weylandt KH, 2001, J BIOL CHEM, V276, P17461, DOI 10.1074/jbc.M011667200	32	72	75	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					863	+		10.1096/fj.01-0845fje	http://dx.doi.org/10.1096/fj.01-0845fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967229				2022-12-28	WOS:000175425900020
J	Hiller, R; Laffer, S; Harwanegg, C; Huber, M; Schmidt, WM; Twardosz, A; Barletta, B; Becker, WM; Blaser, K; Breiteneder, H; Chapman, M; Crameri, R; Duchene, M; Ferreira, F; Fiebig, H; Hoffmann-Sommergruber, K; King, TP; Kleber-Janke, T; Kurup, VP; Lehrer, SB; Lidholm, J; Muller, U; Pini, C; Reese, G; Scheiner, O; Scheynius, A; Shen, HD; Spitzauer, S; Suck, R; Swoboda, I; Thomas, W; Tinghino, R; Van Hage-Hamsten, M; Virtanen, T; Kraft, D; Muller, MW; Valenta, R				Hiller, R; Laffer, S; Harwanegg, C; Huber, M; Schmidt, WM; Twardosz, A; Barletta, B; Becker, WM; Blaser, K; Breiteneder, H; Chapman, M; Crameri, R; Duchene, M; Ferreira, F; Fiebig, H; Hoffmann-Sommergruber, K; King, TP; Kleber-Janke, T; Kurup, VP; Lehrer, SB; Lidholm, J; Muller, U; Pini, C; Reese, G; Scheiner, O; Scheynius, A; Shen, HD; Spitzauer, S; Suck, R; Swoboda, I; Thomas, W; Tinghino, R; Van Hage-Hamsten, M; Virtanen, T; Kraft, D; Muller, MW; Valenta, R			Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment	FASEB JOURNAL			English	Article						type I allergy; IgE; microarray technology; recombinant allergen; diagnosis	GRASS PHLEUM-PRATENSE; HOUSE-DUST MITE; AMINO-ACID-SEQUENCE; ASPERGILLUS-FUMIGATUS ALLERGENS; PENICILLIUM-CITRINUM ALLERGEN; COMPLEMENTARY-DNA CLONING; CROSS-REACTIVE ALLERGEN; BIRCH POLLEN ALLERGEN; HIGH-LEVEL EXPRESSION; IGE-BINDING EPITOPES	Type I allergy is an immunoglobulin E (IgE)-mediated hypersensitivity disease affecting more than 25% of the population. Currently, diagnosis of allergy is performed by provocation testing and IgE serology using allergen extracts. This process defines allergen-containing sources but cannot identify the disease-eliciting allergenic molecules. We have applied microarray technology to develop a miniaturized allergy test containing 94 purified allergen molecules that represent the most common allergen sources. The allergen microarray allows the determination and monitoring of allergic patients' IgE reactivity profiles to large numbers of disease-causing allergens by using single measurements and minute amounts of serum. This method may change established practice in allergy diagnosis, prevention, and therapy. In addition, microarrayed antigens may be applied to the diagnosis of autoimmune and infectious diseases.	Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Univ Vienna, Dept Internal Med 4, Div Pulm, A-1090 Vienna, Austria; VBC GENOMICS, A-1030 Vienna, Austria; Ist Super Sanita, Immunol Lab, I-00161 Rome, Italy; Res Ctr Borstel, D-23845 Borstel, Germany; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Univ Virginia, Dept Internal Med, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Salzburg Univ, Dept Genet & Biol, A-5020 Salzburg, Austria; Allergopharma Joachim Ganzer KG, D-21465 Reinbek, Germany; Rockefeller Univ, New York, NY 10021 USA; Med Coll Wisconsin, Milwaukee, WI 53295 USA; Tulane Univ, Med Ctr, Dept Med, Sect Clin Immunol & Allergy, New Orleans, LA 70112 USA; Pharmacia Diagnost AB, Uppsala, Sweden; Zieglerspital Bern, Dept Internal Med, CH-3007 Bern, Switzerland; Karolinska Inst, S-17176 Stockholm, Sweden; Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan; Univ Vienna, Inst Med & Lab Diagnost, A-1090 Vienna, Austria; Univ W Australia, TVW Telethon Inst Child Hlth Res, Perth 6872, Australia; Karolinska Hosp & Inst, Div Clin Immunol, Dept Lab Med, S-17176 Stockholm, Sweden; Univ Kuopio, Dept Clin Microbiol, FIN-70211 Kuopio, Finland	University of Vienna; University of Vienna; Istituto Superiore di Sanita (ISS); Forschungszentrum Borstel; Swiss Institute of Allergy & Asthma Research; University of Virginia; Salzburg University; Allergopharma; Rockefeller University; Medical College of Wisconsin; Tulane University; Pfizer; Pharmacia Corporation; Karolinska Institutet; University of Vienna; Telethon Kids Institute; University of Western Australia; Karolinska Institutet; Karolinska University Hospital; University of Eastern Finland	Valenta, R (corresponding author), Univ Vienna, Vienna Gen Hosp AKH, Dept Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	Rudolf.valenta@akh-wien.ac.at	Ferreira, Fatima/AAB-4321-2019; Ferreira, Fatima/E-4889-2011; van Hage, Marianne/A-9678-2017; BARLETTA, BIANCA/B-9980-2016; Duchêne, Michael/G-6659-2019	Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; van Hage, Marianne/0000-0003-3091-1596; Duchêne, Michael/0000-0003-1232-3600; Lidholm, Jonas/0000-0002-7779-3411; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X; Schmidt, Wolfgang/0000-0002-6944-2443; Valenta, Rudolf/0000-0001-5944-3365; Swoboda, Ines/0000-0002-9164-1721; Chapman, Martin/0000-0002-0845-3632				Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; Bieber T, 1997, IMMUNOL TODAY, V18, P311, DOI 10.1016/S0167-5699(97)01046-3; Blackley C.H., 1880, HAY FEVER ITS CAUSES; BREITENBACH M, 1995, INT ARCH ALLERGY IMM, V107, P458, DOI 10.1159/000237081; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; Breiteneder H, 1998, INT ARCH ALLERGY IMM, V116, P83, DOI 10.1159/000023930; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Bugajska-Schretter A, 1998, J ALLERGY CLIN IMMUN, V101, P67, DOI 10.1016/S0091-6749(98)70195-2; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Crameri R, 1996, INT ARCH ALLERGY IMM, V110, P41, DOI 10.1159/000237308; Crameri R, 1998, INT ARCH ALLERGY IMM, V115, P99, DOI 10.1159/000023889; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Duro G, 1996, FEBS LETT, V399, P295, DOI 10.1016/S0014-5793(96)01328-2; Eriksson TLJ, 2001, EUR J BIOCHEM, V268, P287, DOI 10.1046/j.1432-1327.2001.01879.x; Eriksson TLJ, 1998, EUR J BIOCHEM, V251, P443, DOI 10.1046/j.1432-1327.1998.2510443.x; Fischer S, 1996, J ALLERGY CLIN IMMUN, V98, P189, DOI 10.1016/S0091-6749(96)70242-7; Ganglberger E, 2001, INT ARCH ALLERGY IMM, V125, P216, DOI 10.1159/000053819; Haab BB, 2001, GENOME BIOL, V2; Heiss S, 1999, J INVEST DERMATOL, V113, P830, DOI 10.1046/j.1523-1747.1999.00796.x; Hemmann S, 1997, AM J RESP CRIT CARE, V156, P1956, DOI 10.1164/ajrccm.156.6.9702087; HENDERSON LL, 1975, J ALLERGY CLIN IMMUN, V55, P10, DOI 10.1016/S0091-6749(75)80003-0; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; Hoffmann-Sommergruber K, 2000, INT ARCH ALLERGY IMM, V122, P115, DOI 10.1159/000024367; Hoffmann-Sommergruber K, 1999, CLIN EXP ALLERGY, V29, P840, DOI 10.1046/j.1365-2222.1999.00529.x; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; JOHANSSON SG, 1967, IMMUNOLOGY, V13, P381; Kay A.B., 1997, ALLERGY ALLERGIC DIS; King TP, 2000, INT ARCH ALLERGY IMM, V123, P99, DOI 10.1159/000024440; Kleber-Janke T, 1999, INT ARCH ALLERGY IMM, V119, P265, DOI 10.1159/000024203; KOS T, 1993, BIOCHEM BIOPH RES CO, V196, P1086, DOI 10.1006/bbrc.1993.2362; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LIN KL, 1994, J ALLERGY CLIN IMMUN, V94, P989, DOI 10.1016/0091-6749(94)90117-1; Lindborg M, 1999, J INVEST DERMATOL, V113, P156, DOI 10.1046/j.1523-1747.1999.00661.x; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; MacBeath G, 2000, SCIENCE, V289, P1760; Mendoza LG, 1999, BIOTECHNIQUES, V27, P778, DOI 10.2144/99274rr01; Monsalve RI, 1999, PROTEIN EXPRES PURIF, V16, P410, DOI 10.1006/prep.1999.1082; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; MOSER M, 1992, J IMMUNOL, V149, P454; Natter S, 1998, FASEB J, V12, P1559, DOI 10.1096/fasebj.12.14.1559; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Niederberger V, 1999, FASEB J, V13, P843, DOI 10.1096/fasebj.13.8.843; Olsson S, 1998, CLIN EXP ALLERGY, V28, P984, DOI 10.1046/j.1365-2222.1998.00375.x; ONEILL GM, 1994, BBA-GENE STRUCT EXPR, V1219, P521, DOI 10.1016/0167-4781(94)90080-9; Pandjaitan B, 2000, J ALLERGY CLIN IMMUN, V105, P279, DOI 10.1016/S0091-6749(00)90077-0; RASANEN L, 1994, ALLERGY, V49, P342, DOI 10.1111/j.1398-9995.1994.tb02279.x; Rasool O, 2000, EUR J BIOCHEM, V267, P4355, DOI 10.1046/j.1432-1327.2000.01475.x; Rautiainen J, 1998, BIOCHEM BIOPH RES CO, V247, P746, DOI 10.1006/bbrc.1998.8851; Reese G, 1997, INT ARCH ALLERGY IMM, V113, P240, DOI 10.1159/000237558; SCHMIDT M, 1995, FEBS LETT, V370, P11, DOI 10.1016/0014-5793(95)98164-E; Schmidt M, 1997, EUR J BIOCHEM, V246, P181, DOI 10.1111/j.1432-1033.1997.00181.x; Schweitzer B, 2000, P NATL ACAD SCI USA, V97, P10113, DOI 10.1073/pnas.170237197; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; Shen HD, 1999, CLIN EXP ALLERGY, V29, P642, DOI 10.1046/j.1365-2222.1999.00509.x; SHEN HD, 1993, CLIN EXP ALLERGY, V23, P934, DOI 10.1111/j.1365-2222.1993.tb00278.x; Shen HD, 2000, J ALLERGY CLIN IMMUN, V105, P827, DOI 10.1067/mai.2000.105220; Shen HD, 1997, CLIN EXP ALLERGY, V27, P682, DOI 10.1111/j.1365-2222.1997.tb01197.x; Simon-Nobbe B, 2000, J ALLERGY CLIN IMMUN, V106, P887, DOI 10.1067/mai.2000.110799; Singh MB, 1999, INT ARCH ALLERGY IMM, V119, P75, DOI 10.1159/000024181; Smith W, 1999, INT ARCH ALLERGY IMM, V118, P15, DOI 10.1159/000024026; Soldatova LN, 1998, J ALLERGY CLIN IMMUN, V101, P691, DOI 10.1016/S0091-6749(98)70179-4; Spitzauer S, 1999, INT ARCH ALLERGY IMM, V120, P259, DOI 10.1159/000024278; Suck R, 2000, INT ARCH ALLERGY IMM, V121, P284, DOI 10.1159/000024341; Thomas WR, 1999, CLIN EXP ALLERGY, V29, P1583, DOI 10.1046/j.1365-2222.1999.00670.x; Tinghino R, 1998, J ALLERGY CLIN IMMUN, V101, P772, DOI 10.1016/S0091-6749(98)70306-9; Twardosz A, 1997, BIOCHEM BIOPH RES CO, V239, P197, DOI 10.1006/bbrc.1997.6860; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 2000, J ALLERGY CLIN IMMUN, V105, P432, DOI 10.1067/mai.2000.104783; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; VALENTA R, 1994, BIOCHEM BIOPH RES CO, V199, P106, DOI 10.1006/bbrc.1994.1201; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Virtanen T, 1999, INT ARCH ALLERGY IMM, V120, P247, DOI 10.1159/000024277; VRTALA S, 1993, J IMMUNOL, V151, P4773; Vrtala S, 1999, J IMMUNOL, V163, P5489; Wagner B, 1999, J ALLERGY CLIN IMMUN, V104, P1084, DOI 10.1016/S0091-6749(99)70093-X; Wagner S, 2000, EUR J BIOCHEM, V267, P7006, DOI 10.1046/j.1432-1327.2000.01801.x; WIDE L, 1967, LANCET, V2, P1105; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0; Zargari A, 1999, J ALLERGY CLIN IMMUN, V103, P877, DOI 10.1016/S0091-6749(99)70433-1	90	348	375	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					414	+		10.1096/fj.01-0711fje	http://dx.doi.org/10.1096/fj.01-0711fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11790727				2022-12-28	WOS:000173656600022
J	Romano, M; Catalano, A; Nutini, M; D'Urbano, E; Crescenzi, C; Claria, J; Libner, R; Davi, G; Procopio, A				Romano, M; Catalano, A; Nutini, M; D'Urbano, E; Crescenzi, C; Claria, J; Libner, R; Davi, G; Procopio, A			5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor	FASEB JOURNAL			English	Article						mesothelioma; arachidonic acid; apoptosis; angiogenesis; eicosanoids	IN-VITRO; CANCER-CELLS; COLON-CANCER; ANTISENSE OLIGONUCLEOTIDES; EXPRESSION; INHIBITION; 12-LIPOXYGENASE; TRANSFORMATION; LIPOXYGENASES; ANGIOGENESIS	Evidence indicates that lipoxygenases (LO) may play a role in cancer cell survival. We show that human malignant pleural mesothelial (MM) cells, but not normal mesothelial (NM) cells, express a catalytically active 5-LO. Pharmacological or genetic inhibition of MM cell 5-LO determined nucleosome formation and induced a DNA fragmentation pattern typical of apoptosis. This was completely reversed by exogenously added 5(S)-HETE but not by 12(S)-, 15(S) HETE, or leukotriene (LT)B(4). A 5-LO antisense oligonucleotide potently and time-dependently reduced vascular endothelial growth factor (VEGF) mRNA and constitutive VEGF accumulation in the conditioned media of MM cells. When NM cells were transfected with a 5-LO cDNA, basal and arachidonic acid-induced VEGF formation increased consistently by 6- and 12-fold, respectively. This was associated with a significant increase in DNA synthesis that was counteracted by a specific anti-VEGF antibody. Arachidonic acid and 5(S) HETE also potently stimulated the activity of a VEGF promoter construct. Thus, 5-LO is a key regulator of MM cell proliferation and survival via a VEGF-related circuit.	Univ Messina, Dept Human Pathol, Messina, Italy; Univ Ancona, Inst Expt Pathol, I-60128 Ancona, Italy; Univ G DAnnunzio, Dept Med & Aging, Chieti, Italy; Hosp Clin Barcelona, DNA Unit, Barcelona, Spain; City Hosp, Dept Pathol, Alessandria, Italy	University of Messina; Marche Polytechnic University; G d'Annunzio University of Chieti-Pescara; University of Barcelona; Hospital Clinic de Barcelona	Romano, M (corresponding author), Univ G DAnnunzio, Cattedra Ematol, Dipartimento Med & Sci Invecchiamento, Via Vestini 31, I-66013 Chieti, Italy.	mromano@unich.it	Procopio, Antonio Domenico/AAB-2451-2021; Claria, Joan/M-7772-2019; Romano, Mario/I-7986-2012	Procopio, Antonio Domenico/0000-0001-6897-8724; Romano, Mario/0000-0001-8512-1458; Claria, Joan/0000-0003-4333-7749				Attanoos RL, 1997, HISTOPATHOLOGY, V30, P403, DOI 10.1046/j.1365-2559.1997.5460776.x; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581; Ding XZ, 1999, BIOCHEM BIOPH RES CO, V261, P218, DOI 10.1006/bbrc.1999.1012; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Froom P, 2000, J OCCUP ENVIRON MED, V42, P19, DOI 10.1097/00043764-200001000-00007; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; Ho L, 2001, Cancer Treat Res, V105, P327; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; Kumar-Singh S, 1999, J PATHOL, V189, P72, DOI 10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Langerak AW, 1996, J PATHOL, V178, P151; LEE TC, 1993, CANCER RES, V53, P2858; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; MANNING LS, 1991, CLIN EXP IMMUNOL, V83, P85; Marrogi A, 2000, CANCER RES, V60, P3696; Marzo AL, 1997, CANCER RES, V57, P3200; Masferrer JL, 2000, CANCER RES, V60, P1306; Natarajan R, 1997, AM J PHYSIOL-HEART C, V273, pH2224, DOI 10.1152/ajpheart.1997.273.5.H2224; Nie DT, 2000, BLOOD, V95, P2304, DOI 10.1182/blood.V95.7.2304.007k23_2304_2311; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Park S, 1998, CANCER LETT, V127, P23, DOI 10.1016/S0304-3835(97)00543-0; ROMANO M, 1992, BIOCHEMISTRY-US, V31, P8269, DOI 10.1021/bi00150a021; ROMANO M, 1993, BIOCHEM J, V296, P127, DOI 10.1042/bj2960127; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; Testa JR, 1998, CANCER RES, V58, P4505; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; Zebrowski BK, 1999, CLIN CANCER RES, V5, P3364	39	101	105	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2326	2336		10.1096/fj.01-0150com	http://dx.doi.org/10.1096/fj.01-0150com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689458				2022-12-28	WOS:000172420500003
J	Hofer, T; Desbaillets, I; Hopfl, G; Gassmann, M; Wenger, RH				Hofer, T; Desbaillets, I; Hopfl, G; Gassmann, M; Wenger, RH			Dissecting hypoxia-dependent and hypoxia-independent steps in the HIF-1 alpha activation cascade: implications for HIF-1 alpha gene therapy	FASEB JOURNAL			English	Article						oxygen; VEGF; therapeutic angiogenesis; inducible gene expression; MAP kinase	INDUCIBLE FACTOR 1-ALPHA; TUMOR-SUPPRESSOR PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; FACTOR-I HIF-1; TRANSCRIPTION FACTOR; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; EXPRESSION; CELLS	The heterodimeric hypoxia-inducible factor (HIF)-1 is a master transcriptional regulator of oxygen homeostasis and a possible target for gene therapy of ischemic disease. Although the role of oxygen concentration in HIF-1 alpha protein stabilization is well established, it is less clear whether and how oxygen-regulated mechanisms contribute to HIF-1 alpha protein modifications, nuclear translocation, heterodimerization with the beta -subunit, recruitment of cofactors, and gene trans-activation. Because the HIF-1 alpha protein is proteolytically degraded under normoxic conditions, we established two HeLa Tet-Off cell lines (HT42 and HT43), which inducibly overexpress high levels of HIF-1 alpha under normoxic conditions, allowing to distinguish hypoxia-dependent from hypoxia-independent activation mechanisms. Using these cells, we found that normoxically induced HIF-1 alpha is localized to the nucleus, binds DNA, and trans-activates reporter and endogenous target genes. The levels of p53 expression remained unaffected. The MAP kinase inhibitor PD98059 attenuated HIF-1 alpha protein modifications and trans-activation ability but not protein stabilization and DNA-binding activity. Because overexpressed HIF-1 alpha is fully localized to the nucleus but displays only partial DNA-binding and trans-activation activity, mitogen-activated protein kinase-dependent phosphorylation might be required for full HIF-1 activation. HIF-1 alpha protein was also overexpressed in vivo, following the transplantation of HT42 cells into nude mice, demonstrating the feasibility of HIF-1 alpha gene transfer.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Vet Physiol, CH-8057 Zurich, Switzerland; Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany	University of Zurich; University of Zurich; University of Lubeck	Gassmann, M (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	maxg@access.unizh.ch	Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839				Agani F, 1998, MOL PHARMACOL, V54, P749, DOI 10.1124/mol.54.5.749; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chen EY, 2001, CANCER RES, V61, P2429; Chilov D, 1999, J CELL SCI, V112, P1203; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gassmann M, 1997, KIDNEY INT, V51, P567, DOI 10.1038/ki.1997.81; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kim CY, 1997, CANCER RES, V57, P4200; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salceda S, 1997, KIDNEY INT, V51, P556, DOI 10.1038/ki.1997.78; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schratzberger P, 2001, J CLIN INVEST, V107, P1083, DOI 10.1172/JCI12188; Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wenger RH, 1998, CANCER RES, V58, P5678; Xia GB, 2001, CANCER-AM CANCER SOC, V91, P1429, DOI 10.1002/1097-0142(20010415)91:8<1429::AID-CNCR1149>3.0.CO;2-V; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	50	69	74	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2715	+		10.1096/fj.01-0546fje	http://dx.doi.org/10.1096/fj.01-0546fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606485				2022-12-28	WOS:000171920400008
J	Hanover, JA				Hanover, JA			Glycan-dependent signaling: O-linked N-acetylglucosamine	FASEB JOURNAL			English	Review						O-GlcNAc; hexosaminidase C; diabetes mellitus; OGT	NUCLEAR-PORE COMPLEX; GLUCOSE-INDUCED DESENSITIZATION; BETA-D-GLUCOSAMINE; RNA-POLYMERASE-II; LARGE T-ANTIGEN; GLCNAC TRANSFERASE; GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; HEXOSAMINE BIOSYNTHESIS; PROTEIN P62; TRANSCRIPTION FACTORS	The addition of O-linked N-acetylglucosamine (O-GlcNAc) to target proteins may serve as a signaling modification analogous to protein phosphorylation. Like phosphorylation, O-GlcNAc is a dynamic modification occurring in the nucleus and cytoplasm. Various analytical methods have been developed to detect O-GlcNAc and distinguish it from glycosylation in the endomembrane system. Many target molecules have been identified; these targets are typically components of supramolecular complexes such as transcription factors, nuclear pore proteins, or cytoskeletal components. The enzymes responsible for O-GlcNAc addition and removal are highly conserved molecules having molecular features consistent with a signaling role. The O-GlcNAc transferase and O-GlcNA case are likely to act in consort with kinases and phosphatases generating various isoforms of physiological substrates. These isoforms may differ in such properties as protein-protein interactions, protein stability, and enzymatic activity. Since O-GlcNAc plays a critical role in the regulation of signaling pathways of higher plants, the glycan modification is likely to perform similar signaling functions in mammalian cells. Glucose and amino acid metabolism generates hexosamine precursors that may be key regulators of a nutrient sensing pathway involving O-GlcNAc signaling. Altered O-linked GlcNAc metabolism may also occur in human diseases including neurodegenerative disorders, diabetes mellitus and cancer.	NIDDK, LCBB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hanover, JA (corresponding author), NIDDK, LCBB, NIH, Bldg 8,Rm 402, Bethesda, MD 20892 USA.	jah@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afrikanova I, 1996, J GEN VIROL, V77, P2059, DOI 10.1099/0022-1317-77-9-2059; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; Arnold CS, 1996, J BIOL CHEM, V271, P28741, DOI 10.1074/jbc.271.46.28741; BAILER SM, 1995, PROTEIN EXPRES PURIF, V6, P546, DOI 10.1006/prep.1995.1072; BALKAN B, 1994, DIABETES, V43, P1173, DOI 10.2337/diabetes.43.10.1173; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Busch C, 2000, INFECT IMMUN, V68, P6378, DOI 10.1128/IAI.68.11.6378-6383.2000; Buse MG, 1997, AM J PHYSIOL-ENDOC M, V272, pE1080, DOI 10.1152/ajpendo.1997.272.6.E1080; BUSTAMANTE JO, 1995, J MEMBRANE BIOL, V146, P253; BUSTAMANTE JO, 1995, J MEMBRANE BIOL, V146, P263; BUSTAMANTE JO, 1995, J MEMBRANE BIOL, V146, P239; Chang Q, 2000, J BIOL CHEM, V275, P21981, DOI 10.1074/jbc.M001049200; CHAO YB, 1994, PROTEIN SCI, V3, P2452; Chen MG, 1997, MOL CELL ENDOCRINOL, V135, P67, DOI 10.1016/S0303-7207(97)00191-3; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Cole RN, 1999, J NEUROCHEM, V73, P418, DOI 10.1046/j.1471-4159.1999.0730418.x; Comer FI, 1999, BBA-GEN SUBJECTS, V1473, P161, DOI 10.1016/S0304-4165(99)00176-2; CORDES VC, 1993, EUR J CELL BIOL, V60, P185; DANIELS MC, 1993, MOL ENDOCRINOL, V7, P1041, DOI 10.1210/me.7.8.1041; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; DATTA B, 1989, J BIOL CHEM, V264, P20620; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; Ding M, 1996, J BIOL CHEM, V271, P12555, DOI 10.1074/jbc.271.21.12555; Dong DLY, 1996, J BIOL CHEM, V271, P20845, DOI 10.1074/jbc.271.34.20845; DONG DLY, 1993, J BIOL CHEM, V268, P16679; DONG DLY, 1994, J BIOL CHEM, V269, P19321; DONOFRIO M, 1988, P NATL ACAD SCI USA, V85, P9595, DOI 10.1073/pnas.85.24.9595; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Duverger E, 1996, GLYCOBIOLOGY, V6, P381, DOI 10.1093/glycob/6.4.381; Fang B, 1998, ARCH BIOCHEM BIOPHYS, V357, P95, DOI 10.1006/abbi.1998.0767; Favreau C, 1996, BIOCHEMISTRY-US, V35, P8035, DOI 10.1021/bi9600660; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Gao Y, 2000, ARCH BIOCHEM BIOPHYS, V383, P296, DOI 10.1006/abbi.2000.2094; GIACCARI A, 1995, DIABETOLOGIA, V38, P518, DOI 10.1007/BF00400719; Greis KD, 1996, ANAL BIOCHEM, V234, P38, DOI 10.1006/abio.1996.0047; GRIFFITH LS, 1995, J NEUROSCI RES, V41, P270, DOI 10.1002/jnr.490410214; GRIFFITH LS, 1995, BIOCHEM BIOPH RES CO, V213, P424, DOI 10.1006/bbrc.1995.2149; HABERHAUSEN G, 1995, AM J HUM GENET, V57, P644; HAGMANN J, 1992, J BIOL CHEM, V267, P14424; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Haltiwanger RS, 1997, J BIOL CHEM, V272, P8752, DOI 10.1074/jbc.272.13.8752; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Han I, 1998, J CELL BIOCHEM, V68, P50, DOI 10.1002/(SICI)1097-4644(19980101)68:1<50::AID-JCB5>3.0.CO;2-V; Hanover JA, 1999, ARCH BIOCHEM BIOPHYS, V362, P38, DOI 10.1006/abbi.1998.1016; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HANOVER JA, 1992, FASEB J, V6, P2288, DOI 10.1096/fasebj.6.6.1312045; HANOVER JA, 1979, J BIOL CHEM, V254, P9237; HANOVER JA, 1982, J BIOL CHEM, V257, P2787; HART GW, 1995, ADV EXP MED BIOL, V376, P115; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hawkins M, 1996, DIABETES, V45, P1734, DOI 10.2337/diabetes.45.12.1734; HAYES BK, 1995, ANAL BIOCHEM, V228, P115, DOI 10.1006/abio.1995.1322; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; Heese-Peck A, 1998, PLANT CELL, V10, P599, DOI 10.1105/tpc.10.4.599; HEESEPECK A, 1995, PLANT CELL, V7, P1459, DOI 10.1105/tpc.7.9.1459; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HOLT GD, 1986, J BIOL CHEM, V261, P8049; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Jiang MS, 1997, J BIOL CHEM, V272, P2421; Jones C, 2000, CARBOHYD RES, V328, P321, DOI 10.1016/S0008-6215(00)00107-5; Jung E, 1997, BIOCHEMISTRY-US, V36, P4034, DOI 10.1021/bi9617825; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1989, CELL, V57, P243, DOI 10.1016/0092-8674(89)90962-8; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KELLY WG, 1989, CELL, V58, P419; Klein C, 2000, NERVENARZT, V71, P431, DOI 10.1007/s001150050604; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Konrad RJ, 2000, BIOCHEM BIOPH RES CO, V267, P26, DOI 10.1006/bbrc.1999.1895; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; KU NO, 1994, EXP CELL RES, V211, P24, DOI 10.1006/excr.1994.1054; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; LIU SH, 1995, DEV GENET, V16, P229, DOI 10.1002/dvg.1020160303; Love DC, 1998, P NATL ACAD SCI USA, V95, P10608, DOI 10.1073/pnas.95.18.10608; Lubas WA, 2000, J BIOL CHEM, V275, P10983, DOI 10.1074/jbc.275.15.10983; LUBAS WA, 1995, BIOCHEMISTRY-US, V34, P1686, DOI 10.1021/bi00005a025; Lubas WA, 1997, J BIOL CHEM, V272, P9316; LUTHI T, 1991, J NEUROCHEM, V56, P1493; MARSHALL S, 1991, J BIOL CHEM, V266, P10155; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Medina L, 1998, GLYCOBIOLOGY, V8, P383, DOI 10.1093/glycob/8.4.383; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; MILLER MW, 1994, J BIOL CHEM, V269, P9289; Miller MW, 1999, ARCH BIOCHEM BIOPHYS, V367, P51, DOI 10.1006/abbi.1999.1237; MURPHY JE, 1994, J BIOL CHEM, V269, P21346; Nerlich AG, 1998, DIABETES, V47, P170, DOI 10.2337/diabetes.47.2.170; Ogas J, 1998, CURR BIOL, V8, pR165, DOI 10.1016/S0960-9822(98)70101-0; PARK MK, 1987, P NATL ACAD SCI USA, V84, P6462, DOI 10.1073/pnas.84.18.6462; Peters U, 1997, HUM GENET, V100, P569, DOI 10.1007/s004390050553; Pollevick GD, 2000, J BIOL CHEM, V275, P27671; POOLA I, 1988, J BIOL CHEM, V263, P19137; PREVIATO JO, 1995, J BIOL CHEM, V270, P7241, DOI 10.1074/jbc.270.13.7241; Ragano-Caracciolo M, 1998, BIOCHEM BIOPH RES CO, V249, P422, DOI 10.1006/bbrc.1998.9159; REASON A J, 1991, Glycobiology, V1, P585, DOI 10.1093/glycob/1.6.585; REASON AJ, 1992, J BIOL CHEM, V267, P16911; Robertson M, 1998, PLANT CELL, V10, P995, DOI 10.1105/tpc.10.6.995; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Roos MD, 1998, P ASSOC AM PHYSICIAN, V110, P422; Roos MD, 2000, BIOCHEM BIOPH RES CO, V271, P275, DOI 10.1006/bbrc.2000.2600; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; Sakoda S, 1993, Nihon Rinsho, V51, P2935; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Selzer J, 1996, J BIOL CHEM, V271, P25173, DOI 10.1074/jbc.271.41.25173; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Shaw P, 1996, ONCOGENE, V12, P921; SHIKHMAN AR, 1994, J IMMUNOL, V152, P4375; SHIKHMAN AR, 1994, J IMMUNOL, V153, P5593; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; SNOW DM, 1996, MOL BIOL CELL, V6, P357; STANLEY SL, 1995, J BIOL CHEM, V270, P4121, DOI 10.1074/jbc.270.8.4121; STARR CM, 1990, BIOESSAYS, V12, P323, DOI 10.1002/bies.950120704; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STARR CM, 1990, J BIOL CHEM, V265, P6868; Thornton TM, 1999, TRENDS PLANT SCI, V4, P424, DOI 10.1016/S1360-1385(99)01485-5; TORRES CR, 1984, J BIOL CHEM, V259, P3308; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; TRAXINGER RR, 1992, J BIOL CHEM, V267, P9718; TURNER JR, 1990, P NATL ACAD SCI USA, V87, P5608, DOI 10.1073/pnas.87.15.5608; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Weigert C, 2001, FEBS LETT, V488, P95, DOI 10.1016/S0014-5793(00)02395-4; WOLFF B, 1991, ARCH BIOCHEM BIOPHYS, V288, P131, DOI 10.1016/0003-9861(91)90174-H; WOLFF B, 1988, EXP CELL RES, V178, P318, DOI 10.1016/0014-4827(88)90402-8; Yao PJ, 1998, J NEUROSCI, V18, P2399; Yoon JH, 2000, MOL CELL BIOL, V20, P8767, DOI 10.1128/MCB.20.23.8767-8782.2000; Zhang X, 1996, J BIOL CHEM, V271, P31391, DOI 10.1074/jbc.271.49.31391	131	236	258	2	38	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					1865	1876		10.1096/fj.01-0094rev	http://dx.doi.org/10.1096/fj.01-0094rev			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532966				2022-12-28	WOS:000171372700001
J	Wallin, R; Hutson, SM; Cain, D; Sweatt, A; Sane, DC				Wallin, R; Hutson, SM; Cain, D; Sweatt, A; Sane, DC			A molecular mechanism for genetic warfarin resistance in the rat	FASEB JOURNAL			English	Article						vitamin K; warfarin; vitamin K-dependent proteins	K-DEPENDENT CARBOXYLASE; EPOXIDE REDUCTASE; BINDING-PROTEIN; 2,3-EPOXIDE REDUCTASE; SECRETORY PATHWAY; HUMAN-LIVER; VITAMIN; METABOLISM; PROTHROMBIN; CALUMENIN	Warfarin targets vitamin K 2,3-epoxide reductase (VKOR), the enzyme that produces reduced vitamin K, a required cofactor for gamma -carboxylation of vitamin K-dependent proteins. To identify VKOR, we used 4'-azido-warfarin-H-3-alcohol as an affinity label. When added to a partially purified preparation of VKOR, two proteins were identified by mass spectrometry as calumenin and cytochrome B-5. Rat calumenin was cloned and sequenced and the recombinant protein was produced. When added to an in vitro test system, the 47 kDa recombinant protein was found to inhibit VKOR activity and to protect the enzyme from warfarin inhibition. Calumenin was also shown to inhibit the overall activity of the complete vitamin K-dependent gamma -carboxylation system. The results were repeated in COS-1 cells overexpressing recombinant calumenin. By comparing calumenin mRNA levels in various tissues from normal rats and warfarin-resistant rats, only the livers from resistant rats were different from normal rats by showing increased levels. Partially purified VKOR from resistant and normal rat livers showed no differences in Km-values, specific activity, and sensitivity to warfarin. A novel model for genetic warfarin resistance in the rat is proposed, whereby the concentration of calumenin in liver determines resistance.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Wallin, R (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	rwallin@wfubmc.edu						ALMONDHIRY H, 1989, THROMB HAEMOSTASIS, V62, P661; Ausubel FM, 1988, MOL REPROD DEV; Begent LA, 2001, J PHARM PHARMACOL, V53, P481, DOI 10.1211/0022357011775776; Cain D, 1998, THROMB HAEMOSTASIS, V80, P128, DOI 10.1055/s-0037-1615151; CAIN D, 1998, J BIOL CHEM, V273, P4982; DEBOERVANDENBERG MAG, 1986, BIOCHIM BIOPHYS ACTA, V884, P150, DOI 10.1016/0304-4165(86)90238-2; Dockal M, 2000, PROTEIN SCI, V9, P1455, DOI 10.1110/ps.9.8.1455; DODDS D, 1995, J NEUROCHEM, V64, P2339; DOWD P, 1995, SCIENCE, V269, P1684, DOI 10.1126/science.7569894; FASCO MJ, 1983, BIOCHEMISTRY-US, V22, P5655, DOI 10.1021/bi00293a031; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HERMODSON MA, 1969, AM J PHYSIOL, V217, P1316, DOI 10.1152/ajplegacy.1969.217.5.1316; HILDEBRANDT EF, 1982, BIOCHEMISTRY-US, V21, P2406, DOI 10.1021/bi00539a020; Honore B, 2000, FEBS LETT, V466, P11, DOI 10.1016/S0014-5793(99)01780-9; Imai T, 1997, BIOCHEM BIOPH RES CO, V233, P765, DOI 10.1006/bbrc.1997.6531; Kaminsky LS, 1997, PHARMACOL THERAPEUT, V73, P67, DOI 10.1016/S0163-7258(96)00140-4; Kohn MH, 2000, BLOOD, V96, P1996, DOI 10.1182/blood.V96.5.1996.h8001996_1996_1998; Kulman JD, 2001, P NATL ACAD SCI USA, V98, P1370, DOI 10.1073/pnas.98.4.1370; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JJ, 1985, BIOCHEMISTRY-US, V24, P7063, DOI 10.1021/bi00346a007; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MYSZKA DG, 1991, J BIOL CHEM, V266, P20725; OBACH RS, 1992, ARCH BIOCHEM BIOPHYS, V294, P215, DOI 10.1016/0003-9861(92)90160-X; OREILLY RA, 1970, NEW ENGL J MED, V282, P1448, DOI 10.1056/NEJM197006252822602; PARK BK, 1988, BIOCHEM PHARMACOL, V37, P19, DOI 10.1016/0006-2952(88)90750-2; SILVERMAN RB, 1988, BIOCHEM BIOPH RES CO, V155, P1248, DOI 10.1016/S0006-291X(88)81274-9; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUTCLIFFE FA, 1990, CHEM-BIOL INTERACT, V75, P171, DOI 10.1016/0009-2797(90)90116-5; Suttie J W, 1987, Adv Exp Med Biol, V214, P3; Suttie J. W., 1978, Handbook of lipid research. Volume 2. The fat-soluble vitamins, P211; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; Taube J, 2000, BLOOD, V96, P1816, DOI 10.1182/blood.V96.5.1816.h8001816_1816_1819; THIJSSEN HHW, 1989, BIOCHEM PHARMACOL, V38, P1115, DOI 10.1016/0006-2952(89)90257-8; THIJSSEN HHW, 1991, BIOCHEM PHARMACOL, V42, P2181, DOI 10.1016/0006-2952(91)90354-8; Vorum H, 2000, FEBS LETT, V465, P129, DOI 10.1016/S0014-5793(99)01734-2; Vorum H, 1999, EXP CELL RES, V248, P473, DOI 10.1006/excr.1999.4431; VORUM H, 1998, BIOCHIM BIOPHYS ACTA, V1368, P121; WALLACE ME, 1976, J HYG-CAMBRIDGE, V76, P173, DOI 10.1017/S0022172400055078; WALLIN R, 1985, J CLIN INVEST, V76, P1879, DOI 10.1172/JCI112182; WALLIN R, 1993, BIOCHEM J, V291, P723, DOI 10.1042/bj2910723; WALLIN R, 1990, BIOCHEM J, V272, P473, DOI 10.1042/bj2720473; WALLIN R, 1991, THROMB RES, V62, P235, DOI 10.1016/0049-3848(91)90144-L; WALLIN R, 1987, INT J BIOCHEM, V19, P1063, DOI 10.1016/0020-711X(87)90307-7; Wallin R, 1997, METHOD ENZYMOL, V282, P395; WALLIN R, 1987, BIOCHEM J, V241, P389, DOI 10.1042/bj2410389; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Yabe D, 1997, J BIOL CHEM, V272, P18232, DOI 10.1074/jbc.272.29.18232	50	73	79	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2542	+		10.1096/fj.01-0337fje	http://dx.doi.org/10.1096/fj.01-0337fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641264				2022-12-28	WOS:000171372700024
J	Trzewik, J; Mallipattu, SK; Artmann, GM; Delano, FA; Schmid-Schonbein, GW				Trzewik, J; Mallipattu, SK; Artmann, GM; Delano, FA; Schmid-Schonbein, GW			Evidence for a second valve system in lymphatics: endothelial microvalves	FASEB JOURNAL			English	Article						initial lymphatics; lymphatic endothelium; lymphatic valves; rat; cremaster muscle; interstitium; permeability	INITIAL LYMPHATICS; SKELETAL-MUSCLE; BLOOD-VESSELS; FLUID; CELLS; MECHANISMS; MICROSCOPY; SKIN; RAT	The mechanism for interstitial fluid uptake into the lymphatics remains speculative and unresolved. A system of intralymphatic valves exists that prevents reflow along the length of the lymphatic channels. However, these valves are not sufficient to provide unidirectional flow at the level of the initial lymphatics. We investigate here the hypothesis that initial lymphatics have a second, separate valve system that permits fluid to enter from the interstitium into the initial lymph channels but prevents escape back out into the tissue. The transport of fluorescent microspheres (0.31 mum) across endothelium of initial lymphatics in rat cremaster muscle was investigated with micropipette manipulation techniques. The results indicate that microspheres can readily pass from the interstitium across the endothelium into the lumen of the initial lymphatics. Once inside the lymphatic lumen, the microspheres cannot be forced out of the lumen even after elevation of the lymphatic pressure by outflow obstruction. Reaspiration of the microspheres inside the lymphatic lumen with a micropipette is blocked by the lymphatic endothelium. This blockade exists whether the aspiration is carried out at the microsphere entry site or anywhere along the initial lymphatics. Nevertheless, puncture of the initial lymphatic endothelium with the micropipette leads to rapid aspiration of intralymphatic microspheres. Investigation of lymphatic endothelial sections fixed during lymph pumping shows open interendothelial junctions not found in resting initial lymphatics. These results suggest that initial lymphatics have a (primary) valve system at the level of the endothelium. In conjunction with the classical (secondary) intralymphatic valves, the primary valves provide the mechanism that facilitates the unidirectional flow during periodic compression and expansion of initial lymphatics.	Univ Calif San Diego, Whitaker Inst Biomed Engn, Dept Bioengn, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Schmid-Schonbein, GW (corresponding author), Univ Calif San Diego, Whitaker Inst Biomed Engn, Dept Bioengn, 9500 Gilman Dr,Engn Bldg 1,Room 5606, La Jolla, CA 92093 USA.	gwsc@bioeng.ucsd.edu	Mallipattu, Sandeep/M-7009-2014	Trzewik, Juergen/0000-0002-0678-2299				AUKLAND K, 1993, PHYSIOL REV, V73, P1, DOI 10.1152/physrev.1993.73.1.1; Azzali G, 1999, MICROVASC RES, V57, P30, DOI 10.1006/mvre.1998.2101; BAEZ S, 1973, MICROVASC RES, V5, P384, DOI 10.1016/0026-2862(73)90054-X; BRACE RA, 1977, MICROVASC RES, V14, P243, DOI 10.1016/0026-2862(77)90023-1; Casley-Smith JR, 1977, MICROCIRCULATION, P423; CASLEYSMITH JR, 1972, ANGIOLOGICA, V9, P106; CASTENHOLZ A, 1984, SCAN ELECTRON MICROS, P1343; COLLAN Y, 1974, LYMPHOLOGY, V7, P175; Ikomi F, 1996, J APPL PHYSIOL, V81, P2060, DOI 10.1152/jappl.1996.81.5.2060; Ikomi F, 1996, AM J PHYSIOL-HEART C, V271, pH173, DOI 10.1152/ajpheart.1996.271.1.H173; Ikomi F, 1997, LYMPHOLOGY, V30, P13; INTAGLIETTA M, 1982, INT J MICROCIRC, V1, P55; MAZZONI MC, 1990, AM J PHYSIOL, V259, pH1860, DOI 10.1152/ajpheart.1990.259.6.H1860; MAZZONI MC, 1987, BLOOD VESSELS, V24, P304; OHHASHI T, 1991, RECENT ADV CARDIOVAS, P125; OHTANI O, 1987, CELL TISSUE RES, V248, P365; Parsons RJ, 1938, J EXP MED, V68, P353, DOI 10.1084/jem.68.3.353; Sauter B, 1998, J HISTOCHEM CYTOCHEM, V46, P165, DOI 10.1177/002215549804600205; SCHMELZ M, 1994, DIFFERENTIATION, V57, P97, DOI 10.1046/j.1432-0436.1994.5720097.x; SCHMIDSCHONBEIN GW, 1990, ARCH HISTOL CYTOL, V53, P107, DOI 10.1679/aohc.53.Suppl_107; SIMMONDS WJQ, 1957, J EXP PHYSL, V42, P205; SKALAK TC, 1984, MICROVASC RES, V28, P95, DOI 10.1016/0026-2862(84)90032-3; Swartz MA, 1999, J BIOMECH, V32, P1297, DOI 10.1016/S0021-9290(99)00125-6; WENZELHORA BI, 1987, LYMPHOLOGY, V20, P126; White JC, 1933, AM J PHYSIOL, V103, P34	25	109	118	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2001	15	10					1711	1717		10.1096/fj.01-0067com	http://dx.doi.org/10.1096/fj.01-0067com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481218				2022-12-28	WOS:000170809900006
J	Hong, F; Nguyen, VA; Gao, B				Hong, F; Nguyen, VA; Gao, B			Tumor necrosis factor alpha attenuates interferon-alpha signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy	FASEB JOURNAL			English	Article						interleukin 6; suppressor of cytokine signaling 3; SH2-containing protein-tyrosine phosphatase liver	CHRONIC HEPATITIS-C; MESSENGER-RNA EXPRESSION; DIFFERENTIAL REGULATION; TARGETED DISRUPTION; SUSTAINED RESPONSE; GENE-EXPRESSION; GROWTH-HORMONE; PROTEIN-KINASE; T-LYMPHOCYTES; MICE LACKING	Although interferon alpha (IFN-alpha) has been used for a decade to treat viral hepatitis, a disease that affects millions of people worldwide, more than 60% of viral hepatitis patients respond poorly. It has been reported that high levels of tumor necrosis factor alpha (TNF-alpha) correlated highly with resistance to IFN-alpha therapy. Here we demonstrate that injection of TNF-alpha suppresses IFN-alpha signaling and markedly induces expression of suppressor of cytokine signaling 3 (SOCS3) and SH2 containing protein-tyrosine phosphatase 2 (SHP2) in the liver. TNF-alpha induction of SOCS3 and SHP2 remains unchanged while induction of STAT1 protein expression is completely abolished in IL-6-deficient mice. Immunoprecipitation experiments show that injection of TNF-alpha increases SHP2 association with JAKs. Overexpression of SOCS3 and SHP2 inhibits IFN-alpha signaling in hepatic cells. Injection of carbon tetrachloride, which is known to induce TNF-alpha in the liver, attenuates IFN-alpha signaling in the liver. This attenuation is also observed in TNF-alpha receptor II- (TNF-R2-) deficient mice but is markedly diminished in TNF-R1-deficient mice. Taken together, these findings suggest that TNF-alpha may be involved in resistance to IFN-alpha therapy by induction of SOCS3 and SHP2, and they could be therapeutic targets for improving the efficacy of IFN-alpha therapy.	NIAAA, Sect Liver Biol, Lab Physiol Studies, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Gao, B (corresponding author), NIAAA, Sect Liver Biol, Lab Physiol Studies, NIH, Pk Bldg,Rm 120,12420 Parklawn Dr,MSC 8115, Bethesda, MD 20892 USA.	bgao@mail.nih.gov						Ahmad F, 1997, J CELL BIOCHEM, V64, P117, DOI 10.1002/(SICI)1097-4644(199701)64:1<117::AID-JCB14>3.0.CO;2-I; Aman NJ, 1997, CURR BIOL, V7, pR784, DOI 10.1016/S0960-9822(06)00405-2; Berenguer M, 1998, P ASSOC AM PHYSICIAN, V110, P98; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; Cassatella MA, 1999, BLOOD, V94, P2880, DOI 10.1182/blood.V94.8.2880.420k31_2880_2889; CHEMELLO L, 1995, J VIRAL HEPATITIS, V2, P91, DOI 10.1111/j.1365-2893.1995.tb00012.x; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Chisari FV, 1996, CURR TOP MICROBIOL, V206, P149; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Colson A, 2000, ENDOCRINOLOGY, V141, P3687, DOI 10.1210/en.141.10.3687; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Davis GL, 2000, GASTROENTEROLOGY, V118, pS104, DOI 10.1016/S0016-5085(00)70009-6; DeCicco LA, 1998, TOXICOL LETT, V98, P115, DOI 10.1016/S0378-4274(98)00110-6; DeSalvo GL, 1997, J VIRAL HEPATITIS, V4, P79; Dumoulin FL, 1999, J INFECT DIS, V180, P1704, DOI 10.1086/315070; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Edwards-Smith CJ, 1999, HEPATOLOGY, V30, P526, DOI 10.1002/hep.510300207; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; GAO B, 1994, J BIOL CHEM, V269, P15762; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; Hanck C, 2000, J HEPATOL, V32, P51, DOI 10.1016/S0168-8278(00)80189-0; Haque SJ, 1998, SEMIN ONCOL, V25, P14; Heim MH, 1999, J VIROL, V73, P8469, DOI 10.1128/JVI.73.10.8469-8475.1999; Hill DB, 2000, J LAB CLIN MED, V135, P387, DOI 10.1067/mlc.2000.106451; Hoofnagle JH, 1998, DIGESTION, V59, P563, DOI 10.1159/000007532; Horn TL, 2000, TOXICOL SCI, V54, P262, DOI 10.1093/toxsci/54.1.262; HUSSAIN MJ, 1994, J CLIN PATHOL, V47, P1112, DOI 10.1136/jcp.47.12.1112; Ito S, 1999, BLOOD, V93, P1456, DOI 10.1182/blood.V93.5.1456; KOZIEL MJ, 1995, J CLIN INVEST, V96, P2311, DOI 10.1172/JCI118287; Krebs DL, 2000, J CELL SCI, V113, P2813; LANDOLFO S, 1995, PHARMACOL THERAPEUT, V65, P415, DOI 10.1016/0163-7258(95)98599-L; Larrea E, 1996, HEPATOLOGY, V23, P210, DOI 10.1002/hep.510230203; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; LOHR HF, 1994, LIVER, V14, P161; McClain CJ, 1998, ALCOHOL CLIN EXP RES, V22, p248S, DOI 10.1111/j.1530-0277.1998.tb04011.x; McKay S, 2000, AM J RESP CELL MOL, V23, P103, DOI 10.1165/ajrcmb.23.1.3765; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Mochida S, 1996, ALCOHOL CLIN EXP RES, V20, pA371, DOI 10.1111/j.1530-0277.1996.tb01811.x; Nelson DR, 1997, DIGEST DIS SCI, V42, P2487, DOI 10.1023/A:1018804426724; Neuman MG, 1999, CLIN BIOCHEM, V32, P537, DOI 10.1016/S0009-9120(99)00053-3; Nguyen VAT, 2000, BIOCHEM J, V349, P427, DOI 10.1042/0264-6021:3490427; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Ohnishi K, 1996, AM J GASTROENTEROL, V91, P1374; Okamoto T, 1998, JPN J PHARMACOL, V77, P219, DOI 10.1254/jjp.77.219; OKAZAKI T, 1994, SCAND J GASTROENTERO, V29, P1039, DOI 10.3109/00365529409094883; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; Paul C, 2000, EUR J BIOCHEM, V267, P5849, DOI 10.1046/j.1432-1327.2000.01395.x; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Schiff ER, 1997, HEPATOLOGY, V26, pS39, DOI 10.1002/hep.510260707; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Schumann J, 2000, AM J PATHOL, V157, P1671, DOI 10.1016/S0002-9440(10)64804-3; Shen XN, 2000, FEBS LETT, V480, P132, DOI 10.1016/S0014-5793(00)01905-0; SHERON N, 1991, J HEPATOL, V12, P241, DOI 10.1016/0168-8278(91)90945-8; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1998, INT J BIOCHEM CELL B, V30, P1081, DOI 10.1016/S1357-2725(98)00067-3; Streetz K, 2000, GASTROENTEROLOGY, V119, P446, DOI 10.1053/gast.2000.9364; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; Tian ZG, 2000, J IMMUNOL, V165, P3959, DOI 10.4049/jimmunol.165.7.3959; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; van Huijsduijnen RH, 1998, GENE, V225, P1; VANDENBROEK MF, 1995, J VIROL, V69, P4792, DOI 10.1128/JVI.69.8.4792-4796.1995; Woo MH, 1997, ANN PHARMACOTHER, V31, P330, DOI 10.1177/106002809703100312; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416	68	63	66	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1595	+		10.1096/fj.00-0908fje	http://dx.doi.org/10.1096/fj.00-0908fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427497				2022-12-28	WOS:000173707700026
J	Schaefer, M; Albrecht, N; Hofmann, T; Gudermann, T; Schultz, G				Schaefer, M; Albrecht, N; Hofmann, T; Gudermann, T; Schultz, G			Diffusion-limited translocation mechanism of protein kinase C isotypes	FASEB JOURNAL			English	Article						protein kinase C; translocation; G-protein coupled receptors; calcium oscillation; green fluorescent protein; diffusion-driven redistribution; collisional coupling	GREEN FLUORESCENT PROTEIN; CELLULAR-DISTRIBUTION; CALCIUM; CELLS; ACTIVATION; ALPHA; VISUALIZATION; RECEPTOR; LOCALIZATION; MEMBRANE	The plasma membrane translocation. of protein kinase C (PKC) is driven by an as yet unidentified mechanism. We investigated the transport mechanisms of classical and novel PKCs coupled to fluorescent proteins. Classical PKCalpha and PKCbetaI half-maximally translocated 300-750 ms after receptor stimulation, whereas the novel isotypes PKCdelta and PKCepsilon were redistributed five to ten times more slowly. Although fluorescence recovery after photobleach experiments demonstrated that PKCs are freely diffusible in quiescent cells, the similar Stokes' radii of all fusion proteins indicated that diffusion velocities cannot account for the kinetic differences. Alternatively, active transport or different collisional coupling efficacies could explain the effects. A diffusion-driven translocation mechanism was demonstrated by confocal line-scan microscopy to follow subcellular PKC concentrations at high spatiotemporal resolution. The observation of a temporary subplasmalemmal depletion zone is direct evidence for a diffusion-limited binding process. Computer-assisted modeling revealed that Ca2+-bound PKCalpha molecules require only 2 or 3 collisions with the plasma membrane to achieve a binding event. Our data further demonstrate that the slower association kinetic of novel PKC isoenzymes relies on lower collisional. coupling efficacies. The superior collisional coupling of classical PKCs points to a role of Ca2+-binding C2-domains to electrostatically facilitate binding, an effect that is lacking in novel isoenzymes.	Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin	Schaefer, M (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 67-73, D-14195 Berlin, Germany.	schae@zedat.fu-berlin.de						Almholt K, 1999, BIOCHEM J, V337, P211, DOI 10.1042/0264-6021:3370211; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Deeney JT, 1996, J BIOL CHEM, V271, P18154, DOI 10.1074/jbc.271.30.18154; Einstein A, 1905, ANN PHYS-BERLIN, V17, P549, DOI 10.1002/andp.19053220806; FAQUIN WC, 1986, BIOCHIM BIOPHYS ACTA, V887, P142, DOI 10.1016/0167-4889(86)90048-0; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; MASTRO AM, 1984, P NATL ACAD SCI-BIOL, V81, P3414, DOI 10.1073/pnas.81.11.3414; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mochly-Rosen D, 1998, FASEB J, V12, P35; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; Stanley EF, 2000, J NEUROPHYSIOL, V83, P477, DOI 10.1152/jn.2000.83.1.477; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wang YL, 1998, FOLD DES, V3, P1, DOI 10.1016/S1359-0278(98)00003-0; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; Zeidman R, 1999, J CELL BIOL, V145, P713, DOI 10.1083/jcb.145.4.713	35	61	62	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1634	+		10.1096/fj.00-0824fje	http://dx.doi.org/10.1096/fj.00-0824fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427510				2022-12-28	WOS:000173707700009
J	Singh, BB; Zheng, CY; Liu, XB; Lockwich, T; Liao, D; Zhu, MX; Birnbaumer, L; Ambudkar, IS				Singh, BB; Zheng, CY; Liu, XB; Lockwich, T; Liao, D; Zhu, MX; Birnbaumer, L; Ambudkar, IS			Trp1-dependent enhancement of salivary gland fluid secretion: role of store-operated calcium entry	FASEB JOURNAL			English	Article						store-operated calcium influx; calcium channel; fluid secretion; salivary glands; basolateral plasma membrane	INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; TRP1; EXPRESSION; CHANNELS; ACETYLCHOLINE; MODULATION; DEPLETION; PROTEIN; CELLS	This study examined the involvement of store-operated Ca2+ entry in agonist-stimulation of salivary gland fluid secretion. A recombinant adenovirus (AdCMV-hTrp1) encoding the store-operated Ca2+ channel protein, human transient receptor potential 1 (hTrp1), was used to direct expression of HA (hemaglutinin)-tagged hTrp1 in vivo in rat submandibular glands (SMG) and in vitro in the human submandibular gland cell line (HSG). Studies with HSG cells demonstrated that AdCMV-hTrp1 was successful in directing the expression of functional hTrp1 and that it did not affect early Ca2+ signaling events. AdCMV-hTrp1-infected SMG displayed an increase in the level of Trp1 and a fivefold increase in pilocarpine-stimulated fluid secretion, compared with glands infected with a control adenovirus encoding luciferase (AdCMV-Luc). The expressed hTrp1 demonstrated polarized localization in the basolateral plasma membrane region of SMG acinar cells and was co-immunoprecipitated with IP(3)Rs. Further, acinar cells isolated from AdCMV-hTrp1-infected glands demonstrated a significant increase in carbachol- and Tg-stimulated Ca2+ entry compared with cells isolated from AdCMV-Luc-infected glands. We conclude that in vivo expression of Trp1 in SMG induces an enhancement of agonist-stimulated fluid secretion via increasing store-operated Ca2+ entry into acinar cells. These data suggest that store-operated Ca2+ entry has a role in agonist-stimulated fluid secretion from salivary glands.	Natl Inst Dent & Craniofacial Res, Secretory Physiol Sect, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Gene Transfer Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA; Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA; Univ Calif Los Angeles, Dept Anesthesiol, Los Angeles, CA 90095 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University System of Ohio; Ohio State University; University of California System; University of California Los Angeles	Ambudkar, IS (corresponding author), Natl Inst Dent & Craniofacial Res, Secretory Physiol Sect, NIH, Bldg 10,Room 1N-113, Bethesda, MD 20892 USA.	ambudkar@yoda.nidcr.nih.gov		Singh, Brij/0000-0003-0535-5997	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ambudkar IS, 2000, CRIT REV ORAL BIOL M, V11, P4, DOI 10.1177/10454411000110010301; Baum BJ, 1999, CRIT REV ORAL BIOL M, V10, P276, DOI 10.1177/10454411990100030201; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Cook D. I., 1994, P1061; Delporte C, 1997, P NATL ACAD SCI USA, V94, P3268, DOI 10.1073/pnas.94.7.3268; DOUGLAS WW, 1963, J PHYSIOL-LONDON, V165, P528, DOI 10.1113/jphysiol.1963.sp007076; Evans RL, 1998, EUR J MORPHOL, V36, P142; FOSKETT JK, 1990, AM J PHYSIOL, V259, pC998; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Ishikawa Y, 1998, BIOCHEM BIOPH RES CO, V245, P835, DOI 10.1006/bbrc.1998.8395; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Lee MG, 1997, J BIOL CHEM, V272, P15771, DOI 10.1074/jbc.272.25.15771; Liu XB, 1998, AM J PHYSIOL-CELL PH, V275, pC571, DOI 10.1152/ajpcell.1998.275.2.C571; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Petersen OH, 1999, EUR J CELL BIOL, V78, P221, DOI 10.1016/S0171-9335(99)80054-5; PUTNEY JW, 1986, ANNU REV PHYSIOL, V48, P75, DOI 10.1146/annurev.ph.48.030186.000451; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Singh BB, 2000, J BIOL CHEM, V275, P36483, DOI 10.1074/jbc.C000529200; Wang SL, 1999, J ORAL PATHOL MED, V28, P145, DOI 10.1111/j.1600-0714.1999.tb02014.x; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211	29	59	60	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1652	+		10.1096/fj.00-0749fje	http://dx.doi.org/10.1096/fj.00-0749fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427516				2022-12-28	WOS:000173707700006
J	Kunduzova, OR; Bianchi, P; Pizzinat, N; Escourrou, G; Seguelas, MH; Parini, A; Cambon, C				Kunduzova, OR; Bianchi, P; Pizzinat, N; Escourrou, G; Seguelas, MH; Parini, A; Cambon, C			Regulation of JNK/ERK activation, cell apoptosis, and tissue regeneration by monoamine oxidases after renal ischemia-reperfusion	FASEB JOURNAL			English	Article						monoamine oxidases; renal ischemia-reperfusion; pargyline; cell death; proliferation	HYDROGEN-PEROXIDE PRODUCTION; FREE-RADICAL PRODUCTION; LIPID-PEROXIDATION; KINASE ACTIVATION; PROTEIN-KINASES; STRESS; INJURY; REQUIREMENT; GENERATION; INHIBITION	Reactive oxygen species (ROS) contribute to the ischemia-reperfusion injury. In kidney, the intracellular sources of ROS during ischemia-reperfusion are still unclear. In the present study, we investigated the role of the catecholamine-degrading enzyme monoamine oxidases (MAOs) in hydrogen peroxide (H2O2) generation after reperfusion and their involvement in cell events leading to tissue injury and recovery. In a rat model of renal ischemia-reperfusion, we show concomitant MAO-dependent H2O2 production and lipid peroxidation in the early reperfusion period. Rat pretreatment with the irreversible MAO inhibitor pargyline resulted in the following: i) prevented H2O2 production and lipid peroxidation; ii) decreased tubular cell apoptosis and necrosis, measured by TUNEL staining and histomorphological criteria; and iii) increased tubular cell proliferation as determined by proliferating cell nuclear antigen expression. MAO inhibition also prevented Jun N-terminal kinase phosphorylation and promoted extracellular signal-regulated kinase activation, two mitogen-activated protein kinases described as a part of a "death" and "survival" pathway after ischemia-reperfusion. This work demonstrates the crucial role of MAOs in mediating the production of injurious ROS, which contribute to acute apoptotic and necrotic cell death induced by renal ischemia-reperfusion in vivo. Targeted inhibition of these oxidases could provide a new avenue for therapy to prevent renal damage and promote renal recovery after ischemia-reperfusion.	CHU Rangueil, Inst Louis Bugnard, INSERM, U388, F-31403 Toulouse 4, France; CHU Rangueil, Dept Pathol, F-31403 Toulouse 4, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Cambon, C (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U388, IFR31,Bat L3, F-31403 Toulouse 4, France.	cambon@toulouse.inserm.fr		Kunduzova, Oksana/0000-0003-2503-6555; Parini, Angelo/0000-0002-9848-8838				Abe J, 2000, CIRC RES, V86, P607, DOI 10.1161/01.RES.86.6.607; ARUOMA OI, 1989, BIOCHEM J, V258, P617, DOI 10.1042/bj2580617; BEERI R, 1995, KIDNEY INT, V47, P1806, DOI 10.1038/ki.1995.249; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Chatterjee PK, 2000, KIDNEY INT, V58, P658, DOI 10.1046/j.1523-1755.2000.00212.x; Chien CT, 2001, J AM SOC NEPHROL, V12, P973, DOI 10.1681/ASN.V125973; Chung H Y, 1999, J Nutr Health Aging, V3, P19; Ciccone CD, 1998, PHYS THER, V78, P313, DOI 10.1093/ptj/78.3.313; Cohen G, 1997, P NATL ACAD SCI USA, V94, P4890, DOI 10.1073/pnas.94.10.4890; De Vecchi E, 1998, KIDNEY INT, V54, P857, DOI 10.1046/j.1523-1755.1998.00072.x; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; Di Mari JF, 1999, AM J PHYSIOL-RENAL, V277, pF195, DOI 10.1152/ajprenal.1999.277.2.F195; DiMari J, 1997, AM J PHYSIOL-RENAL, V272, pF292, DOI 10.1152/ajprenal.1997.272.3.F292; Elliott RM, 2000, FREE RADICAL BIO MED, V28, P1438, DOI 10.1016/S0891-5849(00)00271-9; Eschwege P, 1999, J UROLOGY, V162, P553, DOI 10.1016/S0022-5347(05)68626-0; FERNANDES MH, 1994, J NEURAL TRANSM-SUPP, P101; FERNANDEZ C, 1995, BRIT J CANCER, V72, P1194, DOI 10.1038/bjc.1995.485; Forbes JM, 2000, KIDNEY INT, V57, P2375, DOI 10.1046/j.1523-1755.2000.00097.x; FRANSSEN C, 1995, TRANSPLANT P, V27, P2880; GRISHAM MB, 1986, AM J PHYSIOL, V251, pG567, DOI 10.1152/ajpgi.1986.251.4.G567; Hauptmann N, 1996, ARCH BIOCHEM BIOPHYS, V335, P295, DOI 10.1006/abbi.1996.0510; Hoffmeyer MR, 2000, CIRC RES, V87, P812, DOI 10.1161/01.RES.87.9.812; Ishizuka S, 1999, BIOCHEM BIOPH RES CO, V254, P88, DOI 10.1006/bbrc.1998.9902; IWATA M, 1994, J AM SOC NEPHROL, V5, P1307; JOANNIDIS M, 1990, AM J PHYSIOL, V258, pF232, DOI 10.1152/ajprenal.1990.258.2.F232; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Malorni W, 1998, FEBS LETT, V426, P155, DOI 10.1016/S0014-5793(98)00315-9; Naskalski JW, 2001, ADV CLIN CHEM, V35, P161, DOI 10.1016/S0065-2423(01)35017-5; NOHL H, 1993, FREE RADICAL RES COM, V18, P127, DOI 10.3109/10715769309147486; Offord E, 2000, Free Radic Res, V33 Suppl, pS5; Ozaki M, 2000, FASEB J, V14, P418, DOI 10.1096/fasebj.14.2.418; Ozawa H, 1999, NEUROSCI LETT, V262, P57, DOI 10.1016/S0304-3940(99)00034-8; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; Pizzinat N, 1999, N-S ARCH PHARMACOL, V359, P428, DOI 10.1007/PL00005371; Pizzinat N, 1998, CURR OPIN NEPHROL HY, V7, P33, DOI 10.1097/00041552-199801000-00006; Pizzinat N, 1999, KIDNEY INT, V56, P1391, DOI 10.1046/j.1523-1755.1999.00673.x; POMBO CM, 1994, J BIOL CHEM, V269, P26546; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; Safirstein R, 1998, SEMIN NEPHROL, V18, P519; SANDRI G, 1990, BIOCHIM BIOPHYS ACTA, V1035, P300, DOI 10.1016/0304-4165(90)90092-B; SCHUMER M, 1992, AM J PATHOL, V140, P831; SIMONSON SG, 1993, J CEREBR BLOOD F MET, V13, P125, DOI 10.1038/jcbfm.1993.15; Sun JZ, 1996, J CLIN INVEST, V97, P562, DOI 10.1172/JCI118449; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; SUZUKI T, 1995, PHARMACOLOGY, V50, P357, DOI 10.1159/000139304; TOBACK FG, 1992, KIDNEY INT, V41, P226, DOI 10.1038/ki.1992.32; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuji M, 2000, NEUROSCI LETT, V282, P41, DOI 10.1016/S0304-3940(00)00844-2; Vindis C, 2000, BIOCHEM BIOPH RES CO, V271, P181, DOI 10.1006/bbrc.2000.2524; Vindis C, 2001, KIDNEY INT, V59, P76, DOI 10.1046/j.1523-1755.2001.00468.x; Weight SC, 1996, BRIT J SURG, V83, P162, DOI 10.1002/bjs.1800830206; WERNER P, 1991, FEBS LETT, V280, P44, DOI 10.1016/0014-5793(91)80200-M; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; YU PH, 1986, RES COMMUN CHEM PATH, V51, P163; ZAGER RA, 1994, J AM SOC NEPHROL, V4, P1588	59	84	88	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1129	+		10.1096/fj.01-1008fje	http://dx.doi.org/10.1096/fj.01-1008fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039844				2022-12-28	WOS:000175973900003
J	Bennasser, Y; Bahraoui, E				Bennasser, Y; Bahraoui, E			HIV-1 Tat protein induces interleukin-10 in human peripheral blood monocytes: involvement of protein kinase C-beta II and -delta	FASEB JOURNAL			English	Article						IL-10; PKC isoforms; uninfected monocytes	HUMAN-IMMUNODEFICIENCY-VIRUS; SECONDARY STRUCTURES; PKC-INHIBITOR; ACTIVATION; CELLS; EXPRESSION; DIFFERENTIATION; ISOZYMES; PATHWAY; TYPE-1	In HIV-infected patients, production of interleukin-10 (IL-10), a highly immunosuppressive cytokine, is associated with the disease progression toward AIDS. We have previously shown that HIV-1 Tat induces IL-10 production by human monocytes via a protein kinase C (PKC)-dependent pathway. Here we show that PKC activation by Tat is essential for IL-10 induction. Among the eight PKC isoforms present in human monocytes, we investigated which isoform(s) plays this crucial role in Tat-mediated IL-10 production and show that 1) Tat can activate PKC-alpha, PKC-betaII, PKC-delta, and PKC-epsilon, 2) of these four potential candidates, only PKC-betaII, PKC-delta, and PKC-epsilon are activated by the active domain Tat 1-45, which is responsible for IL-10 production and depleted by long-term exposure to PMA, which abolishes Tat-mediated IL-10 production, 3) whereas selective inhibition of PKC-alpha and PKC-epsilon by specific antisense oligonucleotides has no effect on Tat-mediated IL-10 induction, inhibition of either PKC-betaII or PKC-delta partially inhibits IL-10 production; and 4) the simultaneous inhibition of PKC-betaII and PKC-delta totally inhibits Tat-mediated IL-10. Altogether, these results suggest that the induction of IL-10 by Tat is strictly dependent on the PKC-delta and -betaII isoforms.	Univ Toulouse 3, Lab Immuno Virol, EA 3038, F-31062 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Bahraoui, E (corresponding author), Univ Toulouse 3, Lab Immuno Virol, EA 3038, 118 Route Narbonne Batiment 4R3, F-31062 Toulouse, France.	bahraoui@cict.fr	Bennasser, Yamina/M-4833-2017	BAHRAOUI, ELMOSTAFA/0000-0003-1852-389X				Acs P, 1997, J BIOL CHEM, V272, P22148, DOI 10.1074/jbc.272.35.22148; AMEGLIO E, 1994, J BIOL REG HOMEOS AG, V8, P48; Badou A, 2000, J VIROL, V74, P10551, DOI 10.1128/JVI.74.22.10551-10562.2000; Borgatti P, 1998, BIOCHEM BIOPH RES CO, V242, P332, DOI 10.1006/bbrc.1997.7877; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Chen CC, 1998, J IMMUNOL, V161, P6206; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Frankel AD, 1992, CURR OPIN GENET DEV, V2, P293, DOI 10.1016/S0959-437X(05)80287-4; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; Gallo RC, 1999, P NATL ACAD SCI USA, V96, P8324, DOI 10.1073/pnas.96.15.8324; Gonindard C, 1997, CELL BIOL TOXICOL, V13, P141, DOI 10.1023/A:1007321227010; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KELLER HU, 1993, BIOCHEM BIOPH RES CO, V194, P1111, DOI 10.1006/bbrc.1993.1936; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mochly-Rosen D, 2000, SEMIN IMMUNOL, V12, P55, DOI 10.1006/smim.2000.0207; Monick MM, 1998, AM J PHYSIOL-LUNG C, V275, pL389, DOI 10.1152/ajplung.1998.275.2.L389; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; ZUKER M, 1991, NUCLEIC ACIDS RES, V19, P2707, DOI 10.1093/nar/19.10.2707	40	51	55	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					546	554		10.1096/fj.01-0775com	http://dx.doi.org/10.1096/fj.01-0775com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919157				2022-12-28	WOS:000175425900008
J	Buchwalow, IB; Podzuweit, T; Bocker, W; Samoilova, VE; Thomas, S; Wellnr, M; Baba, HA; Robenek, H; Schnekenburger, J; Lerch, MM				Buchwalow, IB; Podzuweit, T; Bocker, W; Samoilova, VE; Thomas, S; Wellnr, M; Baba, HA; Robenek, H; Schnekenburger, J; Lerch, MM			Vascular smooth muscle and nitric oxide synthase	FASEB JOURNAL			English	Article						vascular smooth muscle cells; NOS; VSMC	SKELETAL-MUSCLE; ENDOTHELIAL-CELLS; GUANYLATE-CYCLASE; OXIDATIVE STRESS; IN-SITU; EXPRESSION; NO; AMPLIFICATION; ADVENTITIA; RELAXATION	The concept of endothelium-derived relaxing factor (EDRF) put forward in 1980 by Furchgott and Zawadzki implies that nitric oxide (NO) produced by NO synthase (NOS) in the endothelium diffuses to the underlying vascular smooth muscle, where it modulates vascular tone as well as vascular smooth muscle cell (VSMC) proliferation by increasing cGMP formation with subsequent activation of cGMP-dependent protein kinase. According to this concept, VSMC do not express NOS by themselves. This attractive, simple scheme is now under considerable debate. To address this issue, we designed this study with the use of a novel supersensitive immunocytochemical technique of signal amplification with tyramide and electron microscopic immunogold labeling complemented with Western blotting, as in our recent studies demonstrating NOS in the myocardial and skeletal muscles. We provide the first evidence that, in contrast to the currently accepted view, VSMC in various blood vessels express all three NOS isoforms depending on the blood vessel type. These findings suggest an alternative mechanism by which local NOS expression may modulate vascular functions in an endothelium-independent manner.	Univ Munster, Dept Med B, D-48149 Munster, Germany; Univ Munster, Gerhard Domagk Inst Pathol, Interdisciplinary Ctr Clin Res, Cent Ultrastruct Res Unit, D-48149 Munster, Germany; Max Planck Inst Clin Res, D-61231 Bad Nauheim, Germany; Humboldt Univ, Fac Med Charite, Franz Volhard Clin, D-13125 Berlin, Germany; Univ Munster, Inst Arteriosclerosis Res, D-48149 Munster, Germany	University of Munster; University of Munster; Max Planck Society; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munster	Buchwalow, IB (corresponding author), Univ Munster, Dept Med B, Domagkstr 17, D-48149 Munster, Germany.	buchwalo@uni-muenster.de	Lerch, Markus M./E-2206-2016	Lerch, Markus M./0000-0002-9643-8263; Schnekenburger, Juergen/0000-0002-0199-2908				ADAMS JC, 1992, J HISTOCHEM CYTOCHEM, V40, P1457, DOI 10.1177/40.10.1527370; Azevedo LCP, 2000, CARDIOVASC RES, V47, P436, DOI 10.1016/S0008-6363(00)00091-2; Banning AP, 1999, ATHEROSCLEROSIS, V145, P17, DOI 10.1016/S0021-9150(99)00010-6; BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; Boulanger CM, 1998, CIRC RES, V83, P1271, DOI 10.1161/01.RES.83.12.1271; Brophy CM, 2000, AM J PHYSIOL-HEART C, V278, pH991, DOI 10.1152/ajpheart.2000.278.3.H991; Buchwalow IB, 1998, CIRCULATION, V98, P118; Buchwalow IB, 1997, ACTA HISTOCHEM, V99, P231, DOI 10.1016/S0065-1281(97)80046-3; Buchwalow IB, 2001, MOL CELL BIOCHEM, V217, P73, DOI 10.1023/A:1007286602865; Buchwalow TB, 2001, P ROY MICROSC SOC, V36, P57; Comini L, 1996, J MOL CELL CARDIOL, V28, P2241, DOI 10.1006/jmcc.1996.0216; Ding H, 2000, J PHARMACOL TOX MET, V44, P441, DOI 10.1016/S1056-8719(00)00127-1; Fleming I, 1999, J MOL CELL CARDIOL, V31, P5, DOI 10.1006/jmcc.1998.0839; FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538, DOI 10.1164/ajrccm.149.2.7508323; Gath I, 1999, BIOCHEM J, V340, P723, DOI 10.1042/0264-6021:3400723; Gath I, 1996, FASEB J, V10, P1614, DOI 10.1096/fasebj.10.14.9002553; GRIFFITH TM, 1989, INT J MICROCIRC, V8, P383; Harris D, 2000, EUR J PHARMACOL, V402, P119, DOI 10.1016/S0014-2999(00)00512-4; Heitzer T, 1999, KIDNEY INT, V55, P252, DOI 10.1046/j.1523-1755.1999.00229.x; Hopman AHN, 1998, J HISTOCHEM CYTOCHEM, V46, P771, DOI 10.1177/002215549804600611; IGNARRO LJ, 1990, PHARMACOL TOXICOL, V67, P1, DOI 10.1111/j.1600-0773.1990.tb00772.x; Kahn AM, 2000, AM J PHYSIOL-ENDOC M, V278, pE627, DOI 10.1152/ajpendo.2000.278.4.E627; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; Kozlov AV, 2001, BBA-MOL BASIS DIS, V1536, P177, DOI 10.1016/S0925-4439(01)00047-3; Li HG, 2000, J PATHOL, V190, P244, DOI 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8; Linas SL, 1997, AM J PHYSIOL-RENAL, V272, pF767, DOI 10.1152/ajprenal.1997.272.6.F767; Luscher TF, 1997, CLIN CARDIOL, V20, P3; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; Miura H, 1999, CIRCULATION, V99, P3132, DOI 10.1161/01.CIR.99.24.3132; Mizutani K, 2000, J HYPERTENS, V18, P1071, DOI 10.1097/00004872-200018080-00012; MOHAUPT MG, 1994, KIDNEY INT, V46, P653, DOI 10.1038/ki.1994.318; Napoli C, 2001, NITRIC OXIDE-BIOL CH, V5, P88, DOI 10.1006/niox.2001.0337; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Ozel SK, 2001, PROSTAG LEUKOTR ESS, V64, P253, DOI 10.1054/plef.2001.0268; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Pernow J, 2001, EUR HEART J SUPPL, V3, pC22, DOI 10.1016/S1520-765X(01)90026-4; Pesic S, 1999, J VET MED A, V46, P509, DOI 10.1046/j.1439-0442.1999.00248.x; Punkt K, 2001, HISTOCHEM J, V33, P213, DOI 10.1023/A:1017994108174; Rajasekaran M, 1998, J UROLOGY, V160, P2210, DOI 10.1016/S0022-5347(01)62298-5; Roth J, 1982, TECHNIQUES IMMUNOCYT, P107; Sanderson M, 2000, KLUW S INF, V7, P235; Schwarz PM, 1999, ARTERIOSCL THROM VAS, V19, P2584, DOI 10.1161/01.ATV.19.11.2584; SHIKANO K, 1987, BRIT J PHARMACOL, V92, P483, DOI 10.1111/j.1476-5381.1987.tb11347.x; STEINHORN RH, 1994, J CLIN INVEST, V94, P1883, DOI 10.1172/JCI117538; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; Teoh H, 2000, MOL CELL BIOCHEM, V207, P65, DOI 10.1023/A:1007090113551; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; Trovati M, 1999, DIABETOLOGIA, V42, P831, DOI 10.1007/s001250051234; Van Zwieten P A, 1997, Blood Press Suppl, V2, P67; vonWasielewski R, 1997, J HISTOCHEM CYTOCHEM, V45, P1455, DOI 10.1177/002215549704501102; Walia M, 2000, EUR J PHARMACOL, V400, P249, DOI 10.1016/S0014-2999(00)00393-9; ZEHETGRUBER M, 1993, LIFE SCI, V52, P1397, DOI 10.1016/0024-3205(93)90063-9	55	127	132	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					500	508		10.1096/fj.01-0842com	http://dx.doi.org/10.1096/fj.01-0842com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919152				2022-12-28	WOS:000175425900003
J	Langevin, HM; Churchill, DL; Wu, JR; Badger, GJ; Yandow, JA; Fox, JR; Krag, MH				Langevin, HM; Churchill, DL; Wu, JR; Badger, GJ; Yandow, JA; Fox, JR; Krag, MH			Evidence of connective tissue involvement in acupuncture	FASEB JOURNAL			English	Article						biomechanics; subcutaneous tissue; mechanical stress; ultrasound; histology	MECHANISM; BRAIN	Acupuncture needle manipulation gives rise to "needle grasp," a biomechanical phenomenon characterized by an increase in the force necessary to pull the needle out of the tissue (pullout force). This study investigates the hypothesis that winding of connective tissue, rather than muscle contraction, is the mechanism responsible for needle grasp. We performed 1) measurements of pullout force in humans with and without needle penetration of muscle; 2) measurements of pullout force in anesthetized rats, with and without needle rotation, followed by measurements of connective tissue volume surrounding the needle; 3) imaging of rat abdominal wall explants, with and without needle rotation, using ultrasound scanning acoustic microscopy. We found 1) no evidence that increased penetration of muscle results in greater pullout force than increased penetration of subcutaneous tissue; 2) that both pullout force and subcutaneous tissue volume were increased by needle rotation; 3) that increased periodic architectural order was present in subcutaneous tissue with rotation, compared with no rotation. These data support connective tissue winding as the mechanism responsible for the increase in pullout force induced by needle rotation. Winding may allow needle movements to deliver a mechanical signal into the tissue and may be key to acupuncture's therapeutic mechanism.	Univ Vermont, Coll Med, Dept Neurol, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Phys, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Orthopaed & Rehabil, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Med Biostat, Burlington, VT 05405 USA	University of Vermont; University of Vermont; University of Vermont; University of Vermont	Langevin, HM (corresponding author), Univ Vermont, Coll Med, Dept Neurol, Given C423, Burlington, VT 05405 USA.	hlangevi@zoo.uvm.edu						ANDERSSON S, 1993, SCAND J REHABIL MED, P31; [Anonymous], 1997, NIH Consens Statement, V15, P1; Banes AJ, 1995, BIOCHEM CELL BIOL, V73, P349, DOI 10.1139/o95-043; Brand RA, 1997, ANN MED, V29, P267, DOI 10.3109/07853899708999346; Briggs A., 1992, ACOUSTIC MICROSCOPY; Cheng X, 1987, CHINESE ACUPUNCTURE; Chiang CY, 1973, SCI SINICA, V16, P210; Cho ZH, 1998, P NATL ACAD SCI USA, V95, P2670, DOI 10.1073/pnas.95.5.2670; De Morant G. S., 1994, CHINESE ACUPUNCTURE; DENMEI S, 1990, INTRO MERIDIAN THERA; DUCK FA, 1990, PHYSICAL PROPERTIES; DUNG HC, 1984, AM J ACUPUNCTURE, V12, P139; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; ERNST M, 1985, PAIN, V21, P25, DOI 10.1016/0304-3959(85)90073-9; GUNN C C, 1976, American Journal of Chinese Medicine, V4, P183, DOI 10.1142/S0192415X76000238; GUNN CC, 1977, AM J ACUPUNCTURE, V5, P115; HAN JS, 1987, NEUROCHEMICAL BASIS; Helms JM., 1995, ACUPUNCTURE ENERGETI; Hibbeler R. C, 1995, ENG MECH STAT DYNAMI; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; Kendall M.G., 1969, ADV THEORY STAT, V1; KIMURA M, 1992, AM J CHINESE MED, V20, P25, DOI 10.1142/S0192415X92000047; Langevin HM, 2001, FASEB J, V15, P2275, DOI 10.1096/fj.01-0015hyp; Langevin HM, 2001, J APPL PHYSIOL, V91, P2471, DOI 10.1152/jappl.2001.91.6.2471; LIU Y K, 1975, American Journal of Chinese Medicine, V3, P347, DOI 10.1142/S0192415X75000426; O'Connor J, 1987, ACUPUNCTURE COMPREHE; POMERANZ B, 1976, LIFE SCI, V19, P1757, DOI 10.1016/0024-3205(76)90084-9; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; *SHANGH I PHYS, 1973, CHIN MED J, V153, P532; Stux G, 1995, BASICS ACUPUNCTURE; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; Willis Jr W. D., 1991, SENSORY MECH SPINAL; WORSLEY JR, 1982, TRADITIONAL CHINESE, V1; YANG J, 1601, GOLDEN NEEDLE OTHER; 1994, YELLOW EMPERORS CLAS	36	179	198	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					872	+		10.1096/fj.01-0925fje	http://dx.doi.org/10.1096/fj.01-0925fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967233				2022-12-28	WOS:000175425900017
J	Galon, J; Franchimont, D; Hiroi, N; Frey, G; Boettner, A; Ehrhart-Bornstein, M; O'Shea, JJ; Chrousos, GP; Bornstein, SR				Galon, J; Franchimont, D; Hiroi, N; Frey, G; Boettner, A; Ehrhart-Bornstein, M; O'Shea, JJ; Chrousos, GP; Bornstein, SR			Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells	FASEB JOURNAL			English	Article						DNA microarray; clinical medicine; immune system	RESPIRATORY-DISTRESS SYNDROME; HUMAN MONOCYTES; T-LYMPHOCYTES; RECEPTOR; DEXAMETHASONE; EXPRESSION; INFLAMMATION; INDUCTION; PROTEIN; FAMILY	Glucocorticoids continue to be the major immunomodulatory agents used in clinical medicine today. However, their actions as anti-inflammatory and immunosuppressive drugs are both beneficial and deleterious. We analyzed the effect of glucocorticoids on the gene expression profile of peripheral blood mononuclear cells from healthy donors. DNA microarray analysis combined with quantitative TaqMan PCR and flow cytometry revealed that glucocorticoids induced the expression of chemokine, cytokine, and complement family members as well as of newly discovered innate immune-related genes, including scavenger and Toll-like receptors. In contrast, glucocorticoids repressed the expression of adaptive immune-related genes. Simultaneous inhibitory and stimulatory effects of glucocorticoids were found on inflammatory T helper subsets and apoptosis-related gene clusters. In cells activated by T cell receptor cross-linking, glucocorticoids down-regulated the expression of specific genes that were previously up-regulated in resting cells, suggesting a potential new mechanism by which they exert positive and negative effects. Considering the broad and continuously renewed interest in glucocorticoid therapy, the profiles we describe here will be useful in designing more specific and efficient treatment strategies.	NIAMS, Lymphocyte Cell Biol Sect, NIH, Bethesda, MD 20892 USA; NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA; Inst Curie, INSERM, U255, Paris, France; Free Univ Brussels, Erasme Hosp, Dept Gastroenterol, B-1050 Brussels, Belgium; Univ Leipzig, Dept Pediat, D-04103 Leipzig, Germany; Univ Dusseldorf, Dept Endocrinol, D-40225 Dusseldorf, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Leipzig University; Heinrich Heine University Dusseldorf	Galon, J (corresponding author), Ctr Rech Biomed Cordeliers, INSERM, U255, Lab Immunol Cellulaire & Clin, 15 Rue Ecole Med, F-75270 Paris 06, France.	jerome.galon@u255.bhdc.jussieu.fr	Körner, Antje/B-3988-2015; Galon, Jerome/G-9838-2019	Körner, Antje/0000-0001-6001-0356; Galon, Jerome/0000-0001-9635-1339; Frey, Gregory/0000-0002-5465-7302	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000615, ZIAHD000618] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000615, Z01HD000618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041106, ZIAAR041106] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Alfonso C, 2000, ANNU REV IMMUNOL, V18, P113, DOI 10.1146/annurev.immunol.18.1.113; ARZT E, 1994, ENDOCRINOLOGY, V134, P672, DOI 10.1210/en.134.2.672; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Blotta MH, 1997, J IMMUNOL, V158, P5589; Bollaert PE, 1998, CRIT CARE MED, V26, P645, DOI 10.1097/00003246-199804000-00010; BOUMPAS DT, 1993, ANN INTERN MED, V119, P1198, DOI 10.7326/0003-4819-119-12-199312150-00007; Bronicki RA, 2000, ANN THORAC SURG, V69, P1490, DOI 10.1016/S0003-4975(00)01082-1; Buechler C, 2000, J LEUKOCYTE BIOL, V67, P97, DOI 10.1002/jlb.67.1.97; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; CRONIN L, 1995, CRIT CARE MED, V23, P1430, DOI 10.1097/00003246-199508000-00019; Dhabhar FS, 1999, P NATL ACAD SCI USA, V96, P1059, DOI 10.1073/pnas.96.3.1059; Dozmorov IM, 1998, J IMMUNOL, V160, P2700; Franchimont D, 1999, J CLIN ENDOCR METAB, V84, P2834, DOI 10.1210/jc.84.8.2834; Franchimont D, 2000, J IMMUNOL, V164, P1768, DOI 10.4049/jimmunol.164.4.1768; Hogger P, 1998, J IMMUNOL, V161, P1883; Jahnsen FL, 1999, J IMMUNOL, V163, P1545; Krutzik SR, 2001, CURR OPIN IMMUNOL, V13, P104, DOI 10.1016/S0952-7915(00)00189-8; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Lane SJ, 1998, J CLIN INVEST, V102, P2156, DOI 10.1172/JCI2680; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; McDevitt HO, 2000, ANNU REV IMMUNOL, V18, P1, DOI 10.1146/annurev.immunol.18.1.1; MCGOWAN JE, 1992, J INFECT DIS, V165, P1, DOI 10.1093/infdis/165.1.1; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Meduri GU, 1998, CRIT CARE MED, V26, P630, DOI 10.1097/00003246-199804000-00003; Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159; Mellor AL, 2001, NAT IMMUNOL, V2, P64, DOI 10.1038/83183; Mellor AL, 1999, IMMUNOL TODAY, V20, P469, DOI 10.1016/S0167-5699(99)01520-0; ODIO CM, 1991, NEW ENGL J MED, V324, P1525, DOI 10.1056/NEJM199105303242201; OPDENAKKER G, 1992, CYTOKINE, V4, P251, DOI 10.1016/1043-4666(92)90064-X; Pype JL, 1999, AM J RESP CELL MOL, V21, P528, DOI 10.1165/ajrcmb.21.4.3660; RE F, 1994, J EXP MED, V179, P739, DOI 10.1084/jem.179.2.739; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Wilckens T, 1997, IMMUNOL TODAY, V18, P418, DOI 10.1016/S0167-5699(97)01111-0; WILDER RL, 1995, ANNU REV IMMUNOL, V13, P307; WU CY, 1991, J CLIN INVEST, V87, P870, DOI 10.1172/JCI115092	42	429	475	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					61	71		10.1096/fj.01-0245com	http://dx.doi.org/10.1096/fj.01-0245com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11772937				2022-12-28	WOS:000173656600008
J	Vaquero, C; Sack, M; Schuster, F; Finnern, R; Drossard, J; Schumann, D; Reimann, A; Fischer, R				Vaquero, C; Sack, M; Schuster, F; Finnern, R; Drossard, J; Schumann, D; Reimann, A; Fischer, R			A carcinoembryonic antigen-specific diabody produced in tobacco	FASEB JOURNAL			English	Article						T84.66 diabody; CEA; agro-infiltration; transgenic tobacco; recombinant protein production	SINGLE-CHAIN FV; ANTIBODY-PRODUCTION; MONOCLONAL-ANTIBODIES; TRANSGENIC PLANTS; CEA ANTIBODIES; EXPRESSION; SCFV; ACCUMULATION; FRAGMENTS; IMMUNOGLOBULIN	The feasibility of using tobacco for production of a recombinant antibody (T84.66/GS8 diabody) directed against the carcinoembryonic antigen (CEA) and used for tumor imaging was investigated. Two constructs were generated for targeting the protein either to the apoplast or to the endoplasmic reticulum. Expression of the diabody in tobacco leaves after vacuum-assisted infiltration of engineered Agrobacteria (agro-infiltration) and in regenerated transgenic tobacco plants was analyzed and compared. Results in terms of protein expression and accumulation between both systems showed a good correlation. His(6)-tagged T84.66 diabody was readily purified from agro-infiltrated tobacco leaves and from transgenic plants by immobilized metal ion affinity chromatography. The purified protein was analyzed by polyacrylamide gel electrophoresis, Western blot, gel filtration, electrospray mass spectrometry, direct and competition ELISA, electrophoretic mobility shift assay, and staining of CEA-positive colon adenocarcinoma cell line LS174T. Our results demonstrate that tobacco is a competent production system for this clinically relevant diabody.	Rhein Westfal TH Aachen, Inst Biol 6, D-52074 Aachen, Germany; IUCT, Fraunhofer Dept Mol Biotechnol, D-57392 Schmallenberg, Germany	RWTH Aachen University	Vaquero, C (corresponding author), Rhein Westfal TH Aachen, Inst Biol 6, Worringerweg 1, D-52074 Aachen, Germany.	vaquero@molbiotech.rwth-aachen.de	Sack, Markus/K-6681-2013; Sack, Markus/AAP-9252-2021	Sack, Markus/0000-0002-7380-9228; 				Adams GP, 1999, J IMMUNOL METHODS, V231, P249, DOI 10.1016/S0022-1759(99)00161-1; Adams GP, 1998, BRIT J CANCER, V77, P1405, DOI 10.1038/bjc.1998.233; ARTSAENKO O, 1995, PLANT J, V8, P745, DOI 10.1046/j.1365-313X.1995.08050745.x; BUCHEGGER F, 1990, J NUCL MED, V31, P1035; Cochlovius B, 2000, J IMMUNOL, V165, P888, DOI 10.4049/jimmunol.165.2.888; Conrad U, 1998, PLANT MOL BIOL, V38, P101, DOI 10.1023/A:1006029617949; Dall'Acqua W, 1998, CURR OPIN STRUC BIOL, V8, P443, DOI 10.1016/S0959-440X(98)80121-8; De Jaeger G, 1999, EUR J BIOCHEM, V259, P426, DOI 10.1046/j.1432-1327.1999.00060.x; Fiedler U, 1997, IMMUNOTECHNOLOGY, V3, P205, DOI 10.1016/S1380-2933(97)00014-6; FIEDLER U, 1995, BIO-TECHNOL, V13, P1090, DOI 10.1038/nbt1095-1090; Fischer R, 2000, TRANSGENIC RES, V9, P279, DOI 10.1023/A:1008975123362; Fischer R, 1999, BIOTECHNOL APPL BIOC, V30, P113; Fischer R, 1999, BIOL CHEM, V380, P825, DOI 10.1515/BC.1999.102; Frigerio L, 2000, PLANT PHYSIOL, V123, P1483, DOI 10.1104/pp.123.4.1483; Garber K, 2000, J NATL CANCER I, V92, P1462, DOI 10.1093/jnci/92.18.1462; Giddings G, 2000, NAT BIOTECHNOL, V18, P1151, DOI 10.1038/81132; Graham RA, 1998, ANN SURG, V228, P59, DOI 10.1097/00000658-199807000-00009; Green MC, 2000, CANCER TREAT REV, V26, P269, DOI 10.1053/ctrv.2000.0176; Hammarstrom S, 2001, TRENDS MICROBIOL, V9, P119, DOI 10.1016/S0966-842X(01)01952-7; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; HASS GM, 1991, CANCER RES, V51, P1876; Hellwig S, 1999, BIOTECHNOL APPL BIOC, V30, P267; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; Holliger P, 1999, CANCER METAST REV, V18, P411, DOI 10.1023/A:1006314421941; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; HORSCH RB, 1985, COLD SPRING HARB SYM, V50, P433, DOI 10.1101/SQB.1985.050.01.054; Hu SZ, 1996, CANCER RES, V56, P3055; Hudson PJ, 1999, J IMMUNOL METHODS, V231, P177, DOI 10.1016/S0022-1759(99)00157-X; Jackson H, 1998, BRIT J CANCER, V78, P181, DOI 10.1038/bjc.1998.462; Kim JC, 2000, CANCER RES, V60, P4825; Kipriyanov SM, 1999, J MOL BIOL, V293, P41, DOI 10.1006/jmbi.1999.3156; Kontermann RE, 1997, NAT BIOTECHNOL, V15, P629, DOI 10.1038/nbt0797-629; Kubo A, 1992, Ann Nucl Med, V6, P21; Kusnadi AR, 1997, BIOTECHNOL BIOENG, V56, P473, DOI [10.1002/(SICI)1097-0290(19971205)56:5<473::AID-BIT1>3.0.CO;2-F, 10.1002/(SICI)1097-0290(19971205)56:5&lt;473::AID-BIT1&gt;3.0.CO;2-F]; MA JKC, 1994, EUR J IMMUNOL, V24, P131, DOI 10.1002/eji.1830240120; Mayer A, 1999, J IMMUNOL METHODS, V231, P261, DOI 10.1016/S0022-1759(99)00162-3; McCormick AA, 1999, P NATL ACAD SCI USA, V96, P703, DOI 10.1073/pnas.96.2.703; Milstein C, 1999, CURR OPIN IMMUNOL, V11, P589, DOI 10.1016/S0952-7915(99)00014-X; Murray JL, 2000, SEMIN ONCOL, V27, P64, DOI 10.1053/sonc.2000.19896; MURRAY JL, 2000, SEMIN ONCOL, V27, P92; NEUMAIER M, 1990, CANCER RES, V50, P2128; Peeters K, 2001, EUR J BIOCHEM, V268, P4251, DOI 10.1046/j.1432-1327.2001.02340.x; Shimada N, 1999, BIOSCI BIOTECH BIOCH, V63, P779, DOI 10.1271/bbb.63.779; Stoger E, 2000, PLANT MOL BIOL, V42, P583, DOI 10.1023/A:1006301519427; STOGER E, IN PRESS MOL BREEDIN; Todorovska A, 2001, J IMMUNOL METHODS, V248, P47, DOI 10.1016/S0022-1759(00)00342-2; Torres E, 1999, TRANSGENIC RES, V8, P441, DOI 10.1023/A:1008969031219; Vaquero C, 1999, P NATL ACAD SCI USA, V96, P11128, DOI 10.1073/pnas.96.20.11128; Verma R, 1998, J IMMUNOL METHODS, V216, P165, DOI 10.1016/S0022-1759(98)00077-5; WAGENER C, 1989, J CLIN CHEM CLIN BIO, V27, P643; WHITELAM GC, 1994, BIOCHEM SOC T, V22, P940, DOI 10.1042/bst0220940; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Wu AM, 2000, P NATL ACAD SCI USA, V97, P8495, DOI 10.1073/pnas.150228297; Wu AM, 1996, IMMUNOTECHNOLOGY, V2, P21, DOI 10.1016/1380-2933(95)00027-5; Wu AM, 1999, TUMOR TARGET, V4, P47; Wu AM, 2000, Q J NUCL MED, V44, P268; YOKOTA T, 1992, CANCER RES, V52, P3402; Zamcheck N, 1988, Prog Clin Biol Res, V279, P251	58	53	63	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					408	+		10.1096/fj.01-0363fje	http://dx.doi.org/10.1096/fj.01-0363fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11790722				2022-12-28	WOS:000173656600017
J	Purves, T; Middlemas, A; Agthong, S; Jude, EB; Boulton, AJM; Fernyhough, P; Tomlinson, DR				Purves, T; Middlemas, A; Agthong, S; Jude, EB; Boulton, AJM; Fernyhough, P; Tomlinson, DR			A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy	FASEB JOURNAL			English	Article						diabetes; DRG; MAPK; stress	C-JUN; OXIDATIVE STRESS; ANTIOXIDANT TREATMENT; NERVE DYSFUNCTION; CELLULAR-RESPONSE; SENSORY NEURONS; MAP-KINASES; PHOSPHORYLATION; RATS; GLYCATION	The onset of diabetic neuropathy, a complication of diabetes mellitus, has been linked to poor glycemic control. We tested the hypothesis that the mitogen-activated protein kinases (MAPK) form transducers for the damaging effects of high glucose. In cultures of adult rat sensory neurons, high glucose activated JNK and p38 MAPK but did not result in cell damage. However, oxidative stress activated ERK and p38 MAPKs and resulted in cellular damage. In the dorsal root ganglia of streptozotocin-induced diabetic rats (a model of type I diabetes), ERK and p38 were activated at 8 wk duration, followed by activation of JNK at 12 wk duration. We report activation of JNK and increases in total levels of p38 and JNK in sural nerve of type I and II diabetic patients. These data implicate MAPKs in the etiology of diabetic neuropathy both via direct effects of glucose and via glucose-induced oxidative stress.	Univ Manchester, Sch Biol Sci, Div Neurosci, Manchester M13 9PT, Lancs, England; Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England	University of Manchester; University of Manchester	Tomlinson, DR (corresponding author), Univ Manchester, Sch Biol Sci, Div Neurosci, Stopford Bldg 1-124,Oxford Rd, Manchester M13 9PT, Lancs, England.	david.tomlinson@man.ac.uk	Purves-Tyson, Tertia D/C-9799-2011	Purves-Tyson, Tertia D/0000-0003-2401-4266; Fernyhough, Paul/0000-0002-9507-1201				Awazu M, 1999, J AM SOC NEPHROL, V10, P738; BRAMHALL S, 1969, ANAL BIOCHEM, V31, P146, DOI 10.1016/0003-2697(69)90251-6; BRAVENBOER B, 1992, DIABETOLOGIA, V35, P813, DOI 10.1007/BF00399926; Caldero J, 1998, J NEUROSCI, V18, P356; CAMERON NE, 1993, DIABETOLOGIA, V36, P299, DOI 10.1007/BF00400231; Cantoni O, 1996, FEBS LETT, V389, P285, DOI 10.1016/0014-5793(96)00605-9; Carrington AL, 1999, DIABETES REV, V7, P275; Cohen DM, 1997, COMP BIOCHEM PHYS A, V117, P291, DOI 10.1016/S0300-9629(96)00266-6; Dyck PJ, 1996, J NEUROPATH EXP NEUR, V55, P1181, DOI 10.1097/00005072-199612000-00001; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Fernyhough P, 1999, DIABETES, V48, P881, DOI 10.2337/diabetes.48.4.881; Fernyhough P, 1999, DIABETES REV, V7, P300; FUKINO H, 1986, J TOXICOL ENV HEALTH, V19, P75, DOI 10.1080/15287398609530908; Geilen CC, 1996, J DERMATOL SCI, V12, P255, DOI 10.1016/0923-1811(95)00481-5; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; Haneda M, 1997, DIABETES, V46, P847, DOI 10.2337/diabetes.46.5.847; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Iordanov MS, 1999, J BIOL CHEM, V274, P25801, DOI 10.1074/jbc.274.36.25801; Ito H, 1998, BBA-GENE STRUCT EXPR, V1397, P223, DOI 10.1016/S0167-4781(98)00010-4; KARASU C, 1995, DIABETOLOGIA, V38, P129, DOI 10.1007/s001250050262; Kenney AM, 1998, J NEUROSCI, V18, P1318; Kultz D, 1998, J EXP BIOL, V201, P3015; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Mizisin AP, 1999, J PERIPHER NERV SYST, V4, P211; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NICKANDER KK, 1994, J NEUROL SCI, V126, P6, DOI 10.1016/0022-510X(94)90088-4; Schmidt RE, 1997, J NEUROPATH EXP NEUR, V56, P1028, DOI 10.1097/00005072-199709000-00008; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIDENIUS P, 1980, DIABETES, V29, P182, DOI 10.2337/diabetes.29.3.182; Simm A, 1997, FEBS LETT, V410, P481, DOI 10.1016/S0014-5793(97)00644-3; Thomas PK, 1999, EUR NEUROL, V41, P35, DOI 10.1159/000052078; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; Tomlinson DR, 1999, DIABETOLOGIA, V42, P1271, DOI 10.1007/s001250051439; Veeranna, 1998, J NEUROSCI, V18, P4008; Vinik AI, 2000, DIABETOLOGIA, V43, P957, DOI 10.1007/s001250051477; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YOUNG MJ, 1993, DIABETOLOGIA, V36, P150, DOI 10.1007/BF00400697; Yu R, 1997, J BIOL CHEM, V272, P28962, DOI 10.1074/jbc.272.46.28962; Zochodne DW, 1999, BRAIN PATHOL, V9, P369	44	207	231	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2508	2514		10.1096/fj.01-0253hyp	http://dx.doi.org/10.1096/fj.01-0253hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689477				2022-12-28	WOS:000172420500022
J	Wagner, AH; Schroeter, MR; Hecker, M				Wagner, AH; Schroeter, MR; Hecker, M			17 beta-estradiol inhibition of NADPH oxidase expression in human endothelial cells	FASEB JOURNAL			English	Article						endothelial nitric oxide synthase; estrogen; monocyte chemoattractant protein-1; CD54; superoxide	SUPEROXIDE ANION PRODUCTION; SYNTHASE GENE-EXPRESSION; SMOOTH-MUSCLE CELLS; NITRIC-OXIDE; ESTROGEN-RECEPTOR; POSTMENOPAUSAL WOMEN; ARTERY ENDOTHELIUM; NAD(P)H OXIDASE; ACTIVATION; DISEASE	We investigated the hypothesis that the antiatherosclerotic effect of 17 beta -estradiol (E-2) is due to a shift in the nitric oxide (NO)/superoxide (O-2(-)) balance in the vessel wall, thereby increasing the bioavailability of NO. In human umbilical vein cultured endothelial cells, E-2 (1-100 nmol/l), but not 17 alpha -estradiol, caused a time- and concentration-dependent decrease in expression of the NADPH oxidase subunit gp91phox (up to 60% inhibition at both the mRNA and protein level). This effect was prevented by coincubation with the estrogen receptor antagonists tamoxifen and ICI 182,780 (1 mu mol/l each). Within the same concentration range, E-2 also up-regulated endothelial nitric oxide synthase expression (similar to twofold). Moreover, preincubation of the cells with E-2 or a gp91phox antisense oligonucleotide significantly decreased their capacity to generate O-2(-) on phorbol ester stimulation (i.e., assembly of the active NADPH oxidase complex). Blockade of NO synthase activity, on the other hand, had no effect on phorbol ester-stimulated O-2(-) formation. In addition, E-2 (100 nmol/l) inhibited the increase in adhesion molecule and chemokine expression in cells exposed to cyclic strain. Cyclic strain enhanced endothelial O-2(-) formation, thereby offsetting the inhibitory effect of NO on the expression of these gene products. E-2 thus seems to act as an antioxidant at the genomic level which by improving the NO/O-2(-) balance normalizes expression of proatherosclerotic gene products in endothelial cells.	Univ Gottingen, Dept Cardiovasc Physiol, D-37073 Gottingen, Germany	University of Gottingen	Hecker, M (corresponding author), Univ Gottingen, Dept Cardiovasc Physiol, Humboldtallee 23, D-37073 Gottingen, Germany.	hecker@veg-physiol.med.uni-goettingen.de						Baker VL, 1997, J SOC GYNECOL INVEST, V4, P316, DOI 10.1016/S1071-5576(97)00082-8; Barbacanne MA, 1999, CARDIOVASC RES, V41, P672, DOI 10.1016/S0008-6363(98)00254-5; Bayraktutan U, 2000, ARTERIOSCL THROM VAS, V20, P1903, DOI 10.1161/01.ATV.20.8.1903; Bekesi G, 2000, STEROIDS, V65, P889, DOI 10.1016/S0039-128X(00)00183-5; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; Busse R, 1996, J VASC RES, V33, P181, DOI 10.1159/000159147; Chen YG, 1998, J ASIAN NAT PROD RES, V1, P125, DOI 10.1080/10286029808039854; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; DE CR, 1995, J CLIN INVEST, V96, P60; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Guetta V, 1997, CIRCULATION, V96, P2795, DOI 10.1161/01.CIR.96.9.2795; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; HECKER M, 1994, BIOCHEM J, V299, P247, DOI 10.1042/bj2990247; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Jensen I, 1998, ENDOTHELIUM-NEW YORK, V6, P9, DOI 10.3109/10623329809053401; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; LECABEC V, 1995, J BIOL CHEM, V270, P2067; Liaudet L, 2000, CRIT CARE MED, V28, pN37, DOI 10.1097/00003246-200004001-00005; Lienenluke B, 2000, EUR J IMMUNOL, V30, P2864, DOI 10.1002/1521-4141(200010)30:10<2864::AID-IMMU2864>3.0.CO;2-W; MacRitchie AN, 1997, CIRC RES, V81, P355, DOI 10.1161/01.RES.81.3.355; Meischl C, 1998, SPRINGER SEMIN IMMUN, V19, P417, DOI 10.1007/BF00792600; Mendelsohn ME, 2000, CIRC RES, V87, P956, DOI 10.1161/01.RES.87.11.956; Mendelsohn ME, 2000, J STEROID BIOCHEM, V74, P337, DOI 10.1016/S0960-0760(00)00110-2; Meyer JW, 1999, ENDOTHELIUM-NEW YORK, V7, P11, DOI 10.3109/10623329909165308; Meyer JW, 2000, FEBS LETT, V472, P1, DOI 10.1016/S0014-5793(00)01397-1; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Possel H, 1997, FEBS LETT, V416, P175, DOI 10.1016/S0014-5793(97)01197-6; RIEDEL M, 1993, CLIN INVESTIGATOR, V71, P406; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; Ruschitzka FT, 1997, CARDIOLOGY, V88, P3, DOI 10.1159/000177500; Russell KS, 2000, J BIOL CHEM, V275, P5026, DOI 10.1074/jbc.275.7.5026; Sohn HY, 2000, FREE RADICAL RES, V32, P265, DOI 10.1080/10715760000300271; Spyridopoulos I, 1997, CIRCULATION, V95, P1505; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Swain SD, 1997, J BIOL CHEM, V272, P29502, DOI 10.1074/jbc.272.47.29502; Venkov CD, 1996, CIRCULATION, V94, P727, DOI 10.1161/01.CIR.94.4.727; Virchow R., 1856, GESAMM ABHANDL WISSE, P458; Virdis A, 2000, CIRCULATION, V101, P2258, DOI 10.1161/01.CIR.101.19.2258; Vogel RA, 1997, CLIN CARDIOL, V20, P426, DOI 10.1002/clc.4960200505; Wagner AH, 2000, MOL PHARMACOL, V58, P1333, DOI 10.1124/mol.58.6.1333; Wagner AH, 2000, ARTERIOSCL THROM VAS, V20, P61, DOI 10.1161/01.ATV.20.1.61; Wang XF, 1997, AM J PHYSIOL-HEART C, V273, pH1962, DOI 10.1152/ajpheart.1997.273.4.H1962; Wellman GC, 1996, CLIN EXP PHARMACOL P, V23, P260, DOI 10.1111/j.1440-1681.1996.tb02608.x; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1; Yang SM, 2000, J CARDIOVASC PHARM, V36, P242, DOI 10.1097/00005344-200008000-00015; ZEIHER AM, 1995, CIRC RES, V76, P980, DOI 10.1161/01.RES.76.6.980	52	178	182	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2121	2130		10.1096/fj.01-0123com	http://dx.doi.org/10.1096/fj.01-0123com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641238				2022-12-28	WOS:000171920400023
J	Kirsch, M; De Groot, H				Kirsch, M; De Groot, H			NAD(P)H, a directly operating antioxidant?	FASEB JOURNAL			English	Article						peroxynitrite; NAD(P)H; scavenging; alkoxyl radicals	CARBON-DIOXIDE; FREE-RADICALS; ASCORBIC-ACID; PEROXYNITRITE; OXIDATION; MECHANISMS; PEROXIDATION; MITOCHONDRIA; NUCLEOTIDES; GLUTATHIONE	Endogenous oxygen- and nitrogen-centered free radicals are considered to play a decisive role in a variety of diseases such as neurodegenerative disorders, atherosclerosis, or cancer. Directly operating antioxidants limit the action of freely diffusing radicals by scavenging the attacking, oxidizing radical and re-reducing the oxidized biomolecule, i.e., the biomolecule-derived radical. From textbooks of biochemistry it is understood that NAD(P)H acts as a hydride (hydrogen anion) donor in a variety of enzymatic processes. One example is the re-reduction of GSSG to GSH, catalyzed by glutathione reductase. Because of this reaction, NADPH has been suggested to also act as an indirectly operating antioxidant, thus maintaining the antioxidative power of glutathione. To the best of our knowledge, however, neither NADPH nor NADH has been considered to be directly operating antioxidants. Based on recently published data, new experiments, and theoretical considerations, we propose that NAD(P)H represents a decisive, directly operating antioxidant that should be considered of major importance in the mitochondrial compartment. NAD(P)H fulfills this task both by scavenging toxic free radicals and repairing biomolecule-derived radicals.	Univ Essen Gesamthsch Klinikum, Inst Physiol Chem, D-45122 Essen, Germany	University of Duisburg Essen	Kirsch, M (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Physiol Chem, Hufelandstr 55, D-45122 Essen, Germany.	michael.kirsch@uni-essen.de						Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BIELSKI BHJ, 1976, J BIOL CHEM, V251, P3841; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; CHAN PC, 1980, J BIOL CHEM, V255, P874; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; DEGROOT H, 1987, BIOCHEM SOC T, V15, P363, DOI 10.1042/bst0150363; FARBER JL, 1990, LAB INVEST, V62, P670; FORNI LG, 1986, BIOCHEM J, V240, P897, DOI 10.1042/bj2400897; Goldstein S, 2000, CHEM RES TOXICOL, V13, P736, DOI 10.1021/tx000099n; Goldstein S, 1998, J AM CHEM SOC, V120, P3458, DOI 10.1021/ja9733043; Halliwell B, 1999, FREE RADICAL RES, V31, P261, DOI 10.1080/10715769900300841; HALLIWELL B, 1994, FREE RADICALS OXIDAT, P73; Hodges GR, 1999, J AM CHEM SOC, V121, P10695, DOI 10.1021/ja991077u; HORNIG D, 1975, ANN NY ACAD SCI, V258, P103, DOI 10.1111/j.1749-6632.1975.tb29271.x; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; KIRKMAN HN, 1986, J BIOL CHEM, V261, P4033; Kirsch M, 1999, J BIOL CHEM, V274, P24664, DOI 10.1074/jbc.274.35.24664; Kirsch M, 2000, J BIOL CHEM, V275, P16702, DOI 10.1074/jbc.M909228199; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; Lehnig M, 1999, ARCH BIOCHEM BIOPHYS, V368, P303, DOI 10.1006/abbi.1999.1268; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1998, INORG CHEM, V37, P294, DOI 10.1021/ic970946i; MARCUS RA, 1993, REV MOD PHYS, V65, P599, DOI 10.1103/RevModPhys.65.599; Meli R, 1999, HELV CHIM ACTA, V82, P722, DOI 10.1002/(SICI)1522-2675(19990505)82:5<722::AID-HLCA722>3.3.CO;2-R; MEREDITH J, 1982, J BIOL CHEM, V257, P3747; Murray R. K., 1996, HARPERS BIOCH; ONEILL P, 1983, RADIAT RES, V96, P198, DOI 10.2307/3576178; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; ROSS AB, 1998, NDRL NIST SOLUTION K; Sies H., 1982, METABOLIC COMPARTMEN, P205; Sies H., 1985, OXIDATIVE STRESS, V1; SLADE R, 1985, AM REV RESPIR DIS, V131, P742; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Sturgeon BE, 1998, J BIOL CHEM, V273, P30116, DOI 10.1074/jbc.273.46.30116; TRUMPER L, 1989, BIOMED BIOCHIM ACTA, V48, P743; TYLER D, 1992, MITOCHONDRION HLTH D; Uppu RM, 1999, J AM CHEM SOC, V121, P9738, DOI 10.1021/ja9921165; VATASSERY GT, 1995, NEUROCHEM INT, V26, P527, DOI 10.1016/0197-0186(94)00147-M; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WELLS WW, 1990, J BIOL CHEM, V265, P15361	42	233	240	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2001	15	9					1569	1574		10.1096/fj.00-0823hyp	http://dx.doi.org/10.1096/fj.00-0823hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427489				2022-12-28	WOS:000170318500009
J	Dabbeni-Sala, F; Floreani, M; Franceschini, D; Skaper, SD; Giusti, P				Dabbeni-Sala, F; Floreani, M; Franceschini, D; Skaper, SD; Giusti, P			Kainic acid induces selective mitochondrial oxidative phosphorylation enzyme dysfunction in cerebellar granule neurons: protective effects of melatonin and GSH ethyl ester	FASEB JOURNAL			English	Article						neurotoxicity; mitochondrial respiratory chain; complex II; BN-PAGE analysis	KAINATE-INDUCED EXCITOTOXICITY; BLUE-NATIVE-ELECTROPHORESIS; ELECTRON-TRANSPORT CHAIN; METHYL-D-ASPARTATE; PARKINSONS-DISEASE; RESPIRATORY-CHAIN; PRIMARY CULTURES; NITRIC-OXIDE; IN-VITRO; GLUTATHIONE DEPLETION	Kainic acid (KA), a potent central excitotoxin, may elicit neuronal death via generation of reactive oxygen species (ROS). The present study was undertaken to further characterize KA neurotoxicity and its relationship to ROS production and mitochondrial dysfunction. Exposure of rat cerebellar granule neurons at 14 days in vitro to 0.5 mM KA for 30 min resulted in the death of 53% of cells 24 h later. ROS production, evaluated by 2',7'-dichlorofluorescein diacetate, increased in KA-treated granule neurons. Resolution of mitochondrial oxidative phosphorylation enzymes by blue native polyacrylamide gel electrophoresis, followed by histochemical staining, showed that KA induced a strong decrease (-40%, P< 0.01) in succinate dehydrogenase (SDH) activity of complex II. Western analysis revealed a marked reduction in quantity of the catalytic portion of complex II enzyme in KA-treated cells. No significant changes were observed in the activities of other mitochondrial complex enzymes. The actions of KA at the mitochondrial level, as well as on ROS generation and cell viability, were prevented by the KA receptor-selective antagonist 6,7-dinitroquinoxaline-2,3(1H, 4H)-dione. Pretreatment of granule neurons with melatonin, a direct scavenger of ROS, or with the reduced glutathione (GSH) delivery agent GSH ethyl ester, before KA challenge prevented both the decrease in cell viability and complex II damage. The last result supports a link between KA-induced mitochondrial oxidative enzyme dysfunction and ROS generation. Together the results suggest mitochondria to be a critical target in KA injury to neurons.	Univ Padua, Dept Pharmacol, I-35131 Padua, Italy; SmithKline Beecham Pharmaceut, Dept Neurosci Res, Harlow CM19 5AW, Essex, England	University of Padua; GlaxoSmithKline	Giusti, P (corresponding author), Univ Padua, Dept Pharmacol, Largo E Meneghetti 2, I-35131 Padua, Italy.	giusti@ux1.unipd.it		GIUSTi, Pietro/0000-0001-9352-4046				Absi E, 2000, J PINEAL RES, V29, P40, DOI 10.1034/j.1600-079X.2000.290106.x; Ackrell BAC, 2000, FEBS LETT, V466, P1, DOI 10.1016/S0014-5793(99)01749-4; Atlante A, 1999, J NEUROCHEM, V73, P237, DOI 10.1046/j.1471-4159.1999.0730237.x; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BONDY SC, 1993, BRAIN RES, V610, P229, DOI 10.1016/0006-8993(93)91405-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIDGES RJ, 1991, EUR J PHARMACOL, V192, P199, DOI 10.1016/0014-2999(91)90093-6; Carriedo SG, 2000, J NEUROSCI, V20, P240, DOI 10.1523/JNEUROSCI.20-01-00240.2000; Carriedo SG, 1998, J NEUROSCI, V18, P7727; Ceccon M, 2000, BRAIN RES, V862, P83, DOI 10.1016/S0006-8993(00)02074-6; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; COYLE JT, 1978, J COMP NEUROL, V180, P301, DOI 10.1002/cne.901800208; DYKENS JA, 1987, J NEUROCHEM, V49, P1222, DOI 10.1111/j.1471-4159.1987.tb10014.x; DYKENS JA, 1994, J NEUROCHEM, V63, P584; Floreani M, 1997, FASEB J, V11, P1309, DOI 10.1096/fasebj.11.14.9409550; Floreani M, 1997, FREE RADICAL RES, V26, P449, DOI 10.3109/10715769709084481; GIUSTI P, 1995, EXP NEUROL, V131, P39, DOI 10.1016/0014-4886(95)90005-5; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; Giusti P, 1996, J PINEAL RES, V20, P226, DOI 10.1111/j.1600-079X.1996.tb00263.x; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Heales SJR, 1996, NEUROCHEM RES, V21, P35, DOI 10.1007/BF02527669; Hoyt KR, 1998, J PHYSIOL-LONDON, V509, P103, DOI 10.1111/j.1469-7793.1998.103bo.x; Kaal ECA, 2000, J NEUROCHEM, V74, P1158; KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martin M, 2000, J PINEAL RES, V28, P242, DOI 10.1034/j.1600-079X.2000.280407.x; MEISTER A, 1994, J BIOL CHEM, V269, P9397; Merad-Boudia M, 1998, BIOCHEM PHARMACOL, V56, P645, DOI 10.1016/S0006-2952(97)00647-3; MIZUI T, 1992, AM J PHYSIOL, V262, pH313, DOI 10.1152/ajpheart.1992.262.2.H313; MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NADLER JV, 1980, J COMP NEUROL, V192, P333, DOI 10.1002/cne.901920209; NICOLETTI F, 1986, J NEUROSCI, V6, P1905; OLNEY JW, 1974, BRAIN RES, V77, P507, DOI 10.1016/0006-8993(74)90640-4; Pang Z, 1997, J NEUROSCI, V17, P3064; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; PATEL J, 1990, J NEUROCHEM, V55, P114, DOI 10.1111/j.1471-4159.1990.tb08828.x; Peng TI, 1998, EXP NEUROL, V149, P1, DOI 10.1006/exnr.1997.6599; PUTTFARCKEN PS, 1993, BRAIN RES, V624, P223, DOI 10.1016/0006-8993(93)90081-W; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Scheffler IE, 1998, PROG NUCLEIC ACID RE, V60, P267, DOI 10.1016/S0079-6603(08)60895-8; Schulz JB, 1996, J NEUROSCI, V16, P4696; Schulz JB, 1997, MOL CELL BIOCHEM, V174, P193, DOI 10.1023/A:1006852306789; Schulz JB, 1996, J NEUROCHEM, V67, P430; SHAPIRA AHV, 1999, BIOCHIM BIOPHYS ACTA, V1410, P159; SKAPER SD, 1990, METHODS NEUROSCIENCE, V2, P17; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; SUN AY, 1992, MOL CHEM NEUROPATHOL, V17, P51, DOI 10.1007/BF03159981; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131	54	29	29	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1786	+		10.1096/fj.00-0427fje	http://dx.doi.org/10.1096/fj.00-0427fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481230				2022-12-28	WOS:000169261200027
J	Tinhofer, I; Bernhard, D; Senfter, M; Anether, G; Loeffler, M; Kroemer, G; Kofler, R; Csordas, A; Greil, R				Tinhofer, I; Bernhard, D; Senfter, M; Anether, G; Loeffler, M; Kroemer, G; Kofler, R; Csordas, A; Greil, R			Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2	FASEB JOURNAL			English	Article						cell death; antioxidant; cytochrome c-independent; lymphoblastic leukemia	INDEPENDENT APOPTOSIS; CYTOCHROME-C; PERMEABILITY TRANSITION; NUCLEAR TRANSLOCATION; CYCLOSPORINE-A; RED WINE; MEMBRANE; EXPRESSION; PROTEIN; CANCER	We report that resveratrol (3,5,4'-trihydroxy-trans-stilbene), a phytoalexin found in grapes and other plant food, induced a breakdown of the mitochondrial transmembrane potential (DeltaPsi(m)) in T-acute lymphoblastic leukemia cells and swelling of isolated rat mitochondria. The breakdown of DeltaPsi(m) was accompanied by the production of reactive oxygen species (ROS), and preceded phosphatidylserine exposure and DNA fragmentation. Breakdown of DeltaPsi(m) was not caused by the activation of caspase-8 or Bid, as no significant cleavage of these proteins could be detected in the induction phase of resveratrol-induced apoptosis. Though loss of DeltaPsi(m) was not followed by cytochrome c translocation to the cytosol, the mitochondrial changes triggered significant activation of caspase-9, -2, -3, and -6. Inhibition of DeltaPsi(m) breakdown and of ROS generation by N-acetylcysteine, or by overexpression of Bcl-2 protein, prevented apoptosis induction by resveratrol. The Bcl-2 expression status of tumor cells should therefore be considered relevant for potential clinical application of resveratrol as anticancer agent.	Univ Innsbruck, Dept Internal Med, Lab Mol Cytol, A-6020 Innsbruck, Austria; Univ Innsbruck, Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Gen & Expt Pathol, A-6020 Innsbruck, Austria; Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France; Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck; University of Innsbruck; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; University of Innsbruck	Greil, R (corresponding author), Univ Innsbruck, Dept Internal Med, Lab Mol Cytol, Anichstr 35, A-6020 Innsbruck, Austria.	Richard.Greil@uibk.ac.at	Kroemer, Guido/AAY-9859-2020; Greil, Richard F/C-7673-2017; KROEMER, Guido/B-4263-2013	Greil, Richard F/0000-0002-4462-3694; KROEMER, Guido/0000-0002-9334-4405; Bernhard, David/0000-0002-2383-6607; Tinhofer, Ingeborg/0000-0002-0512-549X				Bernhard D, 2000, CELL DEATH DIFFER, V7, P834, DOI 10.1038/sj.cdd.4400719; Bossy Wetzel E, 1998, EMBO J, V17, P37; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Chun YJ, 1999, BIOCHEM BIOPH RES CO, V262, P20, DOI 10.1006/bbrc.1999.1152; Clement MV, 1998, BLOOD, V92, P996; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Della Ragione F, 1998, BIOCHEM BIOPH RES CO, V250, P53, DOI 10.1006/bbrc.1998.9263; El-Mowafy AM, 1999, FEBS LETT, V451, P63, DOI 10.1016/S0014-5793(99)00541-4; Fauconneau B, 1997, LIFE SCI, V61, P2103, DOI 10.1016/S0024-3205(97)00883-7; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; Fukuhara K, 1998, BIOORG MED CHEM LETT, V8, P3187, DOI 10.1016/S0960-894X(98)00585-X; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; HENNET T, 1993, CANCER RES, V53, P1456; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hsieh TC, 1999, EXP CELL RES, V249, P109, DOI 10.1006/excr.1999.4471; Hsieh TC, 1999, CANCER RES, V59, P2596; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Iordanov MS, 2000, CANCER RES, V60, P1983; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Mgbonyebi OP, 1998, INT J ONCOL, V12, P865; Olas B, 1999, ACTA BIOCHIM POL, V46, P961, DOI 10.18388/abp.1999_4119; PACEASCIAK CR, 1995, CLIN CHIM ACTA, V235, P207, DOI 10.1016/0009-8981(95)06045-1; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SHARMA S, 1994, CANCER RES, V54, P5848; SHIKAMA Y, 2001, KEYST S MOL MECH AP; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Surh YJ, 1999, CANCER LETT, V140, P1, DOI 10.1016/S0304-3835(99)00039-7; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tsan MF, 2000, BRIT J HAEMATOL, V109, P405, DOI 10.1046/j.1365-2141.2000.01980.x; Uenobe F, 1997, MUTAT RES-FUND MOL M, V373, P197, DOI 10.1016/S0027-5107(96)00191-1; WALTON MI, 1993, CANCER RES, V53, P1853; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zheng JB, 1999, BIOCHEM BIOPH RES CO, V261, P499, DOI 10.1006/bbrc.1999.1063; Zini R, 1999, DRUG EXP CLIN RES, V25, P87; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	54	171	185	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1613	+		10.1096/fj.00-0675fje	http://dx.doi.org/10.1096/fj.00-0675fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427503				2022-12-28	WOS:000173707700016
J	Saeger, B; Schmitt-Wrede, HP; Dehnhardt, M; Benten, WPM; Krucken, J; Harder, A; Von Samson-Himmelstjerna, G; Wiegand, H; Wunderlich, F				Saeger, B; Schmitt-Wrede, HP; Dehnhardt, M; Benten, WPM; Krucken, J; Harder, A; Von Samson-Himmelstjerna, G; Wiegand, H; Wunderlich, F			Latrophilin-like receptor from the parasitic nematode Haemonchus contortus as target for the anthelmintic depsipeptide PF1022A	FASEB JOURNAL			English	Article									Univ Dusseldorf, Div Mol Parasitol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Ctr Biol & Med Res, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Med Inst Environm Hyg, D-40225 Dusseldorf, Germany; Bayer AG, Biol Technol Ctr, Res & Dev, Business Grp Anim Hlth, D-51368 Leverkusen, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Bayer AG	Wunderlich, F (corresponding author), Univ Dusseldorf, Div Mol Parasitol, Univ Str 1, D-40225 Dusseldorf, Germany.		Krücken, Jürgen/AAE-3133-2021; Krücken, Jürgen/B-6794-2009; Krücken, Jürgen/CAF-6903-2022; Schmitt-Wrede, Hans-Peter/ABD-6206-2021; von Samson, Georg/R-1123-2016	Krücken, Jürgen/0000-0002-2842-8100; Krücken, Jürgen/0000-0002-2842-8100; Krücken, Jürgen/0000-0002-2842-8100; 					0	65	69	3	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1332	1334		10.1096/fj.00-0664fje	http://dx.doi.org/10.1096/fj.00-0664fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344131				2022-12-28	WOS:000168655200053
J	Pratico, D; Uryu, K; Sung, S; Tang, S; Trojanowski, JQ; Lee, VMY				Pratico, D; Uryu, K; Sung, S; Tang, S; Trojanowski, JQ; Lee, VMY			Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice	FASEB JOURNAL			English	Article						Alzheimer's disease; Tg2576 transgenic animal model; lipid peroxidation; isoprostanes; amyloid beta protein	ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; DRINKING-WATER; MOUSE MODEL; RISK; APOPTOSIS	Epidemiological studies have implicated aluminum (Al) exposure in the pathogenesis of Alzheimer's disease (AD); however, other studies have failed to confirm these results. Oxidative stress is a feature of AD, and Al can exacerbate oxidative events. This biological property has been suggested as a possible mechanism by which this metal could influence the onset and/or evolution of the disease. To test this hypothesis, we fed transgenic mice that over express human amyloid precursor protein (Tg2576) with a diet enriched in Al and measured isoprostane levels, sensitive and specific markers of in vivo oxidative stress, as well as amyloid beta peptide formation and deposition. Here, we show an increase in brain isoprostane levels that correlated with increased amyloid beta levels and accelerated plaque deposition in Tg2576 mice but not in wildtype (WT) littermates fed with high dietary Al. Significantly, these in vivo effects of Al were reversed by vitamin E, as judged by a reduction of isoprostane production, amyloid beta levels, and plaque deposition. These results indicate that dietary Al can modulate in vivo AD-like amyloidosis in Tg2576 by increasing brain oxidative stress.	Univ Penn, Sch Med, Dept Pharmacol, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Pratico, D (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Ctr Expt Therapeut, BRB2-3,Room 812,421 Curie Blvd, Philadelphia, PA 19104 USA.	domenico@spirit.gcrc.upenn.edu	Pratico, Domenico/ABA-9590-2020					Bondy SC, 1998, NEUROTOXICOLOGY, V19, P65; Campbell A, 2000, CELL MOL BIOL, V46, P721; Clark CM, 2000, NEURODEGENERATIVE DE, P95, DOI [DOI 10.1155/2016/258, 10.1155/2016/258]; Flaten TP, 2001, BRAIN RES BULL, V55, P187, DOI 10.1016/S0361-9230(01)00459-2; Ghribi O, 2001, BRAIN RES, V903, P66, DOI 10.1016/S0006-8993(01)02406-4; Guo GW, 2001, BRAIN RES, V888, P221, DOI 10.1016/S0006-8993(00)03057-2; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; MCLACHLAN DRC, 1995, ENVIRONMETRICS, V6, P233, DOI 10.1002/env.3170060303; McLachlan DRC, 1996, NEUROLOGY, V46, P401, DOI 10.1212/WNL.46.2.401; Nourhashemi F, 2000, AM J CLIN NUTR, V71, p643S; Pratico D, 2000, AM J MED, V109, P577, DOI 10.1016/S0002-9343(00)00547-7; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9; Rondeau V, 2000, AM J EPIDEMIOL, V152, P59, DOI 10.1093/aje/152.1.59; SHARPE WE, 1985, ENV HLTH PERSPECT, V962, P196; Solomon B, 2001, BRAIN RES BULL, V55, P253, DOI 10.1016/S0361-9230(01)00466-X; Tsunoda M, 1999, ARCH TOXICOL, V73, P419, DOI 10.1007/s002040050630; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; WALTON J, 1995, NEUROTOXICOLOGY, V16, P187	23	210	218	4	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1138	+		10.1096/fj.02-0012fje	http://dx.doi.org/10.1096/fj.02-0012fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039845				2022-12-28	WOS:000175973900001
J	Ikeyama, S; Kokkonen, G; Wang, XT; Holbrook, NJ				Ikeyama, S; Kokkonen, G; Wang, XT; Holbrook, NJ			Effects of aging and calorie restriction on growth factor- and oxidant-induced mitogenesis in rat hepatocytes	FASEB JOURNAL			English	Meeting Abstract									NIA, LMBC, Baltimore, MD 21224 USA; Yale Univ, Dept Med, New Haven, CT 06520 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Yale University									0	107	108	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 22	2002	16	5	2				A1163	A1163		10.1096/fj.01-0409fje	http://dx.doi.org/10.1096/fj.01-0409fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	534PC	11709495				2022-12-28	WOS:000174593902416
J	Cristillo, AD; Highbarger, HC; Dewar, RL; Dimitrov, DS; Golding, H; Bierer, BE				Cristillo, AD; Highbarger, HC; Dewar, RL; Dimitrov, DS; Golding, H; Bierer, BE			Up-regulation of HIV coreceptor CXCR4 expression in human T lymphocytes is mediated in part by a cAMP-responsive element	FASEB JOURNAL			English	Article						CXCR4; HIV; cyclic AMP; CREB; chemokine receptors; AIDS	IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR CXCR4; HEMATOPOIETIC PROGENITOR CELLS; DOWN-MODULATION; SURFACE EXPRESSION; CUTTING EDGE; CYCLIC-AMP; INFECTION; CLONING; SDF-1	The chemokine and HIV receptor CXCR4 has been shown to play a role in chemotaxis and HIV-1 entry into T cells. Dibutyryl cAMP (DcAMP), an analog of cAMP, has been shown to increase CXCR4 cell surface expression and HIV-1 infectivity, but the molecular mechanism(s) responsible is unknown. Here we show that DcAMP treatment of purified human T lymphocytes increased transcription of CXCR4 mRNA as well as cell surface and intracellular CXCR4 protein expression. DcAMP-mediated stimulation of human PBL increased T-trophic HIV-1 (X4) fusion and viral replication as measured by syncytia formation and p24 levels, respectively. To determine the region( s) of the CXCR4 promoter required for cAMP responsiveness, truncations and point mutations of the CXCR4 promoter (nucleotides -1098 to +59) fused to luciferase were constructed and transiently transfected into human PBL. Deletional analysis demonstrated that the -1098 to -93 region of the CXCR4 promoter construct could be eliminated; the residual (-93 to +59) promoter retained cAMP responsiveness. Site-directed mutagenesis of a putative cAMP-responsive element (CRE) in the 5' UTR (+41 to +49) significantly and specifically attenuated the ability of DcAMP to drive the minimal CXCR4 promoter. Electrophoretic mobility shift assays demonstrated the formation of a complex between the CREB transcription factor and the putative CXCR4 CRE site. Our findings demonstrate a CRE element within the CXCR4 promoter that regulates CXCR4 transcription in response to changes in cAMP signaling. The cAMP-dependent up-regulation of CXCR4 mRNA results in increased CXCR4 intracellular and cell surface protein expression as well as increased HIV infectivity.	NHLBI, Lab Lymphocyte Biol, NIH, Bethesda, MD 20892 USA; NIAID, SAIC AIDS Monitoring Lab, NIH, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, NIH, Bethesda, MD 20892 USA; US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; US Food & Drug Administration (FDA)	Bierer, BE (corresponding author), NHLBI, Lab Lymphocyte Biol, NIH, Bldg 10,Room 6C208,10 Ctr Dr, Bethesda, MD 20892 USA.	biererb@nih.gov		Bierer, Barbara/0000-0001-6448-8170				Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Ancuta P, 2001, J IMMUNOL, V166, P4244, DOI 10.4049/jimmunol.166.6.4244; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Cole SW, 1999, J IMMUNOL, V162, P1392; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; Dolei A, 1998, AIDS, V12, P183, DOI 10.1097/00002030-199802000-00008; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Forster R, 1998, J IMMUNOL, V160, P1522; GOLDING H, 1992, AIDS RES HUM RETROV, V8, P1593, DOI 10.1089/aid.1992.8.1593; GOLDING H, 1995, J VIROL, V69, P6140, DOI 10.1128/JVI.69.10.6140-6148.1995; GOLDING H, 1994, J VIROL, V68, P1962, DOI 10.1128/JVI.68.3.1962-1969.1994; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gupta SK, 1999, J IMMUNOL, V163, P2368; Hioe CE, 2001, J VIROL, V75, P1077, DOI 10.1128/JVI.75.2.1077-1082.2001; Kawabata T, 1999, P NATL ACAD SCI USA, V96, P5663, DOI 10.1073/pnas.96.10.5663; Kim CH, 1998, BLOOD, V91, P100, DOI 10.1182/blood.V91.1.100.100_100_110; Kusunoki A, 1999, NUCLEOS NUCLEOT, V18, P1705, DOI 10.1080/07328319908044828; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; Ma Q, 1999, IMMUNITY, V10, P463, DOI 10.1016/S1074-7613(00)80046-1; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mackay CR, 1997, CURR BIOL, V7, pR384, DOI 10.1016/S0960-9822(06)00181-3; Melchers F, 1999, CELL, V99, P351, DOI 10.1016/S0092-8674(00)81521-4; Moriuchi M, 1999, J IMMUNOL, V162, P5986; Moriuchi M, 1997, J IMMUNOL, V159, P4322; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Rabbi MF, 1998, VIROLOGY, V245, P257, DOI 10.1006/viro.1998.9158; Rabbi MF, 1997, VIROLOGY, V233, P235, DOI 10.1006/viro.1997.8602; Rohr O, 1999, J CELL BIOCHEM, V75, P404, DOI 10.1002/(SICI)1097-4644(19991201)75:3<404::AID-JCB6>3.0.CO;2-G; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 2000, CURR TOP MICROBIOL, V251, P167; Sallusto F, 2000, IMMUNOL REV, V177, P134, DOI 10.1034/j.1600-065X.2000.17717.x; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Wang JB, 1998, J LEUKOCYTE BIOL, V64, P642, DOI 10.1002/jlb.64.5.642; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; Wegner SA, 1998, J BIOL CHEM, V273, P4754, DOI 10.1074/jbc.273.8.4754; Yang OO, 1999, J VIROL, V73, P4582, DOI 10.1128/JVI.73.6.4582-4589.1999; Zaitseva MB, 1998, J IMMUNOL, V161, P3103; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X; Zoeteweij JP, 1998, J IMMUNOL, V161, P3219; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	56	38	39	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0354	10.1096/fj.01-0744com	http://dx.doi.org/10.1096/fj.01-0744com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874984				2022-12-28	WOS:000174755900027
J	Takimoto, E; Yao, A; Toko, H; Takano, H; Shimoyama, M; Sonoda, M; Wakimoto, K; Takahashi, T; Akazawa, H; Mizukami, M; Nagai, T; Nagai, R; Komuro, I				Takimoto, E; Yao, A; Toko, H; Takano, H; Shimoyama, M; Sonoda, M; Wakimoto, K; Takahashi, T; Akazawa, H; Mizukami, M; Nagai, T; Nagai, R; Komuro, I			Sodium calcium exchanger plays a key role in alteration of cardiac function in response to pressure overload	FASEB JOURNAL			English	Article						Na+-Ca2+ exchanger; sarcoplasmic reticulum; knockout mice; NCX	STAGE HEART-FAILURE; NA-CA EXCHANGER; NA+-CA2+ EXCHANGER; NA+/CA2+ EXCHANGER; SARCOPLASMIC-RETICULUM; VENTRICULAR MYOCYTES; MOLECULAR-CLONING; TRANSGENIC MICE; GENE-EXPRESSION; CONTRACTION	The Na+-Ca2+ exchanger (NCX) on the plasma membrane is thought to be the main calcium extrusion system from the cytosol to the extracellular space in many mammalian excitable cells, including cardiac myocytes. However, the pathophysiological role of NCX in the heart is still unclear because of the lack of known specific inhibitors of NCX. To determine the role of NCX in cardiac contraction and the development of cardiac hypertrophy, we imposed pressure overload on the heart of heterozygous NCX knockout (KO) mice by constricting transverse aorta, and examined cardiac function and morphology 3 wk after operation. Although there was no difference in cardiac function between sham-operated KO mice and sham-operated wild-type (WT) mice, KO mice showed higher left ventricular pressure and better systolic function than WT mice in response to pressure overload. Northern blot analysis revealed that mRNA levels of sarcoplasmic reticulum Ca2+-ATPase were reduced by pressure overload in left ventricles of WT but not of KO mice. However, hypertrophic changes with interstitial fibrosis were more prominent in KO mice than WT mice. These results suggest that reduction of NCX results in supernormalized cardiac function and causes marked cardiac hypertrophy in response to pressure overload.	Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, Chiba 2608670, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan; Tanabe Seiyaku Co Ltd, Discovery Lab, Yodogawa Ku, Osaka 5328505, Japan	Chiba University; University of Tokyo; Mitsubishi Tanabe Pharma Corporation	Komuro, I (corresponding author), Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	komuro-tky@umin.ac.jp	Takimoto, Eiki/AAC-5100-2021					Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; BARRY WH, 1993, CIRCULATION, V87, P1806, DOI 10.1161/01.CIR.87.6.1806; BENOTTI JR, 1980, CIRCULATION, V61, P1206, DOI 10.1161/01.CIR.61.6.1206; BERS DM, 1990, AM J PHYSIOL, V258, pC944, DOI 10.1152/ajpcell.1990.258.5.C944; BERS DM, 1993, CARDIOVASC RES, V27, P1772, DOI 10.1093/cvr/27.10.1772; BERS DM, 1989, CIRC RES, V65, P334, DOI 10.1161/01.RES.65.2.334; Bers DM, 2000, CIRC RES, V87, P275, DOI 10.1161/01.RES.87.4.275; Cernohorsky J, 1998, AM J PHYSIOL-HEART C, V275, pH264, DOI 10.1152/ajpheart.1998.275.1.H264; DEMARIA AN, 1991, CIRCULATION, V8, P1288; GAASCH WH, 1976, AM J CARDIOL, V38, P645, DOI 10.1016/S0002-9149(76)80015-X; Harada K, 1998, CIRC RES, V82, P779, DOI 10.1161/01.RES.82.7.779; Hasenfuss G, 1999, CIRCULATION, V99, P641, DOI 10.1161/01.CIR.99.5.641; Hasenfuss G, 1998, CARDIOVASC RES, V37, P279, DOI 10.1016/S0008-6363(97)00277-0; HATEM SN, 1994, CIRC RES, V74, P253, DOI 10.1161/01.RES.74.2.253; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; KENT RL, 1993, AM J PHYSIOL, V265, pH1024, DOI 10.1152/ajpheart.1993.265.3.H1024; KLITZNER TS, 1991, J AM COLL CARDIOL, V17, P218, DOI 10.1016/0735-1097(91)90730-W; Koban MU, 1998, CARDIOVASC RES, V37, P405, DOI 10.1016/S0008-6363(97)00276-9; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; KOMURO I, 1989, J CLIN INVEST, V83, P1102, DOI 10.1172/JCI113989; LI ZP, 1994, J BIOL CHEM, V269, P17434; LOMPRE AM, 1994, J MOL CELL CARDIOL, V26, P1109, DOI 10.1006/jmcc.1994.1130; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V273, pH2826, DOI 10.1152/ajpheart.1997.273.6.H2826; MORGAN JP, 1991, NEW ENGL J MED, V325, P625; NEGRETTI N, 1993, CARDIOVASC RES, V27, P1826, DOI 10.1093/cvr/27.10.1826; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; O'Rourke B, 1999, CIRC RES, V84, P562, DOI 10.1161/01.RES.84.5.562; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Pogwizd SM, 1999, CIRC RES, V85, P1009; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; Reed TD, 2000, J MOL CELL CARDIOL, V32, P453, DOI 10.1006/jmcc.1999.1095; Reinecke H, 1996, CARDIOVASC RES, V31, P48, DOI 10.1016/0008-6363(95)00176-X; Schillinger W, 2000, CIRC RES, V87, P581, DOI 10.1161/01.RES.87.7.581; SEGUCHI M, 1986, J MOL CELL CARDIOL, V18, P189, DOI 10.1016/S0022-2828(86)80471-0; Shimoyama M, 1999, CIRCULATION, V100, P2449, DOI 10.1161/01.CIR.100.24.2449; STUDER R, 1994, CIRC RES, V75, P443, DOI 10.1161/01.RES.75.3.443; Taffet GE, 1996, AM J PHYSIOL-HEART C, V270, pH2204; TAKAHASHI T, 1992, J CLIN INVEST, V90, P927, DOI 10.1172/JCI115969; Takeshima H, 1998, EMBO J, V17, P3309, DOI 10.1093/emboj/17.12.3309; Terracciano CMN, 1998, J PHYSIOL-LONDON, V512, P651, DOI 10.1111/j.1469-7793.1998.651bd.x; VETTER R, 1995, J MOL CELL CARDIOL, V27, P1689, DOI 10.1016/S0022-2828(95)90788-2; Wakimoto K, 2000, J BIOL CHEM, V275, P36991, DOI 10.1074/jbc.M004035200; Yao AS, 1998, CIRC RES, V82, P657, DOI 10.1161/01.RES.82.6.657	45	28	29	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0373	10.1096/fj.01-0735com	http://dx.doi.org/10.1096/fj.01-0735com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874986				2022-12-28	WOS:000174755900029
J	Afford, SC; Ahmed-Choudhury, J; Randhawa, S; Russell, C; Youster, J; Crosby, HA; Eliopoulos, A; Hubscher, SG; Young, LS; Adams, DH				Afford, SC; Ahmed-Choudhury, J; Randhawa, S; Russell, C; Youster, J; Crosby, HA; Eliopoulos, A; Hubscher, SG; Young, LS; Adams, DH			CD40 activation-induced, Fas-dependent apoptosis and NF-kappa B/AP-1 signaling in human intrahepatic biliary epithelial cells	FASEB JOURNAL			English	Article						CD40-mediated apoptosis; Fas-mediated apoptosis; primary biliary cirrhosis; NF-kappa B and AP-1 activation	ENDOTHELIAL-CELLS; ALLOGRAFT-REJECTION; KAPPA-B; LIVER; EXPRESSION; LIGAND; DISEASE; DEATH; MICE; CHOLANGIOPATHY	Fas-mediated mechanisms of apoptosis are thought to be involved in the bile duct loss that characterizes diseases such as primary biliary cirrhosis (PBC). We have previously shown that activation of CD40 on hepatocytes can amplify Fas-mediated apoptosis; in the present study, we investigated interactions between CD40 and Fas in biliary epithelial cells (BEC). We report that the bile ducts in PBC liver tissue frequently express increased levels of Fas, Fas ligand (FasL), and CD40 associated with apoptotic BEC. The portal mononuclear infiltrate contains CD40L+ve T cells and macrophages, thereby demonstrating a potential mechanism for CD40 engagement in vivo. Primary cultures of human BEC also expressed Fas, FasL, and CD40 but not CD40L protein or mRNA. Activation of CD40 on BEC using recombinant CD40L increased transcriptional expression of FasL and induced apoptosis, which was inhibited by neutralizing antibodies to either Fas or FasL. Thus, CD40-induced apoptosis of BEC is mediated through Fas/FasL. We then investigated the intracellular signals and transcription factors activated in BEC and found that NF-kappaB and AP-1 were both activated after CD40 ligation. Increased functional NF-kappaB was seen early after CD40 ligation, but returned to baseline levels after 4 h. In contrast, the rapid up-regulation of AP-1 was sustained over 24 h. This study provides further functional evidence of the ability of CD40 to induce Fas/FasL-dependent apoptosis of liver epithelial cells supporting the importance of cross-talk between tumor necrosis factor (TNF) receptor family members as an amplification step in apoptosis induction. Sustained activation of AP-1 in the absence of NF-kappaB signaling may be a critical factor in determining the outcome of CD40 engagement.	Univ Birmingham, MRC, Ctr Immune Regulat, Liver Res Labs, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Dept Pathol, Birmingham B15 2TH, W Midlands, England; Queen Elizabeth Hosp, Inst Clin Sci, CRC, Inst Canc Studies, Birmingham B15 2TH, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham	Afford, SC (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Inst Clin Sci, MRC,Ctr Immune Regulat,Liver Res Labs, Birmingham B15 2TH, W Midlands, England.	s.c.afford@bham.ac.uk	Adams, David H/C-9092-2009; Young, Lawrence S/B-7213-2009	Adams, David H/0000-0001-6776-0336; Young, Lawrence S/0000-0003-3919-4298				ABMAYR SM, 1991, CURRENT PROTOCOLS MO; Afford SC, 1999, J EXP MED, V189, P441, DOI 10.1084/jem.189.2.441; AFFORD SC, 1995, J PATHOL, V176, P373, DOI 10.1002/path.1711760408; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; Eliopoulos AG, 2000, MOL CELL BIOL, V20, P5503, DOI 10.1128/MCB.20.15.5503-5515.2000; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; FLOREANI A, 1989, AUTOIMMUNITY, V2, P311, DOI 10.3109/08916938908997157; Gallop JR, 1995, CERN REPORT, V95, P1; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Harada K, 1997, HEPATOLOGY, V26, P1399; Hayward AR, 1997, J IMMUNOL, V158, P977; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; HUBSCHER SG, 1991, TRANSPLANTATION, V51, P1004, DOI 10.1097/00007890-199105000-00014; JOPLIN R, 1994, GUT, V35, P875, DOI 10.1136/gut.35.7.875; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Krzesz R, 1999, FEBS LETT, V453, P191, DOI 10.1016/S0014-5793(99)00683-3; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; Morland CM, 1997, P ASSOC AM PHYSICIAN, V109, P372; Morland CM, 1996, HEPATOLOGY, V24, P823; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OGASAWARA J, 1993, NATURE, V365, P568, DOI 10.1038/365568a0; SHERLOCK S, 1987, LANCET, V2, P493; Stephens J, 1999, HEPATOLOGY, V30, P27, DOI 10.1002/hep.510300138; Strand S, 1998, NAT MED, V4, P588, DOI 10.1038/nm0598-588; Ueno Y, 2000, HEPATOLOGY, V31, P966, DOI 10.1053/he.2000.5764; vanKooten C, 1997, KIDNEY INT, V51, P711, DOI 10.1038/ki.1997.102; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; von Leoprechting A, 1999, CANCER RES, V59, P1287; YOUNG LS, 1989, INT J CANCER, V43, P786, DOI 10.1002/ijc.2910430508	35	100	105	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2345	2354		10.1096/fj.01-0088com	http://dx.doi.org/10.1096/fj.01-0088com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689460				2022-12-28	WOS:000172420500005
J	Cursio, R; Mari, B; Louis, K; Rostagno, P; Saint-Paul, MC; Giudicelli, J; Bottero, V; Anglard, P; Yiotakis, A; Dive, V; Gugenheim, J; Auberger, P				Cursio, R; Mari, B; Louis, K; Rostagno, P; Saint-Paul, MC; Giudicelli, J; Bottero, V; Anglard, P; Yiotakis, A; Dive, V; Gugenheim, J; Auberger, P			Rat liver injury following normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor	FASEB JOURNAL			English	Article						matrix metalloproteinases (MMPs); tissue inhibitors of matrix metalloproteinase; (TIMPs); ischemia/reperfusion; necrosis; apoptosis	HEPATIC STELLATE CELLS; TUMOR-NECROSIS-FACTOR; REPERFUSION INJURY; TISSUE INHIBITOR; TNF-ALPHA; HUMAN STROMELYSIN-3; BASEMENT-MEMBRANE; MMP2 ACTIVATION; FOCAL ISCHEMIA; EXPRESSION	Hepatic ischemia occurs in liver transplantation, hemodynamic or cardiogenic shock, and liver resection associated with trauma or tumor. Ischemia/reperfusion (I/R) injury results in microcirculation failure followed by apoptosis and necrosis. Matrix metalloproteinases (MMPs) are involved in many physiological and pathological processes, but their expression and function during liver I/R remains poorly documented. In this study, we evaluated the expression of nine MMPs and their natural inhibitors, tissue inhibitors of MMPs (TIMPs), in a rat model of liver I/R. Analysis of MMP and TIMP expression show that although most of these genes are not constitutively expressed in the normal liver, they are induced in a specific time-dependent manner following I/R. Stromelysin-1, gelatinase B, and collagenase-3 are induced during the early phase of acute liver injury associated with inflammation and increased necrosis/apoptosis, whereas gelatinase A, membrane type-MMP, stromelysin-3, metalloelastase, TIMP-1, and TIMP-2 are essentially detectable during the recovery phase of liver injury corresponding to hepatocyte regeneration. This observation suggested that MMPs and TIMPs could play both deleterious and beneficial roles following I/R. We thus tested the effect of a specific phosphinic MMP inhibitor on acute liver I/R injury. Inhibition of MMP activity was shown to significantly decrease liver injury in ischemic/reperfused liver tissue as assessed by histological studies and serum hepatic enzyme levels. We therefore propose that MMP inhibitors may be of clinical relevance in liver-associated ischemic diseases or after liver transplantation.	Fac Med Pasteur, INSERM, U526, IFR50, Nice, France; Fac Med Pasteur, IFR50, Lab Rech Chirurg, Nice, France; Ctr Antoine Lacassagne, F-06054 Nice, France; Hop Louis Pasteur, Serv Anat Pathol, Nice, France; Fac Med, Biochim Lab, Nice, France; INSERM, U184, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France; Univ Athens, Organ Chem Lab, Athens, Greece; CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National & Kapodistrian University of Athens; CEA; UDICE-French Research Universities; Universite Paris Saclay	Mari, B (corresponding author), Fac Med Pasteur, INSERM, U526, IFR50, Nice, France.	bmari@unice.fr	Mari, Bernard P/F-8960-2013; AUBERGER, Patrick/G-1491-2013; Mari, Bernard/Q-5832-2019; Mari, Bernard P/GVS-3100-2022; Anglard, Patrick/M-6618-2019; Mari, Bernard P/D-7445-2015	Mari, Bernard P/0000-0002-0422-9182; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Anglard, Patrick/0000-0001-5701-441X; Mari, Bernard P/0000-0002-0422-9182				Alvarez J, 2000, J BONE MINER RES, V15, P82, DOI 10.1359/jbmr.2000.15.1.82; Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; ARTHUR MJP, 1989, J CLIN INVEST, V84, P1076, DOI 10.1172/JCI114270; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Behrendtsen O, 1997, DEV DYNAM, V208, P255; Benyon RC, 1999, HEPATOLOGY, V30, P977, DOI 10.1002/hep.510300431; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boulay A, 2001, CANCER RES, V61, P2189; Brown PD, 2000, EXPERT OPIN INV DRUG, V9, P2167, DOI 10.1517/13543784.9.9.2167; Chambaut-Guerin AM, 2000, J NEUROCHEM, V74, P508, DOI 10.1046/j.1471-4159.2000.740508.x; Cheung PY, 2000, CIRCULATION, V101, P1833, DOI 10.1161/01.CIR.101.15.1833; Clavien PA, 2001, HEPATOLOGY, V33, P1555, DOI 10.1053/jhep.2001.25448; Colletti LM, 1996, HEPATOLOGY, V23, P506; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Cursio R, 1998, J SURG RES, V80, P339, DOI 10.1006/jsre.1998.5445; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; Dive V, 2000, BIOCHEM SOC T, V28, P455, DOI 10.1042/0300-5127:0280455; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Fassina G, 2000, CLIN EXP METASTAS, V18, P111, DOI 10.1023/A:1006797522521; Haro H, 2000, J CLIN INVEST, V105, P133, DOI 10.1172/JCI7090; Haruyama T, 2000, BIOCHEM BIOPH RES CO, V272, P681, DOI 10.1006/bbrc.2000.2837; Herbst H, 1997, AM J PATHOL, V150, P1647; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Iredale JP, 1997, INT J BIOCHEM CELL B, V29, P43, DOI 10.1016/S1357-2725(96)00118-5; JAESCHKE H, 1991, AM J PHYSIOL, V260, P355; Kim TH, 2000, HEPATOLOGY, V31, P75, DOI 10.1002/hep.510310114; Knittel T, 1999, J HEPATOL, V30, P48, DOI 10.1016/S0168-8278(99)80007-5; Knittel T, 2000, HISTOCHEM CELL BIOL, V113, P443; Kohli V, 1999, TRANSPLANTATION, V67, P1099, DOI 10.1097/00007890-199904270-00003; LaFleur M, 1996, J EXP MED, V184, P2311; Leber TM, 1998, BRIT J CANCER, V78, P724, DOI 10.1038/bjc.1998.568; Luo DC, 1999, J BIOL CHEM, V274, P37177, DOI 10.1074/jbc.274.52.37177; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; Mari BP, 1998, J BIOL CHEM, V273, P618, DOI 10.1074/jbc.273.1.618; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; Okada A, 1997, GENE, V185, P187, DOI 10.1016/S0378-1119(96)00615-4; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Planas AM, 2000, BIOCHEM BIOPH RES CO, V278, P803, DOI 10.1006/bbrc.2000.3881; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Roeb E, 1997, J HEPATOL, V27, P535, DOI 10.1016/S0168-8278(97)80359-5; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; SAKR MF, 1993, J HEPATOL, V17, P301, DOI 10.1016/S0168-8278(05)80209-0; Sasaki H, 1996, TRANSPLANT P, V28, P1908; Shapiro SD, 1999, THROMB HAEMOSTASIS, V82, P846; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Soccal PM, 2000, TRANSPLANTATION, V70, P998, DOI 10.1097/00007890-200010150-00002; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Takahara T, 1997, HEPATOLOGY, V26, P1521; Theret N, 1999, HEPATOLOGY, V30, P462, DOI 10.1002/hep.510300236; Theret N, 1997, AM J PATHOL, V150, P51; Theret N, 1998, AM J PATHOL, V153, P945, DOI 10.1016/S0002-9440(10)65636-2; Upadhya AG, 1997, HEPATOLOGY, V26, P922, DOI 10.1002/hep.510260418; Upadhya GA, 2000, HEPATOLOGY, V31, P1115, DOI 10.1053/he.2000.6780; Vassiliou S, 1999, J MED CHEM, V42, P2610, DOI 10.1021/jm9900164; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; WU E, 2001, IN PRESS J CELL BIOC; Yadav SS, 1999, HEPATOLOGY, V30, P1223, DOI 10.1002/hep.510300513; Yoshiji H, 2000, HEPATOLOGY, V32, P1248, DOI 10.1053/jhep.2000.20521; Zhang YH, 1998, J IMMUNOL, V161, P3071	65	91	92	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					93	+		10.1096/fj.01-0279fje	http://dx.doi.org/10.1096/fj.01-0279fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11709491				2022-12-28	WOS:000172420500036
J	Kim, I; Oh, JL; Ryu, YS; So, JN; Sessa, WC; Walsh, K; Koh, GY				Kim, I; Oh, JL; Ryu, YS; So, JN; Sessa, WC; Walsh, K; Koh, GY			Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells	FASEB JOURNAL			English	Article						vascular endothelial growth factor; TNF-alpha; Akt; phosphatidylinositol 3 '-kinase	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION PATHWAY; BLOOD-VESSEL DEVELOPMENT; SERINE-THREONINE KINASE; GROWTH-FACTOR; OVEREXPRESSING ANGIOPOIETIN-1; VASCULAR-PERMEABILITY; TIE2 RECEPTOR; FACTOR GENE	Normally, tissue factor (TF) is not expressed on the surface of endothelial cells, but its expression can be induced by vascular endothelial growth factor (VEGF) and tumor necrosis factor (TNF)-alpha. However, the signaling pathway(s) affecting this induction is unknown. Using human umbilical vein endothelial cells, we found that inhibitors of guanine-cytosine-rich DNA binding protein and nuclear factor (NF)-kappaB suppressed VEGF- and TNF-alpha -induced expression and activity of TF. However, unexpectedly, phosphatidylinositol (PI) 3'-kinase inhibitor enhanced the VEGF- and TNF-alpha -induced expression and activity of TF. Angiopoietin-1 (Ang1), a strong activator of intracellular PI 3'-kinase/Akt, inhibited the induction of TF by VEGF and TNF-alpha, whereas Ang1 itself did not produce any significant effect on TF. Selective activation (or inactivation) of PI 3'-kinase/Akt by using adenoviral transfer reduced (or enhanced) TNF-alpha -induced expression of TF mRNA and protein, regardless of Ang1 treatment. From these results, we conclude that Ang1 inhibits the up-regulation of TF expression, possibly through activation of PI 3'-kinase/Akt in endothelial cells. Ang1 may be useful as an inhibitor of VEGF- and TNF-alpha -induced coagulation, inflammation, and cancer progression.	Pohang Univ Sci & Technol, Dept Life Sci, Natl Creat Res Initiat Ctr Endothelial Cells, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea; Woosuk Univ, Dept Biotechnol, Chonju 560180, South Korea; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; St Elizabeths Med Ctr Boston, Div Cardiovasc Res, Boston, MA 02135 USA	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Woosuk University; Yale University; St. Elizabeth's Medical Center	Koh, GY (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Natl Creat Res Initiat Ctr Endothelial Cells, San 31, Pohang 790784, South Korea.	gykoh@postech.ac.kr	Sessa, William C/B-6844-2011; Koh, Gou Young/C-1615-2011; Kim, Injune/C-1710-2011	Sessa, William C/0000-0001-5759-1938; Kim, Injune/0000-0001-9244-815X				Armesilla AL, 1999, MOL CELL BIOL, V19, P2032; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BIERHAUS A, 1995, J BIOL CHEM, V270, P26419, DOI 10.1074/jbc.270.44.26419; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chae JK, 2000, ARTERIOSCL THROM VAS, V20, P2573, DOI 10.1161/01.ATV.20.12.2573; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 2001, CIRC RES, V89, P477, DOI 10.1161/hh1801.097034; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; KNOLL J, 1997, J BIOL CHEM, V272, P32521; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; MACKMAN N, 1995, FASEB J, V9, P883, DOI 10.1096/fasebj.9.10.7615158; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823; Mechtcheriakova D, 2001, FASEB J, V15, P230, DOI 10.1096/fj.00-0247com; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; NAWROTH PP, 1985, THROMB RES, V40, P677, DOI 10.1016/0049-3848(85)90305-6; NEMERSON Y, 1988, BLOOD, V71, P1; Ozes ON, 1999, NATURE, V401, P82; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Papapetropoulos A, 1999, LAB INVEST, V79, P213; RAO LVM, 1992, CANCER METAST REV, V11, P249; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Shen BQ, 2001, J BIOL CHEM, V276, P5281, DOI 10.1074/jbc.M007969200; Shyu KG, 1998, CIRCULATION, V98, P2081, DOI 10.1161/01.CIR.98.19.2081; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tsurumi Y, 1996, CIRCULATION, V94, P3281, DOI 10.1161/01.CIR.94.12.3281; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	54	99	103	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					126	+		10.1096/fj.01-0556fje	http://dx.doi.org/10.1096/fj.01-0556fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11729102				2022-12-28	WOS:000172420500027
J	Laplante, AF; Germain, L; Auger, FA; Moulin, V				Laplante, AF; Germain, L; Auger, FA; Moulin, V			Mechanisms of wound reepithelialization: hints from a tissue-engineered reconstructed skin to long-standing questions	FASEB JOURNAL			English	Article						wound healing; keratinocyte; epithelia; drug screening	HUMAN KERATINOCYTE MIGRATION; EPIDERMAL BASEMENT-MEMBRANE; IN-VITRO; CELL-MIGRATION; EPITHELIAL-CELLS; FULL-THICKNESS; NUDE-MOUSE; EXPRESSION; LAMININ-5; EQUIVALENT	Wound closure of epithelial tissues must occur efficiently to restore rapidly their barrier function. We have developed a tissue-engineered wound-healing model composed of human skin keratinocytes and fibroblasts to better understand the mechanisms of reepithelialization. It allowed us to quantify the reepithelialization rate, which was significantly accelerated in the presence of fibrin or platelet-rich plasma. The reepithelialization of these 6 mm excisional wounds required the contribution of keratinocyte proliferation, migration, stratification, and differentiation. The epidermis regenerated progressively from the surrounding wound margins. After 3 days, the neoepidermis showed a complete spectrum of changes. Near the wound margin, the differentiation of the neoepidermis (keratins 1/10, filaggrin, and loricrin) and regeneration of the dermoepidermal junction (laminin 5 and collagen IV) were more advanced than toward the wound center, where the proliferative index was significantly increased. The spatial distribution of keratinocytes distinguished by particular features suggests two complementary mechanisms of reepithelialization: 1) the passive displacement of the superficial layers near the wound margin that would rapidly regenerate a barrier function and 2) the crawling of keratinocytes over each other at the tip of the progressing neoepidermis. Therefore, this study brings a new perspective to long-standing questions concerning wound reepithelialization.	Univ Laval, Dept Surg, CHA Quebec, Hop St Sacrement,LOEX, Quebec City, PQ G1S 4L8, Canada	Laval University	Moulin, V (corresponding author), Univ Laval, Dept Surg, CHA Quebec, Hop St Sacrement,LOEX, 1050 Ch St Foy, Quebec City, PQ G1S 4L8, Canada.	veronique.moulin@chg.ulaval.ca	Moulin, Veronique J/P-9668-2018	Moulin, Veronique J/0000-0002-2925-2784; Germain, Lucie/0000-0001-8883-6491				AUGER FA, 1993, BRIT J PLAST SURG, V46, P136, DOI 10.1016/0007-1226(93)90145-2; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; BETZ P, 1993, INT J LEGAL MED, V106, P35, DOI 10.1007/BF01225022; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; BUCK RC, 1979, INVEST OPHTH VIS SCI, V18, P767; CAVANI A, 1993, J INVEST DERMATOL, V101, P600, DOI 10.1111/1523-1747.ep12366057; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; COHEN IK, 1994, PRINCIPLES SURG, P279; Coulombe PA, 2000, TRENDS CELL BIOL, V10, P420, DOI 10.1016/S0962-8924(00)01828-6; Dale B. A., 1994, KERATINOCYTE HDB, P323; DEMARCHEZ M, 1986, DEV BIOL, V113, P90, DOI 10.1016/0012-1606(86)90110-7; DEMARCHEZ M, 1987, DEV BIOL, V121, P119, DOI 10.1016/0012-1606(87)90145-X; DONALDSON DJ, 1988, J INVEST DERMATOL, V90, P623, DOI 10.1111/1523-1747.ep12560762; FLEISCHMAJER R, 1993, J HISTOCHEM CYTOCHEM, V41, P1359, DOI 10.1177/41.9.7689083; FUCHS E, 1993, J CELL SCI, P197; GARLICK JA, 1994, LAB INVEST, V70, P916; GERMAIN L, 1995, BURNS, V21, P175, DOI 10.1016/0305-4179(95)80004-8; GERMAIN L, 1993, BURNS, V19, P99, DOI 10.1016/0305-4179(93)90028-7; GERMAIN L, 1995, ENCY HDB BIOMATERIAL, V1, P699; GIBBINS JR, 1978, PATHOLOGY, V10, P207, DOI 10.3109/00313027809063503; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; GRONDAHLHANSEN J, 1988, J INVEST DERMATOL, V90, P790, DOI 10.1111/1523-1747.ep12461511; Holbrook KA, 1987, DERMATOLOGY GENERAL, P93; Jansson K, 1996, IN VITRO CELL DEV-AN, V32, P534; Kainulainen T, 1998, J HISTOCHEM CYTOCHEM, V46, P353, DOI 10.1177/002215549804600309; KIM JP, 1992, J CELL PHYSIOL, V151, P443, DOI 10.1002/jcp.1041510303; KRAWCZYK WS, 1971, J CELL BIOL, V49, P247, DOI 10.1083/jcb.49.2.247; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; L'Heureux N, 2001, FASEB J, V15, P515, DOI 10.1096/fj.00-0283com; Laplante AF, 1998, J HISTOCHEM CYTOCHEM, V46, P1291, DOI 10.1177/002215549804601109; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; MARINKOVICH MP, 1993, DEV DYNAM, V197, P255, DOI 10.1002/aja.1001970404; MARKS R, 1973, BRIT J DERMATOL, V88, P245, DOI 10.1111/j.1365-2133.1973.tb07542.x; MATOLTSY AG, 1976, J INVEST DERMATOL, V67, P20, DOI 10.1111/1523-1747.ep12512473; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; Michel M, 1999, IN VITRO CELL DEV-AN, V35, P318; ODLAND G, 1968, J CELL BIOL, V39, P135, DOI 10.1083/jcb.39.1.135; ORDMAN LJ, 1966, ARCH SURG-CHICAGO, V93, P857; ORTONNE JP, 1981, VIRCHOWS ARCH A, V392, P217, DOI 10.1007/BF00430822; OToole EA, 1997, EXP CELL RES, V233, P330, DOI 10.1006/excr.1997.3586; PANG SC, 1978, AM J ANAT, V153, P177, DOI 10.1002/aja.1001530202; PINKUS H, 1951, J INVEST DERMATOL, V16, P383, DOI 10.1038/jid.1951.45; RADICE GP, 1980, DEV BIOL, V76, P26, DOI 10.1016/0012-1606(80)90360-7; RIGAL C, 1991, J INVEST DERMATOL, V96, P777, DOI 10.1111/1523-1747.ep12471745; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Rovee D.T., 1972, EPIDERMAL WOUND HEAL, P71; ROVEE DT, 1972, EPIDERMAL WOUND HEAL, P159; Sahuc Florent, 1996, Wound Repair and Regeneration, V4, P93, DOI 10.1046/j.1524-475X.1996.40116.x; SCIUBBA JJ, 1977, J PERIODONTAL RES, V12, P204, DOI 10.1111/j.1600-0765.1977.tb00123.x; Smola H, 1998, EXP CELL RES, V239, P399, DOI 10.1006/excr.1997.3910; STANLEY JR, 1981, J INVEST DERMATOL, V77, P240, DOI 10.1111/1523-1747.ep12480082; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P4097, DOI 10.1073/pnas.78.7.4097; Stenn KS., 1992, WOUND HEALING BIOCH, P115; TIDMAN MJ, 1984, J INVEST DERMATOL, V83, P448, DOI 10.1111/1523-1747.ep12273562; VAUGHAN RB, 1966, J CELL SCI, V1, P407; VIZIAM CB, 1964, J INVEST DERMATOL, V43, P499, DOI 10.1038/jid.1964.192; WEISS P, 1960, HARVEY LECT, P13; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580; Xu W, 1996, BURNS, V22, P191, DOI 10.1016/0305-4179(95)00124-7; YAOITA H, 1978, J INVEST DERMATOL, V70, P191, DOI 10.1111/1523-1747.ep12541313; Zacchi V, 1998, J BIOMED MATER RES, V40, P187, DOI 10.1002/(SICI)1097-4636(199805)40:2<187::AID-JBM3>3.0.CO;2-H; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280	63	150	158	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2377	2389		10.1096/fj.01-0250com	http://dx.doi.org/10.1096/fj.01-0250com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689463				2022-12-28	WOS:000172420500008
J	Kamohara, H; Yamashiro, S; Galligan, C; Yoshimura, T				Kamohara, H; Yamashiro, S; Galligan, C; Yoshimura, T			Discoidin domain receptor 1 isoform-a (DDR1a) promotes migration of leukocytes in three-dimensional collagen lattices	FASEB JOURNAL			English	Article						receptor tyrosine kinase; cell migration; adherence; extracellular matrix; inflammation	TYROSINE KINASE; FOCAL ADHESIONS; MESSENGER-RNA; CELLS; INTEGRINS; EXPRESSION; MATRIX; NEUTROPHILS; ACTIVATION; STRATEGIES	Although integrins are crucial for migration of leukocytes through endothelium, integrin-independent mechanisms appear to take over and mediate the migration of leukocytes through extracellular matrix (ECM) in a three-dimensional tissue microenvironment. Discoidin domain receptor (DDR) 1 is a receptor tyrosine kinase activated by collagen, the most abundant ECM protein. In the present study, we detected that peripheral blood mononuclear cells (PBMC) and polymorphonuclear neutrophils were induced to express DDR1 after incubation in RPMI 1640. The expression level of DDR1 in PBMC was increased further by stimulation with tumor necrosis factor-alpha, interleukin-1 beta, granulocyte-macrophage colony-stimulating factor, lipopolysaccharide, or phytohemagglutinin, but not with interferon-gamma. In vivo, DDR1 mRNA was detectable in mononuclear leukocytes infiltrating human renal tumor tissue. Among three DDR1 isoforms, DDR1a was the major transcript in leukocytes. Functionally, overexpression of either DDR1a or DDR1b in THP-1 cells resulted in increased adherence to collagen-coated plates in a beta1-integrin independent manner. However, only DDR1a-, but not DDR1b-, overexpressing cells exhibited marked pseudopod extension and migrated successfully through three-dimensional collagen lattices. Consequently, we propose that the interaction of DDR1a with collagen of the ECM results in a requisite intracellular signaling that enables leukocytes to migrate in a tissue microenvironment and participate in host defense.	NCI, Mol Immunoregulat Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yoshimura, T (corresponding author), NCI, Mol Immunoregulat Lab, Bldg 559,Room 9, Frederick, MD 21702 USA.	yoshimur@mail.ncifcrf.gov		Yoshimura, Teizo/0000-0002-3853-2075				ABERCROMBIE M, 1970, EXP CELL RES, V60, P437, DOI 10.1016/0014-4827(70)90537-9; AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; ALVES F, 1995, ONCOGENE, V10, P609; Bhatt RS, 2000, GENE DEV, V14, P2216, DOI 10.1101/gad.821600; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Foehr ED, 2000, FASEB J, V14, P973, DOI 10.1096/fasebj.14.7.973; Friedl P, 1998, EUR J IMMUNOL, V28, P2331, DOI 10.1002/(SICI)1521-4141(199808)28:08<2331::AID-IMMU2331>3.0.CO;2-C; Friedl P, 1998, CELL ADHES COMMUN, V6, P225, DOI 10.3109/15419069809004478; Goebeler M, 1996, J CELL SCI, V109, P1957; GUILFORD WH, 1995, AM J PHYSIOL-CELL PH, V268, pC1308, DOI 10.1152/ajpcell.1995.268.5.C1308; Gunzer M, 1997, ADV EXP MED BIOL, V417, P97; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; Hou GP, 2001, J CLIN INVEST, V107, P727, DOI 10.1172/JCI10720; HUNTTENLOCHER A, 1996, J CELL BIOL, V134, P1551; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Mandeville JTH, 1997, J LEUKOCYTE BIOL, V61, P188, DOI 10.1002/jlb.61.2.188; NOBLE PB, 1987, J CELL SCI, V81, P241; Perez JL, 1996, ONCOGENE, V12, P1469; Playford MP, 1996, GENOME RES, V6, P620, DOI 10.1101/gr.6.7.620; Sakuma S, 1996, FEBS LETT, V398, P165, DOI 10.1016/S0014-5793(96)01234-3; SAKUMA S, 1995, RADIAT RES, V143, P1, DOI 10.2307/3578919; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; Werr J, 1998, J EXP MED, V187, P2091, DOI 10.1084/jem.187.12.2091; XU LL, 1995, EUR J IMMUNOL, V25, P2612, DOI 10.1002/eji.1830250931; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yamashiro S, 1999, J LEUKOCYTE BIOL, V65, P671, DOI 10.1002/jlb.65.5.671; YOSHIMURA T, 1993, J IMMUNOL, V150, P5025	36	99	106	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2724	+		10.1096/fj.01-0359fje	http://dx.doi.org/10.1096/fj.01-0359fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606478				2022-12-28	WOS:000171920400015
J	Keller, C; Steensberg, A; Pilegaard, H; Osada, T; Saltin, B; Pedersen, BK; Neufer, PD				Keller, C; Steensberg, A; Pilegaard, H; Osada, T; Saltin, B; Pedersen, BK; Neufer, PD			Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content	FASEB JOURNAL			English	Article						interleukin 6; transcription; exercise; physical activity	EXERCISE-INDUCED INCREASE; RAT HEPATOCYTES; INTERLEUKIN-6; CYTOKINES; DAMAGE; ALPHA	In humans, the plasma interleukin 6 (IL-6) concentration increases dramatically during low-intensity exercise. Measurements across the working limb indicate that skeletal muscle is the source of IL-6 production. To determine whether energy availability influences the regulation of IL-6 expression during prolonged exercise, six male subjects completed two trials consisting of 180 min of two-legged dynamic knee extensor with either normal or low (similar to 60% of control) preexercise muscle glycogen levels. Increases in plasma IL-6 during exercise were significantly higher (P<0.05) in the low-glycogen (16-fold) trial verses the control (10-fold) trial. Transcriptional activation of the IL-6 gene in skeletal muscle was also higher in the low-glycogen trial; it increased by about 40-fold after 90 min of exercise and about 60-fold after 180 min of exercise. Muscle IL-6 mRNA followed a similar but delayed pattern, increasing by more than 100-fold in the low-glycogen trial and by about 30-fold in the control trial. These data demonstrate that exercise activates transcription of the IL-6 gene in working skeletal muscle, a response that is dramatically enhanced when glycogen levels are low. These findings also support the hypothesis that IL-6 may be produced by contracting myofibers when glycogen levels become critically low as a means of signaling the liver to increase glucose production.	John B Pierce Fdn Lab, New Haven, CT 06519 USA; Copenhagen Muscle Res Ctr, DK-2200 Copenhagen, Denmark; Univ Copenhagen, Dept Infect Dis, DK-2200 Copenhagen, Denmark; August Krogh Inst, DK-2200 Copenhagen, Denmark; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	Yale University; The John B Pierce Laboratory, Inc; University of Copenhagen; University of Copenhagen; University of Copenhagen; Yale University	Neufer, PD (corresponding author), John B Pierce Fdn Lab, 290 Congress Ave, New Haven, CT 06519 USA.	dneufer@jbpierce.org	Pilegaard, Henriette/M-2315-2014; Pedersen, Bente Klarlund/AGR-3217-2022	Pilegaard, Henriette/0000-0002-1071-0327; Pedersen, Bente Klarlund/0000-0001-6508-6288; Osada, Takuya/0000-0003-4588-1748				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ANDERSEN P, 1985, J APPL PHYSIOL, V59, P1647, DOI 10.1152/jappl.1985.59.5.1647; BLUMBERG D, 1995, METABOLISM, V44, P145, DOI 10.1016/0026-0495(95)90255-4; Bruunsgaard H, 1997, J PHYSIOL-LONDON, V499, P833, DOI 10.1113/jphysiol.1997.sp021972; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Croisier JL, 1999, MUSCLE NERVE, V22, P208, DOI 10.1002/(SICI)1097-4598(199902)22:2<208::AID-MUS8>3.0.CO;2-B; DRENTH JPH, 1995, J APPL PHYSIOL, V79, P1497, DOI 10.1152/jappl.1995.79.5.1497; EVANS WJ, 1986, J APPL PHYSIOL, V61, P1864, DOI 10.1152/jappl.1986.61.5.1864; Gallucci S, 1998, INT IMMUNOL, V10, P267, DOI 10.1093/intimm/10.3.267; Gleeson M, 2000, J PHYSIOL-LONDON, V529, P1, DOI 10.1111/j.1469-7793.2000.00001.x; Hack CE, 1997, ADV IMMUNOL, V66, P101, DOI 10.1016/S0065-2776(08)60597-0; Hildebrandt AL, 2000, AM J PHYSIOL-ENDOC M, V278, pE1078, DOI 10.1152/ajpendo.2000.278.6.E1078; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Jonsdottir IH, 2000, J PHYSIOL-LONDON, V528, P157, DOI 10.1111/j.1469-7793.2000.00157.x; Kanemaki T, 1998, HEPATOLOGY, V27, P1296, DOI 10.1002/hep.510270515; Kovalovich K, 2000, HEPATOLOGY, V31, P149, DOI 10.1002/hep.510310123; Leu JI, 2001, MOL CELL BIOL, V21, P414, DOI 10.1128/MCB.21.2.414-424.2001; NehlsenCannarella SL, 1997, J APPL PHYSIOL, V82, P1662, DOI 10.1152/jappl.1997.82.5.1662; Nielsen HB, 1996, AM J PHYSIOL-REG I, V271, pR222, DOI 10.1152/ajpregu.1996.271.1.R222; Ostrowski K, 1998, J PHYSIOL-LONDON, V513, P889, DOI 10.1111/j.1469-7793.1998.889ba.x; Ostrowski K, 1999, J PHYSIOL-LONDON, V515, P287, DOI 10.1111/j.1469-7793.1999.287ad.x; Ostrowski K, 1998, J PHYSIOL-LONDON, V508, P949, DOI 10.1111/j.1469-7793.1998.949bp.x; Papanicolaou DA, 1996, AM J PHYSIOL-ENDOC M, V271, pE601; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; Pedersen BK, 2000, PHYSIOL REV, V80, P1055, DOI 10.1152/physrev.2000.80.3.1055; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Starkie RL, 2001, AM J PHYSIOL-CELL PH, V280, pC769, DOI 10.1152/ajpcell.2001.280.4.C769; Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x; STOUTHARD JML, 1995, AM J PHYSIOL-ENDOC M, V268, pE813, DOI 10.1152/ajpendo.1995.268.5.E813; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; Tsigos C, 1997, J CLIN ENDOCR METAB, V82, P4167, DOI 10.1210/jc.82.12.4167; WASSERMAN DH, 1996, HDB PHYSL EXERCISE R, P1037	32	370	391	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2748	+		10.1096/fj.01-0507fje	http://dx.doi.org/10.1096/fj.01-0507fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11687509				2022-12-28	WOS:000171920400001
J	Langevin, HM; Churchill, DL; Cipolla, MJ				Langevin, HM; Churchill, DL; Cipolla, MJ			Mechanical signaling through connective tissue: a mechanism for the therapeutic effect of acupuncture	FASEB JOURNAL			English	Article						collagen; mechanotransduction; meridian	SMOOTH-MUSCLE-CELLS; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; ENDOTHELIAL-CELLS; SHEAR-STRESS; NITRIC-OXIDE; C-FOS; FIBROBLASTS; FORCES; CYTOSKELETON	The mechanism of action of acupuncture remains largely unknown. The reaction to acupuncture needling known as 'de qi', widely viewed as essential to the therapeutic effect of acupuncture, may be a key to understanding its mechanism of action. De qi includes a characteristic needling sensation, perceived by the patient, and 'needle grasp' perceived by the acupuncturist. During needle grasp, the acupuncturist feels pulling and increased resistance to further movement of the inserted needle. We hypothesize that 1) needle grasp is due to mechanical coupling between the needle and connective tissue with winding of tissue around the needle during needle rotation and 2) needle manipulation transmits a mechanical signal to connective tissue cells via mechanotransduction. Such a mechanism may explain local and remote, as well as long-term effects of acupuncture.	Univ Vermont, Coll Med, Dept Neurol, Burlington, VT 05405 USA	University of Vermont	Langevin, HM (corresponding author), Univ Vermont, Coll Med, Dept Neurol, Given C423, Burlington, VT 05405 USA.	hlangevi@zoo.uvm.edu	Cipolla, Marilyn J./B-7098-2009		NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000133, R21AT000300] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01 AT000133-02, R21 AT00300] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		[Anonymous], 1997, NIH CONSENSUS STATEM, V15, P1; APPENZELLER O, 1994, AUTONOMIC NERVOUS SY; Aumailley M, 1998, J MOL MED-JMM, V76, P253, DOI 10.1007/s001090050215; Banes AJ, 1995, BIOCHEM CELL BIOL, V73, P349, DOI 10.1139/o95-043; Bao XP, 2000, AM J PHYSIOL-HEART C, V278, pH1598, DOI 10.1152/ajpheart.2000.278.5.H1598; BESSOU P, 1961, ARCH ITAL BIOL, V99, P293; Brand RA, 1997, ANN MED, V29, P267, DOI 10.3109/07853899708999346; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Cassapakis C., 1995, P 3 S SOC AC RES SEP, P1; Cheng X, 1987, CHINESE ACUPUNCTURE; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Chiquet M, 1999, MATRIX BIOL, V18, P417, DOI 10.1016/S0945-053X(99)00039-6; CHIQUETEHRISMANN R, 1994, J CELL BIOL, V127, P2093, DOI 10.1083/jcb.127.6.2093; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAIFOTIS AG, 1992, J BIOL CHEM, V267, P23455; DARTSCH PC, 1986, EUR J CELL BIOL, V41, P339; DENMEI S, 1990, INTRO MERIDIAN THERA; DESMOULIERE A, 1994, CELL MOTIL CYTOSKEL, V29, P195, DOI 10.1002/cm.970290302; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070; Ezzo J, 2000, PAIN, V86, P217, DOI 10.1016/S0304-3959(99)00304-8; Gan LM, 2000, FEBS LETT, V477, P89, DOI 10.1016/S0014-5793(00)01788-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Glogauer M, 1997, J CELL SCI, V110, P11; GUNN C C, 1976, American Journal of Chinese Medicine, V4, P183, DOI 10.1142/S0192415X76000238; GUNN CC, 1977, AM J ACUPUNCTURE, V5, P115; Gutierrez JA, 1999, AM J PHYSIOL-GASTR L, V277, pG1074, DOI 10.1152/ajpgi.1999.277.5.G1074; HARRIS AK, 1980, SCIENCE, V208, P177, DOI 10.1126/science.6987736; Heidemann SR, 1999, J CELL BIOL, V145, P109, DOI 10.1083/jcb.145.1.109; HELMES JM, 1995, ACUPUNCTURE ENERGETI; Hibbeler R.C., 1995, ENG MECH STATICS DYN; KIMURA M, 1992, AM J CHINESE MED, V20, P25, DOI 10.1142/S0192415X92000047; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; LANGEVIN HM, 2001, IN PRESS J APPL PHYS; LEVINE JD, 1993, J NEUROSCI, V13, P2273, DOI 10.1523/JNEUROSCI.13-06-02273.1993; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Margolin A, 1998, JAMA-J AM MED ASSOC, V280, P1626, DOI 10.1001/jama.280.18.1626; Muller JM, 1997, CIRC RES, V80, P320, DOI 10.1161/01.RES.80.3.320; O'Callaghan CJ, 2000, HYPERTENSION, V36, P319, DOI 10.1161/01.HYP.36.3.319; Pavalko FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591; PIROLA CJ, 1994, ENDOCRINOLOGY, V134, P2230, DOI 10.1210/en.134.5.2230; Pohl U, 1996, PFLUG ARCH EUR J PHY, V432, pR107; Rosenfeldt H, 1998, MOL CELL BIOL, V18, P2659, DOI 10.1128/MCB.18.5.2659; RYAN TJ, 1989, J AM ACAD DERMATOL, V21, P115, DOI 10.1016/S0190-9622(89)70156-0; SAPPINO AP, 1990, LAB INVEST, V63, P144; *SHANGH COLL TRAD, 1987, AC COMPR TEXT; Stoltz JF, 2000, BIORHEOLOGY, V37, P3; Stux G, 1995, BASICS ACUPUNCTURE; SUGIMOTO K, 1991, EXP CELL RES, V196, P353, DOI 10.1016/0014-4827(91)90271-U; SUMPIO BE, 1988, J VASC SURG, V7, P130, DOI 10.1067/mva.1988.avs0070130; TILLMAN LJ, 1992, DYNAMICS HUMAN BIOL, P1; Tyagi SC, 1998, J CELL PHYSIOL, V176, P374, DOI 10.1002/(SICI)1097-4652(199808)176:2<374::AID-JCP16>3.0.CO;2-3; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; van Wamel AJ, 2000, ARCH BIOCHEM BIOPHYS, V381, P67, DOI 10.1006/abbi.2000.1947; VINCENT CA, 1986, PAIN, V24, P1, DOI 10.1016/0304-3959(86)90022-9; WANG KM, 1985, SCI SIN B-CHEM B A M, V28, P963; WANG N, 1993, SCIENCE, V260, P1224; White AR, 1998, ALTERN THER HEALTH M, V4, P66; Williams B, 1998, J HYPERTENS, V16, P1921, DOI 10.1097/00004872-199816121-00011; Willis Jr W. D., 1991, SENSORY MECH SPINAL; Wilson E, 1998, HYPERTENSION, V31, P170, DOI 10.1161/01.HYP.31.1.170; WORSLEY JR, 1982, TRADITIONAL CHINESE, V1; YANG J, 1601, GOLDEN NEEDLE OTHER; Ziegler T, 1998, HYPERTENSION, V32, P351, DOI 10.1161/01.HYP.32.2.351; 1994, COMPLETE TRANSLATION	65	268	311	3	60	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2275	2282		10.1096/fj.01-0015hyp	http://dx.doi.org/10.1096/fj.01-0015hyp			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641255				2022-12-28	WOS:000171920400040
J	Golozoubova, V; Hohtola, E; Matthias, A; Jacobsson, A; Cannon, B; Nedergaard, J				Golozoubova, V; Hohtola, E; Matthias, A; Jacobsson, A; Cannon, B; Nedergaard, J			Only UCP1 can mediate adaptive nonshivering thermogenesis in the cold	FASEB JOURNAL			English	Article						cold acclimation; uncoupling proteins; electromyography; longevity; oxygen consumption	BROWN ADIPOSE-TISSUE; SKELETAL-MUSCLE; UNCOUPLING PROTEIN; ACCLIMATED RATS; ENERGY-BALANCE; MICE; GENE; MITOCHONDRIA; CAPILLARITY; OBESITY	Adaptive nonshivering thermogenesis may have profound effects on energy balance and is therefore therefore is a potential mechanism for counteracting the development of obesity. The molecular basis for adaptive nonshivering thermogenesis has remained a challenge that sparked acute interest with the identification of proteins (UCP2, UCP3, etc.) with high-sequence similarity to the original uncoupling protein-1 (UCP1), which is localized only in brown adipose tissue. Using UCP1-ablated mice, we examined whether any adaptive nonshivering thermogenesis could be recruited by acclimation to cold. Remarkably, by successive acclimation, the UCP1-ablated mice could be made to subsist for several weeks at 4 degreesC during which they had to constantly produce heat at four times their resting levels. Despite these extreme requirements for adaptive nonshivering thermogenesis, however, no substitution of shivering by any adaptive nonshivering thermogenic process occurred. Thus, although the existence of, for example, muscular mechanisms for adaptive nonshivering thermogenesis has recurrently been implied, we did not find any indication of such thermogenesis. Not even during prolonged and enhanced demand for extra heat production was any endogenous hormone or neurotransmitter able to recruit any UCP1-independent adaptive nonshivering thermogenic process in muscle or in any other organ, and no proteins other than UCP1-not even UCP2 or UCP3-therefore have the ability to mediate adaptive nonshivering thermogenesis in the cold.	Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden; Univ Oulu, Dept Biol, FI-90014 Oulu, Finland	Stockholm University; University of Oulu	Nedergaard, J (corresponding author), Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden.	jan@metabol.su.se	Nedergaard, Jan/Q-8286-2019; Nedergaard, Jan/A-1706-2010; Cannon, Barbara/B-3089-2016	Cannon, Barbara/0000-0001-6594-2363; Nedergaard, Jan/0000-0003-2070-1587				Alexander G, 1979, Int Rev Physiol, V20, P43; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; BEHRENS WA, 1977, J BIOENERG BIOMEMBR, V9, P41, DOI 10.1007/BF00745042; BIGARD AX, 1991, PFLUG ARCH EUR J PHY, V419, P225, DOI 10.1007/BF00371099; BLOCK BA, 1994, ANNU REV PHYSIOL, V56, P535; BOURHIM M, 1990, AM J PHYSIOL, V258, pR1291, DOI 10.1152/ajpregu.1990.258.5.R1291; Cannon B, 2000, LIFE IN THE COLD, P387; Cannon B., 2000, Comparative Biochemistry and Physiology Part A Molecular and Integrative Physiology, V126A, pS22; Chilibeck PD, 1998, CAN J APPL PHYSIOL, V23, P74, DOI 10.1139/h98-005; Cinti S, 1999, ADIPOSE ORGAN; DICKER A, 1995, AM J PHYSIOL-REG I, V269, pR767, DOI 10.1152/ajpregu.1995.269.4.R767; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; FOSTER DO, 1979, CAN J PHYSIOL PHARM, V57, P257, DOI 10.1139/y79-039; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Gordon CJ, 1993, TEMPERATURE REGULATI, DOI 10.1017/CBO9780511565595; GREENWAY DC, 1978, AM J PHYSIOL, V234, pC7, DOI 10.1152/ajpcell.1978.234.1.C7; Gute D, 1996, J APPL PHYSIOL, V81, P619, DOI 10.1152/jappl.1996.81.2.619; HOHTOLA E, 1982, COMP BIOCHEM PHYS A, V73, P159, DOI 10.1016/0300-9629(82)90049-4; JANSKY L, 1995, PHYSIOL REV, V75, P237, DOI 10.1152/physrev.1995.75.2.237; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Matthias A, 2000, J BIOL CHEM, V275, P25073, DOI 10.1074/jbc.M000547200; Nechad M., 1986, BROWN ADIPOSE TISSUE; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; Oberkofler H, 1997, J LIPID RES, V38, P2125; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Smith R., 1961, PHYSIOLOGIST, V4, P113; SNYDER GK, 1992, EUR J APPL PHYSIOL O, V65, P158, DOI 10.1007/BF00705074; Soni A, 1997, J THERM BIOL, V22, P95, DOI 10.1016/S0306-4565(96)00037-X; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Suzuki J, 1997, JPN J PHYSIOL, V47, P513, DOI 10.2170/jjphysiol.47.513; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; WALTERS TJ, 1993, J APPL PHYSIOL, V75, P264, DOI 10.1152/jappl.1993.75.1.264; WIBOM R, 1992, J APPL PHYSIOL, V73, P2004, DOI 10.1152/jappl.1992.73.5.2004; WICKLER SJ, 1981, AM J PHYSIOL, V240, pR289, DOI 10.1152/ajpregu.1981.240.5.R289	35	346	355	0	43	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2048	+		10.1096/fj.00-0536fje	http://dx.doi.org/10.1096/fj.00-0536fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511509				2022-12-28	WOS:000170318500026
J	Rodrigues, S; Nguyen, QD; Faivre, S; Bruyneel, E; Thim, L; Westley, B; May, F; Flatau, G; Mareel, M; Gespach, C; Emami, S				Rodrigues, S; Nguyen, QD; Faivre, S; Bruyneel, E; Thim, L; Westley, B; May, F; Flatau, G; Mareel, M; Gespach, C; Emami, S			Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways	FASEB JOURNAL			English	Article						inflammation; cancer progression; heterotrimeric G-proteins; Rho-like GTPases; phospholipase C	FAMILIAL ADENOMATOUS POLYPOSIS; COLON-CANCER CELLS; BREAST-CANCER; SPASMOLYTIC POLYPEPTIDE; COLORECTAL ADENOMAS; EPITHELIAL-CELLS; NORMAL STOMACH; I COLLAGEN; G-PROTEINS; EXPRESSION	We have investigated the possible functional relationships between cellular invasion pathways induced by trefoil factors (TFFs), src, and the cyclooxygenases COX-1 and COX-2. Pharmacological inhibitors of the Rho small GTPase (C3 exoenzyme), phospholipase C (U-73122), cyclooxygenases (SC-560, NS-398), and the thromboxane A2 receptor (TXA2-R) antagonist SQ-295 completely abolished invasion induced by intestinal trefoil factor, pS2, and src in kidney and colonic epithelial cells MDCKts.src and PCmsrc. In contrast, invasion was induced by the TXA2-R mimetic U-46619, constitutively activated forms of the heterotrimeric G-proteins G alphaq (AG alphaq), G alpha 12, G alpha 13 (AG alpha 12/13), which are signaling elements downstream of TXA2-R. Ectopic overexpression of pS2 cDNA and protein in MDCKts.src-pS2 cells and human colorectal cancer cells HCT8/S11-pS2 initiate distinct invasion signals that are Rho independent and COX and TXA2-R dependent. We detected a marked induction of COX-2 protein and accumulation of the stable PGH2/TXA2 metabolite TXB2 in the conditioned medium from cells transformed by src. This led to activation of the TXA2R-dependent invasion pathway, which is monitored via a Rho- and G alpha 12/G alpha 13-independent mechanism using the G alphaq/PKC signaling cascade. These findings identify a new intracrine/paracrine loop that can be monitored by TFFs and src in inflammatory diseases and progression of colorectal cancers.	Hop St Antoine, INSERM, U482, Unite Signal Transduct & Cellular Funct Diabet &, F-75571 Paris 12, France; State Univ Ghent Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark; Univ Newcastle Upon Tyne, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; UFR Med, INSERM, U452, Unite Biol Cellulaire & Mol Microorganismes Patho, F-06107 Nice, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Novo Nordisk; Newcastle University - UK; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Gespach, C (corresponding author), Hop St Antoine, INSERM, U482, Unite Signal Transduct & Cellular Funct Diabet &, F-75571 Paris 12, France.	gespach@st-antoine.inserm.fr		Faivre, Sandrine/0000-0002-1590-485X				Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Benbow U, 1999, J BIOL CHEM, V274, P25371, DOI 10.1074/jbc.274.36.25371; Chadwick MP, 1997, BIOCHEM J, V327, P117, DOI 10.1042/bj3270117; Chapple KS, 2000, AM J PATHOL, V156, P545, DOI 10.1016/S0002-9440(10)64759-1; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DUBOIS RN, 1994, AM J PHYSIOL, V266, P822; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GESPACH C, 1988, CANCER RES, V48, P5079; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G; HANBY AM, 1993, GASTROENTEROLOGY, V105, P1110, DOI 10.1016/0016-5085(93)90956-D; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Jacoby RF, 1996, CANCER RES, V56, P710; Jones MK, 1999, FASEB J, V13, P2186, DOI 10.1096/fasebj.13.15.2186; KARGMAN SL, 1995, CANCER RES, V55, P2556; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LEVINE PH, 1985, JNCI-J NATL CANCER I, V74, P291; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MORROW JD, 1994, J BIOL CHEM, V269, P4317; Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455; Newton JL, 2000, GUT, V46, P312, DOI 10.1136/gut.46.3.312; Noe V, 2001, J CELL SCI, V114, P111; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OUELLET M, 1995, BIOCHEM J, V306, P247, DOI 10.1042/bj3060247; Playford RJ, 1996, P NATL ACAD SCI USA, V93, P2137, DOI 10.1073/pnas.93.5.2137; PODOLSKY DK, 1993, J BIOL CHEM, V268, P6694; Poulsen SS, 1999, GUT, V45, P516, DOI 10.1136/gut.45.4.516; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Probst JC, 1996, FASEB J, V10, P1518, DOI 10.1096/fasebj.10.13.8940297; RAO CV, 1995, CANCER RES, V55, P1464; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Riehl T, 2000, GASTROENTEROLOGY, V118, P1106, DOI 10.1016/S0016-5085(00)70363-5; RIO MC, 1991, GASTROENTEROLOGY, V100, P375, DOI 10.1016/0016-5085(91)90205-Y; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; ROSAM AC, 1986, NATURE, V319, P54, DOI 10.1038/319054a0; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; SAITO Y, 1997, BACTERIAL TOXINS TOO, P85; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; THIM L, 1995, BIOCHEMISTRY-US, V34, P4757, DOI 10.1021/bi00014a033; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; Tran CP, 1999, GUT, V44, P636, DOI 10.1136/gut.44.5.636; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Van Hoorde L, 2000, Prog Mol Subcell Biol, V25, P105; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wong WM, 1999, GUT, V44, P890, DOI 10.1136/gut.44.6.890; WRIGHT NA, 1993, GASTROENTEROLOGY, V104, P12, DOI 10.1016/0016-5085(93)90830-6; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424	72	68	73	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2001	15	9					1517	1528		10.1096/fj.00-0802com	http://dx.doi.org/10.1096/fj.00-0802com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427483				2022-12-28	WOS:000170318500003
J	Brakenhielm, E; Cao, RH; Cao, YH				Brakenhielm, E; Cao, RH; Cao, YH			Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes	FASEB JOURNAL			English	Article						resveratrol; red wine; cancer; angiogenesis; MAP kinase	GREEN TEA; IN-VIVO; CANCER; ANGIOSTATIN; INHIBITOR; RATS; PROLIFERATION; TUMORIGENESIS; PROTECTION; DISEASE	Resveratrol (3,5,4'-trihydroxystilbene) is a natural compound found in several plants, including grapes, peanuts, and pines, and in their related products. Red wine is probably the most frequently consumed drink that is enriched in resveratrol. We investigated whether drinking resveratrol could suppress angiogenesis, a process of blood vessel growth involved in initiation, development, and progression of many diseases, including cancer, metastasis, and diabetic retinopathy. We found that resveratrol suppresses the growth of new blood vessels in animals. It directly inhibits capillary endothelial cell growth. It blocks both VEGF- and FGF-receptor-mediated angiogenic responses. In addition, resveratrol inhibits the phosphorylation of mitogen-activated kinase isoforms (MAPK(p44)/MAPK(p42)) induced by fibroblast growth factor-2 in proliferating endothelial cells in a dose-dependent manner. Oral administration of resveratrol significantly inhibits the growth of a murine fibrosarcoma in mice, and it significantly delays angiogenesis-dependent wound healing in mice. Our findings suggest that ingestion of resveratrol-enriched food could be beneficial for the prevention of cancer. However, its antiangiogenic effect could delay wound healing and possibly other angiogenesis-dependent processes under physiological conditions.	Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Angiogenesis Res, S-17177 Stockholm, Sweden	Karolinska Institutet	Cao, YH (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Angiogenesis Res, S-17177 Stockholm, Sweden.	yihai.cao@mtc.ki.se	Brakenhielm, Ebba/E-9758-2011	Brakenhielm, Ebba/0000-0003-3378-8300				AUERBACH W, 1994, PHARMACOL THERAPEUT, V63, P265, DOI 10.1016/0163-7258(94)90027-2; Bertelli AAE, 1998, DRUG EXP CLIN RES, V24, P51; Bertelli AAE, 1998, DRUG EXP CLIN RES, V24, P207; Caderni G, 2000, CARCINOGENESIS, V21, P1965, DOI 10.1093/carcin/21.11.1965; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; Cao YH, 1999, HAEMATOLOGICA, V84, P643; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; DVORAK HF, SEMIN PERINATOL, V24, P75; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garbisa S, 1999, NAT MED, V5, P1216, DOI 10.1038/15145; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Hsieh TC, 1999, CANCER RES, V59, P2596; Hung LM, 2000, CARDIOVASC RES, V47, P549, DOI 10.1016/S0008-6363(00)00102-4; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; LaMontagne KR, 2000, AM J PATHOL, V157, P1937, DOI 10.1016/S0002-9440(10)64832-8; Mathe G, 1999, BIOMED PHARMACOTHER, V53, P165, DOI 10.1016/S0753-3322(99)80084-5; Mauceri HJ, 1998, NATURE, V394, P287, DOI 10.1038/28412; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PACEASCIAK CR, 1995, CLIN CHIM ACTA, V235, P207, DOI 10.1016/0009-8981(95)06045-1; Turner RT, 1999, ENDOCRINOLOGY, V140, P50, DOI 10.1210/en.140.1.50; Webb T, 2000, J NATL CANCER I, V92, P1038, DOI 10.1093/jnci/92.13.1038	26	283	292	1	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1798	+		10.1096/fj.01-0028fje	http://dx.doi.org/10.1096/fj.01-0028fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481234				2022-12-28	WOS:000169261200038
J	Niederberger, E; Tegeder, I; Vetter, G; Schmidtko, A; Schmidt, H; Euchenhofer, C; Brautigam, L; Grosch, S; Geisslinger, G				Niederberger, E; Tegeder, I; Vetter, G; Schmidtko, A; Schmidt, H; Euchenhofer, C; Brautigam, L; Grosch, S; Geisslinger, G			Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappa B	FASEB JOURNAL			English	Article						arthritis; cyclooxygenase inhibitor; Celebrex (R)	NECROSIS-FACTOR-ALPHA; RHEUMATOID SYNOVIAL FIBROBLASTS; NITRIC-OXIDE SYNTHASE; CYCLOOXYGENASE-2 INHIBITOR; SELECTIVE-INHIBITION; COLON CARCINOGENESIS; ENDOTHELIAL-CELLS; CONTROLLED TRIAL; CANCER CELLS; SPINAL-CORD	Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, has recently been approved for the symptomatic treatment of arthritis. In some clinical studies, doses of 400 and 800 mg/day provided somewhat less efficacy compared with 200 mg/day, which suggests an early ceiling effect. Using the zymosan-induced inflammation model in rats, we show that celecoxib significantly reduces paw swelling at 50 mg/kg but completely loses its anti-inflammatory efficacy at doses greater than or equal to100 mg/kg. To evaluate the underlying mechanisms, we used rat renal mesangial cells as a cell culture model. In these cells, celecoxib (50 muM) increased the interleukin Ibeta stimulated nuclear translocation and DNA binding of NF-kappaB and facilitated the degradation of I-kappaB. Consequently, COX-2 and tumor necrosis factor alpha (TNF-alpha) expression were increased. The up-regulation of COX-2 and TNF-alpha also occurred in the spinal cord of rats treated with celecoxib (greater than or equal to100 mg/kg), indicating that in vitro mechanisms were relevant in vivo. Clinically, the overexpression. of COX-2 might be less important because celecoxib inhibits COX-2 enzymatically. However, the up-regulation of TNF-alpha and possibly other NF-kappaB regulated proinflammatory genes might worsen the pathophysiological processes underlying chronic arthritis.	Univ Frankfurt Klinikum, Inst Klin Pharmakol, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Geisslinger, G (corresponding author), Univ Frankfurt Klinikum, Inst Klin Pharmakol, Pharmazentrum Frankfurt, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	geisslinger@em.uni-frankfurt.de	Schmidtko, Achim/AAB-2122-2019; Groesch, Sabine/H-4251-2018; Tegeder, Irmgard/AAM-2246-2020; Tegeder, Irmgard/AAM-2266-2020	Groesch, Sabine/0000-0002-7262-6307; Tegeder, Irmgard/0000-0001-7524-8025; Tegeder, Irmgard/0000-0001-7524-8025; Schmidtko, Achim/0000-0001-7270-5075				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beiche F, 1998, INFLAMM RES, V47, P482, DOI 10.1007/s000110050362; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Cusack JC, 2000, CANCER RES, V60, P2323; DeWitt DL, 1999, MOL PHARMACOL, V55, P625; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; Emery P, 1999, LANCET, V354, P2106, DOI 10.1016/S0140-6736(99)02332-6; Fort J, 1999, Am J Orthop (Belle Mead NJ), V28, P13; Fujisawa K, 1996, ARTHRITIS RHEUM-US, V39, P197, DOI 10.1002/art.1780390205; GEGEDER I, 2001, FASEB J, V15, P2; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; Gierse JK, 1999, BIOCHEM J, V339, P607, DOI 10.1042/0264-6021:3390607; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gupta RA, 2000, NAT MED, V6, P974, DOI 10.1038/79664; Han SY, 2000, BIOL PHARM BULL, V23, P420; Hanemaaijer R, 1997, J BIOL CHEM, V272, P31504, DOI 10.1074/jbc.272.50.31504; Jones MK, 1999, NAT MED, V5, P1418; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Maihofner C, 2000, NEUROSCI LETT, V290, P71, DOI 10.1016/S0304-3940(00)01302-1; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; Matroule JY, 1999, PHOTOCHEM PHOTOBIOL, V70, P540, DOI 10.1111/j.1751-1097.1999.tb08249.x; McCarthy Denis M., 1999, American Journal of Medicine, V107, p37S; McCarthy DM, 1999, AM J MED, V107, p46S; Meller S T, 1997, Eur J Pain, V1, P43, DOI 10.1016/S1090-3801(97)90052-5; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; RADEKE HH, 1992, CLIN INVESTIGATOR, V70, P825; RAO CV, 1995, CANCER RES, V55, P1464; Reddy BS, 1996, CANCER RES, V56, P4566; Rose MJ, 2000, J CHROMATOGR B, V738, P377, DOI 10.1016/S0378-4347(99)00552-6; Sakurada S, 1996, INT IMMUNOL, V8, P1483, DOI 10.1093/intimm/8.10.1483; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Simon LS, 1999, JAMA-J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stuhlmeier KM, 1999, BIOCHEM PHARMACOL, V57, P313, DOI 10.1016/S0006-2952(98)00301-3; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; Williams CS, 1996, AM J PHYSIOL, V270, P393; XIE QW, 1993, T ASSOC AM PHYSICIAN, V106, P1; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Zhao SZ, 1999, PHARMACOTHERAPY, V19, P1269, DOI 10.1592/phco.19.16.1269.30879	45	131	135	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1622	+		10.1096/fj.00-0716fje	http://dx.doi.org/10.1096/fj.00-0716fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427506				2022-12-28	WOS:000173707700010
J	Cardoso, SM; Santos, S; Swerdlow, RH; Oliveira, CR				Cardoso, SM; Santos, S; Swerdlow, RH; Oliveira, CR			Functional mitochondria are required for amyloid beta-mediated neurotoxicity	FASEB JOURNAL			English	Article						Alzheimer's disease; mitochondria; beta-amyloid; rho 0 cells	COLLAGENASE PERFUSION TECHNIQUE; BROMIDE MTT REDUCTION; ALZHEIMERS-DISEASE; RAT-LIVER; OXIDATIVE STRESS; VASOPRESSIN V1A; PERIVENOUS HEPATOCYTES; ENERGY-METABOLISM; CORTICAL-NEURONS; CYTOSOLIC CA2+	The role of mitochondria. in amyloid betapeptide (Abeta)-induced cytotoxicity is unclear. We therefore exposed NT2 cells, a clonal human teratocarcinoma cell line capable of differentiation into terminal neurons, to Abeta 25-35 or to Abeta 1-42 to evaluate cell viability and altered mitochondrial function. A 24-h incubation of native NT2 cells (rho+ cells) with Abeta 25-35 or with Abeta 1-42 produced a dose-dependent decline in MTT reduction. Abeta 1-42 was shown to be more toxic compared with Abeta 25-35. Abeta 25-35 toxicity was prevented or diminished by a 22-h preincubation with antioxidants (vitamin E, metatonin, and idebenone), as well as by simultaneous incubation with GSH or the nicotinic receptor agonist nicotine. Abeta 25-35 exposure was also associated with (1) inhibition of mitochondrial respiratory chain complexes (I, NADH-ubiquinone oxidoreductase; II/III, succinate-cytochrome c oxidoreductase; and IV, cytochrome c oxidase), (2) ATP depletion, and (3) reduction of the mitochondrial membrane potential. In contrast, NT2 cells rendered incapable of oxidative phosphorylation via depletion of their mitochondrial DNA (rho0 cells) were unaffected by exposure to Abeta 25-35 or Abeta 1-42. These data indicate that Abeta can disrupt mitochondrial function and that such disruption causes oxidative stress. It is further suggested that a functional mitochondrial respiratory chain is required for Abeta toxicity.	Univ Coimbra, Fac Med, Biochem Lab, Ctr Neurosci Coimbra, P-3004504 Coimbra, Portugal; Univ Virginia, Dept Neurol, Charlottesville, VA USA	Universidade de Coimbra; University of Virginia	Oliveira, CR (corresponding author), Univ Coimbra, Fac Med, Biochem Lab, Ctr Neurosci Coimbra, P-3004504 Coimbra, Portugal.	catarina@cnc.cj.uc.pt	Cardoso, Sandra/C-9930-2009; Cardoso, Sandra M/L-1962-2013; Oliveira, Catarina R./F-3685-2010; Cardoso, Sandra M/C-9346-2018	Oliveira, Catarina/0000-0001-6942-4328; Cardoso, Sandra M/0000-0002-2199-0555				AKAIKE A, 1994, BRAIN RES, V644, P181, DOI 10.1016/0006-8993(94)91678-0; Ancellin N, 1998, CELL SIGNAL, V10, P217, DOI 10.1016/S0898-6568(97)00124-1; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BARBERIS C, 1995, NEUROENDOCRINOLOGY, V62, P135, DOI 10.1159/000126998; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERTHOUD VM, 1992, AM J PHYSIOL, V263, pG650, DOI 10.1152/ajpgi.1992.263.5.G650; CANTAU B, 1980, J RECEPTOR RES, V1, P137, DOI 10.3109/10799898009044096; COMBETTES L, 1994, BIOCHEM J, V304, P585, DOI 10.1042/bj3040585; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; CURTI D, 1995, NEUROCHEM RES, V20, P1001, DOI 10.1007/BF00995552; DUNN FL, 1973, J CLIN INVEST, V52, P3212, DOI 10.1172/JCI107521; Dupont G, 2000, FASEB J, V14, P279, DOI 10.1096/fasebj.14.2.279; EXTON JH, 1988, HEPATOLOGY, V8, P152, DOI 10.1002/hep.1840080129; FISHMAN JB, 1985, J BIOL CHEM, V260, P2641; FREEMAN BA, 1982, LAB INVEST, V47, P412; GAZIS D, 1978, P SOC EXP BIOL MED, V157, P584; Grazzini E, 1996, ENDOCRINOLOGY, V137, P3906, DOI 10.1210/en.137.9.3906; GUILLON G, 1986, FEBS LETT, V196, P155, DOI 10.1016/0014-5793(86)80232-0; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HARDONK MJ, 1992, J LEUKOCYTE BIOL, V52, P296, DOI 10.1002/jlb.52.3.296; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; JONES GMM, 1992, PSYCHOPHARMACOLOGY, V108, P485, DOI 10.1007/BF02247426; Jungermann K, 2000, HEPATOLOGY, V31, P255, DOI 10.1002/hep.510310201; JUNGERMANN K, 1989, PHYSIOL REV, V69, P708, DOI 10.1152/physrev.1989.69.3.708; Kaabache T, 1995, ANAL BIOCHEM, V232, P225, DOI 10.1006/abio.1995.0011; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; King T.E., 1967, METHODS ENZYMOL, P216, DOI DOI 10.1016/0076-6879(67)10043-8; KITAMURA T, 1991, HEPATOLOGY, V14, P640, DOI 10.1016/0270-9139(91)90051-V; KrausFriedmann N, 1996, METABOLISM, V45, P389, DOI 10.1016/S0026-0495(96)90296-6; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Mark RJ, 1996, MOL NEUROBIOL, V12, P211, DOI 10.1007/BF02755589; MARK RJ, 1995, J NEUROSCI, V15, P6239; Mark RJ, 1997, J NEUROSCI, V17, P1046; Mark RJ, 1997, BRAIN RES, V756, P205, DOI 10.1016/S0006-8993(97)00196-0; MARTIN EJ, 1994, DRUG DEVELOP RES, V31, P127; Meister A., 1970, METHOD ENZYMOL, V17, P900, DOI 10.1016/0076-6879(71)17304-1; Meyerowitz BE, 1997, J PERS INTERPERS LOS, V2, P49, DOI 10.1080/10811449708414405; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Motoyama K, 1999, AM J PHYSIOL-REG I, V276, pR575, DOI 10.1152/ajpregu.1999.276.2.R575; Munir M, 1995, J NEUROSCI, V15, P7847; NATHANSON MH, 1992, J BIOL CHEM, V267, P23282; Nathanson MH, 1999, GASTROENTEROLOGY, V116, P1176, DOI 10.1016/S0016-5085(99)70021-1; NATHANSON MH, 1995, AM J PHYSIOL-GASTR L, V269, pG167, DOI 10.1152/ajpgi.1995.269.1.G167; NATHANSON MH, 1992, HEPATOLOGY, V15, P107, DOI 10.1002/hep.1840150119; NATHANSON MH, 1996, PROGR LIVER DIS, P1; Newhouse P, 1996, DRUG DEVELOP RES, V38, P278, DOI 10.1002/(SICI)1098-2299(199607/08)38:3/4<278::AID-DDR17>3.0.CO;2-V; NIJLMANS LGJ, 1995, BIOCH BIOPHYS ACT, V1265, P117; Oinonen T, 1998, BIOCHEM J, V329, P17, DOI 10.1042/bj3290017; OSTROWSKI NL, 1993, ENDOCRINOLOGY, V133, P1849, DOI 10.1210/en.133.4.1849; Palmeira CM, 1996, J PHARMACOL TOX MET, V35, P35, DOI 10.1016/1056-8719(95)00131-X; PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302; Patel S, 1999, NAT CELL BIOL, V1, P467, DOI 10.1038/70249; Pereira C, 1998, NEUROREPORT, V9, P1749, DOI 10.1097/00001756-199806010-00015; Peretti J, 1999, EQUINE ATHLETE, V12, P6; Pierre C., 1994, LIFE SCI, V55, P271; PIKE CJ, 1993, J NEUROSCI, V13, P1676; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; QUISTORFF B, 1985, BIOCHEM J, V229, P221, DOI 10.1042/bj2290221; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; SAHAKIAN BJ, 1994, DRUG DEVELOP RES, V31, P80, DOI 10.1002/ddr.430310112; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; SHEARMAN MS, 1995, J NEUROCHEM, V65, P218, DOI 10.1046/j.1471-4159.1995.65010218.x; Sipma H, 1998, CELL CALCIUM, V23, P11, DOI 10.1016/S0143-4160(98)90070-7; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; Starke DW, 1997, FREE RADICAL BIO MED, V23, P373, DOI 10.1016/S0891-5849(97)00009-9; STOCCHI V, 1985, ANAL BIOCHEM, V146, P118, DOI 10.1016/0003-2697(85)90405-1; Swerdlow RH, 1997, NEUROLOGY, V49, P918, DOI 10.1212/WNL.49.4.918; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Tordjmann T, 1998, EMBO J, V17, P4695, DOI 10.1093/emboj/17.16.4695; Tordjmann T, 1997, EMBO J, V16, P5398, DOI 10.1093/emboj/16.17.5398; Tordjmann T, 1997, HEPATOLOGY, V26, P1592; Tordjmann T, 1996, GASTROENTEROLOGY, V111, P1343, DOI 10.1053/gast.1996.v111.pm8898649; Valtin H., 1992, HDB PHYSL, P1281; WALLACE DC, 1994, J BIOENERG BIOMEMBR, V26, P241, DOI 10.1007/BF00763096; WATANABE N, 1991, J CELL BIOL, V113, P1069, DOI 10.1083/jcb.113.5.1069; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; Wharton DC., 1967, METHOD ENZYMOL, P245; WRIGHT SC, 1993, FASEB J, V7, P1045, DOI 10.1096/fasebj.7.11.8370474; YANKNER BA, 1996, NATURE, V382, P685	90	176	186	3	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1439	+		10.1096/fj.00-0561fje	http://dx.doi.org/10.1096/fj.00-0561fje			34	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387250	Green Submitted			2022-12-28	WOS:000173705800018
J	Serriere, V; Berthon, B; Boucherie, S; Jacquemin, E; Guillon, G; Claret, M; Tordjmann, T				Serriere, V; Berthon, B; Boucherie, S; Jacquemin, E; Guillon, G; Claret, M; Tordjmann, T			Vasopressin receptor distribution in the liver controls calcium wave propagation and bile flow	FASEB JOURNAL			English	Article						intercellular signaling; cellular; heterogeneity; receptor; density; bile flow; vasopressin		Arginine vasopressin elicits elaborate Ca2+ signals in the liver (intercellular Ca2+ waves), the functional implications of which are not understood. Waves propagate across hepatocyte plates following a lobular gradient in V1a vasopressin receptor density. Here, we report that changes in this receptor distribution control Ca2+ wave propagation and bile flow. Although basal circulating vasopressin levels do not play a major role in the regulation of V1a receptor expression, increases in vasopressin. concentration within physiological limits for 24 h can abolish the lobular gradient in V1a receptor, as assessed by spectrofluorimetry, videomicroscopy, binding studies, and RNase protection assays. In animals in which the V1a receptor gradient was abolished, intercellular Ca2+ waves were impaired due to the equalization of Ca2+ responses in the various zones of the lobule. In the isolated perfused liver, the early increase in vasopressin-induced bile flow observed in control rats was much smaller if the V1a receptor density gradient was abolished. These findings suggest that V1a vasopressin receptor distribution controls intercellular Ca2+ wave propagation and bile flow. The control of hormone receptor distribution in a tissue by an agonist may turn the signaling and function of this agonist on or off.	Univ Paris 11, INSERM, U442, Unite Rech, F-91405 Orsay, France; INSERM, U469, Unite Rech, F-34094 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Tordjmann, T (corresponding author), Univ Paris 11, INSERM, U442, Unite Rech, Bat 443, F-91405 Orsay, France.	thierry.tordjmann@ibaic.u-psud.fr	Tordjmann, Thierry/K-4706-2013						0	22	22	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1484	+		10.1096/fj.00-0659fje	http://dx.doi.org/10.1096/fj.00-0659fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387265				2022-12-28	WOS:000173705800002
J	Deng, WG; Saunders, MA; Gilroy, DW; He, XZ; Yeh, H; Zhu, Y; Shtivelband, MI; Ruan, KH; Wu, KK				Deng, WG; Saunders, MA; Gilroy, DW; He, XZ; Yeh, H; Zhu, Y; Shtivelband, MI; Ruan, KH; Wu, KK			Purification and characterization of a cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts	FASEB JOURNAL			English	Article						inhibitors of cyclooxygenase-2; inflammation; tumorigenesis	NITRIC-OXIDE SYNTHASE; EXPRESSION; GROWTH; CELLS; INHIBITION; INDUCTION; REPAIR	Cyclooxygenase-2 (COX-2) is an inducible enzyme that plays an important role in several pathophysiological processes, including inflammation, angiogenesis, and tumorigenesis. We have recently observed that COX-2 induction is restrained in proliferating fibroblasts. The mechanism by which this occurs is unclear. Here, we report the detection and isolation from the conditioned medium of proliferating fibroblasts a factor that suppressed COX-2 expression. This factor, which was named cytoguardin, suppressed COX-2 protein levels induced by phorbol 12-myristate 13-acetate, interleukin-1beta, tumor necrosis factor alpha, and lipopolysaccharide (LPS) in fibroblasts and LPS-induced COX-2 protein levels and promoter activities in human endothelial cells and murine RAW 264.7 cells in a comparable concentration-dependent manner. It inhibited COX-2 expression induced by angiogenic factors and endothelial tube formation induced by angiogenic factors and colon cancer cell medium. These findings provide evidence for the control of COX-2 transcription by an endogenous cellular factor.	Univ Texas, Houston Med Sch, Vasc Biol Res Ctr, Inst Mol Med, Houston, TX 77030 USA; Univ Texas, Houston Med Sch, Div Hematol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Wu, KK (corresponding author), Univ Texas, Houston Med Sch, Vasc Biol Res Ctr, Inst Mol Med, 6431 Fannin St, Houston, TX 77030 USA.	Kenneth.K.Wu@uth.tmc.edu	Gilroy, Derek/AAP-7227-2020; Wu, Kenneth Kun-Yu/B-1070-2010; Shtivelband, Mikhail/GXN-0194-2022; Gilroy, Derek W/C-2588-2009	Gilroy, Derek/0000-0003-3476-0844; Deng, wuguo/0000-0002-1193-1500				Bielas JH, 2000, P NATL ACAD SCI USA, V97, P11391, DOI 10.1073/pnas.190330997; Cieslik K, 1998, J BIOL CHEM, V273, P14885, DOI 10.1074/jbc.273.24.14885; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Ghosh AK, 2000, J PHARMACOL EXP THER, V295, P802; Gilroy DW, 2001, AM J PHYSIOL-CELL PH, V281, pC188, DOI 10.1152/ajpcell.2001.281.1.C188; Gilroy DW, 2001, FASEB J, V15, P288; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Jones MK, 1999, NAT MED, V5, P1418; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; Leroy C, 2001, EMBO J, V20, P2896, DOI 10.1093/emboj/20.11.2896; Saunders MA, 2001, J BIOL CHEM, V276, P18897, DOI 10.1074/jbc.M011147200; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wu K K, 1995, Adv Pharmacol, V33, P179, DOI 10.1016/S1054-3589(08)60669-9; Xu XM, 1999, P NATL ACAD SCI USA, V96, P5292, DOI 10.1073/pnas.96.9.5292	19	20	20	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1286	+		10.1096/fj.01-0844fje	http://dx.doi.org/10.1096/fj.01-0844fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060668				2022-12-28	WOS:000176683900030
J	Ermak, G; Harris, CD; Davies, KJA				Ermak, G; Harris, CD; Davies, KJA			The DSCR1 (Adapt78) isoform 1 protein calcipressin 1 inhibits calcineurin and protects against acute calcium-mediated stress damage, including transient oxidative stress	FASEB JOURNAL			English	Article						calcium signaling; apoptosis; stress proteins and genes	SYNDROME CRITICAL REGION; DEPENDENT TRANSCRIPTIONAL PATHWAY; DOWN-SYNDROME; CARDIAC-HYPERTROPHY; MESSENGER-RNA; EXPRESSION; GENE; HOMOLOG; CELLS; OVEREXPRESSION	Although DSCR1 (Adapt78) has been associated with successful adaptation to oxidative stress and calcium stress and with devastating diseases such as Alzheimer's and Down syndrome, no rationale for these apparently contradictory findings has been tested. In fact, DSCR1 (Adapt78) has not yet been proved to provide protection against acute oxidative stress or calcium stress. We have addressed this question using cross-adaptation to H2O2 and the calcium ionophore A23187, stable DSCR1 (Adapt78) transfection and overexpression in hamster HA-1 cells, 'tet-off' regulated DSCR1 (Adapt78) isoform 1 transgene expression in human PC-12 cells, and DSCR1 (Adapt78) antisense oligonucleotides to test the ability of the DSCR1 (Adapt78) protein product calcipressin 1 (a calcineurin inhibitor) to protect against oxidative stress and calcium stress. Under all conditions, resistance to oxidative stress and calcium stress increased as a function of DSCR1 (Adapt78)/calcipressin 1 expression and decreased as gene/protein expression diminished. We conclude that cells may transiently use increased expression of the DSCR1 (Adapt78) gene product calcipressin 1 to provide short-term protection against acute oxidative stress and other calcium-mediated stresses, whereas chronic overexpression may be associated with Alzheimer disease progression.	Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Div Mol & Computat Biol, Los Angeles, CA USA	University of Southern California; University of Southern California	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave,Room 306, Los Angeles, CA 90089 USA.	kelvin@usc.edu		Davies, Kelvin/0000-0001-7790-3003	NATIONAL INSTITUTE ON AGING [R01AG016256] Funding Source: NIH RePORTER; NIA NIH HHS [AG16256] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crawford DR, 1997, SURGERY, V121, P581, DOI 10.1016/S0039-6060(97)90115-X; Crawford DR, 1996, FREE RADICAL BIO MED, V21, P521, DOI 10.1016/0891-5849(96)00160-8; Crawford DR, 1996, ARCH BIOCHEM BIOPHYS, V329, P137, DOI 10.1006/abbi.1996.0202; Crawford DR, 1996, ARCH BIOCHEM BIOPHYS, V325, P256, DOI 10.1006/abbi.1996.0032; Crawford DR, 1997, ARCH BIOCHEM BIOPHYS, V342, P6, DOI 10.1006/abbi.1997.0109; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; DAVIES KJA, 2000, IUBMB LIFE, V50, P35; Ermak G, 1996, CANCER RES, V56, P1037; Ermak G, 2001, J BIOL CHEM, V276, P38787, DOI 10.1074/jbc.M102829200; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; Honig LS, 2000, AM J MED, V108, P317, DOI 10.1016/S0002-9343(00)00291-6; Hughes SM, 1998, CURR BIOL, V8, pR892, DOI 10.1016/S0960-9822(07)00554-4; Joseph JA, 1997, J NEUROCHEM, V69, P1252; Kayyali US, 1997, J NEUROCHEM, V68, P1668; Krebs J, 1998, BIOMETALS, V11, P375, DOI 10.1023/A:1009226316146; Leahy KP, 1999, ARCH BIOCHEM BIOPHYS, V368, P67, DOI 10.1006/abbi.1998.1059; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; MATRSUDA T, 1998, NIPPON YAKURIGAKU S1, V112, pP24; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Pardo JM, 1998, P NATL ACAD SCI USA, V95, P9681, DOI 10.1073/pnas.95.16.9681; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Strippoli P, 2000, GENOMICS, V64, P252, DOI 10.1006/geno.2000.6127; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Wang H, 2000, FREE RADICAL BIO MED, V28, P1222, DOI 10.1016/S0891-5849(00)00241-0; WANG YF, 1996, MACROMOL REP A, V33, P1; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Zhuo M, 1999, P NATL ACAD SCI USA, V96, P4650, DOI 10.1073/pnas.96.8.4650	41	109	110	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0814	10.1096/fj.01-0846com	http://dx.doi.org/10.1096/fj.01-0846com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039863				2022-12-28	WOS:000176683900007
J	Barone, F; Genazzani, AA; Conti, A; Churchill, GC; Palombi, F; Ziparo, E; Sorrentino, V; Galione, A; Filippini, A				Barone, F; Genazzani, AA; Conti, A; Churchill, GC; Palombi, F; Ziparo, E; Sorrentino, V; Galione, A; Filippini, A			A pivotal role for cADPR-mediated Ca2+ signaling: regulation of endothelin-induced contraction in peritubular smooth muscle cells	FASEB JOURNAL			English	Article						ryanodine receptors; calcium signaling; ADP-ribosyl cyclase; seminiferous tubule	CYCLIC ADP-RIBOSE; MYOID CELLS; INOSITOL TRISPHOSPHATE; RAT TESTIS; RYANODINE RECEPTORS; CALCIUM; EXPRESSION; RELEASE; CYCLASE; DIFFERENTIATION	cADPR, a potent calcium-mobilizing intracellular messenger synthesized by ADP-ribosyl cyclases regulates openings of ryanodine receptors (RyR). Here we report that in the rat testis, a functional cADPR Ca2+ release system is essential for the contractile response of peritubular smooth muscle cells (PSMC) to endothelin (ET). We previously showed that this potent smooth muscle agonist elicits intracellular Ca2+ release in PSMC and seminiferous tubule contraction via activation of ETA and ETB receptors. ETB-R induces the mobilization of a thapsigargin-sensitive but IP3-independent intracellular Ca2+ pool. Stimulation of permeabilized PSMC with cADPR was found to elicit large Ca2+ releases blocked by either a selective antagonist of cADPR or a RyR blocker, but not by heparin. Western blotting and confocal fluorescence microscopy indicated the specific expression of type 2 RyR in perinuclear localization. ET was found to stimulate the activity of ADP-ribosyl cyclase. Microinjection of the selective cADPR antagonist 8NH(2)-cADPR completely abolished subsequent stimulation of Ca2+ signaling via ETA and ETB receptors. cADPR therefore appears to have an obligatory role for ETA-R and ETB-R-mediated calcium signaling in PSMC. However, ETB-R seem to be coupled exclusively to cADPR whereas ETA-R activation may be linked to IP3 and cADPR signaling pathways.	Univ Roma La Sapienza, Dept Histol & Med Embryol, Ist Pasteur Fdn Cenci Bolognetti, I-00161 Rome, Italy; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Univ Siena, Dept Neurosci, Mol Med Sect, I-53100 Siena, Italy; DIBIT S Raffaele Sci Inst, I-20132 Milan, Italy; Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England	Fondazione Cenci Bolognetti; Sapienza University Rome; University of Oxford; University of Siena; University of Cambridge	Filippini, A (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, Ist Pasteur Fdn Cenci Bolognetti, Via A Scarpa 14, I-00161 Rome, Italy.	antonio.filippini@uniroma1.it	Conti, Antonio/AAN-7161-2020; Galione, Antony/E-5884-2011; Genazzani, Armando/AAI-8280-2020; Sorrentino, Vincenzo/A-4793-2014	Conti, Antonio/0000-0001-9150-5271; Sorrentino, Vincenzo/0000-0002-8573-8631; Ziparo, Elio/0000-0002-8776-3515; Galione, Antony/0000-0002-4132-7646; filippini, antonio/0000-0001-8453-287X; Genazzani, Armando/0000-0003-1923-7430				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Chiarenza C, 2000, ENDOCRINOLOGY, V141, P2971, DOI 10.1210/en.141.8.2971; Conti M, 1996, ELECTROPHORESIS, V17, P1590, DOI 10.1002/elps.1150171017; FILIPPINI A, 1993, ENDOCRINOLOGY, V133, P1789, DOI 10.1210/en.133.4.1789; FILIPPINI A, 1995, ENDOTHELINS ENDOCRIN, V15, P219; Flucher BE, 1999, J CELL BIOL, V146, P621, DOI 10.1083/jcb.146.3.621; GALIONE A, 1994, MOL CELL ENDOCRINOL, V98, P125, DOI 10.1016/0303-7207(94)90130-9; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GRAEFF RM, 1994, BIOCHEM BIOPH RES CO, V205, P722, DOI 10.1006/bbrc.1994.2725; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Li PL, 2001, AM J PHYSIOL-HEART C, V280, pH208, DOI 10.1152/ajpheart.2001.280.1.H208; PALOMBI F, 1988, BIOL REPROD, V39, P1101, DOI 10.1095/biolreprod39.5.1101; PALOMBI F, 1992, ANAT REC, V233, P32, DOI 10.1002/ar.1092330106; PALOMBI F, 1988, SERONO S, V50, P311; Prakash YS, 1998, AM J PHYSIOL-CELL PH, V274, pC1653, DOI 10.1152/ajpcell.1998.274.6.C1653; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sorrentino V, 2000, CURR OPIN GENET DEV, V10, P662, DOI 10.1016/S0959-437X(00)00139-8; Sorrentino V, 2001, TRENDS PHARMACOL SCI, V22, P459, DOI 10.1016/S0165-6147(00)01760-0; Sun L, 1999, J CELL BIOL, V146, P1161, DOI 10.1083/jcb.146.5.1161; Tarroni P, 1997, J BIOL CHEM, V272, P19808, DOI 10.1074/jbc.272.32.19808; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; Tripiciano A, 1996, BIOL REPROD, V55, P25, DOI 10.1095/biolreprod55.1.25; Tripiciano A, 1999, J CELL BIOL, V145, P1027, DOI 10.1083/jcb.145.5.1027; Tripiciano A, 1997, FASEB J, V11, P276, DOI 10.1096/fasebj.11.4.9068617; TUNG PS, 1990, BIOL REPROD, V42, P351, DOI 10.1095/biolreprod42.2.351; VIRTANEN I, 1986, ANAT RECORD, V215, P10, DOI 10.1002/ar.1092150103; Wilson HL, 2001, J BIOL CHEM, V276, P11180, DOI 10.1074/jbc.M004849200; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	35	48	50	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7							UNSP 0892-6638/02/0016-0697	10.1096/fj.01-0749com	http://dx.doi.org/10.1096/fj.01-0749com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	11978734				2022-12-28	WOS:000175973900024
J	Lu, CR; Li, Y; Zhao, YL; Xing, GC; Tang, F; Wang, QM; Sun, YH; Wei, HD; Yang, XM; Wu, CS; Chen, JG; Guan, KL; Zhang, CG; Chen, HP; He, FC				Lu, CR; Li, Y; Zhao, YL; Xing, GC; Tang, F; Wang, QM; Sun, YH; Wei, HD; Yang, XM; Wu, CS; Chen, JG; Guan, KL; Zhang, CG; Chen, HP; He, FC			Intracrine hepatopoietin potentiates AP-1 activity through JAB1 independent of MAPK pathway	FASEB JOURNAL			English	Article						intracellular signaling; augmenter of liver regeneration	HEPATIC STIMULATOR SUBSTANCE; FIBROBLAST-GROWTH-FACTOR; LIVER-REGENERATION; COP9 SIGNALOSOME; PROTEIN; GENE; KINASE; RECEPTOR; YEAST; TRANSCRIPTION	Many growth factors and cytokines are involved in liver regeneration. Of them, only hepatopoietin (HPO)/ALR (augmenter of liver regeneration) is a specifically hepatotrophic factor originally identified from the cytosol of regenerating or hyperplastic hepatic cells. Previous reports indicate that extracellular HPO triggers the MAPK pathway by binding its specific receptor on the cell surface. However, its function in the cytosol of hepatocytes is unclear. Here we identified that JAB1 (Jun activation domain-binding protein 1), a co-activator of AP-1, which is essential for liver regeneration, specifically interacts with intracellular HPO. JAB1 colocalizes with HPO in nuclei of hepatic cells or COS-7 cells. As an intracrine factor, the intracellular function of HPO is to increase c-Jun phosphorylation independent of c-Jun amino-terminal kinase (JNK), extracellular signal-regulated kinase (ERK) -1 and -2, and leads to potentiation of JAB1-mediated AP-1 activation. Amino acids 1-63 of HPO molecule are sufficient to bind to JAB1, but the full-length HPO is necessary for its intracellular signaling. Taken together, these results elucidate a novel mechanism of intracrine cytokine signaling by specifically modulating the AP-1 pathway through JAB1, in a MAPK-independent fashion.	Chinese Natl Human Genome Ctr Beijing, Beijing Inst Radiat Med, Dept Genom & Proteom, Beijing 100850, Peoples R China; Peking Univ, Sch Life Sci, Beijing 100871, Peoples R China; Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Academy of Military Medical Sciences - China; Peking University; Chinese Academy of Sciences; Institute of Biophysics, CAS	He, FC (corresponding author), Chinese Natl Human Genome Ctr Beijing, Beijing Inst Radiat Med, Dept Genom & Proteom, 27 Taiping Rd, Beijing 100850, Peoples R China.	hefc@nic.bmi.ac.cn	Zhao, Yanlin/M-2360-2013; Zhang, Chenggang/B-1480-2009	Zhao, Yanlin/0000-0002-0278-7543; Zhang, Chenggang/0000-0002-4521-3304				Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Bucala R, 2000, NATURE, V408, P146, DOI 10.1038/35041654; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Gandhi CR, 1999, HEPATOLOGY, V29, P1435, DOI 10.1002/hep.510290522; HAGIYA M, 1994, P NATL ACAD SCI USA, V91, P8142, DOI 10.1073/pnas.91.17.8142; HE FH, 1993, HEPATOLOGY, V17, P225, DOI 10.1016/0270-9139(93)90081-W; HENRIK D, 1997, EMBO J, V16, P7032; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofhaus G, 1999, EUR J CELL BIOL, V78, P349, DOI 10.1016/S0171-9335(99)80069-7; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kleemann R, 1999, EUR J BIOCHEM, V261, P753, DOI 10.1046/j.1432-1327.1999.00327.x; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; KRITEN LP, 2000, P NATL ACAD SCI USA, V97, P1489; LABRECQUE DR, 1991, DIGEST DIS SCI, V36, P669, DOI 10.1007/BF01297036; Li Y, 2000, J BIOL CHEM, V275, P37443, DOI 10.1074/jbc.M004373200; LISOWSKY T, 1995, GENOMICS, V29, P690, DOI 10.1006/geno.1995.9950; NAKANISHI Y, 1992, P NATL ACAD SCI USA, V89, P5216, DOI 10.1073/pnas.89.12.5216; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Senkevich TG, 2000, P NATL ACAD SCI USA, V97, P12068, DOI 10.1073/pnas.210397997; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Wang G, 1999, J BIOL CHEM, V274, P11469, DOI 10.1074/jbc.274.17.11469; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; YANG XM, 1997, ACTA PHYSL SINICA, V49, P599	29	60	69	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					90	92		10.1096/fj.01-0506fje	http://dx.doi.org/10.1096/fj.01-0506fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11709497				2022-12-28	WOS:000173656600024
J	Chavakis, T; Kanse, SM; Pixley, RA; May, AE; Isordia-Salas, I; Colman, RW; Preissner, KT				Chavakis, T; Kanse, SM; Pixley, RA; May, AE; Isordia-Salas, I; Colman, RW; Preissner, KT			Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen	FASEB JOURNAL			English	Article						HK; monoclonal antibody; leukocyte; Mac-1	CELL-BINDING-SITE; UROKINASE RECEPTOR; LIGHT-CHAIN; FACTOR-X; NEUTROPHIL EMIGRATION; ENDOTHELIAL-CELLS; CD11B/CD18 MAC-1; SURFACE-BINDING; P-SELECTIN; ADHESION	Proteolytic cleavage of single-chain, high molecular weight kininogen (HK) by kallikrein releases the short-lived vasodilator bradykinin and leaves behind a two-chain, high molecular weight kininogen (HKa) reported to bind to the beta2-integrin Mac-1 (CR3, CD11b/CD18, alphaM beta2) on neutrophils and exert antiadhesive properties by binding to the urokinase receptor (uPAR) and vitronectin. We define the molecular mechanisms for the antiadhesive effects of HK related to disruption of beta2-integrin-mediated cellular interactions in vitro and in vivo. In a purified system, HK and HKa inhibited the binding of soluble fibrinogen and ICAM-1 to immobilized Mac-1, but not the binding of ICAM-1 to immobilized LFA-1 (CD11a/CD18, alphaL beta2). This inhibitory effect could be attributed to HK domain 5 and to a lesser degree to HK domain 3, consistent with the requirement of both domains for binding to Mac-1. Accordingly, HK, HKa, and domain 5 inhibited the adhesion of Mac-1 but not LFA-1-transfected K562 human erythroleukemic cells to ICAM-1. Moreover, adhesion of human monocytic cells to fibrinogen and to human endothelial cells was blocked by HK, HKa, and domain 5. By using peptides derived from HK domain 5, the sequences including amino acids H475-G497 (and to a lesser extent, G440-H455) were identified as responsible for the antiadhesive effect, which was independent of uPAR. Finally, administration of domain 5 into mice, followed by induction of thioglycollate-provoked peritonitis, decreased the recruitment of neutrophils by A similar to 70% in this model of acute inflammation. Taken together, HKa (and particularly domain 5) specifically interacts with Mac-1 but not with LFA-1, thereby blocking Mac-1-dependent leukocyte adhesion to fibrinogen and endothelial cells in vitro and in vivo and serving as a novel endogenous regulator of leukocyte recruitment into the inflamed tissue.	Univ Giessen, Fachbereich Humanmed, Inst Biochem, D-35392 Giessen, Germany; Univ Giessen, Dept Internal Med 3, D-35392 Giessen, Germany; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19122 USA; Tech Univ Munich, Deutsch Herzzentrum, D-8000 Munich, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich	Chavakis, T (corresponding author), Univ Giessen, Fachbereich Humanmed, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	triantafyllos.chavakis@innere.med.uni-giessen.de	Chavakis, Triantafyllos/ABE-8845-2020	Kanse, Sandip/0000-0003-0782-9957	NCI NIH HHS [CA63938] Funding Source: Medline; NHLBI NIH HHS [HL56914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1991, J IMMUNOL, V147, P1891; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; Asakura S, 1998, J BIOCHEM-TOKYO, V124, P473, DOI 10.1093/oxfordjournals.jbchem.a022138; ASAKURA S, 1992, J CELL BIOL, V116, P465, DOI 10.1083/jcb.116.2.465; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; CARLOS TM, 1994, BLOOD, V84, P2068; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 1999, BLOOD, V93, P2976; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 2000, BLOOD, V95, P543, DOI 10.1182/blood.V95.2.543; de Gaetano G, 1999, HAEMOSTASIS, V29, P41; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; Gahmberg CG, 1997, CURR OPIN CELL BIOL, V9, P643, DOI 10.1016/S0955-0674(97)80117-2; GUSTAFSON EJ, 1989, J CELL BIOL, V109, P377, DOI 10.1083/jcb.109.1.377; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; HERWALD H, 1995, J BIOL CHEM, V270, P14634; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; Khan MMH, 1998, AM J PHYSIOL-HEART C, V275, pH145, DOI 10.1152/ajpheart.1998.275.1.H145; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; Lin YZ, 1997, BLOOD, V90, P690, DOI 10.1182/blood.V90.2.690.690_690_697; Lu HF, 1997, J CLIN INVEST, V99, P1340, DOI 10.1172/JCI119293; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357; NISHIKAWA K, 1992, BLOOD, V80, P1980; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Plescia J, 1996, BIOCHEM J, V319, P873, DOI 10.1042/bj3190873; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; RAMOS OF, 1988, J IMMUNOL, V140, P1239; REBUCK JW, 1983, AM J CLIN PATHOL, V79, P405, DOI 10.1093/ajcp/79.4.405; Renne T, 2000, J BIOL CHEM, V275, P33688, DOI 10.1074/jbc.M000313200; RETZIOS AD, 1987, J BIOL CHEM, V262, P3074; ROTHLEIN R, 1985, J IMMUNOL, V135, P2668; SCHMAIER AH, 1986, J CLIN INVEST, V77, P1565, DOI 10.1172/JCI112472; Sheng N, 2000, BLOOD, V95, P3788; Sitrin RG, 1996, J CLIN INVEST, V97, P1942, DOI 10.1172/JCI118626; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; TAIT JF, 1986, J BIOL CHEM, V261, P5396; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307; WALDMANN R, 1975, LANCET, V1, P949; WEI Y, 1994, J BIOL CHEM, V269, P32380; WEISEL JW, 1994, J BIOL CHEM, V269, P10100; Yung LYL, 1999, BLOOD, V94, P2716, DOI 10.1182/blood.V94.8.2716.420k32_2716_2724; Zhang JC, 2000, FASEB J, V14, P2589, DOI 10.1096/fj.99-1025com	56	55	56	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2365	2376		10.1096/fj.01-0201com	http://dx.doi.org/10.1096/fj.01-0201com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689462				2022-12-28	WOS:000172420500007
J	Yazawa, H; Yu, ZX; Takeda, K; Le, Y; Gong, WH; Ferrans, VJ; Oppenheim, JJ; Li, CCH; Wang, JM				Yazawa, H; Yu, ZX; Takeda, K; Le, Y; Gong, WH; Ferrans, VJ; Oppenheim, JJ; Li, CCH; Wang, JM			beta amyloid peptide (A beta(42)) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages	FASEB JOURNAL			English	Article						amyloid beta; Alzheimer's disease; internalization; colocalization	NECROSIS-FACTOR-ALPHA; A-BETA; ALZHEIMERS-DISEASE; CHEMOATTRACTANT RECEPTOR; SCAVENGER RECEPTOR; MICROGLIA; NEUROTOXICITY; CELLS; PHAGOCYTOSIS; MONOCYTES	The 42 amino acid form of beta amyloid (A beta (42)) plays a pivotal role in neurotoxicity and the activation of mononuclear phagocytes in Alzheimer's disease (AD). Our recent study revealed that FPRL1, a G-protein-coupled receptor, mediates the chemotactic and activating effect of A beta (42) on mononuclear phagocytes (monocytes and microglia), suggesting that FPRL1 may be involved in the proinflammatory responses in AD. We investigated the role of FPRL1 in cellular uptake and the subsequent fibrillar formation of A beta (42) by using fluorescence confocal microscopy. We found that upon incubation with macrophages or HEK293 cells genetically engineered to express FPRL1, A beta (42) associated with FPRL1 and the A beta (42)/FPRL1 complexes were rapidly internalized into the cytoplasmic compartment. The maximal internalization of A beta (42)/FPRL1 complexes occurred by 30 min after incubation. Removal of free A beta (42) from culture supernatants at 30 min resulted in a progressive recycling of FPRL1 to the cell surface and degradation of the internalized A beta (42). However, persistent exposure of the cells to A beta (42) over 24 h resulted in retention of A beta (42)/FPRL1 complexes in the cytoplasmic compartment and the formation of Congo red positive fibrils in macrophages but not in HEK 293 cell transfected with FPRL1. These results suggest that besides mediating the proinflammatory activity of A beta (42), FPRL1 is also involved in the internalization of A beta (42), which culminates in the formation of fibrils only in macrophages.	NCI, Mol Immunoregulat Lab, SAIC Frederick, Ctr Canc Res, Frederick, MD 21702 USA; NCI, Intramural Res Support Program, SAIC Frederick, Ctr Canc Res, Frederick, MD 21702 USA; NHLBI, Pathol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Wang, JM (corresponding author), NCI, Mol Immunoregulat Lab, SAIC Frederick, Ctr Canc Res, Bldg 560,Room 31-40, Frederick, MD 21702 USA.	wangji@mail.ncifcrf.gov	Le, Yingying/L-9785-2017	Le, Yingying/0000-0002-7990-3899	OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Antic A, 2000, EXP NEUROL, V161, P96, DOI 10.1006/exnr.1999.7265; Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chung HY, 1999, J BIOL CHEM, V274, P32301, DOI 10.1074/jbc.274.45.32301; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; Combs CK, 1999, J NEUROSCI, V19, P928; DeWitt DA, 1998, EXP NEUROL, V149, P329, DOI 10.1006/exnr.1997.6738; Dzenko KA, 1997, J NEUROIMMUNOL, V80, P6, DOI 10.1016/S0165-5728(97)00128-8; El Khoury J, 1998, NEUROBIOL AGING, V19, pS81, DOI 10.1016/S0197-4580(98)00036-0; ElKhoury J, 1996, NATURE, V382, P716; Ford AL, 1996, J EXP MED, V184, P1737, DOI 10.1084/jem.184.5.1737; Funato H, 1998, AM J PATHOL, V152, P1633; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Heidenreich S, 1997, J IMMUNOL, V159, P3178; Heinzelmann M, 1999, J IMMUNOL, V162, P4240; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; Hull M, 1999, DRUG DISCOV TODAY, V4, P275, DOI 10.1016/S1359-6446(99)01339-2; Kalaria R N, 1999, Curr Opin Hematol, V6, P15, DOI 10.1097/00062752-199901000-00004; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kuo YM, 1999, BIOCHEM BIOPH RES CO, V257, P787, DOI 10.1006/bbrc.1999.0552; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Le YY, 1999, J IMMUNOL, V163, P6777; Le YY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-02-j0003.2001; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; London JA, 1996, P NATL ACAD SCI USA, V93, P4147, DOI 10.1073/pnas.93.9.4147; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lorton D, 2000, NEUROBIOL AGING, V21, P463, DOI 10.1016/S0197-4580(00)00092-0; MACKENZIE IRA, 1995, NEUROBIOL AGING, V16, P797, DOI 10.1016/0197-4580(95)00092-S; MANGAN DF, 1991, J IMMUNOL, V146, P1541; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; McDonald DR, 1998, J NEUROSCI, V18, P4451; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; McGeer PL, 1999, J LEUKOCYTE BIOL, V65, P409, DOI 10.1002/jlb.65.4.409; Meda L, 1999, J NEUROIMMUNOL, V93, P45, DOI 10.1016/S0165-5728(98)00188-X; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Pachter JS, 1997, MOL PSYCHIATR, V2, P91, DOI 10.1038/sj.mp.4000212; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; Rossi M, 1996, BIOCHEMISTRY-US, V35, P3286, DOI 10.1021/bi950524p; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Seo JK, 1998, CLIN BIOCHEM, V31, P137, DOI 10.1016/S0009-9120(97)00172-0; SHAFFER LM, 1995, NEUROBIOL AGING, V16, P737, DOI 10.1016/0197-4580(95)00055-J; Stalder M, 1999, AM J PATHOL, V154, P1673, DOI 10.1016/S0002-9440(10)65423-5; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Tiffany HL, 2001, J BIOL CHEM, V276, P23645, DOI 10.1074/jbc.M101031200; vanderLaan LJW, 1996, J NEUROIMMUNOL, V70, P145, DOI 10.1016/S0165-5728(96)00110-5; VON ZM, 1992, J BIOL CHEM, V267, P3530; Weltzien RB, 2000, J NEUROSCI RES, V59, P522, DOI 10.1002/(SICI)1097-4547(20000215)59:4<522::AID-JNR7>3.3.CO;2-C; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yates SL, 2000, J NEUROCHEM, V74, P1017, DOI 10.1046/j.1471-4159.2000.0741017.x; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	58	124	144	2	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2454	2462		10.1096/fj.01-0251com	http://dx.doi.org/10.1096/fj.01-0251com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689470				2022-12-28	WOS:000172420500015
J	Pisarchik, A; Slominski, AT				Pisarchik, A; Slominski, AT			Alternative splicing of CRH-R1 receptors in human and mouse skin: identification of new variants and their differential expression	FASEB JOURNAL			English	Article						CRH receptors; mammalian skin; stress	CORTICOTROPIN-RELEASING-FACTOR; CUTANEOUS EXPRESSION; HORMONE-RECEPTOR; FACTOR CRF; CLONING; MELANOGENESIS; DOMAIN; DETERMINANTS; MELANOCYTES; SAUVAGINE	We identified four new isoforms of human CRH-R1 (e-h) and three of mouse (mCRH-R1c, e, and f). In all new forms exon 6 was missing. Human CRH-R1e was characterized by the deletion of exons 3 and 4; exon 12 from CRH-R1f; exon 11, 27 base pairs (bp) of exon 10 and 28 bp of exon 12 from CRH-R1g and CRH-R1h by the addition of a cryptic exon. In mouse CRH-R1c exon 3 was spliced out; in mCRH-R1e exons 3 and 4 and in mCRH-R1f exon 11 were spliced from mRNA. CRH-R1 was expressed in all skin specimens in patterns dependent on the cell type, physiological status, and presence of pathology. CRH-R1, the most prevalent form, was detected in almost all samples. Ultraviolet radiation (UV) changed the splicing pattern and induced or increased expression of CRH-R1 in cultured skin cells. Continuing UV treatment of succeeding generations of cells resulted in a progressive increase in the number of CRH-R1 isoforms, which suggests that receptor heterogeneity might favor cell survival. TPA (phorbol 12-myristate 13-acetate), forskolin, dbcAMP (N6, 2'-O-dibutyryladenosine 3':5'-cyclic monophospate sodium), and IBMX (3-isobutyl-1-methylxanthine) also changed the splicing pattern. We suggest that a polymorphism of CRH-R1 expression is related to anatomic location, skin physiological or pathologic status, specific cell type, and external stress (UV), and that cAMP-dependent pathways and TPA may regulate CRH-R1.	Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Slominski, AT (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol, 899 Madison Ave,Room 576 BMH, Memphis, TN 38163 USA.	aslominski@utmem.edu		Pisarchik, Alexander/0000-0002-8991-919X; Slominski, Andrzej/0000-0001-8963-3995				ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; Arai M, 2001, ENDOCRINOLOGY, V142, P446, DOI 10.1210/en.142.1.446; ARTS E, 2000, HUM MOL GENET, V9, P237; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Black DL, 1998, NEURON, V20, P165, DOI 10.1016/S0896-6273(00)80444-4; Chalmers DT, 1996, TRENDS PHARMACOL SCI, V17, P166, DOI 10.1016/0165-6147(96)81594-X; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Dautzenberg FM, 1997, J NEUROCHEM, V69, P1640; Grammatopoulos DK, 1999, MOL ENDOCRINOL, V13, P2189, DOI 10.1210/me.13.12.2189; HINUMA K, 1997, Patent No. 1997070289; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liaw CW, 1997, MOL ENDOCRINOL, V11, P980, DOI 10.1210/me.11.7.980; Liaw CW, 1996, ENDOCRINOLOGY, V137, P72, DOI 10.1210/en.137.1.72; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; NABHAN C, 1995, BIOCHEM BIOPH RES CO, V212, P1015, DOI 10.1006/bbrc.1995.2071; Owens AH, 1982, TUMOR CELL HETEROGEN; PAWELEK JM, 1992, PIGM CELL RES, V5, P348, DOI 10.1111/j.1600-0749.1992.tb00561.x; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P836; Perrin MH, 1999, ANN NY ACAD SCI, V885, P312, DOI 10.1111/j.1749-6632.1999.tb08687.x; Perrin MH, 1998, ENDOCRINOLOGY, V139, P566, DOI 10.1210/en.139.2.566; Quevedo ME, 2001, IN VITRO CELL DEV-AN, V37, P50; ROBBINS M, 1992, MOL BRAIN RES, V13, P83, DOI 10.1016/0169-328X(92)90047-F; ROSS PC, 1994, BIOCHEM BIOPH RES CO, V205, P1836, DOI 10.1006/bbrc.1994.2884; SAKAI RR, 1998, PERSPECT ANTISEN SCI, V1, P125; SLOMINSKI A, 1992, LIFE SCI, V50, P1103, DOI 10.1016/0024-3205(92)90347-R; Slominski A, 2000, J CLIN ENDOCR METAB, V85, P815, DOI 10.1210/jc.85.2.815; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 1996, BBA-GEN SUBJECTS, V1289, P247, DOI 10.1016/0304-4165(95)00159-X; Slominski A, 1999, IN VITRO CELL DEV-AN, V35, P564; Slominski A, 1998, CLIN DERMATOL, V16, P503, DOI 10.1016/S0738-081X(98)00023-6; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2001, FASEB J, V15, P1678, DOI 10.1096/fj.00-0850rev; Slominski A, 1996, FEBS LETT, V399, P175, DOI 10.1016/S0014-5793(96)01315-4; Slominski A, 2000, J CLIN ENDOCR METAB, V85, P3582, DOI 10.1210/jc.85.10.3582; Slominski AT, 2000, IN VITRO CELL DEV-AN, V36, P211; Slominski AT, 1999, ANN NY ACAD SCI, V885, P287; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Sorek R, 2001, NAT BIOTECHNOL, V19, P196, DOI 10.1038/85613; Spiess J, 1998, TRENDS ENDOCRIN MET, V9, P140, DOI 10.1016/S1043-2760(98)00037-X; STENZEL P, 1995, MOL ENDOCRINOL, V9, P637, DOI 10.1210/me.9.5.637; TsaiMorris CH, 1996, J BIOL CHEM, V271, P14519, DOI 10.1074/jbc.271.24.14519; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; Wille S, 1999, J NEUROCHEM, V72, P388, DOI 10.1046/j.1471-4159.1999.0720388.x	46	151	154	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2754	+		10.1096/fj.01-0487fje	http://dx.doi.org/10.1096/fj.01-0487fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606483				2022-12-28	WOS:000171920400010
J	Hubert, P; Giannini, SL; Vanderplasschen, A; Franzen-Detrooz, E; Jacobs, N; Boniver, J; Delvenne, P				Hubert, P; Giannini, SL; Vanderplasschen, A; Franzen-Detrooz, E; Jacobs, N; Boniver, J; Delvenne, P			Dendritic cells induce the death of human papillomavirus transformed keratinocytes	FASEB JOURNAL			English	Article						cell contact; normal keratinocytes; apoptosis; HPV-transformed keratinocytes	SQUAMOUS INTRAEPITHELIAL LESIONS; NECROSIS-FACTOR-ALPHA; COLONY-STIMULATING FACTOR; ANTIGEN-PRESENTING CELLS; UTERINE CERVIX; LANGERHANS CELLS; FAS-LIGAND; (PRE)NEOPLASTIC LESIONS; PRENEOPLASTIC LESIONS; ORGANOTYPIC CULTURE	Although human papillomavirus (HPV) antigens are expressed in a majority of (pre) neoplastic lesions (squamous intraepithelial lesions; SILs) of the uterine cervix, progression to invasive cancer may occur, which suggests that the presentation of viral antigens to the immune system is deficient in some SILs. To determine whether professional antigen-presenting cells die in SILs, we assayed for the apoptosis of immature dendritic cells (DC) in organotypic cultures of HPV-transformed keratinocytes, which reproduce many features of in vivo observed SILs. Unexpectedly, the infiltration of organotypic cultures by DC specifically induced the apoptosis of HPV+ tumor cells, whereas DC were not affected. In the same conditions and in coculture experiments, apoptosis was not observed in normal keratinocytes. The induction of apoptosis required membrane contacts between DC and HPV-transformed keratinocytes. Although the HPV+ cell lines were sensitive to the effects of TRAIL, soluble TRAILR2-Fc did not block the DC-induced apoptosis. Furthermore, although FasL and Fas were detected on DC and HPV+ cell lines, respectively, functional analysis revealed that this pathway is not responsible for the apoptosis induced by the DC. All together these results suggest that DC may be at the interface between innate and adaptive immunity by inducing the apoptosis of (pre) neoplastic cells.	CHU Sart Tilman, Dept Pathol B35, Univ Hosp Liege, B-4000 Liege, Belgium; Univ Liege, Fac Med Vet, Dept Infect & Parasit Dis, Liege, Belgium	University of Liege; University of Liege	Hubert, P (corresponding author), CHU Sart Tilman, Dept Pathol B35, Univ Hosp Liege, B-4000 Liege, Belgium.	P.Hubert@ulg.ac.be		Jacobs, Nathalie/0000-0002-9895-8465				Al-Saleh W, 1998, J PATHOL, V184, P283, DOI 10.1002/(SICI)1096-9896(199803)184:3<283::AID-PATH25>3.0.CO;2-K; ALSALEH W, 1995, VIRCHOWS ARCH, V427, P41; Andrade W, 1996, J IMMUNOL METHODS, V194, P181, DOI 10.1016/0022-1759(96)00083-X; AUERSPERG N, 1962, J NATL CANCER I, V28, P605; Beaulieu S, 1998, VIROLOGY, V241, P285, DOI 10.1006/viro.1997.8977; BLANTON RA, 1991, AM J PATHOL, V138, P673; Bonham CA, 1997, TRANSPL P, V29, P1116, DOI 10.1016/S0041-1345(96)00458-7; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Chan M, 2000, POPTRONICS, V1, P20; Chaux P, 1997, INT J CANCER, V72, P619, DOI 10.1002/(SICI)1097-0215(19970807)72:4<619::AID-IJC12>3.3.CO;2-Y; COLEMAN N, 1994, AM J CLIN PATHOL, V102, P768, DOI 10.1093/ajcp/102.6.768; DELVENNE P, 1995, AM J PATHOL, V146, P589; Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Freiberg RA, 1996, J BIOL CHEM, V271, P31666, DOI 10.1074/jbc.271.49.31666; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; Giannini SL, 1998, CLIN EXP IMMUNOL, V113, P183; Gilboa E, 1999, CANCER IMMUNOL IMMUN, V48, P382, DOI 10.1007/s002620050590; HERRINGTON CS, 1995, J CLIN PATHOL, V48, P1, DOI 10.1136/jcp.48.1.1; Hirano A, 1999, BLOOD, V93, P2999; Hubert P, 1999, AM J PATHOL, V154, P775, DOI 10.1016/S0002-9440(10)65324-2; Hubert P, 1998, CANCER IMMUNOL IMMUN, V47, P81, DOI 10.1007/s002620050507; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Iwamasa T, 2000, PATHOL RES PRACT, V196, P209, DOI 10.1016/S0344-0338(00)80069-2; Jacobs N, 1998, CLIN EXP IMMUNOL, V111, P219; Jacobs N, 1998, VIRCHOWS ARCH, V432, P323, DOI 10.1007/s004280050173; Kaplan MJ, 2000, J IMMUNOL, V164, P2897, DOI 10.4049/jimmunol.164.6.2897; Kiertscher SM, 2000, J IMMUNOL, V164, P1269, DOI 10.4049/jimmunol.164.3.1269; Kim CH, 2000, INT J ONCOL, V16, P1137; KITABAYASHI A, 1995, INT J HEMATOL, V62, P99; Kobayashi T, 2000, ARTHRITIS RHEUM, V43, P1106, DOI 10.1002/1529-0131(200005)43:5<1106::AID-ANR21>3.0.CO;2-F; Labeur MS, 1999, J IMMUNOL, V162, P168; Lemaire C, 1999, CELL DEATH DIFFER, V6, P813, DOI 10.1038/sj.cdd.4400556; LEWIS GD, 1987, CANCER RES, V47, P5382; Liu YM, 2000, J CELL BIOCHEM, V78, P334, DOI 10.1002/(SICI)1097-4644(20000801)78:2<334::AID-JCB15>3.3.CO;2-6; Nair P, 1999, Pathol Oncol Res, V5, P95, DOI 10.1053/paor.1999.0161; Niehans GA, 1997, CANCER RES, V57, P1007; Nouri-Shirazi M, 2000, J IMMUNOL, V165, P3797, DOI 10.4049/jimmunol.165.7.3797; O'Connell J, 1998, J PATHOL, V186, P240; PATER MM, 1985, VIROLOGY, V145, P313, DOI 10.1016/0042-6822(85)90164-3; Poggi A, 1997, EUR J IMMUNOL, V27, P2965, DOI 10.1002/eji.1830271132; Ramenghi U, 2000, BLOOD, V95, P3176; Reinartz J, 1996, EXP CELL RES, V228, P334, DOI 10.1006/excr.1996.0333; Rosini S, 1996, HUM PATHOL, V27, P834, DOI 10.1016/S0046-8177(96)90458-X; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Subklewe M, 2001, J EXP MED, V193, P405, DOI 10.1084/jem.193.3.405; Sung Kyung Jeh, 1997, Journal of Dermatology (Tokyo), V24, P427; Suss G, 1996, J EXP MED, V183, P1789, DOI 10.1084/jem.183.4.1789; TAZI A, 1993, J CLIN INVEST, V91, P566, DOI 10.1172/JCI116236; Viac J, 1993, In Vivo, V7, P207; VIAC J, 1990, IMMUNOBIOLOGY, V180, P328, DOI 10.1016/S0171-2985(11)80296-2; Vidalain PO, 2000, J VIROL, V74, P556, DOI 10.1128/JVI.74.1.556-559.2000; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Yamamoto K, 1998, CLIN EXP IMMUNOL, V114, P94	55	27	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					2521	+		10.1096/fj.00-0872fje	http://dx.doi.org/10.1096/fj.00-0872fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641258				2022-12-28	WOS:000171372700025
J	Wenzel, S; Taimor, G; Piper, HM; Schlueter, KD				Wenzel, S; Taimor, G; Piper, HM; Schlueter, KD			Redox-sensitve intermediates mediate angiotensin II-induced p38 MAP kinase activation, AP-1 binding activity, and TGF-beta expression in adult ventricular cardiomyocytes	FASEB JOURNAL			English	Article						angiotensin II type I receptor; NAD(P)H oxidase; phox22	SMOOTH-MUSCLE CELLS; CARDIAC-HYPERTROPHY; RECEPTOR ANTAGONIST; HYPERTENSIVE RATS; GENE-EXPRESSION; TRANSFORMING GROWTH-FACTOR-BETA-1; EXTRACELLULAR-MATRIX; NAD(P)H OXIDASE; PROTEIN-KINASE; IN-VITRO	Cardiac hypertrophy as an adaptation to increased blood pressure leads to an increase in ventricular expression of tranforming growth factor beta (TGF-beta), probably via the renin-angiotensin system. We studied in vivo to determine whether angiotensin II affects TGF-beta expression independent from mechanical effects caused by the concomitant increase in blood pressure and in vitro intracellular signaling involved in angiotensin II-dependent TGF-beta induction. In vivo, the AT(1) receptor antagonist losartan, but not reduction of blood pressure by hydralazine, inhibited the increase in TGF-beta (1) expression caused by angiotensin II. In vitro, angiotensin II caused an induction of TGF-beta (1) expression in adult ventricular cardiomyocytes and induced AP-1 binding activity. Transfection with "decoys" directed against the binding site of AP-1 binding proteins inhibited the angiotensin II-dependent TGF-beta induction. Angiotensin II induced TGF-beta expression in a p38-MAP kinase-dependent way. p38-MAP kinase activation was diminished in presence of the antioxidants or diphenyleneiodium chloride, or by pretreatment with antisense nucleotides directed against phox22 and nox, components of smooth muscle type NAD( P) H oxidase. Thus, our study identifies a previously unrecognized coupling of cardiac AT receptors to a NAD( P) H oxidase complex similar to that expressed in smooth muscle cells and identifies p38-MAP kinase activation as an important downstream target.	Univ Giessen, Inst Physiol, D-35392 Giessen, Germany	Justus Liebig University Giessen	Schlueter, KD (corresponding author), Univ Giessen, Inst Physiol, Aulweg 129, D-35392 Giessen, Germany.	Klaus-Dieter.Schlueter@physiologie.med.uni-giessen.de						Baines CP, 1999, J CARDIOVASC ELECTR, V10, P741, DOI 10.1111/j.1540-8167.1999.tb00251.x; BOLUYT MO, 1994, CIRC RES, V75, P23, DOI 10.1161/01.RES.75.1.23; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND T, 1995, J MOL CELL CARDIOL, V27, P5, DOI 10.1016/S0022-2828(08)80003-X; Ehmke H, 1999, HYPERTENSION, V33, P954, DOI 10.1161/01.HYP.33.4.954; Goldberg Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1207, DOI 10.1152/ajpcell.1998.275.5.C1207; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; IZUKA K, 1994, J MOL CELL CARDIOL, V26, P435; Kim S, 1996, BRIT J PHARMACOL, V118, P549, DOI 10.1111/j.1476-5381.1996.tb15437.x; KIM SK, 1995, J PHARMACOL EXP THER, V273, P509; Kimura M, 1999, EUR J PHARMACOL, V386, P271, DOI 10.1016/S0014-2999(99)00739-6; KOJIMA M, 1994, CIRCULATION, V89, P2204, DOI 10.1161/01.CIR.89.5.2204; LEE YA, 1993, EUR HEART J, V14, P42; MAZZAB KM, 1997, CIRCULATION, V96, P614; Moriguchi Y, 1999, CIRC RES, V84, P1073, DOI 10.1161/01.RES.84.9.1073; Morishita R, 1998, BIOCHEM BIOPH RES CO, V243, P361, DOI 10.1006/bbrc.1997.8012; Nishikawa K, 1998, J HUM HYPERTENS, V12, P301, DOI 10.1038/sj.jhh.1000634; NOGAMI M, 1994, AM J PHYSIOL, V266, pL187, DOI 10.1152/ajplung.1994.266.2.L187; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; PIPER HM, 1982, J MOL CELL CARDIOL, V14, P397, DOI 10.1016/0022-2828(82)90171-7; Piper HM, 1990, CELL CULTURE TECHNIQ, P158; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; QIAN SW, 1990, NUCLEIC ACIDS RES, V18, P3059, DOI 10.1093/nar/18.10.3059; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Schluter KD, 2000, CARDIOVASC RES, V45, P410, DOI 10.1016/S0008-6363(99)00351-X; Schluter KD, 1999, AM J PHYSIOL-HEART C, V276, pH1655, DOI 10.1152/ajpheart.1999.276.5.H1655; SCHLUTER KD, 1995, AM J PHYSIOL-CELL PH, V269, pC1311, DOI 10.1152/ajpcell.1995.269.5.C1311; SCHLUTER KD, 1995, BIOCHEM J, V310, P439, DOI 10.1042/bj3100439; Sun YO, 1998, J MOL CELL CARDIOL, V30, P1559, DOI 10.1006/jmcc.1998.0721; Taimor G, 1999, J MOL CELL CARDIOL, V31, P2127, DOI 10.1006/jmcc.1999.1055; Thompson NL, 1988, GROWTH FACTORS, V1, P91, DOI 10.3109/08977198809000251; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; VILLARREAL FJ, 1992, AM J PHYSIOL, V262, pH1861, DOI 10.1152/ajpheart.1992.262.6.H1861; Wada H, 1996, AM J PHYSIOL-HEART C, V271, pH29, DOI 10.1152/ajpheart.1996.271.1.H29; Xi XP, 1999, ARTERIOSCL THROM VAS, V19, P73, DOI 10.1161/01.ATV.19.1.73; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323; Yamazaki T, 1999, AM J CARDIOL, V83, p53H; Zimmermann R, 1999, J MOL CELL CARDIOL, V31, P1447, DOI 10.1006/jmcc.1999.0976	40	116	124	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					2291	+		10.1096/fj.00-0827fje	http://dx.doi.org/10.1096/fj.00-0827fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11511516				2022-12-28	WOS:000170809900019
J	Casado, M; Callejas, NA; Rodrigo, J; Zhao, XM; Dey, SK; Bosca, L; Martin-Sanz, P				Casado, M; Callejas, NA; Rodrigo, J; Zhao, XM; Dey, SK; Bosca, L; Martin-Sanz, P			Contribution of cyclooxygenase-2 to liver regeneration after partial hepatectomy	FASEB JOURNAL			English	Article						prostaglandins; hepatocyte; inflammation	CCAAT/ENHANCER-BINDING-PROTEIN; NITRIC-OXIDE SYNTHASE; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; C/EBP-ALPHA; GENE-EXPRESSION; HEPATOCYTE PROLIFERATION; TRANSCRIPTION FACTORS; CELL-PROLIFERATION; MESSENGER-RNA; KAPPA-B	Partial hepatectomy (PH) triggers a rapid regenerative response in the remaining tissue to reinstate the organ function and the cell numbers. Among the molecules that change in the course of regeneration is an accumulation of prostaglandin E-2 in the sera of rats with PH. Analysis of the cyclooxygenase (COX) isoenzymes in the remnant liver showed the preferential expression of COX-2 in hepatocytes. Cultured regenerating hepatocytes expressed significant levels of COX-2, a process that was not observed in the sham counterparts. Maximal expression of COX-2 was detected 16 h after PH with increased levels present even at 96 h. Pharmacological inhibition of COX-2 activity with NS398 shunted the up-regulation of cell proliferation after PH, which suggests a positive interaction of prostaglandins with the progression of the cell cycle. Similar results were obtained after PH of mice lacking the COX-2 gene. The expression of COX-2 in regenerating liver was concomitant with a decrease in CCAAT-enhancer binding protein (C/EBP-alpha) level and an increase in the expression of C/EBP-beta and C/EBP-delta. These results suggest a contribution of the enhanced synthesis of prostaglandins to liver regeneration observed after PH.	Univ Complutense Madrid, Fac Farm, Inst Bioquim, Ctr Mixto CSIC, E-28040 Madrid, Spain; CSIC, Inst Biomed, E-46010 Valencia, Spain; CSIC, Inst Neurobiol Santiago Ramon & Cajal, Madrid 28071, Spain; Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66103 USA	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Consejo Superior de Investigaciones Cientificas (CSIC); University of Kansas; University of Kansas Medical Center	Martin-Sanz, P (corresponding author), Univ Complutense Madrid, Fac Farm, Inst Bioquim, Ctr Mixto CSIC, E-28040 Madrid, Spain.	pmartin@eucmos.sim.ucm.es	Casado, Marta/L-2078-2014; Bosca, Lisardo/A-2059-2008; Martín-Sanz, Paloma/K-1303-2014	Casado, Marta/0000-0001-6457-4650; Bosca, Lisardo/0000-0002-0253-5469; 				An MR, 1996, MOL CELL BIOL, V16, P2295; Callejas NA, 2000, GASTROENTEROLOGY, V119, P493, DOI 10.1053/gast.2000.9374; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; DAS SK, 1994, DEVELOPMENT, V120, P1071; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DiazGuerra MJM, 1997, BIOCHEM J, V326, P791, DOI 10.1042/bj3260791; DIEHL AM, 1994, GASTROENTEROLOGY, V106, P1625, DOI 10.1016/0016-5085(94)90420-0; DIEHL AM, 1994, HEPATOLOGY, V19, P447; Diehl AM, 1996, J BIOL CHEM, V271, P7343, DOI 10.1074/jbc.271.13.7343; Diehl AM, 1996, FASEB J, V10, P215, DOI 10.1096/fasebj.10.2.8641555; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; FENG J, 1995, NEURAL PROCESS LETT, V2, P1; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HERSCHMAN HR, 1995, ADV PROSTAG THROMB L, V23, P23; HORTELANO S, 1995, HEPATOLOGY, V21, P776; Jun DY, 1997, MOL CELLS, V7, P537; Kinugawa K, 1997, CIRC RES, V81, P911; Koga H, 1999, HEPATOLOGY, V29, P688, DOI 10.1002/hep.510290355; Kramer A, 1996, J BIOL CHEM, V271, P6579; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Ledwith BJ, 1997, J BIOL CHEM, V272, P3707, DOI 10.1074/jbc.272.6.3707; LEE JH, 1995, FEBS LETT, V368, P348, DOI 10.1016/0014-5793(95)00703-C; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Martin-Sanz P, 1998, BRIT J PHARMACOL, V125, P1313, DOI 10.1038/sj.bjp.0702196; MARTINSANZ P, 1989, BIOCHEM J, V257, P795, DOI 10.1042/bj2570795; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Nanji AA, 1997, GASTROENTEROLOGY, V112, P943, DOI 10.1053/gast.1997.v112.pm9041257; PILBEAM CC, 1993, J BIOL CHEM, V268, P25643; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; RODRIGO J, 1994, PHILOS T R SOC B, V345, P175, DOI 10.1098/rstb.1994.0096; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; SIROIS J, 1993, J BIOL CHEM, V268, P12199; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Watkins PJ, 1996, CANCER RES, V56, P1063; Williams CS, 1996, AM J PHYSIOL, V270, P393; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; ZHANG F, 1995, BIOCHEM J, V312, P135, DOI 10.1042/bj3120135	50	87	89	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2016	+		10.1096/fj.01-0158fje	http://dx.doi.org/10.1096/fj.01-0158fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511527				2022-12-28	WOS:000170318500019
J	Guignandon, A; Lafage-Proust, MH; Usson, Y; Laroche, N; Caillot-Augusseau, A; Alexandre, C; Vico, L				Guignandon, A; Lafage-Proust, MH; Usson, Y; Laroche, N; Caillot-Augusseau, A; Alexandre, C; Vico, L			Cell cycling determines integrin-mediated adhesion in osteoblastic ROS 17/2.8 cells exposed to space-related conditions	FASEB JOURNAL			English	Article						microgravity; weightlessness; adhesion; cell cycle; osteoblasts; confocal microscopy; TIRFM; image analysis	PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; HUMAN-LEUKOCYTES; MESSENGER-RNA; MICROGRAVITY; CYTOSKELETON; MATRIX; RHO; SPACEFLIGHT; ACTIVATION	Six days of microgravity (Bion10 mission) induced dramatic shape changes in ROS 17/2.8 osteoblasts (7). During the Foton 11 and 12 space flights, we studied the kinetics (0-4 days) of ROS 17/2.8 morphology and adhesion, the relationships between adhesion and cell cycle progression after 4 days in space, and osteoblastic growth and activity after 6 days in space. Quantitative analysis of high-resolution adhesion [focal adhesion area imaged by total interference reflection fluorescent microscopy (TIRFM)] and integrin-dependent adhesion (imaged on confocal microscope by vinculin and phosphotyrosine staining) as well as cell cycle phase classification [Ki-67 staining, S-G2, mitotic cells and G1 (postmitotic cells)] were performed using programs validated in parabolic flight and clinostat. We observed disorganization of the cytoskeleton associated with disassembling of vinculin spots and phosphorylated proteins within focal contacts with no major change in TIRFM adhesion after 2 and 4 days of microgravity. Postmitotic cells, alone, accounted for the differences observed in the whole population. They are characterized by immature peripheral contacts with complete loss of central spots and decreased spreading. Osteocalcin, P1CP and alkaline phosphatase, and proliferation were similar in flight cells and 1 g centrifuge and ground controls after 6 days. In conclusion, microgravity substantially affected osteoblastic integrin-mediated cell adhesion. ROS17/2.8 cells responded differently, whether or not they were cycling by reorganizing adhesion plaque topography or morphology. In ROS 17/2.8, this reorganization did not impair osteoblastic phenotype.	Univ St Etienne, LBBTO, INSERM, Equipe Mixte E9901, F-42023 St Etienne Du Rouvray 2, France; Univ Grenoble 1, Inst Albert Bonniot, Lab TIMC UMR 5512, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Jean Monnet; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Guignandon, A (corresponding author), Univ St Etienne, LBBTO, INSERM, Equipe Mixte E9901, 15 Rue Ambroise Pare, F-42023 St Etienne Du Rouvray 2, France.	guignand@univ-st-etienne.fr	USSON, Yves/B-2002-2014; Vico, Laurence/ABG-7239-2020; Vico, Laurence/O-1927-2018	USSON, Yves/0000-0003-0242-191X; Vico, Laurence/0000-0002-2110-287X; Vico, Laurence/0000-0002-2110-287X; GUIGNANDON, Alain/0000-0002-0745-5417; Lafage-Proust, Marie-Helene/0000-0002-2091-3961				Alenghat FJ, 2000, BIOCHEM BIOPH RES CO, V277, P93, DOI 10.1006/bbrc.2000.3636; Carmeliet G, 1997, J BONE MINER RES, V12, P786, DOI 10.1359/jbmr.1997.12.5.786; Carmeliet G, 1998, BONE, V22, p139S, DOI 10.1016/S8756-3282(98)00007-6; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; CLARK E, 1998, J CELL BIOL, V18, P3936; Defilippi P, 1997, J BIOL CHEM, V272, P21726, DOI 10.1074/jbc.272.35.21726; Dike LE, 1999, IN VITRO CELL DEV-AN, V35, P441; DUMANOIR S, 1991, CYTOMETRY, V12, P455; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Guignandon A, 1997, BONE, V20, P109, DOI 10.1016/S8756-3282(96)00337-7; GUIGNANDON A, 1995, CELL STRUCT FUNCT, V20, P369, DOI 10.1247/csf.20.369; Guignandon A, 1997, EXP CELL RES, V236, P66, DOI 10.1006/excr.1997.3703; Guillaud P, 1989, Anal Cell Pathol, V1, P25; HANSEN LK, 1994, MOL BIOL CELL, V5, P967, DOI 10.1091/mbc.5.9.967; Harris SA, 2000, BONE, V26, P325, DOI 10.1016/S8756-3282(00)00234-9; Hatton JP, 1999, FASEB J, V13, pS23, DOI 10.1096/fasebj.13.9001.s23; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; Hughes-Fulford M, 1999, FASEB J, V13, pS121; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; Ingber D, 1999, FASEB J, V13, pS3; Kumei Y, 1996, J BIOTECHNOL, V47, P313, DOI 10.1016/0168-1656(96)01412-5; Landis WJ, 2000, J BONE MINER RES, V15, P1099, DOI 10.1359/jbmr.2000.15.6.1099; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; Lim YB, 2000, BIOCHEM BIOPH RES CO, V273, P609, DOI 10.1006/bbrc.2000.2987; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; LOWRY OH, 1957, METHOD ENZYMOL, V4, P366, DOI 10.1016/0076-6879(57)04065-3; MAHLER P, 2000, EXP CELL RES, V260, P189; MAINLY B, 1986, MULTIVARIATE STAT AN, P86; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOSHKOV DA, 1991, TSITOLOGIYA+, V33, P16; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Papaseit C, 2000, P NATL ACAD SCI USA, V97, P8364, DOI 10.1073/pnas.140029597; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rijken P J, 1994, Adv Space Biol Med, V4, P159; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Schmidt C, 1998, J BIOL CHEM, V273, P5081, DOI 10.1074/jbc.273.9.5081; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530; Usson Y, 1997, CYTOMETRY, V28, P298, DOI 10.1002/(SICI)1097-0320(19970801)28:4<298::AID-CYTO4>3.0.CO;2-8; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Whelan RDH, 1999, CELL GROWTH DIFFER, V10, P271; Wozniak M, 2000, J BONE MINER RES, V15, P1731, DOI 10.1359/jbmr.2000.15.9.1731; XIANGDONG R, 2000, J CELL SCI, V113, P3673; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	47	44	52	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2036	+		10.1096/fj.00-0837fje	http://dx.doi.org/10.1096/fj.00-0837fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511518				2022-12-28	WOS:000170318500013
J	Archer, SL; London, B; Hampl, V; Wu, XC; Nsair, A; Puttagunta, L; Hashimoto, K; Waite, RE; Michelakis, ED				Archer, SL; London, B; Hampl, V; Wu, XC; Nsair, A; Puttagunta, L; Hashimoto, K; Waite, RE; Michelakis, ED			Impairment of hypoxic pulmonary vasoconstriction in mice lacking the voltage-gated potassium channel Kv1.5	FASEB JOURNAL			English	Article						pulmonary circulation; Kv1.1; 4-aminopyridine; pulmonary artery; oxygen sensing; knockout mice; pulmonary hypertension; iberiotoxin	RECTIFIER K+ CURRENT; SMOOTH-MUSCLE CELLS; VASCULAR TONE; MOLECULAR-IDENTIFICATION; ARTERY MYOCYTES; RAT; INHIBITION; MECHANISM; HYPERTENSION; FENFLURAMINE	Hypoxic pulmonary vasoconstriction (HPV) is initiated by the inhibition of several 4-aminopyridine (4-AP)-sensitive, voltage-gated, K+ channels (Kv). Several O-2-sensitive candidate channels (Kv1.2, Kv1.5, Kv2.1, and Kv3.1b) have been proposed, based on similarities between their characteristics in expression systems and the properties of the O-2-sensitive K+ current (I-K) in pulmonary artery smooth muscle cells (PASMCs). We used gene targeting to delete Kv1.5 in mice by creating a SWAP mouse that is functionally a Kv1.5 knockout. We hypothesized that SWAP mice would display impaired HPV. The Kv1.5 alpha -subunits present in the endothelium and PASMCs of wild-type mice were absent in the lungs of SWAP mice, whereas expression of other channels Kv (1.1, 1.2, 2.1, 3.1, 4.3), Kir 3.1, Kir 6.1, and BKCa was unaltered. In isolated lungs and resistance PA rings, HPV was reduced significantly in SWAP versus wild-type mice. Consistent with this finding, PASMCs from SWAP PAs were slightly depolarized and lacked I-Kv1.5, a 4-AP and hypoxia-sensitive component of I-K that activated between -50 mV and -30 mV. We conclude that a K+ channel containing Kv1.5 alpha -subunits is an important effector of HPV in mice.	Univ Alberta, Dept Med, Div Cardiol,Vasc Biol Grp, Heart & Stroke Chair Cardiovasc Res, Edmonton, AB T6G 2B7, Canada; Univ Alberta, Dept Physiol, Edmonton, AB T6G 2B7, Canada; Univ Pittsburgh, Cardiovasc Inst, Pittsburgh, PA USA; Charles Univ, Dept Physiol, Sch Med 2, Prague, Czech Republic; Univ Alberta, Dept Pathol, Edmonton, AB T6G 2B7, Canada	University of Alberta; University of Alberta; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Charles University Prague; University of Alberta	Archer, SL (corresponding author), Univ Alberta, Dept Med, Div Cardiol,Vasc Biol Grp, Heart & Stroke Chair Cardiovasc Res, WMC 2C2-36,8440 112th St, Edmonton, AB T6G 2B7, Canada.	sarcher@cha.ab.ca	Hampl, Václav/A-2732-2009; Archer, Stephen L/C-3621-2013	Hampl, Václav/0000-0001-5776-4624; London, Barry/0000-0003-1506-3947				Archer SL, 2000, ADV EXP MED BIOL, V475, P219; ARCHER SL, 1986, HERZ, V11, P127; ARCHER SL, 1993, CIRC RES, V73, P1100, DOI 10.1161/01.RES.73.6.1100; Archer SL, 1999, P NATL ACAD SCI USA, V96, P7944, DOI 10.1073/pnas.96.14.7944; Archer SL, 1998, J CLIN INVEST, V101, P2319, DOI 10.1172/JCI333; Archer SL, 1996, CIRC RES, V78, P431, DOI 10.1161/01.RES.78.3.431; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; Clement-Chomienne O, 1999, J PHYSIOL-LONDON, V515, P653, DOI 10.1111/j.1469-7793.1999.653ab.x; ClementChomienne O, 1996, J PHYSIOL-LONDON, V495, P689, DOI 10.1113/jphysiol.1996.sp021626; COLLEY PS, 1977, ANESTHESIOLOGY, V47, P338, DOI 10.1097/00000542-197710000-00003; Conforti L, 1997, J PHYSIOL-LONDON, V502, P293, DOI 10.1111/j.1469-7793.1997.293bk.x; DANTZKER DR, 1981, J APPL PHYSIOL, V51, P607, DOI 10.1152/jappl.1981.51.3.607; DUPRAT F, 1995, P NATL ACAD SCI USA, V92, P11796, DOI 10.1073/pnas.92.25.11796; Euler Us V, 1946, ACTA PHYSL SCAND, V12, P301, DOI [10.1111/j.1748-1716.1946.tb00389.x, DOI 10.1111/J.1748-1716.1946.TB00389.X]; Gelband CH, 1997, CIRCULATION, V96, P3647; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HASUNUMA K, 1991, AM REV RESPIR DIS, V144, P884, DOI 10.1164/ajrccm/144.4.884; Hulme JT, 1999, CIRC RES, V85, P489, DOI 10.1161/01.RES.85.6.489; JIANG C, 1994, P NATL ACAD SCI USA, V91, P7198, DOI 10.1073/pnas.91.15.7198; London B, 2001, CIRC RES, V88, P940, DOI 10.1161/hh0901.090929; London B, 1998, J PHYSIOL-LONDON, V509, P171, DOI 10.1111/j.1469-7793.1998.171bo.x; LOPEZBARNEO J, 1988, SCIENCE, V241, P580, DOI 10.1126/science.2456613; MADDEN JA, 1992, AM J PHYSIOL, V263, pL384, DOI 10.1152/ajplung.1992.263.3.L384; MCMURTRY IF, 1976, CIRC RES, V38, P99, DOI 10.1161/01.RES.38.2.99; MCMURTRY IF, 1978, AM J PHYSIOL, V235, pH104, DOI 10.1152/ajpheart.1978.235.1.H104; Michelakis E, 2000, LANCET, V356, P134, DOI 10.1016/S0140-6736(00)02452-1; MOHAZZABH KM, 1995, AM J PHYSIOL-LUNG C, V269, pL637, DOI 10.1152/ajplung.1995.269.5.L637; OPARIL S, 1995, AM J PHYSIOL-LUNG C, V268, pL95, DOI 10.1152/ajplung.1995.268.1.L95; Osipenko ON, 2000, CIRC RES, V86, P534, DOI 10.1161/01.RES.86.5.534; Patel AJ, 1997, EMBO J, V16, P6615, DOI 10.1093/emboj/16.22.6615; POST JM, 1995, CIRC RES, V77, P131, DOI 10.1161/01.RES.77.1.131; POST JM, 1992, AM J PHYSIOL, V262, pC882, DOI 10.1152/ajpcell.1992.262.4.C882; Rauer H, 2000, J BIOL CHEM, V275, P1201, DOI 10.1074/jbc.275.2.1201; Reeve HL, 2001, J APPL PHYSIOL, V90, P2249, DOI 10.1152/jappl.2001.90.6.2249; Sato K, 2000, AM J PHYSIOL-LUNG C, V278, pL434, DOI 10.1152/ajplung.2000.278.3.L434; Shimoda L, 1998, AM J PHYSIOL-LUNG C, V274, pL842, DOI 10.1152/ajplung.1998.274.5.L842; SHIRAI M, 1991, JPN J PHYSIOL, V41, P129, DOI 10.2170/jjphysiol.41.129; SMIRNOV SV, 1994, AM J PHYSIOL, V266, pH365, DOI 10.1152/ajpheart.1994.266.1.H365; Uebele VN, 1996, J BIOL CHEM, V271, P2406, DOI 10.1074/jbc.271.5.2406; Wang J, 1997, J CLIN INVEST, V100, P2347, DOI 10.1172/JCI119774; Wang JA, 1998, LANCET, V352, P290, DOI 10.1016/S0140-6736(05)60264-4; WARD JPT, 1995, EXP PHYSIOL, V80, P793, DOI 10.1113/expphysiol.1995.sp003887; Weir EK, 1996, CIRCULATION, V94, P2216, DOI 10.1161/01.CIR.94.9.2216; WEIR EK, 1995, FASEB J, V9, P183, DOI 10.1096/fasebj.9.2.7781921; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0; YUAN XJ, 1995, CIRC RES, V77, P370, DOI 10.1161/01.RES.77.2.370; YUAN XJ, 1996, CIRCULATION, V94, P1; ZHAO Y, 1993, AM J PHYSIOL, V265, pL87	49	116	121	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1801	+		10.1096/fj.00-0649fje	http://dx.doi.org/10.1096/fj.00-0649fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481235				2022-12-28	WOS:000169261200019
J	Muller, DN; Heissmeyer, V; Dechend, R; Hampich, F; Park, JK; Fiebeler, A; Shagdarsuren, E; Theuer, J; Elger, M; Pilz, B; Breu, V; Schroer, K; Ganten, D; Dietz, R; Haller, H; Scheidereit, C; Luft, FC				Muller, DN; Heissmeyer, V; Dechend, R; Hampich, F; Park, JK; Fiebeler, A; Shagdarsuren, E; Theuer, J; Elger, M; Pilz, B; Breu, V; Schroer, K; Ganten, D; Dietz, R; Haller, H; Scheidereit, C; Luft, FC			Aspirin inhibits NF-kappa B and protects from angiotensin II-induced organ damage	FASEB JOURNAL			English	Article						angiotensin II; aspirin, NF-kappa B; end-organ damage; inflammation	VASCULAR SMOOTH-MUSCLE; SODIUM-SALICYLATE; TRANSCRIPTION FACTOR; TISSUE FACTOR; IKK COMPLEX; ACTIVATION; RENIN; PHOSPHORYLATION; EXPRESSION; TARGET	Angiotensin (Ang)-II induces vascular wall inflammation by activating NF-kappaB. Aspirin inhibits IKK beta in vitro; however, the in vivo relevance of the phenomenon is unclear. We tested the hypothesis that aspirin protects from Ang II-induced endorgan damage by inhibiting NF-kappaB activation in vivo. Rats harboring human renin and angiotensinogen genes received high- (600 mg/kg/day) or low- (25 mg/kg/day) dose aspirin. High-dose aspirin reduced mortality, cardiac hypertrophy, fibrosis, and albuminuria independent of blood pressure, whereas both doses reduced cyclooxygenase activity. High-dose aspirin inhibited NF-kappaB and AP-1 activation and inflammation in heart and kidney. These in vivo results serve to explain the clinical utility of high- dose aspirin in inflammatory disorders and suggest additional therapeutic avenues that may be relevant to cardiovascular disease.	Humboldt Univ, Fac Med Charite, Franz Volhard Clin, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Hannover Med Sch, Hannover, Germany; F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland; Free Univ Berlin, D-1000 Berlin, Germany; Univ Dusseldorf, D-4000 Dusseldorf, Germany	Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Hannover Medical School; Roche Holding; Free University of Berlin; Heinrich Heine University Dusseldorf	Luft, FC (corresponding author), Humboldt Univ, Fac Med Charite, Franz Volhard Clin, Wiltberg Str 50, D-13125 Berlin, Germany.	luft@fvk-berlin.de	Shagdarsuren, Erdenechimeg/AGG-0467-2022	Muller, Dominik N/0000-0003-3650-5644; Heissmeyer, Vigo/0000-0002-2263-8545; Luft, Friedrich/0000-0002-8635-1199				AARONS L, 1989, PHARMACEUT RES, V6, P660, DOI 10.1023/A:1015978104017; ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; Alpert D, 2000, J BIOL CHEM, V275, P10925, DOI 10.1074/jbc.275.15.10925; AUTIERI MV, 1995, BIOCHEM BIOPH RES CO, V213, P827, DOI 10.1006/bbrc.1995.2204; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Berk BC, 1999, J AM SOC NEPHROL, V10, pS62; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hernandez-Presa MA, 1998, AM J PATHOL, V153, P1825, DOI 10.1016/S0002-9440(10)65697-0; INGELFINGER JR, 1991, J AM SOC NEPHROL, V2, pS9; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Khoshnan A, 1999, J IMMUNOL, V163, P5444; Klahr S, 2000, KIDNEY INT, V57, pS7, DOI 10.1046/j.1523-1755.2000.07509.x; Klahr S, 1997, KIDNEY INT, pS111; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Krappmann D, 2000, J BIOL CHEM, V275, P29779, DOI 10.1074/jbc.M003902200; KRIZ W, 1995, KIDNEY INT, V48, P1435, DOI 10.1038/ki.1995.433; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Malik FS, 1997, AM HEART J, V134, P514, DOI 10.1016/S0002-8703(97)70089-9; Marra DE, 2000, CIRCULATION, V102, P2124, DOI 10.1161/01.CIR.102.17.2124; Mervaala E, 2000, HYPERTENSION, V35, P587, DOI 10.1161/01.HYP.35.2.587; Moriguchi Y, 1999, CIRC RES, V84, P1073, DOI 10.1161/01.RES.84.9.1073; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Morrissey JJ, 1997, KIDNEY INT, V52, P926, DOI 10.1038/ki.1997.414; Muller DN, 2000, AM J PATHOL, V157, P111, DOI 10.1016/S0002-9440(10)64523-3; Muller DN, 2000, HYPERTENSION, V36, P282, DOI 10.1161/01.HYP.36.2.282; Muller DN, 2000, HYPERTENSION, V35, P193, DOI 10.1161/01.HYP.35.1.193; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; O'Neill EA, 1998, NATURE, V396, P15, DOI 10.1038/23810; Pierce JW, 1996, J IMMUNOL, V156, P3961; Ruiz-Ortega M, 1998, J IMMUNOL, V161, P430; Ruiz-Ortega M, 2000, CIRC RES, V86, P1266, DOI 10.1161/01.RES.86.12.1266; Sadoshima J, 2000, CIRC RES, V86, P1187, DOI 10.1161/01.RES.86.12.1187; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; Tomita N, 2000, J AM SOC NEPHROL, V11, P1244, DOI 10.1681/ASN.V1171244; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Viedt C, 2000, ARTERIOSCL THROM VAS, V20, P940, DOI 10.1161/01.ATV.20.4.940; Vos IHC, 2000, FASEB J, V14, P815, DOI 10.1096/fasebj.14.5.815; Weir MR, 1999, AM J HYPERTENS, V12, p205S; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; WIENTJES MG, 1988, J PHARMACOL EXP THER, V245, P809; Wu KK, 2000, CIRCULATION, V102, P2022, DOI 10.1161/01.CIR.102.17.2022; Xu XM, 1999, P NATL ACAD SCI USA, V96, P5292, DOI 10.1073/pnas.96.9.5292; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	48	79	83	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1822	+		10.1096/fj.00-0843fje	http://dx.doi.org/10.1096/fj.00-0843fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481242				2022-12-28	WOS:000169261200014
J	Zhu, L; Zilbering, A; Wu, XD; Mahadev, K; Joseph, JI; Jabbour, S; Deeb, W; Goldstein, BJ				Zhu, L; Zilbering, A; Wu, XD; Mahadev, K; Joseph, JI; Jabbour, S; Deeb, W; Goldstein, BJ			Use of an anaerobic environment to preserve the endogenous activity of protein-tyrosine phosphatases isolated from intact cells	FASEB JOURNAL			English	Article						signal transduction; redox; cysteine; thiol; protein-tyrosine phosphatase 1B	EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; REDOX REGULATION; REVERSIBLE INACTIVATION; INSULIN SENSITIVITY; RECEPTOR; 1B; CATALYSIS; ROLES; MECHANISM	Protein-tyrosine phosphatases (PTPases) have a common cysteine residue whose reduced state is integral to their phosphocysteine-mediated reaction mechanism. The catalytic cysteine thiol can be oxidized or conjugated during cellular redox reactions, which provides an important means of PTPase regulation in vivo. Because exposure to air can artifactually oxidize this reactive thiol, PTPase assays have typically used potent reducing agents such as dithiothreitol to reactivate the enzymes present. However, this approach does not allow for the measurement of endogenous PTPase activity as directly isolated from the in vivo cellular environment. Here we show that sample processing and assay in an anaerobic chamber by using deoxygenated buffers can preserve the overall activity of PTPases in subcellular fractions of 3T3-L1 adipocytes, HepG2 hepatoma cells, and human adipose tissue, as well as with PTP1B, specifically isolated by immunoprecipitation. Cell lysis into air reduced the PTPase activity to as low as 20% of the level observed with sample handling in the anaerobic environment, which was variably restored towards the activity in the anaerobic samples by treatment with dithiothreitol. The approach reported here provides a new framework for characterizing the activity of PTPases as isolated from the intracellular milieu, which more closely reflects the endogenous reactivity and potential impact of these PTPases on signal transduction pathways involving reversible protein-tyrosine phosphorylation.	Thomas Jefferson Univ, Jefferson Med Coll, Div Endocrinol & Metab Dis, Dept Med,Dorrance H Hamilton Res Labs, Philadelphia, PA 19107 USA	Jefferson University	Goldstein, BJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Div Endocrinol & Metab Dis, Dept Med,Dorrance H Hamilton Res Labs, Room 349 Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	Barry.Goldstein@mail.tju.edu						AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; CZECH MP, 1974, J BIOL CHEM, V249, P1001; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; GOLDSTEIN BJ, 2000, DIABETES MELLITUS FU, P206; GOLDSTEIN BJ, 1998, PROTEIN PROFILE; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; Herrlich P, 2000, BIOCHEM PHARMACOL, V59, P35, DOI 10.1016/S0006-2952(99)00298-1; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KOLACZYNSKI JW, 1994, INT J OBESITY, V18, P161; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; PIKE LJ, 1984, J BIOL CHEM, V259, P9913; POT DA, 1991, J BIOL CHEM, V266, P19688; Rudich A, 1999, DIABETOLOGIA, V42, P949, DOI 10.1007/s001250051253; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161	34	14	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1637	+		10.1096/fj.00-0795fje	http://dx.doi.org/10.1096/fj.00-0795fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427511				2022-12-28	WOS:000173707700012
J	Nickenig, G; Michaelsen, F; Muller, C; Vogel, T; Strehlow, K; Bohm, M				Nickenig, G; Michaelsen, F; Muller, C; Vogel, T; Strehlow, K; Bohm, M			Post-transcriptional regulation of the AT1 receptor mRNA: identification and functional characterization of the mRNA binding motif	FASEB JOURNAL			English	Article						angiotensin II; vascular smooth muscle cells; mRNA binding protein; mRNA stability; RNA turnover	NITRIC-OXIDE SYNTHASE; NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; AGONIST-INDUCED DESTABILIZATION; ANGIOTENSIN-II; UP-REGULATION; GENE-EXPRESSION; AT(1) RECEPTOR; UNTRANSLATED REGION; IN-VITRO; PROTEIN	The expression of the angiotensin AT1 receptor is regulated predominately via post-transcriptional mechanisms. Angiotensin II reduces the AT1 receptor mRNA half-life from approximately 6 to 2 h, as assessed by experiments under transcriptional blockade and by in vitro mRNA decay assays in vascular smooth muscle cells (VSMC). UV light-treated mRNA-protein cross-link assays revealed that the AT1 receptor mRNA interacts with at least six polysomal proteins at its T-end. Multiple mutational studies demonstrated that several binding proteins associated with the AT1 receptor mRNA at bases 2175-2195. Stimulation of VSMC with angiotensin 11 significantly enhanced the binding of 50 and 60 kDa proteins to the 3'-untranslated region of the AT1 receptor mRNA. Transfection decoy assays with AT1 receptor mRNA transcript bases 1864-2213, 2175-2213, and 2175-2195 led to a significantly increased basal expression of AT1 receptor mRNA and inhibited angiotensin II-induced AT1 receptor mRNA down-regulation. In vitro decay assays revealed that competition of binding of polysomal proteins to bases 2175-2195 stabilizes the AT1 receptor mRNA. Polysomal proteins thus bind to the 3'-untranslated region of the AT1 receptor mRNA at the nucleotide sequence 2175-2195. This protein-mRNA interaction is decisively involved in the destabilization of the AT 1 receptor mRNA by angiotensin II.	Univ Saarland, Klin & Poliklin Innere Med 3, D-66421 Homburg, Germany	Saarland University	Nickenig, G (corresponding author), Univ Saarland, Klin & Poliklin Innere Med 3, D-66421 Homburg, Germany.	nickenig@med-in.uni-sb.de	Böhm, Michael/C-3638-2011					BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; GRIENDLING KK, 1993, CIRCULATION, V87, P1816, DOI 10.1161/01.CIR.87.6.1816; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LASSEGUE B, 1995, MOL PHARMACOL, V48, P601; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Linscheid P, 1998, BIOCHEM BIOPH RES CO, V243, P137, DOI 10.1006/bbrc.1998.8072; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Nickenig G, 1997, CIRCULATION, V95, P473; Nickenig G, 1998, CIRCULATION, V98, P2453, DOI 10.1161/01.CIR.98.22.2453; Nickenig G, 1997, AM J PHYSIOL-HEART C, V272, pH2701, DOI 10.1152/ajpheart.1997.272.6.H2701; NICKENIG G, 1994, MOL PHARMACOL, V46, P653; Nickenig G, 1996, MOL PHARMACOL, V50, P743; Nickenig G, 1999, CIRCULATION, V100, P2131, DOI 10.1161/01.CIR.100.21.2131; Nickenig G, 1998, CIRCULATION, V97, P2197, DOI 10.1161/01.CIR.97.22.2197; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PORT JD, 1992, J BIOL CHEM, V267, P24103; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; ROSS J, 1987, J BIOL CHEM, V262, P9374; ROSS J, 1988, MOL BIOL MED, V5, P1; ROSS R, 1970, J CELL BIOL, V47, pA175; SCHIFFRIN EL, 1984, AM J PHYSIOL, V246, pH608, DOI 10.1152/ajpheart.1984.246.4.H608; Searles CD, 1999, CIRC RES, V85, P588, DOI 10.1161/01.RES.85.7.588; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STEITZ JA, 1982, COLD SPRING HARB SYM, V47, P893, DOI 10.1101/SQB.1983.047.01.103; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397	46	17	18	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1490	+		10.1096/fj.00-0842fje	http://dx.doi.org/10.1096/fj.00-0842fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387267				2022-12-28	WOS:000173705800012
J	Rahmouni, S; Aandahl, EM; Trebak, M; Boniver, J; Tasken, K; Moutschen, M				Rahmouni, S; Aandahl, EM; Trebak, M; Boniver, J; Tasken, K; Moutschen, M			Increased cAMP levels and protein kinase (PKA) type I activation in CD4(+) T cells and B cells contribute to the retrovirus-induced immunodeficiency of mice (MAIDS). A useful in vivo model for drug testing in PKA type I-induced immunodeficiency	FASEB JOURNAL			English	Article						immunodeficiency diseases; cellular proliferation; signal transduction; second messengers; protein kinases/phosphatases	BLOOD MONONUCLEAR-CELLS; MURINE AIDS; LYMPHOCYTE SUBSET; LACKING THY-1; MESSENGER-RNA; HUMAN CD7; RI-ALPHA; RECEPTOR; EXPRESSION; ANTIGEN	Murine AIDS (MAIDS) is characterized by a lymphoproliferative disease and a profound anergy, which involves mostly CD4(+) T cells. To better define the mechanisms responsible for anergy, we measured cAMP concentrations in the different lymphocyte subsets of the infected mice. CD4(+) T cells and B cells displayed a dramatic 10- to 30-fold increase of cAMP. cAMP was also significantly increased in CD8(+) T cells, although to a far lesser extent. The unusual CD4(+) CD90(-) T cells, typical of MAIDS, were characterized by a much higher cAMP level than their CD90(+) counterparts. T cells of the infected mice were much more sensitive to inhibition by the cAMP analogue 8-CPT-cAMP, which confirmed increased in vivo exposure to cAMP. In accordance with the increased cAMP levels, PKA type I was constitutively activated and its C subunit was translocated to the nucleus. Finally, the profound T-cell anergy associated with MAIDS could be reversed by treating T cells with a PKA type I-selective antagonist ex vivo. MAIDS could constitute a suitable model for the study of new pharmacological agents aimed at reversing the immunosuppressive effects of cAMP previously shown to be involved in several pathological states, including HIV infection and common variable immunodeficiency.	Univ Liege, Dept Pathol, Liege, Belgium; Univ Oslo, Inst Med Biochem, Oslo, Norway	University of Liege; University of Oslo	Moutschen, M (corresponding author), CHU Liege, Dept Pathol 1, B-35, B-4000 Liege, Belgium.	mmoutschen@chu.ulg.ac.be	Trebak, Mohamed/E-7405-2014	Aandahl, Einar Martin/0000-0002-0115-8382; Tasken, Kjetil/0000-0003-2841-4697				Aandahl EM, 1998, FASEB J, V12, P855, DOI 10.1096/fasebj.12.10.855; ANDERSSON KB, 1994, FEBS LETT, V337, P71, DOI 10.1016/0014-5793(94)80632-2; Andrews C, 1997, J IMMUNOL, V159, P2132; Arakawa T, 1996, J BIOL CHEM, V271, P29569, DOI 10.1074/jbc.271.47.29569; Aukrust P, 1999, J IMMUNOL, V162, P1178; Autran B, 1999, IMMUNOL LETT, V66, P207, DOI 10.1016/S0165-2478(98)00159-X; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAYEUX SJ, 1993, BONE MARROW TRANSPL, V11, P483; CERNY A, 1990, EUR J IMMUNOL, V20, P1577, DOI 10.1002/eji.1830200725; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; COBB CE, 1988, METHOD ENZYMOL, V159, P202; De Leval L, 1998, J VIROL, V72, P5285, DOI 10.1128/JVI.72.6.5285-5290.1998; De Leval L, 1999, IMMUNOLOGY, V98, P630, DOI 10.1046/j.1365-2567.1999.00900.x; Dupraz P, 1997, J VIROL, V71, P2615, DOI 10.1128/JVI.71.4.2615-2620.1997; Dybul M, 2000, J IMMUNOL, V165, P1685, DOI 10.4049/jimmunol.165.3.1685; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; GIESE NA, 1994, J VIROL, V68, P5819, DOI 10.1128/JVI.68.9.5819-5824.1994; Green KA, 1996, J VIROL, V70, P2569, DOI 10.1128/JVI.70.4.2569-2575.1996; HARRIMAN GR, 1990, J IMMUNOL, V145, P2406; HOLMES KL, 1990, EUR J IMMUNOL, V20, P2783, DOI 10.1002/eji.1830201237; INGRAHAM HA, 1986, J IMMUNOL, V136, P1482; JOLICOEUR P, 1991, FASEB J, V5, P2398, DOI 10.1096/fasebj.5.10.2065888; Kalams SA, 1999, J VIROL, V73, P6715, DOI 10.1128/JVI.73.8.6715-6720.1999; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; KNUDSEN JH, 1995, SCAND J CLIN LAB INV, V55, P9, DOI 10.3109/00365519509075373; Kolenko V, 1999, BLOOD, V93, P2308, DOI 10.1182/blood.V93.7.2308.407k16_2308_2318; KUKEL S, 1994, CLIN EXP IMMUNOL, V98, P163; LANDMANN R, 1992, EUR J CLIN INVEST, V22, P30; Leblond V, 1997, TRANSPLANTATION, V64, P1453, DOI 10.1097/00007890-199711270-00014; Lee DM, 1996, IMMUNOGENETICS, V44, P108; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEGAC E, 1992, BLOOD, V79, P1746; LEGRAND E, 1981, LEUKEMIA RES, V5, P223, DOI 10.1016/0145-2126(81)90107-7; Lombardi MS, 1999, FASEB J, V13, P715, DOI 10.1096/fasebj.13.6.715; Masuda A, 1996, CLIN IMMUNOL IMMUNOP, V81, P253, DOI 10.1006/clin.1996.0186; Meroni L, 1999, AIDS, V13, P621, DOI 10.1097/00002030-199904010-00012; MORSE HC, 1989, J IMMUNOL, V143, P844; MOUTSCHEN MP, 1994, SCAND J IMMUNOL, V39, P216, DOI 10.1111/j.1365-3083.1994.tb03363.x; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; Pontesilli O, 1999, J INFECT DIS, V180, P76, DOI 10.1086/314837; RICHARDSON JM, 1990, J BIOL CHEM, V265, P13635; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHANBERG LE, 1991, P NATL ACAD SCI USA, V88, P603, DOI 10.1073/pnas.88.2.603; SELVEY LA, 1995, J IMMUNOL, V154, P171; SIMARD C, 1994, J VIROL, V68, P1903, DOI 10.1128/JVI.68.3.1903-1912.1994; Simard C, 1997, J VIROL, V71, P3013, DOI 10.1128/JVI.71.4.3013-3022.1997; Skalhegg Bjorn S., 1997, Frontiers in Bioscience (online), V2, pD331; Skalhegg BS, 1998, J CELL PHYSIOL, V177, P85, DOI 10.1002/(SICI)1097-4652(199810)177:1<85::AID-JCP9>3.3.CO;2-#; Smith J P, 1998, Dev Immunol, V6, P285, DOI 10.1155/1998/38923; STEINBERG RA, 1981, J BIOL CHEM, V256, P1356; SUNDERPLASSMANN R, 1991, CELL IMMUNOL, V138, P289, DOI 10.1016/0008-8749(91)90154-4; SVETIC A, 1991, J IMMUNOL, V147, P2391; TASKEN K, 1993, J BIOL CHEM, V268, P23483; TASKEN K, 1993, J BIOL CHEM, V268, P21276; Valentine FT, 1998, AIDS RES HUM RETROV, V14, pS161; Wajeman-Chao SA, 1998, J IMMUNOL, V161, P4825; Yu P, 1999, EUR J IMMUNOL, V29, P615, DOI 10.1002/(SICI)1521-4141(199902)29:02<615::AID-IMMU615>3.0.CO;2-I; Zheng B, 1996, J EXP MED, V184, P1083, DOI 10.1084/jem.184.3.1083	65	19	21	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1466	+		10.1096/fj.00-0813fje	http://dx.doi.org/10.1096/fj.00-0813fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387259				2022-12-28	WOS:000173705800008
J	Pralong, FP; Gonzales, C; Voirol, MJ; Palmiter, RD; Brunner, HR; Gaillard, RC; Seydoux, J; Pedrazzini, T				Pralong, FP; Gonzales, C; Voirol, MJ; Palmiter, RD; Brunner, HR; Gaillard, RC; Seydoux, J; Pedrazzini, T			The neuropeptide YY1 receptor regulates leptin-mediated control of energy homeostasis and reproductive functions	FASEB JOURNAL			English	Article						feeding; puberty; reproduction; hypothalamus; metabolism	LUTEINIZING-HORMONE SECRETION; OBESE GENE-PRODUCT; NORMAL FEMALE MICE; FOOD-INTAKE; OB/OB MICE; PARAVENTRICULAR NUCLEUS; SEXUAL-MATURATION; Y-RECEPTOR; MALE-RATS; SUBTYPE	The orexigenic neurotransmitter neuropeptide Y (NPY) plays a central role in the hypothalamic control of food intake and energy balance. NPY also exerts an inhibition of the gonadotrope axis that could be important in the response to poor metabolic conditions. In contrast, leptin provides an anorexigenic signal to centrally control the body needs in energy. Moreover, leptin contributes to preserve adequate reproductive functions by stimulating the activity of the gonadotrope axis. It is of interest that hypothalamic NPY represents a primary target of leptin actions. To evaluate the importance of the NPY Y1 and Y5 receptors in the downstream pathways modulated by leptin and controlling energy metabolism as well as the activity of the gonadotrope axis, we studied the effects of leptin administration on food intake and reproductive functions in mice deficient for the expression of either the Y1 or the Y5 receptor. Furthermore, the role of the Y1 receptor in leptin resistance was determined in leptin-deficient ob/ob mice bearing a null mutation in the NPY Y1 locus. Results point to a crucial role for the NPY Y1 receptor in mediating the NPY pathways situated downstream of leptin actions and controlling food intake, the onset of puberty, and the maintenance of reproductive functions.	Univ Lausanne, Sch Med, Div Endocrinol Diabetol & Metab, CH-1011 Lausanne, Switzerland; Univ Lausanne, Sch Med, Div Hypertens, CH-1011 Lausanne, Switzerland; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Fac Med, Dept Physiol, CH-1211 Geneva 4, Switzerland	University of Lausanne; University of Lausanne; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Geneva	Pralong, FP (corresponding author), Univ Lausanne, Sch Med, Div Endocrinol Diabetol & Metab, BH 19-707, CH-1011 Lausanne, Switzerland.	Francois.Pralong@chuv.hospvd.ch						Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; ALLEN YS, 1983, SCIENCE, V221, P877, DOI 10.1126/science.6136091; Aubert ML, 1998, MOL CELL ENDOCRINOL, V140, P107, DOI 10.1016/S0303-7207(98)00058-6; Baskin DG, 1999, DIABETES, V48, P828, DOI 10.2337/diabetes.48.4.828; Bergonzelli GE, 2001, DIABETES, V50, P2666, DOI 10.2337/diabetes.50.12.2666; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; CATZEFLIS C, 1993, ENDOCRINOLOGY, V132, P224, DOI 10.1210/en.132.1.224; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Cheung CC, 1997, ENDOCRINOLOGY, V138, P855, DOI 10.1210/en.138.2.855; Cheung CC, 2001, NEUROENDOCRINOLOGY, V74, P12, DOI 10.1159/000054666; Cheung CC, 2000, FRONT HORM RES, V26, P87; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; Cowley MA, 1999, NEURON, V24, P155, DOI 10.1016/S0896-6273(00)80829-6; Edwards R, 1999, NEW SCI, V160, P7; El Majdoubi M, 2000, P NATL ACAD SCI USA, V97, P6179; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; GARTHWAITE TL, 1980, ENDOCRINOLOGY, V107, P671, DOI 10.1210/endo-107-3-671; Gehlert DR, 1998, P SOC EXP BIOL MED, V218, P7; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; Gruaz NM, 1998, J NEUROENDOCRINOL, V10, P627, DOI 10.1046/j.1365-2826.1998.00247.x; HAMILTON GD, 1986, AM J PHYSIOL, V250, pR370, DOI 10.1152/ajpregu.1986.250.3.R370; Jain MR, 1999, ENDOCRINOLOGY, V140, P5171, DOI 10.1210/en.140.11.5171; KALRA SP, 1992, ENDOCRINOLOGY, V130, P3323, DOI 10.1210/en.130.6.3323; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; Kanatani A, 1996, ENDOCRINOLOGY, V137, P3177, DOI 10.1210/en.137.8.3177; Leupen SM, 1997, ENDOCRINOLOGY, V138, P2735, DOI 10.1210/en.138.7.2735; Li C, 1999, ENDOCRINOLOGY, V140, P5382, DOI 10.1210/en.140.11.5382; Marsh DJ, 1998, NAT MED, V4, P718, DOI 10.1038/nm0698-718; Pedrazzini T, 1998, NAT MED, V4, P722, DOI 10.1038/nm0698-722; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PIERROZ DD, 1995, NEUROENDOCRINOLOGY, V61, P293, DOI 10.1159/000126851; Pierroz DD, 1996, ENDOCRINOLOGY, V137, P3, DOI 10.1210/en.137.1.3; Pralong FP, 2000, REGUL PEPTIDES, V95, P47, DOI 10.1016/S0167-0115(00)00130-0; Raposinho PD, 1999, ENDOCRINOLOGY, V140, P4046, DOI 10.1210/en.140.9.4046; Schaffhauser AO, 1997, DIABETES, V46, P1792, DOI 10.2337/diabetes.46.11.1792; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	41	74	76	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					712	+		10.1096/fj.01-0754fje	http://dx.doi.org/10.1096/fj.01-0754fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11978737				2022-12-28	WOS:000174755900018
J	Gill, C; Mestril, R; Samali, A				Gill, C; Mestril, R; Samali, A			Losing heart: the role of apoptosis in heart disease - a novel therapeutic target?	FASEB JOURNAL			English	Review						cell death; cardiomyopathy; heat shock proteins; ischemia	TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-I; HEAT-SHOCK-PROTEIN-70 INHIBITS APOPTOSIS; MYOCARDIAL INFARCT SIZE; C-DEPENDENT ACTIVATION; PROGRAMMED CELL-DEATH; SHOCK PROTEINS; CYTOCHROME-C; CARDIOMYOCYTE APOPTOSIS; CARDIAC MYOCYTES	Cardiovascular disease is a leading cause of death worldwide. In recent years it has emerged that loss of myocardial cells may be a major pathogenic factor. Cell death can occur in a destructive, uncontrolled manner via necrosis or by a highly regulated programmed cell suicide mechanism termed apoptosis. As cell death in conditions such as heart failure and myocardial infarction does not always follow a typically apoptotic pathway, it remains to be established whether it occurs by apoptosis, necrosis, or a novel uncharacterized mechanism combining aspects of both types of cell death. Apoptotic pathways have been well studied in nonmyocytes and it is thought that similar pathways exist in cardiomyocytes. These pathways include death initiated by ligation of membrane-bound death receptors or death initiated by release of cytochrome c from mitochondria. Increasing evidence supports the existence of these pathways and their regulators in the heart. These regulators include inhibitors of caspases, which are the key enzymes of apoptosis, the Bcl-2 family of proteins, growth factors, stress proteins, calcium, and oxidants. It is hoped that a better understanding of the pathways of apoptosis and their regulation may yield novel therapeutic targets for cardiovascular disease.	Natl Univ Ireland Galway, Dept Biochem, Cell Stress & Apoptosis Res Grp, Galway, Ireland; Natl Univ Ireland Galway, Natl Ctr Biomed Engn Sci, Galway, Ireland; Loyola Univ, Med Ctr, Cardiovasc Inst, Maywood, IL 60153 USA	Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Loyola University Chicago	Samali, A (corresponding author), Natl Univ Ireland Galway, Dept Biochem, Cell Stress & Apoptosis Res Grp, Univ Rd, Galway, Ireland.	afshin.samali@nuigalway.ic	Samali, Afshin/A-9571-2008	Samali, Afshin/0000-0002-8610-8375; Mestril, Ruben/0000-0003-3631-2236				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akyurek O, 2001, INT J CARDIOL, V80, P29, DOI 10.1016/S0167-5273(01)00451-X; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Brar BK, 1999, J MOL CELL CARDIOL, V31, P135, DOI 10.1006/jmcc.1998.0857; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; Burgess DH, 1999, CELL DEATH DIFFER, V6, P256, DOI 10.1038/sj.cdd.4400489; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Coffin RS, 1996, GENE THER, V3, P560; Concannon CG, 2001, GENE EXPRESSION, V9, P195, DOI 10.3727/000000001783992605; Conde AG, 1997, J MOL CELL CARDIOL, V29, P1927, DOI 10.1006/jmcc.1997.0431; Condorelli G, 1999, CIRCULATION, V99, P3071, DOI 10.1161/01.CIR.99.23.3071; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; Dhalla NS, 2000, CARDIOVASC RES, V47, P446, DOI 10.1016/S0008-6363(00)00078-X; Donahue JK, 1997, P NATL ACAD SCI USA, V94, P4664, DOI 10.1073/pnas.94.9.4664; Ekhterae D, 1999, CIRC RES, V85, pE70; Freude B, 2000, J MOL CELL CARDIOL, V32, P197, DOI 10.1006/jmcc.1999.1066; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Gottlieb RA, 1996, J CLIN INVEST, V97, P2391, DOI 10.1172/JCI118683; Gray CC, 1999, INT J BIOCHEM CELL B, V31, P559, DOI 10.1016/S1357-2725(99)00004-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guerra S, 1999, CIRC RES, V85, P856, DOI 10.1161/01.RES.85.9.856; Hajnoczky G, 2000, CELL CALCIUM, V28, P349, DOI 10.1054/ceca.2000.0169; Halestrap AP, 1999, BIOCHEM SOC SYMP, V66, P181, DOI 10.1042/bss0660181; Imanishi T, 2000, CARDIOVASC RES, V48, P101, DOI 10.1016/S0008-6363(00)00154-1; Iwamoto H, 1999, J CARDIOVASC PHARM, V33, P580, DOI 10.1097/00005344-199904000-00010; James TN, 1999, AM J MED, V107, P606, DOI 10.1016/S0002-9343(99)00308-3; James TN, 1998, CORONARY ARTERY DIS, V9, P291, DOI 10.1097/00019501-199809050-00007; Jeremias I, 2000, CIRCULATION, V102, P915; Kajstura J, 1996, LAB INVEST, V74, P86; Kakkar R, 2001, CELL CALCIUM, V29, P59, DOI 10.1054/ceca.2000.0157; Kanoh M, 1999, CIRCULATION, V99, P2757, DOI 10.1161/01.CIR.99.21.2757; Kavantzas NG, 2000, PATHOLOGY, V32, P176; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim YM, 1999, CIRC RES, V84, P253, DOI 10.1161/01.RES.84.3.253; Kirshenbaum LA, 1997, CIRCULATION, V96, P1580, DOI 10.1161/01.CIR.96.5.1580; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Knaapen MWM, 2001, CARDIOVASC RES, V51, P304, DOI 10.1016/S0008-6363(01)00290-5; Knowlton AA, 1998, J MOL CELL CARDIOL, V30, P811, DOI 10.1006/jmcc.1998.0646; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; Kurrelmeyer KM, 2000, P NATL ACAD SCI USA, V97, P5456, DOI 10.1073/pnas.070036297; Latif N, 2000, J AM COLL CARDIOL, V35, P1769, DOI 10.1016/S0735-1097(00)00647-1; Lee WL, 1999, ENDOCRINOLOGY, V140, P4831, DOI 10.1210/en.140.10.4831; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li Q, 1997, J CLIN INVEST, V100, P1991, DOI 10.1172/JCI119730; Lin KM, 2001, CIRCULATION, V103, P1787, DOI 10.1161/01.CIR.103.13.1787; Lotem J, 1999, P NATL ACAD SCI USA, V96, P12016, DOI 10.1073/pnas.96.21.12016; Mallat Z, 1996, NEW ENGL J MED, V335, P1190, DOI 10.1056/NEJM199610173351604; Matsui T, 2001, CIRCULATION, V104, P330; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Maulik N, 1999, CIRCULATION, V100, P369; Maulik N, 1999, MOL CELL BIOCHEM, V196, P13, DOI 10.1023/A:1006905910140; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; Mocanu MM, 2000, BRIT J PHARMACOL, V130, P197, DOI 10.1038/sj.bjp.0703336; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakamura T, 2000, CIRCULATION, V102, P572; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; Okamura T, 2000, CARDIOVASC RES, V45, P642, DOI 10.1016/S0008-6363(99)00271-0; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Oskarsson HJ, 2000, CARDIOVASC RES, V45, P679, DOI 10.1016/S0008-6363(99)00400-9; Pandey P, 2000, ONCOGENE, V19, P1975, DOI 10.1038/sj.onc.1203531; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Rabkin SW, 2000, EUR J PHARMACOL, V388, P209, DOI 10.1016/S0014-2999(99)00880-8; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Rayment NB, 1999, J PATHOL, V188, P213, DOI 10.1002/(SICI)1096-9896(199906)188:2<213::AID-PATH348>3.0.CO;2-5; Sack MN, 2000, CARDIOVASC RES, V45, P688, DOI 10.1016/S0008-6363(99)00228-X; Saito S, 2000, J BIOL CHEM, V275, P34528, DOI 10.1074/jbc.M002844200; Samali A, 1998, CELL STRESS CHAPERON, V3, P228, DOI 10.1379/1466-1268(1998)003<0228:HSPROS>2.3.CO;2; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; Samali A, 2001, CELL STRESS CHAPERON, V6, P49, DOI 10.1379/1466-1268(2001)006<0049:HPMOTC>2.0.CO;2; Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3; Saraste A, 1999, HERZ, V24, P189, DOI 10.1007/BF03044961; Saraste A, 1997, CIRCULATION, V95, P320; SEARLE J, 1982, PATHOL ANNU, V17, P229; SIVESKIILISKOVIC N, 1995, CIRCULATION, V91, P10, DOI 10.1161/01.CIR.91.1.10; Sliwa K, 1998, LANCET, V351, P1091, DOI 10.1016/S0140-6736(97)09338-0; Sorimachi Y, 1997, J BIOCHEM-TOKYO, V122, P743; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Stephanou A, 1998, J MOL CELL CARDIOL, V30, P849, DOI 10.1006/jmcc.1998.0651; Su CY, 1998, J MOL CELL CARDIOL, V30, P587, DOI 10.1006/jmcc.1997.0622; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TorreAmione G, 1996, CIRCULATION, V93, P704, DOI 10.1161/01.CIR.93.4.704; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang L, 1998, CIRC RES, V83, P516, DOI 10.1161/01.RES.83.5.516; Wollert KC, 2000, CIRCULATION, V101, P1172, DOI 10.1161/01.CIR.101.10.1172; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Yamaguchi S, 1999, AM J CARDIOL, V83, P1500, DOI 10.1016/S0002-9149(99)00133-2; Yaoita H, 2000, CARDIOVASC RES, V45, P630, DOI 10.1016/S0008-6363(99)00349-1; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yue TL, 1998, CIRC RES, V82, P166; Zhao ZQ, 2000, CARDIOVASC RES, V45, P651, DOI 10.1016/S0008-6363(99)00354-5	105	239	258	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					135	146		10.1096/fj.01-0629com	http://dx.doi.org/10.1096/fj.01-0629com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11818361				2022-12-28	WOS:000174203700018
J	Perlemuter, G; Sabile, A; Letteron, P; Vona, G; Topilco, A; Chretien, Y; Koike, K; Pessayre, D; Chapman, J; Barba, G; Brechot, C				Perlemuter, G; Sabile, A; Letteron, P; Vona, G; Topilco, A; Chretien, Y; Koike, K; Pessayre, D; Chapman, J; Barba, G; Brechot, C			Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis	FASEB JOURNAL			English	Article						HCV; VLDL; MTP	APOLIPOPROTEIN-A-II; NONALCOHOLIC STEATOHEPATITIS; LIPID-PEROXIDATION; TRANSGENIC MICE; LIVER; EXPRESSION; ABETALIPOPROTEINEMIA; HISTOPATHOLOGY; KNOCKOUT; FEATURES	Liver steatosis, which involves accumulation of intracytoplasmic lipid droplets, is characteristic of hepatitis C virus (HCV) infection. By use of an in vivo transgenic murine model, we demonstrate that hepatic overexpression of HCV core protein interferes with the hepatic assembly and secretion of triglyceride-rich very low density lipoproteins (VLDL). Core expression led to reduction in microsomal triglyceride transfer protein (MTP) activity and in the particle size of nascent hepatic VLDL without affecting accumulation of MTP and protein disulfide isomerase. Hepatic human apolipoprotein AII (apo AII) expression in double-core/apo AII transgenic mice diminished intrahepatic core protein accumulation and abrogated its effects on VLDL production. Apo AII and HCV core colocalized in human HCV-infected liver biopsies, thus testifying to the relevance of this interaction in productive HCV infection. Our results lead us to propose a new pathophysiological animal model for induction of viral-related steatosis whereby the core protein of HCV targets microsomal triglyceride transfer protein activity and modifies hepatic VLDL assembly and secretion.	Fac Med Necker Enfants Malad, INSERM, U370, F-75730 Paris 15, France; Hop Beaujon, INSERM, U481, F-92118 Clichy, France; Inst Pasteur, Electron Microscopy Lab, F-75015 Paris, France; Univ Tokyo, Grad Sch Med, Dept Infect Dis, Tokyo, Japan; Hop La Pitie Salpetriere, INSERM, U321, F-75013 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Tokyo; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Brechot, C (corresponding author), Fac Med Necker Enfants Malad, INSERM, U370, 156 Rue Vaugirard, F-75730 Paris 15, France.	brechot@necker.fr		Barba Spaeth, Giovanna/0000-0003-2069-9501				AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Aguie GA, 1995, ATHEROSCLEROSIS, V118, P183, DOI 10.1016/0021-9150(95)05605-X; Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; ANGERMULLER S, 1982, HISTOCHEM J, V14, P823, DOI 10.1007/BF01033631; Aoyagi K, 1999, J CLIN MICROBIOL, V37, P1802, DOI 10.1128/JCM.37.6.1802-1808.1999; ARBEENY CM, 1992, J LIPID RES, V33, P843; BACH N, 1992, SEMIN LIVER DIS, V12, P205, DOI 10.1055/s-2007-1007392; BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; CAMUS MC, 1983, J LIPID RES, V24, P1210; CHAPMAN MJ, 1981, J LIPID RES, V22, P339; Colombo M, 1999, SEMIN LIVER DIS, V19, P263, DOI 10.1055/s-2007-1007116; Czaja AJ, 1998, J HEPATOL, V29, P198, DOI 10.1016/S0168-8278(98)80004-4; Day CP, 1998, HEPATOLOGY, V27, P1463, DOI 10.1002/hep.510270601; Escola-Gil JC, 2000, J LIPID RES, V41, P1328; Fong DG, 2000, HEPATOLOGY, V32, P3, DOI 10.1053/jhep.2000.8978; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Girotti AW, 1998, J LIPID RES, V39, P1529; GOODMAN ZD, 1995, SEMIN LIVER DIS, V15, P70, DOI 10.1055/s-2007-1007264; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; GRIMBERT S, 1993, HEPATOLOGY, V17, P628, DOI 10.1002/hep.1840170417; Hasty AH, 1999, J LIPID RES, V40, P1529; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Jin FY, 1999, ARTERIOSCL THROM VAS, V19, P1051, DOI 10.1161/01.ATV.19.4.1051; KANTO T, 1994, HEPATOLOGY, V19, P296; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; Large MK, 1999, J IMMUNOL, V162, P931; Lerat H, 1998, HEPATOLOGY, V28, p498A; Letteron P, 1996, J HEPATOL, V24, P200, DOI 10.1016/S0168-8278(96)80030-4; Luyckx FH, 2000, DIABETES METAB, V26, P98; MAEDA N, 1994, J BIOL CHEM, V269, P23610; Major ME, 1997, HEPATOLOGY, V25, P1527, DOI 10.1002/hep.510250637; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Navasa M, 1998, J LIPID RES, V39, P1220; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Paradis V, 1997, J CLIN PATHOL, V50, P401, DOI 10.1136/jcp.50.5.401; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Rubbia-Brandt L, 2000, J HEPATOL, V33, P106, DOI 10.1016/S0168-8278(00)80166-X; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; SCHULTZ JR, 1992, J BIOL CHEM, V267, P21630; SHIMANO H, 1992, J CLIN INVEST, V90, P2084, DOI 10.1172/JCI116091; Shimotohno K, 1995, INTERVIROLOGY, V38, P162, DOI 10.1159/000150427; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4	50	456	472	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					185	194		10.1096/fj.01-0396com	http://dx.doi.org/10.1096/fj.01-0396com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11818366				2022-12-28	WOS:000174203700023
J	Inoki, I; Shiomi, T; Hashimoto, G; Enomoto, H; Nakamura, H; Makino, K; Ikeda, E; Takata, S; Kobayashi, K; Okada, Y				Inoki, I; Shiomi, T; Hashimoto, G; Enomoto, H; Nakamura, H; Makino, K; Ikeda, E; Takata, S; Kobayashi, K; Okada, Y			Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis	FASEB JOURNAL			English	Article						antiangiogenesis; cartilage; fibrosis	ENDOCHONDRAL BONE-FORMATION; PLATELET FACTOR-IV; RHEUMATOID-ARTHRITIS; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; TYROSINE KINASE; FACTOR-BETA; IN-VIVO; CELLS; IDENTIFICATION	Vascular endothelial growth factor (VEGF) is a strong angiogenic mitogen and plays important roles in angiogenesis under various pathophysiological conditions. The in vivo angiogenic activity of secreted VEGF may be regulated by extracellular inhibitors, because it is also produced in avascular tissues such as the cartilage. To seek the binding inhibitors against VEGF, we screened the chondrocyte cDNA library by a yeast two-hybrid system by using VEGF(165) as bait and identified connective tissue growth factor (CTGF) as a candidate. The complex formation of VEGF(165) with CTGF was first established by immunoprecipitation from the cells overexpressing both binding partners. A competitive affinity-binding assay also demonstrated that CTGF binds specifically to VEGF(165) with two classes of binding sites (Kd = 26 +/- 11 nM and 125 +/- 38 nM). Binding assay using deletion mutants of CTGF indicated that the thrombospondin type-1 repeat (TSP-1) domain of CTGF binds to the exon 7-coded region of VEGF(165) and that the COOH-terminal domain preserves the affinity to both VEGF(165) and VEGF(121). The interaction of VEGF(165) with CTGF inhibited the binding of VEGF(165) to the endothelial cells and the immobilized KDR/IgG Fc; that is, a recombinant protein for VEGF(165) receptor. By in vitro tube formation assay of endothelial cells, full-length CTGF and the deletion mutant possessing the TSP-1 domain inhibited VEGF(165)-induced angiogenesis significantly in the complex form. This antiangiogenic activity of CTGF was demonstrated further by in vivo angiogenesis assay by using Matrigel injection model in mice. These data demonstrate for the first time that VEGF(165) binds to CTGF through a protein-to-protein interaction and suggest that the angiogenic activity of VEGF(165) is regulated negatively by CTGF in the extracellular environment.	Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1600016, Japan; Kanazawa Univ, Sch Med, Dept Internal Med 1, Kanazawa, Ishikawa 9208640, Japan	Keio University; Kanazawa University	Okada, Y (corresponding author), Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1600016, Japan.	okada@sc.itc.keio.ac.jp	Shiomi, Takayuki/A-2228-2014; Okada, Yasunori/B-5550-2014; nakamura, hiroyuki/A-2953-2013	Shiomi, Takayuki/0000-0002-4250-1204; Okada, Yasunori/0000-0001-9208-4755; nakamura, hiroyuki/0000-0002-2524-3063				Abou-Shady M, 2000, LIVER, V20, P296, DOI 10.1034/j.1600-0676.2000.020004296.x; ANTHONY FW, 1994, PLACENTA, V15, P557, DOI 10.1016/S0143-4004(05)80424-2; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Ball DK, 1998, BIOL REPROD, V59, P828, DOI 10.1095/biolreprod59.4.828; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Carlevaro MF, 2000, J CELL SCI, V113, P59; Chen MM, 2000, J MOL CELL CARDIOL, V32, P1805, DOI 10.1006/jmcc.2000.1215; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 2000, ENDOCRINOLOGY, V141, P2254, DOI 10.1210/en.141.6.2254; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; Ikeda M, 2000, J PATHOL, V191, P426; Ishida S, 2000, INVEST OPHTH VIS SCI, V41, P1649; KANAYASU T, 1989, BIOCHEM BIOPH RES CO, V159, P572, DOI 10.1016/0006-291X(89)90032-6; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; KOCH AE, 1994, J IMMUNOL, V152, P4149; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; Oemar BS, 1997, CIRCULATION, V95, P831; Ohnishi H, 1998, J MOL CELL CARDIOL, V30, P2411, DOI 10.1006/jmcc.1998.0799; OKADA Y, 2001, KELLEYS TXB RHEUMATO, P55; Paradis V, 1999, HEPATOLOGY, V30, P968, DOI 10.1002/hep.510300425; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PASSANITI A, 1992, LAB INVEST, V67, P519; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; Shimo T, 1998, J BIOCHEM-TOKYO, V124, P130, DOI 10.1093/oxfordjournals.jbchem.a022071; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Suzuma K, 2000, J BIOL CHEM, V275, P40725, DOI 10.1074/jbc.M006509200; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; THRAILKILL KM, 1995, ENDOCRINOLOGY, V136, P3527, DOI 10.1210/en.136.8.3527; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947	51	304	320	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					219	+		10.1096/fj.01-0332fje	http://dx.doi.org/10.1096/fj.01-0332fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11744618	Green Submitted			2022-12-28	WOS:000172964800020
J	Boccaccio, C; Ando, M; Comoglio, PM				Boccaccio, C; Ando, M; Comoglio, PM			A differentiation switch for genetically modified hepatocytes	FASEB JOURNAL			English	Article						hepatocyte growth factor receptor; FKBP; dimerizer; CID; liver	RECEPTOR TYROSINE KINASE; GROWTH-FACTOR; SCATTER FACTOR; SIGNAL-TRANSDUCTION; MAP KINASE; ACTIVATION; DIMERIZATION; PURIFICATION; 3-KINASE; CELLS	The hepatocyte growth factor (HGF) receptor mediates a two-sided response-cell proliferation and differentiation. This process, defined as "branching morphogenesis," involves cell scatter and redistribution to form ramified hollow tubules within the extracellular matrix, and protection from apoptosis. We have fused the intracellular domain of the HGF receptor (HGFR) with three FK506-binding protein (FKBP) domains and a membrane-targeting signal. This molecule (FKBP-HGFR) dimerizes after administration of a bifunctional ligand specific for FKBP domains. We show that, in mouse hepatocyte progenitors, FKBP-HGFR dimerization elicits the differentiative side of the HGF response, including cell scatter, morphogenesis, and protection from apoptosis. Surprisingly, FKBP-HGFR does not induce cell proliferation. We could correlate the segregation of the differentiative response with a distinctive signaling kinetic of FKBP-HGFR: a) reduced and prolonged tyrosine kinase activation; and b) low early peak of MAP kinase activation (a log lower than the peak induced by the wild-type receptor), followed by a sustained activation over 6 h. These data show that the biological response triggered by the HGFR can be dissected on the basis of the quantitative signaling profile, and that FKBP-HGFR may be used to control selectively the differentiation of hepatocytes, without promoting cell expansion.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Candiolo Torino, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Boccaccio, C (corresponding author), IRCC, Str Prov 142, I-10060 Candiolo Torino, Italy.	cboccaccio@ircc.unito.it	Boccaccio, Carla/AHE-7875-2022	Boccaccio, Carla/0000-0003-2620-9083; Comoglio, Paolo/0000-0002-7056-5328				Amara JF, 1997, P NATL ACAD SCI USA, V94, P10618, DOI 10.1073/pnas.94.20.10618; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Belshaw PJ, 1996, P NATL ACAD SCI USA, V93, P4604, DOI 10.1073/pnas.93.10.4604; Block GD, 1996, J CELL BIOL, V132, P1133, DOI 10.1083/jcb.132.6.1133; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Fornoni A, 2001, AM J PATHOL, V158, P275, DOI 10.1016/S0002-9440(10)63966-1; Freiberg RA, 1996, J BIOL CHEM, V271, P31666, DOI 10.1074/jbc.271.49.31666; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; GOHDA E, 1986, EXP CELL RES, V166, P139, DOI 10.1016/0014-4827(86)90514-8; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Jin LQ, 1998, P NATL ACAD SCI USA, V95, P8093, DOI 10.1073/pnas.95.14.8093; Jin LQ, 2000, NAT GENET, V26, P64, DOI 10.1038/79194; Jin LQ, 1998, BLOOD, V91, P890, DOI 10.1182/blood.V91.3.890.890_890_897; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Spencer DM, 1996, CURR BIOL, V6, P839, DOI 10.1016/S0960-9822(02)00607-3; SPENCER DM, 1995, P NATL ACAD SCI USA, V92, P9805, DOI 10.1073/pnas.92.21.9805; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Strain AJ, 1999, HEPATOLOGY, V29, P288, DOI 10.1002/hep.510290131; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yang JX, 1998, CURR BIOL, V8, P11, DOI 10.1016/S0960-9822(98)70015-6; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZARNEGAR R, 1989, CANCER RES, V49, P3314	53	13	14	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					120	+		10.1096/fj.01-0537fje	http://dx.doi.org/10.1096/fj.01-0537fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11709498				2022-12-28	WOS:000172420500034
J	Horn, MP; Pachlopnik, JM; Vogel, M; Dahinden, M; Wurm, F; Stadler, BM; Miescher, SM				Horn, MP; Pachlopnik, JM; Vogel, M; Dahinden, M; Wurm, F; Stadler, BM; Miescher, SM			Conditional autoimmunity mediated by human natural anti-Fc epsilon RI alpha autoantibodies?	FASEB JOURNAL			English	Article						natural autoantibodies; phage display; IgE receptor	AFFINITY IGE RECEPTOR; PASSIVE SENSITIZATION; HISTAMINE-RELEASE; DOWN-REGULATION; HUMAN BASOPHILS; PHAGE DISPLAY; IN-VIVO; ANTIBODIES; EXPRESSION; SYSTEM	Natural antibodies provide an early defense mechanism against pathogens, show a frequent self-reactivity, and are present throughout life. Two questions concern the physiological control of self-reactivity and the pathogenetic link to autoimmune disease. Here we propose a concept of conditional autoimmunity involving natural antibodies against the alpha chain of the high-affinity receptor for IgE (Fc epsilon RI alpha). Like other natural antibodies, anti-Fc epsilon RI alpha antibodies are found in sera of healthy donors. We now report the first human recombinant anti-Fc epsilon RI alpha autoantibodies isolated by repertoire cloning from a human tonsillar IgM library. These high-affinity antibodies recognize Fc epsilon RI alpha on cells and trigger histamine release from freshly isolated blood basophils. However, the latter effect requires IgE removal from the Fc epsilon RI. The same conditional histamine release is seen when using sera from individual normal donors and affinity-purified anti-Fc epsilon RI alpha antibodies isolated from multidonor therapeutic IgG preparations. We propose that such anti-Fc epsilon RI alpha antibodies can become pathogenic and that this is dependent on the state of occupancy of the Fc epsilon RI alpha by its natural ligand IgE. We suggest that an imbalance between Fc epsilon RI alpha occupancy and natural anti-Fc epsilon RI alpha antibodies may be implicated in the pathogenesis of autoimmune urticaria.	Inselspital Bern, Inst Immunol & Allergol, CH-3010 Bern, Switzerland; Ecole Polytech Fed Lausanne, Ctr Biotechnol UNIL EPFL, Lab Cellular Biotechnol, CH-1015 Lausanne, Switzerland; ZLB Bioplasma AG, CH-3022 Bern, Switzerland	University of Bern; University Hospital of Bern; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Miescher, SM (corresponding author), Inselspital Bern, Inst Immunol & Allergol, Sahlihaus 1, CH-3010 Bern, Switzerland.	sylvia.miescher@insel.ch	Pachlopnik Schmid, Jana/N-8018-2018	Pachlopnik Schmid, Jana/0000-0002-6653-9047				BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARBAS CF, 1991, METHODS COMPANION ME, V2, P119; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Horn MP, 1999, EUR J IMMUNOL, V29, P1139, DOI 10.1002/(SICI)1521-4141(199904)29:04<1139::AID-IMMU1139>3.0.CO;2-J; Hurez V, 1997, BLOOD, V90, P4004, DOI 10.1182/blood.V90.10.4004; Kaveri SV, 1998, IMMUNOLOGIST, V6, P227; KNUTTIMULLER JM, 1986, ALLERGY, V41, P457, DOI 10.1111/j.1398-9995.1986.tb00327.x; Lacroix-Desmazes S, 1999, J CLIN IMMUNOL, V19, P26, DOI 10.1023/A:1020510401233; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Miescher S, 1998, VOX SANG, V75, P278, DOI 10.1046/j.1423-0410.1998.7540278.x; Mouthon L, 1996, SCAND J IMMUNOL, V44, P243, DOI 10.1046/j.1365-3083.1996.d01-306.x; Ochsenbein AF, 2000, IMMUNOL TODAY, V21, P624, DOI 10.1016/S0167-5699(00)01754-0; Persic L, 1997, GENE, V187, P9, DOI 10.1016/S0378-1119(96)00628-2; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Rajakulasingam K, 1997, J ALLERGY CLIN IMMUN, V100, P78, DOI 10.1016/S0091-6749(97)70198-2; SABAN R, 1994, J ALLERGY CLIN IMMUN, V94, P836, DOI 10.1016/0091-6749(94)90151-1; Saini SS, 1999, J IMMUNOL, V162, P5624; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Terada N, 1995, J ALLERGY CLIN IMMUN, V96, P1161, DOI 10.1016/S0091-6749(95)70201-6; TOMLINSON IM, 1998, 5 BASE SEQUENCE DIRE; VOGEL M, 1994, EUR J IMMUNOL, V24, P1200, DOI 10.1002/eji.1830240529; ZURCHER AW, 1995, IMMUNOL LETT, V46, P49, DOI 10.1016/0165-2478(95)00014-V	23	41	48	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2268	2274		10.1096/fj.00-0890hyp	http://dx.doi.org/10.1096/fj.00-0890hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641254				2022-12-28	WOS:000171920400039
J	Rubin, C; Xu, G; Judex, S				Rubin, C; Xu, G; Judex, S			The anabolic activity of bone tissue, suppressed by disuse, is normalized by brief exposure to extremely low-magnitude mechanical stimuli	FASEB JOURNAL			English	Article						bone formation; microgravity; bone density; musculoskeletal; sarcopenia; anabolic osteoporosis	STRAIN; HISTOMORPHOMETRY; WEIGHTLESSNESS; UNIFORMITY; MASS	It is generally believed that mechanical signals must be large in order to be anabolic to bone tissue. Recent evidence indicates, however, that extremely low-magnitude (<10 microstrain) mechanical signals readily stimulate bone formation if induced at a high frequency. We examined the ability of extremely low-magnitude, high-frequency mechanical signals to restore anabolic bone cell activity inhibited by disuse. Adult female rats were randomly assigned to six groups: baseline control, age-matched control, mechanically stimulated for 10 min/day, disuse (hind limb suspension), disuse interrupted by 10 min/day of weight bearing, and disuse interrupted by 10 min/day of mechanical stimulation. After a 28 day protocol, bone formation rates (BFR) in the proximal tibia of mechanically stimulated rats increased compared with age-matched control (+97%). Disuse alone reduced BFR (-92%), a suppression only slightly curbed when disuse was interrupted by 10 min of weight bearing (-61%). In contrast, disuse interrupted by 10 min per day of low-level mechanical intervention normalized BFR to values seen in age-matched controls. This work indicates that this noninvasive, extremely low-level stimulus may provide an effective biomechanical intervention for the bone loss that plagues long-term space flight, bed rest, or immobilization caused by paralysis.	SUNY Stony Brook, Dept Biomed Engn, Musculoskeletal Res Lab, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Rubin, C (corresponding author), SUNY Stony Brook, Dept Biomed Engn, Musculoskeletal Res Lab, 3rd Floor, Stony Brook, NY 11794 USA.	clinton.rubin@sunysb.edu						Baldwin KM, 1996, MED SCI SPORT EXER, V28, P1247, DOI 10.1097/00005768-199610000-00007; Dehority W, 1999, AM J PHYSIOL-ENDOC M, V276, pE62; DESPLANCHES D, 1990, J APPL PHYSIOL, V68, P48, DOI 10.1152/jappl.1990.68.1.48; Erben RG, 1997, J HISTOCHEM CYTOCHEM, V45, P307, DOI 10.1177/002215549704500215; Fritton JC, 1997, ANN BIOMED ENG, V25, P831, DOI 10.1007/BF02684167; Fritton SP, 2000, J BIOMECH, V33, P317, DOI 10.1016/S0021-9290(99)00210-9; FYHRIE DP, 1986, J ORTHOPAED RES, V4, P304, DOI 10.1002/jor.1100040307; GROSS TS, 1995, J ORTHOPAED RES, V13, P708, DOI 10.1002/jor.1100130510; Gross TS, 1997, J BONE MINER RES, V12, P982, DOI 10.1359/jbmr.1997.12.6.982; Huang RP, 1999, J GERONTOL A-BIOL, V54, pB352, DOI 10.1093/gerona/54.8.B352; LeBlanc A, 1998, BONE, V22, p113S, DOI 10.1016/S8756-3282(98)00013-1; LeBlanc A., 1999, 1 BIENN SPAC BIOM IN, V1, P17; Morey-Holton E, 1981, PHYSIOLOGIST, V24, P545; OCONNOR JA, 1982, J BIOMECH, V15, P767, DOI 10.1016/0021-9290(82)90092-6; Osborn MJ, 1998, STRATEGY RES SPACE B; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Qin YX, 1998, J ORTHOPAED RES, V16, P482, DOI 10.1002/jor.1100160414; RAMBAUT PC, 1979, ACTA ASTRONAUT, V6, P1113, DOI 10.1016/0094-5765(79)90059-6; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711; RUBIN CT, 1987, J ORTHOPAED RES, V5, P300, DOI 10.1002/jor.1100050217; Ruff C, 1999, 1 BIENN SPAC BIOM IN, V1, P86; SMITH MC, 1977, PROLONGED WEIGHTLESS; SMITH ML, 1991, ASSESSMENT PROGRAMS; STUPAKOV GP, 1984, KOSM BIOL AVIAK MED+, V18, P33; Turner RT, 2000, J APPL PHYSIOL, V89, P840, DOI 10.1152/jappl.2000.89.2.840	26	223	244	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2225	2229		10.1096/fj.01-0166com	http://dx.doi.org/10.1096/fj.01-0166com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641249				2022-12-28	WOS:000171920400034
J	Temsah, RM; Kawabata, K; Chapman, D; Dhalla, NS				Temsah, RM; Kawabata, K; Chapman, D; Dhalla, NS			Modulation of cardiac sarcoplasmic reticulum gene expression by lack of oxygen and glucose	FASEB JOURNAL			English	Article						cardiac gene expression; hypoxia reoxygenation; ischemia reperfusion; intracellular Ca2+ overload	PRESSURE-OVERLOAD; CA-2+-ATPASE GENE; OXIDATIVE STRESS; RAT; CALCIUM; HEART; HYPERTROPHY; NOREPINEPHRINE; REPERFUSION; PROTEINS	Although ischemia reperfusion has been shown to depress gene expression of the sarcoplasmic reticulum (SR) proteins, such as the ryanodine receptor, Ca2+-pump ATPase, phospholamban, and calsequestrin in the heart, the mechanisms of these changes are not understood. Given the occurrence of hypoxia and the lack of glucose during the ischemic phase, we investigated the effects of these factors on the cardiac SR gene expression. Isolated rat hearts perfused in the absence of oxygen and/or glucose for 30 min showed an increase in the expression of SR genes. However, perfusion of hearts for 60 min with normal oxygenated medium after 30 min of lack of both oxygen and glucose depressed the transcript levels for the SR proteins; these changes did not occur when hearts were deprived of either oxygen or glucose. The effect of intracellular Ca2+-overload, which occurs during reperfusion, was studied by using hearts perfused for 5 min with Ca2+-free medium and then reperfused for 30 min. Ca2+-depletion/repletion induced a dramatic decrease in the transcript levels of the SR genes. These results suggest that the lack of both oxygen and glucose during ischemia are necessary for reperfusion-induced depression in SR gene expression, possibly due to the occurrence of intracellular Ca2+-overload.	St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Fac Med, Dept Physiol, Winnipeg, MB, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Dhalla, NS (corresponding author), St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, 351 Tache Ave, Winnipeg, MB R2H 2A6, Canada.	cvso@sbrc.umanitoba.ca	Dhalla, Naranjan/C-8279-2014	Dhalla, Naranjan/0000-0002-4894-4727				ALTO LE, 1981, CIRC RES, V48, P17, DOI 10.1161/01.RES.48.1.17; ALTO LE, 1979, AM J PHYSIOL, V237, pH713, DOI 10.1152/ajpheart.1979.237.6.H713; Arai M, 1996, J MOL CELL CARDIOL, V28, P1583, DOI 10.1006/jmcc.1996.0149; BOLLI R, 1992, CIRCULATION, V86, P1671, DOI 10.1161/01.CIR.86.6.1671; DELABASTIE D, 1990, CIRC RES, V66, P554, DOI 10.1161/01.RES.66.2.554; Dhalla NS, 2000, J HYPERTENS, V18, P655, DOI 10.1097/00004872-200018060-00002; Dhalla NS, 1999, CAN J CARDIOL, V15, P587; DIXON IMC, 1987, AM J PHYSIOL, V253, pH1026, DOI 10.1152/ajpheart.1987.253.5.H1026; FRASS O, 1993, CARDIOVASC RES, V27, P2037, DOI 10.1093/cvr/27.11.2037; Hashida H, 1999, CLIN SCI, V96, P387, DOI 10.1042/CS19980278; JENNINGS RB, 1991, ANNU REV MED, V42, P225, DOI 10.1146/annurev.med.42.1.225; Lai LP, 1998, J MOL CELL CARDIOL, V30, P175, DOI 10.1006/jmcc.1997.0583; LOMPRE AM, 1991, CIRC RES, V69, P1380, DOI 10.1161/01.RES.69.5.1380; MERCADIER JJ, 1990, J CLIN INVEST, V85, P305, DOI 10.1172/JCI114429; Muller A, 1997, AM J PHYSIOL-HEART C, V272, pH1876, DOI 10.1152/ajpheart.1997.272.4.H1876; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; Netticadan T, 1999, AM J PHYSIOL-CELL PH, V277, pC384, DOI 10.1152/ajpcell.1999.277.3.C384; Netticadan T, 2001, FASEB J, V15, pA891; PEGG W, 1987, AM J PHYSIOL, V252, pH22, DOI 10.1152/ajpheart.1987.252.1.H22; REIMER KA, 1986, HEART CARDIOVASCULAR, P1133; Sharikabad MN, 2000, J MOL CELL CARDIOL, V32, P441, DOI 10.1006/jmcc.1999.1092; Takeo S, 2000, MOL CELL BIOCHEM, V212, P227, DOI 10.1023/A:1007174803993; TAKEO S, 1991, J PHARMACOL EXP THER, V258, P94; TANI M, 1989, CIRC RES, V65, P1045, DOI 10.1161/01.RES.65.4.1045; Tanonaka K, 1996, JPN HEART J, V37, P105; Temsah RM, 1999, AM J PHYSIOL-HEART C, V277, pH584, DOI 10.1152/ajpheart.1999.277.2.H584; Temsah RM, 2000, J PHARMACOL EXP THER, V293, P15; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	28	15	15	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2515	+		10.1096/fj.00-0870fje	http://dx.doi.org/10.1096/fj.00-0870fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641257				2022-12-28	WOS:000171372700021
J	Ten Broeke, R; Folkerts, G; Leusink-Muis, T; van der Linde, HJ; Villain, M; Manion, MK; De Clerck, F; Blalock, JE; Nijkamp, FP				Ten Broeke, R; Folkerts, G; Leusink-Muis, T; van der Linde, HJ; Villain, M; Manion, MK; De Clerck, F; Blalock, JE; Nijkamp, FP			Calcium sensors as new therapeutic targets for airway hyperresponsiveness and asthma	FASEB JOURNAL			English	Article						calcium-like peptide; nitric oxide; epithelium; tracheal reactivity	NITRIC-OXIDE SYNTHASE; CA2+-SENSITIVE INACTIVATION; CA2+ CHANNELS; EPITHELIUM; CALMODULIN; LUNG; INHIBITION; EXACERBATIONS; EXPRESSION; MEDIATOR	Airway hyperresponsiveness and epithelial damage are key features in asthma, a disease reaching epidemic proportions in the developed world. To investigate and modulate airway hyperresponsiveness, we used two novel peptides, CALP1 and CALP2, which interact with calcium-binding EF hand motifs and regulate calcium channels. We found that CALP1 induced, whereas CALP2 blocked, airway hyperresponsiveness. Both effects were epithelium-dependent. In epithelial cells, CALP1 blocked agonist-induced increase in [Ca (2+)](i), whereas CALP2 increased agonist-induced elevation in [Ca (2+)](i). CALP2 causes the release of nitric oxide (NO), a mediator that relaxes airway smooth muscle. We conclude that epithelial calcium channels play a key role in regulating airway hyperresponsiveness by controlling [Ca (2+)](i) and consequently the production of NO. These results bring new insights into the mechanism of airway hyperresponsiveness and suggest new therapeutic targets for asthma.	Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmacol & Pathophysiol, NL-3508 TB Utrecht, Netherlands; Univ Alabama Birmingham, Ctr Neuroimmunol, Dept Physiol & Biophys, Birmingham, AL USA; Univ Geneva, Dept Med Biochem, Geneva, Switzerland; Janssen Res Fdn, B-2340 Beerse, Belgium	Utrecht University; University of Alabama System; University of Alabama Birmingham; University of Geneva; Johnson & Johnson	Folkerts, G (corresponding author), Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmacol & Pathophysiol, POB 80-082, NL-3508 TB Utrecht, Netherlands.	G.Folkerts@pharm.uu.nl		Blalock, J. Edwin/0000-0001-5303-8123				ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BIALECKI RA, 1995, AM J PHYSIOL-LUNG C, V268, pL152, DOI 10.1152/ajplung.1995.268.1.L152; Boitano S, 1995, AM J PHYSIOL-CELL PH, V269, pC1547, DOI 10.1152/ajpcell.1995.269.6.C1547; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; de Gouw HWFM, 1998, EUR RESPIR J, V11, P126, DOI 10.1183/09031936.98.11010126; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; Dietl P, 1995, AM J PHYSIOL-LUNG C, V269, pL873, DOI 10.1152/ajplung.1995.269.6.L873; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; FOLKERTS G, 1995, AM J RESP CRIT CARE, V151, P1666; FOLKERTS G, 1995, J CLIN INVEST, V95, P26, DOI 10.1172/JCI117649; Folkerts G, 2000, IMMUNOL TODAY, V21, P249, DOI 10.1016/S0167-5699(00)01631-5; Folkerts G, 1998, TRENDS PHARMACOL SCI, V19, P334, DOI 10.1016/S0165-6147(98)01232-2; FOLKERTS G, 2000, EUR RESPIR REV, V10, P249; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hart CM, 1999, CHEST, V115, P1407, DOI 10.1378/chest.115.5.1407; HOGMAN M, 1993, AM REV RESPIR DIS, V148, P1474; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; LEIPZIGER J, 1994, PFLUG ARCH EUR J PHY, V426, P427, DOI 10.1007/BF00388306; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; Li HG, 2000, J PATHOL, V190, P244, DOI 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8; Liu Q, 1996, METHOD ENZYMOL, V268, P311; Manion MK, 2000, FASEB J, V14, P1297, DOI 10.1096/fj.14.10.1297; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; MEANS AR, 1991, INTRACELLULAR MESSEN, P265; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; NIJKAMP FP, 1993, AM REV RESPIR DIS, V148, P727, DOI 10.1164/ajrccm/148.3.727; PAVLOVIC D, 1989, J APPL PHYSIOL, V67, P2522, DOI 10.1152/jappl.1989.67.6.2522; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; PERSSON MG, 1993, ACTA PHYSIOL SCAND, V149, P461, DOI 10.1111/j.1748-1716.1993.tb09643.x; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; Sanders SP, 1999, AM J RESP CELL MOL, V21, P147, DOI 10.1165/ajrcmb.21.2.f158; SHAUL PW, 1994, J CLIN INVEST, V94, P2231, DOI 10.1172/JCI117585; Sherman TS, 1999, AM J PHYSIOL-LUNG C, V276, pL383, DOI 10.1152/ajplung.1999.276.2.L383; Taylor DA, 1998, THORAX, V53, P483, DOI 10.1136/thx.53.6.483; Villain M, 2000, J BIOL CHEM, V275, P2676, DOI 10.1074/jbc.275.4.2676; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287	39	19	19	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1831	+		10.1096/fj.01-0018fje	http://dx.doi.org/10.1096/fj.01-0018fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481245				2022-12-28	WOS:000169261200037
J	Baoutina, A; Dean, RT; Jessup, W				Baoutina, A; Dean, RT; Jessup, W			Trans-plasma membrane electron transport induces macrophage-mediated low-density lipoprotein oxidation	FASEB JOURNAL			English	Article						LDL oxidation; plasma membrane electron transport; ascorbate; macrophage; atherosclerosis	VITAMIN-C; ALPHA-TOCOPHEROL; ASCORBIC-ACID; ATHEROSCLEROTIC LESIONS; DEHYDROASCORBIC ACID; LIPID-PEROXIDATION; OXIDIZED LIPIDS; LDL OXIDATION; FOAM CELLS; IRON	Oxidation of low-density lipoprotein (LDL) in the arterial intima has been implicated in atherogenesis. The exact mechanism of this oxidation, however, remains unclear. In the present study we investigated the role of the trans-plasma membrane electron transport (TPMET) system of macrophages in cell-mediated LDL oxidation. We demonstrated that TPMET of mouse and human macrophages, measured as reduction of the impermeable oxidant ferricyanide (FEC), was enhanced strongly by loading macrophages with ascorbate (Asc). This appoach also enhanced the ability of cells to oxidize LDL in Ham's F-10 medium. The stimulatory effect of Asc-enrichment of macrophages on both processes was not due to release of Asc or other reductants into the medium, as demonstrated by the lack of the effects of ascorbate oxidase and the inhibitors of cellular Asc-recycling on these processes. This conclusion is also supported by experiments in which we analyzed the amounts of Asc and DHA secreted by cells and tested their effect of LDL oxidation, and also measured the ability of cell-conditioned medium from control and Asc-enriched cells to reduce FEC. We conclude that TPMET is largely responsible for macrophage-mediated LDL oxidation by means of its capacity to reduce extracellular transition metals.	Heart Res Inst, Cell Biol Grp, Camperdown, NSW 2050, Australia	University of Sydney; Heart Research Institute	Baoutina, A (corresponding author), Heart Res Inst, Cell Biol Grp, 145 Missenden Rd, Camperdown, NSW 2050, Australia.	a.baoutina@hri.org.au		Dean, Roger Thornton/0000-0002-8859-8902				ABDALLA DSP, 1992, ATHEROSCLEROSIS, V97, P149, DOI 10.1016/0021-9150(92)90128-4; AVRON M, 1963, ANAL BIOCHEM, V6, P549, DOI 10.1016/0003-2697(63)90149-0; BALLA G, 1991, ARTERIOSCLER THROMB, V11, P1700, DOI 10.1161/01.ATV.11.6.1700; Baoutina A, 2000, J BIOL CHEM, V275, P1635, DOI 10.1074/jbc.275.3.1635; Baoutina A, 1998, J LIPID RES, V39, P114; Baoutina A, 2000, REDOX REP, V5, P85, DOI 10.1179/135100000101535591; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Camejo G, 1998, J LIPID RES, V39, P755; Carr A, 1999, FASEB J, V13, P1007, DOI 10.1096/fasebj.13.9.1007; Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959; Dai LI, 1996, BBA-LIPID LIPID MET, V1304, P223, DOI 10.1016/S0005-2760(96)00121-X; EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; Garner B, 1997, J BIOL CHEM, V272, P6927, DOI 10.1074/jbc.272.11.6927; Garner B, 1996, REDOX REP, V2, P97, DOI 10.1080/13510002.1996.11747035; Halliwell B, 1999, TRENDS BIOCHEM SCI, V24, P255, DOI 10.1016/S0968-0004(99)01418-8; HUNTER GC, 1991, P SOC EXP BIOL MED, V196, P273; ITABE H, 1994, J BIOL CHEM, V269, P15274; KRITHARIDES L, 1995, ARCH BIOCHEM BIOPHYS, V323, P127, DOI 10.1006/abbi.1995.0018; LAMB DJ, 1995, FEBS LETT, V374, P12, DOI 10.1016/0014-5793(95)01068-P; Lee FY, 1998, ATHEROSCLEROSIS, V138, P281, DOI 10.1016/S0021-9150(98)00033-1; Martin A, 1997, ARTERIOSCL THROM VAS, V17, P1583, DOI 10.1161/01.ATV.17.8.1583; May JM, 1999, FASEB J, V13, P995, DOI 10.1096/fasebj.13.9.995; May JM, 2000, BIOCHEM BIOPH RES CO, V267, P118, DOI 10.1006/bbrc.1999.1906; May JM, 1999, FREE RADICAL BIO MED, V26, P1513, DOI 10.1016/S0891-5849(99)00017-9; MAY JM, 1995, BBA-BIOMEMBRANES, V1238, P127, DOI 10.1016/0005-2736(95)00120-R; Medina MA, 1997, BIOESSAYS, V19, P977, DOI 10.1002/bies.950191107; Merker MP, 1998, AM J PHYSIOL-LUNG C, V274, pL685; Mohr D., 1996, FREE RADICALS PRACTI, P271; Niu XW, 1999, ARTERIOSCL THROM VAS, V19, P1708, DOI 10.1161/01.ATV.19.7.1708; ORRINGER EP, 1979, J CLIN INVEST, V63, P53, DOI 10.1172/JCI109277; Otero P, 1997, FREE RADICAL RES, V27, P619, DOI 10.3109/10715769709097865; RETSKY KL, 1995, BBA-LIPID LIPID MET, V1257, P279, DOI 10.1016/0005-2760(95)00089-U; RICEEVANS C, 1993, FEBS LETT, V326, P177, DOI 10.1016/0014-5793(93)81786-Y; Rumsey SC, 2000, J BIOL CHEM, V275, P28246; SCHIPFER W, 1985, INT J BIOCHEM, V17, P819, DOI 10.1016/0020-711X(85)90270-8; SMITH C, 1992, BIOCHEM J, V286, P901, DOI 10.1042/bj2860901; Stait SE, 1996, BIOCHEM J, V320, P373; STAIT SE, 1994, FEBS LETT, V341, P263, DOI 10.1016/0014-5793(94)80469-9; SUARNA C, 1995, ARTERIOSCL THROM VAS, V15, P1616, DOI 10.1161/01.ATV.15.10.1616; THORSTENSEN K, 1990, BIOCHIM BIOPHYS ACTA, V1052, P29, DOI 10.1016/0167-4889(90)90053-G; Van Duijn MM, 1998, J BIOL CHEM, V273, P13415, DOI 10.1074/jbc.273.22.13415; VanDuijn MM, 2000, J BIOL CHEM, V275, P27720; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Wood JL, 1999, FREE RADICAL RES, V31, P367, DOI 10.1080/10715769900300941; Xing XY, 1998, J LIPID RES, V39, P2201; Yuan XM, 1999, FREE RADICAL RES, V30, P221, DOI 10.1080/10715769900300241; Yuan XM, 1996, ATHEROSCLEROSIS, V124, P61, DOI 10.1016/0021-9150(96)05817-0	50	18	18	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1580	+		10.1096/fj.00-0704fje	http://dx.doi.org/10.1096/fj.00-0704fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427492				2022-12-28	WOS:000173707700030
J	Ido, Y; Chang, K; Woolsey, TA; Williamson, JR				Ido, Y; Chang, K; Woolsey, TA; Williamson, JR			NADH: sensor of blood flow need in brain, muscle, and other tissues	FASEB JOURNAL			English	Article						diabetes; glycolysis; NAD; nitric oxide; redox; superoxide; whisker barrels; work	VASCULAR SMOOTH-MUSCLE; OXIDE SYNTHASE INHIBITION; ENDOTHELIAL GROWTH-FACTOR; ELEVATED GLUCOSE-LEVELS; HUMAN SKELETAL-MUSCLE; REACTIVE OXYGEN; NITRIC-OXIDE; IN-VITRO; SOMATOSENSORY STIMULATION; OXIDATIVE-METABOLISM	The sensor for blood-flow need with neural activity and exercise is not known. We tested the hypothesis that accumulation of electrons in cytosolic free nicotinamide adenine dinucleotide (NAD) activates redox signaling pathways to augment blood flow. NAD is the primary carrier of electrons from glucose and lactate for ATP synthesis. Because increased glycolysis transfers electrons from glucose to NAD(+) faster than they are used for mitochondrial ATP synthesis, electrons accumulate in cytosolic NADH. Because cytosolic NADH and intra- and extracellular lactate/pyravate (L/P) ratios are all in near-equilibrium, NADH can be increased or decreased by i.v. lactate or pyruvate. Here, we report that elevated plasma L/P in normal rats increases blood flow in numerous resting tissues and augments blood flow increases in activated somatosensory (barrel) cortex and contracting skeletal muscle. Increased flows are largely prevented by injection of pyruvate (to lower L/P), a superoxide dismutase mimic (to block vascular effects of superoxide), or an inhibitor of nitric oxide synthase (to block (NO)-N-. vasodilation). Electrons carried by NADH, in addition to fueling ATP synthesis, also fuel redox signaling pathways to augment blood flow in resting and working tissues. These novel findings are fundamental to understanding blood-flow physiology and pathology.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol & Neurol Surg, St Louis, MO 63110 USA; Boston Univ, Med Ctr Hosp, Diabet & Metab Unit, Boston, MA 02215 USA	Washington University (WUSTL); Washington University (WUSTL); Boston University	Williamson, JR (corresponding author), Washington Univ, Sch Med, Dept Pathol, Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	jrw@PATHOLOGY.WUSTL.edu		Ido, Yasuo/0000-0002-3036-9971				ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; Barron JT, 1999, MOL CELL BIOCHEM, V194, P283, DOI 10.1023/A:1006928516648; Barron JT, 1997, J MOL CELL CARDIOL, V29, P2225, DOI 10.1006/jmcc.1997.0461; Berry GT, 1998, METABOLISM, V47, P1423, DOI 10.1016/S0026-0495(98)90317-1; Boero JA, 1999, J APPL PHYSIOL, V86, P1211, DOI 10.1152/jappl.1999.86.4.1211; BROOKS GA, 1986, FASEB J, V45, P2924; CARR DB, 1984, J CLIN PSYCHIAT, V45, P323; Chang K, 1997, AM J PHYSIOL-ENDOC M, V273, pE164, DOI 10.1152/ajpendo.1997.273.1.E164; Cholet N, 1997, J CEREBR BLOOD F MET, V17, P1191, DOI 10.1097/00004647-199711000-00008; Chua CC, 1998, FREE RADICAL BIO MED, V25, P891, DOI 10.1016/S0891-5849(98)00115-4; COGGAN AR, 1992, J APPL PHYSIOL, V72, P1780, DOI 10.1152/jappl.1992.72.5.1780; Demestre M, 1997, J PHYSIOL-LONDON, V499, P825, DOI 10.1113/jphysiol.1997.sp021971; Dowling JL, 1996, J NEUROSCI METH, V66, P113, DOI 10.1016/0165-0270(96)00007-6; DUFFY TE, 1972, J NEUROCHEM, V19, P959, DOI 10.1111/j.1471-4159.1972.tb01417.x; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; Gustafsson T, 1999, AM J PHYSIOL-HEART C, V276, pH679, DOI 10.1152/ajpheart.1999.276.2.H679; Hansen PA, 1997, AM J PHYSIOL-ENDOC M, V273, pE28, DOI 10.1152/ajpendo.1997.273.1.E28; HARDY MM, 1994, J BIOL CHEM, V269, P18535; Hickner RC, 1997, AM J PHYSIOL-HEART C, V273, pH405, DOI 10.1152/ajpheart.1997.273.1.H405; HOGAN MC, 1995, MED SCI SPORT EXER, V27, P371; Huang PL, 1998, PROG BRAIN RES, V118, P13; Hyder F, 1996, P NATL ACAD SCI USA, V93, P7612, DOI 10.1073/pnas.93.15.7612; IKEBUCHI Y, 1991, J BIOL CHEM, V266, P13233; IMRE G, 1964, Br J Ophthalmol, V48, P75, DOI 10.1136/bjo.48.2.75; ISAACS KR, 1992, J CEREBR BLOOD F MET, V12, P110, DOI 10.1038/jcbfm.1992.14; Katz A, 1990, Exerc Sport Sci Rev, V18, P1; KILGORE KS, 1994, J MOL CELL CARDIOL, V26, P995, DOI 10.1006/jmcc.1994.1120; KOBAYASHI K, 1979, CIRC RES, V44, P166, DOI 10.1161/01.RES.44.2.166; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; LADECOLA C, 1993, TRENDS NEUROSCI, V16, P206; Lash JM, 1996, P SOC EXP BIOL MED, V211, P218; LAUGHLIN MR, 1994, J MOL CELL CARDIOL, V26, P1525, DOI 10.1006/jmcc.1994.1173; LAUGHLIN MR, 1993, AM J PHYSIOL, V264, pH2068, DOI 10.1152/ajpheart.1993.264.6.H2068; LEAR JL, 1991, J CEREBR BLOOD F MET, V11, P576, DOI 10.1038/jcbfm.1991.106; Lindauer U, 1996, NEUROSCI LETT, V216, P207, DOI 10.1016/S0304-3940(96)13044-5; Magistretti PJ, 1999, PHILOS T R SOC B, V354, P1155, DOI 10.1098/rstb.1999.0471; MCGILVERY RM, 1983, BIOCH FUNCTIONAL APP, P484; McKinnon W, 1996, J PHYSIOL-LONDON, V490, P783, DOI 10.1113/jphysiol.1996.sp021186; Parolin ML, 2000, AM J PHYSIOL-ENDOC M, V278, pE522, DOI 10.1152/ajpendo.2000.278.3.E522; POOLE RC, 1993, AM J PHYSIOL, V264, P761; Powers WJ, 1996, AM J PHYSIOL-HEART C, V270, pH554, DOI 10.1152/ajpheart.1996.270.2.H554; Reid MB, 1996, NEWS PHYSIOL SCI, V11, P114, DOI 10.1152/physiologyonline.1996.11.3.114; REIMAN EM, 1989, ARCH GEN PSYCHIAT, V46, P493; Roca J, 1998, J APPL PHYSIOL, V85, P1142, DOI 10.1152/jappl.1998.85.3.1142; ROWELL LB, 1986, AM J PHYSIOL, V251, P1038; SHOLTZ TD, 1995, AM J PHYSIOL, V268, pH82; Siesjo B K, 1979, Adv Neurol, V26, P267; Stainsby W N, 1990, Exerc Sport Sci Rev, V18, P29; STROMINGER RN, 1987, J NEUROSCI METH, V22, P113, DOI 10.1016/0165-0270(87)90004-5; STRYER L, 1995, BIOCHEMISTRY-US, P548; SULLIVAN MJ, 1994, J APPL PHYSIOL, V77, P2194, DOI 10.1152/jappl.1994.77.5.2194; Tilton RG, 1997, J CLIN INVEST, V99, P2192, DOI 10.1172/JCI119392; UEKI M, 1988, J CEREBR BLOOD F MET, V8, P486, DOI 10.1038/jcbfm.1988.89; VANDENENDEN MK, 1995, INVEST OPHTH VIS SCI, V36, P1675; VEECH RL, 1986, AM J CLIN NUTR, V44, P519, DOI 10.1093/ajcn/44.4.519; VIGUIE CA, 1993, J APPL PHYSIOL, V75, P566, DOI 10.1152/jappl.1993.75.2.566; Volk T, 1997, MOL CELL BIOCHEM, V171, P11, DOI 10.1023/A:1006886215193; Wagner AD, 1998, SCIENCE, V281, P1188, DOI 10.1126/science.281.5380.1188; WEI EP, 1985, AM J PHYSIOL, V248, P157; WEISS J, 1985, J CLIN INVEST, V75, P436, DOI 10.1172/JCI111718; Williams B, 1997, DIABETES, V46, P1497, DOI 10.2337/diabetes.46.9.1497; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; Willmitzer L, 1999, CURR OPIN BIOTECH, V10, P161, DOI 10.1016/S0958-1669(99)80028-7; Wojtaszewski JFP, 1998, BBA-GEN SUBJECTS, V1380, P396, DOI 10.1016/S0304-4165(98)00011-7; Wolin Michael S., 1996, Microcirculation (Philadelphia), V3, P1, DOI 10.3109/10739689609146778	67	54	58	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1419	+		10.1096/fj.00-0652fje	http://dx.doi.org/10.1096/fj.00-0652fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387243				2022-12-28	WOS:000173705800025
J	Velazquez, OC; Snyder, R; Liu, ZJ; Fairman, RM; Herlyn, M				Velazquez, OC; Snyder, R; Liu, ZJ; Fairman, RM; Herlyn, M			Fibroblast-dependent differentiation of human microvascular endothelial cells into capillary-like, three-dimensional networks	FASEB JOURNAL			English	Article						endothelium; angiogenesis; capillary networks; VEGF; angiopoietin-1	ANGIOGENESIS IN-VITRO; GROWTH-FACTORS; INDUCTION; SURVIVAL	An in vitro model has been developed to study migration, survival, proliferation, and capillary-like differentiation of human microvascular endothelial cells (HMVECs) in an environment that avoids tumor promoters and complex matrices. HMVEC monolayers were plated, then induced to form three-dimensional, capillary-like networks by overlaying with human type I collagen followed by a second overlay of collagen with embedded fibroblasts. Detachment and migration of endothelial cells into the matrix was triggered within hours by the overlaying collagen, and the fibroblasts stimulated survival and formation of cords, vacuoles, tubes, and, after 4 to 5 days, capillary networks. The differentiation into branching capillary-like structures was dependent on direct fibroblast-endothelial cell contact and was not achieved when fibroblasts were replaced by seven types of melanoma cells, which included radial and vertical growth phase primary and metastatic stages. Vascular endothelial growth factor (VEGF), when overexpressed in fibroblasts, stimulated endothelial cell proliferation and migration, whereas angiopoietin-1 (Ang-1) had only motogenic effects. Neutralizing antibodies against VEGF and blocking antibodies for VEGF-receptor 2 (VEGFR2) significantly inhibited but not completely obliterated capillary network formation, suggesting that the VEGF signaling pathway is important but not exclusive and that other fibroblast-derived soluble factors and fibroblast-endothelial cell contact are essential for endothelial cell survival and differentiation.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Surg, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.upenn.edu						Black AF, 1999, CELL BIOL TOXICOL, V15, P81, DOI 10.1023/A:1007541713398; Blau HM, 2001, NAT MED, V7, P532, DOI 10.1038/87850; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hicklin DJ, 2001, DRUG DISCOV TODAY, V6, P517, DOI 10.1016/S1359-6446(01)01759-7; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; Hoying JB, 1996, IN VITRO CELL DEV-AN, V32, P409; Hsu MY, 1999, HUMAN CELL CULTURE, V1, P259; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; IMCKE E, 1991, ARCH DERMATOL RES, V283, P149, DOI 10.1007/BF00372054; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; JACKSON CJ, 1991, EXP CELL RES, V192, P319, DOI 10.1016/0014-4827(91)90194-Y; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Keshet E, 1999, J CLIN INVEST, V104, P1497, DOI 10.1172/JCI8849; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; LATERRA J, 1990, J CELL PHYSIOL, V144, P204, DOI 10.1002/jcp.1041440205; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MONTESANO R, 1993, J CELL SCI, V105, P1013; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Pinney E, 2000, J CELL PHYSIOL, V183, P74, DOI 10.1002/(SICI)1097-4652(200004)183:1<74::AID-JCP9>3.0.CO;2-G; Richard L, 1998, EXP CELL RES, V240, P1, DOI 10.1006/excr.1998.3936; Ruiter D, 2002, LANCET ONCOL, V3, P35, DOI 10.1016/S1470-2045(01)00620-9; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang S, 1999, AM J PATHOL, V155, P887, DOI 10.1016/S0002-9440(10)65188-7	33	106	117	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1316	+		10.1096/fj.01-1011fje	http://dx.doi.org/10.1096/fj.01-1011fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060671				2022-12-28	WOS:000176683900031
J	Grouzmann, E; Monod, M; Landis, B; Wilk, S; Brakch, N; Nicoucar, K; Giger, R; Malis, D; Szalay-Quinodoz, I; Cavadas, C; Morel, DR; Lacroix, JS				Grouzmann, E; Monod, M; Landis, B; Wilk, S; Brakch, N; Nicoucar, K; Giger, R; Malis, D; Szalay-Quinodoz, I; Cavadas, C; Morel, DR; Lacroix, JS			Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa	FASEB JOURNAL			English	Article						DPPIV; chronic rhinosinusitis; substance P; NK1; non-adrenergic; non-cholinergic	GENE-RELATED PEPTIDE; NEUROKININ-A; GUINEA-PIG; AMINOPEPTIDASE-M; SPINAL-CORD; RELEASE; TACHYKININS; HISTAMINE; INCREASE; DIPEPTIDYL(AMINO)PEPTIDASE-IV	In this study, we have found that dipeptidylpeptidase IV (DPPIV) plays in vivo an active role in the modulation of the inflammatory response of chronic rhinosinusitis. Human nasal mucosa expresses DPPIV-like immunoreactivity in submucosal seromucus glands, leukocytes, and endothelial cells of blood vessels. DPPIV enzymatic activity in nasal tissue biopsies taken from patients suffering from chronic rhinosinusitis was correlated inversely with the density of inflammatory cells in the nasal mucosa, and the DPPIV activity rose when chronic rhinosinusitis was treated. By using a pig animal model, we have shown that the intranasal administration of recombinant DPPIV decreased the vasodilatation induced by exogenous substance P (SP), a proinflammatory peptide released by sensory nerves. In contrast, an inhibitor of DPPIV enhanced the vasodilatatory effect at low doses of SP. SP5-11 was 100- to 1000-fold less potent than SP as a vasodilator of the nasal mucosa. The vasodilatatory effect of SP was abolished by a NK1 receptor antagonist. In conclusion, these results suggest a new pathophysiological pathway for rhinitis based on clinical observations in humans, indicating the involvement of an enzyme to modulate non-adrenergic and non-cholinergicnon-cholinergic substrate that occurred during nasal dysfunctions.	CHU Vaudois, Div Hypertens, CH-1011 Lausanne, Switzerland; CHU Vaudois, Div Dermatol, CH-1011 Lausanne, Switzerland; Hop Cantonal Univ Geneva, Lab Rhinol Expt, Clin & Policlin Otorhinolaryngol & Chirurg Cervic, CH-1211 Geneva, Switzerland; CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Hop Cantonal Univ Geneva, Dept Clin Pathol, CH-1211 Geneva, Switzerland; Hop Cantonal Univ Geneva, Div Invest Anesthesiol, CH-1211 Geneva, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Geneva; University of Geneva	Grouzmann, E (corresponding author), CHU Vaudois, Div Hypertens, CH-1011 Lausanne, Switzerland.	Eric.Grouzmann@chuv.hospvd.ch	Cavadas, Claudia/AAB-6904-2021; Cavadas, Claudia/K-8271-2014	Cavadas, Claudia/0000-0001-8020-9266; Cavadas, Claudia/0000-0001-8020-9266; Giger, Roland/0000-0002-5574-3210				AHMAD S, 1992, J PHARMACOL EXP THER, V260, P1257; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; Beauvais A, 1997, INFECT IMMUN, V65, P3042, DOI 10.1128/IAI.65.8.3042-3047.1997; CHATELAIN C, 1995, EUR ARCH OTO-RHINO-L, V252, P83; DEVILLIER P, 1988, EUR RESPIR J, V1, P356; ERJAVEC F, 1981, N-S ARCH PHARMACOL, V317, P67, DOI 10.1007/BF00506259; FLEISCHER B, 1994, IMMUNOL TODAY, V15, P180, DOI 10.1016/0167-5699(94)90316-6; GEPPETTI P, 1991, J PHARMACOL EXP THER, V259, P759; HEYMANN E, 1978, FEBS LETT, V91, P360, DOI 10.1016/0014-5793(78)81210-1; Holzer P, 1998, GEN PHARMACOL, V30, P5, DOI 10.1016/S0306-3623(97)00078-5; HOPSUHAV.VK, 1969, HISTOCHEMISTRY, V17, P30, DOI 10.1007/BF00306327; HUA XY, 1986, NEUROSCIENCE, V19, P313, DOI 10.1016/0306-4522(86)90024-2; KENNY A, 1991, PPETIDASES INVOLVED, P47; KHALAF MR, 1987, J CLIN PATHOL, V40, P480, DOI 10.1136/jcp.40.5.480; Konno A, 1996, ANN OTO RHINOL LARYN, V105, P648, DOI 10.1177/000348949610500811; Lacroix JS, 1995, EUR ARCH OTO-RHINO-L, V252, P465, DOI 10.1007/BF02114752; LACROIX JS, 1989, ACTA PHYSIOL SCAND, V136, P1; LI JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P148, DOI 10.1006/abbi.1995.0020; LOJDA Z, 1977, HISTOCHEMISTRY, V54, P299, DOI 10.1007/BF00508273; LUNDBLAD L, 1984, ACTA PHYSIOL SCAND, P1; MACKAY IS, 1988, BRIT J DIS CHEST, V82, P1, DOI 10.1016/0007-0971(88)90002-2; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; MYGIND N, 1983, EUR J RESPIR DIS, V64, P16; NADEL JA, 1991, EUR RESPIR J, V4, P745; NAKATA Y, 1981, J NEUROCHEM, V37, P1529, DOI 10.1111/j.1471-4159.1981.tb06323.x; NIEBER K, 1992, J ALLERGY CLIN IMMUN, V90, P646, DOI 10.1016/0091-6749(92)90138-R; Ottosson A, 1997, CEPHALALGIA, V17, P166, DOI 10.1046/j.1468-2982.1997.1703166.x; PEDERSENBJERGAARD U, 1989, PEPTIDES, V10, P1147, DOI 10.1016/0196-9781(89)90006-5; PIEDIMONTE G, 1993, J APPL PHYSIOL, V74, P2462, DOI 10.1152/jappl.1993.74.5.2462; PIEDIMONTE G, 1993, J PHARMACOL EXP THER, V265, P36; Sakurada C, 1999, J PHARM SCI-US, V88, P1127, DOI 10.1021/js990149c; SCHARPE SL, 1991, CLIN CHIM ACTA, V195, P125, DOI 10.1016/0009-8981(91)90132-V; SHORE SA, 1988, AM REV RESPIR DIS, V137, P331, DOI 10.1164/ajrccm/137.2.331; STEAD RH, 1987, IMMUNOL REV, V100, P333, DOI 10.1111/j.1600-065X.1987.tb00538.x; STJARNE P, 1989, CELL TISSUE RES, V256, P439; TANI E, 1990, NEUROSCI LETT, V115, P171, DOI 10.1016/0304-3940(90)90450-N; THOMPSON JE, 1988, AM REV RESPIR DIS, V137, P337, DOI 10.1164/ajrccm/137.2.337; ULMER AJ, 1990, SCAND J IMMUNOL, V31, P429, DOI 10.1111/j.1365-3083.1990.tb02789.x; UMENO E, 1989, J APPL PHYSIOL, V66, P2647, DOI 10.1152/jappl.1989.66.6.2647; Van der Velden VHJ, 1998, CLIN EXP ALLERGY, V28, P110; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; WANG LH, 1991, PEPTIDES, V12, P1357, DOI 10.1016/0196-9781(91)90220-J	42	52	54	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1132	+		10.1096/fj.01-0939fje	http://dx.doi.org/10.1096/fj.01-0939fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039843				2022-12-28	WOS:000175973900002
J	Veldman, RJ; Klappe, K; Hinrichs, J; Hummel, I; van der Schaaf, G; Sietsma, H; Kok, JW				Veldman, RJ; Klappe, K; Hinrichs, J; Hummel, I; van der Schaaf, G; Sietsma, H; Kok, JW			Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus	FASEB JOURNAL			English	Article						lactosylceramide; glucosylceramide; gangliosides; P-glycoprotein; brefeldin A	MDR2 P-GLYCOPROTEIN; SDZ PSC 833; PLASMA-MEMBRANE; BREFELDIN-A; IN-VITRO; GLYCOSPHINGOLIPID SYNTHESIS; GLUCOSYLCERAMIDE; CERAMIDE; SPHINGOMYELIN; TRANSPORT	Multidrug-resistant tumor cells display enhanced levels of glucosylceramide. In this study, we investigated how this relates to the overall sphingolipid composition of multidrug-resistant ovarian carcinoma cells and which mechanisms are responsible for adapted sphingolipid metabolism. We found in multidrug-resistant cells substantially lower levels of lactosylceramide and gangliosides in sharp contrast to glucosylceramide, galactosylceramide, and sphingomyelin levels. This indicates a block in the glycolipid biosynthetic pathway at the level of lactosylceramide formation, with concomitant accumulation of glucosylceramide. A series of observations exclude regulation at the enzyme level as the underlying mechanism. First, reduced lactosylceramide formation occurred only in intact resistant cells whereas cell-free activity of lactosylceramide synthase was higher compared with the parental cells. Second, the level of lactosylceramide synthase gene expression was equal in both phenotypes. Third, glucosylceramide synthase (mRNA and protein) expression and activity were equal or lower in resistant cells. Based on the kinetics of sphingolipid metabolism, the observation that brefeldin A does not restore lactosylceramide synthesis, and altered localization of lactosylceramide synthase fused to green fluorescent protein, we conclude that lactosylceramide biosynthesis is highly uncoupled from glucosylceramide biosynthesis in the Golgi apparatus of resistant cells.	Univ Groningen, Inst Drug Explorat, Dept Membrane Cell Biol, NL-9713 AV Groningen, Netherlands	University of Groningen	Kok, JW (corresponding author), Univ Groningen, Inst Drug Explorat, Dept Membrane Cell Biol, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	j.w.kok@med.rug.nl						Babia T, 1998, EUR J BIOCHEM, V258, P233, DOI 10.1046/j.1432-1327.1998.2580233.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cabot MC, 1998, FEBS LETT, V431, P185, DOI 10.1016/S0014-5793(98)00744-3; Callaghan R, 1997, BBA-BIOMEMBRANES, V1328, P109, DOI 10.1016/S0005-2736(97)00079-5; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; Elferink RPJO, 1997, FASEB J, V11, P19, DOI 10.1096/fasebj.11.1.9034162; Goulding CW, 2000, CANCER LETT, V149, P143, DOI 10.1016/S0304-3835(99)00353-5; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kok JW, 1997, J BIOL CHEM, V272, P21128, DOI 10.1074/jbc.272.34.21128; Kok JW, 2000, INT J CANCER, V87, P172, DOI 10.1002/1097-0215(20000715)87:2<172::AID-IJC3>3.0.CO;2-K; Kok JW, 1999, FLUORESCENT LUMINESC, P136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lala P, 2000, J BIOL CHEM, V275, P6246, DOI 10.1074/jbc.275.9.6246; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Lucci A, 1998, ANTICANCER RES, V18, P475; Marks DL, 1999, J BIOL CHEM, V274, P451, DOI 10.1074/jbc.274.1.451; MARSH NL, 1995, J CLIN INVEST, V95, P2903, DOI 10.1172/JCI117997; Maxzud MK, 2000, NEUROCHEM RES, V25, P145, DOI 10.1023/A:1007555903335; MAY GL, 1988, INT J CANCER, V42, P728, DOI 10.1002/ijc.2910420517; Raggers RJ, 1999, J CELL SCI, V112, P415; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Sadeghlar F, 2000, FEBS LETT, V478, P9, DOI 10.1016/S0014-5793(00)01818-4; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; SENN HJ, 1989, EUR J BIOCHEM, V181, P657, DOI 10.1111/j.1432-1033.1989.tb14773.x; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; Sietsma H, 1998, CANCER RES, V58, P4840; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van Helvoort A, 1997, J CELL SCI, V110, P75; VanDerWoude I, 1997, P NATL ACAD SCI USA, V94, P1160, DOI 10.1073/pnas.94.4.1160; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Veldman RJ, 1998, BIOCHEM J, V331, P563, DOI 10.1042/bj3310563; WARNOCK DE, 1994, P NATL ACAD SCI USA, V91, P2708, DOI 10.1073/pnas.91.7.2708; Yokoyama K, 1997, EUR J BIOCHEM, V249, P450, DOI 10.1111/j.1432-1033.1997.00450.x; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; ZIJLSTRA JG, 1990, MED ONCOL TUMOR PHAR, V7, P11, DOI 10.1007/BF03000485	43	78	83	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1111	+		10.1096/fj.01-0863fje	http://dx.doi.org/10.1096/fj.01-0863fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039850				2022-12-28	WOS:000175973900012
J	Abbott, GW; Goldstein, SAN				Abbott, GW; Goldstein, SAN			Disease-associated mutations in KCNE potassium channel subunits (MiRPs) reveal promiscuous disruption of multiple currents and conservation of mechanism	FASEB JOURNAL			English	Article						MinK; MiRP1; MiRP2; KCNQ1; HERG; Kv3.4; periodic paralysis; cardiac arrhythmia	LONG-QT SYNDROME; GATED K+ CHANNEL; I-KS; CARDIAC-ARRHYTHMIA; LANGE-NIELSEN; MINK SUBUNITS; KVLQT1; FORM; GENE; KR	KCNE genes encode single transmembrane-domain subunits, the MinK-related peptides (MiRPs), which assemble with pore-forming alpha subunits to establish the attributes of potassium channels in vivo. To investigate whether MinK, MiRP1, and MiRP2 operate similarly with their known native alpha subunit partners (KCNQ1, HERG, and Kv3.4, respectively) two conserved residues associated with human disease and influential in channel function were evaluated. As MiRPs assemble with a variety of alpha subunits in experimental cells and may do so in vivo, each peptide was also assessed with the other two alpha subunits. Inherited mutation of aspartate to asparagine (D --> N) to yield D76N-MinK is linked to cardiac arrhythmia and deafness; the analogs D82N-MiRP1 and D90N-MiRP2 were studied. Mutation of arginine to histidine (R --> H) to yield R83H-MiRP2 is associated with periodic paralysis; the analogs K69H-MinK and K75H-MiRP1 were also studied. Macroscopic and single-channel currents showed that D 3 N mutations suppressed a subset of functions whereas R/K --> H changes altered the activity of MinK, MiRP1, and MiRP2 with all three alpha subunits. The findings indicate that the KCNE peptides interact similarly with different alpha subunits and suggest a hypothesis: that clinical manifestations of inherited KCNE point mutations result from disruption of multiple native currents via promiscuous interactions.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Cellular & Mol Physiol, New Haven, CT 06536 USA	Yale University; Yale University	Goldstein, SAN (corresponding author), Sect Dev Biol & Biophys, 295 Congress Ave, New Haven, CT 06536 USA.	steve.goldstein@yale.edu	Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061; Abbott, Geoffrey/0000-0003-4552-496X				Abbott G W, 2001, Mol Interv, V1, P95; Abbott GW, 1998, Q REV BIOPHYS, V31, P357, DOI 10.1017/S0033583599003467; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CIRC RES, V88, P981, DOI 10.1161/hh1001.091869; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; Ackerman MJ, 1998, MAYO CLIN PROC, V73, P250, DOI 10.4065/73.3.250; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bianchi L, 1999, HUM MOL GENET, V8, P1499, DOI 10.1093/hmg/8.8.1499; Bockenhauer D, 2001, NAT NEUROSCI, V4, P486, DOI 10.1038/87434; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Duggal P, 1998, CIRCULATION, V97, P142, DOI 10.1161/01.CIR.97.2.142; Franco D, 2001, CARDIOVASC RES, V52, P65, DOI 10.1016/S0008-6363(01)00349-2; Franqueza L, 1999, J BIOL CHEM, V274, P21063, DOI 10.1074/jbc.274.30.21063; Hille B., 1992, IONIC CHANNELS EXCIT; Kaczmarek LK, 1997, PHYSIOL REV, V77, P627, DOI 10.1152/physrev.1997.77.3.627; Kim LA, 2001, BIOPHYS J, V80, p437A; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Melman YF, 2001, J BIOL CHEM, V276, P6439, DOI 10.1074/jbc.M010713200; Nerbonne JM, 1998, J NEUROBIOL, V37, P37, DOI 10.1002/(SICI)1097-4695(199810)37:1<37::AID-NEU4>3.0.CO;2-9; Sanguinetti MC, 2000, J CARDIOVASC ELECTR, V11, P710, DOI 10.1111/j.1540-8167.2000.tb00035.x; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroer TA, 2000, TRAFFIC, V1, P3, DOI 10.1034/j.1600-0854.2000.010102.x; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Sesti F, 1998, J GEN PHYSIOL, V112, P651, DOI 10.1085/jgp.112.6.651; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Tai KK, 1998, NATURE, V391, P605, DOI 10.1038/35416; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Tapper AR, 2000, J GEN PHYSIOL, V116, P379, DOI 10.1085/jgp.116.3.379; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Tristani-Firouzi M, 1998, J PHYSIOL-LONDON, V510, P37, DOI 10.1111/j.1469-7793.1998.037bz.x; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839; Zhu XR, 1999, RECEPTOR CHANNEL, V6, P387	36	73	79	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0390	10.1096/fj.01-0520hyp	http://dx.doi.org/10.1096/fj.01-0520hyp			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874988				2022-12-28	WOS:000174755900031
J	Kakimura, J; Kitamura, Y; Takata, K; Umeki, M; Suzuki, S; Shibagaki, K; Taniguchi, T; Nomura, Y; Gebicke-Haerter, PJ; Smith, MA; Perry, G; Shimohama, S				Kakimura, J; Kitamura, Y; Takata, K; Umeki, M; Suzuki, S; Shibagaki, K; Taniguchi, T; Nomura, Y; Gebicke-Haerter, PJ; Smith, MA; Perry, G; Shimohama, S			Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins	FASEB JOURNAL			English	Article						microglia; neuroprotection; cytokines; Toll-like receptor 4; Alzheimer's disease	CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; HEME OXYGENASE-1; SCAVENGER RECEPTOR; MESSENGER-RNA; CUTTING EDGE; GLIAL-CELLS; MOUSE MODEL; BCL-X	Alzheimer's disease (AD) is characterized by the accumulation of fibrillar amyloid-beta (Abeta) peptides to form amyloid plaques. Understanding the balance of production and clearance of Abeta peptides is the key to elucidating amyloid plaque homeostasis. Microglia in the brain, associated with senile plaques, are likely to play a major role in maintaining this balance. Here, we show that heat-shock proteins (HSPs), such as HSP90, HSP70, and HSP32, induce the production of interleukin 6 and tumor necrosis factor alpha and increase the phagocytosis and clearance of Abeta peptides. This suggests that microglial interaction with Abeta peptides is highly regulated by HSPs. The mechanism of microglial activation by exogenous HSPs involves the nuclear factor kappaB and p38 mitogen-activated protein kinase pathways mediated by Toll-like receptor 4 activation. In AD brains, levels of HSP90 were increased in both the cytosolic and membranous fractions, and HSP90 was colocalized with amyloid plaques. These observations suggest that HSP-induced microglial activation may serve a neuroprotective role by facilitating Abeta clearance and cytokine production.	Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Pharmaceut Univ, Dept Neurobiol, Kyoto 6078412, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sapporo, Hokkaido 0600812, Japan; Cent Inst Mental Hlth, Dept Psychopharmacol, D-68159 Mannheim, Germany; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Kyoto University; Kyoto Pharmaceutical University; Hokkaido University; Central Institute of Mental Health; Case Western Reserve University	Shimohama, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	i53367@sakura.kudpc.kyoto-u.ac	Smith, Mark A/A-9053-2009; Perry, George/A-8611-2009	Perry, George/0000-0002-6547-0172				Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Christie RH, 1996, AM J PATHOL, V148, P399; CRAS P, 1990, AM J PATHOL, V137, P241; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; DUFF GW, 1982, J IMMUNOL METHODS, V52, P333, DOI 10.1016/0022-1759(82)90005-9; ElKhoury J, 1996, NATURE, V382, P716; FILLIT H, 1991, NEUROSCI LETT, V129, P318, DOI 10.1016/0304-3940(91)90490-K; GEBICKEHAERTER PJ, 1989, J NEUROSCI, V9, P183; Hamazaki H, 1996, FEBS LETT, V396, P139, DOI 10.1016/0014-5793(96)01087-3; HAMOS JE, 1991, NEUROLOGY, V41, P345, DOI 10.1212/WNL.41.3.345; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hoshino K, 1999, J IMMUNOL, V162, P3749; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kaneko I, 1997, J NEUROCHEM, V68, P438; Kitamura Y, 1998, GLIA, V22, P138; Kitamura Y, 1999, JPN J PHARMACOL, V79, P1, DOI 10.1254/jjp.79.1; Kitamura Y, 2000, J NEUROIMMUNOL, V106, P95, DOI 10.1016/S0165-5728(00)00239-3; Kitamura Y, 1998, BRAIN RES, V780, P260, DOI 10.1016/S0006-8993(97)01202-X; Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MINOTA S, 1988, J EXP MED, V168, P1475, DOI 10.1084/jem.168.4.1475; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Panahian N, 1999, J NEUROCHEM, V72, P1187; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PEREZ N, 1991, MOL BRAIN RES, V11, P249, DOI 10.1016/0169-328X(91)90033-T; Plumier JCL, 1997, CELL STRESS CHAPERON, V2, P162, DOI 10.1379/1466-1268(1997)002<0162:TMETHI>2.3.CO;2; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PREMKUMAR DRD, 1995, J NEUROCHEM, V65, P1399; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SAWADA M, 1995, INT J DEV NEUROSCI, V13, P253, DOI 10.1016/0736-5748(94)00076-F; Schermer CR, 1999, J GASTROINTEST SURG, V3, P173, DOI 10.1016/S1091-255X(99)80029-8; SCHIPPER HM, 1995, ANN NEUROL, V37, P758, DOI 10.1002/ana.410370609; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; SHIBAHARA S, 1988, SEMIN HEMATOL, V25, P370; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; SMITH MA, 1995, TRENDS NEUROSCI, V18, P172, DOI 10.1016/0166-2236(95)93897-7; SMITH MA, 1994, AM J PATHOL, V145, P42; Stalder M, 1999, AM J PATHOL, V154, P1673, DOI 10.1016/S0002-9440(10)65423-5; STRAUSS S, 1992, LAB INVEST, V66, P223; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; WEGIEL J, 1990, ACTA NEUROPATHOL, V81, P116, DOI 10.1007/BF00334499; Weninger SC, 2001, NAT MED, V7, P527, DOI 10.1038/87839; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yenari MA, 1998, ANN NEUROL, V44, P584, DOI 10.1002/ana.410440403; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	64	250	275	0	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					601	+		10.1096/fj.01-0530fje	http://dx.doi.org/10.1096/fj.01-0530fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919167				2022-12-28	WOS:000174203700002
J	Walther, T; Olah, L; Harms, C; Maul, B; Bader, M; Hortnagl, H; Schultheiss, HP; Mies, G				Walther, T; Olah, L; Harms, C; Maul, B; Bader, M; Hortnagl, H; Schultheiss, HP; Mies, G			Ischemic injury in experimental stroke depends on angiotensin II	FASEB JOURNAL			English	Article						A II; focal cerebral ischemia; transgenic mice; penumbra; collateral flow	CEREBRAL-ARTERY OCCLUSION; CAPTOPRIL PREVENTION PROJECT; TRANSCRIPTION FACTORS; PROTEIN-SYNTHESIS; BLOOD-PRESSURE; BRAIN EDEMA; RECEPTOR; AT(1); MICE; BLOCKADE	Since pharmacological interactions of the renin-angiotensin system appear to alter the neurological outcome of stroke patients significantly, we examined the effect of elevated levels of angiotensin II and the role of its receptor subtype AT1 in brain infarction in transgenic mice after focal cerebral ischemia. Angiotensinogen-overexpressing and angiotensin receptor AT1 knockout mice underwent 1 h or 24 h permanent middle cerebral artery occlusion (MCAO). The current study revealed a much smaller penumbra size, i.e., brain tissue at risk, in angiotensinogen-overexpressing animals compared with their wild-type subgroup after 1 h MCAO, butanenlarged infarct size after 24 h. In contrast, a smaller lesion area of energy failure and a much larger penumbral area were found in AT1 knockout mice compared with wild-type litter-mates. Lower perfusion thresholds for ATP depletion and protein synthesis inhibition after MCAO in AT1-deficient mice and reduced cell damage in an in vitro model using embryonic neurons of AT1 knockout mice suggest injury mechanisms independent of arterial blood pressure. Our data, therefore, demonstrate a direct correlation between brain angiotensin II and the severity of ischemic injury in experimental stroke.	Free Univ Berlin, Dept Cariol & Pneumol, D-12200 Berlin, Germany; Max Planck Inst Neurol Res, Dept Expt Neurol, Cologne, Germany; Humboldt Univ, Fac Med Charite, Inst Pharmacol & Toxicol, D-1086 Berlin, Germany	Free University of Berlin; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Walther, T (corresponding author), Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Cariol & Pneumol, Hindenburgdamm 30, D-12200 Berlin, Germany.	thomas.walther@ukbf.fu-berlin.de	Bader, Michael/K-2124-2013; Harms, Christoph/AAD-7895-2021; Harms, Christoph/HIK-2989-2022	Harms, Christoph/0000-0002-2063-2860; Bader, Michael/0000-0003-4780-4164				BARRY DI, 1982, J CEREBR BLOOD F MET, V2, P347, DOI 10.1038/jcbfm.1982.35; Blume A, 1998, NEUROSCI LETT, V241, P87, DOI 10.1016/S0304-3940(97)00957-9; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Bruer U, 1997, FEBS LETT, V414, P117, DOI 10.1016/S0014-5793(97)00954-X; Catto A, 1996, STROKE, V27, P435, DOI 10.1161/01.STR.27.3.435; Chung O, 1999, AM J HYPERTENS, V12, p150S, DOI 10.1016/S0895-7061(99)00218-6; Dai WJ, 1999, STROKE, V30, P2391, DOI 10.1161/01.STR.30.11.2391; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Diep QN, 1999, HYPERTENSION, V34, P617, DOI 10.1161/01.HYP.34.4.617; Doi Y, 1997, ATHEROSCLEROSIS, V132, P145, DOI 10.1016/S0021-9150(97)00080-4; FERNANDEZ LA, 1994, J CARDIOVASC PHARM, V24, P937, DOI 10.1097/00005344-199424060-00011; FERNANDEZ LA, 1986, STROKE, V17, P82, DOI 10.1161/01.STR.17.1.82; Fournier A, 2000, NEPHROL DIAL TRANSPL, V15, P2, DOI 10.1093/ndt/15.1.2; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Harms C, 2000, FASEB J, V14, P1814, DOI 10.1096/fj.99-0899com; Hata R, 1998, J CEREBR BLOOD F MET, V18, P367, DOI 10.1097/00004647-199804000-00004; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; LEBRUN CJ, 1995, NEUROSCIENCE, V65, P93, DOI 10.1016/0306-4522(94)00482-K; Leri A, 1998, J CLIN INVEST, V101, P1326, DOI 10.1172/JCI316; Li DY, 1999, AM J PHYSIOL-HEART C, V276, pH786, DOI 10.1152/ajpheart.1999.276.3.H786; Lorell BH, 1999, AM J CARDIOL, V83, p48H; Maeda K, 1999, J CEREBR BLOOD F MET, V19, P1092, DOI 10.1097/00004647-199910000-00005; Maeda K, 2000, J CEREBR BLOOD F MET, V20, P10, DOI 10.1097/00004647-200001000-00003; Mark KS, 2000, PEPTIDES, V21, P1965, DOI 10.1016/S0196-9781(00)00346-6; MAUL B, 2001, FASEB J, DOI DOI 10.1096/F4.00-0797FJE; MIES G, 1993, NEUROSCI LETT, V155, P65, DOI 10.1016/0304-3940(93)90674-A; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; Nishimura Y, 2000, STROKE, V31, P2478, DOI 10.1161/01.STR.31.10.2478; Saavedra JM, 1999, REGUL PEPTIDES, V85, P31, DOI 10.1016/S0167-0115(99)00081-6; Scheidegger KJ, 1997, J VASC RES, V34, P436, DOI 10.1159/000159254; SPETH RC, 1985, P NATL ACAD SCI USA, V82, P6340, DOI 10.1073/pnas.82.18.6340; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pH667, DOI 10.1152/ajpheart.1991.261.3.H667; WERNER C, 1991, STROKE, V22, P910, DOI 10.1161/01.STR.22.7.910; Yabuuchi F, 1999, FUND CLIN PHARMACOL, V13, P475, DOI 10.1111/j.1472-8206.1999.tb00006.x	37	92	99	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					169	176		10.1096/fj.01-0601com	http://dx.doi.org/10.1096/fj.01-0601com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11818364				2022-12-28	WOS:000174203700021
J	Bergami, PL; Scaglione, J; Levin, MJ				Bergami, PL; Scaglione, J; Levin, MJ			Antibodies against the carboxyl-terminal end of the Trypanosoma cruzi ribosomal P proteins are pathogenic	FASEB JOURNAL			English	Article						Chagas disease; beta 1-adrenoreceptor; G-protein-coupled receptors; arrhythmia; supraventricular tachycardia	CHAGAS HEART-DISEASE; HUMORAL AUTOIMMUNE-RESPONSE; AUTOANTIBODIES; MICE; INFECTION; RECEPTOR; EPITOPE; LUPUS; CARDIOMYOPATHY; ANTIGENS	Sera from patients with chronic Chagas heart disease recognize the carboxyl-terminal regions of the Trypanosoma cruzi ribosomal P proteins defined by B cell epitopes P013 (EDDDDDFGMGALF) and R13 (EEEDDDMGFGLFD) corresponding to the T. cruzi ribosomal P0 (TcP0) and P2 beta (TcP2 beta) proteins, respectively. It has been hypothesized that both epitopes may induce antibodies that cross-react and stimulate the beta1-adrenoreceptor. However, no proof as to their pathogenicity has been obtained. We investigated the consequences of immunizing mice with either TcP0 or TcP2 beta proteins. Of 24 immunized animals, 16 generated antibodies against the carboxyl-terminal end of the corresponding protein, 13 of which showed an altered ECG (P<0.001, 81%). Immunization with TcP0 induced anti-P013 antibodies that bind to and stimulate cardiac G-protein-coupled receptors and are linked to the induction of supraventricular arrhythmia, repolarization, and conduction abnormalities as monitored by serial electrocardiographic analysis. In contrast, immunization with TcP2<beta> generated anti-R13 antibodies with an exclusive beta1-adrenergic-stimulating activity whose appearance strictly correlated with the recording of supraventricular tachycardia and death. These findings demonstrate that anti-P antibodies are arrhythmogenic in the setting of a normal heart, since no inflammatory lesions or fibrosis were evident to light microscopic examination.	INGEBI, Lab Biol Mol Enfermedad Chagas, RA-1428 Buenos Aires, DF, Argentina		Levin, MJ (corresponding author), INGEBI, Lab Biol Mol Enfermedad Chagas, Vuelta Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	mlevin@dna.uba.ar						ANDRADE S G, 1987, Memorias do Instituto Oswaldo Cruz, V82, P59, DOI 10.1590/S0074-02761987000100010; AZNAR C, 1995, FEMS IMMUNOL MED MIC, V12, P231, DOI 10.1111/j.1574-695X.1995.tb00197.x; Bergami PL, 1997, FEMS IMMUNOL MED MIC, V18, P75, DOI 10.1016/S0928-8244(97)00026-6; Borda ES, 1996, INT J CARDIOL, V54, P149, DOI 10.1016/0167-5273(96)02592-2; BRANDARIZ S, 1995, LANCET, V346, P1370, DOI 10.1016/S0140-6736(95)92388-8; Chiale PA, 2001, CIRCULATION, V103, P1765, DOI 10.1161/01.CIR.103.13.1765; Elies R, 1996, J IMMUNOL, V157, P4203; ELIZARI MV, 2000, ARRHYTMIA MANAGEMENT, P95; FERRARI I, 1995, J EXP MED, V182, P59, DOI 10.1084/jem.182.1.59; Gehrmann J, 2000, J CARDIOVASC ELECTR, V11, P354, DOI 10.1111/j.1540-8167.2000.tb01806.x; GOLDBARG AN, 1968, CARDIOVASC RES, V2, P93, DOI 10.1093/cvr/2.1.93; HALPERIN C, 2000, ARRHYTHMIA MANAGEMEN, P83; Kaplan D, 1997, P NATL ACAD SCI USA, V94, P10301, DOI 10.1073/pnas.94.19.10301; Kierszenbaum F, 1999, CLIN MICROBIOL REV, V12, P210, DOI 10.1128/CMR.12.2.210; KISHIMOTO C, 1984, J AM COLL CARDIOL, V3, P1461, DOI 10.1016/S0735-1097(84)80285-5; LEVIN MJ, 1993, PARASITOL TODAY, V9, P381, DOI 10.1016/0169-4758(93)90088-W; LEVIN MJ, 1993, FEMS IMMUNOL MED MIC, V7, P205, DOI 10.1111/j.1574-695X.1993.tb00400.x; LEVIN MJ, 1989, AM J TROP MED HYG, V41, P530, DOI 10.4269/ajtmh.1989.41.530; LEVITUS G, 1991, CLIN EXP IMMUNOL, V85, P413, DOI 10.1111/j.1365-2249.1991.tb05741.x; LOPETEGUI R, 1983, COMM BIOL, V2, P195; LOPETEGUI R, 1983, COMM BIOL, V2, P79; Mahler E, 2001, EUR J IMMUNOL, V31, P2210, DOI 10.1002/1521-4141(200107)31:7&lt;2210::AID-IMMU2210&gt;3.0.CO;2-J; Masuda MO, 1998, FASEB J, V12, P1551, DOI 10.1096/fasebj.12.14.1551; Matsui S, 1997, J MOL CELL CARDIOL, V29, P641, DOI 10.1006/jmcc.1996.0307; MESRI EA, 1990, J CLIN MICROBIOL, V28, P1219, DOI 10.1128/JCM.28.6.1219-1224.1990; MULLER S, 1985, BIOCHIM BIOPHYS ACTA, V827, P235, DOI 10.1016/0167-4838(85)90208-0; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PILGRIM H I, 1955, Exp Med Surg, V13, P401; POSTAN M, 1987, AM J TROP MED HYG, V37, P541, DOI 10.4269/ajtmh.1987.37.541; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; RUIZ AM, 1985, ACTA TROP, V42, P299; SADIGURSKY M, 1986, BRAZ J MED BIOL RES, V19, P379; Schijman AG, 2000, J HEART LUNG TRANSPL, V19, P1114, DOI 10.1016/S1053-2498(00)00168-6; SCHIJMAN AG, 1992, IMMUNOL LETT, V33, P15, DOI 10.1016/0165-2478(92)90087-5; SKEIKY YAW, 1992, J EXP MED, V176, P201, DOI 10.1084/jem.176.1.201; Tarleton RL, 1999, PARASITOL TODAY, V15, P94, DOI 10.1016/S0169-4758(99)01398-8; TEIXEIRA ARL, 1975, AM J PATHOL, V80, P163; Tekiel VS, 1997, PARASITOLOGY, V115, P495, DOI 10.1017/S0031182097001625; TOMITA M, 1991, CIRCULATION, V83, P635, DOI 10.1161/01.CIR.83.2.635	39	45	45	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2602	2612		10.1096/fj.01-0132com	http://dx.doi.org/10.1096/fj.01-0132com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726536				2022-12-28	WOS:000172964800030
J	Schipke, CG; Boucsein, C; Ohlemeyer, C; Kirchhoff, F; Kettenmann, H				Schipke, CG; Boucsein, C; Ohlemeyer, C; Kirchhoff, F; Kettenmann, H			Astrocyte Ca2+ waves trigger responses in microglial cells in brain slices	FASEB JOURNAL			English	Article						mouse; astrocyte; ATP-release; calcium-wave; microglia; brain slice	GAP JUNCTIONAL COMMUNICATION; DEPENDENT GLUTAMATE RELEASE; GLIAL CALCIUM WAVES; NEURONAL-ACTIVITY; RAT-BRAIN; ACTIVATION; PURINOCEPTOR; PROPAGATION; MORPHOLOGY; MODULATION	Pathologic impacts in the brain lead to a widespread activation of microglial cells far beyond the site of injury. Here, we demonstrate that glial Ca2+ waves can trigger responses in microglial cells. We elicited Ca2+ waves in corpus callosum glial cells by electrical stimulation or local adenosine triphosphate (ATP) ejection in acute brain slices. Macroglial cells, but not microglia, were bulk-loaded with Ca2+-sensitive dyes. Using a transgenic animal in which astrocytes were labeled by the enhanced green fluorescence protein (EGFP) allowed us to identify the reacting cell populations: the wave activated a Ca2+ response in both astrocytes and non-astrocytic glial cells and spread over hundreds of micrometers even into the adjacent cortical and ventricular cell layers. Regenerative ATP release and subsequent activation of metabotropic purinergic receptors caused the propagation of the glial Ca2+ wave: the wave was blocked by the purinergic receptor antagonist Reactive Blue 2 and was not affected by the gap junction blocker octanol, but enhanced in Ca2+ free saline. To test whether microglial cells respond to the wave, microglial cells were labeled with a dye-coupled lectin and membrane currents were recorded with the patch-clamp technique. When the wave passed by, a current with the characteristics of a purinergic response was activated. Thus, Ca2+ waves in situ are not restricted to astrocytic cells, but broadly activate different glial cell types.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Max Planck Inst Expt Med, D-37075 Gottingen, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society	Kettenmann, H (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	hketten@mdc-berlin.de	Kirchhoff, Frank/B-9335-2008; Kettenmann, Helmut/AAJ-5142-2021	Kirchhoff, Frank/0000-0002-2324-2761; Kettenmann, Helmut/0000-0001-8208-0291				ACARIN L, 1994, J HISTOCHEM CYTOCHEM, V42, P1033, DOI 10.1177/42.8.8027523; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; BERGER T, 1991, J NEUROSCI, V11, P3008; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Boucsein C, 2000, EUR J NEUROSCI, V12, P2049, DOI 10.1046/j.1460-9568.2000.00100.x; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHVATAL A, 1995, EUR J NEUROSCI, V7, P129, DOI 10.1111/j.1460-9568.1995.tb01027.x; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; Cotrina ML, 2000, J NEUROSCI, V20, P2835; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; Eugenin EA, 2001, P NATL ACAD SCI USA, V98, P4190, DOI 10.1073/pnas.051634298; Fam SR, 2000, J NEUROSCI, V20, P2800; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; GEHRMANN J, 1993, BRAIN PATHOL, V3, P11, DOI 10.1111/j.1750-3639.1993.tb00720.x; Giaume C, 1998, GLIA, V24, P50, DOI 10.1002/(SICI)1098-1136(199809)24:1<50::AID-GLIA6>3.0.CO;2-4; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; HASSINGER TD, 1995, J NEUROBIOL, V28, P159, DOI 10.1002/neu.480280204; Hide I, 2000, J NEUROCHEM, V75, P965, DOI 10.1046/j.1471-4159.2000.0750965.x; Ilschner S, 1996, NEUROSCIENCE, V73, P1109, DOI 10.1016/0306-4522(96)00107-8; John GR, 1999, P NATL ACAD SCI USA, V96, P11613, DOI 10.1073/pnas.96.20.11613; KIRISCHUK S, 1995, J PHYSIOL-LONDON, V483, P41, DOI 10.1113/jphysiol.1995.sp020566; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lehrmann E, 1997, J COMP NEUROL, V386, P461; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001; Newman EA, 1998, J NEUROSCI, V18, P4022; Newman EA, 1997, SCIENCE, V275, P844, DOI 10.1126/science.275.5301.844; Nolte C, 2001, GLIA, V33, P72; Norenberg W, 1997, BRIT J PHARMACOL, V121, P1087, DOI 10.1038/sj.bjp.0701241; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; Pasti L, 2001, J NEUROSCI, V21, P477, DOI 10.1523/JNEUROSCI.21-02-00477.2001; Prinz M, 1999, J NEUROPATH EXP NEUR, V58, P1078, DOI 10.1097/00005072-199910000-00006; Venance L, 1998, J PHYSIOL-LONDON, V510, P429, DOI 10.1111/j.1469-7793.1998.429bk.x; Verderio C, 2001, J IMMUNOL, V166, P6383, DOI 10.4049/jimmunol.166.10.6383; WALZ W, 1993, J NEUROSCI, V13, P4403; WALZ W, 1994, J NEUROSCI RES, V38, P12, DOI 10.1002/jnr.490380104; Wang ZQ, 2000, ANAL CHEM, V72, P2001, DOI 10.1021/ac9912146; Zahs KR, 1997, GLIA, V20, P10, DOI 10.1002/(SICI)1098-1136(199705)20:1<10::AID-GLIA2>3.3.CO;2-2	40	189	192	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					255	+		10.1096/fj.01-0514fje	http://dx.doi.org/10.1096/fj.01-0514fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11772946				2022-12-28	WOS:000172964800011
J	Layne, MD; Patel, A; Chen, YH; Rebel, VI; Carvajal, IM; Pellacani, A; Ith, B; Zhao, DZ; Schreiber, BM; Yet, SF; Lee, ME; Storch, J; Perrella, MA				Layne, MD; Patel, A; Chen, YH; Rebel, VI; Carvajal, IM; Pellacani, A; Ith, B; Zhao, DZ; Schreiber, BM; Yet, SF; Lee, ME; Storch, J; Perrella, MA			Role of macrophage-expressed adipocyte fatty acid binding protein in the development of accelerated atherosclerosis in hypercholesterolemic mice	FASEB JOURNAL			English	Article						atheroma; inflammatory cytokines; chemokines	COLONY-STIMULATING FACTOR; E-DEFICIENT MICE; APOLIPOPROTEIN-E; AP2(-/-) MICE; CELLS; ARTERIOSCLEROSIS; CHEMOKINES; RECEPTOR; DISEASE; LESIONS	Atherosclerosis is an inflammatory disease process associated with elevated levels of plasma cholesterol, especially low-density lipoproteins. The latter become trapped within the arterial wall and are oxidized and taken up by macrophages to form foam cells. This process is an initiating event for atherosclerosis. Fatty acid binding proteins (FABP) are involved in fatty acid metabolism and cellular lipid transport, and adipocyte FABP (aP2) is also expressed in macrophages. We recently generated mice lacking both apolipoprotein (Apo) E and aP2 (ApoE(-/-) aP2(-/-)) and found that these mice, compared with ApoE(-/-) mice, developed markedly smaller atherosclerotic lesions that contained fewer macrophages. Here we investigated the mechanism(s) responsible for this prevention of atherosclerotic lesion formation. Bone marrow transplantations were performed in ApoE(-/-) mice, receiving cells from either ApoE(-/-) or ApoE(-/-) aP2(-/-) mice. The lack of aP2 in donor marrow cells led to the development of smaller (5.5-fold) atherosclerotic lesions in the recipient mice. No differences were found in plasma cholesterol, glucose, or insulin levels between recipients of bone marrow cells from ApoE(-/-) or ApoE(-/-) aP2(-/-) mice. However, the expression of chemoattractant and inflammatory cytokines was decreased in macrophages from ApoE(-/-) aP2(-/-) mice compared with ApoE(-/-) mice, which may contribute to the decrease in atherosclerotic lesion formation. Taken together, we demonstrate the importance of macrophage aP2 in the development of atherosclerotic lesions.	Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Program Dev Cardiovasc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08903 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Boston University; Rutgers State University New Brunswick	Perrella, MA (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care, 75 Francis St, Boston, MA 02115 USA.	mperrella@rics.bwh.harvard.edu	Yet, Shaw-Fang/O-8583-2019; Yet, Shaw-Fang/B-1067-2010	Schreiber, Barbara/0000-0001-8560-4249; Yet, Shaw-Fang/0000-0001-9097-3962; Rebel, Vivienne/0000-0002-3862-3903; Layne, Matthew/0000-0003-0007-4870; Storch, Judith/0000-0001-5482-1777	NIDDK NIH HHS [R01 DK038389] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiello RJ, 1999, ARTERIOSCL THROM VAS, V19, P1518, DOI 10.1161/01.ATV.19.6.1518; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; CATALA A, 1986, ACTA PHYSIOL PHARM L, V36, P19; Gerszten RE, 2000, J LAB CLIN MED, V136, P87, DOI 10.1067/mlc.2000.108154; Glasser SP, 1996, AM HEART J, V131, P379, DOI 10.1016/S0002-8703(96)90370-1; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; LUNZER MA, 1977, J BIOL CHEM, V252, P5483; Makowski L, 2001, NAT MED, V7, P699, DOI 10.1038/89076; OCKNER RK, 1976, J CLIN INVEST, V58, P632, DOI 10.1172/JCI108510; Orford JL, 2001, J LAB CLIN MED, V137, P82, DOI 10.1067/mlc.2001.110970; Pelton PD, 1999, BIOCHEM BIOPH RES CO, V261, P456, DOI 10.1006/bbrc.1999.1071; PERRELLA MA, 2001, FASEB J         0608; Perrow C., 1994, TECHNOLOGY STUDIES, V1, P1; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Qiao JH, 1997, AM J PATHOL, V150, P1687; Rebel VI, 1999, J EXP MED, V190, P1493, DOI 10.1084/jem.190.10.1493; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rossberg R., 1995, Microsystem Technologies, V2, P11, DOI 10.1007/BF02739522; Scheja L, 1999, DIABETES, V48, P1987, DOI 10.2337/diabetes.48.10.1987; SCHREIBER BM, 1988, ATHEROSCLEROSIS, V69, P69, DOI 10.1016/0021-9150(88)90290-0; Shaughnessy S, 2000, DIABETES, V49, P904, DOI 10.2337/diabetes.49.6.904; SHI CW, 1994, CIRC RES, V75, P199, DOI 10.1161/01.RES.75.2.199; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; SPIEGELMAN BM, 1980, J BIOL CHEM, V255, P8811; STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; THIELE DL, 1989, J CLIN INVEST, V84, P1947, DOI 10.1172/JCI114383; Wilcox J N, 1994, J Atheroscler Thromb, V1 Suppl 1, pS10; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	32	53	62	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2733	+		10.1096/fj.01-0374fje	http://dx.doi.org/10.1096/fj.01-0374fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606480				2022-12-28	WOS:000171920400013
J	Mertens, A; Holvoet, P				Mertens, A; Holvoet, P			Oxidized LDL and HDL: antagonists in atherothrombosis	FASEB JOURNAL			English	Review						atherosclerosis; oxidation; lipoproteins; coronary artery disease	LOW-DENSITY-LIPOPROTEIN; PLATELET-ACTIVATING-FACTOR; SMOOTH-MUSCLE CELLS; CORONARY-ARTERY DISEASE; HUMAN ENDOTHELIAL-CELLS; NITRIC-OXIDE-SYNTHASE; MONOCYTE-DERIVED MACROPHAGES; HUMAN ATHEROSCLEROTIC LESIONS; OXIDATIVELY MODIFIED LDL; SCAVENGER RECEPTOR CD36	Increased LDL oxidation is associated with coronary artery disease. The predictive value of circulating oxidized LDL is additive to the Global Risk Assessment Score for cardiovascular risk prediction based on age, gender, total and HDL cholesterol, diabetes, hypertension, and smoking. Circulating oxidized LDL does not originate from extensive metal ion-induced oxidation in the blood but from mild oxidation in the arterial wall by cell-associated lipoxygenase and/or myeloperoxidase. Oxidized LDL induces atherosclerosis by stimulating monocyte infiltration and smooth muscle cell migration and proliferation. It contributes to atherothrombosis by inducing endothelial cell apoptosis, and thus plaque erosion, by impairing the anticoagulant balance in endothelium, stimulating tissue factor production by smooth muscle cells, and inducing apoptosis in macrophages. HDL cholesterol levels are inversely related to risk of coronary artery disease. HDL prevents atherosclerosis by reverting the stimulatory effect of oxidized LDL on monocyte infiltration. The HDL-associated enzyme paraoxonase inhibits the oxidation of LDL. PAF-acetyl hydrolase, which circulates in association with HDL and is produced in the arterial wall by macrophages, degrades bioactive oxidized phospholipids. Both enzymes actively protect hypercholesterolemic mice against atherosclerosis. Oxidized LDL inhibits these enzymes. Thus, oxidized LDL and HDL are indeed antagonists in the development of cardiovascular disease.	Katholieke Univ Leuven, Ctr Expt Surg & Anesthesiol, B-3000 Louvain, Belgium	KU Leuven	Holvoet, P (corresponding author), Katholieke Univ Leuven, Ctr Expt Surg & Anesthesiol, Campus Gasthuisberg,O&N,Herestr 49, B-3000 Louvain, Belgium.	paul.holvoet@med.kuleuven.ac.be	HOLVOET, PAUL/T-8434-2017	HOLVOET, PAUL/0000-0001-9201-0772; Mertens, Ann/0000-0002-1649-4311				Allison BA, 1999, ARTERIOSCL THROM VAS, V19, P1354, DOI 10.1161/01.ATV.19.5.1354; Anthonsen MW, 2000, ARTERIOSCL THROM VAS, V20, P1276, DOI 10.1161/01.ATV.20.5.1276; Aoyama T, 2000, FEBS LETT, V467, P217, DOI 10.1016/S0014-5793(00)01154-6; ARMSTRONG DA, 1992, MED HYPOTHESES, V38, P244, DOI 10.1016/0306-9877(92)90103-J; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; BERGMARK C, 1995, ARTERIOSCL THROM VAS, V15, P441, DOI 10.1161/01.ATV.15.4.441; Bielicki JK, 1999, J LIPID RES, V40, P948; Bloodsworth A, 2000, ARTERIOSCL THROM VAS, V20, P1707, DOI 10.1161/01.ATV.20.7.1707; BOTTALICO LA, 1991, J BIOL CHEM, V266, P22866; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Calvo D, 1998, J LIPID RES, V39, P777; Carr AC, 2000, ARTERIOSCL THROM VAS, V20, P1716, DOI 10.1161/01.ATV.20.7.1716; Carr AC, 2001, J BIOL CHEM, V276, P1822, DOI 10.1074/jbc.M009082200; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CLINTON SK, 1992, AM J PATHOL, V140, P301; COCKERILL GW, 1995, ARTERIOSCL THROM VAS, V15, P1987, DOI 10.1161/01.ATV.15.11.1987; Cominacini L, 1997, FREE RADICAL BIO MED, V22, P117, DOI 10.1016/S0891-5849(96)00271-7; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; DeGeest B, 1997, CIRCULATION, V96, P4349; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; Desrumaux C, 1999, FASEB J, V13, P883, DOI 10.1096/fasebj.13.8.883; Dhaliwal BS, 2000, J LIPID RES, V41, P1658; Esaki T, 2000, NITRIC OXIDE-BIOL CH, V4, P561, DOI 10.1006/niox.2000.0311; EVANGELOU AM, 1994, PROSTAG LEUKOTR ESS, V50, P1, DOI 10.1016/0952-3278(94)90101-5; Farber A, 1999, J SURG RES, V85, P323, DOI 10.1006/jsre.1999.5663; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Foody JM, 2000, CIRCULATION, V102, P90; FREI B, 1993, J LIPID RES, V34, P2135; Gardner CD, 1996, JAMA-J AM MED ASSOC, V276, P875, DOI 10.1001/jama.276.11.875; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Grafe M, 1998, ATHEROSCLEROSIS, V137, P87, DOI 10.1016/S0021-9150(97)00258-X; Grundy SM, 1999, CIRCULATION, V100, P1481, DOI 10.1161/01.CIR.100.13.1481; Guo JP, 1996, J APPL PHYSIOL, V81, P774, DOI 10.1152/jappl.1996.81.2.774; Harats D, 2000, ARTERIOSCL THROM VAS, V20, P2100, DOI 10.1161/01.ATV.20.9.2100; Hedrick CC, 2000, ARTERIOSCL THROM VAS, V20, P1946, DOI 10.1161/01.ATV.20.8.1946; Hedrick CC, 1999, ADV EXP MED BIOL, V469, P455; Heermeier K, 2001, J AM SOC NEPHROL, V12, P456, DOI 10.1681/ASN.V123456; Heinecke JW, 1997, CURR OPIN LIPIDOL, V8, P268, DOI 10.1097/00041433-199710000-00005; Heller JI, 2000, J BIOL CHEM, V275, P9957, DOI 10.1074/jbc.275.14.9957; Holvoet P, 1997, CURR OPIN LIPIDOL, V8, P320, DOI 10.1097/00041433-199710000-00012; Holvoet P, 1998, CIRCULATION, V98, P1487, DOI 10.1161/01.CIR.98.15.1487; Holvoet P, 2000, ARTERIOSCL THROM VAS, V20, P698, DOI 10.1161/01.ATV.20.3.698; Holvoet P, 1996, THROMB HAEMOSTASIS, V76, P663; Holvoet P, 1998, J CLIN INVEST, V102, P379, DOI 10.1172/JCI3038; Holvoet P, 2001, ARTERIOSCL THROM VAS, V21, P844, DOI 10.1161/01.ATV.21.5.844; Holvoet P, 1998, ARTERIOSCL THROM VAS, V18, P100, DOI 10.1161/01.ATV.18.1.100; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; IMAIZUMI TA, 1995, J INTERN MED, V238, P5, DOI 10.1111/j.1365-2796.1995.tb00894.x; Ishii H, 1996, J BIOL CHEM, V271, P8458, DOI 10.1074/jbc.271.14.8458; Ivandic B, 1999, ARTERIOSCL THROM VAS, V19, P1284, DOI 10.1161/01.ATV.19.5.1284; Jovinge S, 1997, ARTERIOSCL THROM VAS, V17, P490, DOI 10.1161/01.ATV.17.3.490; Kim JG, 1999, ATHEROSCLEROSIS, V143, P335, DOI 10.1016/S0021-9150(98)00320-7; Koba S, 2000, ATHEROSCLEROSIS, V149, P61, DOI 10.1016/S0021-9150(99)00298-1; Kockx MM, 1998, ARTERIOSCL THROM VAS, V18, P1519, DOI 10.1161/01.ATV.18.10.1519; Kohno H, 2000, CLIN BIOCHEM, V33, P243, DOI 10.1016/S0009-9120(00)00065-5; Kohno M, 1998, CIRCULATION, V98, P353, DOI 10.1161/01.CIR.98.4.353; KUGIYAMA K, 1993, CIRC RES, V73, P335, DOI 10.1161/01.RES.73.2.335; Kume N, 1998, CIRC RES, V83, P322, DOI 10.1161/01.RES.83.3.322; Kume N, 2000, ANN NY ACAD SCI, V902, P323; Lamarche B, 1998, JAMA-J AM MED ASSOC, V279, P1955, DOI 10.1001/jama.279.24.1955; Lamarche B, 1997, CIRCULATION, V95, P69, DOI 10.1161/01.CIR.95.1.69; Laursen JB, 2001, CIRCULATION, V103, P1282; Lehtimaki T, 1999, ARTERIOSCL THROM VAS, V19, P23, DOI 10.1161/01.ATV.19.1.23; Leitinger N, 1999, P NATL ACAD SCI USA, V96, P12010, DOI 10.1073/pnas.96.21.12010; Leitinger N, 1999, ARTERIOSCL THROM VAS, V19, P1291, DOI 10.1161/01.ATV.19.5.1291; Li DY, 2000, ARTERIOSCL THROM VAS, V20, P1116, DOI 10.1161/01.ATV.20.4.1116; LI HM, 1995, J CLIN INVEST, V95, P122, DOI 10.1172/JCI117628; Li LX, 1998, ENDOTHELIUM-NEW YORK, V6, P1, DOI 10.3109/10623329809053400; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; MACKNESS MI, 1993, ATHEROSCLEROSIS, V104, P129, DOI 10.1016/0021-9150(93)90183-U; MAIER JAM, 1994, BIOCHEM BIOPH RES CO, V204, P673, DOI 10.1006/bbrc.1994.2512; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; MALORANTA U, 1994, FEBS LETT, V337, P179, DOI 10.1016/0014-5793(94)80269-6; Marathe S, 1999, ARTERIOSCL THROM VAS, V19, P2648, DOI 10.1161/01.ATV.19.11.2648; MCNALLY AK, 1990, J IMMUNOL, V145, P254; Metzler B, 2000, AM J PATHOL, V156, P1875, DOI 10.1016/S0002-9440(10)65061-4; Minami M, 2000, BIOCHEM BIOPH RES CO, V272, P357, DOI 10.1006/bbrc.2000.2778; Murase T, 1998, CIRC RES, V83, P328, DOI 10.1161/01.RES.83.3.328; Nagase M, 2001, BIOCHEM BIOPH RES CO, V281, P720, DOI 10.1006/bbrc.2001.4374; Napoli C, 2000, FASEB J, V14, P1996, DOI 10.1096/fj.99-0986com; Navab M, 1997, J CLIN INVEST, V99, P2005, DOI 10.1172/JCI119369; Navab M, 2000, J LIPID RES, V41, P1481; Navab M, 2000, J LIPID RES, V41, P1495; Newby AC, 1999, CARDIOVASC RES, V41, P345, DOI 10.1016/S0008-6363(98)00286-7; Newby AC, 1996, CURR OPIN CARDIOL, V11, P574, DOI 10.1097/00001573-199611000-00004; NIGON F, 1991, J LIPID RES, V32, P1741; Orchard TJ, 1999, DIABETES, V48, P1454, DOI 10.2337/diabetes.48.7.1454; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; Patel RP, 2000, CARDIOVASC RES, V47, P465, DOI 10.1016/S0008-6363(00)00086-9; Penn MS, 2000, BLOOD, V96, P3056; Petit L, 1999, ARTERIOSCL THROM VAS, V19, P309, DOI 10.1161/01.ATV.19.2.309; Pietzsch J, 2000, ARTERIOSCL THROM VAS, V20, pE63, DOI 10.1161/01.ATV.20.10.e63; Pietzsch J, 2000, BIOCHEM BIOPH RES CO, V270, P852, DOI 10.1006/bbrc.2000.2533; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Quarck R, 2001, CIRCULATION, V103, P2495; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; RAMOS P, 1995, J LIPID RES, V36, P2113; RANKIN SM, 1991, J LIPID RES, V32, P449; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rikitake Y, 1998, ATHEROSCLEROSIS, V136, P51, DOI 10.1016/S0021-9150(97)00186-X; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; Schreyer SA, 1996, J BIOL CHEM, V271, P26174, DOI 10.1074/jbc.271.42.26174; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; STAFFORINI DM, 1991, LIPIDS, V26, P979, DOI 10.1007/BF02536488; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; STIKORAHM A, 1992, ARTERIOSCLER THROMB, V12, P1099, DOI 10.1161/01.ATV.12.9.1099; Subbanagounder G, 1999, CIRC RES, V85, P311, DOI 10.1161/01.RES.85.4.311; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Theilmeier G, 2000, FASEB J, V14, P2032, DOI 10.1096/fj.99-1029com; THORIN E, 1994, ARTERIOSCLER THROMB, V14, P453, DOI 10.1161/01.ATV.14.3.453; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; Toikka JO, 1999, ATHEROSCLEROSIS, V147, P133, DOI 10.1016/S0021-9150(99)00186-0; Toshima S, 2000, ARTERIOSCL THROM VAS, V20, P2243, DOI 10.1161/01.ATV.20.10.2243; TSAOUSSIS V, 1994, J LIPID MEDIAT CELL, V9, P317; TSELEPIS AD, 1995, ARTERIOSCL THROM VAS, V15, P1764, DOI 10.1161/01.ATV.15.10.1764; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Upston JM, 1997, J BIOL CHEM, V272, P30067, DOI 10.1074/jbc.272.48.30067; Uusitupa MIJ, 1996, ARTERIOSCL THROM VAS, V16, P1236, DOI 10.1161/01.ATV.16.10.1236; vandeVijver LPL, 1996, ATHEROSCLEROSIS, V122, P245, DOI 10.1016/0021-9150(95)05759-5; Vidal F, 1998, EUR J BIOCHEM, V252, P378, DOI 10.1046/j.1432-1327.1998.2520378.x; Vohl MC, 1999, BIOCHEMISTRY-US, V38, P5976, DOI 10.1021/bi982258w; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; WILSON BD, 1992, SEMIN THROMB HEMOST, V18, P11, DOI 10.1055/s-2007-1002405; Xu XP, 1999, CIRCULATION, V99, P993, DOI 10.1161/01.CIR.99.8.993; Yoshida H, 1998, ARTERIOSCL THROM VAS, V18, P794, DOI 10.1161/01.ATV.18.5.794	135	324	344	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2073	2084		10.1096/fj.01-0273rev	http://dx.doi.org/10.1096/fj.01-0273rev			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641234				2022-12-28	WOS:000171920400019
J	Goukassian, D; Diez-Juan, A; Asahara, T; Schratzberger, P; Silver, M; Murayama, T; Isner, JM; Andres, V				Goukassian, D; Diez-Juan, A; Asahara, T; Schratzberger, P; Silver, M; Murayama, T; Isner, JM; Andres, V			Overexpression of p27(Kip1) by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis	FASEB JOURNAL			English	Article						p27; adenovirus; gene therapy	DEPENDENT KINASE INHIBITORS; GROWTH-FACTOR EXPRESSION; CYCLIN-E; BREAST-CANCER; METALLOPROTEINASE ACTIVITY; RECOMBINANT ADENOVIRUS; GENE-TRANSFER; P27; DEGRADATION; E2F	Formation of new blood vessels in the adult animal (i.e., angiogenesis) is an important event for tissue repair and for tumor growth and metastasis. Angiogenesis involves the migration and proliferation of endothelial cells. We have investigated the role of the growth suppressor p27(Kip1) (p27) on endothelial cell function in vitro and angiogenesis in vivo. We have generated Ad-TetON, a replication-deficient adenovirus that constitutively expresses the reverse tet-responsive transcriptional activator, and Ad-TRE-p27, which drives expression of p27 under the control of the tet response element. Western blot analysis demonstrated doxycycline-dependent overexpression of p27 in human umbilical vein endothelial cells (HUVECs) coinfected with Ad-TetON and Ad-TRE-p27, which resulted in a marked inhibition of DNA replication and cell migration in vitro. Inducible overexpression of p27 in cultured HUVECs inhibited the formation of tubelike structures and, when applied in a murine model of hind limb ischemia, reduced hind limb blood flow recovery and capillary density. These findings thus underscore a novel role of p27 in regulating endothelial cell migration in vitro and angiogenesis in vivo, suggesting a novel anti-angiogenic therapy based on inducible p27 overexpression.	CSIC, Inst Biomed Valencia, Lab Vasc Biol, Spanish Council Sci Res, Valencia 46010, Spain; Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA; Tufts Univ, St Elizabeths Med Ctr, Sch Med, Dept Med Cardiol, Boston, MA 02135 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Boston University; St. Elizabeth's Medical Center; Tufts University	Andres, V (corresponding author), CSIC, Inst Biomed Valencia, Lab Vasc Biol, Spanish Council Sci Res, Valencia 46010, Spain.	vandres@ibv.csic.es	Diez Juan, Antonio/D-3695-2018; Andres, Vicente/I-6440-2014; Diez-Juan, Antonio/H-5464-2015	Andres, Vicente/0000-0002-0125-7209; Diez-Juan, Antonio/0000-0002-0166-1869; Goukassian, David/0000-0001-5270-5270				BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bouvet M, 1998, CANCER RES, V58, P2288; Boyle JR, 1998, J VASC SURG, V27, P354, DOI 10.1016/S0741-5214(98)70367-2; Braun-Dullaeus RC, 1999, J CLIN INVEST, V104, P815, DOI 10.1172/JCI5339; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; Chen DH, 2000, ARTERIOSCL THROM VAS, V20, P629, DOI 10.1161/01.ATV.20.3.629; Cheung PY, 2000, CIRCULATION, V101, P1833, DOI 10.1161/01.CIR.101.15.1833; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Diez-Juan A, 2001, FASEB J, V15, P1989, DOI 10.1096/fj.01-0130com; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; Feldman AL, 2000, CANCER-AM CANCER SOC, V89, P1181; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fife RS, 2000, CANCER LETT, V153, P75, DOI 10.1016/S0304-3835(00)00348-7; Fiorentino M, 2000, CLIN CANCER RES, V6, P3966; Folkman J, 1999, Forum (Genova), V9, P59; Fukui R, 1997, ATHEROSCLEROSIS, V132, P53, DOI 10.1016/S0021-9150(97)00086-5; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harada H, 1999, CANCER RES, V59, P3783; Harding TC, 1998, NAT BIOTECHNOL, V16, P553, DOI 10.1038/nbt0698-553; Ihling C, 1999, ATHEROSCLEROSIS, V144, P7, DOI 10.1016/S0021-9150(99)00032-5; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Kay MA, 2001, NAT MED, V7, P33, DOI 10.1038/83324; Lavia P, 1999, BIOESSAYS, V21, P221; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Poolman RA, 1999, CIRC RES, V85, P117, DOI 10.1161/01.RES.85.2.117; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Pyo R, 2000, J CLIN INVEST, V105, P1641, DOI 10.1172/JCI8931; Ryan ME, 2001, CURR MED CHEM, V8, P305, DOI 10.2174/0929867013373598; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Smith GN, 1999, ARTHRITIS RHEUM, V42, P1140, DOI 10.1002/1529-0131(199906)42:6<1140::AID-ANR10>3.0.CO;2-7; So JBY, 2000, J SURG RES, V94, P56, DOI 10.1006/jsre.2000.5998; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; Takano Y, 2000, AM J PATHOL, V156, P585, DOI 10.1016/S0002-9440(10)64763-3; Tanner FC, 2000, CIRCULATION, V101, P2022, DOI 10.1161/01.CIR.101.17.2022; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Vieillard-Baron A, 2000, CIRC RES, V87, P418; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1	56	83	88	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					1877	1885		10.1096/fj.01-0065com	http://dx.doi.org/10.1096/fj.01-0065com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532967	Green Submitted			2022-12-28	WOS:000171372700002
J	Lang, CH; Silvis, C; Nystrom, G; Frost, RA				Lang, CH; Silvis, C; Nystrom, G; Frost, RA			Regulation of myostatin by glucocorticoids after thermal injury	FASEB JOURNAL			English	Article						burns; dexamethasone; TNF binding protein; IGF-I; IGF-II; muscle	IGF-BINDING-PROTEINS; SKELETAL-MUSCLE; MESSENGER-RNA; BURN INJURY; EXPRESSION; CYTOKINE; SYSTEM	Myostatin is a negative regulator of muscle mass that may contribute to the muscle wasting observed in response to traumatic injury. The purpose of this study was to determine whether muscle myostatin mRNA abundance was altered by different traumatic insults and whether the change in myostatin was associated with alterations in insulin-like growth factor (IGF)-I and IGF-II mRNA in gastrocnemius, or the concentration of glucocorticoids in plasma. The abundance of myostatin mRNA was increased three- to fourfold in gastrocnemius 24 h after a 30% total body surface area burn injury. In contrast, neither the injection of endotoxin nor the induction of peritonitis significantly altered myostatin mRNA at the same time point. IGF-I mRNA in muscle was decreased (40-60%) by all insults, whereas the abundance of IGF-II mRNA was unaltered. The plasma concentration of corticosterone was increased approximately threefold after burn injury, was only transiently elevated after endotoxin, and was only mildly increased (25%) in septic rats at the time of sacrifice. Pretreatment with the type II glucocorticoid receptor antagonist RU486 prevented the increased myostatin mRNA and decreased muscle protein content after burn. A single injection of dexamethasone in naive control animals increased muscle myostatin mRNA by 60% and 2.7-fold at 4 h and 24 h, respectively. In contrast, pretreatment of burn rats with tumor necrosis factor binding protein (TNFBP), which antagonizes the actions of this cytokine, failed to prevent the burn-induced increase in myostatin mRNA or the loss of muscle protein. The results of this study indicate that thermal injury, but not endotoxin or sepsis, increases myostatin mRNA content. Moreover, the burn-induced increase in myostatin appears to be largely mediated by the enhanced endogenous secretion of glucocorticoids and independent of changes in IGF-I, IGF-II, or TNF.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol H166, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Surg, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Lang, CH (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol H166, Hershey, PA 17033 USA.	clang@psu.edu						Bark TH, 1998, AM J PHYSIOL-ENDOC M, V275, pE118, DOI 10.1152/ajpendo.1998.275.1.E118; BOSCHE WJ, 1995, J CELL PHYSIOL, V164, P324, DOI 10.1002/jcp.1041640213; CANNON JG, 1992, CRIT CARE MED, V20, P1414, DOI 10.1097/00003246-199210000-00009; Carlson CJ, 1999, AM J PHYSIOL-REG I, V277, pR601, DOI 10.1152/ajpregu.1999.277.2.R601; Cooney R, 1999, AM J PHYSIOL-ENDOC M, V276, pE611, DOI 10.1152/ajpendo.1999.276.4.E611; Cooney RN, 1997, SHOCK, V7, P1, DOI 10.1097/00024382-199701000-00001; ELAHI D, 1993, AM J PHYSIOL, V265, pE831, DOI 10.1152/ajpendo.1993.265.6.E831; ESPAT NJ, 1995, J SURG RES, V59, P153, DOI 10.1006/jsre.1995.1147; Fan J, 1996, AM J PHYSIOL-REG I, V270, pR621, DOI 10.1152/ajpregu.1996.270.3.R621; FAN J, 1995, AM J PHYSIOL-REG I, V269, pR1204, DOI 10.1152/ajpregu.1995.269.5.R1204; FANG CH, 1995, J AM COLL SURGEONS, V180, P33; Fang CH, 1998, AM J PHYSIOL-REG I, V275, pR1091, DOI 10.1152/ajpregu.1998.275.4.R1091; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FONG Y, 1989, AM J PHYSIOL, V256, pR659, DOI 10.1152/ajpregu.1989.256.3.R659; Frost R A, 1998, Curr Opin Clin Nutr Metab Care, V1, P195, DOI 10.1097/00075197-199803000-00010; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Ji SQ, 1998, AM J PHYSIOL-REG I, V275, pR1265, DOI 10.1152/ajpregu.1998.275.4.R1265; Kataranovski M, 1999, PHYSIOL RES, V48, P473; KIRK S, 1966, J ENDOCRINOL, V149, P81; Lang CH, 1996, AM J PHYSIOL-ENDOC M, V270, pE430, DOI 10.1152/ajpendo.1996.270.3.E430; Lang CH, 2000, AM J PHYSIOL-ENDOC M, V278, pE1133, DOI 10.1152/ajpendo.2000.278.6.E1133; Lang CH, 2000, AM J PHYSIOL-ENDOC M, V278, pE1087, DOI 10.1152/ajpendo.2000.278.6.E1087; LANG CH, 1984, AM J PHYSIOL, V248, pR471; Lee SJ, 1999, CURR OPIN GENET DEV, V9, P604, DOI 10.1016/S0959-437X(99)00004-0; Li YH, 1997, AM J PHYSIOL-REG I, V272, pR1990, DOI 10.1152/ajpregu.1997.272.6.R1990; MAO J, 1992, MOL CELL BIOCHEM, V109, P1; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Savary I, 1998, BRIT J NUTR, V79, P297, DOI 10.1079/BJN19980047; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V278, pE76, DOI 10.1152/ajpendo.2000.278.1.E76; Sharma M, 1999, J CELL PHYSIOL, V180, P1; SHIVJI R, 1999, 81 ANN M END SOC JUN; Taylor WE, 2001, AM J PHYSIOL-ENDOC M, V280, pE221, DOI 10.1152/ajpendo.2001.280.2.E221; Wehling M, 2000, FASEB J, V14, P103, DOI 10.1096/fasebj.14.1.103; ZAMIR O, 1991, J SURG RES, V50, P579, DOI 10.1016/0022-4804(91)90045-N	35	72	90	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1807	+		10.1096/fj.00-0849fje	http://dx.doi.org/10.1096/fj.00-0849fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481237				2022-12-28	WOS:000169261200024
J	Uz, T; Dwivedi, Y; Qeli, A; Peters-Golden, M; Pandey, G; Manev, H				Uz, T; Dwivedi, Y; Qeli, A; Peters-Golden, M; Pandey, G; Manev, H			Glucocorticoid receptors are required for up-regulation of neuronal 5-lipoxygenase (5LOX) expression by dexamethasone	FASEB JOURNAL			English	Article						cerebellar granule neurons; leukotrienes; arachidonic acid; cerebellar granule neurons	CEREBELLAR GRANULE CELLS; MESSENGER-RNA STABILITY; CENTRAL-NERVOUS-SYSTEM; LEUKOTRIENE C-4; PUTATIVE ROLE; ACTIVATING PROTEIN; PRIMARY CULTURES; GENE-EXPRESSION; BRAIN; ACID	5- lipoxygenase (5LOX) is the key enzyme in the synthesis of leukotrienes from arachidonic acid. Hyperglucocorticoidemia, dexamethasone, and aging up-regulate 5LOX in the brain, including the cerebellum in vivo. We studied the mechanisms of dexamethasone-triggered 5LOX upregulation in primary cultures of rat cerebellar granule neurons (CGN). We measured 5LOX mRNA and protein contents, and the formation of cysteinyl leukotrienes (LTC4, LTD4, and LTE4). The dexamethasone (0.1 muM or 1 muM)-increased 5LOX mRNA and protein contents were already observed at 3 h of treatment, and they persisted for at least 24 h. Dexamethasone also increased the content of cysteinyl leukotrienes, assayed in the presence of 2 muM calcium ionophore A23187 and 10 muM arachidonic acid. The stimulatory effect of dexamethasone on 5LOX expression was inhibited by the glucocorticoid receptor (GR) antagonist RU486 and by reducing the CGN content of GR receptor protein with a GR-specific antisense oligonucleotide. The 5LOX mRNA half-life was longer in dexamethasone than in vehicle-treated CGNs. Our results indicate that dexamethasone increases 5LOX expression in CGNs in a GR-dependent manner and that it also increases the stability of 5LOX mRNA. Further studies are warranted to elucidate the physiologic/pathologic significance of glucocorticoid-regulated expression of 5LOX in the central nervous system.	Univ Illinois, Coll Med, Dept Psychiat, Inst Psychiat, Chicago, IL 60612 USA; Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Michigan System; University of Michigan	Manev, H (corresponding author), Univ Illinois, Coll Med, Dept Psychiat, Inst Psychiat, 1601 W Taylor St,MC 912, Chicago, IL 60612 USA.	HManev@psych.uic.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015347] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG15347] Funding Source: Medline; NIMH NIH HHS [R01-MH56528] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHIMA RS, 1991, ENDOCRINOLOGY, V129, P226, DOI 10.1210/endo-129-1-226; Ahlbom E, 2000, P NATL ACAD SCI USA, V97, P14726, DOI 10.1073/pnas.260501697; BIRMINGHAM MK, 1993, CELL MOL NEUROBIOL, V13, P373, DOI 10.1007/BF00711578; Cadepond F, 1997, ANNU REV MED, V48, P129; Chabot C, 1998, HIPPOCAMPUS, V8, P299, DOI 10.1002/(SICI)1098-1063(1998)8:3<299::AID-HIPO11>3.0.CO;2-W; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Colamorea T, 1999, BIOCHEM BIOPH RES CO, V265, P617, DOI 10.1006/bbrc.1999.1732; de Kloet ER, 1999, TRENDS NEUROSCI, V22, P422, DOI 10.1016/S0166-2236(99)01438-1; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; HINES D, 1994, J RECEPTOR RES, V14, P297, DOI 10.3109/10799899409066038; Korte SM, 1996, EUR J PHARMACOL, V301, P19, DOI 10.1016/0014-2999(96)00064-7; Lammers CH, 1996, J NEUROCHEM, V66, P147; Magri F, 2000, DEMENT GERIATR COGN, V11, P90, DOI 10.1159/000017220; Manev H, 1999, ANN NY ACAD SCI, V890, P183, DOI 10.1111/j.1749-6632.1999.tb07994.x; Manev H, 2000, MED HYPOTHESES, V54, P75, DOI 10.1054/mehy.1998.0824; Manev H, 2000, J NEUROCHEM, V74, pS64; Manev H, 2000, FASEB J, V14, P1464, DOI 10.1096/fj.14.10.1464; Marlier LNJL, 1997, J MOL NEUROSCI, V9, P1, DOI 10.1007/BF02789390; Mayatepek E, 2000, EUR J PEDIATR, V159, P811, DOI 10.1007/s004310000601; Moore FL, 1999, BRAIN BEHAV EVOLUT, V54, P41, DOI 10.1159/000006610; Morimoto M, 1996, NEUROSCI RES, V26, P235, DOI 10.1016/S0168-0102(96)01105-4; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249, DOI 10.1152/ajpheart.1995.268.3.H1249; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; Paris D, 2000, ANN NY ACAD SCI, V903, P97, DOI 10.1111/j.1749-6632.2000.tb06355.x; Peters-Golden M, 1998, CLIN EXP ALLERGY, V28, P1059; PETERSGOLDEN M, 1989, AM REV RESPIR DIS, V140, P1210, DOI 10.1164/ajrccm/140.5.1210; Poon M, 1999, MOL CELL BIOL, V19, P6471; PSHENICHKIN SP, 1995, J BIOL CHEM, V270, P5994, DOI 10.1074/jbc.270.11.5994; QU T, 2001, J NEUROPSYCH CLIN NE; Qu TY, 2000, NEUROBIOL AGING, V21, P647, DOI 10.1016/S0197-4580(00)00167-6; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Riddick CA, 1997, EUR J BIOCHEM, V246, P112, DOI 10.1111/j.1432-1033.1997.00112.x; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; Sanchez MM, 2000, J NEUROSCI, V20, P4657, DOI 10.1523/JNEUROSCI.20-12-04657.2000; SANTI MR, 1994, J NEUROCHEM, V63, P1207; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; SIMMET T, 1991, BRAIN RES, V540, P283, DOI 10.1016/0006-8993(91)90519-2; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Uz T, 1999, J NEUROCHEM, V73, P693, DOI 10.1046/j.1471-4159.1999.0730693.x; Uz T, 1998, FASEB J, V12, P439, DOI 10.1096/fasebj.12.6.439; Uz T, 1997, J NEUROCHEM, V69, P2220; Vaughan CW, 1997, NATURE, V390, P611, DOI 10.1038/37610; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Xu ZX, 1997, AM J PHYSIOL-LUNG C, V272, pL860, DOI 10.1152/ajplung.1997.272.5.L860	44	28	28	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1792	+		10.1096/fj.00-0836fje	http://dx.doi.org/10.1096/fj.00-0836fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481232	Green Submitted			2022-12-28	WOS:000169261200034
J	Parenti, A; Morbidelli, L; Ledda, F; Granger, HJ; Ziche, M				Parenti, A; Morbidelli, L; Ledda, F; Granger, HJ; Ziche, M			The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway	FASEB JOURNAL			English	Article						neovascularization; kinins; endothelial cells; angiogenic factor expression; receptor signaling	FIBROBLAST GROWTH-FACTOR; B-1 RECEPTORS; IN-VIVO; CELL-PROLIFERATION; DNA-SYNTHESIS; B2 RECEPTORS; KININS; EXPRESSION; MECHANISM; RAT	Bradykinin (BK) mediates inflammation and contributes to angiogenesis. We assessed the mechanisms for BK contribution to angiogenesis. Nanomolar concentrations of BK induced angiogenesis in rabbit corneas in absence of inflammation. The effect was dose-dependent and mediated by the B1 receptor. B2 receptor stimulation failed to directly promote vascular growth unless inflammation was induced. Anti-fibroblast growth factor-2 (FGF-2) antibody blocked the effect of BK or 131 receptor agonist. In postcapillary venular endothelial cells (CVEC), B2 receptor activation induced inositol phosphate turnover and calcium transients, whereas the B1 receptor was coupled to nitric oxide synthase (NOS) up-regulation and activation and cGMP increase. Differential RT-PCR and Western blot analysis revealed FGF-2 up-regulation in cells exposed to BK or to the selective B1 agonist, whereas the B2 agonist was without effect. Consistently, BK and the B1 but not the B2 agonist exerted a proliferative effect on CVEC, which was prevented by anti-FGF-2 antibody and by NOS inhibition. These results demonstrate that BK is angiogenic despite its proinflammatory activity and that the B1 receptor is involved. The B 1 receptor is coupled to NOS activation and FGF-2 up-regulation, events not shared by the B2 receptor activation.	Univ Siena, Inst Pharmacol Sci, I-53100 Siena, Italy; Univ Florence, Dept Pharmacol, I-50139 Florence, Italy; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Physiol, College Stn, TX USA; Texas A&M Univ, Syst Hlth Sci Ctr, Microcirculat Res Inst, College Stn, TX USA	University of Siena; University of Florence; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Ziche, M (corresponding author), Univ Siena, Inst Pharmacol Sci, Via S Piccolomini 170, I-53100 Siena, Italy.	ziche@unisi.it	Morbidelli, Lucia/K-4053-2016; Morbidelli, Lucia/AAC-7858-2020	Morbidelli, Lucia/0000-0001-8148-7049; Parenti, Astrid/0000-0002-7980-6853				Ahluwalia A, 1999, TRENDS PHARMACOL SCI, V20, P100, DOI 10.1016/S0165-6147(99)01321-8; Ambs S, 1998, NAT MED, V4, P1371, DOI 10.1038/3957; Bastian S, 1998, BIOCHEM BIOPH RES CO, V253, P750, DOI 10.1006/bbrc.1998.9848; Bouchard JF, 1998, BRIT J PHARMACOL, V123, P413, DOI 10.1038/sj.bjp.0701619; Braun C, 1997, J CARDIOVASC PHARM, V30, P446, DOI 10.1097/00005344-199710000-00007; CAMBRIDGE H, 1995, BRIT J PHARMACOL, V115, P641, DOI 10.1111/j.1476-5381.1995.tb14980.x; Cuevas P, 1997, Eur J Med Res, V2, P282; Dixon BS, 1997, AM J PHYSIOL-CELL PH, V273, pC7, DOI 10.1152/ajpcell.1997.273.1.C7; DORLEANSJUSTE P, 1989, BRIT J PHARMACOL, V96, P920, DOI 10.1111/j.1476-5381.1989.tb11903.x; FARHY RD, 1993, CIRC RES, V72, P1202, DOI 10.1161/01.RES.72.6.1202; Frimm CD, 1996, J MOL CELL CARDIOL, V28, P1279; Gobeil F, 1996, HYPERTENSION, V28, P833, DOI 10.1161/01.HYP.28.5.833; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gualandris A, 1996, CELL GROWTH DIFFER, V7, P147; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; He P, 1998, AM J PHYSIOL-HEART C, V274, pH1865, DOI 10.1152/ajpheart.1998.274.6.H1865; HU DE, 1993, BRIT J PHARMACOL, V109, P14, DOI 10.1111/j.1476-5381.1993.tb13525.x; Kay EP, 1998, CURR EYE RES, V17, P286, DOI 10.1076/ceyr.17.3.286.5212; KOSTYK SK, 1995, AM J PHYSIOL-HEART C, V269, pH1583, DOI 10.1152/ajpheart.1995.269.5.H1583; LEIBOVICH SJ, 1994, P NATL ACAD SCI USA, V91, P4190, DOI 10.1073/pnas.91.10.4190; Marceau F, 1998, PHARMACOL REV, V50, P357; Matoba S, 1999, CIRCULATION, V99, P817, DOI 10.1161/01.CIR.99.6.817; Morbidelli L, 1998, BRIT J PHARMACOL, V124, P1286, DOI 10.1038/sj.bjp.0701943; Pan HL, 2000, AM J PHYSIOL-HEART C, V279, pH116; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PATEL KV, 1992, CANCER RES, V52, P334; REGOLI D, 1994, LIFE SCI, V55, P735, DOI 10.1016/0024-3205(94)00557-5; Safi J, 1997, J MOL CELL CARDIOL, V29, P2311, DOI 10.1006/jmcc.1997.0459; SCHELLING ME, 1988, AM J PHYSIOL, V254, pH1211, DOI 10.1152/ajpheart.1988.254.6.H1211; SCHLEMPER V, 1994, BRIT J PHARMACOL, V111, P83, DOI 10.1111/j.1476-5381.1994.tb14027.x; Schumacher B, 1998, CIRCULATION, V97, P645, DOI 10.1161/01.CIR.97.7.645; Sellke FW, 1996, AM J PHYSIOL-HEART C, V271, pH713, DOI 10.1152/ajpheart.1996.271.2.H713; Su JB, 2000, CIRCULATION, V101, P1848, DOI 10.1161/01.CIR.101.15.1848; SUNG CP, 1988, J PHARMACOL EXP THER, V247, P8; Tabata H, 1997, CARDIOVASC RES, V35, P470, DOI 10.1016/S0008-6363(97)00152-1; TODA N, 1987, EUR J PHARMACOL, V135, P321, DOI 10.1016/0014-2999(87)90681-9; Tsutsui M, 2000, AM J PHYSIOL-HEART C, V278, pH367, DOI 10.1152/ajpheart.2000.278.2.H367; Ueno H, 1997, ARTERIOSCL THROM VAS, V17, P2453, DOI 10.1161/01.ATV.17.11.2453; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; Wohlfart P, 1997, J PHARMACOL EXP THER, V280, P1109; ZICHE M, 1993, AM J PHYSIOL, V265, pH569, DOI 10.1152/ajpheart.1993.265.2.H569; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; Ziche M, 1997, CIRC RES, V80, P845, DOI 10.1161/01.res.80.6.845; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557; Ziche M, 1996, NEUROPEPTIDES, V30, P345, DOI 10.1016/S0143-4179(96)90023-2; ZICHE M, 1993, BIOCHEM BIOPH RES CO, V192, P1198, DOI 10.1006/bbrc.1993.1543	46	127	141	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1487	+		10.1096/fj.00-0503fje	http://dx.doi.org/10.1096/fj.00-0503fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387266				2022-12-28	WOS:000173705800001
J	Bowser, DN; Petrou, S; Panchal, RG; Smart, ML; Williams, DA				Bowser, DN; Petrou, S; Panchal, RG; Smart, ML; Williams, DA			Release of mitochondrial Ca2+ via the permeability transition activates endoplasmic reticulum Ca2+ uptake	FASEB JOURNAL			English	Article						mitochondrial permeability transition; targeted Ca2+ sensors (cameleons)	GREEN FLUORESCENT PROTEINS; RECEPTORS; CHANNEL	Regulatory interactions between the endoplasmic reticulum (ER) and the mitochondria in the control of intracellular free Ca2+ concentration ([Ca2+](I)), may be of importance in the control of many cell functions, and particularly those involved in initiating cell death. We used targeted Ca2+ sensors (cameleons) to investigate the movement of Ca2+ between the ER and mitochondria of intact cells and focused on the role of the mitochondrial permeability transition (MPT) in this interaction. We hypothesized that release of Ca2+ from mitochondria in response to a known MPT agonist (atractyloside) would cause release of ER Ca2+, perpetuating cellular Ca2+ overload, and cell death. Targeted cameleons (mitochondria and ER) were imaged with confocal microscopy 2-3 days following transient transfection of human embryonic kidney 293 cells. Opening of the MPT resulted in specific loss of mitochondrial Ca2+ (blocked by cyclosporin A), which was sequestered initially by ER. The ER subsequently released this Ca2+ load, leading to a global Ca2+ elevation, a response that was not observed when ER Ca2+-ATPases were blocked with cyclopiazonic acid. Thus, ER plays an important role in moderating changes in intracellular Ca2+ following MPT and may play a key role in cell death initiated by mitochondrial mechanisms.	Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia	University of Melbourne	Williams, DA (corresponding author), Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia.	davidaw@unimelb.edu.au	Petrou, Steven/M-8332-2013; Panchal, Rekha/None	Panchal, Rekha/0000-0001-8621-9078; Bowser, David/0000-0002-8974-9442; Petrou, Steven/0000-0002-4960-6375				ANTONSSON B, 1997, SCIENCE; Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241; Bowser D.N., 1999, FLUORESCENT LUMINESC, V2nd, P65; Bowser DN, 1998, BIOPHYS J, V75, P2004, DOI 10.1016/S0006-3495(98)77642-8; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Minamikawa T, 1999, EXP CELL RES, V246, P26, DOI 10.1006/excr.1998.4290; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Querfurth HW, 1998, BIOCHEM J, V334, P79, DOI 10.1042/bj3340079; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, METHOD CELL BIOL, V40, P339; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Trollinger DR, 1997, BIOCHEM BIOPH RES CO, V236, P738, DOI 10.1006/bbrc.1997.7042	19	25	26	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1105	+		10.1096/fj.01-0828fje	http://dx.doi.org/10.1096/fj.01-0828fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039849				2022-12-28	WOS:000175973900015
J	Crozatier, B; Badoual, T; Boehm, E; Ennezat, PV; Guenoun, T; Su, JB; Veksler, V; Hittinger, L; Ventura-Clapier, R				Crozatier, B; Badoual, T; Boehm, E; Ennezat, PV; Guenoun, T; Su, JB; Veksler, V; Hittinger, L; Ventura-Clapier, R			Role of creatine kinase in cardiac excitation-contraction coupling: studies in creatine kinase-deficient mice	FASEB JOURNAL			English	Article						CK; ventricular function; cell shortening	CHANNEL RYANODINE RECEPTOR; RAT VENTRICULAR MYOCYTES; SARCOPLASMIC-RETICULUM; CA2+ RELEASE; CALCIUM; MUSCLE; HEART; MITOCHONDRIAL; ISOENZYMES; COMPARTMENTATION	To understand the role of creatine kinase (CK) in cardiac excitation-contraction coupling, CK-deficient mice (CK-/-) were studied in vitro and in vivo. In skinned fibers, the kinetics of caffeine-induced release of Ca2+ was markedly slowed in CK-/- mice with a partial restoration when glycolytic substrates were added. These abnormalities were almost compensated for at the cellular level: the responses of Ca2+ transient and cell shortening to an increased pacing rate from 1 Hz to 4 Hz were normal with a normal post-rest potentiation of shortening. However, the post-rest potentiation of the Ca2+ transient was absent and the cellular contractile response to isoprenaline was decreased in CK-/- mice. In vivo, echocardiographically determined cardiac function was normal at rest but the response to isoprenaline was blunted in CK-/- mice. Previously described compensatory pathways (glycolytic pathway and closer sarcoplasmic reticulum-mitochondria interactions) allow a quasi-normal SR function in isolated cells and a normal basal in vivo ventricular function, but are not sufficient to cope with a large and rapid increase in energy demand produced by beta-adrenergic stimulation. This shows the specific role of CK in excitation-contraction coupling in cardiac muscle that cannot be compensated for by other pathways.	Fac Med, INSERM, U400, F-94000 Creteil, France; INSERM, U446, Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Institut National de la Sante et de la Recherche Medicale (Inserm)	Crozatier, B (corresponding author), Fac Med, INSERM, U400, 8 Rue Gen Sarrail, F-94000 Creteil, France.	crozatier@im3.inserm.fr	Su, Jin Bo/N-6006-2018	Su, Jin Bo/0000-0002-1823-8928; Crozatier, Bertrand/0000-0001-8557-6911; Ventura-Clapier, Renee/0000-0002-7488-4123; Veksler, Vladimir/0000-0002-8869-9594; Hittinger, Luc/0000-0003-1933-5815				BASSANI RA, 1994, J MOL CELL CARDIOL, V26, P1335, DOI 10.1006/jmcc.1994.1152; BERS DM, 1993, J MOL CELL CARDIOL, V25, P1047, DOI 10.1006/jmcc.1993.1117; BERS DM, 1991, EXCITATION CONTRACTI; Boehm E, 2000, J MOL CELL CARDIOL, V32, P891, DOI 10.1006/jmcc.2000.1130; CHENG H, 1996, AM J PHYSIOL, V270, P148; Dahlstedt AJ, 2000, FASEB J, V14, P982, DOI 10.1096/fasebj.14.7.982; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; Kaasik A, 2001, CIRC RES, V89, P153, DOI 10.1161/hh1401.093440; Maier LS, 2000, J MOL CELL CARDIOL, V32, P2249, DOI 10.1006/jmcc.2000.1252; Marks AR, 2001, J MOL CELL CARDIOL, V33, P615, DOI 10.1006/jmcc.2000.1343; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; Meneton P, 2001, P NATL ACAD SCI USA, V98, P2634, DOI 10.1073/pnas.051619598; Minajeva A, 1996, PFLUG ARCH EUR J PHY, V432, P904, DOI 10.1007/s004240050214; Minajeva A, 1997, AM J PHYSIOL-HEART C, V273, pH2498, DOI 10.1152/ajpheart.1997.273.5.H2498; MONTEROLOMELI M, 1992, J BIOL CHEM, V267, P1829; NEGRETTI N, 1995, J PHYSIOL-LONDON, V486, P581, DOI 10.1113/jphysiol.1995.sp020836; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; Saupe KW, 1998, CIRC RES, V82, P898; Saupe KW, 2000, J BIOL CHEM, V275, P19742, DOI 10.1074/jbc.M001932200; Snyder SM, 2000, BIOPHYS J, V79, P94, DOI 10.1016/S0006-3495(00)76276-X; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; STEELE DS, 1995, J PHYSIOL-LONDON, V483, P155, DOI 10.1113/jphysiol.1995.sp020575; Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Vendelin M, 2000, AM J PHYSIOL-CELL PH, V278, pC747, DOI 10.1152/ajpcell.2000.278.4.C747; Ventura-Clapier R, 1998, MOL CELL BIOCHEM, V184, P231, DOI 10.1023/A:1006840508139; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; XU KY, 1995, CIRC RES, V77, P88, DOI 10.1161/01.RES.77.1.88; Xu L, 1996, CIRC RES, V79, P1100, DOI 10.1161/01.RES.79.6.1100	32	45	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7							UNSP 0892-6638/02/0016-0653	10.1096/fj.01-0652com	http://dx.doi.org/10.1096/fj.01-0652com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	11978729				2022-12-28	WOS:000175973900019
J	Huisman, A; Vos, I; van Faassen, EE; Joles, JA; Grone, HJ; Martasek, P; van Zonneveld, AJ; Vanin, AF; Rabelink, TJ				Huisman, A; Vos, I; van Faassen, EE; Joles, JA; Grone, HJ; Martasek, P; van Zonneveld, AJ; Vanin, AF; Rabelink, TJ			Anti-inflammatory effects of tetrahydrobiopterin on early rejection in renal allografts: modulation of inducible nitric oxide synthase	FASEB JOURNAL			English	Article						renal transplantation; iNOS; superoxide	GENERATES SUPEROXIDE; ENDOTHELIAL FUNCTION; NADPH OXIDASE; FREE-RADICALS; L-ARGININE; RAT-BRAIN; IN-VIVO; INJURY; PEROXYNITRITE; NO	Oxidative stress contributes to the development of early transplant failure. As nitric oxide synthases (NOS) can act as sources of superoxide, we investigated the effect of the NOS cofactor tetrahydrobiopterin (BH4) on oxyradical production and early rejection in a rat kidney transplantation model. Allograft transplantation (Brown Norway to Lewis) showed more renal superoxide production and monocyte infiltration when compared with isografts (Lewis to Lewis). Administration of the stable BH4 precursor sepiapterin had no effect on superoxide production in the isografts (51 +/- 10 vs. 69 +/- 17 cps/10 mg protein), but led to a marked decrease in superoxide production in the allografts (116 +/- 11 vs. 60 +/- 6 cps/10 mg protein; P<0.05) and was accompanied by a reduction in periarterial macrophage infiltration (3.3 +/- 0.7 vs. 1.3 +/- 0.3 cells/vessel; P<0.05) and an increase in NO production (78 +/- 22 vs. 173 +/- 12 AU/g kidney) (P<0.01). In vitro experiments confirm that iNOS can produce superoxide mainly from the heme domain, whereas BH4 administration can reverse this superoxide production in the presence of adequate anti-oxidant defense. Our findings support the hypothesis that BH4 can be used to modulate the function of the inflammatory iNOS isoform and suggest a potential therapeutic role for sepiapterin in early allograft rejection.	Univ Med Ctr, Dept Vasc Med, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr, Dept Hypertens & Nephrol, Utrecht, Netherlands; Univ Utrecht, Debye Inst, Sect Interface Phys, Utrecht, Netherlands; German Canc Inst, Dept Cellular & Mol Pathol, Heidelberg, Germany; Charles Univ, Fac Med 1, Dept Pediat, Prague, Czech Republic; Russian Acad Sci, Inst Chem Phys, Moscow, Russia; Univ Med Ctr, Dept Clin Chem, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Charles University Prague; Russian Academy of Sciences; N.N. Semenov Federal Research Centre for Chemical Physics, Russian Academy of Sciences; Utrecht University; Utrecht University Medical Center	Rabelink, TJ (corresponding author), Univ Med Ctr, Dept Vasc Med, F02-226,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	T.RABELINK@DIGD.AZU.NL	Shumaev, Konstantin/AAI-2362-2020; Huisman, Albert/A-2033-2008; Martásek, Pavel/G-6622-2017; Rabelink, Ton J./A-5316-2008; van Zonneveld, Anton Jan/D-8060-2018; Joles, Jaap/AAX-3249-2020; Anatoly, Vanin/I-1069-2016	Martásek, Pavel/0000-0001-6165-4444; Rabelink, Ton J./0000-0001-6780-5186; van Zonneveld, Anton Jan/0000-0002-1676-7738; Anatoly, Vanin/0000-0001-8392-4601				Adams MR, 1999, ATHEROSCLEROSIS, V146, P329, DOI 10.1016/S0021-9150(99)00157-4; Albrecht EWJA, 2000, TRANSPLANTATION, V70, P1610, DOI 10.1097/00007890-200012150-00013; ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; Attia DM, 2001, J AM SOC NEPHROL, V12, P2585, DOI 10.1681/ASN.V12122585; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bhattacharjee S, 2001, ARCH BIOCHEM BIOPHYS, V395, P69, DOI 10.1006/abbi.2001.2557; CARRUTHERS SG, 1983, CLIN CHEM, V29, P180; DANNENBERG AM, 1994, J LEUKOCYTE BIOL, V56, P436, DOI 10.1002/jlb.56.4.436; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GOLDSTEIN S, 1995, FREE RADICAL BIO MED, V19, P505, DOI 10.1016/0891-5849(95)00034-U; Grone HJ, 1999, FASEB J, V13, P1371, DOI 10.1096/fasebj.13.11.1371; GROSS SS, 1992, J BIOL CHEM, V267, P25722; Hattori Y, 1997, BBA-MOL CELL RES, V1358, P61, DOI 10.1016/S0167-4889(97)00052-9; Heitzer T, 2000, DIABETOLOGIA, V43, P1435, DOI 10.1007/s001250051551; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Kibbe M, 1999, CARDIOVASC RES, V43, P650, DOI 10.1016/S0008-6363(99)00130-3; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; KOJIMA S, 1995, FREE RADICAL RES, V23, P419, DOI 10.3109/10715769509065263; Koo DDH, 2001, KIDNEY INT, V60, P786, DOI 10.1046/j.1523-1755.2001.060002786.x; Laursen JB, 2001, CIRCULATION, V103, P1282; Libby P, 2000, J INTERN MED, V247, P349, DOI 10.1046/j.1365-2796.2000.00654.x; Martasek P, 1998, J BIOL CHEM, V273, P34799, DOI 10.1074/jbc.273.52.34799; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MIESEL R, 1995, INFLAMMATION, V19, P347, DOI 10.1007/BF01534392; MIKOYAN VD, 1994, BIOFIZIKA+, V39, P919; Milstien S, 1999, BIOCHEM BIOPH RES CO, V263, P681, DOI 10.1006/bbrc.1999.1422; Mishra OP, 2000, NEUROCHEM RES, V25, P1559, DOI 10.1023/A:1026610301978; NICHOL CA, 1983, P NATL ACAD SCI-BIOL, V80, P1546, DOI 10.1073/pnas.80.6.1546; Pieper GM, 1997, J CARDIOVASC PHARM, V29, P8, DOI 10.1097/00005344-199701000-00002; Rimbach Gerald, 2000, Molecular Cell Biology Research Communications, V3, P238, DOI 10.1006/mcbr.2000.0219; SCHOTT K, 1991, BIOCHEM BIOPH RES CO, V176, P1430, DOI 10.1016/0006-291X(91)90446-E; SHINOBU LA, 1984, ACTA PHARMACOL TOX, V54, P189; Sjakste N, 1999, BIOCHEM PHARMACOL, V58, P1955, DOI 10.1016/S0006-2952(99)00281-6; Stojanovic T, 1996, LAB INVEST, V74, P496; Stroes E, 1998, FEBS LETT, V438, P161, DOI 10.1016/S0014-5793(98)01292-7; Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131; Vanin AF, 2000, BBA-GEN SUBJECTS, V1474, P365, DOI 10.1016/S0304-4165(00)00033-7; Vanin AF, 1996, BBA-PROTEIN STRUCT M, V1295, P5, DOI 10.1016/0167-4838(95)00247-2; Vanin AF, 2001, FREE RADICAL BIO MED, V30, P813, DOI 10.1016/S0891-5849(01)00466-X; Vasquez-Vivar J, 2001, FREE RADICAL BIO MED, V31, P975, DOI 10.1016/S0891-5849(01)00680-3; Vos IHC, 2000, EUR J PHARMACOL, V391, P31, DOI 10.1016/S0014-2999(00)00021-2; Vos IHC, 2000, FASEB J, V14, P815, DOI 10.1096/fasebj.14.5.815; WERNER ER, 1991, BIOCHEM J, V280, P709, DOI 10.1042/bj2800709; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156	50	42	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7					1135	+		10.1096/fj.01-0890fje	http://dx.doi.org/10.1096/fj.01-0890fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039851				2022-12-28	WOS:000175973900010
J	Suzuki, T; Park, H; Lennarz, WJ				Suzuki, T; Park, H; Lennarz, WJ			Cytoplasmic peptide: N-glycanase (PNGase) in eukaryotic cells: occurrence, primary structure, and potential functions	FASEB JOURNAL			English	Review						ERAD; endoplasmic reticulum; transglutaminase family	UNFOLDED PROTEIN RESPONSE; I HEAVY-CHAINS; TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE EXCISION-REPAIR; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; QUALITY-CONTROL; MOLECULAR CHAPERONES; DEGRADATION PATHWAY; GLYCOPEPTIDE EXPORT	A cytoplasmic peptide: N-glycanase has been implicated in the proteasomal degradation of newly synthesized misfolded glycoproteins exported from the endoplasmic reticulum. The gene encoding this enzyme (Png1p) has been identified in yeast. Based on sequence analysis, Png1p was classified as a member of the 'transglutaminase-like superfamily' that contains a putative catalytic triad of amino acids (cysteine, histidine, and aspartic acid). More recent studies in yeast indicate that Png1p can bind to the 26S proteasome through its interaction with the DNA repair protein Rad23p. A mouse homologue of Png1p (mPng1p) bound not only to the Rad23 protein, but also to various proteins related to ubiquitin and/or the proteasome through an extended amino-terminal domain. This NH2 terminus of mPng1p, which is not found in yeast, contains a PUB domain predicted to be involved in the ubiquitin-related pathway. This review will focus on the primary structure and potential functions of the cytoplasmic PNGases.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lennarz, WJ (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	wlennarz@notes.cc.sunysb.edu	Suzuki, Tadashi/AAX-5707-2021; Suzuki, Tadashi/I-4536-2014	Suzuki, Tadashi/0000-0003-1030-7631; 	NIGMS NIH HHS [GM33184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anantharaman V, 2001, HUM MOL GENET, V10, P1627, DOI 10.1093/hmg/10.16.1627; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; Benaroudj N, 2000, NAT CELL BIOL, V2, P833, DOI 10.1038/35041081; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Casagrande R, 2000, MOL CELL, V5, P729, DOI 10.1016/S1097-2765(00)80251-8; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; Cresswell P, 1997, CURR BIOL, V7, pR552, DOI 10.1016/S0960-9822(06)00279-X; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; Di Cola A, 2001, P NATL ACAD SCI USA, V98, P14726, DOI 10.1073/pnas.251386098; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; Gillece P, 2000, P NATL ACAD SCI USA, V97, P4609, DOI 10.1073/pnas.090083497; Gusarova V, 2001, J BIOL CHEM, V276, P24891, DOI 10.1074/jbc.M100633200; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Hirsch C, 2000, TRENDS CELL BIOL, V10, P268, DOI 10.1016/S0962-8924(00)01768-2; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; Inoue S., 1997, N COMP BIOC B, P143; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson AE, 2000, CELL, V102, P709, DOI 10.1016/S0092-8674(00)00059-3; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KITAJIMA K, 1995, ARCH BIOCHEM BIOPHYS, V319, P393, DOI 10.1006/abbi.1995.1309; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lord JM, 2000, SEMIN CELL DEV BIOL, V11, P159; Makarova KS, 1999, PROTEIN SCI, V8, P1714, DOI 10.1110/ps.8.8.1714; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mosse CA, 1998, J EXP MED, V187, P37, DOI 10.1084/jem.187.1.37; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Park H, 2001, P NATL ACAD SCI USA, V98, P11163, DOI 10.1073/pnas.201393498; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; Romisch K, 1999, J CELL SCI, V112, P4185; ROMISCH K, 1992, P NATL ACAD SCI USA, V89, P7227, DOI 10.1073/pnas.89.15.7227; Romisch K, 1997, P NATL ACAD SCI USA, V94, P6730, DOI 10.1073/pnas.94.13.6730; Russell SJ, 1999, J BIOL CHEM, V274, P21943, DOI 10.1074/jbc.274.31.21943; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; SEKO A, 1991, J BIOL CHEM, V266, P22110; Seko A, 1999, GLYCOBIOLOGY, V9, P887, DOI 10.1093/glycob/9.9.887; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Simpson JC, 1999, FEBS LETT, V459, P80, DOI 10.1016/S0014-5793(99)01222-3; Story CM, 1999, P NATL ACAD SCI USA, V96, P8516, DOI 10.1073/pnas.96.15.8516; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; Suzuki T, 2001, BIOCHEM BIOPH RES CO, V287, P1083, DOI 10.1006/bbrc.2001.5688; Suzuki T, 2001, J BIOL CHEM, V276, P21601, DOI 10.1074/jbc.M100826200; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; SUZUKI T, 1993, BIOCHEM BIOPH RES CO, V194, P1124, DOI 10.1006/bbrc.1993.1938; Suzuki T, 1997, P NATL ACAD SCI USA, V94, P6244, DOI 10.1073/pnas.94.12.6244; Suzuki T, 1998, J BIOL CHEM, V273, P21526, DOI 10.1074/jbc.273.34.21526; SUZUKI T, 1995, GLYCOCONJUGATE J, V12, P183, DOI 10.1007/BF00731318; Suzuki T, 2000, J CELL BIOL, V149, P1039, DOI 10.1083/jcb.149.5.1039; SUZUKI T, 1994, GLYCOCONJUGATE J, V11, P469, DOI 10.1007/BF00731283; SUZUKI T, 1995, J BIOL CHEM, V270, P15181, DOI 10.1074/jbc.270.25.15181; SUZUKI T, 1994, GLYCOBIOLOGY, V4, P777, DOI 10.1093/glycob/4.6.777; SUZUKI T, 1997, GLYCOSCIENCES STATUS, P121; TAKAHASHI N, 1977, BIOCHEM BIOPH RES CO, V76, P1194, DOI 10.1016/0006-291X(77)90982-2; TAKAHASHI N, 1992, CRC HDB ENDOGLYCOSID, P183; TARENTINO AL, 1993, TRENDS GLYCOSCI GLYC, V5, P163; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Urano F, 2000, J CELL SCI, V113, P3697; Wang ZG, 1997, MOL CELL BIOL, V17, P635, DOI 10.1128/MCB.17.2.635; Weng S, 1997, BIOCHEM J, V322, P655, DOI 10.1042/bj3220655; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303	77	126	130	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7							UNSP 0892-6638/02/0016-0635	10.1096/fj.01-0889rev	http://dx.doi.org/10.1096/fj.01-0889rev			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	11978727				2022-12-28	WOS:000175973900017
J	Shirangi, TR; Zaika, A; Moll, UM				Shirangi, TR; Zaika, A; Moll, UM			Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage	FASEB JOURNAL			English	Article						HDM2; ubiquitination; proteasomes; cytoplasm; nucleus	RING-FINGER DOMAIN; SUBCELLULAR-LOCALIZATION; LEPTOMYCIN-B; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; PROTEIN EXPORT; CELL-CYCLE; MDM2; CRM1; SIGNAL	The principal regulator of p53 stability is HDM2, an E3 ligase that mediates p53 degradation via the ubiquitin-26S proteasome pathway. The current model holds that p53 degradation occurs exclusively on cytoplasmic proteasomes and hence has an absolute requirement for nuclear export of p53 via the CRM-1 pathway. However, proteasomes are abundant in both cytosol and nucleus, and no studies have been done to determine under what physiological circumstances p53 degradation might occur in the nucleus. We analyzed HDM2-mediated degradation of endogenous p53 in the presence of various nuclear export inhibitors of CRM-1, including leptomycin B (LMB), a noncompetitive, specific, and fast-acting inhibitor; and HTLV1-Rex protein, a potent competitive inhibitor. We found that significant HDM2-mediated p53 degradation took place in the presence of LMB or HTLV1-Rex, indicating that endogenous p53 degradation occurs locally in the nucleus, in parallel to cytoplasmic degradation. Moreover, p53 null cells that coexpressed export-defective mutants of p53 and HDM2 retained partial competence for p53 degradation. It is important that nuclear degradation of p53 occurred during the poststress recovery phase of a p53 response, after DNA damage ceased. We propose that the capability of local p53 degradation within the nucleus provides a tighter and faster control during the down-regulatory phase, when an active p53 program needs to be turned off quickly.	SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Moll, UM (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.	umoll@notes.cc.sunysb.edu						Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Floer M, 1999, J BIOL CHEM, V274, P16279, DOI 10.1074/jbc.274.23.16279; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hirsch C, 2000, TRENDS CELL BIOL, V10, P268, DOI 10.1016/S0962-8924(00)01768-2; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KATAHIRA J, 1995, J VIROL, V69, P3125, DOI 10.1128/JVI.69.5.3125-3133.1995; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kumar KS, 2000, WIND STRUCT, V3, P1; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; LUNA RMD, 1995, NATURE, V378, P203; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Moll UM, 1996, MOL CELL BIOL, V16, P1126; NISHI K, 1994, J BIOL CHEM, V269, P6320; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PALMER A, 1994, EUR J CELL BIOL, V64, P163; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; Prives C, 1999, J PATHOL, V187, P112; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Wolff R, 1997, GENOME ANAL, V1, P1; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X; Yu ZK, 2000, ONCOGENE, V19, P5892, DOI 10.1038/sj.onc.1203980; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	44	76	78	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					420	+		10.1096/fj.01-0617fje	http://dx.doi.org/10.1096/fj.01-0617fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11790725				2022-12-28	WOS:000173656600020
J	Carson, JA; Nettleton, D; Reecy, JM				Carson, JA; Nettleton, D; Reecy, JM			Differential gene expression in the rat soleus muscle during early work overload-induced hypertrophy	FASEB JOURNAL			English	Article						muscle hypertrophy; messenger ribonucleic acid; soleus	P53-REGULATED PROTEIN GADD45; LEUKEMIA INHIBITORY FACTOR; SKELETAL-MUSCLE; JAK/STAT PATHWAY; CARDIAC MYOCYTES; ANGIOTENSIN-II; COMPENSATORY HYPERTROPHY; MECHANICAL-STRESS; KINASE-ACTIVITY; MESSENGER-RNA	Delineating the molecular mechanisms that are responsive to work overload is crucial to understanding the adaptive processes controlling skeletal muscle mass. We have examined the molecular events associated with increased workload by using microarray analysis to begin to define the mechanotransduction responsive transcription programs in skeletal muscle. Microarray analysis identified 112 mRNAs that were expressed differentially in the soleus muscle of sham-operated vs. gastrocnemius-ablated rats. These genes can be classified into cell proliferation, autocrine/paracrine, extracellular matrix, immune response, intracellular signaling, metabolism, neural, protein synthesis/degradation, structural, and transcription. These findings dramatically increase the number of known, differentially expressed mRNA during early skeletal muscle hypertrophy. In toto, our findings indicate that work overload induced skeletal muscle hypertrophy alters autocrine/paracrine signaling, intracellular signaling, and transcription factor expression, which likely results in a dramatic change in cellular metabolism, cell proliferation, and muscle structure. These data enhance our understanding of the complex molecular mechanisms controlling skeletal muscle mass in response to increased physical activity.	Iowa State Univ, Dept Anim Sci, Ames, IA 50011 USA; Univ S Carolina, Dept Exercise Sci, Columbia, SC 29208 USA; Iowa State Univ, Dept Stat, Ames, IA 50011 USA	Iowa State University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Iowa State University	Reecy, JM (corresponding author), Iowa State Univ, Dept Anim Sci, 2255 Kildee Hall, Ames, IA 50011 USA.	jreecy@iastate.edu	Carson, James/Q-5693-2019	Carson, James/0000-0003-3733-8796; Nettleton, Dan/0000-0002-6045-1036; Reecy, James/0000-0003-4602-0990				Adams GR, 1999, J APPL PHYSIOL, V87, P1705, DOI 10.1152/jappl.1999.87.5.1705; Ali MS, 1998, BIOCHEM BIOPH RES CO, V249, P672, DOI 10.1006/bbrc.1998.9054; ARVILL A, 1967, ACTA ENDOCRINOL-COP, VS 56, P27; Awede B, 1999, FEBS LETT, V461, P263, DOI 10.1016/S0014-5793(99)01469-6; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Blankesteijn WM, 1996, J MOL CELL CARDIOL, V28, P1187; Brizzi MF, 1999, MOL BIOL CELL, V10, P3463, DOI 10.1091/mbc.10.10.3463; Carson J A, 1997, Exerc Sport Sci Rev, V25, P301; Carson JA, 1998, PFLUG ARCH EUR J PHY, V435, P850, DOI 10.1007/s004240050593; Chiquet M, 1999, MATRIX BIOL, V18, P417, DOI 10.1016/S0945-053X(99)00039-6; Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867; Croisier JL, 1999, MUSCLE NERVE, V22, P208, DOI 10.1002/(SICI)1097-4598(199902)22:2<208::AID-MUS8>3.0.CO;2-B; DARR KC, 1987, J APPL PHYSIOL, V63, P1816, DOI 10.1152/jappl.1987.63.5.1816; DeVol DL, 1990, AM J PHYSIOL, V259, P89; DUDOIT S, 2000, STAT METHODS IDENTIF; Fluck M, 2000, J APPL PHYSIOL, V88, P352, DOI 10.1152/jappl.2000.88.1.352; Friddle CJ, 2000, P NATL ACAD SCI USA, V97, P6745, DOI 10.1073/pnas.100127897; GIDDINGS CJ, 1992, ANAT REC, V233, P178, DOI 10.1002/ar.1092330203; GOLDBERG AL, 1967, AM J PHYSIOL, V213, P1193, DOI 10.1152/ajplegacy.1967.213.5.1193; GOLDBERG AL, 1969, AM J PHYSIOL, V216, P1111, DOI 10.1152/ajplegacy.1969.216.5.1111; GOLDBERG AL, 1968, ENDOCRINOLOGY, V83, P1071, DOI 10.1210/endo-83-5-1071; GOLDBERG AL, 1969, J BIOL CHEM, V244, P3217; GOLDBERG AL, 1971, CARDIAC HYPERTROPHY, P301; Goldspink G, 1999, J ANAT, V194, P323, DOI 10.1046/j.1469-7580.1999.19430323.x; GORDON SE, 2000, AM PHYS SOC ANN M, P347; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; JANOFF A, 1982, CURRENT TOPICS INFLA, P62; Jozsi AC, 2000, MECH AGEING DEV, V120, P45, DOI 10.1016/S0047-6374(00)00178-0; Jung N, 2000, EUR J BIOCHEM, V267, P6180, DOI 10.1046/j.1432-1327.2000.01692.x; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kemp TJ, 2001, GENOMICS, V72, P260, DOI 10.1006/geno.2000.6461; Kerr MK, 2000, J COMPUT BIOL, V7, P819, DOI 10.1089/10665270050514954; Kijima K, 1996, CIRC RES, V79, P887, DOI 10.1161/01.RES.79.4.887; Kodama H, 1997, CIRC RES, V81, P656; Kodama H, 1998, CIRC RES, V82, P244; Kunisada K, 1996, CIRCULATION, V94, P2626, DOI 10.1161/01.CIR.94.10.2626; LAMBERT CA, 1992, LAB INVEST, V66, P444; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MACKOVA E, 1972, PHYSIOL BOHEMOSLOV, V21, P9; Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216, DOI 10.1152/ajpcell.1998.275.5.C1216; Mitchell P, 1999, J APPL PHYSIOL, V86, P313, DOI 10.1152/jappl.1999.86.1.313; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Negoro S, 2000, CARDIOVASC RES, V47, P797, DOI 10.1016/S0008-6363(00)00138-3; NETTLETON D, 2001, IOWA STATE U DEP STA; Pan J, 1999, CIRC RES, V84, P1127, DOI 10.1161/01.RES.84.10.1127; Pennica Diane, 1996, Cytokine and Growth Factor Reviews, V7, P81, DOI 10.1016/1359-6101(96)00007-X; ROSENBLATT JD, 1992, J APPL PHYSIOL, V73, P2538, DOI 10.1152/jappl.1992.73.6.2538; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SCHIAFFINO S, 1972, VIRCHOWS ARCH B, V11, P268; Schneider VA, 2001, GENE DEV, V15, P304, DOI 10.1101/gad.855601; SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904; Skarli M, 1998, J PHYSIOL-LONDON, V509P, p192P; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takahashi T, 1999, CIRC RES, V85, P884; Takeda H, 1998, ANIM GENET, V29, P216, DOI 10.1111/j.1365-2052.1998.00325.x; Tidball JG, 1998, AM J PHYSIOL-CELL PH, V275, pC260, DOI 10.1152/ajpcell.1998.275.1.C260; TSIKA RW, 1995, AM J PHYSIOL-CELL PH, V269, pC665, DOI 10.1152/ajpcell.1995.269.3.C665; Tzahor E, 2001, GENE DEV, V15, P255, DOI 10.1101/gad.871501; Welle S, 1999, GENOME RES, V9, P506; WESTFALL PH, 1993, RESAMPLING BASED MUL, P66; WHITELAW PF, 1992, BIOCHEM J, V281, P143, DOI 10.1042/bj2810143; Xia Y, 1997, P NATL ACAD SCI USA, V94, P11399, DOI 10.1073/pnas.94.21.11399; Yayama K, 2001, BIOL PHARM BULL, V24, P34, DOI 10.1248/bpb.24.34; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; [No title captured]; [No title captured]	70	89	95	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					207	+		10.1096/fj.01-0544fje	http://dx.doi.org/10.1096/fj.01-0544fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11744623				2022-12-28	WOS:000172964800013
J	Fraker, PJ; King, LE				Fraker, PJ; King, LE			A distinct role for apoptosis in the changes in lymphopoiesis and myelopoiesis created by deficiencies in zinc	FASEB JOURNAL			English	Review						hematopoiesis; protein/calorie malnutrition; lymphopenia; suboptimal zinc	MURINE BONE-MARROW; IMMUNE FUNCTION; B-LINEAGE; CONTROLLED TRIAL; MICE; LYMPHOCYTES; CELLS; GLUCOCORTICOIDS; MOUSE; SUPPLEMENTATION	Reduced numbers of lymphocytes in the peripheral immune system appeared to be a significant cause of the loss in host defense capacity in humans and animals that are zinc deficient (ZD). A series of studies verified that ZD substantially reduced the lymphocyte compartment of both the marrow and thymus in young adult mice, with large losses noted among the pre-B and pre-T cells. Suboptimal nutriture along with chronic production of glucocorticoids generated during ZD had accelerated apoptosis among these precursor lymphocytes two- to threefold. Thus, the primary cause of the lymphopenia created by ZD was reduced production of lymphocytes and heightened cell death among precursor cells. The data will also show that myelopoiesis in the marrow was protected and enhanced numbers of myeloid progenitor cells were found in S and G(2)/M. Thus, as zinc became limiting the second line of defense appeared to be down-regulated via reduction of lymphopoiesis while cells of the myeloid lineage were protected to maintain the first line of defense that provides innate immunity. This may represent an important adaptation of the immune system to suboptimal nutriture that deserves further exploration.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Fraker, PJ (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	fraker@msu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052289] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 52289-23] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CASTILLODURAN C, 1987, AM J CLIN NUTR, V45, P602, DOI 10.1093/ajcn/45.3.602; Chesters J. K., 1997, Handbook of nutritionally essential mineral elements., P185; COOKMILLS JM, 1993, BRIT J NUTR, V69, P835, DOI 10.1079/BJN19930084; DEBRUIJN MFTR, 1994, EUR J IMMUNOL, V24, P2279, DOI 10.1002/eji.1830241003; DEPASQUALEJARDIEU P, 1979, J NUTR, V109, P1847, DOI 10.1093/jn/109.11.1847; DEPASQUALEJARDIEU P, 1980, J IMMUNOL, V124, P2650; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; ENDRE L, 1990, Journal of Trace Elements in Experimental Medicine, V3, P337; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; FERNANDES G, 1979, P NATL ACAD SCI USA, V76, P457, DOI 10.1073/pnas.76.1.457; Fraker PJ, 2000, J NUTR, V130, p1399S, DOI 10.1093/jn/130.5.1399S; FRAKER PJ, 1995, J AM COLL NUTR, V14, P11; FRAKER PJ, 1982, J NUTR, V112, P1224, DOI 10.1093/jn/112.6.1224; GARVY BA, 1993, IMMUNOLOGY, V79, P270; GARVY BA, 1993, IMMUNOLOGY, V80, P587; GOLDEN MHN, 1978, LANCET, V1, P1226; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Huang STJ, 1999, FASEB J, V13, P467, DOI 10.1096/fasebj.13.3.467; KEEN CL, 1990, ANNU REV NUTR, V10, P415, DOI 10.1146/annurev.nu.10.070190.002215; KING LE, 1995, IMMUNOLOGY, V85, P69; Krause D, 1999, MECH AGEING DEV, V112, P43, DOI 10.1016/S0047-6374(99)00070-6; KUVIBIDILA S, 1993, HUMAN NUTR COMPREHEN, V8, P121; Leonard MB, 1998, J PEDIATR-US, V132, P467, DOI 10.1016/S0022-3476(98)70022-8; LUECKE RW, 1978, J NUTR, V108, P881, DOI 10.1093/jn/108.5.881; MCNEICE IK, 1991, J IMMUNOL, V146, P3785; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; Osati-Ashtiani F, 1998, IMMUNOLOGY, V94, P94, DOI 10.1046/j.1365-2567.1998.00076.x; Sazawal S, 1998, PEDIATRICS, V102, P1, DOI 10.1542/peds.102.1.1; TARLINTON D, 1994, IMMUNOL REV, V137, P203, DOI 10.1111/j.1600-065X.1994.tb00666.x	29	30	31	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					2572	2578		10.1096/fj.01-0430rev	http://dx.doi.org/10.1096/fj.01-0430rev			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726532				2022-12-28	WOS:000172964800026
J	Signorelli, P; Luberto, C; Hannun, YA				Signorelli, P; Luberto, C; Hannun, YA			Ceramide inhibition of NF-kappa B activation involves reverse translocation of classical protein kinase C (PKC) isoenzymes: requirement for kinase activity and carboxyl-terminal phosphorylation of PKC for the ceramide response	FASEB JOURNAL			English	Article						diacylglycerol; sphingolipid; glycerolipid; C(6)-ceramide	SIGNAL-TRANSDUCTION; SELECTIVE INHIBITOR; PHOSPHATIDIC-ACID; INDUCED APOPTOSIS; PHORBOL ESTER; T-LYMPHOCYTES; CELL-DEATH; TNF-ALPHA; ZETA; SPHINGOMYELINASE	Protein kinase C (PKC) is known to activate NF-kappaB whereas the lipid mediator ceramide was recently shown to inhibit activation of this transcription factor (1,2). In this study, the mechanisms by which ceramide interferes with this pathway were examined in Jurkat leukemia and MCF-7 breast cancer cells. Both exogenous and endogenous ceramide inhibited selectively PKC-mediated activation of NF-kappaB by reverting PKC translocation to the membrane. Next, confocal and immunofluorescence studies were performed to evaluate the direct effects of ceramide on PKC. These studies showed that ceramide inhibited translocation of a green fluorescent protein (GFP)-PKCb2 fusion protein in response to PMA. A mutant PKC in which autophosphorylation sites were mutated to alanine (PKC-DA) was resistant to ceramide. A kinase-inactive mutant (PKC-KR) was also resistant to ceramide action, and the results were supported using kinase inhibitors of the enzyme. Finally, overexpression of PKC-DA prevented, at least partly, the ability of ceramide to inhibit activation of NF-kappaB. Taken together, these studies show that ceramide has acute effects on translocation of PKC by inducing reverse translocation, and this reversal requires both the kinase activity of PKC and phosphorylation of the autophosphorylation sites.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 2550509, Charleston, SC 29425 USA.	hannun@musc.edu		signorelli, paola/0000-0003-2368-2393	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43707] Funding Source: Medline; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Boland MP, 1996, BIOCHEM SOC T, V24, pS1, DOI 10.1042/bst024001s; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chen CC, 1998, J IMMUNOL, V161, P6206; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Goni FM, 1999, PROG LIPID RES, V38, P1, DOI 10.1016/S0163-7827(98)00021-6; Goswami R, 2000, J NEUROSCI RES, V60, P141, DOI 10.1002/(SICI)1097-4547(20000415)60:2<141::AID-JNR2>3.0.CO;2-5; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HUANG KP, 1986, J BIOL CHEM, V261, P2134; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Kirtikara K, 1998, MOL CELL BIOCHEM, V181, P41; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Kontny E, 2000, J LEUKOCYTE BIOL, V67, P249, DOI 10.1002/jlb.67.2.249; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lee JY, 2000, J BIOL CHEM, V275, P29290, DOI 10.1074/jbc.M000170200; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Lee Y, 2000, ORG LETT, V2, P303, DOI 10.1021/ol9912480; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Luberto C, 1999, LIPIDS, V34, pS5, DOI 10.1007/BF02562221; Luberto C, 2000, J BIOL CHEM, V275, P14760, DOI 10.1074/jbc.275.19.14760; Manna SK, 2000, FEBS LETT, V473, P113, DOI 10.1016/S0014-5793(00)01501-5; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; Mochly-Rosen D, 1998, FASEB J, V12, P35; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Olivera A, 1997, BBA-LIPID LIPID MET, V1348, P311, DOI 10.1016/S0005-2760(97)00067-2; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Sawai H, 1997, J BIOL CHEM, V272, P2452; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; Venable ME, 1999, BBA-MOL CELL BIOL L, V1439, P291, DOI 10.1016/S1388-1981(99)00101-8; Vertegaal ACO, 2000, CELL SIGNAL, V12, P759, DOI 10.1016/S0898-6568(00)00133-9; Villalba M, 1999, J IMMUNOL, V163, P5813; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Wooten MW, 2000, MOL CELL BIOL, V20, P4494, DOI 10.1128/MCB.20.13.4494-4504.2000; Zhang P, 1997, J BIOL CHEM, V272, P9609; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	59	35	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2401	2414		10.1096/fj.01-0244com	http://dx.doi.org/10.1096/fj.01-0244com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689465				2022-12-28	WOS:000172420500010
J	Singbartl, K; Forlow, SB; Ley, K				Singbartl, K; Forlow, SB; Ley, K			Platelet, but not endothelial, P-selectin is critical for neutrophil-mediated acute postischemic renal failure	FASEB JOURNAL			English	Article						neutrophils; ischemia-reperfusion; acute renal failure	ISCHEMIC-REPERFUSION INJURY; GRANULE MEMBRANE-PROTEIN; DEEP ARTERIAL INJURY; RECRUITMENT IN-VIVO; LEUKOCYTE EMIGRATION; ACTIVATED PLATELETS; ISCHEMIA/REPERFUSION; ADHESION; MICE; ANGIOPLASTY	In a neutrophil-dependent model of acute postischemic renal failure (APRF), eliminating or blocking P-selectin reduces postischemic neutrophil infiltration and preserves kidney function. This study was designed to identify the role of platelet vs. endothelial P-selectin in APRF. Using wild-type (wt) and P-selectin- deficient (P-/-) mice, we generated chimeric mice by bone marrow transplantation. Chimeric mice exclusively expressed either platelet (Plt-P) or endothelial P-selectin (EC-P). APRF was induced by bilateral renal ischemia in situ (32 min), followed by reperfusion; 48 h after reperfusion, EC-P had significantly lower creatinine concentrations (twofold over sham) than Plt-P (eightfold over sham). Compared with wt, protection from renal failure in EC-P was similar to that observed in P-/-. Plt-P and EC-P demonstrated similar overall postischemic neutrophil infiltration as measured by renal myeloperoxidase activity. However, Plt-P showed massive neutrophil infiltration into outer and inner medulla, similar to that in wt. EC-P had only patchy, more diffuse neutrophil influx. Our study identifies platelet P-selectin as crucial for postischemic neutrophil recruitment into outer and inner medulla, which is detrimental to the development of APRF. This suggests that novel therapeutic strategies for postischemic organ failure could be aimed at neutrophil-platelet interactions.	Univ Virginia, Hlth Sci Ctr, Dept Biomed Engn, Charlottesville, VA 22908 USA; Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Univ Klinikum Munster, Klin & Poliklin Anasthesiol & Operat Intens Med, Munster, Germany	University of Virginia; University of Virginia; University of Munster	Ley, K (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biomed Engn, Box 800759, Charlottesville, VA 22908 USA.	klausley@virginia.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BREZIS M, 1995, NEW ENGL J MED, V332, P647, DOI 10.1056/NEJM199503093321006; BULLARD DC, 1995, J CLIN INVEST, V95, P1782, DOI 10.1172/JCI117856; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Chiao H, 1997, J CLIN INVEST, V99, P1165, DOI 10.1172/JCI119272; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; Diacovo TG, 1996, BLOOD, V88, P146; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Gotsch U, 1997, J CELL SCI, V110, P583; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; HELLBERG POA, 1989, KIDNEY INT, V36, P555, DOI 10.1038/ki.1989.230; HIRSCH S, 1983, IMMUNOGENETICS, V18, P229, DOI 10.1007/BF00952962; Ichikawa H, 1997, CIRC RES, V81, P922; Jung U, 1998, J CLIN INVEST, V102, P1526, DOI 10.1172/JCI119893; Jung U, 1999, J IMMUNOL, V162, P6755; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kanwar S, 1998, MICROCIRCULATION, V5, P281, DOI 10.1080/713773894; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; Kogaki S, 1999, CARDIOVASC RES, V43, P968, DOI 10.1016/S0008-6363(99)00140-6; Lefer AM, 1998, CIRCULATION, V98, P1322, DOI 10.1161/01.CIR.98.13.1322; LINAS SL, 1995, KIDNEY INT, V48, P1584, DOI 10.1038/ki.1995.451; Lindner JR, 2000, CIRCULATION, V102, P2745, DOI 10.1161/01.CIR.102.22.2745; Lu HF, 1997, J CLIN INVEST, V99, P1340, DOI 10.1172/JCI119293; MASON J, 1989, MINER ELECTROL METAB, V15, P114; Massberg S, 1998, BLOOD, V92, P507, DOI 10.1182/blood.V92.2.507; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MENGER MD, 1994, MICROSURG, V15, P383, DOI 10.1002/micr.1920150605; Merhi Y, 1999, ARTERIOSCL THROM VAS, V19, P372, DOI 10.1161/01.ATV.19.2.372; MERHI Y, 1994, CIRCULATION, V90, P997, DOI 10.1161/01.CIR.90.2.997; Merhi Y, 1997, ARTERIOSCL THROM VAS, V17, P1185, DOI 10.1161/01.ATV.17.6.1185; Muller JM, 1997, J SURG RES, V71, P1, DOI 10.1006/jsre.1997.5132; MULLER WA, 1995, J LEUKOCYTE BIOL, V57, P523, DOI 10.1002/jlb.57.4.523; OLOF P, 1990, AM J PHYSIOL, V258, pF1018, DOI 10.1152/ajprenal.1990.258.4.F1018; PALLER MS, 1989, J LAB CLIN MED, V113, P379; RABB H, 1994, AM J PHYSIOL-RENAL, V267, pF1052, DOI 10.1152/ajprenal.1994.267.6.F1052; Rabb H, 1996, AM J PHYSIOL-RENAL, V271, pF408, DOI 10.1152/ajprenal.1996.271.2.F408; RABB H, 1995, BIOCHEM BIOPH RES CO, V211, P67, DOI 10.1006/bbrc.1995.1779; Rabb H, 1998, CLIN EXP PHARMACOL P, V25, P286, DOI 10.1111/j.1440-1681.1998.t01-1-.x; RACUSEN LC, 1995, ACUTE RENAL FAILURE, P1; SANDERS WE, 1992, BLOOD, V80, P795; Sawaya DE, 1999, SHOCK, V12, P227, DOI 10.1097/00024382-199909000-00010; Singbartl K, 2000, FASEB J, V14, P48, DOI 10.1096/fasebj.14.1.48; Singbartl K, 2000, CRIT CARE MED, V28, P2507, DOI 10.1097/00003246-200007000-00053; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; THORNTON MA, 1989, AM J PATHOL, V135, P509; VENKATACHALAM MA, 1978, KIDNEY INT, V14, P31, DOI 10.1038/ki.1978.87; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; WILLINGER CC, 1992, VIRCHOWS ARCH B, V62, P237, DOI 10.1007/BF02899687; YEO EL, 1994, BLOOD, V83, P2498	50	121	129	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2337	2344		10.1096/fj.01-0199com	http://dx.doi.org/10.1096/fj.01-0199com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689459				2022-12-28	WOS:000172420500004
J	Dschietzig, T; Richter, C; Bartsch, C; Laule, M; Armbruster, FP; Baumann, G; Stangl, K				Dschietzig, T; Richter, C; Bartsch, C; Laule, M; Armbruster, FP; Baumann, G; Stangl, K			The pregnancy hormone relaxin is a player in human heart failure	FASEB JOURNAL			English	Article						RLX; congestive; endothelin 1; angiotensin II; gene expression	RAT; ENDOTHELIN; VASODILATOR; EXPRESSION; SECRETION; CELLS	Human congestive heart failure is characterized by complex neurohumoral activation associated with the up-regulation of vasoconstricting and salt-retaining mediators and the compensatory rise of counter-regulatory hormones. In the present study, we provide the first evidence that relaxin (RLX), known as a pregnancy hormone, represents a potential compensatory mediator in human heart failure: plasma concentrations of RLX and myocardial expression of the two RLX genes (H1 and H2) correlate with the severity of disease and RLX responds to therapy. The failing human heart is a relevant source of circulating RLX peptides, and myocytes as well as interstitial cells produce RLX. Elevation of ventricular filling pressure up-regulates RLX expression and the hormone acts as a potent inhibitor of endothelin 1, the most powerful vasoconstrictor in heart failure. Furthermore, RLX modulates effects of angiotensin II, another crucial mediator. Our data identify RLX as a new player in human heart failure with potential diagnostic and therapeutic relevance.	Charite, Med Klin & Poliklin S Kardiol Angiol Pulmol, D-10098 Berlin, Germany; Immundiagnost AG, D-64625 Bensheim, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stangl, K (corresponding author), Charite, Med Klin & Poliklin S Kardiol Angiol Pulmol, Campus Mitte,Schumannstr 20-21, D-10098 Berlin, Germany.	karl.stangl@charite.de	Armbruster, Franz Paul/D-7383-2014; Laule, Michael E/A-6548-2013	Laule, Michael/0000-0002-7579-295X; Dschietzig, Thomas Bernd/0000-0003-1186-8713				Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; Bortz JLG., 1990, VERTEILUNGSFREIE MET, DOI 10.1007/978-3-662-22593-6; BRYANTGREENWOOD GD, 1994, ENDOCR REV, V15, P5, DOI 10.1210/er.15.1.5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Danielson LA, 1999, J CLIN INVEST, V103, P525, DOI 10.1172/JCI5630; deBold AJ, 1996, CARDIOVASC RES, V31, P7, DOI 10.1016/S0008-6363(95)00121-2; Douglas SA, 1997, J VASC RES, V34, P152, DOI 10.1159/000159219; FIELDS PA, 1992, ENDOCRINOLOGY, V130, P2985, DOI 10.1210/en.130.5.2985; FRANGOS JA, 1988, BIOTECHNOL BIOENG, V32, P1053, DOI 10.1002/bit.260320812; GEDDES BJ, 1995, J NEUROENDOCRINOL, V7, P411, DOI 10.1111/j.1365-2826.1995.tb00777.x; Gunnersen JM, 1996, MOL CELL ENDOCRINOL, V118, P85, DOI 10.1016/0303-7207(96)03770-7; HAMOLSKY M, 1945, P SOC EXP BIOL MED, V60, P8, DOI 10.3181/00379727-60-15074P; HISAW F, 1926, P SOC EXP BIOL MED, V23, P899; HOLM S, 1979, SCAND J STAT, V6, P65; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; HUDSON P, 1981, NATURE, V291, P127, DOI 10.1038/291127a0; Lippert T. H., 1996, Clinical and Experimental Obstetrics and Gynecology, V23, P65; MARRIOTT D, 1992, MOL ENDOCRINOL, V6, P1441, DOI 10.1210/me.6.9.1441; Rossi GP, 1999, CARDIOVASC RES, V43, P300, DOI 10.1016/S0008-6363(99)00110-8; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; Stangl K, 2000, CIRCULATION, V102, P1132, DOI 10.1161/01.CIR.102.10.1132; TOO CKL, 1982, ENDOCRINOLOGY, V111, P1424, DOI 10.1210/endo-111-4-1424; Toth M, 1996, J ENDOCRINOL, V150, P487, DOI 10.1677/joe.0.1500487; Unemori EN, 1996, J CLIN INVEST, V98, P2739, DOI 10.1172/JCI119099; WEI CM, 1994, CIRCULATION, V89, P1580, DOI 10.1161/01.CIR.89.4.1580	26	170	184	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2187	2195		10.1096/fj.01-0070com	http://dx.doi.org/10.1096/fj.01-0070com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641245				2022-12-28	WOS:000171920400030
J	Cockerill, GW; McDonald, MC; Mota-Filipe, H; Cuzzocrea, S; Miller, NE; Thiemermann, C				Cockerill, GW; McDonald, MC; Mota-Filipe, H; Cuzzocrea, S; Miller, NE; Thiemermann, C			High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock	FASEB JOURNAL			English	Article						cytokines; chemokines; intercellular adhesion molecule 1; interleukin 8; multiple organ failure	MACROPHAGE INFLAMMATORY PROTEIN-2; APOLIPOPROTEIN-A-I; ISCHEMIA-REPERFUSION INJURY; CYTOKINE-INDUCED EXPRESSION; TUMOR-NECROSIS-FACTOR; ADHESION MOLECULES; LUNG INJURY; ALVEOLAR MACROPHAGES; SELECTIN EXPRESSION; ENDOTHELIAL-CELLS	High density lipoproteins (HDLs) inhibit the cytokine-induced expression of endothelial cell adhesion molecules both in vitro and in vivo. We examined the ability of HDLs to mediate a functional anti-inflammatory effect by measuring their ability to prevent neutrophil adhesion and transmigration in vitro. Treatment of human endothelial cell cultures with physiologic concentrations of HDLs inhibited neutrophil binding by 68 +/-5.9% (mean and SE, n=6, P<0.05) and neutrophil transmigration by 48.7<plus/minus>6.7% (n=8, P<0.05). We then examined the effect of HDLs on inflammatory infiltration and subsequent multiple organ dysfunction syndrome (MODS), associated with trauma in a rat model of hemorrhagic shock. Rats given human HDLs (80 mg apo A-I/kg, i.v.) 90 min after hemorrhage (which reduced mean arterial pressure to 50 mmHg) and 1 min before resuscitation showed attenuation of the increases in the serum levels of markers of MODS normally observed in this model. Severe disruption of the architecture of tissues and the extensive cellular infiltration into those tissues were also largely inhibited in animals that received HDLs. Human HDLs attenuate the MODS associated with ischemia and reperfusion injury after hemorrhagic shock in rats.	Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London SMD, London EC1M 6BQ, England; Univ Messina, Sch Med, Inst Pharmacol, I-98123 Messina, Italy	University of London; Queen Mary University London; University of Messina	Cockerill, GW (corresponding author), Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London SMD, London EC1M 6BQ, England.	g.w.cockerill@mds.qmw.ac.uk	Miller, Norman E/P-6032-2017; Mota-Filipe, Helder/GSE-1539-2022; Mota-Filipe, Helder/M-6298-2013; Mota-Filipe, Helder/M-6199-2019	Miller, Norman E/0000-0001-7087-3390; Mota-Filipe, Helder/0000-0003-3045-2553; Mota-Filipe, Helder/0000-0003-3045-2553; Mota-Filipe, Helder/0000-0003-3045-2553; Thiemermann, Christoph/0000-0003-4228-9722				Akgur FM, 1999, J SURG RES, V87, P232, DOI 10.1006/jsre.1999.5758; ANDERSON BO, 1991, SURGERY, V109, P51; Ashby DT, 1998, ARTERIOSCL THROM VAS, V18, P1450, DOI 10.1161/01.ATV.18.9.1450; BADIMON JJ, 1990, J CLIN INVEST, V85, P1234, DOI 10.1172/JCI114558; BRAITHWAITE CEM, 1993, J TRAUMA, V34, P586; CALEBRESI L, 1997, BIOCHEM BIOPH RES CO, V238, P61; COCKERILL GW, 1995, ARTERIOSCL THROM VAS, V15, P1987, DOI 10.1161/01.ATV.15.11.1987; Cockerill GW, 1999, ARTERIOSCL THROM VAS, V19, P910, DOI 10.1161/01.ATV.19.4.910; COCKERILL GW, 1995, BLOOD, V86, P2689; Cockerill GW, 2001, CIRCULATION, V103, P108; Cryer HG, 1997, SHOCK, V8, P26, DOI 10.1097/00024382-199707000-00005; Demetriades D, 1999, J TRAUMA, V46, P667, DOI 10.1097/00005373-199904000-00018; DiPiro JT, 1996, CRIT CARE MED, V24, P440, DOI 10.1097/00003246-199603000-00013; DRISCOLL KE, 1993, AM J RESP CELL MOL, V8, P311, DOI 10.1165/ajrcmb/8.3.311; Eppihimer MJ, 1997, SHOCK, V8, P16, DOI 10.1097/00024382-199707000-00004; FENGE H, 1995, INT J LEGAL PROF, V2, P95; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; Garner B, 1998, J BIOL CHEM, V273, P6080, DOI 10.1074/jbc.273.11.6080; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HEWETT JA, 1993, AM J PHYSIOL, V265, pG1011, DOI 10.1152/ajpgi.1993.265.6.G1011; Kalff JC, 1999, ARCH ORTHOP TRAUM SU, V119, P89, DOI 10.1007/s004020050363; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; KOIKE K, 1994, CRIT CARE MED, V22, P1438, DOI 10.1097/00003246-199409000-00014; Lemay S, 2000, TRANSPLANTATION, V69, P959; Lerch PG, 1996, VOX SANG, V71, P155, DOI 10.1046/j.1423-0410.1996.7130155.x; MACKNESS MI, 1993, BIOCHEM J, V294, P829, DOI 10.1042/bj2940829; Magnotti LJ, 1998, ANN SURG, V228, P518, DOI 10.1097/00000658-199810000-00008; Marubayashi S, 1997, SURGERY, V122, P45, DOI 10.1016/S0039-6060(97)90263-4; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MILLER GJ, 1975, LANCET, V1, P16; MOORE FA, 1991, J TRAUMA, V31, P629, DOI 10.1097/00005373-199105000-00006; Morgan WM, 1998, NEW HORIZ-SCI PRACT, V6, P150; Mota-Filipe H, 1999, SHOCK, V12, P255, DOI 10.1097/00024382-199910000-00002; Nanjee MN, 1999, ARTERIOSCL THROM VAS, V19, P979, DOI 10.1161/01.ATV.19.4.979; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Pajkrt D, 1996, J EXP MED, V184, P1601, DOI 10.1084/jem.184.5.1601; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; Ramamoorthy C, 1996, AM J PHYSIOL-HEART C, V271, pH1871, DOI 10.1152/ajpheart.1996.271.5.H1871; Regel G, 1996, WORLD J SURG, V20, P422, DOI 10.1007/s002689900067; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; Ruetten H, 1997, BRIT J PHARMACOL, V121, P695, DOI 10.1038/sj.bjp.0701180; RYE KA, 1993, BIOCHIM BIOPHYS ACTA, V1167, P316, DOI 10.1016/0005-2760(93)90235-2; Seekamp A, 1998, J TRAUMA, V44, P874, DOI 10.1097/00005373-199805000-00022; SEEKAMP A, 1993, AM J PATHOL, V143, P464; Shanley TP, 1997, J IMMUNOL, V158, P3439; SHAPPELL SB, 1994, HDB IMMUNOPHARMACOLO, P29; Shi MM, 1999, IMMUNOLOGY, V97, P309; Simons RK, 1996, J TRAUMA, V41, P653, DOI 10.1097/00005373-199610000-00010; Smith WB, 1996, J IMMUNOL, V157, P360; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; Thiagarajan RR, 1997, THROMB HAEMOSTASIS, V78, P310; THIEMERMANN C, 1995, BRIT J PHARMACOL, V116, P2845, DOI 10.1111/j.1476-5381.1995.tb15935.x; VEDDER NB, 1990, P NATL ACAD SCI USA, V87, P2643, DOI 10.1073/pnas.87.7.2643; VEDDER NB, 1989, SURGERY, V106, P509; WALL RT, 1978, J CELL PHYSIOL, V96, P203, DOI 10.1002/jcp.1040960209; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; WOLPE SD, 1989, P NATL ACAD SCI USA, V86, P612, DOI 10.1073/pnas.86.2.612; WU X, 1995, AM J PHYSIOL, V269, P248; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025; YAARI S, 1981, LANCET, V1, P1011	61	78	87	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					1941	1952		10.1096/fj.01-0075com	http://dx.doi.org/10.1096/fj.01-0075com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532974				2022-12-28	WOS:000171372700009
J	Lee, JE; Bokoch, G; Liang, BT				Lee, JE; Bokoch, G; Liang, BT			A novel cardioprotective role of RhoA: new signaling mechanism for adenosine	FASEB JOURNAL			English	Article						myocytes; ischemia; cytoprotection; phospholipase D; monomeric G-protein	SENSITIVE POTASSIUM CHANNELS; CHICK VENTRICULAR MYOCYTES; PHOSPHOLIPASE-D; BINDING PROTEINS; A(3) RECEPTORS; KINASE; ISCHEMIA; GTPASES; STIMULATION; ACTIVATION	Adenosine exerts a potent cardioprotective effect that is mediated by adenosine A(1) and A(3) receptors. The signaling pathways activated by the A(1) and A(3) receptors are distinct and involve selective coupling to phospholipases C and D, respectively. The objective of our study was to elucidate the signaling mechanism that mediates the coupling of each receptor to its respective phospholipase and to test the role of RhoA as a novel mediator leading from adenosine receptors to cardioprotection. C3 transferase and dominant negative RhoA (RhoAT19N) blocked the A(3) receptor-mediated phospholipase D activation and cardioprotection but had no effect on A(1) receptor-mediated phospholipase C activation or cardioprotection. In contrast, pertussis toxin treatment caused a greater inhibition of the diacylglycerol accumulation induced by the A(1) agonist than by the A(3) agonist, and it completely abrogated the A(1) agonist-mediated cardioprotection. Thus, adenosine A(1) and A(3) receptors are linked to different G-proteins. The A(3) receptor is coupled via RhoA to activate phospholipase D in exerting its cardioprotective effect, whereas the A(1) receptor is linked via G(i) to phospholipase C to produce cardioprotective responses. The present study identifies a novel role for RhoA and further suggests its importance in regulating cardiac cellular function.	Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pharmacol, Philadelphia, PA 19104 USA; Scripps Res Inst, Dept Immunol & Cell Biol, La Jolla, CA 92037 USA	University of Pennsylvania; University of Pennsylvania; Scripps Research Institute	Liang, BT (corresponding author), Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, Room 956,BRB2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	liang@mail.med.upenn.edu			NHLBI NIH HHS [R01 HL48225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048225] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Auchampach JA, 1997, CIRC RES, V80, P800; BARNETT JV, 1990, BIOCHEM J, V271, P437, DOI 10.1042/bj2710437; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Carr CS, 1997, CARDIOVASC RES, V36, P52, DOI 10.1016/S0008-6363(97)00160-0; DOWNEY JM, 1992, TRENDS CARDIOVAS MED, V2, P170, DOI 10.1016/1050-1738(92)90045-T; ELY SW, 1992, CIRCULATION, V85, P893, DOI 10.1161/01.CIR.85.3.893; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Exton JH, 1998, J BIOL CHEM, V273, P19923, DOI 10.1074/jbc.273.32.19923; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; GROSS GJ, 1995, BASIC RES CARDIOL, V90, P85, DOI 10.1007/BF00789438; GROVER GJ, 1992, CIRCULATION, V86, P1310, DOI 10.1161/01.CIR.86.4.1310; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; LI GC, 1990, CIRCULATION, V82, P609, DOI 10.1161/01.CIR.82.2.609; Liang BT, 1996, AM J PHYSIOL-HEART C, V271, pH1769, DOI 10.1152/ajpheart.1996.271.5.H1769; LIANG BT, 1988, BIOCHEM PHARMACOL, V37, P4549, DOI 10.1016/0006-2952(88)90671-5; Liang BT, 1998, P NATL ACAD SCI USA, V95, P6995, DOI 10.1073/pnas.95.12.6995; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Parsons M, 2000, FASEB J, V14, P1423, DOI 10.1096/fj.14.10.1423; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Sah VP, 1999, J CLIN INVEST, V103, P1627, DOI 10.1172/JCI6842; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Sigvardsson M, 2000, MOL CELL BIOL, V20, P3640, DOI 10.1128/MCB.20.10.3640-3654.2000; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Stambaugh K, 1997, AM J PHYSIOL-HEART C, V273, pH501; Strickler J, 1996, J CLIN INVEST, V98, P1773, DOI 10.1172/JCI118976; Tracey WR, 1997, CARDIOVASC RES, V33, P410, DOI 10.1016/S0008-6363(96)00240-4; XU D, 1992, CIRC RES, V70, P56, DOI 10.1161/01.RES.70.1.56; XU H, 1992, NUCLEIC ACIDS RES, V20, P6425, DOI 10.1093/nar/20.23.6425	37	48	49	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					1886	1894		10.1096/fj.01-0212com	http://dx.doi.org/10.1096/fj.01-0212com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532968				2022-12-28	WOS:000171372700003
J	Senzaki, H; Smith, CJ; Juang, GJ; Isoda, T; Mayer, SP; Ohler, A; Paolocci, N; Tomaselli, GF; Hare, JM; Kass, DA				Senzaki, H; Smith, CJ; Juang, GJ; Isoda, T; Mayer, SP; Ohler, A; Paolocci, N; Tomaselli, GF; Hare, JM; Kass, DA			Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure	FASEB JOURNAL			English	Article						tissue activity; protein expression; coronary blood flow; PDE5	DEPENDENT PROTEIN-KINASE; NITRIC-OXIDE; CYCLIC-GMP; MOLECULAR-CLONING; GENE FAMILY; BINDING; EXPRESSION; SYNTHASE; LOCALIZATION; INHIBITION	Recent studies implicate increased cGMP synthesis as a postreceptor contributor to reduced cardiac sympathetic responsiveness. Here we provide the first evidence that modulation of this interaction by cGMP-specific phosphodiesterase PDE5A is also diminished in failing hearts, providing a novel mechanism for blunted beta -adrenergic signaling in this disorder. In normal conscious dogs chronically instrumented for left ventricular pressure-dimension analysis, PDE5A inhibition by EMD82639 had modest basal effects but markedly blunted dobutamine-enhanced systolic and diastolic function. In failing hearts (tachypacing model), however, EMD82639 had negligible effects on either basal or dobutamine-stimulated function. Whole myocardium from failing hearts had 50% lower PDE5A protein expression and 30% less total and EMD92639-inhibitable cGMP-PDE activity. Although corresponding myocyte protein and enzyme activity was similar among groups, the proportion of EMD82639-inhibitable activity was significantly lower in failure cells. Immunohistochemistry confirmed PDE5A expression in both the vasculature and myocytes of normal and failing hearts, but there was loss of z-band localization in failing myocytes that suggested altered intracellular localization. Thus, PDE5A regulation of cGMP in the heart can potently modulate beta -adrenergic stimulation, and alterations in enzyme localization and reduced synthesis may blunt this pathway in cardiac failure, contributing to dampening of the beta -adrenergic response.	Johns Hopkins Med Inst, Div Cardiol, Dept Med, Baltimore, MD 21287 USA; New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA	Johns Hopkins University; Johns Hopkins Medicine; New York Medical College	Kass, DA (corresponding author), Johns Hopkins Med Inst, Div Cardiol, Dept Med, Halsted 500,600 N Wolfe St, Baltimore, MD 21287 USA.	dkass@bme.jhu.edu	paolocci, nazareno/A-7124-2009	Paolocci, Nazareno/0000-0001-7011-997X; Senzaki, Hideaki/0000-0002-8289-0953	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003228, R01HL047511, R29HL054081] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO8 HL03228, HL47511, R29 HL54081] Funding Source: Medline; PHS HHS [P50-52307] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Balligand JL, 1999, CARDIOVASC RES, V43, P607, DOI 10.1016/S0008-6363(99)00163-7; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; BRISTOW MR, 1993, J CLIN INVEST, V92, P2737, DOI 10.1172/JCI116891; Calderone A, 1998, J CLIN INVEST, V101, P812, DOI 10.1172/JCI119883; Chen HH, 1999, P ASSOC AM PHYSICIAN, V111, P406, DOI 10.1111/paa.1999.111.5.406; Cohen AH, 1996, J CLIN INVEST, V97, P172, DOI 10.1172/JCI118386; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729; DUNDORE RL, 1992, J CARDIOVASC PHARM, V19, P937, DOI 10.1097/00005344-199206000-00015; Fawcett L, 2000, P NATL ACAD SCI USA, V97, P3702, DOI 10.1073/pnas.050585197; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; Fujishige K, 1999, J BIOL CHEM, V274, P18438, DOI 10.1074/jbc.274.26.18438; Gauthier C, 1998, J CLIN INVEST, V102, P1377, DOI 10.1172/JCI2191; Grantham JA, 1997, CIRCULATION, V96, P388; Hare JM, 2000, CIRC RES, V86, P1085, DOI 10.1161/01.RES.86.10.1085; Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161; HARE JM, 1995, CIRCULATION, V92, P2198, DOI 10.1161/01.CIR.92.8.2198; Haywood GA, 1996, CIRCULATION, V93, P1087, DOI 10.1161/01.CIR.93.6.1087; Jackson G, 1999, AM J CARDIOL, V83, p13C; Koch WJ, 1999, TRENDS CARDIOVAS MED, V9, P77, DOI 10.1016/S1050-1738(99)00009-2; Kotera J, 2000, J HISTOCHEM CYTOCHEM, V48, P685, DOI 10.1177/002215540004800512; Kotera J, 1998, J BIOL CHEM, V273, P26982, DOI 10.1074/jbc.273.41.26982; Kotera J, 1999, EUR J BIOCHEM, V262, P866, DOI 10.1046/j.1432-1327.1999.00450.x; LaFevre-Bernt M, 1998, BBA-PROTEIN STRUCT M, V1386, P97, DOI 10.1016/S0167-4838(98)00088-0; Loughney K, 1999, GENE, V234, P109, DOI 10.1016/S0378-1119(99)00171-7; Loughney K, 1998, GENE, V216, P139, DOI 10.1016/S0378-1119(98)00303-5; MARZO KP, 1991, CIRC RES, V69, P1546, DOI 10.1161/01.RES.69.6.1546; Mohan P, 1996, CIRCULATION, V93, P1223, DOI 10.1161/01.CIR.93.6.1223; MOVSESIAN MA, 1991, J CLIN INVEST, V88, P15, DOI 10.1172/JCI115272; O'Rourke B, 1999, CIRC RES, V84, P562, DOI 10.1161/01.RES.84.5.562; Senzaki H, 2000, CIRCULATION, V101, P1040, DOI 10.1161/01.CIR.101.9.1040; SHAH AM, 1994, CIRC RES, V74, P970, DOI 10.1161/01.RES.74.5.970; Smith Carolyn J., 1998, Cell Biochemistry and Biophysics, V29, P67, DOI 10.1007/BF02737829; Smith CJ, 1996, CIRC RES, V78, P58, DOI 10.1161/01.RES.78.1.58; Smith JA, 1997, EXERC IMMUNOL REV, V3, P96; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; Stacey P, 1998, BIOCHEM BIOPH RES CO, V247, P249, DOI 10.1006/bbrc.1998.8769; Straznicka M, 1999, J CARDIOVASC PHARM, V34, P229, DOI 10.1097/00005344-199908000-00008; Traverse JH, 2000, CIRCULATION, V102, P2997; Varghese P, 2000, J CLIN INVEST, V106, P697, DOI 10.1172/JCI9323; Vejlstrup NG, 1998, J MOL CELL CARDIOL, V30, P1215, DOI 10.1006/jmcc.1998.0686; Vila-Petroff MG, 1999, CIRC RES, V84, P1020, DOI 10.1161/01.RES.84.9.1020; Wallis RM, 1999, AM J CARDIOL, V83, p3C; Yanaka N, 1998, EUR J BIOCHEM, V255, P391, DOI 10.1046/j.1432-1327.1998.2550391.x	47	176	183	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2001	15	10					1718	1726		10.1096/fj.00-0538com	http://dx.doi.org/10.1096/fj.00-0538com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481219				2022-12-28	WOS:000170809900007
J	Perrella, MA; Pellacani, A; Layne, MD; Patel, A; Zhao, DZ; Schreiber, BM; Storch, J; Feinberg, MW; Hsieh, CM; Haber, E; Lee, ME				Perrella, MA; Pellacani, A; Layne, MD; Patel, A; Zhao, DZ; Schreiber, BM; Storch, J; Feinberg, MW; Hsieh, CM; Haber, E; Lee, ME			Absence of adipocyte fatty acid binding protein prevents the development of accelerated atherosclerosis in hypercholesterolemic mice	FASEB JOURNAL			English	Article						macrophage; adipocyte; fatty acids; atheroma	E-DEFICIENT MICE; COLONY-STIMULATING FACTOR; APOLIPOPROTEIN-E; TRANSPLANT ARTERIOSCLEROSIS; ADIPOSE CONVERSION; RECEPTOR-DEFICIENT; AP2(-/-) MICE; EXPRESSION; AP2; METABOLISM	Lipid deposition in arterial walls due to elevated levels of plasma cholesterol is central to the development of atherosclerosis and involves the uptake of oxidized low-density lipoprotein (oxLDL) by macrophages. Fatty acid binding proteins (FABPs) belong to a family of low molecular weight cytoplasmic proteins that are involved with intracellular transport and metabolism of fatty acids, and adipocyte FABP (aP2) has recently been shown to be expressed in macrophages. Here, we investigate the role of aP2 in the development of atherosclerosis in mice. We show that atherosclerotic lesions from hypercholesterolemic, apolipoprotein E deficient (ApoE(-/-)) mice (but not arterial walls from normal mice) contain high levels of aP2 mRNA. We also identified aP2 in inflammatory cells that localized in these lesions, as confirmed by its presence in isolated mouse and human macrophages, and demonstrated that aP2 is induced by oxLDL. To determine the importance of aP2 in atherosclerosis, we generated mice lacking both ApoE and aP2 (ApoE(-/-) aP2(-/-)). In comparison with ApoE(-/-) mice, ApoE(-/-)aP2(-/-) mice developed trivial lesions that were markedly smaller, less complex, and less macrophage-rich even though the ApoE(-/-)aP2(-/-) mice remained hypercholesterolemic. Absence of aP2 did not prevent lesion formation and macrophage accumulation in transplant-associated arteriosclerosis that does not depend on elevated levels of cholesterol. These results indicate a critical role for aP2 in the development of hypercholesterolemia-induced atherosclerosis.	Brigham & Womens Hosp, Div Cardiovasc, Program Dev Cardiovasc Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Div Biol Sci, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Cambridge, MA 02138 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Rutgers State University New Brunswick	Perrella, MA (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Program Dev Cardiovasc Biol, 75 Francis St, Boston, MA 02115 USA.	mperrella@rics.bwh.harvard.edu		Schreiber, Barbara/0000-0001-8560-4249; Feinberg, Mark/0000-0001-9523-3859; Storch, Judith/0000-0001-5482-1777; Layne, Matthew/0000-0003-0007-4870	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK038389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNLOHR DA, 1985, BIOCHEM BIOPH RES CO, V132, P850, DOI 10.1016/0006-291X(85)91209-4; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; CATALA A, 1986, ACTA PHYSIOL PHARM L, V36, P19; Coe NR, 1999, J LIPID RES, V40, P967; COLIGAN JE, 1994, CURR PROTOCOLS IMMUN, V2; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Jain MK, 1998, CIRC RES, V83, P980, DOI 10.1161/01.RES.83.10.980; LEENEN PJ, 1994, J IMMUNOL METHODS, V14, P5; LUNZER MA, 1977, J BIOL CHEM, V252, P5483; MALEWIAK MI, 1988, INT J OBESITY, V12, P543; OCKNER RK, 1976, J CLIN INVEST, V58, P632, DOI 10.1172/JCI108510; Pelton PD, 1999, BIOCHEM BIOPH RES CO, V261, P456, DOI 10.1006/bbrc.1999.1071; Perrow C., 1994, TECHNOLOGY STUDIES, V1, P1; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Powell-Braxton L, 1998, NAT MED, V4, P934, DOI 10.1038/nm0898-934; Qiao JH, 1997, AM J PATHOL, V150, P1687; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rossberg R., 1995, Microsystem Technologies, V2, P11, DOI 10.1007/BF02739522; Scheja L, 1999, DIABETES, V48, P1987, DOI 10.2337/diabetes.48.10.1987; SCHREIBER BM, 1988, ATHEROSCLEROSIS, V69, P69, DOI 10.1016/0021-9150(88)90290-0; Shaughnessy S, 2000, DIABETES, V49, P904, DOI 10.2337/diabetes.49.6.904; Shi CW, 1997, CIRCULATION, V96, P2722, DOI 10.1161/01.CIR.96.8.2722; SHI CW, 1994, CIRC RES, V75, P199, DOI 10.1161/01.RES.75.2.199; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; SPIEGELMAN BM, 1980, J BIOL CHEM, V255, P8811; STJOHN LC, 1987, J NUTR, V117, P2021; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Uysal KT, 2000, ENDOCRINOLOGY, V141, P3388, DOI 10.1210/en.141.9.3388; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhang SH, 1997, J CLIN INVEST, V99, P2858, DOI 10.1172/JCI119479	34	32	34	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1774	+		10.1096/fj.01-0017fje	http://dx.doi.org/10.1096/fj.01-0017fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481226				2022-12-28	WOS:000169261200031
J	Mangoni, ML; Miele, R; Renda, TG; Barra, D; Simmaco, M				Mangoni, ML; Miele, R; Renda, TG; Barra, D; Simmaco, M			The synthesis of antimicrobial peptides in the skin of Rana esculenta is stimulated by microorganisms	FASEB JOURNAL			English	Article						amphibian skin glands; innate immunity; glucocorticoid; Amphibia	AMPHIBIAN SKIN; MOLECULAR-CLONING; EPITHELIAL-CELLS; INNATE IMMUNITY; KAPPA-B; GENE; ANTIBIOTICS; EXPRESSION; DROSOPHILA; INDUCTION	Secretions of amphibian skin glands contain numerous antimicrobial peptides that play a crucial role in the defense against microorganisms. The location of these glands on the surface of the animal makes them a useful model for in vivo studies of the relationships between the innate immune system and the natural flora. Here, we present the results of a study showing that in Rana esculenta the total antimicrobial activity of skin secretion is modulated by the presence of the natural flora. Frogs kept in a sterile environment do not produce antimicrobial peptides. This finding represents the first in vivo demonstration of the induction of defense peptides in a vertebrate. We also present data on the morphological changes in skin glands of animals kept in sterile conditions or treated with glucocorticoids. Cells from glands regenerated under normal conditions, but not those from "sterile" frogs, contain kappaB-binding activity in the cytoplasm.	Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Ctr Biol Mol, I-00185 Rome, Italy; Univ Roma La Sapienza, Ist Anat Umana, I-00185 Rome, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Sapienza University Rome	Barra, D (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	donatella.barra@uniroma1.it	Simmaco, Maurizio/AAC-2870-2019; Barra, Donatella/D-1236-2011	Simmaco, Maurizio/0000-0003-4164-1472; Miele, Rossella/0000-0001-9577-3177; Mangoni, Maria Luisa/0000-0002-5991-5868				Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Barra D, 1998, FEBS LETT, V430, P130, DOI 10.1016/S0014-5793(98)00494-3; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; Diamond G, 2000, INFECT IMMUN, V68, P113, DOI 10.1128/IAI.68.1.113-119.2000; ENGSTROM Y, 1993, J MOL BIOL, V232, P327, DOI 10.1006/jmbi.1993.1392; Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LI CY, 1987, J HISTOCHEM CYTOCHEM, V35, P1457, DOI 10.1177/35.12.2824601; Matutte B, 2000, FEBS LETT, V483, P135, DOI 10.1016/S0014-5793(00)02102-5; Miele R, 1998, FEBS LETT, V431, P23, DOI 10.1016/S0014-5793(98)00718-2; Miele R, 2001, EUR J BIOCHEM, V268, P443, DOI 10.1046/j.1432-1327.2001.01908.x; Ponti D, 1999, EUR J BIOCHEM, V263, P921, DOI 10.1046/j.1432-1327.1999.00597.x; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Simmaco M, 1997, FEBS LETT, V416, P273, DOI 10.1016/S0014-5793(97)01216-7; Simmaco M, 1998, SCAND J IMMUNOL, V48, P357; SIMMACO M, 1994, J BIOL CHEM, V269, P11956; Simmaco M, 1998, BIOPOLYMERS, V47, P435, DOI 10.1002/(SICI)1097-0282(1998)47:6<435::AID-BIP3>3.3.CO;2-#; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686	22	74	77	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1431	+		10.1096/fj.00-0695fje	http://dx.doi.org/10.1096/fj.00-0695fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387247				2022-12-28	WOS:000173705800021
J	Marchalonis, JJ; Kaveri, S; Lacroix-Desmazes, S; Kazatchkine, MD				Marchalonis, JJ; Kaveri, S; Lacroix-Desmazes, S; Kazatchkine, MD			Natural recognition repertoire and the evolutionary emergence of the combinatorial immune system	FASEB JOURNAL			English	Article						immune response; natural antibody repertoire; antigenic selection	ANTIGEN RECEPTOR; INNATE IMMUNITY; NORMAL IMMUNOGLOBULIN; MOLECULAR MIMICRY; LIGHT-CHAIN; ANTIBODIES; AUTOANTIBODIES; BINDING; PEPTIDE; HIV-1	The primordial combinatorial immune recognition repertoire arose in the evolution of jawed vertebrates similar to450 million years ago as a rapid genetic process independent of antigenic selection. We propose that it encompassed the entire repertoire of innate immunity involving molecules that had evolved over billions of years. The 'antigen-driven' compartment involving invasive pathogens operates in 'real time' showing inducibility and increases in affinity. Individuals within a species differ in their repertoires because of distinct antigenic challenges, genetics, or local environmental effects. The 'homeostatic' compartment that recognizes invariant cell and serum components should be conserved in all individuals of a species. The potential to recapitulate the entire recognition spectrum must be regenerated during the formation of new species. Evidence for the capacity of the combinatorial response to encompass the entire preexisting repertoire was obtained in studies of natural human IgG antibodies present in intravenous immunoglobulin. Since essential cellular recognition and regulatory elements are conserved throughout evolution, we propose that the natural antibodies of sharks, the most anciently emerged vertebrates to possess the combinatorial immune response, will resemble those of mammals in showing specificity for the conserved recognition/regulatory molecules. If verified, this hypothesis will establish the fundamental importance of natural antibodies not only in defense, but in regulation and functional homeostasis of the individual.	Univ Arizona, Arizona Hlth Sci Ctr, Coll Med, Tucson, AZ 85724 USA; Univ Paris 06, INSERM, U430, Paris, France	University of Arizona; University of Arizona Health Sciences; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Marchalonis, JJ (corresponding author), Univ Arizona, Arizona Hlth Sci Ctr, Coll Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	marchjj@email.arizona.edu		Lacroix-Desmazes, Sebastien/0000-0001-5625-8447				ADIB M, 1990, J IMMUNOL, V145, P3807; Adib-Conquy M, 1998, INT IMMUNOL, V10, P341, DOI 10.1093/intimm/10.3.341; Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Avrameas A, 1998, P NATL ACAD SCI USA, V95, P5601, DOI 10.1073/pnas.95.10.5601; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baumgarth N, 1999, P NATL ACAD SCI USA, V96, P2250, DOI 10.1073/pnas.96.5.2250; Bendtzen K, 1998, IMMUNOL TODAY, V19, P209, DOI 10.1016/S0167-5699(98)01252-3; Bernstein RM, 1996, P NATL ACAD SCI USA, V93, P9454, DOI 10.1073/pnas.93.18.9454; BHARDWAJ V, 1993, J IMMUNOL, V151, P5000; BHATTACHARJEE AK, 1977, J IMMUNOL, V120, P411; Boes M, 2000, MOL IMMUNOL, V37, P1141, DOI 10.1016/S0161-5890(01)00025-6; Boman HG, 1998, SCAND J IMMUNOL, V48, P15; Bouhlal H, 2001, J IMMUNOL, V166, P7606, DOI 10.4049/jimmunol.166.12.7606; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; Chen ZJ, 1998, EUR J IMMUNOL, V28, P989, DOI 10.1002/(SICI)1521-4141(199803)28:03<989::AID-IMMU989>3.0.CO;2-1; Coutinho A, 1995, CURR OPIN IMMUNOL, V7, P812, DOI 10.1016/0952-7915(95)80053-0; Dehghanpisheh K, 1997, SCAND J IMMUNOL, V45, P645, DOI 10.1046/j.1365-3083.1997.d01-439.x; Deng YJ, 2000, CLIN EXP IMMUNOL, V119, P69, DOI 10.1046/j.1365-2249.2000.01096.x; DIGHIERO G, 1983, BLOOD, V62, P264; Du Pasquier L., 1999, FUNDAMENTAL IMMUNOLO, P605; Fahmy TM, 2001, IMMUNITY, V14, P135, DOI 10.1016/S1074-7613(09)00099-5; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; GARZA KM, 1995, J IMMUNOL, V155, P5444; GONZALEZ R, 1988, IMMUNOLOGY, V63, P31; GOOD RA, 1964, ADV IMMUNOL, V4, P1, DOI 10.1016/S0065-2776(08)60706-3; GREENBERG AS, 1995, NATURE, V374, P168, DOI 10.1038/374168a0; HARINDRANATH N, 1993, INT IMMUNOL, V5, P1523, DOI 10.1093/intimm/5.12.1523; Hayakawa K, 1999, SCIENCE, V285, P113, DOI 10.1126/science.285.5424.113; HINDS KR, 1986, NATURE, V320, P546, DOI 10.1038/320546a0; HIORN K, 1998, CELL, V94, P463; HOHMAN VS, 1992, P NATL ACAD SCI USA, V89, P276, DOI 10.1073/pnas.89.1.276; HUREZ V, 1993, SCAND J IMMUNOL, V38, P190, DOI 10.1111/j.1365-3083.1993.tb01712.x; Hurez V, 1997, BLOOD, V90, P4004, DOI 10.1182/blood.V90.10.4004; Hurez V, 1994, Ther Immunol, V1, P269; Janeway CA, 2001, P NATL ACAD SCI USA, V98, P7461, DOI 10.1073/pnas.131202998; JOHNSTON MFM, 1976, J IMMUNOL, V117, P1189; Kaveri S, 1996, J CLIN INVEST, V97, P865, DOI 10.1172/JCI118488; KAY MMB, 1975, P NATL ACAD SCI USA, V72, P3521, DOI 10.1073/pnas.72.9.3521; KAYMAZ H, 1993, J PROTEIN CHEM, V12, P659, DOI 10.1007/BF01024924; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Keitel T, 1997, CELL, V91, P811, DOI 10.1016/S0092-8674(00)80469-9; Kohler H, 2000, IMMUNOLOGIST, V8, P91; Kraj P, 2001, J IMMUNOL, V166, P2251, DOI 10.4049/jimmunol.166.4.2251; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Lacroix-Desmazes S, 1998, J IMMUNOL METHODS, V216, P117, DOI 10.1016/S0022-1759(98)00074-X; LacroixDesmazes S, 1997, INT IMMUNOL, V9, P1175, DOI 10.1093/intimm/9.8.1175; Lake DF, 1999, INT IMMUNOL, V11, P745, DOI 10.1093/intimm/11.5.745; LAKE DF, 1994, P NATL ACAD SCI USA, V91, P10849, DOI 10.1073/pnas.91.23.10849; LESLIE GA, 1970, J IMMUNOL, V105, P1547; LI L, 1995, J IMMUNOL, V154, P3328; Litman GF, 1999, ANNU REV IMMUNOL, V17, P109, DOI 10.1146/annurev.immunol.17.1.109; Marchalonis JJ, 1997, CRIT REV IMMUNOL, V17, P497; Marchalonis JJ, 1998, J THEOR BIOL, V193, P429, DOI 10.1006/jtbi.1998.0711; Marchalonis JJ, 1998, IMMUNOL REV, V166, P103, DOI 10.1111/j.1600-065X.1998.tb01256.x; MARCHALONIS JJ, 1990, SCAND J IMMUNOL, V32, P13, DOI 10.1111/j.1365-3083.1990.tb02886.x; Marchalonis JJ, 1998, ADV IMMUNOL, V70, P417, DOI 10.1016/S0065-2776(08)60392-2; Marchalonis JJ, 2001, ADV EXP MED BIOL, V484, P13; Marchalonis JJ, 2001, J MOL RECOGNIT, V14, P110, DOI 10.1002/jmr.527; Marchalonis JJ, 2000, APPL BIOCHEM BIOTECH, V83, P31, DOI 10.1385/ABAB:83:1-3:31; MARCHALONIS JJ, 1993, DEV COMP IMMUNOL, V17, P41, DOI 10.1016/0145-305X(93)90014-H; MARCHALONIS JJ, 1992, P NATL ACAD SCI USA, V89, P3325, DOI 10.1073/pnas.89.8.3325; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Meister M, 2000, CURR TOP MICROBIOL, V248, P17; MUYDERMANS S, 1994, PROTEIN ENG, V7, P1129; Nuttall SD, 2001, MOL IMMUNOL, V38, P313, DOI 10.1016/S0161-5890(01)00057-8; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; Pincus SH, 1998, J IMMUNOL, V160, P293; Plasterk R, 1998, NATURE, V394, P718, DOI 10.1038/29389; Prasad NKA, 1998, J IMMUNOL, V161, P3781; Putterman C, 2000, J IMMUNOL, V164, P2542, DOI 10.4049/jimmunol.164.5.2542; Ramsland PA, 1997, J COMPUT AID MOL DES, V11, P453, DOI 10.1023/A:1007932211514; Robey IF, 2000, J PROTEIN CHEM, V19, P9, DOI 10.1023/A:1007086608036; Rodman TC, 2001, EXP HEMATOL, V29, P1004, DOI 10.1016/S0301-472X(01)00678-6; ROSSI F, 1989, J IMMUNOL, V143, P4104; SASSO EH, 1992, J IMMUNOL, V149, P1230; Schluter SF, 1999, DEV COMP IMMUNOL, V23, P107; SILVESTRIS F, 1995, CLIN IMMUNOL IMMUNOP, V75, P197, DOI 10.1006/clin.1995.1072; STEWART J, 1992, IMMUNOL TODAY, V13, P396, DOI 10.1016/0167-5699(92)90088-O; SUSAL C, 1993, VOX SANG, V65, P10; VASSILEV T, 1993, CLIN EXP IMMUNOL, V92, P369; Vassilev TL, 1999, BLOOD, V93, P3624, DOI 10.1182/blood.V93.11.3624.411a28_3624_3631; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Williams RC, 1996, CLIN IMMUNOL IMMUNOP, V80, P194	83	49	50	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0842	10.1096/fj.01-0953hyp	http://dx.doi.org/10.1096/fj.01-0953hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039866				2022-12-28	WOS:000176683900010
J	Frigeri, A; Nicchia, GP; Repetto, S; Bado, M; Minetti, C; Svelto, M				Frigeri, A; Nicchia, GP; Repetto, S; Bado, M; Minetti, C; Svelto, M			Altered aquaporin-4 expression in human muscular dystrophies: a common feature?	FASEB JOURNAL			English	Article						AQP4; water channels; DMD	INSENSITIVE WATER CHANNEL; MUSCLE PLASMA-MEMBRANE; SKELETAL-MUSCLE; GLYCOPROTEIN COMPLEX; MDX MOUSE; FREEZE-FRACTURE; EXTRACELLULAR-MATRIX; ORTHOGONAL ARRAYS; KNOCKOUT MICE; RAT-BRAIN	Duchenne Muscular Dystrophy (DMD) is a progressive lethal muscle disease that affects young boys. Dystrophin, absent in DMD and reduced in the milder form Becker Muscular Dystrophy (BMD), binds to several membrane-associated proteins known as dystrophin-associated proteins (DAPs). Once this critical structural link is disrupted, muscle fibers become more vulnerable to mechanical and osmotic stress. Recently, we have reported that the expression of aquaporin-4 (AQP4), a water-selective channel expressed in the sarcolemma of fast-twitch fibers and astrocyte end-feet, is drastically reduced in the muscle and brain of the mdx mouse, the animal model of DMD. In the present study, we analyzed the expression of AQP4 in several DMD/BMD patients of different ages with different mutations in the dystrophin gene. Immunofluorescence results indicate that, compared with healthy control children, AQP4 is reduced severely in all the DMD muscular biopsies analyzed and in 50% of the analyzed BMD. Western blot analysis revealed that the deficiency in sarcolemma AQP4 staining is due to a reduction in total AQP4 muscle protein content rather than to changes in immunoreactivity. Double-immunostaining experiments indicate that AQP4 reduction is independent of changes in the fiber myosin heavy chain composition. AQP4 and alpha-syntrophin analysis of BMD muscular biopsies revealed that the expression and stability of AQP4 in the sarcolemma does not always decrease when alpha-syntrophin is strongly reduced. Finally, limb-girdle muscular dystrophy biopsies and facioscapulohumeral muscular dystrophy revealed that AQP4 expression was not altered in these forms of muscular dystrophy. These experiments provide the first evidence of AQP4 reduction in a human pathology and show that this deficiency is an important feature of DMD/BMD.	Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Univ Bari, CEGBA, I-70126 Bari, Italy; Univ Genoa, Ist Giannina Gaslini, Serv Malattie Neuromuscolari, Genoa, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; University of Genoa; IRCCS Istituto Giannina Gaslini	Frigeri, A (corresponding author), Univ Bari, Dipartimento Fisiol Gen & Ambientale, Via Amendola 165-A, I-70126 Bari, Italy.	a.frigeri@biologia.uniba.it	frigeri, Antonio/AAC-6336-2022; Svelto, Maria/P-6186-2014; Minetti, Carlo/K-4666-2018	Minetti, Carlo/0000-0002-0640-1804; Svelto, Maria/0000-0002-5584-9541; Frigeri, Antonio/0000-0002-5284-2934	Telethon [983] Funding Source: Medline	Telethon(Fondazione Telethon)		Adams ME, 2001, J CELL BIOL, V155, P113, DOI 10.1083/jcb.200106158; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; Crosbie RH, 1998, FEBS LETT, V427, P279, DOI 10.1016/S0014-5793(98)00442-6; Culligan KG, 1998, INT J MOL MED, V2, P639; EMERY AEH, 1987, OXFORD MONOGRAPHS ME, V15; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; Fitzsimons RB, 1999, CURR OPIN NEUROL, V12, P501, DOI 10.1097/00019052-199910000-00003; FRANCOOBREGON A, 1994, J PHYSIOL-LONDON, V481, P299, DOI 10.1113/jphysiol.1994.sp020440; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; Frigeri A, 1998, J CLIN INVEST, V102, P695, DOI 10.1172/JCI2545; FRIGERI A, 1995, J CELL SCI, V108, P2993; Frigeri A, 2001, FASEB J, V15, P90, DOI 10.1096/fj.00-0260com; Frigeri A, 2001, FASEB J, V15, P1282, DOI 10.1096/fj.00-0525fje; Grichko VP, 2000, J APPL PHYSIOL, V88, P473, DOI 10.1152/jappl.2000.88.2.473; Herrmann R, 2000, HUM MOL GENET, V9, P2335, DOI 10.1093/oxfordjournals.hmg.a018926; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; Lidov HGW, 1996, BRAIN PATHOL, V6, P63, DOI 10.1111/j.1750-3639.1996.tb00783.x; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; MARSHALL PA, 1989, MUSCLE NERVE, V12, P528, DOI 10.1002/mus.880120703; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MCDONALD KS, 1992, J APPL PHYSIOL, V73, P1135, DOI 10.1152/jappl.1992.73.3.1135; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Nicchia GP, 2000, GLIA, V31, P29, DOI 10.1002/(SICI)1098-1136(200007)31:1<29::AID-GLIA30>3.0.CO;2-3; Nico B, 2001, J CELL SCI, V114, P1297; Nielsen S, 1997, J NEUROSCI, V17, P171; Ohlendieck K, 1996, EUR J CELL BIOL, V69, P1; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Repetto S, 1999, BIOCHEM BIOPH RES CO, V261, P547, DOI 10.1006/bbrc.1999.1055; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SCHOTLAND DL, 1981, ACTA NEUROPATHOL, V54, P189, DOI 10.1007/BF00687741; SCHOTLAND DL, 1977, SCIENCE, V196, P1005, DOI 10.1126/science.860127; SHIBUYA S, 1991, NEUROPATH APPL NEURO, V17, P335, DOI 10.1111/j.1365-2990.1991.tb00730.x; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Sotgia F, 2000, J BIOL CHEM, V275, P38048, DOI 10.1074/jbc.M005321200; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; Vaghy PL, 1998, FEBS LETT, V431, P125, DOI 10.1016/S0014-5793(98)00738-8; Verbavatz JM, 1997, J CELL SCI, V110, P2855; WAKAYAMA Y, 1989, J NEUROL SCI, V91, P191, DOI 10.1016/0022-510X(89)90087-7; Yang BX, 1996, J BIOL CHEM, V271, P4577; Yang BX, 2000, AM J PHYSIOL-CELL PH, V278, pC1108, DOI 10.1152/ajpcell.2000.278.6.C1108; Yokota T, 2000, P JPN ACAD B-PHYS, V76, P22, DOI 10.2183/pjab.76.22; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	55	53	53	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7					1120	+		10.1096/fj.01-0797fje	http://dx.doi.org/10.1096/fj.01-0797fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039847				2022-12-28	WOS:000175973900016
J	Riedemann, NC; Guo, RF; Laudes, IJ; Keller, K; Sarma, VJ; Padgaonkar, V; Zetoune, FS; Ward, PA				Riedemann, NC; Guo, RF; Laudes, IJ; Keller, K; Sarma, VJ; Padgaonkar, V; Zetoune, FS; Ward, PA			C5a receptor and thymocyte apoptosis in sepsis	FASEB JOURNAL			English	Article						cecal ligation/puncture; caspases; thymus; complement	NON-MYELOID CELLS; POLYMICROBIAL SEPSIS; CECAL LIGATION; FAS LIGAND; ANAPHYLATOXIN; EXPRESSION; ENDOTOXIN; ANTI-C5A; RAT; ANTIBODIES	In sepsis, apoptosis occurs in many different organs. The mediators responsible for induction of apoptosis are not clearly known, although there are some suggestions that C5a and the C5a receptor (C5aR) might be directly linked to apoptosis. In the cecal ligation/puncture (CLP) model of sepsis in rats, apoptosis occurs early in a variety of organs, especially in the thymus. We demonstrate that thymocytes from normal rats show specific, saturable, and high affinity binding of I-125-labeled recombinant rat C5a. C5a binding to thymocytes was significantly increased 3 h after CLP and also when thymocytes from normal rats were first incubated in vitro with lipopolysaccharide (LPS) or IL-6. The expression of C5aR mRNA in thymocytes was markedly increased 3, 6, and 12 h after CLP and increased similarly when normal thymocytes were first exposed to LPS or IL-6 in vitro. Thymocytes obtained 2 or 3 h after CLP and exposed in vitro to C5a, but not normal thymocytes, underwent increased apoptosis, as demonstrated by annexin-V binding, coinciding with increased activation of caspases 3, 6, and 8. These data provide the first direct evidence that in the early onset of sepsis, increased expression of C5aR occurs in thymocytes, which increases their susceptibility to C5a-induced apoptosis.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu	Riedemann, Niels C/C-1633-2010					Ayala A, 1999, SHOCK, V11, P211, DOI 10.1097/00024382-199903000-00010; Ayala A, 1999, IMMUNOLOGY, V97, P45; BARKE RA, 1994, ARCH SURG-CHICAGO, V129, P1256; Bennett GL, 1997, METHOD ENZYMOL, V288, P134; CHENOWETH DE, 1978, P NATL ACAD SCI USA, V75, P3943, DOI 10.1073/pnas.75.8.3943; COCHRANE CG, 1968, J EXP MED, V127, P371, DOI 10.1084/jem.127.2.371; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Floreani AA, 1998, J IMMUNOL, V160, P5073; GERARD NP, 1989, J BIOL CHEM, V264, P1760; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GOLDSTEI.IM, 1974, J IMMUNOL, V113, P1583; Guo RF, 2000, J CLIN INVEST, V106, P1271, DOI 10.1172/JCI10793; HAVILAND DL, 1995, J IMMUNOL, V154, P1861; Hiramatsu M, 1997, SHOCK, V7, P247, DOI 10.1097/00024382-199704000-00002; Hotchkiss RS, 1997, CRIT CARE MED, V25, P1298, DOI 10.1097/00003246-199708000-00015; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang MS, 2001, FASEB J, V15, P568; Izawa M, 1997, ENDOCR J, V44, P677, DOI 10.1507/endocrj.44.677; LACY M, 1995, J NEUROIMMUNOL, V61, P71, DOI 10.1016/0165-5728(95)00075-D; Morris ID, 1997, TOXICOLOGY, V120, P19, DOI 10.1016/S0300-483X(97)03626-3; Mukherjee P, 2001, J NEUROCHEM, V77, P43, DOI 10.1046/j.1471-4159.2001.00167.x; Nataf S, 1999, J IMMUNOL, V162, P4018; SACKS T, 1978, J CLIN INVEST, V61, P1161, DOI 10.1172/JCI109031; Schieferdecker HL, 2000, J IMMUNOL, V164, P5453, DOI 10.4049/jimmunol.164.10.5453; SCHUMACHER WA, 1991, AGENTS ACTIONS, V34, P345, DOI 10.1007/BF01988727; SHIN HS, 1968, SCIENCE, V162, P361, DOI 10.1126/science.162.3851.361; SMEDEGARD G, 1989, AM J PATHOL, V135, P489; Stefanelli C, 1997, BIOCHEM J, V322, P909, DOI 10.1042/bj3220909; STEVENS JH, 1986, J CLIN INVEST, V77, P1812, DOI 10.1172/JCI112506; Tinsley KW, 2000, SHOCK, V13, P1, DOI 10.1097/00024382-200013010-00001; VILLA P, 1995, CLIN DIAGN LAB IMMUN, V2, P549, DOI 10.1128/CDLI.2.5.549-553.1995; WANG SD, 1994, J IMMUNOL, V152, P5014; WETSEL RA, 1995, IMMUNOL LETT, V44, P183, DOI 10.1016/0165-2478(94)00212-A; Zwirner J, 1999, MOL IMMUNOL, V36, P877, DOI 10.1016/S0161-5890(99)00109-1	36	62	67	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					887	+		10.1096/fj.02-0033fje	http://dx.doi.org/10.1096/fj.02-0033fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039868	Green Submitted			2022-12-28	WOS:000175425900029
J	Gobin, AS; West, JL				Gobin, AS; West, JL			Cell migration through defined, synthetic extracellular matrix analogues	FASEB JOURNAL			English	Article						PEG; hydrogel; RGD; proteolysis	SMOOTH-MUSCLE-CELLS; ADHESION PEPTIDES; DEGRADATION; HYDROGELS; COLLAGEN; GELS; PROTEOLYSIS; FIBROBLAST; SURFACES; MOTILITY	We have developed synthetic hydrogel extracellular matrix (ECM) analogues that can be used to study mechanisms involved in cell migration, such as receptor-ligand interactions and proteolysis. The biomimetic hydrogels consist of bioinert polyethylene glycol diacrylate derivatives with proteolytically degradable peptide sequences included in the backbone of the polymer and adhesive peptide sequences grafted to the network. Hydrogels have been developed that degrade as cells secrete proteolytic enzymes. Adhesive peptide sequences grafted to the hydrogel provide ligands that can interact with receptors on the cell surface to mediate adhesion and spreading. In this study, we have characterized the effects of adhesive ligand density on fibroblast migration through collagenase-degradable and plasmin-degradable hydrogels and on smooth muscle cell migration through elastase-degradable hydrogels. In all three cases, we found that cell migration has a biphasic dependence on adhesion ligand concentration, with optimal migration at intermediate ligand levels. Furthermore, both adhesive and proteolytically degradable sequences were required for cell migration to occur. These synthetic ECM analogues may be useful for 3-D mechanistic studies of many aspects of cell migration.	Rice Univ, Dept Bioengn, Houston, TX 77005 USA	Rice University	West, JL (corresponding author), Rice Univ, Dept Bioengn, 6100 Main St,MS 142, Houston, TX 77005 USA.	jwest@rice.edu	West, Jennifer L/A-4582-2008	West, Jennifer L/0000-0001-8550-2875				Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Burgess BT, 2000, ANN BIOMED ENG, V28, P110, DOI 10.1114/1.259; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; Elbert DL, 2001, BIOMACROMOLECULES, V2, P430, DOI 10.1021/bm0056299; Friedl P, 1998, MICROSC RES TECHNIQ, V43, P369, DOI 10.1002/(SICI)1097-0029(19981201)43:5<369::AID-JEMT3>3.0.CO;2-6; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; Heino J, 1996, INT J CANCER, V65, P717, DOI 10.1002/(SICI)1097-0215(19960315)65:6<717::AID-IJC1>3.3.CO;2-P; Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Kuntz RM, 1997, BIOPHYS J, V72, P1472, DOI 10.1016/S0006-3495(97)78793-9; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Mann BK, 2001, BIOMATERIALS, V22, P3045, DOI 10.1016/S0142-9612(01)00051-5; Mann BK, 2002, J BIOMED MATER RES, V60, P86, DOI 10.1002/jbm.10042; Mann BK, 2001, BIOMATERIALS, V22, P439, DOI 10.1016/S0142-9612(00)00196-4; MASSIA SP, 1990, ANAL BIOCHEM, V187, P292, DOI 10.1016/0003-2697(90)90459-M; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; Olbrich KC, 1996, BIOMATERIALS, V17, P759, DOI 10.1016/0142-9612(96)81412-8; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Price JT, 1999, METH MOL B, V129, P231; Schense JC, 2000, NAT BIOTECHNOL, V18, P415, DOI 10.1038/74473; SCOTTBURDEN T, 1989, HYPERTENSION, V13, P295, DOI 10.1161/01.HYP.13.4.295; Sperinde JJ, 1997, MACROMOLECULES, V30, P5255, DOI 10.1021/ma970345a; Tan J, 1999, J BIOMED MATER RES, V46, P465, DOI 10.1002/(SICI)1097-4636(19990915)46:4<465::AID-JBM4>3.0.CO;2-N; West JL, 1999, MACROMOLECULES, V32, P241, DOI 10.1021/ma981296k	25	189	195	0	45	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					751	+		10.1096/fj.01-0759fje	http://dx.doi.org/10.1096/fj.01-0759fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923220				2022-12-28	WOS:000174755900001
J	Laussmann, T; Janosi, RA; Fingas, CD; Schlieper, GR; Schlack, W; Schrader, J; Decking, UKM				Laussmann, T; Janosi, RA; Fingas, CD; Schlieper, GR; Schlack, W; Schrader, J; Decking, UKM			Myocardial proteome analysis reveals reduced NOS inhibition and enhanced glycolytic capacity in areas of low local blood flow	FASEB JOURNAL			English	Article						myocardial blood flow; heterogeneity; energy metabolism; nitric oxide; proteome; protein expression; heart	SPATIAL HETEROGENEITY; NITRIC-OXIDE; DOG HEART; CORONARY RESERVE; ENZYME-ACTIVITY; LEFT-VENTRICLE; GLUCOSE-UPTAKE; AWAKE DOGS; MICROSPHERES; PERFUSION	In the heart, in situ local myocardial blood flow (MBF) varies greater than 10-fold between individual areas and displays a spatially heterogeneous pattern. To analyze its molecular basis, we analyzed protein expression of low and high flow samples (300 mg, <50% or >150% of mean MBF, each n=30) of six beagle dogs by 2-D polyacrylamide gel electrophoresis (380+/-78 spots/gel). In low flow samples, dimethylarginine dimethylaminohydrolase (DDAH1) was increased greatly (+377%, compared with high flow samples). This increase resulted in a 75% reduction of asymmetric dimethylarginine (ADMA), the potent endogenous inhibitor of NO synthase, whereas eNOS showed no difference. Low flow samples exhibited enhanced expression of GAPDH (+89%) and phosphoglycerate kinase (+100%), whereas hydroxyacyl-CoA dehydrogenase, electron transfer flavoprotein, myoglobin, and desmin were decreased. Assessing local MBF on different days within 2 weeks revealed a high degree of MBF stability (r(2) > 0.79). Thus, stable differences in local MBF are associated with significant differences in local gene and protein expression. In low flow areas, the increased DDAH1 reduces ADMA concentration and NOS inhibition, which strongly suggests enhanced NO formation. Low flow areas are also characterized by a higher glycolytic and a lower fatty acid oxidation capacity. Both the shift in substrate utilization and the rise in NO may contribute to the known lower oxygen consumption in these areas.	Univ Dusseldorf, Dept Physiol, D-40001 Dusseldorf, Germany; Univ Dusseldorf, Dept Anesthesiol, D-40001 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Decking, UKM (corresponding author), Univ Dusseldorf, Dept Physiol, POB 10 10 07, D-40001 Dusseldorf, Germany.	decking@uni-duesseldorf.de	Janosi, Rolf Alexander/J-7810-2019	Janosi, Rolf Alexander/0000-0002-9966-6886; Laussmann, Tim/0000-0002-0180-3513				AUSTIN RE, 1990, CIRC RES, V67, P319, DOI 10.1161/01.RES.67.2.319; Balaban RS, 2001, CIRC RES, V88, P265, DOI 10.1161/01.RES.88.3.265; BASSINGTHWAIGHTE JB, 1989, CIRC RES, V65, P578, DOI 10.1161/01.RES.65.3.578; BASSINGTHWAIGHTE JB, 1990, CIRC RES, V66, P1328, DOI 10.1161/01.RES.66.5.1328; Bauer WR, 2001, CIRC RES, V88, P340, DOI 10.1161/01.RES.88.3.340; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BUSSEMAKER J, 1994, J MOL CELL CARDIOL, V26, P1017, DOI 10.1006/jmcc.1994.1122; CALDWELL JH, 1994, AM J PHYSIOL, V267, pH654, DOI 10.1152/ajpheart.1994.267.2.H654; Decking UKM, 2001, PFLUG ARCH EUR J PHY, V441, P663, DOI 10.1007/s004240000464; Deussen A, 1998, BASIC RES CARDIOL, V93, P430, DOI 10.1007/s003950050112; Deussen A, 1997, PFLUG ARCH EUR J PHY, V433, P488, DOI 10.1007/s004240050304; Deussen A, 1996, PFLUG ARCH EUR J PHY, V432, P451, DOI 10.1007/s004240050157; Dunn MJ, 1997, ELECTROPHORESIS, V18, P2795, DOI 10.1002/elps.1150181514; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Ghaleh B, 1996, CIRCULATION, V94, P2210, DOI 10.1161/01.CIR.94.9.2210; GLENNY RW, 1993, J APPL PHYSIOL, V74, P2585, DOI 10.1152/jappl.1993.74.5.2585; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; GRANGER BL, 1979, CELL, V18, P1053, DOI 10.1016/0092-8674(79)90218-6; Griffith OW, 1996, METHOD ENZYMOL, V268, P375; GROENEVELD ABJ, 1993, BASIC RES CARDIOL, V88, P223; Kay L, 1997, BBA-BIOENERGETICS, V1322, P41, DOI 10.1016/S0005-2728(97)00071-6; KING RB, 1989, PFLUG ARCH EUR J PHY, V413, P336, DOI 10.1007/BF00584480; KING RB, 1985, CIRC RES, V57, P285, DOI 10.1161/01.RES.57.2.285; Leiper J, 1999, CARDIOVASC RES, V43, P542, DOI 10.1016/S0008-6363(99)00162-5; Loncar R, 1998, CIRCULATION, V98, P262, DOI 10.1161/01.CIR.98.3.262; MARCUS ML, 1977, AM HEART J, V94, P748, DOI 10.1016/S0002-8703(77)80216-0; MERX MW, 2001, FASEB J; Milner DJ, 2000, J CELL BIOL, V150, P1283, DOI 10.1083/jcb.150.6.1283; Mullenheim J, 2000, ANESTH ANALG, V91, P787; OGAWA T, 1989, J BIOL CHEM, V264, P10205; Pettersson A, 1997, J CHROMATOGR B, V692, P257, DOI 10.1016/S0378-4347(96)00525-7; Ramagli LS, 1999, METH MOL B, V112, P99; Recchia FA, 1998, CIRC RES, V83, P969, DOI 10.1161/01.RES.83.10.969; ROSE CP, 1976, CIRC RES, V39, P541, DOI 10.1161/01.RES.39.4.541; SONNTAG M, 1992, PFLUG ARCH EUR J PHY, V420, P194, DOI 10.1007/BF00374990; Sonntag M, 1996, PFLUG ARCH EUR J PHY, V432, P439, DOI 10.1007/s004240050156; Trochu JN, 2000, CIRC RES, V87, P1108, DOI 10.1161/01.RES.87.12.1108; Van Oosterhout MFM, 1998, AM J PHYSIOL-HEART C, V275, pH110, DOI 10.1152/ajpheart.1998.275.1.H110; YIPINTSOI T, 1973, CIRC RES, V33, P573, DOI 10.1161/01.RES.33.5.573	40	37	38	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					628	+		10.1096/fj.01-0574fje	http://dx.doi.org/10.1096/fj.01-0574fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919176				2022-12-28	WOS:000174203700014
J	Matyash, M; Matyash, V; Nolte, C; Sorrentino, V; Kettenmann, H				Matyash, M; Matyash, V; Nolte, C; Sorrentino, V; Kettenmann, H			Requirement of functional ryanodine receptor type 3 for astrocyte migration	FASEB JOURNAL			English	Article						RyR3 knockout mice; 4-chloro-m-cresol; in vitro wound-healing assay; cell migration	MOUSE SKELETAL-MUSCLE; CA2+ RELEASE CHANNELS; INTRACELLULAR CALCIUM; IN-VITRO; DIFFERENTIAL DISTRIBUTION; ENDOGENOUS EFFECTORS; ACTIN CYTOSKELETON; G-PROTEIN; CONTRACTION; CELLS	Astrocyte motility plays an important role in the response of the brain to injury and during regeneration. We used two in vitro assays, a wound-healing model and a chemotaxis assay, to study mechanisms that control astrocyte motility. Ryanodine receptors (RyR), intracellular calcium-release channels, modulate intracellular Ca2+ levels, and also motility: 1) blocking RyR with antagonizing concentration of ryanodine (200 muM) strongly attenuated motility and 2) motility of astrocytes cultured from homozygous RyR type 3 knockout mice was impaired strongly compared with wild-type. In contrast, MIP-1 alpha -induced chemotaxis was neither impaired in the presence of ryanodine nor in the cells from the knockout animals. Reverse transcription-polymerase chain reaction (RT-PCR) analysis combined with Western blotting and immunocytochemistry confirmed the expression of RyR type 3, but not type 1 or 2 in cultured and acutely isolated astrocytes. RyR in astrocytes are linked to Ca2+ signaling because the RyR agonist 4-chloro-m-cresol induced a release of Ca2+ from intracellular stores. These results indicate that astrocytes express only RyR type 3 and that this receptor is important for controlling astrocyte motility.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Univ Siena, Dept Neurosci, Mol Med Sect, I-53100 Siena, Italy; San Raffaele Sci Inst, I-20132 Milan, Italy	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Siena; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Kettenmann, H (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	hketten@mdc-berlin.de	Sorrentino, Vincenzo/A-4793-2014; Kettenmann, Helmut/AAJ-5142-2021	Sorrentino, Vincenzo/0000-0002-8573-8631; Nolte, Christiane/0000-0001-5398-3440; Kettenmann, Helmut/0000-0001-8208-0291	Telethon [1151] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		ALLEN DG, 1995, J PHYSIOL-LONDON, V487, P331, DOI 10.1113/jphysiol.1995.sp020883; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bertocchini F, 1997, EMBO J, V16, P6956, DOI 10.1093/emboj/16.23.6956; Conti A, 1996, BIOCHEM J, V316, P19, DOI 10.1042/bj3160019; Cotrina ML, 1998, J NEUROSCI, V18, P8794; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Fitch MT, 1999, J NEUROSCI, V19, P8182; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HerrmannFrank A, 1996, BBA-GEN SUBJECTS, V1289, P31, DOI 10.1016/0304-4165(95)00131-X; Horgan AM, 1998, J NEUROSCI, V18, P4189; Kabbara AA, 1999, CELL CALCIUM, V25, P227, DOI 10.1054/ceca.1999.0023; Kornyei Z, 2000, J NEUROSCI RES, V61, P421, DOI 10.1002/1097-4547(20000815)61:4<421::AID-JNR8>3.0.CO;2-4; LANGLEY D, 1994, GLIA, V12, P128, DOI 10.1002/glia.440120206; Lau PM, 1999, J CELL BIOL, V145, P1265, DOI 10.1083/jcb.145.6.1265; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Liu LX, 1999, J IMMUNOL, V163, P5649; MacFarlane SN, 1997, J NEUROSCI, V17, P7316; Mandeville JTH, 1997, J CELL PHYSIOL, V171, P168, DOI 10.1002/(SICI)1097-4652(199705)171:2<168::AID-JCP7>3.0.CO;2-M; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCGRAW J, 2001, MODULATING ASTROGLIO, V63, P109; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Nolte C, 1996, NEUROSCIENCE, V73, P1091, DOI 10.1016/0306-4522(96)00106-6; Nolte C, 2001, GLIA, V33, P72; Ogawa Y, 1999, ADV BIOPHYS, V36, P27, DOI 10.1016/S0065-227X(99)80004-5; Ouyang Y, 1997, BRAIN RES, V775, P52, DOI 10.1016/S0006-8993(97)00840-8; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Simpson PB, 1998, J NEUROSCI RES, V52, P468, DOI 10.1002/(SICI)1097-4547(19980515)52:4<468::AID-JNR11>3.0.CO;2-#; Sorrentino V, 1999, TRENDS CARDIOVAS MED, V9, P54, DOI 10.1016/S1050-1738(99)00003-1; Tanabe S, 1997, J NEUROSCI, V17, P6522; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; TSIEN RY, 1981, NATURE, V290, P527, DOI 10.1038/290527a0; Verkhratsky A, 1998, PHYSIOL REV, V78, P99, DOI 10.1152/physrev.1998.78.1.99; Westerblad H, 1998, CELL CALCIUM, V24, P105, DOI 10.1016/S0143-4160(98)90078-1; Willmott NJ, 2000, J NEUROSCI, V20, P1767; Yoshikawa N, 1999, LIFE SCI, V65, P2643, DOI 10.1016/S0024-3205(99)00533-0; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; Zheng JQ, 2000, NATURE, V403, P89, DOI 10.1038/47501; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192; Zucchi R, 1997, PHARMACOL REV, V49, P1	42	94	95	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					84	+		10.1096/fj.01-0380fje	http://dx.doi.org/10.1096/fj.01-0380fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11709492				2022-12-28	WOS:000172420500038
J	Stroka, DM; Burkhardt, T; Desbaillets, I; Wenger, RH; Neil, DAH; Bauer, C; Gassmann, M; Candinas, D				Stroka, DM; Burkhardt, T; Desbaillets, I; Wenger, RH; Neil, DAH; Bauer, C; Gassmann, M; Candinas, D			HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia	FASEB JOURNAL			English	Article						hypoxia-inducible factor 1; ARNT; tissue hypoxia	INDUCIBLE FACTOR 1-ALPHA; ENDOTHELIAL-GROWTH-FACTOR; TUMOR-SUPPRESSOR PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; PAS DOMAIN PROTEIN-1; TRANSCRIPTION FACTOR; FACTOR-I; RAT-BRAIN; DEGRADATION DOMAIN; VEGF EXPRESSION	Adaptation to hypoxia is regulated by hypoxia-inducible factor 1 (HIF-1), a heterodimeric transcription factor consisting of an oxygen-regulated alpha subunit and a constitutively expressed beta subunit. Although HIF-1 is regulated mainly by oxygen tension through the oxygen-dependent degradation of its alpha subunit, in vitro it can also be modulated by cytokines, hormones and genetic alterations. To investigate HIF-1 activation in vivo, we determined the spatial and temporal distribution of HIF-1 in healthy mice subjected to varying fractions of inspiratory oxygen. Immunohistochemical examination of brain, kidney, liver, heart, and skeletal muscle revealed that HIF-1 alpha is present in mice kept under normoxic conditions and is further increased in response to systemic hypoxia. Moreover, immunoblot analysis showed that the kinetics of HIF-1 alpha expression varies among different organs. In liver and kidney, HIF-1 alpha reaches maximal levels after 1 h and gradually decreases to baseline levels after 4 h of continuous hypoxia. In the brain, however, HIF-1 alpha is maximally expressed after 5 h and declines to basal levels by 12 h. Whereas HIF-1 beta is constitutively expressed in brain and kidney nuclear extracts, its hepatic expression increases concomitantly with HIF-1 alpha. Overall, HIF-1 alpha expression in normoxic mice suggests that HIF-1 has an important role in tissue homeostasis.	Univ Birmingham, Liver Labs, Birmingham, W Midlands, England; Univ Zurich, Inst Physiol, Zurich, Switzerland; Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany	University of Birmingham; University of Zurich; University of Lubeck	Stroka, DM (corresponding author), Queen Elizabeth Hosp, Liver Labs, Clin Res Block, Birmingham B15 2TH, W Midlands, England.	d.m.stroka@bham.ac.uk		Stroka, Deborah/0000-0002-3517-3871; Neil, Desley/0000-0001-9800-6811				Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Feldser D, 1999, CANCER RES, V59, P3915; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Jin KL, 2000, NEUROSCIENCE, V99, P577, DOI 10.1016/S0306-4522(00)00207-4; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kietzmann T, 2001, BIOCHEM J, V354, P531, DOI 10.1042/0264-6021:3540531; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; Martin C, 1998, AM J OBSTET GYNECOL, V178, P527, DOI 10.1016/S0002-9378(98)70433-8; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Royer C, 2000, BRAIN RES, V856, P119, DOI 10.1016/S0006-8993(99)02365-3; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; SCHMIDT EE, 1995, J CELL BIOL, V128, P467, DOI 10.1083/jcb.128.4.467; Smith RW, 1996, AM J PHYSIOL-REG I, V271, pR897, DOI 10.1152/ajpregu.1996.271.4.R897; Smith RW, 1999, AM J PHYSIOL-REG I, V277, pR690, DOI 10.1152/ajpregu.1999.277.3.R690; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1998, INT J MOL MED, V2, P317; Wenger RH, 1998, BLOOD, V91, P3471, DOI 10.1182/blood.V91.9.3471.3471_3471_3480; Wenger RH, 2000, J EXP BIOL, V203, P1253; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; Wenger RH, 1997, BIOL CHEM, V378, P609; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yu AY, 1998, AM J PHYSIOL-LUNG C, V275, pL818, DOI 10.1152/ajplung.1998.275.4.L818; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang X, 1997, BIOTECHNIQUES, V22, P848, DOI 10.2144/97225bm13; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 1999, CANCER RES, V59, P5830; Zundel W, 2000, GENE DEV, V14, P391	52	522	585	0	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2445	2453		10.1096/fj.01-0125com	http://dx.doi.org/10.1096/fj.01-0125com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689469	Green Published			2022-12-28	WOS:000172420500014
J	Chan, HW				Chan, HW			Bone builders: preventing and treating osteoporosis	FASEB JOURNAL			English	Editorial Material																			0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					1677	1677		10.1096/fj.01-0536bkt	http://dx.doi.org/10.1096/fj.01-0536bkt			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481213				2022-12-28	WOS:000170809900002
J	Chu, Y; Hughes, S; Chan-Ling, TL				Chu, Y; Hughes, S; Chan-Ling, TL			Differentiation and migration of astrocyte precursor cells (APCs) and astrocytes in human fetal retina: relevance to optic nerve coloboma	FASEB JOURNAL			English	Article						Pax2; astrocyte; retina; glial fibrillary acidic protein; differentiation	SUBVENTRICULAR ZONE; GLIAL PRECURSORS; VEGF EXPRESSION; BLOOD-VESSELS; CAT RETINA; PAX2 GENE; MOUSE; RAT; VASCULATURE; VIMENTIN	The presence of astrocyte precursor cells (APCs) and time course and topography of astrocyte differentiation during development were investigated by triple-label immunohistochemistry with intact fetal and adult human retinas. Throughout retinal development and adulthood, expression of Pax2 was restricted to cells of the astrocytic lineage. Three distinct stages of astrocytic differentiation were identified during development: i) Pax2(+)/vimentin(+)/GFAP(-) APCs; ii) Pax2(+)/vimentin(+)/GFAP(+) immature perinatal astrocytes; and iii) Pax2(+)/vimentin(-)/GFAP(+) mature perinatal astrocytes. In adult, cells with the antigenic phenotype of mature perinatal astrocytes were restricted to a region surrounding the optic nerve head (ONH), whereas cells at a fourth stage of differentiation, adult astrocytes (Pax2(-)/vimentin(-)/GFAP(+)), were apparent throughout the vascularized retina. APC appearance was centered around the ONH and preceded the appearance of perinatal astrocytes. A cluster of Pax2(+) somas was also present in a small region surrounding the ONH at the ventricular surface of the developing retina, which suggests the existence of two distinct sites of astrocytic differentiation. The coincidence in the location of APCs and perinatal astrocytes at the ventricular zone with that of optic nerve colobomas, together with the association of Pax2 gene mutations with this condition, suggests that coloboma formation may result from impaired astrocyte differentiation during development.	Univ Sydney, Inst Biomed Res, Dept Anat & Histol, Sydney, NSW 2006, Australia	University of Sydney	Chan-Ling, TL (corresponding author), Univ Sydney, Dept Anat & Histol F13, Sydney, NSW 2006, Australia.	tailoi@anatomy.usyd.edu.au	Chan-Ling, Tailoi/A-2177-2008; Chan-Ling, Tailoi/X-2718-2019	Chan-Ling, Tailoi/0000-0002-8225-3671; 				BARISHAK YR, 1992, DEV OPHTHAMOL, V24, P42; CHANLING T, 1991, J COMP NEUROL, V303, P387, DOI 10.1002/cne.903030305; CHANLING T, 1991, J COMP NEUROL, V303, P375, DOI 10.1002/cne.903030304; CHANLING T, 1990, CURR EYE RES, V9, P459, DOI 10.3109/02713689008999612; ChanLing T, 1997, MICROSC RES TECHNIQ, V36, P1; CHANLING T, 1996, P AUST NEUR SOC, V7, P48; CHANLING TL, 1995, INVEST OPHTH VIS SCI, V36, P1201; DAHL D, 1981, EUR J CELL BIOL, V24, P191; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; Favor J, 1996, P NATL ACAD SCI USA, V93, P13870, DOI 10.1073/pnas.93.24.13870; FEDOROFF S, 1983, DEV BRAIN RES, V7, P303, DOI 10.1016/0165-3806(83)90187-6; FOKSEANG J, 1992, J NEUROSCI, V12, P2751; Gariano RF, 1996, INVEST OPHTH VIS SCI, V37, P2367; Hogan MJ, 1971, HISTOLOGY HUMAN EYE; HOLLANDER H, 1991, J COMP NEUROL, V313, P587, DOI 10.1002/cne.903130405; Hu P, 2000, AM J PATHOL, V156, P1139, DOI 10.1016/S0002-9440(10)64982-6; Hughes S, 2000, INVEST OPHTH VIS SCI, V41, P1217; HUXLIN KR, 1992, J NEUROCYTOL, V21, P530, DOI 10.1007/BF01186955; Levison SW, 1997, J NEUROSCI RES, V48, P83, DOI 10.1002/(SICI)1097-4547(19970415)48:2<83::AID-JNR1>3.0.CO;2-8; LEVISON SW, 1993, DEVELOPMENT, V119, P611; LING TL, 1989, J COMP NEUROL, V286, P345, DOI 10.1002/cne.902860305; LING TL, 1988, DEV BRAIN RES, V44, P73, DOI 10.1016/0165-3806(88)90119-8; Maricich SM, 1999, J NEUROBIOL, V41, P281, DOI 10.1002/(SICI)1097-4695(19991105)41:2<281::AID-NEU10>3.0.CO;2-5; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Mi HY, 1999, J NEUROSCI, V19, P1049; NORNES HO, 1990, DEVELOPMENT, V109, P797; OGDEN TE, 1978, INVEST OPHTH VIS SCI, V17, P499; Orentas DM, 1996, GLIA, V16, P27, DOI 10.1002/(SICI)1098-1136(199601)16:1<27::AID-GLIA4>3.0.CO;2-8; Otteson DC, 1998, DEV BIOL, V193, P209, DOI 10.1006/dbio.1997.8794; PERRY VH, 1990, J NEUROCYTOL, V19, P265, DOI 10.1007/BF01217304; Provis JM, 1997, EXP EYE RES, V65, P555, DOI 10.1006/exer.1997.0365; RAFF MC, 1984, DEV BIOL, V106, P53, DOI 10.1016/0012-1606(84)90060-5; RAMIREZ JM, 1994, VISION RES, V34, P1935, DOI 10.1016/0042-6989(94)90024-8; Sandercoe TM, 1999, EXP EYE RES, V69, P511, DOI 10.1006/exer.1999.0730; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SAVELL J, 1976, ARCH OPHTHALMOL-CHIC, V94, P395; SCHNITZER J, 1986, CELL TISSUE RES, V246, P91; SCHNITZER J, 1981, J CELL BIOL, V90, P435, DOI 10.1083/jcb.90.2.435; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; SMITH GM, 1991, BRAIN RES, V543, P111, DOI 10.1016/0006-8993(91)91054-5; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Terzic J, 1998, INT J DEV BIOL, V42, P701; Torres MA, 1996, DEVELOPMENT, V122, P3381; Trivino A, 1996, VISION RES, V36, P2015, DOI 10.1016/0042-6989(95)00317-7; Trivino A, 1997, VISION RES, V37, P1707, DOI 10.1016/S0042-6989(97)00021-7; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; WATANABE T, 1988, NATURE, V332, P834, DOI 10.1038/332834a0; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387; WOLTER JR, 1955, AM J OPHTHALMOL, V40, P88, DOI 10.1016/0002-9394(55)91841-9; [No title captured]	50	80	87	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2013	+		10.1096/fj.00-0868fje	http://dx.doi.org/10.1096/fj.00-0868fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511521				2022-12-28	WOS:000170318500023
J	Yang, HP; Huang, ZZ; Wang, JH; Lu, SC				Yang, HP; Huang, ZZ; Wang, JH; Lu, SC			The role of c-Myb and Sp1 in the up-regulation of methionine adenosyltransferase 2A gene expression in human hepatocellular carcinoma	FASEB JOURNAL			English	Article						methionine adenosyltransferase; transcriptional regulation; HCC; S-adenosylmethionine	S-ADENOSYLMETHIONINE SYNTHETASE; FUNCTIONAL-CHARACTERIZATION; 5'-FLANKING REGION; LIVER; CLONING; RAT; DIFFERENTIATION; ACTIVATION; SUBUNIT; FAMILY	Liver-specific and non-liver-specific methionine adenosyltransferase (MAT) are products of two genes, MAT1A and MAT2A, respectively, that catalyze the formation of S-adenosylmethionine. We showed a switch from MAT1A to MAT2A expression at the transcriptional level in human hepatocellular carcinoma (HCC) that facilitates cancer cell growth. The purpose of the present study was to better understand the molecular mechanism of increased MAT2A expression in HCC. In vitro DNase I footprinting analysis revealed two protected sites (-354 to -312 and -73 to -28) using nuclear proteins from HCC and HepG2 cells, but not normal liver. These sites are also protected in HepG2 cells on in vivo DNase I footprinting analysis. These protected sites contain consensus binding sites for c-Myb and Sp1. In HCC, the mRNA levels of c-myb and Sp1 and binding to their respective sites increased. Mutation of the c-Myb or Sp1 site reduced MAT2A promoter activity by 67% and 50%, respectively. The importance of these cis-acting elements and trans-activating factors was confirmed using heterologous promoter and expression vectors. Increased expression of c-Myb and Sp1 and binding to the MAT2A promoter contribute to transcriptional up-regulation of MAT2A in HCC.	Univ So Calif, Keck Sch Med, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, Liver Dis Res Ctr,Div Gastroenterol & Liver Dis, Los Angeles, CA 90033 USA	University of Southern California	Lu, SC (corresponding author), Univ So Calif, Sch Med, Dept Med, Div Gastrointestinal & Liver Dis, HMR Bldg 415,2011 Zonal Ave, Los Angeles, CA 90033 USA.	shellylu@hsc.usc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48522] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; Cai JX, 1998, CANCER RES, V58, P1444; Cai JX, 1996, HEPATOLOGY, V24, P1090; Cai JX, 1997, BIOCHEM J, V326, P167, DOI 10.1042/bj3260167; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELAROSA J, 1995, J BIOL CHEM, V270, P21860; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; Gil B, 1996, HEPATOLOGY, V24, P876; HORIKAWA S, 1993, FEBS LETT, V330, P307, DOI 10.1016/0014-5793(93)80894-Z; HORIKAWA S, 1992, FEBS LETT, V312, P37, DOI 10.1016/0014-5793(92)81405-B; Hromas R, 1996, CURR TOP MICROBIOL, V211, P159; Huang ZZ, 1999, HEPATOLOGY, V29, P1471, DOI 10.1002/hep.510290525; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; Kitada T, 1997, HEPATOLOGY, V26, P1506; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; Lu SC, 2000, INT J BIOCHEM CELL B, V32, P391, DOI 10.1016/S1357-2725(99)00139-9; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Mao ZB, 1998, BIOCHEM BIOPH RES CO, V248, P479, DOI 10.1006/bbrc.1998.8965; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Ohtaka-Maruyama C, 1998, NUCLEIC ACIDS RES, V26, P407, DOI 10.1093/nar/26.2.407; Ruiz IG, 2000, DNA CELL BIOL, V19, P167, DOI 10.1089/104454900314555; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Tobena R, 1996, BIOCHEM J, V319, P929, DOI 10.1042/bj3190929; TUGORES A, 1994, J BIOL CHEM, V269, P30789; Yang HP, 2001, AM J PHYSIOL-GASTR L, V280, pG184; Yang J, 1997, NUCLEIC ACIDS RES, V25, P2213, DOI 10.1093/nar/25.11.2213; Zeng ZH, 2000, BIOCHEM J, V346, P475, DOI 10.1042/0264-6021:3460475	31	55	59	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					1507	1516		10.1096/fj.01-0040com	http://dx.doi.org/10.1096/fj.01-0040com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427482				2022-12-28	WOS:000170318500002
J	Schafer, K; Fujisawa, K; Konstantinides, S; Loskutoff, DJ				Schafer, K; Fujisawa, K; Konstantinides, S; Loskutoff, DJ			Disruption of the plasminogen activator inhibitor-1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice	FASEB JOURNAL			English	Article						obesity; insulin resistance; animal models; gene disruption; tumor necrosis factor alpha	TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-BETA; POLYMERASE-CHAIN-REACTION; FACTOR-ALPHA; INSULIN-RESISTANCE; IN-VIVO; CELLULAR-LOCALIZATION; FIBRINOLYTIC-ACTIVITY; DEFICIENT MICE; MESSENGER-RNA	Elevated levels of plasma and adipose tissue plasminogen activator inhibitor-1 (PAI-1) are observed frequently in obese humans and rodents. In this report, genetically obese (ob/ob) mice lacking the PAI-1 gene (PAI-1(-/-)) were generated and then used to test the hypothesis that the presence of PAI-1 promotes the hyperglycemia, hyperinsulinemia, and insulin resistance associated with obesity. Both wild-type (WT) ob/ob and PAI-1(-/-) ob/ob mice developed substantial adiposity compared with their lean counterparts. However, the PAI-1(-/-) ob/ob mice weighed significantly less than the WT ob/ob mice, and their hyperglycemia and hyperinsulinemia improved significantly. Although intraperitoneal glucose administration resulted in a dramatic increase in serum insulin levels in WT ob/ob mice, the increase in PAI-1(-/-) ob/ob mice was relatively small. Reverse transcription polymerase chain reaction assays and in situ hybridization studies demonstrated that tumor necrosis factor alpha (TNF-alpha) mRNA expression increased significantly in the adipose tissue of WT ob/ob mice at most ages tested. However, it was not increased, or only mildly increased, in the adipose tissue of the PAI-1(-/-) ob/ob mice. The concentration and rate of secretion of TNF-alpha protein in adipose tissue from PAI-1(-/-) ob/ob mice also were significantly lower compared with their WT ob/ob counterparts as shown by immunohistochemistry and ELISA. These results suggest that PAI-1 contributes to the development of the characteristic hyperglycemia and hyperinsulinemia associated with murine obesity, possibly by facilitating increased adipose tissue TNF-alpha gene expression.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Univ Gottingen, Dept Cardiol, D-37075 Gottingen, Germany; Tokyo Metropolitan Bokutou Gen Hosp, Dept Endocrinol, Toshima Ku, Tokyo 170002, Japan	Scripps Research Institute; University of Gottingen	Loskutoff, DJ (corresponding author), Scripps Res Inst, Dept Vasc Biol, VB-3,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	loskutof@scripps.edu	Konstantinides, Stavros/AAL-3174-2021; Schäfer, Katrin/P-4728-2015	Konstantinides, Stavros/0000-0001-6359-7279; Schafer, Katrin/0000-0003-0846-4718				Alessi MC, 1997, DIABETES, V46, P860, DOI 10.2337/diabetes.46.5.860; ASPLUNDCARLSON A, 1993, DIABETOLOGIA, V36, P817, DOI 10.1007/BF00400356; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; CallesEscandon J, 1996, AM J CLIN NUTR, V64, P7, DOI 10.1093/ajcn/64.1.7; Carmassi F, 1999, AM J MED, V107, P344, DOI 10.1016/S0002-9343(99)00240-5; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; CHOY LN, 1992, J BIOL CHEM, V267, P12736; Chung WK, 1997, OBES RES, V5, P183, DOI 10.1002/j.1550-8528.1997.tb00291.x; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P2108, DOI 10.1210/jc.82.7.2108; EVERETT RM, 1983, MOUSE BIOMEDICAL RES; Fearns C, 1997, AM J PATHOL, V150, P579; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Glantz SA., 1997, PRIMER BIOSTATISTICS; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; *JACKS LAB, 1998, BOD WEIGHTS SEL STRA; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JOHNSON PR, 1972, J LIPID RES, V13, P2; JuhanVague I, 1997, THROMB HAEMOSTASIS, V78, P656; KEETON M, 1993, AM J PATHOL, V142, P59; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; LANDIN K, 1990, METABOLISM, V39, P1044, DOI 10.1016/0026-0495(90)90164-8; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; Lemne C, 1996, EUR J CLIN INVEST, V26, P692, DOI 10.1111/j.1365-2362.1996.tb02155.x; Lundgren CH, 1996, CIRCULATION, V93, P106, DOI 10.1161/01.CIR.93.1.106; MCGILL JB, 1994, DIABETES, V43, P104, DOI 10.2337/diabetes.43.1.104; Morange PE, 2000, ARTERIOSCL THROM VAS, V20, P1150, DOI 10.1161/01.ATV.20.4.1150; Morange PE, 1999, DIABETES, V48, P890, DOI 10.2337/diabetes.48.4.890; MURRAY LJ, 1990, EUR J IMMUNOL, V20, P163, DOI 10.1002/eji.1830200124; PLATZER C, 1992, EUR J IMMUNOL, V22, P1179, DOI 10.1002/eji.1830220511; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Samad F, 1997, MOL MED, V3, P37, DOI 10.1007/BF03401666; Samad F, 1999, P NATL ACAD SCI USA, V96, P6902, DOI 10.1073/pnas.96.12.6902; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Samad F, 1996, MOL MED, V2, P568, DOI 10.1007/BF03401641; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; Schreyer SA, 1998, J CLIN INVEST, V102, P402, DOI 10.1172/JCI2849; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; VAGUE P, 1986, METABOLISM, V35, P250, DOI 10.1016/0026-0495(86)90209-X; VANLOON BJP, 1993, METABOLISM, V42, P945, DOI 10.1016/0026-0495(93)90005-9	53	154	161	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1840	+		10.1096/fj.00-0750fje	http://dx.doi.org/10.1096/fj.00-0750fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481248				2022-12-28	WOS:000169261200011
J	Gunther, C; Schmidt, U; Rudolph, R; Bohm, G				Gunther, C; Schmidt, U; Rudolph, R; Bohm, G			Protein and peptide delivery via engineered polyomavirus-like particles	FASEB JOURNAL			English	Article						drug delivery; in vitro assembly; VP1; WW domain	MURINE POLYOMAVIRUS; WW DOMAIN; BINDING; VP1; DNA; PSEUDOCAPSIDS; COMPLEX; CELLS; SITE	Recent advances in molecular biology have led to the development of new therapeutics to address genetic disorders. The developments in the production and availability of recombinant proteins are likely to have a substantial impact on many diseases in the short term. A major limit for the use of recombinant proteins in clinical applications is their inability to enter cells and be targeted to the appropriate intracellular site. Here, we describe a novel system for the intracellular delivery of peptides and proteins using recombinantly expressed polyomavirus-like particles as universal carriers. The inner surface of the particles was modified by the fusion of a WW domain, which was derived from the mouse formin binding protein 11 (FBP11) to the viral coat protein in order to bind specifically to proline-rich ligands. Physicochemical characterization of the fusion protein demonstrated that the functional units of the VP1-WW protein remained intact. Assembly of the particles in the presence of proline-rich ligands resulted in an efficient encapsidation of the ligands into the particles. Fluorescence-labeled peptides and the green fluorescent protein were used as model ligands. The delivery of the ligands into cultured eukaryotic cells could be demonstrated with confocal laser-scanning microscopy.	Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle An Der Saale, Germany; ACGT ProGenom AG, D-06120 Halle An Der Saale, Germany	Martin Luther University Halle Wittenberg	Gunther, C (corresponding author), Univ Halle Wittenberg, Inst Biotechnol, Kurt Mothes Str 3, D-06120 Halle An Der Saale, Germany.	constanze.guenther@biochemtech.uni-halle.de						Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Braun H, 1999, BIOTECHNOL APPL BIOC, V29, P31; CHANG DC, 1993, J VIROL, V67, P6327, DOI 10.1128/JVI.67.10.6327-6331.1993; Chang YJ, 1996, J ENHANC HEAT TRANSF, V3, P15, DOI 10.1615/JEnhHeatTransf.v3.i1.20; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FORSTOVA J, 1995, HUM GENE THER, V6, P297, DOI 10.1089/hum.1995.6.3-297; Koepf EK, 1999, PROTEIN SCI, V8, P841, DOI 10.1110/ps.8.4.841; Koepf EK, 1999, BIOCHEMISTRY-US, V38, P14338, DOI 10.1021/bi991105l; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAVITT AD, 1985, J BIOL CHEM, V23, P12803; Macias MJ, 2000, NAT STRUCT BIOL, V7, P375, DOI 10.1038/75144; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Russell CS, 1999, CLIN GENET, V55, P389, DOI 10.1034/j.1399-0004.1999.550601.x; SAHLI R, 1993, VIROLOGY, V192, P142, DOI 10.1006/viro.1993.1016; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALUNKE DM, 1989, BIOPHYS J, V56, P887, DOI 10.1016/S0006-3495(89)82735-3; SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1; Schmidt U, 1999, BIOL CHEM, V380, P397, DOI 10.1515/BC.1999.053; Schmidt U, 2000, J VIROL, V74, P1658, DOI 10.1128/JVI.74.4.1658-1662.2000; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Scott MD, 1998, CURR PHARM DESIGN, V4, P423; Soeda E, 1998, GENE THER, V5, P1410, DOI 10.1038/sj.gt.3300748; Stehle T, 1996, STRUCTURE, V4, P183, DOI 10.1016/S0969-2126(96)00021-4; Stehle T, 1997, EMBO J, V16, P5139, DOI 10.1093/emboj/16.16.5139; STEHLE T, 1994, NATURE, V369, P160, DOI 10.1038/369160a0; Stubenrauch K, 2000, J CHROMATOGR B, V737, P77, DOI 10.1016/S0378-4347(99)00392-8; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246	31	22	26	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1646	+		10.1096/fj.00-0645fje	http://dx.doi.org/10.1096/fj.00-0645fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427514				2022-12-28	WOS:000173707700022
J	Yung, S; Woods, A; Chan, TM; Davies, M; Williams, JD; Couchman, JR				Yung, S; Woods, A; Chan, TM; Davies, M; Williams, JD; Couchman, JR			Syndecan-4 up-regulation in proliferative renal disease is related to microfilament organization	FASEB JOURNAL			English	Article						proteoglycans; heparan sulfate; actin; alpha-actinin	HEPARAN-SULFATE PROTEOGLYCAN; CYTOPLASMIC DOMAIN; BASEMENT-MEMBRANE; MESANGIAL CELLS; PROTEIN; EXPRESSION; FAMILY; CYTOSKELETON; CASK/LIN-2; MORPHOLOGY	Syndecan-4 is a transmembrane heparan sulfate proteoglycan (HSPG) expressed widely in mammalian cells. It has been implicated in growth-factor binding, cell-extracellular matrix adhesion, and tissue damage responses. Although several HSPGs are present within kidney mesangium and glomerular basement membranes, no data are available on the synthesis of syndecan-4 by mesangial cells or its expression in human renal disease. We examined renal biopsy specimens from normal controls, nonproliferative disease (thin-membrane disease), and progressive proliferative disease (IgA nephropathy). By using RT-PCR and immunohistochemical staining, we identified an increase in both gene expression (IgA nephropathy vs. thin membrane disease, P = 0.0004) and synthesis of syndecan-4 in progressive proliferative disease. Syndecan-4 increased within both mesangium and tubulo-interstitium, as did alpha-actinin, a microfilament cytoskeletal component. Syndecan-4 was a focal adhesion component in human mesangial cells, colocalizing with vinculin and alpha-actinin, and was present in the cortical, submembraneous myosin sheath as seen for alpha-actinin. Both syndecan-4 and alpha-actinin were retained selectively in detergent-resistant cytoskeleton-matrix preparations, emphasizing their close association in cell-matrix adhesion. Syndecan-4 may be important in the adhesion, migration, and proliferation of HMC, and its up-regulation could indicate proliferative disease.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Cardiff Univ, Inst Nephrol, Cardiff CF4 4XN, S Glam, Wales; Univ Hong Kong, Dept Med, Div Nephrol, Hong Kong, Hong Kong, Peoples R China	University of Alabama System; University of Alabama Birmingham; Cardiff University; University of Hong Kong	Couchman, JR (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA.	jrcouchman@cellbio.bhs.uab.edu	Chan, Daniel Tak Mao/C-4202-2009; Yung, Susan Sou Ying/C-4468-2009					ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BORDER WA, 1991, CIBA F SYMP, V157, P178; BRENNER BM, 1980, NEW ENGL J MED, V307, P652; CAREY DJ, 1994, J CELL BIOL, V124, P161, DOI 10.1083/jcb.124.1.161; Carey DJ, 1997, BIOCHEM J, V327, P1; CizmeciSmith G, 1997, ARTERIOSCL THROM VAS, V17, P172, DOI 10.1161/01.ATV.17.1.172; CLARKSON AR, 1977, CLIN NEPHROL, V8, P459; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Couchman JR, 1999, J CELL SCI, V112, P3415; DAMICO G, 1986, Q J MED, V59, P363; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; Echtermeyer F, 1999, J CELL SCI, V112, P3433; ENG E, 1994, KIDNEY INT, V45, pS45; Ferrario F, 1999, ANN MED INTERNE, V150, P108; FIORETTO P, 1994, DIABETES, V43, P1358, DOI 10.2337/diabetes.43.11.1358; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Greene DK, 2000, MOL BIOL CELL, V11, p394A; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hillis GS, 1997, NEPHROL DIAL TRANSPL, V12, P1137, DOI 10.1093/ndt/12.6.1137; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jin DK, 1996, J AM SOC NEPHROL, V7, P2636; KASHGARIAN M, 1992, KIDNEY INT, V41, P524, DOI 10.1038/ki.1992.74; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; Longley RL, 1999, J CELL SCI, V112, P3421; LYON M, 1991, BIOCHEM J, V273, P415, DOI 10.1042/bj2730415; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; NAMIE S, 1995, NEPHROL DIAL TRANSPL, V10, P1342; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; ODONNELL MP, 1988, FASEB J, V2, P2339, DOI 10.1096/fasebj.2.8.3282959; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Rapraeger AC, 1998, CURR OPIN CELL BIOL, V10, P620, DOI 10.1016/S0955-0674(98)80038-0; Roskams T, 1998, J PATHOL, V185, P290, DOI 10.1002/(SICI)1096-9896(199807)185:3<290::AID-PATH91>3.0.CO;2-I; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; THOMAS GJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P11, DOI 10.1016/0003-9861(90)90224-M; THOMAS GJ, 1991, BIOCHEM J, V277, P81, DOI 10.1042/bj2770081; THOMAS GJ, 1995, KIDNEY INT, V48, P1278, DOI 10.1038/ki.1995.412; Vleming LJ, 1998, CLIN NEPHROL, V49, P337; Wada T, 1997, KIDNEY INT, pS182; Woods A, 2000, J BIOL CHEM, V275, P24233, DOI 10.1074/jbc.R000001200; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 2000, ARCH BIOCHEM BIOPHYS, V374, P66, DOI 10.1006/abbi.1999.1607; WOODS A, 1985, J BIOL CHEM, V260, P872; YOSHIOKA K, 1995, HISTOL HISTOPATHOL, V10, P203; YUNG S, 1995, AM J PATHOL, V146, P520; Zhang YF, 1999, J BIOL CHEM, V274, P14786, DOI 10.1074/jbc.274.21.14786; ZIGMOND SH, 1979, EXP CELL RES, V119, P205, DOI 10.1016/0014-4827(79)90349-5; Zimmerman M, 1999, MED PSYCHIATRY, V13, P1	57	42	44	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1631	+		10.1096/fj.00-0794fje	http://dx.doi.org/10.1096/fj.00-0794fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427509				2022-12-28	WOS:000173707700013
J	Jewell, UR; Kvietikova, I; Scheid, A; Bauer, C; Wenger, RH; Gassmann, M				Jewell, UR; Kvietikova, I; Scheid, A; Bauer, C; Wenger, RH; Gassmann, M			Induction of HIF-1 alpha in response to hypoxia is instantaneous	FASEB JOURNAL			English	Article									Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland	University of Zurich	Gassmann, M (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Wenger, Roland H./B-7953-2009; Jewell, Ursula/AAH-4132-2019	Wenger, Roland H./0000-0001-7592-4839; 					0	429	450	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1312	1314		10.1096/fj.00-0732fje	http://dx.doi.org/10.1096/fj.00-0732fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344124				2022-12-28	WOS:000168655200046
J	Pias, EK; Aw, TY				Pias, EK; Aw, TY			Apoptosis in mitotic competent undifferentiated cells is induced by cellular redox imbalance independent of reactive oxygen species production	FASEB JOURNAL			English	Article						apoptosis in undifferentiated cells; GSH/GSSG status and apoptosis; mitochondrial apoptosis signaling; diamide; NADPH; pentose phosphate pathway	GLUTATHIONE; BCL-2; EXPRESSION; OXIDATION; THIOLS; INHIBITION; MODULATION; PATHWAYS; DIAMIDE; ROLES	Oxidants are known to induce cell apoptosis. Because oxidants also elicit redox imbalance, it is difficult to distinguish the direct effects of cellular redox from that of oxidants. This study tests the hypothesis that induction of redox imbalance independent of reactive oxygen species (ROS), can induce cell apoptosis in a mitotic competent, undifferentiated cell line, PC-12. Cells grown in standard DMEM containing 25 mM glucose were treated with diamide, a thiol oxidant, at a concentration that did not generate ROS. Diamide caused a rapid increase in oxidized glutathione (GSSG) and a loss of mitochondrial cytochrome c in 15-30 min, caspase-3 activation in 2 h, and apoptosis in 24 h. N-Acetyl cysteine attenuated GSSG elevation and diamide-induced apoptosis. Incubation of cells in 5 mM glucose or inhibition of the pentose phosphate pathway maintained GSSG elevation and accelerated cell apoptosis. Collectively, these results show that loss of redox balance is an upstream event that kinetically preceded mitochondrial apoptotic signaling. A sustained redox change was not critical or necessary for apoptotic progression, but its prolongation exacerbated apoptotic death. The potentiation of apoptosis by sustained redox imbalance was correlated with decreases in NADPH supply for GSSG reduction.	Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Aw, TY (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, 1501 Kings Hwy, Shreveport, LA 71130 USA.	taw@lsuhsc.edu		Hines, Erin Pias/0000-0002-2458-6267	NIDDK NIH HHS [DK 44510, R01 DK044510, R01 DK044510-09] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044510] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AW TY, 1994, J CLIN INVEST, V94, P2426, DOI 10.1172/JCI117610; Bustamante J, 1997, ARCH BIOCHEM BIOPHYS, V337, P121, DOI 10.1006/abbi.1996.9754; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Constantini P., 1996, J BIOL CHEM, V271, P6746; Esteve JM, 1999, FASEB J, V13, P1055, DOI 10.1096/fasebj.13.9.1055; GABBAY M, 2000, SHOCK, V14, P605; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; Hour TC, 1999, TOXICOL LETT, V110, P191, DOI 10.1016/S0378-4274(99)00158-7; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kokura S, 1999, CIRC RES, V84, P516, DOI 10.1161/01.RES.84.5.516; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; LeGrand TS, 1998, AM J PHYSIOL-GASTR L, V274, pG376, DOI 10.1152/ajpgi.1998.274.2.G376; Macho A, 1997, J IMMUNOL, V158, P4612; Meredith MJ, 1998, BIOCHEM BIOPH RES CO, V248, P458, DOI 10.1006/bbrc.1998.8998; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MURPHY ME, 1992, EUR J BIOCHEM, V210, P139, DOI 10.1111/j.1432-1033.1992.tb17401.x; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Noda T, 2001, FASEB J, V15, P2131, DOI 10.1096/fj.01-0131com; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SATO N, 1995, J IMMUNOL, V154, P3194; TAIN WN, 1999, AM J PHYSIOL, V276, P1121; Ueda S, 1998, J IMMUNOL, V161, P6689; Ursini MV, 1997, BIOCHEM J, V323, P801, DOI 10.1042/bj3230801; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Wang TG, 2000, FASEB J, V14, P1567, DOI 10.1096/fj.14.11.1567; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wright SC, 1998, CANCER RES, V58, P5570; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zhang ZQ, 2000, ANAL BIOCHEM, V285, P163, DOI 10.1006/abio.2000.4701	34	70	75	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0781	10.1096/fj.01-0784com	http://dx.doi.org/10.1096/fj.01-0784com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039859				2022-12-28	WOS:000176683900003
J	de Kleijn, DPV; Smeets, MB; Kemmeren, PPCW; Lim, SK; van Middelaar, BJ; Velema, E; Schoneveld, A; Pasterkamp, G; Borst, C				de Kleijn, DPV; Smeets, MB; Kemmeren, PPCW; Lim, SK; van Middelaar, BJ; Velema, E; Schoneveld, A; Pasterkamp, G; Borst, C			Acute-phase protein haptoglobin is a cell migration factor involved in arterial restructuring	FASEB JOURNAL			English	Article						artery; extracellular matrix; matrix metalloproteinase	MATRIX-METALLOPROTEINASE INHIBITION; ENDOTHELIAL-CELLS; CAROTID-ARTERY; BLOOD-FLOW; INTRAVASCULAR ULTRASOUND; CORONARY ANGIOPLASTY; BALLOON ANGIOPLASTY; YUCATAN MICROPIG; SMOOTH-MUSCLE; EXPRESSION	Collagen turnover and cell migration are fundamental aspects of arterial restructuring. To identify mRNAs involved in blood flow-induced arterial restructuring, we performed subtraction polymerase chain reaction and found expression of haptoglobin mRNA in adventitial fibroblasts of rabbit arteries. Haptoglobin is highly expressed in liver, but its arterial expression and function are unknown. In vitro studies revealed that stimulation of haptoglobin expression by lipopolysaccharides in mice fibroblasts stimulated migration of wild-type fibroblasts but had no effect on migration of haptoglobin knockout fibroblasts. In vivo studies showed that flow-induced arterial restructuring was delayed in haptoglobin knockout mice. This new function of haptoglobin might be explained by facilitating cell migration through accumulation of a temporary gelatin matrix because cell culture showed that haptoglobin is involved in the breakdown of gelatin. We conclude that haptoglobin is highly expressed in arterial tissue and is involved in arterial restructuring. This new haptoglobin function may also apply to other functional and pathological restructuring processes such as angiogenesis, tissue repair, and tumor cell invasion.	Univ Med Ctr G02 523, Expt Cardiol Lab, NL-3584 CX Utrecht, Netherlands; Interuniv Cardiol Inst Netherlands, Utrecht, Netherlands; Natl Univ Singapore, NUMI, Cardiovasc Res Inst, Singapore 117548, Singapore	Utrecht University; Utrecht University Medical Center; Interuniversity Cardiology Institute of the Netherlands; Utrecht University; National University of Singapore	de Kleijn, DPV (corresponding author), Univ Med Ctr G02 523, Expt Cardiol Lab, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	D.deKleijn@hli.azu.nl		Kemmeren, Patrick/0000-0003-2237-7354				Abbruzzese TA, 1998, SURGERY, V124, P328, DOI 10.1016/S0039-6060(98)70138-2; Baumann H, 2000, J BIOL CHEM, V275, P22014, DOI 10.1074/jbc.M002830200; CASSCELLS W, 1992, CIRCULATION, V86, P723, DOI 10.1161/01.CIR.86.3.723; CASSOT F, 1995, CIRCULATION, V92, P3122, DOI 10.1161/01.CIR.92.10.3122; CID MC, 1993, J CLIN INVEST, V91, P977, DOI 10.1172/JCI116319; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; de Kleijn DPV, 2001, FEBS LETT, V501, P37, DOI 10.1016/S0014-5793(01)02622-9; de Smet BJGL, 2000, CIRCULATION, V101, P2962, DOI 10.1161/01.CIR.101.25.2962; DIMARIO C, 1995, AM J CARDIOL, V75, P772, DOI 10.1016/S0002-9149(99)80409-3; Dobryszycka W, 1997, EUR J CLIN CHEM CLIN, V35, P647; ElGhmati SM, 1996, J IMMUNOL, V156, P2542; Fernandez HA, 1999, J SURG RES, V82, P156, DOI 10.1006/jsre.1998.5534; FROHLANDER N, 1991, BIOCHEM BIOPH RES CO, V178, P343, DOI 10.1016/0006-291X(91)91820-3; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; Godin D, 2000, CIRCULATION, V102, P2861; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Harmon KJ, 2000, AM J PATHOL, V156, P1741, DOI 10.1016/S0002-9440(10)65045-6; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; KARIM MA, 1995, CIRCULATION, V91, P2049, DOI 10.1161/01.CIR.91.7.2049; KATNIK I, 1995, EUR J CLIN CHEM CLIN, V33, P727; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Kumar A, 1997, ARTERIOSCL THROM VAS, V17, P2238, DOI 10.1161/01.ATV.17.10.2238; LANGILLE BL, 1989, AM J PHYSIOL, V256, pH931, DOI 10.1152/ajpheart.1989.256.4.H931; Lim SK, 1998, BLOOD, V92, P1870, DOI 10.1182/blood.V92.6.1870.418k38_1870_1877; Lim YK, 2000, KIDNEY INT, V58, P1033, DOI 10.1046/j.1523-1755.2000.00261.x; Mintz GS, 1996, CIRCULATION, V94, P35, DOI 10.1161/01.CIR.94.1.35; PASTERKAMP G, 1995, CIRCULATION, V91, P1444, DOI 10.1161/01.CIR.91.5.1444; Piva M, 1999, MOL HUM REPROD, V5, P71, DOI 10.1093/molehr/5.1.71; POST MJ, 1994, CIRCULATION, V89, P2816, DOI 10.1161/01.CIR.89.6.2816; Powell J T, 1991, Eur J Vasc Surg, V5, P145, DOI 10.1016/S0950-821X(05)80679-6; Puyraimond A, 1999, J CELL SCI, V112, P1283; REIJERKERK A, 2000, EUR J CANC, V36; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sierevogel MJ, 2001, CIRCULATION, V103, P302; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; Wylie S, 1999, CLIN EXP METASTAS, V17, P111, DOI 10.1023/A:1006573417179	39	81	84	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7					1123	+		10.1096/fj.02-0019fje	http://dx.doi.org/10.1096/fj.02-0019fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039846				2022-12-28	WOS:000175973900006
J	Chen, Y; Peumans, WJ; Hause, B; Bras, J; Kumar, M; Proost, P; Barre, A; Rouge, P; Van Damme, EJM				Chen, Y; Peumans, WJ; Hause, B; Bras, J; Kumar, M; Proost, P; Barre, A; Rouge, P; Van Damme, EJM			Jasmonate methyl ester induces the synthesis of a cytoplasmic/nuclear chitooligosaccharide-binding lectin in tobacco leaves	FASEB JOURNAL			English	Article						chito-oligosaccharides; cytoplasmic/nuclear protein; jasmonate; plant lectin; stress response	HYDROPHOBIC CLUSTER-ANALYSIS; STORAGE PROTEIN GENES; SIGNAL-TRANSDUCTION; N-ACETYLGLUCOSAMINE; NUCLEAR-PORES; PHLOEM LECTIN; HIGHER-PLANTS; SALT STRESS; EXPRESSION; ACID	In contrast to animal lectins, no evidence has indicated the occurrence of plant lectins, which recognize and bind "endogenous" receptors and accordingly are involved in recognition mechanisms within the organism itself. Here we show that the plant hormone jasmonic acid methyl ester (JAME) induces in leaves of Nicotiana tabacum (var. Samsun NN) the expression of a lectin that is absent from untreated plants. The lectin specifically binds to oligomers of N-acetylglucosamine and is detected exclusively in the cytoplasm and the nucleus. Both the subcellular location and specificity indicate that the Nicotiana tabacum agglutinin (called Nictaba) may be involved in the regulation of gene expression in stressed plants through specific protein-carbohydrate interactions with regulatory cytoplasmic/nuclear glycoproteins. Searches in the databases revealed that many flowering plants contain sequences encoding putative homologues of the tobacco lectin, which suggest that Nictaba is the prototype of a widespread or possibly ubiquitous family of lectins with a specific endogenous role.	Katholieke Univ Leuven, Lab Phytopathol & Plant Protect, B-3001 Louvain, Belgium; Katholieke Univ Leuven, Lab Mol Immunol, Rega Inst, B-3001 Louvain, Belgium; Inst Plant Biochem, D-4050 Halle An Der Saale, Germany; CNRS, Inst Pharmacol & Biol Struct, UMR 5089, Toulouse, France	KU Leuven; KU Leuven; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Van Damme, EJM (corresponding author), Katholieke Univ Leuven, Lab Phytopathol & Plant Protect, Willem de Croylaan 42, B-3001 Louvain, Belgium.	Els.VanDamme@agr.kuleuven.ac.be	Rouge, Pierre/T-2059-2019; Van Damme, Els/U-3904-2019; Van Damme, Els J/B-4410-2015; Proost, Paul/V-3052-2017	Van Damme, Els/0000-0001-9848-766X; Proost, Paul/0000-0002-0133-5545; Barre, annick/0000-0002-1360-8491				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BOSTWICK DE, 1994, PLANT MOL BIOL, V26, P887, DOI 10.1007/BF00028856; CLAES B, 1990, PLANT CELL, V2, P19, DOI 10.1105/tpc.2.1.19; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; Dannenhoffer JM, 1997, PLANTA, V201, P405, DOI 10.1007/s004250050083; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Fabre C, 1998, BIOCHEM J, V329, P551, DOI 10.1042/bj3290551; Farras R, 2001, EMBO J, V20, P2742, DOI 10.1093/emboj/20.11.2742; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; Golecki B, 1999, PLANT CELL, V11, P127, DOI 10.1105/tpc.11.1.127; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; HEESEPECK A, 1995, PLANT CELL, V7, P1459, DOI 10.1105/tpc.7.9.1459; Hicks GR, 1996, PLANT CELL, V8, P1337, DOI 10.1105/tpc.8.8.1337; Hirano K, 2000, PLANT CELL PHYSIOL, V41, P258, DOI 10.1093/pcp/41.3.258; Kilpatrick D.C, 2000, HDB ANIMAL LECTINS P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; MASON HS, 1990, PLANT CELL, V2, P569, DOI 10.1105/tpc.2.6.569; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; Moons A, 1997, PLANT CELL, V9, P2243, DOI 10.1105/tpc.9.12.2243; Peumans WJ, 2000, TRENDS GLYCOSCI GLYC, V12, P83, DOI 10.4052/tigg.12.83; READ SM, 1983, EUR J BIOCHEM, V134, P561, DOI 10.1111/j.1432-1033.1983.tb07603.x; REINBOTHE C, 1994, PLANT SCI, V104, P59, DOI 10.1016/0168-9452(94)90191-0; Robertson M, 1998, PLANT CELL, V10, P995, DOI 10.1105/tpc.10.6.995; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANADI AR, 1994, J BIOL CHEM, V269, P5072; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shih CY, 1998, J PLANT PHYSIOL, V152, P358, DOI 10.1016/S0176-1617(98)80247-2; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Smith HMS, 1999, PLANT PHYSIOL, V119, P1157, DOI 10.1104/pp.119.4.1157; Sreerama N, 1999, PROTEIN SCI, V8, P370; STASWICK PE, 1991, PLANT PHYSIOL, V96, P130, DOI 10.1104/pp.96.1.130; Thornton TM, 1999, TRENDS PLANT SCI, V4, P424, DOI 10.1016/S1360-1385(99)01485-5; Van Damme EJM, 1998, CRIT REV PLANT SCI, V17, P575, DOI 10.1016/S0735-2689(98)00365-7; Van Damme EJM, 1999, PLANT PHYSIOL, V119, P1547, DOI 10.1104/pp.119.4.1547; van der Holst PPG, 2001, CURR OPIN STRUC BIOL, V11, P608, DOI 10.1016/S0959-440X(00)00255-4; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG MB, 1994, PLANT MOL BIOL, V24, P159, DOI 10.1007/BF00040582; Wasternack C, 1998, J PLANT PHYSIOL, V152, P345, DOI 10.1016/S0176-1617(98)80149-1; Wasternack C, 1997, TRENDS PLANT SCI, V2, P302, DOI 10.1016/S1360-1385(97)89952-9; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; WIRTH SJ, 1990, J MICROBIOL METH, V12, P197, DOI 10.1016/0167-7012(90)90031-Z; Yamaguchi T, 2000, TRENDS GLYCOSCI GLYC, V12, P113, DOI 10.4052/tigg.12.113; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; Zhang WL, 2000, PLANTA, V210, P970, DOI 10.1007/s004250050705	48	88	91	4	39	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					905	+		10.1096/fj.01-0598fje	http://dx.doi.org/10.1096/fj.01-0598fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039875				2022-12-28	WOS:000175425900022
J	Pazirandeh, A; Xue, YT; Prestegaard, T; Jondal, M; Okret, S				Pazirandeh, A; Xue, YT; Prestegaard, T; Jondal, M; Okret, S			Effects of altered glucocorticoid sensitivity in the T-cell lineage on thymocyte and T-cell homeostasis	FASEB JOURNAL			English	Article						immune system; thymus; spleen; glucocorticoid receptor; apoptosis	PITUITARY-ADRENAL AXIS; NF-KAPPA-B; MOLECULAR MECHANISMS; RECEPTOR EXPRESSION; SIGNALING PATHWAYS; RAPID METHOD; APOPTOSIS; THYMUS; SELECTION; LYMPHOCYTES	The homeostatic regulation that controls total thymocyte and peripheral T-cell numbers is not clearly understood. We describe here a direct hormonal influence of endogenous levels of glucocorticoids (GCs) on thymocyte and peripheral T-cell homeostasis independent of indirect systemic effects of GCs. The results were obtained by generating transgenic mice with an altered GC sensitivity targeted to thymocytes and peripheral T cells by increasing or decreasing glucocorticoid receptor (GR) expression specifically in thymocytes and peripheral T cells. A twofold increase in GC sensitivity resulted in a major decrease in thymocyte number, affecting all subpopulations, although single-positive CD8(+) cells were less influenced. In the thymus, this was due to increased apoptosis in the organ, whereas proliferation of thymocyte populations was unaffected. In the periphery, a pronounced reduction in T-cell number was seen, demonstrating an effect of endogenous GCs also on T-cell homeostasis. The effects were confirmed in transgenic mice with reduced GR expression, which showed increased thymocyte and T-cell numbers. Thus, our data demonstrate that physiological GC levels are directly involved in controlling the size of both thymocyte and T-cell pools.	Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, Novum, SE-14186 Huddinge, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Okret, S (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, Novum, SE-14186 Huddinge, Sweden.	Sam.Okret@mednut.ki.se						Almeida ARM, 2001, J EXP MED, V194, P591, DOI 10.1084/jem.194.5.591; Ashwell JD, 1996, STEM CELLS, V14, P490, DOI 10.1002/stem.140490; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Ashwell JD, 2000, IMMUNOL TODAY, V21, P644, DOI 10.1016/S0167-5699(00)01758-8; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Bender J, 1999, J EXP MED, V190, P367, DOI 10.1084/jem.190.3.367; Berzins SP, 1998, J EXP MED, V187, P1839, DOI 10.1084/jem.187.11.1839; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Buckland J, 2000, EUR J IMMUNOL, V30, P8, DOI 10.1002/1521-4141(200001)30:1<8::AID-IMMU8>3.3.CO;2-#; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CARLSTEDTDUKE J, 1995, ENDOCRINOL METAB, P169; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Delaunay F, 1997, J CLIN INVEST, V100, P2094, DOI 10.1172/JCI119743; DONG Y, 1989, J BIOL CHEM, V264, P13679; Ferreira V, 1999, J IMMUNOL, V162, P6442; Godfrey DI, 2000, IMMUNOL TODAY, V21, P606, DOI 10.1016/S0167-5699(00)01741-2; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; Jaffe HL, 1924, J EXP MED, V40, P325, DOI 10.1084/jem.40.3.325; Jamieson CAM, 2000, P NATL ACAD SCI USA, V97, P7319, DOI 10.1073/pnas.97.13.7319; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KIEFFER JD, 1971, TRANSPLANTATION, V11, P45, DOI 10.1097/00007890-197101000-00006; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; Lechner O, 2000, EUR J IMMUNOL, V30, P337; Lu FWM, 2000, IMMUNITY, V12, P183, DOI 10.1016/S1074-7613(00)80171-5; Mann CL, 2000, ENDOCRINOLOGY, V141, P528, DOI 10.1210/en.141.2.528; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marrack P, 2000, NAT IMMUNOL, V1, P107, DOI 10.1038/77778; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MORALE MC, 1995, ENDOCRINOLOGY, V136, P3949, DOI 10.1210/en.136.9.3949; Newton R, 2000, THORAX, V55, P603, DOI 10.1136/thorax.55.7.603; NIETO MA, 1992, CLIN EXP IMMUNOL, V88, P341; Nyirenda MJ, 1998, J CLIN INVEST, V101, P2174, DOI 10.1172/JCI1567; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Palm S, 1996, CHRONOBIOL INT, V13, P423, DOI 10.3109/07420529609020913; Pazirandeh A, 1999, FASEB J, V13, P893, DOI 10.1096/fasebj.13.8.893; PLAUT M, 1987, ANNU REV IMMUNOL, V5, P621, DOI 10.1146/annurev.iy.05.040187.003201; Purton JF, 2000, IMMUNITY, V13, P179, DOI 10.1016/S1074-7613(00)00018-2; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; Sacedon R, 1999, BLOOD, V94, P2819, DOI 10.1182/blood.V94.8.2819.420k12_2819_2826; Samuelsson MKR, 1999, MOL ENDOCRINOL, V13, P1811, DOI 10.1210/me.13.11.1811; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; Sprent J, 2001, SCIENCE, V293, P245, DOI 10.1126/science.1062416; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Tanchot C, 1997, Semin Immunol, V9, P331, DOI 10.1006/smim.1997.0090; Thompson EB, 1999, TRENDS ENDOCRIN MET, V10, P353, DOI 10.1016/S1043-2760(99)00187-3; Tolosa E, 1998, IMMUNITY, V8, P67, DOI 10.1016/S1074-7613(00)80459-8; Tonko M, 2001, FASEB J, V15, P693, DOI 10.1096/fj.00-0327com; Vacchio MS, 1998, ANN NY ACAD SCI, V840, P317, DOI 10.1111/j.1749-6632.1998.tb09571.x; VACCHIO MS, 1994, J EXP MED, V179, P1835, DOI 10.1084/jem.179.6.1835; Van Laethem F, 2001, J EXP MED, V193, P803, DOI 10.1084/jem.193.7.803; Van Parijs L, 1998, SCIENCE, V280, P243; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; VONBOEHMER H, 1993, J EXP MED, V177, P891, DOI 10.1084/jem.177.4.891; Wang W, 1999, J IMMUNOL, V162, P314; WICK G, 1993, ENDOCR REV, V14, P539, DOI 10.1210/edrv-14-5-539; Wiest DL, 1999, SEMIN IMMUNOL, V11, P251, DOI 10.1006/smim.1999.0181; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	61	81	85	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					727	+		10.1096/fj.01-0891fje	http://dx.doi.org/10.1096/fj.01-0891fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923224				2022-12-28	WOS:000174755900007
J	Laudenbach, V; Medja, F; Zoli, M; Rossi, FM; Evrard, P; Changeux, JP; Gressens, P				Laudenbach, V; Medja, F; Zoli, M; Rossi, FM; Evrard, P; Changeux, JP; Gressens, P			Selective activation of central subtypes of the nicotinic acetylcholine receptor has opposite effects on neonatal excitotoxic brain injuries	FASEB JOURNAL			English	Article						glutamate; excitotoxicity; neuronal death; nicotine; premature newborn	VASOACTIVE-INTESTINAL-PEPTIDE; CULTURED CORTICAL-NEURONS; INDUCED CYTOTOXICITY; SUBUNIT; NEUROPROTECTION; PROTECTION; MODEL; DEATH; MICE; MAGNESIUM	The incidence of neurological disabilities ascribable to perinatal injury is rising in Western countries, raising ethical and financial problems. No curative treatments are available. The pathophysiology of brain lesions of hypoxic-ischemic or inflammatory origin involves various neurotransmitters or neuromodulators. Among these, glutamate plays a key role. By overactivating N-methyl-D-aspartate receptors, it triggers the excitotoxic cascade. Although addictive, nicotine prevents excitotoxic neuronal death in adult animals. Its potential neuroprotective effects have not been evaluated in neonates. We found that nicotine is neuroprotective in vivo, in a murine model of neonatal excitotoxic brain injury, and in vitro, in primary cultures of cortical neurons. We investigated the respective roles in nicotine-related neuroprotection of the two dominant nicotinic acetylcholine receptor (nAChR) isoforms, namely, alpha(4)beta(2) (heteropentameric) and alpha(7) (homopentameric). Inhibition of alpha(4)beta(2), either pharmacological (i.e., an alpha(4)beta(2) nAChR antagonist) or molecular (beta(2)(-/-) knockout mice), abolished the protective effect of nicotine in vivo and in vitro, suggesting the involvement of alpha(4)beta(2) nAChR in neonatal nicotine-related neuroprotection. In contrast, activation of alpha(7) nAChR, which is protective in adult animals, was deleterious in our neonatal model, whereas its blockade, either pharmacological or molecular (alpha(7)(-/-) knockout mice) provided neuroprotection. Neuroprotective strategies must consider these opposite properties of distinct nAChR isoforms in neonates.	Inst Pasteur, Lab Recepteurs & Cognit, CNRS, URA 2182, Paris, France; Univ Modena & Reggio Emilia, Dept Biomed Sci, Physiol Sect, Modena, Italy	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universita di Modena e Reggio Emilia	Laudenbach, V (corresponding author), Hop Robert Debre, Dept Anesthesiol, INSERM,E9935, Lab Neurol Dev, 48 Bd Serurier, F-75019 Paris, France.	vlaudenb@infobiogen.fr	gressens, pierre/M-7557-2017; Zoli, Michele/C-8899-2016; Rossi, Francesco Mattia/K-6544-2015	gressens, pierre/0000-0002-0909-4221; Zoli, Michele/0000-0002-8034-2849; Rossi, Francesco Mattia/0000-0001-9855-5925	Telethon [D.105] Funding Source: Medline	Telethon(Fondazione Telethon)		AKAIKE A, 1994, BRAIN RES, V644, P181, DOI 10.1016/0006-8993(94)91678-0; Bac P, 1998, J NEUROSCI, V18, P4363; BEAL MF, 1992, FASEB J, V6, P3338, DOI 10.1096/fasebj.6.15.1464368; Belluardo N, 2000, BEHAV BRAIN RES, V113, P21, DOI 10.1016/S0166-4328(00)00197-2; BENFENATI F, 1986, ACTA PHYSIOL SCAND, V128, P129, DOI 10.1111/j.1748-1716.1986.tb07960.x; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; BORLONGAN CV, 1995, EXP NEUROL, V136, P261, DOI 10.1006/exnr.1995.1103; Broide RS, 1996, J NEUROSCI, V16, P2956; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Dajas-Bailador FA, 2000, NEUROPHARMACOLOGY, V39, P2799, DOI 10.1016/S0028-3908(00)00127-1; Damaj MI, 2000, NEUROPHARMACOLOGY, V39, P2785, DOI 10.1016/S0028-3908(00)00139-8; DeLima AD, 1997, J COMP NEUROL, V382, P230, DOI 10.1002/(SICI)1096-9861(19970602)382:2<230::AID-CNE7>3.0.CO;2-4; Dommergues MA, 2000, ANN NEUROL, V47, P54, DOI 10.1002/1531-8249(200001)47:1<54::AID-ANA10>3.3.CO;2-P; Donnelly-Roberts DL, 1998, J PHARMACOL EXP THER, V285, P777; DonnellyRoberts DL, 1996, BRAIN RES, V719, P36, DOI 10.1016/0006-8993(96)00063-7; FLORES CM, 1992, MOL PHARMACOL, V41, P31; GALZI JL, 1995, NEUROPHARMACOLOGY, V34, P563, DOI 10.1016/0028-3908(95)00034-4; Gressens P, 1998, J NEUROCHEM, V70, P2574; Gressens P, 1997, J CLIN INVEST, V100, P390, DOI 10.1172/JCI119545; Hagberg B, 1996, ACTA PAEDIATR, V85, P48, DOI 10.1111/j.1651-2227.1996.tb14277.x; HAGBERG H, 1993, ACTA PAEDIATR, V82, P925, DOI 10.1111/j.1651-2227.1993.tb12601.x; HILL JA, 1993, J NEUROSCI, V13, P1551; Kaneko S, 1997, BRAIN RES, V765, P135, DOI 10.1016/S0006-8993(97)00556-8; Klink R, 2001, J NEUROSCI, V21, P1452, DOI 10.1523/JNEUROSCI.21-05-01452.2001; Laudenbach V, 2001, J CLIN INVEST, V107, P457, DOI 10.1172/JCI9716; Li YX, 1999, BRAIN RES, V816, P225, DOI 10.1016/S0006-8993(98)01153-6; Li YX, 1999, BRAIN RES, V830, P218, DOI 10.1016/S0006-8993(99)01372-4; Lukas RJ, 1999, PHARMACOL REV, V51, P397; MARKS MJ, 1992, J NEUROSCI, V12, P2765; MARRET S, 1995, DEV MED CHILD NEUROL, V37, P473; MARRET S, 1995, J NEUROPATH EXP NEUR, V54, P358, DOI 10.1097/00005072-199505000-00009; Molinari EJ, 1998, EUR J PHARMACOL, V347, P131, DOI 10.1016/S0014-2999(98)00084-3; Nanri M, 1998, JPN J PHARMACOL, V76, P23, DOI 10.1254/jjp.76.23; Nanri M, 1997, JPN J PHARMACOL, V74, P285, DOI 10.1254/jjp.74.285; Nelson KB, 1998, AM J OBSTET GYNECOL, V179, P507, DOI 10.1016/S0002-9378(98)70387-4; Nelson KB, 1998, ANN NEUROL, V44, P665, DOI 10.1002/ana.410440413; OrrUrtreger A, 1997, J NEUROSCI, V17, P9165; Patkai J, 2001, PEDIATR RES, V50, P222, DOI 10.1203/00006450-200108000-00010; PICCIOTTO MR, 1995, NATURE, V374, P65, DOI 10.1038/374065a0; Prendergast MA, 2001, NEUROSCIENCE, V102, P75, DOI 10.1016/S0306-4522(00)00450-4; Rossi FM, 2001, P NATL ACAD SCI USA, V98, P6453, DOI 10.1073/pnas.101120998; Ryan RE, 2001, BRIT J PHARMACOL, V132, P1650, DOI 10.1038/sj.bjp.0703989; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SEGUELA P, 1993, J NEUROSCI, V13, P596; Shimohama S, 1998, BRAIN RES, V779, P359, DOI 10.1016/S0006-8993(97)00194-7; Sullivan JP, 1997, J PHARMACOL EXP THER, V283, P235; Zoli M, 1998, J NEUROSCI, V18, P4461; ZOLI M, 1995, J NEUROSCI, V15, P1912, DOI 10.1523/JNEUROSCI.15-03-01912.1995; Zupan V, 1996, DEV MED CHILD NEUROL, V38, P1061	49	85	86	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					423	+		10.1096/fj.01-0532fje	http://dx.doi.org/10.1096/fj.01-0532fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11790724				2022-12-28	WOS:000173656600019
J	van Ruissen, F; Jansen, BJH; de Jongh, GJ; van Vlijmen-Willems, IMJJ; Schalkwijk, J				van Ruissen, F; Jansen, BJH; de Jongh, GJ; van Vlijmen-Willems, IMJJ; Schalkwijk, J			Differential gene expression in premalignant human epidermis revealed by cluster analysis of serial analysis of gene expression (SAGE) libraries	FASEB JOURNAL			English	Article						actinic keratosis; keratinocytes; gene profiles	HIGH-THROUGHPUT ANALYSIS; NONMELANOMA SKIN-CANCER; HUMAN-CHROMOSOME 1Q21; ACID-BINDING-PROTEIN; RENAL-TRANSPLANTATION; MOLECULAR-CLONING; PSORIASIN S100A7; BREAST-CANCER; PPP1R3 GENE; TUMOR	Serial analysis of gene expression (SAGE) has been used for quantitative analysis of gene expression. We applied cluster analysis on multiple SAGE libraries derived from premalignant epidermal tissue (actinic keratosis), normal human epidermis, and cultured keratinocytes. The samples were obtained from skin biopsies without contamination by dermal tissue or blood. A total of 60,000 transcripts (tags) were analyzed. Two-way cluster analysis was applied to both the transcripts and the tissues, resulting in separation of the cultured cells from the epidermal samples, and clustering of many, presumably coregulated, genes. Two clusters of genes, strongly up-regulated in the tumor tissue compared with normal epidermis, were investigated in more detail. The differential expression of genes could be confirmed in actinic keratosis from four patients. Several of these genes have been previously associated with carcinogenesis or are likely to be important on the basis of their presumed function. Automated literature search tools show that a subgroup of these genes is coexpressed in other tissues and is part of an epidermal differentiation gene cluster on chromosome 1q21. We conclude that cluster analysis on large data sets uncovers clear partitions and correlations that could be confirmed by independent methods. We predict that these partitions will lead to biological interpretations that can be relevant for understanding the processes of carcinogenesis and tumor progression.	Radboud Univ Nijmegen Med Ctr, Dept Dermatol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	van Ruissen, F (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Dermatol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	F.vanRuissen@derma.azn.nl	Schalkwijk, Joost/N-1774-2013; van Vlijmen-Willems, Ivonne MJJ/P-5336-2015; Jansen, Bastiaan J. H./C-1091-2009; Schalkwijk, Joost/R-7509-2019	van Vlijmen-Willems, Ivonne MJJ/0000-0002-3522-2573; Jansen, Bastiaan J. H./0000-0001-5985-7656; Schalkwijk, Joost/0000-0002-1308-1319; van Ruissen, Fred/0000-0002-9458-7505				Al-Haddad S, 1999, AM J PATHOL, V155, P2057, DOI 10.1016/S0002-9440(10)65524-1; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; Chen JJ, 2000, P NATL ACAD SCI USA, V97, P349, DOI 10.1073/pnas.97.1.349; Colantuoni C, 2000, J NEUROSCI RES, V59, P1, DOI 10.1002/(SICI)1097-4547(20000101)59:1<1::AID-JNR1>3.0.CO;2-2; Datson NA, 1999, NUCLEIC ACIDS RES, V27, P1300, DOI 10.1093/nar/27.5.1300; El-Meanawy MA, 2000, AM J PHYSIOL-RENAL, V279, pF383, DOI 10.1152/ajprenal.2000.279.2.F383; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; GLOVER MT, 1994, BRIT J PLAST SURG, V47, P86, DOI 10.1016/0007-1226(94)90164-3; Hardas BD, 1996, J INVEST DERMATOL, V106, P753, DOI 10.1111/1523-1747.ep12345807; HARTEVELT MM, 1990, TRANSPLANTATION, V49, P506, DOI 10.1097/00007890-199003000-00006; Hartigan J., 1975, CLUSTERING ALGORITHM; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Jansen BJH, 2001, J INVEST DERMATOL, V116, P12, DOI 10.1046/j.1523-1747.2001.00218.x; Jenssen TK, 2001, NAT GENET, V28, P21, DOI 10.1038/88213; Jing C, 2000, CANCER RES, V60, P2390; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kenzelmann M, 1999, NUCLEIC ACIDS RES, V27, P917, DOI 10.1093/nar/27.3.917; Kohno T, 1999, CANCER RES, V59, P4170; Kondo S, 1996, INT J CANCER, V68, P727, DOI 10.1002/(SICI)1097-0215(19961211)68:6<727::AID-IJC6>3.0.CO;2-5; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Leiter U, 2000, ARCH DERMATOL RES, V292, P225, DOI 10.1007/s004030050479; MADSEN P, 1991, J INVEST DERMATOL, V97, P701, DOI 10.1111/1523-1747.ep12484041; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; Marenholz I, 1996, GENOMICS, V37, P295, DOI 10.1006/geno.1996.0563; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; NELSON MA, 1994, CANCER LETT, V85, P23, DOI 10.1016/0304-3835(94)90234-8; Popp S, 2000, J INVEST DERMATOL, V115, P1095, DOI 10.1046/j.1523-1747.2000.00173.x; REES J, 1994, J INVEST DERMATOL, V103, P747, DOI 10.1111/1523-1747.ep12412256; Ryu B, 2001, CANCER RES, V61, P1833; St Croix B, 2000, SCIENCE, V289, P1197; Stulik J, 1999, ELECTROPHORESIS, V20, P3638, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3638::AID-ELPS3638>3.0.CO;2-W; Suzuki H, 2000, CANCER RES, V60, P4353; Takakura S, 2000, ONCOGENE, V19, P836, DOI 10.1038/sj.onc.1203388; Tanabe L, 1999, BIOTECHNIQUES, V27, P1210, DOI 10.2144/99276bc03; van Ruissen F, 1998, J INVEST DERMATOL, V110, P358, DOI 10.1046/j.1523-1747.1998.00155.x; vanRuissen F, 1996, J CELL PHYSIOL, V168, P442; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Virlon B, 1999, P NATL ACAD SCI USA, V96, P15286, DOI 10.1073/pnas.96.26.15286; Watson PH, 1998, INT J BIOCHEM CELL B, V30, P567, DOI 10.1016/S1357-2725(97)00066-6; Yamamoto M, 2001, J IMMUNOL METHODS, V250, P45, DOI 10.1016/S0022-1759(01)00305-2; Zhou W, 1998, CANCER EPIDEM BIOMAR, V7, P109; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	47	27	28	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					246	+		10.1096/fj.01-0618fje	http://dx.doi.org/10.1096/fj.01-0618fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11772949				2022-12-28	WOS:000172964800006
J	Pfeiffer, S; Lass, A; Schmidt, K; Mayer, B				Pfeiffer, S; Lass, A; Schmidt, K; Mayer, B			Protein tyrosine nitration in mouse peritoneal macrophages activated in vitro and in vivo: evidence against an essential role of peroxynitrite	FASEB JOURNAL			English	Article						3-nitrotyrosine; nitric oxide; superoxide anion; activated macrophages; myeloperoxidase	NITRIC-OXIDE SYNTHASE; ACID PORPHYRIN MNTBAP; NECROSIS-FACTOR-ALPHA; SUPEROXIDE-DISMUTASE; REACTIVE NITROGEN; LEISHMANIA-MAJOR; MURINE MACROPHAGES; HYDROGEN-PEROXIDE; PHYSIOLOGICAL PH; IFN-GAMMA	Tyrosine nitration is considered a key reaction of peroxynitrite-triggered tissue injury in inflammatory diseases. We investigated the potential involvement of peroxynitrite in protein tyrosine nitration in isolated murine peritoneal macrophages activated either in vitro with interferon-gamma /lipopolysaccharide or in vivo by priming mice with Corynebacterium parvum (10 mg x kg(-1)). Both protocols led to release of NO and accumulation of nitrite accompanied by formation of protein-bound 3-nitrotyrosine. Oxidation of dihydrorhodamine 123, a measure of peroxynitrite release, remained close to basal levels upon in vitro activation of the macrophages but was increased;twofold in vivo. Tyrosine nitration in macrophages activated in vitro was inhibited by catalase and the time course of nitration correlated with nitrite accumulation, whereas superoxide (O(2)(radical anion)) and H(2)O(2) release occurred at much earlier times. To address the contribution of O(2)(radical anion) and peroxynitrite to in vivo nitration, a O(2)(radical anion) scavenger (MnTBAP; 1 mg x kg(-1)) was given to C. parvum-primed mice. MnTBAP led to almost complete inhibition of C. parvum-triggered O(2)(radical anion) and peroxynitrite release, whereas nitrite accumulation and formation of 3-nitrotyrosine were less affected (similar to 50% of controls). These results argue against an essential role of peroxynitrite in protein tyrosine nitration in vivo.	Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, A-8010 Graz, Austria	University of Graz	Mayer, B (corresponding author), Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, Univ Pl 2, A-8010 Graz, Austria.	mayer@kfunigraz.ac.at	Mayer, Bernd/B-9391-2008; Lass, Achim/C-3332-2008	Lass, Achim/0000-0002-8190-7151; Mayer, Bernd/0000-0002-2921-3494				ASSREUY J, 1994, EUR J IMMUNOL, V24, P672, DOI 10.1002/eji.1830240328; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BECKMAN JS, 1996, AM J PHYSIOL, V40, pC1424; Berlett BS, 1998, P NATL ACAD SCI USA, V95, P2784, DOI 10.1073/pnas.95.6.2784; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Crow JP, 2000, FREE RADICAL BIO MED, V28, P1487, DOI 10.1016/S0891-5849(00)00249-5; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Cuzzocrea S, 1999, BRIT J PHARMACOL, V128, P1241, DOI 10.1038/sj.bjp.0702826; Cuzzocrea S, 1999, FREE RADICAL BIO MED, V26, P25, DOI 10.1016/S0891-5849(98)00142-7; DELAHARPE J, 1985, J IMMUNOL METHODS, V78, P323, DOI 10.1016/0022-1759(85)90089-4; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1999, P NATL ACAD SCI USA, V96, P6365, DOI 10.1073/pnas.96.11.6365; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; Ferrer-Sueta G, 1997, CHEM RES TOXICOL, V10, P1338, DOI 10.1021/tx970116h; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; GREEN SJ, 1990, J IMMUNOL, V145, P4290; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Hodges GR, 2000, CHEM RES TOXICOL, V13, P1287, DOI 10.1021/tx0001272; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Jourd'heuil D, 2001, J BIOL CHEM, V276, P28799, DOI 10.1074/jbc.M102341200; Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lass A, 1997, J BIOL CHEM, V272, P19199, DOI 10.1074/jbc.272.31.19199; LI Y, 1992, EUR J IMMUNOL, V22, P441, DOI 10.1002/eji.1830220223; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264; MILES AM, 1995, J LEUKOCYTE BIOL, V58, P616, DOI 10.1002/jlb.58.5.616; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; PAUL BB, 1973, SCIENCE, V181, P849, DOI 10.1126/science.181.4102.849; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; REES DD, 1995, BRIT J PHARMACOL, V114, P689, DOI 10.1111/j.1476-5381.1995.tb17193.x; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; Sawa T, 2000, J BIOL CHEM, V275, P32467, DOI 10.1074/jbc.M910169199; SCHMIDT K, 1997, NITRIC OXIDE PROTOCO, P101; SCHOEDON G, 1993, EUR J BIOCHEM, V213, P833, DOI 10.1111/j.1432-1033.1993.tb17826.x; Shigenaga MK, 1999, METHOD ENZYMOL, V301, P27; STRAUSS RR, 1975, NATURE, V255, P343, DOI 10.1038/255343a0; STUEHR DJ, 1987, CANCER RES, V47, P5590; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Szabo C, 1996, FEBS LETT, V381, P82, DOI 10.1016/0014-5793(96)00087-7; UEDA T, 1995, HISTOCHEM CELL BIOL, V103, P11, DOI 10.1007/BF01464470; van der Vliet A, 1998, J BIOL CHEM, V273, P30255, DOI 10.1074/jbc.273.46.30255; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; VODOVOTZ Y, 1994, J IMMUNOL, V152, P4110; Wallerath T, 1997, THROMB HAEMOSTASIS, V77, P163; Weinberg JB, 1998, MOL MED, V4, P557, DOI 10.1007/BF03401758; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; ZHANG XK, 1993, J EXP MED, V177, P511, DOI 10.1084/jem.177.2.511; Zingarelli B, 1997, BRIT J PHARMACOL, V120, P259, DOI 10.1038/sj.bjp.0700872	58	98	102	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2355	2364		10.1096/fj.01-0295com	http://dx.doi.org/10.1096/fj.01-0295com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689461				2022-12-28	WOS:000172420500006
J	Xue, BZ; Greenberg, AG; Kraemer, FB; Zemel, MB				Xue, BZ; Greenberg, AG; Kraemer, FB; Zemel, MB			Mechanism of intracellular calcium ([Ca2+](i)) inhibition of lipolysis in human adipocytes	FASEB JOURNAL			English	Article						agouti; cAMP; hormone-sensitive lipase; phosphodiesterase	HORMONE-SENSITIVE LIPASE; CAMP-PHOSPHODIESTERASE; RAT ADIPOCYTES; ANTILIPOLYTIC ACTION; AGOUTI REGULATION; ADIPOSE-TISSUE; PHOSPHORYLATION; INSULIN; PROTEIN; IDENTIFICATION	We investigated the mechanisms responsible for the anti-lipolytic effect of intracellular Ca2+ ([Ca2+]i) in human adipocytes. Increasing [Ca2+]i inhibited lipolysis induced by beta -adrenergic receptor activation, A1 adenosine receptor inhibition, adenylate cyclase activation, and phosphodiesterase (PDE) inhibition, as well as by a hydrolyzable cAMP analog, but not by a nonhydrolyzable cAMP analog. This finding indicates that the anti-lipolytic effect of [Ca2+]i may be mediated by the activation of adipocyte PDE. Consistent with this theory, [Ca2+]i inhibition of isoproterenol-stimulated lipolysis was reversed completely by the nonselective PDE inhibitor isobutyl methylxanthine and also by the selective PDE 3B inhibitor cilostamide, but not by selective PDE 1 and 4 inhibitors. In addition, phosphatidylinositol-3 kinase inhibition with wortmannin completely prevented insulin's anti-lipolytic effect but only minimally blocked [Ca2+]i's effect, which suggests that [Ca2+]i and insulin may activate PDE 3B via different mechanisms. In contrast, the antilipolytic effect of [Ca2+]i was not affected by inhibitors of calmodulin, Ca2+/calmodulin-dependent kinase, protein phosphatase 2B, and protein kinase C. Finally, [Ca2+]i inhibited significantly isoproterenol-stimulated increases in cAMP levels and hormone-sensitive lipase phosphorylation in human adipocytes. In conclusion, increasing [Ca2+]i exerts an antilipolytic effect mainly by activation of PDE, leading to a decrease in cAMP and HSL phosphorylation and, consequently, inhibition of lipolysis.	Univ Tennessee, Dept Nutr, Knoxville, TN 37996 USA; Tufts Univ, JM USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Stanford Univ, Vet Affairs Palo Alto Hlth Care Syst, Dept Med, Div Endocrinol, Palo Alto, CA 94304 USA	University of Tennessee System; University of Tennessee Knoxville; Tufts University; United States Department of Agriculture (USDA); Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Zemel, MB (corresponding author), Univ Tennessee, Dept Nutr, 1215 W Cumberland Ave Room 229, Knoxville, TN 37996 USA.	mzemel@utk.edu	Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807; Zemel, Michael/0000-0003-4104-5750				Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; ARNER P, 1993, J LIPID RES, V34, P1737; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BEEBE SJ, 1988, METHOD ENZYMOL, V159, P531; BEEBE SJ, 1985, J BIOL CHEM, V260, P5781; BOOBIS LH, 1983, CLIN CHIM ACTA, V132, P173, DOI 10.1016/0009-8981(83)90245-0; Castan I, 1999, BIOCHEM J, V339, P281, DOI 10.1042/0264-6021:3390281; Chabardes D, 1999, CELL SIGNAL, V11, P651, DOI 10.1016/S0898-6568(99)00031-5; DERGERMAN E, 1998, METHODS COMPANION ME, V14, P43; ELKS ML, 1985, ENDOCRINOLOGY, V116, P2119, DOI 10.1210/endo-116-5-2119; ELKS ML, 1984, ENDOCRINOLOGY, V115, P1262, DOI 10.1210/endo-115-4-1262; ERIKSSON H, 1995, BBA-MOL CELL RES, V1266, P101, DOI 10.1016/0167-4889(94)00237-9; GARTON AJ, 1988, FEBS LETT, V229, P68, DOI 10.1016/0014-5793(88)80799-3; GARTON AJ, 1990, EUR J BIOCHEM, V191, P245, DOI 10.1111/j.1432-1033.1990.tb19116.x; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; GOSWAMI A, 1978, ENDOCRINOLOGY, V103, P2223, DOI 10.1210/endo-103-6-2223; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Holm C, 1997, METHOD ENZYMOL, V286, P45; Kim JH, 1997, AM J PHYSIOL-ENDOC M, V272, pE379, DOI 10.1152/ajpendo.1997.272.3.E379; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; KRAEMER FB, 1993, J LIPID RES, V34, P663; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langin D, 1996, P NUTR SOC, V55, P93, DOI 10.1079/PNS19960013; LARROUY D, 1994, EUR J PHARM-MOLEC PH, V267, P225, DOI 10.1016/0922-4106(94)90174-0; LONDOS C, 1978, P NATL ACAD SCI USA, V75, P5362, DOI 10.1073/pnas.75.11.5362; NEMECEK GM, 1978, J CYCLIC NUCL PROT, V4, P299; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; SCHMITZPEIFFER C, 1992, CELL SIGNAL, V4, P37, DOI 10.1016/0898-6568(92)90006-T; SIDDLE K, 1977, BIOCHEM SOC T, V5, P959, DOI 10.1042/bst0050959; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; STRALFORS P, 1983, J BIOL CHEM, V258, P5146; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; Tebar F, 1996, ENDOCRINOLOGY, V137, P4181, DOI 10.1210/en.137.10.4181; TEBAR F, 1993, J BIOL CHEM, V268, P17199; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Xue BZ, 1998, FASEB J, V12, P1391, DOI 10.1096/fasebj.12.13.1391; YEN T T T, 1970, Hormone and Metabolic Research, V2, P200; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733	39	166	176	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2527	+		10.1096/fj.01-0278fje	http://dx.doi.org/10.1096/fj.01-0278fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641262				2022-12-28	WOS:000171372700018
J	Richmonds, CR; Kaminski, HJ				Richmonds, CR; Kaminski, HJ			Nitric oxide synthase expression and effects of nitric oxide modulation on contractility of rat extraocular muscle	FASEB JOURNAL			English	Article						extraocular muscle; nitric oxide; muscle contractility; neuronal nitric oxide synthase	NEURONAL NADPH DIAPHORASE; FUNCTION IN-VITRO; SKELETAL-MUSCLE; SUPERIOR RECTUS; FIBERS; NITROSYLATION; STIMULATION; PROTEINS; PRODUCTS; LEVATOR	Extraocular muscles (EOMs) are specialized skeletal muscles that are constantly active, generate low levels of force for cross sectional area, have rapid contractile speeds, and are highly fatigue resistant. The neuronal isoform of nitric oxide synthase (nNOS) is concentrated at the sarcolemma of fast-twitch muscles fibers, and nitric oxide (NO) modulates contractility. This study evaluated nNOS expression in EOM and the effect of NO modulation on lateral rectus muscle's contractility. nNOS activity was highest in EOM compared with diaphragm, extensor digitorum longus, and soleus. Neuronal NOS was concentrated to the sarcolemma of orbital and global singly innervated fibers, but not evident in the multi-innervated fibers. The N-G-nitro-L-arginine methyl ester (L-NAME, a NOS inhibitor), increased submaximal tetanic and peak twitch forces. The NO donors S-nitroso-N-acetylcysteine (SNAC) and spermineNONOate reduced submaximal tetanic and peak twitch forces. The effect of NO on the contractile force of lateral rectus muscle is greater than previously observed on other skeletal muscle. NO appears more important in modulating contraction of EOM compared with other skeletal muscles, which could be important for the EOM's specialized role in generation of eye movements.	Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med,Dept Neurol, Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med,Dept Neurosci, Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; US Department of Veterans Affairs; Veterans Health Administration (VHA); Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; US Department of Veterans Affairs; Veterans Health Administration (VHA); Louis Stokes Cleveland Veterans Affairs Medical Center	Kaminski, HJ (corresponding author), Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med,Dept Neurol, Louis Stokes Cleveland Vet Affairs Med Ctr, 11100 Euclid Ave, Cleveland, OH 44106 USA.	hjk3@po.cwru.edu		Kaminski, Henry/0000-0002-8195-0141	NATIONAL EYE INSTITUTE [R01EY011998, R01EY013238] Funding Source: NIH RePORTER; NEI NIH HHS [EY-13238, EY-11998, EY-113373-01A1] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andrade FH, 2000, MICROSC RES TECHNIQ, V48, P192, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<192::AID-JEMT7>3.0.CO;2-J; Andrade FH, 1998, J PHYSIOL-LONDON, V509, P577, DOI 10.1111/j.1469-7793.1998.577bn.x; ASMUSSEN G, 1981, PFLUG ARCH EUR J PHY, V392, P183, DOI 10.1007/BF00581270; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Burke R.E., 1981, HDB PHYSL SECTION 1, VII, P345, DOI 10.1002/cphy.cp010210; Christen S, 1996, METHOD ENZYMOL, V269, P267; CLOSE RI, 1974, J PHYSIOL-LONDON, V236, P259, DOI 10.1113/jphysiol.1974.sp010434; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DEMEIS L, 1967, AM J PHYSIOL, V212, P92, DOI 10.1152/ajplegacy.1967.212.1.92; Demer JL, 2000, INVEST OPHTH VIS SCI, V41, P1280; Espey MG, 2000, ANN NY ACAD SCI, V899, P209; FRUEH BR, 1994, J PHYSIOL-LONDON, V475, P327, DOI 10.1113/jphysiol.1994.sp020073; Galler S, 1997, PFLUG ARCH EUR J PHY, V434, P242, DOI 10.1007/s004240050391; Gross WL, 1996, P NATL ACAD SCI USA, V93, P5604, DOI 10.1073/pnas.93.11.5604; HANSON J, 1977, ACTA OPHTHALMOL, V55, P88; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; JACOBY J, 1989, J NEUROPHYSIOL, V61, P116, DOI 10.1152/jn.1989.61.1.116; KAMINSKI HJ, 2001, IN PRESS NEUROMUSC D; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; Kroncke KD, 1996, METHOD ENZYMOL, V269, P279; Kusner LL, 1996, BRAIN RES, V730, P238; Loughlin M., 1993, MUSCLE BIOPSY LAB IN; LYNCH GS, 1994, J PHYSIOL-LONDON, V475, P337, DOI 10.1113/jphysiol.1994.sp020074; MENDEZ J, 1960, METABOLISM, V9, P184; MESZAROS L G, 1991, Biophysical Journal, V59, p252A; MURRANT CL, 1995, CAN J PHYSIOL PHARM, V73, P736, DOI 10.1139/y95-096; MURRANT CL, 1994, CAN J PHYSIOL PHARM, V72, P1089, DOI 10.1139/y94-152; Murrant CL, 1997, CAN J PHYSIOL PHARM, V75, P414, DOI 10.1139/y97-096; Park JH, 1998, J NEUROSCI, V18, P5463, DOI 10.1523/JNEUROSCI.18-14-05463.1998; PORTER JD, 1995, SURV OPHTHALMOL, V39, P451, DOI 10.1016/S0039-6257(05)80055-4; Porter JD, 1996, NEUROLOGY, V46, P30, DOI 10.1212/WNL.46.1.30; Redford EJ, 1997, BRAIN, V120, P2149, DOI 10.1093/brain/120.12.2149; Reid MB, 1998, ACTA PHYSIOL SCAND, V162, P401, DOI 10.1046/j.1365-201X.1998.0303f.x; Reid MB, 1998, COMP BIOCHEM PHYS A, V119, P211, DOI 10.1016/S1095-6433(97)00417-0; Richmonds CR, 1999, MECH AGEING DEV, V109, P177, DOI 10.1016/S0047-6374(99)00035-4; Richmonds CR, 2000, MECH AGEING DEV, V113, P183, DOI 10.1016/S0047-6374(99)00106-2; Ruff R, 1989, Bull Soc Belge Ophtalmol, V237, P321; SARTORE S, 1987, J MUSCLE RES CELL M, V8, P161, DOI 10.1007/BF01753992; SHALL MS, 1992, BRAIN RES, V587, P291, DOI 10.1016/0006-8993(92)91010-C; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; Spencer R F, 1988, Rev Oculomot Res, V2, P33; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; WIECZOREK DF, 1985, J CELL BIOL, V101, P618, DOI 10.1083/jcb.101.2.618; Wolosker H, 1996, FEBS LETT, V392, P274, DOI 10.1016/0014-5793(96)00829-0	48	20	20	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2001	15	10					1764	1770		10.1096/fj.00-0899com	http://dx.doi.org/10.1096/fj.00-0899com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481224				2022-12-28	WOS:000170809900012
J	Tan, DX; Manchester, LC; Burkhardt, S; Sainz, RM; Mayo, JC; Kohen, R; Shohami, E; Huo, YS; Hardeland, R; Reiter, RJ				Tan, DX; Manchester, LC; Burkhardt, S; Sainz, RM; Mayo, JC; Kohen, R; Shohami, E; Huo, YS; Hardeland, R; Reiter, RJ			N-1-acetyl-N-2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant	FASEB JOURNAL			English	Article						cyclic voltammetry; glutamate; amyloid beta-peptide; hydrogen peroxide; 8-hydroxydeoxyguanosine; lipid peroxidation; free radical; neuron	CYCLIC VOLTAMMETRY; OXIDATIVE DAMAGE; IN-VITRO; PROTECTION; CAPACITY; DEATH; CELLS; RATS; SYSTEM; SERUM	The biogenic amine N-1-acetyl-N-2-formyl-5-methoxykynuramine (AFMK) was investigated for its potential antioxidative capacity. AFMK is a metabolite generated through either an enzymatic or a chemical reaction pathway from melatonin. The physiological function of AFMK remains unknown. To our knowledge, this report is the first to document the potent antioxidant action of this biogenic amine. Cyclic voltammetry (CV) shows that AFMK donates two electrons at potentials of 456 mV and 668 mV, and therefore it functions as a reductive force. This function contrasts with all other physiological antioxidants that donate a single electron only when they neutralize free radicals. AFMK reduced 8-hydroxydeoxyguanosine formation induced by the incubation of DNA with oxidants significantly. Lipid peroxidation resulting from free radical damage to rat liver homogenates was also prevented by the addition of AFMK. The inhibitory effects of AFMK on both DNA and lipid damage appear to be dose-response related. In cell culture, AFMK efficiently reduced hippocampal neuronal death induced by either hydrogen peroxide, glutamate, or amyloid beta (25-35) peptide. AFMK is a naturally occurring molecule with potent free radical scavenging capacity (donating two electrons/molecule) and thus may be a valuable new antioxidant for preventing and treating free radical-related disorders.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Gottingen, D-37073 Gottingen, Germany; Antropol Inst Zool, D-37073 Gottingen, Germany; Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, Jerusalem, Israel	University of Texas System; University of Texas Health San Antonio; University of Gottingen; Hebrew University of Jerusalem	Reiter, RJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, Mail Code 7762,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	reiter@uthscsa.edu	Tan, David/HIR-2214-2022; Mayo, Juan Carlos/H-3435-2011; tan, dun-xian/E-3610-2010; Sainz, Rosa M./N-5885-2014	Mayo, Juan Carlos/0000-0002-0882-2047; Sainz, Rosa M./0000-0003-3048-5582; Kohn, Ron/0000-0001-7268-9845				Andrisano V, 2000, J PHARMACEUT BIOMED, V23, P15, DOI 10.1016/S0731-7085(00)00259-4; Avrova N F, 2000, Neurosci Behav Physiol, V30, P535, DOI 10.1007/BF02462611; Bastianetto S, 2000, EUR J NEUROSCI, V12, P1882, DOI 10.1046/j.1460-9568.2000.00069.x; Benot S, 1999, J PINEAL RES, V27, P59, DOI 10.1111/j.1600-079X.1999.tb00597.x; BRADFORD M, 1976, ANN BIOCH, V71, P171; Chevion S, 1997, FREE RADICAL BIO MED, V22, P411, DOI 10.1016/S0891-5849(96)00337-1; Chevion S, 2000, FREE RADICAL BIO MED, V28, P860, DOI 10.1016/S0891-5849(00)00178-7; Ebelt H, 2000, J PINEAL RES, V28, P65, DOI 10.1034/j.1600-079X.2001.280201.x; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hara M, 2001, J PINEAL RES, V30, P129, DOI 10.1034/j.1600-079X.2001.300301.x; HARDELAND R, 1993, NEUROSCI BIOBEHAV R, V17, P347, DOI 10.1016/S0149-7634(05)80016-8; HERBERT V, 1994, STEM CELLS, V12, P289, DOI 10.1002/stem.5530120305; HIRATA F, 1974, J BIOL CHEM, V249, P1311; Hoyos M, 2000, J PINEAL RES, V28, P150; KELLY RW, 1984, BIOCHEM BIOPH RES CO, V121, P372, DOI 10.1016/0006-291X(84)90732-0; KENNAWAY DJ, 1988, AUST J BIOL SCI, V41, P393, DOI 10.1071/BI9880393; Kohen R, 1999, METHOD ENZYMOL, V300, P285; LIU DX, 1994, J NEUROCHEM, V62, P37; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; MELCHIORRI D, 1994, LIFE SCI, V56, P83, DOI 10.1016/0024-3205(94)00928-7; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P572; MORIMOTO BH, 1990, NEURON, V5, P875, DOI 10.1016/0896-6273(90)90347-I; Pappolla MA, 1999, J PINEAL RES, V27, P226, DOI 10.1111/j.1600-079X.1999.tb00619.x; Pappolla MA, 1997, J NEUROSCI, V17, P1683; Pourahmad J, 2000, TOXICOLOGY, V143, P263, DOI 10.1016/S0300-483X(99)00178-X; Price JM, 1997, NEUROL RES, V19, P534, DOI 10.1080/01616412.1997.11740853; Qi WB, 2000, J PINEAL RES, V29, P54, DOI 10.1034/j.1600-079X.2000.290108.x; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Reiter RJ., 2000, CURR TOP BIOPHYS, V24, P171; Sen CK, 2000, J BIOL CHEM, V275, P13049, DOI 10.1074/jbc.275.17.13049; Silva SO, 2000, BIOCHEM BIOPH RES CO, V279, P657, DOI 10.1006/bbrc.2000.3993; Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4; Tan DX, 2000, BIOL SIGNAL RECEPT, V9, P137; Tan DX, 1993, ENDOCR J, V1, P57; Zhou LJ, 2000, ACTA PHARMACOL SIN, V21, P75	35	224	233	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					2294	+		10.1096/fj.01-0309fje	http://dx.doi.org/10.1096/fj.01-0309fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11511530				2022-12-28	WOS:000170809900017
J	Azuma, Y; Tan, SH; Cavenagh, MM; Ainsztein, AM; Saitoh, H; Dasso, M				Azuma, Y; Tan, SH; Cavenagh, MM; Ainsztein, AM; Saitoh, H; Dasso, M			Expression and regulation of the mammalian SUMO-1 E1 enzyme	FASEB JOURNAL			English	Article						SUMO-1; Uba2; Aos1; Ubc9	UBIQUITIN-CONJUGATING ENZYME; GTPASE-ACTIVATING PROTEIN; NUCLEAR-PORE COMPLEX; YEAST; HOMOLOG; RANGAP1; DEGRADATION; KINASE; RANBP2; UBC9P	SUMO-1 is a small ubiquitin-related protein. SUMO-1 conjugation requires enzymes with sequence and biochemical similarity to ubiquitin E1 and E2 enzymes. We have examined the expression, localization, and biochemical behavior of Aos1 and Uba2, subunits of the mammalian SUMO-1 E1 enzyme. Both of these proteins are expressed in multiple tissues and localized to the nucleus. Aos1 protein levels vary through the cell cycle. These changes in Aos1 concentration may play a role in the regulation of the SUMO-1 pathway, because they correlate with changes in the abundance of some SUMO-1-conjugated species. Biochemical analysis reveals that Aos1 and Uba2 associate with each other in a simple heterodimeric complex without other subunits, unlike the budding yeast Uba2 homologue, which apparently associates with several different proteins. Although it is possible to reconstitute SUMO-1 conjugation with purified Uba2, Aos1, and Ubc9, this reaction is significantly less efficient than conjugation observed in cellular extracts, suggesting the possibility that there may be activators of SUMO-1 conjugation in vivo that have not yet been characterized. Taken together, these observations reveal that the SUMO-1 pathway is controlled on multiple levels during the cell cycle.	NICHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dasso, M (corresponding author), NICHD, Mol Embryol Lab, NIH, Bldg 18,Room 106, Bethesda, MD 20892 USA.	mdasso@helix.nih.gov	Tan, Shyh-Han/I-7037-2013	Tan, Shyh-Han/0000-0001-8250-7005; Dasso, Mary/0000-0002-5410-1371	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001902] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001902] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALKHODAIRY F, 1995, J CELL SCI, V108, P486; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Harlow E., 1988, ANTIBODIES LAB MANUA; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shayeghi M, 1997, NUCLEIC ACIDS RES, V25, P1162, DOI 10.1093/nar/25.6.1162; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Tanaka K, 1998, MOL CELLS, V8, P503; Tanaka K, 1999, MOL CELL BIOL, V19, P8660; Tarsounas M, 1997, MOL BIOL CELL, V8, P1405, DOI 10.1091/mbc.8.8.1405; Tashiro K, 1997, P NATL ACAD SCI USA, V94, P7862, DOI 10.1073/pnas.94.15.7862; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	26	44	50	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1825	+		10.1096/fj.00-0818fje	http://dx.doi.org/10.1096/fj.00-0818fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481243				2022-12-28	WOS:000169261200028
J	Garcia, JRC; Krause, A; Schulz, S; Rodriguez-Jimenez, FJ; Kluver, E; Adermann, K; Forssmann, U; Frimpong-Boateng, A; Bals, R; Forssmann, WG				Garcia, JRC; Krause, A; Schulz, S; Rodriguez-Jimenez, FJ; Kluver, E; Adermann, K; Forssmann, U; Frimpong-Boateng, A; Bals, R; Forssmann, WG			Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity	FASEB JOURNAL			English	Article						peptide antibiotics; mucosal immunity; cystic fibrosis; host defense; synergism	INNATE HOST-DEFENSE; HUMAN BETA-DEFENSIN-1; GENE-EXPRESSION; ANTIBIOTICS; ACTIVATION; EPITHELIA; INFECTION; CHEMOKINE; LUNG	beta Defensins are antibiotic peptides involved in host defense at the epithelial surface. Three human beta -defensins (hBDs)-hBD-1, hBD-2, and hBD-3-have been identified so far. We have characterized a new member of the beta -defensin family, hBD-4, based on screening of genomic sequences and subsequent functional analysis. In contrast to hBD-1, hBD-2, and hBD-3, which are diffusely expressed throughout many organs, hBD-4 mRNA expression is confined to testis, stomach, uterus, neutrophils, thyroid, lung, and kidney. hBD-4 expression was up-regulated by infection with gram-positive and gram-negative bacteria in human respiratory epithelial cells, and in response to phorbol 12-myristate 13-acetate, but not in response to other inflammatory factors that up-regulate the expression of hBD-2 or hBD-3. Synthetic hBD-4 exhibits a selective, salt-sensitive spectrum of antimicrobial activity, and it represents one of the most active antimicrobial peptides against Pseudomonas aeruginosa (minimal inhibitory concentration: 4.1 mug/ml) known to date. This new defensin is chemotactic for human blood monocytes, but it is inactive on neutrophils and eosinophils. These findings demonstrate the existence of a family of beta -defensin genes with different functions against diverse classes of microorganisms, regulated by different stimuli, and specific signal pathways, and confirm the relevance of antimicrobial peptides in host defense.	IPF PharmaCeut GmbH, D-30625 Hannover, Germany; Univ Munich, Med Klin 1, D-81377 Munich, Germany	University of Munich	Forssmann, WG (corresponding author), IPF PharmaCeut GmbH, Feodor Lynen Str 31, D-30625 Hannover, Germany.	wgforssmann@gmx.de	Conejo-Garcia, Jose R/V-1897-2019	Conejo-Garcia, Jose R/0000-0001-6431-4074				Bals R, 1999, INFECT IMMUN, V67, P3542, DOI 10.1128/IAI.67.7.3542-3547.1999; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Bevins CL, 1999, GUT, V45, P911, DOI 10.1136/gut.45.6.911; Bieche I, 1999, CANCER RES, V59, P2759; BUCHLER P, 2001, IN PRESS PANCREAS; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Diamond G, 1998, CLIN IMMUNOL IMMUNOP, V88, P221, DOI 10.1006/clin.1998.4587; Diamond G, 2000, INFECT IMMUN, V68, P113, DOI 10.1128/IAI.68.1.113-119.2000; Eliopoulos G.M., 1991, ANTIBIOTICS LAB MED, V3rd Edn, P432; Fehlbaum P, 2000, P NATL ACAD SCI USA, V97, P12723, DOI 10.1073/pnas.220424597; Friedrich C, 1999, ANTIMICROB AGENTS CH, V43, P1542, DOI 10.1128/AAC.43.7.1542; Ganz T, 1999, SCIENCE, V286, P420, DOI 10.1126/science.286.5439.420; GARCIA JRC, 2001, IN PRESS CELL TISSUE; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; Jia HP, 2000, J BIOL CHEM, V275, P33314, DOI 10.1074/jbc.M006603200; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Linzmeier R, 1999, GENE, V233, P205, DOI 10.1016/S0378-1119(99)00136-5; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; Monick MM, 2001, J IMMUNOL, V166, P2681, DOI 10.4049/jimmunol.166.4.2681; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; Pardigol A, 1998, P NATL ACAD SCI USA, V95, P6308, DOI 10.1073/pnas.95.11.6308; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; TANG YQ, 1993, J BIOL CHEM, V268, P6649; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yu QT, 2000, J BIOL CHEM, V275, P3943, DOI 10.1074/jbc.275.6.3943	38	402	447	2	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1819	+		10.1096/fj.00-0865fje	http://dx.doi.org/10.1096/fj.00-0865fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481241				2022-12-28	WOS:000169261200026
J	Ponce, ML; Nomizu, M; Kleinman, HK				Ponce, ML; Nomizu, M; Kleinman, HK			An angiogenic laminin site and its antagonist bind through the alpha v beta 3 and alpha 5 beta 1 integrins	FASEB JOURNAL			English	Article						angiogenesis; laminin-1; bFGF; endothelium; peptides	HUMAN-ENDOTHELIAL CELLS; TUMOR-GROWTH; SYNTHETIC PEPTIDES; ADHESION MOLECULE; ALPHA-1 CHAIN; GAMMA-1 CHAIN; IDENTIFICATION; ALPHA(V)BETA(3); RECEPTORS; PROTEIN	Angiogenesis is important for wound healing, tumor growth, and metastasis. Endothelial cells differentiate into capillary-like structures on a laminin-1-rich matrix (Matrigel). We previously identified 20 angiogenic sites on laminin-1 (alpha1 beta1 gamma1) by screening 559 overlapping synthetic peptides. C16, the most potent gamma1 chain peptide, blocked laminin-1-mediated adhesion and was the only gamma1 chain peptide to block attachment to both collagen I and fibronectin. This suggested that C16 was acting via a receptor common to these substrates. We demonstrated that C16 is angiogenic in vivo. Affinity chromatography identified the integrins alpha5 beta1 and alphav beta3 as surface receptors. Blocking antibodies confirmed the role of these receptors in C16 adhesion. C16 does not contain an RGD sequence and, as expected, an RGD-containing peptide did not block C16 adhesion nor did C16 act via MAP kinase phosphorylation. Furthermore, we identified a C16 scrambled sequence, C16S, which antagonizes the angiogenic activity of bFGF and of C16 by binding to the same receptors. Because the laminin gamma1 chain is ubiquitous in most tissues, C16 is likely an important functional site. Since the biological activity of C16 is blocked by a scrambled peptide, C16S may serve as an anti-angiogenic therapeutic agent.	NIDCR, CDBRB, NIH, Bethesda, MD 20892 USA; Hokkaido Univ, Grad Sch Environm Earth Sci, Sapporo, Hokkaido 060, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Hokkaido University	Kleinman, HK (corresponding author), NIDCR, CDBRB, NIH, Bldg 30,Room 433,30 Convent Dr, Bethesda, MD 20892 USA.	hkleinman@dir.nidcr.nih.gov						BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 2000, CANCER J, V6, pS245; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT DS, 1992, J CELL PHYSIOL, V153, P614, DOI 10.1002/jcp.1041530324; Hauzenberger D, 1999, EUR J IMMUNOL, V29, P1435, DOI 10.1002/(SICI)1521-4141(199905)29:05<1435::AID-IMMU1435>3.0.CO;2-N; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; HORTON MA, 1994, BONE, V15, P639, DOI 10.1016/8756-3282(94)90312-3; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KIBBEY MC, 1992, J NATL CANCER I, V84, P1633, DOI 10.1093/jnci/84.21.1633; KIBBEY MC, 1993, P NATL ACAD SCI USA, V90, P10150, DOI 10.1073/pnas.90.21.10150; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Malinda KM, 1999, FASEB J, V13, P53, DOI 10.1096/fasebj.13.1.53; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; Nath D, 1999, J CELL SCI, V112, P579; Newham P, 1996, MOL MED TODAY, V2, P304, DOI 10.1016/1357-4310(96)10021-6; NICOSIA RF, 1990, LAB INVEST, V63, P115; Nomizu M, 1997, J BIOL CHEM, V272, P32198, DOI 10.1074/jbc.272.51.32198; Nomizu M, 1998, J BIOL CHEM, V273, P32491, DOI 10.1074/jbc.273.49.32491; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OREILLY MS, 1997, CELL, V88, P276; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; PFAFF M, 1994, CELL ADHES COMMUN, V2, P491, DOI 10.3109/15419069409014213; Pike SE, 1999, BLOOD, V94, P2461, DOI 10.1182/blood.V94.7.2461.419a26_2461_2468; Ponce ML, 1999, CIRC RES, V84, P688, DOI 10.1161/01.RES.84.6.688; Ruppert M, 1995, J CELL BIOL, V131, P1881, DOI 10.1083/jcb.131.6.1881; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; TIMPL R, 1979, J BIOL CHEM, V254, P9933	36	71	75	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1389	1397		10.1096/fj.00-0736com	http://dx.doi.org/10.1096/fj.00-0736com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11387236				2022-12-28	WOS:000169261200006
J	van der Goes, A; Wouters, D; van der Pol, SMA; Huizinga, R; Ronken, E; Adamson, P; Greenwood, J; Dijkstra, CD; de Vries, HE				van der Goes, A; Wouters, D; van der Pol, SMA; Huizinga, R; Ronken, E; Adamson, P; Greenwood, J; Dijkstra, CD; de Vries, HE			Reactive oxygen species enhance the migration of monocytes across the blood-brain barrier in vitro	FASEB JOURNAL			English	Article						multiple sclerosis; cerebral endothelial cells; signal transduction; transendothelial migration	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; EXPERIMENTAL OPTIC NEURITIS; CENTRAL-NERVOUS-SYSTEM; FOCAL ADHESION KINASE; ENDOTHELIAL-CELLS; FREE-RADICALS; TYROSINE PHOSPHORYLATION; SUPEROXIDE ANION; XANTHINE-OXIDASE; PERMEABILITY	Reactive oxygen species (ROS) are involved in the pathogenesis of several inflammatory and degenerative diseases, including multiple sclerosis (MS), an inflammatory disease of the central nervous system. We investigated the potential involvement of ROS in the interaction of monocytes with cerebral endothelium, because this is likely to be an early event in the development of MS lesions. ROS are produced via two main pathways, one involving NADPH oxidase complex and the other involving xanthine oxidase (XO). We examined the effects of ROS, ROS scavengers, and ROS inhibitors of both pathways on the migration of monocytes across the blood-brain barrier in vitro. Scavengers and inhibitors of XO predominantly inhibited monocyte migration, whereas inhibitors and scavengers of the NADPH oxidase complex had no effect. Exposure of cerebral endothelial cells (CEC) to superoxide (O(2)(-)) resulted in enhanced migration and adhesion of monocytes as well as disruption of the tight junctions, whereas hydroxyl radicals and hydrogen peroxide induced no significant effect on these parameters. Underlying mechanisms of the observed changes were found to reside in the phospholipase C-mediated signal transduction cascade, subsequent accumulation of inositol 1,4,5- trisphosphate, and mobilization of intracellular calcium. We conclude that O(2)(-) is a signaling molecule that is produced during the firm adhesion of monocytes to CEC, which triggers cytoskeletal rearrangements allowing infiltration of monocytes into the brain.	Vrije Univ Amsterdam, Fac Med, Dept Mol Cell Biol, NL-1081 BT Amsterdam, Netherlands; Solvay Pharmaceut BV, Solvay Res Labs, Weesp, Netherlands; UCL, Inst Ophthalmol, London, England	Vrije Universiteit Amsterdam; Solvay SA; University of London; University College London	de Vries, HE (corresponding author), VUMC, Dept Mol Cell Biol, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	HE.de_Vries.Cell@med.vu.nl		Greenwood, John/0000-0003-4496-2984				Arduini A, 1985, Free Radic Res Commun, V1, P129, DOI 10.3109/10715768509056546; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BRETT R, 1993, NEUROCHEM INT, V23, P35, DOI 10.1016/0197-0186(93)90141-Q; CHIA LS, 1983, BIOCHEM BIOPH RES CO, V117, P141, DOI 10.1016/0006-291X(83)91552-8; DELMAESTRO RF, 1982, CAN J PHYSIOL PHARM, V60, P1406; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; ETINEEMANNEVILL.S, 2000, AM J PHYSIOL, V165, P3375; GLABINSKI A, 1993, ACTA NEUROL SCAND, V88, P174; Gozin A, 1998, FREE RADICAL BIO MED, V25, P1021, DOI 10.1016/S0891-5849(98)00134-8; GREENWOOD J, 1995, IMMUNOLOGY, V86, P408; Grisham MB, 1998, FREE RADICAL BIO MED, V25, P404, DOI 10.1016/S0891-5849(98)00094-X; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUY J, 1993, OPHTHALMIC RES, V25, P253, DOI 10.1159/000267321; GUY J, 1989, CURR EYE RES, V8, P467, DOI 10.3109/02713688909000027; HARTUNG HP, 1988, ANN NEUROL, V23, P453, DOI 10.1002/ana.410230505; Ichikawa H, 1997, AM J PHYSIOL-GASTR L, V273, pG342, DOI 10.1152/ajpgi.1997.273.2.G342; Imaizumi S, 1996, NEUROCHEM INT, V29, P205, DOI 10.1016/0197-0186(95)00120-4; KONAT GW, 1985, J NEUROCHEM, V45, P1113, DOI 10.1111/j.1471-4159.1985.tb05530.x; Lagrange P, 1999, FREE RADICAL BIO MED, V27, P667, DOI 10.1016/S0891-5849(99)00112-4; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LIN RF, 1993, J EXP MED, V178, P643, DOI 10.1084/jem.178.2.643; OLESEN SP, 1987, ACTA PHYSIOL SCAND, V129, P181, DOI 10.1111/j.1748-1716.1987.tb08057.x; PUIG JG, 1989, ANN RHEUM DIS, V48, P883, DOI 10.1136/ard.48.11.883; RUBANYI GM, 1988, FREE RADICAL BIO MED, V4, P107, DOI 10.1016/0891-5849(88)90071-8; RUULS SR, 1995, J NEUROIMMUNOL, V56, P207, DOI 10.1016/0165-5728(94)00154-G; Soldi R, 1996, ONCOGENE, V13, P515; TAKAO S, 1996, AM J PHYSIOL, V271, pC1274; TERADA LS, 1991, J CELL PHYSIOL, V148, P191, DOI 10.1002/jcp.1041480202; TOSHNIWAL PK, 1992, NEUROCHEM RES, V17, P205, DOI 10.1007/BF00966801; van der Goes A, 1998, J NEUROIMMUNOL, V92, P67, DOI 10.1016/S0165-5728(98)00175-1; Ye JM, 1999, AM J PHYSIOL-RENAL, V277, pF524, DOI 10.1152/ajprenal.1999.277.4.F524	31	127	129	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1852	+		10.1096/fj.00-0881fje	http://dx.doi.org/10.1096/fj.00-0881fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481252				2022-12-28	WOS:000169261200012
J	Leonarduzzi, G; Sevanian, A; Sottero, B; Arkan, MC; Biasi, F; Chiarpotto, E; Basaga, H; Poli, G				Leonarduzzi, G; Sevanian, A; Sottero, B; Arkan, MC; Biasi, F; Chiarpotto, E; Basaga, H; Poli, G			Up-regulation of the fibrogenic cytokine TGF-beta 1 by oxysterols: a mechanistic link between cholesterol and atherosclerosis	FASEB JOURNAL			English	Article						7-ketocholesterol; atherogenesis; oxidized low-density lipoproteins	GROWTH-FACTOR-BETA; LOW-DENSITY-LIPOPROTEIN; OXIDATION-PRODUCTS; LIPID-PEROXIDATION; MASS-SPECTROMETRY; PLASMA; TISSUE; EXPRESSION; 7-BETA-HYDROXYCHOLESTEROL; 7-KETOCHOLESTEROL	Deposition of blood cholesterol in the subendothelial space of major arteries is a main feature of the fibrotic plaque as well as the key event in the progression of atherosclerosis. However, the mechanisms by which cholesterol triggers and sustains the fibrotic degeneration of blood arteries remain undefined. The results reported here indicate that a biologically representative mixture of oxysterols, 27-carbon products of cholesterol oxidation, rather than an individual oxysterol at the same concentration, exerts a strong profibrogenic effect when taken up by macrophages. Incubation of murine and human macrophages with such oxysterol mixture markedly promotes both expression and synthesis of one of the most potent proinflammatory and fibrogenic cytokines, transforming growth factor beta1 (TGF-beta1). By contrast, no effect on TGF-beta1 expression and synthesis was found with unoxidized cholesterol. Macrophage uptake of cholesterol and conversion to foam cells is a hallmark of early atherogenesis, but it appears that cholesterol oxidation products, as well as other low-density lipoprotein oxidation products, are required to generate a proper fibrogenic stimulus that is not fulfilled by cholesterol deposition alone.	Univ Turin, S Luigi Gonzaga Hosp, Dept Clin & Biol Sci, I-10043 Turin, Italy; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Sabanci Univ, Fac Engn & Nat Sci, Istanbul, Turkey; CNR, Ctr Immunogenet & Expt Oncol, I-10126 Turin, Italy	University of Turin; University of Southern California; Sabanci University; Consiglio Nazionale delle Ricerche (CNR)	Poli, G (corresponding author), Univ Turin, S Luigi Gonzaga Hosp, Dept Clin & Biol Sci, I-10043 Turin, Italy.	giuseppe.poli@unito.it	Leonarduzzi, Gabriella/AAA-6575-2019	LEONARDUZZI, Gabriella Marisa/0000-0002-3422-821X				ADDIS PB, 1989, FREE RADICAL BIO MED, V7, P179, DOI 10.1016/0891-5849(89)90011-7; BEDOSSA P, 1995, J HEPATOL, V22, P37; BJORKHEM I, 1988, J LIPID RES, V29, P1031; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Brooks C.J.W., 1983, BIOCHEM SOC T, V11, P700; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; Chang YH, 1997, FREE RADICAL BIO MED, V23, P202, DOI 10.1016/S0891-5849(96)00626-0; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; ESTERBAUER H, 1986, BIOCHIM BIOPHYS ACTA, V876, P154, DOI 10.1016/0005-2760(86)90329-2; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Grande JP, 1997, P SOC EXP BIOL MED, V214, P27; GRAY MF, 1971, LIPIDS, V6, P836, DOI 10.1007/BF02531214; HODIS HN, 1991, ATHEROSCLEROSIS, V89, P117, DOI 10.1016/0021-9150(91)90051-4; HODIS HN, 1994, J LIPID RES, V35, P669; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; KOVACS EJ, 1991, IMMUNOL TODAY, V12, P17, DOI 10.1016/0167-5699(91)90107-5; KUDO K, 1989, J LIPID RES, V30, P1097; Lemaire S, 1998, FEBS LETT, V440, P434, DOI 10.1016/S0014-5793(98)01496-3; Leonarduzzi G, 1997, FASEB J, V11, P851, DOI 10.1096/fasebj.11.11.9285483; Liu Y, 1997, ARTERIOSCL THROM VAS, V17, P317, DOI 10.1161/01.ATV.17.2.317; Lizard G, 1997, FEBS LETT, V419, P276, DOI 10.1016/S0014-5793(97)01473-7; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mol MJTM, 1997, ATHEROSCLEROSIS, V129, P169, DOI 10.1016/S0021-9150(96)06022-4; Napoli C, 1997, J CLIN INVEST, V100, P2680, DOI 10.1172/JCI119813; Poli G, 1997, FREE RADICAL BIO MED, V22, P287, DOI 10.1016/S0891-5849(96)00327-9; Poli Giuseppe, 2000, Molecular Aspects of Medicine, V21, P49, DOI 10.1016/S0098-2997(00)00004-2; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; SEVANIAN A, 1994, FREE RADICAL BIO MED, V17, P397, DOI 10.1016/0891-5849(94)90166-X; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Yuan XM, 2000, FREE RADICAL BIO MED, V28, P208, DOI 10.1016/S0891-5849(99)00220-8	31	62	63	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1619	+		10.1096/fj.00-0668fje	http://dx.doi.org/10.1096/fj.00-0668fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427505				2022-12-28	WOS:000173707700024
J	Pifl, C; Zezula, R; Spittler, A; Kattinger, A; Reither, H; Caron, MG; Hornykiewicz, O				Pifl, C; Zezula, R; Spittler, A; Kattinger, A; Reither, H; Caron, MG; Hornykiewicz, O			Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter	FASEB JOURNAL			English	Article						neurodegeneration; neuroprotection; cell differentiation; cell cycle; oxidative stress apoptosis; iron	PARKINSONS-DISEASE; NERVOUS-SYSTEM; MITOCHONDRIAL RESPIRATION; TYROSINE-HYDROXYLASE; HYDROGEN-PEROXIDE; SERUM DEPRIVATION; CORTICAL-NEURONS; OXIDATIVE STRESS; CEREBRAL-CORTEX; BRAIN DOPAMINE	The classical catecholamine transmitters dopamine and norepinephrine are also involved in neurodevelopment and neuron cell death. These effects are thought to be mediated by receptors coupled to intracellular second messengers and by oxidative stress, respectively. Using human SK-N-MC neuroblastoma cells stably transfected with the dopamine or norepinephrine transporter, we show that catecholamines have profound effects on cell viability not mediated by any of the above mechanisms. Low micromolar concentrations of dopamine or norepinephrine (1-10 muM) affected cell growth depending on the expression level of plasmalemmal transport. The growth inhibition was accompanied by a profound effect on the cell cycle profile with an arrest in G, as determined by flow cytometry measuring DNA content. In a proportion of cells, apoptosis was present. Various antioxidants did not prevent the catecholamine effect, and there was no indication of accumulation of reactive oxygen species (as determined by hydroethidine, dichlorofluorescein, and the inactivation-reactivation pattern of aconitase), ruling out involvement of oxidative stress. Reversal by FeCl3 and parallel effects of the iron-chelator deferoxamine suggest that the catecholamine action was related to intracellular iron chelation. This novel biological action of dopamine and norepinephrine unrelated to neurotransmitter receptors, second messengers, or oxidative stress may be important for cell differentiation during neurodevelopment and survival of differentiated neurons.	Univ Vienna, Inst Brain Res, Div Biochem & Mol Biol, A-1090 Vienna, Austria; Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Univ Vienna, Dept Surg, A-1090 Vienna, Austria; Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst Labs, Durham, NC 27710 USA	University of Vienna; University of Vienna; University of Vienna; Duke University	Pifl, C (corresponding author), Univ Vienna, Inst Brain Res, Div Biochem & Mol Biol, Spitalgasse 4, A-1090 Vienna, Austria.	christian.pifl@univie.ac.at		Pifl, Christian/0000-0003-1456-4264; Spittler, Andreas/0000-0003-2657-6836				Alagarsamy S, 1997, DRUG ALCOHOL DEPEN, V48, P105, DOI 10.1016/S0376-8716(97)00118-X; BENSHACHAR D, 1995, J NEUROCHEM, V64, P718, DOI 10.1046/j.1471-4159.1995.64020718.x; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; Burke WJ, 1997, BRAIN RES, V760, P290, DOI 10.1016/S0006-8993(97)00447-2; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; COLBURN RW, 1965, NATURE, V208, P37, DOI 10.1038/208037a0; COYLE JT, 1972, J NEUROCHEM, V19, P1117, DOI 10.1111/j.1471-4159.1972.tb01431.x; CUBELLS JF, 1994, J NEUROSCI, V14, P2260, DOI 10.1523/jneurosci.14-04-02260.1994; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GRAHAM DG, 1978, MOL PHARMACOL, V14, P644; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GROL CJ, 1979, NEUROBIOLOGY DOPAMIN, P7; HARTIKKA J, 1992, J NEUROSCI RES, V32, P190, DOI 10.1002/jnr.490320208; HASTINGS TG, 1995, J NEUROCHEM, V64, P919; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; HIRAMATSU M, 1994, FREE RADICAL BIO MED, V16, P201, DOI 10.1016/0891-5849(94)90144-9; HOWARD MK, 1993, J NEUROCHEM, V60, P1783, DOI 10.1111/j.1471-4159.1993.tb13404.x; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Langston JW, 1996, NEUROLOGY, V47, pS153, DOI 10.1212/WNL.47.6_Suppl_3.153S; LAUDER JM, 1993, TRENDS NEUROSCI, V16, P233, DOI 10.1016/0166-2236(93)90162-F; LAUDER JM, 1988, PROG BRAIN RES, V73, P365; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; MAKER HS, 1981, J NEUROCHEM, V36, P589, DOI 10.1111/j.1471-4159.1981.tb01631.x; Masserano JM, 1996, MOL PHARMACOL, V50, P1309; MATTAMMAL MB, 1995, NEURODEGENERATION, V4, P271, DOI 10.1016/1055-8330(95)90016-0; Miller JW, 1996, FREE RADICAL BIO MED, V21, P241, DOI 10.1016/0891-5849(96)00033-0; Morikawa N, 1996, J NEUROCHEM, V66, P1174; MUSCHEL RJ, 1995, CANCER RES, V55, P995; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; OFFEN D, 1995, BBA-MOL CELL RES, V1268, P171, DOI 10.1016/0167-4889(95)00075-4; Offen D, 1996, EXP NEUROL, V141, P32, DOI 10.1006/exnr.1996.0136; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; Pifl C, 1996, J PHARMACOL EXP THER, V277, P1437; PIFL C, 1988, EUR J PHARMACOL, V153, P33, DOI 10.1016/0014-2999(88)90585-7; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; RAJAN KS, 1971, J NEUROCHEM, V18, P345, DOI 10.1111/j.1471-4159.1971.tb11963.x; Ratan RR, 1996, NEUROCHEM INT, V29, P153, DOI 10.1016/0197-0186(95)00115-8; Richardson DR, 1997, CAN J PHYSIOL PHARM, V75, P1164, DOI 10.1139/cjpp-75-10-11-1164; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; Ross ME, 1996, TRENDS NEUROSCI, V19, P62, DOI 10.1016/0166-2236(96)89622-6; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; Simantov R, 1996, NEUROSCIENCE, V74, P39, DOI 10.1016/0306-4522(96)00102-9; TERADA N, 1991, J IMMUNOL, V147, P698; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; VelezPardo C, 1997, PHARMACOL TOXICOL, V80, P76, DOI 10.1111/j.1600-0773.1997.tb00287.x; VYAS I, 1986, J NEUROCHEM, V46, P1501, DOI 10.1111/j.1471-4159.1986.tb01768.x; Yaginuma H, 1996, J NEUROSCI, V16, P3685; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	59	20	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1607	+		10.1096/fj.00-0738fje	http://dx.doi.org/10.1096/fj.00-0738fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427501				2022-12-28	WOS:000173707700018
J	Savignac, M; Badou, A; Moreau, M; Leclerc, C; Guery, JC; Paulet, P; Druet, P; Ragab-Thomas, J; Pelletier, L				Savignac, M; Badou, A; Moreau, M; Leclerc, C; Guery, JC; Paulet, P; Druet, P; Ragab-Thomas, J; Pelletier, L			Protein kinase C-mediated calcium entry dependent upon dihydropyridine-sensitive channels: a T-cell receptor-coupled signaling pathway involved in interleukin 4 synthesis	FASEB JOURNAL			English	Article						interleukin 4; L-type calcium channels; T lymphocyte	ALTERED PEPTIDE LIGANDS; CYTOKINE PRODUCTION; IL-4 PRODUCTION; CA2+ CHANNELS; TRANSDUCTION PATHWAYS; DOWN-REGULATION; ACTIVATION; TH1; MODULATION; INDUCTION	Signaling events induced by T-cell receptor (TCR) engagement involve a cascade of tyrosine phosphorylation events leading to activation of several downstream pathways and resulting in cytokine production. TCR-dependent interferon gamma (IFN-gamma) production by Th1 cells has been shown to require tyrosine phosphorylation of numerous proteins, intracellular Ca2+ mobilization, and mitogen-activated protein kinase activation. In contrast, the signaling pathways responsible for TCR-dependent interleukin (IL) 4 production remain poorly understood. By using a T-cell hybridoma that displays a hierarchized production of IL-4 and IFN-gamma following TCR engagement (IL-4 being produced at a lower threshold of activation than IFN-gamma), we showed that IL-4 can be produced in spite of the absence of tyrosine phosphorylation of phospholipase Cgamma1. However, protein kinase C (PKC) was found to be translocated to the cell membrane, and an increase in intracellular Ca2+ concentration was observed. The PKC-dependent Ca2+ response and IL-4 expression were accounted for by a dihydropyridine-sensitive Ca2+ entry, which could occur through L-type calcium channels. This pathway was also functional in the D10G4.1 Th2 clone. The fact that this pathway, allowing IL-4 production, did not require optimal activation might explain why low doses of peptides or altered peptide ligands favor Th2 responses.	Hop Purpan, INSERM, U326, F-31059 Toulouse, France; Hop Purpan, Inst Federatif Rech IFR 30, F-31059 Toulouse, France; Univ Toulouse 3, CNRS, UMR 5547, F-31062 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Pelletier, L (corresponding author), Hop Purpan, INSERM, U28, Pl Dr Baylac, F-31059 Toulouse, France.	Lucette.Pelletier@purpan.inserm.fr	Savignac, Magali/K-1757-2014; Pelletier, Lucette/L-2956-2014; Leclerc, Catherine/O-6514-2015; GUERY, Jean-Charles/G-1452-2013	GUERY, Jean-Charles/0000-0003-4499-3270; Badou, Abdallah/0000-0003-4849-9085				ADORINI L, 1988, P NATL ACAD SCI USA, V85, P5181, DOI 10.1073/pnas.85.14.5181; Akha AAS, 1996, J BIOL CHEM, V271, P7297, DOI 10.1074/jbc.271.13.7297; Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; AlRamadi BK, 1996, J IMMUNOL, V157, P4751; Badou A, 1997, J BIOL CHEM, V272, P32411, DOI 10.1074/jbc.272.51.32411; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Boutin Y, 1997, J IMMUNOL, V159, P5802; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Carballido JM, 1997, EUR J IMMUNOL, V27, P515, DOI 10.1002/eji.1830270224; Chau LA, 1999, J IMMUNOL, V163, P1853; Chau LA, 1998, J EXP MED, V187, P1699, DOI 10.1084/jem.187.10.1699; CHEN CS, 1993, J BIOL CHEM, V268, P15812; Chen YZ, 1998, EUR J IMMUNOL, V28, P3929, DOI 10.1002/(SICI)1521-4141(199812)28:12<3929::AID-IMMU3929>3.0.CO;2-8; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Dumont FJ, 1998, J IMMUNOL, V160, P2579; Egerton M, 1996, EUR J IMMUNOL, V26, P2279, DOI 10.1002/eji.1830261002; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; GAJEWSKI TF, 1994, J EXP MED, V179, P481, DOI 10.1084/jem.179.2.481; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Guery JC, 1996, J EXP MED, V183, P485, DOI 10.1084/jem.183.2.485; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harada Y, 1996, J ALLERGY CLIN IMMUN, V98, pS161, DOI 10.1016/S0091-6749(96)70063-5; Hartzell HC, 1996, AM J PHYSIOL-CELL PH, V270, pC1293; Janoshazi A, 1999, BIOCHEMISTRY-US, V38, P13316, DOI 10.1021/bi990427m; KNAUS HG, 1992, P NATL ACAD SCI USA, V89, P3586, DOI 10.1073/pnas.89.8.3586; KUBO M, 1994, J BIOL CHEM, V269, P19441; KUBO M, 1994, INT IMMUNOL, V6, P179, DOI 10.1093/intimm/6.2.179; KUBO RT, 1989, J IMMUNOL, V142, P2736; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; LECLERC C, 1995, CELL CALCIUM, V17, P216, DOI 10.1016/0143-4160(95)90036-5; Legendre V, 1999, INT IMMUNOL, V11, P1731, DOI 10.1093/intimm/11.11.1731; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Lombardi G, 1996, J IMMUNOL, V156, P2769; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MOREAU M, 1994, P NATL ACAD SCI USA, V91, P12639, DOI 10.1073/pnas.91.26.12639; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; Poggi A, 1998, J BIOL CHEM, V273, P7205, DOI 10.1074/jbc.273.13.7205; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; Rabinowitz JD, 1996, IMMUNITY, V5, P125, DOI 10.1016/S1074-7613(00)80489-6; Ron D, 1999, J BIOL CHEM, V274, P19003, DOI 10.1074/jbc.274.27.19003; Salio M, 1997, EUR J IMMUNOL, V27, P1769, DOI 10.1002/eji.1830270726; SCOTT P, 1991, IMMUNOL TODAY, V12, P346, DOI 10.1016/0167-5699(91)90063-Y; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; Singh RAK, 1999, J IMMUNOL, V163, P6393; SloanLancaster J, 1997, J IMMUNOL, V159, P1160; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; TAMURA T, 1993, J IMMUNOL, V151, P6051; TAMURA T, 1995, J IMMUNOL, V155, P4692; Tao X, 1997, J IMMUNOL, V158, P4237; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; Viard P, 1999, FASEB J, V13, P685, DOI 10.1096/fasebj.13.6.685; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Zocchi MR, 1998, J IMMUNOL, V161, P2938	58	47	49	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1577	+		10.1096/fj.00-0733fje	http://dx.doi.org/10.1096/fj.00-0733fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427491				2022-12-28	WOS:000173707700031
J	Oshima, Y; Puri, RK				Oshima, Y; Puri, RK			A novel interleukin-13 (IL-13) antagonist that blocks the biological activity of human IL-13 in immune and nonimmune cells	FASEB JOURNAL			English	Article						pleiotropic cytokine; inflammatory disease	HIGH-AFFINITY INTERLEUKIN-4; CHIMERIC PROTEIN; CARCINOMA-CELLS; PSEUDOMONAS EXOTOXIN; RECEPTOR-BINDING; PROLIFERATIVE ACTIVITY; SIGNAL-TRANSDUCTION; ATOPIC-DERMATITIS; SARCOMA-CELLS; TUMOR-CELLS	The pleiotropic cytokine interleukin-13 (IL-13) plays a major role in the pathogenesis of inflammatory diseases, including allergic rhinitis, atopic dermatitis, allergic asthma, and malignancies. Therefore, specific inhibitors of IL-13 may have important clinical applications. We have previously produced a super agonist of IL-13 (termed IL-13R112D) by single amino acid substitution changing Arg to Asp at position 112. In an effort to create a cell-selective IL-13 agonist, we performed a second mutation in the IL-13R112D molecule substituting Lys for Glu at position 13. Unexpectedly, rather than an agonist, this novel double mutein (IL-13 DM, termed IL-13E13KR112D, turned out to be an IL-13 antagonist. It competes for I-125-IL-13 binding sites as effectively as wtIL-13. Designation of IL-13E13KR112D as an IL-13 antagonist is supported further by a second assay involving a fusion protein consisting of the bacterial cytotoxic molecule PE38QQR as well as wtIL-13 (IL-13-PE38QQR or IL-13 cytotoxin). IL-13E13KR112D neutralizes the cytotoxic activity of IL-13 cytotoxin exhibited in U251 and PM-RCC cancer cell lines. In addition, IL-13E13KR112D inhibits the proliferative activity of wtIL-13 in TF-1 and L1236 hematopoietic cell lines, neutralizes wtIL-13 induced inhibition of CD14 expression on primary monocytes, and prevents wtIL-13 induced activation of signal transducer and activator of transcription (STAT-6) protein in KSY-1 and THP-1 cell lines. Thus, IL-13E13KR112D may be a useful agent for the study of interaction between IL-13 and its cognate receptors and may contribute to the development of new treatments for inflammatory diseases, even malignancies, in which IL-13 plays a central role.	US FDA, Lab Mol Tumor Biol, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA)	Puri, RK (corresponding author), US FDA, Lab Mol Tumor Biol, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res,NIH, 29 Lincoln Dr,NIH Bldg 29B,Room 2NN10, Bethesda, MD 20892 USA.	puri@cber.fda.gov	Oshima, Yasuo/AGN-3291-2022	Oshima, Yasuo/0000-0002-6236-6986				Akdis M, 1997, J IMMUNOL, V159, P4611; ALTMANN SW, 1995, J BIOL CHEM, V270, P2233, DOI 10.1074/jbc.270.5.2233; Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; COSENTINO G, 1995, J IMMUNOL, V155, P3145; Debinski W, 1998, NAT BIOTECHNOL, V16, P449, DOI 10.1038/nbt0598-449; Debinski W, 1995, CLIN CANCER RES, V1, P1253; Debinski W, 1996, J BIOL CHEM, V271, P22428, DOI 10.1074/jbc.271.37.22428; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Fricker J, 1999, MOL MED TODAY, V5, P463, DOI 10.1016/S1357-4310(99)01586-5; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hage T, 1999, CELL, V97, P271, DOI 10.1016/S0092-8674(00)80736-9; Harding PA, 1996, J BIOL CHEM, V271, P6708, DOI 10.1074/jbc.271.12.6708; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HON FSD, 1994, J EXP MED, V180, P2395; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; Husain SR, 1999, NAT MED, V5, P817, DOI 10.1038/10541; Husain SR, 2000, BLOOD, V95, P3506, DOI 10.1182/blood.V95.11.3506.011k47_3506_3513; Husain SR, 1997, CLIN CANCER RES, V3, P151; Kapp U, 1999, J EXP MED, V189, P1939, DOI 10.1084/jem.189.12.1939; Katagiri K, 1997, CLIN EXP IMMUNOL, V108, P289, DOI 10.1046/j.1365-2249.1997.d01-1015.x; Kawakami K, 2000, HUM GENE THER, V11, P1829, DOI 10.1089/10430340050129459; Kim YS, 1998, J IMMUNOL, V160, P5742; KREITMAN RJ, 1995, CYTOKINE, V7, P311, DOI 10.1006/cyto.1995.0039; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; KRUSE N, 1991, FEBS LETT, V286, P58, DOI 10.1016/0014-5793(91)80939-Z; LELAND P, 1995, ONCOL RES, V7, P227; LEMM JD, 1998, ANNU REV IMMUNOL, V16, P569; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Maini A, 1997, J UROLOGY, V158, P948, DOI 10.1016/S0022-5347(01)64369-6; MARUYAMA K, 1994, J BIOL CHEM, V269, P5976; Matthews DJ, 2000, J IMMUNOL, V164, P1458, DOI 10.4049/jimmunol.164.3.1458; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Murad AM, 1997, CLIN DRUG INVEST, V13, P90, DOI 10.2165/00044011-199713020-00005; Murata T, 1998, INT J MOL MED, V1, P551; Murata T, 1997, INT J CANCER, V70, P230, DOI 10.1002/(SICI)1097-0215(19970117)70:2<230::AID-IJC15>3.0.CO;2-M; Murata T, 1996, J IMMUNOL, V156, P2972; Murata T, 1998, BLOOD, V91, P3884; Muthukumaran G, 1997, J BIOL CHEM, V272, P4993, DOI 10.1074/jbc.272.8.4993; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Obiri NI, 1997, J IMMUNOL, V158, P756; Obiri NI, 1996, CLIN CANCER RES, V2, P1743; OHASHI H, 1994, P NATL ACAD SCI USA, V91, P158, DOI 10.1073/pnas.91.1.158; Oshima Y, 2000, J BIOL CHEM, V275, P14375, DOI 10.1074/jbc.275.19.14375; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776; Pettit DK, 1997, J BIOL CHEM, V272, P2312; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; PURI RK, 1991, CANCER RES, V51, P3011; Puri RK, 1996, BLOOD, V87, P4333, DOI 10.1182/blood.V87.10.4333.bloodjournal87104333; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Skinnider BF, 2001, BLOOD, V97, P250, DOI 10.1182/blood.V97.1.250; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; Wang YH, 1997, P NATL ACAD SCI USA, V94, P1657, DOI 10.1073/pnas.94.5.1657; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; WEIGEL U, 1989, EUR J BIOCHEM, V180, P295, DOI 10.1111/j.1432-1033.1989.tb14647.x; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	66	6	6	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1469	+		10.1096/fj.00-0711fje	http://dx.doi.org/10.1096/fj.00-0711fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387260				2022-12-28	WOS:000173705800007
J	Kim, I; Ryu, YS; Kwak, HJ; Ahn, SY; Oh, JL; Yancopoulos, GD; Gale, NW; Koh, GY				Kim, I; Ryu, YS; Kwak, HJ; Ahn, SY; Oh, JL; Yancopoulos, GD; Gale, NW; Koh, GY			EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin-1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells	FASEB JOURNAL			English	Article						capillary mprphogenesis; p120-RasGAP; ERK1/2; Flk1; Tie2	RECEPTOR TYROSINE KINASE; GROWTH-FACTOR; SPECIFICITY; SURVIVAL; TIE2	Interaction between ephrinB2 and EphB4 in endothelial cells at the arterial-venous capillary interface is critical for proper embryonic capillary morphogenesis. However, the intracellular downstream signaling of ephrinB2-EphB in vascular endothelial cells is unknown. This study examined the effect of ephrinB2-induced activation of EphB kinases on vascular endothelial growth factor (VEGF)- and angiopoietin-1 (Ang1)-induced Ras/mitogen-activated protein kinase (MAPK) signaling cascades in human umbilical vein endothelial cells (HUVECs). Reverse transcriptase-polymer chain reaction results showed that HUVECs expressed three kinds of EphB kinases known to bind to ephrinB2: EphB2, EphB3, and EphB4. EphrinB2 not only increased the phosphorylation of EphB2 and EphB4 in a time-dependent manner but also increased recruitment of p120-Ras-GTPase-activating protein (p120-RasGAP) to EphB2 and EphB4. Accordingly, ephrinB2 inhibited VEGF- and Ang1-induced Ras-MAPK activities, whereas ephrinB2 did not alter VEGF-induced Flk phosphorylation or Ang1-induced Tie2 phosphorylation. Furthermore, ephrinB2 suppressed VEGF- and Ang1-induced proliferation and/or migration, which are mediated mainly through Ras/MAPK signaling cascades. From these results, we propose that ephrinB2-EphB, signaling through Ras/MAPK cascade, may be critical for proper morphogenesis of capillary endothelium through the arrest of endothelial cell proliferation and migration at the arterial-venous interface.	Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Natl Creat Res Initiat Ctr Endothelial Cells, Pohang 790784, South Korea; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Pohang University of Science & Technology (POSTECH); Regeneron	Koh, GY (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Natl Creat Res Initiat Ctr Endothelial Cells, San 31, Pohang 790784, South Korea.	gykoh@postech.ac.kr	Kim, Injune/C-1710-2011; Koh, Gou Young/C-1615-2011	Kim, Injune/0000-0001-9244-815X; 				Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Chae JK, 2000, ARTERIOSCL THROM VAS, V20, P2573, DOI 10.1161/01.ATV.20.12.2573; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Holder N, 1999, DEVELOPMENT, V126, P2033; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Zhang XQ, 2001, BLOOD, V98, P1028, DOI 10.1182/blood.V98.4.1028	22	137	146	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1126	+		10.1096/fj.01-0805fje	http://dx.doi.org/10.1096/fj.01-0805fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039842				2022-12-28	WOS:000175973900004
J	Hafezi, W; Eing, BR; Lorentzen, EU; Thanos, S; Kuhn, JE				Hafezi, W; Eing, BR; Lorentzen, EU; Thanos, S; Kuhn, JE			Reciprocal transmission of herpes simplex virus type 1 (HSV-1) between corneal epithelium and trigeminal neurites in an embryonic chick organ culture	FASEB JOURNAL			English	Article						animal use alternatives; neurons; eye; simplexvirus; coculture	HUMAN FETAL NEURONS; EPIDERMAL-CELLS; ENDOPLASMIC-RETICULUM; ANTEROGRADE TRANSPORT; AXONAL-TRANSPORT; INFECTION; VIRIONS; GROWTH; ENTRY; REENVELOPMENT	Reciprocal transmission between epithelia and sensory neurons of the peripheral nervous system is a crucial step in the life cycle of herpes simplex virus type 1 (HSV-1) and related alphaherpesviruses. In searching for an easy-to-perform and generally applicable experimental approach that enables the direct analysis of virus transfer between primary epithelial cells and sensory neurites, we investigated the spread of HSV-1 in a dual-chamber organ model comprising chick embryonic corneal epithelia and trigeminal sensory neurons. Embryonic chick corneal and trigeminal tissues were found to be permissive for productive infection with HSV-1. Our data show that HSV-1 efficiently enters neurites re-innervating the cornea and reaches the ganglion explant by retrograde axonal transport, with the first antigen-positive cells being detectable 12 h postinfection. After direct infection of trigeminal tissues, the virus is transported by anterograde axonal transport to the corneal epithelium, causing a visible cytopathic effect 48 h postinfection. These results suggest that the organ model presented in this study holds particular promise for the direct observation and molecular analysis of herpes simplex virus spread between primary epithelia and sensory neurons and that it may be an attractive alternative to current experimental approaches based on laboratory animals or human fetal tissues.	Univ Munster, Inst Med Mikrobiol, Abt Klin Virol, D-48151 Munster, Germany; Univ Munster, Klin & Poliklin Augenheilkunde, Abt Expt Ophthalmol, D-48151 Munster, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munster; University of Munster	Kuhn, JE (corresponding author), Univ Munster, Inst Med Mikrobiol, Abt Klin Virol, Von Stauffenberg Str 36, D-48151 Munster, Germany.	kuehnj@uni-muenster.de		Lorentzen, Eva/0000-0002-5570-1897				Anderson K, 1940, AM J PATHOL, V16, P137; Browne H, 1996, J VIROL, V70, P4311, DOI 10.1128/JVI.70.7.4311-4316.1996; Cleator GM, 2000, PRINCIPLES PRACTICE, P23; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; Enquist LW, 1999, ADV VIRUS RES, V51, P237; ERZURUMLU RS, 1993, P NATL ACAD SCI USA, V90, P7235, DOI 10.1073/pnas.90.15.7235; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Holland DJ, 1999, J VIROL, V73, P8503, DOI 10.1128/JVI.73.10.8503-8511.1999; Holland DJ, 1998, J MICROSC-OXFORD, V192, P69, DOI 10.1046/j.1365-2818.1998.00401.x; Immergluck LC, 1998, J GEN VIROL, V79, P549, DOI 10.1099/0022-1317-79-3-549; LOWRY SP, 1971, J GEN VIROL, V10, P1, DOI 10.1099/0022-1317-10-1-1; Miranda-Saksena M, 2000, J VIROL, V74, P1827, DOI 10.1128/JVI.74.4.1827-1839.2000; NAHMIAS AJ, 1983, INFECT DIS, P636; PAVLIDIS C, 1994, INT J DEV NEUROSCI, V12, P587, DOI 10.1016/0736-5748(94)90066-3; PENFOLD MET, 1994, P NATL ACAD SCI USA, V91, P6529, DOI 10.1073/pnas.91.14.6529; Penfold MET, 1996, IN VITRO CELL DEV-AN, V32, P420; RODGERS FG, 1981, BRIT J EXP PATHOL, V62, P317; Roizman B, 1996, FIELDS VIROLOGY, P2231; Skepper JN, 2001, J VIROL, V75, P5697, DOI 10.1128/JVI.75.12.5697-5702.2001; Smith GA, 2001, P NATL ACAD SCI USA, V98, P3466, DOI 10.1073/pnas.061029798; VALYINAGY T, 1991, J VIROL, V65, P4142, DOI 10.1128/JVI.65.8.4142-4152.1991; Whiteley A, 1999, J VIROL, V73, P9515, DOI 10.1128/JVI.73.11.9515-9520.1999; WHITLEY RJ, 1983, PEDIATRICS, V72, P778; Whitley RJ, 1996, FIELDS VIROLOGY, P2297	24	6	6	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					878	+		10.1096/fj.01-0803fje	http://dx.doi.org/10.1096/fj.01-0803fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967226				2022-12-28	WOS:000175425900015
J	Semov, A; Semova, N; Lacelle, C; Marcotte, R; Petroulakis, E; Proestou, G; Wang, E				Semov, A; Semova, N; Lacelle, C; Marcotte, R; Petroulakis, E; Proestou, G; Wang, E			Alterations in TNF- and IL-related gene expression in spaceflown WI38 human fibroblasts	FASEB JOURNAL			English	Article						cDNA microarray; spaceflight; aging; bone density; gene expression profile	PROTEIN-TYROSINE-PHOSPHATASE; NECROSIS-FACTOR-ALPHA; MESSENGER-RNA; CDNA MICROARRAYS; RECEPTOR; CELLS; OSTEOBLASTS; SPHINGOMYELINASE; SAMPLES; CLONING	Spaceflight, just like aging, causes profound changes in musculoskeletal parameters, which result in decreased bone density and muscular weakness. As these conditions decrease our ability to conduct long-term manned space missions, and increase bone frailty in the elderly, the identification of genes responsible for the apparition of these physiological changes will be of great benefit. Thus, we developed and implemented a new microarray approach to investigate the changes in normal WI38 human fibroblast gene expression that arise as a consequence of space flight. Using our microarray, we identified changes in the level of expression of 10 genes, belonging to either the tumor necrosis factor- (TNF) or interleukin- (IL) related gene families in fibroblasts when WI38 cells exposed to microgravity during the STS-93 Space Shuttle mission were compared with ground controls. The genes included two ligands from the TNF superfamily, TWEAK and TNFSF15; two TNF receptor-associated proteins, NSMAF and PTPN13; three TNF-inducible genes, ABC50, PTX3, and SCYA13; TNF-alpha converting enzyme, IL-1 receptor antagonist, and IL-15 receptor alpha chain. Most of these are involved in either the regulation of bone density, and as such the development of spaceflight osteopenia, or in the development of proinflammatory status.	Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada	University of Louisville; Lady Davis Institute; McGill University; McGill University	Wang, E (corresponding author), Univ Louisville, Sch Med, Dept Biochem & Mol Biol, 570 S Preston,Baxter Bldg Room 304, Louisville, KY 40202 USA.	eugenia.wang@louisville.edu						AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Akiyama H, 1996, J BIOTECHNOL, V47, P325, DOI 10.1016/0168-1656(96)01401-0; Alleva DG, 1997, J IMMUNOL, V159, P2941; ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; BACKUP P, 1994, AM J PHYSIOL, V266, pE567, DOI 10.1152/ajpendo.1994.266.4.E567; Bertucci F, 1999, HUM MOL GENET, V8, P1715, DOI 10.1093/hmg/8.9.1715; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Carmeliet G, 2001, CRIT REV EUKAR GENE, V11, P131; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CHAPES SK, 1992, J LEUKOCYTE BIOL, V52, P104, DOI 10.1002/jlb.52.1.104; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Doherty TJ, 2001, CURR OPIN CLIN NUTR, V4, P503, DOI 10.1097/00075197-200111000-00007; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Gerhold D, 1999, TRENDS BIOCHEM SCI, V24, P168, DOI 10.1016/S0968-0004(99)01382-1; Haridas V, 1999, ONCOGENE, V18, P6496, DOI 10.1038/sj.onc.1203059; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Inazawa J, 1996, GENOMICS, V31, P240, DOI 10.1006/geno.1996.0039; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kumei Y, 1998, J APPL PHYSIOL, V85, P139, DOI 10.1152/jappl.1998.85.1.139; Kumei Y, 1996, J BIOTECHNOL, V47, P313, DOI 10.1016/0168-1656(96)01412-5; Landis WJ, 2000, J BONE MINER RES, V15, P1099, DOI 10.1359/jbmr.2000.15.6.1099; Langdahl BL, 2000, J BONE MINER RES, V15, P402, DOI 10.1359/jbmr.2000.15.3.402; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; Lepple-Wienhues A, 1999, P NATL ACAD SCI USA, V96, P13795, DOI 10.1073/pnas.96.24.13795; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0; Martorana AM, 1999, BIOTECHNIQUES, V27, P136, DOI 10.2144/99271rr02; Naruse K, 1996, GENOMICS, V34, P236, DOI 10.1006/geno.1996.0274; Richard M, 1998, GENOMICS, V53, P137, DOI 10.1006/geno.1998.5480; Rittweger J, 1999, J Gravit Physiol, V6, pP133; SARAS J, 1994, J BIOL CHEM, V269, P24082; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schneider P, 1999, EUR J IMMUNOL, V29, P1785, DOI 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U; Semov A, 2002, ANAL BIOCHEM, V302, P38, DOI 10.1006/abio.2001.5515; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Taylor R L, 1993, J Br Interplanet Soc, V46, P97; Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Wang E, 1999, FASEB J, V13, pS167; Wen XL, 1998, P NATL ACAD SCI USA, V95, P334, DOI 10.1073/pnas.95.1.334; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	45	35	38	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					899	+		10.1096/fj.01-1002fje	http://dx.doi.org/10.1096/fj.01-1002fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039873				2022-12-28	WOS:000175425900026
J	Wu, ZLL; Zhang, LJ; Beeler, DL; Kuberan, B; Rosenberg, RD				Wu, ZLL; Zhang, LJ; Beeler, DL; Kuberan, B; Rosenberg, RD			A new strategy for defining critical functional groups on heparan sulfate	FASEB JOURNAL			English	Article						heparin; gel mobility shift assay; in vitro modification; antithrombin III; sulfotransferase	D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; CDNA CLONING; EXPRESSION; BIOSYNTHESIS; MICE; BINDING; GENE	Heparan sulfate (HS) is a sulfated polysaccharide present on cell surfaces and in the extracellular matrix. Accumulating evidence shows that HS plays key roles in many biological systems by interacting with various proteins in a structural-specific manner. Due to technical difficulties, however, the understanding of critical functional groups on HS for protein interaction is vague. We report a rapid, convenient, sensitive, and inexpensive strategy using in vitro modification with pure enzymes and gel mobility shift assay to study the subject. We demonstrated the requirements of 3-O, 6-O sulfates and the minimal length of oligosaccharide for antithrombin III (AT-III) binding. We regenerated the binding sites for AT-III on completely desulfated N-resulfated heparin and revealed the critical modification enzymes. This new strategy could be used to identify critical functional groups on HS and to generate HS library and biologically active HS, providing information applicable to the design of HS drugs, such as anticoagulant reagents and viral infection blockers. The binding assay with fibroblast growth factors and receptors confirmed the general usefulness of this approach.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Rosenberg, RD (corresponding author), MIT, Dept Biol, Bldg 68-480,77 Massachusetts Ave, Cambridge, MA 02139 USA.	rdrrosen@mit.edu						Arikawa-Hirasawa E, 2001, NAT GENET, V27, P431, DOI 10.1038/86941; ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Damus P S, 1976, Methods Enzymol, V45, P653; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; MacRae IJ, 1998, J BIOL CHEM, V273, P28583, DOI 10.1074/jbc.273.44.28583; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PETITOU M, 1988, EUR J BIOCHEM, V176, P637, DOI 10.1111/j.1432-1033.1988.tb14324.x; Reizes O, 2001, CELL, V106, P105, DOI 10.1016/S0092-8674(01)00415-9; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; TURNBULL J, 1999, CELL SURFACE PROTEOG, V6, P13; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; Zhang LJ, 2001, J BIOL CHEM, V276, P28806, DOI 10.1074/jbc.M100204200; Zhang LJ, 2001, J BIOL CHEM, V276, P42311, DOI 10.1074/jbc.M101441200	41	48	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					539	545		10.1096/fj.01-0807com	http://dx.doi.org/10.1096/fj.01-0807com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919156				2022-12-28	WOS:000175425900007
J	De Giorgi, F; Lartigue, L; Bauer, MKA; Schubert, A; Grimm, S; Hanson, GT; Remington, SJ; Youle, RJ; Ichas, F				De Giorgi, F; Lartigue, L; Bauer, MKA; Schubert, A; Grimm, S; Hanson, GT; Remington, SJ; Youle, RJ; Ichas, F			The permeability transition pore signals apoptosis by directing Bax translocation and multimerization	FASEB JOURNAL			English	Article						apoptosis; bax; cytochrome c; FRET; permeability transition pore	CYTOCHROME-C RELEASE; ADENINE-NUCLEOTIDE TRANSLOCATOR; MITOCHONDRIAL INNER MEMBRANE; DEPENDENT ANION CHANNEL; CELL-DEATH; CASPASE ACTIVATION; CA2+; BCL-2; OLIGOMERIZATION; CYCLOPHILIN	Mitochondria are key players of apoptosis and can irreversibly commit the cell to death by releasing cytochrome c (Cyt.c) to the cytosol, where caspases 9 and 3 subsequently get activated. Under conditions of oxidative stress, opening of the mitochondrial permeability transition pore (PTP) represents an early trigger and is crucial in causing Cyt.c release. To account for the latter, current models propose that PTP gating would result, as is the case in vitro, in the rupture of the outer mitochondrial membrane caused by mitochondrial matrix swelling. Using live cell imaging and recombinant fluorescent probes based on the green fluorescent protein (GFP) and its mutants, we report that directed repetitive gating of the PTP triggers a delayed Cyt.c efflux, which is not associated with mitochondrial swelling. Instead, subcellular imaging shows that PTP opening signals the redistribution of the cytosolic protein Bax to the mitochondria, where it secondarily forms clusters that appear to be a prerequisite for Cyt.c release. Fluorescence resonance energy transfer imaging further reveals that Bax clustering coincides with the formation of Bax multimers. We conclude that the PTP is not itself a component of the Cyt.c release machinery, but that it acts indirectly by signaling Bax translocation and multimerization.	Univ Bordeaux 2, European Inst Chem & Biol, INSERM, E9929, F-33076 Bordeaux, France; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Oregon, Dept Chem, Eugene, OR 97403 USA; Univ Oregon, Dept Phys, Eugene, OR 97403 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; NINCDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Max Planck Society; University of Oregon; University of Oregon; University of Oregon; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Ichas, F (corresponding author), Univ Bordeaux 2, European Inst Chem & Biol, INSERM, E9929, F-33076 Bordeaux, France.	ichas@u-bordeaux2.fr	lartigue, lydia/I-9548-2014; Ichas, François/ABD-8277-2020	Ichas, François/0000-0001-8184-5248; De Giorgi, Francesca/0000-0003-4850-3582	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002859, ZIANS002859] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Elsliger MA, 1999, BIOCHEMISTRY-US, V38, P5296, DOI 10.1021/bi9902182; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Evtodienko YV, 1996, FEBS LETT, V393, P86, DOI 10.1016/0014-5793(96)00875-7; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; GUNTER TE, 1990, AM J PHYSIOL, V258, P755; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Johnson N, 1999, EUR J BIOCHEM, V263, P353, DOI 10.1046/j.1432-1327.1999.00490.x; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rolls MM, 1999, J CELL BIOL, V146, P29, DOI 10.1083/jcb.146.1.29; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YU WH, 1995, J BIOL CHEM, V270, P13998, DOI 10.1074/jbc.270.23.13998	37	215	221	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					607	+		10.1096/fj.01-0269fje	http://dx.doi.org/10.1096/fj.01-0269fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919169				2022-12-28	WOS:000174203700007
J	Knox, AJ; Corbett, L; Stocks, J; Holland, E; Zhu, YM; Pang, LH				Knox, AJ; Corbett, L; Stocks, J; Holland, E; Zhu, YM; Pang, LH			Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoid-dependent mechanism	FASEB JOURNAL			English	Article						VEGF; BK; cyclooxygenase; PKC	NECROSIS-FACTOR-ALPHA; ASTHMATIC AIRWAYS; NASAL SECRETIONS; RELEASE; EXPRESSION; CYTOKINE; BETA(2)-AGONISTS; INHIBITION; KALLIKREIN; ICATIBANT	Bronchial vascular remodeling is an important feature of the pathology of chronic asthma, but the responsible mechanisms and main sources of angiogenic factors are unclear. Here we report that human airway smooth muscle cells express vascular endothelial growth factor (VEGF)(121, 165, 189, 206) splice variants and secrete VEGF protein constitutively. VEGF protein secretion was increased by the proinflammatory asthma mediator bradykinin through post-transcriptional mechanisms. Bradykinin-induced VEGF secretion was dependent on the B-2 bradykinin receptor, activation of protein kinase C, and generation of endogenous prostanoids. This is the first report that bradykinin can increase VEGF secretion in any biological system and the first to show that airway smooth muscle cells produce VEGF. Our results suggest a novel role for human airway smooth muscle in contributing to bronchial mucosal angiogenesis in chronic asthma by secretion of VEGF and suggest a wider role for mesenchymal cell products in mediating angiogenesis in inflammatory and allergic diseases.	City Hosp, Div Resp Med, Nottingham NG5 1PB, England	University of Nottingham	Knox, AJ (corresponding author), City Hosp, Div Resp Med, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.	alan.knox@nottingham.ac.uk	Stocks, Joanne/K-4403-2019; Stocks, Joanne/A-3307-2017	Stocks, Joanne/0000-0002-7800-6002; Stocks, Joanne/0000-0002-7800-6002; Knox, Alan/0000-0002-5906-4143				Akbary AM, 1996, IMMUNOPHARMACOLOGY, V33, P238, DOI 10.1016/0162-3109(96)00065-3; Asano K, 1996, AM J PHYSIOL-LUNG C, V271, pL126, DOI 10.1152/ajplung.1996.271.1.L126; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; Berse B, 1999, CLIN EXP IMMUNOL, V115, P176; Boesiger J, 1998, J EXP MED, V188, P1135, DOI 10.1084/jem.188.6.1135; Boussat S, 2000, AM J PHYSIOL-LUNG C, V279, pL371, DOI 10.1152/ajplung.2000.279.2.L371; Carroll NG, 1997, AM J RESP CRIT CARE, V155, P689, DOI 10.1164/ajrccm.155.2.9032214; Charan NB, 1997, EUR RESPIR J, V10, P1173, DOI 10.1183/09031936.97.10051173; CHRISTIANSEN SC, 1987, J CLIN INVEST, V79, P188, DOI 10.1172/JCI112782; Elias JA, 1997, AM J PHYSIOL-LUNG C, V273, pL648, DOI 10.1152/ajplung.1997.273.3.L648; Fehrenbach H, 1999, ANAT REC, V254, P61; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933, DOI 10.1164/ajrccm.159.6.9805039; Griga T, 1999, HEPATO-GASTROENTEROL, V46, P920; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hogg JC, 1999, THORAX, V54, P283, DOI 10.1136/thx.54.4.283; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; John M, 1997, J IMMUNOL, V158, P1841; Johnson S, 1999, AM J PHYSIOL-LUNG C, V277, pL1109, DOI 10.1152/ajplung.1999.277.6.L1109; Johnson SR, 1997, TRENDS PHARMACOL SCI, V18, P288, DOI 10.1016/S0165-6147(97)01092-4; KNOX AJ, 1994, CLIN SCI, V86, P647, DOI 10.1042/cs0860647; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; NARUMIYA S, 1994, ANN NY ACAD SCI, V744, P126, DOI 10.1111/j.1749-6632.1994.tb52729.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOVERAL JP, 1994, AM J PHYSIOL-LUNG C, V267, pL761, DOI 10.1152/ajplung.1994.267.6.L761; Orsida BE, 1999, THORAX, V54, P289, DOI 10.1136/thx.54.4.289; PAEGELOW I, 1995, INFLAMM RES, V44, P306, DOI 10.1007/BF02032574; Pang LH, 1998, J IMMUNOL, V161, P2509; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; Pang LH, 1997, AM J PHYSIOL-LUNG C, V273, pL1132, DOI 10.1152/ajplung.1997.273.6.L1132; Pang LH, 2001, FASEB J, V15, P261, DOI 10.1096/fj.00-0103com; Pang LH, 2000, AM J RESP CELL MOL, V23, P79, DOI 10.1165/ajrcmb.23.1.3985; PANG LH, 2000, AM J RESP CRIT CARE, V161, pA473; PEACOCK DJ, 1992, J EXP MED, V175, P1135, DOI 10.1084/jem.175.4.1135; Peters KG, 1998, CIRC RES, V83, P342, DOI 10.1161/01.RES.83.3.342; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; *SPSS INC, 1996, SPSS BAS WIND US GUI; Turner P, 2001, J ALLERGY CLIN IMMUN, V107, P105, DOI 10.1067/mai.2001.111145; Yoshiji H, 1999, CANCER RES, V59, P4413	42	110	118	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2480	2488		10.1096/fj.01-0256com	http://dx.doi.org/10.1096/fj.01-0256com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689473				2022-12-28	WOS:000172420500018
J	Shi, H; Norman, AW; Okamura, WH; Sen, A; Zemel, MB				Shi, H; Norman, AW; Okamura, WH; Sen, A; Zemel, MB			1 alpha,25-dihydroxyvitamin D-3 modulates human adipocyte metabolism via nongenomic action	FASEB JOURNAL			English	Article						human adipocytes; Ca2+ signaling; lipid metabolism	VITAMIN-D-RECEPTOR; CYTOSOLIC-FREE CALCIUM; D-ENDOCRINE SYSTEM; GENOMIC BIOLOGICAL RESPONSES; INSULIN-RESISTANCE; INTRACELLULAR CALCIUM; MEMBRANE-RECEPTOR; CELLS; AGOUTI; OBESITY	We reported recently that suppression of the renal 1 alpha ,25-dihyroxyvitamin D-3 (1 alpha ,25-(OH)(2)-D-3) production in aP2-agouti transgenic mice by increasing dietary calcium decreases adiposity. However, it was not clear whether this modulation of adipocyte metabolism by dietary calcium is a direct effect of inhibition of 1 alpha ,25-(OH)(2)-D-3-induced [Ca2+]i. Accordingly, we have now evaluated the direct role of 1 alpha ,25-(OH)(2)-D-3. Human adipocytes exhibited a 1 alpha ,25-(OH)(2)-D-3 dose-responsive (1-50 nM) increase in [Ca2+]i (P<0.01). This action was mimicked by 1<alpha>,25-dihydroxyluministerol(3) (1 alpha ,25-(OH)(2)-lumisterol(3)) (P<0.001), a specific agonist for a putative membrane vitamin D receptor (mVDR), and completely prevented by 1<beta>,25-dihydroxyvitamin D-3 (1 beta ,25-(OH)(2)-D-3), a specific antagonist for the mVDR. Similarly, 1 alpha ,25-(OH)(2)-D-3 (5 mM) caused 50%-100% increases in adipocyte fatty acid synthase (FAS) expression and activity (P<0.02), 61% increase in glycerol-3-phosphate dehydrogenase (GPDH) activity (P<0.01), and an 80% inhibition of isoproterenol-stimulated lipolysis (P<0.001), whereas 1<beta>,25-(OH)(2)-D-3 completely blocked all these effects. Notably, 1 alpha ,25-OH)(2)-lumisterol(3) exerted more potent effects in modulating adipocyte lipid metabolism, with 2.5- to 3.0-fold increases in FAS expression and activity (P<0.001) and a threefold increase in GPDH activity (P<0.001). Also 1 alpha ,25-(OH)(2)-lumisterol3 was approximately twice as potent in inhibiting basal lipolysis (P<0.025), whereas 1<beta>,25-(OH)(2)-D-3 completely blocked all these effects. These data suggest that 1 alpha ,25-(OH)(2)-D-3 modulates adipocyte Ca2+ signaling and, consequently, exerts a coordinated control over lipogenesis and lipolysis. Thus, a direct inhibition of 1 alpha ,25-(OH)(2)-D-3-induced [Ca2+](i) may contribute to an anti-obesity effect of dietary calcium, and the mVDR may represent an important target for obesity.	Univ Tennessee, Knoxville, TN 37996 USA; Univ Calif Riverside, Riverside, CA 92521 USA; Zen Bio, Res Triangle Pk, NC USA	University of Tennessee System; University of Tennessee Knoxville; University of California System; University of California Riverside	Zemel, MB (corresponding author), Univ Tennessee, 1215 W Cumberland Ave 229, Knoxville, TN 37996 USA.	mzemel@utk.edu		Zemel, Michael/0000-0003-4104-5750				Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982; ANDERSEN T, 1988, METABOLISM, V37, P425, DOI 10.1016/0026-0495(88)90041-8; BARAN DT, 1991, J BONE MINER RES, V6, P1269; Baran DT, 2000, J CELL BIOCHEM, V78, P34, DOI 10.1002/(SICI)1097-4644(20000701)78:1<34::AID-JCB4>3.3.CO;2-Q; BELL NH, 1988, J BONE MINER RES, V3, P489; BELL NH, 1985, J CLIN INVEST, V76, P370, DOI 10.1172/JCI111971; BOOBIS LH, 1983, CLIN CHIM ACTA, V132, P173, DOI 10.1016/0009-8981(83)90245-0; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; BYYNY RL, 1992, AM J HYPERTENS, V5, P459, DOI 10.1093/ajh/5.7.459; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; Davies KM, 2000, J CLIN ENDOCR METAB, V85, P4635, DOI 10.1210/jc.85.12.4635; DeLuca HF, 1998, NUTR REV, V56, pS4; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; DUSSO AS, 1991, ENDOCRINOLOGY, V128, P1687, DOI 10.1210/endo-128-4-1687; EPSTEIN S, 1986, J BONE MINER RES, V1, P181; Fleet JC, 1999, NUTR REV, V57, P60, DOI 10.1111/j.1753-4887.1999.tb01779.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Jones BH, 1996, AM J PHYSIOL-ENDOC M, V270, pE192, DOI 10.1152/ajpendo.1996.270.1.E192; Kajikawa M, 1999, ENDOCRINOLOGY, V140, P4706, DOI 10.1210/en.140.10.4706; Kim JH, 1997, AM J PHYSIOL-ENDOC M, V272, pE379, DOI 10.1152/ajpendo.1997.272.3.E379; Kim JH, 1996, FASEB J, V10, P1646, DOI 10.1096/fasebj.10.14.9002558; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; LI YC, 1998, BONE, V23, pS263; Nemere I, 1998, J BONE MINER RES, V13, P1353, DOI 10.1359/jbmr.1998.13.9.1353; NEMERE I, 1994, J BIOL CHEM, V269, P23750; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; Norman AW, 1997, MOL ENDOCRINOL, V11, P1518, DOI 10.1210/me.11.10.1518; Norman AW, 1998, J BONE MINER RES, V13, P1360, DOI 10.1359/jbmr.1998.13.9.1360; NORMAN AW, 1992, BIOCHEM BIOPH RES CO, V189, P1450, DOI 10.1016/0006-291X(92)90237-F; Resnick L, 1999, PROG CARDIOVASC DIS, V42, P1, DOI 10.1016/S0033-0620(99)70006-X; Sanchez M, 1997, HYPERTENSION, V29, P531, DOI 10.1161/01.HYP.29.1.531; SHAN J, 1993, AM J HYPERTENS, V6, P983, DOI 10.1093/ajh/6.12.983; Shi H, 2000, PHYSIOL GENOMICS, V3, P75, DOI 10.1152/physiolgenomics.2000.3.2.75; Shi H, 1999, FASEB J, V13, P1833, DOI 10.1096/fasebj.13.13.1833; SHI H, 2000, FASEB J         1208; TORNQUIST K, 1989, ENDOCRINOLOGY, V124, P2765, DOI 10.1210/endo-124-6-2765; XUE B, 2001, FASEB J         0917; Xue BZ, 1998, FASEB J, V12, P1391, DOI 10.1096/fasebj.12.13.1391; Xue BZ, 2000, J NUTR, V130, P2478, DOI 10.1093/jn/130.10.2478; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733; Zemel MB, 2000, FASEB J, V14, P1132, DOI 10.1096/fasebj.14.9.1132	43	181	210	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2751	+		10.1096/fj.01-0584fje	http://dx.doi.org/10.1096/fj.01-0584fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606486				2022-12-28	WOS:000171920400007
J	Yen, CLE; Mar, MH; Meeker, RB; Fernandes, A; Zeisel, SH				Yen, CLE; Mar, MH; Meeker, RB; Fernandes, A; Zeisel, SH			Choline deficiency induces apoptosis in primary cultures of fetal neurons	FASEB JOURNAL			English	Article						primary neurons; hippocampus; PC12 cells	LONG-TERM POTENTIATION; RAT HEPATOCYTES; PHOSPHATIDYLCHOLINE SYNTHESIS; LIQUID-CHROMATOGRAPHY; HIPPOCAMPAL-NEURONS; SPATIAL MEMORY; CERAMIDE; SUPPLEMENTATION; AVAILABILITY; ALTERS	Treatment of rats with choline during brain development results in long-lasting enhancement of spatial memory whereas choline deficiency has the opposite effect. Changes in rates of apoptosis may be responsible. We previously demonstrated that choline deficiency induced apoptosis in PC12 cells and suggested that interruption of cell cycling due to a decrease in membrane phosphatidylcholine concentration was the critical mechanism. We now examine whether choline deprivation induces apoptosis in nondividing primary neuronal cultures of fetal rat cortex and hippocampus. Choline deficiency induced widespread apoptosis in primary neuronal cells, indicating that cells do not have to be dividing to be sensitive to choline deficiency. When switched to a choline-deficient medium, both types of cells became depleted of choline, phosphocholine and phosphatidylcholine, and in primary neurons neurite outgrowth was dramatically attenuated. Primary cells could be rescued from apoptosis by treatment with phosphocholine or lysophosphatidylcholine. As described previously for PC12 cells, an increase in ceramide (Cer) was associated with choline deficiency-induced apoptosis in primary neurons. The primary neuronal culture appears to be an excellent model to explore the mechanism whereby maternal dietary choline intake modulates apoptosis in the fetal brain.	Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Neurol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zeisel, SH (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, CB 7400,Room 2213,McGavran Greenberg Hall, Chapel Hill, NC 27599 USA.	steven_zeisel@unc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [AG09525] Funding Source: Medline; NIDDK NIH HHS [DK56350] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 1996, FASEB J, V10, P510, DOI 10.1096/fasebj.10.4.8647350; Albright CD, 1998, J NUTR BIOCHEM, V9, P476, DOI 10.1016/S0955-2863(98)00047-3; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; Brann AB, 1999, J NEUROSCI, V19, P8199; Cermak JM, 1999, DEV NEUROSCI-BASEL, V21, P94, DOI 10.1159/000017371; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; deChaves EIP, 1997, J BIOL CHEM, V272, P3028, DOI 10.1074/jbc.272.5.3028; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FURUYA S, 1995, J NEUROCHEM, V65, P1551; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Holler T, 1996, FASEB J, V10, P1653, DOI 10.1096/fasebj.10.14.9002559; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; *I MED FOOD NUTR B, 1998, DIET REF INT FOL OTH; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Jones JP, 1999, DEV BRAIN RES, V118, P159, DOI 10.1016/S0165-3806(99)00103-0; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lehtonen JYA, 1999, J BIOL CHEM, V274, P16901, DOI 10.1074/jbc.274.24.16901; LOY R, 1991, ADV EXP MED BIOL, V295, P373; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3053, DOI 10.1097/00001756-199709290-00010; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1997, NEUROREPORT, V8, P2831, DOI 10.1097/00001756-199709080-00005; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; Mitoma J, 1998, J NEUROSCI RES, V51, P712, DOI 10.1002/(SICI)1097-4547(19980315)51:6<712::AID-JNR5>3.3.CO;2-Q; NEWBERNE PM, 1986, ANNU REV NUTR, V6, P407, DOI 10.1146/annurev.nu.06.070186.002203; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; POMFRET EA, 1989, ANAL BIOCHEM, V180, P85, DOI 10.1016/0003-2697(89)90091-2; Previati M, 1996, ANAL BIOCHEM, V233, P108, DOI 10.1006/abio.1996.0014; Pyapali GK, 1998, J NEUROPHYSIOL, V79, P1790, DOI 10.1152/jn.1998.79.4.1790; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shin OH, 1997, J CELL BIOCHEM, V64, P196, DOI 10.1002/(SICI)1097-4644(199702)64:2<196::AID-JCB3>3.0.CO;2-S; Taniwaki T, 1999, NEUROCHEM RES, V24, P685, DOI 10.1023/A:1021008626887; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135	42	53	55	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					1704	1710		10.1096/fj.00-0800com	http://dx.doi.org/10.1096/fj.00-0800com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481217	Green Submitted			2022-12-28	WOS:000170809900005
J	Alexakis, C; Guettoufi, A; Mestries, P; Strup, C; Mathe, D; Barbaud, C; Barritault, D; Caruelle, JP; Kern, P				Alexakis, C; Guettoufi, A; Mestries, P; Strup, C; Mathe, D; Barbaud, C; Barritault, D; Caruelle, JP; Kern, P			Heparan mimetic regulates collagen expression and TGF-beta 1 distribution in gamma-irradiated human intestinal smooth muscle cells	FASEB JOURNAL			English	Article						gamma radiation; intestinal fibrosis; collagen; transforming growth factor beta 1	GROWTH-FACTOR BETA-1; CHRONIC RADIATION ENTEROPATHY; CHEMICALLY-MODIFIED DEXTRANS; TRANSFORMING GROWTH-FACTOR-BETA-1; V COLLAGEN; INDUCED FIBROSIS; CROHNS-DISEASE; THERAPY; FIBROBLASTS; PHENOTYPE	Radiation-induced intestinal fibrosis is characterized by collagen accumulation, a process in which TGF-beta1 plays a key role. We analyzed the effects of gamma radiation on collagen expression and TGF-beta1 distribution in human intestinal smooth muscle cells (HISM). We investigated the activity of a carboxymethylated and sulfated dextran (RG-1503), exhibiting antifibrotic properties and promoting in vivo intestinal tissue repair, on irradiated HISM. After Co-60 irradiation (10 Gy), HISM were labeled with [H-3] proline (+/-RG-1503). Radiolabeled collagen I, III, and V were quantified by SDS-PAGE. TGF-beta1 was quantified by ELISA in culture medium, pericellular and intracellular compartments. Irradiation induced a specific 2.85-fold increase in collagen III production by HISM. Collagen V decreased by 80% 72 h after irradiation. Pericellular TGF-beta1 was increased (up to two-fold) in irradiated HISM. RG-1503 added before or after irradiation reversed both mRNA and protein levels of collagen III and V to control values. RG-1503 decreased the amount of TGF-beta1 in the cell layer below the control values. Irradiation of HISM induced the development of a fibrotic phenotype in terms of collagen production and TGF-beta1 distribution. The antifibrotic RG-1503 restored HISM physiological characteristics and may represent a promising therapeutic approach for radiation-induced intestinal fibrosis.	Univ Paris 12, Fac Sci Creteil, CRRET CNRS UPRESA 7053, F-94010 Creteil, France; Inst Protect & Surete Nucl, Dept Protect Sante Homme & Dosimetrie, Sect Autonome Radiobiol Appl Med, F-92265 Fontenay Aux Roses, France	Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Barritault, D (corresponding author), Univ Paris 12, Fac Sci Creteil, CRRET CNRS UPRESA 7053, Ave Gen de Gaulle, F-94010 Creteil, France.	Barritault@univ-paris12.fr						Aamiri A, 1995, NEUROSCI LETT, V201, P243, DOI 10.1016/0304-3940(95)12182-X; ADAMS MD, 1995, NATURE, V377, P3; ASSELOTCHAPEL C, 1995, BIOCHEM PHARMACOL, V49, P653, DOI 10.1016/0006-2952(94)00462-U; Becker JM, 1999, GASTROENTEROL CLIN N, V28, P371, DOI 10.1016/S0889-8553(05)70061-3; BENAZZOUG Y, 1995, BIOCHEM PHARMACOL, V49, P847, DOI 10.1016/0006-2952(94)00455-U; Benazzoug Y, 1998, EXP GERONTOL, V33, P445, DOI 10.1016/S0531-5565(98)00015-1; BIRK DE, 1990, J CELL SCI, V95, P649; Blanquaert F, 1999, J BIOMED MATER RES, V44, P63, DOI 10.1002/(SICI)1097-4636(199901)44:1<63::AID-JBM7>3.0.CO;2-S; Burger A, 1998, INT J RADIAT BIOL, V73, P401, DOI 10.1080/095530098142239; Ceol M, 2000, J AM SOC NEPHROL, V11, P2324, DOI 10.1681/ASN.V11122324; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CHU ML, 1985, J BIOL CHEM, V260, P4357; COIA LR, 1995, INT J RADIAT ONCOL, V31, P1213, DOI 10.1016/0360-3016(94)00419-L; DECROMBRUGGHE B, 1990, ANN NY ACAD SCI, V580, P88, DOI 10.1111/j.1749-6632.1990.tb17921.x; Ehrhart EJ, 1997, FASEB J, V11, P991, DOI 10.1096/fasebj.11.12.9337152; EIFEL PJ, 1995, INT J RADIAT ONCOL, V32, P1289, DOI 10.1016/0360-3016(95)00118-I; ELNABOUT R, 1989, MATRIX, V9, P411, DOI 10.1016/S0934-8832(89)80047-2; FOLLOWILL DS, 1995, RADIAT RES, V144, P318, DOI 10.2307/3578952; GRAHAM MF, 1984, P SOC EXP BIOL MED, V176, P503; GRAHAM MF, 1990, GASTROENTEROLOGY, V99, P447, DOI 10.1016/0016-5085(90)91028-5; Hauer-Jensen M, 1998, RADIAT RES, V150, P673, DOI 10.2307/3579890; Herskind C, 1998, STRAHLENTHER ONKOL, V174, P12; Lafont J, 1998, GROWTH FACTORS, V16, P23, DOI 10.3109/08977199809017489; LANDBERG CW, 1994, RADIOTHER ONCOL, V32, P29; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; Ledoux D, 2000, J BIOL CHEM, V275, P29383, DOI 10.1074/jbc.M000837200; Logeart D, 1996, J BIOMED MATER RES, V30, P501, DOI 10.1002/(SICI)1097-4636(199604)30:4<501::AID-JBM8>3.0.CO;2-T; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; MAJACK RA, 1985, J CELL BIOL, V100, P613, DOI 10.1083/jcb.100.2.613; MARTIN N, 1997, HDB ORGANIC CONDUCTI, V1, P1; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; MCCAFFREY TA, 1994, J CELL PHYSIOL, V159, P51, DOI 10.1002/jcp.1041590108; Meddahi A, 1996, J BIOMED MATER RES, V31, P293, DOI 10.1002/(SICI)1097-4636(199607)31:3<293::AID-JBM1>3.0.CO;2-H; MEDDAHI A, 1994, PATHOL RES PRACT, V190, P923; Mestries P, 1998, J BIOMED MATER RES, V42, P286, DOI 10.1002/(SICI)1097-4636(199811)42:2<286::AID-JBM14>3.3.CO;2-F; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; Parekh TV, 1998, CELL GROWTH DIFFER, V9, P423; Pucilowska JB, 2000, AM J PHYSIOL-GASTR L, V279, pG653; RANDALL K, 1995, INT J RADIAT BIOL, V68, P301, DOI 10.1080/09553009514551231; REMY J, 1991, RADIAT RES, V125, P14, DOI 10.2307/3577976; Richter KK, 1997, INT J RADIAT ONCOL, V39, P187, DOI 10.1016/S0360-3016(97)00290-3; Rodemann HP, 1996, KIDNEY INT, V49, pS32; SCHMIDT A, 1995, EUR J CELL BIOL, V67, P130; STALLMACH A, 1992, GASTROENTEROLOGY, V102, P1920, DOI 10.1016/0016-5085(92)90314-O; Wang JR, 1998, AM J PATHOL, V153, P1531, DOI 10.1016/S0002-9440(10)65741-0; YEOH E, 1993, INT J RADIAT ONCOL, V26, P229, DOI 10.1016/0360-3016(93)90202-7	47	21	23	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					1546	1554		10.1096/fj.00-0756com	http://dx.doi.org/10.1096/fj.00-0756com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427486				2022-12-28	WOS:000170318500006
J	Peumans, WJ; Hao, Q; Van Damme, EJM				Peumans, WJ; Hao, Q; Van Damme, EJM			Ribosome-inactivating proteins from plants: more than RNA N-glycosidases?	FASEB JOURNAL			English	Review						antiviral activity; DNA glycosylase/AP lyase; polynucleotide : adenosine glycosidase	POKEWEED ANTIVIRAL PROTEIN; POLYNUCLEOTIDE-ADENOSINE GLYCOSIDASE; RICIN-A-CHAIN; SINGLE-STRANDED-DNA; VIRUS-RESISTANCE; ANTI-HIV; DEOXYRIBONUCLEASE ACTIVITY; RIBONUCLEASE-ACTIVITY; EUKARYOTIC RIBOSOMES; ALPHA-MOMORCHARIN	Many plants contain proteins that are capable of inactivating ribosomes and accordingly are called ribosome-inactivating proteins or RIPs. These typical plant proteins receive a lot of attention in biological and biomedical research because of their unique biological activities toward animal and human cells. In addition, evidence is accumulating that some RIPs play a role in plant defense and hence can be exploited in plant protection. To understand the mode of action of RIPs and to optimize their medical and therapeutical applications and their use as antiviral compounds in plant protection, intensive efforts have been made to unravel the enzymatic activities of RIPs and provide a structural basis for these activities. Though marked progress has been made during the last decade, the enzymatic activity of RIPs has become a controversial issue because of the concept that RIPs possess, in addition to their classical RNA N-glycosidase and polynucleotide: adenosine glycosidase activity, other unrelated enzymatic activities. Moreover, the presumed novel enzymatic activities, especially those related to diverse nuclease activities, are believed to play an important role in various biological activities of RIPs. However, both the novel enzymatic activities and their presumed involvement in the biological activities of RIPs have been questioned because there is evidence that the activities observed are due to contaminating enzymes. We offer a critical review of the pros and cons of the putative novel enzymatic activities of RIPs. Based on the available data, it is suggested that there is little conclusive evidence in support of the presumed activities and that in the past too little attention has been given to the purity of the RIP preparation. The antiviral activity and mode of action of RIPs in plants are discussed in view of their classical and presumed novel enzymatic activities.	Katholieke Univ Leuven, Lab Phytopathol & Plant Protect, B-3001 Louvain, Belgium	KU Leuven	Van Damme, EJM (corresponding author), Katholieke Univ Leuven, Lab Phytopathol & Plant Protect, Willem de Croylaan 42, B-3001 Louvain, Belgium.	Els.VanDamme@agr.kuleuven.ac.be	Van Damme, Els/U-3904-2019; Jansen, Heiko T./A-5770-2008; Van Damme, Els J/B-4410-2015	Van Damme, Els/0000-0001-9848-766X; Jansen, Heiko T./0000-0003-0178-396X; 				Barbieri L, 2000, BBA-PROTEIN STRUCT M, V1480, P258, DOI 10.1016/S0167-4838(00)00077-7; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; Barbieri L, 1996, BIOCHEM J, V319, P507, DOI 10.1042/bj3190507; BARBIERI L, 1994, NATURE, V372, P624, DOI 10.1038/372624a0; BARBIERI L, 1992, BIOCHEM J, V286, P1; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Barbieri L, 2000, J BIOCHEM-TOKYO, V128, P883, DOI 10.1093/oxfordjournals.jbchem.a022827; Battelli MG, 1997, ARCH TOXICOL, V71, P360, DOI 10.1007/s002040050399; Brigotti M, 1999, RNA, V5, P1357, DOI 10.1017/S135583829999060X; Brigotti M, 1998, FEBS LETT, V431, P259, DOI 10.1016/S0014-5793(98)00769-8; Brigotti M, 1996, BIOCHEM MOL BIOL INT, V40, P181; BRIGOTTI M, 1995, BIOCHEM J, V310, P249, DOI 10.1042/bj3100249; CARNICELLI D, 1992, BIOCHEM BIOPH RES CO, V182, P579, DOI 10.1016/0006-291X(92)91771-H; Chaddock JA, 1996, EUR J BIOCHEM, V235, P159, DOI 10.1111/j.1432-1033.1996.00159.x; Chen H., 1996, CHINESE BIOCH J, V12, P125; DALLAL JA, 1978, FEBS LETT, V89, P257, DOI 10.1016/0014-5793(78)80230-0; Day PJ, 1998, EUR J BIOCHEM, V258, P540, DOI 10.1046/j.1432-1327.1998.2580540.x; DUGGAR B. M., 1925, Ann. Mo. Bot. Gdn., V12, P359, DOI 10.2307/2394061; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1987, J BIOL CHEM, V262, P5908; ENDO Y, 1991, J MOL BIOL, V254, P848; FRANKEL J, 1996, INT J FINANC ECON, V1, P1; GIRBES T, 1993, J BACTERIOL, V175, P6721, DOI 10.1128/jb.175.20.6721-6724.1993; HABUKA N, 1991, J MOL BIOL, V221, P737, DOI 10.1016/0022-2836(91)80168-T; Hartley MR, 1996, TRENDS PLANT SCI, V1, P254, DOI 10.1016/1360-1385(96)10030-3; Helmy M, 1999, BIOCHEM BIOPH RES CO, V258, P252, DOI 10.1006/bbrc.1999.0618; Hesselberth JR, 2000, J BIOL CHEM, V275, P4937, DOI 10.1074/jbc.275.7.4937; Hirao I, 2000, J BIOL CHEM, V275, P4943, DOI 10.1074/jbc.275.7.4943; Huang PL, 1999, BIOCHEM BIOPH RES CO, V262, P615, DOI 10.1006/bbrc.1999.1213; Hudak KA, 2000, RNA, V6, P369, DOI 10.1017/S1355838200991337; Hudak KA, 1999, J BIOL CHEM, V274, P3859, DOI 10.1074/jbc.274.6.3859; KUMAR MA, 1993, J BIOL CHEM, V268, P25176; Lam YH, 1996, PLANT SCI, V114, P111, DOI 10.1016/0168-9452(95)04310-1; LAW LK, 1983, J REPROD FERTIL, V69, P597; LEEHUANG S, 1994, P NATL ACAD SCI USA, V91, P12208, DOI 10.1073/pnas.91.25.12208; LEEHUANG S, 1995, P NATL ACAD SCI USA, V92, P8818, DOI 10.1073/pnas.92.19.8818; LI MX, 1991, NUCLEIC ACIDS RES, V19, P6309, DOI 10.1093/nar/19.22.6309; Li XD, 1996, BIOL CHEM, V377, P825, DOI 10.1515/bchm3.1996.377.12.825; LIN JY, 1970, NATURE, V227, P292, DOI 10.1038/227292a0; LING J, 1995, BIOL CHEM H-S, V376, P637, DOI 10.1515/bchm3.1995.376.11.637; LING J, 1994, FEBS LETT, V345, P143, DOI 10.1016/0014-5793(94)00421-8; LODGE JK, 1993, P NATL ACAD SCI USA, V90, P7089, DOI 10.1073/pnas.90.15.7089; MCGRATH MS, 1989, P NATL ACAD SCI USA, V86, P2844, DOI 10.1073/pnas.86.8.2844; Mehta AD, 1998, LOOK BEYOND TRANSCRIPTION, P145; Mock JWY, 1996, LIFE SCI, V59, P1853, DOI 10.1016/S0024-3205(96)00532-2; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; Moon YH, 1997, MOL CELLS, V7, P807; Nicolas E, 2000, J BIOL CHEM, V275, P31399, DOI 10.1074/jbc.M004505200; Nicolas E, 1997, FEBS LETT, V406, P162, DOI 10.1016/S0014-5793(97)00267-6; Nicolas E, 1998, J BIOL CHEM, V273, P17216, DOI 10.1074/jbc.273.27.17216; Nicolas E, 1997, BIOCHEM J, V327, P413, DOI 10.1042/bj3270413; Pallanca A, 1998, BBA-PROTEIN STRUCT M, V1384, P277, DOI 10.1016/S0167-4838(98)00019-3; PRESTLE J, 1992, NUCLEIC ACIDS RES, V20, P3179, DOI 10.1093/nar/20.12.3179; Putnam CD, 2000, NAT STRUCT BIOL, V7, P17, DOI 10.1038/71211; Rajamohan F, 1999, BIOCHEM BIOPH RES CO, V263, P419, DOI 10.1006/bbrc.1999.1335; REINBOTHE S, 1994, P NATL ACAD SCI USA, V91, P7012, DOI 10.1073/pnas.91.15.7012; Roncuzzi L, 1996, FEBS LETT, V392, P16, DOI 10.1016/0014-5793(96)00776-4; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; Shih NR, 1997, PLANT SCI, V130, P145, DOI 10.1016/S0168-9452(97)00229-X; Smirnov S, 1997, PLANT PHYSIOL, V114, P1113, DOI 10.1104/pp.114.3.1113; SPERTI S, 1975, BIOCHEM J, V148, P447, DOI 10.1042/bj1480447; SPERTI S, 1991, BIOCHEM J, V277, P281, DOI 10.1042/bj2770281; Steeves RM, 1999, BIOCHEMISTRY-US, V38, P11677, DOI 10.1021/bi990493o; Stillmark H., 1888, UEBER RICIN; TAYLOR BE, 1990, FEBS LETT, V273, P144, DOI 10.1016/0014-5793(90)81070-5; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; Valbonesi P, 1999, LIFE SCI, V65, P1485, DOI 10.1016/S0024-3205(99)00389-6; Van Damme EJM, 1998, CRIT REV PLANT SCI, V17, P575, DOI 10.1016/S0735-2689(98)00365-7; VATER CA, 1995, J BIOL CHEM, V270, P12933, DOI 10.1074/jbc.270.21.12933; Wang P, 1999, NUCLEIC ACIDS RES, V27, P1900, DOI 10.1093/nar/27.8.1900; Wang PG, 2000, ADV VIRUS RES, V55, P325, DOI 10.1016/S0065-3527(00)55007-6; Wang PG, 1998, PLANT MOL BIOL, V38, P957, DOI 10.1023/A:1006084925016; Wang YX, 1999, CELL, V99, P433, DOI 10.1016/S0092-8674(00)81529-9; Yan XJ, 1997, J MOL BIOL, V266, P1043, DOI 10.1006/jmbi.1996.0865; YEUNG HW, 1988, INT J PEPT PROT RES, V31, P265; ZAMBONI M, 1989, BIOCHEM J, V259, P639, DOI 10.1042/bj2590639; ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0; Zoubenko O, 2000, PLANT MOL BIOL, V44, P219, DOI 10.1023/A:1006443626864; Zoubenko O, 1997, NAT BIOTECHNOL, V15, P992, DOI 10.1038/nbt1097-992	79	239	266	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2001	15	9					1493	1506		10.1096/fj.00-0751rev	http://dx.doi.org/10.1096/fj.00-0751rev			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427481				2022-12-28	WOS:000170318500001
J	Hess, DA; O'Leary, EF; Lee, JT; Almawi, WY; Madrenas, J; Rieder, MJ				Hess, DA; O'Leary, EF; Lee, JT; Almawi, WY; Madrenas, J; Rieder, MJ			Inhibition of cytokine production and interference in IL-2 receptor-mediated Jak-Stat signaling by the hydroxylamine metabolite of sulfamethoxazole	FASEB JOURNAL			English	Article						sulfonamides; reactive metabolites; Janus kinases; adverse drug reactions; immune suppression	ADVERSE DRUG-REACTIONS; SULFONAMIDE HYPERSENSITIVITY REACTIONS; CALCINEURIN PHOSPHATASE-ACTIVITY; T-CELL SUBSETS; CYCLOSPORINE-A; GAMMA-CHAIN; BETA-CHAIN; INTERLEUKIN-2 RECEPTOR; TRIMETHOPRIM-SULFAMETHOXAZOLE; TYROSINE PHOSPHORYLATION	Sulfonamides, used for the treatment of opportunistic infections in immunocompromised patients, are associated with a high incidence of adverse drug events, including severe hypersensitivity reactions. Imbalances in the production and detoxification of reactive sulfonamide metabolites have been implicated in the pathogenesis of these life-threatening reactions. The hydroxylamine metabolite of sulfamethoxazole (SMX-HA) inhibits the proliferation of mitogen-stimulated peripheral blood mononuclear cells (PBMCs) in vitro without reducing Interleukin 2 (IL-2) expression. We investigated the effects of SMX-HA on accessory cytokine expression and IL-2 receptor (IL-2R) mediated signal transduction. SMX-HA did not reduce significantly mRNA production of proinflammatory [tumor necrosis factor alpha (TNF-alpha) and IL-1 beta], Th1-type (IFN-gamma), Th2-type cytokines (IL-4 and IL-10). Sublethal concentrations of SMX-HA (25 muM) reduced significantly the production of TNF-alpha, IL-1 beta, and IL4 protein without inhibiting the production of IFN-gamma. This finding suggests that exposure to SMX-HA might direct a response towards a Th-1 vs. a Th-2 response. Immunoblot analysis of IL-2R-mediated Janus kinases and signal transduction activators of transcription (Jak-Stat) signal transduction revealed diminished phosphorylation of Jak1 and Jak3 and inhibited downstream phosphorylation of Stat3, Stat5a, and IL-2R gamma in phytohemagglutinin/rIL-2 activated PBMCs treated with SMX-HA. SMX-HA did not inhibit Jak association with IL-2R gamma or IL-2R beta. These data illustrated that sublethal concentrations of SMX-HA interfere with IL-2R-mediated signal transduction, resulting in altered cytokine production and inhibition of lymphocyte proliferation.	Univ Western Ontario, Childrens Hosp Western Ontario, Dept Paediat,Gene Therapy & mol Virol Grp, John P Robarts Res Inst, London, ON N6J 1Y5, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6J 1Y5, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6J 1Y5, Canada; Arabian Gulf Univ, Dept Biochem Med, Manama, Bahrain	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Arabian Gulf University	Rieder, MJ (corresponding author), Univ Western Ontario, Childrens Hosp Western Ontario, Dept Paediat,Gene Therapy & mol Virol Grp, John P Robarts Res Inst, 800 Commissioners Rd E, London, ON N6J 1Y5, Canada.	mrieder@julian.uwo.ca	Almawi, Wassim/FGW-0821-2022; Hess, David A/M-2828-2013; Madrenas, Quim/P-5008-2019; Rieder, Michael J/L-2397-2013					Almawi WY, 1996, J LEUKOCYTE BIOL, V60, P563, DOI 10.1002/jlb.60.5.563; BIERER BE, 1993, CURR OPIN IMMUNOL, V5, P763, DOI 10.1016/0952-7915(93)90135-F; BIERER BE, 1995, P ASSOC AM PHYSICIAN, V107, P28; BIERER BE, 1991, TRANSPLANT P, V23, P2850; BLUMBERG DD, 1987, METHOD ENZYMOL, V152, P20; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CARR A, 1993, CLIN EXP IMMUNOL, V94, P21; CARR A, 1993, J INFECT DIS, V167, P180, DOI 10.1093/infdis/167.1.180; CARR A, 1994, AIDS, V8, P333, DOI 10.1097/00002030-199403000-00006; CARR A, 1993, J ACQ IMMUN DEF SYND, V6, pS56; Chau LA, 1998, J EXP MED, V187, P1699, DOI 10.1084/jem.187.10.1699; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRIBB AE, 1991, DRUG METAB DISPOS, V19, P900; CRIBB AE, 1995, DRUG METAB DISPOS, V23, P406; CRIBB AE, 1992, CLIN PHARMACOL THER, V51, P522, DOI 10.1038/clpt.1992.57; CRIBB AE, 1990, DRUG METAB DISPOS, V18, P784; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FONG TAT, 1989, J IMMUNOL, V143, P2887; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; Gesbert F, 1998, J CLIN IMMUNOL, V18, P307, DOI 10.1023/A:1023223614407; Gill HJ, 1997, J PHARMACOL EXP THER, V282, P795; GIRI JG, 1995, J LEUKOCYTE BIOL, V57, P763, DOI 10.1002/jlb.57.5.763; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; Gomez J, 1998, CRIT REV IMMUNOL, V18, P185, DOI 10.1615/CritRevImmunol.v18.i3.20; GREENBERGER PA, 1987, J ALLERGY CLIN IMMUN, V79, P484, DOI 10.1016/0091-6749(87)90366-6; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; Hess DA, 1997, ANN PHARMACOTHER, V31, P1378, DOI 10.1177/106002809703101116; Hess DA, 1999, FASEB J, V13, P1688, DOI 10.1096/fasebj.13.13.1688; Hess DA, 1997, J PHARMACOL EXP THER, V281, P540; ISHII N, 1994, INT IMMUNOL, V6, P1273, DOI 10.1093/intimm/6.8.1273; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KIRKEN RA, 1995, CYTOKINE, V7, P689, DOI 10.1006/cyto.1995.0081; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; Liu KD, 1997, CURR BIOL, V7, P817, DOI 10.1016/S0960-9822(06)00369-1; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MALABARBA MG, 1995, J BIOL CHEM, V270, P9630, DOI 10.1074/jbc.270.16.9630; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MEEKINS CV, 1994, J ALLERGY CLIN IMMUN, V94, P1017, DOI 10.1016/0091-6749(94)90120-1; MOSMANN TR, 1991, CURR OPIN IMMUNOL, V3, P311, DOI 10.1016/0952-7915(91)90029-Z; MOSMANN TR, 1994, ADV IMMUNOL, V56, P1, DOI 10.1016/S0065-2776(08)60449-6; Mosmann TR, 1995, CIBA F SYMP, V195, P42; MOSMANN TR, 1991, IMMUNOL RES, V10, P183, DOI 10.1007/BF02919690; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1992, ANN NY ACAD SCI, V664, P89, DOI 10.1111/j.1749-6632.1992.tb39751.x; Nakamura M, 1993, Semin Immunol, V5, P309, DOI 10.1006/smim.1993.1037; NAYLOR MS, 1995, CYTOKINES PRACTICAL, P35; PAI SY, 1994, BLOOD, V84, P3974, DOI 10.1182/blood.V84.11.3974.bloodjournal84113974; Pirmohamed M, 1998, BRIT MED J, V316, P1295, DOI 10.1136/bmj.316.7140.1295; Pirmohamed M, 1996, CLIN PHARMACOKINET, V31, P215, DOI 10.2165/00003088-199631030-00005; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RIEDER MJ, 1992, INT J IMMUNOPHARMACO, V14, P1175, DOI 10.1016/0192-0561(92)90052-M; RIEDER MJ, 1995, TOXICOLOGY, V95, P141, DOI 10.1016/0300-483X(94)02900-F; RIEDER MJ, 1988, J PHARMACOL EXP THER, V244, P724; RIEDER MJ, 1993, J CLIN PHARMACOL, V33, P316, DOI 10.1002/j.1552-4604.1993.tb04663.x; RIEDER MJ, 1995, J ACQ IMMUN DEF SYND, V8, P134, DOI 10.1097/00042560-199502000-00004; RIEDER MJ, 1994, DRUG SAFETY, V11, P196, DOI 10.2165/00002018-199411030-00005; RIEDER MJ, 1991, CLIN PHARMACOL THER, V49, P13, DOI 10.1038/clpt.1991.3; RIEDER MJ, 1989, ANN INTERN MED, V110, P286, DOI 10.7326/0003-4819-110-4-286; SAD S, 1994, J IMMUNOL, V153, P3514; SHEAR NH, 1986, ANN INTERN MED, V105, P179, DOI 10.7326/0003-4819-105-2-179; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; Sisson ME, 1997, INT J IMMUNOPHARMACO, V19, P299, DOI 10.1016/S0192-0561(97)00027-1; SPIELBERG SP, 1986, CLIN BIOCHEM, V19, P142, DOI 10.1016/S0009-9120(86)80061-3; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1989, COLD SH Q B, V54, P689; Vig E, 1999, J BIOL CHEM, V274, P13077, DOI 10.1074/jbc.274.19.13077; WEINSHILBOUM RM, 1987, CLIN PHARMACOL THER, V42, P481, DOI 10.1038/clpt.1987.184; YANG X, 1993, J EXP MED, V178, P349, DOI 10.1084/jem.178.1.349	77	10	11	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1855	+		10.1096/fj.00-0583fje	http://dx.doi.org/10.1096/fj.00-0583fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481253				2022-12-28	WOS:000169261200015
J	Leopold, JA; Cap, A; Scribner, AW; Stanton, RC; Loscalzo, J				Leopold, JA; Cap, A; Scribner, AW; Stanton, RC; Loscalzo, J			Glucose-6-phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailability	FASEB JOURNAL			English	Article						glutathione; nitric oxide; reactive oxygen species	SYNTHASE GENERATES SUPEROXIDE; OXIDATIVE STRESS; CELL-DEATH; TETRAHYDROBIOPTERIN; EXPRESSION; DEHYDROEPIANDROSTERONE; INTERLEUKIN-1-BETA; EPIANDROSTERONE; FIBROBLASTS; INHIBITION	The vascular endothelium compensates for oxidant stress by increasing the activity of antioxidant enzymes such as glucose-6-phophate dehydrogenase (G6PD). G6PD provides reducing equivalents of NAPDH to maintain glutathione stores and modulates nitric oxide synthase (eNOS) activity. To determine whether deficient G6PD activity perturbs these responses, we treated bovine aortic endothelial cells with dehydroepiandrosterone or an antisense oligodeoxynucleotide to G6PD mRNA to decrease G6PD activity and expression. When exposed to hydrogen peroxide, reactive oxygen species (ROS) accumulation was increased in G6PD-deficient cells compared with those with normal activity. To determine the source of increased oxidant stress in G6PD-deficient cells, we used inhibitors of ROS generation, which suggested that eNOS was contributing to ROS production. Treatment with L-NMMA, an inhibitor of eNOS mediated-nitric oxide (NO) but not superoxide, production confirmed this observation; in contrast to L-NAME, L-NMMA promoted ROS generation in G6PD-deficient cells. In addition, deficient G6PD activity was associated with a decrease in endothelium-derived bioavailable NO in response to the agonists A23187 and bradykinin as demonstrated by decreased endothelial cGMP and nitrate/nitrite levels. Enhanced ROS accumulation and decreased NO bioavailability may represent one mechanism by which G6PD deficiency contributes to vascular oxidant stress and endothelial dysfunction.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA	Boston University; Boston University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Leopold, JA (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, CABR-507,715 Albany St, Boston, MA 02118 USA.	jane.leopold@bmc.org	Stanton, Robert C/AAG-7584-2020; Loscalzo, Joseph/ABD-8980-2021	Stanton, Robert C/0000-0002-3056-1277; 				BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Cheng ML, 2000, FEBS LETT, V475, P257, DOI 10.1016/S0014-5793(00)01687-2; CRISS WE, 1969, BIOCHIM BIOPHYS ACTA, V184, P486, DOI 10.1016/0304-4165(69)90262-1; Garcia-Nogales P, 1999, J NEUROCHEM, V72, P1750, DOI 10.1046/j.1471-4159.1999.721750.x; Ho HY, 2000, FREE RADICAL BIO MED, V29, P156, DOI 10.1016/S0891-5849(00)00331-2; Ishii M, 1999, J CARDIOVASC PHARM, V33, P295, DOI 10.1097/00005344-199902000-00018; Laychock SG, 1998, BIOCHEM PHARMACOL, V55, P1453, DOI 10.1016/S0006-2952(97)00666-7; Laychock SG, 1996, ENDOCRINOLOGY, V137, P3375, DOI 10.1210/en.137.8.3375; Leopold JA, 2000, AM J PHYSIOL-HEART C, V279, pH2477, DOI 10.1152/ajpheart.2000.279.5.H2477; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mei JJM, 1998, CANCER LETT, V129, P191, DOI 10.1016/S0304-3835(98)00102-5; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; Sasaki K, 1998, BBA-GEN SUBJECTS, V1380, P275, DOI 10.1016/S0304-4165(97)00152-9; Shimizu S, 1998, LIFE SCI, V63, P1585, DOI 10.1016/S0024-3205(98)00427-5; STANTON RC, 1991, J BIOL CHEM, V266, P12442; Tian WN, 1998, J BIOL CHEM, V273, P10609, DOI 10.1074/jbc.273.17.10609; Tian WN, 1999, AM J PHYSIOL-CELL PH, V276, pC1121, DOI 10.1152/ajpcell.1999.276.5.C1121; Ursini MV, 1997, BIOCHEM J, V323, P801, DOI 10.1042/bj3230801; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Wang WH, 2000, J BIOL CHEM, V275, P16899, DOI 10.1074/jbc.M000301200; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; Zhang ZQ, 2000, ANAL BIOCHEM, V285, P163, DOI 10.1006/abio.2000.4701; Zhang ZQ, 2000, J BIOL CHEM, V275, P40042, DOI 10.1074/jbc.M007505200	28	119	122	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1771	+		10.1096/fj.00-0893fje	http://dx.doi.org/10.1096/fj.00-0893fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481225				2022-12-28	WOS:000169261200023
J	Lewis, ML; Cubano, LA; Zhao, BT; Dinh, HK; Pabalan, JG; Piepmeier, EH; Bowman, PD				Lewis, ML; Cubano, LA; Zhao, BT; Dinh, HK; Pabalan, JG; Piepmeier, EH; Bowman, PD			cDNA microarray reveals altered cytoskeletal gene expression in space-flown leukemic T lymphocytes (Jurkat)	FASEB JOURNAL			English	Article						gene expression; cDNA microarray; cytoskeleton; spaceflight; vibration; plectin	PROTEIN-KINASE-C; HUMAN-LEUKOCYTES; PLECTIN; CELL; GRAVITY; RNA; ORGANIZATION; ASSOCIATION; CALPONIN; BINDING	Cytoskeletal disruption and growth arrest consistently occur in space-flown human acute leukemic T cells (Jurkat). Although the microtubules appear to reorganize during spaceflight, cells remain nonproliferative. To test the hypothesis that spaceflight alters cytoskeletal gene expression and may thus affect cytoskeletal function, we flew Jurkat cells on Space Transportation System (STS) 95 and compared RNA message by cDNA microarray in space-flown vs. ground controls at 24 h (4,324 genes) and 48 h (> 20,000 genes). Messages for 11 cytoskeleton-related genes, including calponin, dynactin, tropomodulin, keratin 8, two myosins, an ankyrin EST, an actinlike protein, the cytoskeletal linker (plectin), and a centriole-associated protein (C-NAP1), were up-regulated in space-flown compared with ground control cells; gelsolin precursor was down-regulated. Up-regulation of plectin and C-NAP1 message in both space-flown cells and vibrated controls is a novel finding and implies their role in vibration damage repair. This first report of cDNA microarray screening of gene expression in space-flown leukemic T cells also identifies differential expression of genes that regulate growth, metabolism, signal transduction, adhesion, transcription, apoptosis, and tumor suppression. Based on differential expression of cytoskeletal genes, we conclude that centriole-centriole, membrane-cytoskeletal, and cytoskeletal filament associations are altered in the orbital phase of spaceflight.	Univ Alabama, Dept Biol Sci, Huntsville, AL 35899 USA; Tulane Univ, Med Ctr, Dept Med, New Orleans, LA 70112 USA; Univ Texas, Coll Pharm, Austin, TX 78712 USA; Univ Texas, Med Branch, Galveston, TX 77550 USA; USA, Inst Surg Res, San Antonio, TX USA	University of Alabama System; University of Alabama Huntsville; Tulane University; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Medical Branch Galveston	Lewis, ML (corresponding author), Univ Alabama, Dept Biol Sci, Wilson Hall 360, Huntsville, AL 35899 USA.	lewismml@email.uah.edu						Andra K, 1998, GENE DEV, V12, P3442, DOI 10.1101/gad.12.21.3442; BENNETT V, 1982, J CELL BIOCHEM, V18, P49, DOI 10.1002/jcb.1982.240180106; Burkhardt JK, 1998, BBA-MOL CELL RES, V1404, P113, DOI 10.1016/S0167-4889(98)00052-4; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cogoli A, 1996, J Gravit Physiol, V3, P1; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; CogoliGreuter M, 1996, J BIOTECHNOL, V47, P279, DOI 10.1016/0168-1656(96)01380-6; Cubano LA, 2000, EXP GERONTOL, V35, P389, DOI 10.1016/S0531-5565(00)00090-5; CUBANO LA, 2001, IN PRESS J LEUKOCYTE; DEGROOT RP, 1991, EXP CELL RES, V197, P87, DOI 10.1016/0014-4827(91)90483-B; Eger A, 1997, J CELL SCI, V110, P1307; FANG J, 1996, P NATL ACAD SCI USA, V93, P9154; Fitzgerald J, 1996, EXP CELL RES, V228, P168, DOI 10.1006/excr.1996.0313; FOISNER R, 1991, P NATL ACAD SCI USA, V88, P3812, DOI 10.1073/pnas.88.9.3812; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; Fujii T, 1997, J BIOCHEM, V122, P344; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; Hammond TG, 1999, NAT MED, V5, P359, DOI 10.1038/7331; Hatton JP, 1999, FASEB J, V13, pS23, DOI 10.1096/fasebj.13.9001.s23; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; Ingber D, 1999, FASEB J, V13, pS3; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; Lewis ML, 2000, J CELL BIOCHEM, V77, P127, DOI 10.1002/(SICI)1097-4644(20000401)77:1<127::AID-JCB13>3.3.CO;2-S; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; Masuda H, 1996, J BIOCHEM-TOKYO, V120, P415; MOSHKOV DA, 1991, TSITOLOGIYA+, V33, P16; MURTI KG, 1992, EXP CELL RES, V202, P36, DOI 10.1016/0014-4827(92)90401-S; Papaseit C, 2000, P NATL ACAD SCI USA, V97, P8364, DOI 10.1073/pnas.140029597; Piepmeier EH, 1997, EXP CELL RES, V237, P410, DOI 10.1006/excr.1997.3813; Rijken P J, 1994, Adv Space Biol Med, V4, P159; Schatten H, 1999, CELL BIOL INT, V23, P407, DOI 10.1006/cbir.1999.0371; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; Smith FJD, 1996, NAT GENET, V13, P450, DOI 10.1038/ng0896-450; Szymanski PT, 1999, BIOCHEMISTRY-US, V38, P3778, DOI 10.1021/bi981394y; Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530; Wiche G, 1998, J CELL SCI, V111, P2477	39	74	83	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1783	+		10.1096/fj.00-0820fje	http://dx.doi.org/10.1096/fj.00-0820fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481229				2022-12-28	WOS:000169261200022
J	White, P; Burton, KA; Fowden, AL; Dauncey, MJ				White, P; Burton, KA; Fowden, AL; Dauncey, MJ			Developmental expression analysis of thyroid hormone receptor isoforms reveals new insights into their essential functions in cardiac and skeletal muscles	FASEB JOURNAL			English	Article						cardiac and skeletal muscle; myosin; prenatal and postnatal development; TR	POSTNATAL-DEVELOPMENT; BINDING CAPACITY; PORCINE SKELETAL; GENE-EXPRESSION; ENERGY-BALANCE; BETA; GROWTH; ACID; MICE; RAT	Nuclear thyroid hormone (TH) receptors (TR) play a critical role in mediating the diverse actions of TH in development, differentiation, and metabolism of most tissues, but the role of TR isoforms in muscle development and function is unclear. Therefore, we have undertaken a comprehensive expression analysis of TR alpha 1, TR beta 1, TR beta 2 (TH binding), and TR alpha 2 (non-TH binding) in functionally distinct porcine muscles during prenatal and postnatal development. Use of a novel and highly sensitive RNase protection assay revealed striking muscle-specific developmental profiles of all four TR isoform mRNAs in cardiac, longissimus, soleus, rhomboideus, and diaphragm. Distribution of TR isoforms varied markedly between muscles; TR alpha expression was considerably greater than TR beta and there were significant differences in the ratios TR alpha 1:TR alpha 2, and TR beta1:TR beta 2. Together with immunohistochemistry of myosin heavy chain isoforms and data on myogenesis and maturation of the TH axis, these findings provide new evidence that highlights central roles for 1) TR alpha isoforms in fetal myogenesis, 2) the ratio TR alpha 1: TR alpha 2 in determining cardiac and skeletal muscle phenotype and function; 3) TR beta in maintaining a basal level of cellular response to TH throughout development and a specific maturational function around birth. These findings suggest that events disrupting normal developmental profiles of TR isoforms may impair optimal function of cardiac and skeletal muscles.	Babraham Inst, Dev Genet Programme, Cambridge CB2 4AT, England; Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	Dauncey, MJ (corresponding author), Babraham Inst, Dev Genet Programme, Bldg 540,Babraham Hall, Cambridge CB2 4AT, England.	dauncey@bbsrc.ac.uk	White, Peter/E-4301-2011	White, Peter/0000-0002-5218-5903				Bakker O, 1998, BIOCHEM BIOPH RES CO, V242, P492, DOI 10.1006/bbrc.1997.7992; BERTHON D, 1993, J DEV PHYSIOL, V19, P253; Brown K, 1999, CRIT REV EUKAR GENE, V9, P203, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.50; Chatterjee VKK, 1997, HORM RES, V48, P43, DOI 10.1159/000191312; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANFORTH E, 1989, ANNU REV NUTR, V9, P201, DOI 10.1146/annurev.nu.09.070189.001221; Dauncey MJ, 1996, P NUTR SOC, V55, P543, DOI 10.1079/PNS19960047; DAUNCEY MJ, 1990, P NUTR SOC, V49, P203, DOI 10.1079/PNS19900024; Dauncey MJ, 2001, P NUTR SOC, V60, P63, DOI 10.1079/PNS200071; DAUNCEY MJ, 1995, THERMOCHIM ACTA, V250, P305, DOI 10.1016/0040-6031(94)01967-L; Dauncey MJ, 1996, ACTA PHYSIOL SCAND, V156, P313, DOI 10.1046/j.1365-201X.1996.188000.x; Drvota V, 1998, BIOCHEM BIOPH RES CO, V242, P593, DOI 10.1006/bbrc.1997.8013; DUCHAMP C, 1994, AM J PHYSIOL-ENDOC M, V267, pE687, DOI 10.1152/ajpendo.1994.267.5.E687; ErcanFang S, 1996, ENDOCRINOLOGY, V137, P3228, DOI 10.1210/en.137.8.3228; Fisher D A, 1976, Recent Prog Horm Res, V33, P59; Fisher Delbert A., 1996, P974; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; FOWDEN AL, 1995, REPROD FERT DEVELOP, V7, P351, DOI 10.1071/RD9950351; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; Gauthier K, 1999, EMBO J, V18, P623, DOI 10.1093/emboj/18.3.623; Harrison AP, 1997, REPROD FERT DEVELOP, V9, P731, DOI 10.1071/R97026; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; Johansson C, 1999, AM J PHYSIOL-HEART C, V276, pH2006, DOI 10.1152/ajpheart.1999.276.6.H2006; Johansson C, 2000, AM J PHYSIOL-REG I, V278, pR598, DOI 10.1152/ajpregu.2000.278.3.R598; Katsumata M, 1999, FASEB J, V13, P1405, DOI 10.1096/fasebj.13.11.1405; Katsumata M, 2000, J NUTR, V130, P2482, DOI 10.1093/jn/130.10.2482; Laudet V, 1997, J MOL ENDOCRINOL, V19, P207, DOI 10.1677/jme.0.0190207; LEFAUCHEUR L, 1995, DEV DYNAM, V203, P27, DOI 10.1002/aja.1002030104; MOROVAT A, 1995, J ENDOCRINOL, V144, P233, DOI 10.1677/joe.0.1440233; MUSCAT GEO, 1995, BIOESSAYS, V17, P211, DOI 10.1002/bies.950170307; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; POLK D, 1989, AM J PHYSIOL, V256, pE543, DOI 10.1152/ajpendo.1989.256.4.E543; RODD C, 1992, ENDOCRINOLOGY, V131, P2559, DOI 10.1210/en.131.6.2559; SCHIAFFINO S, 1994, J APPL PHYSIOL, V77, P493, DOI 10.1152/jappl.1994.77.2.493; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; Tumbleson ME, 1996, ADV SWINE BIOMEDICAL; White P, 1999, J MOL ENDOCRINOL, V23, P241, DOI 10.1677/jme.0.0230241; White P, 2000, BRIT J NUTR, V84, P185; WHITE P, 1998, LIFE SCI NEWS, V0001, P00023; Yu FS, 2000, AM J PHYSIOL-REG I, V278, pR1545, DOI 10.1152/ajpregu.2000.278.6.R1545; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	42	34	36	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1367	1376		10.1096/fj.00-0725com	http://dx.doi.org/10.1096/fj.00-0725com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11387234				2022-12-28	WOS:000169261200004
J	Lefer, DJ; Scalia, R; Jones, SP; Sharp, BR; Hoffmeyer, MR; Farvid, AR; Gibson, MF; Lefer, AM				Lefer, DJ; Scalia, R; Jones, SP; Sharp, BR; Hoffmeyer, MR; Farvid, AR; Gibson, MF; Lefer, AM			HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury	FASEB JOURNAL			English	Article						nitric oxide; endothelium; infarct; heart; leukocytes	NITRIC-OXIDE SYNTHASE; ENDOTHELIAL CELL-INTERACTIONS; CORONARY-ARTERY DISEASE; MONOCLONAL-ANTIBODY; MELLITUS; ADHESION; CHOLESTEROL; SIMVASTATIN; INFARCTION; PRAVASTATIN	HMG-CoA reductase inhibitors (statins) exert beneficial effects independently of reducing blood cholesterol levels. We tested the hypothesis that statin therapy could reduce injury in the diabetic heart following myocardial ischemia (MI) and reperfusion (R) by increasing the bioavailability of nitric oxide (NO). The db/db diabetic mouse exhibits obesity, hyperinsulinemia, hyperglycemia, and endothelial dysfunction similar to Type II diabetes in humans. Diabetic mice received daily injections of simvastatin (0.5 mg/kg) or vehicle for 5 days before MI-R. Simvastatin did not reduce serum cholesterol levels (105 +/- 2 mg/dl vs. 103 3 mg/dl). However, simvastatin increased eNOS mRNA levels in diabetic hearts (n=7) by 97 +/- 31% (P<0.05) compared with vehicle (n=7). Simvastatin also significantly augmented (P<0.05) vascular NO production compared with vehicle (16.0 +/- 1.6 vs. 8.9 +/- 1.5 nmol/g). Diabetic (n=12) and nondiabetic (n=10) mice were subjected to 30 min of MI and 2 h of R. Simvastatin treatment (n=11) in diabetic mice reduced (P<0.02) myocardial necrosis from 62.6 +/- 3.3 % to 37.0 +/- 6.4%. Neutrophil infiltration in the I-R myocardium was attenuated by 62% (P<0.01) in simvastatin-treated mice. Intravital microscopy demonstrated reduced leukocyte-endothelial cell interactions in simvastatin-treated diabetic mice. Thus, simvastatin attenuates injury in the diabetic myocardium by enhanced NO production without reducing cholesterol levels.	Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Surg, Shreveport, LA 71130 USA; Thomas Jefferson Univ, Dept Physiol, Philadelphia, PA 19107 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Jefferson University	Lefer, AM (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, 1501 Kings Highway, Shreveport, LA 71130 USA.	dlefer@lsuhsc.edu	Lefer, David/A-6372-2012; Jones, Steven P./D-5092-2009	Jones, Steven P./0000-0001-5376-8089; Scalia, Rosario/0000-0002-1829-943X; Lefer, David/0000-0003-2293-7278				ABBOTT RD, 1988, JAMA-J AM MED ASSOC, V260, P3456, DOI 10.1001/jama.260.23.3456; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; ENTMAN ML, 1993, CIRCULATION, V88, P800, DOI 10.1161/01.CIR.88.2.800; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; Goldberg RB, 1998, CIRCULATION, V98, P2513, DOI 10.1161/01.CIR.98.23.2513; Guo JP, 1996, J APPL PHYSIOL, V81, P774, DOI 10.1152/jappl.1996.81.2.774; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; HOGAN M, 1992, J CLIN INVEST, V90, P1110, DOI 10.1172/JCI115928; Jones SP, 1999, AM J PHYSIOL-HEART C, V277, pH763, DOI 10.1152/ajpheart.1999.277.2.H763; Jones SP, 1999, AM J PHYSIOL-HEART C, V276, pH1567, DOI 10.1152/ajpheart.1999.276.5.H1567; Kaesemeyer WH, 1999, J AM COLL CARDIOL, V33, P234, DOI 10.1016/S0735-1097(98)00514-2; Kawachi S, 2000, BIOCHEM BIOPH RES CO, V276, P851, DOI 10.1006/bbrc.2000.3559; Kimura M, 1997, ARTERIOSCL THROM VAS, V17, P1521, DOI 10.1161/01.ATV.17.8.1521; KRAEMER R, 1991, CARDIOVASC RES, V25, P172, DOI 10.1093/cvr/25.2.172; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Laufs U, 1997, J BIOL CHEM, V272, P31725, DOI 10.1074/jbc.272.50.31725; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Lefer AM, 1999, CIRCULATION, V100, P178, DOI 10.1161/01.CIR.100.2.178; Lefer DJ, 1999, AM J PHYSIOL-HEART C, V276, pH1943, DOI 10.1152/ajpheart.1999.276.6.H1943; Lekakis J, 1997, CARDIOVASC RES, V34, P164, DOI 10.1016/S0008-6363(97)00015-1; MA XL, 1992, CIRCULATION, V86, P937, DOI 10.1161/01.CIR.86.3.937; MA XL, 1991, J CLIN INVEST, V88, P1237, DOI 10.1172/JCI115427; Massy ZA, 1996, LANCET, V347, P102, DOI 10.1016/S0140-6736(96)90217-2; MAYHAN WG, 1989, AM J PHYSIOL, V256, pH621, DOI 10.1152/ajpheart.1989.256.3.H621; MAZZONE A, 1993, CIRCULATION, V88, P358, DOI 10.1161/01.CIR.88.2.358; ODriscoll G, 1997, CIRCULATION, V95, P1126, DOI 10.1161/01.cir.95.5.1126; OHRVALL M, 1995, METABOLISM, V44, P212, DOI 10.1016/0026-0495(95)90267-8; Packard CJ, 1998, CIRCULATION, V97, P1440; PEDERSEN TR, 1994, LANCET, V344, P1383; Pieper GM, 1997, CARDIOVASC RES, V34, P145, DOI 10.1016/S0008-6363(96)00237-4; PIEWPER GM, 1988, AM J PHYSIOL, V255, pH825; Pruefer D, 1999, ARTERIOSCL THROM VAS, V19, P2894, DOI 10.1161/01.ATV.19.12.2894; RASKIN P, 1995, AM J MED, V99, P362, DOI 10.1016/S0002-9343(99)80182-X; SIMPSON PJ, 1988, J CLIN INVEST, V81, P624, DOI 10.1172/JCI113364; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; ZUANETTI G, 1993, J AM COLL CARDIOL, V22, P1788, DOI 10.1016/0735-1097(93)90758-S	36	82	85	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1454	+		10.1096/fj.00-0819fje	http://dx.doi.org/10.1096/fj.00-0819fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387255				2022-12-28	WOS:000173705800010
J	Weng, S; Lauven, M; Schaefer, T; Polontchouk, L; Grover, R; Dhein, S				Weng, S; Lauven, M; Schaefer, T; Polontchouk, L; Grover, R; Dhein, S			Pharmacological modification of gap junction coupling by an antiarrhythmic peptide via protein kinase C activation	FASEB JOURNAL			English	Article						connexin; intercellular coupling; radioligand binding; phosphorylation	NUCLEAR-MAGNETIC-RESONANCE; VENTRICULAR CELL PAIRS; GUINEA-PIG HEART; PHOSPHORYLATING CONDITIONS; PHOSPHOLIPASE-C; CONDUCTANCE; CHANNELS; CONNEXIN43; FIBRILLATION; PERMEABILITY	Antiarrhythmic peptides enhance gap junction current in pairs of cardiomyocytes and coupling in cardiac tissue. To elucidate the underlying mechanisms, we investigated the effects of the antiarrhythmic peptide AAP10 (GAG-4Hyp-PY-CONH2) on pairs of adult guinea pig ventricular cardiomyocytes and pairs of HeLa cells transfected with rat cardiac connexin 43 (Cx43). By using a double-cell voltage-clamp technique in pairs of cardiomyocytes, we found that under control conditions the gap junction conductance (gj) steadily decreased with time (by 0.292 +/- 0.130 nS/min). Use of 50 nmol/L AAP10 reversed this rundown and increased gj (by +0.290 +/- 0.231 nS/min, P<0.05). This effect of AAP10 could be significantly antagonized by bisindolylmaleimide I (BIM) and by the protein kinase C (PKC) subtype-specific inhibitor CGP54345 (PKC alpha). In HeLa-Cx43 cells, AAP10 exerted the same electrophysiological effect. In these cells, AAP10 activated PKC (determined by using ELISA) in CGP54345-sensitive manner and significantly enhanced incorporation of P-32 into Cx43 with dependence on PKC. If G-protein coupling was inhibited with 1 mM GDP-beta S, we found the effects of AAP10 on P-32 incorporation were also completely abolished. Next, we performed a radioligand binding study with C-14-AAP10 as radioligand and AAPnat as competitor. We found saturable binding of C-14-AAP10 to cardiac membrane preparations, which could be displaced with AAPnat. The K-d of AAP10 was 0.88 nmol/L. We conclude that 1) AAP10 increases gj both in adult cardiomyocytes and in transfected HeLa-Cx43 cells, 2) AAP10 exerts its effect via enhanced PKC-dependent phosphorylation of Cx43, 3) AAP10 activates PKC alpha, and 4) a membrane receptor exists for antiarrhythmic peptides in cardiomyocytes.	Univ Leipzig, Ctr Heart, Clin Cardiac Surg, D-04289 Leipzig, Germany; Univ Halle Wittenberg, Inst Pharmacol, D-06097 Halle An Der Saale, Saale, Germany; Univ Cologne, Inst Pharmacol, D-50931 Cologne, Germany	Heart Center Leipzig GMBH; Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Martin Luther University Halle Wittenberg; University of Cologne	Dhein, S (corresponding author), Univ Leipzig, Ctr Heart, Clin Cardiac Surg, Strumpellstr 39, D-04289 Leipzig, Germany.	dhes@medizin.uni-leipzig.de						ALLEN DG, 1985, J PHYSIOL-LONDON, V361, P185, DOI 10.1113/jphysiol.1985.sp015640; AONUMA S, 1980, CHEM PHARM BULL, V28, P3332; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUKAUSKAS FF, 1995, BIOPHYS J, V68, P2289, DOI 10.1016/S0006-3495(95)80411-X; Daleau P, 1998, J PHARMACOL EXP THER, V284, P1174; DHEIN S, 1994, N-S ARCH PHARMACOL, V350, P174; Dhein S, 1998, TRENDS PHARMACOL SCI, V19, P229, DOI 10.1016/S0165-6147(98)01192-4; Doble BW, 2000, CIRC RES, V86, P293, DOI 10.1161/01.RES.86.3.293; Grover R, 1998, PEPTIDES, V19, P1725, DOI 10.1016/S0196-9781(98)00129-6; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; HRBOLICH JK, 1987, BIOCHEM J, V243, P457, DOI 10.1042/bj2430457; KAMEYAMA M, 1983, J PHYSIOL-LONDON, V336, P345, DOI 10.1113/jphysiol.1983.sp014585; Kjolbye AL, 2000, FASEB J, V14, pA698; KLEBER AG, 1987, CIRC RES, V61, P271, DOI 10.1161/01.RES.61.2.271; KOHAMA Y, 1987, CHEM PHARM BULL, V35, P3928; KUCERA GL, 1988, BIOCHEM BIOPH RES CO, V153, P417, DOI 10.1016/S0006-291X(88)81240-3; KWAK BR, 1995, MOL BIOL CELL, V6, P1707, DOI 10.1091/mbc.6.12.1707; KWAK BR, 1995, EXP CELL RES, V220, P456, DOI 10.1006/excr.1995.1337; Kwak BR, 1996, MOL CELL BIOCHEM, V157, P93; Lau AF, 1996, J BIOENERG BIOMEMBR, V28, P359, DOI 10.1007/BF02110112; LIMBIRD LE, 1996, CELL SURFACE RECEPTO; LOEWENSTEIN WR, 1968, PERSPECT BIOL MED, V11, P260; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MESNIL M, 1993, MOL CARCINOGEN, V7, P14, DOI 10.1002/mc.2940070103; METZGER P, 1985, J PHYSIOL-LONDON, V366, P177, DOI 10.1113/jphysiol.1985.sp015791; MORENO AP, 1994, CIRC RES, V74, P1050, DOI 10.1161/01.RES.74.6.1050; Muller A, 1999, AM J PHYSIOL-CELL PH, V276, pC980, DOI 10.1152/ajpcell.1999.276.4.C980; MUNSTER PN, 1993, PFLUG ARCH EUR J PHY, V423, P181, DOI 10.1007/BF00374392; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; Nagy JI, 1997, EXP CELL RES, V236, P127, DOI 10.1006/excr.1997.3716; NOMA A, 1987, J PHYSIOL-LONDON, V382, P193, DOI 10.1113/jphysiol.1987.sp016363; Polontchouk L, 2001, J AM COLL CARDIOL, V38, P883, DOI 10.1016/S0735-1097(01)01443-7; SONTHEIMER H, 1995, NEUROMETH, V26, P37; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; SPRAY DC, 1990, AM J PHYSIOL, V258, P195; SUGIURA H, 1990, CIRC RES, V66, P1095, DOI 10.1161/01.RES.66.4.1095; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRAUB O, 1994, EUR J CELL BIOL, V64, P101; Verrecchia F, 1999, J PHYSIOL-LONDON, V516, P447, DOI 10.1111/j.1469-7793.1999.0447v.x; Verrecchia F, 1997, AM J PHYSIOL-CELL PH, V272, pC875, DOI 10.1152/ajpcell.1997.272.3.C875; WEINGART R, 1986, J PHYSIOL-LONDON, V370, P267, DOI 10.1113/jphysiol.1986.sp015934; WIT AL, 1992, VENTRICULAR ARRHYTHM	43	80	88	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1114	+		10.1096/fj.01-0918fje	http://dx.doi.org/10.1096/fj.01-0918fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039852				2022-12-28	WOS:000175973900011
J	Medina, D; Kittrell, FS; Shepard, A; Stephens, LC; Jiang, C; Lu, JX; Allred, DC; McCarthy, M; Ullrich, RL				Medina, D; Kittrell, FS; Shepard, A; Stephens, LC; Jiang, C; Lu, JX; Allred, DC; McCarthy, M; Ullrich, RL			Biological and genetic properties of the p53 null preneoplastic mammary epithelium	FASEB JOURNAL			English	Article						mammary; premalignant; p53 null; immortal; model	GLANDS IN-VIVO; TELOMERASE ACTIVITY; TUMOR-DEVELOPMENT; TRANSGENIC MICE; BREAST-CANCER; MODEL; ESTROGEN; CELLS; TUMORIGENESIS; PROGESTERONE	The absence of the tumor suppressor gene p53 confers an increased tumorigenic risk for mammary epithelial cells. In this report, we describe the biological and genetic properties of the p53 null preneoplastic mouse mammary epithelium in a p53 wild-type environment. Mammary epithelium from p53 null mice was transplanted serially into the cleared mammary fat pads of p53 wild-type BALB/c female to develop stable outgrowth lines. The outgrowth lines were transplanted for 10 generations. The outgrowths were ductal in morphology and progressed through ductal hyperplasia and ductal carcinoma in situ before invasive cancer. The preneoplastic outgrowth lines were immortal and exhibited activated telomerase activity. They are estrogen and progesterone receptor-positive, and aneuploid, and had various levels of tumorigenic potential. The biological and genetic properties of these lines are distinct from those found in most hyperplastic alveolar outgrowth lines, the form of mammary preneoplasia occurring in most traditional models of murine mammary tumorigenesis. These results indicate that the preneoplastic cell populations found in this genetically engineered model are similar in biological properties to a subset of precurser lesions found in human breast cancer and provide a unique model to identify secondary events critical for tumorigenicity and invasiveness.	Baylor Coll Med, Dept Cellular & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA; AMC Canc Res Ctr, Denver, CO USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Microbiol, Galveston, TX 77550 USA; Colorado State Univ, Dept Radiol Hlth Sci, Ft Collins, CO 80523 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; AMC Cancer Research Center; Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston; Colorado State University	Medina, D (corresponding author), Baylor Coll Med, Dept Cellular & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	dmedina@bcm.tmc.edu		Lu, Junxuan/0000-0002-2354-7186				ADAMS LM, 1987, CANCER RES, V47, P4425; BOUFFLER SD, 1994, INT REV CYTOL, V153, P171, DOI 10.1016/S0074-7696(08)62191-9; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Brown P, 2000, CONT ENDOCRINOL, P49; Cardiff RD, 2000, J MAMMARY GLAND BIOL, V5, P421, DOI 10.1023/A:1009534129331; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Cardiff RD, 1996, J MAMMARY GLAND BIOL, V1, P61, DOI 10.1007/BF02096303; Di Carlo E, 1999, LAB INVEST, V79, P1261; Drissi R, 2001, J BIOL CHEM, V276, P29994, DOI 10.1074/jbc.M101899200; Goepfert TM, 2000, FASEB J, V14, P2221, DOI 10.1096/fj.00-0165com; Greer J, 2000, MAT SCI SEMICON PROC, V3, P1, DOI 10.1016/S1369-8001(00)00003-2; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; JERRY DJ, 1993, CANCER RES, V53, P3374; Jiang C, 1997, CARCINOGENESIS, V18, P2085, DOI 10.1093/carcin/18.11.2085; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Maglione JE, 2001, CANCER RES, V61, P8298; MEDINA D, 1976, J NATL CANCER I, V57, P1185, DOI 10.1093/jnci/57.5.1185; Medina D, 1998, MOL CARCINOGEN, V22, P199, DOI 10.1002/(SICI)1098-2744(199807)22:3<199::AID-MC8>3.0.CO;2-G; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; MEDINA D, 1976, J NATL CANCER I, V57, P331, DOI 10.1093/jnci/57.2.331; MEDINA D, 2000, J MAMMARY GLAND BIOL, V5, P55; MEDINA D, 2000, METHODS MAMMARY GLAN, P137; MEDINA D, 1996, MAMMARY TUMOR CELL C, P37; MEDINA D, 1978, EXPT BREAST CANC, V2, P47; Medina D., 2000, METHODS MAMMARY GLAN, P3; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; Meyn RE, 1996, INT J CANCER, V65, P466, DOI 10.1002/(SICI)1097-0215(19960208)65:4<466::AID-IJC13>3.0.CO;2-8; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Said TK, 1997, ENDOCRINOLOGY, V138, P3933, DOI 10.1210/en.138.9.3933; Schulze-Garg C, 2000, ONCOGENE, V19, P1028, DOI 10.1038/sj.onc.1203281; TSUKADA T, 1993, ONCOGENE, V8, P3313; Yoshidome K, 2000, CANCER RES, V60, P6901; YOUNG LJT, 1971, EXP GERONTOL, V6, P49, DOI 10.1016/0531-5565(71)90048-9	35	82	83	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					881	+		10.1096/fj.01-0885fje	http://dx.doi.org/10.1096/fj.01-0885fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967232				2022-12-28	WOS:000175425900013
J	Ho, WZ; Lai, JP; Li, Y; Douglas, SD				Ho, WZ; Lai, JP; Li, Y; Douglas, SD			HIV enhances substance P expression in human immune cells	FASEB JOURNAL			English	Article						lymphocytes; gp120; tachykinin; neuroimmunoregulation; monocyte-derived macrophages	HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN BLOOD MONOCYTES; FACTOR-ALPHA RELEASE; NF-KAPPA-B; SYSTEM INTERACTIONS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; MACROPHAGES; INFECTION; NEUROPEPTIDE	Substance P (SP), a potent modulator of neuroimmunoregulation, is expressed in human immune cells. We observed elevated plasma SP levels in HIV-infected men compared with uninfected subjects. In the present study, we investigated the possible cellular source of the increased SP level caused by HIV infection. Using real-time reverse transcriptase-polymerase chain reaction, we demonstrated that monocyte-derived macrophages (MDM) and lymphocytes from both placental cord blood and adult peripheral blood expressed SP mRNA, which was significantly increased by HIV infection. HIV-induced SP expression was positively related to virus replication in the infected MDM. Purified recombinant HIV envelope glycoprotein 120 (gp120) derived from both the macrophage-tropic strain (MN) and the T lymphocyte-tropic strain (IIIB), when added to MDM cultures, enhanced SP mRNA expression. The gp120-induced SP expression was abrogated by pretreating the cells with soluble CD4. Furthermore, the activation of HIV in the latently infected promonocytic cell line (U1) and T-cell line (ACH-2) up-regulated SP mRNA expression. These data support the hypothesis that interaction of HIV and SP may have significant in vivo relevance to the immunopathogenesis of HIV infection and AIDS.	Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat,Div Immunol & Infect Dis, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Douglas, SD (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat,Div Immunol & Infect Dis, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	douglas@email.chop.edu	Lai, Jianping/E-3583-2015	Lai, Jianping/0000-0002-3217-692X				ALIAKBARI J, 1987, BIOCHEM BIOPH RES CO, V148, P1440, DOI 10.1016/S0006-291X(87)80293-0; Annunziata P, 1998, AIDS, V12, P2377, DOI 10.1097/00002030-199818000-00006; Azzari C, 1992, Pediatr Med Chir, V14, P577; BLACK PH, 1994, ANTIMICROB AGENTS CH, V38, P7, DOI 10.1128/AAC.38.1.7; BLACK PH, 1994, ANTIMICROB AGENTS CH, V38, P1; BOST K L, 1992, Regional Immunology, V4, P105; CHIWAKATA C, 1991, ENDOCRINOLOGY, V128, P2441, DOI 10.1210/endo-128-5-2441; CLOUSE KA, 1989, J IMMUNOL, V142, P431; COVAS MJ, 1994, CLIN EXP IMMUNOL, V96, P384, DOI 10.1111/j.1365-2249.1994.tb06039.x; Douglas SD, 2001, AIDS, V15, P2043, DOI 10.1097/00002030-200110190-00019; Fehder WP, 1998, CLIN DIAGN LAB IMMUN, V5, P303, DOI 10.1128/CDLI.5.3.303-307.1998; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOLKS TM, 1988, J IMMUNOL, V140, P1117; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; GILBERT MS, 1991, FRONT NEUROENDOCRIN, V12, P299; HASSAN NF, 1986, J IMMUNOL METHODS, V95, P273, DOI 10.1016/0022-1759(86)90415-1; HASSAN NF, 1990, J IMMUNOL METHODS, V130, P283, DOI 10.1016/0022-1759(90)90058-4; Ho WZ, 1996, J NEUROIMMUNOL, V71, P73, DOI 10.1016/S0165-5728(96)00132-4; Ho WZ, 1998, J NEUROIMMUNOL, V82, P126, DOI 10.1016/S0165-5728(97)00175-6; Ho WZ, 1997, J IMMUNOL, V159, P5654; Ho WZ, 1996, AIDS RES HUM RETROV, V12, P195, DOI 10.1089/aid.1996.12.195; Lai JP, 1998, J NEUROIMMUNOL, V86, P80, DOI 10.1016/S0165-5728(98)00025-3; Lai JP, 2001, P NATL ACAD SCI USA, V98, P3970, DOI 10.1073/pnas.071052298; Lai JP, 1999, J IMMUNOL METHODS, V230, P149, DOI 10.1016/S0022-1759(99)00120-9; Lai JP, 2000, NEUROSCIENCE, V101, P1137, DOI 10.1016/S0306-4522(00)00398-5; LAURENZI MA, 1990, SCAND J IMMUNOL, V31, P529, DOI 10.1111/j.1365-3083.1990.tb02801.x; LEE HR, 1994, CLIN DIAGN LAB IMMUN, V1, P419, DOI 10.1128/CDLI.1.4.419-423.1994; Li Y, 2001, J NEUROIMMUNOL, V121, P67, DOI 10.1016/S0165-5728(01)00439-8; Lieb K, 1997, J IMMUNOL, V159, P4952; LINNIK MD, 1989, PEPTIDES, V10, P957, DOI 10.1016/0196-9781(89)90175-7; Liu R, 1998, AIDS RES HUM RETROV, V14, P1509, DOI 10.1089/aid.1998.14.1509; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; Marriott I, 2000, J NEUROIMMUNOL, V102, P163, DOI 10.1016/S0165-5728(99)00182-4; MCGILLIS JP, 1990, ANN NY ACAD SCI, V594, P85; MILNER P, 1990, P ROY SOC B-BIOL SCI, V241, P245, DOI 10.1098/rspb.1990.0092; NAKANISHI S, 1987, PHYSIOL REV, V67, P1117, DOI 10.1152/physrev.1987.67.4.1117; PASCUAL DW, 1990, IMMUNOLOGY, V71, P52; PAYAN DG, 1984, J CLIN INVEST, V74, P1532, DOI 10.1172/JCI111567; PERNOW B, 1983, PHARMACOL REV, V35, P85; ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; SHARKEY KA, 1992, GASTROENTEROLOGY, V103, P18, DOI 10.1016/0016-5085(92)91090-Q; Toneatto S, 1999, AIDS, V13, P2343, DOI 10.1097/00002030-199912030-00005; WEINSTOCK JV, 1990, CELL IMMUNOL, V125, P380, DOI 10.1016/0008-8749(90)90092-6; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988	45	46	46	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					616	+		10.1096/fj.01-0655fje	http://dx.doi.org/10.1096/fj.01-0655fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919172				2022-12-28	WOS:000174203700010
J	Draghia-Akli, R; Malone, PB; Hill, LA; Ellis, KM; Schwartz, RJ; Nordstrom, JL				Draghia-Akli, R; Malone, PB; Hill, LA; Ellis, KM; Schwartz, RJ; Nordstrom, JL			Enhanced animal growth via ligand regulated GHRH myogenic injectable vectors	FASEB JOURNAL			English	Article						growth hormone; insulin-like growth factor I; growth; plasmid DNA; gene therapy; electroporation	HORMONE-RELEASING HORMONE; LONG-TERM GROWTH; FACTOR-I; PROGESTERONE-RECEPTOR; DEPENDENT REGULATION; SYSTEMIC DELIVERY; GENE-THERAPY; NORMAL MEN; SECRETION; EXPRESSION	Regulated animal growth occurred following a single electroporated injection of a mixture of two plasmids (10 mug of DNA), one expressing the GeneSwitch(TM) regulator protein, the other an inducible growth hormone releasing hormone (GHRH) gene, into the tibialis anterior muscles of adult SCID mice. Administration of the ligand mifepristone (MFP) up-regulated GHRH expression, as shown by elevations of IGF-I levels, and when MFP dosing was withdrawn, IGF-I returned to baseline levels. Five cycles of IGF-I induction were observed during a five-month period. Chronic MFP dosing for 25 days increased lean body mass, weight gain, and bone mineral density significantly compared with non-MFP treated controls. In summary, long-term drug-regulated GHRH expression was achieved following plasmid-based gene therapy, and chronic induction of GHRH expression in adult animals led to improvements in weight gain and body composition.	Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA; Valentis Inc, Woodland Hills, CA USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; United States Department of Agriculture (USDA)	Draghia-Akli, R (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, Room 1120N,1 Baylor Plaza, Houston, TX 77030 USA.	ada@bcm.tmc.edu		Draghia-Akli, Ruxandra/0000-0001-6372-4039				Abruzzese RV, 2000, MOL THER, V2, P276, DOI 10.1006/mthe.2000.0115; Abruzzese RV, 1999, HUM GENE THER, V10, P1499, DOI 10.1089/10430349950017833; Argente J, 1996, HORM RES, V45, P1, DOI 10.1159/000184814; Auernhammer CJ, 1995, EUR J ENDOCRINOL, V133, P635, DOI 10.1530/eje.0.1330635; Barber MD, 1999, SURG ONCOL, V8, P133, DOI 10.1016/S0960-7404(99)00045-6; BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; Blau CA, 1997, BLOOD, V89, P146, DOI 10.1182/blood.V89.1.146.146_146_154; Blethen Sandra L., 1995, Current Opinion in Pediatrics, V7, P466, DOI 10.1097/00008480-199508000-00020; Blethen SL, 1996, HORM RES, V46, P113, DOI 10.1159/000185006; Bluet-Pajot MT, 1998, CELL MOL NEUROBIOL, V18, P101, DOI 10.1023/A:1022579327647; Bowers CY, 2001, ENDOCRINE, V14, P79, DOI 10.1385/ENDO:14:1:079; CORPAS E, 1993, ENDOCR REV, V14, P20, DOI 10.1210/er.14.1.20; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; Draghia-Akli R, 1999, NAT BIOTECHNOL, V17, P1179, DOI 10.1038/70718; Draghia-Akli R, 1997, NAT BIOTECHNOL, V15, P1285, DOI 10.1038/nbt1197-1285; Dubreuil P, 1996, CAN J VET RES, V60, P7; DUBREUIL P, 1990, J ANIM SCI, V68, P1254; EVANS WS, 1985, J CLIN ENDOCR METAB, V61, P846, DOI 10.1210/jcem-61-5-846; Hataya Y, 2001, J CLIN ENDOCR METAB, V86, P4552, DOI 10.1210/jc.86.9.4552; Horvath TL, 2001, ENDOCRINOLOGY, V142, P4163, DOI 10.1210/en.142.10.4163; Iglesias P, 1999, Expert Opin Pharmacother, V1, P97, DOI 10.1517/14656566.1.1.97; Kalu DN, 1998, J GERONTOL A-BIOL, V53, pB452, DOI 10.1093/gerona/53A.6.B452; Lebl J, 2000, Endocr Regul, V34, P169; Li XY, 1999, NAT BIOTECHNOL, V17, P241, DOI 10.1038/6981; LIEBERMAN SA, 1994, J CLIN ENDOCR METAB, V78, P404, DOI 10.1210/jc.78.2.404; Lissett CA, 2000, GROWTH HORM IGF RES, V10, P95; Lopez-Calderon A, 1999, LIFE SCI, V64, P1473, DOI 10.1016/S0024-3205(99)00084-3; Meyer NA, 1996, J TRAUMA, V41, P1008, DOI 10.1097/00005373-199612000-00011; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; Moldawer LL, 1998, SEMIN ONCOL, V25, P73; Morel G, 1999, NEUROENDOCRINOLOGY, V70, P128, DOI 10.1159/000054467; Murray R D, 2000, Expert Opin Pharmacother, V1, P975, DOI 10.1517/14656566.1.5.975; Murray RA, 2000, AM J NEURORADIOL, V21, P685; OgilvyStuart AL, 1997, CLIN ENDOCRINOL, V46, P571, DOI 10.1046/j.1365-2265.1997.1790998.x; Powell C, 1999, HUM GENE THER, V10, P565, DOI 10.1089/10430349950018643; Prank K, 1997, HUM REPROD UPDATE, V3, P215, DOI 10.1093/humupd/3.3.215; Satozawa N, 2000, GROWTH HORM IGF RES, V10, P187, DOI 10.1054/ghir.2000.0149; Thorner M, 1996, J CLIN ENDOCR METAB, V81, P1189, DOI 10.1210/jc.81.3.1189; THORNER MO, 1986, HORM RES, V24, P91, DOI 10.1159/000180547; THORNER MO, 1995, NEUROSCI BIOBEHAV R, V19, P465, DOI 10.1016/0149-7634(94)00046-4; THORNER MO, 1984, J CLIN ENDOCR METAB, V59, P846, DOI 10.1210/jcem-59-5-846; THORNER MO, 1986, RECENT PROG HORM RES, V42, P589; Tsunekawa B, 1999, ENDOCRINOLOGY, V140, P3909, DOI 10.1210/en.140.9.3909; VANCE ML, 1989, J CLIN ENDOCR METAB, V68, P22, DOI 10.1210/jcem-68-1-22; VANCE ML, 1985, J CLIN INVEST, V75, P1584, DOI 10.1172/JCI111864; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; Verhelst J, 1997, CLIN ENDOCRINOL, V47, P485, DOI 10.1046/j.1365-2265.1997.3041112.x; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195	49	31	40	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					426	+		10.1096/fj.01-0702fje	http://dx.doi.org/10.1096/fj.01-0702fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11790726				2022-12-28	WOS:000173656600021
J	Fruhbeck, G; Gomez-Ambrosi, J				Fruhbeck, G; Gomez-Ambrosi, J			Rationale for the existence of additional adipostatic hormones	FASEB JOURNAL			English	Article						leptin; parabiosis; lipostatic factor; obesity; energy balance	DIABETES-OBESITY SYNDROMES; BODY-WEIGHT; ENERGY-BALANCE; FEMALE MICE; REPRODUCTIVE DEVELOPMENT; PARABIOTIC PARTNERS; FOOD RESTRICTION; LEPTIN TREATMENT; TRANSGENIC MICE; OB PROTEIN	Parabiosis studies with obese rodents demonstrated that circulating factors are involved in the long-term control of food intake and energy balance. More than 40 years ago it was hypothesized that rats made obese by hypothalamic or dietary means, as well as genetically obese fa/fa rats and db/db mice, produce a circulating factor that either inhibits food intake or acts metabolically to reduce the fat content of non-obese ad libitum-fed partners. However, none of these obese rodents showed a significant change in weight when parabiosed to a normal animal. It was therefore postulated that these obese rodents produced a circulating lipostatic factor but were unable to respond to it. In contrast, genetically obese ob/ob mice were thought to be deficient in the circulating signal, as they lost weight when parabiosed to lean or obese db/db mice. The discovery of leptin suggested that the circulating lipostatic signal had been identified. However, a closer look at the outcome of the parabiotic studies reveals that leptin alone does not explain all of the findings of the parabiotic experiments. Another (or more than one) as yet unidentified factor(s) may be involved in energy balance regulation. The evidence for the existence of further leptin-like hormones comes from observations in which the direct effect of leptin has been eliminated or can be excluded.	Univ Navarra Clin, Dept Endocrinol, Pamplona 31008, Spain; Univ Navarra, Metab Res Lab, E-31080 Pamplona, Spain	University of Navarra; University of Navarra	Fruhbeck, G (corresponding author), Univ Navarra Clin, Dept Endocrinol, Pamplona 31008, Spain.	gfruhbeck@unav.es	Gómez-Ambrosi, Javier/D-2984-2017	Gómez-Ambrosi, Javier/0000-0001-5601-1604				Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Ailhaud G., 1998, HDB OBESITY, P359; Andreelli F, 2000, J CLIN ENDOCR METAB, V85, P715, DOI 10.1210/jc.85.2.715; Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Chehab FF, 2000, TRENDS PHARMACOL SCI, V21, P309, DOI 10.1016/S0165-6147(00)01514-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; COLEMAN DL, 1969, AM J PHYSIOL, V217, P1298; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1982, DIABETOLOGIA, V22, P205, DOI 10.1007/BF00283754; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DEBONS AF, 1983, ENDOCRINOLOGY, V112, P1847, DOI 10.1210/endo-112-5-1847; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Ewart-Toland A, 1999, ENDOCRINOLOGY, V140, P732, DOI 10.1210/en.140.2.732; Fruhbeck G, 2000, JAMA-J AM MED ASSOC, V283, P1567, DOI 10.1001/jama.283.12.1567; Fruhbeck G, 1998, BIOCHEM BIOPH RES CO, V250, P99, DOI 10.1006/bbrc.1998.9277; Fruhbeck G, 1998, CLIN PHYSIOL, V18, P399, DOI 10.1046/j.1365-2281.1998.00129.x; FRUHBECK G, 2001, IN PRESS P NUT SOC; GATES RJ, 1974, DIABETOLOGIA, V10, P401, DOI 10.1007/BF01221628; GATES RJ, 1972, LANCET, V2, P567; Gavrilova O, 1999, P NATL ACAD SCI USA, V96, P14623, DOI 10.1073/pnas.96.25.14623; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Hamann A, 1997, DIABETOLOGIA, V40, P810, DOI 10.1007/s001250050753; HAMILTON GD, 1986, AM J PHYSIOL, V250, pR370, DOI 10.1152/ajpregu.1986.250.3.R370; HAMILTON GD, 1985, BIOL REPROD, V32, P773, DOI 10.1095/biolreprod32.4.773; HARRIS RBS, 1990, FASEB J, V4, P3310, DOI 10.1096/fasebj.4.15.2253845; HARRIS RBS, 1989, AM J PHYSIOL, V257, pR326, DOI 10.1152/ajpregu.1989.257.2.R326; Harris RBS, 1997, AM J PHYSIOL-REG I, V272, pR1800, DOI 10.1152/ajpregu.1997.272.6.R1800; Harris RBS, 1998, ENDOCRINOLOGY, V139, P8, DOI 10.1210/en.139.1.8; HARRIS RBS, 1984, AM J PHYSIOL, V247, pR380, DOI 10.1152/ajpregu.1984.247.2.R380; Harris RBS, 1997, AM J PHYSIOL-REG I, V272, pR1809; Harris RBS, 1999, ENDOCRINOLOGY, V140, P138, DOI 10.1210/en.140.1.138; HARRISON LB, 1990, J SURG ONCOL, V45, P52, DOI 10.1002/jso.2930450112; HAUSBERGER FX, 1958, ANAT REC, V130, P313; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; HERVEY GR, 1959, J PHYSIOL-LONDON, V145, P336, DOI 10.1113/jphysiol.1959.sp006145; Himms-Hagen J, 1999, PROG OBES R, P27; Holness MJ, 1999, MOL CELL ENDOCRINOL, V157, P11, DOI 10.1016/S0303-7207(99)00126-4; HUFF RL, 1950, AM J PHYSIOL, V161, P56, DOI 10.1152/ajplegacy.1950.161.1.56; HUMMEL KP, 1966, SCIENCE, V153, P1127, DOI 10.1126/science.153.3740.1127; Igel M, 1997, ENDOCRINOLOGY, V138, P4234, DOI 10.1210/en.138.10.4234; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; KANG JS, 1992, J NUTR, V122, P895, DOI 10.1093/jn/122.4.895; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; Kortner G, 2000, CHRONOBIOL INT, V17, P103, DOI 10.1081/CBI-100101036; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MARCHINGTON D, 1983, J NUTR, V113, P1395; Melnyk A, 1997, AM J PHYSIOL-REG I, V272, pR1088, DOI 10.1152/ajpregu.1997.272.4.R1088; Melnyk A, 1998, AM J PHYSIOL-REG I, V274, pR1131, DOI 10.1152/ajpregu.1998.274.4.R1131; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; MOOK DG, 1972, J COMP PHYSIOL PSYCH, V81, P198, DOI 10.1037/h0033526; Mounzih K, 1997, ENDOCRINOLOGY, V138, P1190, DOI 10.1210/en.138.3.1190; NISHIZAWA Y, 1980, AM J PHYSIOL, V239, pR344, DOI 10.1152/ajpregu.1980.239.3.R344; Ozata M, 1999, J CLIN ENDOCR METAB, V84, P3686, DOI 10.1210/jc.84.10.3686; PARAMESWARAN SV, 1977, AM J PHYSIOL, V232, pR150, DOI 10.1152/ajpregu.1977.232.5.R150; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Robinson SW, 2000, ANNU REV GENET, V34, P687, DOI 10.1146/annurev.genet.34.1.687; SCHMIDT P, 1969, ACTA PHYSIOL HUNG, V36, P293; SMITH CK, 1985, AM J PHYSIOL, V249, pR13, DOI 10.1152/ajpregu.1985.249.1.R13; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; STRAUTZ RL, 1970, DIABETOLOGIA, V6, P306, DOI 10.1007/BF01212243; WEBB GP, 1982, COMP BIOCHEM PHYS A, V72, P211, DOI 10.1016/0300-9629(82)90035-4; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; WEIGLE DS, 1998, AM J PHYSIOL, V275, pR975; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	72	92	93	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					1996	2006		10.1096/fj.00-0829hyp	http://dx.doi.org/10.1096/fj.00-0829hyp			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532980				2022-12-28	WOS:000171372700015
J	Panther, E; Idzko, M; Herouy, Y; Rheinen, H; Gebicke-Haerter, PJ; Mrowietz, U; Dichmann, S; Norgauer, J				Panther, E; Idzko, M; Herouy, Y; Rheinen, H; Gebicke-Haerter, PJ; Mrowietz, U; Dichmann, S; Norgauer, J			Expression and function of adenosine receptors in human dendritic cells	FASEB JOURNAL			English	Article						DCs; calcium; chemotaxis; cytokine release	OXYGEN RADICAL PRODUCTION; CD11B UP-REGULATION; ACTIN REORGANIZATION; CHEMOKINE PRODUCTION; HUMAN EOSINOPHILS; G-PROTEIN; MATURATION; INHIBITION; IL-12; ACTIVATION	Dendritic cells (DCs) are specialized antigen-presenting cells characterized by their ability to migrate into target sites, process antigens, and activate naive T cells. In this study, we analyzed the biological activity and intracellular signaling of adenosine by using reverse transcriptase-polymerase chain reaction assays to investigate mRNA expression of A(1),A(2a) and A(3) adenosine receptors in immature and mature human DCs. Functional experiments on adenosine stimulation showed chemotaxis, intracellular calcium transients, and actin polymerization, but no activation of adenylate cyclase in immature DCs. Experiments with receptor isotype-selective agonists and antagonists as well as pertussis toxin revealed that chemotaxis, calcium transients, and actin polymerization were mediated via G(i)- or G(0)-protein-coupled A(1) and A(3) receptors. Maturation of DCs induced by lipopolysaccharide (LPS) resulted in down-regulation of A(1) and A(3) receptor mRNAs, although A(2a) receptor mRNA was still expressed. However, in LPS-differentiated DCs, adenosine and an A(2a) receptor agonist stimulated adenylate cyclase activity, enhanced intracellular cAMP levels, and inhibited interleukin 12 (IL-12) production. These effects could be completely prevented by pretreatment with A(2) receptor antagonist. These findings strongly suggest that adenosine has important but distinct biological effects in DCs activity as a chemotaxin for immature DCs and as a modulator of IL-12 production in mature DCs. These effects can be explained by differential expression of adenosine receptor subtypes.	Univ Freiburg, Dept Expt Dermatol, D-79104 Freiburg, Germany; Univ Freiburg, Dept Psychiat, D-79104 Freiburg, Germany; Univ Kiel, Dept Dermatol, D-24098 Kiel, Germany	University of Freiburg; University of Freiburg; University of Kiel	Norgauer, J (corresponding author), Univ Freiburg, Dept Expt Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.	Norgauer@haut.ukl.uni-freiburg.de	Mrowietz, U/B-1645-2010	Mrowietz, U/0000-0002-9539-0712				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; Braun MC, 1999, J EXP MED, V189, P541, DOI 10.1084/jem.189.3.541; COUTINHO SR, 1999, AM J PHYSIOL, V276, pC1139; CRONSTEIN BN, 1983, J EXP MED, V158, P1160, DOI 10.1084/jem.158.4.1160; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Dichmann S, 2000, BLOOD, V95, P973, DOI 10.1182/blood.V95.3.973.003k47_973_978; Dichmann S, 2000, J CELL PHYSIOL, V185, P394, DOI 10.1002/1097-4652(200012)185:3<394::AID-JCP9>3.3.CO;2-Q; DiVirgilio F, 1996, DRUG DEVELOP RES, V39, P319; Elsner J, 1996, J CELL PHYSIOL, V167, P548, DOI 10.1002/(SICI)1097-4652(199606)167:3<548::AID-JCP18>3.3.CO;2-Y; Foti M, 1999, INT IMMUNOL, V11, P979, DOI 10.1093/intimm/11.6.979; FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P228, DOI 10.1111/j.1600-0773.1995.tb00135.x; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; Gagliardi MC, 2000, EUR J IMMUNOL, V30, P2394, DOI 10.1002/1521-4141(2000)30:8<2394::AID-IMMU2394>3.0.CO;2-Y; GREEN HN, 1950, BIOL ACTIONS ADENINE; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; ILLES P, 1993, TRENDS PHARMACOL SCI, V14, P50, DOI 10.1016/0165-6147(93)90030-N; Kalinski P, 1998, J IMMUNOL, V161, P2804; Kohno Y, 1996, BLOOD, V88, P3569, DOI 10.1182/blood.V88.9.3569.bloodjournal8893569; Nardelli B, 1999, J LEUKOCYTE BIOL, V65, P822, DOI 10.1002/jlb.65.6.822; PaninaBordignon P, 1997, J CLIN INVEST, V100, P1513, DOI 10.1172/JCI119674; Ralevic V, 1998, PHARMACOL REV, V50, P413; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; Sozzani S, 1998, J IMMUNOL, V161, P1083; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; Tenscher K, 1997, BIOCHEM BIOPH RES CO, V240, P32, DOI 10.1006/bbrc.1997.7601; TRANQUILLO RT, 1988, J CELL BIOL, V106, P303, DOI 10.1083/jcb.106.2.303; Vassort Guy, 1992, News in Physiological Sciences, V7, P212; WOLBERG G, 1975, SCIENCE, V187, P957, DOI 10.1126/science.167434	31	147	152	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					1963	1970		10.1096/fj.01-0169com	http://dx.doi.org/10.1096/fj.01-0169com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532976				2022-12-28	WOS:000171372700011
J	Vrtala, S; Hirtenlehner, K; Susani, M; Akdis, M; Kussebi, F; Akdis, CA; Blaser, K; Hufnagl, P; Binder, BR; Politou, A; Pastore, A; Vangelista, L; Sperr, WR; Semper, H; Valent, P; Ebner, C; Kraft, D; Valenta, R				Vrtala, S; Hirtenlehner, K; Susani, M; Akdis, M; Kussebi, F; Akdis, CA; Blaser, K; Hufnagl, P; Binder, BR; Politou, A; Pastore, A; Vangelista, L; Sperr, WR; Semper, H; Valent, P; Ebner, C; Kraft, D; Valenta, R			Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1	FASEB JOURNAL			English	Article						type I allergy; vaccine; genetic engineering	T-CELL-CLONES; PHL P 1; QUANTITATIVE IGE INHIBITION; FC EPSILON RI; RBET V 1; IMMUNOLOGICAL CHANGES; CROSS-REACT; WILD-TYPE; EPITOPES; IMMUNOTHERAPY	An estimated 100 million individuals suffer from birch pollen allergy. Specific immunotherapy, the only curative allergy treatment, can cause life-threatening anaphylactic side effects. Here, we report the genetic engineering of a recombinant trimer consisting of three covalently linked copies of the major birch pollen allergen, Bet v 1. The trimer exhibited profoundly reduced allergenic activity but contained similar secondary structures such as Bet v 1 wild type, Bet v 1-specific B cell and T-cell epitopes, and induced Th1 cytokine release. As immunogen, rBet v 1 trimer induced IgG antibodies, which blocked patients' IgE binding to Bet v 1 and related allergens. Thus, rBet v 1 trimer represents a novel hypoallergenic vaccine prototype for treatment of one of the most frequent allergy forms.	Univ Vienna, Vienna Gen Hosp, Sch Med, Dept Pathophysiol, A-1090 Vienna, Austria; Austrian Acad Sci, Inst Mol Biol, A-5020 Salzburg, Austria; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Univ Vienna, Sch Med, Dept Vasc Biol, A-1090 Vienna, Austria; Univ Crete, Sch Med, Iraklion 71100, Greece; Natl Inst Med Res, Mol Struct Div, London NW7 1AA, England; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Vienna, Vienna Gen Hosp, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria	University of Vienna; Austrian Academy of Sciences; Swiss Institute of Allergy & Asthma Research; University of Vienna; University of Crete; MRC National Institute for Medical Research; International Center for Genetic Engineering & Biotechnology (ICGEB); University of Vienna	Valenta, R (corresponding author), Univ Vienna, Vienna Gen Hosp, Sch Med, Dept Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@akh-wien.ac.at	Akdis, Cezmi/AAV-4844-2020; Test, Test/Y-7921-2019; Gamperl, Susi/V-2715-2019; Sperr, Mast/V-4767-2019; Test, PV/U-9451-2019; Valent, Peter/B-8533-2016	Akdis, Cezmi/0000-0001-8020-019X; Gamperl, Susi/0000-0003-0456-5095; Sperr, Mast/0000-0002-7778-5219; Valent, Peter/0000-0003-0456-5095; Sperr, Wolfgang/0000-0003-3288-8027; Valenta, Rudolf/0000-0001-5944-3365; Vrtala, Susanne/0000-0003-4250-8243; Vangelista, Luca/0000-0003-0764-5031				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis M, 1999, J IMMUNOL, V163, P466; Ball T, 1999, FASEB J, V13, P1277, DOI 10.1096/fasebj.13.11.1277; Bieber T, 1996, CURR OPIN IMMUNOL, V8, P773, DOI 10.1016/S0952-7915(96)80003-3; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1993, MOL IMMUNOL, V30, P1323, DOI 10.1016/0161-5890(93)90093-Q; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HoffmannSommergruber K, 1997, PROTEIN EXPRES PURIF, V9, P33, DOI 10.1006/prep.1996.0671; Kay A.B., 1997, ALLERGY ALLERGIC DIS; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Nopp A, 2000, J ALLERGY CLIN IMMUN, V106, P101, DOI 10.1067/mai.2000.106924; ORTEGA E, 1988, EMBO J, V7, P4101, DOI 10.1002/j.1460-2075.1988.tb03304.x; Pauli G, 2000, CLIN EXP ALLERGY, V30, P1076; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; Torigoe C, 1998, SCIENCE, V281, P568, DOI 10.1126/science.281.5376.568; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969, DOI 10.1016/S0091-6749(99)70077-1; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Vrtala S, 1998, J IMMUNOL, V160, P6137; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; ZWEIMAN B, 2000, INFLAMMATORY MECH AL	35	107	113	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2045	+		10.1096/fj.00-0767fje	http://dx.doi.org/10.1096/fj.00-0767fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511511				2022-12-28	WOS:000170318500016
J	Vitale, M; Matteucci, A; Manzoli, L; Rodella, L; Mariani, AR; Zauli, G; Falconi, M; Billi, AM; Martelli, AM; Gilmour, RS; Cocco, L				Vitale, M; Matteucci, A; Manzoli, L; Rodella, L; Mariani, AR; Zauli, G; Falconi, M; Billi, AM; Martelli, AM; Gilmour, RS; Cocco, L			Interleukin-2 activates nuclear phospholipase-C beta by mitogen-activated protein kinase-dependent phosphorylation in human natural killer cells	FASEB JOURNAL			English	Article						phospholipase C beta; NK cells; nucleus; interleukin-2; MAPK	FC-GAMMA-RIIIA; TYROSINE PHOSPHORYLATION; SWISS 3T3-CELLS; FRIEND-CELLS; IGF-I; RECEPTOR; SIGNAL; CYCLE; LOCALIZATION; STIMULATION	It is not yet clear whether nuclear phospholipase C (PLC) signaling is implicated in the response of primary cells to cytokines or not and, in particular, whether lymphocytes utilize the nuclear phosphoinositides breakdown as a step in the signal transduction generated by cytokine receptor triggering. Therefore, we have studied the repertoire and functional regulation of nuclear PLC, the key enzyme of phosphoinositides turnover, by interleukin-2 (IL-2) in primary human natural killer (NK) cells and its effects on the IL-2-driven NK cell proliferation. We found that 1) IL-2 stimulates nuclear PLC activity within 60 min of treatment; 2) NK cells express only the beta family of PLCs in the nucleus, and the isoform of this enzyme regulated by IL- 2 is PLC beta (1)b; 3) IL- 2 induces nuclear translocation of extracellular signal-related kinase (ERK)-2, or p42, and to a lesser extent, of ERK-1, or p44, of mitogen-activated protein kinase (MAPK), whose specific inhibition prevents the IL-2-driven nuclear PLC beta (1) activation; 4) PLC beta (1)b is serine-phosphorylated after IL- 2, and the phosphorylation is abolished after MAPK inhibition; and 5) inhibition of nuclear PLC activation leads to the inhibition of the IL-2-induced proliferation of NK cells. Altogether, our data indicate that nuclear PLC signaling is a downstream target of the ERK/MAPK pathway stimulated by IL-2 receptor triggering in human primary NK cells, and that the nuclear phosphoinositides turnover is a key step in proliferative response of NK cells to IL-2.	Univ Bologna, Dept Anat Sci, Cellular Signaling Lab, I-40126 Bologna, Italy; Univ Parma, Osped Maggiore, Inst Human Anat, I-43100 Parma, Italy; Res Inst Codivilla Putti, CNR, Inst Cytomorphol, I-40100 Bologna, Italy; Univ Brescia, Human Anat Div, Dept Biomed Sci & Biotechnol, I-25123 Brescia, Italy; Univ G dAnnunzio, Inst Human Morphol, I-66100 Chieti, Italy; Univ Bologna, Sch Pharm, Dept Anat Sci, I-40126 Bologna, Italy; Univ Auckland, Sch Med, Liggins Inst, Auckland, New Zealand	University of Bologna; University of Parma; University Hospital of Parma; Consiglio Nazionale delle Ricerche (CNR); University of Brescia; G d'Annunzio University of Chieti-Pescara; University of Bologna; University of Auckland	Cocco, L (corresponding author), Univ Bologna, Dept Anat Sci, Cellular Signaling Lab, Via Irnerio 48, I-40126 Bologna, Italy.	lcocco@biocfarm.unibo.it	Cocco, Lucio/AAI-2206-2020; Zauli, Giorgio/ABE-8001-2020; Rodella, Luigi Fabrizio/F-1079-2010; Vitale, Marco/O-8751-2015; Falconi, Massimo/K-2194-2016	Cocco, Lucio/0000-0002-9206-8277; Vitale, Marco/0000-0002-3261-6868; Falconi, Massimo/0000-0001-9654-7243; Rodella, Luigi Fabrizio/0000-0002-9497-4708; Zauli, Giorgio/0000-0002-3750-8698				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AZZONI L, 1992, J EXP MED, V176, P1745, DOI 10.1084/jem.176.6.1745; Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; Bahk YY, 1998, BBA-LIPID LIPID MET, V1389, P76, DOI 10.1016/S0005-2760(97)00128-8; COCCO L, 1994, CELL SIGNAL, V6, P481, DOI 10.1016/0898-6568(94)90001-9; Crawley JB, 1996, EUR J IMMUNOL, V26, P2717, DOI 10.1002/eji.1830261125; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; HEATON KM, 1995, HUM IMMUNOL, V42, P274, DOI 10.1016/0198-8859(94)00106-Z; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IRVINE R, 2000, SCIENCE; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; Karnitz LM, 1996, ADV IMMUNOL, V61, P147, DOI 10.1016/S0065-2776(08)60867-6; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; LEE CW, 1993, J BIOL CHEM, V268, P21318; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LIAO F, 1993, J IMMUNOL, V150, P2668; Liu KD, 1997, CURR BIOL, V7, P817, DOI 10.1016/S0960-9822(06)00369-1; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; MANZOLI L, 1995, CANCER RES, V55, P2978; Manzoli L, 1997, CANCER RES, V57, P2137; MARMIROLI S, 1994, J BIOL CHEM, V269, P13; Martelli AM, 1999, J CELL BIOCHEM, V72, P339, DOI 10.1002/(SICI)1097-4644(19990301)72:3<339::AID-JCB3>3.0.CO;2-L; MARTELLI AM, 1994, CANCER RES, V54, P2536; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; Martelli AM, 2000, FEBS LETT, V486, P230, DOI 10.1016/S0014-5793(00)02313-9; Matteucci A, 1998, CANCER RES, V58, P5057; MAZZONI M, 1992, BIOCHEM BIOPH RES CO, V187, P114, DOI 10.1016/S0006-291X(05)81466-4; MINAMI Y, 1995, CURR OPIN CELL BIOL, V7, P156, DOI 10.1016/0955-0674(95)80023-9; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Nelson BH, 1996, MOL CELL BIOL, V16, P309; NERI LM, 1994, FEBS LETT, V347, P63, DOI 10.1016/0014-5793(94)00508-7; PARK DG, 1993, J BIOL CHEM, V268, P3710; RABEN DM, 1994, J MEMBRANE BIOL, V142, P1; Rebollo A, 1996, ADV IMMUNOL, V63, P127, DOI 10.1016/S0065-2776(08)60856-1; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Sun B, 1997, J BIOL CHEM, V272, P26313, DOI 10.1074/jbc.272.42.26313; Taniguchi T, 1995, ANN NY ACAD SCI, V766, P235, DOI 10.1111/j.1749-6632.1995.tb26671.x; TING AT, 1992, J EXP MED, V176, P1751, DOI 10.1084/jem.176.6.1751; Trotta R, 1998, J IMMUNOL, V161, P6648; Umehara H, 1997, J IMMUNOL, V159, P1200; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; Wei S, 1998, J EXP MED, V187, P1753, DOI 10.1084/jem.187.11.1753; WHALEN MM, 1993, IMMUNOLOGY, V79, P542; Xu AM, 2001, MOL CELL BIOL, V21, P2981, DOI 10.1128/MCB.21.9.2981-2990.2001; York JD, 1998, ADV ENZYME REGUL, V38, P365, DOI 10.1016/S0065-2571(97)00018-6; YORK JD, 1994, J BIOL CHEM, V269, P7847; ZAHO K, 1998, CELL, V95, P625	51	37	39	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1789	+		10.1096/fj.01-0008fje	http://dx.doi.org/10.1096/fj.01-0008fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481231				2022-12-28	WOS:000169261200029
J	Coelho, ALJ; De Freitas, MS; Mariano-Oliveira, A; Oliveira-Carvalho, AL; Zingali, RB; Barja-Fidalgo, C				Coelho, ALJ; De Freitas, MS; Mariano-Oliveira, A; Oliveira-Carvalho, AL; Zingali, RB; Barja-Fidalgo, C			Interaction of disintegrins with human neutrophils induces cytoskeleton reorganization, focal adhesion kinase activation, and extracellular-regulated kinase-2 nuclear translocation, interfering with the chemotactic function	FASEB JOURNAL			English	Article						disintegrins; neutrophils; chemotaxis; tyrosine kinase pathway; actin cytoskeleton	SNAKE-VENOM DISINTEGRIN; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; CELL-ADHESION; ACTIN CYTOSKELETON; BINDING PROTEIN; INTEGRIN; CONTORTROSTATIN; ECHISTATIN	We previously demonstrated that jarastatin (JT), a new disintegrin from Bothrops jararaca venom, altered actin dynamics in human polymorphonuclear neutrophils (PMNs) and inhibited cell migration in vivo and in vitro (14). In this study, we evaluated the effects of JT and two other monomeric disintegrins, kistrin (KR) and flavoridin (FL), on PMN chemotaxis and chemokinesis in vitro and on the activation of integrin-mediated pathways. Although JT, but not KR or FL, was chemotactic, only KR was chemokinetic to PMN. However, preincubation of PMN with any disintegrins inhibited chemotaxis for fMLP. Treatment of PMN with JT and KR increased actin polymerization, whereas FL reduced the content of F-actin. The effects of JT and KR on actin dynamics were inhibited (50%) by genistein, a tyrosine kinase inhibitor. Accordingly, JT and KR induced an increase in tyrosine phosphorylation, whereas FL had no effect. The three disintegrins were able to induce focal adhesion kinase activation. However, JT and KR promoted Erk-2 nuclear translocation, and FL inhibited Erk-2 activation. The data suggest that although the disintegrins JT and KR directly activate integrin-coupled signaling, FL may interact differently with integrins, triggering an inhibitory pathway modulated by focal adhesion kinase activation.	Univ Estado Rio de Janeiro, Inst Biol, Dept Farmacol, BR-20551030 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, ICB, CCS, Dept Bioquim Med, Rio De Janeiro, Brazil	Universidade do Estado do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Barja-Fidalgo, C (corresponding author), Univ Estado Rio de Janeiro, Inst Biol, Dept Farmacol, Av 28 Setembro 87,5th Floor,Vila Isabel, BR-20551030 Rio De Janeiro, Brazil.	barja-fidalgo@uerj.br	de Freitas, Marta Sampaio/AAE-8422-2021; Zingali, Russolina/G-4862-2012	Zingali, Russolina/0000-0003-3156-6923				ANDERSON NG, 1992, CELL SIGNAL, V4, P239, DOI 10.1016/0898-6568(92)90063-E; Aplin AE, 1998, PHARMACOL REV, V50, P197; Asthagiri AR, 1999, J BIOL CHEM, V274, P27119, DOI 10.1074/jbc.274.38.27119; Belisario MA, 2000, BBA-MOL CELL RES, V1497, P227, DOI 10.1016/S0167-4889(00)00061-6; BOGOMOLSKIYAHALOM V, 1995, BLOOD REV, V9, P183, DOI 10.1016/0268-960X(95)90024-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN EJ, 1988, J EXP MED, V167, P777, DOI 10.1084/jem.167.3.777; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CARRENO MP, 1993, CLIN IMMUNOL IMMUNOP, V69, P43, DOI 10.1006/clin.1993.1148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chicurel ME, 1998, NATURE, V392, P730, DOI 10.1038/33719; Coelho ALJ, 1999, EXP CELL RES, V251, P379, DOI 10.1006/excr.1999.4583; Danen EHJ, 1998, EXP CELL RES, V238, P188, DOI 10.1006/excr.1997.3821; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOOLEY DC, 1982, EXP HEMATOL, V10, P591; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Juliano D, 1996, EXP CELL RES, V225, P132, DOI 10.1006/excr.1996.0164; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TH, 1989, CLIN SCI, V77, P195, DOI 10.1042/cs0770195; Lian JP, 1999, J IMMUNOL, V163, P4527; Lowell CA, 1999, J LEUKOCYTE BIOL, V65, P313, DOI 10.1002/jlb.65.3.313; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; McLane MA, 1996, FEBS LETT, V391, P139, DOI 10.1016/0014-5793(96)00716-8; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; Ritter MR, 2001, TOXICON, V39, P283, DOI 10.1016/S0041-0101(00)00126-4; Ritter MR, 2000, BIOCHEM BIOPH RES CO, V274, P142, DOI 10.1006/bbrc.2000.3111; Ritter MR, 2000, J CELL BIOCHEM, V79, P28, DOI 10.1002/1097-4644(2000)79:1<28::AID-JCB40>3.0.CO;2-Y; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Sheikh S, 1997, BIOCHEM BIOPH RES CO, V238, P910, DOI 10.1006/bbrc.1997.7407; Staiano N, 1997, EUR J CELL BIOL, V73, P298; Stanton KJ, 1999, J LEUKOCYTE BIOL, V65, P515, DOI 10.1002/jlb.65.4.515; Williams MA, 1999, J LEUKOCYTE BIOL, V65, P725, DOI 10.1002/jlb.65.6.725; Zouki C, 2001, FASEB J, V15, P25	42	34	34	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1643	+		10.1096/fj.00-0812fje	http://dx.doi.org/10.1096/fj.00-0812fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427513				2022-12-28	WOS:000173707700007
J	Elkin, M; Ilan, N; Ishai-Michaeli, R; Friedmann, Y; Papo, O; Pecker, I; Vlodavsky, I				Elkin, M; Ilan, N; Ishai-Michaeli, R; Friedmann, Y; Papo, O; Pecker, I; Vlodavsky, I			Heparanase as mediator of angiogenesis: mode of action	FASEB JOURNAL			English	Article						heparan sulfate proteoglycans; extracellular matrix; endothelial cells; basic fibroblast growth factor; wound healing	FIBROBLAST-GROWTH-FACTOR; EXTRACELLULAR-MATRIX; TUMOR-METASTASIS; SULFATE PROTEOGLYCANS; MAMMALIAN HEPARANASE; ENDOTHELIAL-CELLS; BASEMENT-MEMBRANE; RECEPTOR-BINDING; HEPARIN; EXPRESSION	Extracellular matrix (ECM) and basement membranes (BMs) present a physical barrier that requires enzymatic degradation during endothelial cell (EC) sprouting at early stages of angiogenesis. These multimolecular structures also serve as a storage depot for heparin-binding angiogenic factors. Heparan sulfate proteoglycans (HSPGs) are responsible for the self-assembly and integrity of the ECM and BM structure, as well as for sequestration of growth and differentiation factors. Recently, we reported the cloning of heparanase, an endo-beta-D-glucuronidase degrading heparan sulfate (HS), and provided direct evidence for its role in tumor metastasis. We now demonstrate that heparanase is intimately involved in angiogenesis and elucidate its mode of action. Apart from its direct involvement in ECM degradation and EC migration (vascular sprouting), heparanase releases active basic fibroblast growth factor (bFGF) from the subendothelial ECM, as well as bFGF-stimulating HS degradation fragments from the EC surface. Interestingly, ECM-derived HS fragments induced little or no potentiation of the growth-promoting activity of bFGF. The angiogenic effect of heparanase was demonstrated in vivo (via the Matrigel plug assay) by showing a three- to fourfold increase in neovascularization induced by murine T-lymphoma cells after stable transfection with the heparanase gene. Increased tissue vascularity was also observed in a mouse wound-healing model in response to topical administration of recombinant heparanase. Immunohistochemical staining of human colon carcinoma tissue revealed a high expression of the heparanase protein in the endothelium of sprouting capillaries and small vessels, but not of mature quiescent blood vessels. The ability of heparanase to promote tumor angiogenesis and its involvement in tumor metastasis make it a promising target for cancer therapy.	Hadassah Hebrew Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Hadassah Hebrew Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; InSight, IL-76121 Rehovot, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	Vlodavsky, I (corresponding author), Hadassah Hebrew Univ Hosp, Dept Oncol, POB 12000, IL-91120 Jerusalem, Israel.	vlodavsk@cc.huji.ac.il						AIRBANKS MB, 1999, J BIOL CHEM, V274, P29587; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Chang Z, 2000, FASEB J, V14, P137, DOI 10.1096/fasebj.14.1.137; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; GILAT D, 1995, J EXP MED, V181, P1929, DOI 10.1084/jem.181.5.1929; GODDER K, 1991, J CELL PHYSIOL, V148, P274, DOI 10.1002/jcp.1041480213; Goshen R, 1996, MOL HUM REPROD, V2, P679, DOI 10.1093/molehr/2.9.679; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Ilan N, 1999, J CELL SCI, V112, P3005; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; Miao HQ, 1997, J CLIN INVEST, V99, P1565, DOI 10.1172/JCI119319; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Parish CR, 1999, CANCER RES, V59, P3433; PARISH CR, 1987, INT J CANCER, V40, P511, DOI 10.1002/ijc.2910400414; PASSANITI A, 1992, LAB INVEST, V67, P519; Pillarisetti S, 1997, J BIOL CHEM, V272, P15753, DOI 10.1074/jbc.272.25.15753; Schweitzer KM, 1997, LAB INVEST, V76, P25; SLOANE BF, 1994, J CELL SCI, V107, P373; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; VLODAVSKY I, 1994, INVAS METAST, V14, P290; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; VLODAVSKY I, 1993, BASEMENT MEMBRANES C, P327; VLODAVSKY I, 1999, CURRENT PROTOCOLS CE, V1; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q	34	271	295	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1661	+		10.1096/fj.00-0895fje	http://dx.doi.org/10.1096/fj.00-0895fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427519				2022-12-28	WOS:000173707700003
J	Rimondini, R; Arlinde, C; Sommer, W; Heilig, M				Rimondini, R; Arlinde, C; Sommer, W; Heilig, M			Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol	FASEB JOURNAL			English	Article						alcoholism; gene chip; expression profiling; cingulate cortex; amygdala	CANNABINOID RECEPTOR; COUPLING EFFICIENCY; PLASMA-MEMBRANE; GENE-EXPRESSION; ANIMAL-MODEL; KAPPA-B; PROTEIN; GLUTAMATE; BINDING; ACAMPROSATE	Prolonged exposure of the brain to ethanol is a prerequisite for developing ethanol dependence, but the underlying neural adaptations are unknown. Here we demonstrate that rats subjected to repeated cycles of intoxication and withdrawal develop a marked and long-lasting increase in voluntary ethanol intake. Exposure-induced but not spontaneous alcohol intake is antagonized by acamprosate, a compound clinically effective in human alcoholism. Expression analysis of cingulate cortex and amygdala reveals a set of long-term up-regulated transcripts in this model. These include members of pathways previously implicated in alcohol dependence (glutamatergic, endocannabinoid, and monoaminergic neurotransmission), as well as pathways not previously thought to be involved in this disorder (e. g., members of the mitogen-activated protein kinase pathway). Thus, alternating periods of ethanol intoxication and withdrawal are sufficient to induce an altered functional brain state, which is likely to be encoded by long-term changes in gene expression. These observations may have important implications for how alcoholism is managed clinically. Novel clinically effective treatments may be possible to develop by targeting the products of genes found to be regulated in our model.	Karolinska Inst, NEUROTEC, Stockholm, Sweden	Karolinska Institutet	Heilig, M (corresponding author), M46 Huddinge Univ Hosp, S-14186 Huddinge, Sweden.	Markus.Heilig@neurotec.ki.se	Sommer, Wolfgang H./I-4809-2019; roberto, rimondini/AAC-3525-2019; Rimondini, Roberto/B-2500-2010	Sommer, Wolfgang H./0000-0002-5903-6521; roberto, rimondini/0000-0003-4099-513X; Rimondini, Roberto/0000-0003-4099-513X				al Qatari M, 1998, ALCOHOL CLIN EXP RES, V22, P810, DOI 10.1097/00000374-199806000-00006; Basavarajappa BS, 1998, BRAIN RES, V793, P212, DOI 10.1016/S0006-8993(98)00175-9; Basavarajappa BS, 1999, J NEUROCHEM, V72, P522, DOI 10.1046/j.1471-4159.1999.0720522.x; Basavarajappa BS, 2000, BBA-MOL BASIS DIS, V1535, P78, DOI 10.1016/S0925-4439(00)00085-5; Blondeau N, 2001, J NEUROSCI, V21, P4668, DOI 10.1523/JNEUROSCI.21-13-04668.2001; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; BREESE CR, 1995, BRAIN RES, V674, P82, DOI 10.1016/0006-8993(94)01384-T; Colombo G, 1998, ALCOHOL ALCOHOLISM, V33, P126; CONNOR JR, 1994, DEV NEUROSCI-BASEL, V16, P233, DOI 10.1159/000112115; Daaka Y, 1997, DNA CELL BIOL, V16, P301, DOI 10.1089/dna.1997.16.301; De Fonseca FR, 1999, ACTA PHARMACOL SIN, V20, P1109; Dingledine R, 1999, PHARMACOL REV, V51, P7; Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597; Fadda F, 1998, PROG NEUROBIOL, V56, P385, DOI 10.1016/S0301-0082(98)00032-X; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fletcher LM, 1996, J GASTROEN HEPATOL, V11, P1039, DOI 10.1111/j.1440-1746.1996.tb00032.x; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Gallate JE, 1999, PSYCHOPHARMACOLOGY, V142, P302, DOI 10.1007/s002130050893; Gerlach M, 2001, ALCOHOL ALCOHOLISM, V36, P65, DOI 10.1093/alcalc/36.1.65; Gurguis GNM, 1998, EUR J PHARMACOL, V363, P241, DOI 10.1016/S0014-2999(98)00810-3; Gurguis GNM, 1999, PSYCHOPHARMACOLOGY, V145, P31, DOI 10.1007/s002130051029; Heaton MB, 2000, NEUROSCI LETT, V291, P121, DOI 10.1016/S0304-3940(00)01398-7; Heyser CJ, 1998, NEUROPSYCHOPHARMACOL, V18, P125, DOI 10.1016/S0893-133X(97)00130-9; HYYTIA P, 1995, EUR J PHARMACOL, V283, P151, DOI 10.1016/0014-2999(95)00314-B; Ingvar M, 1998, J STUD ALCOHOL, V59, P258, DOI 10.15288/jsa.1998.59.258; Koob GF, 2000, ADDICTION, V95, pS73; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lee PDK, 1997, P SOC EXP BIOL MED, V216, P319; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; Liu J, 2000, BIOCHEM J, V346, P835, DOI 10.1042/0264-6021:3460835; LOGAN A, 1994, ENDOCRINOLOGY, V135, P2255, DOI 10.1210/en.135.5.2255; Madrigal JLM, 2001, J NEUROCHEM, V76, P532, DOI 10.1046/j.1471-4159.2001.00108.x; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Mason B J, 2000, CNS Spectr, V5, P58; McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40; Moller C, 1997, BRAIN RES, V760, P94, DOI 10.1016/S0006-8993(97)00308-9; Naassila M, 1998, ALCOHOL CLIN EXP RES, V22, P802; Naassila M, 2000, PHARMACOL BIOCHEM BE, V67, P629, DOI 10.1016/S0091-3057(00)00407-X; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nielsen DM, 1999, BRAIN RES, V823, P59, DOI 10.1016/S0006-8993(99)01099-9; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66; Otten U, 2000, ANN NY ACAD SCI, V917, P322; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; Pesce L, 2000, FEBS LETT, V486, P310, DOI 10.1016/S0014-5793(00)02298-5; Porrino LJ, 1998, ALCOHOL CLIN EXP RES, V22, P176, DOI 10.1097/00000374-199802000-00024; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; Roberts AJ, 1999, ALCOHOL CLIN EXP RES, V23, P1151, DOI 10.1097/00000374-199907000-00003; Roberts AJ, 2000, NEUROPSYCHOPHARMACOL, V22, P581, DOI 10.1016/S0893-133X(99)00167-0; Roche JP, 1999, MOL PHARMACOL, V56, P611, DOI 10.1124/mol.56.3.611; ROGERS J, 1979, BEHAV NEURAL BIOL, V27, P466, DOI 10.1016/S0163-1047(79)92061-2; ROSSETTI ZL, 1995, EUR J PHARMACOL, V283, P177, DOI 10.1016/0014-2999(95)00344-K; Ryu J, 2000, J BIOL CHEM, V275, P29955, DOI 10.1074/jbc.M001220200; SHERIF F, 1993, ALCOHOL CLIN EXP RES, V17, P1313, DOI 10.1111/j.1530-0277.1993.tb05247.x; Spanagel R, 1997, TRENDS PHARMACOL SCI, V18, P54, DOI 10.1016/S0165-6147(97)89800-8; Spanagel R, 2000, J NEURAL TRANSM, V107, P669, DOI 10.1007/s007020070068; Thorsell A, 2000, P NATL ACAD SCI USA, V97, P12852, DOI 10.1073/pnas.220232997; Ulrichsen J, 1998, ALCOHOL ALCOHOLISM, V33, P230; Vanhoutte P, 1999, MOL CELL BIOL, V19, P136; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999	63	251	255	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					27	35		10.1096/fj.01-0593com	http://dx.doi.org/10.1096/fj.01-0593com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11772933				2022-12-28	WOS:000173656600004
J	van Royen, N; Hoefer, I; Buschmann, I; Heil, M; Kostin, S; Deindl, E; Vogel, S; Korff, T; Augustin, H; Bode, C; Piek, JJ; Schaper, W				van Royen, N; Hoefer, I; Buschmann, I; Heil, M; Kostin, S; Deindl, E; Vogel, S; Korff, T; Augustin, H; Bode, C; Piek, JJ; Schaper, W			Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation	FASEB JOURNAL			English	Article						collateral circulation; angiogenesis; arteries; remodeling; leukocytes	GROWTH-FACTOR-BETA; HUMAN ATHEROSCLEROTIC LESIONS; FEMORAL-ARTERY OCCLUSION; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; CORONARY ANGIOGENESIS; MYOCARDIAL-INFARCTION; ENDOTHELIAL-CELLS; RABBIT HINDLIMB; EXPRESSION	Increased expression of transforming growth factor beta1 (TGF-beta(1)) during collateral artery growth, as well as its numerous effects on monocytes/macrophages and the smooth muscle cell cycle and differentiation, suggest a modulating role for this growth factor during arteriogenesis. We studied the effects of exogenously applied TGF-beta(1) on arteriogenesis as well as its interactions with monocytes, endothelial cells, and smooth muscle cells. In a New Zealand White (NZW) rabbit model of femoral artery ligation, increased expression of active TGF-beta(1) was found around proliferating arteries in NZW rabbits. The exogenous application of TGF-beta(1) led to an increase in both the number of visible collateral arteries as well as the conductance of the collateral circulation (4.0 +/- 0.5 ml/min/100 mmHg vs. 28.9 +/- 3.7 ml/min/100 mmHg, P < 0.05). Fluorescence activated cell sorting analysis showed an increase in the expression of the MAC-1 receptor in both rabbit and human monocytes after treatment with TGF-beta(1) (control: 91.2 +/- 4.2/482 +/- 21.7; TGF-beta(1) 200 ng/ml 193.9 +/- 6.7/675.5 +/- 25.7, P < 0.05 for all differences). TGF-beta(1) treated monocytes showed an increased endothelial adhesion and transmigration in transendothelial migration assays (5.75 +/- 0.63 x 10(5) vs. 10.11 +/- 0.04 x 10(5), P < 0.05). TGF-beta(1) had no direct pro-angiogenic effect on human umbilical vein endothelial cells in a spheroid model of angiogenesis and inhibited the angiogenic effects of vascular endothelial growth factor.	Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands; Max Planck Inst Physiol & Clin Res, Dept Expt Cardiol, D-6350 Bad Nauheim, Germany; Univ Freiburg, Dept Cardiol & Angiol, Res Grp Expt & Clin Arteriogenesis, Freiburg, Germany; Clin Tumorbiol Angiogenesis Res Ctr, Freiburg, Germany	University of Amsterdam; Academic Medical Center Amsterdam; Max Planck Society; University of Freiburg	van Royen, N (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Cardiol, Room B2-250,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	n.vanroyen@amc.uva.nl	Augustin, Hellmut/AAA-5246-2020; van Royen, Niels/Q-1097-2017; Deindl, Elisabeth/A-2511-2013	Augustin, Hellmut/0000-0002-7173-4242; 				Arras M, 1998, BASIC RES CARDIOL, V93, P97, DOI 10.1007/s003950050069; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BAROLDI G, 1956, CIRC RES, V4, P223, DOI 10.1161/01.RES.4.2.223; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; Blumgart HL, 1940, AM HEART J, V19, P1, DOI 10.1016/S0002-8703(40)90305-2; Bobik A, 1999, CIRCULATION, V99, P2883, DOI 10.1161/01.CIR.99.22.2883; Cai WJ, 2000, J MOL CELL CARDIOL, V32, P997, DOI 10.1006/jmcc.2000.1137; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CHANTRY D, 1989, J IMMUNOL, V142, P4295; Cucina A, 1998, SURGERY, V123, P212, DOI 10.1067/msy.1998.83187; Deindl E, 2001, CIRC RES, V89, P779, DOI 10.1161/hh2101.098613; Epstein SE, 2001, CIRCULATION, V104, P115, DOI 10.1161/01.CIR.104.1.115; FALANGA V, 1991, J INVEST DERMATOL, V97, P634, DOI 10.1111/1523-1747.ep12483126; Fuchs S, 2001, CORONARY ARTERY DIS, V12, P173, DOI 10.1097/00019501-200105000-00003; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195-74; Grainger DJ, 1998, J CELL SCI, V111, P2977; GRAINGER DJ, 1995, BIOL REV, V70, P571, DOI 10.1111/j.1469-185X.1995.tb01652.x; Heil M, 2000, EUR J CELL BIOL, V79, P850, DOI 10.1078/0171-9335-00113; Hershey JC, 2001, CARDIOVASC RES, V49, P618, DOI 10.1016/S0008-6363(00)00232-7; Hoefer IE, 2001, CARDIOVASC RES, V49, P609, DOI 10.1016/S0008-6363(00)00243-1; ITO N, 1995, CANCER LETT, V89, P45, DOI 10.1016/0304-3835(94)03651-X; Ito WD, 1997, AM J PHYSIOL-HEART C, V273, pH1255, DOI 10.1152/ajpheart.1997.273.3.H1255; Ito WD, 1997, CIRC RES, V80, P829; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kern MJ, 1999, J INTERV CARDIOL, V12, P313, DOI 10.1111/j.1540-8183.1999.tb00251.x; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Korff T, 1999, J CELL SCI, V112, P3249; Kostin S, 1999, CIRC RES, V85, P154, DOI 10.1161/01.RES.85.2.154; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; LONGLAND CJ, 1953, ANN ROY COLL SURG, V13, P161; Lutgens E, 2000, P NATL ACAD SCI USA, V97, P7464, DOI 10.1073/pnas.97.13.7464; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; McCaffrey TA, 1995, J CLIN INVEST, V96, P2667, DOI 10.1172/JCI118333; McCartney-Francis N, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011007; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; OBrien ER, 1996, ARTERIOSCL THROM VAS, V16, P576, DOI 10.1161/01.ATV.16.4.576; Panousis CG, 2001, J LIPID RES, V42, P856; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; Reckless J, 1997, CIRCULATION, V95, P1542; Rinsch C, 2001, GENE THER, V8, P523, DOI 10.1038/sj.gt.3301436; SAKUDA H, 1992, AM J PATHOL, V141, P1507; SCHAPER J, 1976, VIRCHOWS ARCH A, V370, P193, DOI 10.1007/BF00427580; Schaper W, 1993, COLLATERAL CIRCULATI; Scholz D, 2000, VIRCHOWS ARCH, V436, P257, DOI 10.1007/s004280050039; Simons M, 2000, CIRCULATION, V102, pE73, DOI 10.1161/01.CIR.102.11.e73; Simons M, 2001, AM J PHYSIOL-HEART C, V280, pH1923, DOI 10.1152/ajpheart.2001.280.5.H1923; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; Tomanek RJ, 2001, CIRC RES, V88, P1135, DOI 10.1161/hh1101.091191; TURNER M, 1990, Cytokine, V2, P211, DOI 10.1016/1043-4666(90)90018-O; van Royen N, 2001, CARDIOVASC RES, V49, P543, DOI 10.1016/S0008-6363(00)00206-6; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Wang XL, 1997, CARDIOVASC RES, V34, P404, DOI 10.1016/S0008-6363(97)00033-3; WISEMAN DM, 1988, BIOCHEM BIOPH RES CO, V157, P793, DOI 10.1016/S0006-291X(88)80319-X; WUNSCH M, 1991, J MOL CELL CARDIOL, V23, P1051, DOI 10.1016/0022-2828(91)91640-D; Youn TJ, 1999, BASIC RES CARDIOL, V94, P246, DOI 10.1007/s003950050149; Zheng W, 2001, AM J PHYSIOL-HEART C, V280, pH909, DOI 10.1152/ajpheart.2001.280.2.H909; [No title captured]	61	126	129	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					432	+		10.1096/fj.01-0563fje	http://dx.doi.org/10.1096/fj.01-0563fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11821255				2022-12-28	WOS:000173656600011
J	Hwang, YC; Sato, SN; Tsai, JY; Yan, SD; Bakr, S; Zhang, HP; Oates, PJ; Ramasamy, R				Hwang, YC; Sato, SN; Tsai, JY; Yan, SD; Bakr, S; Zhang, HP; Oates, PJ; Ramasamy, R			Aldose reductase activation is a key component of myocardial response to ischemia	FASEB JOURNAL			English	Article						aldose reductase; ischemia-reperfusion; myocardial metabolism	LIPID-PEROXIDATION PRODUCT; PERFUSED RAT-HEART; MUSCLE CELL-GROWTH; DIABETIC COMPLICATIONS; GLUCOSE-OXIDATION; NITRIC-OXIDE; ALDEHYDE REDUCTASE; IN-VITRO; METABOLISM; INJURY	Aldose reductase, a member of the aldo-keto reductase family, has been implicated in the development of vascular and neurological complications in diabetes. Despite recent studies from our laboratory demonstrating protection of ischemic hearts by an aldose reductase inhibitor, the presence and influence of aldose reductase in cardiac tissue remain unknown. Our goal in this study was to isolate and characterize the kinetic properties of cardiac aldose reductase, as well as to study the impact of flux via this enzyme on glucose metabolism and contractile function in hearts subjected to ischemia-reperfusion. Results demonstrate that ischemia increases myocardial aldose reductase activity and that these increases are, in part, due to activation by nitric oxide. The kinetic parameter of cardiac aldose reductase (K-cat) was significantly higher in ischemic tissues. Aldose reductase inhibition increased glycolysis and glucose oxidation. Aldose reductase inhibited hearts, when subjected to ischemia/reperfusion, exhibited less ischemic injury and was associated with lower lactate/pyruvate ratios (a measure of cytosolic NADH/NAD(+)), greater tissue content of adenosine triphosphate, and improved cardiac function. These findings indicate that aldose reductase is a component of ischemic injury and that pharmacological inhibitors of aldose reductase present a novel adjunctive approach for protecting ischemic hearts.	Columbia Univ Coll Phys & Surg, Dept Med, Div Cardiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; NEI, Lab Ocular Therapeut, NIH, Bethesda, MD 20892 USA; Pfizer Global Res & Dev, Dept Cardiovasc & Metab Dis, Groton, CT USA	Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Pfizer	Ramasamy, R (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, Div Cardiol, PH 10-403,630 W 168th St, New York, NY 10032 USA.	rr260@columbia.edu		Ramasamy, Ravichandran/0000-0002-3666-3346				BERGMEYER HU, 1995, METHOD ENZYMAT AN, V6, P570; Bhatnagar A, 1999, ADV EXP MED BIOL, V463, P223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODERICK TL, 1992, J BIOL CHEM, V267, P3758; BRODERICK TL, 1993, CIRCULATION, V87, P972, DOI 10.1161/01.CIR.87.3.972; Busik JV, 1997, J CLIN INVEST, V100, P1685, DOI 10.1172/JCI119693; DAS B, 1985, DIABETES, V34, P1145, DOI 10.2337/diabetes.34.11.1145; DEPRE C, 1994, FEBS LETT, V345, P241, DOI 10.1016/0014-5793(94)00459-5; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; GHAHARY A, 1991, DIABETES, V40, P1391, DOI 10.2337/diabetes.40.11.1391; GREENE DA, 1993, DIABETES METAB REV, V9, P189, DOI 10.1002/dmr.5610090304; GREENE DA, 1987, NEW ENGL J MED, V316, P599; GREENE DA, 1985, DIABETES CARE, V8, P290, DOI 10.2337/diacare.8.3.290; Grimshaw CE, 1996, ARCH BIOCHEM BIOPHYS, V327, P89, DOI 10.1006/abbi.1996.0096; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; GRIMSHAW CE, 1990, ARCH BIOCHEM BIOPHYS, V278, P273, DOI 10.1016/0003-9861(90)90259-2; HARRISON DH, 1994, BIOCHEMISTRY-US, V33, P2011, DOI 10.1021/bi00174a006; Jez JM, 1997, ADV EXP MED BIOL, V414, P579; KADOR PF, 1985, AM J MED, V79, P8, DOI 10.1016/0002-9343(85)90504-2; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; Keogh RJ, 1997, METABOLISM, V46, P41, DOI 10.1016/S0026-0495(97)90165-7; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; LOPASCHUK GD, 1992, J PHARMACOL EXP THER, V260, P1220; Lundmark JL, 1999, AM J PHYSIOL-HEART C, V277, pH999, DOI 10.1152/ajpheart.1999.277.3.H999; MALONE JI, 1980, DIABETES, V29, P861, DOI 10.2337/diabetes.29.11.861; McCormack JG, 1996, CIRCULATION, V93, P135, DOI 10.1161/01.CIR.93.1.135; Obrosova I, 1997, CURR EYE RES, V16, P34, DOI 10.1076/ceyr.16.1.34.5113; Ramasamy R, 2001, AM J PHYSIOL-HEART C, V281, pH290, DOI 10.1152/ajpheart.2001.281.1.H290; Ramasamy R, 2001, CARDIOVASC RES, V51, P275, DOI 10.1016/S0008-6363(01)00301-7; Ramasamy R, 1997, DIABETES, V46, P292, DOI 10.2337/diabetes.46.2.292; Ramasamy R, 1999, CARDIOVASC RES, V42, P130, DOI 10.1016/S0008-6363(98)00303-4; Ramasamy R, 1998, AM J PHYSIOL-HEART C, V275, pH195, DOI 10.1152/ajpheart.1998.275.1.H195; Ruef J, 1998, CIRCULATION, V97, P1071, DOI 10.1161/01.CIR.97.11.1071; Ruef J, 2000, ARTERIOSCL THROM VAS, V20, P1745, DOI 10.1161/01.ATV.20.7.1745; SATO S, 1992, AM J PHYSIOL, V263, pF799, DOI 10.1152/ajprenal.1992.263.5.F799; SATO S, 1990, BIOCHEM PHARMACOL, V40, P1033, DOI 10.1016/0006-2952(90)90490-C; Seo HG, 2000, MOL PHARMACOL, V57, P709, DOI 10.1124/mol.57.4.709; Srivastava S, 2001, BIOCHEM J, V358, P111, DOI 10.1042/0264-6021:3580111; Srivastava S, 1998, J BIOL CHEM, V273, P10893, DOI 10.1074/jbc.273.18.10893; SRIVASTAVA SK, 1986, METABOLISM, V35, P114, DOI 10.1016/0026-0495(86)90199-X; Stanley WC, 1997, CARDIOVASC RES, V33, P243, DOI 10.1016/S0008-6363(96)00245-3; Tracey WR, 2000, AM J PHYSIOL-HEART C, V279, pH1447, DOI 10.1152/ajpheart.2000.279.4.H1447; Trueblood N, 1998, AM J PHYSIOL-HEART C, V275, pH75, DOI 10.1152/ajpheart.1998.275.1.H75; Trueblood NA, 2000, AM J PHYSIOL-HEART C, V279, pH764, DOI 10.1152/ajpheart.2000.279.2.H764; Turner A J, 1982, Prog Clin Biol Res, V114, P401; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804	47	85	95	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					243	+		10.1096/fj.01-0368fje	http://dx.doi.org/10.1096/fj.01-0368fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11772943				2022-12-28	WOS:000172964800004
J	Li, DL; Turi, TG; Schuck, A; Freedberg, IM; Khitrov, G; Blumenberg, M				Li, DL; Turi, TG; Schuck, A; Freedberg, IM; Khitrov, G; Blumenberg, M			Rays and arrays: the transcriptional program in the response of human epidermal keratinocytes to UVB illumination	FASEB JOURNAL			English	Article						aging; cornified envelope; DNA repair; IL-8; skin	NF-KAPPA-B; PROTEIN-KINASE PATHWAYS; GENE-EXPRESSION; DNA-DAMAGE; ULTRAVIOLET-LIGHT; C-JUN; GROWTH-FACTOR; HUMAN SKIN; IN-VIVO; POSTTRANSCRIPTIONAL REGULATION	The epidermis, our first line of defense from ultraviolet (UV) light, bears the majority of photodamage, which results in skin thinning, wrinkling, keratosis, and malignancy. Hypothesizing that skin has specific mechanisms to protect itself and the organism from UV damage, we used DNA arrays to follow UV-caused gene expression changes in epidermal keratinocytes. Of the 6,800 genes examined, UV regulates the expression of at least 198. Three waves of changes in gene expression can be distinguished, 0.5-2, 4-8, and 16-24 h after illumination. The first contains transcription factors, signal transducing, and cytoskeletal proteins that change cell phenotype from a normal, fast-growing cell to an activated, paused cell. The second contains secreted growth factors, cytokines, and chemokines; keratinocytes, having changed their own physiology, alert the surrounding tissues to the UV damage. The third wave contains components of the cornified envelope, as keratinocytes enhance the epidermal protective covering and, simultaneously, terminally differentiate and die, removing a carcinogenic threat. UV also induces the expression of mitochondrial proteins that provide additional energy, and the enzymes that synthesize raw materials for DNA repair. Using a novel skin organ culture model, we demonstrated that the UV-induced changes detected in keratinocyte cultures also occur in human epidermis in vivo.	NYU, Sch Med, RO Perelman Dept Dermatol, New York, NY 10016 USA; Pfizer Inc, Div Cent Res, Groton, CT 06340 USA; NYU, Sch Med, Kaplan Canc Res Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA	New York University; Pfizer; New York University; New York University; New York University	Blumenberg, M (corresponding author), NYU, Sch Med, RO Perelman Dept Dermatol, 550 1st Ave, New York, NY 10016 USA.	blumem01@med.nyu.edu						ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Alhonen L, 1998, J BIOL CHEM, V273, P1964, DOI 10.1074/jbc.273.4.1964; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Aragane Y, 1997, P NATL ACAD SCI USA, V94, P11490, DOI 10.1073/pnas.94.21.11490; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Batty DP, 2000, GENE, V241, P193, DOI 10.1016/S0378-1119(99)00489-8; Beissert S, 1999, J INVEST DERM SYMP P, V4, P61, DOI 10.1038/sj.jidsp.5640183; Bernerd F, 1999, P NATL ACAD SCI USA, V96, P11329, DOI 10.1073/pnas.96.20.11329; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; De Matteis MA, 2000, J CELL SCI, V113, P2331; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fujisawa H, 1997, J INTERF CYTOK RES, V17, P347, DOI 10.1089/jir.1997.17.347; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GARMYN M, 1995, DERMATOLOGY, V190, P305, DOI 10.1159/000246722; GEISER T, 1993, J BIOL CHEM, V268, P15419; Gilchrest BA, 1995, PHOTODAMAGE; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Hanada K, 1998, J INVEST DERMATOL, V111, P582, DOI 10.1046/j.1523-1747.1998.00342.x; HERRLICH P, 1994, ADV ENZYME REGUL, V34, P381, DOI 10.1016/0065-2571(94)90024-8; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; IYER V, 1998, SCIENCE, V283, P17; JIANG CK, 1994, MOL CELL BIOL, V14, P4759, DOI 10.1128/MCB.14.7.4759; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KEMENY L, 1995, INT ARCH ALLERGY IMM, V106, P351, DOI 10.1159/000236866; Kennedy M, 1997, INVEST OPHTH VIS SCI, V38, P2483; Komine M, 2001, J INVEST DERMATOL, V116, P330, DOI 10.1046/j.1523-1747.2001.01249.x; Komine M, 2000, J BIOL CHEM, V275, P32077, DOI 10.1074/jbc.M001253200; KREIS T, 1999, GUIDEBOOK CYTSKELETA; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Leverkus M, 1998, J INVEST DERMATOL, V110, P353, DOI 10.1046/j.1523-1747.1998.00154.x; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; MOSER B, 1993, BIOCHEM J, V294, P285, DOI 10.1042/bj2940285; Niu M, 2000, CELL ADHES COMMUN, V7, P311, DOI 10.3109/15419060009015002; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2000, CURR OPIN GENET DEV, V10, P100, DOI 10.1016/S0959-437X(99)00046-5; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; SIMON MM, 1994, J INVEST DERMATOL, V102, P422, DOI 10.1111/1523-1747.ep12372194; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARANI J, 1993, AM J PATHOL, V142, P189; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Zhang MC, 1999, MOL CELL BIOL, V19, P7314; Zhuang LH, 2000, J INTERF CYTOK RES, V20, P445, DOI 10.1089/10799900050023852	66	106	111	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2533	+		10.1096/fj.01-0172fje	http://dx.doi.org/10.1096/fj.01-0172fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641260				2022-12-28	WOS:000171372700022
J	Berry, D; Kwan, CP; Shriver, Z; Venkataraman, G; Sasisekharan, R				Berry, D; Kwan, CP; Shriver, Z; Venkataraman, G; Sasisekharan, R			Distinct heparan sulfate glycosaminoglycans are responsible for mediating fibroblast growth factor-2 biological activity through different fibroblast growth factor receptors	FASEB JOURNAL			English	Article						heparin; smooth muscle cells; BaF3	SMOOTH-MUSCLE CELLS; ENZYMATIC DEGRADATION; FACTOR-BINDING; PROTEOGLYCANS; ACTIVATION; BFGF; OLIGOSACCHARIDES; MITOGENESIS; SPECIFICITY; INHIBITION	Fibroblast growth factor (FGF) signaling is involved in many important biological processes such as smooth muscle cell (SMC) proliferation, a key event leading to atherosclerosis. It is well known that heparin/heparan sulfate-like glycosaminoglycans (HLGAGs), found ubiquitously on the cell surface and in the extracellular matrix, modulate FGF signaling by interacting with both FGF and FGF receptor (FGFR). To study the modulatory effect of SMC-derived HLGAGs on FGF2 signaling, we employed a panel of HLGAG-degrading enzymes, or heparinases, to depolymerize cell surface HLGAGs isolated from SMCs and assayed their abilities to modulate FGF2 activity on engineered cell lines expressing defined FGFR isoforms. Our findings indicate that FGF2-mediated proliferation is dependent on the composition of the SMC-derived HLGAG fragments as well as the type of FGFR isoform expressed. We postulate that the chemical composition and sequence of HLGAGs dictate the specificity of interactions between FGF2 and a given FGFR.	MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA	Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Harvard MIT Div Hlth Sci & Technol, 77 Massachusetts Ave,Bldg 16-561, Cambridge, MA 02139 USA.	rams@mit.edu		KWAN, CHI-PONG/0000-0002-7654-0826				Bjornsson S, 1998, ANAL BIOCHEM, V256, P229, DOI 10.1006/abio.1997.2494; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P21, DOI 10.1002/jcp.1041240105; Conrad H. E., 1998, HEPARIN BINDING PROT; Davis JC, 1999, BIOCHEM J, V341, P613, DOI 10.1042/0264-6021:3410613; Dowd CJ, 1999, J BIOL CHEM, V274, P5236, DOI 10.1074/jbc.274.8.5236; Duteil S, 1999, RAPID COMMUN MASS SP, V13, P1889, DOI 10.1002/(SICI)1097-0231(19991015)13:19<1889::AID-RCM719>3.0.CO;2-#; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Forsten KE, 1997, J CELL PHYSIOL, V172, P209, DOI 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S; FRITZE LMS, 1985, J CELL BIOL, V100, P1041, DOI 10.1083/jcb.100.4.1041; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Godavarti R, 1996, BIOCHEM BIOPH RES CO, V229, P770, DOI 10.1006/bbrc.1996.1879; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; HAHNENBERGER R, 1993, GLYCOBIOLOGY, V3, P567, DOI 10.1093/glycob/3.6.567; Han RO, 1997, AM J PHYSIOL-HEART C, V273, pH2586, DOI 10.1152/ajpheart.1997.273.6.H2586; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; LIN X, 1999, HEPARAN SULFATE PROT; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; MAJACK RA, 1984, J CELL PHYSIOL, V118, P253, DOI 10.1002/jcp.1041180306; Natke B, 1999, Angiogenesis, V3, P249, DOI 10.1023/A:1009008824246; NUGENT MA, 1993, CIRC RES, V73, P1051, DOI 10.1161/01.RES.73.6.1051; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; Padera R, 1999, FASEB J, V13, P1677, DOI 10.1096/fasebj.13.13.1677; Park YM, 1999, BIOCHEM J, V344, P723, DOI 10.1042/0264-6021:3440723; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P4176, DOI 10.1073/pnas.95.8.4176; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sasisekharan R, 1997, Angiogenesis, V1, P45, DOI 10.1023/A:1018318914258; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; Sperinde GV, 1998, BIOCHEMISTRY-US, V37, P13153, DOI 10.1021/bi980600z; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; VANNECK JW, 1995, BBA-GENE STRUCT EXPR, V1261, P210, DOI 10.1016/0167-4781(94)00247-Z; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P1892, DOI 10.1073/pnas.96.5.1892; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	50	13	13	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1422	+		10.1096/fj.00-0661fje	http://dx.doi.org/10.1096/fj.00-0661fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387244				2022-12-28	WOS:000173705800024
J	Cicala, C; Morello, S; Santagada, V; Caliendo, G; Sorrentino, L; Cirino, G				Cicala, C; Morello, S; Santagada, V; Caliendo, G; Sorrentino, L; Cirino, G			Pharmacological dissection of vascular effects caused by activation of protease-activated receptor 1 and 2 in anesthetized rats	FASEB JOURNAL			English	Article						nitric oxide; hypertension; blood pressure	THROMBIN-RECEPTOR; SMOOTH-MUSCLE; RECEPTOR-2-ACTIVATING PEPTIDES; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; IN-VIVO; PAR-2; CONTRACTILE; RESPONSES; DISTINCT	To clarify the role of protease-activated receptor 1 and 2 (PAR-1 and PAR-2) in controlling blood pressure, we evaluated changes in blood pressure induced by a peptide that activates the receptor PAR-1 (PAR-1AP, SFLLRNPND) and a peptide that activates the receptor PAR-2 (PAR-2AP, SLIGRL) in naive and ganglion-blocked anesthetized rats. The role of nitric oxide on the effects observed was also investigated. Intravenous injection of PAR-1AP induced a biphasic change in mean arterial blood pressure (MABP) characterized by hypotension followed by hypertension, the latter was enhanced strongly by ganglion-blockade. After L-NAME infusion in ganglion-blocked rats, hypertension induced by PAR-1AP was still increased, which returned to control value after L-arginine infusion. L-NAME did not inhibit PAR-1AP-induced hypotension. Intravenous injection of PAR-2AP induced a biphasic change in MABP, characterized by hypotension followed by a hypertensive phase that reached the maximum value in 5-6 min. Hypertension was abolished by ganglion-blockade and was restored by an infusion of L-NAME. This effect was reverted by L-arginine. L-NAME reduced the duration of hypotension induced by PAR-2AP. In conclusion, we define that PAR-1 mainly mediates hypertension, whereas PAR-2 mainly is responsible for hypotension. Furthermore, we give evidence for a hypertensive effect of PAR-2AP linked to a reflex mechanism that is modulated by nitric oxide.	Univ Naples Federico II, Dipartimento Farmacol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Chim Farmaceut, I-80131 Naples, Italy	University of Naples Federico II; University of Naples Federico II	Cicala, C (corresponding author), Univ Naples Federico II, Dipartimento Farmacol Sperimentale, Via Domenico Montesano 49, I-80131 Naples, Italy.	cicala@unina.it	Morello, Silvana/E-9328-2012; cicala, carla/AAK-3831-2020	Morello, Silvana/0000-0002-6541-0997; cicala, carla/0000-0002-8977-8251; Caliendo, Giuseppe/0000-0002-5098-6045; Cirino, Giuseppe/0000-0003-3954-4083				ALANI B, 1995, CAN J PHYSIOL PHARM, V73, P1203, DOI 10.1139/y95-172; ANTONACCIO MJ, 1993, J PHARMACOL EXP THER, V266, P125; Capers Q, 1997, CIRC RES, V80, P838; Cheung WM, 1998, CAN J PHYSIOL PHARM, V76, P16, DOI 10.1139/cjpp-76-1-16; Chintala MS, 1998, EUR J PHARMACOL, V349, P237, DOI 10.1016/S0014-2999(98)00200-3; Cicala C, 1999, CIRCULATION, V99, P2590, DOI 10.1161/01.CIR.99.19.2590; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; DEITCHMAN D, 1980, J PHARMACOL METHOD, V3, P311, DOI 10.1016/0160-5402(80)90073-X; DENNINGTON PM, 1994, CLIN EXP PHARMACOL P, V21, P349, DOI 10.1111/j.1440-1681.1994.tb02527.x; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Emilsson K, 1997, J VASC RES, V34, P267, DOI 10.1159/000159233; Fox MT, 1997, FEBS LETT, V417, P267, DOI 10.1016/S0014-5793(97)01298-2; Glusa E, 1996, SEMIN THROMB HEMOST, V22, P261, DOI 10.1055/s-2007-999017; Hamilton JR, 2000, BRIT J PHARMACOL, V130, P181, DOI 10.1038/sj.bjp.0703146; Hollenberg MD, 1996, MOL PHARMACOL, V49, P229; Hwa JJ, 1996, CIRC RES, V78, P581, DOI 10.1161/01.RES.78.4.581; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Komuro T, 1997, BRIT J PHARMACOL, V120, P851, DOI 10.1038/sj.bjp.0701003; LANIYONU AA, 1995, BRIT J PHARMACOL, V114, P1680, DOI 10.1111/j.1476-5381.1995.tb14957.x; Moffatt JD, 1998, BRIT J PHARMACOL, V125, P591, DOI 10.1038/sj.bjp.0702157; Molino M, 1998, ARTERIOSCL THROM VAS, V18, P825, DOI 10.1161/01.ATV.18.5.825; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; MURAMATSU I, 1992, CAN J PHYSIOL PHARM, V70, P996, DOI 10.1139/y92-137; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; NYSTEDT S, 1996, J BIOL CHEM, V21, P14010; ROY S, 1997, P W PHARMACOL SOC, V40, P50; Roy SS, 1998, BRIT J PHARMACOL, V123, P1434, DOI 10.1038/sj.bjp.0701726; Saifeddine M, 1996, BRIT J PHARMACOL, V118, P521, DOI 10.1111/j.1476-5381.1996.tb15433.x; Saifeddine M, 1998, BRIT J PHARMACOL, V125, P1445, DOI 10.1038/sj.bjp.0702213; SIMONET S, 1992, EUR J PHARMACOL, V216, P135, DOI 10.1016/0014-2999(92)90222-P; TESFAMARIAM B, 1994, CIRC RES, V74, P930, DOI 10.1161/01.RES.74.5.930; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	33	21	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1433	+		10.1096/fj.00-0633fje	http://dx.doi.org/10.1096/fj.00-0633fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387248				2022-12-28	WOS:000173705800020
J	Frangogiannis, NG; Mendoza, LH; Lewallen, M; Michael, LH; Smith, CW; Entman, ML				Frangogiannis, NG; Mendoza, LH; Lewallen, M; Michael, LH; Smith, CW; Entman, ML			Induction and suppression of interferon-inducible protein (IP)-10 in reperfused myocardial infarcts may regulate angiogenesis	FASEB JOURNAL			English	Article						endothelium; IP-10; TGF-beta; infarction; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; MICROVASCULAR HYPERPERMEABILITY; CHEMOKINE EXPRESSION; IN-VITRO; ISCHEMIA; CELLS; BETA; INHIBITION; ALPHA	Regulation of angiogenesis is dependent on the net biological balance between expression of angiogenic and angiostatic molecules in the injured tissue. Using a canine model of myocardial ischemia/reperfusion, we demonstrated that expression of the angiostatic chemokine interferon-inducible protein (IP-10) peaked at 1-3 h of reperfusion and virtually disappeared by 24 h of reperfusion. IP-10 mRNA and protein were localized in the venular endothelium during early reperfusion of ischemic myocardial segments and were not detected after 24 h. Endothelial cell proliferation was first noted after 24 h of reperfusion, and alphav beta3 expressing neovessels were seen after 72-120 h of reperfusion, suggesting that neovascularization began only when IP-10 expression was markedly reduced. Isolated canine venular endothelial cells expressed high levels of IP-10 and IL-8 mRNA upon stimulation with tumor necrosis factor (TNF) -alpha and endotoxin. Transforming growth factor (TGF) -beta, but not interleukin (IL) -10, decreased TNF-alpha-mediated IP-10 expression in canine endothelial cells. In contrast, TNF-alpha-mediated IL-8 induction was not affected by incubation with IL-10 or TGF-beta. Induction of angiostatic factors, such as IP-10, in the first hours following injury may be important in inhibiting premature neovessel formation, until the appropriate supportive matrix is present. IP-10 down-regulation by active TGF-beta may mediate the onset of neovascularization by allowing unopposed VEGF- and IL-8-mediated angiogenic activity.	Baylor Coll Med, Methodist Hosp, Dept Med, Cardiovasc Sci Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Sect Leukocyte Biol, DeBakey Heart Ctr, Houston, TX 77030 USA	Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Methodist DeBakey Heart & Vascular Center	Frangogiannis, NG (corresponding author), Baylor Coll Med, Dept Med, Cardiovasc Sci Sect, 1 Baylor Plaza,M-S F-602, Houston, TX 77030 USA.	ngf@bcm.tmc.edu		Frangogiannis, Nikolaos/0000-0002-8186-5131				ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Becker LC, 1999, AM J PHYSIOL-HEART C, V277, pH243, DOI 10.1152/ajpheart.1999.277.1.H243; Birdsall HH, 1997, CIRCULATION, V95, P684, DOI 10.1161/01.CIR.95.3.684; BONINI JA, 1991, BIOTECHNIQUES, V11, P708; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Buschmann I, 2000, J PATHOL, V190, P338, DOI 10.1002/(SICI)1096-9896(200002)190:3<338::AID-PATH594>3.0.CO;2-7; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Clark RAF, 1996, AM J PATHOL, V148, P1407; CLEUTJENS JPM, 1995, AM J PATHOL, V147, P325; Davis S, 1999, CURR TOP MICROBIOL, V237, P173; DiPietro LA, 1996, AM J PATHOL, V148, P1851; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1995, AM J PATHOL, V146, P1029; ENTMAN ML, 1994, CARDIOVASC RES, V28, P1301, DOI 10.1093/cvr/28.9.1301; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Folkman J, 1983, Symp Fundam Cancer Res, V36, P201; FORD JW, 1981, IN VITRO CELL DEV B, V17, P44, DOI 10.1007/BF02618029; Frangogiannis NG, 1999, HISTOCHEM J, V31, P221, DOI 10.1023/A:1003541332070; Frangogiannis NG, 1998, CIRCULATION, V98, P699, DOI 10.1161/01.CIR.98.7.699; Frangogiannis NG, 1998, CIRCULATION, V98, P687, DOI 10.1161/01.CIR.98.7.687; Frangogiannis NG, 1998, J MOL CELL CARDIOL, V30, P2567, DOI 10.1006/jmcc.1998.0829; Frangogiannis NG, 2000, J IMMUNOL, V165, P2798, DOI 10.4049/jimmunol.165.5.2798; Frangogiannis NG, 2000, CELL TISSUE RES, V302, P365, DOI 10.1007/s004410000274; GRANT DS, 1994, PATHOL RES PRACT, V190, P854; HASHIMOTO E, 1994, AM J PHYSIOL-HEART C, V267, pH1948; HERSKOWITZ A, 1995, AM J PATHOL, V146, P419; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; Ito S, 1999, BLOOD, V93, P1456, DOI 10.1182/blood.V93.5.1456; Keane M P, 1999, Chem Immunol, V72, P86, DOI 10.1159/000058728; Keane MP, 1999, J IMMUNOL, V163, P5686; Keane MP, 1998, P ASSOC AM PHYSICIAN, V110, P288; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kopydlowski KM, 1999, J IMMUNOL, V163, P1537; KUKIELKA GL, 1995, J CLIN INVEST, V95, P89, DOI 10.1172/JCI117680; KUNKEL SL, 1995, AGENT ACTION SUPPL, V46, P11; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; LEFER AM, 1993, P NATL ACAD SCI USA, V90, P1018, DOI 10.1073/pnas.90.3.1018; LEFER AM, 1990, SCIENCE, V249, P61, DOI 10.1126/science.2164258; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Oh JW, 1999, J NEUROVIROL, V5, P82, DOI 10.3109/13550289909029749; Papapetropoulos A, 1999, LAB INVEST, V79, P213; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; PHAN SH, 1992, J IMMUNOL, V149, P103; PLOUET J, 1989, J CELL PHYSIOL, V141, P392, DOI 10.1002/jcp.1041410221; RICHARD V, 1995, CIRCULATION, V92, P1891, DOI 10.1161/01.CIR.92.7.1891; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com; SCHAPER W, 1991, BASIC RES CARDIOL, V86, P51; Simonini A, 2000, CIRCULATION, V101, P1519, DOI 10.1161/01.CIR.101.13.1519; STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11; STRIETER RM, 1995, J LEUKOCYTE BIOL, V57, P752, DOI 10.1002/jlb.57.5.752; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Sun Y, 2000, CARDIOVASC RES, V46, P250, DOI 10.1016/S0008-6363(00)00032-8; Sun YO, 1998, J MOL CELL CARDIOL, V30, P1559, DOI 10.1006/jmcc.1998.0721; Tebo JM, 1998, BLOOD, V92, P4742, DOI 10.1182/blood.V92.12.4742.424k26_4742_4749; Thompson NL, 1988, GROWTH FACTORS, V1, P91, DOI 10.3109/08977198809000251; VANGURI P, 1990, J BIOL CHEM, V265, P15049; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; WUNSCH M, 1991, J MOL CELL CARDIOL, V23, P1051, DOI 10.1016/0022-2828(91)91640-D	72	84	96	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1428	+		10.1096/fj.00-0745fje	http://dx.doi.org/10.1096/fj.00-0745fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387246	Bronze			2022-12-28	WOS:000173705800022
J	Wagner, KD; Wagner, N; Bondke, A; Nafz, B; Flemming, B; Theres, H; Scholz, H				Wagner, KD; Wagner, N; Bondke, A; Nafz, B; Flemming, B; Theres, H; Scholz, H			The Wilms' tumor suppressor Wt1 is expressed in the coronary vasculature after myocardial infarction	FASEB JOURNAL			English	Article						hypoxia; epicardium; cardiac ischemia; transcription factor; immunohistochemistry	ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; GENE-PRODUCT; SUBNUCLEAR LOCALIZATION; SPLICE VARIANTS; PROTEIN; DNA; PECAM-1/CD31; FIBROBLASTS; MODULATION	Expression of the Wilms' tumor gene Wt1 in the epicardium is critical for normal heart development. Mouse embryos with inactivated Wt1 gene have extremely thin ventricles, which can result in heart failure and death. Here, we demonstrate that Wt1 can be activated in adult hearts by local ischemia. Wt1 mRNA was increased more than twofold in the left ventricular myocardium of rats between 1 day and 9 wk after infarction. Wt1 expression was localized by means of mRNA in situ hybridization and immunohistochemistry to vascular endothelial and vascular smooth muscle cells in the border zone of the infarcted tissue. A strikingly similar distribution was seen for vascular endothelial growth factor and two different cell proliferation markers in the coronary vessels of the ischemic heart. No Wt1 could be detected in the vasculature of the noninfarcted right ventricles. Wt1 expression in the coronary vessels of the ischemic heart was mimicked by exposure of rats to normobaric hypoxia (8% O-2) and 0.1% CO, respectively. These findings demonstrate that Wt1 is expressed in the vasculature of the heart in response to local ischemia and hypoxia. They suggest that Wt1 has a role in the growth of coronary vessels after myocardial infarction.	Humboldt Univ, Med Fak Charite, Johannes Muller Inst Physiol, D-10117 Berlin, Germany; Humboldt Univ, Med Fak Charite, Innere Med Klin 1, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Scholz, H (corresponding author), Humboldt Univ, Med Fak Charite, Johannes Muller Inst Physiol, Tucholskystr 2, D-10117 Berlin, Germany.	holger.scholz@charite.de	Wagner, Kay-Dietrich/E-6119-2016	Wagner, Kay-Dietrich/0000-0001-5483-7760; Wagner, Nicole/0000-0002-2746-0707				Algar EM, 1996, ONCOGENE, V12, P1005; ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; Bohlender J, 1997, HYPERTENSION, V29, P428, DOI 10.1161/01.HYP.29.1.428; Braissant O, 1998, BIOCHEMICA, V1, P10; Carmona R, 2001, CELL TISSUE RES, V303, P173, DOI 10.1007/s004410000307; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DeLisser HM, 1997, AM J PATHOL, V151, P671; Dettman RW, 1998, DEV BIOL, V193, P169, DOI 10.1006/dbio.1997.8801; Englert C, 1997, CANCER RES, V57, P1429; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; Farrell MJ, 2001, INT REV CYTOL, V202, P99, DOI 10.1016/S0074-7696(01)02004-6; Ghatpande S, 1999, MOL CELL BIOCHEM, V196, P93, DOI 10.1023/A:1006974330613; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Ladomery MR, 1999, J BIOL CHEM, V274, P36520, DOI 10.1074/jbc.274.51.36520; Laity JH, 2000, P NATL ACAD SCI USA, V97, P11932, DOI 10.1073/pnas.97.22.11932; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Matsunaga T, 2000, CIRCULATION, V102, P3098; Maurer U, 2001, J BIOL CHEM, V276, P3727, DOI 10.1074/jbc.M005292200; Menke AL, 1996, ONCOGENE, V12, P537; Mikawa T, 1996, DEV BIOL, V174, P221, DOI 10.1006/dbio.1996.0068; Moore AW, 1999, DEVELOPMENT, V126, P1845; Moore AW, 1998, MECH DEVELOP, V79, P169, DOI 10.1016/S0925-4773(98)00188-9; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; Peeters MPFMV, 1999, ANAT EMBRYOL, V199, P367, DOI 10.1007/s004290050235; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; Perez-Pomares JM, 1998, DEV BIOL, V200, P57, DOI 10.1006/dbio.1998.8949; Pinter E, 1997, AM J PATHOL, V150, P1523; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1023; RAUSCHER FJ, 1993, ADV EXP MED BIOL, V348, P23; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X; Scholz F, 1997, J SOLID STATE ELECTR, V1, P1, DOI 10.1007/s100080050017; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; SHARMA PM, 1992, CANCER RES, V52, P6407; SHEIBANI N, 1999, HISTOPATHOLOGY, V14, P185; Su H, 2000, P NATL ACAD SCI USA, V97, P13801, DOI 10.1073/pnas.250488097; Theres HP, 2000, CARDIOVASC DRUG THER, V14, P597, DOI 10.1023/A:1007846311040; Tio RA, 1999, HUM GENE THER, V10, P2953, DOI 10.1089/10430349950016366; Wagner KD, 2001, J AM SOC NEPHROL, V12, P1188, DOI 10.1681/ASN.V1261188; Wagner KD, 1998, J MOL CELL CARDIOL, V30, P2341, DOI 10.1006/jmcc.1998.0794; Wenger RH, 2000, J EXP BIOL, V203, P1253	50	99	100	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1117	+		10.1096/fj.01-0986fje	http://dx.doi.org/10.1096/fj.01-0986fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039855				2022-12-28	WOS:000175973900013
J	Hudrisier, D; Bongrand, P				Hudrisier, D; Bongrand, P			Intercellular transfer of antigen-presenting cell determinants onto T cells: molecular mechanisms and biological significance	FASEB JOURNAL			English	Review						T cell activation; T cell receptor; adhesion; biomembranes	CLASS-II MOLECULES; GROWTH-FACTOR; TARGET-CELLS; B-CELLS; IMMUNOLOGICAL SYNAPSE; ACTIN CYTOSKELETON; CYTOPLASMIC DOMAIN; EGF RECEPTOR; FATTY-ACID; SURFACE	Upon physiological stimulation, receptors with tyrosine kinase activity (RTK) are rapidly internalized together with their soluble ligands. T cell activation is the consequence of recognition by the T cell receptor (TCR) of specific peptide-major histocompatibility protein complexes (peptide-MHC) present at the membrane of antigen-presenting cells (APC). The TCR belongs to the RTK family and is known to be endocytosed upon ligand recognition. It differs from most other RTK in that its ligand, the peptide-MHC complex, is membrane bound and the TCR-ligand interaction is quite weak. Recent experiments have shown that the TCR ligand becomes internalized by T cells upon stimulation. Here we review current knowledge on the molecular mechanisms by which the membrane-bound MHC molecules can be transferred onto T cells, and propose hypotheses on the role this phenomenon could play in physio-pathological situations involving T cells.	CHU Purpan, INSERM, U395, F-31024 Toulouse 3, France; Univ Toulouse 3, F-31024 Toulouse 3, France; Hop St Marguerite, Immunol Lab, INSERM, U387, F-13274 Marseille 09, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Hudrisier, D (corresponding author), CHU Purpan, INSERM, U395, BP3028, F-31024 Toulouse 3, France.	Denis.Hudrisier@toulouse.inserm.fr	Bongrand, Pierre/C-4456-2013	Bongrand, Pierre/0000-0001-6185-6572; Hudrisier, Denis/0000-0002-3631-9561				Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; ANDRE P, 1990, J CELL SCI, V97, P335; Andre P, 1997, J IMMUNOL, V159, P5253; Arnold PY, 1997, EUR J IMMUNOL, V27, P3198, DOI 10.1002/eji.1830271217; Arnold PY, 1999, EUR J IMMUNOL, V29, P1363, DOI 10.1002/(SICI)1521-4141(199904)29:04<1363::AID-IMMU1363>3.0.CO;2-0; Batista FD, 2001, NATURE, V411, P489, DOI 10.1038/35078099; Batista FD, 2000, EMBO J, V19, P513, DOI 10.1093/emboj/19.4.513; BAZIL V, 1995, IMMUNOL TODAY, V16, P135, DOI 10.1016/0167-5699(95)80130-8; BECKER JC, 1991, J IMMUNOL, V147, P4398; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BENOLIEL AM, 1987, CELL BIOPHYS, V10, P87, DOI 10.1007/BF02797075; Black P H, 1980, Adv Cancer Res, V32, P75, DOI 10.1016/S0065-230X(08)60361-9; BONA C, 1973, IMMUNOLOGY, V24, P831; BONGRAND P, 1983, J IMMUNOL METHODS, V58, P209, DOI 10.1016/0022-1759(83)90276-4; Bongrand P, 1998, BIOESSAYS, V20, P412; BRECHER P, 1984, J BIOL CHEM, V259, P3395; Brezinschek RI, 1999, J IMMUNOL, V162, P1677; CAGAN RL, 1992, CELL, V69, P393, DOI 10.1016/0092-8674(92)90442-F; CAPO C, 1987, CYTOMETRY, V8, P468, DOI 10.1002/cyto.990080506; Carlin LM, 2001, J EXP MED, V194, P1507, DOI 10.1084/jem.194.10.1507; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; DOBBE LME, 1988, IMMUNOGENETICS, V27, P203, DOI 10.1007/BF00346587; DOODY MC, 1980, BIOCHEMISTRY-US, V19, P108, DOI 10.1021/bi00542a017; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Dustin ML, 2001, NAT IMMUNOL, V2, P480, DOI 10.1038/88666; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Dwir O, 2001, J CELL BIOL, V155, P145, DOI 10.1083/jcb.200103042; EVANS E, 1991, BIOPHYS J, V59, P849, DOI 10.1016/S0006-3495(91)82297-4; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FOA C, 1985, J HISTOCHEM CYTOCHEM, V33, P647, DOI 10.1177/33.7.2861226; FOX JEB, 1994, BLOOD COAGUL FIBRIN, V5, P291, DOI 10.1097/00001721-199404000-00020; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; GRIMM E, 1979, CELL IMMUNOL, V46, P77, DOI 10.1016/0008-8749(79)90247-8; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; Huang JF, 1999, SCIENCE, V286, P952, DOI 10.1126/science.286.5441.952; Hudrisier D, 1998, J IMMUNOL, V161, P553; Hudrisier D, 2001, J IMMUNOL, V166, P3645, DOI 10.4049/jimmunol.166.6.3645; Hwang I, 2000, J EXP MED, V191, P1137, DOI 10.1084/jem.191.7.1137; Hwang I, 2001, J IMMUNOL, V166, P5099, DOI 10.4049/jimmunol.166.8.5099; Jeannin P, 2000, IMMUNITY, V13, P303, DOI 10.1016/S1074-7613(00)00030-3; Jose ES, 2000, IMMUNITY, V12, P161, DOI 10.1016/S1074-7613(00)80169-7; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Kramer Helmut, 1993, Trends in Cell Biology, V3, P103, DOI 10.1016/0962-8924(93)90165-W; LAMB JR, 1984, NATURE, V308, P72, DOI 10.1038/308072a0; Lang P, 2001, SCIENCE, V291, P1537, DOI 10.1126/science.291.5508.1537; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LEE ST, 1978, CELL IMMUNOL, V40, P141, DOI 10.1016/0008-8749(78)90322-2; Liu HY, 2000, IMMUNITY, V13, P665, DOI 10.1016/S1074-7613(00)00066-2; LORBER MI, 1982, J IMMUNOL, V128, P2798; Matala E, 2001, J IMMUNOL, V167, P1617, DOI 10.4049/jimmunol.167.3.1617; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Montero-Julian FA, 2001, CELL MOL BIOL, V47, P583; Montes M, 1999, INT IMMUNOL, V11, P1725, DOI 10.1093/oxfordjournals.intimm.a019878; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; MORGAN BP, 1987, J IMMUNOL, V138, P246; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; NAGY Z, 1976, J EXP MED, V144, P1545, DOI 10.1084/jem.144.6.1545; Nath D, 2001, J CELL SCI, V114, P1213; Ohno N, 1997, INFLAMMATION, V21, P313, DOI 10.1023/A:1027349900279; Patel DM, 1999, J IMMUNOL, V163, P5201; Penna D, 1999, J IMMUNOL, V163, P50; Pierres A, 2000, PHYSICAL CHEMISTRY OF BIOLOGICAL INTERFACES, P459; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Richelme F, 2000, CELL MOTIL CYTOSKEL, V45, P93; SATTA N, 1994, J IMMUNOL, V153, P3245; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmal H, 1998, J IMMUNOL, V161, P3685; SCHMID E, 1995, J INTERF CYTOK RES, V15, P819, DOI 10.1089/jir.1995.15.819; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; SHARROW SO, 1981, J IMMUNOL, V126, P1327; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; Sheetz MP, 2001, NAT REV MOL CELL BIO, V2, P392, DOI 10.1038/35073095; Shi M, 2001, J IMMUNOL, V167, P123, DOI 10.4049/jimmunol.167.1.123; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sjostrom A, 2001, J EXP MED, V194, P1519, DOI 10.1084/jem.194.10.1519; Slifka MK, 1999, NATURE, V401, P76, DOI 10.1038/43454; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Valitutti S, 1997, IMMUNOL TODAY, V18, P299, DOI 10.1016/S0167-5699(97)01075-X; Valitutti S, 1996, EUR J IMMUNOL, V26, P2012, DOI 10.1002/eji.1830260907; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; Valitutti S, 1996, J EXP MED, V183, P1917, DOI 10.1084/jem.183.4.1917; VANBLITTERSWIJK WJ, 1982, BIOCHIM BIOPHYS ACTA, V688, P495, DOI 10.1016/0005-2736(82)90361-3; Vyas YM, 2001, J IMMUNOL, V167, P4358, DOI 10.4049/jimmunol.167.8.4358; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Zavazava N, 1996, NAT MED, V2, P1005, DOI 10.1038/nm0996-1005; Zhang ZX, 2000, NAT MED, V6, P782, DOI 10.1038/77513; Zimmer J, 2001, J EXP MED, V194, P1531, DOI 10.1084/jem.194.10.1531	100	82	84	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					477	486		10.1096/fj.01-0933rev	http://dx.doi.org/10.1096/fj.01-0933rev			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919150				2022-12-28	WOS:000175425900001
J	Lloberas, NR; Torras, J; Herrero-Fresneda, I; Cruzado, JM; Riera, M; Hurtado, I; Grinyo, JM				Lloberas, NR; Torras, J; Herrero-Fresneda, I; Cruzado, JM; Riera, M; Hurtado, I; Grinyo, JM			Postischemic renal oxidative stress induces an inflammatory response through PAF and oxidized phospholipids: prevention by antioxidant treatment	FASEB JOURNAL			English	Article						PAF-like lipids; renal ischemia-reperfusion; oxygen free radicals; PMN leukocyte; vitamin C	PLATELET-ACTIVATING-FACTOR; LOW-DENSITY-LIPOPROTEIN; ISCHEMIA-REPERFUSION; VITAMIN-C; ENDOTHELIAL-CELLS; BLOOD-PLASMA; RECEPTOR; ANTAGONIST; NEUTROPHILS; ADHESION	Reperfusion injury is considered primarily an inflammatory response to oxidative stress. In vitro, oxygen free radicals induce the formation of oxidized phospholipids with platelet-activating factor (PAF) activity (PAF-like lipids). We examined the following: 1) whether PAF and PAF-like lipids are released during reperfusion; 2) the relationship between these phospholipids and oxidative damage on the one hand, and leukocyte recruitment in renal tissue on the other; and 3) whether antioxidant treatment influences the behavior of these phospholipids, the renal inflammatory response, and the outcome of postischemic acute renal failure. After 60 min of warm renal ischemia in rabbits, a release of PAF and, particularly, PAF-like lipids was seen in the first 15 min of reperfusion. In addition, the release of those phospholipids was associated with intense tissue DNA oxidation and with an increase in myeloperoxidase activity. Vitamin C was able to attenuate these postischemic oxidative changes, decrease PAF and PAF-like lipid levels, and, consequently, reduce myeloperoxidase activity. After 40 min of warm renal ischemia in rats, vitamin C treatment ameliorated renal function and structure. This is the first in vivo demonstration of the release of phospholipid oxidation products as part of an oxidative-inflammatory response after renal ischemia-reperfusion, with the release of phospholipid oxidation products significantly reduced by antioxidant treatment.	Univ Barcelona, Dept Med, Lab Expt Nephrol, Barcelona, Spain; Bellvitge Hosp, CSUB,Dept Med, Lab Expt Nephrol 4122, Med Unit,Nephrol Serv, E-08907 Barcelona, Spain	University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona	Grinyo, JM (corresponding author), Bellvitge Hosp, CSUB,Dept Med, Lab Expt Nephrol 4122, Med Unit,Nephrol Serv, Pavello Govern 4A Plta,Feixa Llarga S-N, E-08907 Barcelona, Spain.	jmgrinyo@medicina.ub.es	Torras, Joan/AAH-8131-2021					ARNOULD T, 1993, AM J PHYSIOL, V264, pC1102, DOI 10.1152/ajpcell.1993.264.5.C1102; BALLMER PE, 1994, J THORAC CARDIOV SUR, V108, P311; Balsa D, 1997, DRUG EXP CLIN RES, V23, P191; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Bunting M, 1997, J CLIN INVEST, V100, P565, DOI 10.1172/JCI119566; Carceller E, 1996, J MED CHEM, V39, P487, DOI 10.1021/jm950555i; CLAVIEN PA, 1992, TRANSPLANTATION, V53, P957, DOI 10.1097/00007890-199205000-00001; De Zwart LL, 1999, FREE RADICAL BIO MED, V26, P202, DOI 10.1016/S0891-5849(98)00196-8; DREYER WJ, 1989, CIRC RES, V65, P1751, DOI 10.1161/01.RES.65.6.1751; FERREIRA R, 1988, AM HEART J, V115, P307, DOI 10.1016/0002-8703(88)90475-9; FRANSSEN C, 1995, TRANSPLANT P, V27, P2880; FREI B, 1991, BIOCHEM J, V277, P133, DOI 10.1042/bj2770133; FREI B, 1991, AM J CLIN NUTR, V54, pS1113, DOI 10.1093/ajcn/54.6.1113s; Frey B, 2000, J LIPID RES, V41, P1145; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HENSON PM, 1976, J EXP MED, V143, P937, DOI 10.1084/jem.143.4.937; Herrero I, 1999, NEPHROL DIAL TRANSPL, V14, P872, DOI 10.1093/ndt/14.4.872; IMAIZUMI TA, 1995, J INTERN MED, V238, P5, DOI 10.1111/j.1365-2796.1995.tb00894.x; IMAIZUMI TA, 1991, ATHEROSCLEROSIS, V87, P47, DOI 10.1016/0021-9150(91)90231-Q; KALUZNY MA, 1985, J LIPID RES, V26, P135; KUBES P, 1990, AM J PHYSIOL, V259, pG300, DOI 10.1152/ajpgi.1990.259.2.G300; LEFER AM, 1993, ANNU REV PHARMACOL, V33, P71, DOI 10.1146/annurev.pa.33.040193.000443; Lefer DJ, 2000, AM J MED, V109, P315, DOI 10.1016/S0002-9343(00)00467-8; LEHR HA, 1993, ARTERIOSCLER THROMB, V13, P1013, DOI 10.1161/01.ATV.13.7.1013; LEHR HA, 1994, P NATL ACAD SCI USA, V91, P7688, DOI 10.1073/pnas.91.16.7688; Lehr HA, 1997, J CLIN INVEST, V99, P2358, DOI 10.1172/JCI119417; LEHR HA, 1991, J CLIN INVEST, V88, P9, DOI 10.1172/JCI115309; Lloberas N, 2002, TRANSPLANT P, V34, P47, DOI 10.1016/S0041-1345(01)02660-4; LORANT DE, 1999, PROG INFLAM RES, P81; MA XL, 1992, J PHARMACOL EXP THER, V260, P1229; Marathe GK, 2000, FREE RADICAL BIO MED, V28, P1762, DOI 10.1016/S0891-5849(00)00234-3; McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189; PARKS DA, 1983, SURGERY, V94, P428; PATEL KD, 1992, J BIOL CHEM, V267, P15168; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; PRESCOTT SM, 1993, ATHEROSCLER REV, V25, P59; Riera M, 1997, J PHARMACOL EXP THER, V280, P786; Riera M, 2001, TRANSPLANTATION, V72, P1217, DOI 10.1097/00007890-200110150-00006; SALARI H, 1990, CIRC SHOCK, V32, P189; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; TORRAS J, 1993, TRANSPLANT INT, V6, P236, DOI 10.1007/BF00337106; Weber C, 1996, CIRCULATION, V93, P1488, DOI 10.1161/01.CIR.93.8.1488; WHATLEY RE, 1996, HANDB LIP R, V8, P239; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2; ZIMMERMAN GA, 1992, INFLAMMATION BASIC P, V2, P149	47	70	73	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					908	+		10.1096/fj.01-0880fje	http://dx.doi.org/10.1096/fj.01-0880fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039876				2022-12-28	WOS:000175425900028
J	McNally, JD; Wu, SB; Sturgeon, CM; Storey, KB				McNally, JD; Wu, SB; Sturgeon, CM; Storey, KB			Identification and characterization of a novel freezing-inducible gene, li16, in the wood frog Rana sylvatica	FASEB JOURNAL			English	Article						cryobiology; gene expression; protein expression; freeze tolerance; liver	DEPENDENT PROTEIN-KINASE; CRYOPROTECTANT SYNTHESIS; TOLERANT FROG; NITRIC-OXIDE; HEPATOCYTES; DEHYDRATION; RESPONSES; LIVER; CGMP; TRANSCRIPTION	The wood frog Rana sylvatica survives for weeks during winter hibernation with up to 65% body water frozen as ice. Natural freeze tolerance includes both seasonal and freeze-induced molecular adaptations that control ice formation, deal with long-term ischemia, regulate cell volume changes, and protect macromolecules. This report identifies and characterizes a novel freeze-inducible gene, li16, that codes for a protein of 115 amino acids. Northern blot analysis showed that li16 transcript levels rose quickly during freezing to reach levels 3.7-fold higher than control values after 24 h; immunoblotting showed a parallel 2.4-fold rise in Li16 protein. Regulatory influences on gene expression were assessed. Nuclear runoff assays confirmed that freezing initiated an increase in the rate of li16 transcription, and analysis of signal transduction pathways via in vitro incubation of liver slices implicated a cGMP-mediated pathway in li16 expression. Gene and protein expression in liver was also strongly stimulated by anoxia exposure, whereas the gene was less responsive to dehydration stress. The strong response of li16 to both freezing and anoxia, and the rapid down-regulation of the gene when oxygen was reintroduced, suggest that the Li16 protein may play a role in ischemia resistance during freezing.	Carleton Univ, Inst Biochem, Ottawa, ON K1S 5B6, Canada; Carleton Univ, Dept Biol, Ottawa, ON K1S 5B6, Canada; Carleton Univ, Dept Chem, Ottawa, ON K1S 5B6, Canada	Carleton University; Carleton University; Carleton University	Storey, KB (corresponding author), Carleton Univ, Inst Biochem, 1125 Colonel By Drive, Ottawa, ON K1S 5B6, Canada.	kenneth_storey@carleton.ca	Storey, Kenneth B/G-9883-2011	Storey, Kenneth/0000-0002-7363-1853				BALLS M, 1976, LONG TERM AMPHIBIAN; BIRCH HE, 1986, J BIOL CHEM, V261, P8077; Cai Q, 1997, AM J PHYSIOL-REG I, V272, pR1480, DOI 10.1152/ajpregu.1997.272.5.R1480; Cai QY, 1997, GENE, V198, P305, DOI 10.1016/S0378-1119(97)00332-6; Cai QY, 1997, BBA-GENE STRUCT EXPR, V1353, P69, DOI 10.1016/S0167-4781(97)00057-2; CHURCHILL TA, 1993, AM J PHYSIOL, V265, pR1324, DOI 10.1152/ajpregu.1993.265.6.R1324; CHURCHILL TA, 1994, CAN J ZOOL, V72, P1420, DOI 10.1139/z94-188; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Gudi T, 1996, J BIOL CHEM, V271, P4597; HEMMINGS SJ, 1994, CAN J PHYSIOL PHARM, V72, P1552, DOI 10.1139/y94-223; HILLMAN SS, 1987, PHYSIOL ZOOL, V60, P608, DOI 10.1086/physzool.60.5.30156135; Holden CP, 1996, AM J PHYSIOL-REG I, V271, pR1205, DOI 10.1152/ajpregu.1996.271.5.R1205; Holden CP, 1997, J COMP PHYSIOL B, V167, P305, DOI 10.1007/s003600050078; Immenschuh S, 1998, BIOCHEM J, V334, P141, DOI 10.1042/bj3340141; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larade K, 2001, J EXP ZOOL, V290, P759, DOI 10.1002/jez.1126; Li JR, 1999, CELL DEATH DIFFER, V6, P952, DOI 10.1038/sj.cdd.4400579; MOMMSEN TP, 1992, GEN COMP ENDOCR, V87, P44, DOI 10.1016/0016-6480(92)90148-D; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Rakhit RD, 2000, AM J PHYSIOL-HEART C, V278, pH1211, DOI 10.1152/ajpheart.2000.278.4.H1211; RUBINSKY B, 1994, AM J PHYSIOL, V266, pR1771, DOI 10.1152/ajpregu.1994.266.6.R1771; Salamov AA, 1998, BIOINFORMATICS, V14, P384, DOI 10.1093/bioinformatics/14.5.384; Sambrook J., 2002, MOL CLONING LAB MANU; STOREY JM, 1985, J COMP PHYSIOL B, V156, P191, DOI 10.1007/BF00695773; Storey JM, 1996, CRYOBIOLOGY, V33, P186, DOI 10.1006/cryo.1996.0019; STOREY KB, 1987, J COMP PHYSIOL B, V157, P373, DOI 10.1007/BF00693364; STOREY KB, 1992, ANNU REV PHYSIOL, V54, P619, DOI 10.1146/annurev.physiol.54.1.619; STOREY KB, 1986, COMP BIOCHEM PHYS A, V83, P613, DOI 10.1016/0300-9629(86)90699-7; Storey KB, 1996, ANNU REV ECOL SYST, V27, P365, DOI 10.1146/annurev.ecolsys.27.1.365; STOREY KB, 1994, AM J PHYSIOL, V266, pR1477, DOI 10.1152/ajpregu.1994.266.5.R1477; Storey KB, 1999, CLIN EXP PHARMACOL P, V26, P57, DOI 10.1046/j.1440-1681.1999.02990.x; STOREY KB, 2001, CELL MOL RESPONSES S, V2, P263	32	30	30	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					902	+		10.1096/fj.02-0017fje	http://dx.doi.org/10.1096/fj.02-0017fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039874				2022-12-28	WOS:000175425900025
J	Cellai, C; Laurenzana, A; Vannucchi, AM; Della Malva, N; Bianchi, L; Paoletti, F				Cellai, C; Laurenzana, A; Vannucchi, AM; Della Malva, N; Bianchi, L; Paoletti, F			Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells	FASEB JOURNAL			English	Article						inducer; PAF receptor; maturation; neoplasia; differentiation therapy	PLATELET-ACTIVATING-FACTOR; HYBRID POLAR COMPOUNDS; TRANSFORMED-CELLS; IN-VITRO; MYELOGENOUS LEUKEMIA; HISTONE DEACETYLASE; POTENT INDUCERS; ACID; STIMULATION; EXPRESSION	A pharmacological approach to neoplasia by differentiation therapy relies on the availability of cytodifferentiating agents whose antitumor efficacy is usually assayed first on malignant cells in vitro. Using murine erythroleukemia cells (MELCs) as the model, we found that WEB-2086, a triazolobenzodiazepine-derived PAF antagonist originally developed as an anti-inflammatory drug, induces a dose-dependent inhibition of MELC growth and hemoglobin accumulation as a result of a true commitment to differentiation. MELCs treated for 5 days with 1 mM WEB-2086 show greater than or equal to85% benzidine-positive cells, increased expression of alpha- and beta-globin genes, and down-regulation of c-Myb. This differentiation pattern, which does not involve histone H4 acetylation and is abrogated by the action of phorbol 12-myristate 13-acetate, recalls the pattern induced by hexamethylene bisacetamide (HMBA). In addition to MELCs, human erythroleukemia K562 and HEL and myeloid HL60 cells are massively committed to maturation by WEB-2086 and, with some differences, by its analog, WEB-2170. This suggests that WEB-2086, structurally distant from other known inducers, might be a member of a new class of cytodifferentiation agents active on a broad range of transformed cells in vitro and useful, prospectively, for anticancer therapy due to their high tolerability in vivo.	Univ Florence, Dept Expt Path & Oncol, I-50134 Florence, Italy; Careggi Hosp, Dept Hematol, I-50139 Florence, Italy	University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi	Paoletti, F (corresponding author), Univ Florence, Dept Expt Path & Oncol, Viale GB Morgagni 50, I-50134 Florence, Italy.	fcplt@unifi.it	Vannucchi, Alessandro M./K-7499-2016	Vannucchi, Alessandro M./0000-0001-5755-0730				ADAMUS WS, 1989, CLIN PHARMACOL THER, V45, P270, DOI 10.1038/clpt.1989.27; ANDREEFF M, 1992, BLOOD, V80, P2604; BIRKE FW, 1988, CLIN EXP PHARM PHY S, V13, P2; Boccellino M, 2000, J CELL PHYSIOL, V183, P254, DOI 10.1002/(SICI)1097-4652(200005)183:2<254::AID-JCP12>3.0.CO;2-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bussolati B, 2000, AM J PATHOL, V157, P1713, DOI 10.1016/S0002-9440(10)64808-0; CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974; CASALSSTENZEL J, 1990, METHOD ENZYMOL, V187, P455; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; Denizot Y, 1996, J LIPID MEDIAT CELL, V15, P1, DOI 10.1016/S0929-7855(96)00447-6; Dupuis F, 1997, BBA-MOL CELL RES, V1359, P241, DOI 10.1016/S0167-4889(97)00106-7; Dupuis F, 1998, MEDIAT INFLAMM, V7, P99, DOI 10.1080/09629359891243; FALETTO DL, 1985, CELL, V43, P315, DOI 10.1016/0092-8674(85)90037-6; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; FRIEND C, 1976, HARVEY LECT, V72, P253; GIERS G, 1990, BLUT, V61, P21, DOI 10.1007/BF01739429; GUSELLA JF, 1980, BLOOD, V56, P481; HARRISON PR, 1976, NATURE, V262, P353, DOI 10.1038/262353a0; HEUER HO, 1990, HDB PAF PAF ANTAGONI, P171; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Im SY, 1996, CANCER RES, V56, P2662; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; KOSTRABA NC, 1975, J BIOL CHEM, V250, P1548; LOHMANN HF, 1988, LANCET, V2, P1147; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Lukashova V, 2001, J BIOL CHEM, V276, P24113, DOI 10.1074/jbc.M100720200; Marks P A, 1984, Cancer, V54, P2766, DOI 10.1002/1097-0142(19841201)54:2+<2766::AID-CNCR2820541424>3.0.CO;2-N; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARKS PA, 1987, CANCER RES, V47, P659; MARKS PA, 1994, P NATL ACAD SCI USA, V91, P10251, DOI 10.1073/pnas.91.22.10251; Marks PA, 1996, INT J HEMATOL, V63, P1; MELLONI E, 1987, P NATL ACAD SCI USA, V84, P5282, DOI 10.1073/pnas.84.15.5282; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PAPAYANNOPOULOU MP, 1982, SCIENCE, V216, P1233; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; Stojanov T, 1999, BIOL REPROD, V60, P674, DOI 10.1095/biolreprod60.3.674; TAHRAOUI L, 1988, MOL PHARMACOL, V34, P145; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; UKENA D, 1988, FEBS LETT, V228, P285, DOI 10.1016/0014-5793(88)80017-6; Vannucchi AM, 1997, BRIT J HAEMATOL, V99, P500, DOI 10.1046/j.1365-2141.1997.4273230.x; VENABLE ME, 1993, J LIPID RES, V34, P691; WAXMAN S, 1986, CANCER DETECT PREV, V9, P395; YAMASAKI H, 1977, P NATL ACAD SCI USA, V74, P3451, DOI 10.1073/pnas.74.8.3451; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	53	18	33	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					733	+		10.1096/fj.01-0602fje	http://dx.doi.org/10.1096/fj.01-0602fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923217				2022-12-28	WOS:000174755900006
J	Verwer, RWH; Hermens, WTJMC; Dijkhuizen, PA; Ter Brake, O; Baker, RE; Salehi, A; Sluiter, AA; Kok, MJM; Muller, LJ; Verhaagen, J; Swaab, DF				Verwer, RWH; Hermens, WTJMC; Dijkhuizen, PA; Ter Brake, O; Baker, RE; Salehi, A; Sluiter, AA; Kok, MJM; Muller, LJ; Verhaagen, J; Swaab, DF			Cells in human postmortem brain tissue slices remain alive for several weeks in culture	FASEB JOURNAL			English	Article						aging; Alzheimer's disease; human brain; tissue culture; transgene expression	CYTOCHROME-OXIDASE; RAT-BRAIN; NEURONS; DISEASE; RECOVERY; PROTEIN	Animal models for human neurological and psychiatric diseases only partially mimic the underlying pathogenic processes. Therefore, we investigated the potential use of cultured postmortem brain tissue from adult neurological patients and controls. The present study shows that human brain tissue slices obtained by autopsy within 8 h after death can be maintained in vitro for extended periods (up to 78 days) and can be manipulated experimentally. We report for the first time that 1) neurons and glia in such cultures could be induced to express the reporter gene LacZ after transduction with adeno-associated viral vectors and 2) cytochrome oxidase activity could be enhanced by the addition of pyruvate to the medium. These slice cultures offer new opportunities to study the cellular and molecular mechanisms of neurological and psychiatric diseases and new therapeutic strategies.	Netherlands Inst Brain Res, Grad Sch Neurosci Amsterdam, NL-1105 AZ Amsterdam, Netherlands; Netherlands Ophthalm Res Inst, NL-1105 AZ Amsterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Verwer, RWH (corresponding author), Netherlands Inst Brain Res, Grad Sch Neurosci Amsterdam, Meibergdreef 33, NL-1105 AZ Amsterdam, Netherlands.	r.verwer@nih.knaw.nl	Salehi, Ahmad/A-1148-2007; Salehi, Ahmad/H-2746-2019; Verhaagen, Joost/G-4773-2012	Salehi, Ahmad/0000-0001-8257-3280; Salehi, Ahmad/0000-0001-8257-3280; Swaab, Dick/0000-0002-9665-7845				BLASS JP, 1994, J NEUROL SCI, V121, P132, DOI 10.1016/0022-510X(94)90341-7; BLASS JP, 1992, J NEUROL SCI, V113, P1, DOI 10.1016/0022-510X(92)90257-L; Charpak S, 1998, P NATL ACAD SCI USA, V95, P4748, DOI 10.1073/pnas.95.8.4748; COSTERO I, 1951, AM J ANAT, V89, P405, DOI 10.1002/aja.1000890304; CRAGG B, 1979, TRENDS NEUROSCI, V2, P159, DOI 10.1016/0166-2236(79)90062-6; Dai JP, 1998, LANCET, V351, P499, DOI 10.1016/S0140-6736(05)78689-X; DARRIET D, 1986, J CEREBR BLOOD F MET, V6, P8, DOI 10.1038/jcbfm.1986.2; Ezaki J, 1999, J NEUROCHEM, V72, P2573, DOI 10.1046/j.1471-4159.1999.0722573.x; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; GILDEN DH, 1975, J COMP NEUROL, V161, P295, DOI 10.1002/cne.901610302; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; Hardy J, 1999, NEUROBIOL AGING, V20, P85; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; HARDY JA, 1985, J NEURAL TRANSM, V61, P253, DOI 10.1007/BF01251916; Hermens WTJMC, 1999, HUM GENE THER, V10, P1885, DOI 10.1089/10430349950017563; HIGGINS LS, 1995, NEURODEGENERATION, V4, P117, DOI 10.1006/neur.1995.0015; HOGUE MJ, 1953, AM J ANAT, V93, P397, DOI 10.1002/aja.1000930305; IQBAL K, 1972, BRAIN RES, V45, P296, DOI 10.1016/0006-8993(72)90241-7; KIM SU, 1979, NEUROSCI LETT, V11, P137, DOI 10.1016/0304-3940(79)90116-2; McManus DQ, 1997, NEUROSCI LETT, V224, P193, DOI 10.1016/S0304-3940(97)00172-9; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; Mesulam NM, 1999, NEURON, V24, P521, DOI 10.1016/S0896-6273(00)81109-5; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Mrak RE, 1997, J NEUROPATH EXP NEUR, V56, P1269, DOI 10.1097/00005072-199712000-00001; Palmer TD, 2001, NATURE, V411, P42, DOI 10.1038/35075141; Pinheiro J, 2001, MIXED EFFECTS MODELS; Price DL, 1999, NATURE, V399, pA3, DOI 10.1038/399a003; RAVID R, 1992, PROG BRAIN RES, V93, P83; ROMIJN HJ, 1988, J NEUROSCI METH, V23, P75, DOI 10.1016/0165-0270(88)90025-8; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; Tsai L, 1998, P NATL ACAD SCI USA, V95, P7975, DOI 10.1073/pnas.95.14.7975; Verwer RWH, 2000, EXP NEUROL, V163, P440, DOI 10.1006/exnr.2000.7385; Viel JJ, 2001, J NEUROSCI RES, V64, P311, DOI 10.1002/jnr.1081; VILALBA M, 1994, J BIOL CHEM, V269, P2468; VISSER TD, 1994, SCANNING, V16, P198, DOI 10.1002/sca.4950160403	35	87	88	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					54	60		10.1096/fj.01-0504com	http://dx.doi.org/10.1096/fj.01-0504com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11772936				2022-12-28	WOS:000173656600007
J	Wessler, S; Rapp, UR; Wiedenmann, B; Meyer, TF; Schoneberg, T; Hocker, M; Naumann, M				Wessler, S; Rapp, UR; Wiedenmann, B; Meyer, TF; Schoneberg, T; Hocker, M; Naumann, M			B-Raf/Rap1 signaling, but not c-Raf-1/Ras, induces the histidine decarboxylase promoter in Helicobacter pylori infection	FASEB JOURNAL			English	Article						adenylate cyclase; cAMP; MAP kinases; pathogenicity island; type IV secretion system	PROTEIN-COUPLED RECEPTORS; FACTOR-KAPPA-B; GASTRIC EPITHELIAL-CELLS; PATHOGENICITY ISLAND; DEPENDENT ACTIVATION; HUMAN PLATELETS; KINASE PATHWAY; CANCER CELLS; SMALL GTPASE; MAP KINASE	Histidine decarboxylase (HDC) is the key enzyme for gastric histamine synthesis, and enhanced HDC expression is critically involved in the pathogenesis of gastric disorders, including gastroduodenal ulcer disease. We characterized the pathogenicity mechanism underlying activation of the HDC promoter in H. pylori-infected gastric epithelial cells and performed a detailed analysis of the participating signaling elements. We found that H. pylori infection of gastric epithelial cells activated the MEK1-2/ERK1-2 cascade through cAMP-dependent stimulation of Rap1 and B-Raf, but not Ras/c-Raf-1, leading to potent transactivation of the human HDC promoter. H. pylori-triggered elevation of adenylate cyclase activity was directed by Galpha(S)-subunits of heterotrimeric G proteins. Stimulation of this signaling cascade was triggered independent of bacterial-cell contact by a small molecular-weight component(s) (similar to1 kDa) released by H. pylori and did not require a functional type IV secretion system. Thus, our studies demonstrate for the first time to our knowledge that the Galpha(S)-->cAMP-->Rap1-->B-Raf-->MEK1/2-->ERK1/2 pathway is critical for H. pylori-dependent epithelial gene regulation, which can be induced via a bioactive component( s) apart from the site of bacterial colonization. These results further elucidate the molecular mechanisms underlying interaction of H. pylori with gastric epithelial cells and help to define potential molecular targets for therapeutic interventions in the context of H. pylori-related gastric diseases.	Max Planck Infekt Biol, Mol Biol Abt, D-10117 Berlin, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97070 Wurzburg, Germany; Humboldt Univ, Univ Klinikum Charite, Med Klin Schwerpunkt Hepatol & Zellforsch, D-1086 Berlin, Germany; Free Univ Berlin, Inst Pharmakol, D-1000 Berlin, Germany	Max Planck Society; University of Wurzburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin	Naumann, M (corresponding author), Max Planck Infekt Biol, Mol Biol Abt, Schumannstr 21-22, D-10117 Berlin, Germany.	naumann@mpiib-berlin.mpg.de	Wessler, Silja/C-6309-2015; Naumann, Michael/B-5285-2011; Meyer, Thomas F. F/J-2485-2013	Wessler, Silja/0000-0001-7011-6162; Naumann, Michael/0000-0002-8060-2313; Meyer, Thomas F. F/0000-0002-6120-8679; Wiedenmann, Bertram/0000-0002-7890-2552				Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Bechi P, 1996, AM J GASTROENTEROL, V91, P2338; Ben-Hamida A, 1998, DIGEST DIS SCI, V43, P126, DOI 10.1023/A:1018888423882; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Burnette W N, 1994, Bioprocess Technol, V19, P185; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Calam J, 1999, YALE J BIOL MED, V72, P195; Censini S, 2001, CURR OPIN MICROBIOL, V4, P41, DOI 10.1016/S1369-5274(00)00162-4; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; Foryst-Ludwig A, 2000, J BIOL CHEM, V275, P39779, DOI 10.1074/jbc.M007617200; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Hagemann D, 1999, ONCOGENE, V18, P1391, DOI 10.1038/sj.onc.1202431; Hocker M, 1997, J BIOL CHEM, V272, P27015, DOI 10.1074/jbc.272.43.27015; Hocker M, 1998, J BIOL CHEM, V273, P23046, DOI 10.1074/jbc.273.36.23046; Hocker M, 1996, AM J PHYSIOL-GASTR L, V270, pG619, DOI 10.1152/ajpgi.1996.270.4.G619; HYDAR A, 1999, J BIOL CHEM, V273, P11012; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; Kilts JD, 2000, CIRC RES, V87, P705, DOI 10.1161/01.RES.87.8.705; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Macala LJ, 1998, KIDNEY INT, V54, P1746, DOI 10.1046/j.1523-1755.1998.00140.x; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Munzenmaier A, 1997, J IMMUNOL, V159, P6140; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Pomorski T, 2001, J BIOL CHEM, V276, P804, DOI 10.1074/jbc.M003819200; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; Raychowdhury R, 1999, J BIOL CHEM, V274, P20961, DOI 10.1074/jbc.274.30.20961; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Sexl V, 1997, J BIOL CHEM, V272, P5792, DOI 10.1074/jbc.272.9.5792; Sharma SA, 1998, J IMMUNOL, V160, P2401; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; VAN BT, 1995, NATURE, V376, P781; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; Winstanley C, 2001, J MED MICROBIOL, V50, P116, DOI 10.1099/0022-1317-50-2-116; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	50	36	37	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					417	+		10.1096/fj.01-0766fje	http://dx.doi.org/10.1096/fj.01-0766fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11790728				2022-12-28	WOS:000173656600023
J	Abounader, R; Lal, B; Luddy, C; Koe, G; Davidson, B; Rosen, EM; Laterra, J				Abounader, R; Lal, B; Luddy, C; Koe, G; Davidson, B; Rosen, EM; Laterra, J			In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis	FASEB JOURNAL			English	Article						glioma; scatter factor; hepatocyte growth factor; c-met; U1snRNA/ribozyme	FACTOR SCATTER FACTOR; HUMAN GLIOBLASTOMA; IN-VIVO; FACTOR PROTECTS; FACTOR HGF/SF; HEPATOCYTE; RECEPTOR; CELLS; METASTASIS; RECURRENCE	The multifunctional growth factor scatter factor/hepatocyte growth factor (SF/HGF) and its receptor c-met have been implicated in the genesis, malignant progression, and chemo/radioresistance of multiple human malignancies, including gliomas. We examined the antitumor effects of targeting SF/HGF and c-met expression in pre-established glioma xenografts by using novel chimeric U1snRNA/ribozymes. Transient expression of anti-SF/HGF and anti-c-met U1snRNA/ribozymes inhibited SF/HGF and c-met expression, c-met receptor activation, tumor cell migration, and anchorage-independent colony formation in vitro. Delivery of U1snRNA/ribozymes to established subcutaneous glioma xenografts via liposome-DNA complexes significantly inhibited tumor growth as well as tumor SF/HGF and c-met expression levels. Histologic analysis of tumors treated with U1snRNA/ribozymes showed a significant decrease in blood vessel density, an increase in activation of the pro-apoptotic enzyme caspase-3, and an increase in tumor cell apoptosis. Treatment of animals bearing intracranial glioma xenografts with anti-SF/HGF and anti-c-met U1snRNA/ribozymes by either intratumoral injections of adenoviruses expressing the transgenes or intravenous injections of U1snRNA/ribozyme-liposome complexes substantially inhibited tumor growth and promoted animal survival. We demonstrate that SF/HGF and/ or c-met expression can be targeted in vivo to inhibit tumor growth. In addition, our findings represent the first in vivo application of chimeric U1snRNA/ribozymes, which have numerous potential therapeutic gene-targeting applications.	Kennedy Krieger Res Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Valentis Inc, Burlingame, CA USA; Univ Iowa, Coll Med, Iowa City, IA USA; Long Isl Jewish Med Ctr, Albert Einstein Coll Med, New Hyde Pk, NY 11042 USA	Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Iowa; Northwell Health; Yeshiva University	Laterra, J (corresponding author), Kennedy Krieger Res Inst, 707 N Broadway, Baltimore, MD 21205 USA.	laterra@kennedykrieger.org						Abounader R, 1999, J NATL CANCER I, V91, P1548, DOI 10.1093/jnci/91.18.1548; Beckley SA, 2001, MOL CELL BIOL, V21, P2815, DOI 10.1128/MCB.21.8.2815-2825.2001; Bowers DC, 2000, CANCER RES, V60, P4277; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; DIRENZO MF, 1991, ONCOGENE, V6, P1997; Dow SW, 1999, J IMMUNOL, V163, P1552; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hendrix MJC, 1998, AM J PATHOL, V152, P855; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Koochekpour S, 1997, CANCER RES, V57, P5391; Krieg AM, 1999, BBA-GENE STRUCT EXPR, V1489, P107, DOI 10.1016/S0167-4781(99)00147-5; Kuba K, 2000, CANCER RES, V60, P6737; Lamszus K, 1998, INT J CANCER, V75, P19, DOI 10.1002/(SICI)1097-0215(19980105)75:1<19::AID-IJC4>3.0.CO;2-4; Laterra J, 1997, BIOCHEM BIOPH RES CO, V235, P743, DOI 10.1006/bbrc.1997.6853; Laterra J, 1997, LAB INVEST, V76, P565; Liu RT, 2000, J BIOL CHEM, V275, P8711, DOI 10.1074/jbc.275.12.8711; Montevecchi PC, 1997, RRD ORG BIOORG CHEM, V1, P1; Moriyama T, 1998, CANCER LETT, V124, P149, DOI 10.1016/S0304-3835(97)00469-2; Ramirez R, 2000, CLIN ENDOCRINOL, V53, P635, DOI 10.1046/j.1365-2265.2000.01124.x; Rosen E M, 1997, EXS, V79, P193; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt NO, 1999, INT J CANCER, V84, P10, DOI 10.1002/(SICI)1097-0215(19990219)84:1<10::AID-IJC3>3.3.CO;2-C; Song YK, 1997, HUM GENE THER, V8, P1585, DOI 10.1089/hum.1997.8.13-1585; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tan YD, 1999, HUM GENE THER, V10, P2153, DOI 10.1089/10430349950017149; Wallenius V, 2000, AM J PATHOL, V156, P821, DOI 10.1016/S0002-9440(10)64950-4; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; YAMASHITA J, 1994, CANCER RES, V54, P1630; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	33	148	170	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					108	+		10.1096/fj.01-0421fje	http://dx.doi.org/10.1096/fj.01-0421fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11729097				2022-12-28	WOS:000172420500025
J	Loufrani, L; Matrougui, K; Li, ZL; Levy, BI; Lacolley, P; Paulin, D; Henrion, D				Loufrani, L; Matrougui, K; Li, ZL; Levy, BI; Lacolley, P; Paulin, D; Henrion, D			Selective microvascular dysfunction in mice lacking the gene encoding for desmin	FASEB JOURNAL			English	Article						vascular; myogenic tone; flow-dependent dilation; endothelium; smooth muscle, myopathies	MESENTERIC RESISTANCE ARTERIES; VASCULAR SMOOTH-MUSCLE; FLOW-INDUCED DILATION; CELLS; RATS; REACTIVITY; FILAMENTS; VIMENTIN; MECHANOTRANSDUCTION; CARDIOMYOPATHY	The intermediate filament desmin has a key role in the integrity and contractility of skeletal and cardiac myocytes. Its absence or aggregation leads to cardiomyopathies. In arteries desmin is distributed heterogeneously; vascular disorders might also occur in its absence. We studied endothelial and muscular functions in arteries from mice lacking desmin (des-/-), compared with control (des+/+). Carotid and mesenteric resistance arteries were mounted in vitro in arteriographs. Desmin was located exclusively in smooth muscle cells. In arteries from des-/- mice, pressure-induced (myogenic) tone was unchanged, but agonist-induced tone decreased in resistance arteries (no change in large arteries). Flow (shear stress)- and acetylcholine-induced, endothelium-dependent dilation, as well as endothelium-independent dilation, were also decreased in resistance arteries. To our knowledge, this is the first study of vascular contractile and dilatory functions in arteries lacking desmin. Although vascular reactivity was normal in large arteries, it decreased strongly in small resistance arteries. Thus, desmin is required in vascular smooth muscle cells and in resistance arteries, for efficient control of vascular tone and consequently for an optimal blood flow supply. This microvascular defect found in the absence of desmin might play a major role in myopathies seen in desmin-related diseases.	Univ Paris 07, INSERM, U541, IFR6, Paris, France; Univ Paris 07, AP HP Hop Lariboisiere, Dept Physiol, Paris, France; Univ Paris 06, INSERM, EMI 0107, Paris, France; Univ Paris 07, Lab Biol Mol Differentiat, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite	Henrion, D (corresponding author), Hop Lariboisiere, INSERM, U541, 41 Bd Chapelle, F-75475 Paris 10, France.	daniel.henrion@inserm.lrb.ap-hop-paris.fr	Li, Zhenlin/E-3937-2016; Henrion, Daniel/J-8141-2015; Lacolley, Patrick/G-3118-2013; Henrion, Daniel/AAK-1995-2021	Henrion, Daniel/0000-0003-1094-0285; Henrion, Daniel/0000-0003-1094-0285; LI, Zhenlin/0000-0002-3706-4505				BERNER PF, 1981, J MUSCLE RES CELL M, V2, P439, DOI 10.1007/BF00711969; BEVAN JA, 1991, FASEB J, V5, P2267, DOI 10.1096/fasebj.5.9.1860618; BEVAN JA, 1994, ANNU REV PHARMACOL, V34, P173, DOI 10.1146/annurev.pa.34.040194.001133; CHALLANDE P, 2001, IN PRESS CARDIOVASC; Dalakas MC, 2000, NEW ENGL J MED, V342, P770, DOI 10.1056/NEJM200003163421104; DANGELO G, 1994, HYPERTENSION, V23, P1096, DOI 10.1161/01.HYP.23.6.1096; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Dowell FJ, 1996, BRIT J PHARMACOL, V117, P341, DOI 10.1111/j.1476-5381.1996.tb15196.x; GABBIANI G, 1981, P NATL ACAD SCI-BIOL, V78, P298, DOI 10.1073/pnas.78.1.298; GALLI A, 1994, BIOPHYS J, V67, P2296, DOI 10.1016/S0006-3495(94)80715-5; Galou M, 1997, BIOL CELL, V89, P85, DOI 10.1016/S0248-4900(99)80068-9; HALPERN W, 1984, ANN BIOMED ENG, V12, P463, DOI 10.1007/BF02363917; Henrion D, 1999, J AM COLL CARDIOL, V34, P830, DOI 10.1016/S0735-1097(99)00299-5; Henrion D, 1997, J CLIN INVEST, V100, P2909, DOI 10.1172/JCI119840; Henrion D, 1999, ARTERIOSCL THROM VAS, V19, P2148, DOI 10.1161/01.ATV.19.9.2148; Henrion D, 1997, BRIT J PHARMACOL, V121, P83, DOI 10.1038/sj.bjp.0701109; Iglarz M, 1998, EUR J PHARMACOL, V359, P69, DOI 10.1016/S0014-2999(98)00616-5; Inada H, 1999, J BIOL CHEM, V274, P34932, DOI 10.1074/jbc.274.49.34932; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; Johnson P.C., 1991, RESISTANCE VASCULATU, P159; Ko YS, 1999, ARTERIOSCL THROM VAS, V19, P1669, DOI 10.1161/01.ATV.19.7.1669; KRAUSFRIEDMANN N, 1994, CELL MOTIL CYTOSKEL, V28, P279, DOI 10.1002/cm.970280402; Li ZL, 1997, J CELL BIOL, V139, P129, DOI 10.1083/jcb.139.1.129; Loufrani L, 2001, CIRCULATION, V103, P864, DOI 10.1161/01.CIR.103.6.864; Matrougui K, 1999, HYPERTENSION, V34, P659, DOI 10.1161/01.HYP.34.4.659; Milner DJ, 1999, J MOL CELL CARDIOL, V31, P2063, DOI 10.1006/jmcc.1999.1037; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; OSOL G, 1991, RESISTANCE VASCULATU, P143; SEGAL SS, 1994, HYPERTENSION, V23, P1113, DOI 10.1161/01.HYP.23.6.1113; Sjuve R, 1998, J MUSCLE RES CELL M, V19, P415, DOI 10.1023/A:1005353805699; SMALL JV, 1992, EUR J BIOCHEM, V208, P559, DOI 10.1111/j.1432-1033.1992.tb17220.x; SMIESKO V, 1993, NEWS PHYSIOL SCI, V8, P34; Stromer MH, 1998, HISTOL HISTOPATHOL, V13, P283, DOI 10.14670/HH-13.283; Thornell LE, 1997, J MOL CELL CARDIOL, V29, P2107, DOI 10.1006/jmcc.1997.0446	35	53	54	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					117	+		10.1096/fj.01-0505fje	http://dx.doi.org/10.1096/fj.01-0505fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11729100				2022-12-28	WOS:000172420500026
J	Zhang, WJ; Frei, B				Zhang, WJ; Frei, B			alpha-lipoic acid inhibits TNF-alpha-induced NF-kappa B activation and adhesion molecule expression in human aortic endothelial cells	FASEB JOURNAL			English	Article						antioxidants; adhesion molecules; endothelium; nuclear factor kappa B	TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; E-SELECTIN; SIGNAL-TRANSDUCTION; LIPID-PEROXIDATION; DIHYDROLIPOIC ACID; ICAM-1 EXPRESSION; MONOCYTE ADHESION; REDOX REGULATION; CYTOKINE	Endothelial activation and monocyte adhesion are initiating steps in atherogenesis thought to be caused in part by oxidative stress. The metabolic thiol antioxidant alpha -lipoic acid has been suggested to be of therapeutic value in pathologies associated with redox imbalances. We investigated the role of (R)-alpha -lipoic acid (LA) vs. glutathione and ascorbic acid in tumor necrosis factor alpha (TNF-alpha)-induced adhesion molecule expression and nuclear factor kappaB (NF-kappaB) signaling in human aortic endothelial cells (HAEC). Preincubation of HAEC for 48 h with LA (0.05-1 mmol/l) dose-dependently inhibited TNF-alpha (10 U/ml) -induced adhesion of human monocytic THP-1 cells, as well as mRNA and protein expression of E-selectin, vascular cell adhesion molecule 1 and intercellular adhesion molecule 1. LA also strongly inhibited TNF-alpha -induced mRNA expression of monocyte chemoattractant protein-1 but did not affect expression of TNF-alpha receptor 1. Furthermore, LA dose-dependently inhibited TNF-alpha -induced I kappaB kinase activation, subsequent degradation of I kappaB, the cytoplasmic NF-kappaB inhibitor, and nuclear translocation of NF-kappaB. In contrast, TNF-alpha -induced NF-kappaB activation and adhesion molecule expression were not affected by ascorbic acid or by manipulating cellular glutathione status with L-2-oxo-4-thiazolidinecarboxylic acid, N-acetyl-L-cysteine, or D,L-buthionine-S,R-sulfoximine. Our data show that clinically relevant concentrations of LA, but neither vitamin C nor glutathione, inhibit adhesion molecule expression in HAEC and monocyte adhesion by inhibiting the I kappaB/NF-kappaB signaling pathway at the level, or upstream, of I kappaB kinase.	Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA	Oregon State University	Frei, B (corresponding author), Oregon State Univ, Linus Pauling Inst, 571 Weniger Hall, Corvallis, OR 97331 USA.	Balz.frei@orst.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060886, R01HL056170] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-60886, HL-56170] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Aoki T, 1996, AM J RESP CELL MOL, V15, P319, DOI 10.1165/ajrcmb.15.3.8810635; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BAST A, 1988, BIOCHIM BIOPHYS ACTA, V963, P558, DOI 10.1016/0005-2760(88)90326-8; BEVILACQUA MP, 1994, ANNU REV MED, V45, P361, DOI 10.1146/annurev.med.45.1.361; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; BRADLEY JR, 1993, AM J PATHOL, V142, P1598; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; CARLOS TM, 1994, BLOOD, V84, P2068; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DE CR, 1995, J CLIN INVEST, V96, P60; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIENER AM, 1985, J IMMUNOL, V135, P537; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; Friedrichs B, 1998, ARTERIOSCL THROM VAS, V18, P1829, DOI 10.1161/01.ATV.18.12.1829; HANDELMAN GJ, 1994, BIOCHEM PHARMACOL, V47, P1725, DOI 10.1016/0006-2952(94)90298-4; Haramaki N, 1997, FREE RADICAL BIO MED, V22, P535, DOI 10.1016/S0891-5849(96)00400-5; Hoare GS, 1999, AM J PHYSIOL-HEART C, V277, pH1975, DOI 10.1152/ajpheart.1999.277.5.H1975; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KAWAI M, 1995, J IMMUNOL, V154, P2333; Knowles JW, 2000, ARTERIOSCL THROM VAS, V20, P2336, DOI 10.1161/01.ATV.20.11.2336; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Lodge JK, 1998, FREE RADICAL BIO MED, V25, P287, DOI 10.1016/S0891-5849(98)00048-3; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MEYER GA, 1993, YELLOWSTONE SCI, V2, P2; Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OU PM, 1995, BIOCHEM PHARMACOL, V50, P123, DOI 10.1016/0006-2952(95)00116-H; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; PETER G, 1995, ARZNEIMITTELFORSCH, V45-1, P293; POSTON RN, 1992, AM J PATHOL, V140, P665; RICHARDSON M, 1994, ARTERIOSCLER THROMB, V14, P760, DOI 10.1161/01.ATV.14.5.760; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Roy S, 1998, FREE RADICAL BIO MED, V25, P229, DOI 10.1016/S0891-5849(98)00062-8; ROYALL JA, 1992, ARCH BIOCHEM BIOPHYS, V294, P686, DOI 10.1016/0003-9861(92)90742-F; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHOLICH H, 1989, BIOCHIM BIOPHYS ACTA, V1001, P256, DOI 10.1016/0005-2760(89)90108-2; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, BIOCHEM BIOPH RES CO, V218, P148, DOI 10.1006/bbrc.1996.0026; SEN CK, 1996, OXIDATIVE STRESS CAN, P251; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAAL FJT, 1995, METHOD ENZYMOL, V252, P168; Suzuki YJ, 1995, BIOCHEM MOL BIOL INT, V36, P241; SUZUKI YJ, 1992, BIOCHEM BIOPH RES CO, V189, P1709, DOI 10.1016/0006-291X(92)90275-P; SUZUKI YJ, 1991, FREE RADICAL RES COM, V15, P255, DOI 10.3109/10715769109105221; SUZUKI YJ, 1995, BIOCHEM BIOPH RES CO, V210, P537, DOI 10.1006/bbrc.1995.1693; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; True AL, 2000, AM J PHYSIOL-LUNG C, V279, pL302, DOI 10.1152/ajplung.2000.279.2.L302; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WEBER C, 1994, ARTERIOSCLER THROMB, V14, P1665, DOI 10.1161/01.ATV.14.10.1665; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; Zhang WJ, 1997, ARTERIOSCL THROM VAS, V17, P465, DOI 10.1161/01.ATV.17.3.465; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	61	198	216	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2423	2432		10.1096/fj.01-0260com	http://dx.doi.org/10.1096/fj.01-0260com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689467				2022-12-28	WOS:000172420500012
J	von der Thusen, JH; Kuiper, J; Fekkes, ML; de Vos, P; van Berkel, TJC; Biessen, EAL				von der Thusen, JH; Kuiper, J; Fekkes, ML; de Vos, P; van Berkel, TJC; Biessen, EAL			Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr - /- Mice	FASEB JOURNAL			English	Article						adenoviral gene transfer; atherosclerosis; anti-inflammatory therapy; transgenic mice	TUMOR-NECROSIS-FACTOR; HUMORAL IMMUNE-RESPONSES; ATHEROSCLEROTIC PLAQUES; IL-10; EXPRESSION; ENDOTOXIN; RECEPTOR; CELL; INFLAMMATION; CHOLESTEROL	In view of its multifaceted anti-inflammatory properties, interleukin-10 (IL-10) has been deemed to be potentially anti-atherogenic. We have evaluated the capacity of adenoviral gene transfer of IL-10 for the modulation of de novo atherosclerotic lesion formation by systemic and by local overexpression. Atherogenesis was initiated in the carotid arteries of low-density lipoprotein receptor deficient mice by perivascular placement of silastic collars. One week after collar placement, mice were injected intravenously with 1 x 10(9) plaque-forming units (pfu's) of IL-10 (Ad.IL-10) or control adenovirus (Ad.empty). Administration of Ad.IL-10 resulted in extended systemic expression of IL-10 (peak serum level 3.0 +/- 1.1 ng/ml) and a reduction in atherosclerotic lumen stenosis by 62.2% (P<0.02). This finding was accompanied by monocyte deactivation and lowering of serum cholesterol levels (maximum decrease 44%). In a second experiment, collared arteries were transfected locally by transluminal instillation of adenovirus (titer 1.5x10(10) pfu/ml). Systemic parameters remained unchanged following local transfection, but the degree of stenosis was, nonetheless, decreased by 44.9% (P<0.05). We conclude that a marked inhibition of atherogenesis can be achieved by systemic overexpression of Ad.IL-10, owing to its metabolic and immunomodulatory effects. Local IL-10 transfer is virtually equipotent, however, and it may represent a valuable addition to the armory of antiatherosclerotic therapies.	Leiden Univ, Sylvius Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Biessen, EAL (corresponding author), Leiden Univ, Sylvius Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, Wassenaarseweg 72,POB 9503, NL-2300 RA Leiden, Netherlands.	biessen@lacdr.leidenuniv.nl	Van Berkel, Theo/ABD-7677-2021	von der Thusen, Jan/0000-0001-9699-4860				Apostolopoulos J, 1996, ARTERIOSCL THROM VAS, V16, P1007, DOI 10.1161/01.ATV.16.8.1007; BARATH P, 1990, AM J CARDIOL, V65, P297, DOI 10.1016/0002-9149(90)90291-8; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207; CLINTON SK, 1991, AM J PATHOL, V138, P1005; Feingold KR, 1996, J LIPID RES, V37, P223; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792; Gudmundsson G, 1998, AM J RESP CELL MOL, V19, P812, DOI 10.1165/ajrcmb.19.5.3153; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; Lalani I, 1997, ANN ALLERG ASTHMA IM, V79, P469, DOI 10.1016/S1081-1206(10)63052-9; Lee TS, 1999, ARTERIOSCL THROM VAS, V19, P734, DOI 10.1161/01.ATV.19.3.734; Lindner H, 1997, TRANSPLANTATION, V64, P1370, DOI 10.1097/00007890-199711150-00023; MALEFYT RD, 1991, J EXP MED, V174, P1209; MALEFYT RD, 1991, J EXP MED, V174, P915; Mallat Z, 1999, CIRC RES, V85, pE17, DOI 10.1161/01.RES.85.8.e17; Mallat Z, 1999, ARTERIOSCL THROM VAS, V19, P611, DOI 10.1161/01.ATV.19.3.611; MEMON RA, 1993, ENDOCRINOLOGY, V132, P2246, DOI 10.1210/en.132.5.2246; Minter RM, 2000, J IMMUNOL, V164, P443, DOI 10.4049/jimmunol.164.1.443; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; MOSMANN TR, 1994, ADV IMMUNOL, V56, P1, DOI 10.1016/S0065-2776(08)60449-6; Oslund LJP, 1999, ARTERIOSCL THROM VAS, V19, P2847, DOI 10.1161/01.ATV.19.12.2847; Reape TJ, 1999, ATHEROSCLEROSIS, V147, P213, DOI 10.1016/S0021-9150(99)00346-9; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SANDSTROM LP, 1993, ALCOHOL, V10, P303, DOI 10.1016/0741-8329(93)90010-L; Schieffer B, 2000, CIRCULATION, V101, P1372, DOI 10.1161/01.CIR.101.12.1372; Schreiber S, 2000, GASTROENTEROLOGY, V119, P1461, DOI 10.1053/gast.2000.20196; SEINO Y, 1994, CYTOKINE, V6, P87, DOI 10.1016/1043-4666(94)90013-2; Smith EM, 1999, J NEUROIMMUNOL, V100, P140, DOI 10.1016/S0165-5728(99)00206-4; Song S, 1997, BLOOD, V89, P4461, DOI 10.1182/blood.V89.12.4461; 't Hoen PAC, 2000, BIOCHEM PHARMACOL, V60, P1509; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; Terkeltaub RA, 1999, ARTERIOSCL THROM VAS, V19, P2823, DOI 10.1161/01.ATV.19.12.2823; Uyemura K, 1996, J CLIN INVEST, V97, P2130, DOI 10.1172/JCI118650; von der Thusen JH, 2001, CIRCULATION, V103, P1164, DOI 10.1161/01.CIR.103.8.1164; Werner W, 1971, Quad Sclavo Diagn, V7, P232; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995	38	138	140	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2730	+		10.1096/fj.01-0483fje	http://dx.doi.org/10.1096/fj.01-0483fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11687507				2022-12-28	WOS:000171920400002
J	Taimor, G; Rakow, A; Piper, HM				Taimor, G; Rakow, A; Piper, HM			Transcription activator protein 1 (AP-1) mediates NO-induced apoptosis of adult cardiomyocytes	FASEB JOURNAL			English	Article						c-Jun amino-terminal kinase; decoy-oligonucleotides; extracellular signal-regulated kinase	CARDIAC MYOCYTES; NITRIC-OXIDE; VENTRICULAR MYOCYTES; KINASE PATHWAY; P53 PROMOTER; CELL-DEATH; GENE; JUN; P38; PHOSPHORYLATION	Release of nitric oxide (NO) during inflammation can induce apoptosis in the heart. Here we analyzed the involvement of members of the mitogen-activated protein kinase (MAPK) family and their downstream target, the transcription factor AP-1, in induction of apoptosis by NO in isolated adult cardiomyocytes of rat. The NO-donor (+/-)- S-nitroso-N-acetylpenicillamine (100 muM SNAP)- induced apoptosis in 10.5 +/- 0.7% of cardiomyocytes and activated the transcription activator protein AP-1 by 333.6 +/- 122.3%. Intracellular scavenging of AP-1 with decoyoligonucleotides blocked NO-induced apoptosis to control levels (3.8 +/- 0.5% apoptotic cells). Activation of AP-1 with a c-Jun amino-terminal kinase (JNK) activator (Ro318220, 10 muM) provoked apoptosis in 18.7 +/- 1.2% cardiomyocytes, which was again blocked by intracellular scavenging of AP-1. NO activated JNK by 87.0 +/- 27.3% and extracellular signal-regulated kinase (ERK) by 35 +/- 3%. Inhibition of ERK by the mitogen-activated protein kinase kinase (MEK1) inhibitor PD98059 (10 muM) abolished AP-1 activation and apoptosis induction with SNAP. Evidence that p38 MAPK plays a role in NO-induced apoptosis was not found. These results clearly demonstrate the involvement of the transcription factor AP-1 in NO-induced apoptosis in cardiomyocytes. The activation of AP-1 is mediated by the two MAP kinases JNK and ERK.	Univ Giessen, Inst Physiol, D-35392 Giessen, Germany	Justus Liebig University Giessen	Taimor, G (corresponding author), Univ Giessen, Inst Physiol, Aulweg 129, D-35392 Giessen, Germany.	Gerhild.Taimor@physiologie.med.uni-giessen.de						Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Andreka P, 2001, CIRC RES, V88, P305, DOI 10.1161/01.RES.88.3.305; Babu GJ, 2000, J MOL CELL CARDIOL, V32, P1447, DOI 10.1006/jmcc.2000.1185; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Ing DJ, 1999, CIRC RES, V84, P21; Ishikawa Y, 1999, BIOCHEM BIOPH RES CO, V264, P696, DOI 10.1006/bbrc.1999.1542; Jiang K, 1998, BIOCHEM BIOPH RES CO, V246, P192, DOI 10.1006/bbrc.1998.8591; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029, DOI 10.1152/ajplung.1997.273.5.L1029; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kankaanranta H, 1999, J PHARMACOL EXP THER, V290, P621; KIA Z, 1995, SCIENCE, V270, P1326; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Kirshenbaum LA, 1997, CIRCULATION, V96, P1580, DOI 10.1161/01.CIR.96.5.1580; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Leppa S, 2001, MOL CELL BIOL, V21, P4369, DOI 10.1128/MCB.21.13.4369-4378.2001; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; Mandal M, 2001, GASTROENTEROLOGY, V120, P71, DOI 10.1053/gast.2001.20897; Maulik N, 2000, FEBS LETT, V485, P7, DOI 10.1016/S0014-5793(00)02174-8; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Park YG, 1999, J BIOL CHEM, V274, P1573, DOI 10.1074/jbc.274.3.1573; PIPER HM, 1982, J MOL CELL CARDIOL, V14, P397, DOI 10.1016/0022-2828(82)90171-7; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; *SAS STAT, 1993, US GUID, V2, P946; Schluter KD, 1999, AM J PHYSIOL-HEART C, V276, pH1655, DOI 10.1152/ajpheart.1999.276.5.H1655; Taimor G, 2000, CARDIOVASC RES, V45, P588, DOI 10.1016/S0008-6363(99)00272-2; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743	33	54	56	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					2518	+		10.1096/fj.01-0353fje	http://dx.doi.org/10.1096/fj.01-0353fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641266				2022-12-28	WOS:000171372700020
J	Jayanthi, S; Deng, XL; Bordelon, M; McCoy, MT; Cadet, JL				Jayanthi, S; Deng, XL; Bordelon, M; McCoy, MT; Cadet, JL			Methamphetamine causes differential regulation of pro-death and anti-death Bcl-2 genes in the mouse neocortex	FASEB JOURNAL			English	Article						neurotoxicity; apoptosis; bcl-2 gene family; cDNA array	DISMUTASE TRANSGENIC MICE; CYTOCHROME-C; CELL-DEATH; BRAIN DOPAMINE; PERMEABILITY TRANSITION; ENDOPLASMIC-RETICULUM; LIPID-PEROXIDATION; PREFRONTAL CORTEX; INDUCED APOPTOSIS; RELEASE	Bcl-2, an inner mitochondrial membrane protein, inhibits apoptotic neuronal cell death. Expression of Bcl-2 inhibits cell death by decreasing the net cellular generation of reactive oxygen species. Studies by different investigators have provided unimpeachable evidence of a role for oxygen-based free radicals in methamphetamine (METH)-induced neurotoxicity. In addition, studies from our laboratory have shown that immortalized rat neuronal cells that overexpress Bcl-2 are protected against METH-induced apoptosis in vitro. Moreover, the amphetamines can cause differential changes in the expression of Bcl-X splice variants in primary cortical cell cultures. These observations suggested that METH might also cause perturbations of Bcl-2-related genes when administered to rodents. Thus, the present study was conducted to determine whether the use of METH might indeed be associated with transcriptional and translational changes in the expression of Bcl-2-related genes in the mouse brain. Here we report that a toxic regimen of METH did cause significant increases in the pro-death Bcl-2 family genes BAD, BAX, and BID. Concomitantly, there were significant decreases in the anti-death genes Bcl-2 and Bcl-X-L. These results thus support the notion that injections of toxic doses of METH trigger the activation of the programmed death pathway in the mammalian brain.	NIDA, Mol Neuropsychiat Sect, Intramural Res Program, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Cadet, JL (corresponding author), NIDA, Mol Neuropsychiat Sect, Intramural Res Program, NIH, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.	JCADET@intra.nida.nih.gov	Jayanthi, Subramaniam/ABI-4023-2020	Jayanthi, Subramaniam/0000-0002-5209-303X	NATIONAL INSTITUTE ON DRUG ABUSE [Z01DA000174, ZIADA000174] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Acikgoz O, 2000, EUR NEUROPSYCHOPHARM, V10, P415, DOI 10.1016/S0924-977X(00)00103-6; Allen RT, 1998, CELL MOL LIFE SCI, V54, P427, DOI 10.1007/s000180050171; Bogdanov MB, 1999, NEUROSCI LETT, V262, P33, DOI 10.1016/S0304-3940(99)00047-6; BOYD JM, 1995, ONCOGENE, V11, P1921; Cadet JL, 1997, SYNAPSE, V25, P176; Cadet JL, 2001, SYNAPSE, V41, P40, DOI 10.1002/syn.1058; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; De Miglio MR, 2000, HEPATOLOGY, V31, P956, DOI 10.1053/he.2000.5411; Deng XL, 1999, J NEUROSCI, V19, P10107; Deng XL, 2000, MOL BRAIN RES, V83, P121, DOI 10.1016/S0169-328X(00)00169-8; DeRisi J, 1996, NAT GENET, V14, P457; Diehn M, 2000, NAT GENET, V25, P58, DOI 10.1038/75603; Eisch AJ, 1998, SYNAPSE, V30, P329, DOI 10.1002/(SICI)1098-2396(199811)30:3<329::AID-SYN10>3.0.CO;2-V; Eisch AJ, 1998, SYNAPSE, V30, P433, DOI 10.1002/(SICI)1098-2396(199812)30:4<433::AID-SYN10>3.3.CO;2-F; Ernst T, 2000, NEUROLOGY, V54, P1344, DOI 10.1212/WNL.54.6.1344; Gibb JW, 1997, J PHARMACOL EXP THER, V283, P630; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HENKART PA, 1995, J IMMUNOL, V154, P4905; Jayanthi S, 1998, ANN NY ACAD SCI, V844, P92, DOI 10.1111/j.1749-6632.1998.tb08224.x; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McCann UD, 1998, J NEUROSCI, V18, P8417; Nau ME, 2000, J CLIN MICROBIOL, V38, P1901, DOI 10.1128/JCM.38.5.1901-1908.2000; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; PRESTON KL, 1985, BRAIN RES, V338, P243, DOI 10.1016/0006-8993(85)90153-2; REED JC, 1996, MECH BCL 2 FAMILY PR, P72; RICAURTE GA, 1980, BRAIN RES, V193, P153, DOI 10.1016/0006-8993(80)90952-X; RICAURTE GA, 1982, BRAIN RES, V235, P93, DOI 10.1016/0006-8993(82)90198-6; Robinson TE, 1997, J NEUROSCI, V17, P8491; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; RYAN LJ, 1990, BRAIN RES, V518, P67, DOI 10.1016/0006-8993(90)90955-B; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Seiden L S, 1996, NIDA Res Monogr, V163, P251; Shimizu S, 1996, AM J PHYSIOL-GASTR L, V271, pG949, DOI 10.1152/ajpgi.1996.271.6.G949; STERANKA LR, 1980, EUR J PHARMACOL, V65, P439, DOI 10.1016/0014-2999(80)90351-9; Stumm G, 1999, FASEB J, V13, P1065, DOI 10.1096/fasebj.13.9.1065; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Vander Heiden MG, 1999, MOL CELL, V3, P159; Volkow ND, 2001, AM J PSYCHIAT, V158, P383, DOI 10.1176/appi.ajp.158.3.383; Volkow ND, 1999, J PHARMACOL EXP THER, V291, P409; WAGNER GC, 1979, DRUG ALCOHOL DEPEN, V4, P435, DOI 10.1016/0376-8716(79)90076-0; WHITE E, 1996, GENE DEV, V10, P10; Wilson JM, 1996, NAT MED, V2, P699, DOI 10.1038/nm0696-699; WON L, 1992, BRAIN RES, V575, P6, DOI 10.1016/0006-8993(92)90416-7; Yamamoto H, 1996, ANN NY ACAD SCI, V801, P327, DOI 10.1111/j.1749-6632.1996.tb17453.x; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin X M, 1995, Curr Top Microbiol Immunol, V194, P331; Zamorano PL, 1996, NEUROENDOCRINOLOGY, V63, P397, DOI 10.1159/000127065	62	137	153	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					1745	1752		10.1096/fj.01-0025com	http://dx.doi.org/10.1096/fj.01-0025com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481222				2022-12-28	WOS:000170809900010
J	Larcher, F; Del Rio, M; Serrano, F; Segovia, JC; Ramirez, A; Meana, A; Page, A; Abad, JL; Gonzalez, MA; Bueren, J; Bernad, A; Jorcano, JL				Larcher, F; Del Rio, M; Serrano, F; Segovia, JC; Ramirez, A; Meana, A; Page, A; Abad, JL; Gonzalez, MA; Bueren, J; Bernad, A; Jorcano, JL			A cutaneous gene therapy approach to human leptin deficiencies: correction of the murine ob/ob phenotype using leptin-targeted keratinocyte grafts	FASEB JOURNAL			English	Article						skin; lipodistrophy; diabetes; leptin replacement	GENETICALLY-OBESE MICE; HUMAN EPIDERMAL-CELLS; TRANSGENIC MICE; STEM-CELLS; GROWTH-HORMONE; INSULIN SENSITIVITY; DIABETES-MELLITUS; HEMOPHILIA-B; IN-VITRO; EXPRESSION	Leptin deficiency produces a phenotype of obesity, diabetes, and infertility in the ob/ob mouse. In humans, leptin deficiency occurs in some cases of congenital obesity and in lipodystrophic disorders characterized by reduced adipose tissue and insulin resistance. Cutaneous gene therapy is considered an attractive potential method to correct circulating protein deficiencies, since gene-transferred human keratinocytes can produce and secrete gene products with systemic action. However, no studies showing correction of a systemic defect have been reported. We report the successful correction of leptin deficiency using cutaneous gene therapy in the ob/ob mouse model. As a feasibility approach, skin explants from transgenic mice overexpressing leptin were grafted on immunodeficient ob/ob mice. One month later, recipient mice reached body weight values of lean animals. Other biochemical and clinical parameters were also normalized. In a second human gene therapy approach, a retroviral vector encoding both leptin and EGFP cDNAs was used to transduce HK and, epithelial grafts enriched in high leptin-producing HK were transplanted to immunosuppressed ob/ob mice. HK-derived leptin induced body weight reduction after a drop in blood glucose and food intake. Leptin replacement through genetically engineered HK grafts provides a valuable therapeutic alternative for permanent treatment of human leptin deficiency conditions.	CIEMAT, Project Cell & Mol Biol & Gene Therapy, E-28040 Madrid, Spain; Fdn Marcelino Botin Gene Therapy, Madrid, Spain; Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid, Spain; Ctr Transfus Principado Asturias, Oviedo, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Larcher, F (corresponding author), CIEMAT, Project Cell & Mol Biol & Gene Therapy, Ave Complutense 22 Edificio 7, E-28040 Madrid, Spain.	Fernando.larcher@ciemat.es	Bueren, Juan/L-6112-2014; Segovia, Jose Carlos/L-2922-2014; Meana, Alvaro/D-9710-2019; Bernad, Antonio/P-8573-2017; Gonzalez, Manuel A/A-3404-2013; Ramirez, Angel/A-4800-2018; Larcher, Fernando/J-1527-2016; DEL RIO, MARCELA/H-2796-2015	Bueren, Juan/0000-0002-3228-7013; Segovia, Jose Carlos/0000-0003-4101-6124; Meana, Alvaro/0000-0001-9434-6042; Ramirez, Angel/0000-0001-7745-5108; Larcher, Fernando/0000-0002-6771-3561; DEL RIO, MARCELA/0000-0003-2910-7189; Page, Angustias/0000-0002-0231-8536; Bernad, Antonio/0000-0003-0620-9668				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Albella B, 1999, TRANSPLANTATION, V67, P1348, DOI 10.1097/00007890-199905270-00010; ALEXANDER MY, 1995, HUM MOL GENET, V4, P993, DOI 10.1093/hmg/4.6.993; BARRANDON Y, 1988, J INVEST DERMATOL, V91, P315, DOI 10.1111/1523-1747.ep12475646; Bouloumie A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Compton Carolyn C., 1994, Journal of Burn Care and Rehabilitation, V15, P393, DOI 10.1097/00004630-199409000-00002; Del Rio M, 1999, GENE THER, V6, P1734, DOI 10.1038/sj.gt.3300986; DeLuca M, 1997, GENE THER, V4, P381, DOI 10.1038/sj.gt.3300434; Deng H, 1998, BIOTECHNIQUES, V25, P274, DOI 10.2144/98252gt02; Deng H, 1997, NAT BIOTECHNOL, V15, P1388, DOI 10.1038/nbt1297-1388; DiGiovanni J, 2000, CANCER RES, V60, P1561; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Ebihara K, 2000, DIABETES, V49, pA210; Fakharzadeh SS, 2000, BLOOD, V95, P2799, DOI 10.1182/blood.V95.9.2799.009k23_2799_2805; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; FENJVES ES, 1994, HUM GENE THER, V5, P1241, DOI 10.1089/hum.1994.5.10-1241; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; GERRARD AJ, 1993, NAT GENET, V3, P180, DOI 10.1038/ng0293-180; Guerra L, 2000, ARCH DERMATOL, V136, P1380, DOI 10.1001/archderm.136.11.1380; Ioffe E, 1998, P NATL ACAD SCI USA, V95, P11852, DOI 10.1073/pnas.95.20.11852; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kolodka TM, 1998, P NATL ACAD SCI USA, V95, P4356, DOI 10.1073/pnas.95.8.4356; LEITER EH, 1992, JAX NOTES, V451; Mathor MB, 1996, P NATL ACAD SCI USA, V93, P10371, DOI 10.1073/pnas.93.19.10371; Meana A, 1998, BURNS, V24, P621, DOI 10.1016/S0305-4179(98)00107-7; Meng XM, 1998, J CLIN INVEST, V101, P1462, DOI 10.1172/JCI1031; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MORGAN JR, 1987, SCIENCE, V237, P1476; Morsy MA, 1998, GENE THER, V5, P8, DOI 10.1038/sj.gt.3300565; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; Murphy JE, 1997, P NATL ACAD SCI USA, V94, P13921, DOI 10.1073/pnas.94.25.13921; Muzzin P, 1996, P NATL ACAD SCI USA, V93, P14804, DOI 10.1073/pnas.93.25.14804; Namae M, 1998, LAB ANIM SCI, V48, P103; Ogawa Y, 1999, DIABETES, V48, P1822, DOI 10.2337/diabetes.48.9.1822; Pardini VC, 1998, J CLIN ENDOCR METAB, V83, P503, DOI 10.1210/jc.83.2.503; Pellegrini G, 1998, MED BIOL ENG COMPUT, V36, P778, DOI 10.1007/BF02518885; Pfutzner W, 1999, HUM GENE THER, V10, P2811, DOI 10.1089/10430349950016546; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; SEIP M, 1996, ACTA PEDIAT S, V13, P2; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; TAICHMAN LB, 1994, KERATINOCYTE HDB, P543; TEUMER J, 1990, FASEB J, V4, P3245, DOI 10.1096/fasebj.4.14.2227214; Wang MY, 1998, P NATL ACAD SCI USA, V95, P714, DOI 10.1073/pnas.95.2.714; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219; Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255	53	53	57	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2001	15	9					1529	1538		10.1096/fj.01-0082com	http://dx.doi.org/10.1096/fj.01-0082com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427484				2022-12-28	WOS:000170318500004
J	Perez, P; Page, A; Bravo, A; del Rio, M; Gimenez-Conti, I; Budunova, I; Slaga, TJ; Jorcano, JL				Perez, P; Page, A; Bravo, A; del Rio, M; Gimenez-Conti, I; Budunova, I; Slaga, TJ; Jorcano, JL			Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor	FASEB JOURNAL			English	Article						skin; aplasia cutis congenita; ectodermal dysplasia; NF-kappa B	APLASIA-CUTIS-CONGENITA; GROWTH-FACTOR RECEPTOR; FACTOR-KAPPA-B; TRANSCRIPTION FACTORS; HAIR FOLLICLE; DNA-BINDING; MOUSE SKIN; EXPRESSION; P50-NF-KAPPA-B; ACTIVATION	Glucocorticoids (GCs) are potent inhibitors of epidermal proliferation and effective antiinflammatory compounds, which make them the drug of choice for a wide range of inflammatory and hyperproliferative skin disorders. GC action is mediated via the glucocorticoid receptor (GR). To study the role of GR in skin development and the molecular mechanisms underlying its action, we generated transgenic mice overexpressing GR in epidermis and other stratified epithelia, under the control of the keratin K5 promoter. Newborn mice show altered skin development, manifested as variable-sized skin lesions that range from epidermal hypoplasia and underdeveloped dysplastic hair follicles to a complete absence of this tissue. In the most affected individuals, skin was absent at the cranial and umbilical regions, and the vibrissae and eyebrows appear scarce, short, and curly. In addition, as a consequence of transgene expression in other ectodermally derived epithelia, K5-GR mice exhibited further abnormalities that strikingly resemble the clinical findings in patients with ectodermal dysplasia, which includes aplasia cutis congenita. In adult transgenic skin, topical application of the tumor promoter TPA did not elicit hyperplasia or transcriptional induction of several proinflammatory cytokines. This antiinflammatory role of GR was due at least in part to interference with NF-kappaB, leading to a strong reduction in the kappaB-binding activity without altering the transcriptional levels of the inhibitor I kappaB alpha.	CIEMAT, Project Cell & Mol Biol & Gene Therapy, E-28040 Madrid, Spain; Univ Santiago de Compostela, Fac Vet, Dept Anim Pathol, E-27002 Lugo, Spain; Univ Texas, MD Anderson Canc Ctr, Smithville, TX USA; AMC Canc Res Ctr, Denver, CO USA	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Universidade de Santiago de Compostela; University of Texas System; UTMD Anderson Cancer Center; AMC Cancer Research Center	Jorcano, JL (corresponding author), CIEMAT, Project Cell & Mol Biol & Gene Therapy, Av Complutense 22, E-28040 Madrid, Spain.	jl.jorcano@ciemat.es	Moral, Ana María Bravo/AAD-3339-2021; Perez, Paloma/K-8841-2017; DEL RIO, MARCELA/H-2796-2015	Moral, Ana María Bravo/0000-0002-5282-8921; Perez, Paloma/0000-0002-7166-2824; DEL RIO, MARCELA/0000-0003-2910-7189; Page, Angustias/0000-0002-0231-8536				Ahluwalia A, 1998, MEDIAT INFLAMM, V7, P183, DOI 10.1080/09629359891126; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; CHITAYAT D, 1992, AM J MED GENET, V44, P562, DOI 10.1002/ajmg.1320440506; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; FRIEDEN IJ, 1986, J AM ACAD DERMATOL, V14, P646, DOI 10.1016/S0190-9622(86)70082-0; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; Hansen LA, 1997, AM J PATHOL, V150, P1959; Hogan B, 1994, MANIPULATING MOUSE E; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; LEBOUCQ N, 1994, NEURORADIOLOGY, V36, P480, DOI 10.1007/BF00593689; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MOORE KL, 1999, CLIN EMBRYOLOGY; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; Perez P, 2000, MOL CARCINOGEN, V27, P272, DOI 10.1002/(SICI)1098-2744(200004)27:4<272::AID-MC5>3.0.CO;2-P; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SLAGA TJ, 1996, J INVEST DERMATOL, V2, P151; STEPHAN MJ, 1982, J PEDIATR-US, V101, P850, DOI 10.1016/S0022-3476(82)80346-6; Tobin D, 1996, ONCOGENE, V12, P785; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365	25	67	69	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2030	+		10.1096/fj.00-0772fje	http://dx.doi.org/10.1096/fj.00-0772fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511512				2022-12-28	WOS:000170318500014
J	Beck, MA; Nelson, HK; Shi, Q; Van Dael, P; Schiffrin, EJ; Blum, S; Barclay, D; Levander, OA				Beck, MA; Nelson, HK; Shi, Q; Van Dael, P; Schiffrin, EJ; Blum, S; Barclay, D; Levander, OA			Selenium deficiency increases the pathology of an influenza virus infection	FASEB JOURNAL			English	Article						oxidative stress; cytokine; chemokine	NF-KAPPA-B; T-CELLS; COXSACKIEVIRUS B3; HUMAN ENTEROVIRUS; GENE-EXPRESSION; VIRAL-INFECTION; KESHAN-DISEASE; A VIRUS; MICE; THIOREDOXIN	Selenium (Se) deficiency has previously been shown to induce myocarditis in mice infected with a benign strain of coxsackievirus. To determine if Se deficiency would also intensify an infection with influenza virus, Se-deficient and Se-adequate mice were infected with a mild strain of influenza, influenza A/Bangkok/1/79 (H3N2). Infected Se-deficient mice developed much more severe interstitial pneumonitis than did Se-adequate mice. This increase in pathology was associated with significant alterations in mRNA levels for cytokines and chemokines involved in pro-inflammatory responses. These results demonstrate that adequate nutrition is required for protection against viral infection and suggest that nutritional deprivation may be one of many factors that increase the susceptibility of individuals to influenza infection.	Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA; Nestle Res Ctr, Dept Nutr, CH-1000 Lausanne, Switzerland; ARS, USDA, Beltsville Human Nutr Res Ctr, Beltsville, MD 20705 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Nestle SA; United States Department of Agriculture (USDA)	Beck, MA (corresponding author), Univ N Carolina, Dept Pediat, 535 Burnett Womack,CB 7220, Chapel Hill, NC 27599 USA.	melinda_beck@unc.edu						Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Allan CB, 1999, ANNU REV NUTR, V19, P1, DOI 10.1146/annurev.nutr.19.1.1; ALLEN W, 1990, J IMMUNOL, V144, P3980; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Baum MK, 1998, NUTR REV, V56, pS135; BECK MA, 1994, J INFECT DIS, V170, P351, DOI 10.1093/infdis/170.2.351; BECK MA, 1995, NAT MED, V1, P433, DOI 10.1038/nm0595-433; BECK MA, 1994, J MED VIROL, V43, P166, DOI 10.1002/jmv.1890430213; Bender B S, 1992, Semin Respir Infect, V7, P38; BENDER BS, 1992, J EXP MED, V175, P1143, DOI 10.1084/jem.175.4.1143; Bernstein E, 1999, VACCINE, V17, P82, DOI 10.1016/S0264-410X(98)00117-0; Burk RF, 1999, BIOESSAYS, V21, P231, DOI 10.1002/(SICI)1521-1878(199903)21:3<231::AID-BIES7>3.3.CO;2-4; Campa A, 1999, J ACQ IMMUN DEF SYND, V20, P508, DOI 10.1097/00042560-199904150-00015; *CDCP, 2000, MMWR-MORBID MORTAL W, V49, P113; Chakraborti S, 1998, CELL SIGNAL, V10, P675, DOI 10.1016/S0898-6568(98)00014-X; CLEMENTS ML, 1986, J CLIN MICROBIOL, V24, P157, DOI 10.1128/JCM.24.1.157-160.1986; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; COUCH RB, 1983, ANNU REV MICROBIOL, V37, P529, DOI 10.1146/annurev.mi.37.100183.002525; DAS KC, 2000, J BIOL CHEM     1103; DHUR A, 1990, COMP BIOCHEM PHYS C, V96, P271, DOI 10.1016/0742-8413(90)90007-V; DOWDLE WR, 1975, INFLUENZA VIRUSES IN, P243; EICHELBERGER M, 1991, J EXP MED, V174, P875, DOI 10.1084/jem.174.4.875; EICHELBERGER MC, 1991, J GEN VIROL, V72, P1695, DOI 10.1099/0022-1317-72-7-1695; Flory E, 2000, J BIOL CHEM, V275, P8307, DOI 10.1074/jbc.275.12.8307; GU BQ, 1983, CHINESE MED J-PEKING, V96, P251; Harbige Laurence S., 1996, Nutrition and Health (Bicester), V10, P285; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HENNET T, 1992, J IMMUNOL, V149, P932; Hill KE, 1997, BIOCHEM BIOPH RES CO, V234, P293, DOI 10.1006/bbrc.1997.6618; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; Knobil K, 1998, AM J PHYSIOL-LUNG C, V274, pL134, DOI 10.1152/ajplung.1998.274.1.L134; Kukreja Rajni, 1998, Indian Journal of Experimental Biology, V36, P203; Levander OA, 1997, BIOL TRACE ELEM RES, V56, P5, DOI 10.1007/BF02778980; LIGHTMAN S, 1987, IMMUNOLOGY, V62, P139; Matsukura S, 1998, AM J RESP CELL MOL, V18, P255, DOI 10.1165/ajrcmb.18.2.2822; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; PAHL HL, 1995, J VIROL, V69, P1480, DOI 10.1128/JVI.69.3.1480-1484.1995; Palmer DF, 1975, IMMUNOLOGY SERIES US; Schwarz KB, 1996, FREE RADICAL BIO MED, V21, P641, DOI 10.1016/0891-5849(96)00131-1; SCRIMSHAW N S, 1975, Progress in Food and Nutrition Science, V1, P393; SCRIMSHAW NS, 1968, WHO MONOGRAPH SERIES, V57; Stadtman TC, 2000, ANN NY ACAD SCI, V899, P399, DOI 10.1111/j.1749-6632.2000.tb06203.x; VanDael P, 1995, ATOM SPECTROSC, V16, P251; Ward AC, 1997, VIRUS GENES, V14, P187, DOI 10.1023/A:1007979709403; Ward SG, 1998, BIOCHEM J, V333, P457, DOI 10.1042/bj3330457	49	206	212	2	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1481	+		10.1096/fj.00-0721fje	http://dx.doi.org/10.1096/fj.00-0721fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387264				2022-12-28	WOS:000173705800003
J	Tomasetti, M; Alleva, R; Collins, AR				Tomasetti, M; Alleva, R; Collins, AR			In vivo supplementation with coenzyme Q(10) enhances the recovery of human lymphocytes from oxidative DNA damage	FASEB JOURNAL			English	Article						ubiquinone-10; ubiquinol-10; DNA oxidation; DNA recovery; DNA repair enzymes; comet assay	NF-KAPPA-B; DEGENERATIVE DISEASES; OXYGEN RADICALS; ANTIOXIDANTS; AP-1; CARCINOGENESIS; THIOREDOXIN; CONSUMPTION; ACTIVATION	We investigated the effect of in vitro and in vivo CoQ(10) supplementation on the recovery of lymphocytes from oxidative DNA damage. Furthermore, we investigated whether CoQ(10) supplementation modulates the activity of DNA repair enzymes by using cellular extracts from lymphocytes. Exposure of lymphocytes to oxidizing agents leads to an increase of DNA strand breaks, oxidized purines, and pyrimidines. Enrichment of cells with CoQ(10) prevents DNA strand-break formation and affects the kinetics of repair, which occurs faster in enriched than in native lymphocytes. In contrast, CoQ(10) supplementation neither prevents endogenous formation of oxidized bases nor affects their repair. DNA repair enzyme activity is enhanced by in vivo CoQ(10) supplementation. Changes in the redox state of several transcriptional factors have been proposed as mechanisms regulating cell proliferation and apoptosis. Because CoQ(10) is mainly present as ubiquinol-10, both in plasma and lymphocytes, it can feasibly modulate the intracellular redox potential involved in the regulation of gene expression. The redox mechanism implicated in the enzyme transactivation could explain the property of CoQ(10) to enhance the DNA repair activity and protect DNA from oxidative damage.	Rowett Res Inst, Aberdeen AB21 9SB, Scotland	University of Aberdeen	Tomasetti, M (corresponding author), Corso Mazzini, I-63039 San Benedetto Del Tr Asc, Italy.	ralleva@jth.it		Alleva, Renata/0000-0001-7327-3833				Alleva R, 1997, MOL ASPECTS MED, V18, pS105; AMES BN, 1993, ENVIRON HEALTH PERSP, V101, P35, DOI 10.2307/3431840; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; COLLINS AR, 1993, CARCINOGENESIS, V14, P1733, DOI 10.1093/carcin/14.9.1733; Collins AR, 1997, ENVIRON MOL MUTAGEN, V29, P152; Duthie SJ, 1996, CANCER RES, V56, P1291; EPE B, 1988, CHEM-BIOL INTERACT, V67, P149, DOI 10.1016/0009-2797(88)90094-4; EPE B, 1995, REV PHYSL BIOCH PHAR, V127, P223; Fillion L, 1998, ACTA BIOCHIM POL, V45, P183, DOI 10.18388/abp.1998_4300; HALLIWELL B, 1994, NUTR REV, V52, P253; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; JEMOLARZEMINSKA M, 1996, CHEM PHYS LIPIDS, V79, P55; Kim GM, 1996, INT J HIGH SPEED COM, V8, P115, DOI 10.1142/S0129053396000094; Lee HS, 1998, FREE RADICAL BIO MED, V24, P1193, DOI 10.1016/S0891-5849(97)00427-9; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MOHR D, 1992, BIOCHIM BIOPHYS ACTA, V26, P347; Muller-Scharer H., 1997, Integrated Pest Management Reviews, V2, P45, DOI 10.1023/A:1018428412868; Navarro F, 1999, BIOFACTORS, V9, P163, DOI 10.1002/biof.5520090211; NEGRI E, 1991, INT J CANCER, V48, P350, DOI 10.1002/ijc.2910480307; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; Pool-Zobel BL, 1998, CANCER EPIDEM BIOMAR, V7, P891; Poulsen HE, 1998, EUR J CANCER PREV, V7, P9; POULSEN HE, 1996, J MOL MED, V74, P297; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; Tomasetti M, 1999, FREE RADICAL BIO MED, V27, P1027, DOI 10.1016/S0891-5849(99)00132-X; VERHAGEN H, 1995, CARCINOGENESIS, V16, P969, DOI 10.1093/carcin/16.4.969; WATTENBERG LW, 1992, CANCER RES, V52, pS2085; Weber C, 1997, MOL ASPECTS MED, V18, pS251; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	31	108	113	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1425	+		10.1096/fj.00-0694fje	http://dx.doi.org/10.1096/fj.00-0694fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387245				2022-12-28	WOS:000173705800023
J	Crochemore, C; Michaelidis, TM; Fischer, D; Loeffler, JP; Almeida, OFX				Crochemore, C; Michaelidis, TM; Fischer, D; Loeffler, JP; Almeida, OFX			Enhancement of p53 activity and inhibition of neural cell proliferation by glucocorticoid receptor activation	FASEB JOURNAL			English	Article						corticosteroid; cell cycle arrest; apoptosis; HT-22 neural cell line	TUMOR-SUPPRESSOR P53; HIPPOCAMPAL GRANULE CELLS; RAT HEPATOMA-CELLS; GENE-EXPRESSION; CYCLE ARREST; DNA-DAMAGE; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; CORTICOSTEROID RECEPTORS; PROMOTER ACTIVITY	In analyzing the molecular mechanisms underlying glucocorticoid-induced apoptosis in neural cells, we observed that dexamethasone, by activating glucocorticoid receptors, causes arrest of HT-22 cells in the G(1) phase of the cell cycle; upon withdrawal of the agonist, cells resume proliferation. Our investigations revealed that glucocorticoid treatment, although having no effects on endogenous p53 protein stability, induces rapid translocation of p53 to the nucleus and enhances its transcriptional activity. Consistently, transfection studies with p53-responsive promoters revealed a substantial stimulation of the trans-activation potential of exogenous p53 by dexamethasone. Cells arrested in G(1) failed to show signs of apoptosis even after overexpression of p53. Although dexamethasone induced transcription of the proapoptotic gene bax, there was no increase of Bax protein levels. We conclude that glucocorticoid receptor-induced neural cell cycle arrest is associated with an increase in nuclear translocation and transcriptional activity of p53, and suggest that potentiation of p53 may serve as a brake on cell proliferation and may prime cells for differentiation or death induced by other signals.	Max Planck Inst Psychiat, D-80804 Munich, Germany; Univ Strasbourg, Fac Med, F-67000 Strasbourg, France	Max Planck Society; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Almeida, OFX (corresponding author), Max Planck Inst Psychiat, Kraepelinstr 2-10, D-80804 Munich, Germany.	osa@mpipsykl.mpg.de	Almeida, Osborne F.X. F/E-8402-2010; LOEFFLER, Jean-Philippe/AAS-4401-2020	Almeida, Osborne F.X. F/0000-0001-7331-6928; 				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Almeida OFX, 2000, FASEB J, V14, P779, DOI 10.1096/fasebj.14.5.779; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTHEL F, 1993, DNA CELL BIOL, V12, P553, DOI 10.1089/dna.1993.12.553; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Behl C, 1997, ENDOCRINOLOGY, V138, P101, DOI 10.1210/en.138.1.101; BOURGEOIS S, 1984, EMBO J, V3, P751, DOI 10.1002/j.1460-2075.1984.tb01879.x; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BURNSTEIN KL, 1994, MOL ENDOCRINOL, V8, P1764, DOI 10.1210/me.8.12.1764; Cadepond F, 1997, ANNU REV MED, V48, P129; Campagne MV, 1998, J COMP NEUROL, V397, P181; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; CIDLOWSKI JA, 1977, NATURE, V266, P643, DOI 10.1038/266643a0; COLEMAN RE, 1992, BIOTHERAPY, V4, P37, DOI 10.1007/BF02171708; CORRELL PH, 1997, GENES FUNCTION, V1, P1; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DAVIS JB, 1994, BRAIN RES, V652, P169, DOI 10.1016/0006-8993(94)90334-4; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; Dempster DW, 1997, J ENDOCRINOL, V154, P397, DOI 10.1677/joe.0.1540397; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Geley S, 1996, CANCER RES, V56, P5033; Glass CK, 2000, GENE DEV, V14, P121; Glick RD, 2000, J PEDIATR SURG, V35, P465, DOI 10.1016/S0022-3468(00)90216-1; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Gould E, 1999, BIOL PSYCHIAT, V46, P1472, DOI 10.1016/S0006-3223(99)00247-4; Hassan AHS, 1999, FASEB J, V13, P115, DOI 10.1096/fasebj.13.1.115; Hassan AHS, 1996, EXP NEUROL, V140, P43, DOI 10.1006/exnr.1996.0113; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jordan J, 1997, J NEUROSCI, V17, P1397; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOEHLER PJ, 1995, ANTI-CANCER DRUG, V6, P19, DOI 10.1097/00001813-199502000-00002; Kren BT, 1996, CELL GROWTH DIFFER, V7, P1633; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lupien SJ, 1998, NAT NEUROSCI, V1, P69, DOI 10.1038/271; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; Meagher LC, 1996, J IMMUNOL, V156, P4422; MEYER JS, 1985, PHYSIOL REV, V65, P946, DOI 10.1152/physrev.1985.65.4.946; Miller FD, 2000, CELL DEATH DIFFER, V7, P880, DOI 10.1038/sj.cdd.4400736; MIYASHITA T, 1995, CELL, V80, P293; Oldenburg NBE, 1997, ENDOCRINOLOGY, V138, P810, DOI 10.1210/en.138.2.810; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Ramalingam A, 1997, MOL ENDOCRINOL, V11, P577, DOI 10.1210/me.11.5.577; Reagan LP, 1997, J CHEM NEUROANAT, V13, P149, DOI 10.1016/S0891-0618(97)00031-8; RHEE K, 1995, CELL GROWTH DIFFER, V6, P691; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; ROSENFELD P, 1988, BRAIN RES, V470, P113; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1222; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBER SS, 1994, EXP NEUROL, V130, P368, DOI 10.1006/exnr.1994.1216; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; Sengupta S, 2000, EMBO J, V19, P6051, DOI 10.1093/emboj/19.22.6051; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLOVITER RS, 1989, SCIENCE, V243, P535, DOI 10.1126/science.2911756; Sousa N, 1999, NEUROSCIENCE, V89, P1079, DOI 10.1016/S0306-4522(98)00311-X; STEFFEN M, 1988, CANCER RES, V48, P7212; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; TCHEKNEVA E, 1994, J IMMUNOL, V152, P5912; Thompson EB, 1999, TRENDS ENDOCRIN MET, V10, P353, DOI 10.1016/S1043-2760(99)00187-3; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WHITTEMORE SR, 1991, J NEUROSCI RES, V28, P156, DOI 10.1002/jnr.490280203; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; WOOLLEY CS, 1991, BRAIN RES, V554, P312, DOI 10.1016/0006-8993(91)90207-C; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Zuo Z, 1999, BIOCHEMISTRY-US, V38, P8849, DOI 10.1021/bi990842e	85	57	63	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0761	10.1096/fj.01-0577com	http://dx.doi.org/10.1096/fj.01-0577com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039857				2022-12-28	WOS:000176683900001
J	Saadi, S; Wrenshall, LE; Platt, JL				Saadi, S; Wrenshall, LE; Platt, JL			Regional manifestations and control of the immune system	FASEB JOURNAL			English	Article						immunity; vascular endothelium; heparan sulfate proteoglycan; complement; antigen-presenting cells	VON-WILLEBRAND-FACTOR; INDUCED PLATELET-AGGREGATION; RENAL-ALLOGRAFT REJECTION; ENDOTHELIAL-CELLS; HEPARAN-SULFATE; REPERFUSION INJURY; INNATE IMMUNITY; EXTRACELLULAR-MATRIX; CARDIAC XENOGRAFTS; ADHESION MOLECULES	Although immune responses are generally considered to be systemic, local events such as interaction of complement products with blood vessels and with inflammatory cells play a pivotal role in determining the nature and manifestations of immune responses. This paper will discuss how blood vessel physiology and immunity influence one another to reach homeostasis upon exposure to an infectious agent. We review new insights into the mechanisms by which the microenvironment of tissues protects against microbial invasion yet facilitates migration of leukocytes and 'decides' whether immunity or tolerance ensues and whether, in the face of immunity, protective responses or tissue injury ensues. These 'decisions' are made based on interaction of components of normal tissues such as proteoglycans and injured tissues such as cell-associated cytokines with receptors on immune cells and blood vessels.	Mayo Clin, Dept Surg, Rochester, MN 55905 USA; Mayo Clin, Dept Mol Biol & Biochem, Rochester, MN USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA; Mayo Clin, Dept Immunol, Rochester, MN USA; Mayo Clin, Dept Pediat, Rochester, MN USA	Mayo Clinic; Mayo Clinic; University of Washington; University of Washington Seattle; Mayo Clinic; Mayo Clinic	Platt, JL (corresponding author), Mayo Clin, Dept Surg, Rochester, MN 55905 USA.	Platt.jeffrey@mayo.edu	Platt, Jeffrey/AHB-0480-2022	Platt, Jeffrey/0000-0002-4915-0419				Ajzenberg N, 2000, BLOOD, V95, P3796; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Binion DG, 1998, AM J PHYSIOL-GASTR L, V275, pG592, DOI 10.1152/ajpgi.1998.275.3.G592; BRAUER RB, 1995, TRANSPLANTATION, V59, P288, DOI 10.1097/00007890-199501270-00023; BRAUER RB, 1993, J IMMUNOL, V151, P7240; Bustos M, 1997, J CLIN INVEST, V100, P1150, DOI 10.1172/JCI119626; Bustos M, 2001, TRANSPLANTATION, V72, P509, DOI 10.1097/00007890-200108150-00025; Cohn J, 2001, CURR OPIN IMMUNOL, V13, P55, DOI 10.1016/S0952-7915(00)00182-5; Cybulsky AV, 2000, KIDNEY INT, V57, P1052, DOI 10.1046/j.1523-1755.2000.00932.x; DARDIK R, 1993, THROMB HAEMOSTASIS, V70, P522; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Engwerda CR, 2000, IMMUNOL TODAY, V21, P73, DOI 10.1016/S0167-5699(99)01549-2; Eppinger MJ, 1997, AM J PATHOL, V150, P1773; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; Gilat D, 1996, IMMUNOL TODAY, V17, P16, DOI 10.1016/0167-5699(96)80563-9; Goulet JL, 2001, J IMMUNOL, V167, P6631, DOI 10.4049/jimmunol.167.11.6631; Hammerberg C, 1998, J EXP MED, V187, P1133, DOI 10.1084/jem.187.7.1133; Haq M, 1998, J AM SOC NEPHROL, V9, P614; HARDY MM, 1994, J BIOL CHEM, V269, P18535; HATTORI R, 1989, J BIOL CHEM, V264, P9053; HENSON PM, 1978, J IMMUNOL, V121, P851; Ihrcke NS, 1996, J CELL PHYSIOL, V168, P625, DOI 10.1002/(SICI)1097-4652(199609)168:3<625::AID-JCP15>3.3.CO;2-A; IHRCKE NS, 1993, IMMUNOL TODAY, V14, P500, DOI 10.1016/0167-5699(93)90265-M; Ihrcke NS, 1998, J CELL PHYSIOL, V175, P255, DOI 10.1002/(SICI)1097-4652(199806)175:3<255::AID-JCP3>3.0.CO;2-N; Irikura VM, 1999, INFECT IMMUN, V67, P1901; Juffermans NP, 2000, J INFECT DIS, V182, P902, DOI 10.1086/315771; Kalady MF, 1998, MOL MED, V4, P629, DOI 10.1007/BF03401762; KANNO K, 1994, AM J PHYSIOL-HEART C, V267, pH2318, DOI 10.1152/ajpheart.1994.267.6.H2318; Kilgore KS, 1996, AM J PATHOL, V149, P953; Kirschfink M, 1997, J IMMUNOL, V158, P1324; KODAIRA Y, 2000, J IMMUNOL, V165, P1599; LABOW JM, 1997, J IMMUNOL, P159; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; LIDER O, 1989, J CLIN INVEST, V83, P752, DOI 10.1172/JCI113953; LOZADA C, 1995, P NATL ACAD SCI USA, V92, P8378, DOI 10.1073/pnas.92.18.8378; MICHALEK MT, 1988, J IMMUNOL, V140, P1588; Moroi M, 1997, BLOOD, V90, P4413; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; Nagayasu T, 2000, TRANSPLANTATION, V69, P475, DOI 10.1097/00007890-200002270-00003; NEMERSON Y, 1986, PROG ALLERGY, V11, P1; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; Pratt JR, 1996, AM J PATHOL, V149, P2055; Prodeus AP, 1998, IMMUNITY, V9, P721, DOI 10.1016/S1074-7613(00)80669-X; RHEINS LA, 1987, CELL IMMUNOL, V106, P33, DOI 10.1016/0008-8749(87)90147-X; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; ROBERTS HR, 1992, HOSP PRACT, V27, P97; Saadi S, 2000, CIRCULATION, V101, P1867, DOI 10.1161/01.CIR.101.15.1867; SAADI S, 1995, J EXP MED, V181, P21, DOI 10.1084/jem.181.1.21; SAADI S, 1995, J EXP MED, V182, P1807, DOI 10.1084/jem.182.6.1807; SAKURABA M, 1989, J PERINAT MED, V17, P99, DOI 10.1515/jpme.1989.17.2.99; Schmid E, 1997, INFLAMMATION, V21, P325, DOI 10.1023/A:1027302017117; Selvan RS, 1998, J IMMUNOL, V161, P4388; Soslau G, 2001, J BIOL CHEM, V276, P21173, DOI 10.1074/jbc.M008249200; SOZZANI S, 1995, J IMMUNOL, V155, P3292; STEVENS RR, 1993, TRANSPLANT P, V25, P382; SUTTORP N, 1987, AM J PHYSIOL, V253, pC13, DOI 10.1152/ajpcell.1987.253.1.C13; Takano T, 2000, AM J PATHOL, V156, P2091, DOI 10.1016/S0002-9440(10)65080-8; TAPPY L, 1984, THROMB RES, V33, P117, DOI 10.1016/0049-3848(84)90172-5; Taylor PW, 1993, ACTIVATORS INHIBITOR, P37; Tedesco F, 1997, J EXP MED, V185, P1619, DOI 10.1084/jem.185.9.1619; Terry CM, 1998, AM J PHYSIOL-HEART C, V274, pH883, DOI 10.1152/ajpheart.1998.274.3.H883; VARANI J, 1989, AM J PATHOL, V135, P435; VERCELLOTTI GM, 1991, J IMMUNOL, V146, P730; Wang CZ, 1998, J ASIAN NAT PROD RES, V1, P1, DOI 10.1080/10286029808039839; Weiser MR, 1996, J EXP MED, V183, P2343, DOI 10.1084/jem.183.5.2343; Williams JP, 1999, J APPL PHYSIOL, V86, P938, DOI 10.1152/jappl.1999.86.3.938; Wrenshall LE, 1999, J LEUKOCYTE BIOL, V66, P391, DOI 10.1002/jlb.66.3.391; WRENSHALL LE, 1995, J IMMUNOL, V154, P871; WRENSHALL LE, 1991, J IMMUNOL, V147, P455; Wrenshall LE, 1999, J IMMUNOL, V163, P3793; Wuillemin WA, 1997, J IMMUNOL, V159, P1953; Yang D, 2000, J IMMUNOL, V165, P2694, DOI 10.4049/jimmunol.165.5.2694; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621	77	87	88	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0849	10.1096/fj.01-0690hyp	http://dx.doi.org/10.1096/fj.01-0690hyp			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039867				2022-12-28	WOS:000176683900011
J	Supp, DM; Wilson-Landy, K; Boyce, ST				Supp, DM; Wilson-Landy, K; Boyce, ST			Human dermal microvascular endothelial cells form vascular analogs in cultured skin substitutes after grafting to athymic mice	FASEB JOURNAL			English	Article						cultured skin substitute; endothelial cell; angiogenesis; tissue engineering	FULL-THICKNESS BURNS; HUMAN BLOOD-VESSEL; IN-VITRO; WOUND CLOSURE; GROWTH-FACTOR; KERATINOCYTES; TISSUE; MICROVESSELS; BIOPOLYMERS; ENGRAFTMENT	Cultured skin substitutes (CSS) consisting of autologous fibroblasts and keratinocytes combined with biopolymers are an adjunctive treatment for large excised burns. CSS containing two cell types are limited by anatomical deficiencies, including lack of a vascular plexus, leading to slower vascularization after grafting than split-thickness autograft. To address this limitation, CSS were prepared containing human keratinocytes, fibroblasts, and dermal microvascular endothelial cells (HDMEC) isolated from a single skin sample. After 16 days in culture, control CSS and CSS containing HDMEC (CSS+EC) were grafted to full-thickness wounds in athymic mice. In CSS+EC in vitro, HDMEC persisted in the dermal substitutes and formed multicellular aggregates. One wk after grafting, HDMEC in CSS+EC organized into multicellular structures, some containing lumens. By 4 wk after grafting, HDMEC were found in linear and circular organizations resembling vascular analogs associated with basement membrane deposition. In some cases, colocalization of HDMEC with mouse perivascular cells was observed. The results demonstrate HDMEC transplantation in a clinically relevant cultured skin model, persistence of HDMEC after grafting, and HDMEC organization into vascular analogs in vitro and in vivo. All cells were derived from the same donor tissue, indicating the feasibility of preparing CSS containing autologous HDMEC for grafting to patients.	Cincinnati Burns Hosp, Shriners Hosp Children, Dept Res, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Boyce, ST (corresponding author), Cincinnati Burns Hosp, Shriners Hosp Children, Dept Res, 3229 Burnet Ave, Cincinnati, OH 45229 USA.	boycest@uc.edu	Supp, Dorothy/ABQ-7999-2022	Supp, Dorothy/0000-0002-2429-6630	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050509] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01GM050509, R01 GM050509, R01 GM050509-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; Boyce S T, 1996, Tissue Eng, V2, P255, DOI 10.1089/ten.1996.2.255; Boyce ST, 1996, J INVEST DERMATOL, V107, P82, DOI 10.1111/1523-1747.ep12298286; Boyce ST, 2002, ANN SURG, V235, P269, DOI 10.1097/00000658-200202000-00016; BOYCE ST, 1993, PLAST RECONSTR SURG, V91, P632, DOI 10.1097/00006534-199304000-00010; BOYCE ST, 1991, SURGERY, V110, P866; BOYCE ST, 1988, J BIOMED MATER RES, V22, P939, DOI 10.1002/jbm.820221008; BOYCE ST, 1995, J INVEST DERMATOL, V104, P345, DOI 10.1111/1523-1747.ep12665374; BOYCE ST, 1995, ANN SURG, V222, P743, DOI 10.1097/00000658-199512000-00008; Boyce ST, 1999, J BURN CARE REHABIL, V20, P453, DOI 10.1097/00004630-199920060-00006; BOYCE ST, 1985, J TISSUE CULTURE MET, V9, P83; Boyce Steven T., 1998, V18, P365; Caruso DM, 1999, BURNS, V25, P771, DOI 10.1016/S0305-4179(99)00083-2; DAVISON PM, 1980, J INVEST DERMATOL, V75, P316, DOI 10.1111/1523-1747.ep12530941; HANSBROUGH JF, 1989, JAMA-J AM MED ASSOC, V262, P2125, DOI 10.1001/jama.262.15.2125; HEWETT PW, 1993, IN VITRO CELL DEV-AN, V29A, P823; Karasek M. A., 1989, J INVEST DERMATOL S, V93, p33S; KUROYANAGI Y, 1993, ANN PLAS SURG, V31, P340, DOI 10.1097/00000637-199310000-00011; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; LHEUREUX N, 1993, J VASC SURG, V17, P499, DOI 10.1016/0741-5214(93)90150-K; Nor JE, 2001, LAB INVEST, V81, P453, DOI 10.1038/labinvest.3780253; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Supp AP, 1999, WOUND REPAIR REGEN, V7, P226, DOI 10.1046/j.1524-475X.1999.00226.x; Supp DM, 2000, J INVEST DERMATOL, V114, P5, DOI 10.1046/j.1523-1747.2000.00824.x; SUPP SM, 2002, J BURN CARE REHABIL, V23, P10; Swope VB, 2001, J INVEST DERMATOL, V116, P650, DOI 10.1046/j.1523-1747.2001.01325.x; Young D. M., 1996, Journal of Burn Care and Rehabilitation, V17, P305, DOI 10.1097/00004630-199607000-00005; Zacchi V, 1998, J BIOMED MATER RES, V40, P187, DOI 10.1002/(SICI)1097-4636(199805)40:2<187::AID-JBM3>3.0.CO;2-H; Zheng L, 2000, J IMMUNOL, V164, P4665, DOI 10.4049/jimmunol.164.9.4665	29	103	107	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0797	10.1096/fj.01-0868com	http://dx.doi.org/10.1096/fj.01-0868com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039861				2022-12-28	WOS:000176683900005
J	Aavik, E; Luoto, NM; Petrov, L; Aavik, S; Patel, YC; Hayry, P				Aavik, E; Luoto, NM; Petrov, L; Aavik, S; Patel, YC; Hayry, P			Elimination of vascular fibrointimal hyperplasia by somatostatin receptor 1.4 selective agonist	FASEB JOURNAL			English	Article						SMS201-995; BIM23014; arterial injury	MUSCLE CELL-MIGRATION; ALLOGRAFT ARTERIOSCLEROSIS; MYOINTIMAL PROLIFERATION; ANGIOPEPTIN TREATMENT; CORONARY ANGIOPLASTY; BALLOON ANGIOPLASTY; ARTERIAL INJURY; CLINICAL EVENTS; RESTENOSIS; INHIBITION	The somatostatin analogs octreotide and lanreotide, selective to receptor subtypes 2 and 5, failed clinical efficacy for the prevention of restenosis after percutaneous transluminal angioplasty. These findings might have been the result of targeting a wrong subset of receptors. In rat arteries, subtypes 1 and 4 are expressed 3-4 times more prominently than 2 and 5, and subtype 1 is the nearly exclusive subtype in atherosclerotic human vessels. Here, we demonstrate that daily s.c. injections (50-500 g/kg/d) of CH275 (DesAA1,2,5(D-W8,IAmp9)Somatostatine-14), selective to subtypes 1 and 4, dose-dependently inhibited intimal hyperplasia 14 days after rat carotid denudation injury (for intimal area P=0.0002 across the dose range). CH275 was more effective than somatostatin-14 (equal affinity to all five subtypes, P=0.03), or octreotide (selective to subtypes 2 and 5, P=0.098). When rats were given the peptides for 14 days with end-point at 28 days, CH275 still significantly inhibited intimal area expansion. Both CH275 and octreotide inhibited the outgrowth of cells from postinjury aortic tissue punch-explants and the distance migrated in vitro, but not cell replication, which indicated that the effects of somatostatin analogs were directed on the migration of intimal cell progenitors rather than on their proliferation.	Univ Helsinki, Transplantat Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Rat Drug Design Program, Biomedicum, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; Juvantia Pharma Ltd, Turku, Finland; McGill Univ, Royal Victoria Hosp, Dept Med, Fraser Labs, Montreal, PQ H3A 1A1, Canada	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; McGill University; Royal Victoria Hospital	Hayry, P (corresponding author), Univ Helsinki, Transplantat Lab, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	pekka.hayry@helsinki.fi						BAUTERS C, 1994, CIRCULATION, V89, P2327, DOI 10.1161/01.CIR.89.5.2327; Bruns C, 2000, EUR J ENDOCRINOL, V143, pS3, DOI 10.1530/eje.0.143S003; Chen LC, 1999, BIOCHEM BIOPH RES CO, V258, P689, DOI 10.1006/bbrc.1999.0699; CLOWES AW, 1983, LAB INVEST, V49, P327; CLOWES AW, 1983, LAB INVEST, V49, P208; Curtis SB, 2000, AM J PHYSIOL-HEART C, V278, pH1815, DOI 10.1152/ajpheart.2000.278.6.H1815; Du Toit D, 2001, ANN MED, V33, P63, DOI 10.3109/07853890109002061; EMANUELSSON H, 1995, CIRCULATION, V91, P1689, DOI 10.1161/01.CIR.91.6.1689; ERIKSEN UH, 1995, AM HEART J, V130, P1, DOI 10.1016/0002-8703(95)90227-9; FOEGH ML, 1994, J VASC SURG, V19, P1084, DOI 10.1016/S0741-5214(94)70221-7; Grimm PC, 2001, NEW ENGL J MED, V345, P93, DOI 10.1056/NEJM200107123450203; GRUNWALD J, 1984, ARTERIOSCLEROSIS, V4, P183, DOI 10.1161/01.ATV.4.3.183; HAYRY P, 1993, FASEB J, V7, P1055, DOI 10.1096/fasebj.7.11.8370476; Hillebrands JL, 2001, J CLIN INVEST, V107, P1411, DOI 10.1172/JCI10233; Hong MK, 1997, CIRCULATION, V95, P449; HOWELL MH, 1993, CLIN SCI, V85, P183, DOI 10.1042/cs0850183; Khare S, 1999, FASEB J, V13, P387, DOI 10.1096/fasebj.13.2.387; Li J, 2001, AM J PATHOL, V158, P1943, DOI 10.1016/S0002-9440(10)64663-9; Liapakis G, 1996, J PHARMACOL EXP THER, V276, P1089; LUNDERGAN C, 1989, ATHEROSCLEROSIS, V80, P49, DOI 10.1016/0021-9150(89)90067-1; LUNDERGAN CF, 1991, J AM COLL CARDIOL, V17, pB132; Makela S, 1999, P NATL ACAD SCI USA, V96, P7077, DOI 10.1073/pnas.96.12.7077; MENNANDER A, 1993, TRANSPLANTATION, V55, P124, DOI 10.1097/00007890-199301000-00023; Myllarniemi LM, 1999, CARDIOVASC PATHOL, V8, P339, DOI 10.1016/S1054-8807(99)00026-5; Myllarniemi M, 1997, FASEB J, V11, P1119, DOI 10.1096/fasebj.11.13.9367346; Ottesen LH, 2001, HEPATOLOGY, V34, P471, DOI 10.1053/jhep.2001.26754; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PATEL YC, 1995, LIFE SCI, V57, P1249, DOI 10.1016/0024-3205(95)02082-T; PLISSONNIER D, 1995, TRANSPLANTATION, V60, P414, DOI 10.1097/00007890-199509000-00003; REISINE T, 1995, ENDOCR REV, V16, P427, DOI 10.1210/er.16.4.427; Rohrer SP, 1998, SCIENCE, V282, P737, DOI 10.1126/science.282.5389.737; SANTOIAN EC, 1993, CIRCULATION, V88, P11, DOI 10.1161/01.CIR.88.1.11; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; TAKAHASHI T, 1995, LIFE SCI, V57, pPL91, DOI 10.1016/0024-3205(95)02013-9; vonEssen R, 1997, CIRCULATION, V96, P1482, DOI 10.1161/01.CIR.96.5.1482; Yumi K, 1997, LAB INVEST, V76, P329; Zhao YJ, 1997, PROSTAG OTH LIPID M, V54, P781, DOI 10.1016/S0090-6980(97)00160-3	37	16	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					724	+		10.1096/fj.01-0272fje	http://dx.doi.org/10.1096/fj.01-0272fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923215				2022-12-28	WOS:000174755900011
J	Chekenya, M; Hjelstuen, M; Enger, PO; Thorsen, F; Jacob, AL; Probst, B; Haraldseth, O; Pilkington, G; Butt, A; Levine, JM; Bjerkvig, R				Chekenya, M; Hjelstuen, M; Enger, PO; Thorsen, F; Jacob, AL; Probst, B; Haraldseth, O; Pilkington, G; Butt, A; Levine, JM; Bjerkvig, R			NG2 proteoglycan promotes angiogenesis-dependent tumor growth in the central nervous system by sequestering angiostatin	FASEB JOURNAL			English	Article						angiogenesis; glioblastoma; pericytes	CHONDROITIN-SULFATE PROTEOGLYCAN; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; PROGENITOR CELLS; MELANOMA-CELLS; EXPRESSION; PERICYTES; BINDING; PERMEABILITY; INHIBITION	During embryogenesis, the NG2 proteoglycan is expressed on immature capillary vessels, but as the vessels mature they lose this expression. NG2 is up-regulated in high-grade gliomas, but it is not clear to what extent it contributes to malignant progression. Using a combination of high spatial and temporal resolution functional magnetic resonance imaging and histopathological analyses, we show here that overexpression of NG2 increases tumor initiation and growth rates, neovascularization, and cellular proliferation, which predisposes to a poorer survival outcome. By confocal microscopy and cDNA gene array expression profiles, we also show that NG2 tumors express lower levels of hypoxia inducible factor-1alpha, vascular endothelial growth factor, and endogenous angiostatin in vivo compared with wild-type tumors. Moreover, we demonstrate that NG2-positive cells bind, internalize, and coimmunoprecipitate with angiostatin. These results indicate a unique role for NG2 in regulating the transition from small, poorly vascularized tumors to large, highly vascular gliomas in situ by sequestering angiostatin.	Univ Bergen, Dept Anat & Cell Biol, N-5009 Bergen, Norway; SINTEF, Unimed MR Ctr, N-7465 Trondheim, Norway; Norwegian Univ Sci & Technol, Dept Anesthesia & Med Imaging, N-7034 Trondheim, Norway; Kings Coll London, Inst Psychiat, Dept Neuropathol, London SE5 8AF, England; Kings Coll London, Guys Kings & St Thomas Sch Biomed Sci, Ctr Neurosci, London SE1 1UL, England; SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA	University of Bergen; SINTEF; Norwegian University of Science & Technology (NTNU); University of London; King's College London; University of London; King's College London; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bjerkvig, R (corresponding author), Univ Bergen, Dept Anat & Cell Biol, Arstadveien 19, N-5009 Bergen, Norway.	Rolf.Bjerkvig@pki.uib.no		Butt, Arthur/0000-0001-7579-0746; Chekenya, PhD, Dr Philos, Dr. Martha/0000-0001-7241-3451; Thorsen, Frits/0000-0002-7762-3703				Behm FG, 1996, BLOOD, V87, P1134, DOI 10.1182/blood.V87.3.1134.bloodjournal8731134; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; BIGNER DD, 1995, J NEURO-ONCOL, V24, P109, DOI 10.1007/BF01052668; BUMOL TF, 1983, P NATL ACAD SCI-BIOL, V80, P529, DOI 10.1073/pnas.80.2.529; Burg MA, 1997, EXP CELL RES, V235, P254, DOI 10.1006/excr.1997.3674; Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO;2-0; Burg MA, 1999, CANCER RES, V59, P2869; D'Amore P A, 1992, Semin Cancer Biol, V3, P49; Fang XX, 1999, MOL BIOL CELL, V10, P3373, DOI 10.1091/mbc.10.10.3373; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gillies RJ, 2000, NEOPLASIA, V2, P139, DOI 10.1038/sj.neo.7900076; Goretzki L, 1999, J BIOL CHEM, V274, P16831, DOI 10.1074/jbc.274.24.16831; Goretzki L, 2000, J BIOL CHEM, V275, P28625, DOI 10.1074/jbc.M002290200; GRAKO KA, 1995, EXP CELL RES, V221, P231, DOI 10.1006/excr.1995.1371; HARPER JR, 1983, J NATL CANCER I, V71, P259; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Horner PJ, 2000, J NEUROSCI, V20, P2218; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Mahesparan R, 1999, ACTA NEUROPATHOL, V97, P231, DOI 10.1007/s004010050979; MANTEL N, 1959, J NATL CANCER I, V22, P719; NISHIYAMA A, 1993, MOL BIOL CELL, V4, P1097, DOI 10.1091/mbc.4.11.1097; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; Noble M, 2001, CONT NEUROS, P123; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; Ozerdem U, 2002, MICROVASC RES, V63, P129, DOI 10.1006/mvre.2001.2376; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Pouly S, 2001, ACTA NEUROPATHOL, V102, P313; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; REAL FX, 1985, CANCER RES, V45, P4401; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SCHLINGEMANN RO, 1990, AM J PATHOL, V136, P1393; SCHLINGEMANN RO, 1991, AM J PATHOL, V138, P1335; SCHRAPPE M, 1991, CANCER RES, V51, P4986; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; Shoshan Y, 1999, P NATL ACAD SCI USA, V96, P10361, DOI 10.1073/pnas.96.18.10361; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; SU MY, 1994, MAGN RESON MED, V32, P714, DOI 10.1002/mrm.1910320606; TOFTS PS, 1991, MAGNET RESON MED, V17, P357, DOI 10.1002/mrm.1910170208; YUHAS JM, 1977, CANCER RES, V37, P3639	45	77	81	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					586	+		10.1096/fj.01-0632fje	http://dx.doi.org/10.1096/fj.01-0632fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919162				2022-12-28	WOS:000174203700015
J	Prest, SJ; May, FEB; Westley, BR				Prest, SJ; May, FEB; Westley, BR			The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells	FASEB JOURNAL			English	Article						pS2; estrogen; metastasis; trefoil peptide; migration	INTESTINAL TREFOIL FACTOR; INDUCED PS2 PROTEIN; NORMAL STOMACH; MESSENGER-RNA; TAMOXIFEN; DOMAIN; EXPRESSION; PNR-2/PS2; PEPTIDE; RECEPTOR	The human trefoil protein TFF1 is a small cysteine-rich secreted protein that is frequently expressed in breast tumors under the control of estrogen. The function of TFF1 in breast cancer is unknown. To test the hypothesis that it promotes tumor dissemination, we produced recombinant TFF1 and assessed its ability to stimulate the movement of breast cancer cells by using in vitro wounding and migration assays. Recombinant TFF1 stimulated migration at concentrations of TFF1 found in culture medium. Migration of MCF-7 breast cancer cells, which secrete TFF1, was stimulated by lower concentrations of TFF1 than MDA MB231 cells that do not produce TFF1. Dimeric TFF1, linked by a disulfide bond, and monomeric TFF1 are produced by estrogen-responsive breast cancer cell lines. Recombinant TFF1 dimer was eightfold more potent than TFF1 monomer, implying that the interaction of TFF1 with its receptor is facilitated by dimerization. The majority of TFF1-stimulated migration resulted from chemotaxis, but dimeric TFF1 stimulated some chemokinesis. These results show that estrogens can stimulate the motility of breast cancer cells via the induction of TFF1 and suggest that one reason for the efficacy of hormonal therapies is their ability to reduce expression of TFF1 and, hence, the migration of breast tumor cells.	Univ Newcastle Upon Tyne, Royal Victoria Infirm, Sch Clin & Lab Sci, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK	Westley, BR (corresponding author), Univ Newcastle Upon Tyne, Royal Victoria Infirm, Sch Clin & Lab Sci, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	B.R.Westley@ncl.ac.uk			Breast Cancer Now [1999:88] Funding Source: Medline	Breast Cancer Now		BAKER ME, 1988, BIOCHEM J, V253, P307, DOI 10.1042/bj2530307; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; CARR M, 1995, BRIT J CANCER, V72, P1427, DOI 10.1038/bjc.1995.525; Chadwick MP, 1997, BIOCHEM J, V327, P117, DOI 10.1042/bj3270117; CHADWICK MP, 1995, BIOCHEM J, V308, P1001, DOI 10.1042/bj3081001; Crosier M, 2001, AM J PATHOL, V159, P215, DOI 10.1016/S0002-9440(10)61687-2; FOEKENS JA, 1994, BRIT J CANCER, V70, P1217, DOI 10.1038/bjc.1994.476; HARRIS M, 1984, BRIT J CANCER, V50, P23, DOI 10.1038/bjc.1984.135; HAUSER F, 1993, P NATL ACAD SCI USA, V90, P6961, DOI 10.1073/pnas.90.15.6961; HENRY JA, 1991, BRIT J CANCER, V63, P615, DOI 10.1038/bjc.1991.141; HENRY JA, 1991, BRIT J CANCER, V64, P677, DOI 10.1038/bjc.1991.380; HENRY JA, 1989, BRIT J CANCER, V61, P32; JOHNSON ME, 1989, CLIN SUPERV, V7, P59; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Marchbank T, 1998, J PATHOL, V185, P153; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MAY FEB, 1988, J BIOL CHEM, V263, P12901; May FEB, 1997, J PATHOL, V183, P4; MAY FEB, 1986, CANCER RES, V46, P6034; MAY FEB, 1987, J BIOL CHEM, V262, P15894; McClelland RA, 1996, BREAST CANCER RES TR, V41, P31, DOI 10.1007/BF01807034; Newton JL, 2000, GUT, V46, P312, DOI 10.1136/gut.46.3.312; NUNEZ AM, 1987, ENDOCRINOLOGY, V121, P1759, DOI 10.1210/endo-121-5-1759; PIGGOTT NH, 1991, J PATHOL, V163, P95, DOI 10.1002/path.1711630204; POLSHAKOV VI, 1995, EUR J BIOCHEM, V233, P847, DOI 10.1111/j.1432-1033.1995.847_3.x; Polshakov VI, 1997, J MOL BIOL, V267, P418, DOI 10.1006/jmbi.1997.0896; POULSOM R, 1993, AM J PHYSIOL, V265, P205; PRUDHOMME JF, 1995, DNA CELL BIOL, V4, P11; Ribieras S, 1998, BBA-REV CANCER, V1378, pF61, DOI 10.1016/S0304-419X(98)00016-X; RIO MC, 1987, P NATL ACAD SCI USA, V84, P9243, DOI 10.1073/pnas.84.24.9243; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; RIO MC, 1988, CR ACAD SCI III-VIE, V307, P825; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHWARTZ LH, 1991, CANCER RES, V51, P624; Soubeyran I, 1996, BRIT J CANCER, V74, P1120, DOI 10.1038/bjc.1996.500; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; WESTLEY B, 1978, CELL, V15, P367, DOI 10.1016/0092-8674(78)90005-3; WESTLEY B, 1984, J BIOL CHEM, V259, P30; Wiede A, 1999, AM J RESP CRIT CARE, V159, P1330, DOI 10.1164/ajrccm.159.4.9804149; Williams MA, 2001, FEBS LETT, V493, P70, DOI 10.1016/S0014-5793(01)02276-1; WILSON YG, 1994, BRIT J SURG, V81, P1155, DOI 10.1002/bjs.1800810824; WISEMAN LR, 1989, J STEROID BIOCHEM, V33, P1, DOI 10.1016/0022-4731(89)90349-X	45	147	149	2	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					592	+		10.1096/fj.01-0498fje	http://dx.doi.org/10.1096/fj.01-0498fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919164				2022-12-28	WOS:000174203700013
J	De Vrij, FMS; Sluijs, JA; Gregori, L; Fischer, DF; Hermens, WTJMC; Goldgaber, D; Verhaagen, J; Van Leeuwen, FW; Hol, EM				De Vrij, FMS; Sluijs, JA; Gregori, L; Fischer, DF; Hermens, WTJMC; Goldgaber, D; Verhaagen, J; Van Leeuwen, FW; Hol, EM			Mutant ubiquitin expressed in Alzheimer's disease causes neuronal death	FASEB JOURNAL			English	Article						AD; molecular misreading; neurodegeneration; proteasomal degradation	POLYUBIQUITIN CHAINS; PROTEIN-DEGRADATION; CELL LINE; IN-VITRO; PROTEASOME; APOPTOSIS; SIGNAL; SYSTEM	Ubiquitin-B+1 (UBB+1) is a mutant ubiquitin that accumulates in the neurones of patients with Alzheimer's disease (AD). Here we report on the biochemical and functional differences between ubiquitin and UBB+1 and the effect of the mutant protein on neuronal cells. UBB+1 lacks the capacity to ubiquitinate, and although it is ubiquitinated itself, UBB+1 is not degraded by the ubiquitin-proteasomal system and is quite stable in neuronal cells. Overexpression of UBB+1 in neuroblastoma cells significantly induces nuclear fragmentation and cell death. Our results demonstrate that accumulation of UBB+1 in neurones is detrimental and may contribute to neuronal dysfunction in AD patients.	Netherlands Inst Brain Res, Grad Sch Neurosci Amsterdam, Res Grp Mol Misreading, NL-1105 AZ Amsterdam, Netherlands; Vet Affairs Res Serv, Mol Neurovirol Unit, Baltimore, MD USA; SUNY Stony Brook, Sch Med, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hol, EM (corresponding author), Netherlands Inst Brain Res, Grad Sch Neurosci Amsterdam, Res Grp Mol Misreading, Meibergdreef 33, NL-1105 AZ Amsterdam, Netherlands.	e.hol@nih.knaw.nl	Verhaagen, Joost/G-4773-2012; Hol, Elly M/F-1891-2013; Hol, Elly/J-2025-2019; de Vrij, Femke M.S./O-9706-2019	Hol, Elly M/0000-0001-5604-2603; Hol, Elly/0000-0001-5604-2603; de Vrij, Femke M.S./0000-0003-0825-3806; Fischer, David/0000-0002-6690-0197				Amerik AY, 1997, EMBO J, V16, P4826; Anderson AJ, 2000, NEUROBIOL AGING, V21, P511, DOI 10.1016/S0197-4580(00)00126-3; BAMEZAI S, 1991, ARCH BIOCHEM BIOPHYS, V289, P343, DOI 10.1016/0003-9861(91)90421-E; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; Cummings JL, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.1_Suppl_1.S2; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; GREGORI L, 1995, J BIOL CHEM, V270, P19702, DOI 10.1074/jbc.270.34.19702; Hermens WTJMC, 1997, J NEUROSCI METH, V71, P85, DOI 10.1016/S0165-0270(96)00129-X; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Lenk U, 2000, J BIOL CHEM, V275, P39403, DOI 10.1074/jbc.M006949200; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Pasquini LA, 2000, J NEUROSCI RES, V59, P601, DOI 10.1002/(SICI)1097-4547(20000301)59:5<601::AID-JNR3>3.0.CO;2-1; PICKART CM, 1998, UBIQUITIN BIOL CELL, P40; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Rohn TT, 2001, AM J PATHOL, V158, P189, DOI 10.1016/S0002-9440(10)63957-0; Salon ML, 2000, J NEUROSCI RES, V62, P302, DOI 10.1002/1097-4547(20001015)62:2<302::AID-JNR15>3.0.CO;2-L; SLACK R, 1992, EXP CELL RES, V202, P17, DOI 10.1016/0014-4827(92)90399-S; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; van Leeuwen FW, 2000, NEUROBIOL AGING, V21, P879, DOI 10.1016/S0197-4580(00)00151-2; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; van Leeuwen FW, 1998, TRENDS NEUROSCI, V21, P331, DOI 10.1016/S0166-2236(98)01280-6; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032	30	118	119	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2680	2688		10.1096/fj.01-0438com	http://dx.doi.org/10.1096/fj.01-0438com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726544				2022-12-28	WOS:000172964800038
J	L'hote, CGML; Thomas, PH; Ganesan, TS				L'hote, CGML; Thomas, PH; Ganesan, TS			Functional analysis of discoidin domain receptor 1: effect of adhesion on DDR1 phosphorylation	FASEB JOURNAL			English	Article						fibronectin; pervanadate; collagen; nerve growth factor	TYROSINE KINASE; SIGNAL-TRANSDUCTION; CELL-MIGRATION; FACTOR-VIII; PROTEIN; ACTIVATION; EXPRESSION; DIFFERENTIATION; DICTYOSTELIUM; INHIBITION	Discoidin domain receptor 1 (DDR1), a receptor tyrosine kinase (RTK), has been shown to be activated mainly by soluble fibrillar collagen. Unusually, the kinetics of phosphorylation of the receptor is slow, with maximal phosphorylation observed after 90 min. To understand the reasons for slow phosphorylation of the receptor, we examined several cell lines under different conditions. We confirm that endogenous DDR1 is phosphorylated slowly by collagen in adherent T47D and HCT116 cells. In detached and resuspended cells, collagen induced rapid phosphorylation of DDR1. This was further confirmed with a semiadherent cell line (COLO201) and one that grows as a suspension (K562), both of which express endogenous DDR1. Replating K562 on fibronectin to mimic adherent conditions altered the kinetics of phosphorylation from rapid to slow, similar to those of adherent cells. The slow kinetics of phosphorylation in the adherent state was probably not due to cell-cell contacts because EDTA had no major effect. However, pervanadate in the absence of collagen was able to induce strong DDR1 phosphorylation, indicating that a phosphatase may inhibit or delay the phosphorylation of DDR1. Further, downstream signals after phosphorylation of DDR1 by collagen were not transmitted through the classical mitogen-activated protein kinase pathway. In addition, a chimeric TrkA-DDR1 receptor failed to become phosphorylated on stimulation with nerve growth factor (NGF), although it dimerized normally. This is the first RTK whose kinetics of phosphorylation is dependent on cellular context. The interaction of the cells with the matrix, rather than cell-cell contact, is probably responsible for the inhibition of phosphorylation.	John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Mol Oncol Labs, Oxford OX3 9DS, England	University of Oxford	Ganesan, TS (corresponding author), John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Mol Oncol Labs, Oxford OX3 9DS, England.	ganesan@icrf.icnet.uk	GANESAN, Trivadi Sundaram/AAU-1499-2020	GANESAN, Trivadi Sundaram/0000-0002-4671-8099				ALEXANDER S, 1992, DIFFERENTIATION, V51, P149, DOI 10.1111/j.1432-0436.1992.tb00691.x; ALVES F, 1995, ONCOGENE, V10, P609; Alves F, 2001, FASEB J, V15, P1321, DOI 10.1096/fj.00-0626fje; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BARKER KT, 1995, ONCOGENE, V10, P569; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; Bhatt RS, 2000, GENE DEV, V14, P2216, DOI 10.1101/gad.821600; BURGER SR, 1992, EXP CELL RES, V202, P28, DOI 10.1016/0014-4827(92)90400-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chiang TM, 1999, HISTOL HISTOPATHOL, V14, P579, DOI 10.14670/HH-14.579; den Dunnen JT, 1998, HUM MOL GENET, V7, P1185; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; Edwards GM, 1998, J BIOL CHEM, V273, P9495, DOI 10.1074/jbc.273.16.9495; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Foehr ED, 2000, FASEB J, V14, P973, DOI 10.1096/fasebj.14.7.973; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; JARVINEN M, 1993, CELL BIOL INT, V17, P399, DOI 10.1006/cbir.1993.1078; Jin MH, 2000, MOL CELL BIOL, V20, P2098, DOI 10.1128/MCB.20.6.2098-2107.2000; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; Kandikonda S, 1996, CELL ADHES COMMUN, V4, P13, DOI 10.3109/15419069609010760; Katso RM, 1999, MOL CELL BIOL, V19, P6427; KINASHI T, 1995, BLOOD, V86, P2086, DOI 10.1182/blood.V86.6.2086.bloodjournal8662086; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Knutson JR, 1996, MOL BIOL CELL, V7, P383, DOI 10.1091/mbc.7.3.383; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; MEYER RA, 1992, J CELL BIOL, V119, P179, DOI 10.1083/jcb.119.1.179; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nakagawa K, 1998, DIFFERENTIATION, V62, P249, DOI 10.1046/j.1432-0436.1998.6250249.x; PARTANEN J, 1993, PHILOS T R SOC B, V340, P297, DOI 10.1098/rstb.1993.0071; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Playford MP, 1996, GENOME RES, V6, P620, DOI 10.1101/gr.6.7.620; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; ROSEN SD, 1973, P NATL ACAD SCI USA, V70, P2554, DOI 10.1073/pnas.70.9.2554; Rusciano D, 1996, J BIOL CHEM, V271, P20763, DOI 10.1074/jbc.271.34.20763; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; SEMPLE TU, 1978, CANCER RES, V38, P1345; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; Sudhalter J, 1996, GLIA, V17, P28, DOI 10.1002/(SICI)1098-1136(199605)17:1<28::AID-GLIA3>3.0.CO;2-3; UDAGAWA T, 1995, CLIN EXP METASTAS, V13, P427, DOI 10.1007/BF00118182; Vinos J, 2000, ONCOGENE, V19, P3560, DOI 10.1038/sj.onc.1203702; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	56	45	47	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					234	+		10.1096/fj.01-0414fje	http://dx.doi.org/10.1096/fj.01-0414fje			31	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11772944				2022-12-28	WOS:000172964800012
J	Bifulco, M; Laezza, C; Portella, G; Vitale, M; Orlando, P; De Petrocellis, L; Di Marzo, V				Bifulco, M; Laezza, C; Portella, G; Vitale, M; Orlando, P; De Petrocellis, L; Di Marzo, V			Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth	FASEB JOURNAL			English	Article						anandamide; CB1 receptor; K-ras oncogene; thyroid cell; cancer	HUMAN BREAST-CANCER; THYROID EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; ENDOCANNABINOIDS; ANANDAMIDE; CB1; TRANSFORMATION; PROLIFERATION; INVOLVEMENT; INHIBITION	We investigated the effect of 2-methyl-arachidonyl-2'-fluoro-ethylamide (Met-F-AEA), a stable analog of the endocannabinoid anandamide, on a rat thyroid epithelial cell line (FRTL-5) transformed by the K-ras oncogene, and on epithelial tumors derived from these cells. Met-F-AEA effect in vivo was evaluated in a nude mouse xenograft model, where K-ras-transformed (KiMol) cells were implanted subcutaneously. Met-F-AEA (0.5 mg/kg/dose) induced a drastic reduction in tumor volume. This effect was inhibited by the CB1 receptor antagonist SR141716A (0.7 mg/kg/dose) and was accompanied by a strong reduction of K-ras activity. Accordingly, KiMol cells and tumors express CB1 receptors. Met-F-AEA inhibited (IC50 similar to5 muM) the proliferation in vitro and the transition to the S phase of KiMol cells and it reduced K-ras activity; these effects were antagonized by SR141716A. Met-F-AEA cytostatic action was significantly smaller in nontransformed FRTL-5 cells than in KiMol cells. Met-F-AEA treatment exerted opposite effects on the expression of CB1 receptors in KiMol and FRTL-5 cells, with a strong up-regulation in the former case and a suppression in nontransformed cells. The data suggest that: 1) Met-F-AEA inhibits ras oncogene-dependent tumor growth in vivo through CB1 cannabinoid receptors; and 2) responsiveness of FRTL-5 cells to endocannabinoids depends on whether or not they are transformed by K-ras.	CNR, Ctr Endocrinol & Oncol Sperimentale, Endocannabinoid Res Grp, I-80078 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, I-80078 Naples, Italy; Univ Catanzaro, Dipartimento Med Sperimentale & Clin G Salvatore, I-80078 Naples, Italy; CNR, Ist Biochim Prot & Enzimol, I-80078 Naples, Italy; CNR, Ist Cibernet, I-80078 Naples, Italy; CNR, Ist Chim Biomol, I-80078 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR)	Bifulco, M (corresponding author), CNR, Ctr Endocrinol & Oncol Sperimentale, Endocannabinoid Res Grp, Via Campi Flegrei 34,Comprensorio Olivetti,Fabbr, I-80078 Naples, Italy.	maubiful@unina.it; vdimarzo@icmib.na.cnr.it	Di Marzo, Vincenzo/AAD-7742-2019; laez, chi/AAW-4437-2020; Portella, Giuseppe/AFU-6826-2022	Di Marzo, Vincenzo/0000-0002-1490-3070; PORTELLA, Giuseppe/0000-0001-8276-9769; Bifulco, Maurizio/0000-0002-1771-4531				Aceto MD, 1998, J PHARMACOL EXP THER, V287, P598; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIFULCO M, 1993, J CELL PHYSIOL, V155, P340, DOI 10.1002/jcp.1041550215; Bisogno T, 1998, EUR J BIOCHEM, V254, P634, DOI 10.1046/j.1432-1327.1998.2540634.x; BOS JL, 1989, CANCER RES, V49, P4682; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; Derkinderen P, 2001, J NEUROCHEM, V77, P957, DOI 10.1046/j.1471-4159.2001.00333.x; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Di Marzo V, 1998, BBA-LIPID LIPID MET, V1392, P153, DOI 10.1016/S0005-2760(98)00042-3; FOULDS L, 1969, NEOPLASTIC DEV, V1; FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519; FUSCO A, 1982, CANCER RES, V42, P618; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Guzman M, 2001, TRENDS PHARMACOL SCI, V22, P19, DOI 10.1016/S0165-6147(00)01586-8; Guzman M, 2001, J MOL MED-JMM, V78, P613, DOI 10.1007/s001090000177; Kobayashi Y, 2001, J BIOCHEM-TOKYO, V129, P665, DOI 10.1093/oxfordjournals.jbchem.a002904; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; Laezza C, 1998, P NATL ACAD SCI USA, V95, P13646, DOI 10.1073/pnas.95.23.13646; Martin BR, 1999, LIFE SCI, V65, P573, DOI 10.1016/S0024-3205(99)00281-7; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; Melck D, 2000, ENDOCRINOLOGY, V141, P118, DOI 10.1210/en.141.1.118; Melck D, 1999, FEBS LETT, V463, P235, DOI 10.1016/S0014-5793(99)01639-7; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814; Sanchez C, 2001, CANCER RES, V61, P5784; Sanchez C, 1998, FEBS LETT, V436, P6, DOI 10.1016/S0014-5793(98)01085-0; SCHWAB G, 1994, P NATL ACAD SCI USA, V91, P10460, DOI 10.1073/pnas.91.22.10460; SUAREZ HG, 1988, ONCOGENE, V2, P403	31	114	119	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2745	+		10.1096/fj.01-0320fje	http://dx.doi.org/10.1096/fj.01-0320fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11687506				2022-12-28	WOS:000171920400006
J	Massiera, F; Bloch-Faure, M; Ceiler, D; Murakami, K; Fukamizu, A; Gasc, JM; Quignard-Boulange, A; Negrel, R; Ailhaud, G; Seydoux, J; Meneton, P; Teboul, M				Massiera, F; Bloch-Faure, M; Ceiler, D; Murakami, K; Fukamizu, A; Gasc, JM; Quignard-Boulange, A; Negrel, R; Ailhaud, G; Seydoux, J; Meneton, P; Teboul, M			Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation	FASEB JOURNAL			English	Article						adipose tissue development; transgenic mice; renin	GENE-EXPRESSION; RENIN-ACTIVITY; HYPERTENSION; SECRETION; SUBSTRATE; OBESITY; PLASMA; SYSTEM; NUMBER; WHITE	White adipose tissue and liver are important angiotensinogen (AGT) production sites. Until now, plasma AGT was considered to be a reflection of hepatic production. Because plasma AGT concentration has been reported to correlate with blood pressure, and to be associated with body mass index, we investigated whether adipose AGT is released locally and into the blood stream. For this purpose, we have generated transgenic mice either in which adipose AGT is overexpressed or in which AGT expression is restricted to adipose tissue. This was achieved by the use of the aP2 adipocyte-specific promoter driving the expression of rat agt cDNA in both wild-type and hypotensive AGT-deficient mice. Our results show that in both genotypes, targeted expression of AGT in adipose tissue increases fat mass. Mice whose AGT expression is restricted to adipose tissue have AGT circulating in the blood stream, are normotensive, and exhibit restored renal function compared with AGT-deficient mice. Moreover, mice that overexpress adipose AGT have increased levels of circulating AGT, compared with wild-type mice, and are hypertensive. These animal models demonstrate that AGT produced by adipose tissue plays a role in both local adipose tissue development and in the endocrine system, which supports a role of adipose AGT in hypertensive obese patients.	Fac Sci, Inst Signaling Dev & Canc, CNRS, UMR 6543, F-06108 Nice 2, France; INSERM, U367, Paris, France; Univ Tsukuba, Tsukuba, Ibaraki 305, Japan; Coll France, INSERM, U36, Paris, France; INSERM, U465, Paris, France; Fac Med, Dept Physiol, Geneva, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Tsukuba; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Geneva	Teboul, M (corresponding author), Fac Sci, Inst Signaling Dev & Canc, CNRS, UMR 6543, Parc Valrose, F-06108 Nice 2, France.	teboulm@unice.fr	Meneton, Pierre/T-1216-2019; fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020; Teboul, Michele/0000-0002-3418-4384; Ailhaud, Gerard/0000-0003-0596-2906				Aubert J, 1997, BIOCHEM J, V328, P701, DOI 10.1042/bj3280701; Aubert J, 1998, BIOCHEM BIOPH RES CO, V250, P77, DOI 10.1006/bbrc.1998.9185; BAZIN R, 2000, ASSAYS LIPOGENIC ENZ; BLOEM LJ, 1995, J CLIN INVEST, V95, P948, DOI 10.1172/JCI117803; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; Caulfield M, 1996, HYPERTENSION, V28, P1123, DOI 10.1161/01.HYP.28.6.1123; CRANDALL DL, 1994, J LIPID RES, V35, P1378; Engeli S, 1999, J HYPERTENS, V17, P555, DOI 10.1097/00004872-199917040-00014; Forrester T, 1996, J HYPERTENS, V14, P315, DOI 10.1097/00004872-199603000-00007; GIRARDIER L, 1995, J PHYSIOL-LONDON, V488, P779, DOI 10.1113/jphysiol.1995.sp021009; HEGELE RA, 1995, CIRCULATION, V92, P1089, DOI 10.1161/01.CIR.92.5.1089; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; Jones BH, 1997, ENDOCRINOLOGY, V138, P1512, DOI 10.1210/en.138.4.1512; KANNEL WB, 1967, ANN INTERN MED, V67, P48, DOI 10.7326/0003-4819-67-1-48; Karlsson C, 1998, J CLIN ENDOCR METAB, V83, P3925, DOI 10.1210/jc.83.11.3925; Kihara M, 1998, KIDNEY INT, V53, P548, DOI 10.1046/j.1523-1755.1998.00801.x; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; Kim HS, 1999, J BIOL CHEM, V274, P14210, DOI 10.1074/jbc.274.20.14210; LAVAU M, 1977, P SOC EXP BIOL MED, V156, P251, DOI 10.3181/00379727-156-39916; Mark AL, 1999, HYPERTENSION, V33, P537, DOI 10.1161/01.HYP.33.1.537; Mazzolai L, 1998, HYPERTENSION, V31, P1324, DOI 10.1161/01.HYP.31.6.1324; MENARD J, 1972, ENDOCRINOLOGY, V90, P422, DOI 10.1210/endo-90-2-422; Mynatt RL, 1997, P NATL ACAD SCI USA, V94, P919, DOI 10.1073/pnas.94.3.919; OLIVER WJ, 1966, P SOC EXP BIOL MED, V122, P923; ROCCHINI AP, 1995, J NUTR, V125, pS1718; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Saint-Marc P, 2001, ENDOCRINOLOGY, V142, P487, DOI 10.1210/en.142.1.487; Schling P, 1999, INT J OBESITY, V23, P336, DOI 10.1038/sj.ijo.0800821; Schorr U, 1998, J HYPERTENS, V16, P1475, DOI 10.1097/00004872-199816100-00011; Shenoy U, 1997, AM J PHYSIOL-CELL PH, V272, pC989, DOI 10.1152/ajpcell.1997.272.3.C989; SIBONY M, 1995, LAB INVEST, V73, P586; Stec DE, 1999, J BIOL CHEM, V274, P21285, DOI 10.1074/jbc.274.30.21285; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; Umemura S, 1997, AM J HYPERTENS, V10, P629, DOI 10.1016/S0895-7061(97)00053-8; van Harmelen V, 2000, OBES RES, V8, P337, DOI 10.1038/oby.2000.40; WALKER WG, 1979, HYPERTENSION, V1, P287, DOI 10.1161/01.HYP.1.3.287	36	380	395	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2727	+		10.1096/fj.01-0457fje	http://dx.doi.org/10.1096/fj.01-0457fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606482				2022-12-28	WOS:000171920400011
J	Tegeder, I; Pfeilschifter, J; Geisslinger, G				Tegeder, I; Pfeilschifter, J; Geisslinger, G			Cyclooxygenase-independent actions of cyclooxygenase inhibitors	FASEB JOURNAL			English	Review						aspirin; NSAIDs; apoptosis; metalloproteinase	NF-KAPPA-B; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLON-CANCER CELLS; ACTIVATED RECEPTOR-GAMMA; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; TUMOR-SUPPRESSOR PROTEIN; ASPIRIN-LIKE DRUGS; PROSTAGLANDIN ENDOPEROXIDE SYNTHASES; VIRUS LATENT MEMBRANE-PROTEIN-1	Several studies have demonstrated unequivocally that certain nonsteroidal anti-inflammatory drugs (NSAIDs) such as sodium salicylate, sulindac, ibuprofen, and flurbiprofen cause anti-inflammatory and antiproliferative effects independent of cyclooxygenase activity and prostaglandin synthesis inhibition. These effects are mediated through inhibition of certain transcription factors such as NF-kappaB and AP-1. The respective NSAIDs might interfere directly with the transcription factors, but their effects are probably mediated predominantly through alterations of the activity of cellular kinases such as IKK beta, Erk, p38 MAPK, or Cdks. These effects apparently are not shared by all NSAIDs, since indomethacin failed to inhibit NF-kappaB and AP-1 activation as well as Erk and Cdk activity. In contrast, indomethacin was able to activate PPAR gamma, which was not affected by sodium salicylate or aspirin. The differences in cyclooxygenase-independent mechanisms may have consequences for the specific use of these drugs in individual patients because additional effects may either enhance the efficacy or reduce the toxicity of the respective compounds.	Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Geisslinger, G (corresponding author), Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	geisslinger@em.uni-frankfurt.de	Tegeder, Irmgard/AAM-2246-2020; Tegeder, Irmgard/AAM-2266-2020	Tegeder, Irmgard/0000-0001-7524-8025; Tegeder, Irmgard/0000-0001-7524-8025				ABRAMSON S, 1985, P NATL ACAD SCI USA, V82, P7227, DOI 10.1073/pnas.82.21.7227; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; Alonso A, 2000, INT IMMUNOL, V12, P547, DOI 10.1093/intimm/12.4.547; Amberger A, 1999, MOL MED, V5, P117, DOI 10.1007/BF03402146; APRIL P, 1990, SEMIN ARTHRITIS RHEU, V19, P20; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bales KR, 1998, MOL BRAIN RES, V57, P63, DOI 10.1016/S0169-328X(98)00066-7; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barnes CJ, 1998, BRIT J CANCER, V77, P573, DOI 10.1038/bjc.1998.93; BAUM J, 1983, AM J MED, V74, P10, DOI 10.1016/0002-9343(83)90523-5; Bayon Y, 1999, BRIT J PHARMACOL, V126, P1359, DOI 10.1038/sj.bjp.0702441; Beard CM, 1998, MAYO CLIN PROC, V73, P951, DOI 10.4065/73.10.951; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; Bitko V, 1997, VIROLOGY, V232, P369, DOI 10.1006/viro.1997.8582; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chen B, 2000, CANCER RES, V60, P3290; Chen LC, 1999, BIOCHEM J, V342, P503, DOI 10.1042/0264-6021:3420503; CHIABRANDO C, 1989, EUR J PHARMACOL, V159, P257, DOI 10.1016/0014-2999(89)90156-8; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Cianferoni A, 2001, BLOOD, V97, P1742, DOI 10.1182/blood.V97.6.1742; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; Clay CE, 1999, CARCINOGENESIS, V20, P1905, DOI 10.1093/carcin/20.10.1905; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; Coccia EM, 1999, INT IMMUNOL, V11, P1075, DOI 10.1093/intimm/11.7.1075; Cronstein BN, 1999, P NATL ACAD SCI USA, V96, P6377, DOI 10.1073/pnas.96.11.6377; de Miguel LS, 1999, EUR J CLIN INVEST, V29, P93, DOI 10.1046/j.1365-2362.1999.00425.x; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; DENNING DW, 1983, LANCET, V2, P621; Diener HC, 1999, BIOMED PHARMACOTHER, V53, P309, DOI 10.1016/S0753-3322(00)88501-7; Djordjevic B, 1998, ACTA ONCOL, V37, P735, DOI 10.1080/028418698430124; Dong ZG, 1997, J BIOL CHEM, V272, P9962; DuBois RN, 1996, GASTROENTEROL CLIN N, V25, P773, DOI 10.1016/S0889-8553(05)70274-0; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; FIRESTEIN GS, 1991, ARTHRITIS RHEUM, V34, P1094, DOI 10.1002/art.1780340905; Flynn BL, 1999, ANN PHARMACOTHER, V33, P840, DOI 10.1345/aph.17093; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; Fujihara SM, 1999, EMBO J, V18, P411, DOI 10.1093/emboj/18.2.411; GAUTAM SC, 1995, BLOOD, V86, P2541; Geisslinger G, 2000, J NEUROCHEM, V74, P2094, DOI 10.1046/j.1471-4159.2000.0742094.x; GEISSLINGER G, 1994, LIFE SCI, V54, pPL173, DOI 10.1016/0024-3205(94)00555-9; Giardina C, 1999, BBA-MOL CELL RES, V1448, P425, DOI 10.1016/S0167-4889(98)00156-6; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; GIMBLE JM, 1992, J CELL BIOCHEM, V50, P73, DOI 10.1002/jcb.240500112; Giuliano F, 1999, BRIT J PHARMACOL, V126, P1824, DOI 10.1038/sj.bjp.0702518; Goldberg Y, 1996, ONCOGENE, V12, P893; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Han SY, 2000, BIOL PHARM BULL, V23, P420; Han ZN, 1998, AUTOIMMUNITY, V28, P197, DOI 10.3109/08916939808995367; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Heneka MT, 1999, J NEUROIMMUNOL, V100, P156, DOI 10.1016/S0165-5728(99)00192-7; Housby JN, 1999, CYTOKINE, V11, P347, DOI 10.1006/cyto.1998.0437; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Hsu SC, 1999, EUR J IMMUNOL, V29, P2948, DOI 10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jacoby RF, 2000, CANCER RES, V60, P5040; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jones MK, 1999, NAT MED, V5, P1418; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; JURIVICH DA, 1995, J BIOL CHEM, V270, P24489, DOI 10.1074/jbc.270.41.24489; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; Kang HJ, 2000, BIOL PHARM BULL, V23, P815; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kawai S, 1998, EUR J PHARMACOL, V347, P87, DOI 10.1016/S0014-2999(98)00078-8; Keelan JA, 1999, BIOCHEM BIOPH RES CO, V262, P579, DOI 10.1006/bbrc.1999.1257; KEYSZER GM, 1995, ARTHRITIS RHEUM-US, V38, P976, DOI 10.1002/art.1780380714; Kishimoto Y, 2000, GUT, V47, P812, DOI 10.1136/gut.47.6.812; Klampfer L, 1999, BLOOD, V93, P2386, DOI 10.1182/blood.V93.7.2386.407k15_2386_2394; Kleinert H, 1996, MOL PHARMACOL, V49, P15; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KNIGHT DM, 1987, MOL ENDOCRINOL, V1, P36, DOI 10.1210/mend-1-1-36; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kuang AA, 1999, EUR J IMMUNOL, V29, P3722, DOI 10.1002/(SICI)1521-4141(199911)29:11<3722::AID-IMMU3722>3.0.CO;2-N; Kubota T, 1998, CANCER RES, V58, P3344; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Law BK, 2000, J BIOL CHEM, V275, P38261, DOI 10.1074/jbc.M005545200; Lawton LN, 1997, GENE, V203, P17, DOI 10.1016/S0378-1119(97)00485-X; Lee RT, 2001, CIRC RES, V88, P262, DOI 10.1161/01.RES.88.3.262; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemay S, 1999, CLIN DIAGN LAB IMMUN, V6, P567, DOI 10.1128/CDLI.6.4.567-572.1999; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; LEWIS RA, 1982, J IMMUNOL, V129, P1627; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Liu XH, 1998, CANCER RES, V58, P4245; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Ljungdahl S, 1997, ANTI-CANCER DRUG, V8, P62, DOI 10.1097/00001813-199701000-00008; Mahmoud NN, 1998, SURGERY, V124, P225, DOI 10.1016/S0039-6060(98)70124-2; Marra DE, 2000, CIRCULATION, V102, P2124, DOI 10.1161/01.CIR.102.17.2124; Masferrer JL, 2000, CANCER RES, V60, P1306; Matasic R, 2000, IMMUNOLOGY, V101, P53, DOI 10.1046/j.1365-2567.2000.00065.x; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McCracken JD, 1996, J CLIN PHARMACOL, V36, P540, DOI 10.1002/j.1552-4604.1996.tb05043.x; McDade TP, 1999, J SURG RES, V83, P56, DOI 10.1006/jsre.1998.5560; McKenzie ANJ, 2000, PHARMACOL THERAPEUT, V88, P143, DOI 10.1016/S0163-7258(00)00088-7; Mehta JL, 1998, CLIN CARDIOL, V21, P879, DOI 10.1002/clc.4960211204; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Mukamal KJ, 1999, AM HEART J, V137, P1120, DOI 10.1016/S0002-8703(99)70372-8; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Murono S, 2000, CANCER RES, V60, P2555; NADLER SG, 1995, THER DRUG MONIT, V17, P700, DOI 10.1097/00007691-199512000-00026; NADLER SG, 1992, SCIENCE, V258, P484, DOI 10.1126/science.1411548; Neupert W, 1997, BRIT J PHARMACOL, V122, P487, DOI 10.1038/sj.bjp.0701415; NEVINS JR, 1992, SCIENCE, V258, P424; Niederberger E, 2001, FASEB J, V15, P1622, DOI 10.1096/fj.00-0716fje; OETH P, 1995, BLOOD, V86, P4144, DOI 10.1182/blood.V86.11.4144.bloodjournal86114144; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Paillard F, 1999, HUM GENE THER, V10, P1, DOI 10.1089/10430349950019138; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Pasinetti GM, 1998, J NEUROSCI RES, V54, P1; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; Perugini RA, 2000, J GASTROINTEST SURG, V4, P24, DOI 10.1016/S1091-255X(00)80029-3; Piazza GA, 1997, CANCER RES, V57, P2909; Pierce JW, 1996, J IMMUNOL, V156, P3961; Pillinger MH, 1998, P NATL ACAD SCI USA, V95, P14540, DOI 10.1073/pnas.95.24.14540; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PRESTON SJ, 1989, BRIT J CLIN PHARMACO, V27, P607, DOI 10.1111/j.1365-2125.1989.tb03423.x; RAO CV, 1995, CANCER RES, V55, P1464; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reddy BS, 1996, CANCER RES, V56, P4566; Reddy BS, 2000, CANCER RES, V60, P293; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Riendeau D, 2001, J PHARMACOL EXP THER, V296, P558; Rodriguez LAG, 2000, EPIDEMIOLOGY, V11, P382, DOI 10.1097/00001648-200007000-00004; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sakurada S, 1996, INT IMMUNOL, V8, P1483, DOI 10.1093/intimm/8.10.1483; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Scharf S, 1999, NEUROLOGY, V53, P197, DOI 10.1212/WNL.53.1.197; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schoderbock P, 1996, APPL SURF SCI, V93, P109, DOI 10.1016/0169-4332(95)00327-4; Schwenger P, 1999, J CELL PHYSIOL, V179, P109, DOI 10.1002/(SICI)1097-4652(199904)179:1<109::AID-JCP13>3.0.CO;2-W; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Shackelford RE, 1997, MOL PHARMACOL, V52, P421, DOI 10.1124/mol.52.3.421; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Sheng HM, 1998, CANCER RES, V58, P362; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Sinha D, 1999, METABOLISM, V48, P786, DOI 10.1016/S0026-0495(99)90180-4; Slieker LJ, 1998, BIOCHEM BIOPH RES CO, V251, P225, DOI 10.1006/bbrc.1998.9433; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stevenson MA, 1999, J IMMUNOL, V163, P5608; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Stuhlmeier KM, 1999, BIOCHEM PHARMACOL, V57, P313, DOI 10.1016/S0006-2952(98)00301-3; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Sugiyama H, 2000, FEBS LETT, V467, P259, DOI 10.1016/S0014-5793(00)01169-8; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tegeder I, 2001, FASEB J, V15, P2, DOI 10.1096/fasebj.15.1.2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tobetto K, 1997, JPN J PHARMACOL, V75, P371, DOI 10.1254/jjp.75.371; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; URADE Y, 1989, J IMMUNOL, V143, P2982; van den Brink MRM, 1999, J BIOL CHEM, V274, P11178, DOI 10.1074/jbc.274.16.11178; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XZ, 2000, CELL STRESS CHAPERON, V5, P432, DOI 10.1379/1466-1268(2000)005<0432:RRHADH>2.0.CO;2; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; Wechter WJ, 2000, CANCER RES, V60, P2203; Wechter WJ, 1997, CANCER RES, V57, P4316; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS DH, 1992, BIOCHIM BIOPHYS ACTA, V1180, P9, DOI 10.1016/0925-4439(92)90020-N; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Woltman AM, 2000, EUR J IMMUNOL, V30, P1807, DOI 10.1002/1521-4141(200007)30:7<1807::AID-IMMU1807>3.0.CO;2-N; Wong E, 1997, INFLAMM RES, V46, P51, DOI 10.1007/s000110050063; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yamazaki R, 2000, INFLAMM RES, V49, P133, DOI 10.1007/s000110050571; Ye H, 1998, BIOCHEM J, V330, P803, DOI 10.1042/bj3300803; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Young JM, 1996, INFLAMM RES, V45, P246, DOI 10.1007/BF02259611; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	218	630	666	0	65	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2057	2072		10.1096/fj.01-0390rev	http://dx.doi.org/10.1096/fj.01-0390rev			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641233				2022-12-28	WOS:000171920400018
J	Gorin, Y; Kim, NH; Feliers, D; Bhandari, B; Choudhury, GG; Abboud, HE				Gorin, Y; Kim, NH; Feliers, D; Bhandari, B; Choudhury, GG; Abboud, HE			Angiotensin II activates Akt/protein kinase B by an arachidonic acid/redox-dependent pathway and independent of phosphoinositide 3-kinase	FASEB JOURNAL			English	Article						kidney; mesangium; hypertrophy; Akt/PKB; Ang II	NF-KAPPA-B; CYTOSOLIC PHOSPHOLIPASE A(2); GLYCOGEN-SYNTHASE KINASE-3; PROTEIN-KINASE; NADPH OXIDASE; GROWTH-FACTOR; MESANGIAL CELLS; ENDOTHELIAL-CELLS; MESSENGER-RNA; DNA-SYNTHESIS	Angiotensin II (Ang II) exerts contractile and trophic effects in glomerular mesangial cells (MCs). One potential downstream target of Ang II is the protein kinase Akt/protein kinase B (PKB). We investigated the effect of Ang II on Akt/PKB activity in MCs. Ang II causes rapid activation of Akt/PKB (5-10 min) but delayed activation of phosphoinositide 3-kinase (PI3-K) (30 min). Activation of Akt/PKB by Ang II was not abrogated by the PI3-K inhibitors or by the introduction of a dominant negative PI3-K, indicating that in MCs, PI3-K is not an upstream mediator of Akt/PKB activation by Ang II. Incubation of MCs with phospholipase A(2) Inhibitors also blocked Akt/PKB activation by Ang II. AA mimicked the effect of Ang II. Inhibitors of cyclooxygenase-, lipoxyogenase-, and cytochrome P450-dependent metabolism did not influence AA-induced Akt/PKB activation. However, the antioxidants N-acetylcysteine and diphenylene iodonium inhibited both AA- and Ang II-induced Akt/PKB activation. Dominant negative mutant of Akt/PKB or antioxidants, but not the dominant negative form of PI3-K, inhibited Ang II-induced protein synthesis and cell hypertrophy. These data provide the first evidence that Ang II induces protein synthesis and hypertrophy in MCs through AA/redox-dependent pathway and Akt/PKB activation independent of PI3-K.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol MC 7882, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Abboud, HE (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol MC 7882, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	abboud@uthscsa.edu		Feliers, Denis/0000-0003-1952-1386	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050190, R01DK043988, R29DK050190] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43988, DK 50190] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arar M, 2000, J BIOL CHEM, V275, P9527, DOI 10.1074/jbc.275.13.9527; Ardaillou R, 1999, J AM SOC NEPHROL, V10, pS40; BHANDARI B, 1995, J BIOL CHEM, V270, P5541, DOI 10.1074/jbc.270.10.5541; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dulin NO, 1998, P NATL ACAD SCI USA, V95, P8098, DOI 10.1073/pnas.95.14.8098; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Hack N, 1996, CLIN EXP PHARMACOL P, V23, P71; Haendeler J, 2000, REGUL PEPTIDES, V95, P1, DOI 10.1016/S0167-0115(00)00133-6; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Huang SM, 1999, KIDNEY INT, V55, P1740, DOI 10.1046/j.1523-1755.1999.00440.x; Ishikawa Y, 1997, BIOCHEM BIOPH RES CO, V240, P496, DOI 10.1006/bbrc.1997.7665; Jacobs LS, 1996, HYPERTENSION, V28, P663, DOI 10.1161/01.HYP.28.4.663; Jaimes EA, 1998, KIDNEY INT, V54, P775, DOI 10.1046/j.1523-1755.1998.00068.x; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Leusen Jeanette H. W., 1996, Frontiers in Bioscience (online), V1, pD72; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; Metzler B, 1998, J BIOL CHEM, V273, P33320, DOI 10.1074/jbc.273.50.33320; Moreno-Manzano V, 1999, J BIOL CHEM, V274, P20251, DOI 10.1074/jbc.274.29.20251; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; Rizzo MT, 1996, BLOOD, V88, P3792, DOI 10.1182/blood.V88.10.3792.bloodjournal88103792; Ruiz-Ortega M, 1998, J IMMUNOL, V161, P430; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; SCHLONDORFF D, 1987, AM J PHYSIOL, V253, pC113, DOI 10.1152/ajpcell.1987.253.1.C113; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Shin EA, 1999, FEBS LETT, V452, P355, DOI 10.1016/S0014-5793(99)00657-2; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Sugiyama H, 1999, J BIOL CHEM, V274, P19532, DOI 10.1074/jbc.274.28.19532; Takahashi T, 1999, AM J PHYSIOL-HEART C, V276, pH1927, DOI 10.1152/ajpheart.1999.276.6.H1927; Torrecillas G, 2001, MOL PHARMACOL, V59, P104, DOI 10.1124/mol.59.1.104; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wilmer WA, 1997, J BIOL CHEM, V272, P10877; Zhang H, 1999, CARDIOVASC RES, V44, P215, DOI 10.1016/S0008-6363(99)00183-2; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	51	89	89	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					1909	1920		10.1096/fj..01-0165com	http://dx.doi.org/10.1096/fj..01-0165com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532971				2022-12-28	WOS:000171372700006
J	Soudais, C; Laplace-Builhe, C; Kissa, K; Kremer, EJ				Soudais, C; Laplace-Builhe, C; Kissa, K; Kremer, EJ			Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo	FASEB JOURNAL			English	Article						canine adenovirus; neurons; retrograde axonal transport; neurodegenerative diseases	CENTRAL-NERVOUS-SYSTEM; COLI BETA-GALACTOSIDASE; VIRAL CODING SEQUENCES; GENE-TRANSFER; LONG-TERM; NEUROTROPHIC FACTOR; BRAIN INFLAMMATION; IMMUNE-RESPONSES; RECEPTOR PROTEIN; SKELETAL-MUSCLE	In the central nervous system (CNS), there are innate obstacles to the modification of neurons: their relative low abundance versus glia and oligodendrocytes, the inaccessibility of certain target populations, and the volume one can inject safely. Our aim in this study was to characterize the in vivo efficacy of a novel viral vector derived from a canine adenovirus (CAV-2). Here we show that CAV-2 preferentially transduced i) rat olfactory sensory neurons; ii) rodent CNS neurons in vitro and in vivo; and, more clinically relevant, iii) neurons in organotypic slices of human cortical brain. CAV-2 also showed a high disposition for retrograde axonal transport in vivo. We examined the molecular basis of neuronal targeting by CAV-2 and suggest that due to CAR (coxsackie adenovirus receptor) expression on neuronal cells-and not oligodendrocytes, glia, myofibers, and nasal epithelial cells-CAV-2 vectors transduced neurons preferentially in these diverse tissues.	Genethon III, CNRS, URA 1923, F-91002 Evry, France; Inst Pasteur, Paris, France; Inst Genet Mol Montpellier, CNRS, UMR 5535, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Kremer, EJ (corresponding author), Genethon III, CNRS, URA 1923, 1Bis,Rue Int, F-91002 Evry, France.	ekremer@genethon.fr	Kremer, EJ/P-9838-2019; LAPLACE-BUILHE, Corinne/ABD-4479-2020; soudais, claire/F-9756-2016; Kissa, Karima/N-6801-2018; Kremer, Eric J/D-3734-2013	Kremer, EJ/0000-0001-6114-7530; soudais, claire/0000-0002-4387-6649; Kissa, Karima/0000-0002-7683-3661; LAPLACE-BUILHE, Corinne/0000-0003-2885-6073				AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; ANDERS KH, 1991, PEDIATR NEUROSURG, V16, P316; BAILEY A, 1994, VIROLOGY, V205, P438, DOI 10.1006/viro.1994.1664; Bechade C, 1996, EUR J NEUROSCI, V8, P429, DOI 10.1111/j.1460-9568.1996.tb01226.x; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; BilangBleuel A, 1997, P NATL ACAD SCI USA, V94, P8818, DOI 10.1073/pnas.94.16.8818; Blomer U, 1997, J VIROL, V71, P6641; Bosch A, 2000, MOL THER, V1, P63, DOI 10.1006/mthe.1999.0005; Byrnes AP, 1996, J NEUROSCI, V16, P3045; Byrnes AP, 1996, GENE THER, V3, P644; BYRNES AP, 1995, NEUROSCIENCE, V66, P1015, DOI 10.1016/0306-4522(95)00068-T; CAILLAUD C, 1993, EUR J NEUROSCI, V5, P1287, DOI 10.1111/j.1460-9568.1993.tb00914.x; Charles PC, 1998, VIROLOGY, V245, P216, DOI 10.1006/viro.1998.9180; Chen HH, 1997, P NATL ACAD SCI USA, V94, P1645, DOI 10.1073/pnas.94.5.1645; Chillon M, 1999, J VIROL, V73, P2537, DOI 10.1128/JVI.73.3.2537-2540.1999; DAVIDSON BL, 1994, EXP NEUROL, V125, P258, DOI 10.1006/exnr.1994.1028; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; Davidson BL, 2000, P NATL ACAD SCI USA, V97, P3428, DOI 10.1073/pnas.050581197; Davison E, 1997, J VIROL, V71, P6204, DOI 10.1128/JVI.71.8.6204-6207.1997; Dechecchi MC, 2000, VIROLOGY, V268, P382, DOI 10.1006/viro.1999.0171; Dewey RA, 1999, NAT MED, V5, P1256, DOI 10.1038/15207; DRAGHIA R, 1995, GENE THER, V2, P418; Finiels F, 1995, NEUROREPORT, V7, P373, DOI 10.1097/00001756-199512000-00088; FLOMENBERG P, 1995, J INFECT DIS, V171, P1090, DOI 10.1093/infdis/171.5.1090; GELLER AI, 1990, P NATL ACAD SCI USA, V87, P8950, DOI 10.1073/pnas.87.22.8950; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; GHADGE GD, 1995, GENE THER, V2, P132; GUIDA JD, 1995, J VIROL, V69, P7674, DOI 10.1128/JVI.69.12.7674-7681.1995; Hemmi S, 1998, HUM GENE THER, V9, P2363, DOI 10.1089/hum.1998.9.16-2363; HENDERSON CE, 1988, CIBA F SYMP, V138, P172; HERMONAT PL, 1984, P NATL ACAD SCI-BIOL, V81, P6466, DOI 10.1073/pnas.81.20.6466; Holtmaat AJGD, 1996, MOL BRAIN RES, V41, P148, DOI 10.1016/0169-328X(96)00085-X; Honda T, 2000, MOL BRAIN RES, V77, P19, DOI 10.1016/S0169-328X(00)00036-X; Hong SS, 1997, EMBO J, V16, P2294, DOI 10.1093/emboj/16.9.2294; HORWITZ MS, 1996, FIELDS VIROLOGY, P2149; HSU KHL, 1988, J VIROL, V62, P1647, DOI 10.1128/JVI.62.5.1647-1652.1988; Huang S, 1996, J VIROL, V70, P4502, DOI 10.1128/JVI.70.7.4502-4508.1996; HUTTUNEN L, 1970, Scandinavian Journal of Infectious Diseases, V2, P151, DOI 10.3109/inf.1970.2.issue-2.13; JACKSON MB, 1982, J NEUROSCI, V2, P1052; Kajiwara K, 2000, J NEUROIMMUNOL, V103, P8, DOI 10.1016/S0165-5728(99)00220-9; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; KELLER A, 1975, J NEUROCHEM, V24, P1101, DOI 10.1111/j.1471-4159.1975.tb03883.x; Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; Kremer EJ, 2000, J VIROL, V74, P505, DOI 10.1128/JVI.74.1.505-512.2000; LE GLS, 1993, SCIENCE, V259, P988; Levi S, 1999, J NEUROSCI, V19, P7434, DOI 10.1523/JNEUROSCI.19-17-07434.1999; Lisovoski F, 1997, J NEUROSCI, V17, P7228; Mandel RJ, 1997, P NATL ACAD SCI USA, V94, P14083, DOI 10.1073/pnas.94.25.14083; Millecamps S, 1999, NAT BIOTECHNOL, V17, P865, DOI 10.1038/12849; Morral N, 1999, P NATL ACAD SCI USA, V96, P12816, DOI 10.1073/pnas.96.22.12816; Morsy MA, 1998, P NATL ACAD SCI USA, V95, P7866, DOI 10.1073/pnas.95.14.7866; Nalbantoglu J, 1999, HUM GENE THER, V10, P1009, DOI 10.1089/10430349950018409; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; OConnor WM, 1997, EXP NEUROL, V148, P167, DOI 10.1006/exnr.1997.6658; OHTAKI S, 1989, BRIT J EXP PATHOL, V70, P415; OSAMURA T, 1993, EUR J PEDIATR, V152, P496, DOI 10.1007/BF01955058; PALELLA TD, 1989, GENE, V80, P137, DOI 10.1016/0378-1119(89)90258-8; Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; RAPP F, 1969, CANCER RES, V29, P1173; RIDOUX V, 1994, BRAIN RES, V648, P171, DOI 10.1016/0006-8993(94)91919-4; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; SLIFKIN M, 1969, J NATL CANCER I, V43, P423; Soudais C, 2000, J VIROL, V74, P10639, DOI 10.1128/JVI.74.22.10639-10649.2000; Soudais C, 2001, MOL THER, V3, P631, DOI 10.1006/mthe.2001.0263; Swanson L. W., 1992, BRAIN MAPS STRUCTURE; Thomas CE, 2000, P NATL ACAD SCI USA, V97, P7482, DOI 10.1073/pnas.120474397; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; WICKHAM TJ, 1994, J CELL BIOL, V127, P257, DOI 10.1083/jcb.127.1.257; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Wood MJA, 1996, TRENDS NEUROSCI, V19, P497, DOI 10.1016/S0166-2236(96)10060-6; Zabner J, 1997, J CLIN INVEST, V100, P1144, DOI 10.1172/JCI119625; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	74	181	187	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2001	15	10					2283	+		10.1096/fj.01-0321fje	http://dx.doi.org/10.1096/fj.01-0321fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11511531				2022-12-28	WOS:000170809900015
J	Hirsch, E; Bosco, O; Tropel, P; Laffargue, M; Calvez, R; Altruda, F; Wymann, MP; Montrucchio, G				Hirsch, E; Bosco, O; Tropel, P; Laffargue, M; Calvez, R; Altruda, F; Wymann, MP; Montrucchio, G			Resistance to thromboembolism in PI3K gamma-deficient mice	FASEB JOURNAL			English	Article						platelet aggregation; thrombosis; G protein-coupled receptors	PHOSPHOINOSITIDE 3-KINASE; HUMAN PLATELETS; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; ADENOSINE-DIPHOSPHATE; ADP RECEPTORS; ACTIVATION; THROMBIN; PHOSPHORYLATION; AGGREGATION; INTEGRIN	Platelet aggregation and subsequent thrombosis are the major cause of ischemic diseases such as heart attack and stroke. ADP, acting via G protein-coupled receptors (GPCRs), is an important signal in thrombus formation and involves activation of phosphoinositide 3-kinases (PI3K). When platelets from mice lacking the G protein-activated PI3K gamma isoform were stimulated with ADP, aggregation was impaired. Collagen or thrombin, however, evoked a normal response. ADP stimulation of PI3K gamma -deficient platelets resulted in decreased PKB/Akt phosphorylation and alpha (IIb)beta (3) fibrinogen receptor activation. These effects did not influence bleeding time but protected PI3K gamma -null mice from death caused by ADP-induced platelet-dependent thromboembolic vascular occlusion. This result demonstrates an unsuspected, well-defined role for PI3K gamma downstream of ADP and suggests that pharmacological targeting of PI3K gamma has a potential use as antithrombotic therapy.	Univ Turin, Dipartimento Genet Biol & Biochim, I-10126 Turin, Italy; Univ Turin, Dipartimento Fisiopatol Clin, I-10126 Turin, Italy; Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland	University of Turin; University of Turin; University of Fribourg	Hirsch, E (corresponding author), Univ Turin, Dipartimento Genet Biol & Biochim, Via Santena 5 Bis, I-10126 Turin, Italy.	emilio.hirsch@unito.it	Laffargue, Muriel/AAE-7849-2021; Hirsch, Emilio/F-4848-2013; Wymann, Matthias P/C-3227-2008; Bosco, Ornella/AAB-2105-2019	Hirsch, Emilio/0000-0002-9073-6024; Wymann, Matthias P/0000-0003-3349-4281; Calvez, Ronan/0000-0001-5762-1244; Laffargue, Muriel/0000-0003-1833-639X				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Bennett CL, 2000, NEW ENGL J MED, V342, P1773, DOI 10.1056/NEJM200006153422402; Brass LF, 1999, J CLIN INVEST, V104, P1663, DOI 10.1172/JCI8944; CATTANEO M, 1990, BLOOD, V75, P1081; Cattaneo M, 1999, ARTERIOSCL THROM VAS, V19, P2281, DOI 10.1161/01.ATV.19.10.2281; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; Gachet C, 1997, J BIOL CHEM, V272, P4850, DOI 10.1074/jbc.272.8.4850; Gironcel D, 1996, FEBS LETT, V389, P253, DOI 10.1016/0014-5793(96)00595-9; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; Heraud JM, 1998, J BIOL CHEM, V273, P17817, DOI 10.1074/jbc.273.28.17817; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Ingall AH, 1999, J MED CHEM, V42, P213, DOI 10.1021/jm981072s; Kirk RI, 2000, J BIOL CHEM, V275, P30901, DOI 10.1074/jbc.M001908200; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; NORDOY A., 1964, SCAND J HAEMATOL, V1, P16; Quinn MJ, 1999, CIRCULATION, V100, P1667, DOI 10.1161/01.CIR.100.15.1667; Rittenhouse SE, 1996, BLOOD, V88, P4401, DOI 10.1182/blood.V88.12.4401.bloodjournal88124401; Selheim F, 1999, BIOCHEM BIOPH RES CO, V263, P780, DOI 10.1006/bbrc.1999.1450; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Trumel C, 1999, BLOOD, V94, P4156, DOI 10.1182/blood.V94.12.4156.424k29_4156_4165; Tsakiris DA, 1999, THROMB HAEMOSTASIS, V81, P177, DOI 10.1055/s-0037-1614439; vanWilligen G, 1996, BIOCHEM J, V314, P769, DOI 10.1042/bj3140769; Watson SP, 1999, THROMB HAEMOSTASIS, V82, P365; Wymann MP, 2000, IMMUNOL TODAY, V21, P260, DOI 10.1016/S0167-5699(00)01649-2; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; YATOMI Y, 1992, BIOCHEM J, V285, P745, DOI 10.1042/bj2850745; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	37	176	189	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2001	15	9					2019	+		10.1096/fj.00-0810fje	http://dx.doi.org/10.1096/fj.00-0810fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511514				2022-12-28	WOS:000170318500025
J	Shofuda, K; Hasenstab, D; Kenagy, RD; Shofuda, T; Li, ZY; Lieber, A; Clowes, AW				Shofuda, K; Hasenstab, D; Kenagy, RD; Shofuda, T; Li, ZY; Lieber, A; Clowes, AW			Membrane-type matrix metalloproteinase-1 and-3 activity in primate smooth muscle cells	FASEB JOURNAL			English	Article						membrane-type matrix metalloporteinases (MT-MMPs); smooth muscle cells (SMCs); adenovirus; migration	TISSUE INHIBITOR; EXTRACELLULAR-MATRIX; IV COLLAGENASE; PRO-GELATINASE; ACTIVATION; EXPRESSION; MIGRATION; INVASION; CLEAVAGE; ASSOCIATION	Membrane-type matrix metalloproteinases-1 and -3 (MT1- and MT3-MMPs) are expressed by activated smooth muscle cells (SMCs) both in vitro and in vivo (19). To define their functions in SMCs, we transduced MT1- and MT3-MMP cDNAs into baboon SMCs by using adenoviral vectors. Overexpression of MT1-MMP increased the conversion of proMMP-2 to the intermediate and active forms. In contrast, in MT3-MMP-overexpressing cells, MMP-2 was activated partially. Immunoblot analyses revealed that MT1-MMP protein was present in the SMCs and accumulated in the presence of the synthetic MMP inhibitor, BB94, or tissue inhibitor of metalloproteinase-2 (TIMP-2). However, MT3-MMP protein was detectable only when BB94, but not TIMP-2, was present. Zymographic analyses showed that MT3-MMP had much stronger casein- and gelatin-degrading activities than did MT1- MMP. Furthermore, when MT3-MMP and MT1- MMP were coexpressed, MT1- MMP degradation was enhanced; this result supports the possibility that MT3-MMP can degrade MT1- MMP. SMCs overexpressing either MT1- or MT3-MMP exhibited altered morphology, without changing their proliferation. This alteration was prevented by BB94 addition. The cells, which underwent this change, showed reduced adhesion to both collagen and fibronectin and increased migration in a Boyden chamber. The present study demonstrates that MT1- and MT3-MMPs have different enzymatic activities but may nevertheless affect SMC function in the same way.	Univ Washington, Sch Med, Dept Surg, Div Vasc Surg, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Clowes, AW (corresponding author), Univ Washington, Sch Med, Dept Surg, Div Vasc Surg, HSB BB442,Box 356410,1959 NE Pacific St, Seattle, WA 98195 USA.	clowes@u.washington.edu		Kenagy, Richard/0000-0002-2021-5565				AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; Fabunmi RP, 1996, BIOCHEM J, V315, P335, DOI 10.1042/bj3150335; FUKAI F, 1991, J BIOL CHEM, V266, P8807; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; KENAGY RD, 1994, J CLIN INVEST, V93, P1987, DOI 10.1172/JCI117191; KOSHIKAWA N, 1992, CANCER RES, V52, P5046; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Koyama N, 1996, AM J PATHOL, V148, P749; Koyama N, 1998, CIRC RES, V83, P305, DOI 10.1161/01.RES.83.3.305; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; LIEBER A, 1995, P NATL ACAD SCI USA, V92, P6210, DOI 10.1073/pnas.92.13.6210; LIOTTA LA, 1986, CANCER RES, V46, P1; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Nagase H, 1998, Cell Res, V8, P179; NEWBY AC, 1994, BASIC RES CARDIOL, V89, P59; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Rabbani R, 1999, CARDIOVASC RES, V41, P402, DOI 10.1016/S0008-6363(98)00279-X; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Shofuda K, 1998, LAB INVEST, V78, P915; Shofuda K, 1997, J BIOL CHEM, V272, P9749; Shofuda K, 1998, J BIOCHEM-TOKYO, V124, P462, DOI 10.1093/oxfordjournals.jbchem.a022136; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; THOMPSON RW, 1996, ANN NY ACAD SCI, V18, P157; Yamanaka H, 2000, LAB INVEST, V80, P677, DOI 10.1038/labinvest.3780071; Yoshiyama Y, 1998, ACTA NEUROPATHOL, V96, P347, DOI 10.1007/s004010050904; Zempo N, 1996, ARTERIOSCL THROM VAS, V16, P28, DOI 10.1161/01.ATV.16.1.28	38	23	25	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2010	+		10.1096/fj.00-0871fje	http://dx.doi.org/10.1096/fj.00-0871fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511522				2022-12-28	WOS:000170318500022
J	Henn, AD; Berleth, ES; Mihich, E; Ehrke, MJ				Henn, AD; Berleth, ES; Mihich, E; Ehrke, MJ			Changes in cytosolic and membrane TNF inhibitory protein-B1 (TIP-B1) levels associated with protection from TNF-induced cytotoxicity	FASEB JOURNAL			English	Article									Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Ehrke, MJ (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.								0	6	7	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1315	1317		10.1096/fj.00-0543fje	http://dx.doi.org/10.1096/fj.00-0543fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344125	Bronze			2022-12-28	WOS:000168655200047
J	Ameye, L; Aria, D; Jepsen, K; Oldberg, A; Xu, TS; Young, MF				Ameye, L; Aria, D; Jepsen, K; Oldberg, A; Xu, TS; Young, MF			Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis	FASEB JOURNAL			English	Article						leucine-rich; proteoglycans; cartilage; bone; matrix	DEGENERATIVE JOINT DISEASE; PROTEOGLYCANS BIGLYCAN; TARGETED DISRUPTION; SKIN FRAGILITY; KNEE-JOINT; FIBROMODULIN; DECORIN; LUMICAN; GENE; EXPRESSION	Small leucine-rich proteoglycans (SLRPs) regulate extracellular matrix organization, a process essential in development, tissue repair, and metastasis. In vivo interactions of biglycan and fibromodulin, two SLRPs highly expressed in tendons and bones, were investigated by generating biglycan/fibromodulin double-deficient mice. Here we show that collagen fibrils in tendons from mice deficient in biglycan and/or fibromodulin are structurally and mechanically altered resulting in unstable joints. As a result, the mice develop successively and progressively 1) gait impairment, 2) ectopic tendon ossification, and 3) severe premature osteoarthritis. Forced use of the joints increases ectopic ossification and osteoarthritis in the double-deficient mice, further indicating that structurally weak tendons cause the phenotype. The study shows that mutations in SLRPs may predispose to osteoarthritis and offers a valuable and unique animal model for spontaneous osteoarthritis characterized by early onset and a rapid progression of the disease.	NIDCR, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD USA; CUNY Mt Sinai Sch Med, Dept Orthopaed, New York, NY 10029 USA; Lund Univ, Dept Cell & Mol Biol, Lund, Sweden	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Lund University	Ameye, L (corresponding author), Nestle Res Ctr, Dept Nutr, G35 Vers Chez Blanc,POB 44, CH-1000 Lausanne 26, Switzerland.	Laurent.Ameye@rdls.nestle.com		Young, Marian F/0000-0003-0929-8854	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000379] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anderson-MacKenzie JM, 1999, BIOCHEM BIOPH RES CO, V258, P763, DOI 10.1006/bbrc.1999.0713; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Chen XD, 2002, J BONE MINER RES, V17, P331, DOI 10.1359/jbmr.2002.17.2.331; Cipolla M, 1995, Knee Surg Sports Traumatol Arthrosc, V3, P21, DOI 10.1007/BF01553521; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Ezura Y, 2000, J CELL BIOL, V151, P779, DOI 10.1083/jcb.151.4.779; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; HELMINEN HJ, 1993, J CLIN INVEST, V92, P582, DOI 10.1172/JCI116625; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Lapvetelainen T, 2001, OSTEOARTHR CARTILAGE, V9, P152, DOI 10.1053/joca.2000.0370; Malaviya P, 2000, J ORTHOP RES, V18, P116, DOI 10.1002/jor.1100180117; Matsushima N, 2000, PROTEINS, V38, P210, DOI 10.1002/(SICI)1097-0134(20000201)38:2<210::AID-PROT9>3.0.CO;2-1; NAKATA K, 1993, P NATL ACAD SCI USA, V90, P2870, DOI 10.1073/pnas.90.7.2870; Nuki G, 1999, Z RHEUMATOL, V58, P142, DOI 10.1007/s003930050164; PRITCHETT JW, 1984, J BONE JOINT SURG AM, V66A, P1379, DOI 10.2106/00004623-198466090-00009; REINHOLT FP, 1982, J ULTRA MOL STRUCT R, V80, P270, DOI 10.1016/S0022-5320(82)80040-3; Saamanen AMK, 2001, BIOCHEM J, V355, P577; Saamanen AMK, 2000, OSTEOARTHR CARTILAGE, V8, P248, DOI 10.1053/joca.2000.0298; Sarin VK, 1999, ANAT RECORD, V257, P174, DOI 10.1002/(SICI)1097-0185(19991015)257:5<174::AID-AR6>3.0.CO;2-O; Schwartz S T, 1999, Med Health R I, V82, P321; SEEGMILLER RE, 2001, OSTEOARTHR CARTILAGE, V9, pS15; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; Vikkula M, 1996, ANN MED, V28, P301, DOI 10.3109/07853899608999084; Wada M, 1996, BRIT J RHEUMATOL, V35, P560; WALTON M, 1977, J PATHOL, V123, P109, DOI 10.1002/path.1711230207; Wilda M, 2000, J BONE MINER RES, V15, P2187, DOI 10.1359/jbmr.2000.15.11.2187; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746	30	252	263	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7							UNSP 0892-6638/02/0016-0673	10.1096/fj.01-0848com	http://dx.doi.org/10.1096/fj.01-0848com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	11978731				2022-12-28	WOS:000175973900021
J	Hidaka, S; Yoshimatsu, H; Kondou, S; Tsuruta, Y; Oka, K; Noguchi, H; Okamoto, K; Sakino, H; Teshima, Y; Okeda, T; Sakata, T				Hidaka, S; Yoshimatsu, H; Kondou, S; Tsuruta, Y; Oka, K; Noguchi, H; Okamoto, K; Sakino, H; Teshima, Y; Okeda, T; Sakata, T			Chronic central leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin-induced diabetic rats	FASEB JOURNAL			English	Article						STZ-induced insulin-deficient diabetes; glucose transporters; uncoupling proteins; anti-diabetic drugs	PERIPHERAL GLUCOSE-UPTAKE; BROWN ADIPOSE-TISSUE; SKELETAL-MUSCLE; UNCOUPLING PROTEIN; MESSENGER-RNA; BODY-WEIGHT; EXPRESSION; MICE; RESISTANCE; STIMULATION	We examined the effects of chronic centrally administered leptin on the glucose metabolism of streptozotocin-induced diabetic (STZ-D) rats, a model for insulin-dependent diabetes mellitus. When 3 mug . rat(-1) . day(-1) of leptin was infused into the third ventricle for 6 consecutive days (STZ-LEP), STZ-D rats became completely euglycemic. The effect was not seen when the same dosage was administered s.c. Centrally administered leptin did not affect peripheral insulin levels. The feeding volume of STZ-LEP rats was suppressed to the level of non-STZ-D control rats. No improvement of hyperglycemia was noted when STZ-D rats were pair-fed to match the feeding volume of STZ-LEP rats. Thus, the euglycemia of STZ-LEP rats cannot be due to the decreased feeding volume. In the STZ-D rat, glucokinase mRNA, a marker of glycolysis, is down-regulated whereas glucose-6-phosphatase mRNA, a marker of gluconeogenesis, and glucose transporter (GLUT) 2, which is implicated in the release of glucose from liver, are up-regulated. GLUT4, uncoupling protein (UCP) 1, and UCP3 were down-regulated in brown adipose tissue. These parameters returned to normal upon central infusion of leptin. GLUT4 was not down-regulated in the skeletal muscle of STZ-D rats; however, fatty acid binding protein and carnitine palmitoyltransferase I, markers for utilization and beta-oxidation of fatty acids, were up-regulated and restored when the rats were treated with leptin. The increase and subsequent decrease of fatty acid utilization suggests a decrease of glucose uptake in the skeletal muscle of STZ-D rats, which was restored upon central leptin administration. We conclude that centrally infused leptin does not control serum glucose by regulating feeding volume or elevating peripheral insulin, but by regulating hepatic glucose production, peripheral glucose uptake, and energy expenditure. The present study indicates the possibility of future development of a new class of anti-diabetic agents that act centrally and independent of insulin action.	Oita Med Univ, Sch Med, Dept Internal Med 1, Oita 8795593, Japan	Oita University	Sakata, T (corresponding author), Oita Med Univ, Sch Med, Dept Internal Med 1, Oita 8795593, Japan.	SAKATA@oita-med.ac.jp						Auwerx J, 1998, LANCET, V351, P737, DOI 10.1016/S0140-6736(97)06348-4; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Berti L, 1997, DIABETOLOGIA, V40, P606, DOI 10.1007/s001250050722; BURCELIN R, 1993, BIOCHEM J, V291, P109, DOI 10.1042/bj2910109; Chinookoswong N, 1999, DIABETES, V48, P1487, DOI 10.2337/diabetes.48.7.1487; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Dunbar JC, 1997, DIABETES, V46, P2040, DOI 10.2337/diabetes.46.12.2040; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Emilsson V, 1997, DIABETES, V46, P313, DOI 10.2337/diabetes.46.2.313; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fruhbeck G, 2000, DIABETOLOGIA, V43, P3, DOI 10.1007/s001250050002; FUJIMOTO K, 1986, AM J PHYSIOL, V251, pR481, DOI 10.1152/ajpregu.1986.251.3.R481; Haque MS, 1999, DIABETES, V48, P1706, DOI 10.2337/diabetes.48.9.1706; Havel PJ, 1998, AM J PHYSIOL-REG I, V274, pR1482, DOI 10.1152/ajpregu.1998.274.5.R1482; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; Hidaka S, 2000, P SOC EXP BIOL MED, V224, P172, DOI 10.1046/j.1525-1373.2000.22417.x; Hidaka S, 1998, BBA-LIPID LIPID MET, V1389, P178, DOI 10.1016/S0005-2760(97)00188-4; Hidaka S, 1999, DIABETES, V48, P430, DOI 10.2337/diabetes.48.2.430; Hidaka S, 2001, J NEUROCHEM, V77, P993, DOI 10.1046/j.1471-4159.2001.00317.x; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; Kahn BB, 1996, DIABETES, V45, P1644, DOI 10.2337/diabetes.45.11.1644; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Kim EM, 1999, AM J PHYSIOL-REG I, V276, pR1320, DOI 10.1152/ajpregu.1999.276.5.R1320; LANG CH, 1995, AM J PHYSIOL-REG I, V268, pR492, DOI 10.1152/ajpregu.1995.268.2.R492; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Minokoshi Y, 1999, DIABETES, V48, P287, DOI 10.2337/diabetes.48.2.287; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; NEUFER PD, 1993, J BIOL CHEM, V268, P13824; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OKA Y, 1990, DIABETES, V39, P441, DOI 10.2337/diabetes.39.4.441; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PENICAUD L, 1985, AM J PHYSIOL, V249, pE514, DOI 10.1152/ajpendo.1985.249.5.E514; RENOLD AE, 1953, J BIOL CHEM, V204, P533; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; Shi ZQ, 1998, METABOLISM, V47, P1274, DOI 10.1016/S0026-0495(98)90336-5; SHIBATA H, 1989, AM J PHYSIOL, V257, pR96, DOI 10.1152/ajpregu.1989.257.1.R96; SHIMADA M, 2000, GEOMECH RES SER, V2, P1; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; SUDO M, 1991, AM J PHYSIOL, V261, pE298, DOI 10.1152/ajpendo.1991.261.3.E298; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; TSAKIRIDIS T, 1995, BIOCHEM J, V309, P1; WILLIAMS G, 1989, DIABETES, V38, P321, DOI 10.2337/diabetes.38.3.321	48	83	84	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					509	518		10.1096/fj.01-0164com	http://dx.doi.org/10.1096/fj.01-0164com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919153				2022-12-28	WOS:000175425900004
J	Sounni, NE; Devy, L; Hajitou, A; Frankenne, F; Munaut, C; Gilles, C; Deroanne, C; Thompson, EW; Foidart, JM; Noel, A				Sounni, NE; Devy, L; Hajitou, A; Frankenne, F; Munaut, C; Gilles, C; Deroanne, C; Thompson, EW; Foidart, JM; Noel, A			MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression	FASEB JOURNAL			English	Article						matrix metalloproteinases; MCF7 cells; MT1-MMP overexpression; VEGF	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; BREAST-CARCINOMA CELLS; IN-SITU HYBRIDIZATION; MT-MMP EXPRESSION; INTEGRIN ALPHA-V-BETA-3; TISSUE INHIBITOR; STROMAL CELLS; ACTIVATION; PROGRESSION; CANCER	Membrane type 1 metalloprotease (MT1-MMP) is a transmembrane metalloprotease that plays a major role in the extracellular matrix remodeling, directly by degrading several of its components and indirectly by activating pro-MMP2. We investigated the effects of MT1-MMP overexpression on in vitro and in vivo properties of human breast adenocarcinoma MCF7 cells, which do not express MT1-MMP or MMP-2. MT1-MMP and MMP-2 cDNAs were either transfected alone or cotransfected. All clones overexpressing MT1-MMP 1) were able to activate endogenous or exogenous pro-MMP-2, 2) displayed an enhanced in vitro invasiveness through matrigel-coated filters independent of MMP-2 transfection, 3) induced the rapid development of highly vascularized tumors when injected subcutanously in nude mice, and 4) promoted blood vessels sprouting in the rat aortic ring assay. These effects were observed in all clones overexpressing MT1-MMP regardless of MMP-2 expression levels, suggesting that the production of MMP-2 by tumor cells themselves does not play a critical role in these events. The angiogenic phenotype of MT1-MMP producing cells was associated with an up-regulation of VEGF expression. These results emphasize the importance of MT1-MMP during tumor angiogenesis and open new opportunities for the development of antiangiogenic strategies combining inhibitors of MT1-MMP and VEGF antagonists.	Univ Liege, Lab Biol Tumor & Dev, B-4000 Sart Tilman Par Liege, Belgium; Univ Liege, Lab Connect Tissues Biol, B-4000 Sart Tilman Par Liege, Belgium; St Vincents Inst Med Res, Victorian Breast Canc Res Consortium, Invas & Metastasis Unit, Fitzroy, Vic 3065, Australia	University of Liege; University of Liege; St. Vincent's Institute of Medical Research	Noel, A (corresponding author), Univ Liege, Lab Biol Tumor & Dev, B-4000 Sart Tilman Par Liege, Belgium.	agnes.noel@ulg.ac.be	Thompson, Erik W/A-1425-2009; Sounni, Nor Eddine/AAY-8766-2021; Thompson, Erik/GPK-2067-2022; Munaut, Carine/K-8138-2019	Thompson, Erik W/0000-0002-9723-4924; Sounni, Nor Eddine/0000-0001-9962-9236; Thompson, Erik/0000-0002-9723-4924; Noel, Agnes/0000-0002-7670-6179				Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Blacher Silvia, 2001, Angiogenesis, V4, P133, DOI 10.1023/A:1012251229631; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Gilles C, 1996, INT J CANCER, V65, P209; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; Hajitou A, 2001, CANCER RES, V61, P3450; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hofmann UB, 2000, J PATHOL, V191, P245; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Itoh T, 1998, CANCER RES, V58, P1048; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; MILLER DL, 1994, CELL GROWTH DIFFER, V5, P1263; Mori M, 1997, INT J CANCER, V74, P316, DOI 10.1002/(SICI)1097-0215(19970620)74:3<316::AID-IJC14>3.0.CO;2-9; Nawrocki B, 1997, INT J CANCER, V72, P556, DOI 10.1002/(SICI)1097-0215(19970807)72:4<556::AID-IJC2>3.3.CO;2-#; NICOSIA RF, 1990, LAB INVEST, V63, P115; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; Noel A, 1997, INVAS METAST, V17, P221; NOEL A, 1994, PATHOL RES PRACT, V190, P934; NOMURA H, 1995, CANCER RES, V55, P3263; Ohtani H, 1996, INT J CANCER, V68, P565, DOI 10.1002/(SICI)1097-0215(19961127)68:5<565::AID-IJC2>3.0.CO;2-X; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Polette M, 1996, VIRCHOWS ARCH, V428, P29; POLETTE M, 1994, VIRCHOWS ARCH, V424, P641, DOI 10.1007/BF01069745; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; SOUNNI NE, 2001, IN PRESS INT J CANC; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TOKURAKU M, 1995, INT J CANCER, V64, P355, DOI 10.1002/ijc.2910640513; Ueno H, 1997, CANCER RES, V57, P2055; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	44	220	245	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					555	564		10.1096/fj.01-0790com	http://dx.doi.org/10.1096/fj.01-0790com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919158				2022-12-28	WOS:000175425900009
J	Tsuruta, D; Gonzales, M; Hopkinson, SB; Otey, C; Khuon, S; Goldman, RD; Jones, JCR				Tsuruta, D; Gonzales, M; Hopkinson, SB; Otey, C; Khuon, S; Goldman, RD; Jones, JCR			Microfilament-dependent movement of the beta 3 integrin subunit within focal contacts of endothelial cells	FASEB JOURNAL			English	Article						matrix adhesion; matrix receptors; FRAP; actin cytoskeleton; actinin	INTERMEDIATE FILAMENT NETWORKS; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; LATERAL MOBILITY; ALPHA-ACTININ; ADHESION; FIBROBLASTS; DYNAMICS; GROWTH; ALPHA(V)BETA(3)	To gain insight into the dynamic properties of focal contacts, we induced expression of green fluorescent protein-tagged beta3 integrin (GFP-beta3) and actinin-1 (GFP-actinin-1) in endothelial cells. Both tagged proteins localize with alphavbeta3 integrin in focal contacts distributed towards the periphery of transfected cells. Labeled focal contacts migrate at about 0.1 mum/min in stationary live endothelial cells. We compared beta3 integrin and actinin-1 dynamics in focal contacts by using fluorescence recovery after photobleaching. Recovery of signal in bleached focal contacts that have incorporated actinin-1 is rapid and occurs within less than 4 min. This recovery is energy-dependent. In contrast, recovery of bleached focal contacts that contain GFP-beta3 integrin takes longer than 30 min. Yet, when a narrow stripe of fluorescence is bleached across a beta3 integrin-labeled focal contact, recovery is complete within 16 min. The latter recovery is energy-dependent and is blocked not only by actin-filament disrupting drugs but also by a myosin light chain kinase inhibitor. Thus, integrins are not immobile when incorporated into focal contacts, as some have suggested. We propose that integrins are mobile within the confines of focal contacts and that this mobility is supported by an actin-associated molecular motor.	Northwestern Univ, Sch Med, Dept Mol & Cell Biol, Chicago, IL 60611 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC USA	Northwestern University; University of North Carolina; University of North Carolina Chapel Hill	Jones, JCR (corresponding author), Northwestern Univ, Sch Med, Dept Mol & Cell Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.	j-jones3@nwu.edu	Jones, Jonathan C R/T-9467-2017	Jones, Jonathan C R/0000-0002-1496-4922				Broday DM, 2000, B MATH BIOL, V62, P891, DOI 10.1006/bulm.2000.0183; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Dogic D, 1999, CURR TOPICS PATHOL, V93, P75; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; Edlund M, 2001, CELL MOTIL CYTOSKEL, V48, P190, DOI 10.1002/1097-0169(200103)48:3<190::AID-CM1008>3.0.CO;2-C; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; FUJIWARA K, 1976, J CELL BIOL, V71, P848, DOI 10.1083/jcb.71.3.848; GEIGER B, 1982, J CELL BIOL, V93, P495, DOI 10.1083/jcb.93.2.495; GEIGER B, 1984, J CELL BIOL, V99, pS83, DOI 10.1083/jcb.99.1.83s; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GOLDMAN RD, 1973, COLD SPRING HARB SYM, V37, P523, DOI 10.1101/SQB.1973.037.01.063; Gonzales M, 2001, MOL BIOL CELL, V12, P85, DOI 10.1091/mbc.12.1.85; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLATTE DH, 1989, J CELL BIOL, V109, P3377, DOI 10.1083/jcb.109.6.3377; KREIS TE, 1982, CELL, V29, P835, DOI 10.1016/0092-8674(82)90445-7; PLANCON S, 2001, BIOCHEM J, V15, P529; Ren XD, 2000, J CELL SCI, V113, P3673; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Ruoslahti E, 1997, J CLIN INVEST, V99, P1149, DOI 10.1172/JCI119269; SCHLESSINGER J, 1983, CELL MOTIL CYTOSKEL, V3, P399, DOI 10.1002/cm.970030508; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schootemeijer A, 1997, THROMB HAEMOSTASIS, V77, P143; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schweitzer KM, 1997, LAB INVEST, V76, P25; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; Simon K. O., 1994, INTEGRINS MOL BIOL R, P49; Smilenov LB, 1999, SCIENCE, V286, P1172, DOI 10.1126/science.286.5442.1172; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; STICKEL SK, 1987, J CELL BIOL, V104, P1521, DOI 10.1083/jcb.104.6.1521; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; VIKSTROM KL, 1992, J CELL BIOL, V118, P121, DOI 10.1083/jcb.118.1.121; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zamir E, 1999, J CELL SCI, V112, P1655	41	61	63	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					866	+		10.1096/fj.01-0878fje	http://dx.doi.org/10.1096/fj.01-0878fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967230				2022-12-28	WOS:000175425900014
J	Zhao, M; Pu, J; Forrester, JV; McCaig, CD				Zhao, M; Pu, J; Forrester, JV; McCaig, CD			Membrane lipids, EGF receptors, and intracellular signals colocalize and are polarized in epithelial cells moving directionally in a physiological electric field	FASEB JOURNAL			English	Article						directional cell migration; electric fields; EGF receptor; MAP kinase ERK1/2; wound healing; eletrotaxis/galvanotaxis	ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; DIRECTED MIGRATION; CHEMOATTRACTANT RECEPTOR; NEUTROPHIL CHEMOTAXIS; LEADING-EDGE; MOTILITY; KERATINOCYTES; PATHWAY; ORIENTATION	Directed cell migration is essential for tissue formation, inflammation, and wound healing. Chemotaxis plays a major role in these situations and is underpinned by asymmetric intracellular signaling. Endogenous electric fields (EFs) are common where cell movement occurs, such as in wound healing, and cells respond to electric field gradients by reorienting and migrating directionally (galvanotaxis/electrotaxis). We show that a physiological EF redistributed both EGF (epidermal growth factor) receptors and detergent-insoluble membrane lipids asymmetrically, leading to cathodal polarization and enhanced activation of the MAP kinase, ERK1/2. This induced leading-edge actin polymerization in directionally migrating mammalian epithelial cells. Inhibiting the EGF receptor-MAP kinase signaling pathway significantly decreased leading edge actin asymmetry and directional migration. We propose a model in which EF-polarized membrane lipid domains and EGF receptors cause asymmetric signaling through MAP kinase, which drives directional cell migration. A comparison is made with the mechanisms underpinning chemotaxis.	Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Inst Med Sci, Dept Ophthalmol, Aberdeen AB25 2ZD, Scotland	University of Aberdeen; University of Aberdeen	Zhao, M (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland.	m.zhao@abdn.ac.uk; c.mccaig@abdn.ac.uk						AHMED T, 1992, J PHYSIOL-LONDON, V446, pP42; BORGENS RB, 1995, DEV DYNAM, V203, P456, DOI 10.1002/aja.1002030408; BORGENS RB, 1983, J EXP ZOOL, V228, P491, DOI 10.1002/jez.1402280309; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CHIANG MC, 1992, EXP EYE RES, V54, P999, DOI 10.1016/0014-4835(92)90164-N; Dekker LV, 2000, SCIENCE, V287, P982, DOI 10.1126/science.287.5455.982; Fang KS, 1999, J CELL SCI, V112, P1967; Fang KS, 1998, J INVEST DERMATOL, V111, P751, DOI 10.1046/j.1523-1747.1998.00366.x; Gipson I K, 1995, Curr Opin Ophthalmol, V6, P3; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Graf K, 1997, HYPERTENSION, V29, P334, DOI 10.1161/01.HYP.29.1.334; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; Hirotsu T, 2000, NATURE, V404, P289, DOI 10.1038/35005101; HOTARY KB, 1992, DEVELOPMENT, V114, P985; HOTARY KB, 1994, DEV BIOL, V166, P789, DOI 10.1006/dbio.1994.1357; Iglesia DDS, 1996, J EXP ZOOL, V274, P56, DOI 10.1002/(SICI)1097-010X(19960101)274:1<56::AID-JEZ6>3.0.CO;2-E; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Liang QW, 1998, INVEST OPHTH VIS SCI, V39, P1329; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; McCaig CD, 1997, BIOESSAYS, V19, P819, DOI 10.1002/bies.950190912; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; MESSERLI M, 1997, MOL BIOL CELL S, V8, P129; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; NUCCITELLI R, 1993, CELL MOTIL CYTOSKEL, V24, P54, DOI 10.1002/cm.970240107; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Pierini LM, 2001, P NATL ACAD SCI USA, V98, P9471, DOI 10.1073/pnas.181353098; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; ROBINSON KR, 1985, J CELL BIOL, V101, P2023, DOI 10.1083/jcb.101.6.2023; SCHULTZ G, 1991, J CELL BIOCHEM, V45, P346, DOI 10.1002/jcb.240450407; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; SHI RY, 1995, DEV DYNAM, V202, P101, DOI 10.1002/aja.1002020202; Sta Iglesia Drina D., 1998, Wound Repair and Regeneration, V6, P531; Wang YW, 1998, J CELL SCI, V111, P373; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; Zhao M, 1999, MOL BIOL CELL, V10, P1259, DOI 10.1091/mbc.10.4.1259; Zhao M, 1996, J CELL SCI, V109, P1405; Zhao M, 1997, CURR EYE RES, V16, P973, DOI 10.1076/ceyr.16.10.973.9014; Zhao M, 1996, INVEST OPHTH VIS SCI, V37, P2548; Zhao M, 1999, P NATL ACAD SCI USA, V96, P4942, DOI 10.1073/pnas.96.9.4942; Zieske JD, 2000, INVEST OPHTH VIS SCI, V41, P1346	47	143	153	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					857	+		10.1096/fj.01-0811fje	http://dx.doi.org/10.1096/fj.01-0811fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967227				2022-12-28	WOS:000175425900021
J	Villalobos, C; Nunes, L; Montero, M; Garcia, AG; Alonso, MT; Chamero, P; Alvarez, J; Garcia-Sancho, J				Villalobos, C; Nunes, L; Montero, M; Garcia, AG; Alonso, MT; Chamero, P; Alvarez, J; Garcia-Sancho, J			Redistribution of Ca2+ among cytosol and organella during stimulation of bovine chromaffin cells	FASEB JOURNAL			English	Article						calcium; mitochondria; aequorin; nucleus	ENDOPLASMIC-RETICULUM; SYMPATHETIC NEURONS; CALCIUM; MITOCHONDRIA; RELEASE; PARTICIPATION; MICRODOMAINS; CLEARANCE; AEQUORIN; KINETICS	Recent results indicate that Ca2+ transport by organella contributes to shaping Ca2+ signals and exocytosis in adrenal chromaffin cells. Therefore, accurate measurements of [Ca2+] inside cytoplasmic organella are essential for a comprehensive analysis of the Ca2+ redistribution that follows cell stimulation. Here we have studied changes in Ca2+ inside the endoplasmic reticulum, mitochondria, and nucleus by imaging aequorins targeted to these compartments in cells stimulated by brief depolarizing pulses with high K+ solutions. We find that Ca2+ entry through voltage-gated Ca2+ channels generates subplasmalemmal high [Ca2+](c) domains adequate for triggering exocytosis. A smaller increase of [Ca2+](c) is produced in the cell core, which is adequate for recruitment of the reserve pool of secretory vesicles to the plasma membrane. Most of the Ca2+ load is taken up by a mitochondrial pool, M1, closer to the plasma membrane; the increase of [Ca2+](M) stimulates respiration in these mitochondria, providing local support for the exocytotic process. Relaxation of the [Ca2+](c) transient is due to Ca2+ extrusion through the plasma membrane. At this stage, mitochondria release Ca2+ to the cytosol through the Na+/Ca2+ exchanger, thus maintaining [Ca2+](c) discretely increased, especially at core regions of the cell, for periods that outlast the duration of the stimulus.	Fac Med, Dept Bioquim & Fisiol, Consejo Super Invest Cient, E-47005 Valladolid, Spain; Univ Valladolid, IBGM, E-47005 Valladolid, Spain; Univ Autonoma Madrid, Fac Med, Dept Farmacol & Terapeut, Inst Teofilo Hernando, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Autonomous University of Madrid	Garcia-Sancho, J (corresponding author), Fac Med, IBGM, Dept Bioquim & Fisiol, E-47005 Valladolid, Spain.	jgsancho@ibgm.uva.es	Alvarez, Javier/K-8210-2014; Villalobos, Carlos/M-9839-2017; Alonso Alonso, Maria Teresa/K-5003-2014; Montero, Mayte/K-8212-2014; GARCIA, ANTONIO G/E-9961-2018; Garcia-Sancho, Javier/K-2975-2014	Alvarez, Javier/0000-0003-0636-5521; Villalobos, Carlos/0000-0002-0429-3846; Montero, Mayte/0000-0001-7702-6653; GARCIA, ANTONIO G/0000-0002-6517-3565; Nunez, Lucia/0000-0002-9638-5747; Garcia-Sancho, Javier/0000-0003-4573-7930; Chamero, Pablo/0000-0002-4305-1073				Alonso MT, 1998, CELL CALCIUM, V24, P87, DOI 10.1016/S0143-4160(98)90076-8; Alonso MT, 1999, J CELL BIOL, V144, P241, DOI 10.1083/jcb.144.2.241; Alvarez J, 1999, NEWS PHYSIOL SCI, V14, P161; Alvarez Javier, 2001, P147; ARTALEJO CR, 1987, J BIOL CHEM, V262, P915; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; Colegrove SL, 2000, J GEN PHYSIOL, V115, P351, DOI 10.1085/jgp.115.3.351; COLL KE, 1982, J BIOL CHEM, V257, P8696; DOUGLAS WW, 1968, BRIT J PHARMACOL, V34, P451, DOI 10.1111/j.1476-5381.1968.tb08474.x; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; FRAWLEY LS, 1994, ENDOCRINOLOGY, V135, P468, DOI 10.1210/en.135.1.468; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; HOLMAN ME, 1994, J PHYSIOL-LONDON, V478, P115, DOI 10.1113/jphysiol.1994.sp020235; Horikawa Y, 1998, BIOPHYS J, V74, P1579, DOI 10.1016/S0006-3495(98)77869-5; Mogami H, 1999, J PHYSIOL-LONDON, V518, P463, DOI 10.1111/j.1469-7793.1999.0463p.x; Montero M, 1997, FASEB J, V11, P881, DOI 10.1096/fasebj.11.11.9285486; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Montero M, 2001, MOL BIOL CELL, V12, P63, DOI 10.1091/mbc.12.1.63; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Naraghi M, 1998, BIOPHYS J, V75, P1635, DOI 10.1016/S0006-3495(98)77606-4; Neher E, 1998, CELL CALCIUM, V24, P345, DOI 10.1016/S0143-4160(98)90058-6; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Nunez L, 1995, AM J PHYSIOL-CELL PH, V269, pC1540, DOI 10.1152/ajpcell.1995.269.6.C1540; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; Park YB, 1996, J PHYSIOL-LONDON, V492, P329, DOI 10.1113/jphysiol.1996.sp021312; Petersen OH, 1996, TRENDS NEUROSCI, V19, P411; Pivovarova NB, 1999, J NEUROSCI, V19, P6372; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; Skulachev VP, 2001, TRENDS BIOCHEM SCI, V26, P23, DOI 10.1016/S0968-0004(00)01735-7; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; UCEDA G, 1995, EUR J PHARM-MOLEC PH, V289, P73, DOI 10.1016/0922-4106(95)90170-1; Xu T, 1997, BIOPHYS J, V73, P532, DOI 10.1016/S0006-3495(97)78091-3; ZHOU ZA, 1993, J PHYSIOL-LONDON, V469, P245, DOI 10.1113/jphysiol.1993.sp019813	44	103	105	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0343	10.1096/fj.01-0630com	http://dx.doi.org/10.1096/fj.01-0630com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874983				2022-12-28	WOS:000174755900026
J	Idzko, M; Panther, E; Corinti, S; Morelli, A; Ferrari, D; Herouy, Y; Dichmann, S; Mockenhaupt, M; Gebicke-Haerter, P; Di Virgilio, F; Girolomoni, G; Norgauer, J				Idzko, M; Panther, E; Corinti, S; Morelli, A; Ferrari, D; Herouy, Y; Dichmann, S; Mockenhaupt, M; Gebicke-Haerter, P; Di Virgilio, F; Girolomoni, G; Norgauer, J			Sphingosine 1-phosphate induces chemotaxis of immature dendritic cells and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses	FASEB JOURNAL			English	Article						Ca2+; actin polymerization; IL-12; IL-10	MULTIPLE SIGNALING PATHWAYS; G-PROTEINS; SPHINGOSINE-1-PHOSPHATE; RECEPTOR; ACTIVATION; ANGIOGENESIS; INHIBITION; PLATELETS; PHOSPHATE; SUBTYPES	Sphingosine 1-phosphate (S1P) is a potent extracellular lysolipid phosphoric acid mediator that is released after IgE-stimulation of mast cells. Here we investigated the biological activity and intracellular signaling of S1P on human dendritic cells (DC), which are specialized antigen presenting cells with the ability to migrate into peripheral tissues and lymph nodes, as well as control the activation of naive T cells. We show that immature and mature DC express the mRNA for different S1P receptors, such as endothelial differentiation gene (EDG)-1, EDG-3, EDG-5, and EDG-6. In immature DC, S1P stimulated pertussis toxin-sensitive Ca2+ increase actin-polymerization and chemotaxis. These responses were lost by DC matured with lipopolysaccharide. In maturing DC, however, S1P inhibited the secretion of tumor necrosis factor and interleukin (IL)-12, whereas it enhanced secretion of IL-10. As a consequence, mature DC exposed to S1P showed a reduced and increased capacity to generate allogeneic Th1 and Th2 responses, respectively. In summary, our study implicates that S1P might regulate the trafficking of DC and ultimately favor Th2 lymphocyte-dominated immunity.	Dept Expt Dermatol, D-79104 Freiburg, Germany; Ist Dermopatico Immacolata, Immunol Lab, Rome, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Ferrara	Norgauer, J (corresponding author), Dept Expt Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.	Norgauer@haut.ukl.uni-freiburg.de	GIROLOMONI, Giampiero/AAC-3405-2022; Ferrari, Davide/F-5644-2015; Eckhardt, Erik/G-1567-2010; Di Virgilio, Francesco/J-3754-2018; DI VIRGILIO, Francesco/O-4634-2019	Ferrari, Davide/0000-0002-5727-9204; Di Virgilio, Francesco/0000-0003-3566-1362; DI VIRGILIO, Francesco/0000-0003-3566-1362				Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Berger A, 1996, MOL PHARMACOL, V50, P451; BROCKLYN JR, 2000, BLOOD, V95, P2624; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dichmann S, 2000, J CELL PHYSIOL, V185, P394, DOI 10.1002/1097-4652(200012)185:3<394::AID-JCP9>3.3.CO;2-Q; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; la Sala A, 2001, J IMMUNOL, V166, P1611, DOI 10.4049/jimmunol.166.3.1611; Lanzavecchia A, 2000, SCIENCE, V290, P92, DOI 10.1126/science.290.5489.92; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Panther E, 2001, FASEB J, V15, P1963, DOI 10.1096/fj.01-0169com; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Siffert W, 1998, NAT GENET, V18, P45, DOI 10.1038/ng0198-45; Sozzani S, 2000, J CLIN IMMUNOL, V20, P151, DOI 10.1023/A:1006659211340; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Wollenberg A, 2000, CLIN EXP DERMATOL, V25, P530, DOI 10.1046/j.1365-2230.2000.00699.x; Yatomi Y, 2000, BLOOD, V96, P3431; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	37	155	158	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					625	+		10.1096/fj.01-0625fje	http://dx.doi.org/10.1096/fj.01-0625fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919175				2022-12-28	WOS:000174203700011
J	Pance, A; Chantome, A; Reveneau, S; Bentrari, F; Jeannin, JF				Pance, A; Chantome, A; Reveneau, S; Bentrari, F; Jeannin, JF			A repressor in the proximal human inducible nitric oxide synthase promoter modulates transcriptional activation	FASEB JOURNAL			English	Article						AP-1; repressor; transcriptional regulation; NOSII	CYTOKINE INDUCTION; MOLECULAR-CLONING; AP-1 REPRESSOR; DLD-1 CELLS; L-ARGININE; GENE; EXPRESSION; INHIBITION; REQUIRES; NITRATE	The human inducible nitric oxide synthase (iNOS or NOSII) gene is regulated through an extended and complex promoter. In this study, the transcriptional regulation of human NOSII is investigated in the human colon cell line HCT-8R. Stimulation with a cytokine mix (interferon-gamma, interleukin 1-beta, and tumor necrosis factor alpha) induces NOSII mRNA accumulation, as well as promoter activity in these cells. Several random deletions were performed within the proximal 7 kb of the promoter, which led to the identification of a region, whose deletion provokes a marked increase in transcriptional activity upon cytokine stimulation. Furthermore, this region is shown to repress a viral-driven luciferase construct, mainly at basal levels. An AP-1-like sequence present in this region that is specifically recognized by nuclear proteins is shown to be involved in the repressive effect. This element is capable of repressing a viral promoter, and its deletion augments cytokine-stimulated transcription. These findings are confirmed in various cell lines and suggest a general mechanism for the control of basal levels of NOSII expression, to avoid unnecessary toxicity under normal conditions.	Univ Bourgogne, Fac Med, Ecole Prat Hautes Etud, Canc Immunotherapy Lab, F-21000 Dijon, France; Univ Bourgogne, Fac Med, INSERM, U517, F-21000 Dijon, France	Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Pance, A (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	apance@reacciun.ve	Pance, Alena/AAH-2878-2021	Pance, Alena/0000-0002-9017-2644				Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; BUNE AJ, 1995, FEBS LETT, V366, P127, DOI 10.1016/0014-5793(95)00495-U; CHU SC, 1995, J BIOL CHEM, V270, P10625, DOI 10.1074/jbc.270.18.10625; Chu SC, 1998, BIOCHEM BIOPH RES CO, V248, P871, DOI 10.1006/bbrc.1998.9062; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Goldring CEP, 2000, FASEB J, V14, P2393; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; Laubach VE, 1997, BBA-GENE STRUCT EXPR, V1351, P287, DOI 10.1016/S0167-4781(96)06909-6; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; Patterson T, 2001, ONCOGENE, V20, P634, DOI 10.1038/sj.onc.1204134; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; Prabhakar SS, 2001, AM J PHYSIOL-RENAL, V281, pF179, DOI 10.1152/ajprenal.2001.281.1.F179; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Ravi R, 1998, CANCER RES, V58, P4531; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316	30	25	26	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					631	+		10.1096/fj.01-0450fje	http://dx.doi.org/10.1096/fj.01-0450fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919177				2022-12-28	WOS:000174203700005
J	Yu, XX; Lewin, DA; Forrest, W; Adams, SH				Yu, XX; Lewin, DA; Forrest, W; Adams, SH			Cold elicits the simultaneous induction of fatty acid synthesis and beta-oxidation in murine brown adipose tissue: prediction from differential gene expression and confirmation in vivo	FASEB JOURNAL			English	Article						PPAR; glucose transport; obesity; ACC	COENZYME-A CARBOXYLASE; MITOCHONDRIAL RESPIRATION; PYRUVATE-DEHYDROGENASE; GLYCEROLIPID SYNTHESIS; GLUCOSE-TRANSPORTER; UNCOUPLING PROTEIN; RAT; EXPOSURE; INSULIN; INVIVO	A survey of genes differentially expressed in the brown adipose tissue (BAT) of mice exposed to a range of environmental temperatures was carried out to identify novel genes and pathways associated with the transition of this tissue toward an amplified thermogenic state. The current report focuses on an analysis of the expression patterns of 50 metabolic genes in BAT under control conditions (22degrees C), cold exposure (4degrees C, 1 to 48 h), warm acclimation (33degrees C, 3 wk), or food restriction/meal feeding (animals fed the same amount as warm mice). In general, expression of genes encoding proteins involving glucose uptake and catabolism was significantly elevated in the BAT of cold-exposed mice. The levels of mRNAs encoding proteins critical to de novo lipogenesis were also increased. Gene expression for enzymes associated with procurement and combustion of long chain fatty acids (LCFAs) was increased in the cold. Thus, a model was proposed in which coordinated activation of glucose uptake, fatty acid synthesis, and fatty acid combustion occurs as part of the adaptive thermogenic processes in BAT. Confirmation emerged from in vivo assessments of cold-induced changes in BAT 2-deoxyglucose uptake (increased 2.7-fold), BAT lipogenesis (2.8-fold higher), and incorporation of LCFA carboxyl-carbon into BAT water-soluble metabolites (elevated similar totwofold). It is proposed that temperature-sensitive regulation of distinct intracellular malonyl-CoA pool sizes plays an important role in driving this unique metabolic profile via maintenance of the lipogenic pool but diminution of the carnitine palmitoyltransferase 1 inhibitory pool under cold conditions.	Genentech Inc, Dept Endocrinol, San Francisco, CA 94080 USA; Genentech Inc, Dept Biostat, San Francisco, CA 94080 USA; CuraGen Corp, Dept Collaborat Res, New Haven, CT 06511 USA	Roche Holding; Genentech; Roche Holding; Genentech	Adams, SH (corresponding author), Novartis Pharmaceut Corp, Metab & Cardiovasc Dis Pharmacol Dept, 556 Morris Ave, Summit, NJ 07901 USA.	adams@pharma.novartis.com	ADAMS, SEAN/N-9262-2018	ADAMS, SEAN/0000-0002-9515-2319				Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Adams SH, 2001, BIOCHEM J, V360, P135, DOI 10.1042/bj3600135; BIANCHI A, 1990, J BIOL CHEM, V265, P1502; BUCKLEY MG, 1987, BIOCHEM J, V243, P437, DOI 10.1042/bj2430437; Clarke SD, 2001, J NUTR, V131, P1129, DOI 10.1093/jn/131.4.1129; Daikoku T, 2000, BBA-BIOENERGETICS, V1457, P263, DOI 10.1016/S0005-2728(00)00107-9; DARNLEY AC, 1988, BIOCHEM J, V253, P351, DOI 10.1042/bj2530351; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fukuda H, 1999, J BIOCHEM-TOKYO, V126, P437, DOI 10.1093/oxfordjournals.jbchem.a022469; GRANNEMAN JG, 1992, ENDOCRINOLOGY, V130, P109, DOI 10.1210/en.130.1.109; Guardiola-Diaz HM, 1999, J BIOL CHEM, V274, P23368, DOI 10.1074/jbc.274.33.23368; Guerra C, 1998, J CLIN INVEST, V102, P1724, DOI 10.1172/JCI4532; HIMMSHAGEN J, 1965, CAN J PHYSIOL PHARM, V43, P379, DOI 10.1139/y65-039; HIMMSHAGEN J, 1985, AM J PHYSIOL, V248, pE531, DOI 10.1152/ajpendo.1985.248.5.E531; HIMMSHAGEN J, 1998, HDB OBESITY; HOM FG, 1984, DIABETES, V33, P141, DOI 10.2337/diabetes.33.2.141; Klingenberg M, 1999, J BIOENERG BIOMEMBR, V31, P419, DOI 10.1023/A:1005440221914; KNIGHT BL, 1972, BIOCHEM J, V129, P1175, DOI 10.1042/bj1291175; Mardia K., 1979, MULTIVARIATE ANAL, V15, P518; MARETTE A, 1990, INT J OBESITY, V14, P857; MARETTE A, 1991, BIOCHEM J, V277, P119, DOI 10.1042/bj2770119; MASORO EJ, 1963, FED PROC, V22, P868; MCCORMACK JG, 1977, BIOCHEM J, V166, P627, DOI 10.1042/bj1660627; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MITCHELL JRD, 1991, BIOCHEM J, V277, P665, DOI 10.1042/bj2770665; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Ntambi JM, 1999, J LIPID RES, V40, P1549; OMATSUKANBE M, 1992, FEBS LETT, V314, P246, DOI 10.1016/0014-5793(92)81481-Z; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; RATH EA, 1979, FEBS LETT, V108, P33, DOI 10.1016/0014-5793(79)81172-2; Reszko AE, 2001, ANAL BIOCHEM, V298, P69, DOI 10.1006/abio.2001.5349; REVELLI JP, 1992, BIOCHEM J, V286, P743, DOI 10.1042/bj2860743; Saha AK, 2000, J BIOL CHEM, V275, P24279, DOI 10.1074/jbc.C000291200; SHIMIZU Y, 1993, AM J PHYSIOL, V264, pE890, DOI 10.1152/ajpendo.1993.264.6.E890; SHIMIZU Y, 1991, J BIOCHEM, V110, P688, DOI 10.1093/oxfordjournals.jbchem.a123642; Shimkets RA, 1999, NAT BIOTECHNOL, V17, P798, DOI 10.1038/11743; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STANSBIE D, 1976, BIOCHEM J, V160, P413, DOI 10.1042/bj1600413; STEINER G, 1964, AM J PHYSIOL, V207, P840, DOI 10.1152/ajplegacy.1964.207.4.840; TAKAHASHI A, 1992, JPN J PHYSIOL, V42, P653, DOI 10.2170/jjphysiol.42.653; TRAYHURN P, 1979, FEBS LETT, V104, P13, DOI 10.1016/0014-5793(79)81075-3; VALLERAND AL, 1987, AM J PHYSIOL, V253, pE179, DOI 10.1152/ajpendo.1987.253.2.E179; VALLERAND AL, 1990, AM J PHYSIOL, V259, pR1043, DOI 10.1152/ajpregu.1990.259.5.R1043; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Yu XX, 2001, BIOCHEM J, V353, P369, DOI 10.1042/bj3530369; Yu XX, 2000, AM J PHYSIOL-ENDOC M, V279, pE433, DOI 10.1152/ajpendo.2000.279.2.E433	47	154	156	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					155	168		10.1096/fj.01-0568com	http://dx.doi.org/10.1096/fj.01-0568com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11818363				2022-12-28	WOS:000174203700020
J	Chilov, D; Hofer, T; Bauer, C; Wenger, RH; Gassmann, M				Chilov, D; Hofer, T; Bauer, C; Wenger, RH; Gassmann, M			Hypoxia affects expression of circadian genes PER1 and CLOCK in mouse brain	FASEB JOURNAL			English	Article						circadian clock; hypoxia; HIF; PAS proteins	SUPRACHIASMATIC NUCLEUS; MESSENGER-RNA; INDUCIBLE FACTOR-1-ALPHA; RHYTHMIC EXPRESSION; PERIOD HOMOLOGS; HIF-ALPHA; PROTEIN; SLEEP; CLONING; MPER2	The key elements of circadian clockwork and oxygen homeostasis are the PAS protein family members PER and CLOCK and hypoxia-inducible factor 1 alpha (HIF-1 alpha). The PAS domain serves as an interface for protein-protein interactions. We asked whether a cross-talk exists between the PAS components of hypoxic and circadian pathways. We found several isoforms of PER1 protein that exhibit tissue-specific size differences. In the mouse brain, a predominantly nuclear 48 kDa isoform that followed a daily rhythm was observed. The 48 kDa form was found in the nuclear fractions derived from mouse liver, Swiss3T3 fibroblasts, and N2A neuroblastoma cells. In mouse kidney and human 293 kidney cells, a 55 kDa PER1 form was detected. CLOCK was observed as a predicted 100 kDa protein in rat-1 cells and in all analyzed mouse tissues including brain, liver, kidney, and spleen. In contrast to PER1, CLOCK protein expression was not rhythmic. Exposure to hypoxia led to increased PER1 and CLOCK protein levels in mice. Based on coimmunoprecipitation experiments that showed protein-protein interaction between PER1 and the a subunit of HIF-1, we suggest that these hypoxic effects may be modulated by HIF-1 alpha.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Vet Physiol, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich	Gassmann, M (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	maxg@access.unizh.ch	Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839; chilov, dmitri/0000-0002-2279-0854				Akashi M, 2000, GENE DEV, V14, P645; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Bae K, 2001, NEURON, V30, P525, DOI 10.1016/S0896-6273(01)00302-6; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Chavez JC, 2000, J APPL PHYSIOL, V89, P1937, DOI 10.1152/jappl.2000.89.5.1937; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; COOTE JH, 1992, EUR J APPL PHYSIOL O, V64, P178, DOI 10.1007/BF00717957; COOTE JH, 1993, EUR J APPL PHYSIOL O, V66, P249, DOI 10.1007/BF00235102; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Edery I, 1999, CHRONOBIOL INT, V16, P377, DOI 10.3109/07420529908998716; Edery I, 2000, PHYSIOL GENOMICS, V3, P59, DOI 10.1152/physiolgenomics.2000.3.2.59; Foulkes NS, 1997, TRENDS NEUROSCI, V20, P487, DOI 10.1016/S0166-2236(97)01109-0; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Gorlach A, 2000, BBA-GENE STRUCT EXPR, V1493, P125, DOI 10.1016/S0167-4781(00)00172-X; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALE B, 1984, J APPL PHYSIOL, V57, P1564, DOI 10.1152/jappl.1984.57.5.1564; Hastings M H, 1999, J Neurosci, V19, pRC11; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hofer T, 2001, FASEB J, V15, P2715, DOI 10.1096/fj.01-0546fje; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 2000, J NEUROSCI, V20, part. no.; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Honma S, 1998, BIOCHEM BIOPH RES CO, V250, P83, DOI 10.1006/bbrc.1998.9275; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Kozak KR, 1997, DEV BIOL, V191, P297, DOI 10.1006/dbio.1997.8758; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lawler JF, 1998, J BIOL CHEM, V273, P5053, DOI 10.1074/jbc.273.9.5053; Liu Y, 1998, SCIENCE, V281, P825, DOI 10.1126/science.281.5378.825; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maywood ES, 1999, P NATL ACAD SCI USA, V96, P15211, DOI 10.1073/pnas.96.26.15211; MROSOVSKY N, 1991, J BIOL RHYTHM, V6, P167, DOI 10.1177/074873049100600207; Oishi K, 2000, BIOCHEM BIOPH RES CO, V268, P164, DOI 10.1006/bbrc.1999.2054; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; POLLARD MJ, 1987, J APPL PHYSIOL, V63, P2189, DOI 10.1152/jappl.1987.63.6.2189; PROSSER RA, 1989, J NEUROSCI, V9, P1073; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Reppert SM, 1997, CELL, V89, P487, DOI 10.1016/S0092-8674(00)80229-9; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sakamoto K, 1998, J BIOL CHEM, V273, P27039, DOI 10.1074/jbc.273.42.27039; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Schibler U, 1999, J SLEEP RES, V8, P1; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Steeves TDL, 1999, GENOMICS, V57, P189, DOI 10.1006/geno.1998.5675; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Takahata S, 1998, BIOCHEM BIOPH RES CO, V248, P789, DOI 10.1006/bbrc.1998.9012; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Wager-Smith K, 2000, NAT GENET, V26, P23, DOI 10.1038/79134; Weaver DR, 1998, J BIOL RHYTHM, V13, P100, DOI 10.1177/074873098128999952; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845; Wenger RH, 1996, BLOOD, V87, P756, DOI 10.1182/blood.V87.2.756.bloodjournal872756; Wenger RH, 1997, BIOL CHEM, V378, P609; Yagita K, 2000, FEBS LETT, V465, P79, DOI 10.1016/S0014-5793(99)01724-X; Yagita K, 2001, SCIENCE, V292, P278, DOI 10.1126/science.1059542; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	85	98	101	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2613	2622		10.1096/fj.01-0092com	http://dx.doi.org/10.1096/fj.01-0092com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726537				2022-12-28	WOS:000172964800031
J	Negro, A; Brunati, AM; Donella-Deana, A; Massimino, ML; Pinna, LA				Negro, A; Brunati, AM; Donella-Deana, A; Massimino, ML; Pinna, LA			Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation	FASEB JOURNAL			English	Article						Syk tyrosine kinase; tyrosine phosphorylation; alpha-synuclein multimerization; regulation by phosphorylation; protein kinase CK2	A-BETA COMPONENT; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; SEQUENTIAL PHOSPHORYLATION; PRECURSOR PROTEIN; OXIDATIVE STRESS; 14-KDA PROTEIN; HS1 PROTEIN; LEWY BODIES; C-FGR	The presence of aggregated alpha -synuclein molecules is a common denominator in a variety of neurodegenerative disorders. Here, we show that alpha -synuclein (alpha -syn) is an outstanding substrate for the protein tyrosine kinase p72(syk) (Syk), which phosphorylates three tyrosyl residues in its C-terminal domain (Y-125, Y-133, and Y-136), as revealed from experiments with mutants where these residues have been individually or multiply replaced by phenylalanine. In contrast, only Y-125 is phosphorylated by Lyn and c-Fgr. Eosin-induced multimerization is observed with wildtype alpha -syn, either phosphorylated or not by Lyn, and with all its Tyr to Phe mutants but not with the protein previously phosphorylated by Syk. Syk-mediated phosphorylation also counteracts syn assembly into filaments as judged from the disappearance of alpha -syn precipitated upon centrifugation at 100,000 x g. We also show that Syk and alpha -syn colocalize in the brain, and upon cotransfection in Chinese hamster ovary cells, alpha -syn becomes Tyr-phosphorylated by Syk. Moreover, Syk and alpha -syn interact with each other as judged from the mammalian two-hybrid system approach. These data suggest that Syk or tyrosine kinase(s) with similar specificity may play an antineurodegenerative role by phosphorylating alpha -syn, thereby preventing its aggregation.	Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Studio Biomembrane, I-35121 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Pinna, LA (corresponding author), Univ Padua, Dipartimento Chim Biol, Viale G Colombo 3, I-35121 Padua, Italy.	pinna@civ.bio.unipd.it	Brunati, Anna Maria/I-8136-2018; Massimino, Maria Lina/AAX-8773-2020	Brunati, Anna Maria/0000-0002-3481-9503; NEGRO, ALESSANDRO/0000-0003-3142-7632; massimino, maria lina/0000-0002-1839-1404				BROOKES AJ, 1994, TRENDS NEUROSCI, V17, P404, DOI 10.1016/0166-2236(94)90013-2; Brunati AM, 2000, BLOOD, V96, P1550, DOI 10.1182/blood.V96.4.1550.h8001550_1550_1557; Brunati AM, 2000, FEBS LETT, V471, P151, DOI 10.1016/S0014-5793(00)01378-8; Brunati AM, 1999, J BIOL CHEM, V274, P7557, DOI 10.1074/jbc.274.11.7557; BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; BRUNATI AM, 1992, FEBS LETT, V313, P291, DOI 10.1016/0014-5793(92)81212-5; BRUNATI AM, 1993, EUR J BIOCHEM, V216, P323, DOI 10.1111/j.1432-1033.1993.tb18149.x; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; DonellaDeana A, 1996, EUR J BIOCHEM, V235, P18, DOI 10.1111/j.1432-1033.1996.00018.x; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; FEARON ER, 1992, P NATL ACAD SCI USA, V89, P7958, DOI 10.1073/pnas.89.17.7958; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; Kaytor MD, 1999, J BIOL CHEM, V274, P37507, DOI 10.1074/jbc.274.53.37507; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Marks Friedrich, 1996, P1, DOI 10.1002/9783527615032.ch1; MEGGIO F, 1981, J BIOL CHEM, V256, P1958; NAKAJO S, 1990, J NEUROCHEM, V55, P2031, DOI 10.1111/j.1471-4159.1990.tb05792.x; NAKAJO S, 1993, EUR J BIOCHEM, V217, P1057, DOI 10.1111/j.1432-1033.1993.tb18337.x; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V280, P1085, DOI 10.1006/bbrc.2000.4253; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Pulgar V, 1999, EUR J BIOCHEM, V260, P520, DOI 10.1046/j.1432-1327.1999.00195.x; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Ruzzene M, 1996, BIOCHEMISTRY-US, V35, P5327, DOI 10.1021/bi9528614; Shin HJ, 2000, BBA-PROTEIN STRUCT M, V1481, P139, DOI 10.1016/S0167-4838(00)00106-0; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Trojanowski JQ, 2001, PARKINSONISM RELAT D, V7, P247, DOI 10.1016/S1353-8020(00)00065-1; Tsujimura T, 2001, FEBS LETT, V489, P129, DOI 10.1016/S0014-5793(01)02097-X; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Yamanashi Y, 1997, J EXP MED, V185, P1387, DOI 10.1084/jem.185.7.1387; Yoneya H, 1998, BIOCHEM BIOPH RES CO, V245, P140, DOI 10.1006/bbrc.1998.8309; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141	44	82	84	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					210	+		10.1096/fj.01-0517fje	http://dx.doi.org/10.1096/fj.01-0517fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11744621				2022-12-28	WOS:000172964800017
J	Virador, VM; Muller, J; Wu, XF; Abdel-Malek, ZA; Yu, ZX; Ferrans, VJ; Kobayashi, N; Wakamatsu, K; Ito, S; Hammer, JA; Hearing, VJ				Virador, VM; Muller, J; Wu, XF; Abdel-Malek, ZA; Yu, ZX; Ferrans, VJ; Kobayashi, N; Wakamatsu, K; Ito, S; Hammer, JA; Hearing, VJ			Influence of alpha-melanocyte-stimulating hormone and of ultraviolet radiation on the transfer of melanosomes to keratinocytes	FASEB JOURNAL			English	Article						skin color; tanning; melanosome transfer	MOUSE MELANOCYTES; EPIDERMAL-KERATINOCYTES; IN-VITRO; PROTEIN; CELLS; EXOCYTOSIS; SYNTAXIN-4; TRANSPORT; SECRETION; SNAP-23	The epidermal melanin unit in human skin is composed of melanocytes and keratinocytes. Melanocytes, located in the basal layer of the epidermis, manufacture melanin-loaded organelles called melanosomes. Through their dendritic processes, melanocytes distribute melanosomes to neighboring keratinocytes, where their presence confers to the skin its characteristic color and photoprotective properties. In this study, we used murine melanocytes and keratinocytes alone and in coculture to characterize the processes involved in melanosome transfer. Ultraviolet (UV) radiation induced an accumulation of melanosomes in melanocytes, whereas treatment with alpha -melanocyte-stimulating hormone (MSH) induced exocytosis of melanosomes accompanied by ruffling of the melanocyte membrane. We found that keratinocytes phagocytose melanosomes and latex beads equally well and that this phagocytic process was increased by exposure of keratinocytes to UV radiation or to MSH. Coculture of melanocytes and keratinocytes resulted in an increase in MSH released to the medium. Gene array analysis of MSH-treated melanocytes showed up-regulation of many genes associated with exocytosis. In our studies, we never observed cytophagocytosis of melanosome-filled processes. This result, together with the other findings, suggests that a combination of signals that increase melanosome production and release by melanocytes and that stimulate phagocytosis by keratinocytes are the most relevant mechanisms involved in skin tanning.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Div Viral Prod, Bethesda, MD 20892 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Cincinnati, Dept Dermatol, Cincinnati, OH 45267 USA; NHLBI, Pathol Sect, Bethesda, MD 20892 USA; Nara Med Univ, Dept Dermatol, Kashihara, Nara 634, Japan; Fujita Hlth Univ, Sch Hlth Sci, Dept Chem, Toyoake, Aichi 4701192, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Nara Medical University; Fujita Health University	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Room 1B25, Bethesda, MD 20892 USA.	hearingv@nih.gov	Virador, Victoria M./A-8173-2009; Wakamatsu, Kazumasa/AAZ-5877-2020	Wakamatsu, Kazumasa/0000-0003-1748-9001; Ito, Shosuke/0000-0001-9182-5144				Abdel-Malek ZA, 2001, J CELL SCI, V114, P1019; Bandorowicz-Pikula J, 2001, BIOESSAYS, V23, P170, DOI 10.1002/1521-1878(200102)23:2<170::AID-BIES1024>3.0.CO;2-#; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Berg EA, 2000, J NEUROSCI RES, V62, P830, DOI 10.1002/1097-4547(20001215)62:6<830::AID-JNR10>3.3.CO;2-5; Bessou-Touya S, 1998, J INVEST DERMATOL, V111, P1103, DOI 10.1046/j.1523-1747.1998.00405.x; BIRBECK MSC, 1956, EXP CELL RES, V10, P505, DOI 10.1016/0014-4827(56)90022-2; Bock JB, 1999, P NATL ACAD SCI USA, V96, P12227, DOI 10.1073/pnas.96.22.12227; Breuza L, 2000, AM J PHYSIOL-CELL PH, V279, pC1239, DOI 10.1152/ajpcell.2000.279.4.C1239; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; Chen D, 2000, BLOOD, V96, P1782, DOI 10.1182/blood.V96.5.1782.h8001782_1782_1788; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; Dillon SR, 2001, J IMMUNOL, V166, P58, DOI 10.4049/jimmunol.166.1.58; DIMENT S, 1995, J BIOL CHEM, V270, P4213, DOI 10.1074/jbc.270.9.4213; Faigle W, 2000, MOL BIOL CELL, V11, P3485, DOI 10.1091/mbc.11.10.3485; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Golczak M, 2001, FEBS LETT, V496, P49, DOI 10.1016/S0014-5793(01)02402-4; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Hodel A, 2000, BIOCHEM J, V350, P637, DOI 10.1042/0264-6021:3500637; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; ITO S, 1985, ANAL BIOCHEM, V144, P527, DOI 10.1016/0003-2697(85)90150-2; Jimbow K., 1998, PIGMENTARY SYSTEM, P107; Kippenberger S, 1997, PIGM CELL RES, V10, P85, DOI 10.1111/j.1600-0749.1997.tb00472.x; Kits KS, 2000, BRAIN RES REV, V33, P78, DOI 10.1016/S0165-0173(00)00023-0; KLAUS SN, 1969, ARCH DERMATOL, V100, P756, DOI 10.1001/archderm.100.6.756; Koh DS, 2000, J GEN PHYSIOL, V116, P507, DOI 10.1085/jgp.116.4.507; Lee YS, 1997, MOL CARCINOGEN, V18, P44, DOI 10.1002/(SICI)1098-2744(199701)18:1<44::AID-MC6>3.0.CO;2-R; LEVINE N, 1991, JAMA-J AM MED ASSOC, V266, P2730, DOI 10.1001/jama.266.19.2730; MINWALLA L, 2001, IN PRESS PIGMENT CEL; MISAKI Y, 1994, J BIOL CHEM, V269, P4240; OKAZAKI K, 1976, J INVEST DERMATOL, V67, P541, DOI 10.1111/1523-1747.ep12664554; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; ORTONNE JP, 1990, J INT MED RES, V18, pC8; Perego L, 1997, MOL REPROD DEV, V47, P370, DOI 10.1002/(SICI)1098-2795(199708)47:4&lt;370::AID-MRD3&gt;3.0.CO;2-H; Potterf SB, 1996, J BIOL CHEM, V271, P4002; Rosenquist M, 2000, J MOL EVOL, V51, P446, DOI 10.1007/s002390010107; Roth D, 1999, FEBS LETT, V460, P411, DOI 10.1016/S0014-5793(99)01383-6; Sadoul K, 1997, J BIOL CHEM, V272, P33023, DOI 10.1074/jbc.272.52.33023; Scott G, 2001, J INVEST DERMATOL, V116, P296, DOI 10.1046/j.1523-1747.2001.01221.x; SEIBERG M, 2001, IN PRESS PIGMENT CEL; SERVENTI IM, 1993, J BIOL CHEM, V268, P4863; Sharlow ER, 2000, J CELL SCI, V113, P3093; Stewart BA, 2000, P NATL ACAD SCI USA, V97, P13955, DOI 10.1073/pnas.250491397; Tarsounas M, 1999, J CELL BIOL, V147, P207, DOI 10.1083/jcb.147.2.207; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Virador VM, 1999, ANAL BIOCHEM, V270, P207, DOI 10.1006/abio.1999.4090; Virador VM, 2000, EXP CELL RES, V259, P54, DOI 10.1006/excr.2000.4975; WOLFF K, 1974, J ULTRA MOL STRUCT R, V47, P400, DOI 10.1016/S0022-5320(74)90017-3; WOLFF K, 1972, J ULTRA MOL STRUCT R, V39, P262, DOI 10.1016/S0022-5320(72)90022-6; Wu XF, 1997, J CELL SCI, V110, P847; Wu XF, 2000, PIGM CELL RES, V13, P241, DOI 10.1034/j.1600-0749.2000.130405.x; YAMAMOTO O, 1994, PIGM CELL RES, V7, P158, DOI 10.1111/j.1600-0749.1994.tb00044.x; YUSPA SH, 1983, CARCINOGENESIS, V4, P1413, DOI 10.1093/carcin/4.11.1413	53	119	124	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					105	+		10.1096/fj.01-0518fje	http://dx.doi.org/10.1096/fj.01-0518fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11729101				2022-12-28	WOS:000172420500031
J	Engelhardt, S; Boknik, P; Keller, U; Neumann, J; Lohse, MJ; Hein, L				Engelhardt, S; Boknik, P; Keller, U; Neumann, J; Lohse, MJ; Hein, L			Early impairment of calcium handling and altered expression of junctin in hearts of mice overexpressing the beta(1)-adrenergic receptor	FASEB JOURNAL			English	Article						transgenic mouse; heart failure; triadin; sarcoplasmic reticulum	CALSEQUESTRIN-BINDING-PROTEIN; SARCOPLASMIC-RETICULUM; BETA(2)-ADRENERGIC RECEPTOR; MYOCARDIAL-FUNCTION; CA2+ TRANSPORT; MOUSE HEARTS; IN-VIVO; PHOSPHOLAMBAN; GENE; FAILURE	Chronic stimulation of cardiac beta (1)-adrenergic receptors contributes to disease progression and mortality in patients and animal models of heart failure. To search for the mechanism of adrenergic impairment of cardiac function in vivo, we studied transgenic mice with cardiac-specific overexpression of beta (1)-adrenergic receptors. Transgenic mice with cardiac overexpression of beta (1)-adrenergic receptors showed progressive left ventricular fibrosis starting at 4 months of age. Left ventricular catheterization revealed a modest enhancement of contractility and relaxation at 2 months of age, followed by progressive dysfunction in both parameters and ultimately cardiac failure. When the effects of endogenous catecholamines were blocked by the beta -receptor antagonist propranolol, maximal rate of contractility (dp/dt(max)) and maximal rate of relaxation (dp/dt(min)) were significantly blunted in 2-month-old beta (1)-receptor transgenic mice. Isolated cardiomyocytes from these animals displayed markedly altered calcium transients with significant prolongation of the intracellular calcium transient compared with nontransgenic littermates. We determined the expression of sarcoplasmic reticulum proteins involved in calcium handling by RNase protection assay and by immunoblotting. Although the expression of calsequestrin, triadin, and phospholamban was not altered, we observed a progressive decrease in junctin abundance in beta (1)-receptor transgenic mice (P<0.001 TG vs. WT). Altered expression of the sarcoplasmic reticulum protein junctin may be involved in the pathogenesis of cardiac failure after chronic stimulation of <beta>(1)-adrenergic receptors.	Univ Wurzburg, Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany; Univ Munster, Inst Pharmakol & Toxikol, D-4400 Munster, Germany	University of Wurzburg; University of Munster	Lohse, MJ (corresponding author), Univ Wurzburg, Inst Pharmakol & Toxikol, Versbacher Str 9, D-97078 Wurzburg, Germany.	lohse@toxi.uni-wuerzburg.de	Engelhardt, Stefan/AAA-9329-2019; Lohse, Martin J/A-7160-2012	Engelhardt, Stefan/0000-0001-5378-8661; Lohse, Martin J/0000-0002-0599-3510				Akhter SA, 1997, P NATL ACAD SCI USA, V94, P12100, DOI 10.1073/pnas.94.22.12100; Bisognano JD, 2000, J MOL CELL CARDIOL, V32, P817, DOI 10.1006/jmcc.2000.1123; BRILLANTES AM, 1992, CIRC RES, V71, P18, DOI 10.1161/01.RES.71.1.18; Bristow MR, 2000, CIRCULATION, V101, P558, DOI 10.1161/01.CIR.101.5.558; Brodde OE, 1999, PHARMACOL REV, V51, P651; BRODDE OE, 1993, PHARMACOL THERAPEUT, V60, P405, DOI 10.1016/0163-7258(93)90030-H; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; Hajjar RJ, 1997, CIRCULATION, V95, P423; Harding VB, 2001, P NATL ACAD SCI USA, V98, P5809, DOI 10.1073/pnas.091102398; HASENFUSS G, 1994, CIRC RES, V75, P434, DOI 10.1161/01.RES.75.3.434; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; Hjalmarson A, 1999, LANCET, V353, P2001; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; Kirchhefer U, 2001, J BIOL CHEM, V276, P4142, DOI 10.1074/jbc.M006443200; Knollmann BC, 2000, J PHYSIOL-LONDON, V525, P483, DOI 10.1111/j.1469-7793.2000.t01-1-00483.x; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Lechat P, 1999, LANCET, V353, P9; Liggett SB, 2000, CIRCULATION, V101, P1707; Linck B, 2000, J PHARMACOL EXP THER, V294, P648; Loukianov E, 1998, CIRC RES, V83, P889; Lowes BD, 2000, CLIN CARDIOL, V23, P11; MacMahon S, 1997, LANCET, V349, P375; Maurice JP, 1999, J CLIN INVEST, V104, P21, DOI 10.1172/JCI6026; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; MOVSESIAN MA, 1994, CIRCULATION, V90, P653, DOI 10.1161/01.CIR.90.2.653; Neumann J, 1998, J MOL CELL CARDIOL, V30, P1991, DOI 10.1006/jmcc.1998.0760; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Rockman HA, 1996, J CLIN INVEST, V97, P1618, DOI 10.1172/JCI118587; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; RONA G, 1985, J MOL CELL CARDIOL, V17, P291, DOI 10.1016/S0022-2828(85)80130-9; Shah AS, 2000, CIRCULATION, V101, P408, DOI 10.1161/01.CIR.101.4.408; Shorofsky SR, 1999, CIRC RES, V84, P424, DOI 10.1161/01.RES.84.4.424; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Steinberg SF, 1999, CIRC RES, V85, P1101; VATNER DE, 1994, CIRCULATION, V90, P1423, DOI 10.1161/01.CIR.90.3.1423; White DC, 2000, P NATL ACAD SCI USA, V97, P5428, DOI 10.1073/pnas.090091197; Wiesmann F, 2001, CIRC RES, V88, P563, DOI 10.1161/01.RES.88.6.563; Xiao RP, 1999, CIRC RES, V85, P1092; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; Yamaguchi N, 1998, BIOCHEM J, V335, P541, DOI 10.1042/bj3350541; Zaugg M, 2000, CIRCULATION, V102, P344; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; Zhang L, 2001, J MOL CELL CARDIOL, V33, P233, DOI 10.1006/jmcc.2000.1295	49	50	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2718	+		10.1096/fj.01-0107fje	http://dx.doi.org/10.1096/fj.01-0107fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606476				2022-12-28	WOS:000171920400017
J	Enshell-Seijffers, D; Smelyanski, L; Vardinon, N; Yust, I; Gershoni, JM				Enshell-Seijffers, D; Smelyanski, L; Vardinon, N; Yust, I; Gershoni, JM			Dissection of the humoral immune response toward an immunodominant epitope of HIV: a model for the analysis of antibody diversity in HIV plus individuals	FASEB JOURNAL			English	Article						AIDS; phage display; humoral response; peptides	HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODIES; RANDOM PEPTIDE LIBRARIES; NEUTRALIZING ANTIBODIES; TRANSMEMBRANE GLYCOPROTEIN; PASSIVE-IMMUNIZATION; PROTECTIVE IMMUNITY; AFFINITY MATURATION; GLOBULIN THERAPY; HUMAN SERA	Understanding the dynamics of the humoral immune response to HIV epitopes in the presence of genetic drift and antigenic variation of the virus may reveal critical elements of protective immunity against HIV. Analysis of antibody maturation and diversity is difficult to study at the molecular level in humans. We used a combinatorial phage display peptide library to elucidate antibody diversity in HIV-infected individuals to a single immunodominant epitope in gp41. A serum sample derived from an HIV+ individual was used to screen a phage display a 12 mer cysteine-constrained loop peptide library. In doing so, we isolated mimotope-presenting phages corresponding to the immunodominant gp41 epitope CSGKLIC (residues 603-609). The mimotopes and control phages expressing epitope variants were reacted with a panel of 30 HIV+ sera. The patients showed distinct and variable recognition patterns compared with one another. Subfractions of the polyclonal sera were affinity purified and analyzed for epitope specificities. These analyses illustrated that epitope variants can be used to decipher antibody diversity. Elucidation of the plasticity of the humoral response and its polyclonality toward discrete epitopes contributes to our understanding of the antibody maturation process in individuals infected with viruses such as HIV.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; Tel Aviv Sourasky Med Ctr, Dept Clin Immunol, IL-64239 Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Gershoni, JM (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.	gershoni@post.tau.ac.il		Enshell-Seijffers, David/0000-0002-8228-2659				ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; ARENDRUP M, 1993, J GEN VIROL, V74, P855, DOI 10.1099/0022-1317-74-5-855; ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303; Arvin AM, 1996, CLIN MICROBIOL REV, V9, P361, DOI 10.1128/CMR.9.3.361; BACHMANN MF, 1994, J IMMUNOL, V152, P4235; BANAPOUR B, 1987, J IMMUNOL, V139, P4027; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; Borrebaeck CAK, 1998, IMMUNOL TODAY, V19, P524, DOI 10.1016/S0167-5699(98)01329-2; BUGGE TH, 1990, J VIROL, V64, P4123, DOI 10.1128/JVI.64.9.4123-4129.1990; Burton DR, 1998, NAT MED, V4, P495, DOI 10.1038/nm0598supp-495; Burton DR, 1997, AIDS, V11, pS87; Cole KS, 1997, J VIROL, V71, P5069, DOI 10.1128/JVI.71.7.5069-5079.1997; Conley AJ, 1996, J VIROL, V70, P6751, DOI 10.1128/JVI.70.10.6751-6758.1996; CORTESE R, 1994, TRENDS BIOTECHNOL, V12, P262, DOI 10.1016/0167-7799(94)90137-6; Cortese Riccardo, 1995, Current Opinion in Biotechnology, V6, P73, DOI 10.1016/0958-1669(95)80012-3; Cotropia J, 1996, J ACQ IMMUN DEF SYND, V12, P221, DOI 10.1097/00042560-199607000-00002; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Delmastro P, 1997, VACCINE, V15, P1276, DOI 10.1016/S0264-410X(97)00072-8; DENISOVA G, 1995, FASEB J, V9, P127, DOI 10.1096/fasebj.9.1.7529735; Denisova GF, 2000, MOL IMMUNOL, V37, P53, DOI 10.1016/S0161-5890(00)00022-5; EATON AM, 1994, AIDS RES HUM RETROV, V10, P13, DOI 10.1089/aid.1994.10.13; EICHBERG JW, 1992, AIDS RES HUM RETROV, V8, P1515, DOI 10.1089/aid.1992.8.1515; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; FOLGORI A, 1994, EMBO J, V13, P2236, DOI 10.1002/j.1460-2075.1994.tb06501.x; GNANN JW, 1987, J INFECT DIS, V156, P261, DOI 10.1093/infdis/156.2.261; Gonzalez-Fernandez A, 1998, IMMUNOLOGY, V93, P149; GORNY MK, 1989, P NATL ACAD SCI USA, V86, P1624, DOI 10.1073/pnas.86.5.1624; GOUDSMIT J, 1990, INTERVIROLOGY, V31, P327, DOI 10.1159/000150169; GOUDSMIT J, 1991, FASEB J, V5, P2427, DOI 10.1096/fasebj.5.10.2065891; Haigwood N L, 1998, AIDS, V12 Suppl A, pS121; Haigwood NL, 1996, IMMUNOL LETT, V51, P107, DOI 10.1016/0165-2478(96)02563-1; HAIGWOOD NL, 1995, VACCINES, P149; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HORAL P, 1991, J VIROL, V65, P2718, DOI 10.1128/JVI.65.5.2718-2723.1991; Kalinke U, 1996, IMMUNITY, V5, P639, DOI 10.1016/S1074-7613(00)80277-0; KELLER PM, 1993, VIROLOGY, V193, P709, DOI 10.1006/viro.1993.1179; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LANE DP, 1993, CURR OPIN IMMUNOL, V5, P268, DOI 10.1016/0952-7915(93)90016-L; PAL R, 1992, INTERVIROLOGY, V86, P86; POLLOCK BJ, 1989, CLIN EXP IMMUNOL, V78, P323; Prezzi C, 1996, J IMMUNOL, V156, P4504; PRIGENT S, 1990, AIDS, V4, P11, DOI 10.1097/00002030-199001000-00002; PRINCE AM, 1991, AIDS RES HUM RETROV, V7, P971, DOI 10.1089/aid.1991.7.971; Puntoriero G, 1998, EMBO J, V17, P3521, DOI 10.1093/emboj/17.13.3521; ROBERTGUROFF M, 1988, AIDS RES HUM RETROV, V4, P343, DOI 10.1089/aid.1988.4.343; Scala G, 1999, J IMMUNOL, V162, P6155; SCHRIER RD, 1988, J VIROL, V62, P2531, DOI 10.1128/JVI.62.8.2531-2536.1988; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; TEEUWSEN VJP, 1990, AIDS RES HUM RETROV, V6, P381, DOI 10.1089/aid.1990.6.381; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; TYLER DS, 1990, J IMMUNOL, V145, P3276; UGEN KE, 1992, J CLIN INVEST, V89, P1923, DOI 10.1172/JCI115798; Urbanelli L, 2000, J IMMUNOL METHODS, V236, P167, DOI 10.1016/S0022-1759(99)00238-0; VANINI S, 1993, AIDS, V7, P164; XU JY, 1991, J VIROL, V65, P4832, DOI 10.1128/JVI.65.9.4832-4838.1991; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	57	37	39	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2112	2120		10.1096/fj.00-0898com	http://dx.doi.org/10.1096/fj.00-0898com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641237				2022-12-28	WOS:000171920400022
J	Kallio, MJ; Nieminen, M; Eriksson, JE				Kallio, MJ; Nieminen, M; Eriksson, JE			Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit	FASEB JOURNAL			English	Article						survivin; mitosis; spindle checkpoint	ANAPHASE-PROMOTING COMPLEX; SPINDLE CHECKPOINT; CELL-DIVISION; AURORA-LIKE; KINASE; MAD2; KINETOCHORE; ANTIBODY; MITOSIS; ONSET	A signaling cascade termed the "spindle checkpoint" monitors interactions between the kinetochores of chromosomes and spindle microtubules to prevent precocious separation of sister chromatids. We have investigated the role of human inhibitor of apoptosis protein (IAP) survivin in regulation of cell division. We demonstrate that HeLa and PtK1 cells transfected or microinjected with survivin anti-sense oligonucleotides produce significantly more polyploid and micronucleated progeny cells and show abortive mitosis when treated with spindle poisons. Furthermore, perturbation of survivin function in HeLa and PtK1 cells with anti-survivin antibodies at the beginning of mitosis affects the normal timing of separation of sister chromatids and disturbs the 3F3/2 phosphoepitope-recognized tension sensing mechanism of the spindle checkpoint. This leads to premature separation of sister chromatids, which results in an uneven distribution of chromosomes between the newly formed progeny cells-an event associated with tumor formation in many cell types. Finally, cells injected with anti-survivin antibody exit mitotic block induced with microtubule drugs. Our data suggest that survivin protein may function within the spindle checkpoint pathway.	Univ Oklahoma, Hlth Sci Ctr, Ctr Biomed Res, Dept Cell Biol, Oklahoma City, OK 73104 USA; Univ Turku, Turku Ctr Biotechnol, FIN-20521 Turku, Finland; Abo Akad Univ, FIN-20521 Turku, Finland; Univ Turku, Dept Biol, FIN-20014 Turku, Finland	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Turku; Abo Akademi University; University of Turku	Kallio, MJ (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Ctr Biomed Res, Dept Cell Biol, 975 NE 10th St,Room 266, Oklahoma City, OK 73104 USA.	Marko-Kallio@ouhsc.edu		Kallio, Marko/0000-0002-6345-1680				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Daum JR, 2000, CURR BIOL, V10, pR850, DOI 10.1016/S0960-9822(00)00836-8; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Gorbsky GJ, 1999, FASEB J, V13, pS231, DOI 10.1096/fasebj.13.9002.S231; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; JORDAN MA, 1992, J CELL SCI, V102, P401; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Page AM, 1997, CANCER SURV, V29, P133; Peters JM, 1999, EXP CELL RES, V248, P339, DOI 10.1006/excr.1999.4443; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Tatsuka M, 1998, CANCER RES, V58, P4811; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Zhao J, 2000, J CELL SCI, V113, P4363	30	58	63	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2721	+		10.1096/fj.01-0280fje	http://dx.doi.org/10.1096/fj.01-0280fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11687505				2022-12-28	WOS:000171920400005
J	Okada, M; Fujita, T; Sakaguchi, T; Olson, KE; Collins, T; Stern, DM; Yan, SF; Pinsky, DJ				Okada, M; Fujita, T; Sakaguchi, T; Olson, KE; Collins, T; Stern, DM; Yan, SF; Pinsky, DJ			Extinguishing Egr-1-dependent inflammatory and thrombotic cascades following lung transplantation	FASEB JOURNAL			English	Article						early growth response-1; antisense oligodeoxyribonucleotide; transcription factor; ischemia	INTERCELLULAR-ADHESION MOLECULE-1; PRIMARY GRAFT FAILURE; GENE-EXPRESSION; FIBRIN DEPOSITION; COMPARATIVE INHIBITION; OXYGEN DEPRIVATION; HYPOXIA; PRESERVATION; INJURY; TRANSCRIPTION	Hypoxic induction of the early growth response-1 (Egr-1) transcription factor initiates proinflammatory and procoagulant gene expression. Orthotopic/isogeneic rat lung transplantation triggers Egr-1 expression and nuclear DNA binding activity corresponding to Egr-1, which leads to increased expression of downstream target genes such as interleukin-1, tissue factor, and plasminogen activator inhibitor-1. The devastating functional consequences of Egr-1 up-regulation in this setting are prevented by treating donor lungs with a phosphorothioate antisense oligodeoxyribonucleotide directed against the Egr-1 translation initiation site, which blocks expression of Egr-1 and its gene targets. Post-transplant graft leukostasis, inflammation, and thrombosis are consequently diminished, with marked improvement in graft function and recipient survival. Blocking expression of a proximal transcription factor, which activates deleterious inflammatory and coagulant effector mechanisms, is an effective molecular strategy to improve organ preservation.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Harvard Univ, Sch Med, Boston, MA USA	Columbia University; Harvard University; Harvard Medical School	Pinsky, DJ (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.	djp5@columbia.edu	Tomoyuki, Fujita/AAC-7464-2020					Belperio JA, 2000, J IMMUNOL, V165, P461, DOI 10.4049/jimmunol.165.1.461; Boasquevisque CHR, 1999, J THORAC CARDIOV SUR, V117, P8; CANONICO AE, 1994, J APPL PHYSIOL, V77, P415, DOI 10.1152/jappl.1994.77.1.415; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; Christie JD, 1998, CHEST, V114, P51, DOI 10.1378/chest.114.1.51; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dragun D, 1998, KIDNEY INT, V54, P2113, DOI 10.1046/j.1523-1755.1998.00189.x; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRANCIS CW, 1980, BLOOD, V56, P456; GOLDBLUM SE, 1985, J APPL PHYSIOL, V59, P1978, DOI 10.1152/jappl.1985.59.6.1978; Harringer W, 1999, EUR J CARDIO-THORAC, V16, P546, DOI 10.1016/S1010-7940(99)00313-9; Hopkinson DN, 1998, J HEART LUNG TRANSPL, V17, P525; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Lawson CA, 1997, J CLIN INVEST, V99, P1729, DOI 10.1172/JCI119337; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; Mal H, 1998, CHEST, V113, P645, DOI 10.1378/chest.113.3.645; MARCUSSEKURA CJ, 1987, NUCLEIC ACIDS RES, V15, P5749, DOI 10.1093/nar/15.14.5749; Meyers BF, 1999, ANN SURG, V230, P362, DOI 10.1097/00000658-199909000-00009; Naka Y, 1997, P NATL ACAD SCI USA, V94, P757, DOI 10.1073/pnas.94.2.757; Naka Y, 1997, TRANSPLANTATION, V64, P1248, DOI 10.1097/00007890-199711150-00004; NAKA Y, 1995, J THORAC CARDIOV SUR, V109, P206, DOI 10.1016/S0022-5223(95)70380-2; Okada K, 2000, J BIOL CHEM, V275, P21468, DOI 10.1074/jbc.M002682200; PINSKY DJ, 1995, THROMB HAEMOSTASIS, V74, P58; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; Pinsky DJ, 1996, J CLIN INVEST, V97, P493, DOI 10.1172/JCI118440; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; SACHAR DB, 1996, GASTR HEPAT, V1, P309; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Toda K, 2000, CIRC RES, V86, P166, DOI 10.1161/01.RES.86.2.166; Wang CY, 2000, CIRC RES, V86, P982, DOI 10.1161/01.RES.86.9.982; WHITEHEAD BF, 1993, TRANSPLANTATION, V56, P956, DOI 10.1097/00007890-199310000-00034; Yan SF, 2000, J BIOL CHEM, V275, P11921, DOI 10.1074/jbc.275.16.11921; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030	41	54	67	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2757	+		10.1096/fj.01-0490fje	http://dx.doi.org/10.1096/fj.01-0490fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606484				2022-12-28	WOS:000171920400009
J	Diez-Juan, A; Andres, V				Diez-Juan, A; Andres, V			The growth suppressor p27(Kip1) protects against diet-induced atherosclerosis	FASEB JOURNAL			English	Article						cell cycle; p27; hypercholesterolemia	DEPENDENT KINASE INHIBITOR; MUSCLE CELL-PROLIFERATION; NUCLEAR ANTIGEN; CYCLIN-E; IN-VIVO; BALLOON ANGIOPLASTY; PARAFFIN SECTIONS; APOLIPOPROTEIN-E; BREAST-CANCER; MICE LACKING	The molecular basis of atherosclerosis is associated with excessive proliferation of vascular cells. Previous studies have suggested an inverse correlation between the expression of the growth suppressor p27(Kip1) (p27) and cellular proliferation within human atherosclerotic tissue. However, no causal link between diminished p27 expression and atherogenesis has been established. We investigated the effect of p27 inactivation on diet-induced atherogenesis. We find that p27-deficient mice challenged with a high-fat diet for 1 month remain normocholesterolemic and have essentially no visible atheromas. However, when generated in an apolipoprotein E-null genetic background that leads to severe hypercholesterolemia in response to the atherogenic diet, deletion of p27 enhances arterial cell proliferation (similar to fourfold) and accelerates atherogenesis (similar to sixfold) compared with apolipoprotein E-deficient mice with an intact p27 gene. Analysis of apolipoprotein E-null mice bearing only one p27 allele inactivated reveals that a moderate decrease in p27 protein expression in the setting of hypercholesterolemia is sufficient to predispose to atherogenesis. Thus, our study establishes a molecular link between decreased p27 protein expression and atherogenesis in hypercholesterolemic animals.	CSIC, IBV, Spanish Council Sci Res, Valencia 46010, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV)	Andres, V (corresponding author), CSIC, IBV, Spanish Council Sci Res, C Jaime Roig 11, Valencia 46010, Spain.	vandres@ibv.csic.es	Diez Juan, Antonio/D-3695-2018; Andres, Vicente/I-6440-2014; Diez-Juan, Antonio/H-5464-2015	Andres, Vicente/0000-0002-0125-7209; Diez-Juan, Antonio/0000-0002-0166-1869				Braun-Dullaeus RC, 1999, J CLIN INVEST, V104, P815, DOI 10.1172/JCI5339; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; Chen HM, 2000, SUPERLATTICE MICROST, V27, P1, DOI 10.1006/spmi.1999.0794; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; GALAND P, 1989, CELL TISSUE KINET, V22, P383, DOI 10.1111/j.1365-2184.1989.tb00223.x; Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; Ihling C, 1999, ATHEROSCLEROSIS, V144, P7, DOI 10.1016/S0021-9150(99)00032-5; KAWAKITA N, 1992, AM J PATHOL, V140, P513; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lavia P, 1999, BIOESSAYS, V21, P221; Libby P, 1997, PROG CARDIOVASC DIS, V40, P97, DOI 10.1016/S0033-0620(97)80002-3; Liu Q, 1999, MOL CELL BIOL, V19, P6229; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lutgens E, 1999, NAT MED, V5, P1313, DOI 10.1038/15271; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakano T, 1996, SYST COMPUT JPN, V27, P1, DOI 10.1002/scj.4690270601; Ophascharoensuk V, 1998, NAT MED, V4, P575, DOI 10.1038/nm0598-575; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; Tanner FC, 2000, CIRCULATION, V101, P2022, DOI 10.1161/01.CIR.101.17.2022; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; Ueno H, 1997, ANN NY ACAD SCI, V811, P401, DOI 10.1111/j.1749-6632.1997.tb52020.x; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; Yonemitsu Y, 1998, CIRC RES, V82, P147; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903	41	73	73	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					1989	1995		10.1096/fj.01-0130com	http://dx.doi.org/10.1096/fj.01-0130com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532979	Green Submitted			2022-12-28	WOS:000171372700014
J	Tseng, YT; Kopel, R; Stabila, JP; McGonnigal, BG; Nguyen, TT; Gruppuso, PA; Padbury, JF				Tseng, YT; Kopel, R; Stabila, JP; McGonnigal, BG; Nguyen, TT; Gruppuso, PA; Padbury, JF			beta-Adrenergic receptors (bAR) regulate cardiomyocyte proliferation during early postnatal life	FASEB JOURNAL			English	Article						MAPK; p70 S6K; propranolol	PROTEIN-KINASE PATHWAY; NEONATAL RAT; TARGETED DISRUPTION; CARDIAC GROWTH; HEART; ADRENOCEPTOR; STIMULATION; ACTIVATION; AGONISTS; CASCADE	Cardiomyocyte development switches from hyperplasmic to hypertrophic growth between postnatal days 3 and 4 in rats. The mechanisms responsible for this transition have been controversial. beta -Adrenergic receptor (beta AR) activation of mitogenic responses in vitro has been reported. We hypothesized that tonic activation of the beta AR signaling regulates cell division in neonatal cardiomyocytes via effects on signaling kinases known to be important in cell cycle regulation. The purpose of the current study was to elucidate the roles of beta AR in rat cardiomyocyte growth in vivo. We demonstrated that beta AR blockade induced a significant reduction in cardiomyocyte proliferation as measured by the BrdU labeling index. Blockade of beta AR did not affect p38 or p44/42 MAPK activities. We further demonstrated that beta AR blockade induced a prompt deactivation of the p70 ribosomal protein S6 kinase (p70 S6K). To confirm these results, we measured p70 S6K activity directly. Basal activity of p70 S6K in neonatal cardiomyocytes was fourfold higher than that of insulin-treated adult rat liver. The activity of p70 S6K was reduced by 60% within 1 min after beta AR blockade. We conclude that the beta AR are involved in regulation of neonatal cardiomyocyte proliferation and that this mitogenic control may be mediated via the p70 S6K pathway.	Women & Infants Hosp Rhode Isl, Rhode Isl Hosp, Brown Med Sch, Dept Pediat, Providence, RI 02905 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Women & Infants Hospital Rhode Island	Tseng, YT (corresponding author), Women & Infants Hosp Rhode Isl, Rhode Isl Hosp, Brown Med Sch, Dept Pediat, 101 Dudley St, Providence, RI 02905 USA.	Yi-Tang_Tseng@brown.edu			NICHD NIH HHS [2P01 HD11343] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD011343] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Agarwal D, 1999, CELL PROLIFERAT, V32, P215, DOI 10.1046/j.1365-2184.1999.3240215.x; Bisognano JD, 2000, J MOL CELL CARDIOL, V32, P817, DOI 10.1006/jmcc.2000.1123; Boney CM, 1998, ENDOCRINOLOGY, V139, P1638, DOI 10.1210/en.139.4.1638; Boylan JM, 1998, J BIOL CHEM, V273, P3784, DOI 10.1074/jbc.273.6.3784; Bueno OF, 2001, CIRC RES, V88, P88, DOI 10.1161/01.RES.88.1.88; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chruscinski AJ, 1999, J BIOL CHEM, V274, P16694, DOI 10.1074/jbc.274.24.16694; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; De Paepe ME, 1998, AM J PATHOL, V152, P179; Dzimiri N, 1999, PHARMACOL REV, V51, P465; Ghatpande S, 1999, MOL CELL BIOCHEM, V196, P93, DOI 10.1023/A:1006974330613; Kim D, 1999, IEEE COMMUN LETT, V3, P9, DOI 10.1109/4234.740114; KUDLACZ EM, 1990, J DEV PHYSIOL, V14, P307; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; Li FQ, 1996, J MOL CELL CARDIOL, V28, P1737, DOI 10.1006/jmcc.1996.0163; Liggett SB, 2000, CIRCULATION, V101, P1707; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; MCGILL CJ, 1995, CARDIOVASC RES, V30, P557, DOI 10.1016/S0008-6363(95)00113-1; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Renick SE, 1997, PEDIATR RES, V41, P359, DOI 10.1203/00006450-199703000-00009; Rohrer DK, 1999, J BIOL CHEM, V274, P16701, DOI 10.1074/jbc.274.24.16701; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; Sabri A, 2000, CIRC RES, V86, P1047, DOI 10.1161/01.RES.86.10.1047; Sauer H, 2000, FEBS LETT, V476, P218, DOI 10.1016/S0014-5793(00)01747-6; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Simm A, 1998, J MOL CELL CARDIOL, V30, P2059, DOI 10.1006/jmcc.1998.0768; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Weinbrenner C, 1997, J MOL CELL CARDIOL, V29, P2383, DOI 10.1006/jmcc.1997.0473; Yamazaki T, 1997, CIRCULATION, V95, P1260; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	32	25	25	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					1921	1926		10.1096/fj.01-0151com	http://dx.doi.org/10.1096/fj.01-0151com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532972				2022-12-28	WOS:000171372700007
J	Vrablic, AS; Albright, CD; Craciunescu, CN; Salganik, RI; Zeisel, SH				Vrablic, AS; Albright, CD; Craciunescu, CN; Salganik, RI; Zeisel, SH			Altered mitochondrial function and overgeneration of reactive oxygen species precede the induction of apoptosis by 1-O-octadecyl-2-methyl-rac-glycero-3-phosphocholine in p53-defective hepatocytes	FASEB JOURNAL			English	Article						apoptosis; cancer; edelfosine; mitochondria; phosphatidylcholine; reactive oxygen species	MEMBRANE-PERMEABILITY TRANSITION; PROTEIN-KINASE-C; CHOLINE-DEFICIENCY; RAT HEPATOCYTES; CYTOCHROME-C; SIMIAN VIRUS-40; PC12 CELLS; COMPLEX-I; EXPRESSION; ACTIVATION	The mechanism of induction of apoptosis by the novel anti-cancer drug 1-O-octadecyl-2-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3) was investigated in p53-defective SV40 immortalized rat hepatocytes (CWSV1). Exposure to 12 muM ET-18-OCH3 for 36 h induced apoptosis as determined using classical morphological features and agarose gel electrophoresis of genomic DNA. Increased levels of reactive oxygen species (ROS) were detected spectrophotometrically using a nitroblue tetrazolium (NBT) assay in cells treated with ET-18-OCH3. Both the increased generation of ROS and the induction of apoptosis were inhibited when cells were treated concurrently with ET-18-OCH3 in the presence of the antioxidant alpha -tocopherol. Similar results were achieved when cells were switched acutely to choline- deficient (CD) medium in the presence of the antioxidant. The possible role of mitochondria in the generation of ROS was investigated. Both ET-18-OCH3 and CD decreased the phosphatidylcholine (PC) content of mitochondrial and associated membranes, which correlated with depolarization of the mitochondrial membrane as analyzed using 5,5', 6,6'- tetramethylbenzimidazolcarbocyanine iodide (JC-1), a sensitive probe of mitochondrial membrane potential. Rotenone, an inhibitor of the mitochondrial electron transport chain, significantly reduced the intracellular level of ROS and prevented mitochondrial membrane depolarization, correlating with a reduction of apoptosis in response to either ET-18-OCH3 or CD. Taken together, these results suggest that the form of p53-independent apoptosis induced by ET-18-OCH3 is mediated by alterations in mitochondrial membrane PC, a loss of mitochondrial membrane potential, and the release of ROS, resulting in completion of apoptosis.	Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zeisel, SH (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, CB 7400,2213 McGavran Greenberg Hall, Chapel Hill, NC 27599 USA.	steven_zeisel@unc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [AG09525] Funding Source: Medline; NIDDK NIH HHS [DK55865] Funding Source: Medline; NIGMS NIH HHS [GM14840] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albright CD, 1996, FASEB J, V10, P510, DOI 10.1096/fasebj.10.4.8647350; Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boggs K, 1998, BBA-LIPID LIPID MET, V1389, P1, DOI 10.1016/S0005-2760(97)00145-8; Bossy-Wetzel E, 1999, MUTAT RES-DNA REPAIR, V434, P243, DOI 10.1016/S0921-8777(99)00032-4; Camilleri-Broet S, 1998, EXP CELL RES, V239, P277, DOI 10.1006/excr.1997.3899; Castedo M, 1995, EUR J IMMUNOL, V25, P3277, DOI 10.1002/eji.1830251212; Chandel NS, 2000, ONCOGENE, V19, P3840, DOI 10.1038/sj.onc.1203727; Chinopoulos C, 1999, J NEUROCHEM, V73, P220, DOI 10.1046/j.1471-4159.1999.0730220.x; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; DACOSTA KA, 1993, J BIOL CHEM, V268, P2100; Decaudin D, 1998, INT J ONCOL, V12, P141; DRYER RL, 1975, BIOCHIM BIOPHYS ACTA, V380, P370, DOI 10.1016/0005-2760(75)90105-8; Hardman WE, 1997, BRIT J CANCER, V76, P347, DOI 10.1038/bjc.1997.389; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; Isenberg JS, 2000, TOXICOL SCI, V53, P340, DOI 10.1093/toxsci/53.2.340; Kates, 1975, TECHNIQUES LIPIDOLOG; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; KunzSchughart LA, 1997, AM J PHYSIOL-CELL PH, V273, pC1487, DOI 10.1152/ajpcell.1997.273.5.C1487; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Li LW, 1999, MOL CELL BIOL, V19, P8547; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Matsunaga T, 1996, LEUKEMIA LYMPHOMA, V20, P487, DOI 10.3109/10428199609052434; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Mollinedo F, 1997, CANCER RES, V57, P1320; Okun JG, 2000, BBA-BIOENERGETICS, V1459, P77, DOI 10.1016/S0005-2728(00)00115-8; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; ROOK GAW, 1985, J IMMUNOL METHODS, V82, P161, DOI 10.1016/0022-1759(85)90235-2; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Schuler F, 1999, P NATL ACAD SCI USA, V96, P4149, DOI 10.1073/pnas.96.7.4149; Sestili P, 2000, EUR J NEUROSCI, V12, P145, DOI 10.1046/j.1460-9568.2000.00891.x; Shin OH, 1997, J CELL BIOCHEM, V64, P196, DOI 10.1002/(SICI)1097-4644(199702)64:2<196::AID-JCB3>3.0.CO;2-S; SULIK K, 1994, DEV DYNAM, V201, P260, DOI 10.1002/aja.1002010309; WAGNER BA, 1993, CANCER RES, V53, P711; WOODWORTH C, 1986, CANCER RES, V46, P4018; WOODWORTH CD, 1987, MOL CELL BIOL, V7, P3740, DOI 10.1128/MCB.7.10.3740; WOODWORTH CD, 1988, MOL CELL BIOL, V8, P4492, DOI 10.1128/MCB.8.10.4492; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Zeisel SH, 1997, CARCINOGENESIS, V18, P731, DOI 10.1093/carcin/18.4.731	45	116	119	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					1739	1744		10.1096/fj.00-0300com	http://dx.doi.org/10.1096/fj.00-0300com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481221				2022-12-28	WOS:000170809900009
J	Choi, SH; Park, CH; Koo, JW; Seo, JH; Kim, HS; Jeong, SJ; Lee, JH; Kim, SS; Suh, YH				Choi, SH; Park, CH; Koo, JW; Seo, JH; Kim, HS; Jeong, SJ; Lee, JH; Kim, SS; Suh, YH			Memory impairment and cholinergic dysfunction by centrally administered A beta and carboxyl-terminal fragment of Alzheimer's APP in mice	FASEB JOURNAL			English	Article						amyloid beta peptide; learning and memory; acetylcholine; pyruvate dehydrogenase	AMYLOID PRECURSOR PROTEIN; PYRUVATE-DEHYDROGENASE ACTIVITY; HIPPOCAMPUS IN-VIVO; ACETYLCHOLINE-RELEASE; CALCIUM HOMEOSTASIS; CORTICAL-NEURONS; SENILE DEMENTIA; RAT-BRAIN; DISEASE; NEUROTOXICITY	Alzheimer's disease (AD) is characterized by cognitive impairment and excessive deposition of neurite plaques (NPs). Although the pathogenic mechanism of AD is not exactly known, there is increasing evidence that amyloid beta protein (A beta), which is the major constituent of NPs and is derived from amyloid precursor protein (APP), plays a key role in the neuronal degeneration in AD. However, because there are several discrepancies between A beta deposition and neurodegeneration or cognitive impairment in AD, the possible effects of other cleavage products of APP need to be explored. We previously showed that a recombinant carboxyl-terminal 105 amino acid fragment of APP (CT105) induced neurotoxicities both in vitro and in vivo. However, it is unclear whether learning and memory impairments and neurochemical changes are induced by CT105. To elucidate the in vivo neurotoxicities of A beta and CT105, we examined behavioral changes using a Y-maze and a water maze task following a single intracerebroventricular injection of CT105 (68.5, 342 and 685 pmol) or A beta (1-42) (685 pmol) to mice. We also quantified the changes in the acetylcholine (ACh) level and assayed mitochondrial pyruvate dehydrogenase (PDH) activity. CT105 caused much more significant impairments in cued, spatial, and working memory performances of mice in Y-maze and water maze tasks in a dose-dependent manner than A beta (1-42). Also, the mice injected with CT105 revealed significant decreases in ACh levels and reduced PDH activities in the cerebral cortex and hippocampus compared with the saline-treated control and A beta (1-42)-treated groups. These results suggest that learning and memory impairment induced by centrally administered CT105 is in some way related to the reduced ACh levels and mitochondrial PDH activities and that CT105 is more potent than A beta in inducing cognitive dysfunction.	Seoul Natl Univ, Natl Creat Res Initiat Ctr Alzheimers Dementia, Coll Med, Dept Pharmacol, Seoul 110799, South Korea; Seoul Natl Univ, MRC, Neurosci Res Inst, Seoul 110799, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151741, South Korea; Chung Ang Univ, Coll Med, Dept Anat, Seoul 156756, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Chung Ang University; Chung Ang University Hospital	Suh, YH (corresponding author), Seoul Natl Univ, Natl Creat Res Initiat Ctr Alzheimers Dementia, Coll Med, Dept Pharmacol, Seoul 110799, South Korea.	ysuh@plaza.snu.ac.kr	Kim, Hye Sun/J-2752-2012; Suh, Yoo-Hun/J-2761-2012					ABE E, 1994, BRAIN RES, V636, P162, DOI 10.1016/0006-8993(94)90193-7; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Berger-Sweeney J, 1999, MOL BRAIN RES, V66, P150, DOI 10.1016/S0169-328X(99)00014-5; BIERER LM, 1995, J NEUROCHEM, V64, P749; BROWNING M, 1981, J NEUROCHEM, V36, P1932, DOI 10.1111/j.1471-4159.1981.tb10817.x; CAPUTO CB, 1992, BIOCHEM BIOPH RES CO, V185, P1034, DOI 10.1016/0006-291X(92)91730-E; CHONG YH, 1994, LIFE SCI, V54, P1259; CLEARY J, 1995, BRAIN RES, V682, P69, DOI 10.1016/0006-8993(95)00323-I; CLEMENS JA, 1992, NEUROBIOL AGING, V13, P581, DOI 10.1016/0197-4580(92)90059-7; DeGiorgio LA, 2000, BRAIN RES, V874, P137, DOI 10.1016/S0006-8993(00)02545-2; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Fraser SP, 1996, J NEUROCHEM, V66, P2034; FRICK KM, 1995, NEUROBIOL AGING, V16, P149, DOI 10.1016/0197-4580(94)00155-3; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; GEARING M, 1993, J NEUROPATH EXP NEUR, V52, P22, DOI 10.1097/00005072-199301000-00004; GEULA C, 1994, BRAIN RES, V644, P327, DOI 10.1016/0006-8993(94)91697-7; Hartell NA, 2000, J NEUROCHEM, V74, P1112; Holcomb LA, 1999, BEHAV GENET, V29, P177, DOI 10.1023/A:1021691918517; Hoshi M, 1996, P NATL ACAD SCI USA, V93, P2719, DOI 10.1073/pnas.93.7.2719; ISRAEL M, 1982, J NEUROCHEM, V39, P248, DOI 10.1111/j.1471-4159.1982.tb04727.x; KAMETANI F, 1994, FEBS LETT, V351, P165, DOI 10.1016/0014-5793(94)00851-5; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; Kim HJ, 1999, NEUROREPORT, V10, P1427, DOI 10.1097/00001756-199905140-00008; Kim HS, 2000, FASEB J, V14, P1508, DOI 10.1096/fj.14.11.1508; Kim SH, 1996, J NEUROCHEM, V67, P1172; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P7508, DOI 10.1073/pnas.90.16.7508; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; KOWALL NW, 1992, NEUROBIOL AGING, V13, P537, DOI 10.1016/0197-4580(92)90053-Z; LAURSEN SE, 1986, J PHARMACOL METHOD, V16, P355, DOI 10.1016/0160-5402(86)90038-0; Lee JP, 2000, J NEUROSCI RES, V60, P565, DOI 10.1002/(SICI)1097-4547(20000515)60:4<565::AID-JNR16>3.0.CO;2-I; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; MATSUMOTO A, 1991, BIOCHEM BIOPH RES CO, V175, P361, DOI 10.1016/0006-291X(91)91572-T; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; NEVE RL, 1992, P NATL ACAD SCI USA, V89, P3448, DOI 10.1073/pnas.89.8.3448; PALMER AM, 1990, FASEB J, V4, P2745, DOI 10.1096/fasebj.4.10.2165009; PARNETTI L, 1995, NEUROSCI LETT, V199, P231, DOI 10.1016/0304-3940(95)12058-C; PERRY EK, 1980, NEUROSCI LETT, V18, P105, DOI 10.1016/0304-3940(80)90220-7; PIKE CJ, 1993, NEUROSCIENCE, V56, P269, DOI 10.1016/0306-4522(93)90331-9; QUIRION R, 1993, J PSYCHIATR NEUROSCI, V18, P226; SARTER M, 1988, PSYCHOPHARMACOLOGY, V94, P491, DOI 10.1007/BF00212843; Sberna G, 1998, J NEUROCHEM, V71, P723; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; Song DK, 1998, J NEUROCHEM, V71, P875; SORBI S, 1983, ANN NEUROL, V13, P72, DOI 10.1002/ana.410130116; STERRI SH, 1980, J NEUROCHEM, V35, P249, DOI 10.1111/j.1471-4159.1980.tb12511.x; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TERRY RD, 1983, ANN NEUROL, V14, P497, DOI 10.1002/ana.410140502; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; Yamada K, 1999, EUR J NEUROSCI, V11, P83, DOI 10.1046/j.1460-9568.1999.00408.x; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	56	40	40	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1816	+		10.1096/fj.00-0859fje	http://dx.doi.org/10.1096/fj.00-0859fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481240				2022-12-28	WOS:000169261200018
J	Maul, J; Siems, WE; Hoehe, MR; Grecksch, G; Bader, M; Walther, T				Maul, J; Siems, WE; Hoehe, MR; Grecksch, G; Bader, M; Walther, T			Alcohol consumption is controlled by angiotensin II	FASEB JOURNAL			English	Article						transgenic mice; ACE inhibition; spirapril	CONVERTING ENZYME-INHIBITORS; ETHANOL-CONSUMPTION; DEFICIENT MICE; MECHANISMS; RECEPTORS; HUMANS; RATS	Pharmacological manipulation of the renin-angiotensin system (RAS) appears to alter voluntary alcohol consumption in animals. We have now addressed the role of angiotensin II (AII) in alcohol intake by comparing the alcohol-drinking behavior of mice lacking or overexpressing the angiotensinogen gene in a two-bottle choice paradigm. We found that alcohol consumption was directly related to AII levels. Animals harboring a rat angiotensinogen transgene consumed significantly more of the alcoholic beverage than did controls. This effect could be remarkably reduced by spirapril, an inhibitor of the angiotensin-converting enzyme (ACE). However, mice lacking the angiotensinogen gene exhibited a markedly reduced alcohol intake. These results indicate a role for the angiotensinogen gene in alcohol consumption via modulation of AII.	Inst Mol Pharmacol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Magdeburg, Inst Pharmacol & Toxicol, D-39106 Magdeburg, Germany; Free Univ Berlin, Univ Hosp, Dept Cardiol & Pneumol, D-1000 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Otto von Guericke University; Free University of Berlin	Maul, J (corresponding author), Inst Mol Pharmacol, Robert Roessle Str 10, D-13125 Berlin, Germany.	maul@fmp-berlin.de	Bader, Michael/K-2124-2013	Bader, Michael/0000-0003-4780-4164				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRABBE JC, 1996, NAT GENET, V14, P89; Daubert DL, 1999, BRAIN RES, V816, P8, DOI 10.1016/S0006-8993(98)00930-5; FITTS DA, 1993, PHARMACOL BIOCHEM BE, V45, P35, DOI 10.1016/0091-3057(93)90082-5; FRIEDLAND J, 1976, AM J CLIN PATHOL, V66, P416; FUXE K, 1980, NEURAL PEPTIDES NEUR, P37; GARRIB A, 1998, BIOCHEM SOC T, V26, P136; Grupp LA, 1997, ALCOHOL, V14, P71, DOI 10.1016/S0741-8329(96)00109-7; GRUPP LA, 1988, PHARMACOL BIOCHEM BE, V31, P813, DOI 10.1016/0091-3057(88)90389-9; GRUPP LA, 1988, PHARMACOL BIOCHEM BE, V29, P479, DOI 10.1016/0091-3057(88)90007-X; GRUPP LA, 1993, NIAAA RES MONOGRAPH, V23, P37; HUBBELL CL, 1992, ALCOHOL, V9, P53, DOI 10.1016/0741-8329(92)90010-8; HULME EC, 1992, RECEPTOR LIGAND INTE, P177; Jenkins TA, 1997, BRAIN RES, V748, P137, DOI 10.1016/S0006-8993(96)01276-0; Kiefer SW, 1998, ALCOHOL CLIN EXP RES, V22, P1146, DOI 10.1097/00000374-199808000-00025; Kihara M, 1998, KIDNEY INT, V53, P548, DOI 10.1046/j.1523-1755.1998.00801.x; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; LINGHAM T, 1990, ALCOHOL CLIN EXP RES, V14, P92, DOI 10.1111/j.1530-0277.1990.tb00453.x; Phillips TJ, 1998, NAT NEUROSCI, V1, P610, DOI 10.1038/2843; ROACH MK, 1968, CLIN CHIM ACTA, V21, P275, DOI 10.1016/0009-8981(68)90138-1; SPINOSA G, 1988, ALCOHOL CLIN EXP RES, V12, P65, DOI 10.1111/j.1530-0277.1988.tb00134.x; SYBERTZ EJ, 1987, J CARDIOVASCULAR S7, V10, P105; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; TERDAL ES, 1994, ALCOHOL CLIN EXP RES, V18, P542, DOI 10.1111/j.1530-0277.1994.tb00907.x; Thiele TE, 1998, NATURE, V396, P366, DOI 10.1038/24614; Urata H, 1995, EUR HEART J, V16, P79, DOI 10.1093/eurheartj/16.suppl_N.79; Walther T, 1999, BEHAV BRAIN RES, V100, P1, DOI 10.1016/S0166-4328(98)00078-3; Weisinger RS, 1999, AM J PHYSIOL-REG I, V277, pR162; Weisinger RS, 1999, PHYSIOL BEHAV, V67, P369, DOI 10.1016/S0031-9384(99)00085-2	29	30	34	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1640	+		10.1096/fj.00-097fje	http://dx.doi.org/10.1096/fj.00-097fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427512				2022-12-28	WOS:000173707700008
J	Wilting, J; Papoutsi, M; Christ, B; Nicolaides, KH; von Kaisenberg, CS; Borges, J; Stark, GB; Alitalo, K; Tomarev, SI; Niemeyer, C; Rossler, J				Wilting, J; Papoutsi, M; Christ, B; Nicolaides, KH; von Kaisenberg, CS; Borges, J; Stark, GB; Alitalo, K; Tomarev, SI; Niemeyer, C; Rossler, J			The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues	FASEB JOURNAL			English	Article						human fetus; lymphedema; lymphangioma; hemangioma; lymphangiogenesis	GROWTH-FACTOR RECEPTOR-3; VASCULAR TUMORS; VEGF-C; EXPRESSION; BLOOD; GENE; LYMPHANGIOGENESIS; PROMOTES; CD31; LOCALIZATION	Detection of lymphatic endothelal cells (LECs) has been problematic because of the lack of specific markers. The homeobox transcription factor Prox1 is expressed in LECs of murine and avian embryos. We have studied expression of Prox1 in human tissues with immunofluorescence. In 19-wk-old human fetuses, Prox1 and vascular endothelial growth factor receptor-3 (VEGFR-3) are coexpressed in LECs of lymphatic trunks and lymphatic capillaries. Prox1 is located in the nucleus, and its expression is mutually exclusive with that of the blood vascular marker PAL-E. Prox1 is a constitutive marker of LECs and is found in tissues of healthy adults and lymphedema patients. Blood vascular endothelial cells (BECs) of hemangiomas express CD31 and CD34, but not Prox1. A subset of these cells is positive for VEGFR-3. Lymphatics in the periphery of hemangiomas express Prox1 and CD31, but not CD34. In lymphangiomas, LECs express Prox1, CD31, and VEGFR-3, but rarely CD34. In the stroma, spindle-shaped CD34-positive cells are present. We show that Prox1 is a reliable marker for LECs in normal and pathologic human tissues, coexpressed with VEGFR-3 and CD31. VEGFR-3 and CD34 are less reliable markers for LECs and BECs, respectively, because exceptions from their normal expression patterns are found in pathologic tissues.	Univ Freiburg, Inst Anat, D-79104 Freiburg, Germany; Kings Coll Hosp London, Harris Birthright Res Ctr Fetal Med, London, England; Univ Kiel, Frauenklin, D-24105 Kiel, Germany; Univ Freiburg, Abt Plast & Handchirurg, D-79104 Freiburg, Germany; Univ Helsinki, Mol & Canc Biol Lab, FIN-00014 Helsinki, Finland; NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Freiburg, Zentrum Kinderheilkunde & Jugendmed, D-79104 Freiburg, Germany	University of Freiburg; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Kiel; University of Freiburg; University of Helsinki; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of Freiburg	Wilting, J (corresponding author), Univ Freiburg, Inst Anat, Albertstr 17, D-79104 Freiburg, Germany.	Joerg.Wilting@anat.uni-freiburg.de	von Kaisenberg, Constantin/AAR-2756-2021; Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Nicolaides, Kypros/0000-0003-1266-0711; Rossler, Jochen/0000-0003-4022-4917	NATIONAL EYE INSTITUTE [Z01EY000311, ZIAEY000311] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141; Carreira CM, 2001, CANCER RES, V61, P8079; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Duncan GS, 1999, J IMMUNOL, V162, P3022; FOLKMAN J, 1974, CANCER RES, V34, P2109; Folpe AL, 2000, MODERN PATHOL, V13, P180, DOI 10.1038/modpathol.3880033; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KATO S, 1990, ACTA HISTOCHEM CYTOC, V23, P613, DOI 10.1267/ahc.23.613; Kinmonth JB, 1972, LYMPHATICS DIS LYMPH, V1st; Kriehuber E, 2001, J EXP MED, V194, P797, DOI 10.1084/jem.194.6.797; Lymboussaki A, 1998, AM J PATHOL, V153, P395, DOI 10.1016/S0002-9440(10)65583-6; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; MCNEILL GC, 1989, RADIOLOGY, V172, P495, DOI 10.1148/radiology.172.2.2748831; MIETTINEN M, 1994, MODERN PATHOL, V7, P82; NOSE K, 1990, CELL GROWTH DIFFER, V1, P511; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; Paal E, 1998, CANCER-AM CANCER SOC, V82, P2150, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2150::AID-CNCR9>3.0.CO;2-Z; Papoutsi M, 2000, HISTOCHEM CELL BIOL, V113, P105, DOI 10.1007/s004180050013; Papoutsi M, 2001, DEV DYNAM, V222, P238, DOI 10.1002/dvdy.1187; Papoutsi M, 2000, HISTOCHEM CELL BIOL, V114, P373; Partanen TA, 1999, CANCER-AM CANCER SOC, V86, P2406, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.3.CO;2-5; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; POLKINGHORNE J, 1989, CM762; Rodriguez-Niedenfuhr M, 2001, ANAT EMBRYOL, V204, P399, DOI 10.1007/s00429-001-0214-9; Sauter B, 1998, J HISTOCHEM CYTOCHEM, V46, P165, DOI 10.1177/002215549804600205; SCHLINGEMANN RO, 1985, LAB INVEST, V52, P71; SIMMONS DL, 1990, J EXP MED, V171, P2147, DOI 10.1084/jem.171.6.2147; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sleeman JP, 2001, MICROSC RES TECHNIQ, V55, P61, DOI 10.1002/jemt.1157; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sosa-Pineda B, 2000, NAT GENET, V25, P254, DOI 10.1038/76996; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Tomarev SI, 1996, DEV DYNAM, V206, P354, DOI 10.1002/(SICI)1097-0177(199608)206:4<354::AID-AJA2>3.0.CO;2-H; Tomarev SI, 1998, BIOCHEM BIOPH RES CO, V248, P684, DOI 10.1006/bbrc.1998.8989; Vikkula M, 1998, TRENDS CARDIOVAS MED, V8, P281, DOI 10.1016/S1050-1738(98)00024-3; von Kaisenberg CS, 1999, HUM REPROD, V14, P823, DOI 10.1093/humrep/14.3.823; Wetterwald A, 1996, BONE, V18, P125, DOI 10.1016/8756-3282(95)00457-2; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wilting J, 1997, CELL TISSUE RES, V288, P207, DOI 10.1007/s004410050807; Wilting J, 2001, MICROSC RES TECHNIQ, V55, P81, DOI 10.1002/jemt.1159; Witte MH, 2001, MICROSC RES TECHNIQ, V55, P122, DOI 10.1002/jemt.1163; Zinovieva RD, 1996, GENOMICS, V35, P517, DOI 10.1006/geno.1996.0392	44	135	150	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1271	+		10.1096/fj.01-1010fje	http://dx.doi.org/10.1096/fj.01-1010fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060670				2022-12-28	WOS:000176683900038
J	Zhu, XL; Wheeler, MT; Hadhazy, M; Lam, MYJ; McNally, EM				Zhu, XL; Wheeler, MT; Hadhazy, M; Lam, MYJ; McNally, EM			Cardiomyopathy is independent of skeletal muscle disease in muscular dystrophy	FASEB JOURNAL			English	Article						gene therapy; dystrophin; sarcoglycan	MDX MOUSE; GLYCOPROTEIN COMPLEX; GAMMA-SARCOGLYCAN; ANIMAL-MODELS; DILATED CARDIOMYOPATHY; DELTA-SARCOGLYCAN; MOLECULAR-BASIS; SMOOTH-MUSCLE; GENE; DUCHENNE	Dystrophin and its associated proteins, the sarcoglycans, are normally expressed in heart and skeletal muscle. Mutations that alter the expression of these membrane-associated proteins lead to muscular dystrophy (MD) and cardiomyopathy in humans. Because of the timing and nature of the accompanying cardiomyopathy, it has been suggested that cardiomyopathy develops as a secondary consequence of skeletal muscle dysfunction in the muscular dystrophies. To determine whether skeletal muscle dystrophy contributes to the development of sarcoglycan-mediated cardiomyopathy, we used mice lacking gamma-sarcoglycan and inserted a transgene that "rescued" sarcoglycan expression only in skeletal muscle. gamma-Sarcoglycan was expressed in skeletal muscle under the control of the skeletal muscle-specific myosin light chain 1/3 promoter. gamma-Sarcoglycan-null mice expressing this transgene fully restore gamma-sarcoglycan expression. Furthermore, the transgene-rescued mice lack the focal necrosis and membrane permeability defects that are a hallmark of MD. Despite correction of the skeletal muscle disease, focal degeneration and membrane permeability abnormalities persisted in cardiac muscle, and notably persisted in the right ventricle. Therefore, heart and skeletal muscle defects are independent processes in sarcoglycan-mediated muscular dystrophies and, as such, therapy should target both skeletal and cardiac muscle correction to prevent sudden death due to cardiomyopathy in the muscular dystrophies.	Univ Chicago, Dept Med, Cardiol Sect, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	McNally, EM (corresponding author), Univ Chicago, Dept Med, Cardiol Sect, 5841 S Maryland,MC 6088, Chicago, IL 60637 USA.	emcnally@medicine.bsd.uchicago.edu		Wheeler, Matthew/0000-0001-8721-3022; McNally, Elizabeth/0000-0002-1221-719X				Allamand V, 2000, HUM MOL GENET, V9, P2459, DOI 10.1093/hmg/9.16.2459; ANDERSON JE, 1987, ANAT REC, V219, P243, DOI 10.1002/ar.1092190305; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; Bonnemann Carsten G., 1996, Current Opinion in Pediatrics, V8, P569; Bonnemann CG, 1996, HUM MOL GENET, V5, P1953, DOI 10.1093/hmg/5.12.1953; Calvo F, 2000, NEUROMUSCULAR DISORD, V10, P560, DOI 10.1016/S0960-8966(00)00147-4; CONWAY RS, 1987, CARDIOVASC RES, V21, P796, DOI 10.1093/cvr/21.11.796; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P299, DOI 10.1111/j.1365-2990.1988.tb00890.x; Cox GF, 1997, CURR OPIN CARDIOL, V12, P329; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; Fadic R, 1996, NEW ENGL J MED, V334, P362, DOI 10.1056/NEJM199602083340604; Gnecchi-Ruscone T, 1999, MUSCLE NERVE, V22, P1549, DOI 10.1002/(SICI)1097-4598(199911)22:11<1549::AID-MUS10>3.0.CO;2-A; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Hack AA, 2000, MICROSC RES TECHNIQ, V48, P167, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<167::AID-JEMT5>3.0.CO;2-T; Hack AA, 2000, J CELL SCI, V113, P2535; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; Hack AA, 1999, P NATL ACAD SCI USA, V96, P10723, DOI 10.1073/pnas.96.19.10723; Heydemann A, 2001, CURR OPIN CARDIOL, V16, P211, DOI 10.1097/00001573-200105000-00009; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOGAN B, 1994, MANIPULATING MOUSE E, P115; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; McNally EM, 1996, HUM MOL GENET, V5, P1841, DOI 10.1093/hmg/5.11.1841; McNally EM, 1996, NEW ENGL J MED, V334, P1610; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; Megeney LA, 1999, P NATL ACAD SCI USA, V96, P220, DOI 10.1073/pnas.96.1.220; Muntoni F, 1997, HEART, V78, P608, DOI 10.1136/hrt.78.6.608; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; PERLOFF JK, 1967, AM J MED, V42, P179, DOI 10.1016/0002-9343(67)90017-4; PERLOFF JK, 1984, J AM COLL CARDIOL, V3, P1263, DOI 10.1016/S0735-1097(84)80186-2; Petrof BJ, 1998, MOL CELL BIOCHEM, V179, P111, DOI 10.1023/A:1006812004945; Politano L, 1996, JAMA-J AM MED ASSOC, V275, P1335, DOI 10.1001/jama.275.17.1335; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Stedman Hansell, 2000, Human Gene Therapy, V11, P777; Straub V, 1999, J BIOL CHEM, V274, P27989, DOI 10.1074/jbc.274.39.27989; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Tsubata S, 2000, J CLIN INVEST, V106, P655, DOI 10.1172/JCI9224; van der Kooi AJ, 1998, HEART, V79, P73, DOI 10.1136/hrt.79.1.73; YAMAMOTO H, 1994, J BIOCHEM-TOKYO, V115, P162, DOI 10.1093/oxfordjournals.jbchem.a124294; Zatz M, 2000, CURR OPIN NEUROL, V13, P511, DOI 10.1097/00019052-200010000-00002; Zhu XL, 2000, FEBS LETT, V474, P71, DOI 10.1016/S0014-5793(00)01570-2	48	16	18	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7					1096	+		10.1096/fj.01-0954fje	http://dx.doi.org/10.1096/fj.01-0954fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039854				2022-12-28	WOS:000175973900014
J	Charron, G; Laforest, S; Gagnon, C; Drolet, G; Mouginot, D				Charron, G; Laforest, S; Gagnon, C; Drolet, G; Mouginot, D			Acute sodium deficit triggers plasticity of the brain angiotensin type 1 receptors	FASEB JOURNAL			English	Article						hydromineral hemeostasis; salt appetite; furosemide; renin-angiotensin system; hypothalamus	MEDIAN PREOPTIC NUCLEUS; C-FOS EXPRESSION; SUBFORNICAL ORGAN; SALT APPETITE; LAMINA TERMINALIS; PARAVENTRICULAR NUCLEUS; PERIPHERAL ANGIOTENSIN; AT(1) RECEPTOR; II RECEPTORS; RAT-BRAIN	The brain renin-angiotensin system (bRAS) is involved in the control of hydromineral balance. However, little information is available on the functional regulation of the bRAS as a consequence of sodium deficit in the extracellular fluid compartments. We used a pharmacological model of acute Na+ depletion (furosemide injections) to investigate changes of a major component of the bRAS, the hypothalamic angiotensin type 1A (AT(1A)) receptors. Furosemide induced a rapid and long-lasting expression of the AT(1A) mRNA in the subfornical organ, the median preoptic nucleus (MnPO), and the parvocellular division of the paraventricular nucleus (pPVN). Na+ depletion increased the number of cells expressing AT(1A) mRNA in the pPVN, but not in the MnPO. The enhancement of AT(1A) mRNA expression was associated with an increase in AT(1) binding sites in all the regions studied. It is of interest that in the paraventricular nucleus, the majority of the neurons expressing AT(1A) mRNA also showed an increase in metabolic activity (Fos-related antigen immunoreactivity [FRA-ir]). By contrast, in the MnPO, we observe two distinct cell populations. Our data demonstrated that an acute Na+ deficit induced a functional regulation of the hypothalamic AT(1A) receptors, indicating that these receptors are subject to plasticity in response to hydromineral perturbations.	Univ Laval, CHUL, Ctr Rech, Unite Neurosci, Quebec City, PQ G1V 4G2, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada	Laval University; Universite de Montreal	Mouginot, D (corresponding author), Univ Laval, CHUL, Ctr Rech, Unite Neurosci, Local RC9800,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	didier.mouginot@crchul.ulaval.ca						AGUILERA G, 1981, CIRC RES, V49, P751, DOI 10.1161/01.RES.49.3.751; AGUILERA G, 1995, J NEUROENDOCRINOL, V7, P775, DOI 10.1111/j.1365-2826.1995.tb00714.x; BADOER E, 1993, BRAIN RES, V610, P216, DOI 10.1016/0006-8993(93)91403-F; Bai D, 1998, AM J PHYSIOL-REG I, V275, pR632, DOI 10.1152/ajpregu.1998.275.2.R632; BELLUCCI A, 1984, J CLIN INVEST, V74, P1593, DOI 10.1172/JCI111575; CHENG HF, 1995, J CLIN INVEST, V95, P2012, DOI 10.1172/JCI117886; Denton DA, 1996, P NATL ACAD SCI USA, V93, P7397, DOI 10.1073/pnas.93.14.7397; Dumont EC, 1999, NEUROSCIENCE, V93, P877, DOI 10.1016/S0306-4522(99)00206-7; Ferguson AV, 2001, EXP BIOL MED, V226, P85, DOI 10.1177/153537020122600205; Ferguson AV, 1998, PROG NEUROBIOL, V54, P169, DOI 10.1016/S0301-0082(97)00065-8; Fitch GK, 2000, BRAIN RES, V861, P363, DOI 10.1016/S0006-8993(00)02048-5; Fitch GK, 2000, BRAIN RES, V861, P377, DOI 10.1016/S0006-8993(00)02049-7; Fitts DA, 1996, AM J PHYSIOL-REG I, V270, pR1092, DOI 10.1152/ajpregu.1996.270.5.R1092; FITTS DA, 1990, BEHAV NEUROSCI, V104, P818, DOI 10.1037/0735-7044.104.5.818; Fitzsimons JT, 1998, PHYSIOL REV, V78, P583, DOI 10.1152/physrev.1998.78.3.583; FLUHARTY SJ, 1983, BEHAV NEUROSCI, V97, P746, DOI 10.1037/0735-7044.97.5.746; GALAVERNA O, 1992, BRAIN RES BULL, V28, P89, DOI 10.1016/0361-9230(92)90234-O; GENOVESI S, 1993, CIRC RES, V73, P906, DOI 10.1161/01.RES.73.5.906; Giles ME, 1999, J HISTOCHEM CYTOCHEM, V47, P507, DOI 10.1177/002215549904700409; HAN L, 1995, NEUROSCI LETT, V193, P173, DOI 10.1016/0304-3940(95)11693-Q; HERBERT J, 1992, NEUROSCIENCE, V51, P867, DOI 10.1016/0306-4522(92)90526-8; JALOWIEC JE, 1974, BEHAV BIOL, V10, P313, DOI 10.1016/S0091-6773(74)91914-2; JARVIS MF, 1994, PEPTIDES, V15, P1037, DOI 10.1016/0196-9781(94)90068-X; Johnson AK, 1997, FRONT NEUROENDOCRIN, V18, P292, DOI 10.1006/frne.1997.0153; Lane JM, 1997, NEUROSCIENCE, V78, P1167, DOI 10.1016/S0306-4522(96)00604-5; LEBRUN CJ, 1995, NEUROSCIENCE, V65, P93, DOI 10.1016/0306-4522(94)00482-K; Lenkei Z, 1998, NEUROSCIENCE, V82, P827; LI Z, 1993, NEUROSCIENCE, V55, P197, DOI 10.1016/0306-4522(93)90466-S; LI ZH, 1993, AM J PHYSIOL, V265, pR302, DOI 10.1152/ajpregu.1993.265.2.R302; LIND RW, 1984, BRAIN RES, V321, P209, DOI 10.1016/0006-8993(84)90174-4; Mansi JA, 1997, AM J PHYSIOL-REG I, V272, pR813, DOI 10.1152/ajpregu.1997.272.3.R813; McKinley MJ, 1999, J CLIN NEUROSCI, V6, P289, DOI 10.1016/S0967-5868(99)90050-4; MCKINLEY MJ, 1995, BRAIN RES BULL, V37, P131, DOI 10.1016/0361-9230(94)00266-4; Nickenig G, 1998, HYPERTENSION, V31, P1272, DOI 10.1161/01.HYP.31.6.1272; NISSEN R, 1994, J PHYSIOL-LONDON, V479, P207, DOI 10.1113/jphysiol.1994.sp020289; Oldfield BJ, 2001, J NEUROENDOCRINOL, V13, P139, DOI 10.1046/j.1365-2826.2001.00597.x; OLDFIELD BJ, 1994, NEUROSCIENCE, V60, P255, DOI 10.1016/0306-4522(94)90219-4; Potts PD, 2000, NEUROSCIENCE, V95, P499; ROWLAND NE, 1994, BRAIN RES BULL, V33, P427, DOI 10.1016/0361-9230(94)90286-0; Rowland NE, 1996, BRAIN RES, V728, P90; SAKAI RR, 1989, BEHAV NEUROSCI, V103, P186, DOI 10.1037/0735-7044.103.1.186; SAKAI RR, 1987, BEHAV NEUROSCI, V101, P724, DOI 10.1037/0735-7044.101.5.724; SAKAI RR, 1990, APPETITE, V15, P161, DOI 10.1016/0195-6663(90)90017-3; SANDBERG K, 1994, HYPERTENSION S1, V23, P137; Schmid C, 1997, HYPERTENSION, V29, P923, DOI 10.1161/01.HYP.29.4.923; SHEN E, 1992, J AUTONOM NERV SYST, V37, P227, DOI 10.1016/0165-1838(92)90045-I; SPINEDI E, 1983, NEUROENDOCRINOLOGY, V37, P446, DOI 10.1159/000123591; Starbuck EM, 1998, APPETITE, V31, P309, DOI 10.1006/appe.1998.0169; Strehlow K, 1999, AM J PHYSIOL-HEART C, V277, pH1701, DOI 10.1152/ajpheart.1999.277.5.H1701; Swanson L. W., 1992, BRAIN MAPS STRUCTURE; THUNHORST RL, 1994, AM J PHYSIOL, V267, pR171, DOI 10.1152/ajpregu.1994.267.1.R171; THUNHORST RL, 1990, BEHAV NEUROSCI, V104, P637, DOI 10.1037/0735-7044.104.4.637; Thunhorst RL, 1998, AM J PHYSIOL-REG I, V274, pR1807; THUNHORST RL, 1987, AM J PHYSIOL, V252, pR409, DOI 10.1152/ajpregu.1987.252.2.R409; Thunhorst RL, 1996, NEUROSCI BIOBEHAV R, V20, P101, DOI 10.1016/0149-7634(95)00050-O; TRAVIS KA, 1993, AM J PHYSIOL, V264, pR1200, DOI 10.1152/ajpregu.1993.264.6.R1200; Wang DH, 1998, J HYPERTENS, V16, P467, DOI 10.1097/00004872-199816040-00008; WEISINGER RS, 1990, BRAIN RES, V526, P23, DOI 10.1016/0006-8993(90)90245-7; WEISS ML, 1986, AM J PHYSIOL, V250, pR250, DOI 10.1152/ajpregu.1986.250.2.R250; ZHANG DM, 1984, PHYSIOL BEHAV, V32, P677, DOI 10.1016/0031-9384(84)90325-1	60	26	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					610	+		10.1096/fj.01-0531fje	http://dx.doi.org/10.1096/fj.01-0531fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919170				2022-12-28	WOS:000174203700004
J	Benelli, R; Morini, M; Carrozzino, F; Ferrari, N; Minghelli, S; Santi, L; Cassatella, M; Noonan, DM; Albini, A				Benelli, R; Morini, M; Carrozzino, F; Ferrari, N; Minghelli, S; Santi, L; Cassatella, M; Noonan, DM; Albini, A			Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation	FASEB JOURNAL			English	Article						neutrophils; chemokines; tumor growth; CXCR2; monocytes	MICROVASCULAR ENDOTHELIAL-CELLS; ACTIVATED PROTEIN-KINASES; LEWIS-LUNG-CARCINOMA; HIV-1 TAT PROTEIN; GROWTH-FACTOR; IN-VIVO; CARCINOGENESIS; CHEMOTAXIS; CHEMOKINES; MACROPHAGE	Angiostatin effectively blocks tumor angiogenesis through still poorly understood mechanisms. Given the close association between immune and vascular regulation, we investigated the effects of angiostatin on angiogenesis-associated leukocytes. Angiostatin inhibited the migration of monocytes and, even more markedly, neutrophils. Angiostatin blocked chemotaxis of neutrophils to CXCR2 chemokine receptor agonists (IL-8, MIP-2, and GRO alpha), formyl-Met-Leu-Phe (fMLP), and 12-O-tetradecanoylphorbol 13-acetate, and repressed fMLP-induced mitochondrial activity. Two different angiostatin forms (kringles 1-4 and 1-3) were effective, whereas whole plasminogen had no effect. IL-8, MIP-2, and GRO alpha induced intense angiogenic reactions in vivo, but no angiogenic response to these factors was observed in neutropenic mice, demonstrating an essential role for neutrophils. Angiostatin potently inhibited chemokine-induced angiogenesis in vivo, and consistent with in vitro observations, both angiostatin forms were active and whole plasminogen had little effect. Angiostatin inhibition of angiogenesis in vivo was accompanied by a striking reduction in the number of recruited leukocytes. In vivo, the inflammatory agent lipopolysaccharide also induced extensive leukocyte infiltration and angiogenesis that were blocked by angiostatin. Neutrophils expressed mRNAs for ATP synthase and angiomotin, two known angiostatin receptors. These data show that angiostatin directly inhibits neutrophil migration and neutrophil-mediated angiogenesis and indicate that angiostatin might inhibit inflammation.	Ctr Biotecnol Avanzate, Ist Nazl Ric Canc, Mol Biol Lab, I-16132 Genoa, Italy; Ist Nazl Ric Canc, Tumor Progress Sect, I-16132 Genoa, Italy; Univ Genoa, Dept Oncol Biol & Biotechnol, Genoa, Italy; Univ Verona, Dept Pathol, Gen Pathol Sect, I-37134 Verona, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS AOU San Martino IST; University of Genoa; University of Verona	Albini, A (corresponding author), Ctr Biotecnol Avanzate, Ist Nazl Ric Canc, Mol Biol Lab, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.	adriana.albini@istge.it	Benelli, Roberto/AAF-3143-2019; Noonan, Douglas M/A-8620-2010; Ferrari, Nicoletta/AAG-6049-2019; Cassatella, M A/B-8037-2013	Benelli, Roberto/0000-0002-9769-0954; Noonan, Douglas M/0000-0001-8058-0719; Ferrari, Nicoletta/0000-0002-6027-1035; Cassatella, M A/0000-0001-7824-1806; Albini, Adriana/0000-0002-9624-5103				Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; Albini A, 1996, ONCOGENE, V12, P289; Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Albini A, 1998, J BIOL CHEM, V273, P15895, DOI 10.1074/jbc.273.26.15895; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Benelli R, 2000, J INFECT DIS, V182, P1643, DOI 10.1086/317597; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; Cassatella MA, 1999, ADV IMMUNOL, V73, P369, DOI 10.1016/S0065-2776(08)60791-9; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Di Carlo E, 2001, BLOOD, V97, P339, DOI 10.1182/blood.V97.2.339; Di Carlo E, 2000, J IMMUNOL, V165, P3111, DOI 10.4049/jimmunol.165.6.3111; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Falcone DJ, 1998, J BIOL CHEM, V273, P31480, DOI 10.1074/jbc.273.47.31480; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; Fidler IJ, 2000, CANCER J, V6, pS134; Griscelli F, 1998, P NATL ACAD SCI USA, V95, P6367, DOI 10.1073/pnas.95.11.6367; Herren T, 2001, BLOOD, V97, P1070, DOI 10.1182/blood.V97.4.1070; Kasama T, 2000, CLIN EXP IMMUNOL, V121, P533, DOI 10.1046/j.1365-2249.2000.01272.x; KIBBEY MC, 1994, J CELL PHYSIOL, V160, P185, DOI 10.1002/jcp.1041600121; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Liu J, 1999, J BIOL CHEM, V274, P15781, DOI 10.1074/jbc.274.22.15781; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Lu H, 1999, BIOCHEM BIOPH RES CO, V258, P668, DOI 10.1006/bbrc.1999.0612; Lucas R, 1998, BLOOD, V92, P4730; Luo JY, 1998, BIOCHEM BIOPH RES CO, V245, P906, DOI 10.1006/bbrc.1998.8529; Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PASSANITI A, 1992, LAB INVEST, V67, P519; Polverini P J, 1997, EXS, V79, P11; Redlitz A, 1999, J VASC RES, V36, P28, DOI 10.1159/000025623; Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com; Schnyder B, 1999, LAB INVEST, V79, P1403; Stack MS, 1999, BIOCHEM J, V340, P77, DOI 10.1042/0264-6021:3400077; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Underwood DC, 2000, AM J PHYSIOL-LUNG C, V279, pL895, DOI 10.1152/ajplung.2000.279.5.L895	47	145	156	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					267	+		10.1096/fj.01-0651fje	http://dx.doi.org/10.1096/fj.01-0651fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11772950				2022-12-28	WOS:000172964800003
J	Deluca, HF; Cantorna, MT				Deluca, HF; Cantorna, MT			Vitamin D: its role and uses in immunology	FASEB JOURNAL			English	Review						autoimmune diseases; vitamin D as immunomodulator; inflammatory disease; vitamin D and immunity	1,25-DIHYDROXYVITAMIN D-3; PARATHYROID-GLANDS; IMMUNE-SYSTEM; UP-REGULATION; D RECEPTOR; IN-VIVO; MICE; EXPRESSION; ENCEPHALOMYELITIS; DIFFERENTIATION	In recent years there has been an effort to understand possible noncalcemic roles of vitamin D, including its role in the immune system and, in particular, on T cell-medicated immunity. Vitamin D receptor is found in significant concentrations in the T lymphocyte and macrophage populations. However, its highest concentration is in the immature immune cells of the thymus and the mature CD-8 T lymphocytes. The significant role of vitamin D compounds as selective immunosuppressants is illustrated by their ability to either prevent or markedly suppress animal models of autoimmune disease. Results show that 1,25-dihydroxyvitamin D-3 can either prevent or markedly suppress experimental autoimmune encephalomyelitis, rheumatoid arthritis, systemic lupus erythematosus, type I diabetes, and inflammatory bowel disease. In almost every case, the action of the vitamin D hormone requires that the animals be maintained on a normal or high calcium diet. Possible mechanisms of suppression of these autoimmune disorders by the vitamin D hormone have been presented. The vitamin D hormone stimulates transforming growth factor TGF beta -1 and interleukin 4 (IL-4) production, which in turn may suppress inflammatory T cell activity. In support of this, the vitamin D hormone is unable to suppress a murine model of the human disease multiple sclerosis in IL-4-deficient mice. The results suggest an important role for vitamin D in autoimmune disorders and provide a fertile and interesting area of research that may yield important new therapies.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Penn State Univ, Dept Nutr, University Pk, PA 16802 USA	University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Deluca, HF (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	deluca@biochem.wisc.edu						ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; ABE J, 1989, ENDOCRINOLOGY, V124, P2645, DOI 10.1210/endo-124-5-2645; BRUMBAUGH PF, 1975, LIFE SCI, V16, P353, DOI 10.1016/0024-3205(75)90256-8; Cantorna MT, 1999, J NUTR, V129, P1966, DOI 10.1093/jn/129.11.1966; Cantorna MT, 2000, J NUTR, V130, P2648, DOI 10.1093/jn/130.11.2648; Cantorna MT, 1996, P NATL ACAD SCI USA, V93, P7861, DOI 10.1073/pnas.93.15.7861; Cantorna MT, 1998, TRANSPLANTATION, V66, P828, DOI 10.1097/00007890-199810150-00003; Cantorna MT, 2000, ARCH BIOCHEM BIOPHYS, V377, P135, DOI 10.1006/abbi.2000.1765; Cantorna MT, 1998, J NUTR, V128, P68, DOI 10.1093/jn/128.1.68; Cantorna MT, 1998, J IMMUNOL, V160, P5314; DELUCA HF, 1992, ANN NY ACAD SCI, V669, P59; DELUCA HF, 1981, HARVEY LECT, V75, P333; DELUCA HF, 1974, FED PROC, V33, P2211; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; Fleming JO, 2000, NEUROLOGY, V54, pA338; HUGHES MR, 1978, J BIOL CHEM, V253, P1065; Hullett DA, 1998, TRANSPLANTATION, V66, P824, DOI 10.1097/00007890-199810150-00002; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; KORKOR AB, 1987, NEW ENGL J MED, V316, P1573, DOI 10.1056/NEJM198706183162504; KREAM BE, 1976, ARCH BIOCHEM BIOPHYS, V176, P779, DOI 10.1016/0003-9861(76)90222-8; Leeuwen J. P. T. M. van, 1997, Vitamin D., P1089; LEMIRE JM, 1992, AUTOIMMUNITY, V12, P143, DOI 10.3109/08916939209150321; LEMIRE JM, 1992, TRANSPLANTATION, V54, P762, DOI 10.1097/00007890-199210000-00046; LUND J, 1966, J LIPID RES, V7, P739; MANOLAGAS SC, 1985, MOL CELL ENDOCRINOL, V43, P113, DOI 10.1016/0303-7207(85)90074-7; MANOLAGAS SC, 1986, J LAB CLIN MED, V108, P595; MATHIEU C, 1994, DIABETOLOGIA, V37, P552, DOI 10.1007/BF00403372; MORII H, 1967, ARCH BIOCHEM BIOPHYS, V120, P508, DOI 10.1016/0003-9861(67)90510-3; REINHARDT TA, 1984, J CLIN ENDOCR METAB, V58, P91, DOI 10.1210/jcem-58-1-91; SLATOPOLSKY ES, 1997, VITAMIN D, V52, P840; STUMPF WE, 1979, SCIENCE, V206, P1188, DOI 10.1126/science.505004; Stumpf WE, 1981, HORMONAL CONTROL CAL, P222; TANAKA H, 1982, BIOCHEM J, V204, P713, DOI 10.1042/bj2040713; USKOKOVIC MR, 2000, VITAMIN D, P1045; Veldman CM, 2000, ARCH BIOCHEM BIOPHYS, V374, P334, DOI 10.1006/abbi.1999.1605; WIESE RJ, 1992, J BIOL CHEM, V267, P20082; YANG SL, 1993, ARCH BIOCHEM BIOPHYS, V303, P98, DOI 10.1006/abbi.1993.1260; YANG SL, 1993, BIOCHIM BIOPHYS ACTA, V1158, P279, DOI 10.1016/0304-4165(93)90026-5; YU XP, 1991, J BIOL CHEM, V266, P7588; Zella JB, 2001, FASEB J, V15, pA959	40	618	668	0	85	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					2579	2585		10.1096/fj.01-0433rev	http://dx.doi.org/10.1096/fj.01-0433rev			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726533				2022-12-28	WOS:000172964800027
J	Karymov, MA; Tomschik, M; Leuba, SH; Caiafa, P; Zlatanova, J				Karymov, MA; Tomschik, M; Leuba, SH; Caiafa, P; Zlatanova, J			DNA methylation-dependent chromatin fiber compaction in vivo and in vitro: requirement for linker histone	FASEB JOURNAL			English	Article						histone H1; chromatin fibers; atomic force microscopy	SCANNING FORCE MICROSCOPY; CPG METHYLATION; CORE PARTICLES; H1 HISTONE; RNA GENE; NUCLEOSOME; POLY(ADP-RIBOSYL)ATION; BINDING; TRANSCRIPTION; REPRESSION	Dynamic alterations in chromatin structure mediated by postsynthetic histone modifications and DNA methylation constitute a major regulatory mechanism in DNA functioning. DNA methylation has been implicated in transcriptional silencing, in part by inducing chromatin condensation. To understand the methylation-dependent chromatin structure, we performed atomic force microscope (AFM) studies of fibers isolated from cultured cells containing normal or elevated levels of m(5)C. Chromatin fibers were reconstituted on control or methylated DNA templates in the presence or absence of linker histone. Visual inspection of AFM images, combined with quantitative analysis of fiber structural parameters, suggested that DNA methylation induced fiber compaction only in the presence of linker histones. This conclusion was further substantiated by biochemical results.	Polytech Univ, Dept Chem & Chem Engn, Brooklyn, NY 11201 USA; NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA; Univ Roma La Sapienza, Dept Cellular Biotechnol & Haematol, I-00161 Rome, Italy	New York University; Polytechnic University Puerto Rico; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Sapienza University Rome	Zlatanova, J (corresponding author), Polytech Univ, Dept Chem & Chem Engn, 6 Metrotech Ctr, Brooklyn, NY 11201 USA.	leuba@nih.gov; jzlatano@duke.poly.edu	, Miroslav/AAD-9416-2020; Zlatanova, Jordanka/B-3273-2009	, Miroslav/0000-0002-0758-6169; Leuba, Sanford/0000-0003-0278-7997				An WJ, 1998, P NATL ACAD SCI USA, V95, P3396, DOI 10.1073/pnas.95.7.3396; Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; CAIAFA P, 1986, BIOCHIM BIOPHYS ACTA, V867, P195, DOI 10.1016/0167-4781(86)90034-5; CARTWRIGHT IL, 1989, METHOD ENZYMOL, V170, P359; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Davey C, 1997, J MOL BIOL, V267, P276, DOI 10.1006/jmbi.1997.0899; De Capoa A, 1999, FASEB J, V13, P89; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; DREW HR, 1987, J MOL BIOL, V197, P485, DOI 10.1016/0022-2836(87)90560-2; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; Feil R, 1999, TRENDS GENET, V15, P431, DOI 10.1016/S0168-9525(99)01822-3; FELSENFELD G, 1982, COLD SPRING HARB SYM, V47, P577; GEORGEL P, 1993, J BIOL CHEM, V268, P1947; Gunjan A, 1999, J BIOL CHEM, V274, P37950, DOI 10.1074/jbc.274.53.37950; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 2000, CURR BIOL, V10, pR60, DOI 10.1016/S0960-9822(00)00286-4; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HULETSKY A, 1989, J BIOL CHEM, V264, P8878; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leuba SH, 1998, BIOPHYS J, V74, P2830, DOI 10.1016/S0006-3495(98)77990-1; LEUBA SH, 1994, J MOL BIOL, V235, P871, DOI 10.1006/jmbi.1994.1045; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; Leuba SH, 1998, BIOPHYS J, V74, P2823, DOI 10.1016/S0006-3495(98)77989-5; Leuba SH, 1999, METH MOL B, V119, P143; LEWIS J, 1991, FEBS LETT, V285, P155, DOI 10.1016/0014-5793(91)80795-5; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; NIGHTINGALE K, 1995, J BIOL CHEM, V270, P4197, DOI 10.1074/jbc.270.9.4197; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; RANKIN PW, 1989, J BIOL CHEM, V264, P4312; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Razin Aharon, 1999, Results and Problems in Cell Differentiation, V25, P189; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; van Holde K.E., 1988, CHROMATIN; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; YAGER TD, 1989, BIOCHEMISTRY-US, V28, P2271, DOI 10.1021/bi00431a045; Zardo G, 1999, FASEB J, V13, P1518, DOI 10.1096/fasebj.13.12.1518; Zardo G, 1998, BIOL CHEM, V379, P647; Zardo G, 1998, J BIOL CHEM, V273, P16517, DOI 10.1074/jbc.273.26.16517; Zardo G, 1997, BIOCHEMISTRY-US, V36, P7937, DOI 10.1021/bi970241s; Zlatanova J, 1998, BIOPHYS J, V74, P2554, DOI 10.1016/S0006-3495(98)77963-9; Zlatanova J, 1999, CRIT REV EUKAR GENE, V9, P245, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.90; ZLATANOVA J, 1994, P NATL ACAD SCI USA, V91, P5277, DOI 10.1073/pnas.91.12.5277	60	50	55	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					2631	2641		10.1096/fj.01-0345com	http://dx.doi.org/10.1096/fj.01-0345com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726539				2022-12-28	WOS:000172964800033
J	Schuh, JM; Blease, K; Hogaboam, CM				Schuh, JM; Blease, K; Hogaboam, CM			The role of CC chemokine receptor 5 (CCR5) and RANTES/CCL5 during chronic fungal asthma in mice	FASEB JOURNAL			English	Article						Aspergillus fumigatus; eosinophil; fibrosis; airway hyperreactivity	MESSENGER-RNA; DIFFERENTIAL EXPRESSION; EOSINOPHIL RECRUITMENT; SUBEPITHELIAL FIBROSIS; ALLERGIC INFLAMMATION; MOLECULAR-CLONING; EPITHELIAL-CELLS; CUTTING EDGE; LAVAGE FLUID; HOST-DEFENSE	In the present study, we explored the role of CC chemokine receptor 5 (CCR5) in a murine model of chronic fungal asthma induced by an intrapulmonary challenge with Aspergillus fumigatus conidia (or spores). Airway hyperresponsiveness was significantly lower in A. fumigatus-sensitized mice lacking CCR5 (CCR5-/-) compared with similarly sensitized wildtype (CCR5+/+) control mice at days 2, 21, 30, and 40 after the conidia challenge. CCR5-/- mice exhibited significantly less peribronchial T-cell and eosinophil accumulation and airway-remodeling features, such as goblet cell hyperplasia and peribronchial fibrosis, compared with CCR5+/+ mice at these times after conidia. However, both groups of mice exhibited similar allergic airway disease at day 12 after the conidia challenge. In CCR5-/- mice at day 12, the allergic airway disease was associated with airway hyperresponsiveness, peribronchial allergic inflammation, and goblet cell hyperplasia. Immunoneutralization of RANTES/CCL5 in sensitized CCR5+/+ and CCR5-/- mice for 12 days after the conidia challenge significantly reduced the peribronchial inflammation and airway hyperresponsiveness in comparison with control wild-type and knockout mice at this time. These data demonstrate that functional CCR5 and RANTES/CCL5 are required for the persistence of chronic fungal asthma in mice.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Hogaboam, CM (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Room 5214,1301 Catherine Rd, Ann Arbor, MI 48109 USA.	hogaboam@med.umich.edu	Hogaboam, Cory M./AAI-1433-2021; hogaboam, cory/M-3578-2014	Hogaboam, Cory M./0000-0003-3366-4850; 				ALAM R, 1993, J IMMUNOL, V150, P3442; Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572; Becker S, 1997, AM J PHYSIOL-LUNG C, V272, pL512, DOI 10.1152/ajplung.1997.272.3.L512; Bento AM, 1998, ALLERGY ASTHMA PROC, V19, P353, DOI 10.2500/108854198778612672; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804, DOI 10.1164/ajrccm.154.6.8970374; Blanpain C, 1999, BLOOD, V94, P1899; Blease K, 2000, J IMMUNOL, V165, P2603, DOI 10.4049/jimmunol.165.5.2603; Blease K, 2000, J IMMUNOL, V165, P1564, DOI 10.4049/jimmunol.165.3.1564; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Campbell JJ, 2001, J IMMUNOL, V166, P2842, DOI 10.4049/jimmunol.166.4.2842; Chensue SW, 1999, J IMMUNOL, V163, P165; Chihara J, 1997, J ALLERGY CLIN IMMUN, V100, pS52, DOI 10.1016/S0091-6749(97)70005-8; Chihara J, 1997, INT ARCH ALLERGY IMM, V114, P33, DOI 10.1159/000237714; Dawson TC, 2000, AM J PATHOL, V156, P1951, DOI 10.1016/S0002-9440(10)65068-7; Djukanovic R, 2000, J ALLERGY CLIN IMMUN, V105, pS522, DOI 10.1016/S0091-6749(00)90055-1; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Elsner J, 1997, EUR J IMMUNOL, V27, P2892, DOI 10.1002/eji.1830271122; EVANS GP, 1992, ADV ELECTROCHEMICAL, V1, P1; Fahy J V, 2000, Curr Opin Pulm Med, V6, P15, DOI 10.1097/00063198-200001000-00004; Folkard SG, 1997, EUR RESPIR J, V10, P2097, DOI 10.1183/09031936.97.10092097; Fryer AA, 2000, GENES IMMUN, V1, P509, DOI 10.1038/sj.gene.6363717; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; Hajeer AH, 1999, EUR J IMMUNOGENET, V26, P375, DOI 10.1046/j.1365-2370.1999.00163.x; Hall IP, 1999, LANCET, V354, P1264, DOI 10.1016/S0140-6736(99)03425-X; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; Holgate ST, 1997, AM J RESP CRIT CARE, V156, P1377, DOI 10.1164/ajrccm.156.5.9610064; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Huffnagle GB, 1999, J IMMUNOL, V163, P4642; Humbert M, 1997, AM J RESP CELL MOL, V16, P1; Kawai T, 1999, J IMMUNOL, V163, P3269; Lampinen M, 1999, CLIN EXP ALLERGY, V29, P314; Lukacs NW, 1996, J LEUKOCYTE BIOL, V60, P573, DOI 10.1002/jlb.60.5.573; MARSHALL H, 2001, TRENDS IMMUNOL, V22, P13; Maune S, 1997, Otolaryngol Pol, V51, P3; Mehrad B, 2000, J IMMUNOL, V165, P962, DOI 10.4049/jimmunol.165.2.962; Mehrad B, 1999, J IMMUNOL, V163, P6086; Michelson S, 1997, J VIROL, V71, P6495, DOI 10.1128/JVI.71.9.6495-6500.1997; Mitchell TJ, 2000, LANCET, V356, P1491, DOI 10.1016/S0140-6736(00)03144-5; Murdoch C, 2000, BLOOD, V95, P3032; Nanki T, 2000, INT IMMUNOL, V12, P1659, DOI 10.1093/intimm/12.12.1659; Odum N, 1999, TISSUE ANTIGENS, V54, P572, DOI 10.1034/j.1399-0039.1999.540606.x; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; Powell N, 1996, EUR RESPIR J, V9, P2454, DOI 10.1183/09031936.96.09122454; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Pype JL, 1999, AM J RESP CELL MOL, V21, P528, DOI 10.1165/ajrcmb.21.4.3660; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Sato I, 1999, IEEE T VIS COMPUT GR, V5, P1, DOI 10.1109/2945.764865; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; Siveke JT, 1998, J IMMUNOL, V160, P550; Stewart GJ, 1997, AIDS, V11, P1833, DOI 10.1097/00002030-199715000-00007; Szalai C, 2000, LANCET, V355, P66, DOI 10.1016/S0140-6736(05)72005-5; Terada N, 1996, J ALLERGY CLIN IMMUN, V98, pS230, DOI 10.1016/S0091-6749(96)70071-4; Teran LM, 1996, J IMMUNOL, V157, P1806; Tillie-Leblond I, 2000, AM J RESP CRIT CARE, V162, P586, DOI 10.1164/ajrccm.162.2.9907014; Venge J, 1996, J ALLERGY CLIN IMMUN, V97, P1110, DOI 10.1016/S0091-6749(96)70265-8; Ying S, 1999, J IMMUNOL, V163, P6321; Zang YCQ, 2000, BRAIN, V123, P1874, DOI 10.1093/brain/123.9.1874; Zapico I, 2000, GENES IMMUN, V1, P288, DOI 10.1038/sj.gene.6363673; Zhou YH, 1998, J IMMUNOL, V160, P4018	62	51	54	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					228	+		10.1096/fj.01-0528fje	http://dx.doi.org/10.1096/fj.01-0528fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11744622	Green Submitted			2022-12-28	WOS:000172964800022
J	Schrauwen, P; Saris, WHM; Hesselink, MKC				Schrauwen, P; Saris, WHM; Hesselink, MKC			An alternative function for human uncoupling protein 3: protection of mitochondria against accumulation of nonesterified fatty acids inside the mitochondrial matrix	FASEB JOURNAL			English	Article						UCP3; fatty acid metabolism; fatty acid transport	MESSENGER-RNA EXPRESSION; HUMAN SKELETAL-MUSCLE; GENE-EXPRESSION; ENERGY-EXPENDITURE; UP-REGULATION; WEIGHT-REDUCTION; THYROID-HORMONE; UCP3; EXERCISE; OBESITY	The physiological function of the human uncoupling protein 3 UCP3, which was discovered in 1997, is unknown. Here we evaluate the available data on human UCP3 expression and show that UCP3 is up-regulated in situations where fatty acid delivery to the mitochondria exceeds oxidative capacity, whereas down-regulation of UCP3 is observed when oxidative capacity is enhanced. With a surplus of fatty acid delivery, accumulation of nonesterified fatty acids in the cytoplasm is likely to occur. Although the inner mitochondrial membrane provides a barrier for nonesterified fatty acids, neutral nonesterified fatty acids can partition into the phospholipid bilayer and flip-flop to the other side of the membrane, where they can be released into the mitochondrial matrix. Due to pH differences, these nonesterified fatty acids will be protonated. Because fatty acid anions can neither be metabolized inside the matrix or cross the inner mitochondrial membrane, accumulation of nonesterified fatty acids inside the matrix might occur. Therefore, we postulate that UCP3 is required for the outward translocation of fatty acids from the mitochondrial matrix. In this way, UCP3 is involved in the protection of mitochondria against accumulation of nonesterified fatty acids inside the mitochondrial matrix.	Maastricht Univ, Dept Human Biol, NUTRIM, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, Dept Movement Sci, NL-6200 MD Maastricht, Netherlands	Maastricht University; Maastricht University	Schrauwen, P (corresponding author), Maastricht Univ, Dept Human Biol, NUTRIM, POB 616, NL-6200 MD Maastricht, Netherlands.	p.schrauwen@hb.unimaas.nl		schrauwen, patrick/0000-0002-0973-847X				Barbe P, 2001, FASEB J, V15, P13; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; Bouchard C, 1997, HUM MOL GENET, V6, P1887, DOI 10.1093/hmg/6.11.1887; Buemann B, 2001, INT J OBESITY, V25, P467, DOI 10.1038/sj.ijo.0801564; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Cortright RN, 1999, AM J PHYSIOL-ENDOC M, V276, pE217, DOI 10.1152/ajpendo.1999.276.1.E217; Emilsson V, 2000, METABOLISM, V49, P1610, DOI 10.1053/meta.2000.18692; Esterbauer H, 1999, DIABETOLOGIA, V42, P302, DOI 10.1007/s001250051155; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; FREAKE HC, 1995, ANNU REV NUTR, V15, P263, DOI 10.1146/annurev.nu.15.070195.001403; GARDNER AW, 1989, HUM BIOL, V61, P559; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; GISSLINGER H, 1991, CLIN EXP RHEUMATOL, V9, P383; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; JEZEK P, 1994, J BIOL CHEM, V269, P26184; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; Keys A, 1950, BIOL HUMAN STARVATIO; Khalfallah Y, 2000, DIABETES, V49, P25, DOI 10.2337/diabetes.49.1.25; Klannemark M, 1998, EUR J ENDOCRINOL, V139, P217, DOI 10.1530/eje.0.1390217; Klingenberg M, 1999, INT J OBESITY, V23, pS24, DOI 10.1038/sj.ijo.0800939; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Matsuda J, 1997, FEBS LETT, V418, P200, DOI 10.1016/S0014-5793(97)01381-1; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Samec S, 1999, PFLUG ARCH EUR J PHY, V438, P452, DOI 10.1007/s004240051061; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Schrauwen P, 2000, DIABETOLOGIA, V43, P1408, DOI 10.1007/s001250051547; Schrauwen P, 1999, INT J OBESITY, V23, P966, DOI 10.1038/sj.ijo.0801026; Schrauwen P, 1999, OBES RES, V7, P97, DOI 10.1002/j.1550-8528.1999.tb00396.x; Schrauwen P, 2001, FASEB J, V15, P2497, DOI 10.1096/fj.01-0400hyp; Schrauwen P, 1999, DIABETES, V48, P146, DOI 10.2337/diabetes.48.1.146; Schrauwen P, 2001, INT J OBESITY, V25, P449, DOI 10.1038/sj.ijo.0801566; Schrauwen P, 1997, AM J CLIN NUTR, V66, P276, DOI 10.1093/ajcn/66.2.276; SCHRAUWEN P, 2001, IN PRESS AM J PHYSL; Tsuboyama-Kasaoka N, 1998, BIOCHEM BIOPH RES CO, V247, P498, DOI 10.1006/bbrc.1998.8818; Vidal-Puig A, 1999, OBES RES, V7, P133, DOI 10.1002/j.1550-8528.1999.tb00694.x; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Walder K, 1998, HUM MOL GENET, V7, P1431, DOI 10.1093/hmg/7.9.1431; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE622, DOI 10.1152/ajpendo.2000.279.3.E622	46	157	159	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2497	2502		10.1096/fj.01-0400hyp	http://dx.doi.org/10.1096/fj.01-0400hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689475	Green Submitted			2022-12-28	WOS:000172420500020
J	Hasler, P; Zouali, M				Hasler, P; Zouali, M			B cell receptor signaling and autoimmunity	FASEB JOURNAL			English	Review						T cell; BCR; gene expression; SLE	SYSTEMIC-LUPUS-ERYTHEMATOSUS; PROTEIN-TYROSINE-PHOSPHATASE; LYN-DEFICIENT MICE; MOTH-EATEN MICE; LYMPHOCYTE ANTIGEN RECEPTORS; PERIPHERAL-BLOOD LYMPHOCYTES; SRC HOMOLOGY-2 DOMAINS; MRL/MP-LPR/LPR MICE; T-CELL; POSITIVE SELECTION	The immune receptors of lymphocytes are able to sense the nature of bound ligands. Through coupled signaling pathways the generated signals are appropriately delivered to the intracellular machinery, allowing specific functional responses. A central issue in contemporary immunology is how the fate of B lymphocytes is determined at the successive developmental stages and how the B cell receptor distinguishes between signals that induce immune response or tolerance. Experiments with mice expressing transgenes or lacking signal transduction molecules that lead to abnormal lymphocyte development and/or response are providing important clues to the mechanisms that regulate signaling thresholds at different developmental stages. The studies are also revealing novel potential mechanisms of induction of autoimmunity, which may have a bearing on the understanding of human diseases.	Hop Broussais, Unite Immunopathol Humaine, INSERM, U430, F-75674 Paris 14, France; Univ Basel, Felix Platter Spital, Rheumatol Klin, CH-4055 Basel, Switzerland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Basel	Zouali, M (corresponding author), Hop Broussais, Unite Immunopathol Humaine, INSERM, U430, 96 Rue Didot, F-75674 Paris 14, France.	moncef.zouali@wanadoo.fr		Zouali, Moncef/0000-0002-8225-456X				ALBRECHT DL, 1988, J IMMUNOL, V141, P3915; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P4204, DOI 10.1073/pnas.91.10.4204; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bachmann MF, 1999, J IMMUNOL, V163, P137; Baixeras E, 1996, SCAND J IMMUNOL, V43, P406, DOI 10.1046/j.1365-3083.1996.d01-63.x; Batten M, 2000, J EXP MED, V192, P1453, DOI 10.1084/jem.192.10.1453; BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; Benschop RJ, 1999, J EXP MED, V190, P749, DOI 10.1084/jem.190.6.749; Bikah G, 1996, SCIENCE, V274, P1906, DOI 10.1126/science.274.5294.1906; Blasini AM, 1998, J AUTOIMMUN, V11, P387, DOI 10.1006/jaut.1998.0230; Brundula V, 1999, ARTHRITIS RHEUM-US, V42, P1908, DOI 10.1002/1529-0131(199909)42:9<1908::AID-ANR17>3.0.CO;2-7; BURKHARDT AL, 1994, MOL CELL BIOL, V14, P1095, DOI 10.1128/MCB.14.2.1095; CAMBIER JC, 1992, FASEB J, V6, P3207, DOI 10.1096/fasebj.6.13.1397843; CHALUPNY NJ, 1995, EUR J IMMUNOL, V25, P2978, DOI 10.1002/eji.1830251040; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; CHO EA, 1993, J IMMUNOL, V151, P20; Cornall RJ, 2000, P NATL ACAD SCI USA, V97, P1713, DOI 10.1073/pnas.97.4.1713; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DesJardin LE, 1996, CLIN IMMUNOL IMMUNOP, V81, P145, DOI 10.1006/clin.1996.0170; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Elly C, 1999, ONCOGENE, V18, P1147, DOI 10.1038/sj.onc.1202411; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; ERNST P, 1995, IMMUNITY, V2, P427, DOI 10.1016/1074-7613(95)90024-1; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; GABBIANI G, 1977, NATURE, V269, P697, DOI 10.1038/269697a0; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; HARDY RR, 1991, P NATL ACAD SCI USA, V88, P11550, DOI 10.1073/pnas.88.24.11550; HASLER P, 1990, P NATL ACAD SCI USA, V87, P1978, DOI 10.1073/pnas.87.5.1978; Hatta Y, 1999, IMMUNOGENETICS, V49, P280, DOI 10.1007/s002510050494; HAYAKAWA K, 1994, J IMMUNOL, V152, P4801; Hayakawa K, 2000, CURR OPIN IMMUNOL, V12, P346, DOI 10.1016/S0952-7915(00)00098-4; Hayakawa K, 1999, SCIENCE, V285, P113, DOI 10.1126/science.285.5424.113; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Henderson A, 1998, ANNU REV IMMUNOL, V16, P163, DOI 10.1146/annurev.immunol.16.1.163; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Hippen KL, 2000, J EXP MED, V191, P883, DOI 10.1084/jem.191.5.883; Huck S, 1997, ANN NY ACAD SCI, V815, P122, DOI 10.1111/j.1749-6632.1997.tb52053.x; Hucka S, 2001, AUTOIMMUNITY, V33, P213, DOI 10.3109/08916930109008048; Inaoki M, 1997, J EXP MED, V186, P1923, DOI 10.1084/jem.186.11.1923; Jugloff LS, 1997, J IMMUNOL, V159, P1096; KAMMER GM, 1988, ARTHRITIS RHEUM, V31, P88, DOI 10.1002/art.1780310113; KATAGIRI T, 1995, J BIOL CHEM, V270, P27987; KEANE MM, 1995, ONCOGENE, V10, P2367; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; Kersh GJ, 1998, J IMMUNOL, V161, P585; Keshvara LM, 1998, J IMMUNOL, V161, P5276; Khaled AR, 1999, AUTOIMMUNITY, V30, P115, DOI 10.3109/08916939908994769; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KNAPP MR, 1982, P NATL ACAD SCI-BIOL, V79, P2996, DOI 10.1073/pnas.79.9.2996; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; Kung C, 2000, NAT MED, V6, P343; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Lang P, 2001, SCIENCE, V291, P1537, DOI 10.1126/science.291.5508.1537; Larbolette O, 1999, MOL CELL BIOL, V19, P1539; LAW CL, 1994, J BIOL CHEM, V269, P12310; Levine MH, 2000, P NATL ACAD SCI USA, V97, P2743, DOI 10.1073/pnas.050552997; Levy FO, 1996, EUR J IMMUNOL, V26, P1290, DOI 10.1002/eji.1830260617; Li HL, 1999, J BIOL CHEM, V274, P9812, DOI 10.1074/jbc.274.14.9812; Li YS, 1996, IMMUNITY, V5, P527, DOI 10.1016/S1074-7613(00)80268-X; Lin SY, 1997, J EXP MED, V185, P707, DOI 10.1084/jem.185.4.707; Liossis SNC, 1996, J CLIN INVEST, V98, P2549, DOI 10.1172/JCI119073; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; Majeti R, 2000, CELL, V103, P1059, DOI 10.1016/S0092-8674(00)00209-9; Mary C, 2000, J IMMUNOL, V165, P2987, DOI 10.4049/jimmunol.165.6.2987; Matache C, 1999, AUTOIMMUNITY, V29, P111, DOI 10.3109/08916939908995380; Matsumoto I, 1999, SCIENCE, V286, P1732, DOI 10.1126/science.286.5445.1732; Maurice MM, 1997, J IMMUNOL, V159, P2973; Melamed I, 1999, CELL IMMUNOL, V194, P136, DOI 10.1006/cimm.1999.1506; MELAMED I, 1991, J IMMUNOL, V147, P1139; MELCHERS F, 1995, CURR OPIN IMMUNOL, V7, P214, DOI 10.1016/0952-7915(95)80006-9; Mimura T, 1997, J IMMUNOL, V158, P2977; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Morel L, 1997, J IMMUNOL, V158, P6019; Nemazee D, 2000, ANNU REV IMMUNOL, V18, P19, DOI 10.1146/annurev.immunol.18.1.19; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; O'Keefe TL, 1999, J EXP MED, V189, P1307, DOI 10.1084/jem.189.8.1307; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pani G, 1997, J EXP MED, V186, P581, DOI 10.1084/jem.186.4.581; Pao LI, 1997, J IMMUNOL, V158, P2663; Pao LI, 1997, J IMMUNOL, V158, P1116; Qian Y, 2001, J IMMUNOL, V166, P2412, DOI 10.4049/jimmunol.166.4.2412; Radic MZ, 1996, IMMUNITY, V5, P505, DOI 10.1016/S1074-7613(00)80266-6; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Richards JD, 1996, J BIOL CHEM, V271, P6458, DOI 10.1074/jbc.271.11.6458; Romagnoli P, 2001, INT IMMUNOL, V13, P305, DOI 10.1093/intimm/13.3.305; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Sato S, 2000, J IMMUNOL, V165, P6635, DOI 10.4049/jimmunol.165.11.6635; Sato S, 1997, P NATL ACAD SCI USA, V94, P13158, DOI 10.1073/pnas.94.24.13158; Sato S, 1996, J IMMUNOL, V157, P4371; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Schmidt KN, 1998, J EXP MED, V187, P929, DOI 10.1084/jem.187.6.929; Shores EW, 1997, J EXP MED, V185, P893, DOI 10.1084/jem.185.5.893; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIERAKOWSKI S, 1989, J CLIN IMMUNOL, V9, P469, DOI 10.1007/BF00918016; SILLMAN AL, 1994, J LEUKOCYTE BIOL, V56, P812, DOI 10.1002/jlb.56.6.812; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smith BP, 1998, EXP APPL ACAROL, V22, P187, DOI 10.1023/A:1006010230247; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Sproul TW, 2000, J IMMUNOL, V165, P6020, DOI 10.4049/jimmunol.165.11.6020; SunderPlassmann R, 1997, EUR J IMMUNOL, V27, P2001, DOI 10.1002/eji.1830270826; Takahashi T, 1997, J IMMUNOL, V159, P2532; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takeuchi T, 1997, CLIN EXP IMMUNOL, V109, P20, DOI 10.1046/j.1365-2249.1997.4371334.x; Takeuchi T, 1998, INT IMMUNOL, V10, P911, DOI 10.1093/intimm/10.7.911; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Tsokos GC, 1999, IMMUNOL TODAY, V20, P119, DOI 10.1016/S0167-5699(98)01395-4; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; VASSILOPOULOS D, 1995, J IMMUNOL, V155, P2269; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; WECHSLER RJ, 1995, J IMMUNOL, V154, P1919; Weintraub BC, 2000, J EXP MED, V191, P1443, DOI 10.1084/jem.191.8.1443; Wu YM, 2000, J BIOL CHEM, V275, P35478, DOI 10.1074/jbc.M005224200; Yamazaki T, 1997, J IMMUNOL, V158, P1634; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832; Yankee TM, 1999, J IMMUNOL, V163, P5827; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; Zhao QH, 1996, MOL CELL BIOL, V16, P6765; ZOUALI M, 1992, IMMUNOL TODAY, V13, P41, DOI 10.1016/0167-5699(92)90130-Y; Zouali M, 1998, LUPUS, V7, P499, DOI 10.1191/096120398678920668; ZOUALI M, 1994, NAT GENET, V7, P118, DOI 10.1038/ng0694-118	149	68	68	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2085	2098		10.1096/fj.00-0860rev	http://dx.doi.org/10.1096/fj.00-0860rev			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641235				2022-12-28	WOS:000171920400020
J	Hu, B; Mei, QB; Yao, XJ; Smith, E; Barry, WH; Liang, BT				Hu, B; Mei, QB; Yao, XJ; Smith, E; Barry, WH; Liang, BT			A novel contractile phenotype with cardiac transgenic expression of the human P2X(4) receptor	FASEB JOURNAL			English	Article						contractility; heart; P2X channel; purines; heart failure	ADENOSINE-TRIPHOSPHATE; MOLECULAR-CLONING; EXTRACELLULAR ATP; ISOLATED RAT; RELEASE; MECHANISM; HEART; DIFFERENTIATION; NOMENCLATURE; TRANSIENTS	The P2X(4) receptor is a newly identified receptor expressed in the heart cell. Its function was elucidated with cardiac transgenic (TG) expression of the receptor by using the myocardium-specific alpha -myosin heavy chain promoter. The presence of the transgene was determined by polymerase chain reaction by using primers specific to the receptor and the vector linker region, by Southern blotting of the genomic DNA, and by immunoblotting and immunohistochemistry of both isolated cardiac myocytes and intact hearts. In intact heart study, the P2X(4) receptor TG mouse exhibited significantly elevated basal cardiac contractility with greater rates of contraction and relaxation, left ventricular developed pressure, and cardiac output compared with nontransgenic (NTG) animals but showed no evidence of hypertrophy or heart failure. The TG heart also showed a greater increase of cardiac contractility in response to the P2X receptor agonist 2-methylthioATP, consistent with overexpression of a functional P2X(4) receptor with consequent increase in the receptor-mediated response. In isolated cardiac cell study, the TG heart cell showed a similar level of basal contraction amplitude as the NTG heart cell while exhibiting a threefold greater increase in contractility during stimulation by 2-methylthioATP. Thus, an increased responsiveness of the overexpressed P2X(4) receptor to endogenous ATP is responsible for the enhanced basal cardiac performance in the intact TG heart. The sustained enhanced contractile function with no associated heart pathology in the P2X(4) receptor TG mouse suggests a novel physiologic role of the P2X(4) receptor, that of stimulating the cardiac contractility.	Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Utah, Med Ctr, Dept Med, Salt Lake City, UT 84132 USA	University of Pennsylvania; University of Pennsylvania; Utah System of Higher Education; University of Utah	Liang, BT (corresponding author), Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, 956 BRBII III,421 Curie Blvd, Philadelphia, PA 19104 USA.	liangb@mail.med.upenn.edu						CHRISTIE A, 1992, J PHYSIOL-LONDON, V445, P369, DOI 10.1113/jphysiol.1992.sp018929; CLEMENS MG, 1981, J PHYSIOL-LONDON, V312, P143, DOI 10.1113/jphysiol.1981.sp013621; Collo G, 1996, J NEUROSCI, V16, P2495; DANZIGER RS, 1988, CELL CALCIUM, V9, P193, DOI 10.1016/0143-4160(88)90023-1; DEYOUNG MB, 1989, AM J PHYSIOL, V257, pC750, DOI 10.1152/ajpcell.1989.257.4.C750; Dougherty C, 1998, FASEB J, V12, P1785, DOI 10.1096/fasebj.12.15.1785; FORRESTER T, 1977, J PHYSIOL-LONDON, V268, P371, DOI 10.1113/jphysiol.1977.sp011862; FREDHOLM BB, 1982, ACTA PHYSIOL SCAND, V116, P285, DOI 10.1111/j.1748-1716.1982.tb07142.x; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; GarciaGuzman M, 1996, FEBS LETT, V388, P123, DOI 10.1016/0014-5793(96)00499-1; Khakh BS, 2001, PHARMACOL REV, V53, P107; Le KT, 1998, NEUROSCIENCE, V83, P177, DOI 10.1016/S0306-4522(97)00365-5; Le KT, 1998, J NEUROSCI, V18, P7152; Mei QB, 2001, AM J PHYSIOL-HEART C, V281, pH334, DOI 10.1152/ajpheart.2001.281.1.H334; Murry CE, 1996, J CLIN INVEST, V98, P2209, DOI 10.1172/JCI119030; PEARSON JD, 1979, NATURE, V281, P384, DOI 10.1038/281384a0; PODRASKY E, 1997, AM J PHYSIOL-HEART C, V273, pH2380; RALEVIC V, 1991, CIRCULATION, V84, P1, DOI 10.1161/01.CIR.84.1.1; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rubio ME, 2001, J NEUROSCI, V21, P641, DOI 10.1523/JNEUROSCI.21-02-00641.2001; SCAMPS F, 1990, CIRC RES, V67, P1007, DOI 10.1161/01.RES.67.4.1007; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Soto M, 1996, BIOCHEM BIOPH RES CO, V223, P456, DOI 10.1006/bbrc.1996.0915; Townsend-Nicholson A, 1999, MOL BRAIN RES, V64, P246, DOI 10.1016/S0169-328X(98)00328-3; Vassort G, 2001, PHYSIOL REV, V81, P767, DOI 10.1152/physrev.2001.81.2.767; VIAL C, 1987, J MOL CELL CARDIOL, V19, P187, DOI 10.1016/S0022-2828(87)80561-8; Yao AS, 1998, CIRC RES, V82, P657, DOI 10.1161/01.RES.82.6.657; Zhang JCL, 2001, MOL CELL BIOL, V21, P1336, DOI 10.1128/MCB.2001.21.4.1336-1344.2001	28	43	44	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2739	+		10.1096/fj.01-0445fje	http://dx.doi.org/10.1096/fj.01-0445fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606481				2022-12-28	WOS:000171920400012
J	Hoffmann, KF; McCarty, TC; Segal, DH; Chiaramonte, M; Hesse, M; Davis, EM; Cheever, AW; Meltzer, PS; Morse, HC; Wynn, TA				Hoffmann, KF; McCarty, TC; Segal, DH; Chiaramonte, M; Hesse, M; Davis, EM; Cheever, AW; Meltzer, PS; Morse, HC; Wynn, TA			Disease fingerprinting with cDNA microarrays reveals distinct gene expression profiles in lethal type-1 and type-2 cytokine-mediated inflammatory reactions	FASEB JOURNAL			English	Article						schistosomiasis; Th1/Th2; liver; mice; fibrosis	SCHISTOSOMA-MANSONI EGGS; GRANULOMA-FORMATION; HEPATIC-FIBROSIS; TNF-ALPHA; MURINE SCHISTOSOMIASIS; INHIBITS APOPTOSIS; LIVER PATHOLOGY; DEFICIENT MICE; INFECTED MICE; IFN-GAMMA	Development of polarized immune responses controls resistance and susceptibility to many microorganisms. However, studies of several infectious, allergic, and autoimmune diseases have shown that chronic type-1 and type-2 cytokine responses can also cause significant morbidity and mortality if left unchecked. We used mouse cDNA microarrays to molecularly phenotype the gene expression patterns that characterize two disparate but equally lethal forms of liver pathology that develop in Schistosoma mansoni infected mice polarized for type-1 and type-2 cytokine responses. Hierarchical clustering analysis identified at least three groups of genes associated with a polarized type-2 response and two linked with an extreme type-1 cytokine phenotype. Predictions about liver fibrosis, apoptosis, and granulocyte recruitment and activation generated by the microarray studies were confirmed later by traditional biological assays. The data show that cDNA microarrays are useful not only for determining coordinated gene expression profiles but are also highly effective for molecularly "fingerprinting" diseased tissues. Moreover, they illustrate the potential of genome-wide approaches for generating comprehensive views on the molecular and biochemical mechanisms regulating infectious disease pathogenesis.	NIAID, Immunobiol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; NIAID, Immunopathol Lab, NIH, Bethesda, MD 20892 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Biomed Res Inst, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Wynn, TA (corresponding author), NIAID, Immunobiol Sect, Parasit Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	twynn@niaid.nih.gov	Wynn, Thomas A/AAO-3523-2021; McCarty, Tom/ABG-6003-2020; Wynn, Thomas A/C-2797-2011; McCarty, Thomas/GVU-0812-2022	Wynn, Thomas A/0000-0002-7244-8731; McCarty, Tom/0000-0001-5815-2531; McCarty, Thomas/0000-0001-5815-2531; Hoffmann, Karl/0000-0002-3932-5502; Morse, Herbert/0000-0002-9331-3705	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000465, Z01AI000829, ZIAAI000829] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVDI NJ, 2000, J BIOL CHEM; Ayala A, 1998, J SURG RES, V76, P165, DOI 10.1006/jsre.1998.5314; Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; Bergquist NR, 1998, PARASITOL TODAY, V14, P99, DOI 10.1016/S0169-4758(97)01207-6; Brunet LR, 1999, J IMMUNOL, V163, P4976; Brunet LR, 1997, J IMMUNOL, V159, P777; Cheever AW, 1999, INFECT IMMUN, V67, P2201, DOI 10.1128/IAI.67.5.2201-2208.1999; CHEEVER AW, 1993, AM J TROP MED HYG, V48, P496, DOI 10.4269/ajtmh.1993.48.496; CHEEVER AW, 1994, J IMMUNOL, V153, P753; CHENSUE SW, 1994, CLIN EXP IMMUNOL, V98, P395, DOI 10.1111/j.1365-2249.1994.tb05503.x; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Chiaramonte MG, 1999, J IMMUNOL, V162, P920; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; CZAJA MJ, 1989, HEPATOLOGY, V10, P795, DOI 10.1002/hep.1840100508; Dallaporta B, 2000, CELL DEATH DIFFER, V7, P368, DOI 10.1038/sj.cdd.4400661; Decitre M, 1998, LAB INVEST, V78, P143; DeRisi J, 1996, NAT GENET, V14, P457; DOY TG, 1984, RES VET SCI, V37, P219, DOI 10.1016/S0034-5288(18)31908-8; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fallon PG, 2000, J IMMUNOL, V164, P2585, DOI 10.4049/jimmunol.164.5.2585; Fallon PG, 2000, EUR J IMMUNOL, V30, P470, DOI 10.1002/1521-4141(200002)30:2&lt;470::AID-IMMU470&gt;3.0.CO;2-T; GIBODA M, 1992, ANN TROP MED PARASIT, V86, P631, DOI 10.1080/00034983.1992.11812719; GRIMAUD JA, 1987, AM J TROP MED HYG, V37, P335, DOI 10.4269/ajtmh.1987.37.335; HARRIS AW, 2000, ATLAS MOUSE HEMATOPA, V1, P21; Hoffmann KF, 1999, J IMMUNOL, V163, P927; Hoffmann KF, 1998, J IMMUNOL, V161, P4201; Hoffmann KF, 2000, J IMMUNOL, V164, P6406, DOI 10.4049/jimmunol.164.12.6406; Jaeschke H, 1998, J IMMUNOL, V160, P3480; Jankovic D, 1998, J EXP MED, V187, P619, DOI 10.1084/jem.187.4.619; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Khan J, 1998, CANCER RES, V58, P5009; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kristensen DB, 2000, HEPATOLOGY, V32, P268; Louis H, 1998, HEPATOLOGY, V28, P1607, DOI 10.1002/hep.510280621; Lundy SK, 2001, INFECT IMMUN, V69, P271, DOI 10.1128/IAI.69.1.271-280.2001; Mahidhara R, 2000, CRIT CARE MED, V28, pN105, DOI 10.1097/00003246-200004001-00013; Matesic LE, 2000, FASEB J, V14, P2247, DOI 10.1096/fj.99-1051com; Musashi M, 2000, INT J HEMATOL, V72, P12; NAUMOVSKI L, 1994, BLOOD, V83, P2261; NODES BR, 1987, J BIOL CHEM, V262, P5422; Ortiz LA, 1998, AM J PHYSIOL-LUNG C, V275, pL1208, DOI 10.1152/ajplung.1998.275.6.L1208; Pearce EJ, 1998, ADV EXP MED BIOL, V452, P67; Perks B, 2000, AM J RESP CRIT CARE, V162, P1767, DOI 10.1164/ajrccm.162.5.9908107; Phimister B, 1999, NAT GENET, V21, P1, DOI 10.1038/4423; Robinson MJ, 2000, BIOCHEM BIOPH RES CO, V275, P865, DOI 10.1006/bbrc.2000.3407; Rodriguez I, 1997, DEV BIOL, V184, P115, DOI 10.1006/dbio.1997.8522; SABIN EA, 1995, J IMMUNOL, V155, P4844; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SHER A, 1991, J IMMUNOL, V147, P2713; Smelt SC, 2000, J IMMUNOL, V164, P3681, DOI 10.4049/jimmunol.164.7.3681; SVETIC A, 1991, J IMMUNOL, V147, P2391; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; Tsamandas AC, 1996, MODERN PATHOL, V9, P767; Wang J, 2000, J CELL SCI, V113, P753; WU CH, 1982, HEPATOLOGY, V2, P366; WYNN TA, 1995, CURR OPIN IMMUNOL, V7, P505, DOI 10.1016/0952-7915(95)80095-6; WYNN TA, 1993, J IMMUNOL, V151, P1430; Wynn TA, 1996, ANN NY ACAD SCI, V797, P191, DOI 10.1111/j.1749-6632.1996.tb52960.x; WYNN TA, 1995, NATURE, V376, P594, DOI 10.1038/376594a0; ZWINGENBERGER K, 1991, SCAND J IMMUNOL, V34, P243, DOI 10.1111/j.1365-3083.1991.tb01543.x	62	78	82	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					2545	+		10.1096/fj.01-0306fje	http://dx.doi.org/10.1096/fj.01-0306fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641263				2022-12-28	WOS:000171372700027
J	Kersten, S; Mandard, S; Escher, P; Gonzalez, FJ; Tafuri, S; Desvergne, B; Wahli, W				Kersten, S; Mandard, S; Escher, P; Gonzalez, FJ; Tafuri, S; Desvergne, B; Wahli, W			The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism	FASEB JOURNAL			English	Article						fasting; microarray; PPAR alpha; SABRE	CYCLE ENZYME GENES; CHAIN FATTY-ACIDS; UREA CYCLE; LIPOPROTEIN METABOLISM; ADAPTIVE RESPONSE; PPAR-ALPHA; EXPRESSION; INDUCTION; SUPPRESSION; GLUCONEOGENESIS	The peroxisome proliferator-activated receptor a is alpha ligand-activated transcription factor that plays an important role in the regulation of lipid homeostasis. PPAR alpha mediates the effects of fibrates, which are potent hypolipidemic drugs, on gene expression. To better understand the biological effects of fibrates and PPAR alpha, we searched for genes regulated by PPAR alpha using oligonucleotide microarray and subtractive hybridization. By comparing liver RNA from wild-type and PPAR alpha null mice, it was found that PPAR alpha decreases the mRNA expression of enzymes involved in the metabolism of amino acids. Further analysis by Northern blot revealed that PPAR alpha influences the expression of several genes involved in trans- and deamination of amino acids, and urea synthesis. Direct activation of PPAR alpha using the synthetic PPAR alpha ligand WY14643 decreased mRNA levels of these genes, suggesting that PPAR alpha is directly implicated in the regulation of their expression. Consistent with these data, plasma urea concentrations are modulated by PPAR alpha in vivo. It is concluded that in addition to oxidation of fatty acids, PPAR alpha also regulates metabolism of amino acids in liver, indicating that PPAR alpha is a key controller of intermediary metabolism during fasting.	Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland; Pfizer Global Res & Dev, Ann Arbor Labs, Ann Arbor, MI 48105 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	University of Lausanne; Pfizer; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kersten, S (corresponding author), Univ Wageningen & Res Ctr, Nutr Metab & Genom Grp, POB 8129, NL-6700 EV Wageningen, Netherlands.	sander.kersten@staff.nutepi.wau.nl	Wahli, Walter/B-1398-2009; Kersten, Sander/A-1116-2011; Mandard, Stéphane/J-4800-2019; Wahli, Walter/I-3194-2019; Desvergne, Beatrice/C-8892-2016	Wahli, Walter/0000-0002-5966-9089; Kersten, Sander/0000-0003-4488-7734; Mandard, Stéphane/0000-0002-7298-821X; Desvergne, Beatrice/0000-0001-5483-288X				Anderson SP, 1999, MOL CARCINOGEN, V26, P226, DOI 10.1002/(SICI)1098-2744(199912)26:4<226::AID-MC2>3.0.CO;2-Q; Auwerx J, 1999, CELL, V97, P161; Corton JC, 1998, MOL PHARMACOL, V54, P463, DOI 10.1124/mol.54.3.463; DERR RF, 1976, J PHARMACOL EXP THER, V197, P675; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Edgar AD, 1998, TOXICOL LETT, V98, P13, DOI 10.1016/S0378-4274(98)00042-3; HAGGERTY DF, 1983, MOL CELL BIOCHEM, V53-4, P57; Hashimoto T, 2000, J BIOL CHEM, V275, P28918, DOI 10.1074/jbc.M910350199; Hertz R, 1996, J BIOL CHEM, V271, P218, DOI 10.1074/jbc.271.1.218; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; JUNGAS RL, 1992, PHYSIOL REV, V72, P419, DOI 10.1152/physrev.1992.72.2.419; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kimura T, 1998, J BIOL CHEM, V273, P27505, DOI 10.1074/jbc.273.42.27505; Kockx M, 1999, BLOOD, V93, P2991; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; Lavery DJ, 1997, P NATL ACAD SCI USA, V94, P6831, DOI 10.1073/pnas.94.13.6831; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; Pan DA, 2000, J LIPID RES, V41, P742; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; Strang BD, 1998, J DAIRY SCI, V81, P728, DOI 10.3168/jds.S0022-0302(98)75629-2; Tomomura M, 1996, FEBS LETT, V399, P310, DOI 10.1016/S0014-5793(96)01344-0; Tomomura M, 1997, J BIOCHEM-TOKYO, V121, P172, DOI 10.1093/oxfordjournals.jbchem.a021562; ULBRIGHT C, 1993, ARCH BIOCHEM BIOPHYS, V301, P237, DOI 10.1006/abbi.1993.1139; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2	32	173	178	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					1971	1978		10.1096/fj.01-0147com	http://dx.doi.org/10.1096/fj.01-0147com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532977				2022-12-28	WOS:000171372700012
J	Escargueil, AE; Plisov, SY; Skladanowski, A; Borgne, A; Meijer, L; Gorbsky, GJ; Larsen, AK				Escargueil, AE; Plisov, SY; Skladanowski, A; Borgne, A; Meijer, L; Gorbsky, GJ; Larsen, AK			Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling	FASEB JOURNAL			English	Article						mitosis; condensation; phosphorylation; nuclear targeting; chromosome structure; nuclear docking; scaffolding protein	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; IN-VIVO; CHROMOSOME CONDENSATION; MITOTIC CHROMOSOMES; ALPHA; PROTEIN; PHOSPHORYLATION; INHIBITION; INTERACTS	Although initiation of chromosome condensation during early prophase is linked temporally to the appearance of the mitotic cdc2 kinase in the nucleus, it is not known what targets the kinase to the nucleus and how this is coupled to chromatin remodeling. We now report that cdc2 kinase forms stable molecular complexes with the nuclear enzyme DNA topoisomerase II, which is associated with marked stimulation of both DNA binding and catalytic activity of topoisomerase II, albeit in a phosphorylation-independent manner. The molecular interaction is required for recruitment of cdc2 kinase, as shown by incubation of purified enzymes with chicken erythrocyte nuclei, which have neither endogenous topoisomerase II nor cdc2 kinase. The physical association between the two enzymes alters the DNA/topoisomerase II interaction as shown by pulse-field electrophoresis after incubation of intact nuclei with the specific topoisomerase II inhibitor VM-26. Furthermore, the presence of both enzymes, but not either enzyme alone, is accompanied by extensive chromatin remodeling converting the interphase nuclei into precondensation chromosomes with striking resemblance to early prophase structures. Our results reveal a novel property of cyclin-dependent kinases and demonstrate that the recruitment of cdc2 kinase by topoisomerase II is coupled to chromatin remodeling.	Inst Gustave Roussy PR2, CNRS, UMR 8532, Lab Tumor Biol & Pharmacol, F-94805 Villejuif, France; Gdansk Univ Technol, Dept Pharmaceut Technol & Biochem, PL-80952 Gdansk, Poland; CNRS, Biol Stn, F-29682 Roscoff, France; Univ Oklahoma, Dept Cell Biol, Oklahoma City, OK USA	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Fahrenheit Universities; Gdansk University of Technology; Centre National de la Recherche Scientifique (CNRS); University of Oklahoma System; University of Oklahoma Health Sciences Center	Larsen, AK (corresponding author), Inst Gustave Roussy PR2, CNRS, UMR 8532, Lab Tumor Biol & Pharmacol, F-94805 Villejuif, France.	aklarsen@igr.fr	Escargueil, Alexandre/K-5192-2019	Escargueil, Alexandre/0000-0002-7419-7518; , laurent/0000-0003-3511-4916; Gorbsky, Gary/0000-0003-3076-4725				ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; Bhat UG, 1999, P NATL ACAD SCI USA, V96, P7859, DOI 10.1073/pnas.96.14.7859; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Bojanowski K, 1998, J CELL BIOCHEM, V69, P127, DOI 10.1002/(SICI)1097-4644(19980501)69:2<127::AID-JCB4>3.0.CO;2-U; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Cowell IG, 2000, EXP CELL RES, V255, P86, DOI 10.1006/excr.1999.4772; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; Durrieu F, 2000, CURR BIOL, V10, P923, DOI 10.1016/S0960-9822(00)00620-5; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1994, FASEB J, V8, P947, DOI 10.1096/fasebj.8.12.8088460; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; JACKSON DA, 1990, EMBO J, V9, P567, DOI 10.1002/j.1460-2075.1990.tb08144.x; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; KROLL DJ, 1993, MOL ENDOCRINOL, V7, P305, DOI 10.1210/me.7.3.305; Kurz EU, 2000, J BIOL CHEM, V275, P13948, DOI 10.1074/jbc.275.18.13948; Larsen AK, 1998, BBA-GENE STRUCT EXPR, V1400, P257, DOI 10.1016/S0167-4781(98)00140-7; MEGGIO F, 1995, EUR J BIOCHEM, V230, P1025, DOI 10.1111/j.1432-1033.1995.tb20651.x; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Rattner JB, 1996, J CELL BIOL, V134, P1097, DOI 10.1083/jcb.134.5.1097; RAZIN SV, 1991, P NATL ACAD SCI USA, V88, P8515, DOI 10.1073/pnas.88.19.8515; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WELLS NJ, 1995, EUR J BIOCHEM, V231, P491, DOI 10.1111/j.1432-1033.1995.tb20723.x; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	47	26	28	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2001	15	10					2288	+		10.1096/fj.00-0726fje	http://dx.doi.org/10.1096/fj.00-0726fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11511510	Bronze			2022-12-28	WOS:000170809900018
J	Kono, M; Nagata, H; Umemura, S; Kawana, S; Osamura, RY				Kono, M; Nagata, H; Umemura, S; Kawana, S; Osamura, RY			In situ expression of corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) genes in human skin	FASEB JOURNAL			English	Article						reverse-transcription; central nervous system; hypothalamus	MELANOCYTE-STIMULATING HORMONE; BLOOD MONONUCLEAR-CELLS; HUMAN KERATINOCYTES; ALPHA-MSH; PEPTIDES; STRESS; PROLIFERATION; IMMUNOMODULATION; DIFFERENTIATION; EPIDERMIS	Systemic stresses induce corticotropin-releasing hormone (CRH) expression in hypothalamus. CRH is released to the pituitary gland, where it stimulates proopiomelanocortin (POMC) production acting via the CRH receptor (CRH-R). CRH and POMC peptides are also detected in sites outside of the central nervous system (CNS), such as the skin. However, it has not been elucidated whether these peptides detected in the skin are derived from CNS or are produced locally. Using immunohistochemical and in situ reverse-transcription (RT)-PCR techniques, we demonstrated coexpression of CRH and POMC mRNAs in the epidermis and pilosebaceous units of the human skin. This coexpression was confirmed by the combination of laser-capture microdissection (LCM) with RT-PCR, analyzing mRNA expressions in captured sebaceous cells. Immunoreactivities and expressions of CRH and POMC mRNAs were strong in inflammatory lesions, melanocytic nevus, seborrheic keratosis, and also in the periphery of the benign tumor. These findings suggest that CRH and POMC peptides are produced locally in the skin and are regulated by inflammatory cells as well as by autocrine mechanisms. The skin may have "a local stress response system," whose activity is mediated by CRH and POMC peptides, in an equivalent to hypothalamus-pituitary adrenal axis.	Tokai Univ, Dept Pathol, Sch Med, Boseidai Isehara, Kanagawa 2591193, Japan; Nippon Med Coll, Dept Dermatol, Tokyo 113, Japan	Tokai University; Nippon Medical School	Osamura, RY (corresponding author), Tokai Univ, Dept Pathol, Sch Med, Boseidai Isehara, Kanagawa 2591193, Japan.	osamura@is.icc.u-tokai.ac.jp						ANGIONI S, 1993, LIFE SCI, V53, P1735, DOI 10.1016/0024-3205(93)90160-5; AUDHYA T, 1991, CELL IMMUNOL, V134, P77, DOI 10.1016/0008-8749(91)90332-6; Can G, 1998, J INVEST DERMATOL, V111, P485, DOI 10.1046/j.1523-1747.1998.00315.x; Chakraborty AK, 1999, J INVEST DERMATOL, V112, P853, DOI 10.1046/j.1523-1747.1999.00608.x; Grabbe S, 1996, J IMMUNOL, V156, P473; HILTZ ME, 1990, PEPTIDES, V11, P979, DOI 10.1016/0196-9781(90)90020-6; Jin L, 1999, LAB INVEST, V79, P511; KAVELAARS A, 1989, J IMMUNOL, V142, P2338; Lipton JM, 1997, IMMUNOL TODAY, V18, P140, DOI 10.1016/S0167-5699(97)01009-8; LIU MY, 1995, J FOOD DRUG ANAL, V3, P203; LLOYD RV, 1995, DIAGN MOL PATHOL, V4, P143, DOI 10.1097/00019606-199506000-00011; Luger TA, 1998, ANN NY ACAD SCI, V840, P381, DOI 10.1111/j.1749-6632.1998.tb09577.x; LUGER TA, 1993, ANN NY ACAD SCI, V680, P567, DOI 10.1111/j.1749-6632.1993.tb19741.x; MAKRIGIANNAKIS A, 1995, J CLIN ENDOCR METAB, V80, P185, DOI 10.1210/jc.80.1.185; MCGILLIS JP, 1989, J NEUROSCI RES, V23, P346, DOI 10.1002/jnr.490230316; Orel L, 1997, J INVEST DERMATOL, V108, P401, DOI 10.1111/1523-1747.ep12289699; Roloff B, 1998, FASEB J, V12, P287, DOI 10.1096/fasebj.12.3.287; Rose J, 1998, J INVEST DERMATOL, V110, P456, DOI 10.1046/j.1523-1747.1998.00142.x; Sanno N, 1997, J CLIN ENDOCR METAB, V82, P2731, DOI 10.1210/jc.82.8.2731; Sanno N, 1997, J CLIN ENDOCR METAB, V82, P1974, DOI 10.1210/jc.82.6.1974; SCHAUER E, 1994, J CLIN INVEST, V93, P2258, DOI 10.1172/JCI117224; Shibutani M, 2000, LAB INVEST, V80, P199, DOI 10.1038/labinvest.3780023; SINGH VK, 1989, J NEUROIMMUNOL, V23, P257, DOI 10.1016/0165-5728(89)90058-1; SINGH VK, 1988, IMMUNOL LETT, V18, P5, DOI 10.1016/0165-2478(88)90061-2; Slominski A, 1996, BBA-GEN SUBJECTS, V1289, P247, DOI 10.1016/0304-4165(95)00159-X; Slominski A, 1996, INT J DERMATOL, V35, P849, DOI 10.1111/j.1365-4362.1996.tb05049.x; SLOMINSKI A, 1993, J LAB CLIN MED, V122, P658; SLOMINSKI A, 1995, FEBS LETT, V374, P113, DOI 10.1016/0014-5793(95)01090-2; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 1996, FEBS LETT, V399, P175, DOI 10.1016/S0014-5793(96)01315-4; Slominski A, 1999, HUM PATHOL, V30, P208, DOI 10.1016/S0046-8177(99)90278-2; Slominski AT, 1999, ANN NY ACAD SCI, V885, P287; SMITH EM, 1992, P NATL ACAD SCI USA, V89, P782, DOI 10.1073/pnas.89.2.782; Suzuki I, 1996, ENDOCRINOLOGY, V137, P1627, DOI 10.1210/en.137.5.1627; Toda Y, 1999, PATHOL INT, V49, P479, DOI 10.1046/j.1440-1827.1999.00875.x; Wintzen M, 1996, J INVEST DERMATOL, V106, P673, DOI 10.1111/1523-1747.ep12345496	36	88	90	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					2297	+		10.1096/fj.01-0254fje	http://dx.doi.org/10.1096/fj.01-0254fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11511529				2022-12-28	WOS:000170809900014
J	Lopez, F; Ferjoux, G; Cordelier, P; Saint-Laurent, N; Esteve, JP; Vaysse, N; Buscail, L; Susini, C				Lopez, F; Ferjoux, G; Cordelier, P; Saint-Laurent, N; Esteve, JP; Vaysse, N; Buscail, L; Susini, C			Neuronal nitric oxide synthase is a SHP-1 substrate involved in sst2 somatostatin receptor growth inhibitory signaling	FASEB JOURNAL			English	Article						CHO; acini; pancreas; motheaten mice; cGMP	SMOOTH-MUSCLE CELLS; PROTEIN-TYROSINE PHOSPHATASES; GASTROINTESTINAL-TRACT; GENE-EXPRESSION; TERMINAL REGION; TUMOR-GROWTH; CYCLE ARREST; PROLIFERATION; KINASE; PHOSPHORYLATION	Somatostatin receptor sst2 is an inhibitory G protein-coupled receptor, which inhibits normal and tumor cell growth by a mechanism involving the tyrosine phosphatase SHP-1. We reported previously that SHP-1 associates transiently with and is activated by sst2 and is a critical component for sst2 growth inhibitory signaling. Here, we demonstrate that in Chinese hamster ovary cells expressing sst2, SHP-1 is associated at the basal level with the neuronal nitric oxide synthase (nNOS). Following sst2 activation by the somatostatin analog RC-160, SHP-1 rapidly recruits nNOS tyrosine dephosphorylates and activates it. The resulting NO activates guanylate cyclase and inhibits cell proliferation. Coexpression of a catalytically inactive SHP-1 mutant with sst2 blocks RC-160-induced nNOS dephosphorylation and activation, as well as guanylate cyclase activation. In mouse pancreatic acini, RC-160 treatment reduces nNOS tyrosine phosphorylation accompanied by an increase of its activity. By opposition, in acini from viable motheaten (me(v)/me(v)) mice, which express a markedly inactive SHP-1, RC-160 has no effect on nNOS activity. Finally, expression of a dominant-negative form of nNOS prevents both RC-160-induced p27 up-regulation and cell proliferation inhibition. We therefore identified nNOS as a novel SHP-1 substrate critical for sst2-induced cell-growth arrest.	CHU Rangueil, IFR 31, INSERM, U531, F-31403 Toulouse 4, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Susini, C (corresponding author), CHU Rangueil, IFR 31, INSERM, U531, F-31403 Toulouse 4, France.	susinich@rangueil.inserm.fr	Cordelier, Pierre/D-1150-2014; Nathalie, Saint-Laurent/G-5487-2017	Cordelier, Pierre/0000-0003-2096-7967; 				Bandyopadhyay A, 1997, AM J PHYSIOL-CELL PH, V272, pC1790, DOI 10.1152/ajpcell.1997.272.6.C1790; Benali N, 2000, P NATL ACAD SCI USA, V97, P9180, DOI 10.1073/pnas.130196697; Berg KL, 1999, J BIOL CHEM, V274, P35855, DOI 10.1074/jbc.274.50.35855; Blery M, 2000, HUM IMMUNOL, V61, P51, DOI 10.1016/S0198-8859(99)00157-3; Bousquet C, 1998, J BIOL CHEM, V273, P7099, DOI 10.1074/jbc.273.12.7099; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BROWN PJ, 1993, J BIOL CHEM, V268, P6668; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; Buscail L, 1996, CANCER RES, V56, P1823; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; Christopoulos A., 1999, Life Sciences, V64, P1; Colasanti M, 1999, J BIOL CHEM, V274, P9915, DOI 10.1074/jbc.274.15.9915; Cordelier P, 1999, FASEB J, V13, P2037, DOI 10.1096/fasebj.13.14.2037; Feniuk W, 2000, NEUROPHARMACOLOGY, V39, P1443, DOI 10.1016/S0028-3908(00)00035-6; GARBERS DL, 1992, CELL, V71, P1; Gu YZ, 1995, MOL PHARMACOL, V48, P1004; Guh JH, 1998, MOL PHARMACOL, V53, P467, DOI 10.1124/mol.53.3.467; Hajri A, 1998, BRIT J CANCER, V78, P841, DOI 10.1038/bjc.1998.591; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Ishida A, 1997, J BIOL CHEM, V272, P10050; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Khaled AR, 1998, CELL IMMUNOL, V185, P49, DOI 10.1006/cimm.1998.1272; Kibbe MR, 2000, J VASC SURG, V31, P1214, DOI 10.1016/S0741-5214(00)90112-5; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Komeima K, 2000, J BIOL CHEM, V275, P28139; Kuzin B, 2000, CURR BIOL, V10, P459, DOI 10.1016/S0960-9822(00)00443-7; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; LOGSDON CD, 1983, GASTROENTEROLOGY, V85, P339; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; Meyerhof W, 1998, Rev Physiol Biochem Pharmacol, V133, P55; Moncada S, 1997, ANN NY ACAD SCI, V811, P60, DOI 10.1111/j.1749-6632.1997.tb51989.x; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Pages P, 1999, J BIOL CHEM, V274, P15186, DOI 10.1074/jbc.274.21.15186; Patel HJ, 1999, FASEB J, V13, P1810, DOI 10.1096/fasebj.13.13.1810; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; Richards MK, 1996, BIOCHEMISTRY-US, V35, P7772, DOI 10.1021/bi952582g; RODRIGUEZMARTIN E, 1995, PEPTIDES, V16, P1461, DOI 10.1016/0196-9781(95)02023-3; Rupprecht HD, 2000, KIDNEY INT, V57, P70, DOI 10.1046/j.1523-1755.2000.00828.x; Sarkar R, 1997, J HYPERTENS, V15, P275, DOI 10.1097/00004872-199715030-00009; Sato J, 2000, CARDIOVASC RES, V47, P697, DOI 10.1016/S0008-6363(00)00137-1; Saur D, 2000, GASTROENTEROLOGY, V118, P849, DOI 10.1016/S0016-5085(00)70171-5; SCHALLY AV, 1988, CANCER RES, V48, P6977; SCHALLY AV, 1989, CANCER RES, V49, P1618; Sharma K, 1999, MOL ENDOCRINOL, V13, P82, DOI 10.1210/me.13.1.82; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; Tamir I, 2000, CURR OPIN IMMUNOL, V12, P307, DOI 10.1016/S0952-7915(00)00092-3; Tanner FC, 2000, CIRCULATION, V101, P1982, DOI 10.1161/01.CIR.101.16.1982; Taylor-Gooby P, 1999, SOC POLICY ADMIN, V33, P1, DOI 10.1111/1467-9515.00128; Viollet C, 2000, EUR J NEUROSCI, V12, P3761, DOI 10.1046/j.1460-9568.2000.00249.x; Wang Y, 1999, CRIT REV NEUROBIOL, V13, P21, DOI 10.1615/CritRevNeurobiol.v13.i1.20; Weinstock JV, 2000, EUR J ENDOCRINOL, V143, pS15, DOI 10.1530/eje.0.143S015; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YU SM, 1997, BIOCHIM BIOPHYS ACTA, V1334, P123; [No title captured]	58	43	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					2300	+		10.1096/fj.00-0867fje	http://dx.doi.org/10.1096/fj.00-0867fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11511520				2022-12-28	WOS:000170809900013
J	Brignone, C; Munoz, O; Batoz, M; Rouquette-Jazdanian, A; Cousin, JL				Brignone, C; Munoz, O; Batoz, M; Rouquette-Jazdanian, A; Cousin, JL			Proteases produced by activated neutrophils release soluble CD23 fragments endowed with proinflammatory effects	FASEB JOURNAL			English	Article						polymorphonuclear neutrophils; cathepsin G; monocytes	REGULATES MONOCYTE ACTIVATION; COLLAGEN-INDUCED ARTHRITIS; EPSILON RECEPTOR-II; RHEUMATOID-ARTHRITIS; PROTEOLYTIC ACTIVITY; CATHEPSIN-G; CELL-SURFACE; STIMULATED NEUTROPHILS; MONOCLONAL-ANTIBODY; CYTOKINE PRODUCTION	Polymorphonuclear neutrophils (PMNs) are the major source of proteolytic activities involved mainly in tissue injuries observed in chronic inflammatory disorders. High levels of soluble forms of CD23 (the low-affinity receptor for IgE) were found in biological fluids from these patients, and recent reports focused on a CD23-mediated regulation of inflammatory response. In this context, we show here that co-culture of activated PMN with CD23(+) B cells resulted in a drastic release of soluble CD23 fragments from the cell surface. This cleavage was inhibited by serine proteases inhibitors, including alpha1-antitrypsin. We next demonstrated that purified human leukocyte elastase or cathepsin G efficiently cleaved membrane CD23 on B cells with a high specificity. Soluble fragments released by serine proteases-mediated CD23 proteolysis stimulated resting monocytes to produce oxidative burst and proinflammatory cytokine without any co-stimulatory signal. This work strongly supports the idea that the capacity of PMN-derived proteases to release soluble forms of CD23 participates in the inflammatory process mediated by these cells.	Hop Archet, INSERM, U343, F-06202 Nice 3, France; Dana Farber Canc Inst, Boston, MA 02115 USA	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Harvard University; Dana-Farber Cancer Institute	Cousin, JL (corresponding author), Hop Archet, INSERM, U343, BP 79, F-06202 Nice 3, France.	cousin@unice.fr		ROUQUETTE-JAZDANIAN, Alexandre K./0000-0003-2646-0040				ARMANT M, 1995, J IMMUNOL, V155, P4868; ARMANT M, 1994, J EXP MED, V180, P1005, DOI 10.1084/jem.180.3.1005; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BEAVIL RL, 1995, IMMUNOLOGY, V84, P202; Boccafogli A, 1997, ALLERGY, V52, P357, DOI 10.1111/j.1398-9995.1997.tb01009.x; BONNEFOY JY, 1987, J IMMUNOL, V138, P2970; BONNEFOY JY, 1993, CURR OPIN IMMUNOL, V5, P944, DOI 10.1016/0952-7915(93)90110-E; Bonnefoy JY, 1996, IMMUNOL TODAY, V17, P418, DOI 10.1016/0167-5699(96)10054-2; BORISH L, 1991, J IMMUNOL, V146, P63; BRISTOW CL, 1991, BIOCHEM BIOPH RES CO, V181, P232, DOI 10.1016/S0006-291X(05)81407-X; CAMPBELL EJ, 1989, J IMMUNOL, V143, P2961; CARP H, 1980, J CLIN INVEST, V66, P987, DOI 10.1172/JCI109968; Champagne B, 1998, J IMMUNOL, V161, P6398; CHOMARAT P, 1993, ARTHRITIS RHEUM-US, V36, P234, DOI 10.1002/art.1780360215; Christie G, 1997, EUR J IMMUNOL, V27, P3228, DOI 10.1002/eji.1830271221; Dasic G, 1999, EUR J IMMUNOL, V29, P2957, DOI 10.1002/(SICI)1521-4141(199909)29:09<2957::AID-IMMU2957>3.0.CO;2-4; de Leon D, 1991, J Neurosci Nurs, V23, P191; DIERKS SE, 1993, J IMMUNOL, V150, P2372; DORING G, 1994, AM J RESP CRIT CARE, V150, pS114; DORING G, 1995, J IMMUNOL, V154, P4842; Dugas N, 1996, EUR J IMMUNOL, V26, P1394, DOI 10.1002/eji.1830260632; FLORESROMO L, 1989, IMMUNOLOGY, V67, P547; Fremeaux-Bacchi V, 1998, EUR J IMMUNOL, V28, P4268, DOI 10.1002/(SICI)1521-4141(199812)28:12<4268::AID-IMMU4268>3.0.CO;2-9; GRENIERBROSSETTE N, 1992, EUR J IMMUNOL, V22, P1573, DOI 10.1002/eji.1830220634; Gu B, 1998, BLOOD, V92, P946; Hermann P, 1999, J CELL BIOL, V144, P767, DOI 10.1083/jcb.144.4.767; Hofman P, 1998, INFECT IMMUN, V66, P2494, DOI 10.1128/IAI.66.6.2494-2500.1998; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; JASIN HE, 1991, J CLIN INVEST, V87, P1531, DOI 10.1172/JCI115164; KATIRA A, 1995, ALLERGY, V50, P689, DOI 10.1111/j.1398-9995.1995.tb02587.x; KINTNER C, 1981, NATURE, V294, P458, DOI 10.1038/294458a0; Kleinau S, 1999, J IMMUNOL, V162, P4266; Kutukculer N, 1998, AUTOIMMUNITY, V27, P155, DOI 10.3109/08916939809003863; Le-Barillec K, 1999, J CLIN INVEST, V103, P1039, DOI 10.1172/JCI5779; LecoanetHenchoz S, 1997, EUR J IMMUNOL, V27, P2290, DOI 10.1002/eji.1830270924; LECOANETHENCHOZ S, 1995, IMMUNITY, V3, P119, DOI 10.1016/1074-7613(95)90164-7; LETELLIER M, 1990, J EXP MED, V172, P693, DOI 10.1084/jem.172.3.693; LEVINE JJ, 1993, PEDIATR RES, V34, P204, DOI 10.1203/00006450-199308000-00021; Munoz O, 1998, J BIOL CHEM, V273, P31795, DOI 10.1074/jbc.273.48.31795; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; OWEN CA, 1995, J IMMUNOL, V155, P5803; OWEN CA, 1995, J CELL BIOL, V131, P775, DOI 10.1083/jcb.131.3.775; PLATERZYBERK C, 1995, NAT MED, V1, P781, DOI 10.1038/nm0895-781; PORTEU F, 1991, J BIOL CHEM, V266, P18846; REDDY VY, 1994, J BIOL CHEM, V269, P4683; REMOLDODONNELL E, 1995, BLOOD, V86, P2395, DOI 10.1182/blood.V86.6.2395.bloodjournal8662395; Ribbens C, 2000, CLIN EXP IMMUNOL, V120, P194, DOI 10.1046/j.1365-2249.2000.01198.x; ROUSSOU E, 1991, BR J RHEUMATOL S2, V30, P110; SARFATI M, 1987, IMMUNOLOGY, V60, P539; TOSI MF, 1992, J CLIN INVEST, V90, P462, DOI 10.1172/JCI115882; vanderPoll T, 1996, BLOOD, V88, P922; Vella A, 1999, INFLAMMATION, V23, P471, DOI 10.1023/A:1021969127489; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P505, DOI 10.1164/ajrccm.157.2.9703070; Walzog B, 1999, FASEB J, V13, P1855, DOI 10.1096/fasebj.13.13.1855; WOODMAN RC, 1993, BLOOD, V82, P2188; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X; YUKAWA K, 1987, J IMMUNOL, V138, P2576	57	15	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2001	15	9					2027	+		10.1096/fj.00-0773fje	http://dx.doi.org/10.1096/fj.00-0773fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511513				2022-12-28	WOS:000170318500015
J	Rudling, M; Angelin, B				Rudling, M; Angelin, B			Growth hormone reduces plasma cholesterol in LDL receptor-deficient mice	FASEB JOURNAL			English	Article						hypercholesterolemia; familial; cholesterol 7 alpha-monooxygenase; statins; resins	LOW-DENSITY-LIPOPROTEIN; MEDIATED GENE DELIVERY; BILE-ACID SYNTHESIS; RAT-LIVER; KNOCKOUT MICE; 7-ALPHA-HYDROXYLASE; HYPERCHOLESTEROLEMIA; ENZYME; INVIVO; METABOLISM	Growth hormone (GH) has pleiotropic effects on cholesterol and lipoprotein metabolism. Pituitary GH is important for the normal regulation of hepatic LDL receptors (LDLR), for the enzymatic activity of bile acid regulatory cholesterol 7 alpha -hydroxylase (C7 alpha OH), and for the maintenance of resistance to dietary cholesterol. The present study aimed to determine whether GH has beneficial effects on plasma lipids and hepatic cholesterol metabolism in mice devoid of LDLR. Compared with wild-type controls, LDLR-deficient mice had similar to 250% elevated plasma total cholesterol and similar to 50% increased hepatic cholesterol levels; hepatic HMG CoA reductase activity was reduced by 70%, whereas C7 alpha OH activity was increased by 40%. In LDLR mice, GH infusion reduced plasma cholesterol and triglycerides up to 40%, whereas HMG CoA reductase and C7 alpha OH activities were stimulated by similar to 50% and 110% respectively. GH also stimulated HMG CoA reductase and C7 alpha OH activities in control mice, whereas hepatic LDLR and plasma lipoproteins were unchanged. The effects of cholestyramine and atorvastatin on C7 alpha OH in LDLR-deficient mice were potentiated by GH, and this was associated with a further reduction in plasma cholesterol. GH treatment reduces plasma cholesterol and triglycerides and stimulates C7 alpha OH activity in mice devoid of LDLR, particularly in combination with resin or statin treatment. The potential of GH therapy in patients with homozygous familial hypercholesterolemia should be evaluated.	Huddinge Univ Hosp, Ctr Metab & Endocrinol, Metab Unit, Dept Med, S-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Novum, Ctr Nutr & Toxicol,Mol Nutr Unit, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Rudling, M (corresponding author), Huddinge Univ Hosp, Ctr Metab & Endocrinol, Metab Unit, Dept Med, M63, S-14186 Huddinge, Sweden.	mats.rudling@cnt.ki.se						ANGELIN B, 1984, J LIPID RES, V25, P1159; Angelin Bo, 1994, Current Opinion in Lipidology, V5, P160, DOI 10.1097/00041433-199405030-00002; EDEN S, 1993, ARTERIOSCLER THROMB, V13, P296, DOI 10.1161/01.ATV.13.2.296; EINARSSON K, 1986, J LIPID RES, V27, P82; ELAM MB, 1992, ENDOCRINOLOGY, V131, P2717, DOI 10.1210/en.131.6.2717; FRIEDMAN M, 1970, NATURE, V255, P464; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KITA T, 1981, P NATL ACAD SCI-BIOL, V78, P2268, DOI 10.1073/pnas.78.4.2268; OSCARSSON J, 1991, METABOLISM, V40, P1191, DOI 10.1016/0026-0495(91)90215-I; Parini P, 1999, ARTERIOSCL THROM VAS, V19, P832, DOI 10.1161/01.ATV.19.4.832; RUDLING M, 1993, P NATL ACAD SCI USA, V90, P8851, DOI 10.1073/pnas.90.19.8851; Rudling M, 1997, J CLIN INVEST, V99, P2239, DOI 10.1172/JCI119398; RUDLING M, 1992, J LIPID RES, V33, P493; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; RUDLING M, 1993, J CLIN INVEST, V91, P2796, DOI 10.1172/JCI116522; SJOBERG A, 1992, ENDOCRINOLOGY, V130, P3356, DOI 10.1210/en.130.6.3356; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; Spady DK, 1998, J BIOL CHEM, V273, P126, DOI 10.1074/jbc.273.1.126; Teng BB, 1997, ARTERIOSCL THROM VAS, V17, P889, DOI 10.1161/01.ATV.17.5.889; XU GR, 1995, J CLIN INVEST, V95, P1497, DOI 10.1172/JCI117821; Zsigmond E, 1997, HUM GENE THER, V8, P1921, DOI 10.1089/hum.1997.8.16-1921	22	24	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1350	1356		10.1096/fj.00-0715com	http://dx.doi.org/10.1096/fj.00-0715com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11387232				2022-12-28	WOS:000169261200002
J	Kypreos, KE; Teusink, B; van Dijk, KOW; Havekes, LM; Zannis, VI				Kypreos, KE; Teusink, B; van Dijk, KOW; Havekes, LM; Zannis, VI			Analysis of the structure and function relationship of human apolipoprotein E in vivo, using adenovirus-mediated gene transfer	FASEB JOURNAL			English	Article						triglyceride-rich lipoproteins; remnant lipoprotein catabolism hypertriglyceridemia; hypercholesterolemia	LOW-DENSITY-LIPOPROTEIN; RECEPTOR-BINDING DOMAIN; E-DEFICIENT MICE; TRANSGENIC MICE; APO-E; CHOLESTEROL EFFLUX; A-I; ATHEROSCLEROSIS; HYPERLIPOPROTEINEMIA; DIET	We have used adenovirus-mediated gene transfer in apolipoprotein E (apoE)-deficient mice (E-/-) to dissect the domains of apoE required for cholesterol and triglyceride homeostasis in vivo. A dose of 2 x 10(9) pfu of apoE2- apoE3-, or apoE4-expressing adenoviruses failed to decrease the cholesterol levels of E-/- mice and caused severe hypertriglyceridemia, characterized by accumulation of apoE-rich and triglyceride-rich very low density lipoprotein (VLDL). In contrast, the truncated forms apoE4-229 and apoE4-259 at doses of 2 x 10(9) pfu, or 4 x 10(9) pfu, resulted in a 90% reduction in the cholesterol levels of E-/- mice, without affecting plasma triglyceride levels. The triglyceride secretion of mice infected with apoE4 was increased 2.7-fold compared with that of mice infected with apoE4-259. The apoE truncations did not influence apoE secretion by cells and association with VLDL. The levels of apoE4 and apoE4-229 and apoE4-259 mRNA in the livers of infected animals were similar. The findings suggest that the an-lino-terminal 1-229 region of apoE4 contains the domains required for the association of apoE with lipoproteins and their subsequent clearance via apoE-recognizing receptors. Furthermore, the carboxy-terminal 260-299 residues of apoE contribute to the apoE-induced hypertriglyceridemia. Thus, truncated forms of apoE may find useful future application in gene therapy for correction of high cholesterol profiles without triggering hypertriglyceridemia.	Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Leiden Univ, TNO PG Prevent & Hlth, Leiden, Netherlands; Gaubius Lab, Dept Human & Clin Genet, Leiden, Netherlands; Univ Crete, Dept Biochem, Iraklion, Crete, Greece; Univ Crete, Inst Mol Biol & Biotechnol, Iraklion, Crete, Greece	Boston University; Leiden University; Leiden University - Excl LUMC; Netherlands Organization Applied Science Research; University of Crete; University of Crete	Zannis, VI (corresponding author), Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst, 700 Albany St,W-509, Boston, MA 02118 USA.	vzannis@bu.edu	KYPREOS, KYRIAKOS/AAN-4485-2020; Kypreos, Kyriakos/AAG-1745-2020; Willems van Dijk, Ko/A-1798-2008	Kypreos, Kyriakos/0000-0001-6784-2710; Teusink, Bas/0000-0003-3929-0423; Willems van Dijk, Ko/0000-0002-2172-7394				AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; ALESHKOV SA, BIOCHEMISTRY, V36, P10571; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; CHAIT A, 1978, METABOLISM, V27, P1055, DOI 10.1016/0026-0495(78)90151-8; CLADARAS C, 1987, J BIOL CHEM, V262, P2310; Cohn JS, 1996, ARTERIOSCL THROM VAS, V16, P149, DOI 10.1161/01.ATV.16.1.149; Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; DONG LM, 1994, J BIOL CHEM, V269, P22358; EHNHOLM C, 1984, P NATL ACAD SCI-BIOL, V81, P5566, DOI 10.1073/pnas.81.17.5566; ENSEN PCN, 1998, J BIOL CHEM, V271, P14791; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Fan JL, 1998, J CLIN INVEST, V101, P2151, DOI 10.1172/JCI1599; FAZIO S, 1994, ARTERIOSCLER THROMB, V14, P1873, DOI 10.1161/01.ATV.14.11.1873; FAZIO S, 1994, J LIPID RES, V35, P408; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; GHISELLI G, 1981, SCIENCE, V214, P1239, DOI 10.1126/science.6795720; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; Huang YD, 1999, ARTERIOSCL THROM VAS, V19, P2952, DOI 10.1161/01.ATV.19.12.2952; Huang YD, 1998, J BIOL CHEM, V273, P17483, DOI 10.1074/jbc.273.28.17483; Huang YD, 1997, ARTERIOSCL THROM VAS, V17, P2010, DOI 10.1161/01.ATV.17.10.2010; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1995, J LIPID RES, V36, P583; Jong MC, 1997, BIOCHEM J, V328, P745; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KULPERS F, 1997, J CLIN INVEST, V100, P2915; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MANN WA, 1989, BIOCHIM BIOPHYS ACTA, V1005, P239, DOI 10.1016/0005-2760(89)90043-X; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; RALL SC, 1982, P NATL ACAD SCI-BIOL, V79, P4696, DOI 10.1073/pnas.79.15.4696; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Salah D, 1997, J LIPID RES, V38, P904; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; SMIT M, 1990, GENETIC HETEROGENEIT; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; VANDENMAAGDENBERG AMJM, 1989, BIOCHEM BIOPH RES CO, V165, P851, DOI 10.1016/S0006-291X(89)80044-0; VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540; vanVlijmen BJM, 1996, J BIOL CHEM, V271, P30595, DOI 10.1074/jbc.271.48.30595; VANVLIJMEN BJM, 1994, J CLIN INVEST, V93, P1403, DOI 10.1172/JCI117117; WARDELL MR, 1987, J CLIN INVEST, V80, P483, DOI 10.1172/JCI113096; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WOLF BB, 1992, AM J PATHOL, V141, P37; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhu YH, 1998, P NATL ACAD SCI USA, V95, P7585, DOI 10.1073/pnas.95.13.7585	62	29	31	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1598	+		10.1096/fj.00-0882fje	http://dx.doi.org/10.1096/fj.00-0882fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427498				2022-12-28	WOS:000173707700020
J	Kovaleva, ES; Yakovlev, AG; Masler, EP; Chitwood, DJ				Kovaleva, ES; Yakovlev, AG; Masler, EP; Chitwood, DJ			Human proprotein convertase 2 homologue from a plant nematode: Cloning, characterization, and comparison with other species	FASEB JOURNAL			English	Article						cDNA cloning; (G plus C) content; plant-parasitic nematode; Heterodera glycines	CAENORHABDITIS-ELEGANS; PROHORMONE CONVERTASES; PARASITIC NEMATODES; NEUROPEPTIDE GENE; CODON USAGE; PROPROTEIN; PEPTIDES; BINDING; DOMAIN; 7B2	Proprotein convertases (PCs) are evolutionarily conserved enzymes responsible for processing the precursors of many bioactive peptides in mammals. The invertebrate homologues of PC2 play important roles during development that makes the enzyme a good target for practical applications in pest management. Screening of a plant nematode Heterodera glycines cDNA library resulted in isolation of a full-length clone encoding a PC2-like precursor. The deduced protein (74.2 kD) exhibits strong amino acid homology to all known PC2s, including human, and shares the main structural characteristics: signal peptide; prosegment; catalytic domain, with D/H/S catalytic triad, PC2-specific residues, and 7B2 binding sites; P domain (with RRGDT pentapeptide); and carboxyl terminus. Comparative analysis of PC2s from 15 species discloses the presence of an insert in the catalytic domain unique to nematodes. Expression of PC2-like mRNA found in eggs and juveniles was undetectable in adult stages of H. glycines. Nucleotide analysis reveals distinctive differences in base composition and codon usage between H. glycines and Caenorhabditis elegans PC2s. The H. glycines cDNA clone encoding PC2 is the first one isolated from plant-parasitic nematodes.	ARS, Nematol Lab, USDA, PSI, Beltsville, MD 20705 USA; Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA	United States Department of Agriculture (USDA); Georgetown University	Kovaleva, ES (corresponding author), ARS, Nematol Lab, USDA, PSI, 10300 Baltimore Ave,Bldg 011A, Beltsville, MD 20705 USA.	kovaleve@ba.ars.usda.gov						Apletalina EV, 2000, J BIOL CHEM, V275, P14667, DOI 10.1074/jbc.275.19.14667; Benjannet S, 1998, FEBS LETT, V428, P37, DOI 10.1016/S0014-5793(98)00480-3; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Bird DM, 2000, J PLANT GROWTH REGUL, V19, P183; Blaxter ML, 1998, NATURE, V392, P71, DOI 10.1038/32160; CHITWOOD DJ, 1995, LIPIDS, V30, P567, DOI 10.1007/BF02537032; Creemers JWM, 1998, SEMIN CELL DEV BIOL, V9, P3, DOI 10.1006/scdb.1997.0195; Davis EL, 2000, ANNU REV PHYTOPATHOL, V38, P365, DOI 10.1146/annurev.phyto.38.1.365; Fadiel A, 2001, GENOMICS, V74, P197, DOI 10.1006/geno.2001.6531; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GOLDSTEIN B, 2001, DIABETES, V356, P1521; HAMMOND MP, 1992, PARASITOL TODAY, V8, P299, DOI 10.1016/0169-4758(92)90100-G; ISHIZAKI H, 1994, INT J DEV BIOL, V38, P301; Jin JM, 1999, GENE, V237, P161, DOI 10.1016/S0378-1119(99)00282-6; Kimber MJ, 2001, MOL BIOCHEM PARASIT, V116, P199, DOI 10.1016/S0166-6851(01)00323-1; Klumperman J, 1996, J NEUROSCI, V16, P7930; Lacombe C, 1999, NEUROPEPTIDES, V33, P71, DOI 10.1054/npep.1999.0016; Li C, 1999, ANN NY ACAD SCI, V897, P239, DOI 10.1111/j.1749-6632.1999.tb07895.x; Lilley CJ, 1999, PARASITOL TODAY, V15, P414, DOI 10.1016/S0169-4758(99)01513-6; Lilley CJ, 1999, PARASITOLOGY, V118, pS63, DOI 10.1017/S0031182099004059; Masler EP, 1999, J NEMATOL, V31, P224; Mbikay M, 2001, BIOCHEM J, V357, P329, DOI 10.1042/0264-6021:3570329; Milligan SB, 1998, PLANT CELL, V10, P1307, DOI 10.1105/tpc.10.8.1307; Muller L, 2000, PROG NUCLEIC ACID RE, V63, P69, DOI 10.1016/S0079-6603(08)60720-5; Pryon SC, 2000, ACTA BIOL HUNG, V51, P331; Rehemtulla Alnawaz, 1992, Current Opinion in Biotechnology, V3, P560, DOI 10.1016/0958-1669(92)90086-X; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Siekhaus DE, 1999, J NEUROSCI, V19, P6942, DOI 10.1523/JNEUROSCI.19-16-06942.1999; Sithigorngul P, 1996, J COMP NEUROL, V370, P427; STENICO M, 1994, NUCLEIC ACIDS RES, V22, P2437, DOI 10.1093/nar/22.13.2437; Thacker C, 2000, BIOESSAYS, V22, P545, DOI 10.1002/(SICI)1521-1878(200006)22:6&lt;545::AID-BIES7&gt;3.0.CO;2-F; Thacker C, 1999, GENOME RES, V9, P348; Waggoner LF, 2000, GENETICS, V154, P1181; Waterston Robert H., 1997, Cold Spring Harbor Monograph Series, V33, P23; Zahn TR, 2001, J COMP NEUROL, V429, P127, DOI 10.1002/1096-9861(20000101)429:1&lt;127::AID-CNE10&gt;3.0.CO;2-H; Zhou A, 1998, J BIOL CHEM, V273, P11107, DOI 10.1074/jbc.273.18.11107	37	7	7	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1099	+		10.1096/fj.01-0940fje	http://dx.doi.org/10.1096/fj.01-0940fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039853				2022-12-28	WOS:000175973900009
J	Laird, AD; Christensen, JG; Li, GM; Carver, J; Smith, K; Xin, XH; Moss, KG; Louie, SG; Mendel, DB; Cherrington, JM				Laird, AD; Christensen, JG; Li, GM; Carver, J; Smith, K; Xin, XH; Moss, KG; Louie, SG; Mendel, DB; Cherrington, JM			SU6668 inhibits Flk-1/KDR and PDGFR beta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice	FASEB JOURNAL			English	Article						angiogenesis; kinase inhibitor; VEGF; platelet-derived growth factor	ENDOTHELIAL GROWTH-FACTOR; RECEPTOR; VEGF; CANCER; WITHDRAWAL; INDUCTION; VESSELS; THERAPY	SU6668 is a small molecule inhibitor of the angiogenic receptor tyrosine kinases Flk-1/KDR, PDGFRbeta, and FGFR1. In mice, SU6668 treatment resulted in regression or growth arrest of all large established human tumor xenografts examined associated with loss of tumor cellularity. The events underlying loss of tumor cellularity were elucidated in detail in several tumor models. SU6668 treatment induced apoptosis in tumor microvessels within 6 h of the initiation of treatment. Dose-dependent decreases in tumor microvessel density were observed within 3 days of the first treatment. These changes were accompanied by decreased tumor cell proliferation and increased tumor cell apoptosis. Rapid increases in VEGF transcript levels were seen, consistent with the induction of tumor hypoxia. Using Western blot analyses, we determined that these in vivo antiangiogenic and proapoptotic effects of SU6668 occur at doses comparable to those required to inhibit Flk-1/KDR and PDGFRbeta phosphorylation in tumors. Potent, dose-dependent inhibition of Flk-1/KDR activity in vivo was independently demonstrated using vascular permeability as a readout. These data demonstrate that SU6668-induced inhibition of angiogenic receptor tyrosine kinase activity in vivo is associated with rapid vessel killing in tumors, leading to broad and potent antitumor effects.	SUGEN Inc, Preclin Res & Translat Med, San Francisco, CA 94080 USA	Pfizer	Laird, AD (corresponding author), SUGEN Inc, Preclin Res & Translat Med, 230 E Grand Ave, San Francisco, CA 94080 USA.	Douglas-Laird@sugen.com						Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Boehm-Viswanathan T, 2000, CURR OPIN ONCOL, V12, P89, DOI 10.1097/00001622-200001000-00015; Cherrington JM, 2000, ADV CANCER RES, V79, P1, DOI 10.1016/S0065-230X(00)79001-4; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Fong TAT, 1999, CANCER RES, V59, P99; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gerber HP, 2000, CANCER RES, V60, P6253; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KLINT P, 1999, FRONT BIOSCI, V4, P165; Laird AD, 2000, CANCER RES, V60, P4152; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liu B, 1995, BIOCHEM BIOPH RES CO, V217, P721, DOI 10.1006/bbrc.1995.2832; McMahon G, 1998, Curr Opin Drug Discov Devel, V1, P131; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; Millauer B, 1996, CANCER RES, V56, P1615; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shaheen RM, 1999, CANCER RES, V59, P5412	23	150	165	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7							UNSP 0892-6638/02/0016-0681	10.1096/fj.01-0700com	http://dx.doi.org/10.1096/fj.01-0700com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	11978732				2022-12-28	WOS:000175973900022
J	Robey, IF; Edmundson, AB; Schluter, SF; Yocum, DE; Marchalonis, JJ				Robey, IF; Edmundson, AB; Schluter, SF; Yocum, DE; Marchalonis, JJ			Specificity mapping of human anti-T cell receptor monoclonal natural antibodies: defining the properties of epitope recognition promiscuity	FASEB JOURNAL			English	Article						antigen binding site; polyreactivity; mAbs; affinity	POLYREACTIVE ANTIBODIES; EXQUISITE SPECIFICITY; IGM; AUTOANTIBODIES; BINDING; AUTOIMMUNE; REACTIVITY; AFFINITY; SHARKS; HEAVY	The classical concept of antibody binding is defined as an exclusive and high-affinity interaction with one epitope. The emerging reality about antibody combing sites, however, is that some can bind unrelated determinants. The studies presented here define this quality as epitope recognition promiscuity by analyzing the capacity of monoclonal human auto-antibodies to bind sets of overlapping peptides duplicating the complete structures of T cell receptor (TCR) alpha and beta chains and immunoglobulin lambda chain. We assessed the binding of these monoclonal antibodies (mAbs) to a set of homologous peptides corresponding to the CDR1 segments of human Vbeta gene products, a major epitope used in the selection of the antibodies. We present data on the binding characteristics of four human mAbs selected for the ability to bind TCR epitopes. These mAbs are IgM molecules with V-H and V-L sequences in germline configuration, but have diverse V-H CDR3 regions. These studies aim to characterize the property of epitope promiscuity and show that the relationship between the binding site and its epitope is a complex interaction and unpredictable from antigen sequence alone. Our results support the conclusion that epitope recognition promiscuity is a genuine feature of antibody and TCR recognition.	Univ Arizona, Coll Med, Dept Microbiol & Immunol, Tucson, AZ 85724 USA; Univ Arizona, Coll Med, Arizona Arthrit Ctr, Tucson, AZ 85724 USA; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA	University of Arizona; University of Arizona; Oklahoma Medical Research Foundation	Marchalonis, JJ (corresponding author), Univ Arizona, Coll Med, Dept Microbiol & Immunol, Tucson, AZ 85724 USA.	marchjj@email.arizona.edu						Adib-Conquy M, 1998, INT IMMUNOL, V10, P341, DOI 10.1093/intimm/10.3.341; ADIBCONQUY M, 1994, MOL IMMUNOL, V31, P555, DOI 10.1016/0161-5890(94)90043-4; Arden Bernhard, 1995, Immunogenetics, V42, P455; BERZOFSKY JA, 1981, MOL IMMUNOL, V18, P751, DOI 10.1016/0161-5890(81)90067-5; Boes M, 2000, MOL IMMUNOL, V37, P1141, DOI 10.1016/S0161-5890(01)00025-6; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CASALI P, 1989, ANNU REV IMMUNOL, V7, P513, DOI 10.1146/annurev.immunol.7.1.513; Casali P, 1988, Int Rev Immunol, V3, P17, DOI 10.3109/08830188809051180; CHEN C, 1991, J IMMUNOL, V147, P2359; Dehghanpisheh K, 1996, IMMUNOL INVEST, V25, P241, DOI 10.3109/08820139609059306; Deng YJ, 2000, CLIN EXP IMMUNOL, V119, P69, DOI 10.1046/j.1365-2249.2000.01096.x; Diaw L, 1997, J IMMUNOL, V158, P968; EDMUNDSON AB, 1975, BIOCHEMISTRY-US, V14, P3953, DOI 10.1021/bi00689a005; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; Hurez V, 1997, BLOOD, V90, P4004, DOI 10.1182/blood.V90.10.4004; ICHIYOSHI Y, 1994, J EXP MED, V180, P885, DOI 10.1084/jem.180.3.885; KAYMAZ H, 1993, INT IMMUNOL, V5, P491, DOI 10.1093/intimm/5.5.491; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Keitel T, 1997, CELL, V91, P811, DOI 10.1016/S0092-8674(00)80469-9; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Lake DF, 1997, J PROTEIN CHEM, V16, P309, DOI 10.1023/A:1026361110795; Marchalonis JJ, 1997, CRIT REV IMMUNOL, V17, P497; Marchalonis JJ, 1998, IMMUNOL REV, V166, P103, DOI 10.1111/j.1600-065X.1998.tb01256.x; Marchalonis JJ, 2001, ADV EXP MED BIOL, V484, P13; Marchalonis JJ, 2001, J MOL RECOGNIT, V14, P110, DOI 10.1002/jmr.527; Marchalonis JJ, 2000, APPL BIOCHEM BIOTECH, V83, P31, DOI 10.1385/ABAB:83:1-3:31; MARCHALONIS JJ, 1992, P NATL ACAD SCI USA, V89, P3325, DOI 10.1073/pnas.89.8.3325; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; Robey IF, 2000, J PROTEIN CHEM, V19, P9, DOI 10.1023/A:1007086608036; ROBEY IF, 2001, IN PRESS IMMUNOLOGY; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Seidl KJ, 1999, P NATL ACAD SCI USA, V96, P2262, DOI 10.1073/pnas.96.5.2262; Van Regenmortel MHV, 1998, J IMMUNOL METHODS, V216, P37, DOI 10.1016/S0022-1759(98)00069-6; Weller S, 1997, J IMMUNOL, V159, P3890; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; YANAGI Y, 1985, P NATL ACAD SCI USA, V82, P3430, DOI 10.1073/pnas.82.10.3430	37	15	18	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7							UNSP 0832-6638/02/0046-0642	10.1096/fj.01-0884com	http://dx.doi.org/10.1096/fj.01-0884com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	11978728				2022-12-28	WOS:000175973900018
J	Gafni, RI; McCarthy, EF; Hatcher, T; Meyers, JL; Inoue, N; Reddy, C; Weise, M; Barnes, KM; Abad, V; Baron, J				Gafni, RI; McCarthy, EF; Hatcher, T; Meyers, JL; Inoue, N; Reddy, C; Weise, M; Barnes, KM; Abad, V; Baron, J			Recovery from osteoporosis through skeletal growth: early bone mass acquisition has little effect on adult bone density	FASEB JOURNAL			English	Article						child; glucocorticoids; dexamethasone; adolescence; bone density	ACUTE LYMPHOBLASTIC-LEUKEMIA; MINERAL DENSITY; DIETARY CALCIUM; CHILDREN; MECHANISMS; CHILDHOOD; RABBIT; GLUCOCORTICOIDS; DETERMINANTS; DEFICIENCY	It is often assumed that bone mineral accretion should be optimized throughout childhood to maximize peak bone mass. In contrast, we hypothesized that bone mineral acquisition early in life would have little or no effect on adult bone mass because many areas of the juvenile skeleton are replaced in toto through skeletal growth. To test this hypothesis, we induced osteoporosis by administering dexamethasone to 5-week-old rabbits for 5 weeks and then allowed them to recover for 16 weeks. Tibial bone mineral density (ash weight/volume) was decreased in the dexamethasone-treated animals at the end of treatment but recovered completely. Bone structure in the femur was assessed by histomorphometry. Trabecular and cortical bone in the distal metaphysis was made osteoporotic by dexamethasone, but was then replaced through endochondral bone formation and recovered. Periosteal bone formation rate in the diaphysis was decreased during dexamethasone treatment but afterwards rebounded above controls and normalized cortical width. Our data suggest that bone mineral acquisition early in life has little effect on adult bone density because the juvenile bone is largely replaced through growth. If this concept generalizes, then interventions to maximize peak bone mass should be directed at adolescents rather than young children.	NICHHD, Unit Growth & Dev, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Bone Histomorphometry Lab, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Orthopaed Biomech Lab, Dept Orthopaed Surg, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Johns Hopkins University; Johns Hopkins University	Gafni, RI (corresponding author), NICHHD, Unit Growth & Dev, Dev Endocrinol Branch, NIH, Bldg 10,Room 10N262,10 Ctr Dr MSC 1862, Bethesda, MD 20892 USA.	gafnir@mail.nih.gov		Gafni, Rachel/0000-0002-7970-3491	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000640] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000640] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abad Veronica, 1997, Hormone Research (Basel), V48, P173; An YHH, 1996, AM J VET RES, V57, P1786; Bachrach LK, 2001, TRENDS ENDOCRIN MET, V12, P22, DOI 10.1016/S1043-2760(00)00336-2; Bass S, 1998, J BONE MINER RES, V13, P500, DOI 10.1359/jbmr.1998.13.3.500; BERGER M, 1982, ACTA ENDOCRINOL-COP, V99, P459, DOI 10.1530/acta.0.0990459; COOPER C, 1995, J BONE MINER RES, V10, P940; FRISANCHO AR, 1970, HUM BIOL, V42, P639; Gafni RI, 2001, PEDIATR RES, V50, P618, DOI 10.1203/00006450-200111000-00014; Gafni RI, 2000, PEDIATR NEPHROL, V14, P616, DOI 10.1007/s004670000338; GILSANZ V, 1990, J PEDIATR-US, V117, P238, DOI 10.1016/S0022-3476(05)80536-0; GILSANZ V, 1988, RADIOLOGY, V166, P847, DOI 10.1148/radiology.166.3.3340782; GILSANZ V, 1991, AM J PHYSIOL, V260, pE471, DOI 10.1152/ajpendo.1991.260.3.E471; GRARDEL B, 1994, OSTEOPOROSIS INT, V4, P204, DOI 10.1007/BF01623240; Haapasalo H, 2000, BONE, V27, P351, DOI 10.1016/S8756-3282(00)00331-8; Haugen M, 2000, ARTHRITIS RHEUM-US, V43, P1504, DOI 10.1002/1529-0131(200007)43:7<1504::AID-ANR13>3.3.CO;2-S; Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413; JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204; Lee WTK, 1997, ACTA PAEDIATR, V86, P570, DOI 10.1111/j.1651-2227.1997.tb08936.x; Li M, 1996, BONE, V19, P81, DOI 10.1016/8756-3282(96)00170-6; Loro ML, 2000, J CLIN ENDOCR METAB, V85, P3908; Lucidarme N, 2000, J PEDIATR-US, V137, P56, DOI 10.1067/mpd.2000.106219; MASOUD I, 1986, J ORTHOP RES, V4, P221, DOI 10.1002/jor.1100040211; *NAT RES COUNC, 1996, GUID CAR US LAB; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PETERSON CA, 1995, J BONE MINER RES, V10, P81; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; Rizzoli R, 1999, OSTEOPOROSIS INT, V9, P17, DOI 10.1007/PL00004155; SANDLER RB, 1985, AM J CLIN NUTR, V42, P270, DOI 10.1093/ajcn/42.2.270; Shen V, 1997, BONE, V21, P345, DOI 10.1016/S8756-3282(97)00153-1; Slemenda CW, 1997, J BONE MINER RES, V12, P676, DOI 10.1359/jbmr.1997.12.4.676; Soyka LA, 2000, J CLIN ENDOCR METAB, V85, P3951, DOI 10.1210/jc.85.11.3951; Thearle M, 2000, J CLIN ENDOCR METAB, V85, P2122, DOI 10.1210/jc.85.6.2122; Warner JT, 1999, PEDIATR RES, V45, P544, DOI 10.1203/00006450-199904010-00014; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799	34	47	50	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					736	+		10.1096/fj.01-0640fje	http://dx.doi.org/10.1096/fj.01-0640fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923218				2022-12-28	WOS:000174755900003
J	Fernandez-Patron, C; Zouki, C; Whittal, R; Chan, JSD; Davidge, ST; Filep, JG				Fernandez-Patron, C; Zouki, C; Whittal, R; Chan, JSD; Davidge, ST; Filep, JG			Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1[1-32]	FASEB JOURNAL			English	Article						gelatinases; ETA receptor; L-selectin; CD11b/CD18; leukocyte trafficking; endothelium; inflammation	ACTIVATED PROTEIN-KINASE; C-REACTIVE PROTEIN; BIG ENDOTHELIN-1; L-SELECTIN; LEUCYL-PHENYLALANINE; ISCHEMIA-REPERFUSION; LEUKOCYTE ADHESION; NITRIC-OXIDE; IN-VITRO; EXPRESSION	We recently reported that matrix metalloproteinase 2 (MMP-2, gelatinase A) cleaves big endothelin 1 (ET-1), yielding the vasoactive peptide ET-1[1-32]. We tested whether ET-1[1-32] could affect the adhesion of human neutrophils to coronary artery endothelial cells (HCAEC). ET-1[1-32] rapidly downregulated the expression of L-selectin and up-regulated expression of CD11b/CD18 on the neutrophil surface, with EC50 values of 1-3 nM. These actions of ET-1[1-32] were mediated via ETA receptors and did not require conversion of ET-1[1-32] into ET-1 by neutrophil proteases, as revealed by liquid chromatography and mass spectroscopy. Moreover, ET-1[1-32] evoked release of neutrophil gelatinase B, which cleaved big ET-1 to yield ET-1[1-32], thus revealing a positive feedback loop for ET-1[1-32] generation. Up-regulation of CD11b/CD18 expression and gelatinase release was tightly associated with activation of extracellular signal-regulated kinase (Erk). Stimulation of Erk activity was due to activation of Ras, Raf-1, and MEK (MAPK kinase). ET-1[1-32] also produced slight increases in the expression of ICAM-1 and E-selectin on HCAEC, and markedly enhanced beta (2) integrin-dependent adhesion of neutrophils to activated HCAEC. These results are the first indication that gelatinolytic MMPs via cleavage of big ET-1 to yield ET-1[1-32] activate neutrophils and promote leukocyte-endothelial cell adhesion and, consequently, neutrophil trafficking into inflamed tissues.	Univ Montreal, Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ H1T 2M4, Canada; Univ Montreal, Dept Med, Montreal, PQ H1T 2M4, Canada; Univ Alberta, Perinatal Res Ctr, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Chem, Lab Mass Spectrometry, Edmonton, AB T6G 2S2, Canada	Universite de Montreal; Universite de Montreal; University of Alberta; University of Alberta	Filep, JG (corresponding author), Univ Montreal, Maisonneuve Rosemont Hosp, Res Ctr, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.	janos.g.filep@umontreal.ca		Whittal, Randy/0000-0003-1174-8172				AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARAMORI I, 1993, MOL PHARMACOL, V43, P127; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Boros M, 1998, GASTROENTEROLOGY, V114, P103, DOI 10.1016/S0016-5085(98)70638-9; BORREGAARD N, 1987, SCIENCE, V237, P1204, DOI 10.1126/science.3629236; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Espinosa G, 1996, KIDNEY INT, V50, P776, DOI 10.1038/ki.1996.376; FARRE AL, 1993, CIRCULATION, V88, P1166, DOI 10.1161/01.CIR.88.3.1166; Fernandez-Patron C, 2000, CIRC RES, V87, P670, DOI 10.1161/01.RES.87.8.670; Fernandez-Patron C, 1999, CIRC RES, V85, P906; Fernandez-Patron C, 1999, THROMB HAEMOSTASIS, V82, P1353; FILEP J, 1989, LIFE SCI, V44, P517, DOI 10.1016/0024-3205(89)90613-9; FILEP JG, 1995, BRIT J PHARMACOL, V115, P227, DOI 10.1111/j.1476-5381.1995.tb15868.x; Filep JG, 1997, CIRCULATION, V96, P295; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; GOMEZGARRE D, 1992, EUR J PHARMACOL, V224, P167, DOI 10.1016/0014-2999(92)90801-A; HALIM A, 1995, THROMB RES, V77, P321, DOI 10.1016/0049-3848(95)93835-N; Hayasaki Y, 1996, BIOCHEM BIOPH RES CO, V229, P817, DOI 10.1006/bbrc.1996.1886; Helset E, 1996, AM J PHYSIOL-LUNG C, V271, pL538, DOI 10.1152/ajplung.1996.271.4.L538; ISHIDA K, 1990, BIOCHEM BIOPH RES CO, V173, P496, DOI 10.1016/S0006-291X(05)80061-0; ISHIKAWA K, 1994, P NATL ACAD SCI USA, V91, P4892, DOI 10.1073/pnas.91.11.4892; Jenkins GM, 1998, CIRCULATION, V97, P82, DOI 10.1161/01.CIR.97.1.82; KAW S, 1992, P NATL ACAD SCI USA, V89, P6886, DOI 10.1073/pnas.89.15.6886; Khimenko PL, 1996, J APPL PHYSIOL, V80, P203, DOI 10.1152/jappl.1996.80.1.203; LEFER AM, 1993, ANNU REV PHARMACOL, V33, P71, DOI 10.1146/annurev.pa.33.040193.000443; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; LOPEZFARRE A, 1995, CIRCULATION, V91, P2080, DOI 10.1161/01.CIR.91.7.2080; MCCARRON RM, 1993, NEUROSCI LETT, V156, P31, DOI 10.1016/0304-3940(93)90432-K; MIYAUCHI T, 1989, LANCET, V2, P53, DOI 10.1016/S0140-6736(89)90303-6; Murohara T, 1996, BLOOD, V88, P3894, DOI 10.1182/blood.V88.10.3894.bloodjournal88103894; Nakano A, 1997, J IMMUNOL, V159, P1987; NEWBY AC, 1994, BASIC RES CARDIOL, V89, P59; Parks WC, 1998, BIOL EXTRAC, P263; Pillinger MH, 1996, J BIOL CHEM, V271, P12049, DOI 10.1074/jbc.271.20.12049; Sanz MJ, 1999, AM J PHYSIOL-HEART C, V277, pH1823, DOI 10.1152/ajpheart.1999.277.5.H1823; Sawicki G, 1997, NATURE, V386, P616, DOI 10.1038/386616a0; SPERTINI O, 1991, J IMMUNOL, V147, P2565; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; WATANABE T, 1991, CIRC RES, V69, P370, DOI 10.1161/01.RES.69.2.370; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YU H, 1995, J BIOL CHEM, V270, P15719, DOI 10.1074/jbc.270.26.15719; Zouki C, 1997, J CLIN INVEST, V100, P522, DOI 10.1172/JCI119561; Zouki C, 1999, BRIT J PHARMACOL, V127, P969, DOI 10.1038/sj.bjp.0702593; ZOUKI C, 2000, FASEB J         1109	51	106	110	3	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2230	2240		10.1096/fj.01-0178com	http://dx.doi.org/10.1096/fj.01-0178com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641250				2022-12-28	WOS:000171920400035
J	Tchougounova, E; Pejler, G				Tchougounova, E; Pejler, G			Regulation of extravascular coagulation and fibrinolysis by heparin-dependent mast cell chymase	FASEB JOURNAL			English	Article						heparin proteoglycan; plasmin; thrombin	MOLECULAR-CLONING; HYPERSENSITIVITY REACTIONS; MIGRATION-INHIBITION; GRANULE CHYMASE; MICE LACKING; IN-VIVO; MOUSE; TRYPTASE; GENE; DEFICIENT	We recently characterized a heparin-deficient mouse strain generated by targeting the gene for N-deacetylase/N-sulfotransferase-2 (NDST-2). The NDST-2(-/-) mice show severe defects in their organization of mast cell (MC) secretory granules, with an almost total absence of the various heparin-binding MC proteases. In the present report we have studied the consequences of heparin/MC protease deficiency for extravascular coagulation and fibrinolysis. Addition of prothrombin to peritoneal cells-a mixture of macrophages, lymphocytes, and MCs-resulted in formation of thrombin but the accumulation of thrombin occurred faster in the NDST-2(-/-) cells than in normal controls. Further, the generated thrombin was subsequently inactivated in the NDST-2(+/+) cell cultures but not in the NDST-2(-/-) cells. Plasminogen was activated to plasmin at an apparently higher rate in peritoneal cells from NDST-2 null mice than in the normal controls. Similar to thrombin, the generated plasmin was inactivated by NDST-2(+/+) but not by the NDST-2(-/-) cells. Subsequent experiments with normal cells showed that cell surface-associated MC chymase, in a strongly heparin-dependent manner, was responsible for both the thrombinin-activating- and plasmin-inactivating activities. These results show that MC chymase-heparin complexes have the potential to regulate extravascular coagulation processes, as well as the plasminogen activator/plasmin system.	Swedish Univ Agr Sci, Ctr Biomed, Dept Vet Med Chem, S-75123 Uppsala, Sweden	Swedish University of Agricultural Sciences	Pejler, G (corresponding author), Swedish Univ Agr Sci, Ctr Biomed, Dept Vet Med Chem, Box 575, S-75123 Uppsala, Sweden.	Gunnar.Pejler@vmk.slu.se						Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BAUER PI, 1983, INT J BIOCHEM, V15, P871, DOI 10.1016/0020-711X(83)90161-1; Bugge TH, 1997, BLOOD, V90, P4522; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ENERBACK L, 1985, BIOCHEM J, V227, P661, DOI 10.1042/bj2270661; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; GECZY CL, 1981, J IMMUNOL, V126, P1059; GERVASONI JE, 1986, J IMMUNOL, V136, P285; Gotis-Graham I, 1998, ANN RHEUM DIS, V57, P664, DOI 10.1136/ard.57.11.664; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; He SH, 1997, J IMMUNOL, V159, P6216; He SH, 1998, BRIT J PHARMACOL, V125, P1491, DOI 10.1038/sj.bjp.0702223; He SH, 1998, EUR J PHARMACOL, V352, P91, DOI 10.1016/S0014-2999(98)00343-4; HOPPER KE, 1981, J IMMUNOL, V126, P1052; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J IMMUNOL, V160, P1910; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Knight PA, 2000, J EXP MED, V192, P1849, DOI 10.1084/jem.192.12.1849; KOKKONEN JO, 1986, J BIOL CHEM, V261, P6067; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1989, ARCH BIOCHEM BIOPHYS, V273, P180, DOI 10.1016/0003-9861(89)90177-X; Majima M, 1989, Adv Exp Med Biol, V247A, P487; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; Molinari JF, 1995, J APPL PHYSIOL, V79, P1966, DOI 10.1152/jappl.1995.79.6.1966; Molinari JF, 1996, AM J RESP CRIT CARE, V154, P649, DOI 10.1164/ajrccm.154.3.8810600; Pejler G, 1999, BIOCHEMISTRY-US, V38, P12187, DOI 10.1021/bi991046b; PEJLER G, 1995, EUR J BIOCHEM, V233, P192, DOI 10.1111/j.1432-1033.1995.192_1.x; PEJLER G, 1993, J BIOL CHEM, V268, P11817; PEJLER G, 1995, EUR J BIOCHEM, V227, P102, DOI 10.1111/j.1432-1033.1995.tb20364.x; PEJLER G, 1994, BIOCHEM J, V299, P507, DOI 10.1042/bj2990507; Pejler G, 1999, INFLAMM RES, V48, P344, DOI 10.1007/s000110050470; Pejler G, 2000, THROMB HAEMOSTASIS, V84, P429; PEJLER G, 1994, J BIOL CHEM, V269, P14451; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; Sabapathy KT, 1997, J CELL BIOL, V137, P953, DOI 10.1083/jcb.137.4.953; SCHECHTER NM, 1995, BIOCHEMISTRY-US, V34, P10628, DOI 10.1021/bi00033a038; SCHWARTZ LB, 1981, J IMMUNOL, V126, P2071; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; Shapiro RL, 1996, CANCER RES, V56, P3597; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; Sommerhoff CP, 2000, BBA-PROTEIN STRUCT M, V1477, P75, DOI 10.1016/S0167-4838(99)00265-4; STERK AR, 1982, J IMMUNOL, V128, P838; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; Tchougounova E, 2001, J BIOL CHEM, V276, P3772, DOI 10.1074/jbc.M008434200; Trautmann A, 2000, J PATHOL, V190, P100, DOI 10.1002/(SICI)1096-9896(200001)190:1<100::AID-PATH496>3.0.CO;2-Q; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X	60	40	41	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2763	+		10.1096/fj.01-0486fje	http://dx.doi.org/10.1096/fj.01-0486fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11687508				2022-12-28	WOS:000171920400003
J	Kim, D; Kim, S; Koh, H; Yoon, SO; Chung, AS; Cho, KS; Chung, J				Kim, D; Kim, S; Koh, H; Yoon, SO; Chung, AS; Cho, KS; Chung, J			Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production	FASEB JOURNAL			English	Article						cell migration; PI3 kinase; NF-kappa B; MMP-9; tumor invasion	NF-KAPPA-B; AKT PROTOONCOGENE; MATRIX METALLOPROTEINASES-2; ACTIN ORGANIZATION; IV COLLAGENASE; KINASE; ACTIVATION; RAC; EXPRESSION; GROWTH	The Akt/protein kinase B (PKB) serine/threonine kinase is well known as an important mediator of many cell survival signaling pathways. Here, we demonstrate for the first time a major role of Akt/PKB in the cell invasion properties of the highly metastatic cell line HT1080. Using confocal microscopic analyses of live samples, we found Akt/PKB to be localized in the leading edge membrane area of migrating HT1080 cells. This localization was dependent on phosphoinositide 3-kinase and required the lipid binding ability of the phosphoinositide binding pleckstrin homology domain of Akt/PKB. We examined the possible function of Akt/PKB in HT1080 invasion. Surprisingly, Akt/PKB potently promoted HT1080 invasion, by increasing cell motility and matrix metalloproteinase-9 (MMP-9) production, in a manner highly dependent on its kinase activity and membrane-translocating ability. The increase in MMP-9 production was mediated by activation of nuclear factor-kappaB transcriptional activity by Akt/PKB. However, Akt/PKB did not affect the cell-cell or cell-matrix adhesion properties of HT1080. Our findings thus establish Akt/PKB as a major factor in the invasive abilities of cancer cells.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Cell Growth Regulat, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Chung, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Kusong Dong, Taejon 305701, South Korea.	jchung@mail.kaist.ac.kr	Koh, Hyoungjong/C-1615-2012	Koh, Hyongjong/0000-0003-2594-4799				ALBINI A, 1987, CANCER RES, V47, P3239; Allen WE, 1997, J CELL SCI, V110, P707; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Bohle AS, 1999, LANGENBECK ARCH SURG, V384, P133, DOI 10.1007/s004230050183; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Hua J, 1996, CANCER RES, V56, P5279; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LIOTTA LA, 1991, CANCER RES, V51, pS5054; Majka M, 2000, BLOOD, V96, P4142, DOI 10.1182/blood.V96.13.4142.h8004142_4142_4151; Matsudaira Paul, 1994, Seminars in Cell Biology, V5, P165, DOI 10.1006/scel.1994.1021; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; Nishizaka T, 2000, P NATL ACAD SCI USA, V97, P692, DOI 10.1073/pnas.97.2.692; OKADA Y, 1992, J BIOL CHEM, V267, P21712; Ozes ON, 1999, NATURE, V401, P82; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sugiura Y, 1998, CANCER RES, V58, P2209; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tanno S, 2001, CANCER RES, V61, P589; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	45	416	443	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					1953	1962		10.1096/fj.01-0198com	http://dx.doi.org/10.1096/fj.01-0198com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532975				2022-12-28	WOS:000171372700010
J	Focke, M; Mahler, V; Ball, T; Sperr, WR; Majlesi, Y; Valent, P; Kraft, D; Valenta, R				Focke, M; Mahler, V; Ball, T; Sperr, WR; Majlesi, Y; Valent, P; Kraft, D; Valenta, R			Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination	FASEB JOURNAL			English	Article						Type I allergy; IgE; non-allergenic allergy vaccine	FC-EPSILON-RI; IGG MONOCLONAL-ANTIBODIES; ANTIGEN-PRESENTING CELLS; BET V 1; HAY-FEVER; P-I; RECOMBINANT ALLERGENS; IMMUNOTHERAPY; BINDING; DISEASES	Worldwide more than 200 million individuals are allergic to group 1 grass pollen allergens. We have used the major timothy grass pollen allergen Phl p 1, which cross-reacts with most grass-, corn-, and monocot-derived group 1 allergens to develop a generally applicable strategy for the production of hypoallergenic allergy vaccines. On the basis of the experimentally determined B cell epitopes of Phl p 1, we have synthesized five synthetic peptides. These peptides are derived from the major Phl p 1 IgE epitopes and were between 28-32 amino acids long. We demonstrate by nuclear magnetic resonance that the peptides exhibit no secondary and tertiary structure and accordingly failed to bind IgE antibodies from grass pollen allergic patients. The five peptides, as well as an equimolar mixture thereof, lacked allergenic activity as demonstrated by basophil histamine release and skin test experiments in grass pollen allergic patients. When used as immunogens in mice and rabbits, the peptides induced protective IgG antibodies, which recognized the complete Phl p 1 wild-type allergen and group 1 allergens from other grass species. Moreover, peptide-induced antibodies inhibited the binding of grass pollen allergic patients IgE antibodies to the wild-type allergen. We thus demonstrate that synthetic hypoallergenic peptides derived from B cell epitopes of major allergens represent safe vaccine candidates for the treatment of IgE-mediated allergies.	Univ Vienna, Vienna Gen Hosp, AKH, Dept Pathophysiol,Mol Immunopathol Grp, A-1090 Vienna, Austria; Univ Vienna, Vienna Gen Hosp, AKH, Dept Hematol & Hemostaseol, A-1090 Vienna, Austria; Univ Erlangen Nurnberg, Dept Dermatol, D-8520 Erlangen, Germany	University of Vienna; University of Vienna; University of Erlangen Nuremberg	Valenta, R (corresponding author), Univ Vienna, Vienna Gen Hosp, AKH, Dept Pathophysiol,Mol Immunopathol Grp, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	valenta@akh-wien.ac.at	Test, Test/Y-7921-2019; Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019; Test, PV/U-9451-2019; Sperr, Mast/V-4767-2019	Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Sperr, Mast/0000-0002-7778-5219; Valenta, Rudolf/0000-0001-5944-3365; Sperr, Wolfgang/0000-0003-3288-8027				Akdis CA, 1999, FASEB J, V13, P603, DOI 10.1096/fasebj.13.6.603; ATTALLAH NA, 1969, IMMUNOCHEMISTRY, V6, P609, DOI 10.1016/0019-2791(69)90199-2; Ball T, 1999, FASEB J, V13, P1277, DOI 10.1096/fasebj.13.11.1277; BALL T, 1994, J BIOL CHEM, V269, P28323; Bieber T, 1996, CURR OPIN IMMUNOL, V8, P773, DOI 10.1016/S0952-7915(96)80003-3; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cooke RA, 1937, J EXP MED, V66, P689, DOI 10.1084/jem.66.6.689; Denepoux S, 2000, FEBS LETT, V465, P39, DOI 10.1016/S0014-5793(99)01703-2; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Focke M, 2001, INT ARCH ALLERGY IMM, V124, P398, DOI 10.1159/000053769; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; GRAMMER LC, 1985, J ALLERGY CLIN IMMUN, V76, P397, DOI 10.1016/0091-6749(85)90661-X; Harley D, 1937, J PATHOL BACTERIOL, V44, P589, DOI 10.1002/path.1700440307; Haselden BM, 2000, INT ARCH ALLERGY IMM, V122, P229, DOI 10.1159/000024403; Heiss S, 1999, J INVEST DERMATOL, V113, P830, DOI 10.1046/j.1523-1747.1999.00796.x; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; Kay A.B., 1997, ALLERGY ALLERGIC DIS; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Laffer S, 1996, MOL IMMUNOL, V33, P417, DOI 10.1016/0161-5890(95)00152-2; Loveless MH, 1940, J IMMUNOL, V38, P25; MALLEY O, 1969, J ALLERGY, V43, P59; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1993, ANN ALLERGY, V71, P330; SCHEFFER GL, 1995, NAT MED, V1, P1; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; Valenta R, 1998, INT ARCH ALLERGY IMM, V116, P167, DOI 10.1159/000023942; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; Valenta R, 2001, IMMUNOL REV, V179, P119, DOI 10.1034/j.1600-065X.2001.790112.x; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Visco V, 1996, J IMMUNOL, V157, P956; Vrtala S, 1998, J IMMUNOL, V160, P6137; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Wheeler AW, 1997, ALLERGY, V52, P602, DOI 10.1111/j.1398-9995.1997.tb01038.x	39	110	121	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2042	+		10.1096/fj.01-0016fje	http://dx.doi.org/10.1096/fj.01-0016fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511525				2022-12-28	WOS:000170318500017
J	Campana, WM; Myers, RR				Campana, WM; Myers, RR			Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury	FASEB JOURNAL			English	Article						erythropoietin; glial cells; signaling; apoptosis	COLONY-STIMULATING FACTOR; GANGLION NEURONS; IN-VITRO; RAT; ADULT; JAK2; LOCALIZATION; DEATH	Erythropoietin (Epo) is a hematopoietic factor that has recently been shown to function in the central nervous system. The presence or function of Epo or the erythropoietin receptor (EpoR) in the peripheral nervous system is unknown. Our results demonstrate the presence of both Epo and EpoR in the rat sciatic nerve. Epo was present in axons and was up-regulated in Schwann cells after chronic constriction injury (CCI). EpoR was present in endothelial cells, cell bodies of the dorsal root ganglia (DRG), axons, and Schwann cells; it was not changed after injury. Using two different models of nerve injury, CCI and crush injury adjacent to the DRG, we demonstrated TUNEL labeling in DRG cell bodies after adjacent nerve crush, but not after CCI. TUNEL labeling in crush injury correlated with a significant reduction of EpoR in DRG as determined by morphometry and Western blotting. Immunoblotting of uninjured DRG homogenates revealed an immunoreactive band at 90 kDa and 70 kDa. After crush injury, both 70 kDa and 90 kDa proteins were reduced and the 90 kDa protein showed enhanced tyrosine phosphorylation, whereas the 70 kDa showed less. EpoR colocalized with NF200 in normal DRG, but not after crush injury to the adjacent axon. These findings demonstrate Epo and EpoR in the peripheral nervous system and their regulation after painful nerve injury.	Univ Calif San Diego, Sch Med, Dept Anesthesiol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; Vet Affairs Med Ctr, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Campana, WM (corresponding author), Univ Calif San Diego, Sch Med, Dept Anesthesiol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	wcampana@ucsd.edu						ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; Assandri R, 1999, J PHYSIOL-LONDON, V516, P343, DOI 10.1111/j.1469-7793.1999.0343v.x; ASSOULINE JG, 1989, DISSECTION TISSUE CU, P247; AVERILL S, 1995, EUR J NEUROSCI, V7, P1484, DOI 10.1111/j.1460-9568.1995.tb01143.x; BAUER C, 1995, J PERINAT MED, V23, P7, DOI 10.1515/jpme.1995.23.1-2.7; Benes FM, 2001, TRENDS NEUROSCI, V24, P11, DOI 10.1016/S0166-2236(00)01660-X; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.3.CO;2-8; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bittorf T, 1997, CELL SIGNAL, V9, P85, DOI 10.1016/S0898-6568(96)00121-0; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Campana WM, 1998, INT J MOL MED, V1, P235; Campana WM, 1998, FASEB J, V12, P307, DOI 10.1096/fasebj.12.3.307; Degn J, 1999, J COMP NEUROL, V412, P186, DOI 10.1002/(SICI)1096-9861(19990913)412:1<186::AID-CNE14>3.0.CO;2-H; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; EICHLER ME, 1989, BRAIN RES, V482, P340, DOI 10.1016/0006-8993(89)91197-9; HIMES BT, 1989, J COMP NEUROL, V284, P215, DOI 10.1002/cne.902840206; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Juul SE, 1998, EARLY HUM DEV, V52, P235, DOI 10.1016/S0378-3782(98)00030-9; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; KRANTZ SB, 1991, BLOOD, V77, P419; LANFRANCONE L, 1995, ONCOGENE, V10, P907; Lawson SN., 1992, SENSORY NEURONS DIVE, P27; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Mirsky R, 1999, BRAIN PATHOL, V9, P293; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; NAGAO M, 1992, BIOCHEM BIOPH RES CO, V188, P888, DOI 10.1016/0006-291X(92)91139-H; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pulkkanen KJ, 2000, APOPTOSIS, V5, P329, DOI 10.1023/A:1009631424351; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Studer L, 2000, J NEUROSCI, V20, P7377	35	102	111	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1804	+		10.1096/fj.00-0857fje	http://dx.doi.org/10.1096/fj.00-0857fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481236				2022-12-28	WOS:000169261200030
J	Trivedi, HN; Plummer, FA; Anzala, AO; Njagi, E; Bwayo, JJ; Ngugi, EN; Embree, JE; HayGlass, KT				Trivedi, HN; Plummer, FA; Anzala, AO; Njagi, E; Bwayo, JJ; Ngugi, EN; Embree, JE; HayGlass, KT			Resistance to HIV-1 infection among African sex workers is associated with global hyporesponsiveness in interleukin4 production	FASEB JOURNAL			English	Article						HIV-1 resistance; type 1/type 2 immune responses; immunity	CYTOTOXIC T-LYMPHOCYTES; IFN-GAMMA; ANTIRETROVIRAL THERAPY; SERONEGATIVE PARTNERS; CELLULAR-IMMUNITY; IN-VITRO; RESPONSES; EXPRESSION; CELLS; CD4(+)	We previously identified HIV-1 resistant prostitutes who remain persistently HIV-1 PCR- and antibody-negative despite continued heavy exposure to HIV-1 through sex work. We hypothesized that differences in virus-specific cytokine responses are associated with resistance vs. susceptibility to infection. Although polyclonal activation failed to reveal such difference, antigen-mediated activation of peripheral blood mononuclear cells (PBMC) in primary culture by using intact HIV (IIIB) demonstrates that resistance is associated with enhanced virus-driven interferon gamma and markedly reduced IL-4 responses relative to those seen in HIV-1 seropositive prostitutes (CDC stage A1, CD4>500/ml). No changes were detectable in HIV-stimulated interleukin (IL) 10 and IL-13 production, but IL-5 responses were somewhat increased in resistant sex workers. Moreover, the IL-4 response of HIV-1 resistant woman to a panel of unrelated recall antigens were more than 20-fold reduced relative to HIV-infected prostitutes or those of healthy Kenyan women not involved in sex work. Thus, resistant women differ from seropositive-infected women and healthy controls by exhibiting a profound global hyporesponsiveness in their capacity to generate IL-4 responses.	Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3E 0W3, Canada; Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya; Univ Nairobi, Dept Community Hlth, Nairobi, Kenya	University of Manitoba; University of Manitoba; University of Manitoba; University of Nairobi; University of Nairobi	HayGlass, KT (corresponding author), Univ Manitoba, Dept Immunol, 626-730 William Ave, Winnipeg, MB R3E 0W3, Canada.	hayglass@ms.umanitoba.ca		Njagi, Ephantus/0000-0002-1484-0241; HayGlass, Kent/0000-0002-4621-7737				Allen JE, 1997, IMMUNOL TODAY, V18, P387, DOI 10.1016/S0167-5699(97)01102-X; Annunziato F, 1999, J LEUKOCYTE BIOL, V65, P691, DOI 10.1002/jlb.65.5.691; Bertoletti A, 1998, J VIROL, V72, P2439, DOI 10.1128/JVI.72.3.2439-2448.1998; Bienzle D, 2000, J INFECT DIS, V182, P123, DOI 10.1086/315670; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Brinchmann JE, 2000, AIDS, V14, P1689, DOI 10.1097/00002030-200008180-00002; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Clerici M, 1999, IMMUNOL LETT, V66, P21, DOI 10.1016/S0165-2478(98)00181-3; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; Dorrell L, 2000, AIDS, V14, P1117, DOI 10.1097/00002030-200006160-00008; Fowke KR, 1998, AIDS RES HUM RETROV, V14, P1521, DOI 10.1089/aid.1998.14.1521; Fowke KR, 1996, LANCET, V348, P1347, DOI 10.1016/S0140-6736(95)12269-2; Galli G, 1998, EUR J IMMUNOL, V28, P3280, DOI 10.1002/(SICI)1521-4141(199810)28:10<3280::AID-IMMU3280>3.0.CO;2-M; Gangur V, 1998, FASEB J, V12, P705, DOI 10.1096/fasebj.12.9.705; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; Hanke T, 2000, NAT MED, V6, P951, DOI 10.1038/79626; Hay CM, 1999, J VIROL, V73, P5509, DOI 10.1128/JVI.73.7.5509-5519.1999; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; IMADA M, 1995, INT IMMUNOL, V7, P229, DOI 10.1093/intimm/7.2.229; Jourdan P, 2000, J IMMUNOL, V165, P716, DOI 10.4049/jimmunol.165.2.716; Jourdan P, 1998, J IMMUNOL, V160, P4153; Kalams SA, 1999, J VIROL, V73, P6715, DOI 10.1128/JVI.73.8.6715-6720.1999; Kaul R, 1999, AIDS, V13, P23, DOI 10.1097/00002030-199901140-00004; Kelso A, 1999, SPRINGER SEMIN IMMUN, V21, P231, DOI 10.1007/s002810050065; Kokkotou EG, 2000, P NATL ACAD SCI USA, V97, P6797, DOI 10.1073/pnas.97.12.6797; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Li Y, 1998, J IMMUNOL, V161, P7007; Lopalco L, 2000, J IMMUNOL, V164, P3426, DOI 10.4049/jimmunol.164.6.3426; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; Maini MK, 1999, GASTROENTEROLOGY, V117, P1386, DOI 10.1016/S0016-5085(99)70289-1; Malhotra U, 2000, J INFECT DIS, V181, P121, DOI 10.1086/315202; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; Mosmann T, 2000, IMMUNOL TODAY, V21, P199, DOI 10.1016/S0167-5699(00)01587-5; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Oxenius A, 2000, P NATL ACAD SCI USA, V97, P3382, DOI 10.1073/pnas.97.7.3382; Panus JF, 2000, J EXP MED, V192, P1301, DOI 10.1084/jem.192.9.1301; Pape GR, 1999, J VIRAL HEPATITIS, V6, P36, DOI 10.1046/j.1365-2893.1999.00006.x; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Poss M, 1997, AIDS RES HUM RETROV, V13, P493, DOI 10.1089/aid.1997.13.493; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; ROMAGNANI S, 1994, IMMUNOL REV, V140, P73, DOI 10.1111/j.1600-065X.1994.tb00865.x; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rowland-Jones S, 1997, ADV IMMUNOL, V65, P277, DOI 10.1016/S0065-2776(08)60745-2; Rowland-Jones SL, 1999, IMMUNOL LETT, V66, P9, DOI 10.1016/S0165-2478(98)00179-5; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; Shearer GM, 1998, AIDS RES HUM RETROV, V14, pS149; Stranford SA, 1999, P NATL ACAD SCI USA, V96, P1030, DOI 10.1073/pnas.96.3.1030; Valentin A, 1998, P NATL ACAD SCI USA, V95, P8886, DOI 10.1073/pnas.95.15.8886; Zhu TF, 1998, NATURE, V391, P594, DOI 10.1038/35400; Zoeteweij JP, 1998, J IMMUNOL, V161, P3219	57	12	12	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1795	+		10.1096/fj.00-0619fje	http://dx.doi.org/10.1096/fj.00-0619fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481233				2022-12-28	WOS:000169261200020
J	Koh, YH; Suzuki, K; Che, WY; Park, YS; Miyamoto, Y; Higashiyama, S; Taniguchi, N				Koh, YH; Suzuki, K; Che, WY; Park, YS; Miyamoto, Y; Higashiyama, S; Taniguchi, N			Inactivation of glutathione peroxidase by nitric oxide leads to the accumulation of H2O2 and the induction of HB-EGF via c-Jun NH2-terminal kinase in rat aortic smooth muscle cells	FASEB JOURNAL			English	Article						gluthathione peroxidase; nitric oxide; JNK; HB-EGF; apoptosis	NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR; SUPEROXIDE-DISMUTASE; SURVIVAL FACTOR; UP-REGULATION; ACTIVATION; APOPTOSIS; PEROXYNITRITE; VASODILATORS; SUPPRESSION	We describe the effect of nitric oxide (NO) on the expression of the heparin-binding EGF-like growth factor (HB-EGF), a potent chemoattractant and mitogen for smooth muscle cells, and its anti-apoptotic effect against NO cytotoxicity. Previous studies have shown that glutathione peroxidase (GPx), a major peroxide scavenging enzyme is selectively inactivated by an NO donor, S-nitroso-N-acetyl-DL-penicillamine (SNAP), in vitro and in vivo and results in the accumulation of peroxide (6, 7). The SNAP or peroxynitrite induces HB-EGF through the inactivation of GPx and the accumulation of peroxide. This induction is accompanied by JNK and c-Jun/AP-1 activation. The blocking of the HB-EGF induction by curcumin, c-jun antisense oligonucleotide, and a dominant-negative mutant of JNK1 provides support for these results. A longer pretreatment of rat aortic smooth muscle cells (RASMCs) by SNAP induces HB-EGF and reduces the TNFalpha+actinomycin D-induced apoptosis. This protection is blocked by antisense HB-EGF s-oligonucleotide. These findings indicate that the induction of HB-EGF by NO would be an adaptive response as an autocrine protective factor against apoptosis by NO in RASMCs.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Hyogo Med Univ, Dept Biochem, Nishinomiya, Hyogo, Japan	Osaka University; Hyogo College of Medicine; University of Hyogo	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Park, Yong Seek/ABG-6398-2021; Taniguchi, Naoyuki/I-4182-2014	Park, Yong Seek/0000-0002-9260-3102; Taniguchi, Naoyuki/0000-0001-5889-5968				Arkonac BM, 1998, J BIOL CHEM, V273, P4400, DOI 10.1074/jbc.273.8.4400; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; Asahi M, 1997, J BIOL CHEM, V272, P19152, DOI 10.1074/jbc.272.31.19152; Asakawa H, 1996, CELL BIOCHEM FUNCT, V14, P181; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; Che WY, 1997, J BIOL CHEM, V272, P18453, DOI 10.1074/jbc.272.29.18453; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Fukuo K, 1996, HYPERTENSION, V27, P823, DOI 10.1161/01.HYP.27.3.823; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; Horikawa M, 1999, FEBS LETT, V459, P100, DOI 10.1016/S0014-5793(99)01213-2; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; KARIYA K, 1989, ATHEROSCLEROSIS, V80, P143, DOI 10.1016/0021-9150(89)90022-1; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; MAGRINAT G, 1992, BLOOD, V80, P1880; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; Miyazaki Y, 1996, BIOCHEM BIOPH RES CO, V226, P542, DOI 10.1006/bbrc.1996.1391; Miyoshi E, 1997, J BIOL CHEM, V272, P14349, DOI 10.1074/jbc.272.22.14349; NAKAKI T, 1990, EUR J PHARM-MOLEC PH, V189, P347, DOI 10.1016/0922-4106(90)90031-R; NAKATA T, 1993, INT J CANCER, V55, P646, DOI 10.1002/ijc.2910550422; Nishio E, 1996, BIOCHEM BIOPH RES CO, V221, P163, DOI 10.1006/bbrc.1996.0563; Pascall JC, 2000, BBA-GENE STRUCT EXPR, V1492, P434, DOI 10.1016/S0167-4781(00)00123-8; Pollman MJ, 1996, CIRC RES, V79, P748, DOI 10.1161/01.RES.79.4.748; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takemura T, 1997, J BIOL CHEM, V272, P31036, DOI 10.1074/jbc.272.49.31036; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	42	27	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1472	+		10.1096/fj.00-0572fje	http://dx.doi.org/10.1096/fj.00-0572fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387261				2022-12-28	WOS:000173705800006
J	Wittwer, M; Fluck, M; Hoppeler, H; Muller, S; Desplanches, D; Billeter, R				Wittwer, M; Fluck, M; Hoppeler, H; Muller, S; Desplanches, D; Billeter, R			Prolonged unloading of rat soleus muscle causes distinct adaptations of the gene profile	FASEB JOURNAL			English	Review						atrophy; array; hindlimb suspension; L1 regression	DENSITY-LIPOPROTEIN RECEPTOR; RECTIFIER POTASSIUM CHANNEL; GLUCOSE-TRANSPORTER GLUT4; SKELETAL-MUSCLE; HINDLIMB SUSPENSION; MOLECULAR-CLONING; MESSENGER-RNA; SATELLITE CELLS; NEUROPEPTIDE-Y; MYOGENIC DIFFERENTIATION	Using commercially available microarray technology, we investigated a series of transcriptional adaptations caused by atrophy of rat m. soleus due to 35 days of hindlimb suspension. We detected 395 out of 1,200 tested transcripts, which reflected 1%-5% of totally expressed genes. From various cellular functional pathways, we detected multiple genes that spanned a 200-fold range of gene expression levels. Statistical analysis combining L1 regression with the sign test based on the conservative Bonferroni correction identified 105 genes that underwent transcriptional adaptations with atrophy. Generally, expressional changes were discrete (<50%) and pointed in the same direction for genes belonging to the same cellular functional units. In particular, a distinct expressional adaptation of genes involved in fiber transformation; that is, metabolism, protein turnover, and cell regulation were noted and matched to corresponding transcriptional changes in nutrient trafficking. Expressional changes of extracellular proteases, and of genes involved in nerve-muscle interaction and excitation-contraction coupling identify previously not recognized adaptations that occur in atrophic m. soleus. Considerations related to technical and statistical aspects of the array approach for profiling the skeletal muscle genome and the impact of observed novel adaptations of the m. soleus transcriptome are put into perspective of the physiological adaptations occurring with muscular atrophy.	Univ Bern, Inst Anat, CH-3012 Bern, Switzerland; Univ Bern, Dept Math Stat & Actuarial Sci, CH-3012 Bern, Switzerland; Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Lyon 1, CNRS, UMR 5123, F-69622 Villeurbanne, France	University of Bern; University of Bern; University of Leeds; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Fluck, M (corresponding author), Univ Bern, Inst Anat, Buhlstr 26, CH-3012 Bern, Switzerland.	flueck@ana.unibe.ch	Muller, Samuel/N-1371-2019; Wittwer, Matthias/K-4512-2014; Mueller, Samuel/D-4850-2009	Muller, Samuel/0000-0002-3087-8127; Wittwer, Matthias/0000-0003-4713-8392; Mueller, Samuel/0000-0002-3087-8127				Adams GR, 1999, J APPL PHYSIOL, V87, P1705, DOI 10.1152/jappl.1999.87.5.1705; Allen DL, 1997, AM J PHYSIOL-CELL PH, V273, pC579, DOI 10.1152/ajpcell.1997.273.2.C579; ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; Atherton GT, 1996, CELL GROWTH DIFFER, V7, P1059; Attaix D, 1997, MOL BIOL REP, V24, P95, DOI 10.1023/A:1006806103675; Awede B, 1999, FEBS LETT, V461, P263, DOI 10.1016/S0014-5793(99)01469-6; BACH LA, 1994, ENDOCRINOLOGY, V135, P2168, DOI 10.1210/en.135.5.2168; Balcerzak D, 2001, J ANIM SCI, V79, P94; Bloomfield P, 1983, LEAST ABSOLUTE DEVIA; BONEN A, 1988, J APPL PHYSIOL, V65, P1833, DOI 10.1152/jappl.1988.65.4.1833; Bonini JA, 1997, BIOCHEM BIOPH RES CO, V234, P190, DOI 10.1006/bbrc.1997.6591; BOOTH FW, 1992, AM J PHYSIOL, V262, pR329, DOI 10.1152/ajpregu.1992.262.3.R329; BRENNER HR, 1990, NATURE, V344, P544, DOI 10.1038/344544a0; Campbell WG, 2001, AM J PHYSIOL-CELL PH, V280, pC763, DOI 10.1152/ajpcell.2001.280.4.C763; Carlson CJ, 1999, AM J PHYSIOL-REG I, V277, pR601, DOI 10.1152/ajpregu.1999.277.2.R601; Catterall W A, 1999, Adv Neurol, V79, P441; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Cros N, 1999, AM J PHYSIOL-REG I, V276, pR308, DOI 10.1152/ajpregu.1999.276.2.R308; Delp MD, 2000, AM J PHYSIOL-HEART C, V278, pH1866, DOI 10.1152/ajpheart.2000.278.6.H1866; DESPLANCHES D, 1987, J APPL PHYSIOL, V63, P558, DOI 10.1152/jappl.1987.63.2.558; DESPLANCHES D, 1990, J APPL PHYSIOL, V69, P504, DOI 10.1152/jappl.1990.69.2.504; DESPLANCHES D, 1987, J APPL PHYSIOL, V63, P1739, DOI 10.1152/jappl.1987.63.5.1739; DONOGHUE MJ, 1994, TRENDS GENET, V10, P396, DOI 10.1016/0168-9525(94)90056-6; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Durkin MM, 2000, EXP NEUROL, V165, P90, DOI 10.1006/exnr.2000.7446; ELDER GCB, 1987, J APPL PHYSIOL, V62, P1917, DOI 10.1152/jappl.1987.62.5.1917; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; Ewton DZ, 1998, J CELL PHYSIOL, V177, P47, DOI 10.1002/(SICI)1097-4652(199810)177:1<47::AID-JCP5>3.0.CO;2-E; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FITTS RH, 1989, AM J PHYSIOL, V256, pC1082, DOI 10.1152/ajpcell.1989.256.5.C1082; Fitts RH, 2000, J APPL PHYSIOL, V89, P823, DOI 10.1152/jappl.2000.89.2.823; Glatz JFC, 1998, ADV EXP MED BIOL, V441, P207; GOLDSPINK DF, 1986, PFLUG ARCH EUR J PHY, V407, P333, DOI 10.1007/BF00585311; Gomez-Pinilla F, 2001, EUR J NEUROSCI, V13, P1078, DOI 10.1046/j.0953-816x.2001.01484.x; Grichko VP, 2000, J APPL PHYSIOL, V88, P473, DOI 10.1152/jappl.2000.88.2.473; Guidry G, 2000, AUTON NEUROSCI-BASIC, V82, P97, DOI 10.1016/S0165-1838(00)00094-1; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; Haas TL, 2000, AM J PHYSIOL-HEART C, V279, pH1540, DOI 10.1152/ajpheart.2000.279.4.H1540; Haddad F, 1998, J APPL PHYSIOL, V85, P2227, DOI 10.1152/jappl.1998.85.6.2227; Hajduch E, 1999, BIOCHEM BIOPH RES CO, V257, P369, DOI 10.1006/bbrc.1999.0471; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hamilton MT, 1998, AM J PHYSIOL-ENDOC M, V275, pE1016, DOI 10.1152/ajpendo.1998.275.6.E1016; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; HENRIKSEN EJ, 1986, J BIOL CHEM, V261, P707; HENRIKSEN EJ, 1993, J APPL PHYSIOL, V74, P1653, DOI 10.1152/jappl.1993.74.4.1653; HENRIKSEN EJ, 1988, METABOLISM, V37, P201, DOI 10.1016/0026-0495(88)90096-0; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; HIETANENPELTOLA M, 1992, BRAIN RES, V579, P327, DOI 10.1016/0006-8993(92)90069-L; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; HOWARD G, 1989, J APPL PHYSIOL, V66, P1093, DOI 10.1152/jappl.1989.66.3.1093; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; Johnson MSC, 1998, ENDOCRINOLOGY, V139, P72, DOI 10.1210/en.139.1.72; JOSHUA IG, 1991, PEPTIDES, V12, P37, DOI 10.1016/0196-9781(91)90163-J; JOZSA L, 1988, EXP MOL PATHOL, V49, P267, DOI 10.1016/0014-4800(88)90039-1; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kawano Y, 1999, DIABETOLOGIA, V42, P1071, DOI 10.1007/s001250051273; Kerr MK, 2000, J COMPUT BIOL, V7, P819, DOI 10.1089/10665270050514954; Kherif S, 1999, DEV BIOL, V205, P158, DOI 10.1006/dbio.1998.9107; KOYAMA H, 1994, FEBS LETT, V341, P303, DOI 10.1016/0014-5793(94)80478-8; Kraus B, 1997, EUR J BIOCHEM, V247, P98, DOI 10.1111/j.1432-1033.1997.t01-1-00098.x; KRIPPENDORF BB, 1993, MUSCLE NERVE, V16, P99, DOI 10.1002/mus.880160116; KUES WA, 1995, EUR J NEUROSCI, V7, P1376, DOI 10.1111/j.1460-9568.1995.tb01129.x; Langfort J, 1997, BIOCHEM CELL BIOL, V75, P41; Lee SB, 1996, J BIOL CHEM, V271, P25, DOI 10.1074/jbc.271.1.25; Leterme D, 1996, PFLUG ARCH EUR J PHY, V432, P313, DOI 10.1007/s004240050138; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu TJ, 2001, CIRC RES, V88, P1231, DOI 10.1161/hh1201.092036; Lluis F, 2001, BLOOD, V97, P1703, DOI 10.1182/blood.V97.6.1703; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; LOWELL BB, 1986, BIOCHEM J, V234, P237, DOI 10.1042/bj2340237; Luiken JJFP, 1999, LIPIDS, V34, pS169, DOI 10.1007/BF02562278; Lukes A, 1999, MOL NEUROBIOL, V19, P267, DOI 10.1007/BF02821717; Mahns DA, 1998, J AUTONOM NERV SYST, V68, P14, DOI 10.1016/S0165-1838(97)00111-2; MAKITA N, 1994, J BIOL CHEM, V269, P7571; Martin Sally, 1999, Cell Biochemistry and Biophysics, V30, P89, DOI 10.1007/BF02737886; Matteo RG, 2000, CARDIOVASC RES, V45, P961, DOI 10.1016/S0008-6363(99)00409-5; McArthur MJ, 1999, J LIPID RES, V40, P1371; MILLER WC, 1988, P SOC EXP BIOL MED, V189, P183; Morey E R, 1979, Physiologist, V22, pS23; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Muir E, 1998, GLIA, V23, P24, DOI 10.1002/(SICI)1098-1136(199805)23:1<24::AID-GLIA3>3.3.CO;2-J; Nakamura M, 1997, BBA-BIOMEMBRANES, V1328, P83, DOI 10.1016/S0005-2736(97)00131-4; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; O'Harte FPM, 1998, J ENDOCRINOL, V156, P237, DOI 10.1677/joe.0.1560237; OSCAI LB, 1971, J BIOL CHEM, V246, P6968; Pol A, 1997, BIOCHEM J, V327, P741, DOI 10.1042/bj3270741; Reid B, 1999, J NEUROSCI, V19, P2511; RILEY DA, 1990, FASEB J, V4, P84, DOI 10.1096/fasebj.4.1.2153085; Roh C, 2001, J BIOL CHEM, V276, P35990, DOI 10.1074/jbc.M102791200; ROSEBOOM PH, 1994, DNA CELL BIOL, V13, P629, DOI 10.1089/dna.1994.13.629; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHULTZ E, 1994, J APPL PHYSIOL, V76, P266, DOI 10.1152/jappl.1994.76.1.266; SPRINGHORN JP, 1994, J BIOL CHEM, V269, P5132; St-Amand J, 2001, FASEB J, V15, P684, DOI 10.1096/fj.00-0150com; Standaert ML, 1999, ENDOCRINOLOGY, V140, P4470, DOI 10.1210/en.140.10.4470; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; Stohwasser R, 2000, EUR J BIOCHEM, V267, P6221, DOI 10.1046/j.1432-1327.2000.01706.x; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; Suzuki Y, 1998, AM J PHYSIOL-CELL PH, V274, pC1674, DOI 10.1152/ajpcell.1998.274.6.C1674; Swoap SJ, 2000, AM J PHYSIOL-CELL PH, V279, pC915, DOI 10.1152/ajpcell.2000.279.4.C915; Taillandier D, 1996, BIOCHEM J, V316, P65, DOI 10.1042/bj3160065; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; THOMASON DB, 1989, AM J PHYSIOL, V257, pR300, DOI 10.1152/ajpregu.1989.257.2.R300; THOMASON DB, 1990, J APPL PHYSIOL, V68, P1, DOI 10.1152/jappl.1990.68.1.1; Thompson CB, 1996, J BIOL CHEM, V271, P32653, DOI 10.1074/jbc.271.51.32653; Tiainen M, 1996, CELL GROWTH DIFFER, V7, P1039; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Tuvim MJ, 2001, NEWS PHYSIOL SCI, V16, P56; Van Nieuwenhoven FA, 1999, INT J BIOCHEM CELL B, V31, P489, DOI 10.1016/S1357-2725(98)00122-8; VARGHESE S, 1988, J BIOL CHEM, V263, P9776; Vernon SD, 2000, J MOL DIAGN, V2, P124, DOI 10.1016/S1525-1578(10)60626-5; Vettor R, 1998, DIABETOLOGIA, V41, P1361, DOI 10.1007/s001250051077; WALLNER M, 1993, FEBS LETT, V336, P535, DOI 10.1016/0014-5793(93)80871-Q; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wang EW, 2000, P NATL ACAD SCI USA, V97, P9990, DOI 10.1073/pnas.180328897; Wildsmith SE, 2001, BIOTECHNIQUES, V30, P202, DOI 10.2144/01301dd04; Willmann R, 2001, AM J PHYSIOL-CELL PH, V280, pC273, DOI 10.1152/ajpcell.2001.280.2.C273; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; Zhang LF, 1997, J GRAVIT PHYSL, V4, pP97	128	77	80	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					884	+		10.1096/fj.01-0792fje	http://dx.doi.org/10.1096/fj.01-0792fje			33	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967225				2022-12-28	WOS:000175425900012
J	Heim, M; Johnson, J; Boess, F; Bendik, I; Weber, P; Hunziker, W; Fluhmann, B				Heim, M; Johnson, J; Boess, F; Bendik, I; Weber, P; Hunziker, W; Fluhmann, B			Phytanic acid, a natural peroxisome proliferator-activated receptor agonist, regulates glucose metabolism in rat primary hepatocytes	FASEB JOURNAL			English	Article						phytol; glucose transporter; glucokinase; insulin resistance; adipocyte	RETINOID-X-RECEPTOR; LIPID-METABOLISM; TISSUE DISTRIBUTION; SIGNALING PATHWAYS; PRISTANIC ACID; FATTY-ACIDS; PPAR-ALPHA; INSULIN; LIVER; EXPRESSION	Phytanic acid, a metabolite of the chlorophyll molecule, is part of the human diet and is present in normal human serum at low micromolar concentrations. It was previously shown to be a ligand of the 9-cis-retinoic acid receptor and peroxisome proliferator-activated receptor (PPAR)alpha. PPAR agonists are widely used in the treatment of type 2 diabetes. Here, we report that phytanic acid is not only a transactivator of PPARalpha, but it also acts via PPARbeta and PPARgamma in CV-1 cells that have been cotransfected with the respective full-length receptor and an acyl-CoA oxidase-PPAR-responsive element-luciferase construct. We observed that, in contrast to other fatty acids, phytanic acid at physiological concentrations enhances uptake of 2-deoxy-D-glucose in rat primary hepatocytes. This result could be explained by the increase in mRNA expression of glucose transporters-1 and -2 and glucokinase, as determined by quantitative real-time reverse transcriptase-polymerase chain reaction. Compared with the PPARgamma-specific agonist ciglitazone, phytanic acid exerts only minor effects on the differentiation of C3H10T1/2 cells into mature adipocytes. These results clearly demonstrate that phytanic acid acts via different PPAR isoforms to modulate expression of genes involved in glucose metabolism, thus suggesting a potential role of phytanic acid in the management of insulin resistance.	Roche Vitamins Ltd, Dept Human Nutr & Hlth, Res & Dev, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Pharma Res, CH-4070 Basel, Switzerland; Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	Roche Holding; Roche Holding; University of Freiburg	Fluhmann, B (corresponding author), Roche Vitamins Ltd, Dept Human Nutr & Hlth, Res & Dev, Bldg 93-8-56, CH-4070 Basel, Switzerland.	beat.fluehmann@roche.com	Johnson, James R/D-9721-2014; Johnson, James R/A-8174-2012	Johnson, James R/0000-0002-8849-0993; 				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; AVIGAN J, 1966, BIOCHIM BIOPHYS ACTA, V116, P391, DOI 10.1016/0005-2760(66)90022-1; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Ellinghaus P, 1999, J BIOL CHEM, V274, P2766, DOI 10.1074/jbc.274.5.2766; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOLDLIN CR, 1991, TOXICOLOGY, V69, P79, DOI 10.1016/0300-483X(91)90155-T; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kim H, 2000, DIABETES, V49, P1517, DOI 10.2337/diabetes.49.9.1517; Kitareewan S, 1996, MOL BIOL CELL, V7, P1153, DOI 10.1091/mbc.7.8.1153; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemberger T, 1996, ANN NY ACAD SCI, V804, P231, DOI 10.1111/j.1749-6632.1996.tb18619.x; Lemotte PK, 1996, EUR J BIOCHEM, V236, P328, DOI 10.1111/j.1432-1033.1996.00328.x; Lenhard JM, 1997, BIOCHEM PHARMACOL, V54, P801, DOI 10.1016/S0006-2952(97)00229-3; Lohray BB, 2001, J MED CHEM, V44, P2675, DOI 10.1021/jm010143b; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; McCarty MF, 2001, MED HYPOTHESES, V56, P217, DOI 10.1054/mehy.2000.1153; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Radziuk J, 2001, DIABETES-METAB RES, V17, P250, DOI 10.1002/dmrr.217; RATNAYAKE WMN, 1989, LIPIDS, V24, P630, DOI 10.1007/BF02535080; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; VANDENBRANDEN C, 1986, PEDIATR RES, V20, P411, DOI 10.1203/00006450-198605000-00007; Verhoeven NM, 1998, J INHERIT METAB DIS, V21, P697, DOI 10.1023/A:1005476631419; VidalPuig AJ, 1997, J CLIN INVEST, V99, P2416, DOI 10.1172/JCI119424; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Wolfrum C, 1999, J LIPID RES, V40, P708; Zimmermann U, 1997, J ENDOCRINOL, V155, P423, DOI 10.1677/joe.0.1550423; Zomer AWM, 2000, J LIPID RES, V41, P1801	36	91	97	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					718	+		10.1096/fj.01-0816fje	http://dx.doi.org/10.1096/fj.01-0816fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923221				2022-12-28	WOS:000174755900004
J	Hwang, GW; Furuchi, T; Naganuma, A				Hwang, GW; Furuchi, T; Naganuma, A			Ubiquitin-proteasome system is responsible for the protection of yeast and human cells against methylmercury	FASEB JOURNAL			English	Article						resistance; Cdc34; Ubc3; ubiquitination	SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; CONJUGATING ENZYME; MERCURY; GENE; INHIBITORS; EXPOSURE; COMPLEX; DISEASE; FISH	The mechanism responsible for the toxic effects of methylmercury (MeHg), an important environmental pollutant, is poorly understood. We have identified a gene, CDC34, that confers resistance to MeHg in Saccharomyces cerevisiae by screening a yeast genomic DNA library. CDC34 encodes a ubiquitin-conjugating enzyme, Cdc34, which is involved in ubiquitin-dependent proteolysis. Overexpression of Cdc34 results in significant resistance to MeHg both in yeast and human cells, and it increases the cellular level of ubiquitinated proteins. The ubiquitin-conjugating activity of Cdc34 is essential for the Cdc34-mediated resistance to MeHg, and the protective effect of the overexpression of Cdc34 is depressed by inhibition of proteasome activity. Our results support the hypothesis that MeHg induces the cellular accumulation of a certain protein(s) that causes cell damage and that this protein(s) is degraded after its ubiquitination in proteasomes.	Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Mol & Biochem Toxicol, Sendai, Miyagi 9808578, Japan	Tohoku University	Naganuma, A (corresponding author), Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Mol & Biochem Toxicol, Sendai, Miyagi 9808578, Japan.	naganuma@mail.pharm.tohoku.ac.jp	NAGANUMA, AKIRA/V-2918-2019					Akagi H, 2000, J HEALTH SCI, V46, P323; Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Clarkson T, 1998, SCIENCE, V279, P459; Clarkson T. W., 1972, CRITICAL REV TOXICOL, V1, P203; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; FITZGERALD WF, 1991, ENVIRON HEALTH PERSP, V96, P159, DOI 10.2307/3431225; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOYER RA, 1985, ENVIRON HEALTH PERSP, V60, P355, DOI 10.2307/3429982; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMAN CS, 1993, CURRENT PROTOCOLS MO; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; LIU Y, 1995, MOL CELL BIOL, V15, P5635; Mathias N, 1998, J BIOL CHEM, V273, P4040, DOI 10.1074/jbc.273.7.4040; Naganuma A, 2000, FASEB J, V14, P968, DOI 10.1096/fasebj.14.7.968; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; PITLUK ZW, 1995, MOL CELL BIOL, V15, P1210; Schrope M, 2001, NATURE, V409, P124, DOI 10.1038/35051770; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; SKERFVING S, 1974, TOXICOLOGY, V2, P3, DOI 10.1016/0300-483X(74)90038-9; Tsubaki T., 1968, CLIN NEUROL, V8, P511	30	43	43	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					709	+		10.1096/fj.01-0899fje	http://dx.doi.org/10.1096/fj.01-0899fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11978736				2022-12-28	WOS:000174755900017
J	Grimm, D; Bauer, J; Kossmehl, P; Shakibaei, M; Schonberger, J; Pickenhahn, H; Schulze-Tanzil, G; Vetter, R; Eilles, C; Paul, M; Cogoli, A				Grimm, D; Bauer, J; Kossmehl, P; Shakibaei, M; Schonberger, J; Pickenhahn, H; Schulze-Tanzil, G; Vetter, R; Eilles, C; Paul, M; Cogoli, A			Simulated microgravity alters differentiation and increases apoptosis in human follicular thyroid carcinoma cells	FASEB JOURNAL			English	Article						extracellular matrix proteins; hormones; clinorotation; thyroid tumor; programmed cell death	EXTRACELLULAR-MATRIX PROTEINS; MULTICELLULAR SPHEROIDS; POLY(ADP-RIBOSE) POLYMERASE; PRESSURE-OVERLOAD; GENE-EXPRESSION; TUMOR-CELL; GROWTH; CULTURE; SPACE; DEATH	This study focuses on the effects of simulated microgravity (0g) on the human follicular thyroid carcinoma cell line ML-1. Cultured on a three-dimensional clinostat, ML-1 cells formed three-dimensional MCTSs (MCTS diameter: 0.3+/-0.01 mm). After 24 and 48 h of clinorotation, the cells significantly decreased fT3 and fT4 secretion but up-regulated the thyroid-stimulating hormone-receptor expression as well as the production of vimentin, vinculin, and extracellular matrix proteins (collagen I and III, laminin, fibronectin, chondroitin sulfate) compared with controls. Furthermore, ML-1 cells grown on the clinostat showed elevated amounts of the apoptosis-associated Fas protein, of p53, and of bax but showed reduced quantities of bcl-2. In addition, signs of apoptosis became detectable, as assessed by terminal deoxynucleotidyl transferase-mediated dUTP digoxigenin nick end labeling, 4', 6-diamidino-2-phenylindole staining, DNA laddering, and 85-kDa apoptosis-related cleavage fragments. These fragments resulted from enhanced 116-kDa poly(ADP-ribose)polymerase (PARP) activity and apoptosis. These observations suggest that clinorotation elevates intermediate filaments, cell adhesion molecules, and extracellular matrix proteins and simultaneously induces apoptosis in follicular thyroid cancer cells. In conclusion, our experiments could provide a regulatory basis for the finding that astronauts show low thyroid hormone levels after space flight, which may be explained by the increase of apoptosis in thyrocytes as a result of simulated 0g.	Free Univ Berlin, Benjamin Franklin Med Ctr, Inst Clin Pharmacol & Toxicol, D-14195 Berlin, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Free Univ Berlin, Inst Anat, D-14195 Berlin, Germany; Univ Regensburg, Dept Nucl Med, D-8400 Regensburg, Germany; Swiss Fed Inst Technol, Space Biol Grp, Zurich, Switzerland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; Free University of Berlin; University of Regensburg; Swiss Federal Institutes of Technology Domain; ETH Zurich	Grimm, D (corresponding author), Free Univ Berlin, Benjamin Franklin Med Ctr, Inst Clin Pharmacol & Toxicol, Garystr 5, D-14195 Berlin, Germany.	dgrimm@zedat.fu-berlin.de	Paul, Martin/K-5425-2015; Prof. Dr. Shakibaei, Mehdi/AAA-7004-2020	Prof. Dr. Shakibaei, Mehdi/0000-0002-6304-7506; Grimm, Daniela/0000-0002-4991-3105				Arscott PL, 1999, J CLIN ENDOCR METAB, V84, P4246, DOI 10.1210/jc.84.11.4246; Buechner SA, 1997, J CLIN INVEST, V100, P2691, DOI 10.1172/JCI119814; CARLSSON J, 1984, RECENT RESULTS CANC, V95, P1; Chappell DB, 1998, CANCER IMMUNOL IMMUN, V47, P65, DOI 10.1007/s002620050505; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; Cogoli M, 1992, ASGSB Bull, V5, P59; Davies CD, 1997, ANTICANCER RES, V17, P4317; Grimm D, 1998, J HYPERTENS, V16, P1345, DOI 10.1097/00004872-199816090-00016; Grimm D, 1997, THYROID, V7, P859, DOI 10.1089/thy.1997.7.859; GRIMM D, 1995, THYROID, V5, P155, DOI 10.1089/thy.1995.5.155; Grimm D, 2001, J MOL CELL CARDIOL, V33, P487, DOI 10.1006/jmcc.2000.1321; GRIMM D, 1999, APOPTOSIS CARDIAC BI, P317; GRINDELAND RE, 1990, FASEB J, V4, P105, DOI 10.1096/fasebj.4.1.2295371; GUNGA HC, 1994, SCI RESULTS GERMAN S, P732; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hammond TG, 2000, PHYSIOL GENOMICS, V3, P163, DOI 10.1152/physiolgenomics.2000.3.3.163; Hammond TG, 1999, NAT MED, V5, P359, DOI 10.1038/7331; Hashemi BB, 1999, FASEB J, V13, P2071, DOI 10.1096/fasebj.13.14.2071; Hermann S, 2001, INT J CANCER, V92, P805, DOI 10.1002/ijc.1284; HOSEN T, 1992, BOT MAG, V105, P53; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; Ingram M, 1997, IN VITRO CELL DEV-AN, V33, P459; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Khaoustov VI, 1999, IN VITRO CELL DEV-AN, V35, P501; Kim M, 1997, EXP CELL RES, V231, P235, DOI 10.1006/excr.1996.3462; Kohrle J, 2000, CELL MOL LIFE SCI, V57, P1853, DOI 10.1007/PL00000667; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; LEWIS ML, 1996, FUNDAMENTALS SPACE L, P21; LEWIS ML, 2001, FASEB J; Margolis L, 1999, J UROLOGY, V161, P290, DOI 10.1016/S0022-5347(01)62134-7; Martin A, 2000, THYROID, V10, P481, DOI 10.1089/thy.2000.10.481; Mizutani Y, 1997, CANCER, V79, P1180, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1180::AID-CNCR17>3.0.CO;2-W; Mountz JD, 1999, RECENT PROG HORM RES, V54, P235; NEDERMAN T, 1984, CANCER RES, V44, P3090; Ohnishi T, 1999, MUTAT RES-FUND MOL M, V430, P271, DOI 10.1016/S0027-5107(99)00138-4; PAULUS W, 1994, INT J CANCER, V58, P841, DOI 10.1002/ijc.2910580616; SAKAR D, 2000, J BONE MINER RES, V15, P489; Schatten H, 2001, ACTA ASTRONAUT, V49, P399, DOI 10.1016/S0094-5765(01)00116-3; Schonberger J, 2000, J MOL MED, V78, P102, DOI 10.1007/s001090000085; Schwarzenberg M, 1999, ADV SPACE RES, V24, P793, DOI 10.1016/S0273-1177(99)00075-7; SHAKIBAEI M, 1995, J HISTOCHEM CYTOCHEM, V43, P1061, DOI 10.1177/43.10.7560884; SOLDATENKOV VA, 1995, CANCER RES, V55, P4240; Soldatenkov VA, 2000, INT J CANCER, V90, P59, DOI 10.1002/(SICI)1097-0215(20000420)90:2<59::AID-IJC1>3.0.CO;2-4; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Strollo F, 1999, ADV SPACE B, V7, P99, DOI 10.1016/S1569-2574(08)60008-8; SUTHERLAND R, 1981, CANCER RES, V41, P2980; SUTHERLAND RM, 1986, CANCER RES, V46, P5320; TANIMOTO C, 1995, ENDOCR J, V42, P193, DOI 10.1507/endocrj.42.193; WALTENBERGER J, 1998, ANGIOGENESIS, V2, P115; White RJ, 2001, NATURE, V409, P1115, DOI 10.1038/35059243; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUHAS JM, 1977, CANCER RES, V37, P3639; Zhau HE, 1997, IN VITRO CELL DEV-AN, V33, P375	53	149	159	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					604	+		10.1096/fj.01-0673fje	http://dx.doi.org/10.1096/fj.01-0673fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919168				2022-12-28	WOS:000174203700003
J	Failli, P; Nistri, S; Quattrone, S; Mazzetti, L; Bigazzi, M; Sacchi, TB; Bani, D				Failli, P; Nistri, S; Quattrone, S; Mazzetti, L; Bigazzi, M; Sacchi, TB; Bani, D			Relaxin up-regulates inducible nitric oxide synthase expression and nitric oxide generation in rat coronary endothelial cells	FASEB JOURNAL			English	Article						intracellular calcium; NOSII; dexamethasone	IN-VIVO; BINDING; HEARTS; GENE; TRANSCRIPTION; REPERFUSION; STIMULATION; INVOLVEMENT; INDUCTION; ISCHEMIA	Relaxin (RLX) is a reproductive hormone with vasodilatatory properties on several organs, including the heart. RLX-induced vasodilatation appears to depend on the stimulation of endogenous NO production. Here, we investigate whether RLX acts on rat coronary endothelial (RCE) cells in vitro by inducing changes of NO generation and, if so, to clarify the possible mechanism of action. RCE cells were treated for 24 h with vehicle (controls) or RLX, alone or in association with inhibitors of NO synthesis or dexamethasone, which inhibits transcription of NO synthase gene. In some experiments, inactivated RLX was given in the place of authentic RLX. Expression of NO synthase isozymes II and III was analyzed by immunocytochemistry, Western blot, and RT-PCR. NO production was evaluated by the Griess reaction for nitrite and the NO-sensitive fluorophore DAF-2/DA. Agonist-induced changes of intracellular Ca2+ transient were studied with the Ca2+-sensitive fluorophore Fura 2-AM. RLX was found to up regulate NOS II mRNA and protein and to stimulate intrinsic NO generation, likely through the activation of a dexamethasone-sensitive transcription factor, and to decrease agonist-induced intracellular Ca2+ transient. Conversely, RLX had negligible effects on NOS III expression. By these biological effects, RLX may afford significant protection against cardiovascular disease.	Univ Florence, Dept Preclin & Clin Pharmacol, Florence, Italy; Univ Florence, Sect Histol, Dept Anat Histol & Forens Med, Florence, Italy; Prosperius Inst, Florence, Italy	University of Florence; University of Florence	Bani, D (corresponding author), Univ Florence, Sez Istol, Dipartimento Anat Istol & Med Legale, Vle G Pieraccini 6, I-50139 Florence, Italy.	daniele.bani@unifi.it		Bani, Daniele/0000-0001-6302-901X; Failli, Paola/0000-0003-3879-9068				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bani D, 1998, HYPERTENSION, V31, P1240, DOI 10.1161/01.HYP.31.6.1240; Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; Bani D, 2001, HORM METAB RES, V33, P175, DOI 10.1055/s-2001-14935; Bani D, 1998, AM J PATHOL, V152, P1367; BANI G, 1995, BIOL REPROD, V53, P253, DOI 10.1095/biolreprod53.2.253; BANI G, 1988, HISTOL HISTOPATHOL, V3, P337; BANISACCHI T, 1995, BRIT J PHARMACOL, V116, P1589, DOI 10.1111/j.1476-5381.1995.tb16377.x; BIGAZZI M, 1988, ACTA ENDOCRINOL-COP, V117, P181, DOI 10.1530/acta.0.1170181; BIGAZZI M, 1986, ACTA ENDOCRINOL-COP, V112, P296, DOI 10.1530/acta.0.1120296; BULLESBACH EE, 1988, INT J PEPT PROT RES, V32, P361; Danielson LA, 1999, J CLIN INVEST, V103, P525, DOI 10.1172/JCI5630; Failli P, 2000, BRIT J PHARMACOL, V130, P1468, DOI 10.1038/sj.bjp.0703453; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; Hu FB, 2000, NEW ENGL J MED, V343, P530, DOI 10.1056/NEJM200008243430802; Kaku Y, 1997, BBA-MOL CELL RES, V1356, P43, DOI 10.1016/S0167-4889(96)00156-5; Kleinert H, 1998, HYPERTENSION, V31, P582, DOI 10.1161/01.HYP.31.2.582; Kohsaka T, 1998, BIOL REPROD, V59, P991, DOI 10.1095/biolreprod59.4.991; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Kuboki K, 2000, CIRCULATION, V101, P676, DOI 10.1161/01.CIR.101.6.676; LEE AB, 1992, ENDOCRINOLOGY, V130, P2386, DOI 10.1210/en.130.4.2386; Masini E, 1997, ENDOCRINOLOGY, V138, P4713, DOI 10.1210/en.138.11.4713; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; OBYRNE EM, 1976, P SOC EXP BIOL MED, V152, P272, DOI 10.3181/00379727-152-39377; OSHEROFF PL, 1993, J BIOL CHEM, V268, P15193; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Piper HM, 1990, CELL CULTURE TECHNIQ, P158; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; SEYEDI N, 1995, HYPERTENSION, V26, P164, DOI 10.1161/01.HYP.26.1.164; TAYLOR MJ, 1994, J ENDOCRINOL, V143, pR5, DOI 10.1677/joe.0.143R005; Wang BY, 1999, CIRCULATION, V99, P1236, DOI 10.1161/01.CIR.99.9.1236; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914	38	73	76	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					252	+		10.1096/fj.01-0569fje	http://dx.doi.org/10.1096/fj.01-0569fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11744624				2022-12-28	WOS:000172964800018
J	Rodriguez-Nieto, S; Gonzalez-Iriarte, M; Carmona, R; Munoz-Chapuli, R; Medina, MA; Quesada, AR				Rodriguez-Nieto, S; Gonzalez-Iriarte, M; Carmona, R; Munoz-Chapuli, R; Medina, MA; Quesada, AR			Antiangiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge	FASEB JOURNAL			English	Article						angiogenesis; angiogenesis inhibitor; endothelial cells; apoptosis	FIBROBLAST-GROWTH-FACTOR; CAPILLARY-LIKE STRUCTURES; ENDOTHELIAL-CELL DIFFERENTIATION; TYROSINE KINASE INHIBITORS; IN-VITRO; MATRIX METALLOPROTEINASES; TUMOR ANGIOGENESIS; BASEMENT-MEMBRANE; POTENT INHIBITOR; ASSAY	(+)- Aeroplysinin-1, an antibacterial brominated compound produced by certain sponges, was selected during a blind high-throughput screening for new potential antiangiogenic compounds obtained from marine organisms. In a variety of experimental systems, representing the sequential events of the angiogenic process, aeroplysinin-1 treatment of endothelial cells resulted in strong inhibitory effects. Aeroplysinin-1 inhibited the growth of endothelial cells in culture and induced endothelial cell apoptosis. Capillary tube formation on Matrigel was completely abrogated by addition of aeroplysinin-1 at the low micromolar range. Aeroplysinin-1 also exhibited a clear inhibitory effect on the migration capabilities of endothelial cells. Zymographic assays showed that aeroplysinin-1 treatment produced a decrease in the concentration of matrix metalloproteinase-2 and urokinase in conditioned medium from endothelial cells. Finally, aeroplysinin-1 exhibited a dose-dependent inhibitory effect on the in vivo chorioallantoic membrane assay, showing potent apoptosis-inducing activity in the developing endothelium. The in vivo inhibition of angiogenesis by aeroplysinin-1 was confirmed by the Matrigel plug assay. Together, our data indicate that aeroplysinin-1 is a compound that interferes with key events in angiogenesis, making it a promising drug for further evaluation in the treatment of angiogenesis-related pathologies.	Univ Malaga, Fac Ciencias, Dept Bioquim & Biol Mol, E-29071 Malaga, Spain; Univ Malaga, Fac Ciencias, Dept Biol Anim, E-29071 Malaga, Spain	Universidad de Malaga; Universidad de Malaga	Quesada, AR (corresponding author), Univ Malaga, Fac Ciencias, Dept Bioquim & Biol Mol, Campus Teatinos, E-29071 Malaga, Spain.	quesada@uma.es	Medina, Miguel Ángel/K-1763-2014; Munoz-Chapuli, Ramon/K-7306-2014; Carmona, Rita/K-4217-2014	Medina, Miguel Ángel/0000-0001-7275-6462; Munoz-Chapuli, Ramon/0000-0001-6392-6802; Carmona, Rita/0000-0002-9686-473X; Rodriguez Quesada, Ana Maria/0000-0002-6419-8867				ALBINI A, 1987, CANCER RES, V47, P3239; AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N; BRAKENHIELM E, 2001, FASEB J         0608; de Veas RG, 1998, EUR J CANCER, V34, P1736, DOI 10.1016/S0959-8049(98)00285-8; Elkin M, 2000, FASEB J, V14, P2477, DOI 10.1096/fj.00-0292com; Fajardo I, 2000, ANTICANCER RES, V20, P1691; Fattorusso E, 1972, J Chem Soc Perkin 1, V1, P16; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; Garrido T, 1996, ANAL BIOCHEM, V235, P234, DOI 10.1006/abio.1996.0117; GARRIDO T, 1995, BRIT J CANCER, V71, P770, DOI 10.1038/bjc.1995.149; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GOLDBERGER A, 1998, TECH B BECTON DICKIN, V428; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Harris AL, 1998, RECENT RES CANCER, V152, P341; Hayes AJ, 1999, MICROVASC RES, V58, P224, DOI 10.1006/mvre.1999.2179; Hinterding K, 1998, BIOORGAN MED CHEM, V6, P1153, DOI 10.1016/S0968-0896(98)00070-4; Hisa T, 1998, ANTICANCER RES, V18, P783; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; Kanda S, 1999, EXP CELL RES, V248, P203, DOI 10.1006/excr.1999.4400; Kim MS, 2000, INT J CANCER, V87, P269, DOI 10.1002/1097-0215(20000715)87:2&lt;269::AID-IJC19&gt;3.0.CO;2-W; Koulman A, 1996, J NAT PROD, V59, P591, DOI 10.1021/np960167z; KREUTER MH, 1989, Z NATURFORSCH C, V44, P680; KREUTER MH, 1990, COMP BIOCHEM PHYS B, V97, P151, DOI 10.1016/0305-0491(90)90194-X; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Lucas R, 1998, BLOOD, V92, P4730; Morris AD, 1997, ANTI-CANCER DRUG, V8, P746, DOI 10.1097/00001813-199709000-00003; MOSES MA, 1991, BIO-TECHNOL, V9, P630, DOI 10.1038/nbt0791-630; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Paleolog E M, 1998, Angiogenesis, V2, P295, DOI 10.1023/A:1009229508096; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; PASSANITI A, 1992, LAB INVEST, V67, P519; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; RIBATTI D, 1995, DEV BIOL, V170, P39, DOI 10.1006/dbio.1995.1193; SATO Y, 1993, FEBS LETT, V322, P155, DOI 10.1016/0014-5793(93)81558-H; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Sun L, 2000, DRUG DISCOV TODAY, V5, P344, DOI 10.1016/S1359-6446(00)01534-8; Thaloor D, 1998, CELL GROWTH DIFFER, V9, P305; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Trochon V, 2000, INT J CANCER, V85, P691, DOI 10.1002/(SICI)1097-0215(20000301)85:5&lt;691::AID-IJC15&gt;3.0.CO;2-Q; Vermeulen PB, 1996, EUR J CANCER, V32A, P2474, DOI 10.1016/S0959-8049(96)00379-6	49	75	77	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					261	+		10.1096/fj.01-0427fje	http://dx.doi.org/10.1096/fj.01-0427fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11772945				2022-12-28	WOS:000172964800010
J	Alvarado-Kristensson, M; Porn-Ares, MI; Grethe, S; Smith, D; Zheng, LM; Andersson, T				Alvarado-Kristensson, M; Porn-Ares, MI; Grethe, S; Smith, D; Zheng, LM; Andersson, T			p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase activities have opposite effects on human neutrophil apoptosis	FASEB JOURNAL			English	Article						caspases; cell death; leukocytes; survival	NF-KAPPA-B; GRANULOCYTE APOPTOSIS; FAS LIGAND; TYROSINE PHOSPHORYLATION; DIFFERENTIAL EXPRESSION; INHIBITION; CASPASES; ALPHA; RAS; MODULATION	Neutrophil apoptosis is essential for resolution of inflammatory reactions. Here, we studied the role of two apoptosis/survival-associated protein kinases in this process. We discovered a previously undetected early and transient inhibition of the activity of p38 mitogen-activated protein kinase (p38 MAPK) during both spontaneous and Fas-induced apoptosis. Pharmacological inhibition of this enzyme augmented the activation of caspases and the apoptotic response, which suggests that the p38 MAPK signals survival in neutrophils. Our finding that caspase-3 activity was initiated during the transient inhibition of p38 MAPK suggests that apoptosis is initiated during this inhibition. Furthermore, such transient inhibition was counteracted by granulocyte-macrophage colony-stimulating factor, which elicits survival. We also found that neither this inhibition of p38 MAPK nor the spontaneous apoptotic response depended on Fas. Instead, the early inhibition of p38 MAPK concurred with a Fas-induced activation of phosphatidylinositol 3-kinase, inhibition of which reduced apoptosis. Thus, the Fas-induced augmentation of spontaneous apoptosis can be explained by its activation of phosphatidylinositol 3-kinase. We conclude that p38 MAPK activity represents a survival signal that is inactivated transiently during both spontaneous and Fas-induced apoptosis, whereas Fas-induced phosphatidylinositol 3-kinase activity is a proapoptotic signal in isolated human neutrophils.	Lund Univ, Dept Lab Med, SE-20502 Malmo, Sweden	Lund University	Andersson, T (corresponding author), Lund Univ, Dept Lab Med, U-MAS,Ent 78,Fl 3, SE-20502 Malmo, Sweden.	tommy.andersson@exppat.mas.lu.se	Alvarado-Kristensson, Maria T./C-4543-2014; zheng, limin/HGB-2510-2022	Alvarado Kristensson, Maria Teresa/0000-0003-0598-7986; Zheng, Limin/0000-0002-8281-1450				Aoshiba K, 1999, J IMMUNOL, V162, P1692; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Brown SB, 1999, J IMMUNOL, V162, P480; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dong Q, 1999, J IMMUNOL, V162, P3220; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GRISWOLD DE, 1987, BIOCHEM PHARMACOL, V36, P3463, DOI 10.1016/0006-2952(87)90327-3; Gulbins E, 1998, J LEUKOCYTE BIOL, V63, P253, DOI 10.1002/jlb.63.2.253; Hale KK, 1999, J IMMUNOL, V162, P4246; Haslett C, 1997, BRIT MED BULL, V53, P669; HASLETT C, 1985, AM J PATHOL, V119, P101; HOMBURG CHE, 1995, BLOOD, V85, P532; Kankaanranta H, 1999, J PHARMACOL EXP THER, V290, P621; KLEMPNER MS, 1980, J CELL BIOL, V86, P21, DOI 10.1083/jcb.86.1.21; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Nick JA, 1996, J IMMUNOL, V156, P4867; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Scheid MP, 2000, CURR BIOL, V10, pR191, DOI 10.1016/S0960-9822(00)00349-3; Sen J, 1996, J IMMUNOL, V156, P4535; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Villunger A, 2000, J EXP MED, V192, P647, DOI 10.1084/jem.192.5.647; Ward C, 1999, TRENDS PHARMACOL SCI, V20, P503, DOI 10.1016/S0165-6147(99)01391-7; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Waterman WH, 1996, BIOCHEM J, V319, P17, DOI 10.1042/bj3190017; Wei S, 1996, J IMMUNOL, V157, P5155; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zheng LM, 1997, J BIOL CHEM, V272, P23448, DOI 10.1074/jbc.272.37.23448; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431	42	67	70	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					129	+		10.1096/fj.01-0817fje	http://dx.doi.org/10.1096/fj.01-0817fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11729103				2022-12-28	WOS:000172420500029
J	Noda, T; Iwakiri, R; Fujimoto, K; Aw, TY				Noda, T; Iwakiri, R; Fujimoto, K; Aw, TY			Induction of mild intracellular redox imbalance inhibits proliferation of CaCo-2 cells	FASEB JOURNAL			English	Article						cellular redox; GSH : GSSG ratio; cell cycle arrest; intestinal cell turnover; EGF	OXIDATIVE STRESS; GLUTATHIONE SYNTHESIS; GROWTH-FACTOR; ORNITHINE DECARBOXYLASE; BUTHIONINE SULFOXIMINE; CELLULAR PROLIFERATION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; GENE-EXPRESSION; DNA-SYNTHESIS	Intracellular redox status plays a critical role in cell function, such as proliferation. Oxidative stress, which elicits redox imbalance, also affects cell growth. Therefore, it is often difficult to distinguish the effects of redox imbalance from those of oxidative stress. The objective of this study was to determine the role of redox imbalance independent of reactive oxygen species (ROS) production, in proliferation of human colonic CaCo-2 cells. Low concentrations of diamide plus 1,3-bis(2 chloroethyl)-1-nitrosourea (BCNU) increased intracellular GSSG and decreased GSH and the GSH: GSSG ratio. These changes occurred within 30 min, which preceded a decrease in thymidine incorporation at 6 and 24 h. ROS formation was not detected under these conditions. This suppression of cell proliferative activity was attenuated by N-acetyl cysteine, in parallel with restoration of the intracellular GSH redox status. DL-buthionine-[S, R]-sulfoximine (BSO) decreased intracellular GSH level, but did not change the GSH: GSSG ratio. BSO alone had no effect on cell proliferation, but its presence exaggerated the suppressive effect of diamide plus BCNU. Flow cytometric analysis showed that cells were arrested at G(1)-to-S transition and G(2)/M phase. Collectively, this study shows that mild intracellular redox imbalance inhibited cell proliferation independent of ROS generation. Moreover, cells with compromised cellular GSH were susceptible to redox imbalance-induced inhibition of proliferation.	Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA; Saga Med Sch, Dept Internal Med, Saga, Japan	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Saga University	Aw, TY (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, 1501 Kings Highway, Shreveport, LA 71130 USA.	taw@lsuhsc.edu			NIDDK NIH HHS [R01 DK044510, DK 44510, R01 DK044510-08] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044510] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; Aw TY, 1999, AM J CLIN NUTR, V70, P557; BILL CA, 1988, CANCER RES, V48, P3389; BISHOP WP, 1995, GASTROENTEROLOGY, V109, P1882, DOI 10.1016/0016-5085(95)90755-6; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; Brigellius R., 1985, OXIDATIVE STRESS, P243; BURDON RH, 1994, FREE RADICAL RES, V21, P121, DOI 10.3109/10715769409056564; Chang WK, 1999, CLIN EXP IMMUNOL, V117, P482, DOI 10.1046/j.1365-2249.1999.01009.x; CLARK S, 1993, BIOCHEM J, V292, P17; COSTA LG, 1986, BIOCHEM PHARMACOL, V35, P3383, DOI 10.1016/0006-2952(86)90439-9; DAGOSTINO L, 1989, GASTROENTEROLOGY, V97, P888, DOI 10.1016/0016-5085(89)91493-5; Davis MA, 2000, TOXICOL SCI, V53, P48, DOI 10.1093/toxsci/53.1.48; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Engler JA, 1999, DIGEST DIS SCI, V44, P1902, DOI 10.1023/A:1018815327769; Esposito F, 2000, FEBS LETT, V470, P211, DOI 10.1016/S0014-5793(00)01318-1; Flattery-O'Brien JA, 1998, J BIOL CHEM, V273, P8564, DOI 10.1074/jbc.273.15.8564; FRISCHER H, 1977, J LAB CLIN MED, V89, P1080; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GRIMM LM, 1985, BIOCHIM BIOPHYS ACTA, V844, P50, DOI 10.1016/0167-4889(85)90232-0; Hutter DE, 1997, EXP CELL RES, V232, P435, DOI 10.1006/excr.1997.3527; Iantomasi T, 1999, BBA-MOL CELL RES, V1452, P303, DOI 10.1016/S0167-4889(99)00142-1; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; Jonas CR, 1999, J NUTR, V129, P1278, DOI 10.1093/jn/129.7.1278; KANG YJ, 1994, J CELL PHYSIOL, V161, P589, DOI 10.1002/jcp.1041610323; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MOLDEUS P, 1994, METHOD ENZYMOL, V234, P482; NOELLE RJ, 1981, BIOCHEM J, V198, P571, DOI 10.1042/bj1980571; Obrador E, 1997, BIOCHEM J, V325, P183, DOI 10.1042/bj3250183; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; SHAW JP, 1986, J CELL PHYSIOL, V129, P193, DOI 10.1002/jcp.1041290210; Smith J, 2000, P NATL ACAD SCI USA, V97, P10032, DOI 10.1073/pnas.170209797; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TABATA K, 1986, AM J PHYSIOL, V251, pG370, DOI 10.1152/ajpgi.1986.251.3.G370; TERRADEZ P, 1993, BIOCHEM J, V292, P477, DOI 10.1042/bj2920477; Voehringer DW, 1999, FREE RADICAL BIO MED, V27, P945, DOI 10.1016/S0891-5849(99)00174-4; Wang TG, 2000, FASEB J, V14, P1567, DOI 10.1096/fj.14.11.1567; WHITE AC, 1992, AM J RESP CELL MOL, V6, P364, DOI 10.1165/ajrcmb/6.4.364	44	82	84	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2131	2139		10.1096/fj.01-0131com	http://dx.doi.org/10.1096/fj.01-0131com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641239				2022-12-28	WOS:000171920400024
J	Avis, I; Hong, SH; Martinez, A; Moody, T; Choi, YH; Trepel, J; Das, R; Jett, M; Mulshine, JL				Avis, I; Hong, SH; Martinez, A; Moody, T; Choi, YH; Trepel, J; Das, R; Jett, M; Mulshine, JL			Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions	FASEB JOURNAL			English	Article						breast cancer; leukotrienes; 5-lipoxygenase pathway; peroxisome proliferator-activated receptor; apoptosis	PROLIFERATOR-ACTIVATED RECEPTORS; PROTEIN-KINASE-C; IN-VITRO GROWTH; ARACHIDONIC-ACID; CYCLOOXYGENASE-2 EXPRESSION; GENE-EXPRESSION; RETINOIC ACID; GAMMA; LIGANDS; FLAP	Many arachidonic acid metabolites function in growth signaling for epithelial cells, and we previously reported the expression of the major arachidonic acid enzymes in human breast cancer cell lines. To evaluate the role of the 5-lipoxygenase (5-LO) pathway on breast cancer growth regulation, we exposed cells to insulinlike growth factor-1 or transferrin, which increased the levels of the 5-LO metabolite, 5(S)-hydrooxyeicosa-6E,8C,11Z,14Z-tetraenoic acid (5-HETE), by radioimmunoassay and high-performance liquid chromatography. Addition of 5-HETE to breast cancer cells resulted in growth stimulation, whereas selective biochemical inhibitors of 5-LO reduced the levels of 5-HETE and related metabolites. Application of 5-LO or 5-LO activating protein-directed inhibitors, but not a cyclooxygenase inhibitor, reduced growth, increased apoptosis, down-regulated bcl-2, up-regulated bax, and increased G1 arrest. Exposure of breast cancer cells to a 5-LO inhibitor up-regulated peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma expression, and these same cells were growth inhibited when exposed to relevant PPAR agonists. These results suggest that disruption of the 5-LO signaling pathway mediates growth arrest and apoptosis in breast cancer cells. Additional experiments suggest that this involves the interplay of several factors, including the loss of growth stimulation by 5-LO products, the induction of PPAR gamma, and the potential activation of PPAR gamma by interactions with shunted endoperoxides.	NCI, Dept Cell & Canc Biol, Med Branch, Div Clin Sci, Bethesda, MD 20892 USA; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Div Pathol, Washington, DC 20307 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center	Mulshine, JL (corresponding author), NCI, Intervent Sect, CCB,MB, DCS,NIH,Clin Ctr, B10,12N226,9000 Rockville Pike, Bethesda, MD 20892 USA.	mulshinj@mail.nih.gov	Martinez, Alfredo/GQH-5998-2022	Martinez, Alfredo/0000-0003-4882-4044; Mulshine, James/0000-0002-4648-9177				Avis IM, 1996, J CLIN INVEST, V97, P806, DOI 10.1172/JCI118480; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Battu S, 1998, FEBS LETT, V437, P49, DOI 10.1016/S0014-5793(98)01196-X; Bishop-Bailey D, 2000, BRIT J PHARMACOL, V129, P823, DOI 10.1038/sj.bjp.0703149; BOYLE T, 1994, ANAL BIOCHEM, V216, P373, DOI 10.1006/abio.1994.1055; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Byrum RS, 1997, J EXP MED, V185, P1065, DOI 10.1084/jem.185.6.1065; Chang TH, 2000, CANCER RES, V60, P1129; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CLEMENS MJ, 1992, J CELL SCI, V103, P881; Cordon-Cardo C, 1999, J EXP MED, V190, P1367, DOI 10.1084/jem.190.10.1367; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; CULLEN KJ, 1990, CANCER RES, V50, P48; Datta K, 1999, BIOCHEM J, V340, P371, DOI 10.1042/0264-6021:3400371; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; EARASHI M, 1995, ONCOLOGY-BASEL, V52, P150; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; FORDHUTCHINSON AW, 1994, CANCER METAST REV, V13, P257, DOI 10.1007/BF00666096; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gupta N, 1997, CAN J PHYSIOL PHARM, V75, P1212, DOI 10.1139/cjpp-75-10-11-1212; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hong SH, 1999, CANCER RES, V59, P2223; Hong SH, 2000, FASEB J, V14, P1499, DOI 10.1096/fj.99-0802com; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Hussey HJ, 1996, BRIT J CANCER, V74, P683, DOI 10.1038/bjc.1996.422; Inoue H, 2000, J BIOL CHEM, V275, P28028; Kliewer SA, 1999, RECENT PROG HORM RES, V54, P345; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Mancini JA, 1998, J BIOL CHEM, V273, P32842, DOI 10.1074/jbc.273.49.32842; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Menck HR, 1997, CA-CANCER J CLIN, V47, P161, DOI 10.3322/canjclin.47.3.161; Miller AM, 1997, J CELL PHYSIOL, V170, P309, DOI 10.1002/(SICI)1097-4652(199703)170:3<309::AID-JCP12>3.3.CO;2-Y; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nakayama K., 1988, CIRP ANN MANUF TECHN, V37, P89, DOI 10.1016/S0007-8506(07)61592-3; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NOGUCHI M, 1995, ONCOLOGY-BASEL, V52, P265; ONDREY F, 1989, CANCER RES, V49, P1138; Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8; PIAZZA GA, 1995, CANCER RES, V55, P3110; Przylipiak A, 1998, GYNECOL OBSTET INVES, V46, P61, DOI 10.1159/000010000; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; SHEARMAN MS, 1989, FEBS LETT, V243, P177, DOI 10.1016/0014-5793(89)80125-5; Smirnov SV, 1998, BRIT J PHARMACOL, V124, P572, DOI 10.1038/sj.bjp.0701855; Smith T, 1893, B BUREAU ANIM IND, P1; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Tsujii M, 1998, CELL, V94; Wallace JL, 1998, GASTROENTEROLOGY, V115, P101, DOI 10.1016/S0016-5085(98)70370-1; WANG TTY, 1995, CANCER RES, V55, P2487; WEINSTEIN I, 1991, ORIGINS HUMAN CANC C; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wu GD, 1998, GASTROENTEROLOGY, V115, P1283, DOI 10.1016/S0016-5085(98)70102-7; YAMAMOTO S, 1992, CANCER CHEMOPREVENTION, P141; YANO T, 1992, CANCER RES, V52, P4545; Yee D, 1991, Cancer Treat Res, V53, P93; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	74	166	174	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2007	+		10.1096/fj.00-0866fje	http://dx.doi.org/10.1096/fj.00-0866fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511519				2022-12-28	WOS:000170318500024
J	Maehara, K; Oh-Hashi, K; Isobe, K				Maehara, K; Oh-Hashi, K; Isobe, K			Early growth responsive-1-dependent manganese superoxide dismutase gene transcription mediated by platelet-derived growth factor	FASEB JOURNAL			English	Article						Mn-SOD; Egr-1; PDGF; MAPK	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; FLUID SHEAR-STRESS; AGE-1 PI3 KINASE; MEK-ERK PATHWAY; CAENORHABDITIS-ELEGANS; OXIDATIVE STRESS; FACTOR-ALPHA; LIFE-SPAN; ENCODING GENE	Manganese superoxide dismutase (Mn-SOD) plays a major role in protecting mitochondria from oxidative damage. Overexpression of Mn-SOD maintains cell survival under conditions that lead to apoptotic death. In addition to the antioxidative enzyme, platelet-derived growth factor (PDGF) is a principal survival factor that inhibits apoptosis and promotes proliferation by activating survival signaling pathways in various cells. Here we show that PDGF induced the expression of the Mn-SOD gene in NIH3T3 cells, and its induction was associated with early growth response-1 (Egr-1), a transcription factor. An electrophoretic mobility shift assay demonstrated that Egr-1 bound to the proximal promoter of the Mn-SOD gene in response to PDGF. The proximal promoter region of Mn-SOD was shown to be transcriptionally responsive to both basal and PDGF stimulation by transfection studies. Forced expression of Egr-1 in the cells activated Mn-SOD transcription in a dose-dependent manner. The pathway by which PDGF induced Egr-1 involved the mitogen-activated protein kinase kinase-1 (MEK1) and extracellular signal-regulated kinases 1 and 2 (ERK1/2), because the effect of PDGF on the induction of Egr-1 was blocked by U0126, a specific MEK1 inhibitor. These findings indicate that the induction of Mn-SOD is part of the anti-apoptotic properties mediated by PDGF.	Natl Inst Longev Sci, Dept Basic Gerontol, Aichi 4748522, Japan		Isobe, K (corresponding author), Natl Inst Longev Sci, Dept Basic Gerontol, 36-3 Gengo,Morioka Cho, Aichi 4748522, Japan.	kenisobe@nils.go.jp	isobe, ken-ichi/A-6685-2011	isobe, ken-ichi/0000-0002-8150-2496				Bertrand F, 1999, J BIOL CHEM, V274, P30596, DOI 10.1074/jbc.274.43.30596; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HO YS, 1987, NUCLEIC ACIDS RES, V15, P10070, DOI 10.1093/nar/15.23.10070; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; JONES PL, 1995, GENE, V153, P155, DOI 10.1016/0378-1119(94)00666-G; JONES S, 1997, WORKING PAPERS LIT, V1, P17; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, ARTERIOSCL THROM VAS, V17, P2280, DOI 10.1161/01.ATV.17.10.2280; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Li JJ, 1997, CANCER RES, V57, P1991; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Maehara K, 1999, FEBS LETT, V449, P115, DOI 10.1016/S0014-5793(99)00408-1; Maehara K, 2000, J CELL BIOCHEM, V77, P474, DOI 10.1002/(SICI)1097-4644(20000601)77:3<474::AID-JCB12>3.0.CO;2-H; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; McCaffrey TA, 2000, J CLIN INVEST, V105, P653, DOI 10.1172/JCI8592; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Minc E, 1999, J BIOL CHEM, V274, P503, DOI 10.1074/jbc.274.1.503; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; PARK J, 1996, MED IMAGE ANAL J, V1, P1; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1990, EXP GERONTOL, V25, P499, DOI 10.1016/0531-5565(90)90017-V; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	47	32	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2001	15	9					2025	+		10.1096/fj.00-0909fje	http://dx.doi.org/10.1096/fj.00-0909fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511524				2022-12-28	WOS:000170318500021
J	Bachmeyer, C; Benz, R; Barth, H; Aktories, K; Gibert, M; Popoff, MR				Bachmeyer, C; Benz, R; Barth, H; Aktories, K; Gibert, M; Popoff, MR			Interaction of Clostridium botulinum C2-toxin with lipid bilayer membranes and vero cells: inhibition of channel function by chloroquine and related compounds in vitro and intoxification in vivo	FASEB JOURNAL			English	Article						channel-formation; chloroquine-analogues; malaria	ANTHRAX PROTECTIVE ANTIGEN; DIPHTHERIA-TOXIN; C2 TOXIN; BINARY TOXIN; ION CHANNELS; TRANSLOCATION; IDENTIFICATION; ACTIN; SPIROFORME; COMPONENTS	Several intracellularly acting bacterial protein toxins, which are known to enter cells by endocytosis, are shown to produce channels. This finding also holds true for the C2-II binding component of C2-toxin of Clostridium botulinum. There is evidence that toxin translocation across the target cell membrane and channel formation by the binding component are related phenomena. Here, we demonstrate that C2-II is fully reconstituted when it is added to only one side of the lipid bilayer membrane. Chloroquine and some related compounds, known as potent drugs against malaria infection of humans, efficiently block the C2-II-mediated channel in a dose-dependent way. The half-saturation constant for binding of chloroquine and some of the related compounds to C2-II is in the micromolar to millimolar range. Their binding to the C2-II channel is asymmetric with respect to its addition to one side of the membrane, and the half-saturation constant is smaller when both inhibitor and protein are added to the same side of the membrane, the cis-side, which corresponds to the external surface of target cells. In vivo experiments with Vero cells demonstrate that chloroquine and related compounds also efficiently block intoxication of the cells by C2-toxin in the same concentration range as they block in vitro the channels.	Univ Wurzburg, Biozentrum, Theodor Boveri Inst, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany; Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany; Inst Pasteur, F-75724 Paris 15, France	University of Wurzburg; University of Freiburg; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Benz, R (corresponding author), Univ Wurzburg, Biozentrum, Theodor Boveri Inst, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany.	roland.benz@mail.uni-wuerzburg.de	Barth, Holger/E-7920-2013; Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436; Benz, Roland/0000-0002-9510-9265				AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P97; Barth H, 2000, J BIOL CHEM, V275, P18704, DOI 10.1074/jbc.M000596200; Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1986, J BACTERIOL, V165, P978, DOI 10.1128/jb.165.3.978-986.1986; BENZ R, 1987, J MEMBRANE BIOL, V100, P21, DOI 10.1007/BF02209137; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BOQUET P, 1982, P NATL ACAD SCI-BIOL, V79, P7614, DOI 10.1073/pnas.79.24.7614; Bray Patrick G., 1999, Novartis Foundation Symposium, V226, P252; CONSIDINE RV, 1991, TOXICON, V29, P913, DOI 10.1016/0041-0101(91)90076-4; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; DONOVAN JJ, 1986, BIOCHEMISTRY-US, V25, P2872, DOI 10.1021/bi00358a020; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; Kimura K, 1998, VET MICROBIOL, V62, P27, DOI 10.1016/S0378-1135(98)00195-3; LEPPLA SH, 1980, J BIOL CHEM, V255, P2247; LEPPLA SH, 1999, COMPREHENSIVE SOURCE, P243; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; Oh KJ, 1999, P NATL ACAD SCI USA, V96, P8467, DOI 10.1073/pnas.96.15.8467; OHISHI I, 1987, INFECT IMMUN, V55, P1461, DOI 10.1128/IAI.55.6.1461-1465.1987; OHISHI I, 1980, INFECT IMMUN, V30, P668; OHISHI I, 1992, INFECT IMMUN, V60, P4648, DOI 10.1128/IAI.60.11.4648-4655.1992; OLSNES S, 1999, COMPREHENSIVE SOURCE, P73; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; Perelle S, 1997, FEMS MICROBIOL LETT, V146, P117, DOI [10.1016/S0378-1097(96)00463-6, 10.1111/j.1574-6968.1997.tb10180.x]; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; POPOFF MR, 1988, BIOCHEM BIOPH RES CO, V152, P1361, DOI 10.1016/S0006-291X(88)80435-2; REUNER KH, 1987, EUR J CELL BIOL, V43, P134; Sanchez CP, 1997, J BIOL CHEM, V272, P2652, DOI 10.1074/jbc.272.5.2652; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SCHERING B, 1988, EUR J BIOCHEM, V171, P225, DOI 10.1111/j.1432-1033.1988.tb13780.x; SCHMID A, 1994, J BIOL CHEM, V269, P16706; SCHMID MF, 1993, NATURE, V364, P827, DOI 10.1038/364827a0; SCHULEIN K, 1991, MOL MICROBIOL, V5, P2233, DOI 10.1111/j.1365-2958.1991.tb02153.x; SIMPSON LI, 1989, J PHARMACOL EXP THER, V251, P1223; SIMPSON LL, 1989, INFECT IMMUN, V57, P255, DOI 10.1128/IAI.57.1.255-261.1989; SIMPSON LL, 1987, INFECT IMMUN, V55, P118, DOI 10.1128/IAI.55.1.118-122.1987; SIMPSON LL, 1982, J PHARMACOL EXP THER, V222, P43; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WELKOS SL, 1988, GENE, V69, P287, DOI 10.1016/0378-1119(88)90439-8; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; Wunsch S, 1998, J CELL BIOL, V140, P335, DOI 10.1083/jcb.140.2.335; ZHAO JM, 1995, J BIOL CHEM, V270, P18626, DOI 10.1074/jbc.270.31.18626	45	66	67	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1658	+		10.1096/fj.00-0671fje	http://dx.doi.org/10.1096/fj.00-0671fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427518				2022-12-28	WOS:000173707700004
J	Gredilla, R; Sanz, A; Lopez-Torres, M; Barja, G				Gredilla, R; Sanz, A; Lopez-Torres, M; Barja, G			Caloric restriction decreases mitochondrial free radical generation at complex I and lowers oxidative damage to mitochondrial DNA in the rat heart	FASEB JOURNAL			English	Article						8-hydroxydeoxyguanosine; aging; oxygen radical production; hydrogen peroxide	FOOD RESTRICTION; AGE; STRESS; MUTATIONS; SITES; BRAIN	The effect of caloric restriction (CR) (40%) on the rates of mitochondrial H2O2 production and oxygen consumption and oxidative damage to nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) was studied for short-term (6-wk) and long-term (1-year) periods in the heart of young and old rats. Short-term CR did not change any of the parameters measured. However, long-term CR significantly decreased the rate of mitochondrial H2O2 generation (by 45%) and significantly lowered oxidative damage to mtDNA (by 30%) without modifying damage to nDNA. The decrease in H2O2 production occurred exclusively at the complex I free radical generator of the respiratory chain. The mechanism allowing that decrease was not a simple decrease in mitochondrial oxygen consumption. Instead, the mitochondria of caloric-restricted animals released fewer oxygen radicals per unit electron flow in the respiratory chain. This was due to a decrease in the degree of reduction of the complex I generator in caloric-restricted mitochondria. The results are consistent with die concept that CR decreases the aging rate at least in part by decreasing the rate of mitochondrial oxygen radical generation and then the rate of attack on mtDNA.	Univ Complutense, Fac Biol, Dept Anim Biol Anim Physiol 2, E-28040 Madrid, Spain	Complutense University of Madrid	Barja, G (corresponding author), Univ Complutense, Fac Biol, Dept Biol Anim 2, E-28040 Madrid, Spain.		Sanz, Alberto/O-2329-2015; Barja, Gustavo/AAA-5903-2019; Gustavo, Barja/B-5591-2012; SANZ, ALBERTO/F-8432-2011	Sanz, Alberto/0000-0003-2149-1753; Barja, Gustavo/0000-0001-5736-4735; GREDILLA, RICARDO/0000-0003-4501-1355				Barja G, 2000, FASEB J, V14, P312, DOI 10.1096/fasebj.14.2.312; Barja G, 2000, AGING CLIN EXP RES, V12, P342, DOI 10.1007/BF03339859; Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188; Barja G, 1999, METHODS AGING RES, P533; Beckman K B, 1996, Methods Enzymol, V264, P442, DOI 10.1016/S0076-6879(96)64040-3; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; CHUNG MH, 1992, FREE RADICAL BIO MED, V12, P523, DOI 10.1016/0891-5849(92)90105-P; de Grey ADNJ, 2000, ARCH BIOCHEM BIOPHYS, V373, P295, DOI 10.1006/abbi.1999.1509; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; DJURIC Z, 1992, TOXICOL APPL PHARM, V115, P156, DOI 10.1016/0041-008X(92)90318-M; Gabbita SP, 1997, FREE RADICAL BIO MED, V23, P191, DOI 10.1016/S0891-5849(97)00043-9; Greenberg JA, 2000, MECH AGEING DEV, V113, P37, DOI 10.1016/S0047-6374(99)00094-9; GUARNIERI C, 1992, FREE RADICALS AGING, P73; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M; Herrero A, 1997, J BIOENERG BIOMEMBR, V29, P241, DOI 10.1023/A:1022458010266; Herrero A, 1997, MECH AGEING DEV, V98, P95, DOI 10.1016/S0047-6374(97)00076-6; Kaneko T, 1996, MUTAT RES-DNAGING G, V316, P277, DOI 10.1016/S0921-8734(96)90010-7; Kovalenko SA, 1998, ANN NY ACAD SCI, V854, P171, DOI 10.1111/j.1749-6632.1998.tb09900.x; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; LATORRE A, 1986, P NATL ACAD SCI USA, V83, P8649, DOI 10.1073/pnas.83.22.8649; Lee J, 1999, FREE RADICAL BIO MED, V26, P260, DOI 10.1016/S0891-5849(98)00195-6; Loft S, 1999, METHOD ENZYMOL, V300, P166; MCCARTER R, 1985, AM J PHYSIOL, V248, pE488; Mela L, 1979, Methods Enzymol, V55, P39; Melov S, 1999, MUTAT RES-DNA REPAIR, V434, P233, DOI 10.1016/S0921-8777(99)00031-2; Muscari C, 1996, AGING-CLIN EXP RES, V8, P429, DOI 10.1007/BF03339606; NAGLEY P, 1998, MITOCHONDRIAL DNA MU, P205; NAPIWOTZKI J, 1999, OXIDAT STRESS DIS, V2, P251; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; NOHL H, 1978, EUR J BIOCHEM, V82, P563, DOI 10.1111/j.1432-1033.1978.tb12051.x; Orr W. C., 2000, ANTIOXIDANTS REDOX R, P517; OZAWA T, 1995, EXP GERONTOL, V30, P269, DOI 10.1016/0531-5565(94)00057-A; Ozawa T, 1999, J BIOENERG BIOMEMBR, V31, P377, DOI 10.1023/A:1005479920097; RUCH W, 1983, J IMMUNOL METHODS, V63, P347, DOI 10.1016/S0022-1759(83)80008-8; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; SOHAL RS, 1995, MECH AGEING DEV, V81, P15, DOI 10.1016/0047-6374(94)01578-A; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang ED, 1997, MUTAT RES-FUND MOL M, V377, P157, DOI 10.1016/S0027-5107(97)00091-2; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407	45	293	304	0	28	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1589	+		10.1096/fj.00-0764fje	http://dx.doi.org/10.1096/fj.00-0764fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427495				2022-12-28	WOS:000173707700027
J	Murphy, JF; Fitzgerald, DJ				Murphy, JF; Fitzgerald, DJ			Vascular endothelial cell growth factor (VEGF) induces cyclooxygenase (COX)-dependent proliferation of endothelial cells (EC) via the VEGF-2 receptor	FASEB JOURNAL			English	Article						vascular endothelial growth factor; cyclooxygenase; endothelial cell; prostacyclin		Vascular endothelial cell growth factor (VEGF) stimulates endothelial cell (EC) proliferation and migration and mediates vascular growth and angiogenesis through two receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR). Similar biological activity has been attributed to cyclooxygenase (COX)-1 and -2, particularly in the angiogenic response to colon cancer. VEGF(165) (50 ng/ml for 3 h) increased the generation of 6-keto-PGF(1alpha) in EC (2.8+/-0.36 ng/ml vs. 0.69+/-0.08 ng/ml, P<0.05; n=9), which was prevented by the specific COX-2 inhibitor NS398 (0.7+/-0.5 ng/ml). VEGF also induced COX-2 protein expression. Extended exposure to VEGF (8-10 h) leads to COX-1 protein expression. A peptide derived from the third globular domain of the VEGFR-2 consisting of residues 247-261 (1 mu M-1 mM) inhibited VEGF-induced 6-keto-PGF(1 alpha) generation and COX induction. Prolonged exposure (7-9 h) of EC to VEGF induced cell proliferation that was inhibited by a combination of COX-1 and -2 inhibitors (SC560 and NS398), suggesting that proliferation is dependent on both isoforms. The inhibitory effect of the combined inhibitors was also seen with aspirin and was reversed by the addition of the stable PGI(2) analog iloprost but not by the PGE(2) or PGH(2) analogs dinoprostone or U46619. In an angiogenic assay, new blood vessel formation induced by VEGF over 14 days was blocked by COX-1 inhibition. COX induction and prostaglandin formation are downstream effectors of VEGF-dependent EC activation and angiogenesis.	Royal Coll Surgeons Ireland, Dept Clin Pharmacol, Dublin 2, Ireland	Royal College of Surgeons - Ireland	Murphy, JF (corresponding author), Royal Coll Surgeons Ireland, Dept Clin Pharmacol, 123 St Stephens Green, Dublin 2, Ireland.	jmurphy@rcsi.ie						Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; ANGELOV L, 1999, CANCER RES, P5536; Bamba H, 2000, BIOCHEM BIOPH RES CO, V273, P485, DOI 10.1006/bbrc.2000.2969; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Bryant CE, 1998, LIFE SCI, V62, P2195, DOI 10.1016/S0024-3205(98)00197-0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JONES DA, 1993, J BIOL CHEM, V268, P9049; Jones MK, 1999, NAT MED, V5, P1418; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIU XH, 2000, J UROLOGY, P820; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; MASFERRER JL, 2000, CANCER RES, P1306; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; OIDA H, 1995, BRIT J PHARMACOL, P2828; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Piossek C, 1999, J BIOL CHEM, V274, P5612, DOI 10.1074/jbc.274.9.5612; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Prescott SM, 2000, J CLIN INVEST, V105, P1511, DOI 10.1172/JCI10241; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SALEH M, 1996, CANCER RES, P393; Sawaoka H, 1999, LAB INVEST, V79, P1469; SHEEHAN KM, 1999, JAMA-J AM MED ASSOC, P1254; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Smith T, 1893, B BUREAU ANIM IND, P1; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Wallace JL, 2000, GASTROENTEROLOGY, V119, P706, DOI 10.1053/gast.2000.16510; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Zachary I, 1998, INT J BIOCHEM CELL B, V30, P1169, DOI 10.1016/S1357-2725(98)00082-X	49	55	58	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1667	+		10.1096/fj.00-0757fje	http://dx.doi.org/10.1096/fj.00-0757fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427521				2022-12-28	WOS:000173707700001
J	Rah, JC; Kim, HS; Kim, SS; Bach, JH; Jeong, SJ; Seo, JH; Park, CH; Kim, YS; Suh, YH				Rah, JC; Kim, HS; Kim, SS; Bach, JH; Jeong, SJ; Seo, JH; Park, CH; Kim, YS; Suh, YH			Effects of the carboxyl-terminal fragment of Alzheimer's amyloid precursor protein and amyloid beta-peptide on the production of cytokines and nitric oxide in glial cells	FASEB JOURNAL			English	Article						Alzheimer's disease; chemokines; inflammation; cell death	SELECTIVE NEUROTOXICITY; REACTIVE ASTROCYTES; TNF-ALPHA; DISEASE; SYNTHASE; BRAIN; INDUCTION; IMMUNOREACTIVITY; ALPHA-1-ANTICHYMOTRYPSIN; INTERLEUKIN-1	In a brain with Alzheimer's disease (AD), activated glial cells are observed surrounding amyloid plaque. In this study, to investigate the roles of carboxyl-terminal fragments (CTs) of amyloid precursor protein (APP) and amyloid beta-peptide (Abeta) in inflammatory processes possibly linked to neurodegeneration associated with AD, we examined the effects of the CT of APP with 105 amino acid residues (CT105) on the alteration of inflammatory mediators in rat cortical astrocytes and microglial cells and compared these effects to those of Abeta. We found that cytokines including interleukin 1beta (IL-1beta) and tumor necrosis factor a and chemokines such as macrophage inflammatory protein 1alpha, monocyte chemoattractant protein 1, and RANTES (regulated on activation, normal T expressed and secreted) were highly induced by 100 nM CT105 in a time-dependent manner, whereas the same amount of Abeta(1-42) did not significantly induce these mediators. In addition, inducible nitric oxide synthase (iNOS) expression and nitrite accumulation induced by CT105 were inhibited by IL-1 receptor antagonist (IL-1ra). Furthermore, the addition of conditioned media from CT105-treated astrocytes to rat cortical neurons caused a decrease in cell viability. Pretreatment with IL-1ra, N-G-nitro-L-arginine methyl ester (a specific inhibitor of NOS), and pyrollidine dithiocarbamate [an inhibitor of nuclear factor-kappaB (NF-kappaB)] prevented neuronal cell death caused by conditioned media from CT105-treated astrocytes. Our results indicate that the activation of astrocytes by CT105 leads to neuronal cell death in vitro, presumably caused by the increase in nitric oxide derived from the induction of iNOS through the activation of cytokines and NF-kappaB. Thus, CT105 may contribute to stimulation of inflammatory processes linked to delayed neuro degeneration in AD.	Seoul Natl Univ, Natl Creat Res Initiat Ctr Alzheimers Dementia, Coll Med, Dept Pharmacol, Seoul 110799, South Korea; Seoul Natl Univ, MRC, Neurosci Res Inst, Seoul 110799, South Korea; Chung Ang Univ, Coll Med, Dept Anat, Seoul 156756, South Korea	Seoul National University (SNU); Seoul National University (SNU); Chung Ang University; Chung Ang University Hospital	Suh, YH (corresponding author), Seoul Natl Univ, Natl Creat Res Initiat Ctr Alzheimers Dementia, Coll Med, Dept Pharmacol, Seoul 110799, South Korea.	yhsuh@plaza.snu.ac.kr	Kim, Yong-Sik/J-5418-2012; Suh, Yoo-Hun/J-2761-2012; Kim, Hye Sun/J-2752-2012	Kim, Yong-Sik/0000-0003-3763-4544; Rah, Jong-Cheol/0000-0003-3780-0522				ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Chan ED, 1998, BIOCHEM BIOPH RES CO, V253, P790, DOI 10.1006/bbrc.1998.9857; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG YH, 1994, LIFE SCI, V54, P1259; Cuzzocrea S, 1998, LIFE SCI, V63, P789, DOI 10.1016/S0024-3205(98)00334-8; DYRKS T, 1992, J BIOL CHEM, V267, P18210; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; Ferrer I, 1998, NEUROPATH APPL NEURO, V24, P271; Fiala M, 1998, MOL MED, V4, P480, DOI 10.1007/BF03401753; FUKUCHI K, 1993, NEUROSCI LETT, V154, P145, DOI 10.1016/0304-3940(93)90192-N; FUKUCHI K, 1992, MOL BRAIN RES, V16, P37, DOI 10.1016/0169-328X(92)90191-D; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Gura T, 1996, SCIENCE, V272, P954, DOI 10.1126/science.272.5264.954; Hardy J, 1998, NAT NEUROSCI, V1, P355, DOI 10.1038/1565; Johnstone M, 1999, J NEUROIMMUNOL, V93, P182, DOI 10.1016/S0165-5728(98)00226-4; KAMETANI F, 1994, FEBS LETT, V351, P165, DOI 10.1016/0014-5793(94)00851-5; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; Koeberle PD, 1999, EXP NEUROL, V158, P366, DOI 10.1006/exnr.1999.7113; KOZLOWSKI MR, 1992, J NEUROSCI, V12, P1679; Lee JP, 2000, J NEUROSCI RES, V60, P565, DOI 10.1002/(SICI)1097-4547(20000515)60:4<565::AID-JNR16>3.0.CO;2-I; Licastro F, 2000, J NEUROIMMUNOL, V103, P97, DOI 10.1016/S0165-5728(99)00226-X; Lombardi VRM, 1999, J NEUROIMMUNOL, V97, P163, DOI 10.1016/S0165-5728(99)00046-6; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MATSUMOTO A, 1994, BBA-MOL BASIS DIS, V1225, P304, DOI 10.1016/0925-4439(94)90011-6; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Meda L, 1999, J NEUROIMMUNOL, V93, P45, DOI 10.1016/S0165-5728(98)00188-X; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; PODLISNY MB, 1993, AM J PATHOL, V142, P17; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHEARMAN MS, 1995, J NEUROCHEM, V65, P218, DOI 10.1046/j.1471-4159.1995.65010218.x; Suh YH, 1997, J NEUROCHEM, V68, P1781; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Wallace MN, 1997, EXP NEUROL, V144, P266, DOI 10.1006/exnr.1996.6373; Xia MQ, 1999, J NEUROVIROL, V5, P32, DOI 10.3109/13550289909029743; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201	47	22	23	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1463	+		10.1096/fj.00-0724fje	http://dx.doi.org/10.1096/fj.00-0724fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387258				2022-12-28	WOS:000173705800013
J	Segura, I; Serrano, A; De Buitrago, GG; Gonzalez, MA; Abad, JL; Claveria, C; Gomez, L; Bernad, A; Martinez-A, C; Riese, HH				Segura, I; Serrano, A; De Buitrago, GG; Gonzalez, MA; Abad, JL; Claveria, C; Gomez, L; Bernad, A; Martinez-A, C; Riese, HH			Inhibition of programmed cell death impairs in vitro vascular-like structure formation and reduces in vivo angiogenesis	FASEB JOURNAL			English	Article						vasculogenesis; apoptosis; caspase inhibitors	HUMAN-ENDOTHELIAL-CELLS; CYTOCHROME-C; GROWTH; MECHANISMS; APOPTOSIS; PATHWAYS; PROTEIN; COMPLEX; DIFFERENTIATION; VASCULOGENESIS	Tissue remodeling during embryonic development and in the adult organism relies on a subtle balance between cell growth and apoptosis. As angiogenesis involves restructuring of preexisting endothelium, we examined the role of apoptosis in new vessel formation. We show that apoptosis occurs before capillary formation but not after vessels have assembled. Using the human umbilical vein endothelial cell (HUVEC) in vitro Matrigel angiogenesis model, we show that vascular-like structure formation requires apoptotic cell death through activation of a caspase-dependent mechanism and mitochondrial cytochrome c release. Vascular-like structure formation was further blocked by caspase inhibitors such as z-VAD or Ac-DEVD-CHO, using HUVEC and human lung microvascular endothelial cells. Overexpression of anti-apoptotic human Bcl-2 or baculovirus p35 genes in HUVEC altered endothelial cell rearrangement during in vitro angiogenesis, causing impaired vessel-like structure formation. Caspase inhibitors blocked VEGF- or bFGF-induced HUVEC angiogenesis on 2- or 3-D collagen gels, respectively, confirming that apoptosis was not the result of nonspecific cell death after seeding on the matrix. In an in vivo angiogenesis assay, caspase inhibitors blocked VEGF- dependent vascular formation at the alignment step, as demonstrated histologically. This evidence indicates that endothelial cell apoptosis may be relevant for precise vascular tissue rearrangement in in vitro and in vivo angiogenesis.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Martinez-A, C (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.	cmartineza@cnb.uam.es	Bernad, Antonio/P-8573-2017; Gonzalez, Manuel A/A-3404-2013; Segura, Inmaculada/D-2878-2013; Segura, Inmaculada/AAA-7958-2020	Segura, Inmaculada/0000-0003-1849-5569; Serrano, Antonio/0000-0003-1993-640X; Bernad, Antonio/0000-0003-0620-9668				ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; BROOKS PC, 1994, CELL, V79, P1147; DAVIS GE, 1995, EXP CELL RES, V216, P113, DOI 10.1006/excr.1995.1015; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Huang S, 2000, EXP CELL RES, V261, P91, DOI 10.1006/excr.2000.5044; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jones MK, 1999, NAT MED, V5, P1418; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; PASSANITI A, 1992, LAB INVEST, V67, P519; Pluda JM, 1997, SEMIN ONCOL, V24, P203; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Segura I, 2001, ANAL BIOCHEM, V296, P143, DOI 10.1006/abio.2001.5200; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Vailhe B, 2001, LAB INVEST, V81, P439, DOI 10.1038/labinvest.3780252; Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	32	83	92	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0833	10.1096/fj.01-0819com	http://dx.doi.org/10.1096/fj.01-0819com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039865				2022-12-28	WOS:000176683900009
J	Shaw, G; Morse, S; Ararat, M; Graham, FL				Shaw, G; Morse, S; Ararat, M; Graham, FL			Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells	FASEB JOURNAL			English	Article						neurofilaments; cytoskeleton; viral transformation; cell line; cancer	MALIGNANT RHABDOID-TUMOR; INTERMEDIATE FILAMENT PROTEIN; EMBRYONAL CARCINOMA-CELLS; ACETYLCHOLINE-RECEPTOR; NEUROFILAMENT PROTEINS; STEM-CELLS; LINE; KIDNEY; DIFFERENTIATION; EXPRESSION	The 293 cell line was derived by transformation of primary cultures of human embryonic kidney (HEK) cells with sheared adenovirus (Ad)5 DNA. A combination of immunostaining, immunoblot, and microarray analysis showed that 293 cells express the neurofilament (NF) subunits NF-L, NF-M, NF-H, and alpha-internexin as well as many other proteins typically found in neurons. Three other independently derived HEK lines, two transformed by Ad5 and one by Ad12, also expressed NFs, as did one human embryonic retinal cell line transformed with Ad5. Two rodent kidney lines transformed with Ad12 were also found to express NF proteins, although several rodent kidney cell lines transformed by Ad5 DNA and three HEK cell lines transformed by the SV40 early region did not express NFs. These results suggest that human Ads preferentially transform human neuronal lineage cells. We also demonstrate that the widely used HEK293 cells have an unexpected relationship to neurons, a finding that may require reinterpretation of many previous studies in which it was assumed that HEK293 cells resembled more typical kidney epithelial cells.	Univ Florida, Coll Med, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Pathol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Mol Med, Hamilton, ON L8S 4K1, Canada	State University System of Florida; University of Florida; McMaster University; McMaster University; McMaster University	Shaw, G (corresponding author), Univ Florida, Coll Med, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA.	shaw@mbi.ufl.edu	, Gerry/X-2377-2019					ANDERSON L, 1995, BIOCHEM J, V311, P385, DOI 10.1042/bj3110385; BYRD P, 1982, NATURE, V298, P69, DOI 10.1038/298069a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DAMJANOV I, 1984, CELL DIFFER DEV, V15, P133, DOI 10.1016/0045-6039(84)90065-4; Dautzenberg FM, 2000, EUR J PHARMACOL, V390, P51, DOI 10.1016/S0014-2999(99)00915-2; Elliott KJ, 1996, J MOL NEUROSCI, V7, P217, DOI 10.1007/BF02736842; Evans J, 2002, J NEUROPHYSIOL, V87, P1076, DOI 10.1152/jn.00088.2001; Fallaux FJ, 1998, HUM GENE THER, V9, P1909, DOI 10.1089/hum.1998.9.13-1909; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; FISCHER HP, 1989, PATHOL RES PRACT, V184, P541, DOI 10.1016/S0344-0338(89)80149-9; GALLIMORE PH, 1979, COLD SPRING HARB SYM, V44, P703, DOI 10.1101/SQB.1980.044.01.075; Geschwind DH, 2001, NEURON, V29, P325, DOI 10.1016/S0896-6273(01)00209-4; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAHAM FL, 1984, ADENOVIRUSES, P339; GREEN M, 1979, P NATL ACAD SCI USA, V76, P6606, DOI 10.1073/pnas.76.12.6606; GREEN M, 1980, VIRUSES NATURALLY OC, V7, P373; HARRIS J, 1991, J NEUROSCI RES, V30, P47, DOI 10.1002/jnr.490300107; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; IBELGAUFTS H, 1982, ACTA NEUROPATHOL, V56, P113, DOI 10.1007/BF00690581; ISHIKAWA S, 1979, ACTA PATHOL JAPON, V29, P289; KAPLAN MP, 1990, J NEUROSCI, V10, P2735; LEDOUARI.NM, 1974, DEV BIOL, V41, P162, DOI 10.1016/0012-1606(74)90291-7; LEE VMY, 1986, J NEUROSCI, V6, P514; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lin KD, 1999, BIOTECHNIQUES, V26, P318, DOI 10.2144/99262rr02; Liu L, 1998, NEUROSCI LETT, V251, P161, DOI 10.1016/S0304-3940(98)00513-8; Louis N, 1997, VIROLOGY, V233, P423, DOI 10.1006/viro.1997.8597; LUTHER MA, 1989, J NEUROSCI, V9, P1082; MACKEY JK, 1979, JNCI-J NATL CANCER I, V62, P23; MACKEY JK, 1976, P NATL ACAD SCI USA, V73, P4657, DOI 10.1073/pnas.73.12.4657; MAK S, 1982, INT J CANCER, V30, P697, DOI 10.1002/ijc.2910300604; Makoff A, 1996, MOL BRAIN RES, V37, P239, DOI 10.1016/0169-328X(95)00321-I; MIZOBUCHI K, 1984, ACTA PATHOL JAPON, V34, P1313; MOTOI M, 1985, ACTA NEUROPATHOL, V66, P218, DOI 10.1007/BF00688586; MUKAI N, 1980, SCIENCE, V210, P1023, DOI 10.1126/science.7434012; MUKAI N, 1973, AM J PATHOL, V73, P671; Mukai N, 1975, No Shinkei Geka, V3, P91; NAKAJIMA T, 1979, ACTA NEUROPATHOL, V45, P187, DOI 10.1007/BF00702670; OHTAKI S, 1989, BRIT J EXP PATHOL, V70, P415; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; RAJU T, 1981, DEV BIOL, V85, P344, DOI 10.1016/0012-1606(81)90266-9; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; Rolle U, 1999, BJU INT, V83, P1045; SAINIO K, 1994, INT J DEV BIOL, V38, P77; Schachter JB, 1997, NEUROPHARMACOLOGY, V36, P1181, DOI 10.1016/S0028-3908(97)00138-X; Schiedner G, 2000, HUM GENE THER, V11, P2105, DOI 10.1089/104303400750001417; Schmidt U, 1998, AM J DERMATOPATH, V20, P346, DOI 10.1097/00000372-199808000-00004; SHAW G, 1982, NATURE, V298, P277, DOI 10.1038/298277a0; SHAW G, 1998, NEUROFILAMENTS; Soudais C, 2001, FASEB J, V15, P2283, DOI 10.1096/fj.01-0321fje; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; Sugimoto T, 1999, INT J CANCER, V82, P678, DOI 10.1002/(SICI)1097-0215(19990827)82:5<678::AID-IJC10>3.0.CO;2-K; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; TSOKOS M, 1989, ARCH PATHOL LAB MED, V113, P115; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; WOLD WSM, 1979, CANCER RES, V39, P3479; Yarwood SJ, 2001, P NATL ACAD SCI USA, V98, P4472, DOI 10.1073/pnas.081069098; Zhu GY, 1998, J NEUROSCI METH, V81, P73, DOI 10.1016/S0165-0270(98)00019-3	62	542	559	5	55	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					869	+		10.1096/fj.01-0995fje	http://dx.doi.org/10.1096/fj.01-0995fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11967234				2022-12-28	WOS:000175425900018
J	Goukassian, DA; Bagheri, S; El-Keeb, L; Eller, MS; Gilchrest, BA				Goukassian, DA; Bagheri, S; El-Keeb, L; Eller, MS; Gilchrest, BA			DNA oligonucleotide treatment corrects the age-associated decline in DNA repair capacity	FASEB JOURNAL			English	Article						aging; oligonucleotide therapy; p53; NER	NUCLEOTIDE EXCISION-REPAIR; REPLICATION PROTEIN-A; XERODERMA-PIGMENTOSUM; SKIN-CANCER; ENDONUCLEASE-V; P53; DAMAGE; CELLS; MELANOGENESIS; EPIDEMIOLOGY	Age-related decline in DNA repair capacity (DRC) is associated with decreased constitutive levels of p53 and other nucleotide excision repair proteins. To determine whether pretreatment of cells with small DNA oligonucleotides compensates for decreased DRC in the elderly, fibroblasts from donors of different ages were pretreated with thymidine dinucleotide (pTT), a 5' phosphorylated 9 base oligonucleotide (p9mer) or diluent alone for 48 h, then UV-irradiated with solar-simulated light. Western blot analysis revealed age-associated decreases of 40%-80% between newborn and old adult donor cells in the constitutive protein levels of p53, p21, XPA, RPA, ERCC1, and PCNA. Treatment with pTT or p9mer up-regulated these proteins by 200%-650% at 24, 48, and 72 h. Moreover, pretreatment with oligonucleotides significantly increased the removal rate of photoproducts as determined by reacting DNA with thymine dimer-specific antibodies: 40+/-5% vs. 20+/-9% and 15+/-11% remained after 24 h in diluent, pTT and p9mer treated cells, respectively. Oligonucleotide-treated adult cells removed thymine dimers at least as rapidly as diluent treated newborn cells, demonstrating that pTT and p9mer completely corrected the age-associated decrease in DRC. Our studies suggest that topical oligonucleotide treatment may enhance DRC in older adults and thus reduce the carcinogenic risk from solar UV irradiation in this age group.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA	Boston University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA.	bgilchre@bu.edu		Goukassian, David/0000-0001-5270-5270				BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; Coultas L, 2000, APOPTOSIS, V5, P491, DOI 10.1023/A:1009617727938; Cruz PD, 2000, J INVEST DERMATOL, V114, P253, DOI 10.1046/j.1523-1747.2000.00866.x; ELLER MS, 1994, NATURE, V372, P413, DOI 10.1038/372413a0; Eller MS, 1996, P NATL ACAD SCI USA, V93, P1087, DOI 10.1073/pnas.93.3.1087; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; FEARS TR, 1977, AM J EPIDEMIOL, V105, P420, DOI 10.1093/oxfordjournals.aje.a112400; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Francis MA, 1999, CARCINOGENESIS, V20, P19, DOI 10.1093/carcin/20.1.19; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Germanier M, 2000, NUCLEIC ACIDS RES, V28, P4674, DOI 10.1093/nar/28.23.4674; Gilchrest BA, 1999, J INVEST DERM SYMP P, V4, P35, DOI 10.1038/sj.jidsp.5640178; GILCHREST BA, 1993, J INVEST DERMATOL, V101, P666, DOI 10.1111/1523-1747.ep12371673; Goukassian D, 2000, FASEB J, V14, P1325, DOI 10.1096/fj.14.10.1325; Goukassian DA, 1999, J INVEST DERMATOL, V112, P25, DOI 10.1046/j.1523-1747.1999.00468.x; Grossman L, 1997, ENVIRON HEALTH PERSP, V105, P927, DOI 10.2307/3433305; GROSSMAN L, 1995, CLIN CHEM, V41, P1854; Hadshiew IM, 2001, J DERMATOL SCI, V25, P127, DOI 10.1016/S0923-1811(00)00125-0; HALL PA, 1993, ONCOGENE, V8, P203; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; JEEVES WP, 1983, INT J RADIAT BIOL, V43, P625, DOI 10.1080/09553008314550731; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi T, 1998, NUCLEIC ACIDS RES, V26, P4662, DOI 10.1093/nar/26.20.4662; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; Kraemer KH, 1999, ALFRED BENZON SYMP S, V44, P256; KRIPKE ML, 1999, DERMATOLOGY GEN MED, P1717; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI L, 1995, MOL CELL BIOL, V15, P5396; LUNDER EJ, 1998, NEW ENGL J MED, V17, P1247; Maeda T, 1999, MUTAT RES-DNA REPAIR, V433, P137, DOI 10.1016/S0921-8777(98)00071-8; Marcil I, 2000, ARCH DERMATOL, V136, P1524, DOI 10.1001/archderm.136.12.1524; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; MORIWAKI SC, 1996, MUTAT RES, V364, P119; PATHAK MA, 1999, DERMATOLOGY GEN MED, P1627; Pedeux R, 1998, J INVEST DERMATOL, V111, P472, DOI 10.1046/j.1523-1747.1998.00324.x; PLAZA S, 1991, PHOTOCHEM PHOTOBIOL, V53, P217, DOI 10.1111/j.1751-1097.1991.tb03926.x; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; Radman M, 1975, Basic Life Sci, V5A, P355; RADMAN M, 1970, MUTAT RES, V9, P553, DOI 10.1016/0027-5107(70)90100-4; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; ROSENSTEIN BS, 1991, RADIAT RES, V126, P338, DOI 10.2307/3577923; Sancar Gwendolyn B., 1996, Mutation Research, V362, P127, DOI 10.1016/0921-8777(95)00029-1; SCOTTO J, 1981, NIH PUBLICATION; SCOTTO J, 1987, CANC INVEST, V4, P275; SERRANO H, 1991, J AM ACAD DERMATOL, V24, P574, DOI 10.1016/0190-9622(91)70086-H; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; TANAKA K, 1975, P NATL ACAD SCI USA, V72, P4071, DOI 10.1073/pnas.72.10.4071; van Dam RM, 1999, AM J EPIDEMIOL, V150, P459, DOI 10.1093/oxfordjournals.aje.a010034; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WEI QY, 1993, P NATL ACAD SCI USA, V90, P1614, DOI 10.1073/pnas.90.4.1614; WEI QY, 1995, J INVEST DERMATOL, V104, P933, DOI 10.1111/1523-1747.ep12606207; Weinstock MA, 1997, ARCH DERMATOL, V133, P1207, DOI 10.1001/archderm.133.10.1207; WERNINGHAUS K, 1991, PHOTODERMATOL PHOTO, V8, P236; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821; Yarosh D, 2001, LANCET, V357, P926, DOI 10.1016/S0140-6736(00)04214-8; Young AR, 1996, J INVEST DERMATOL, V106, P1307, DOI 10.1111/1523-1747.ep12349031; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896	64	51	54	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					754	+		10.1096/fj.01-0829fje	http://dx.doi.org/10.1096/fj.01-0829fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923222				2022-12-28	WOS:000174755900010
J	Steinert, JR; Wyatt, AW; Poston, L; Jacob, R; Mann, GE				Steinert, JR; Wyatt, AW; Poston, L; Jacob, R; Mann, GE			Preeclampsia is associated with altered Ca2+ regulation and nitric oxide production in human fetal venous endothelial cells	FASEB JOURNAL			English	Article						intracellular calcium; human umbilical vein; histamine; cGMP; Gd3+	NORMAL-PREGNANCY; DEPENDENT RELAXATION; RESISTANCE ARTERIES; LIPID-PEROXIDATION; HEME OXYGENASE; PLACENTAL BED; SYNTHASE; WOMEN; ENTRY; HISTAMINE	Preeclampsia (PE) is a leading cause of maternal hypertension in pregnancy, fetal growth restriction, premature birth, and fetal and maternal mortality (1). Activation and dysfunction of the maternal and fetal endothelium in PE may be the consequence of increased oxidative stress associated with circulating lipid peroxides (2-4), and in cases of severe maternal hypertension, uterine and umbilical artery waveforms are abnormal (5). We have investigated PE-associated abnormalities in the regulation of intracellular Ca2+ ([Ca2+](i)) and cyclic guanosine monophosphate (cGMP) production (index of nitric oxide [NO]) in human fetal umbilical vein endothelial cells. Basal [Ca2+](i) was slightly elevated in PE cells, whereas agonist-stimulated Ca2+ entry was reduced in cells from PE compared with normal term or age-matched preterm pregnancies. Furthermore, PE cells exhibited a decreased permeability to Ba2+ but an increased permeability to Mn2+ and Gd3+, suggesting that PE is associated with phenotypic alterations in fetal endothelial cation channel(s). Basal and histamine-stimulated cGMP levels were elevated in PE compared with preterm or normal cells, implying an increased NO production in PE. However, immunoblots for endothelial NO synthase (eNOS) and soluble guanylyl cyclase (sGC) revealed reduced eNOS expression in PE and preterm cells, with negligible changes in sGC levels. This study provides important and novel insights into abnormalities of fetal endothelial cells isolated from women with PE, revealing an altered cation membrane permeability and activity of eNOS-sGC pathway. As these changes are sustained in culture in vitro, this may reflect long-term "programming" of the fetal cardiovascular system.	Kings Coll London, GKT Sch Biomed Sci, Ctr Cardiovasc Biol & Med, London SE1 1UL, England	University of London; King's College London	Mann, GE (corresponding author), Kings Coll London, GKT Sch Biomed Sci, Ctr Cardiovasc Biol & Med, New Hunts House,Rm 2-34B,Guys Campus, London SE1 1UL, England.	giovanni.mann@kcl.ac.uk	Steinert, Joern/ABB-4561-2020; Steinert, Joern/A-6678-2008; Steinert, Joern R/AAI-2742-2020	Steinert, Joern/0000-0003-1640-0845; Steinert, Joern R/0000-0003-1640-0845; Mann, Giovanni/0000-0001-7311-2044				AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003; Ashworth JR, 1997, BRIT J OBSTET GYNAEC, V104, P1152, DOI 10.1111/j.1471-0528.1997.tb10939.x; Barber A, 2001, FASEB J, V15, P1158, DOI 10.1096/fj.00-0376com; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; Bertrand C, 1999, AM J OBSTET GYNECOL, V180, P650, DOI 10.1016/S0002-9378(99)70268-1; BOGLE RG, 1992, BRIT J PHARMACOL, V105, P768, DOI 10.1111/j.1476-5381.1992.tb09053.x; Brennecke SP, 1997, CLIN SCI, V93, P51, DOI 10.1042/cs0930051; Broad LM, 1996, BIOCHEM J, V316, P759, DOI 10.1042/bj3160759; BROWN MA, 1995, CLIN EXP PHARMACOL P, V22, P781, DOI 10.1111/j.1440-1681.1995.tb01937.x; Chappell LC, 1999, LANCET, V354, P810, DOI 10.1016/S0140-6736(99)80010-5; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Cockell AP, 1997, HYPERTENSION, V30, P247, DOI 10.1161/01.HYP.30.2.247; Di Iorio R, 1998, EUR J OBSTET GYN R B, V76, P65, DOI 10.1016/S0301-2115(97)00159-0; Esplin MS, 2001, NEW ENGL J MED, V344, P867, DOI 10.1056/NEJM200103223441201; Faxen M., 2001, Archives of Gynecology and Obstetrics, V265, P45, DOI 10.1007/s004040000152; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Green J, 2000, J AM SOC NEPHROL, V11, P1188, DOI 10.1681/ASN.V1171188; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; HUBEL CA, 1989, AM J OBSTET GYNECOL, V161, P1025, DOI 10.1016/0002-9378(89)90778-3; Hyrc KB, 2000, CELL CALCIUM, V27, P75, DOI 10.1054/ceca.1999.0092; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; Kohler R, 1998, J HYPERTENS, V16, P1149, DOI 10.1097/00004872-199816080-00011; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; Kwan HY, 2000, J BIOL CHEM, V275, P6758, DOI 10.1074/jbc.275.10.6758; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; LYALL F, 1995, AM J OBSTET GYNECOL, V173, P714, DOI 10.1016/0002-9378(95)90328-3; LYALL F, 1994, J HYPERTENS, V12, P1339; Mahdy Z, 1998, J PHYSIOL-LONDON, V508, P609, DOI 10.1111/j.1469-7793.1998.00609.x; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Matteo R, 1998, AM J OBSTET GYNECOL, V178, P402, DOI 10.1016/S0002-9378(98)80033-1; MCCARTHY AL, 1993, AM J OBSTET GYNECOL, V168, P1323, DOI 10.1016/0002-9378(93)90389-Z; Morgan AJ, 1998, J PHYSIOL-LONDON, V513, P83, DOI 10.1111/j.1469-7793.1998.083by.x; Morgan AJ, 1996, BIOCHEM J, V320, P505; Nanno H, 1998, PRENAT NEONAT MED, V3, P222; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Oguogho A, 1996, CLIN AUTON RES, V6, P153, DOI 10.1007/BF02281902; OHTA A, 1989, BIOCHIM BIOPHYS ACTA, V984, P151, DOI 10.1016/0005-2736(89)90210-1; Orpana AK, 1996, AM J OBSTET GYNECOL, V174, P1056, DOI 10.1016/S0002-9378(96)70350-2; Paltauf-Doburzynska J, 1998, J PHYSIOL-LONDON, V513, P369, DOI 10.1111/j.1469-7793.1998.369bb.x; Parra MC, 2001, AM J OBSTET GYNECOL, V184, P497, DOI 10.1067/mob.2001.110311; Pascoal IF, 1998, J CLIN INVEST, V101, P464, DOI 10.1172/JCI557; Poston L, 1996, J HUM HYPERTENS, V10, P391; Ranta VH, 1998, HYPERTENS PREGNANCY, V17, P307, DOI 10.3109/10641959809009604; ROBERTSON WB, 1967, J PATHOL BACTERIOL, V93, P581, DOI 10.1002/path.1700930219; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Shaamash AH, 2001, INT J GYNECOL OBSTET, V72, P127, DOI 10.1016/S0020-7292(00)00314-3; Silver RK, 1996, AM J OBSTET GYNECOL, V175, P1013, DOI 10.1016/S0002-9378(96)80044-5; SOBREVIA L, 1995, J PHYSIOL-LONDON, V489, P183, DOI 10.1113/jphysiol.1995.sp021040; SOWERS JR, 1989, AM J OBSTET GYNECOL, V161, P441, DOI 10.1016/0002-9378(89)90539-5; Suzuki Y, 2000, BRIT J PHARMACOL, V131, P37, DOI 10.1038/sj.bjp.0703529; Takacs P, 2001, FASEB J, V15, P279; TRUDINGER BJ, 1985, AM J OBSTET GYNECOL, V152, P155, DOI 10.1016/S0002-9378(85)80016-8; Walsh SW, 2000, FASEB J, V14, P1289, DOI 10.1096/fj.14.10.1289; Wang J, 1998, J NEPHROL, V11, P53; WANG YI, 1994, HYPERTENS PREGNANCY, V13, P171, DOI 10.3109/10641959409009570	56	58	63	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					721	+		10.1096/fj.01-0916fje	http://dx.doi.org/10.1096/fj.01-0916fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923225				2022-12-28	WOS:000174755900005
J	Sun, L; Adebanjo, OA; Koval, A; Anandatheerthavarada, HK; Iqbal, J; Wu, XY; Moonga, BS; Wu, XB; Biswas, G; Bevis, PJR; Kumegawa, M; Epstein, S; Huang, CLH; Avadhani, NG; Abe, E; Zaidi, M				Sun, L; Adebanjo, OA; Koval, A; Anandatheerthavarada, HK; Iqbal, J; Wu, XY; Moonga, BS; Wu, XB; Biswas, G; Bevis, PJR; Kumegawa, M; Epstein, S; Huang, CLH; Avadhani, NG; Abe, E; Zaidi, M			A novel mechanism for coupling cellular intermediary metabolism to cytosolic Ca2+ signaling via CD38/ADP-ribosyl cyclase, a putative intracellular NAD(+) sensor	FASEB JOURNAL			English	Article						endoplasmic reticulum; ryanodine receptor; myristoylation; osteoblasts	CYCLIC ADP-RIBOSE; TRANSMEMBRANE GLYCOPROTEIN CD38; ENDOPLASMIC-RETICULUM; INSULIN-SECRETION; OUTER SURFACE; HYDROLYSIS; PROTEIN; INTERNALIZATION; INACTIVATION; MITOCHONDRIA	CD38 is an ectocyclase that converts NAD(+) to the Ca2+ -releasing second messenger cyclic ADP- ribose (cADPr). Here we report that in addition to CD38 ecto- catalysis, intracellularly expressed CD38 may catalyze NAD(+) --> cADPr conversion to cause cytosolic Ca2+ release. High levels of CD38 were found in the plasma membranes, endoplasmic reticulum, and nuclear membranes of osteoblastic MC3T3- E1 cells. More important, intracellular CD38 was colocalized with target ryanodine receptors. The cyclase also converted a NAD(+) surrogate, NGD(+), to its fluorescent product, cGDPr (K-m similar to5.13 muM). NAD(+) also triggered a cytosolic Ca2+ signal. Similar results were obtained with NIH3T3 cells, which overexpressed a CD38- EGFP fusion protein. The Delta(-49) - CD38- EGFP mutant with a deleted amino- terminal tail and transmembrane domain appeared mainly in the mitochondria with an expected loss of its membrane localization, but the NAD(+) -induced cytosolic Ca2+ signal was preserved. Likewise, Ca2+ release persisted in cells transfected with the Myr-Delta(-49) -CD38- EGFP or Delta(-49) -CD38- EGFP- Fan mutants, both directed to the plasma membrane but in an opposite topology to the full- length CD38- EGFP. Finally, ryanodine inhibited Ca2+ signaling, indicating the downstream activation of ryanodine receptors by cADPr. We conclude that intracellularly expressed CD38 might link cellular NAD(+) production to cytosolic Ca2+ signaling.	Mt Sinai Bone Program, Dept Med, New York, NY 10029 USA; Mt Sinai Bone Program, Dept Geriatr, New York, NY 10029 USA; Bronx Vet Affairs Geriatr Res Educ & Clin Ctr, New York, NY 10029 USA; Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA; Physiol Lab, Cambridge CB2 3EG, England; Meikai Univ, Kawagoe, Saitama, Japan	Geriatric Research Education & Clinical Center; University of Pennsylvania; University of Cambridge; Meikai University	Zaidi, M (corresponding author), Mt Sinai Sch Med, Div Endocrinol, POB 1055,Annenberg 5,1 Gustave Levy Pl, New York, NY 10029 USA.	mone.zaidi@mssm.edu	Huang, Christopher LH/A-6248-2008		NCI NIH HHS [CA 22762] Funding Source: Medline; NIA NIH HHS [R01 AG14917-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022762, R37CA022762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014917] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; ADDAYA S, 1999, J CELL BIOL, V139, P589; Adebanjo OA, 1999, NAT CELL BIOL, V1, P409, DOI 10.1038/15640; Adebanjo OA, 2000, AM J PHYSIOL-RENAL, V278, pF784, DOI 10.1152/ajprenal.2000.278.5.F784; Adebanjo OA, 1996, AM J PHYSIOL-RENAL, V270, pF469, DOI 10.1152/ajprenal.1996.270.3.F469; Anandatheerthavarada HK, 1999, J BIOL CHEM, V274, P6617, DOI 10.1074/jbc.274.10.6617; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Berthelier V, 1998, BIOCHEM J, V330, P1383, DOI 10.1042/bj3301383; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Bruzzone S, 1998, FEBS LETT, V433, P275, DOI 10.1016/S0014-5793(98)00929-6; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; De Flora A, 2000, CHEM IMMUNOL, V75, P79; De Flora Antonio, 1998, Cell Biochemistry and Biophysics, V28, P45; Deaglio S, 1998, J IMMUNOL, V160, P395; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; Ferrero E, 2000, CHEM IMMUNOL, V75, P1; Franco L, 1998, FASEB J, V12, P1507; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869; LEE CL, 2000, HUMAN CD38 RELATED M, P39; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; Liang M, 1999, ARCH BIOCHEM BIOPHYS, V371, P317, DOI 10.1006/abbi.1999.1463; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Morita K, 1997, J BIOL CHEM, V272, P21002, DOI 10.1074/jbc.272.34.21002; Munshi CB, 1997, METHOD ENZYMOL, V280, P318; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; Sun L, 1999, J CELL BIOL, V146, P1161, DOI 10.1083/jcb.146.5.1161; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; Yamada M, 1997, BRAIN RES, V756, P52, DOI 10.1016/S0006-8993(97)00117-0; ZAIDI M, 1995, J CLIN INVEST, V96, P1582, DOI 10.1172/JCI118197; Ziegler M, 1997, BIOCHEM J, V326, P401, DOI 10.1042/bj3260401; Zocchi E, 1999, FASEB J, V13, P273, DOI 10.1096/fasebj.13.2.273; Zocchi E, 1996, FEBS LETT, V396, P327, DOI 10.1016/0014-5793(96)01125-8; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416	43	54	60	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0302	10.1096/fj.01-0705com	http://dx.doi.org/10.1096/fj.01-0705com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874980				2022-12-28	WOS:000174755900023
J	Rudiger, JJ; Roth, M; Bihl, MP; Cornelius, BC; Johnson, M; Ziesche, R; Block, LH				Rudiger, JJ; Roth, M; Bihl, MP; Cornelius, BC; Johnson, M; Ziesche, R; Block, LH			Interaction of C/EBP alpha and the glucocorticoid receptor in vivo and in nontransformed human cells	FASEB JOURNAL			English	Article; Proceedings Paper	39th Annual Meeting of the American-Society-for-Cell-Biology	DEC, 1999	WASHINGTON, D.C.	Amer Soc Cell Biol		glucocorticoids; CCAAT/enhancer binding protein alpha; cell proliferation; protein complex	AIRWAY SMOOTH-MUSCLE; RAT HEPATOMA-CELLS; NF-KAPPA-B; TRANSCRIPTION FACTOR; NUCLEAR FACTOR; CHRONIC ASTHMA; HUMAN LUNG; BINDING; PROLIFERATION; PROTEIN	Belonging to the family of steroid hormones, glucocorticoids are essential for development and survival of vertebrates. The cellular response to glucocorticoids is attributed to the glucocorticoid receptor, which functions as a transcription factor. However, the majority of glucocorticoid-modulated genes lack a DNA binding site for the glucocorticoid receptor, raising the question of which mechanism mediates the responses to glucocorticoids. It has been suggested that besides direct DNA binding of the glucocorticoid receptor, interaction with members of other transcription factor families modulates the effect of the glucocorticoid receptor. However, the significance of such transcription factor interaction is not clear. In cultured human mesenchymal cells and peripheral blood leukocytes of human volunteers treated with glucocorticoids, we detected the formation of a complex between the GR and the CCAAT/enhancer binding protein alpha. In in vitro experiments, this interaction turned out to be responsible for the inhibitory action of glucocorticoids on lymphocytic and mesenchymal cell proliferation. Our results suggest that complex formation of the GR with C/EBPalpha accounts for a novel pathway of glucocorticoid action.	Univ Hosp Vienna, AKH, Dept Internal Med 4, A-1090 Vienna, Austria; Univ Basel, Dept Forsch, CH-4031 Basel, Switzerland; Univ Sydney, Inst Resp Med, Camperdown, NSW 2050, Australia; Univ Sydney, Dept Pharmacol, Camperdown, NSW 2050, Australia; GlaxoSmithKline, Res & Dev, Dept Resp Commercial Strategy, Stockley Pk UB11 1BU, Middx, England	University Hospital Vienna; University of Basel; University of Sydney; University of Sydney; GlaxoSmithKline	Block, LH (corresponding author), Univ Hosp Vienna, AKH, Dept Internal Med 4, Wahringer Gurtel 18-22, A-1090 Vienna, Austria.	lutz-henning.block@akh-wien.ac.at	Roth, Michael/H-8657-2019	Roth, Michael/0000-0002-8139-2821				ADCOCK IM, 1994, LIFE SCI, V55, P1147, DOI 10.1016/0024-3205(94)00243-6; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Beurton F, 1999, BIOCHEM J, V343, P687, DOI 10.1042/0264-6021:3430687; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; CHESTERMAN CN, 1983, BIOCHEM BIOPH RES CO, V116, P809, DOI 10.1016/S0006-291X(83)80214-9; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; DEMOLY P, 1994, AM J RESP CRIT CARE, V150, P214, DOI 10.1164/ajrccm.150.1.7912988; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Gelfand EW, 1998, ALLERGY ASTHMA PROC, V19, P365, DOI 10.2500/108854198778612744; GRUNFELD C, 1981, ENDOCRINOLOGY, V109, P1723, DOI 10.1210/endo-109-5-1723; HACZKU A, 1994, J ALLERGY CLIN IMMUN, V93, P510, DOI 10.1016/0091-6749(94)90361-1; Hirst SJ, 1998, AM J RESP CRIT CARE, V158, pS201, DOI 10.1164/ajrccm.158.supplement_2.13tac190; HOLZ O, 1991, CARCINOGENESIS, V12, P2181, DOI 10.1093/carcin/12.11.2181; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PINKSTON P, 1987, J IMMUNOL, V139, P755; POZNANSKY MC, 1985, CLIN EXP IMMUNOL, V61, P135; Ramos RA, 1999, FASEB J, V13, P169, DOI 10.1096/fasebj.13.1.169; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Roth M, 1996, P NATL ACAD SCI USA, V93, P5478, DOI 10.1073/pnas.93.11.5478; Stewart AG, 1995, BRIT J PHARMACOL, V116, P3219, DOI 10.1111/j.1476-5381.1995.tb15127.x; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; van der Velden VHJ, 1998, MEDIAT INFLAMM, V7, P229, DOI 10.1080/09629359890910; VANMAARSSEVEEN T, 1991, J IMMUNOL METHODS, V143, P95, DOI 10.1016/0022-1759(91)90277-M; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; Ziesche R, 1999, NEW ENGL J MED, V341, P1264, DOI 10.1056/NEJM199910213411703	40	57	57	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					177	184		10.1096/fj.01-0226com	http://dx.doi.org/10.1096/fj.01-0226com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11818365				2022-12-28	WOS:000174203700022
J	Rabbitt, EH; Lavery, GG; Walker, EA; Cooper, MS; Stewart, PM; Hewison, M				Rabbitt, EH; Lavery, GG; Walker, EA; Cooper, MS; Stewart, PM; Hewison, M			Prereceptor regulation of glucocorticoid action by 11 beta-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation	FASEB JOURNAL			English	Article						11 beta-HSD; glucocorticoid metabolism; glucocorticoid receptor; intracrine	FACTOR-KAPPA-B; CYCLE PROGRESSION; RECEPTOR-BETA; EXPRESSION; ARREST; MECHANISMS; TYPE-2; LINES; INHIBITOR; ISOFORM	Isozymes of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) act at a prereceptor level to regulate the tissue-specific availability of active glucocorticoids. To examine the effect of this on cell proliferation and differentiation, we have developed transfectant variants of a rat osteosarcoma cell line that express cDNA for 11beta-HSD1 (ROS 17/2.8beta1) or 11beta-HSD2 (ROS 17/2.8beta2). ROS 17/2.8beta1 showed net conversion of cortisone to cortisol whereas ROS 17/ 2.8beta2 showed only inactivation of cortisol to cortisone. There was no significant difference in glucocorticoid receptor (GR) expression between the different clones. However, in proliferation and differentiation studies, ROS 17/ 2.8beta2 cells were completely resistant to cortisol. In contrast, ROS 17/ 2.8beta1 were sensitive to both cortisone and cortisol. Expression of 11beta-HSD1 decreased cell proliferation whereas 11beta-HSD2 increased proliferation. These responses appear to be due to metabolism of endogenous serum glucocorticoids; proliferation of ROS 17/ 2.8beta1 decreased further with exogenous cortisone or cortisol whereas ROS 17/ 2.8beta2 were resistant to both compounds. The pro-proliferative effects of 11beta-HSD2 were abrogated by 18beta-glycyrrhetinic acid, an 11beta-HSD inhibitor, and in cells transfected with cDNA encoding inactive 11beta-HSD2. Data indicate that differential regulation of 11beta-HSD1 and 2 (rather than GR expression) is a key determinant of cell proliferation. Dysregulated expression of 11beta-HSD2 may be a novel feature of tumorigenesis.	Univ Birmingham, Queen Elizabeth Hosp, Inst Clin Res, Dept Med, Birmingham B15 2TH, W Midlands, England	University of Birmingham	Hewison, M (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Inst Clin Res, Dept Med, Birmingham B15 2TH, W Midlands, England.	M.Hewison@bham.ac.uk	Cooper, Mark S/C-9529-2012; Lavery, Gareth/F-9346-2010	Cooper, Mark/0000-0003-3112-7728				ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; Bland R, 1999, J ENDOCRINOL, V161, P455, DOI 10.1677/joe.0.1610455; Bujalska IJ, 1999, ENDOCRINOLOGY, V140, P3188, DOI 10.1210/en.140.7.3188; Bujalska O, 1997, STEROIDS, V62, P77, DOI 10.1016/S0039-128X(96)00163-8; Chang DJ, 1998, J BIOL CHEM, V273, P4892, DOI 10.1074/jbc.273.9.4892; Cooper MS, 2000, BONE, V27, P375, DOI 10.1016/S8756-3282(00)00344-6; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; Eyre LJ, 2001, J CELL BIOCHEM, V81, P453, DOI 10.1002/1097-4644(20010601)81:3<453::AID-JCB1059>3.0.CO;2-Z; Ferrari P, 2000, J HYPERTENS, V18, P241, DOI 10.1097/00004872-200018030-00001; Ferrari P, 2000, KIDNEY INT, V57, P1374, DOI 10.1046/j.1523-1755.2000.00978.x; Hundertmark S, 1997, J ENDOCRINOL, V155, P171, DOI 10.1677/joe.0.1550171; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; Korbonits M, 2001, J CLIN ENDOCR METAB, V86, P2728, DOI 10.1210/jc.86.6.2728; Krozowski Z, 1999, MOL CELL ENDOCRINOL, V151, P121, DOI 10.1016/S0303-7207(98)00256-1; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Li KXZ, 1997, ENDOCRINOLOGY, V138, P2948, DOI 10.1210/en.138.7.2948; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; MOTOO Y, 1994, CANCER LETT, V86, P91, DOI 10.1016/0304-3835(94)90184-8; Oakley RH, 1999, STEROIDS, V64, P742, DOI 10.1016/S0039-128X(99)00059-8; Oakley RH, 1999, J BIOL CHEM, V274, P27857, DOI 10.1074/jbc.274.39.27857; Reichardt HM, 1998, MOL CELL ENDOCRINOL, V146, P1, DOI 10.1016/S0303-7207(98)00208-1; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Samuelsson MKR, 1999, MOL ENDOCRINOL, V13, P1811, DOI 10.1210/me.13.11.1811; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; Stewart PM, 1999, VITAM HORM, V57, P249; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; Traynor Ann, 1995, Current Opinion in Oncology, V7, P572, DOI 10.1097/00001622-199511000-00017; Wei P, 1998, MOL ENDOCRINOL, V12, P1322, DOI 10.1210/me.12.9.1322; YANO H, 1994, CANCER RES, V54, P448	32	74	80	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					36	44		10.1096/fj.01-0582com	http://dx.doi.org/10.1096/fj.01-0582com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11772934				2022-12-28	WOS:000173656600005
J	Jones, MK; Szabo, IL; Kawanaka, H; Husain, SS; Tarnawski, AS				Jones, MK; Szabo, IL; Kawanaka, H; Husain, SS; Tarnawski, AS			Von Hippel-Lindau tumor suppressor and HIF-1 alpha: new targets of NSAID inhibition of hypoxia-induced angiogenesis	FASEB JOURNAL			English	Article						gastrointestinal wounding; colon cancer; ischemia; hypoxia-inducible factor; vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLON-CANCER CELLS; INDUCIBLE FACTOR-1; UP-REGULATION; IN-VITRO; ACTIVATION; APOPTOSIS; CYCLOOXYGENASE-2; PROLIFERATION	Nonsteroidal anti-inflammatory drugs (NSAIDs) block prostaglandin synthesis and impair healing of gastrointestinal ulcers and growth of colonic tumors, in part, by inhibiting angiogenesis. The mechanisms of this inhibition are incompletely explained. Here we demonstrate that both nonselective (indomethacin) and COX-2-selective (NS-398) NSAIDs inhibit hypoxia-induced in vitro angiogenesis in gastric microvascular endothelial cells via coordinated sequential events: 1) increased expression of the von Hippel-Lindau (VHL) tumor suppressor, which targets proteins for ubiquitination leading to 2) reduced accumulation of hypoxia-inducible factor-1 alpha (HIF-1 alpha) and, as a result, 3) reduced expression of vascular endothelial growth factor (VEGF) and its specific receptor Flt-1. Because HIF-1 alpha is the major trigger for hypoxia-induced activation of the VEGF and Flt-1 genes, this could explain how NSAIDs inhibit hypoxia-induced angiogenesis. Exogenous VEGF and, to a lesser extent, exogenous prostaglandins partly reversed the NSAIDs inhibition of hypoxia-induced angiogenesis. Taken together, these results indicate that NSAIDs inhibit hypoxia-induced angiogenesis in endothelial cells by inhibiting VEGF and Flt-1 expression through increased VHL expression and the resulting ubiquitination and degradation of HIF-1 alpha. This action of NSAIDs has both prostaglandin-dependent and prostaglandin-independent components.	Vet Affairs Med Ctr, Dept Med, Long Beach, CA 90822 USA; Vet Affairs Med Ctr, Dept Surg, Long Beach, CA 90822 USA; Univ Calif Irvine, Irvine, CA 92697 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine	Tarnawski, AS (corresponding author), Univ Calif Irvine, DVA Med Ctr Long Beach CA, Div Gastroenterol, 5901 E 7th St, Long Beach, CA 90822 USA.	atarnawski@yahoo.com						Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; HVIDBERG E, 1972, EUR J CLIN PHARMACOL, V4, P119, DOI 10.1007/BF00562508; Jones MK, 1999, AM J PHYSIOL-GASTR L, V276, pG1345, DOI 10.1152/ajpgi.1999.276.6.G1345; Jones MK, 1999, NAT MED, V5, P1418; Jones MK, 2000, J PHYSIOL PHARMACOL, V51, P813; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Kohyama T, 2001, AM J PHYSIOL-LUNG C, V281, pL1257, DOI 10.1152/ajplung.2001.281.5.L1257; LEITH JT, 1995, CELL PROLIFERAT, V28, P415, DOI 10.1111/j.1365-2184.1995.tb00082.x; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; Liu XH, 1999, CLIN EXP METASTAS, V17, P687, DOI 10.1023/A:1006728119549; MARTIN BK, 1963, NATURE, V198, P896, DOI 10.1038/198896b0; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MCCARTHY DM, 1995, SCNA J GASTROENTEROL, V208, P9; MINCHENKO A, 1994, LAB INVEST, V71, P374; Ravi R, 2000, GENE DEV, V14, P34; SCHMASSMANN A, 1995, AM J PHYSIOL-GASTR L, V268, pG276, DOI 10.1152/ajpgi.1995.268.2.G276; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023; Tarnawski A., 1990, J CLIN GASTROENTEROL, V12, P148; TARNAWSKI A, 1988, J CLIN GASTROENTEROL, V10, P535; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; WALEH NS, 1995, CANCER RES, V55, P6222; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Zhu GH, 1999, BIOCHEM PHARMACOL, V58, P193, DOI 10.1016/S0006-2952(99)00058-1	34	87	88	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					264	+		10.1096/fj.01-0589fje	http://dx.doi.org/10.1096/fj.01-0589fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11772947				2022-12-28	WOS:000172964800009
J	Sesti, G; Federici, M; Hribal, ML; Lauro, D; Sbraccia, P; Lauro, R				Sesti, G; Federici, M; Hribal, ML; Lauro, D; Sbraccia, P; Lauro, R			Defects of the insulin receptor substrate (IRS) system in human metabolic disorders	FASEB JOURNAL			English	Review						insulin signaling; IRS-1; IRS-2; IRS-3; IRS-4; type 2 diabetes	AMINO-ACID POLYMORPHISMS; GROWTH-FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; 60-KDA PHOSPHOTYROSINE PROTEIN; SKELETAL-MUSCLE; DIABETES-MELLITUS; GLUCOSE-TRANSPORT; KINASE-B; CODON-972 POLYMORPHISM; GLUT4 TRANSLOCATION	Insulin receptor substrate (IRS) molecules are key mediators in insulin signaling and play a central role in maintaining basic cellular functions such as growth, survival, and metabolism. They act as docking proteins between the insulin receptor and a complex network of intracellular signaling molecules containing Src homology 2 (SH2) domains. Four members (IRS-1, IRS-2, IRS-3, IRS-4) of this family have been identified that differ as to tissue distribution, subcellular localization, developmental expression, binding to the insulin receptor, and interaction with SH2 domain-containing proteins. Results from targeted disruption of the IRS genes in mice have provided important clues to the functional differences among these related molecules, suggesting they play different and specific roles in vivo. The available data are consistent with the notion that IRS-1 and IRS-2 are not functionally interchangeable in tissues that are responsible for glucose production (liver), glucose uptake (skeletal muscle and adipose tissue), and insulin production (pancreatic beta cells). In fact, IRS-1 appears to have its major role in skeletal muscle whereas IRS-2 appears to regulate hepatic insulin action as well as pancreatic b cell development and survival. By contrast, IRS-3 and IRS-4 genes appear to play a redundant role in the IRS signaling system. Defects in muscle IRS-1 expression and function have been reported in insulin-resistant states such as obesity and type 2 diabetes. Several polymorphisms in the IRS genes have been identified, but only the Gly-->Arg(972) substitution of IRS-1, interacting with environmental factors, seems to have a pathogenic role in the development of type 2 diabetes. In contrast, polymorphisms of the other IRS genes do not appear to contribute to type 2 diabetes.	Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Univ Roma Tor Vergata, Dept Internal Med, Mol Med Lab, I-00133 Rome, Italy	Magna Graecia University of Catanzaro; University of Rome Tor Vergata	Sesti, G (corresponding author), Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale & Clin, Via Tommaso Campanella 115, I-88100 Catanzaro, Italy.	sesti@unicz.it	Federici, Massimo/G-9940-2012; Sesti, Giorgio/B-1509-2012; Lauro, Davide/K-4683-2018	Federici, Massimo/0000-0003-4989-5194; Sesti, Giorgio/0000-0002-1618-7688; Lauro, Davide/0000-0002-8597-4415	Telethon [E.1309] Funding Source: Medline	Telethon(Fondazione Telethon)		Abe H, 1998, J CLIN INVEST, V101, P1784, DOI 10.1172/JCI1594; Almind K, 1999, DIABETOLOGIA, V42, P1244, DOI 10.1007/s001250051299; Almind K, 1998, DIABETOLOGIA, V41, P969, DOI 10.1007/s001250051015; Almind K, 1996, J CLIN INVEST, V97, P2569, DOI 10.1172/JCI118705; ALMIND K, 1993, LANCET, V342, P828, DOI 10.1016/0140-6736(93)92694-O; Anai O, 1998, J BIOL CHEM, V273, P29686, DOI 10.1074/jbc.273.45.29686; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Aspinwall CA, 2000, J BIOL CHEM, V275, P22331, DOI 10.1074/jbc.M909647199; Baroni MG, 1999, ARTERIOSCL THROM VAS, V19, P2975, DOI 10.1161/01.ATV.19.12.2975; Bektas A, 1999, DIABETES, V48, P640, DOI 10.2337/diabetes.48.3.640; Bernal D, 1998, DIABETES, V47, P976, DOI 10.2337/diabetes.47.6.976; Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Carvalho E, 1999, FASEB J, V13, P2173, DOI 10.1096/fasebj.13.15.2173; CELI FS, 1995, J CLIN ENDOCR METAB, V80, P2827, DOI 10.1210/jc.80.9.2827; CHEN DI, 1995, MOL CELL BIOL, V15, P4711; Choi WS, 2000, BIOCHEM BIOPH RES CO, V272, P953, DOI 10.1006/bbrc.2000.2869; CLAUSEN JO, 1995, LANCET, V346, P397, DOI 10.1016/S0140-6736(95)92779-4; DeFronzo RA, 1997, DIABETES REV, V5, P177; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Fantin VR, 1999, ENDOCRINOLOGY, V140, P1329, DOI 10.1210/en.140.3.1329; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; Fantin VR, 1999, BIOCHEM BIOPH RES CO, V260, P718, DOI 10.1006/bbrc.1999.0967; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Federici M, 2001, FASEB J, V15, P22; Friedman JE, 1999, DIABETES, V48, P1807, DOI 10.2337/diabetes.48.9.1807; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; GRANT PJ, 1995, LANCET, V346, P841, DOI 10.1016/S0140-6736(95)91654-7; HAGER J, 1993, LANCET, V342, P1430, DOI 10.1016/0140-6736(93)92793-S; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791; HITMAN GA, 1995, DIABETOLOGIA, V38, P481, DOI 10.1007/s001250050309; Hribal ML, 2000, J CLIN ENDOCR METAB, V85, P2004, DOI 10.1210/jc.85.5.2004; IMAI Y, 1994, J CLIN ENDOCR METAB, V79, P1655, DOI 10.1210/jc.79.6.1655; Imai Y, 1997, J CLIN ENDOCR METAB, V82, P4201, DOI 10.1210/jc.82.12.4201; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; Kalidas K, 1998, DIABETOLOGIA, V41, P1389, DOI 10.1007/s001250051081; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kulkarni RN, 1999, J CLIN INVEST, V104, pR69, DOI 10.1172/JCI8339; LAAKSO M, 1994, J CLIN INVEST, V94, P1141, DOI 10.1172/JCI117429; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lee-Ming C, 1996, DIABETES CARE, V19, P446; Lei HH, 1999, DIABETES, V48, P1868, DOI 10.2337/diabetes.48.9.1868; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; Mammarella S, 2000, HUM MOL GENET, V9, P2517, DOI 10.1093/hmg/9.17.2517; MORI H, 1995, J CLIN ENDOCR METAB, V80, P2822, DOI 10.1210/jc.80.9.2822; Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; Pederson T, 2000, BIOCHEM BIOPH RES CO, V276, P162, DOI 10.1006/bbrc.2000.3429; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pete G, 1999, ENDOCRINOLOGY, V140, P5478, DOI 10.1210/en.140.12.5478; Porzio O, 1999, J CLIN INVEST, V104, P357, DOI 10.1172/JCI5870; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; Qu BH, 1999, J BIOL CHEM, V274, P31179, DOI 10.1074/jbc.274.44.31179; QUON MJ, 1994, J BIOL CHEM, V269, P27920; Rasmussen SK, 2000, J CLIN ENDOCR METAB, V85, P2951, DOI 10.1210/jc.85.8.2951; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Schuppin GT, 1998, DIABETES, V47, P1074, DOI 10.2337/diabetes.47.7.1074; Sciacchitano S, 1997, ENDOCRINOLOGY, V138, P4931, DOI 10.1210/en.138.11.4931; SHIMOKAWA K, 1994, BIOCHEM BIOPH RES CO, V202, P463, DOI 10.1006/bbrc.1994.1951; Sigal RJ, 1996, J CLIN ENDOCR METAB, V81, P1657, DOI 10.1210/jc.81.4.1657; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; Stumvoll M, 2001, DIABETES, V50, P882, DOI 10.2337/diabetes.50.4.882; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; 't Hart LM, 1999, J CLIN ENDOCR METAB, V84, P1002, DOI 10.1210/jc.84.3.1002; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Terauchi Y, 1997, J CLIN INVEST, V99, P861, DOI 10.1172/JCI119250; Tsuruzoe K, 2001, MOL CELL BIOL, V21, P26, DOI 10.1128/MCB.21.1.26-38.2001; Uchida T, 2000, MOL CELL BIOL, V20, P126, DOI 10.1128/MCB.20.1.126-138.2000; Ura S, 1996, DIABETOLOGIA, V39, P600; Valverde AM, 1999, DIABETES, V48, P2122, DOI 10.2337/diabetes.48.11.2122; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wu XK, 2000, FERTIL STERIL, V74, P564, DOI 10.1016/S0015-0282(00)00688-9; Xu GG, 1999, J BIOL CHEM, V274, P18067, DOI 10.1074/jbc.274.25.18067; Xu P, 1999, J BIOL CHEM, V274, P15262, DOI 10.1074/jbc.274.21.15262; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yoshimura R, 1997, DIABETES, V46, P929, DOI 10.2337/diabetes.46.6.929; Zhang JJ, 1996, COMPUT MECH, V19, P1, DOI 10.1007/BF02757779; Zhou LX, 1999, MOL ENDOCRINOL, V13, P505, DOI 10.1210/me.13.3.505	94	265	278	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2099	2111		10.1096/fj.01-0009rev	http://dx.doi.org/10.1096/fj.01-0009rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641236				2022-12-28	WOS:000171920400021
J	Anders, A; Gilbert, S; Garten, W; Postina, R; Fahrenholz, F				Anders, A; Gilbert, S; Garten, W; Postina, R; Fahrenholz, F			Regulation of the alpha-secretase ADAM10 by its prodomain and proprotein convertases	FASEB JOURNAL			English	Article						PC7; furin; Alzheimer's disease; alpha-secretase; ADAM10	AMYLOID-PRECURSOR PROTEIN; TRANS-GOLGI NETWORK; BETA-SECRETASE; INTRACELLULAR MATURATION; CYSTEINE SWITCH; PROHORMONE CONVERTASES; ALZHEIMERS-DISEASE; SNAKE-VENOM; PRO-REGION; CLEAVAGE	Ectodomain shedding of the Alzheimer's amyloid precursor protein is mediated by alpha- and beta -secretases, which, for their part, are also proteolytically processed. The disintegrin metalloproteinase ADAM10 is synthesized as a zymogen with a proprotein convertase (PC) recognition sequence between the prodomain and the catalytic domain. In this study, we investigated the role of the prodomain in the regulation of the alpha -secretase activity of ADAM10. Overexpression of the proprotein convertases PC7 and furin in human embryonic kidney 293 cells revealed an increased ADAM10 maturation resulting in enhanced alpha -secretase-mediated processing of amyloid precursor protein. Mutation of the PC recognition sequence in ADAM10 as well as the use of a PC inhibitor and of the furin-deficient LoVo cell line confirmed the role of PCs, in particular, of PC7, in ADAM10 maturation and activation. Furthermore, we demonstrated that the prodomain of ADAM10 has a dual function. When coexpressed in trans as separate polypeptide, it inhibited the alpha -secretase activity of wild-type ADAM10. However, the prodomain acted as a chaperone and functionally rescued the alpha -secretase activity of a former inactive ADAM10 mutant lacking the prodomain. The results of our study suggest new approaches to enhance the nonamyloidogenic alpha -secretase pathway.	Univ Mainz, Inst Biochem, D-55128 Mainz, Germany; Univ Marburg, Inst Virol, D-35037 Marburg, Germany	Johannes Gutenberg University of Mainz; Philipps University Marburg	Fahrenholz, F (corresponding author), Univ Mainz, Inst Biochem, Becherweg 30, D-55128 Mainz, Germany.	bio.chemie@uni-mainz.de						ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cao J, 2000, J BIOL CHEM, V275, P29648, DOI 10.1074/jbc.M001920200; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; DAY R, 1993, NEUROSCI LETT, V149, P27, DOI 10.1016/0304-3940(93)90339-M; DESTROOPER B, 1995, BBA-PROTEIN STRUCT M, V1246, P185, DOI 10.1016/0167-4838(94)00194-L; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; FABRE E, 1992, J BIOL CHEM, V267, P15049; Furukawa K, 1998, NEUROSCIENCE, V83, P429, DOI 10.1016/S0306-4522(97)00398-9; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; Galazka G, 1996, BIOCHEMISTRY-US, V35, P11221, DOI 10.1021/bi960618e; GARTEN W, 1989, VIROLOGY, V172, P25, DOI 10.1016/0042-6822(89)90103-7; GRAMS F, 1993, FEBS LETT, V335, P76, DOI 10.1016/0014-5793(93)80443-X; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Lopez-Perez E, 1999, J NEUROCHEM, V73, P2056; Lopez-Perez E, 2001, J NEUROCHEM, V76, P1532, DOI 10.1046/j.1471-4159.2001.00180.x; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Marcinkiewicz M, 2000, J NEUROCHEM, V75, P2133, DOI 10.1046/j.1471-4159.2000.0752133.x; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; SMALL DH, 1994, J NEUROSCI, V14, P2117; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STOCKER W, 1995, PROTEIN SCI, V4, P823; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; Wouters S, 1998, BIOCHEM J, V336, P311, DOI 10.1042/bj3360311; Yavari R, 1998, HUM MOL GENET, V7, P1161, DOI 10.1093/hmg/7.7.1161	56	178	188	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1837	+		10.1096/fj.01-0007fje	http://dx.doi.org/10.1096/fj.01-0007fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481247				2022-12-28	WOS:000169261200010
J	Huang, RM; Wu, TM; Xu, L; Liu, AH; Ji, Y; Hu, GX				Huang, RM; Wu, TM; Xu, L; Liu, AH; Ji, Y; Hu, GX			Upstream binding factor up-regulated in hepatocellular carcinoma is related to the survival and cisplatin-sensitivity of cancer cells	FASEB JOURNAL			English	Article						representational difference analysis; UBF; HCC; antisense oligodeoxynucleotide; cisplatin	TRANSCRIPTION FACTOR UBF; RNA-POLYMERASE-I; ANTISENSE OLIGODEOXYNUCLEOTIDES; FACTOR HUBF; PROTOONCOGENE EXPRESSION; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; DNA ADDUCTS; INHIBITION; APOPTOSIS	Upstream binding factor (UBF) is an RNA polymerase I- specific transcription factor. By representational difference analysis, Northern blot, and cDNA array analysis, up- regulation of UBF was detected in 12 of 17 clinical hepatocellular carcinoma samples comparing to the paired normal liver tissues. Introduction of UBF in human lung fibroblast cells that do not express UBF resulted in an accelerated rate of cell growth; on the other hand, antisense oligode-oxynucleotides (ODNs) treatment of UBF- expressing hepatoma cell lines reduced the level of UBF protein, suppressed the colony formation capacity of these cells on soft agarose, and finally caused cell death. Annexin V binding analysis suggested that anti- UBF ODN-caused cell death might involve weak apoptosis, however, DNA laddering and cleavage of poly (ADP- ribose) polymerase were not observed in these ODN- treated cells. Expression profiling of the anti- UBF ODN-treated cells using a human cDNA array revealed that the expression of 30 genes was altered in response to the inhibition of UBF expression. Notably, UBF expression could increase the cell sensitivity to the chemotherapeutic reagent cis- diaminedichloroplatinum (II). We proposed that UBF is fundamental to the survival of cells expressing the gene, and is potential as a target for screening anti- cancer drugs and an indicator in selecting chemotherapeutic reagents.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Max Planck Guest Lab,Jr Grp 2, Shanghai 200031, Peoples R China; Zhongshan Hosp, Dept Pathol, Shanghai 200032, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Fudan University	Hu, GX (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Max Planck Guest Lab,Jr Grp 2, Shanghai 200031, Peoples R China.	hgxgene@sunm.shcnc.ac.cn						ANAZODO MI, 1995, J VIROL, V69, P1794, DOI 10.1128/JVI.69.3.1794-1801.1995; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; CALABRETTA B, 1991, CANCER RES, V51, P4505; Casiano CA, 1996, MOL BIOL REP, V23, P211, DOI 10.1007/BF00351171; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHAN EKL, 1991, J EXP MED, V174, P1239, DOI 10.1084/jem.174.5.1239; CHEN R, 1980, SCI SINICA, V23, P236; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; Denko N, 2000, CLIN CANCER RES, V6, P480; Derenzini M, 1998, AM J PATHOL, V152, P1291; Farshid M, 1997, ACTA VIROL, V41, P125; FUKUDA M, 1995, ANTICANCER RES, V15, P393; GOLDSTONE SD, 1993, BIOCHEM BIOPH RES CO, V196, P619, DOI 10.1006/bbrc.1993.2294; Hannan KM, 1998, FRONT BIOSCI, V3, P376, DOI [10.2741/A282, DOI 10.2741/A282]; Hannan RD, 1996, J BIOL CHEM, V271, P3213, DOI 10.1074/jbc.271.6.3213; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JUNFENG Y, 2000, NUCL MED BIOL, V27, P347; KANEMATSU T, 1991, ONCOLOGY, V48, P34; KELLAND LR, 1994, EUR J CANCER, V30A, P725, DOI 10.1016/0959-8049(94)90281-X; KITAMURA A, 1994, EUR J BIOCHEM, V224, P877, DOI 10.1111/j.1432-1033.1994.00877.x; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; LUO KX, 1997, HEPATITIS B BASIC BI, P435; MORRISON RS, 1991, J BIOL CHEM, V266, P728; NICHOLS GL, 1995, ANTISENSE RES DEV, V5, P67, DOI 10.1089/ard.1995.5.67; NISHIMURA T, 1994, BIOCHEM BIOPH RES CO, V205, P1217, DOI 10.1006/bbrc.1994.2795; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; PERSAUD SJ, 1994, J MOL ENDOCRINOL, V12, P127, DOI 10.1677/jme.0.0120127; REED JC, 1990, CANCER RES, V50, P6565; Riley HD, 1997, CARCINOGENESIS, V18, P2453, DOI 10.1093/carcin/18.12.2453; ROUSSEL P, 1994, EXP CELL RES, V214, P465, DOI 10.1006/excr.1994.1283; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; TIMMERBOSSCHA H, 1992, BRIT J CANCER, V66, P227, DOI 10.1038/bjc.1992.249; Torres-Montaner A, 1998, J PATHOL, V184, P77, DOI 10.1002/(SICI)1096-9896(199801)184:1<77::AID-PATH958>3.0.CO;2-X; TREIBER DK, 1994, P NATL ACAD SCI USA, V91, P5672, DOI 10.1073/pnas.91.12.5672; VOIT R, 1995, NUCLEIC ACIDS RES, V23, P2593, DOI 10.1093/nar/23.14.2593; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; White Barbara, 1995, Current Opinion in Rheumatology, V7, P541, DOI 10.1097/00002281-199511000-00013; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Xu L, 2001, CANCER RES, V61, P3176; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; Zhai XQ, 1998, BIOCHEMISTRY-US, V37, P16307, DOI 10.1021/bi981708h	51	36	39	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0293	10.1096/fj.01-0687com	http://dx.doi.org/10.1096/fj.01-0687com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874979				2022-12-28	WOS:000174755900022
J	Smoyer, WE; Ransom, RF				Smoyer, WE; Ransom, RF			Hsp27 regulates podocyte cytoskeletal changes in an in vitro model of podocyte process retraction	FASEB JOURNAL			English	Article						actin; stress fibers; nephrotic syndrome; puromycin aminonucleoside	HEAT-SHOCK PROTEIN; PUROMYCIN AMINONUCLEOSIDE NEPHROSIS; GLOMERULAR EPITHELIAL-CELLS; ACTIN POLYMERIZATION; CELLULAR THERMORESISTANCE; CONFERS RESISTANCE; OXIDATIVE STRESS; PHOSPHORYLATION; EXPRESSION; ORGANIZATION	Nephrotic syndrome (NS) is characterized by structural changes in the actin- rich foot processes of glomerular podocytes. We previously identified high concentrations of the small heat shock protein hsp27 within podocytes as well as increased glomerular accumulation and phosphorylation of hsp27 in puromycin aminonucleoside (PAN) -induced experimental NS. Here we analyzed murine podocytes stably transfected with hsp27 sense, antisense, and vector control constructs using a newly developed in vitro PAN model system. Cell morphology and the microfilament structure of untreated sense and antisense transfectants were altered compared with controls. Vector cell survival, polymerized actin content, cell area, and hsp27 content increased after 1.25 mug/ ml PAN treatment and decreased after 5.0 mug/ ml treatment. In contrast, sense cells were unaffected by 1.25 mug/ ml PAN treatment whereas antisense cells showed decreases or no changes in all parameters. Treatment of sense cells with 5.0 mug/ ml PAN resulted in increased cell survival and cell area whereas antisense cells underwent significant decreases in all parameters. Hsp27 provided dramatic protection against PAN- induced microfilament disruption in sense > vector > antisense cells. We conclude that hsp27 is able to regulate both the morphological and actin cytoskeletal response of podocytes in an in vitro model of podocyte injury.	Univ Michigan, Med Ctr, Pediat Nephrol Div, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Ransom, RF (corresponding author), Univ Michigan, Med Ctr, Pediat Nephrol Div, 8220D MSRB 3,Box 0646,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	rransom@umich.edu			NIDDK NIH HHS [K08 DK02455-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002455] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS PM, 1984, ANAT REC, V210, P1, DOI 10.1002/ar.1092100102; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; CAULFIELD JP, 1976, LAB INVEST, V34, P43; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FARQUHAR MG, 1957, J EXP MED, V106, P649, DOI 10.1084/jem.106.5.649; FISHMAN JA, 1985, AM J PATHOL, V118, P398; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; GLASSOCK RJ, 1988, NEPHROTIC SYNDROME, P163; Hara M, 1998, AM J NEPHROL, V18, P35, DOI 10.1159/000013302; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HUOT J, 1991, CANCER RES, V51, P5245; Huot J, 1996, CANCER RES, V56, P273; Inokuchi S, 1996, KIDNEY INT, V50, P1278, DOI 10.1038/ki.1996.439; ITO K, 1986, ACTA PATHOL JAPON, V36, P253; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; LACHAPELLE M, 1991, VIRCHOWS ARCH B, V60, P105, DOI 10.1007/BF02899534; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Nakamura T, 2000, AM J NEPHROL, V20, P175, DOI 10.1159/000013580; Reiser J, 2000, KIDNEY INT, V57, P2035, DOI 10.1046/j.1523-1755.2000.00070.x; RYAN GB, 1975, KIDNEY INT, V8, P219, DOI 10.1038/ki.1975.105; Schneider GB, 1998, J CELL PHYSIOL, V177, P575, DOI 10.1002/(SICI)1097-4652(199812)177:4<575::AID-JCP8>3.0.CO;2-1; Shelden E, 1999, CELL MOTIL CYTOSKEL, V42, P12, DOI 10.1002/(SICI)1097-0169(1999)42:1<12::AID-CM2>3.0.CO;2-W; SINGHAL PC, 1992, J AM SOC NEPHROL, V3, P80; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smoyer WE, 1998, J MOL MED, V76, P172, DOI 10.1007/s001090050206; Smoyer WE, 1996, J CLIN INVEST, V97, P2697, DOI 10.1172/JCI118723; STOKOE D, 1992, FEBS LETT, V313, P317; VASMANT D, 1984, ANAT REC, V210, P17, DOI 10.1002/ar.1092100104; VERNIER RL, 1959, J EXP MED, V109, P115, DOI 10.1084/jem.109.1.115; WHITESIDE CI, 1993, AM J PATHOL, V142, P1641; Wu W, 1996, TOXICOL APPL PHARM, V141, P330	43	55	62	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0315	10.1096/fj.01-0681com	http://dx.doi.org/10.1096/fj.01-0681com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874981				2022-12-28	WOS:000174755900024
J	Voice, JK; Dorsam, G; Lee, H; Kong, Y; Goetzl, EJ				Voice, JK; Dorsam, G; Lee, H; Kong, Y; Goetzl, EJ			Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor	FASEB JOURNAL			English	Article						neuropeptide; IgE; cytokines; eosinophils; hypersensitivity	MESSENGER-RNA; CHROMOSOMAL LOCALIZATION; MURINE SCHISTOSOMIASIS; LYMPHOCYTES; VIP; POLYPEPTIDE; MODEL; MOUSE; GENE	Vasoactive intestinal peptide (VIP) and its G-protein-coupled receptors (VPAC1 and VPAC2 Rs) are prominent in the immune system. In T cells, VPAC1 R is expressed constitutively whereas VPAC2 R is induced only after stimulation of the T cell receptor (TCR) or exposure to some cytokines. VPAC1 R and VPAC2 R also transduce different effects of VIP on T cells. Constitutive expression of VPAC2 R selectively in CD4(+) T cells (helper-inducer Th cells) of transgenic (TG) C57BL/6 mice directed by the lck tyrosine kinase promoter is now shown to evoke production of more Th2-type interleukins 4 and 5, and less Th1-type interferon gamma after TCR activation. VPAC2 R TG mice consequently have significant elevations of blood IgE, IgG1, and eosinophils. VPAC2 R TG mice also show increased IgE antibody responses, which mediate heightened cutaneous allergic reactions, and have depressed delayed-type hypersensitivity. VIP enhancement of the ratio of Th2 cell to Th1 cell cytokines thus evokes an allergic state in normally nonallergic mice, which suggests the possibility of neuropeptide contributions to immune phenotypic alterations in human hypersensitivity diseases.	Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Ctr, Dept Microbiol Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Med, UB8B,Box 0711,533 Parnassus & 4th, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu	Dorsam, Glenn/GYD-8815-2022	Lee, Hsinyu/0000-0002-1477-0183	NIAID NIH HHS [AI 29912] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029912, R37AI029912] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; Bellinger DL, 1996, ADV NEUROIMMUNOL, V6, P5, DOI 10.1016/S0960-5428(96)00008-3; Delgado M, 1999, NEUROIMMUNOMODULAT, V6, P97, DOI 10.1159/000026369; Delgado M, 1996, J NEUROIMMUNOL, V68, P27, DOI 10.1016/0165-5728(96)00063-X; DORSAM G, 2001, ANN NY ACAD SCI, V952, P79; Fujieda S, 1996, J CLIN INVEST, V98, P1527, DOI 10.1172/JCI118944; Ganea D, 1996, ADV NEUROIMMUNOL, V6, P61, DOI 10.1016/S0960-5428(96)00007-1; Goetzl EJ, 1996, J IMMUNOL, V156, P1; GOETZL EJ, 1994, MOL CELL NEUROSCI, V5, P145, DOI 10.1006/mcne.1994.1016; GOETZL EJ, 2001, IN PRESS P NATL ACAD; GOMARIZ RP, 1994, REGUL PEPTIDES, V50, P177, DOI 10.1016/0167-0115(94)90033-7; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Harmar AJ, 1998, PHARMACOL REV, V50, P265; HASSNER A, 1993, J ALLERGY CLIN IMMUN, V92, P891, DOI 10.1016/0091-6749(93)90067-P; Hernanz A, 1996, J NEUROIMMUNOL, V71, P25, DOI 10.1016/S0165-5728(96)00118-X; Jabrane-Ferrat N, 2000, BIOCHEMISTRY-US, V39, P9771, DOI 10.1021/bi0008783; JOHNSTON JA, 1994, J IMMUNOL, V153, P1762; Kaltreider HB, 1997, AM J RESP CELL MOL, V16, P133, DOI 10.1165/ajrcmb.16.2.9032120; Lara-Marquez ML, 2001, J IMMUNOL, V166, P2522, DOI 10.4049/jimmunol.166.4.2522; Mackay M, 1996, GENOMICS, V37, P345, DOI 10.1006/geno.1996.0569; Martinez C, 1996, J IMMUNOL, V156, P4128; MATHEW RC, 1992, J IMMUNOL, V148, P3572; Metwali A, 2000, FASEB J, V14, P948, DOI 10.1096/fasebj.14.7.948; Pankhaniya R, 1998, FASEB J, V12, P119, DOI 10.1096/fasebj.12.1.119; SAID SI, 1988, ANN NY ACAD SCI, V527, P1; SREEDHARAN SP, 1994, BIOCHEM BIOPH RES CO, V203, P141, DOI 10.1006/bbrc.1994.2160; SREEDHARAN SP, 1995, P NATL ACAD SCI USA, V92, P2939, DOI 10.1073/pnas.92.7.2939; SUN L, 1993, J NEUROIMMUNOL, V48, P59, DOI 10.1016/0165-5728(93)90059-8; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629; Xia MH, 1996, J IMMUNOL, V156, P160	30	72	73	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2489	2496		10.1096/fj.01-0671com	http://dx.doi.org/10.1096/fj.01-0671com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689474				2022-12-28	WOS:000172420500019
J	Grosch, S; Tegeder, I; Niederberger, E; Brautigam, L; Geisslinger, G				Grosch, S; Tegeder, I; Niederberger, E; Brautigam, L; Geisslinger, G			COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib	FASEB JOURNAL			English	Article						G(0)/G(1)-phase block; NSAIDs; cyclooxygenase; SC560	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE-2 INHIBITOR; IONIZING-RADIATION; COLORECTAL-CANCER; SULINDAC SULFONE; PROSTATE-CANCER; KINASE-ACTIVITY; RECTAL POLYPS; UP-REGULATION; EXPRESSION	The regular use of various nonsteroidal anti-inflammatory drugs (NSAIDs) was shown to decrease the incidence of colorectal cancer. This effect is thought to be caused predominantly by inhibition of cyclooxygenase-2 (COX-2) and, subsequently, prostaglandin synthesis. However, recent studies have suggested that COX-independent pathways may contribute considerably to these antiproliferative effects. To evaluate the involvement of COX-dependent and COX-independent mechanisms further, we assessed the effects of celecoxib (selective COX-2 inhibitor) and SC560 (selective COX-1 inhibitor) on cell survival, cell cycle distribution, and apoptosis in three colon cancer cell lines, which differ in their expression of COX-2. Both drugs induced a G(0)/G(1) phase block and reduced cell survival independent of whether or not the cells expressed COX-2. Celecoxib was more potent than SC560. The G(0)/G(1) block caused by celecoxib could be attributed to a decreased expression of cyclin A, cyclin B1, and cyclin-dependent kinase-1 and an increased expression of the cell cycle inhibitory proteins p21(Waf1) and p27(Kip1). In addition, celecoxib, but not SC560, induced apoptosis, which was also independent of the COX-2 expression of the cells. In vivo, celecoxib as well as SC560 reduced the proliferation of HCT-15 (COX-2 deficient) colon cancer xenografts in nude mice, but both substances had no significant effect on HT-29 tumors, which express COX-2 constitutively. Thus, our in vitro and in vivo data indicate that the antitumor effects of celecoxib probably are mediated through COX-2 independent mechanisms and are not restricted to COX-2 over-expressing tumors.	Univ Frankfurt Klinikum, Inst Klin Pharmakol, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Geisslinger, G (corresponding author), Univ Frankfurt Klinikum, Inst Klin Pharmakol, Pharmazentrum Frankfurt, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	geisslinger@em.uni-frankfurt.de	Tegeder, Irmgard/AAM-2266-2020; Tegeder, Irmgard/AAM-2246-2020; Groesch, Sabine/H-4251-2018	Tegeder, Irmgard/0000-0001-7524-8025; Tegeder, Irmgard/0000-0001-7524-8025; Groesch, Sabine/0000-0002-7262-6307				Azzam EI, 1997, CELL GROWTH DIFFER, V8, P1161; Bak AW, 1998, LIFE SCI, V62, pPL367; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Damiens E, 2000, Prog Cell Cycle Res, V4, P219; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Davies NM, 2000, CLIN PHARMACOKINET, V38, P225, DOI 10.2165/00003088-200038030-00003; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Marra DE, 2000, CIRCULATION, V102, P2124, DOI 10.1161/01.CIR.102.17.2124; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Niederberger E, 2001, FASEB J, V15, P1622, DOI 10.1096/fj.00-0716fje; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Qiao L, 1998, INT J CANCER, V76, P99, DOI 10.1002/(SICI)1097-0215(19980330)76:1<99::AID-IJC16>3.0.CO;2-B; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; Rice PL, 2001, CANCER RES, V61, P1541; RIGAS B, 1999, NONSTEROIDAL ANTIINF; Rose MJ, 2000, J CHROMATOGR B, V738, P377, DOI 10.1016/S0378-4347(99)00552-6; SANO H, 1995, CANCER RES, V55, P3785; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Smalley W, 1999, ARCH INTERN MED, V159, P161, DOI 10.1001/archinte.159.2.161; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Soh JW, 2000, CLIN CANCER RES, V6, P4136; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stoner GD, 1999, ADV EXP MED BIOL, V470, P45; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; van Stolk R, 2000, CLIN CANCER RES, V6, P78; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wechter WJ, 2000, CANCER RES, V60, P2203; Wechter WJ, 1997, CANCER RES, V57, P4316; Wechter WJ, 2000, LIFE SCI, V66, P745, DOI 10.1016/S0024-3205(99)00645-1; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	48	434	457	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2742	+		10.1096/fj.01-0299fje	http://dx.doi.org/10.1096/fj.01-0299fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606477				2022-12-28	WOS:000171920400016
J	Mor, I; Grisaru, D; Titelbaum, L; Evron, T; Richler, C; Wahrman, J; Sternfeld, M; Yogev, L; Meiri, N; Seidman, S; Soreq, H				Mor, I; Grisaru, D; Titelbaum, L; Evron, T; Richler, C; Wahrman, J; Sternfeld, M; Yogev, L; Meiri, N; Seidman, S; Soreq, H			Modified testicular expression of stress-associated "readthrough" acetylcholinesterase predicts male infertility	FASEB JOURNAL			English	Article						psychological stress; sperm motility; spermatogenesis	SEMEN QUALITY; VARIANT; GENE; DIFFERENTIATION; SPERMATOZOA; PESTICIDE; PROTEINS; SYSTEM; GROWTH; CELLS	Male infertility is often attributed to stress. However, the protein or proteins that mediate stress-related infertility are not yet known. Overexpression of the "readthrough" variant of acetylcholinesterase (AChE-R) is involved in the cellular stress response in a variety of mammalian tissues. Here, we report testicular overexpression of AChE-R in heads, but not tails, of postmeiotic spermatozoa from mice subjected to a transient psychological stress compared with age-matched control mice. Transgenic mice overexpressing AChE-R displayed reduced sperm counts, decreased seminal gland weight, and impaired sperm motility compared with age-matched nontransgenic controls. AChE-R was prominent in meiotic phase spermatocytes and in tails, but not heads, of testicular spermatozoa from AChE-R transgenic mice. Head-localized AChE-R was characteristic of human sperm from fertile donors. In contrast, sperm head AChE-R staining was conspicuously reduced in samples from human couples for whom the cause of infertility could not be determined, similar to the pattern found in transgenic mice. These findings indicate AChE-R involvement in impaired sperm quality, which suggests that it is a molecular marker for stress-related infertility.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, Jerusalem, Israel; Surasky Med Ctr, Inst Study Fertil, Tel Aviv, Israel; Sackler Sch Med, Tel Aviv, Israel; Agr Res Org, Volcani Ctr, Inst Anim Sci, Bet Dagan, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, Jerusalem, Israel.	soreq@cc.huji.ac.il	Mor, Inbal/GON-5297-2022	Soreq, Hermona/0000-0002-0955-526X; Mor, Inbal/0000-0003-4564-9690				Bigbee JW, 2000, BRAIN RES, V861, P354, DOI 10.1016/S0006-8993(00)02046-1; Clarke RN, 1999, HUM REPROD, V14, P753, DOI 10.1093/humrep/14.3.753; DWIVEDI C, 1989, BIOCHEM MED METAB B, V42, P66, DOI 10.1016/0885-4505(89)90042-X; EGBUNIKE GN, 1980, INT J ANDROL, V3, P459, DOI 10.1111/j.1365-2605.1980.tb00134.x; Garner DL, 1999, MOL REPROD DEV, V53, P222, DOI 10.1002/(SICI)1098-2795(199906)53:2&lt;222::AID-MRD11&gt;3.0.CO;2-L; GIBLIN PT, 1988, FERTIL STERIL, V49, P127; Grisaru D, 1999, MOL CELL BIOL, V19, P788; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; Grisaru D, 2001, MOL MED, V7, P93, DOI 10.1007/BF03401943; Jolly C, 1999, GENE EXPRESSION, V7, P261; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Koenigsberger C, 1997, J NEUROCHEM, V69, P1389; Kronman C, 2000, J BIOL CHEM, V275, P29488, DOI 10.1074/jbc.M004298200; LEONHARDT H, 1993, COLOR ATLAS TXB HUMA, V2, P274; Lev-Lehman E, 2000, J MOL NEUROSCI, V14, P93, DOI 10.1385/JMN:14:1-2:093; LevLehman E, 1997, BLOOD, V89, P3644, DOI 10.1182/blood.V89.10.3644.3644_3644_3653; LIFSON YL, 1992, P NATL ACAD SCI USA, V89, P579; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; NEGROVILAR A, 1993, ENVIRON HEALTH PERSP, V101, P59, DOI 10.2307/3431377; Palmero S, 1999, EUR J HISTOCHEM, V43, P277; PRINCE FP, 1992, CELL TISSUE RES, V269, P383, DOI 10.1007/BF00353893; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Sarkar R, 2000, J REPROD FERTIL, V118, P29, DOI 10.1530/reprod/118.1.29; Shapira M, 2000, HUM MOL GENET, V9, P1273, DOI 10.1093/hmg/9.9.1273; Shohami E, 2000, J MOL MED-JMM, V78, P228, DOI 10.1007/s001090000104; Sternfeld M, 2000, P NATL ACAD SCI USA, V97, P8647, DOI 10.1073/pnas.140004597; Sternfeld M, 1998, J NEUROSCI, V18, P1240; Taylor P, 1996, GOODMAN GILMANS PHAR, P177; Tielemans E, 1999, LANCET, V354, P484, DOI 10.1016/S0140-6736(99)00599-1; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; YOUNG RJ, 1991, MOL REPROD DEV, V28, P55, DOI 10.1002/mrd.1080280109; Zhang Q, 1999, ENDOCRINOLOGY, V140, P2790, DOI 10.1210/en.140.6.2790; [No title captured]	34	27	28	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2039	+		10.1096/fj.00-0814fje	http://dx.doi.org/10.1096/fj.00-0814fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511515				2022-12-28	WOS:000170318500027
J	Xiao, GQ; Qu, YX; Hu, K; Boutjdir, M				Xiao, GQ; Qu, YX; Hu, K; Boutjdir, M			Down-regulation of L-type calcium channel in pups born to 52 kDa SSA/Ro immunized rabbits	FASEB JOURNAL			English	Article						autoantibody; AV block; immunization; cardiac myocyte	CONGENITAL HEART-BLOCK; SS-A/RO; HUMAN KERATINOCYTES; MURINE MODEL; ANTIBODIES; AUTOANTIBODIES; EXPRESSION; ANTIGENS; CHILDREN; MOTHERS	Congenital heart block is considered a model of passively acquired autoimmune disease in which the mother generates anti-SSA/Ro and/or anti-SSB/La antibodies that cross the placenta and presumably injure the heart of developing fetus. CHB is accompanied by ECG abnormalities including AV block, sinus bradycardia, and ventricular dysfunction. Our previous data indicate that these abnormalities are caused by maternal autoantibody-mediated disturbance of L-type Ca channels. To investigate the consequence of chronic exposure of L-type Ca channels in newborn pups to maternal autoantibodies during pregnancy, we immunized female rabbits with human 52 kDa-SSA/Ro (Ro52) recombinant protein. ECG revealed that pups from the immunized group had varying degrees of conduction defects. In addition, I-CaL density and protein were reduced in hearts of pups from the immunized group. Sera and purified IgG from immunized rabbits inhibited I-Ba recorded from oocytes with expressed alpha (1C) and beta (2a) subunits of L-type Ca channel. Pups born to Ro52 immunized mothers exhibited down-regulation of L-type calcium channels in heart. The data provide new insight into the pathogenesis of congenital heart block.	New York Harbor Hlth Care Syst, Mol & Cellular Cardiol Program, Res & Dev Off 151, Brooklyn, NY 11209 USA; SUNY Hlth Sci Ctr, Brooklyn, NY 11209 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Boutjdir, M (corresponding author), New York Harbor Hlth Care Syst, Mol & Cellular Cardiol Program, Res & Dev Off 151, 800 Poly Pl, Brooklyn, NY 11209 USA.	mohamed.boutjdir@med.va.gov		Boutjdir, Mohamed/0000-0002-6068-223X	NHLBI NIH HHS [HL55401] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNAIZVILLENA A, 1989, ARTHRITIS RHEUM-US, V32, P1421, DOI 10.1002/anr.1780321111; BOUCEK RJ, 1984, PEDIATR RES, V18, P948, DOI 10.1203/00006450-198418100-00008; Boutjdir M, 1998, PEDIATR RES, V44, P11, DOI 10.1203/00006450-199807000-00002; Boutjdir M, 1997, CIRC RES, V80, P354, DOI 10.1161/01.RES.80.3.354; Brucato A, 2000, CIRCULATION, V102, pE88, DOI 10.1161/01.CIR.102.11.e88; Buyon JP, 1998, J AM COLL CARDIOL, V31, P1658, DOI 10.1016/S0735-1097(98)00161-2; BUYON JP, 1995, LUPUS, V4, P116, DOI 10.1177/096120339500400207; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; DEUTSCHER SL, 1988, P NATL ACAD SCI USA, V85, P9479, DOI 10.1073/pnas.85.24.9479; DORNER T, 1995, ANN RHEUM DIS, V54, P904, DOI 10.1136/ard.54.11.904; FURUKAWA F, 1988, J IMMUNOL, V141, P1480; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; HO SY, 1986, AM J CARDIOL, V58, P291, DOI 10.1016/0002-9149(86)90064-0; Hoerter J A, 1982, Adv Myocardiol, V3, P373; HUYNH TV, 1992, CIRC RES, V70, P508, DOI 10.1161/01.RES.70.3.508; LEE LA, 1983, ANN INTERN MED, V99, P592, DOI 10.7326/0003-4819-99-5-592; Li JM, 1996, CLIN EXP IMMUNOL, V104, P388; MAYLIE JG, 1982, AM J PHYSIOL, V242, pH834, DOI 10.1152/ajpheart.1982.242.5.H834; Mazel JA, 1999, CIRCULATION, V99, P1914, DOI 10.1161/01.CIR.99.14.1914; Miranda ME, 1998, J IMMUNOL, V161, P5061; Miranda-Carus ME, 1998, J IMMUNOL, V161, P5886; Qu YX, 2000, CARDIOVASC RES, V45, P866, DOI 10.1016/S0008-6363(99)00402-2; RENGASAMY A, 1985, BIOCHEM BIOPH RES CO, V126, P1, DOI 10.1016/0006-291X(85)90563-7; WALTUCK J, 1994, ANN INTERN MED, V120, P544, DOI 10.7326/0003-4819-120-7-199404010-00003; Wang DR, 1999, J CLIN INVEST, V104, P1265, DOI 10.1172/JCI8003; Xiao GQ, 2001, CIRCULATION, V103, P1599	26	28	28	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2001	15	9					1539	1545		10.1096/fj.01-0052com	http://dx.doi.org/10.1096/fj.01-0052com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427485				2022-12-28	WOS:000170318500005
J	Lindstedt, KA; Wang, YF; Shiota, N; Saarinen, J; Hyytiainen, M; Kokkonen, JO; Keski-Oja, J; Kovanen, PT				Lindstedt, KA; Wang, YF; Shiota, N; Saarinen, J; Hyytiainen, M; Kokkonen, JO; Keski-Oja, J; Kovanen, PT			Activation of paracrine TGF-beta 1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase	FASEB JOURNAL			English	Article						recombinant chymase; proteolysis; TGF-beta activation; TGF-beta receptors; gene regulation	GROWTH-FACTOR-BETA; LOW-DENSITY LIPOPROTEINS; NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE-CELLS; LATENT TGF-BETA; EXTRACELLULAR-MATRIX; BINDING-PROTEIN; TRANSFORMING GROWTH-FACTOR-BETA-1; PERICELLULAR MATRIX; ENDOTHELIAL-CELLS	As a source of transforming growth factor beta1 (TGF-beta1), mast cells have been implicated as potential effector cells in many pathological processes. However, the mechanisms by which mast cells express, secrete, and activate TGF-beta1 have remained vague. We show here by means of RT-PCR, immunoblotting, and immunocytochemistry that isolated rat peritoneal mast cells synthesize and store large latent TGF-beta1 in their chymase 1-containing secretory granules. Mast cell stimulation and degranulation results in rapid secretion of the latent TGF-beta1, which is converted by chymase 1 into an active form recognized by the type II TGF-beta serine/threonine kinase receptor (T beta RII). Thus, mast cells secrete active TGF-beta1 by a unique secretory mechanism in which latent TGF-beta1 and the activating enzyme chymase 1 are coreleased. The activation of latent TGF-beta1 specifically by chymase was verified using recombinant human latent TGF-beta1 and recombinant human chymase. In isolated T beta RI- and T beta RII-expressing peritoneal macrophages, the activated TGF-beta1 induces the expression of the plasminogen activator inhibitor 1 (PAI-1), whereas in the mast cells, the levels of T beta RI, T beta RII, and PAI-1 expression were below detection. Selective stimulation of mast cells in vivo in the rat peritoneal cavity leads to rapid overexpression of TGF-beta1 in peritoneal mast cells and of T beta Rs in peritoneal macrophages. These data strongly suggest that mast cells can act as potent paracrine effector cells both by secreting active TGF-beta1 and by enhancing its response in target cells.	Wihuri Res Inst, FIN-00140 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Prot Chem Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland	Wihuri Research Institute; University of Helsinki; University of Helsinki; University of Helsinki	Lindstedt, KA (corresponding author), Wihuri Res Inst, Kalliolinnantie 4, FIN-00140 Helsinki, Finland.	ken.lindstedt@wri.fi						Bissonnette EY, 1997, AM J RESP CELL MOL, V16, P275, DOI 10.1165/ajrcmb.16.3.9070612; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BROIDE DH, 1990, J IMMUNOL, V145, P1838; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Caughey GH, 2000, BBA-PROTEIN STRUCT M, V1480, P245, DOI 10.1016/S0167-4838(00)00076-5; Chandrasekharan UM, 1996, SCIENCE, V271, P502, DOI 10.1126/science.271.5248.502; Chen HX, 1998, J EXP MED, V188, P1657, DOI 10.1084/jem.188.9.1657; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; D'Angelo M, 2001, J BIOL CHEM, V276, P11347, DOI 10.1074/jbc.M009725200; DVORAK AM, 1986, LAB INVEST, V54, P663; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GORDON JR, 1994, J EXP MED, V180, P2027, DOI 10.1084/jem.180.6.2027; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; HEDMAN K, 1979, J CELL BIOL, V81, P83, DOI 10.1083/jcb.81.1.83; IEMURA A, 1994, AM J PATHOL, V144, P321; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; Kanbe N, 1999, CLIN EXP ALLERGY, V29, P105; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KAWAMOTO K, 1995, BLOOD, V86, P4638, DOI 10.1182/blood.V86.12.4638.bloodjournal86124638; KOKKONEN JO, 1985, J BIOL CHEM, V260, P4756; KOKKONEN JO, 1987, P NATL ACAD SCI USA, V84, P2287, DOI 10.1073/pnas.84.8.2287; KOKKONEN JO, 1989, J LIPID RES, V30, P1341; KOVANEN PT, 1993, EUR HEART J, V14, P105; LAWRENCE D, 1985, BIOCHEM BIOPH RES CO, V133, P1026, DOI 10.1016/0006-291X(85)91239-2; LI QY, 1992, TRANSPLANTATION, V53, P1047, DOI 10.1097/00007890-199205000-00015; LINDSTEDT KA, 1992, J LIPID RES, V33, P65; Lindstedt L, 1996, J CLIN INVEST, V97, P2174, DOI 10.1172/JCI118658; LIU MC, 1986, J IMMUNOL, V136, P2588; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; Patella V, 1998, CIRCULATION, V97, P971; PENNINGTON DW, 1992, J CLIN INVEST, V90, P35, DOI 10.1172/JCI115853; Pinxteren JA, 1998, EMBO J, V17, P6210, DOI 10.1093/emboj/17.21.6210; QIAN SW, 1991, CELL REGUL, V2, P241, DOI 10.1091/mbc.2.3.241; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROHLICH P, 1971, J CELL BIOL, V51, P465, DOI 10.1083/jcb.51.2.465; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanker S, 1997, J BIOL CHEM, V272, P2963, DOI 10.1074/jbc.272.5.2963; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SEDGWICK JD, 1981, CLIN EXP IMMUNOL, V45, P409; SEIBOLD JR, 1990, ARTHRITIS RHEUM, V33, P1702, DOI 10.1002/art.1780331114; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sillalber C, 1999, J IMMUNOL, V162, P1032; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; URATA H, 1990, J BIOL CHEM, V265, P22348; WANG YF, 1995, ARTERIOSCL THROM VAS, V15, P801, DOI 10.1161/01.ATV.15.6.801; Yang LJ, 1999, AM J PATHOL, V154, P105, DOI 10.1016/S0002-9440(10)65256-X; Yu Q, 2000, GENE DEV, V14, P163	55	160	173	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1377	1388		10.1096/fj.00-0273com	http://dx.doi.org/10.1096/fj.00-0273com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11387235				2022-12-28	WOS:000169261200005
J	Smith, AR; Visioli, F; Hagen, TM				Smith, AR; Visioli, F; Hagen, TM			Vitamin C matters: increased oxidative stress in cultured human aortic endothelial cells without supplemental ascorbic acid	FASEB JOURNAL			English	Article						vitamin C; human aortic endothelium; tissue culture; nitric oxide	NITRIC-OXIDE SYNTHESIS; PYRIDINE-NUCLEOTIDES; RESISTANCE VESSELS; HYDROGEN-PEROXIDE; ALPHA-TOCOPHEROL; S-NITROSOTHIOLS; FREE-RADICALS; HUMAN PLASMA; GLUTATHIONE; OXYGEN	Because standard culture media for human aortic endothelial cells (HAEC) do not contain vitamin C, we hypothesized that HAEC may be under significant oxidative insult compared with the situation in vivo. To assess parameters of oxidative stress, intracellular vitamin C, glutathione (GSH), GSH/GSSG, and NAD(P)H/NAD(P)(+) ratios, as well as oxidant appearance and oxidative damage, were measured in HAEC with or without vitamin C addition. The effect of vitamin C on eNOS activity was also determined. Results showed that HAEC without vitamin C treatment were essentially scorbutic. On addition of 100 muM vitamin C to the culture media, intracellular vitamin C levels increased and peaked at 6 h. A concomitant increase in the total GSH and the GSH/GSSG ratio was also observed; the NAD(P)H/NAD(P) + ratio increased more slowly over the 24-h time course. Significantly lower (P<0.05) oxidant appearance and steady-state oxidative damage were also observed following vitamin C repletion. Vitamin C treatment increased eNOS activity by 600%. Thus, HAEC are scorbutic under normal culture conditions and exhibit higher oxidative stress than vitamin C repleted cells. Vitamin C supplementation should be considered when using cultured cells, especially when experimental endpoints are related to cellular redox status and eNOS activity.	Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Univ Milan, Dept Pharmacol Sci, I-20122 Milan, Italy	Oregon State University; Oregon State University; University of Milan	Hagen, TM (corresponding author), Oregon State Univ, Linus Pauling Inst, 571 Weniger Hall, Corvallis, OR 97331 USA.	tory.hagen@orst.edu	Visioli, Francesco/AAE-8510-2020; Visioli, Francesco/J-9356-2013	Visioli, Francesco/0000-0002-1756-1723				Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Aust AE, 1999, P SOC EXP BIOL MED, V222, P246, DOI 10.1046/j.1525-1373.1999.d01-141.x; Baker RA, 2001, J CARDIOVASC PHARM, V37, P333, DOI 10.1097/00005344-200103000-00012; Boulares AH, 2000, TOXICOL SCI, V55, P370, DOI 10.1093/toxsci/55.2.370; Brandes RP, 2000, P NATL ACAD SCI USA, V97, P9747, DOI 10.1073/pnas.97.17.9747; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; Burger MS, 2001, ENVIRON MOL MUTAGEN, V38, P1, DOI 10.1002/em.1044; Buyukafsar K, 1999, ACTA MED OKAYAMA, V53, P209; CANESTRARI F, 1994, ACTA HAEMATOL-BASEL, V91, P187; Carr A, 2000, FREE RADICAL BIO MED, V28, P1806, DOI 10.1016/S0891-5849(00)00225-2; Carr AC, 2000, CIRC RES, V87, P349, DOI 10.1161/01.RES.87.5.349; Chepda T, 2001, IN VITRO CELL DEV-AN, V37, P26; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; EK A, 1995, BIOCHEM PHARMACOL, V50, P1339; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FURCHGOTT RF, 1987, BLOOD VESSELS, V24, P145; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; HAGEN TM, 1990, AM J PHYSIOL, V259, pG524; HALLIWELL B, 1999, PROOXIDANT EFFECTS A, P206; Heller R, 1999, J BIOL CHEM, V274, P8254, DOI 10.1074/jbc.274.12.8254; Heller R, 2001, J BIOL CHEM, V276, P40, DOI 10.1074/jbc.M004392200; HENSCHKE PN, 1995, BIOCHEM J, V312, P485, DOI 10.1042/bj3120485; Hoffmann A, 2001, J CELL PHYSIOL, V188, P33, DOI 10.1002/jcp.1092; Hogg N, 2000, FREE RADICAL BIO MED, V28, P1478, DOI 10.1016/S0891-5849(00)00248-3; Huang A, 2000, J BIOL CHEM, V275, P17399, DOI 10.1074/jbc.M002248200; Ischiropoulos H, 1996, FREE RADICAL BIO MED, V20, P373, DOI 10.1016/0891-5849(95)02098-5; Jones DP, 1998, CLIN CHIM ACTA, V275, P175, DOI 10.1016/S0009-8981(98)00089-8; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V365, P92, DOI 10.1006/abbi.1999.1143; Knowles RG, 1998, METH MOL B, V100, P67; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; LUTGERINK JT, 1992, MUTAT RES, V275, P377, DOI 10.1016/0921-8734(92)90040-V; Lynch SM, 1997, ARTERIOSCL THROM VAS, V17, P2975, DOI 10.1161/01.ATV.17.11.2975; Marley R, 2001, FREE RADICAL BIO MED, V31, P688, DOI 10.1016/S0891-5849(01)00627-X; Martin A, 1997, ARTERIOSCL THROM VAS, V17, P1583, DOI 10.1161/01.ATV.17.8.1583; MASAKI H, 1995, BIOCHEM BIOPH RES CO, V206, P474, DOI 10.1006/bbrc.1995.1067; May JM, 2000, FREE RADICAL BIO MED, V28, P1421, DOI 10.1016/S0891-5849(00)00269-0; Messner KR, 1999, J BIOL CHEM, V274, P10119, DOI 10.1074/jbc.274.15.10119; MICHELI V, 1993, CLIN CHIM ACTA, V220, P1, DOI 10.1016/0009-8981(93)90002-L; MONTGOMERY MR, 1991, J TOXICOL ENV HEALTH, V34, P115, DOI 10.1080/15287399109531552; Moon SK, 2001, AM J PHYSIOL-HEART C, V280, pH2779, DOI 10.1152/ajpheart.2001.280.6.H2779; Morgan WA, 1998, TOXICOL LETT, V94, P209, DOI 10.1016/S0378-4274(98)00024-1; MURAD S, 1981, P NATL ACAD SCI-BIOL, V78, P2879, DOI 10.1073/pnas.78.5.2879; Parmentier C, 1999, ELECTROPHORESIS, V20, P2938; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Possel H, 1997, FEBS LETT, V416, P175, DOI 10.1016/S0014-5793(97)01197-6; Puskas F, 2000, FASEB J, V14, P1352, DOI 10.1096/fj.14.10.1352; REBOUCHE CJ, 1991, AM J CLIN NUTR, V54, pS1147, DOI 10.1093/ajcn/54.6.1147s; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Rumsey SC, 2000, J BIOL CHEM, V275, P28246; Sogo N, 2000, BRIT J PHARMACOL, V131, P1236, DOI 10.1038/sj.bjp.0703700; Sogo N, 2000, CLIN PHARMACOL THER, V68, P75, DOI 10.1067/mcp.2000.107049; Taguchi H, 1998, INVEST OPHTH VIS SCI, V39, P358; Vanhoutte PM, 2001, J CLIN INVEST, V107, P23, DOI 10.1172/JCI11832; WAGNER TC, 1994, ANAL BIOCHEM, V222, P417, DOI 10.1006/abio.1994.1511; Wang WH, 2000, J BIOL CHEM, V275, P16899, DOI 10.1074/jbc.M000301200; Zhang ZQ, 2000, ANAL BIOCHEM, V285, P163, DOI 10.1006/abio.2000.4701; ZYCHLINSKI L, 1989, J BIOCHEM TOXICOL, V4, P251, DOI 10.1002/jbt.2570040408	58	61	69	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1102	+		10.1096/fj.01-0825fje	http://dx.doi.org/10.1096/fj.01-0825fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039848				2022-12-28	WOS:000175973900007
J	Sachinidis, A; Skach, RA; Seul, C; Ko, Y; Hescheler, J; Ahn, HY; Fingerle, J				Sachinidis, A; Skach, RA; Seul, C; Ko, Y; Hescheler, J; Ahn, HY; Fingerle, J			Inhibition of the platelet-derived growth factor beta-receptor tyrosine-phosphorylation and its downstream intracellular signal transduction pathway in rat and human vascular smooth muscle cells by different catechins	FASEB JOURNAL			English	Article						catechins; smooth muscle growth; PDGF-R beta; cardiovascular disease	CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASES; OXIDATIVE MODIFICATION; HUMAN GLIOBLASTOMA; FLAVONOID INTAKE; TEA FLAVONOIDS; ATHEROSCLEROSIS; PROLIFERATION; TRANSFORMATION; ANTIOXIDANTS	Abnormal proliferation of vascular smooth muscle cells (VSMC) as well as the platelet-derived growth factor (PDGF) plays an important role in the development of proliferative cardiovascular diseases. In this study, we show that treatment of rat and human aortic VSMC with 50 muM 2- (3,4-dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol (catechin) and epicatechin (EC) fails to inhibit the PDGF-Rbeta-activated intracellular signal transduction pathway and VSMC growth. In contrast, 10-50 muM epigallocatechin-3 gallate (EGCG), epicatechin-3 gallate (ECG), and catechin-3 gallate (CG), which all have a galloyl group in the 3-position of the catechin structure, effectively inhibit tyrosine-phosphorylation of PDGF-R, PI 3'-K, and PLC-gamma1 as well as the PDGF-BB-induced increase in [Ca2+](i). The PDGF-BB-induced increase in DNA synthesis and cell number was inhibited by ECG, EGCG, and CG, but not by catechin and EC. Epigallocatechin (EGC) that has a galloyl group in the 2-position effectively inhibited VSMC growth without affecting the PDGF-Rbeta signal pathway. A reduction of 45% and 70% of the intimal and medial cell number in the S-phase, respectively, has been observed in the catheter-injured left carotid artery 7 days after treatment of Wistar Kyoto rats with 10 mg/day EGCG. These results suggest that the galloyl group in the 3-position of the catechin structure is essential for inhibiting the PDGF-Rbeta-mediated intracellular signal transduction pathway.	Univ Cologne, Ctr Physiol & Pathophysiol, D-50931 Cologne, Germany; Med Univ, Poliklin, D-53111 Bonn, Germany; Chungbuk Natl Univ, Coll Med, Dept Pharmacol, Cheongju 361763, South Korea; Hoffmann La Roche AG, Preclin Pharma Res, Vasc & Metab Dis, CH-4070 Basel, Switzerland	University of Cologne; University of Bonn; University of Hamburg; University Medical Center Hamburg-Eppendorf; Chungbuk National University; Roche Holding	Sachinidis, A (corresponding author), Univ Cologne, Ctr Physiol & Pathophysiol, Robert Koch Str 39, D-50931 Cologne, Germany.	A.Sachinidis@uni-koeln.de	Sachinidis, Agapios/AAD-4178-2020; Sachinidis, Agapios/AAM-7988-2020					Ahn HY, 1999, MOL BIOL CELL, V10, P1093, DOI 10.1091/mbc.10.4.1093; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CLOWES AW, 1983, LAB INVEST, V49, P208; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; Duarte J, 2001, BRIT J PHARMACOL, V133, P117, DOI 10.1038/sj.bjp.0704064; Ferns GAA, 2000, INT J EXP PATHOL, V81, P63, DOI 10.1046/j.1365-2613.2000.00143.x; Geleijnse JM, 1999, ARCH INTERN MED, V159, P2170, DOI 10.1001/archinte.159.18.2170; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Hollman PCH, 1999, FREE RADICAL RES, V31, pS75, DOI 10.1080/10715769900301351; HOPPE J, 1989, BIOCHEMISTRY-US, V28, P2956, DOI 10.1021/bi00433a032; Hu C, 2001, MOL CELL BIOCHEM, V218, P147, DOI 10.1023/A:1007220928446; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; Karim M, 2000, J NUTR, V130, p2105S, DOI 10.1093/jn/130.8.2105S; Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Liang YC, 1999, J CELL BIOCHEM, V75, P1; Liang YC, 1999, CARCINOGENESIS, V20, P733, DOI 10.1093/carcin/20.4.733; Lu LH, 1998, BRIT J PHARMACOL, V124, P1227, DOI 10.1038/sj.bjp.0701912; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIURA S, 1995, BIOL PHARM BULL, V18, P1; MULVANY MJ, 1990, PHYSIOL REV, V70, P921, DOI 10.1152/physrev.1990.70.4.921; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; SACHINIDIS A, 1995, HYPERTENSION, V26, P771, DOI 10.1161/01.HYP.26.5.771; Sachinidis A, 1999, BRIT J PHARMACOL, V128, P1761, DOI 10.1038/sj.bjp.0702969; Sachinidis A, 2000, FEBS LETT, V471, P51, DOI 10.1016/S0014-5793(00)01360-0; SALAH N, 1995, ARCH BIOCHEM BIOPHYS, V322, P339, DOI 10.1006/abbi.1995.1473; Tijburg LBM, 1997, CRIT REV FOOD SCI, V37, P771, DOI 10.1080/10408399709527802	35	62	65	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					893	+		10.1096/fj.01-0799fje	http://dx.doi.org/10.1096/fj.01-0799fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039871				2022-12-28	WOS:000175425900023
J	Pintucci, G; Moscatelli, D; Saponara, F; Biernacki, PR; Baumann, FG; Bizekis, C; Galloway, AC; Basilico, C; Mignatti, P				Pintucci, G; Moscatelli, D; Saponara, F; Biernacki, PR; Baumann, FG; Bizekis, C; Galloway, AC; Basilico, C; Mignatti, P			Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells	FASEB JOURNAL			English	Article						MAPK; wound healing	FIBROBLAST GROWTH-FACTOR; SEX MYOBLAST MIGRATION; PROTEIN-KINASES; SIGNAL; ELEGANS; ROLES	The formation of blood capillaries from preexisting vessels (angiogenesis) and vascular remodeling secondary to atherosclerosis or vessel injury are characterized by endothelial cell migration and proliferation. Numerous growth factors control these cell functions. Basic fibroblast growth factor (FGF-2), a potent angiogenesis inducer, stimulates endothelial cell proliferation, migration, and proteinase production in vitro and in vivo. However, mice genetically deficient in FGF-2 have no apparent vascular defects. We have observed that endothelial cell migration in response to mechanical damage in vitro is accompanied by activation of the extracellular signal-regulated kinase (ERK) pathway, which can be blocked by neutralizing anti-FGF-2 antibodies. Endothelial cells from mice that are genetically deficient in FGF-2 neither migrate nor activate ERK in response to mechanical wounding. Addition of exogenous FGF-2 restores a normal cell response, which shows that impaired migration results from the genetic deficiency of this growth factor. Injury-induced ERK activation in endothelial cells occurs only at the edge of the wound. In addition, FGF-2-induced ERK activation mediates endothelial cell migration in response to wounding without a significant effect on proliferation. These data show that FGF-2 is a key regulator of endothelial cell migration during wound repair.	NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Dept Surg, John HC Ranson Basic Sci Res Lab, New York, NY 10016 USA; NYU, Sch Med, Seymour Cohn Cardiovasc Surg Res Lab, Div Cardiothorac Surg, New York, NY 10016 USA	New York University; New York University; New York University; New York University	Mignatti, P (corresponding author), NYU, Sch Med, Dept Cell Biol, 550 1st Ave, New York, NY 10016 USA.	mignap01@med.nyu.edu		Bizekis, Costas/0000-0001-5763-2306; Galoway, Aubrey/0000-0001-5461-3820; Mignatti, Paolo/0000-0002-8157-457X				Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bogoyevitch MA, 2000, CARDIOVASC RES, V45, P826, DOI 10.1016/S0008-6363(99)00386-7; Burdine RD, 1997, P NATL ACAD SCI USA, V94, P2433, DOI 10.1073/pnas.94.6.2433; Chen EB, 1998, TRENDS GENET, V14, P322, DOI 10.1016/S0168-9525(98)01507-8; Cines DB, 1998, BLOOD, V91, P3527; Cospedal R, 1999, CARDIOVASC RES, V41, P708, DOI 10.1016/S0008-6363(98)00232-6; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; ETTENSON DS, 1995, ARTERIOSCL THROM VAS, V15, P515, DOI 10.1161/01.ATV.15.4.515; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; KLINT P, 1999, FRONT BIOSCI, V4, P165; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meurice T, 1996, CIRCULATION, V93, P18, DOI 10.1161/01.CIR.93.1.18; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; Pintucci G, 1999, SURGERY, V126, P422, DOI 10.1067/msy.1999.99169; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SCHWARTZ SM, 1995, THROMB HAEMOSTASIS, V74, P541; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Zieske JD, 2000, PROG RETIN EYE RES, V19, P257, DOI 10.1016/S1350-9462(99)00018-X; Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231	29	92	102	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					598	+		10.1096/fj.01-0815fje	http://dx.doi.org/10.1096/fj.01-0815fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11919166				2022-12-28	WOS:000174203700008
J	Mato, JM; Corrales, FJ; Lu, SC; Avila, MA				Mato, JM; Corrales, FJ; Lu, SC; Avila, MA			S-adenosylmethionine: a control switch that regulates liver function	FASEB JOURNAL			English	Article						knockout mouse; gene expression; liver injury; hepatocyte proliferation	ADENOSYL-L-METHIONINE; ADENOSYLTRANSFERASE 2A GENE; RAT-LIVER; NONALCOHOLIC STEATOHEPATITIS; NITRIC-OXIDE; DIFFERENTIAL EXPRESSION; GLUTATHIONE SYNTHESIS; CYTOCHROME-P450 2E1; HISTONE ACETYLATION; CRYSTAL-STRUCTURE	Genome sequence analysis reveals that all organisms synthesize S-adenosylmethionine (AdoMet) and that a large fraction of all genes is AdoMet-dependent methyltransferases. AdoMet-dependent methylation has been shown to be central to many biological processes. Up to 85% of all methylation reactions and as much as 48% of methionine metabolism occur in the liver, which indicates the crucial importance of this organ in the regulation of blood methionine. Of the two mammalian genes (MAT1A, MAT2A) that encode methionine adenosyltransferase (MAT, the enzyme that makes AdoMet), MAT1A is specifically expressed in adult liver. It now appears that growth factors, cytokines, and hormones regulate liver MAT mRNA levels and enzyme activity and that AdoMet should not be viewed only as an intermediate metabolite in methionine catabolism, but also as an intracellular control switch that regulates essential hepatic functions such as regeneration, differentiation, and the sensitivity of this organ to injury. The aim of this review is to integrate these recent findings linking AdoMet with liver growth, differentiation, and injury into a comprehensive model. With the availability of AdoMet as a nutritional supplement and evidence of its beneficial role in various liver diseases, this review offers insight into its mechanism of action.	Univ Navarra, Sch Med, Div Hepatol & Gene Therapy, Pamplona 31008, Spain; Univ So Calif, Keck Sch Med,Div Gastrointestinal & Liver Dis, USC Liver Dis Res Ctr, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90033 USA	University of Navarra; University of Southern California	Mato, JM (corresponding author), Univ Navarra, Sch Med, Div Hepatol & Gene Therapy, C Irunlarrea 1, Pamplona 31008, Spain.	jmmato@unav.es	Lu, Shelly/AAH-5937-2021; MATO, JOSE/A-5187-2011; Avila, Matias A/Y-6342-2019	Lu, Shelly/0000-0003-2128-5407; MATO, JOSE/0000-0003-1264-3153; Avila, Matias A/0000-0001-6570-3557; Corrales, Fernando/0000-0002-0231-5159	NIAAA NIH HHS [R0I AA-12677, P50 AA11999] Funding Source: Medline; NIDDK NIH HHS [P30 DK48522, R01 DK45334, R01 DK51719] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051719, P30DK048522, R01DK045334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA011999, R01AA012677] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Alvarez L, 1997, J BIOL CHEM, V272, P22875, DOI 10.1074/jbc.272.36.22875; ALVAREZ L, 1991, FEBS LETT, V290, P142, DOI 10.1016/0014-5793(91)81245-4; Avila MA, 2000, J HEPATOL, V33, P907, DOI 10.1016/S0168-8278(00)80122-1; Avila MA, 1998, GASTROENTEROLOGY, V114, P364, DOI 10.1016/S0016-5085(98)70489-5; Avila MA, 1997, HEPATOLOGY, V25, P391; AVILA MA, 2000, METHIONINE METABOLIS, P91; Best CH, 1932, J PHYSIOL-LONDON, V75, P56, DOI 10.1113/jphysiol.1932.sp002875; CABRERO C, 1988, HEPATOLOGY, V8, P1530, DOI 10.1002/hep.1840080610; Cai JX, 1998, CANCER RES, V58, P1444; Cai JX, 1996, HEPATOLOGY, V24, P1090; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; Castro C, 1999, FEBS LETT, V459, P319, DOI 10.1016/S0014-5793(99)01267-3; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Chou JY, 2000, PHARMACOL THERAPEUT, V85, P1, DOI 10.1016/S0163-7258(99)00047-9; COOK RJ, 1989, J NUTR, V119, P612, DOI 10.1093/jn/119.4.612; Corrales FJ, 1999, J HEPATOL, V31, P887, DOI 10.1016/S0168-8278(99)80291-8; DAI Y, 1993, BIOCHEMISTRY-US, V32, P6928, DOI 10.1021/bi00078a017; del Pino MMS, 2000, J BIOL CHEM, V275, P23476, DOI 10.1074/jbc.M002730200; Diehl AM, 1999, SEMIN LIVER DIS, V19, P221, DOI 10.1055/s-2007-1007111; Downward J, 2001, NATURE, V411, P759, DOI 10.1038/35081138; Enriquez A, 1999, BIOCHEM BIOPH RES CO, V255, P300, DOI 10.1006/bbrc.1999.0202; Finkelstein JD, 2000, NUTR REV, V58, P193, DOI 10.1111/j.1753-4887.2000.tb01862.x; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FINKELSTEIN JD, 1984, BIOCHEM BIOPH RES CO, V118, P14, DOI 10.1016/0006-291X(84)91060-X; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; Fu ZJ, 1996, J BIOMOL STRUCT DYN, V13, P727, DOI 10.1080/07391102.1996.10508887; GARCEA R, 1989, CANCER RES, V49, P1850; Garcia-Trevijano ER, 2000, FASEB J, V14, P2511, DOI 10.1096/fj.00-0121com; Gil B, 1997, ENDOCRINOLOGY, V138, P1251, DOI 10.1210/en.138.3.1251; Gil B, 1996, HEPATOLOGY, V24, P876; Gonzalez B, 2000, J MOL BIOL, V300, P363, DOI 10.1006/jmbi.2000.3858; Halim AB, 1999, J BIOL CHEM, V274, P29720, DOI 10.1074/jbc.274.42.29720; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hiroki T, 1997, EUR J BIOCHEM, V250, P653, DOI 10.1111/j.1432-1033.1997.00653.x; HOROWITZ JH, 1981, GASTROENTEROLOGY, V81, P668; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; Kato A, 1998, BIOCHEM BIOPH RES CO, V245, P70, DOI 10.1006/bbrc.1998.8377; KINSELL LW, 1947, SCIENCE, V106, P589, DOI 10.1126/science.106.2763.589; Kono H, 1999, AM J PHYSIOL-GASTR L, V277, pG1259, DOI 10.1152/ajpgi.1999.277.6.G1259; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; KUTZBACH C, 1967, BIOCHIM BIOPHYS ACTA, V139, P217, DOI 10.1016/0005-2744(67)90140-4; KUTZBACH C, 1971, BIOCHIM BIOPHYS ACTA, V250, P459, DOI 10.1016/0005-2744(71)90247-6; LATASA MU, 2001, FASEB J         0305; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; LeGros HL, 1997, J BIOL CHEM, V272, P16040, DOI 10.1074/jbc.272.25.16040; LeGros HL, 2000, J BIOL CHEM, V275, P2359, DOI 10.1074/jbc.275.4.2359; LeGros L, 2001, J BIOL CHEM, V276, P24918, DOI 10.1074/jbc.M102816200; Lieber CS, 1999, J HEPATOL, V30, P1155, DOI 10.1016/S0168-8278(99)80274-8; Lieber CS, 1997, PHYSIOL REV, V77, P517, DOI 10.1152/physrev.1997.77.2.517; Lieber CS, 2000, ANNU REV NUTR, V20, P395, DOI 10.1146/annurev.nutr.20.1.395; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Lu SC, 2001, P NATL ACAD SCI USA, V98, P5560, DOI 10.1073/pnas.091016398; LU SC, 2000, J PHYSL, V379, pG178; Mao ZB, 1998, BIOCHEM BIOPH RES CO, V248, P479, DOI 10.1006/bbrc.1998.8965; Mari R, 2000, J BIOL CHEM, V275, P15563; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; MARTINDUCE C, 1988, HEPATOLOGY, V8, P65; Mato IP, 2001, J BIOL CHEM, V276, P13803, DOI 10.1074/jbc.M009017200; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; Mato JM, 1999, J HEPATOL, V30, P1081, DOI 10.1016/S0168-8278(99)80263-3; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MORIMOTO M, 1995, HEPATOLOGY, V21, P1610, DOI 10.1016/0270-9139(95)90466-2; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; MUDD SH, 1962, J BIOL CHEM, V237, P1372; MUDD SH, 2001, IN PRESS J INHERIT M, V24; Newberne P M, 1986, Adv Exp Med Biol, V206, P223; PAJARES MA, 1992, J BIOL CHEM, V267, P17598; PASCALE RM, 1992, CANCER RES, V52, P4979; Perez-Mato I, 1999, J BIOL CHEM, V274, P17075, DOI 10.1074/jbc.274.24.17075; Rai RM, 1998, P NATL ACAD SCI USA, V95, P13829, DOI 10.1073/pnas.95.23.13829; Ruiz F, 1998, HEPATOLOGY, V28, P1051, DOI 10.1002/hep.510280420; SanchezGongora E, 1997, FASEB J, V11, P1013, DOI 10.1096/fasebj.11.12.9337154; SanchezGongora E, 1996, BIOCHEM J, V319, P767, DOI 10.1042/bj3190767; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; ShimizuSaito K, 1997, HEPATOLOGY, V26, P424, DOI 10.1002/hep.510260224; SHIVAPURKAR N, 1983, CARCINOGENESIS, V4, P1051, DOI 10.1093/carcin/4.8.1051; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; TONETTI M, 1999, AJ243721 GENB; Torres L, 2000, INT J BIOCHEM CELL B, V32, P397, DOI 10.1016/S1357-2725(99)00140-5; Torres L, 2000, FASEB J, V14, P95, DOI 10.1096/fasebj.14.1.95; Tsukamoto H, 2001, FASEB J, V15, P1335, DOI 10.1096/fj.00-0650rev; WAGNER C, 1998, METHIONINE METABOLIS, P35; Weltman MD, 1998, HEPATOLOGY, V27, P128, DOI 10.1002/hep.510270121; Wu DF, 1996, J BIOL CHEM, V271, P23914, DOI 10.1074/jbc.271.39.23914; Yang HP, 2001, FASEB J, V15, P1507, DOI 10.1096/fj.01-0040com; Yang HP, 2001, AM J PHYSIOL-GASTR L, V280, pG184; Yang J, 2001, CANCER RES, V61, P4010; Yoshida Y, 1999, J BIOL CHEM, V274, P16933, DOI 10.1074/jbc.274.24.16933; ZENG Z, 1999, BIOCHEM J, V346, P475; Zeng ZH, 2001, BIOCHEM J, V353, P163, DOI 10.1042/bj3530163	96	333	357	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					15	26		10.1096/fj.01-0401rev	http://dx.doi.org/10.1096/fj.01-0401rev			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11772932				2022-12-28	WOS:000173656600003
J	Rosenfeldt, HM; Hobson, JP; Maceyka, M; Olivera, A; Nava, VE; Milstien, S; Spiegel, S				Rosenfeldt, HM; Hobson, JP; Maceyka, M; Olivera, A; Nava, VE; Milstien, S; Spiegel, S			EDG-1 links the PDGF receptor to Src and focal adhesion kinase activation leading to lamellipodia formation and cell migration	FASEB JOURNAL			English	Article						sphingosine-1-phosphate; motility; Src; FAK	PROTEIN-COUPLED RECEPTORS; HUMAN ENDOTHELIAL-CELLS; AIRWAY SMOOTH-MUSCLE; SPHINGOSINE 1-PHOSPHATE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; LYSOPHOSPHATIDIC ACID; FAMILY KINASES; DEFICIENT MICE	Sphingosine-1-phosphate (SPP), formed by sphingosine kinase, is the ligand for EDG-1, a GPCR important for cell migration and vascular maturation. Here we show that cytoskeletal rearrangements, lamel-lipodia extensions, and cell motility induced by platelet-derived growth factor (PDGF) are abrogated in EDG-1 null fibroblasts. However, EDG-1 appears to be dispensable for mitogenicity and survival effects, even those induced by its ligand SPP and by PDGF. Furthermore, PDGF induced focal adhesion formation and activation of FAK, Src, and stress-activated protein kinase 2, p38, were dysregulated in the absence of EDG-1. In contrast, tyrosine phosphorylation of the PDGFR and activation of extracellular signal regulated kinase (ERK1/2), important for growth and survival, were unaltered. Our results suggest that EDG-1 functions as an integrator linking the PDGFR to lamel-lipodia extension and cell migration. PDGF, which stimulates sphingosine kinase, leading to increased SPP levels in many cell types, also induces translocation of sphingosine kinase to membrane ruffles. Hence, recruitment of sphingosine kinase to the cell's leading edge and localized formation of SPP may spatially and temporally stimulate EDG-1, resulting in activation and integration of downstream signals important for directional movement toward chemoattractants, such as PDGF. These results may also shed light on the vital role of EDG-1 in vascular maturation.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; NIMH, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Spiegel, S (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, W226A Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	spiegel@bc.georgetown.edu	Maceyka, Michael/B-9277-2008		NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880, R37GM043880] Funding Source: NIH RePORTER; NCI NIH HHS [2P30-CA-51008] Funding Source: Medline; NIGMS NIH HHS [GM43880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Cary LA, 1996, J CELL SCI, V109, P1787; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Edsall LC, 1997, J NEUROSCI, V17, P6952; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Goetzl EJ, 2001, PROSTAG OTH LIPID M, V64, P11, DOI 10.1016/S0090-6980(01)00104-6; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hisano N, 1999, BLOOD, V93, P4293, DOI 10.1182/blood.V93.12.4293.412k26_4293_4299; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264-6021:3480071; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Lee OH, 2000, BIOCHEM BIOPH RES CO, V268, P47, DOI 10.1006/bbrc.2000.2087; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Ohmori T, 2001, J BIOL CHEM, V276, P5274, DOI 10.1074/jbc.M005405200; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Rani CSS, 1997, J BIOL CHEM, V272, P10777; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wang F, 1999, EXP CELL RES, V247, P17, DOI 10.1006/excr.1998.4327; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	64	135	138	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					2649	2659		10.1096/fj.01-0523com	http://dx.doi.org/10.1096/fj.01-0523com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726541				2022-12-28	WOS:000172964800035
J	Obrosova, IG; Van Huysen, C; Fathallah, L; Cao, XH; Greene, DA; Stevens, MJ				Obrosova, IG; Van Huysen, C; Fathallah, L; Cao, XH; Greene, DA; Stevens, MJ			An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense	FASEB JOURNAL			English	Review						diabetic neuropathy; NAD(+)/NADH ratio; nerve blood flow; nerve conduction; oxidative stress; reversal	PROTEIN-KINASE-C; ENDONEURIAL BLOOD-FLOW; ALPHA-LIPOIC ACID; NICOTINAMIDE-ADENINE DINUCLEOTIDE; DORSAL-ROOT GANGLIA; CONDUCTION-VELOCITY; ENERGY-METABOLISM; SCIATIC-NERVE; SORBITOL DEHYDROGENASE; OXIDATIVE STRESS	Aldose reductase inhibitors (ARIs) prevent peripheral nerve dysfunction and morphological abnormalities in diabetic animal models. However, some experimental intervention studies and clinical trials of ARIs on diabetic neuropathy appeared disappointing because of either 1) their inadequate design and, in particular, insufficient correction of the sorbitol pathway activity or 2) the inability to reverse established functional and metabolic deficits of diabetic neuropathy by AR inhibition in general. We evaluated whether diabetes-induced changes in nerve function, metabolism, and antioxidative defense are corrected by the dose of ARI (sorbinil, 65 mg/kg/d in the diet), resulting in complete inhibition of increased sorbitol pathway activity. The groups included control rats and streptozotocin-diabetic rats treated with/without ARI for 2 weeks after 4 weeks of untreated diabetes. ARI treatment corrected diabetes-induced nerve functional changes; that is, decrease in endoneurial nutritive blood flow, motor and sensory nerve conduction velocities, and metabolic abnormalities (i.e., mitochondrial and cytosolic NAD(+)/NADH redox imbalances and energy deficiency). ARI restored nerve concentrations of two major non-enzymatic antioxidants, reduced glutathione (GSH) and ascorbate, and completely arrested diabetes-induced lipid peroxidation. In conclusion, treatment with adequate doses of ARIs (that is, doses that completely inhibit increased sorbitol pathway activity) is an effective approach for reversal of, at least, early diabetic neuropathy.	Univ Michigan, Med Ctr, Dept Internal Med, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA; Vet Adm Med Ctr, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Obrosova, IG (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Endocrinol & Metab, 1150 W Med Ctr Dr,MSRB 2,Room 5570, Ann Arbor, MI 48109 USA.	iobrosso@umich.edu						[Anonymous], 1995, ANN INTERN MED, V122, P561, DOI 10.7326/0003-4819-122-8-199504150-00001; Ashizawa N, 1997, JPN J PHARMACOL, V73, P133, DOI 10.1254/jjp.73.133; BertiMattera L, 1996, METABOLISM, V45, P320, DOI 10.1016/S0026-0495(96)90285-1; BRAVENBOER B, 1992, DIABETOLOGIA, V35, P813, DOI 10.1007/BF00399926; BRISMAR T, 1981, ACTA PHYSIOL SCAND, V112, P495, DOI 10.1111/j.1748-1716.1981.tb06851.x; BRISMAR T, 1993, J PHYSIOL-LONDON, V460, P365, DOI 10.1113/jphysiol.1993.sp019476; BRUBACHER G, 1974, CLIN BIOCH PRINCIPLE, V2, P989; CALCUTT NA, 1994, EUR J PHARMACOL, V251, P27, DOI 10.1016/0014-2999(94)90439-1; Calcutt NA, 1998, METABOLISM, V47, P650, DOI 10.1016/S0026-0495(98)90025-7; CAMERON NE, 1992, EXP PHYSIOL, V77, P89, DOI 10.1113/expphysiol.1992.sp003585; Cameron NE, 1996, J DIABETES COMPLICAT, V10, P43, DOI 10.1016/1056-8727(94)00076-X; Cameron NE, 1999, DIABETOLOGIA, V42, P1120, DOI 10.1007/s001250051280; CAMERON NE, 1994, DIABETOLOGIA, V37, P651, DOI 10.1007/s001250050160; CAMERON NE, 1994, DIABETOLOGIA, V37, P449, DOI 10.1007/s001250050131; Cameron NE, 1997, DIABETOLOGIA, V40, P271, DOI 10.1007/s001250050674; CAMERON NE, 1986, DIABETOLOGIA, V29, P168, DOI 10.1007/BF02427088; Cameron NE, 1996, METABOLISM, V45, P1147, DOI 10.1016/S0026-0495(96)90015-3; COTTER M, 1989, Q J EXP PHYSIOL CMS, V74, P65, DOI 10.1113/expphysiol.1989.sp003240; Cotter MA, 1998, J PERIPHER NERV SYST, V3, P217; Dewhurst M, 1997, BRIT J PHARMACOL, V120, P593, DOI 10.1038/sj.bjp.0700946; DIEMEL LT, 1992, NEUROSCI LETT, V137, P253, DOI 10.1016/0304-3940(92)90416-5; Erdelmeier I, 1998, CHEM RES TOXICOL, V11, P1184, DOI 10.1021/tx970180z; Giardino I, 1996, J CLIN INVEST, V97, P1422, DOI 10.1172/JCI118563; Greene DA, 1999, NEUROLOGY, V53, P580, DOI 10.1212/WNL.53.3.580; GUPTA S, 2001, IN PRESS AM J PHYSL; Heesom AE, 1998, J NEUROL NEUROSUR PS, V64, P213, DOI 10.1136/jnnp.64.2.213; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; HO ECM, 2000, J PERIPHER NERV SYST, V5, P169; Hohman T. C., 1997, Diabetologia, V40, pA549; Hotta N, 1996, DIABETES, V45, P361, DOI 10.2337/diabetes.45.3.361; Hotta N, 1996, J PHARMACOL EXP THER, V276, P49; Hounsom L, 1998, DIABETOLOGIA, V41, P839, DOI 10.1007/s001250050996; Ido Y, 1996, DIABETOLOGIA, V39, P943; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; Ishii H, 1998, DIABETOLOGIA, V41, P362, DOI 10.1007/s001250050916; Ito M, 1998, EUR J PHARMACOL, V354, P189, DOI 10.1016/S0014-2999(98)00448-8; Ito T, 1997, DIABETES RES CLIN PR, V36, P161, DOI 10.1016/S0168-8227(97)00046-6; Kalichman MW, 1998, BRAIN RES, V810, P130, DOI 10.1016/S0006-8993(98)00898-1; Kalichman MW, 1998, ACTA NEUROPATHOL, V95, P47, DOI 10.1007/s004010050764; KAMIJO M, 1994, DIABETES RES CLIN PR, V25, P117, DOI 10.1016/0168-8227(94)90037-X; KARASU C, 1995, DIABETOLOGIA, V38, P129, DOI 10.1007/s001250050262; Kato N, 2000, DIABETES RES CLIN PR, V50, P77, DOI 10.1016/S0168-8227(00)00164-9; KIHARA M, 1994, AM J PHYSIOL, V266, pE980, DOI 10.1152/ajpendo.1994.266.6.E980; KIHARA M, 1991, P NATL ACAD SCI USA, V88, P6107, DOI 10.1073/pnas.88.14.6107; Kilic F, 1999, EXP EYE RES, V69, P291, DOI 10.1006/exer.1999.0697; KIM J, 1991, DIABETES, V40, P1545, DOI 10.2337/diabetes.40.11.1545; Kishi Y, 1999, DIABETES, V48, P2045, DOI 10.2337/diabetes.48.10.2045; Kurata C, 1997, J NUCL MED, V38, P1677; Kuruvilla R, 1998, J NEUROCHEM, V71, P775; Lee AYW, 1999, FASEB J, V13, P23, DOI 10.1096/fasebj.13.1.23; Love A, 1996, EUR J CLIN INVEST, V26, P698, DOI 10.1111/j.1365-2362.1996.tb02156.x; LOW PA, 1988, EXP NEUROL, V99, P201, DOI 10.1016/0014-4886(88)90139-2; LOW PA, 1985, AM J PHYSIOL, V248, pE457, DOI 10.1152/ajpendo.1985.248.4.E457; LOWITT S, 1995, METABOLISM, V44, P677, DOI 10.1016/0026-0495(95)90128-0; MASUDA T, 1990, J BIOL CHEM, V265, P20321; MCMANIS PG, 1986, AM J PHYSIOL, V251, pE92, DOI 10.1152/ajpendo.1986.251.1.E92; Mizisin AP, 1997, DIABETES, V46, P647, DOI 10.2337/diabetes.46.4.647; Mizuno K, 1999, J DIABETES COMPLICAT, V13, P141, DOI 10.1016/S1056-8727(99)00038-0; MIZUNO K, 1992, METABOLISM, V41, P1081, DOI 10.1016/0026-0495(92)90289-M; NAGAMATSU M, 1995, DIABETES CARE, V18, P1160, DOI 10.2337/diacare.18.8.1160; Nakamura J, 1999, DIABETES, V48, P2090, DOI 10.2337/diabetes.48.10.2090; Nishikawa T, 2000, KIDNEY INT, V58, pS26, DOI 10.1046/j.1523-1755.2000.07705.x; NUKADA H, 1992, J NEUROPATH EXP NEUR, V51, P523, DOI 10.1097/00005072-199209000-00007; Oates, 1999, Expert Opin Investig Drugs, V8, P2095, DOI 10.1517/13543784.8.12.2095; Obrosova I, 1998, DIABETOLOGIA, V41, P1442, DOI 10.1007/s001250051090; Obrosova IG, 1999, INVEST OPHTH VIS SCI, V40, P680; Obrosova IG, 1999, DIABETOLOGIA, V42, P1187, DOI 10.1007/s001250051290; Obrosova IG, 2000, OXIDAT STRESS DIS, V4, P93; Obrosova IG, 2000, FASEB J, V14, P1548, DOI 10.1096/fj.14.11.1548; Obrosova IG, 2000, DIABETOLOGIA, V43, P1048, DOI 10.1007/s001250051488; Ohi T, 1998, EXP NEUROL, V151, P215, DOI 10.1006/exnr.1998.6821; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; Patel J, 1999, MUSCLE NERVE, V22, P1403, DOI 10.1002/(SICI)1097-4598(199910)22:10<1403::AID-MUS10>3.0.CO;2-Z; Pfeifer MA, 1997, DIABETES, V46, pS82, DOI 10.2337/diab.46.2.S82; Pop-Busui R, 2001, EXP NEUROL, V168, P259, DOI 10.1006/exnr.2000.7591; Raccah D, 1998, J DIABETES COMPLICAT, V12, P154, DOI 10.1016/S1056-8727(97)00093-7; Ryle C, 1997, MUSCLE NERVE, V20, P577, DOI 10.1002/(SICI)1097-4598(199705)20:5<577::AID-MUS6>3.0.CO;2-6; Sagara M, 1996, DIABETOLOGIA, V39, P263; Sasaki H, 1997, ACTA NEUROPATHOL, V93, P118, DOI 10.1007/s004010050592; SCHMIDT RE, 1989, DIABETES, V38, P569, DOI 10.2337/diabetes.38.5.569; Sima AAF, 1999, DIABETOLOGIA, V42, P773, DOI 10.1007/s001250051227; SREDY J, 1991, P SOC EXP BIOL MED, V197, P135; STEVENS EJ, 1994, J PHYSIOL-LONDON, V475P, pP68; STEVENS MJ, 1993, DIABETOLOGIA, V36, P608, DOI 10.1007/BF00404069; Stevens MJ, 2000, DIABETES, V49, P1006, DOI 10.2337/diabetes.49.6.1006; Tomlinson DR, 1999, DIABETOLOGIA, V42, P1271, DOI 10.1007/s001250051439; TOMLINSON DR, 1984, DIABETES, V33, P470, DOI 10.2337/diabetes.33.5.470; TOMLINSON DR, 1982, NEUROSCI LETT, V31, P189, DOI 10.1016/0304-3940(82)90115-X; Tomlinson DR, 1998, DIABETIC MED, V15, P579, DOI 10.1002/(SICI)1096-9136(199807)15:7<579::AID-DIA633>3.3.CO;2-X; TUCK RR, 1984, BRAIN, V107, P935, DOI 10.1093/brain/107.3.935; van Dam PS, 1999, EUR J PHARMACOL, V376, P217, DOI 10.1016/S0014-2999(99)00376-3; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; Vinik Aaron I., 1999, American Journal of Medicine, V107, p17S; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; Yagihashi S, 1996, DIABETES, V45, P56, DOI 10.2337/diabetes.45.1.56; YAN SD, 1994, J BIOL CHEM, V269, P9889; YASUDA H, 1989, DIABETES, V38, P832, DOI 10.2337/diabetes.38.7.832; YIM HS, 1995, J BIOL CHEM, V270, P28228; ZATECHKA DS, 2000, EXP EYE RES, V71, pS42; ZHANG WX, 1990, DIABETES, V39, P613, DOI 10.2337/diabetes.39.5.613; ZOLLMAN PJ, 1991, EXP NEUROL, V114, P315, DOI 10.1016/0014-4886(91)90157-8	103	165	175	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					123	+		10.1096/fj.01-0603fje	http://dx.doi.org/10.1096/fj.01-0603fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11709499	Green Submitted			2022-12-28	WOS:000172420500032
J	Sauer, H; Klimm, B; Hescheler, J; Wartenberg, M				Sauer, H; Klimm, B; Hescheler, J; Wartenberg, M			Activation of p90RSK and growth stimulation of multicellular tumor spheroids are dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP	FASEB JOURNAL			English	Article						mitogen-activated protein kinase; suramin; radical scavengers	CYTOSOLIC PHOSPHOLIPASE A(2); SMOOTH-MUSCLE CELLS; RIBOSOMAL S6 KINASE; PROTEIN-KINASE; EXTRACELLULAR ATP; HYDROGEN-PEROXIDE; FREE-RADICALS; SIGNAL-TRANSDUCTION; REDOX-REGULATION; MESANGIAL CELLS	Mitogenic stimulation by growth factors may be mediated through intracellular reactive oxygen species (ROS) acting as signaling molecules. Incubation of multicellular prostate tumor spheroids with adenosine 5' triphosphate (ATP) dose-dependently stimulated tumor growth. ATP, uridine 5'-triphosphate (UTP), adenosine 5'-diphosphate (ADP), and 2-methylthio-ATP (2-MeS-ATP) increased intracellular ROS levels significantly. ROS generation by ATP was inhibited by the P-2 receptor antagonist suramin, by the reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitors diphenylene iodonium chloride (DPI) and 4-(2-aminoethyl) benzenesulfonylfluoride (AEBSF), as well as by the Ca2+-dependent phospholipase A(2) (PLA(2)) inhibitors indomethacin and methyl arachidonyl fluorophosphonate (MAFP). The generation of ROS was dependent on the intracellular Ca2+ response evoked by ATP. Exogenous ATP activated the extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) pathway, which was blunted by the MAPK/ERK kinase 1/2 (MEK1/2) antagonist PD98059. The radical scavengers vitamin E, dimethyl thiourea (DMTU), and N-acetyl cysteine (NAC) failed to inhibit ERK1/2 activation but abolished p90 ribosomal S6 kinase (p90RSK) activation downstream of ERK1/2, as well as the growth stimulation of tumor spheroids. Our data indicate that p90RSK downstream of ERK1/2 is the molecular target for ROS generated through stimulation of purinergic receptors by ATP.	Univ Cologne, Dept Neurophysiol, D-50931 Cologne, Germany	University of Cologne	Wartenberg, M (corresponding author), Univ Cologne, Dept Neurophysiol, Robert Koch Str 39, D-50931 Cologne, Germany.	mw@physiologie.uni-koeln.de						Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bestilny LJ, 2000, EXP CELL RES, V256, P264, DOI 10.1006/excr.2000.4821; BURDON RH, 1989, FREE RADICAL RES COM, V6, P345, DOI 10.3109/10715768909087918; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; Dichmann S, 2000, BLOOD, V95, P973, DOI 10.1182/blood.V95.3.973.003k47_973_978; Dixon CJ, 1997, BRIT J CANCER, V75, P34, DOI 10.1038/bjc.1997.6; Dixon CJ, 1999, BRIT J PHARMACOL, V127, P1680, DOI 10.1038/sj.bjp.0702653; Erlinge D, 1998, GEN PHARMACOL-VASC S, V31, P1, DOI 10.1016/S0306-3623(97)00420-5; FANG WG, 1992, J CLIN INVEST, V89, P191, DOI 10.1172/JCI115562; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; FRENKEL K, 1991, FREE RADICAL RES COM, V12-3, P783, DOI 10.3109/10715769109145860; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; Harada H, 2000, KIDNEY INT, V57, P949, DOI 10.1046/j.1523-1755.2000.00911.x; Harper S, 1998, BRIT J PHARMACOL, V124, P703, DOI 10.1038/sj.bjp.0701895; Hazan I, 1997, BIOCHEM J, V326, P867, DOI 10.1042/bj3260867; Janssens R, 2001, BRIT J PHARMACOL, V132, P536, DOI 10.1038/sj.bjp.0703833; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; Nakamura E, 2000, AM J PHYSIOL-CELL PH, V279, pC510, DOI 10.1152/ajpcell.2000.279.2.C510; Neary JT, 1999, J NEUROSCI, V19, P4211, DOI 10.1523/jneurosci.19-11-04211.1999; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Ruiz-Gines JA, 2000, J CARDIOVASC PHARM, V35, P109, DOI 10.1097/00005344-200001000-00014; Sauer H, 1997, FEBS LETT, V419, P201, DOI 10.1016/S0014-5793(97)01456-7; Sauer H, 2000, AM J PHYSIOL-CELL PH, V279, pC295, DOI 10.1152/ajpcell.2000.279.2.C295; Sauer H, 1999, FREE RADICAL BIO MED, V27, P1276, DOI 10.1016/S0891-5849(99)00164-1; SCHULZELOHOFF E, 1992, AM J PHYSIOL, V263, pF374, DOI 10.1152/ajprenal.1992.263.3.F374; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tu MT, 2000, BRIT J PHARMACOL, V129, P1481, DOI 10.1038/sj.bjp.0703182; Wagstaff SC, 2000, CARCINOGENESIS, V21, P2175, DOI 10.1093/carcin/21.12.2175; Wartenberg M, 1999, J BIOL CHEM, V274, P27759, DOI 10.1074/jbc.274.39.27759; Wartenberg M, 2000, INT J CANCER, V85, P267, DOI 10.1002/(SICI)1097-0215(20000115)85:2<267::AID-IJC19>3.0.CO;2-H; Wartenberg M, 2001, J BIOL CHEM, V276, P17420, DOI 10.1074/jbc.M100141200; Wever RMF, 1997, BIOCHEM BIOPH RES CO, V237, P340, DOI 10.1006/bbrc.1997.7069; Wilden PA, 1998, AM J PHYSIOL-HEART C, V275, pH1209, DOI 10.1152/ajpheart.1998.275.4.H1209; Yu SM, 1996, MOL PHARMACOL, V50, P1000; Zafari AM, 1999, ANTIOXID REDOX SIGN, V1, P167, DOI 10.1089/ars.1999.1.2-167	42	52	53	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					2539	+		10.1096/fj.01-0360fje	http://dx.doi.org/10.1096/fj.01-0360fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11641267				2022-12-28	WOS:000171372700028
J	Hu, VW; Heikka, DS; Dieffenbach, PB; Ha, L				Hu, VW; Heikka, DS; Dieffenbach, PB; Ha, L			Metabolic radiolabeling: experimental tool or Trojan horse? S-35-Methionine induces DNA fragmentation and p53-dependent ROS production	FASEB JOURNAL			English	Article						metabolic labeling; radioisotopes; DNA fragmentation; reactive oxygen species; p53	MAMMALIAN-CELLS; SIGNAL-TRANSDUCTION; GROWTH ARREST; RADIATION; APOPTOSIS	Despite the general assumption that widely used radiolabeled metabolites such as [S-35] methionine and H-3-thymidine do not adversely affect or perturb cell function, we and others have shown that such low-energy beta -emitters can cause cell cycle arrest and apoptosis of proliferating cells. The goal of the present study was to elucidate the targets and mechanisms of [S-35] methionine-induced cellular toxicity. Comet analyses (single-cell electrophoresis) demonstrated dose-dependent DNA fragmentation in rabbit smooth muscle cells within a time frame (1-4 h) well within that of most radiolabeling protocols, whereas fluorescence analyses using a peroxide/hydroperoxide-sensitive dye revealed production of reactive oxygen species (ROS). Although ROS generation was inhibitable by antioxidants, DNA fragmentation was not inhibited and was in fact observed even under hypoxic conditions, suggesting that beta -radiation-induced DNA damage can occur independently of ROS formation. Studies with p53(+/+) and p53(-/-) human colorectal carcinoma cells further demonstrated the dissociation of early DNA damage from ROS formation in that both cell types exhibited DNA fragmentation in response to radiolabeling whereas only the p53(+/+) cells exhibited significant increases in ROS formation, which occurred well after significant DNA damage was observed. These findings demonstrate that metabolically incorporated low-energy beta -emitters such as [S-35] methionine and H-3-thymidine can induce DNA damage, thereby initiating cellular responses leading to cell cycle arrest or apoptosis. The results of this study require a reevaluation using low-energy beta -emitters to follow not only experimental protocols in vivo processes, but also acceptable exposure levels of these genotoxic compounds in the workplace and environment.	George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Washington, DC 20037 USA	George Washington University	Hu, VW (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, 2300 Eye St NW,Ross Hall 526, Washington, DC 20037 USA.	bcmvwh@gwumc.edu		Hu, Valerie/0000-0002-3357-0777				Bond JA, 1999, ONCOGENE, V18, P3788, DOI 10.1038/sj.onc.1202733; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; DOVER R, 1994, J CELL SCI, V107, P1181; Hu VW, 2000, FASEB J, V14, P448, DOI 10.1096/fasebj.14.3.448; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; OSTLING O, 1984, BIOCHEM BIOPH RES CO, V123, P291, DOI 10.1016/0006-291X(84)90411-X; POLLARD JW, 1996, PROTEIN PROTOCOLS HD; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RADFORD IR, 1986, INT J RADIAT BIOL, V49, P611; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; SOLARY E, 1992, EXP CELL RES, V203, P495, DOI 10.1016/0014-4827(92)90027-6; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; Yanokura M, 2000, INT J RADIAT BIOL, V76, P295, DOI 10.1080/095530000138637; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	17	31	31	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					1562	1568		10.1096/fj.01-0102com	http://dx.doi.org/10.1096/fj.01-0102com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427488				2022-12-28	WOS:000170318500008
J	Stanford, SJ; Pepper, JR; Burke-Gaffney, A; Mitchell, JA				Stanford, SJ; Pepper, JR; Burke-Gaffney, A; Mitchell, JA			Cytokine-activated human vascular smooth muscle delays apoptosis of neutrophils: Relevance of interactions between cyclo-oxygenase-2 and colony stimulating factors	FASEB JOURNAL			English	Article						colony-stimulating factors; cyclo-oxygenase; vascular smooth muscle cells; neutrophils; apoptosis	GRANULOCYTE-MACROPHAGE-CSF; GM-CSF; ENDOTHELIAL-CELLS; HUMAN ARTERIAL; INTERLEUKIN-1; SURVIVAL; CYCLOOXYGENASE-2; FIBROBLASTS; MODULATION; EXPRESSION	Leukocytes undergo programmed cell death (apoptosis) as part of the normal course of inflammatory responses. The colony stimulating factors (CSF) are important inhibitors of neutrophil apoptosis. We have recently shown that cytokines stimulate human vascular smooth muscle cells (HVSMCs) to release granulocyte macophage-CSF (GM-CSF) and granulocyte-CSF (G-CSF)-like immunoreactivity, and that the inflammatory form of cyclo-oxygenase (COX-2) differentially modulates their release. However, the biological relevance of these observations is not known. here we have measured human neutrophil apoptosis as a bioassay for the activity of authentic GM-CSF and G-CSF, as well as products released by cytokine-stimulated HVSMCs. Furthermore, we have assessed the biological relevance of COX-2 in the production of survival-promoting factors by HVSMCs. We demonstrate that (i) GM-CSF is more potent than G-CSF as an inhibitor of neutrophil apoptosis; (ii) of the two CSF's, the activity of G-CSF released by HVSMCs predominates when cells are stimulated with cytokines; and (iii), this situation is reversed when COX activity is blocked such that GM-CSF becomes the predominant active CSF produced by cells. These observations identify HVSMCs as important modulators of inflammatory and immune responses and identify a setting where COX-2 activity regulated neutrophil survival indirectly via the production of CSFs.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Royal Brompton & Harefield NHS Trust, Crit Care Unit, London SW3 6NP, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Royal Brompton & Harefield NHS Trust, Dept Cardiothorac Surg, London SW3 6NP, England	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital	Mitchell, JA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Royal Brompton & Harefield NHS Trust, Crit Care Unit, Sydney St, London SW3 6NP, England.	j.a.mitchell@ic.ac.uk	Mitchell, Jane A/A-1991-2009					Bishop-Bailey D, 1998, ARTERIOSCL THROM VAS, V18, P1655, DOI 10.1161/01.ATV.18.10.1655; BRACH MA, 1992, BLOOD, V80, P2920; BROUDY VC, 1987, J IMMUNOL, V139, P464; BurkeGaffney A, 1996, AM J PHYSIOL-CELL PH, V270, pC552, DOI 10.1152/ajpcell.1996.270.2.C552; COLOTTA F, 1992, BLOOD, V80, P2012; COX G, 1992, AM J RESP CELL MOL, V7, P507, DOI 10.1165/ajrcmb/7.5.507; Coxon A, 1999, J EXP MED, V190, P923, DOI 10.1084/jem.190.7.923; Daffern PJ, 1999, AM J RESP CELL MOL, V21, P259, DOI 10.1165/ajrcmb.21.2.3605; FIBBE WE, 1988, BLOOD, V72, P860; FLIEDNER TM, 1964, BLOOD, V24, P402, DOI 10.1182/blood.V24.4.402.402; Fortenberry JD, 1998, AM J RESP CELL MOL, V18, P421, DOI 10.1165/ajrcmb.18.3.2875; Hallsworth MP, 1998, AM J RESP CELL MOL, V19, P910, DOI 10.1165/ajrcmb.19.6.3275; HAMILTON JA, 1992, BLOOD, V79, P1413; HASLETT C, 1985, AM J PATHOL, V119, P101; Ina K, 1999, J GASTROEN HEPATOL, V14, P46, DOI 10.1046/j.1440-1746.1999.01807.x; KAWAKAMI M, 1990, BLOOD, V76, P1962; LEE MT, 1990, J LEUKOCYTE BIOL, V47, P275, DOI 10.1002/jlb.47.3.275; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MAUER AM, 1960, J CLIN INVEST, V39, P1481, DOI 10.1172/JCI104167; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Stanford SJ, 2000, ARTERIOSCL THROM VAS, V20, P677, DOI 10.1161/01.ATV.20.3.677; Stanford SJ, 2000, BRIT J PHARMACOL, V129, P835, DOI 10.1038/sj.bjp.0703151; ZSEBO KM, 1988, BLOOD, V71, P99	23	13	13	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1813	+		10.1096/fj.00-0670fje	http://dx.doi.org/10.1096/fj.00-0670fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481239				2022-12-28	WOS:000169261200021
J	Lew, RA; Boulos, E; Stewart, KM; Perlmutter, P; Harte, MF; Bond, S; Reeve, SB; Norman, MU; Lew, MJ; Aguilar, MI; Smith, AI				Lew, RA; Boulos, E; Stewart, KM; Perlmutter, P; Harte, MF; Bond, S; Reeve, SB; Norman, MU; Lew, MJ; Aguilar, MI; Smith, AI			Substrate analogues incorporating beta-amino acids: potential application for peptidase inhibition	FASEB JOURNAL			English	Article						bradykinin; peptidomimetic; peptidase inhibitor; endopeptidase 24.15	ENDOPEPTIDASE EC-3.4.24.15; RAT TESTES; SPECIFICITY; BRADYKININ; STABILITY; ENZYME; TETRAPEPTIDE; ANTAGONISTS; NO	We hypothesize that substitution of alpha-amino acids at or around the scissile bond of a peptide substrate with beta-amino acids (containing an extra carbon in the peptide backbone) will confer resistance to proteolytic cleavage without necessarily abolishing enzyme binding; indeed, such a stabilized analogue may act as a specific inhibitor of the peptidase. To test this possibility, we synthesised a series of beta-amino acid-containing bradykinin analogues and examined their degradation by the soluble metalloendopeptidase EC 3.4.24.15. Inclusion of a beta-amino acid at or near the cleavage site of bradykinin completely prevented degradation by this enzyme. Furthermore, such analogues could still act as competitive inhibitors, with die most potent peptides exhibiting affinities for recombinant EC 3.4.24.15 only 1.5- to 2.5-fold lower than bradykinin itself. Interestingly, these analogues also acted as agonists at the B-2 bradykinin receptor in coronary artery segments, although their potencies were 2-3 orders of magnitude less than the native peptide. In conclusion, substitution of beta-amino acids at the scissile bond can stabilize peptides against hydrolysis with only a moderate decrease in enzyme affinity. Thus, peptidomimetics incorporating beta-amino acids may have utility in the design and development of novel, specific, substrate-based peptidase inhibitors.	Baker Med Res Inst, Melbourne, Vic 8008, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Monash Univ, Dept Chem, Clayton, Vic 3800, Australia; Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia	Baker Heart and Diabetes Institute; Monash University; Monash University; University of Melbourne	Smith, AI (corresponding author), Baker Med Res Inst, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	ian.smith@baker.edu.au	Lew, Rebecca A/C-5454-2008; Lew, Michael/E-1247-2012	Smith, Ian/0000-0002-4143-2892; Lew, Michael/0000-0002-2523-7990; Perlmutter, Patrick/0000-0003-4105-4526; Norman, Maarit/0000-0002-3032-3957				AHMAD S, 1992, P SOC EXP BIOL MED, V200, P115; DANDO PM, 1993, BIOCHEM J, V294, P451, DOI 10.1042/bj2940451; Dendorfer A, 1999, IMMUNOPHARMACOLOGY, V45, P199, DOI 10.1016/S0162-3109(99)00078-8; Gademann K, 1999, ANGEW CHEM INT EDIT, V38, P1223, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1223::AID-ANIE1223>3.0.CO;2-A; Guichard G, 1998, HELV CHIM ACTA, V81, P187, DOI 10.1002/hlca.19980810202; Hintermann T, 1997, CHIMIA, V51, P244; KILPATRICK EV, 1994, BRIT J PHARMACOL, V112, P557, DOI 10.1111/j.1476-5381.1994.tb13110.x; Lew RA, 1996, BRIT J PHARMACOL, V118, P1269, DOI 10.1111/j.1476-5381.1996.tb15533.x; LEW RA, 1995, BIOCHEM BIOPH RES CO, V209, P788, DOI 10.1006/bbrc.1995.1569; Lew RA, 2000, J PEPT SCI, V6, P440, DOI 10.1002/1099-1387(200009)6:9<440::AID-PSC280>3.0.CO;2-K; ONDETTI MA, 1975, J MED CHEM, V18, P761, DOI 10.1021/jm00241a024; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; Poenaru S, 1999, J MED CHEM, V42, P2318, DOI 10.1021/jm981123l; REGOLI D, 1980, PHARMACOL REV, V32, P1; Rioli V, 1998, BIOCHEM BIOPH RES CO, V250, P5, DOI 10.1006/bbrc.1998.8941; RODRIGUEZ M, 1989, J MED CHEM, V32, P522, DOI 10.1021/jm00123a003; Roques BP, 1998, PATHOL BIOL, V46, P191; Scarborough RM, 1999, CURR MED CHEM, V6, P971; Seebach D, 1998, CHIMIA, V52, P734; SHRIMPTON CN, 2000, BIOCHEM J, V345, P341; Vincent B, 1996, BRAIN RES, V709, P51, DOI 10.1016/0006-8993(95)01260-5	21	11	11	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1664	+		10.1096/fj.00-0805fje	http://dx.doi.org/10.1096/fj.00-0805fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427520				2022-12-28	WOS:000173707700002
J	Meyer, MG; Park, S; Zeringue, L; Staley, M; McKinstry, M; Kaufman, RI; Zhang, H; Yan, DL; Yennawar, N; Yennawar, H; Farber, GK; Nixon, BT				Meyer, MG; Park, S; Zeringue, L; Staley, M; McKinstry, M; Kaufman, RI; Zhang, H; Yan, DL; Yennawar, N; Yennawar, H; Farber, GK; Nixon, BT			A dimeric two-component receiver domain inhibits the sigma 54-dependent ATPase in DctD	FASEB JOURNAL			English	Article									Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 6, University Pk, PA 16802 USA; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California Berkeley	Nixon, BT (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 6, University Pk, PA 16802 USA.		ID, IMCACAT/D-5867-2014	Yennawar, Hemant P./0000-0003-2869-1109					0	32	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1326	1328		10.1096/fj.00-0516fje	http://dx.doi.org/10.1096/fj.00-0516fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344129				2022-12-28	WOS:000168655200051
J	Nadeau, S; Rivest, S				Nadeau, S; Rivest, S			The complement system is an integrated part of the natural innate immune response in the brain	FASEB JOURNAL			English	Article						blood-brain barrier; circumventricular organs; infection; neuroinflammation; innate immune recognition; lipopolysaccharide; mice; microglia; septic shock	CENTRAL-NERVOUS-SYSTEM; KAPPA-B ACTIVITY; ANAPHYLATOXIN RECEPTORS; CELLULAR-POPULATIONS; HUMAN MONOCYTES; NUCLEAR-FACTOR; 3RD COMPONENT; C3A RECEPTOR; RAT-BRAIN; LIPOPOLYSACCHARIDE	The complement system consists of a group of proteins that play essential roles in coordinating the host defense to infection. It can be activated by two primary pathways, namely the classical and the alternative. This study aimed to determine the cellular distribution and the regulation of the genes encoding the proteins that are essential in guiding these pathways in the central nervous system (CNS) during innate immune recognition in mice. The results show a low-to-moderate C3 mRNA signal in few nonneuronal structures under basal conditions, whereas a robust C5 expression level was found in numerous populations of neuronal and nonneuronal cells. However, hybridization signal for the gene encoding the anaphylatoxin C5a receptor (C5aR) was low in the brain of vehicle-administered mice. The constitutive C5 mRNA levels remained unaltered during endotoxemia, but a strong and transient de novo expression of the other members of the complement protein family was found in the brain of mice that received a single systemic bolus of lipopolysaccharide (LPS). Indeed, transcriptional activation C3 and factor B genes occurred in the circumventricular organs and a wave of C3aR-expressing cells took place from the regions devoid of blood-brain barrier to deeper brain parenchyma. The C5aR mRNA levels also increased in the cerebral endothelium at 1 h post-LPS challenge, and the signal became gradually positive in microglial cells surrounding the capillaries and thereafter across the brain parenchyma. The present data provide evidence of an elegant pattern of expression and de novo transcription of key members of the complement system in the CNS, which underlies a sophisticated innate immune system that is triggered by circulating cell wall components of gram-negative bacteria.	Univ Laval, CHUL, Res Ctr, Mol Endocrinol Lab, Quebec City, PQ, Canada; Univ Laval, Dept Anat & Physiol, Quebec City, PQ, Canada	Laval University; Laval University	Rivest, S (corresponding author), Univ Laval, CHUL, Res Ctr, Mol Endocrinol Lab, 2705 Boul Laurier, Quebec City, PQ, Canada.	Serge.Rivest@crchul.ulaval.ca		Rivest, Serge/0000-0002-6082-770X				ARDITI M, 1995, J IMMUNOL, V155, P3994; BUCKLIN SE, 1993, INFECT IMMUN, V61, P3184, DOI 10.1128/IAI.61.8.3184-3189.1993; COLTEN HR, 1994, NATURE, V371, P474, DOI 10.1038/371474a0; Elmquist JK, 1997, TRENDS NEUROSCI, V20, P565, DOI 10.1016/S0166-2236(97)01138-7; FABRY Z, 1994, IMMUNOL TODAY, V15, P218, DOI 10.1016/0167-5699(94)90247-X; Fukuoka Y, 1998, BIOCHEM BIOPH RES CO, V242, P663, DOI 10.1006/bbrc.1997.8034; GASQUE P, 1995, J IMMUNOL, V154, P4726; Gasque P, 1998, J IMMUNOL, V160, P3543; Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; HAMILTON AO, 1987, BIOCHEM J, V242, P809, DOI 10.1042/bj2420809; HOGASEN AKM, 1993, J IMMUNOL, V151, P3215; HOGASEN AKM, 1995, J LEUKOCYTE BIOL, V57, P287, DOI 10.1002/jlb.57.2.287; Lacroix S, 1998, BRAIN PATHOL, V8, P625, DOI 10.1111/j.1750-3639.1998.tb00189.x; Laflamme N, 1999, J NEUROCHEM, V73, P309, DOI 10.1046/j.1471-4159.1999.0730309.x; Laflamme N, 1999, J NEUROSCI, V19, P10923, DOI 10.1523/JNEUROSCI.19-24-10923.1999; Laflamme N, 2001, FASEB J, V15, P155, DOI 10.1096/fj.00-0339com; LEVISTRAUSS M, 1987, J IMMUNOL, V139, P2361; Mayhan WG, 1998, BRAIN RES, V792, P353, DOI 10.1016/S0006-8993(98)00259-5; Merino S, 1998, INFECT IMMUN, V66, P3825, DOI 10.1128/IAI.66.8.3825-3831.1998; Morgan BP, 1996, IMMUNOL TODAY, V17, P461, DOI 10.1016/0167-5699(96)20028-F; Nadeau S, 1999, J NEUROPATH EXP NEUR, V58, P61, DOI 10.1097/00005072-199901000-00008; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; Quan N, 1998, NEUROSCIENCE, V83, P281, DOI 10.1016/S0306-4522(97)00350-3; Quan N, 1997, P NATL ACAD SCI USA, V94, P10985, DOI 10.1073/pnas.94.20.10985; Rivest S, 2000, P SOC EXP BIOL MED, V223, P22, DOI 10.1046/j.1525-1373.2000.22304.x; RUS HG, 1992, J IMMUNOL, V148, P928; Stahel PF, 1997, J IMMUNOL, V159, P861; STRUNK RC, 1985, J CLIN INVEST, V76, P985, DOI 10.1172/JCI112099; SUTTON MBS, 1986, J IMMUNOL, V136, P1366; Swanson L. W., 1992, BRAIN MAPS STRUCTURE; Taylor P, 1998, CURR BIOL, V8, pR259, DOI 10.1016/S0960-9822(98)70167-8; Tornetta MA, 1997, J IMMUNOL, V158, P5277; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X	37	40	40	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1410	+		10.1096/fj.00-0709fje	http://dx.doi.org/10.1096/fj.00-0709fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387240				2022-12-28	WOS:000173705800028
J	Humar, R; Kiefer, FN; Berns, H; Resink, TJ; Battegay, EJ				Humar, R; Kiefer, FN; Berns, H; Resink, TJ; Battegay, EJ			Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) -dependent signaling	FASEB JOURNAL			English	Article						microvessels; smooth muscle; endothelium; embryogenesis; neovascularization	ENDOTHELIAL GROWTH-FACTOR; RAS-TRANSFORMED-CELLS; CYCLIN D1 EXPRESSION; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-B; P70 S6 KINASE; IN-VITRO; MAMMALIAN TARGET; PHOSPHATIDYLINOSITOL 3-KINASE; FRAP-P70(S6K) PATHWAY	Angiogenesis and vascular cell proliferation are pivotal in physiological and pathological processes including atherogenesis, restenosis, wound healing, and cancer development. Here we show that mammalian target of rapamycin (mTOR) signaling plays a key role in hypoxia-triggered smooth muscle and endothelial proliferation and angiogenesis in vitro. Hypoxia significantly increased DNA synthesis and proliferative responses to platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) in rat and human smooth muscle and endothelial cells. In an in vitro 3-dimensional model of angiogenesis, hypoxia increased PDGF- and FGF-stimulated sprout formation from rat and mouse aortas. Hypoxia did not modulate PDGF receptor mRNA, protein, or phosphorylation. PI3K activity was essential for cell proliferation under normoxic and hypoxic conditions. Activities of PI3K-downstream target PKB under hypoxia and normoxia were comparable. However, mTOR inhibition by rapamycin specifically abrogated hypoxia-mediated amplification of proliferation and angiogenesis, but was without effect on proliferation under normoxia. Accordingly, hypoxia-mediated amplification of proliferation was further augmented in mTOR-overexpressing endothelial cells. Thus, signaling via mTOR may represent a novel mechanism whereby hypoxia augments mitogen-stimulated vascular cell proliferation and angiogenesis.	Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; Univ Basel Hosp, Univ Med Outpatient Dept, CH-4031 Basel, Switzerland	University of Basel; University of Basel	Battegay, EJ (corresponding author), Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland.	ebattegay@uhbs.ch						Abizaid Alexandre, 2001, Curr Interv Cardiol Rep, V3, P1; Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ALTMAN LK, 2001, NY TIMES        0106; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Barbe E., 1996, MEDITERR POLIT, V1, P25; Battegay EJ, 1996, TRENDS GLYCOSCI GLYC, V8, P231, DOI 10.4052/tigg.8.231; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BJORNHEDEN T, 1987, ARTERIOSCLEROSIS, V7, P238, DOI 10.1161/01.ATV.7.3.238; Bjornheden T, 1996, ARTERIOSCL THROM VAS, V16, P178, DOI 10.1161/01.ATV.16.1.178; Bjornheden T, 1999, ARTERIOSCL THROM VAS, V19, P870, DOI 10.1161/01.ATV.19.4.870; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Choi Jai-Pil, 1996, EUROPEAN J POLITICAL, V12, P273, DOI DOI 10.1016/0176-2680(95)00017-8; Das M, 2001, J BIOL CHEM, V276, P15631, DOI 10.1074/jbc.M010690200; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Frid MG, 1998, CHEST, V114, p28S, DOI 10.1378/chest.114.1_Supplement.28S; Frid MG, 1997, CIRC RES, V81, P940; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Grewe M, 1999, CANCER RES, V59, P3581; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; MANNE V, 1995, ONCOGENE, V10, P1763; MARX M, 1994, J CLIN INVEST, V93, P131, DOI 10.1172/JCI116936; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Ross MA, 2001, HEPATOLOGY, V34, P1135, DOI 10.1053/jhep.2001.29624; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; SAKAKI T, 1995, NEUROSCI RES, V23, P289, DOI 10.1016/0168-0102(95)00954-X; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; Spyridopoulos Ioakim, 1998, Frontiers in Bioscience, V3, pD269; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Thommen R, 1997, J CELL BIOCHEM, V64, P403; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Zhong H, 2000, CANCER RES, V60, P1541	54	328	354	2	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0771	10.1096/fj.01-0658com	http://dx.doi.org/10.1096/fj.01-0658com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039858				2022-12-28	WOS:000176683900002
J	Doherty, TM; Uzui, H; Fitzpatrick, LA; Tripathi, PV; Dunstan, CR; Asotra, K; Rajavashisth, TB				Doherty, TM; Uzui, H; Fitzpatrick, LA; Tripathi, PV; Dunstan, CR; Asotra, K; Rajavashisth, TB			Rationale for the role of osteoclast-like cells in arterial calcification	FASEB JOURNAL			English	Article						atherosclerosis; mineral resorption; mononuclear phagocytes; OLCs	COLONY-STIMULATING FACTOR; CARBONIC-ANHYDRASE-II; KAPPA-B LIGAND; FMS PROTOONCOGENE PRODUCT; BEAM COMPUTED-TOMOGRAPHY; MATRIX GLA PROTEIN; RECEPTOR ACTIVATOR; IN-VITRO; VASCULAR CALCIFICATION; BONE-RESORPTION	Atherosclerotic arteries frequently become calcified, and these calcium deposits are associated with a high risk of adverse clinical events. Descriptive studies suggest calcification is an organized and regulated process with many similarities to osteogenesis, yet the mechanism and its relationship to atherosclerosis remain largely unknown. In bone development and homeostasis, mineral deposition by osteoblasts and mineral resorption by osteoclasts are delicately balanced such that there is no overall gain or loss in bone mass. We hypothesize that there exists in arteries a mechanism that similarly balances mineral deposition with resorption. We propose that the cellular mediators of arterial mineral resorption are osteoclast-like cells (OLCs) derived from hematopoietic precursors of the mononuclear phagocytic lineage. In arterial microenvironments, mononuclear precursors are induced to differentiate toward OLCs by macrophage-colony stimulating factor and receptor activator of NF-kappaB ligand, both of which are necessary and sufficient for osteoclastogenesis and mineral resorption in bone. OLCs may participate in normal mineral homeostasis within the arterial wall or, alternatively, may be recruited to specific sites within developing plaque. Net calcium deposition occurs as a result of focal perturbation of the balance between the activity of osteoblast-like cells and OLCs. Our proposed mechanism thus views arterial mineral deposition not so much as an active pathological process, but as a localized failure of protective mechanisms that actively oppose mineral deposition within the disordered metabolic milieu of developing atherosclerotic plaque.	Cedars Sinai Med Ctr, Div Cardiol, Atherosclerosis Res Ctr, Dept Med, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Div Endocrinol, Rochester, MN 55905 USA; Amgen Inc, Dept Dev, Thousand Oaks, CA 91320 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Mayo Clinic; Amgen	Rajavashisth, TB (corresponding author), Cedars Sinai Med Ctr, Div Cardiol, Atherosclerosis Res Ctr, Dept Med, Davis Res Bldg,Room 1062,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	rajavashisth@cshs.org	Dunstan, Colin/G-6214-2013; Rajavashisth, Tripathi/ABB-6379-2020	Dunstan, Colin/0000-0001-7586-4071; 	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013717] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058555, R29HL051980, R01HL051980] Funding Source: NIH RePORTER; NCRR NIH HHS [1S10RR13717] Funding Source: Medline; NHLBI NIH HHS [HL 58555, HL 51980] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391; Bostrom K, 2001, AM J CARDIOL, V88, p20E; Bostrom K, 2000, CRIT REV EUKAR GENE, V10, P151; Boyce BF, 1999, LAB INVEST, V79, P83; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Canfield AE, 2000, FEBS LETT, V487, P267, DOI 10.1016/S0014-5793(00)02363-2; Canfield AE, 2000, Z KARDIOL, V89, P20; CLINTON SK, 1992, AM J PATHOL, V140, P301; Collin-Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200; Detrano RC, 2000, CURR PROB CARDIOLOGY, V25, P374, DOI 10.1067/mcd.2000.104848; DOHERTY TM, 1994, CALCIFIED TISSUE INT, V54, P224, DOI 10.1007/BF00301683; Doherty TM, 1999, AM HEART J, V137, P806, DOI 10.1016/S0002-8703(99)70403-5; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; Han CL, 2001, J VASC RES, V38, P113, DOI 10.1159/000051038; Heinemann DEH, 2000, IMMUNOBIOLOGY, V202, P68, DOI 10.1016/S0171-2985(00)80054-6; Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Itoh K, 2001, ENDOCRINOLOGY, V142, P3656, DOI 10.1210/en.142.8.3656; Jono S, 1998, CIRCULATION, V98, P1302, DOI 10.1161/01.CIR.98.13.1302; Jono S, 1997, ARTERIOSCL THROM VAS, V17, P1135, DOI 10.1161/01.ATV.17.6.1135; Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10; Kartsogiannis V, 1999, BONE, V25, P525, DOI 10.1016/S8756-3282(99)00214-8; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LAITALA T, 1994, J CLIN INVEST, V93, P2311, DOI 10.1172/JCI117235; Lehenkari P, 1998, EXP CELL RES, V242, P128, DOI 10.1006/excr.1998.4071; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; McGowan NWA, 2001, ENDOCRINOLOGY, V142, P1678, DOI 10.1210/en.142.4.1678; Min H, 2000, J EXP MED, V192, P463, DOI 10.1084/jem.192.4.463; Miyamoto N, 2000, J ORTHOP RES, V18, P647, DOI 10.1002/jor.1100180418; Mori K, 1998, FEBS LETT, V433, P19, DOI 10.1016/S0014-5793(98)00870-9; Mori K, 1999, ARTERIOSCL THROM VAS, V19, P2112, DOI 10.1161/01.ATV.19.9.2112; Neale SD, 2000, BONE, V27, P409, DOI 10.1016/S8756-3282(00)00345-8; O'Malley PG, 2000, AM J CARDIOL, V85, P945, DOI 10.1016/S0002-9149(99)00906-6; O'Rourke RA, 2000, J AM COLL CARDIOL, V36, P326, DOI 10.1016/S0735-1097(00)00831-7; Price PA, 2001, ARTERIOSCL THROM VAS, V21, P1610, DOI 10.1161/hq1001.097102; Proudfoot D, 1998, ARTERIOSCL THROM VAS, V18, P379, DOI 10.1161/01.ATV.18.3.379; Qiao JH, 1997, AM J PATHOL, V150, P1687; Quinn JMW, 2000, J BONE MINER RES, V15, P1459, DOI 10.1359/jbmr.2000.15.8.1459; Rajavashisth T, 1998, J CLIN INVEST, V101, P2702, DOI 10.1172/JCI119891; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; ROSENFELD ME, 1992, AM J PATHOL, V140, P291; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Shalhoub V, 2000, BRIT J HAEMATOL, V111, P501, DOI 10.1046/j.1365-2141.2000.02379.x; SHERR CJ, 1988, COLD SPRING HARB SYM, V53, P521, DOI 10.1101/SQB.1988.053.01.060; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIOI A, 1995, ARTERIOSCL THROM VAS, V15, P2003, DOI 10.1161/01.ATV.15.11.2003; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SPICER SS, 1989, AM J PATHOL, V134, P947; Stary HC, 2000, Z KARDIOL, V89, P28; Stary HC, 1999, ATLAS ATHEROSCLEROSI; Suda T, 2001, Novartis Found Symp, V232, P235; Suda Tatsuo, 1996, P87; Sundquist KT, 1999, HISTOCHEM CELL BIOL, V111, P55, DOI 10.1007/s004180050333; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tintut Y, 2001, CURR OPIN LIPIDOL, V12, P555, DOI 10.1097/00041433-200110000-00012; Tsurukai T, 2000, J BONE MINER METAB, V18, P177, DOI 10.1007/s007740070018; Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478; WATSON KE, 1994, J CLIN INVEST, V93, P2106, DOI 10.1172/JCI117205; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	66	83	87	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6							UNSP 0892-6638/02/0016-0577	10.1096/fj.01-0898hyp	http://dx.doi.org/10.1096/fj.01-0898hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919160				2022-12-28	WOS:000175425900011
J	Slominski, A; Pisarchik, A; Semak, I; Sweatman, T; Wortsman, J; Szczesniewski, A; Slugocki, G; McNulty, J; Kauser, S; Tobin, DJ; Jing, C; Johansson, O				Slominski, A; Pisarchik, A; Semak, I; Sweatman, T; Wortsman, J; Szczesniewski, A; Slugocki, G; McNulty, J; Kauser, S; Tobin, DJ; Jing, C; Johansson, O			Serotoninergic and melatoninergic systems are fully expressed in human skin	FASEB JOURNAL			English	Article						serotonin; melatonin; tryptophan hydroxylase; arylalkylamine N-acetyltransferase; hydroxyindole-O-methyltransferase	CORTICOTROPIN-RELEASING HORMONE; PERFORMANCE LIQUID-CHROMATOGRAPHY; N-ACETYLTRANSFERASE; ENZYME-ACTIVITIES; ASSAY; ACETYLSEROTONIN; IDENTIFICATION; PROLIFERATION; MELANOGENESIS; SPECIFICITY	We investigated the cutaneous expression of genes and enzymes responsible for the multistep conversion of tryptophan to serotonin and further to melatonin. Samples tested were human skin, normal and pathologic (basal cell carcinoma and melanoma), cultured normal epidermal and follicular melanocytes, melanoma cell lines, normal neonatal and adult epidermal and follicular keratinocytes, squamous cell carcinoma cells, and fibroblasts from dermis and follicular papilla. The majority of the samples showed simultaneous expression of the genes for tryptophan hydroxylase, arylalkylamine N-acetyltransferase (AANAT), and hydroxyindole-O-methyltransferase (HIOMT). The products of AANAT activity were identified by RP-HPLC with fluorimetric detection in human skin and in cultured normal and malignant melanocytes and immortalized keratinocytes; HIOMT activity was detected in human skin, keratinocytes, and melanoma cells. N-acetylserotonin (NAS) was detected by RP-HPLC in human skin extracts. NAS identity was confirmed further by LC/MS in keratinocytes. In conclusion, we provide evidence that the human skin expresses intrinsic serotonin and melatonin biosynthetic pathways.	Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA; Belarusian State Univ, Dept Biochem, Minsk, BELARUS; So Illinois Univ, Dept Internal Med, Springfield, IL USA; Agilent Technol, Schaumburg, IL USA; Loyola Med Ctr, Dept Anat Cell Biol & Neurobiol, Maywood, IL USA; Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England; Karolinska Inst, Expt Dermatol Unit, Dept Neurosci, Stockholm, Sweden	University of Tennessee System; University of Tennessee Health Science Center; Belarusian State University; Southern Illinois University System; Southern Illinois University; Agilent Technologies; Loyola University Chicago; University of Bradford; Karolinska Institutet	Slominski, A (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol, 899 Madison Ave,Room 576M, Memphis, TN 38163 USA.	aslominski@utmem.edu	Semak, Igor/AAT-9273-2020; Tobin, Desmond/A-5228-2009	Semak, Igor/0000-0001-9430-8492; Slominski, Andrzej/0000-0001-8963-3995; Tobin, Desmond/0000-0003-4566-9392; Pisarchik, Alexander/0000-0002-8991-919X				Abe M, 1999, EXP EYE RES, V68, P255, DOI 10.1006/exer.1998.0601; BEEVERS SJ, 1983, J NEUROCHEM, V40, P894, DOI 10.1111/j.1471-4159.1983.tb08066.x; Bos JD, 1997, SKIN IMMUNE SYSTEM S; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buznikov GA, 2001, CELL TISSUE RES, V305, P177, DOI 10.1007/s004410100408; Coon SL, 2001, J BIOL CHEM, V276, P24097, DOI 10.1074/jbc.M011298200; Ebling FJG, 1990, HAIR HAIR DIS, P267; Ferry G, 2000, J BIOL CHEM, V275, P8794, DOI 10.1074/jbc.275.12.8794; FINOCCHIARO LME, 1991, BIOCHEM J, V280, P727, DOI 10.1042/bj2800727; GAUDET SJ, 1993, J INVEST DERMATOL, V101, P660, DOI 10.1111/1523-1747.ep12371672; GRACE MS, 1991, BRAIN RES, V559, P56, DOI 10.1016/0006-8993(91)90286-5; GRACE MS, 1993, J NEUROCHEM, V60, P990, DOI 10.1111/j.1471-4159.1993.tb03246.x; GRANDO SA, 1997, CUR OPIN DERMATOL, V4, P462; GUPTA D, 1988, PINEAL GLAND CANC; Itoh MT, 1999, MOL HUM REPROD, V5, P402, DOI 10.1093/molehr/5.5.402; Itoh MT, 1997, J CHROMATOGR B, V692, P217, DOI 10.1016/S0378-4347(96)00503-8; Johansson O, 1998, J INVEST DERMATOL, V111, P1010, DOI 10.1046/j.1523-1747.1998.00460.x; Karbownik M, 2001, INT J BIOCHEM CELL B, V33, P735, DOI 10.1016/S1357-2725(01)00059-0; Kema IP, 2000, J CHROMATOGR B, V747, P33, DOI 10.1016/S0378-4347(00)00341-8; Le Poole IC, 2000, IN VITRO CELL DEV-AN, V36, P309; MAGERL M, IN PRESS EXPT DERMAT; Maurer M, 1997, J DERMATOL SCI, V16, P79, DOI 10.1016/S0923-1811(97)00043-1; MCEWAN M, 1987, J INVEST DERMATOL, V89, P82, DOI 10.1111/1523-1747.ep12580425; Mockus SM, 1998, J MOL NEUROSCI, V10, P163, DOI 10.1007/BF02761772; NORDLUND JJ, 1988, PIGMENTARY SYSTEM PH; Pacak K, 2001, ENDOCR REV, V22, P502, DOI 10.1210/er.22.4.502; Pisarchik A, 2001, FASEB J, V15, P2754, DOI 10.1096/fj.01-0487fje; Quevedo ME, 2001, IN VITRO CELL DEV-AN, V37, P50; SCHALLREUTER KU, 1995, J INVEST DERMATOL, V104, P953, DOI 10.1111/1523-1747.ep12606218; SCHULZ MK, 1995, RESTOR NEUROL NEUROS, V7, P127, DOI 10.3233/RNN-1994-7301; SEUWEN K, 1990, BIOCHEM PHARMACOL, V39, P985, DOI 10.1016/0006-2952(90)90276-Q; SLOMINSKI A, 1993, J THEOR BIOL, V164, P103, DOI 10.1006/jtbi.1993.1142; Slominski A, 1994, Exp Dermatol, V3, P45, DOI 10.1111/j.1600-0625.1994.tb00265.x; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 1996, J BIOL CHEM, V271, P12281, DOI 10.1074/jbc.271.21.12281; Slominski A, 1996, INT J DERMATOL, V35, P849, DOI 10.1111/j.1365-4362.1996.tb05049.x; Slominski A, 2002, FEBS LETT, V511, P102, DOI 10.1016/S0014-5793(01)03319-1; Slominski A, 1999, IN VITRO CELL DEV-AN, V35, P564; Slominski A, 1998, CLIN DERMATOL, V16, P503, DOI 10.1016/S0738-081X(98)00023-6; SLOMINSKI A, 1993, EXP CELL RES, V206, P189, DOI 10.1006/excr.1993.1137; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2001, FASEB J, V15, P1678, DOI 10.1096/fj.00-0850rev; Stefulj J, 2001, J PINEAL RES, V30, P243, DOI 10.1034/j.1600-079X.2001.300408.x; SUGDEN D, 1987, METHOD ENZYMOL, V142, P590; THOMAS KB, 1990, ANAL BIOCHEM, V184, P228, DOI 10.1016/0003-2697(90)90673-W; TOBIN DJ, 1995, J INVEST DERMATOL, V104, P86, DOI 10.1111/1523-1747.ep12613573; Tobin DJ, 1996, PIGM CELL RES, V9, P304, DOI 10.1111/j.1600-0749.1996.tb00122.x; Tsai SY, 1997, GLIA, V20, P243, DOI 10.1002/(SICI)1098-1136(199707)20:3<243::AID-GLIA8>3.0.CO;2-8; Yu H. L., 2020, ARXIV PREPRINT ARXIV	49	212	220	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					896	+		10.1096/fj.01-0952fje	http://dx.doi.org/10.1096/fj.01-0952fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039872				2022-12-28	WOS:000175425900024
J	Vidaltamayo, R; Sanchez-Soto, MC; Hiriart, M				Vidaltamayo, R; Sanchez-Soto, MC; Hiriart, M			Nerve growth factor increases sodium channel expression in pancreatic beta cells: implications for insulin secretion	FASEB JOURNAL			English	Article						NGF; sodium channel type III; RHPA; RT-PCR; electrical activity	B-CELLS; NGF; RAT; DBCAMP; CANINE; GENE; CDNA; FGF	The importance of nerve growth factor (NGF) modulation of pancreatic beta cells is demonstrated by the fact that these cells secrete and respond to this trophic factor. Among NGF effects on beta cells is an increase in Na+ and Ca2+ current densities. This study investigates the mechanisms involved in the NGF-induced increase in Na+ current and the implications of this effect for insulin secretion. The following results were obtained in single beta cells cultured with NGF for 5-7 days: 1) A steady-state level of mRNA coding for type III sodium channel subunit increased twofold compared with that for control cells. 2) The increase in Na+ current density was blocked either by cycloheximide or by actinomycin D, indicating that it is mediated by protein synthesis and mRNA transcription. 3) NGF treatment strengthened, by nearly fourfold, the beta-cell electrical activity; this effect is partially related to the increased Na+ current, because tetrodotoxin (TTX) decreased the duration of the depolarized plateau level. 4) Single beta cells secreted nearly two times more insulin in response to 5.6 or 15.6 mM glucose. This effect was inhibited by TTX, indicating that the enhanced Na+ current plays an important role. These data suggest that NGF could preserve an adequate expression of sodium channels and that impairment of NGF modulation could lead to deficient insulin secretion and diabetes mellitus.	Natl Autonomous Univ Mexico, Inst Fisiol Celular, Dept Biophys, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Hiriart, M (corresponding author), Natl Autonomous Univ Mexico, Inst Fisiol Celular, Dept Biophys, AP 70-253,Ciudad Univ, Mexico City 04510, DF, Mexico.	mhiriart@ifisiol.unam.mx	Vidaltamayo, Roman/A-3613-2014; Vidaltamayo, Roman/V-6035-2019; Hiriart, Marcia/A-3988-2008	Vidaltamayo, Roman/0000-0002-4747-0830; Vidaltamayo, Roman/0000-0002-4747-0830; Hiriart, Marcia/0000-0001-5711-8868				ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; DARCANGELO G, 1993, J CELL BIOL, V122, P915, DOI 10.1083/jcb.122.4.915; del Pliego MG, 2001, CELL TISSUE RES, V305, P365; EIZIRIK DL, 1991, ENDOCRINOLOGY, V128, P1611, DOI 10.1210/endo-128-3-1611; FARADJI V, 1990, ACTA NEUROL SCAND, V81, P402; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRIART M, 1991, ENDOCRINOLOGY, V128, P3193, DOI 10.1210/endo-128-6-3193; HIRIART M, 1988, J GEN PHYSIOL, V91, P617, DOI 10.1085/jgp.91.5.617; HIRIART M, 1993, MOL CELL ENDOCRINOL, V93, P63, DOI 10.1016/0303-7207(93)90140-F; KANAKAGANTENBEIN C, 1995, ENDOCRINOLOGY, V136, P761, DOI 10.1210/en.136.2.761; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; Madsen OD, 1996, EUR J BIOCHEM, V242, P435, DOI 10.1111/j.1432-1033.1996.435rr.x; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; OSAWA S, 1986, PHYSIOL REV, V66, P887; PHILIPSON LH, 1993, DIABETES, V42, P1372, DOI 10.2337/diabetes.42.9.1372; Pierucci D, 2001, DIABETOLOGIA, V44, P1281, DOI 10.1007/s001250100650; PLANT TD, 1988, PFLUEGERS ARCH EUR J, V414, pS71; POLAK M, 1993, P NATL ACAD SCI USA, V90, P5781, DOI 10.1073/pnas.90.12.5781; POLLOCK JD, 1990, J NEUROSCI, V10, P2626; PRESSEL DM, 1990, J MEMBRANE BIOL, V116, P273, DOI 10.1007/BF01868466; Rosenbaum T, 1996, J MEMBRANE BIOL, V153, P53, DOI 10.1007/s002329900109; Rosenbaum T, 1998, P NATL ACAD SCI USA, V95, P7784, DOI 10.1073/pnas.95.13.7784; Rosenbaum T, 2001, DIABETES, V50, P1755, DOI 10.2337/diabetes.50.8.1755; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Vidaltamayo R, 1996, ENDOCRINE, V4, P19, DOI 10.1007/BF02738870	26	28	32	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					891	+		10.1096/fj.01-0934fje	http://dx.doi.org/10.1096/fj.01-0934fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039870				2022-12-28	WOS:000175425900027
J	Chew, LJ; Pan, HG; Yu, JY; Tian, S; Huang, WQ; Zhang, JY; Pang, S; Li, LY				Chew, LJ; Pan, HG; Yu, JY; Tian, S; Huang, WQ; Zhang, JY; Pang, S; Li, LY			A novel secreted splice variant of vascular endothelial cell growth inhibitor	FASEB JOURNAL			English	Article						angiogenesis; autocrine; endothelium; secretion; VEGI	TUMOR-NECROSIS-FACTOR; ALPHA IN-VITRO; MESSENGER-RNA; PROTEIN-KINASE; TNF-ALPHA; LENTIVIRAL VECTOR; PREMESSENGER RNA; DOWN-REGULATION; SOLUBLE FORM; FACTOR-BETA	Vascular endothelial cell growth inhibitor (VEGI), a member of the tumor necrosis factor (TNF) family, is an endothelial cell-specific inhibitor of angiogenesis. Overexpression by cancer cells of a secretable VEGI fusion protein resulted in abrogation of xenograft tumor progression, but overexpression of full-length VEGI was completely without effect. This finding indicates that secretion is essential for VEGI action. Here we report the identification of two new VEGI isoforms consisting of 251 and 192 amino acid residues. Both isoforms show endothelial cell-specific expression and share a C-terminal 151-residue segment with the previously described VEGI, which comprises 174 residues. The isoforms are generated from a 17 kb human gene by alternative splicing. Their expression is regulated in parallel by inflammatory cytokines TNF-alpha and interferon-gamma. VEGI-251, the most abundant isoform, contains a putative secretion signal. VEGI protein is detected in conditioned media of endothelial cells and VEGI-251-transfected mammalian cells. Overexpression of VEGI-251 in endothelial cells causes dose-dependent cell death. VEGI-251-transfected cancer cells form xenograft tumors of reduced growth rate and microvessel density compared with tumors of empty vector transfectants. These findings support the view that endothelial cell-secreted VEGI may function as an autocrine inhibitor of angiogenesis and a naturally existing modulator of vascular homeostasis.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA; Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA; Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA	Georgetown University; Medical University of South Carolina; University of California System; University of California Los Angeles	Li, LY (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Oncol, 3970 Reservoir Rd NW,RB-E301, Washington, DC 20007 USA.	lilu@georgetown.edu	Li, Luyuan/E-8951-2012					BALDWIN HS, 1996, CARDIOVASC RES, V31, P34; Boldrini L, 2000, BRIT J CANCER, V83, P480, DOI 10.1054/bjoc.2000.1345; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Derrigo M, 2000, INT J MOL MED, V5, P111; DOUKAS J, 1990, J IMMUNOL, V145, P1727; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184; ENGERMAN RL, 1967, LAB INVEST, V17, P738; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Haridas V, 1999, ONCOGENE, V18, P6496, DOI 10.1038/sj.onc.1203059; He YL, 1999, MOL ENDOCRINOL, V13, P537, DOI 10.1210/me.13.4.537; Hohlbaum AM, 2000, J EXP MED, V191, P1209, DOI 10.1084/jem.191.7.1209; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Horrevoets AJG, 1999, BLOOD, V93, P3418, DOI 10.1182/blood.V93.10.3418.410k23_3418_3431; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; LEEK RD, 1994, J LEUKOCYTE BIOL, V56, P423, DOI 10.1002/jlb.56.4.423; Lou H, 2001, ENDOCR REV, V22, P205, DOI 10.1210/er.22.2.205; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MCKAY NG, 1994, BIOCHEM BIOPH RES CO, V199, P1005, DOI 10.1006/bbrc.1994.1329; Metheny LJ, 1996, EXP CELL RES, V228, P44, DOI 10.1006/excr.1996.0297; Molostvov G, 2001, BRIT J HAEMATOL, V113, P891, DOI 10.1046/j.1365-2141.2001.02835.x; Mueller C, 1999, J BIOL CHEM, V274, P38112, DOI 10.1074/jbc.274.53.38112; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Ono Y, 1999, HYPERTENSION, V34, P609, DOI 10.1161/01.HYP.34.4.609; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; Pollman MJ, 1999, J CELL PHYSIOL, V178, P359, DOI 10.1002/(SICI)1097-4652(199903)178:3<359::AID-JCP10>3.3.CO;2-F; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; RIO DC, 1993, CURR OPIN GENET DEV, V3, P574, DOI 10.1016/0959-437X(93)90093-5; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; SHIFRIN VI, 1993, J BIOL CHEM, V268, P25376; Shudo K, 2001, EUR J IMMUNOL, V31, P2504, DOI 10.1002/1521-4141(200108)31:8<2504::AID-IMMU2504>3.0.CO;2-C; Stewart SA, 1999, P NATL ACAD SCI USA, V96, P12039, DOI 10.1073/pnas.96.21.12039; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; WANG A, 1991, J BIOL CHEM, V266, P15598; Wang JH, 1999, SHOCK, V11, P311, DOI 10.1097/00024382-199905000-00002; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Wright P, 1999, CANCER BIOTHER RADIO, V14, P49, DOI 10.1089/cbr.1999.14.49; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yu JY, 2001, CIRC RES, V89, P1161, DOI 10.1161/hh2401.101909; Yue TL, 1999, J BIOL CHEM, V274, P1479, DOI 10.1074/jbc.274.3.1479; Zhai YF, 1999, INT J CANCER, V82, P131, DOI 10.1002/(SICI)1097-0215(19990702)82:1<131::AID-IJC22>3.3.CO;2-F; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181	48	86	109	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					742	+		10.1096/fj.01-0757fje	http://dx.doi.org/10.1096/fj.01-0757fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923219				2022-12-28	WOS:000174755900009
J	Moritz, W; Meier, F; Stroka, D; Giuliani, M; Kugelmeier, P; Nett, PC; Lehmann, R; Candinas, D; Gassmann, M; Weber, M				Moritz, W; Meier, F; Stroka, D; Giuliani, M; Kugelmeier, P; Nett, PC; Lehmann, R; Candinas, D; Gassmann, M; Weber, M			Apoptosis in hypoxic human pancreatic islets correlates with HIF-1 alpha expression	FASEB JOURNAL			English	Article						caspase-3; hypoxia; islet transplantation	INDUCIBLE FACTOR 1-ALPHA; FACTOR-I HIF-1; NUCLEAR TRANSLOCATION; INSULIN-SECRETION; FACTOR-1-ALPHA; TRANSPLANTATION; INDUCTION; PROTEIN; GENE; RAT	To become insulin independent, patients with type 1 diabetes mellitus require transplantation of at least two donor pancreata because of massive beta-cell loss in the early post-transplantation period. Many studies describing the introduction of new immunosuppressive protocols have shown that this loss is due to not only immunological events but also nonimmunological factors. To test to what extent hypoxia may contribute to early graft loss, we analyzed the occurrence of apoptotic events and the expression of hypoxia-inducible factor 1 (HIF-1), a heterodimeric transcription factor consisting of an oxygen-dependent alpha subunit and a constitutive beta subunit. Histological analysis of human and rat islets revealed nuclear pyknosis as early as 6 h after hypoxic exposure (1% O-2). Moreover, immunoreactivity to activated caspase-3 was observed in the core region of isolated human islets. Of note, both of these markers of apoptosis topographically overlap with HIF-1alpha immunoreactivity. HIF-1alpha mRNA was detected in islets from human and rat as well as in several murine beta-cell lines. When exposed to hypoxia, mouse insulinoma cells (MIN6) had an increased HIF-1alpha protein level, whereas its mRNA level did not alter. In conclusion, our data provide convincing evidence that reduced oxygenation is an important cause of beta-cell loss and suggest that HIF-1alpha protein level is an indicator for hypoxic regions undergoing apoptotic cell death. These observations suggest that gene expression under the control of HIF-1 represents a potential therapeutic tool for improving engraftment of transplanted islets.	Univ Zurich Hosp, Clin Visceral & Transplant Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Div Endocrinol & Diabetol, CH-8091 Zurich, Switzerland; Univ Birmingham, Liver Labs, Birmingham B15 2TH, W Midlands, England; Univ Zurich, Inst Physiol & Vet Physiol, CH-8057 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Birmingham; University of Zurich	Weber, M (corresponding author), Univ Zurich Hosp, Clin Visceral & Transplant Surg, Ramistr 100, CH-8091 Zurich, Switzerland.	markus.weber@chi.usz.ch	Stroka, Deborah M/F-1806-2013; Lehmann, Roger/B-9120-2015	Lehmann, Roger/0000-0002-3681-4431; Stroka, Deborah/0000-0002-3517-3871; Gassmann, Max/0000-0003-2750-8878				ALEJANDRO R, 1988, TRANSPLANTATION, V45, P1036, DOI 10.1097/00007890-198806000-00008; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; BONNERWEIR S, 1982, DIABETES, V31, P883, DOI 10.2337/diabetes.31.10.883; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Camenisch G, 2001, PFLUG ARCH EUR J PHY, V443, P240, DOI 10.1007/s004240100679; Carlsson PO, 2001, DIABETES, V50, P489, DOI 10.2337/diabetes.50.3.489; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chilov D, 1999, J CELL SCI, V112, P1203; DAVALLI AM, 1995, TRANSPLANTATION, V59, P817, DOI 10.1097/00007890-199503270-00003; DECOURTEN M, 1997, EPIDEMIOLOGY NIDDM N; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Hanke J, 2001, CELLS TISSUES ORGANS, V169, P113, DOI 10.1159/000047869; Hofer T, 2001, FASEB J, V15, P2715, DOI 10.1096/fj.01-0546fje; HOFER T, 2002, IN PRESS EUR J PHYSL; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Ilieva A, 1999, J ENDOCRINOL, V161, P357, DOI 10.1677/joe.0.1610357; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; KENDALL DM, 1990, NEW ENGL J MED, V322, P898, DOI 10.1056/NEJM199003293221305; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Linetsky E, 1997, DIABETES, V46, P1120, DOI 10.2337/diabetes.46.7.1120; Mandal M, 1999, BIOCHEM BIOPH RES CO, V260, P775, DOI 10.1006/bbrc.1999.0966; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; MENGER MD, 1989, DIABETES, V38, P199, DOI 10.2337/diab.38.1.S199; MENGER MD, 1992, J CLIN INVEST, V90, P1361, DOI 10.1172/JCI116002; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Moede T, 1999, FEBS LETT, V461, P229, DOI 10.1016/S0014-5793(99)01446-5; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; Paraskevas S, 1997, TRANSPL P, V29, P750, DOI 10.1016/S0041-1345(96)00452-6; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Rosenberg L, 1999, SURGERY, V126, P393, DOI 10.1067/msy.1999.98783; Ryan EA, 2001, DIABETES, V50, P710, DOI 10.2337/diabetes.50.4.710; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Stratta RJ, 1998, SURGERY, V124, P823, DOI 10.1067/msy.1998.91366; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Thomas FT, 1999, SURGERY, V126, P299, DOI 10.1067/msy.1999.99164; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang RN, 1999, J ENDOCRINOL, V163, P181, DOI 10.1677/joe.0.1630181; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Wenger RH, 1996, BLOOD, V87, P756, DOI 10.1182/blood.V87.2.756.bloodjournal872756; Wenger RH, 1997, BIOL CHEM, V378, P609; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 1999, CANCER RES, V59, P5830	54	148	161	2	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					745	+		10.1096/fj.01-0403fje	http://dx.doi.org/10.1096/fj.01-0403fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923216				2022-12-28	WOS:000174755900008
J	Moller, P; Wallin, H; Holst, E; Knudsen, LE				Moller, P; Wallin, H; Holst, E; Knudsen, LE			Sunlight-induced DNA damage in human mononuclear cells	FASEB JOURNAL			English	Article						epidermis; UVA; non-Hodgkins lymphoma; mononuclear cells	NON-HODGKINS-LYMPHOMA; CYCLOBUTANE PYRIMIDINE DIMERS; SOLAR ULTRAVIOLET-RADIATION; NONMELANOMA SKIN-CANCER; WHITE BLOOD-CELLS; HUMAN-LYMPHOCYTES; COMET ASSAY; SEASONAL-VARIATION; VITAMIN-C; EXPOSURE	In this study of 301 blood samples from 21 subjects, we found markedly higher levels of DNA damage (nonpyrimidine dimer types) in the summer than in the winter detected by single-cell gel electrophoresis. The level of DNA damage was influenced by the average daily influx of sunlight < 50 days prior to blood sampling. The 3 and 6 day periods before sampling influenced DNA damage the most. The importance of sunlight was further emphasized by a positive association of the DNA damage level to the amount of time the subjects had spent in the sun over a 3 day period prior to the sampling. The effect of sunlight was comparable to the interindividual variation, indicating that sunlight exposure and the individual's background were the two most important determinants for the basal level of DNA damage. Influence of other lifestyle factors such as exercise, intake of foods, infections, and age could not be detected. Our results suggest that sunlight penetrates the outer layer of the human epidermis and damages the DNA in mononuclear cells circulating in the vessels of the skin.	Natl Inst Occupat Hlth, DK-2100 Copenhagen O, Denmark		Moller, P (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.	fipm@farmakol.ku.dk	Wallin, Håkan/I-6459-2012; Knudsen, Lisbeth E./W-9392-2018	Wallin, Håkan/0000-0001-7716-0166; Knudsen, Lisbeth E./0000-0002-9576-1202				ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; Anderson D, 1997, ENVIRON MOL MUTAGEN, V30, P161, DOI 10.1002/(SICI)1098-2280(1997)30:2<161::AID-EM9>3.0.CO;2-Q; BECHTHOMSEN N, 1993, ACTA DERM-VENEREOL, V73, P422; Bentham G, 1999, MUTAGENESIS, V14, P527, DOI 10.1093/mutage/14.6.527; Bentham G, 1996, BRIT MED J, V312, P1128; BETTI C, 1995, MUTAT RES-GENET TOX, V343, P201, DOI 10.1016/0165-1218(95)90015-2; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; CHADWICK CA, 1995, J PHOTOCH PHOTOBIO B, V28, P163, DOI 10.1016/1011-1344(94)07096-7; Collins A, 1997, ENVIRON MOL MUTAGEN, V30, P139, DOI 10.1002/(SICI)1098-2280(1997)30:2<139::AID-EM6>3.0.CO;2-I; Collins AR, 1998, CARCINOGENESIS, V19, P2159, DOI 10.1093/carcin/19.12.2159; De Boeck M, 2000, MUTAT RES-GEN TOX EN, V469, P181, DOI 10.1016/S1383-5718(00)00075-9; Diggle P, 1998, ANAL LONGITUDINAL DA; EBBESEN P, 1981, J NATL CANCER I, V67, P1077; Farmer PB, 1996, MUTAGENESIS, V11, P363, DOI 10.1093/mutage/11.4.363; Frenzilli G, 1997, MUTAT RES-FUND MOL M, V375, P117, DOI 10.1016/S0027-5107(97)00007-9; Frisch M, 1996, ANN INTERN MED, V125, P815, DOI 10.7326/0003-4819-125-10-199611150-00005; GREEN MHL, 1994, MUTAT RES-DNAGING G, V316, P91, DOI 10.1016/0921-8734(94)90011-6; Hardell L, 1998, ONCOL RES, V10, P1; Hartge P, 1996, J NATL CANCER I, V88, P298, DOI 10.1093/jnci/88.5.298; HOLZ O, 1995, INT ARCH OCC ENV HEA, V67, P305, DOI 10.1007/BF00385645; *IARC, 1992, IARC MON EV CARC RIS, V55; Kahn HS, 1998, JAMA-J AM MED ASSOC, V280, P910, DOI 10.1001/jama.280.10.910; LARCOM LL, 1991, PHOTOCHEM PHOTOBIOL, V53, P511, DOI 10.1111/j.1751-1097.1991.tb03663.x; Levi F, 1998, AM J EPIDEMIOL, V147, P722; Levi F, 1996, BRIT J CANCER, V74, P1847, DOI 10.1038/bjc.1996.642; McMichael AJ, 1996, BRIT J CANCER, V73, P945, DOI 10.1038/bjc.1996.169; Moller P, 1996, CHEM-BIOL INTERACT, V102, P17, DOI 10.1016/0009-2797(96)03729-5; Moller P, 1998, MUTAT RES-DNA REPAIR, V407, P25, DOI 10.1016/S0921-8777(97)00057-8; Moller P, 2000, CANCER EPIDEM BIOMAR, V9, P1005; MORISON WL, 1979, BRIT J DERMATOL, V101, P513, DOI 10.1111/j.1365-2133.1979.tb15094.x; MUNCHPETERSEN B, 1985, SCAND J CLIN LAB INV, V45, P37, DOI 10.3109/00365518509160969; Newton R, 1997, BRIT MED J, V314, P1483, DOI 10.1136/bmj.314.7092.1483b; OVREBO S, 1992, CANCER RES, V52, P1510; PAIGEN B, 1981, CANCER RES, V41, P2757; Peluso M, 1998, CANCER EPIDEM BIOMAR, V7, P3; PERERA F, 1989, CANCER RES, V49, P4446; RICHTER A, 1978, RES COMMUN CHEM PATH, V19, P453; STRICKLAND PT, 1988, PHOTODERMATOLOGY, V5, P1; SUOLINNA EM, 1982, TOXICOLOGY, V24, P73, DOI 10.1016/0300-483X(82)90064-6; Therrien JP, 1999, CANCER RES, V59, P285; Vink AA, 1997, P NATL ACAD SCI USA, V94, P5255, DOI 10.1073/pnas.94.10.5255	42	74	79	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					45	53		10.1096/fj.01-0386com	http://dx.doi.org/10.1096/fj.01-0386com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11772935				2022-12-28	WOS:000173656600006
J	Muruganandam, A; Tanha, J; Narang, S; Stanimirovic, D				Muruganandam, A; Tanha, J; Narang, S; Stanimirovic, D			Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium	FASEB JOURNAL			English	Article						phage display library; brain endothelium; drug delivery	DRUG-DELIVERY; ESCHERICHIA-COLI; IN-VITRO; CELLS; EXPRESSION; FRAGMENTS; GENE	Delivery to the brain of drugs, peptides, and genes depends on the availability of brain-specific delivery vectors. We used a phage-displayed library of llama single-domain antibodies (sdAbs) to enrich for species that selectively bind to and are internalized by human cerebromicrovascular endothelial cells (HCEC). Two sdAbs (FC5 and FC44) were selected, sequenced, subcloned, and expressed as fusion proteins with c-Myc-His(5) tags. Similar to phage-displayed sdAbs, soluble FC5 and FC44 were shown to selectively bind HCEC and to transmigrate across an in vitro human blood-brain barrier (BBB) model. Both FC5 and FC44, in contrast to an unrelated llama sdAb, were also detected in the brain after i.v. injection into mice. These small (similar to 14 kDa) antibodies have characteristics essential for a carrier-vector and can be used to facilitate drug transport across the BBB.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Stanimirovic, D (corresponding author), Natl Res Council Canada, Inst Biol Sci, Montreal Rd Campus,Bldg M-54, Ottawa, ON K1A 0R6, Canada.	danica.stanimirovic@nrc.ca						Abbott NJ, 1996, MOL MED TODAY, V2, P106, DOI 10.1016/1357-4310(96)88720-X; ANAND NN, 1991, GENE, V100, P39, DOI 10.1016/0378-1119(91)90347-E; Banks WA, 1998, J CELL SCI, V111, P533; Becerril B, 1999, BIOCHEM BIOPH RES CO, V255, P386, DOI 10.1006/bbrc.1999.0177; Bickel U, 2001, ADV DRUG DELIVER REV, V46, P247, DOI 10.1016/S0169-409X(00)00139-3; Boado RJ, 1998, J PHARM SCI-US, V87, P1308, DOI 10.1021/js9800836; BOWMAN PD, 1983, ANN NEUROL, V14, P396, DOI 10.1002/ana.410140403; BROADWELL RD, 1993, BLOOD BRAIN BARRIER, P156; DEHOUCK MP, 1992, J NEUROCHEM, V58, P1790, DOI 10.1111/j.1471-4159.1992.tb10055.x; GERHART DZ, 1988, BRAIN RES BULL, V21, P785, DOI 10.1016/0361-9230(88)90047-0; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; Girod J, 1999, J NEUROCHEM, V73, P2002; Harmsen MM, 2000, MOL IMMUNOL, V37, P579, DOI 10.1016/S0161-5890(00)00081-X; Harrison JL, 1996, METHOD ENZYMOL, V267, P83; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li JY, 1999, PROTEIN ENG, V12, P787, DOI 10.1093/protein/12.9.787; MACKENZIE CR, 1994, BIO-TECHNOL, V12, P390, DOI 10.1038/nbt0494-390; Moos T, 2000, CELL MOL NEUROBIOL, V20, P77, DOI 10.1023/A:1006948027674; Muruganandam A, 1997, FASEB J, V11, P1187, DOI 10.1096/fasebj.11.13.9367354; Muyldermans S, 1999, J MOL RECOGNIT, V12, P131, DOI 10.1002/(SICI)1099-1352(199903/04)12:2<131::AID-JMR454>3.0.CO;2-M; PARDRIDGE WM, 1990, J PHARMACOL EXP THER, V253, P884; PARDRIDGE WM, 1995, ADV DRUG DELIVER REV, V15, P109, DOI 10.1016/0169-409X(95)00007-T; Pardridge WM, 1997, J CEREBR BLOOD F MET, V17, P713, DOI 10.1097/00004647-199707000-00001; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Poul MA, 1999, J MOL BIOL, V288, P203, DOI 10.1006/jmbi.1999.2678; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Stanimirovic D, 1996, J CELL PHYSIOL, V169, P455; Stanimirovic DB, 1997, GLIA, V19, P123, DOI 10.1002/(SICI)1098-1136(199702)19:2<123::AID-GLIA4>3.0.CO;2-1; Tanha J, 2001, J BIOL CHEM, V276, P24774, DOI 10.1074/jbc.M100770200; TANHA J, 2001, IN PRESS J IMMUNOL M; Tsuji A, 1999, ADV DRUG DELIVER REV, V36, P277, DOI 10.1016/S0169-409X(98)00084-2	33	172	216	3	35	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					240	+		10.1096/fj.01-0343fje	http://dx.doi.org/10.1096/fj.01-0343fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11772942				2022-12-28	WOS:000172964800008
J	Lin, H; Bhatia, R; Lal, R				Lin, H; Bhatia, R; Lal, R			Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology	FASEB JOURNAL			English	Article						atomic force microscope; A beta P; calcium uptake; AD	RAPID CELLULAR DEGENERATION; INSULIN-DEGRADING ENZYME; BLOOD-BRAIN-BARRIER; ZN2+-SENSITIVE CHANNEL; BILAYER-MEMBRANES; PC12 CELLS; IN-VITRO; PEPTIDE; CALCIUM; NEURONS	Amyloid beta protein (A betaP) is the major constituent of senile plaques associated with Alzheimer's disease (AD). However, its mechanistic role in AD pathogenesis is poorly understood. Globular and nonfibrillar A beta Ps are continuously released during normal metabolism. Using techniques of atomic force microscopy, laser confocal microscopy, electrical recording, and biochemical assays, we have examined the molecular conformations of reconstituted globular A beta Ps as well as their real-time and acute effects on neuritic degeneration. Atomic force microscopy (AFM) of A betaP(1-42) shows globular structures that do not form fibers in physiological-buffered solution for up to 8 h of continuous imaging. AFM of A betaP(1-42) reconstituted in a planar lipid bilayer reveals multimeric channel-like structures. Consistent with these AFM resolved channel-like structures, biochemical analysis demonstrates that predominantly monomeric A beta Ps in solution form stable tetramers and hexamers after incorporation into lipid membranes. Electrophysiological recordings demonstrate the presence of multiple single channel currents of different sizes. At the cellular level, A betaP(1-42) allows calcium uptake and induces neuritic abnormality in a dose- and time-dependent fashion. At physiological nanomolar concentrations, rapid neuritic degeneration was observed within minutes; at micromolar concentrations, neuronal death was observed within 3-4 h. These effects are prevented by zinc (an A betaP channel blocker) and by the removal of extracellular calcium, but are not prevented by antagonists of putative AbP cell surface receptors. Thus, A betaP channels may provide a direct pathway for calcium-dependent A betaP toxicity in AD.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Lal, R (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.	lal@lifesci.ucsb.edu						Anderton BH, 1998, PROG NEUROBIOL, V55, P595, DOI 10.1016/S0301-0082(98)00022-7; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Arispe N, 1996, P NATL ACAD SCI USA, V93, P1710, DOI 10.1073/pnas.93.4.1710; Bhatia R, 2000, FASEB J, V14, P1233, DOI 10.1096/fasebj.14.9.1233; Biere AL, 1996, J BIOL CHEM, V271, P32916, DOI 10.1074/jbc.271.51.32916; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Cummings JL, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.1_Suppl_1.S2; DURELL SR, 1994, BIOPHYS J, V67, P2137, DOI 10.1016/S0006-3495(94)80717-9; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; GhersiEgea JF, 1996, J NEUROCHEM, V67, P880; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Harkany T, 1999, NEUROBIOL DIS, V6, P109, DOI 10.1006/nbdi.1998.0230; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hirakura Y, 1999, J NEUROSCI RES, V57, P458, DOI 10.1002/(SICI)1097-4547(19990815)57:4<458::AID-JNR5>3.0.CO;2-4; Huang HM, 2000, LIFE SCI, V66, P1525, DOI 10.1016/S0024-3205(00)00470-7; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jensen M, 1999, ANN NEUROL, V45, P504, DOI 10.1002/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO;2-9; Kawahara M, 2000, BRAIN RES BULL, V53, P389, DOI 10.1016/S0361-9230(00)00370-1; Kawahara M, 1997, BIOPHYS J, V73, P67, DOI 10.1016/S0006-3495(97)78048-2; Kourie JI, 2000, AM J PHYSIOL-CELL PH, V278, pC1063, DOI 10.1152/ajpcell.2000.278.6.C1063; Kuo YM, 1996, J BIOL CHEM, V271, P4077; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; LAL R, 1994, AM J PHYSIOL, V266, pC1, DOI 10.1152/ajpcell.1994.266.1.C1; Lane NJ, 1998, J NEUROCYTOL, V27, P707, DOI 10.1023/A:1006976400227; Lin H, 1999, BIOCHEMISTRY-US, V38, P11189, DOI 10.1021/bi982997c; Mason RP, 1999, J BIOL CHEM, V274, P18801, DOI 10.1074/jbc.274.26.18801; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; MIRZABEKOV T, 1998, METH ENZ, V294, P67; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; Mou JX, 1996, BIOCHEMISTRY-US, V35, P3222, DOI 10.1021/bi9520242; NAIDU A, 1995, J BIOL CHEM, V270, P1369, DOI 10.1074/jbc.270.3.1369; Pallitto MM, 1999, BIOCHEMISTRY-US, V38, P3570, DOI 10.1021/bi982119e; PARBHU A, 2001, IN PRESS PEPTIDES; Pillot T, 1999, J NEUROCHEM, V73, P1626, DOI 10.1046/j.1471-4159.1999.0731626.x; Poduslo JF, 1999, NEUROBIOL DIS, V6, P190, DOI 10.1006/nbdi.1999.0238; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Rhee SK, 1998, J BIOL CHEM, V273, P13379, DOI 10.1074/jbc.273.22.13379; Sanderson KL, 1997, BRAIN RES, V744, P7, DOI 10.1016/S0006-8993(96)01060-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMMONS MA, 1993, NEUROSCI LETT, V150, P133, DOI 10.1016/0304-3940(93)90519-Q; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Torp R, 2000, PROG NEURO-PSYCHOPH, V24, P801, DOI 10.1016/S0278-5846(00)00107-X; Tseng BP, 1999, BIOCHEMISTRY-US, V38, P10424, DOI 10.1021/bi990718v; Vargas J, 2000, BIOPHYS J, V79, P934, DOI 10.1016/S0006-3495(00)76348-X; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; WHITSON JS, 1995, NEUROBIOL AGING, V16, P5, DOI 10.1016/0197-4580(95)80002-9; Yamin R, 1999, J BIOL CHEM, V274, P18777, DOI 10.1074/jbc.274.26.18777; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Zhu YJ, 2000, FASEB J, V14, P1244, DOI 10.1096/fasebj.14.9.1244; ZLOKOVIC BV, 1993, BIOCHEM BIOPH RES CO, V197, P1034, DOI 10.1006/bbrc.1993.2582	53	525	550	2	133	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2433	2444		10.1096/fj.01-0377com	http://dx.doi.org/10.1096/fj.01-0377com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689468				2022-12-28	WOS:000172420500013
J	Berdyshev, EV; Schmid, PC; Krebsbach, RJ; Schmid, HHO				Berdyshev, EV; Schmid, PC; Krebsbach, RJ; Schmid, HHO			Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells	FASEB JOURNAL			English	Article						anandamide; platelet-activating factor; macrophages; human platelets	CANNABINOID CB1 RECEPTOR; RAT KUPFFER CELLS; NF-KAPPA-B; PLATELET-AGGREGATION; GENE-EXPRESSION; NUCLEAR FACTOR; T-CELLS; ANANDAMIDE; ACID; ACYLETHANOLAMINES	The endocannabinoid signaling system is believed to play a down-regulatory role in the control of cell functions. However, little is known about the factors activating endocannabinoid synthesis and which of two known endocannabinoids, 2-arachidonoylglycerol (2-AG) or N-arachidonoylethanolamine (20:4n-6 NAE, anandamide), is of physiological importance. We approached these questions by studying a possible link between cell activation with 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor, PAF) and the generation of 2-AG and anandamide in human platelets and mouse P388D1 macrophages. Human platelets responded to stimulation with the production of various 1- and 2-monoacylglycerols, including 2-AG, whereas stimulation of P388D1 macrophages induced the rapid and selective generation of 2-AG, which was immediately released into the medium. The effect of PAF was receptor mediated, as PAF receptor antagonist BN52021 blocked the effect. The treatment did not change the content of anandamide in either macrophages or platelet-rich plasma. The inhibitors of PI- and PC-specific phospholipases C (U73122 and D609) as well as PI3-kinase inhibitor (wortmannin) attenuated PAF-induced 2-AG production in macrophages. These data suggest a direct role for the endocannabinoid system in controlling immune cell activation status and indicate that 2-AG rather than anandamide is the endocannabinoid rapidly produced in response to proinflammatory stimulation of immune cells.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Berdyshev, EV (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	eberdyshev@hotmail.com			NIGMS NIH HHS [GM45741] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045741] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ben-Shabat S, 1998, EUR J PHARMACOL, V353, P23, DOI 10.1016/S0014-2999(98)00392-6; Berdyshev E, 1998, LIFE SCI, V63, pPL125, DOI 10.1016/S0024-3205(98)00324-5; Berdyshev EV, 2000, BIOCHEM J, V346, P369, DOI 10.1042/0264-6021:3460369; Berdyshev EV, 1997, EUR J PHARMACOL, V330, P231, DOI 10.1016/S0014-2999(97)01007-8; Berdyshev EV, 2000, CHEM PHYS LIPIDS, V108, P169, DOI 10.1016/S0009-3084(00)00195-X; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONAVIDA B, 1994, CLIN REV ALLERG, V12, P381; BOTTECCHIA D, 1984, SCAND J HAEMATOL, V32, P33; Boulay F, 1997, ANN NY ACAD SCI, V832, P69, DOI 10.1111/j.1749-6632.1997.tb46238.x; BRAQUET P, 1991, MED RES REV, V11, P295, DOI 10.1002/med.2610110303; CATTANEO M, 1985, THROMB HAEMOSTASIS, V53, P221; Condie R, 1996, J BIOL CHEM, V271, P13175, DOI 10.1074/jbc.271.22.13175; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1999, EUR J BIOCHEM, V264, P258, DOI 10.1046/j.1432-1327.1999.00631.x; DUDLEY DT, 1986, BIOCHEM J, V236, P235, DOI 10.1042/bj2360235; ElBawab S, 1996, J LIPID RES, V37, P2098; Gallily R, 2000, EUR J PHARMACOL, V406, pR5, DOI 10.1016/S0014-2999(00)00653-1; GANDHI CR, 1991, LIPIDS, V26, P1038, DOI 10.1007/BF02536498; GANDHI CR, 1990, J BIOL CHEM, V265, P18234; Gonsiorek W, 2000, MOL PHARMACOL, V57, P1045; HANAHAN DJ, 1985, METHOD BIOCHEM ANAL, V31, P195, DOI 10.1002/9780470110522.ch4; Kaminski NE, 1998, J NEUROIMMUNOL, V83, P124, DOI 10.1016/S0165-5728(97)00228-2; Kaminski NE, 1996, BIOCHEM PHARMACOL, V52, P1133, DOI 10.1016/0006-2952(96)00480-7; Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0; Klein TW, 1998, IMMUNOL TODAY, V19, P373, DOI 10.1016/S0167-5699(98)01300-0; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Lauener RW, 1999, BBA-MOL CELL RES, V1452, P197, DOI 10.1016/S0167-4889(99)00125-1; LEE M, 1995, J PHARMACOL EXP THER, V275, P529; Maccarrone M, 2001, EUR J BIOCHEM, V268, P819, DOI 10.1046/j.1432-1327.2001.01942.x; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 1998, EUR J PHARMACOL, V362, pR1, DOI 10.1016/S0014-2999(98)00777-8; MUTOH H, 1994, BIOCHEM BIOPH RES CO, V205, P1137, DOI 10.1006/bbrc.1994.2784; Ouyang YL, 1998, MOL PHARMACOL, V53, P676, DOI 10.1124/mol.53.4.676; Pestonjamasp VK, 1998, BBA-LIPID LIPID MET, V1394, P249, DOI 10.1016/S0005-2760(98)00110-6; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Schmid HHO, 2000, CHEM PHYS LIPIDS, V108, P71, DOI 10.1016/S0009-3084(00)00188-2; Schmid PC, 1997, CHEM PHYS LIPIDS, V87, P103, DOI 10.1016/S0009-3084(97)00032-7; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; Schmid PC, 2000, CHEM PHYS LIPIDS, V104, P185, DOI 10.1016/S0009-3084(99)00124-3; SEBALDT RJ, 1992, BIOCHEM J, V284, P367, DOI 10.1042/bj2840367; SHUKLA SD, 1991, LIPIDS, V26, P1028, DOI 10.1007/BF02536496; SOLOWIJ N, 1999, HLTH EFFECTS CANNABI, P195; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 2000, CHEM PHYS LIPIDS, V108, P89, DOI 10.1016/S0009-3084(00)00189-4; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; Sugiura T, 1998, BIOCHEM BIOPH RES CO, V243, P838, DOI 10.1006/bbrc.1998.8187; Varga K, 1998, FASEB J, V12, P1035, DOI 10.1096/fasebj.12.11.1035; Wagner JA, 1997, NATURE, V390, P518, DOI 10.1038/37371; Yea SS, 2000, J PHARMACOL EXP THER, V292, P597	52	77	80	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2171	2178		10.1096/fj.01-0181com	http://dx.doi.org/10.1096/fj.01-0181com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641243				2022-12-28	WOS:000171920400028
J	Forteza, R; Lieb, T; Aoki, T; Savani, RC; Conner, GE; Salathe, M				Forteza, R; Lieb, T; Aoki, T; Savani, RC; Conner, GE; Salathe, M			Hyaluronan serves a novel role in airway mucosal host defense	FASEB JOURNAL			English	Article						kallikrein; lactoperoxidase; cilia; epithelium; airway	IMMUNOREACTIVE TISSUE KALLIKREIN; LOWER RESPIRATORY-TRACT; CILIARY BEAT FREQUENCY; BRONCHOALVEOLAR LAVAGE; ASTHMATIC SUBJECTS; EPITHELIAL-CELLS; BINDING-PROTEIN; RECEPTOR RHAMM; SPERM MOTILITY; GUINEA-PIG	Enzymes secreted onto epithelial surfaces play a vital role in innate mucosal defense, but are believed to be steadily removed from the surface by mechanical actions. Thus, the amount and availability of enzymes on the surface are thought to be maintained by secretion. In contrast to this paradigm, we show here that enzymes are retained at the apical surface of the airway epithelium by binding to surface-associated hyaluronan, providing an apical enzyme pool 'ready for use' and protected from ciliary clearance. We have studied lactoperoxidase, which prevents bacterial colonization of the airway, and kallikrein, which mediates allergic bronchoconstriction that limits the inhalation of noxious substances. Binding to hyaluronan inhibits kallikrein, which is needed only in certain situations, whereas lactoperoxidase, useful at all times, does not change its activity. Hyaluronan itself interacts with the receptor for hyaluronic acid-mediated motility (RHAMM or CD168) that is expressed at the apex of ciliated airway epithelial cells. Functionally, hyaluronan binding to RHAMM stimulates ciliary beating. Thus, hyaluronan plays a previously unrecognized pivotal role in mucosal host defense by stimulating ciliary clearance of foreign material while simultaneously retaining enzymes important for homeostasis at the apical surface so that they cannot be removed by ciliary action.	Univ Miami, Sch Med, Div Pulm & Crit Care Med R47, Miami, FL 33136 USA; Univ Penn, Sch Med, Div Neonatol, Philadelphia, PA 19104 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA	University of Miami; University of Pennsylvania; University of Miami	Salathe, M (corresponding author), Univ Miami, Sch Med, Div Pulm & Crit Care Med R47, 1600 NW 10th Ave,RMSB 7063, Miami, FL 33136 USA.	msalathe@miami.edu	Conner, Gregory/AAI-1285-2021; Rashmin C. Savani, MBChB/AAG-2041-2021	Conner, Gregory/0000-0003-2217-2252; Rashmin C. Savani, MBChB/0000-0002-9533-5422; Salathe, Matthias/0000-0001-9092-4861	PHS HHS [R01-62472, K01-03534, R01-60644] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BASBAUM CB, 1987, BIORHEOLOGY, V24, P585; BJERMER L, 1992, EUR RESPIR J, V5, P785; BRAY BA, 1994, EXP LUNG RES, V20, P317, DOI 10.3109/01902149409064390; CHRISTENSEN TG, 1984, SURV SYN PATHOL RES, V3, P201; CHRISTENSEN TG, 1981, CELL TISSUE RES, V214, P407; CHRISTIANSEN SC, 1992, AM REV RESPIR DIS, V145, P900, DOI 10.1164/ajrccm/145.4_Pt_1.900; Cole AM, 1999, INFECT IMMUN, V67, P3267, DOI 10.1128/IAI.67.7.3267-3275.1999; Forteza R, 1999, AM J RESP CELL MOL, V21, P666, DOI 10.1165/ajrcmb.21.6.3651; FRESCURA M, 1994, BIOCHEM SOC T, V22, pS228; Gerson C, 2000, AM J RESP CELL MOL, V22, P665, DOI 10.1165/ajrcmb.22.6.3980; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HARLOW E, 1988, ANTIBODIES LAB MAN; HUBBARD RC, 1989, P NATL ACAD SCI USA, V86, P680, DOI 10.1073/pnas.86.2.680; HUSZAR G, 1990, FERTIL STERIL, V54, P1127; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Korngreen A, 1996, J PHYSIOL-LONDON, V497, P53, DOI 10.1113/jphysiol.1996.sp021749; KORNOVSKI BS, 1994, FERTIL STERIL, V61, P935; Lackie PM, 1997, AM J RESP CELL MOL, V16, P14, DOI 10.1165/ajrcmb.16.1.8998074; LARSSON K, 1992, CHEST, V101, P109, DOI 10.1378/chest.101.1.109; Lieb T, 2000, J AEROSOL MED, V13, P231, DOI 10.1089/jam.2000.13.231; Lin WQ, 1997, J HISTOCHEM CYTOCHEM, V45, P1157, DOI 10.1177/002215549704500813; LONGAKER MT, 1990, J PEDIATR SURG, V25, P430, DOI 10.1016/0022-3468(90)90387-O; NILSSON K, 1990, INT J RADIAT BIOL, V58, P519, DOI 10.1080/09553009014551861; PAUL A, 1988, ARCH BIOCHEM BIOPHYS, V260, P75, DOI 10.1016/0003-9861(88)90426-2; POBLETE MT, 1993, HISTOCHEM J, V25, P834; PROUD D, 1993, AM J RESP CELL MOL, V8, P16, DOI 10.1165/ajrcmb/8.1.16; Salathe M, 1997, AM J RESP CELL MOL, V17, P97, DOI 10.1165/ajrcmb.17.1.2719; SALATHE M, 1995, J CELL SCI, V108, P431; Salathe M, 1999, J PHYSIOL-LONDON, V520, P851, DOI 10.1111/j.1469-7793.1999.00851.x; Salathe M, 1997, AM J PHYSIOL-LUNG C, V272, pL301, DOI 10.1152/ajplung.1997.272.2.L301; SAVANI RC, 1995, J CLIN INVEST, V95, P1158, DOI 10.1172/JCI117764; SAVANI RC, 1995, P W PHARMACOL SOC, V38, P131; Sbracia M, 1997, HUM REPROD, V12, P1949, DOI 10.1093/humrep/12.9.1949; SCOTT JE, 1998, SCI HYALURONAN TODAY; Turley E., 1999, SCI HYALURONAN TODAY; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; Uzlaner N, 1999, J PHYSIOL-LONDON, V516, P179, DOI 10.1111/j.1469-7793.1999.179aa.x; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; WEISSMANN B, 1954, J AM CHEM SOC, V76, P1753, DOI 10.1021/ja01636a010; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YOSHITSUGU M, 1993, ACTA OTO-LARYNGOL, V113, P655, DOI 10.3109/00016489309135880	46	100	100	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2179	2186		10.1096/fj.01-0036com	http://dx.doi.org/10.1096/fj.01-0036com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641244				2022-12-28	WOS:000171920400029
J	Brandenburger, Y; Jenkins, A; Autelitano, DJ; Hannan, RD				Brandenburger, Y; Jenkins, A; Autelitano, DJ; Hannan, RD			Increased expression of UBF is a critical determinant for rRNA synthesis and hypertrophic growth of cardiac myocytes	FASEB JOURNAL			English	Article						rDNA transcription; cardiomyocyte hypertrophy; antisense RNA; adenovirus	POLYMERASE-I TRANSCRIPTION; UPSTREAM BINDING-FACTOR; RDNA TRANSCRIPTION; DNA-TRANSCRIPTION; HEART-CELLS; NEONATAL CARDIOMYOCYTES; PROTEIN-SYNTHESIS; ACTIVATION; KINASE; RECEPTOR	Recent evidence suggests that increased translational efficiency of existing ribosomes alone is insufficient to account for the hypertrophic growth of cardiomyocytes and that synthesis of new functional ribosomes must occur. The rate-limiting step in ribosome accumulation is the transcription of the ribosomal 45S genes (rDNA) by RNA polymerase I. Our previous studies have demonstrated that increases in the expression of the rDNA transcription factor UBF correlated with hypertrophy of neonatal cardiomyocytes. These studies expand this observation to examine directly the hypothesis that increased UBF levels are an essential requirement for the initiation of cardiac hypertrophy. We demonstrate that the introduction of UBF antisense RNA into myocytes, using adenovirus approaches, efficiently inhibits UBF accumulation during induction of cardiomyocyte hypertrophy. Moreover, this approach results in a significant reduction in rDNA transcription, rRNA levels, and protein accumulation, which are all the hallmarks of cardiac growth. Furthermore, UBF antisense RNA expression did not alter reexpression of the fetal gene program, which confirmed that the effect was specific for transcription by RNA polymerase I. These findings demonstrate that an increase in rRNA synthesis is required for hypertrophy of cardiomyocytes and also implicate UBF as a major regulatory factor in this process. Approaches that target UBF activity may be of therapeutic use in the regression of pathophysiological cardiac hypertrophy.	Baker Med Res Inst, Mol Physiol Lab, Melbourne, Vic 8008, Australia	Baker Heart and Diabetes Institute	Hannan, RD (corresponding author), Baker Med Res Inst, Mol Physiol Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	ross.hannan@baker.edu.au	Jenkins, Alicia/N-2482-2015	Hannan, Ross/0000-0002-2166-4493				ARDATI A, 1993, EMBO J, V12, P5131, DOI 10.1002/j.1460-2075.1993.tb06208.x; Boluyt MO, 1997, CIRC RES, V81, P176, DOI 10.1161/01.RES.81.2.176; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHIEN KR, 1998, MOL BASIS CARDIOVASC, P211; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; DROUET C, 1991, J IMMUNOL, V147, P1694; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; GLIBETIC M, 1995, J BIOL CHEM, V270, P4209, DOI 10.1074/jbc.270.9.4209; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; Hannan KM, 2000, ONCOGENE, V19, P4988, DOI 10.1038/sj.onc.1203875; Hannan KM, 1998, FRONT BIOSCI, V3, P376, DOI [10.2741/A282, DOI 10.2741/A282]; Hannan R, 1999, NUCLEIC ACIDS RES, V27, P1205, DOI 10.1093/nar/27.4.1205; HANNAN R, 1998, TRANSCRIPTION RIBOSO, V1, P221; HANNAN RD, 1995, J BIOL CHEM, V270, P8290, DOI 10.1074/jbc.270.14.8290; Hannan RD, 1996, J BIOL CHEM, V271, P3213, DOI 10.1074/jbc.271.6.3213; Hannan RD, 1996, P NATL ACAD SCI USA, V93, P8750, DOI 10.1073/pnas.93.16.8750; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HISATAKE K, 1991, NUCLEIC ACIDS RES, V19, P4631, DOI 10.1093/nar/19.17.4631; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kihm AJ, 1998, P NATL ACAD SCI USA, V95, P14816, DOI 10.1073/pnas.95.25.14816; Klein J, 1999, P NATL ACAD SCI USA, V96, P6096, DOI 10.1073/pnas.96.11.6096; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; Laser M, 1998, J BIOL CHEM, V273, P24610, DOI 10.1074/jbc.273.38.24610; Luyken J, 1996, CIRC RES, V78, P354, DOI 10.1161/01.RES.78.3.354; MATHEWS MB, 1975, CELL, V6, P223, DOI 10.1016/0092-8674(75)90013-6; MATHEWS MB, 1993, SEMIN VIROL, V4, P247, DOI 10.1006/smvy.1993.1021; MCDERMOTT PJ, 1989, CIRC RES, V64, P542, DOI 10.1161/01.RES.64.3.542; MCDERMOTT PJ, 1991, J BIOL CHEM, V266, P4409; MCDERMOTT PJ, 1989, J BIOL CHEM, V264, P18220; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; Morgan HECB, 1992, HEART CARDIOVASCULAR, P1505; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; Nagatomo Y, 1999, AM J PHYSIOL-HEART C, V277, pH2176; OMAHONY DJ, 1991, P NATL ACAD SCI USA, V88, P3180, DOI 10.1073/pnas.88.8.3180; PAULE M, 1998, TRANSCRIPTION EUKARY; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; PETTERSSON U, 1975, CELL, V6, P1, DOI 10.1016/0092-8674(75)90066-5; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Sheridan DJ, 2000, CARDIOVASC RES, V47, P133, DOI 10.1016/S0008-6363(00)00065-1; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SIEHL D, 1985, AM J PHYSIOL, V248, pC309, DOI 10.1152/ajpcell.1985.248.3.C309; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; Tuan JC, 1999, MOL CELL BIOL, V19, P2872; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	53	51	51	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2051	+		10.1096/fj.00-0853fje	http://dx.doi.org/10.1096/fj.00-0853fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511532				2022-12-28	WOS:000170318500018
J	Mandal, AK; Zhang, ZJ; Chou, JY; Mukherjee, AB				Mandal, AK; Zhang, ZJ; Chou, JY; Mukherjee, AB			Pancreatic phospholipase A(2) via its receptor regulates the expression of key enzymes of phospholipid and sphingolipid metabolism	FASEB JOURNAL			English	Article						phospholipase A(2-)receptor; signal-transduction/cyclooxygenase-2; Mg++-dependent neutral sphingomyelinase; acid ceramidase	ACTIVATED PROTEIN-KINASE; CYCLOOXYGENASE-2 GENE-EXPRESSION; SMOOTH-MUSCLE CELLS; BINDING-SITE; TRANSCRIPTIONAL REGULATION; MOLECULAR-CLONING; ARACHIDONIC-ACID; MESANGIAL CELLS; MESSENGER-RNA; CANCER-CELLS	Although the pancreatic secretory phospholipase A(2) (sPLA(2)IB) is considered a digestive enzyme, it has several important, nonenzymatic, receptor-mediated functions. In this study, we demonstrate that via its receptor, sPLA(2)IB stimulates the expression of cytosolic PLA(2) (cPLA(2))-, cyclooxygenase-2 (COX-2)-, Mg++-dependent neutral sphingomyelinase (NSMase)- and acid ceramidase (AC)- mRNAs in NIH 3T3 cells. Moreover, through its receptor, sPLA(2)IB also mediates the activation of cPLA(2) and p38 MAPK. We also found similar effects when the NIH 3T3 cells were treated with interleukin 1 beta (IL-beta), fibroblast growth factor (FGF), and hepatocyte growth factor (HGF) under identical conditions. These effects are not dependent on the catalytic activity of sPLA(2)IB, as both heat- and chemically inactivated enzyme induced these effects. Although protein kinase C and p38 mitogen-activated protein kinases are critical for the sPLA(2) receptor-mediated stimulation of expression of cytosolic PLA(2) and cyclooxygenase-2 mRNAs, respectively, the activation of these kinases is not required for neutral sphingomyelinase and acid ceramidase mRNA expression. Our results, for the first time, raise the possibility that, via its receptor, sPLA(2)IB plays important roles in the regulation of both phospholipid and sphingolipid metabolism.	NICHHD, Sect Dev Genet, NIH, Bethesda, MD 20892 USA; NICHHD, Sect Cellular Differentiat, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mukherjee, AB (corresponding author), NICHHD, Sect Dev Genet, NIH, Bldg 10,Room 9S241, Bethesda, MD 20892 USA.	mukherja@exchange.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912, ZIAHD000910] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000910, Z01HD000912] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; ARITA H, 1991, J BIOL CHEM, V266, P19139; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; Cao WB, 2000, GASTROENTEROLOGY, V119, P1243, DOI 10.1053/gast.2000.19581; Chen BC, 1999, IMMUNOLOGY, V97, P124, DOI 10.1046/j.1365-2567.1999.00747.x; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Ershov AV, 1999, J NEUROSCI RES, V58, P254, DOI 10.1002/(SICI)1097-4547(19991015)58:2<254::AID-JNR5>3.3.CO;2-L; Fenard D, 1999, J CLIN INVEST, V104, P611, DOI 10.1172/JCI6915; Fonteh AN, 2000, J IMMUNOL, V165, P2773, DOI 10.4049/jimmunol.165.5.2773; Fonteh AN, 1998, BBA-LIPID LIPID MET, V1393, P253, DOI 10.1016/S0005-2760(98)00079-4; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352; GRONROOS JM, 1992, DIGESTION, V52, P232, DOI 10.1159/000200958; HANADA K, 1995, FEBS LETT, V373, P85, DOI 10.1016/0014-5793(95)01005-Y; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; Hanasaki K, 1999, ARCH BIOCHEM BIOPHYS, V372, P215, DOI 10.1006/abbi.1999.1511; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; Huwiler A, 1997, BBA-LIPID LIPID MET, V1348, P257, DOI 10.1016/S0005-2760(97)00073-8; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; ISHIZAKI J, 1993, FEBS LETT, V324, P349, DOI 10.1016/0014-5793(93)80149-O; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Jones MK, 1999, FASEB J, V13, P2186, DOI 10.1096/fasebj.13.15.2186; KANEMASA T, 1992, FEBS LETT, V303, P217, DOI 10.1016/0014-5793(92)80523-J; KANEMASA T, 1992, BIOCHIM BIOPHYS ACTA, V1125, P210, DOI 10.1016/0005-2760(92)90047-Y; Kinoshita E, 1997, FEBS LETT, V407, P343, DOI 10.1016/S0014-5793(97)00373-6; Kinoshita E, 1996, INT J ONCOL, V9, P1219; KISHINO J, 1994, J BIOL CHEM, V269, P5092; KISHINO J, 1992, BIOCHEM BIOPH RES CO, V186, P1025, DOI 10.1016/0006-291X(92)90849-G; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Kundu GC, 1997, J BIOL CHEM, V272, P2346; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SOMMERS CD, 1992, EUR J PHARMACOL, V216, P87, DOI 10.1016/0014-2999(92)90213-N; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; VADAS P, 1986, LAB INVEST, V55, P391; Wadleigh DJ, 1999, BIOCHEM BIOPH RES CO, V264, P865, DOI 10.1006/bbrc.1999.1606; WAITE M, 1987, HDB LIPID RES, V5, P111; WHATLEY RE, 1993, J BIOL CHEM, V268, P16130; Yuan CJ, 2000, CANCER RES, V60, P1084	60	23	24	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1834	+		10.1096/fj.00-0831fje	http://dx.doi.org/10.1096/fj.00-0831fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481246				2022-12-28	WOS:000169261200009
J	Bezombes, C; Plo, I; Mas, WMD; Quillet-Mary, A; Negre-Salvayre, A; Laurent, G; Jaffrezou, JP				Bezombes, C; Plo, I; Mas, WMD; Quillet-Mary, A; Negre-Salvayre, A; Laurent, G; Jaffrezou, JP			Oxidative stress-induced activation of Lyn recruits sphingomyelinase and is requisite for its stimulation by Ara-C	FASEB JOURNAL			English	Article						apoptosis; Lyn kinase; reactive oxygen species	INTERNUCLEOSOMAL DNA FRAGMENTATION; P56/P53(LYN) TYROSINE KINASE; MYELOID-LEUKEMIA CELLS; INDUCED APOPTOSIS; CERAMIDE GENERATION; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; IONIZING-RADIATION; HYDROGEN-PEROXIDE; CELLULAR-RESPONSE	Induction of apoptosis is considered to be the underlying mechanism that accounts for the efficiency of chemotherapeutic drugs. The identification of ceramide as a key mediator of apoptosis has made it possible to identify cellular entities that regulate drug-induced sphingomyelinase activation. Using human leukemia cell lines, we demonstrate that 1-beta-D-arabinofuranosylcytosine (Ara-C) stimulated ceramide generation, which was dependent on reactive oxygen species (ROS). Co-immunoprecipitation studies revealed that Ara-C-generated ROS activated the scr kinase p53/p56 Lyn, which then recruited neutral sphingomyelinase and was responsible for its activation. These effects were blocked by herbimycin A and Lyn antisense oligonucleotides. In conclusion, this study establishes a series of events in which early ROS generated by Ara-C leads to Lyn-dependent neutral sphingomyelinase activation, JNK phosphorylation, and apoptosis.	Inst Claudius Regaud, INSERM, E9910, F-31052 Toulouse, France; CHU Purpan, Hematol Serv, F-31059 Toulouse, France; CHU Rangueil, INSERM, U466, Lab Biochim Med, F-31403 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; CHU de Toulouse; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Jaffrezou, JP (corresponding author), Inst Claudius Regaud, INSERM, E9910, 20 Rue Pont St Pierre, F-31052 Toulouse, France.	jaffrezou@icr.fnclcc.fr	Bezombes, Christine/G-2743-2017; QUILLET-MARY, Anne/H-4690-2013; Plo, Isabelle/C-9056-2017; Bezombes, christine/X-8479-2019; Plo, Isabelle/AAT-6742-2021; Bezombes, Christine/AAC-1724-2020	Plo, Isabelle/0000-0002-5915-6910; Bezombes, christine/0000-0003-4079-4872; QUILLET-MARY, Anne/0000-0002-1849-6388; Negre-Salvayre, Anne/0000-0003-2136-5706				Backway KL, 1997, CANCER RES, V57, P2446; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bradshaw CD, 1996, BIOCHEM MOL BIOL INT, V40, P709; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; CHABNER BA, 1989, CANC PRINCIPALS PRAC, P154; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; FRAM RJ, 1982, CANCER RES, V42, P4050; FREI E, 1969, CANCER RES, V29, P1325; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Goldkorn T, 1998, J CELL SCI, V111, P3209; Goldman R, 1997, ADV EXP MED BIOL, V400, P25; GUNJI H, 1991, CANCER RES, V51, P741; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HU ZB, 1995, LEUKEMIA, V9, P789; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JI L, 1995, BIOCHEM BIOPH RES CO, V212, P640, DOI 10.1006/bbrc.1995.2017; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KHARBANDA S, 1994, ONCOGENE, V9, P3005; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Mansat-De Mas V, 1999, MOL PHARMACOL, V56, P867, DOI 10.1124/mol.56.5.867; Maziere C, 2001, BIOCHEM BIOPH RES CO, V281, P289, DOI 10.1006/bbrc.2001.4348; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; NAKANISHI O, 1993, J BIOL CHEM, V268, P10754; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; STRUM JC, 1994, J BIOL CHEM, V269, P15493; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041	31	30	31	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1583	+		10.1096/fj.00-0787fje	http://dx.doi.org/10.1096/fj.00-0787fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427493				2022-12-28	WOS:000173707700029
J	Park, JS; Park, WY; Cho, KA; Kim, DI; Jhun, BH; Kim, SR; Park, SC				Park, JS; Park, WY; Cho, KA; Kim, DI; Jhun, BH; Kim, SR; Park, SC			Down-regulation of amphiphysin-1 is responsible for reduced receptor-mediated endocytosis in the senescent cells	FASEB JOURNAL			English	Article						amphiphysin-1; endocytosis; senescence; human diploid fibroblast	EPIDERMAL GROWTH-FACTOR; HUMAN-FIBROBLASTS; DOMAIN; BINDING; DYNAMIN; PHOSPHORYLATION; EXPRESSION; CULTURE; PROTEIN; SITE	Senescent cells have been generally characterized to have improper responsiveness to external stimuli and inefficient uptake of materials compared with presenescent cells, probably by down-regulation of receptor-mediated endocytosis. Using transferrin-uptake assay and Western blot of endocytosis-related proteins, we found that a significant decrease of amphiphysin-1 is strongly related to the reduction of receptor-mediated endocytosis in both human diploid fibroblasts of multipassages and hydrogen peroxide-induced premature senescence. We reconfirmed the pivotal role of amphiphysin-1 in senescence by showing that transfection of dominant negative amphiphysin-1 reduces transferrin uptake in presenescent cells and that microinjection of wild-type amphiphysin-1 into senescent cells restores the ability of the transferrin uptake nearly up to that of the presenescent cell. We conclude that the loss of endocytotic activity of senescent cells is directly related to the down-regulation of amphiphysin-1, and its functional restorability can be induced by simple microinjection of amphiphysin-1 gene in the senescent cells.	Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 110799, South Korea; Pusan Natl Univ, Coll Pharm, Dept Pharmacol, Pusan 609735, South Korea; Chungbuk Natl Univ, Coll Med, Dept Biochem, Cheongju, South Korea	Seoul National University (SNU); Pusan National University; Chungbuk National University	Park, SC (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, 28 Yongondong, Seoul 110799, South Korea.	separk@snu.ac.kr	park, woongyang/D-5727-2012					Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JIN Y, 2001, IN PRESS EXP MOL MED; MATRISIAN LM, 1987, EXP GERONTOL, V22, P81, DOI 10.1016/0531-5565(87)90043-X; MATSUDA T, 1992, J CELL PHYSIOL, V150, P510, DOI 10.1002/jcp.1041500311; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; Park SC, 1999, J GERONTOL A-BIOL, V54, pB78, DOI 10.1093/gerona/54.2.B78; Park WY, 2000, J BIOL CHEM, V275, P20847, DOI 10.1074/jbc.M908162199; PHILLIPS PD, 1983, J CELL PHYSIOL, V114, P311, DOI 10.1002/jcp.1041140309; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; TANG ZQ, 1994, MECH AGEING DEV, V73, P57, DOI 10.1016/0047-6374(94)90038-8; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5	24	33	33	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1625	+		10.1096/fj.00-0723fje	http://dx.doi.org/10.1096/fj.00-0723fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427507				2022-12-28	WOS:000173707700023
J	Alves, F; Saupe, S; Ledwon, M; Schaub, F; Hiddemann, W; Vogel, WF				Alves, F; Saupe, S; Ledwon, M; Schaub, F; Hiddemann, W; Vogel, WF			Identification of two novel, kinase-deficient variants of discoidin domain receptor 1: differential expression in human colon cancer cell lines	FASEB JOURNAL			English	Article									Univ Gottingen, Dept Hematol & Oncol, D-37075 Gottingen, Germany; Univ Gottingen, Dept Cardiol & Pneumol, D-37075 Gottingen, Germany; Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, D-81377 Munich, Germany; Univ Frankfurt, Georg Speyer Haus Inst Biomed Res, Dept Extracellular Matrix Signaling, D-60596 Frankfurt, Germany	University of Gottingen; University of Gottingen; University of Munich; Goethe University Frankfurt	Alves, F (corresponding author), Univ Gottingen, Dept Hematol & Oncol, Robert Koch Str 40, D-37075 Gottingen, Germany.								0	78	82	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1321	1323		10.1096/fj.00-0626fje	http://dx.doi.org/10.1096/fj.00-0626fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344127				2022-12-28	WOS:000168655200049
J	Liu, ZT; Chang, GQ; Leibowitz, SF				Liu, ZT; Chang, GQ; Leibowitz, SF			Apolipoprotein D interacts with the long-form leptin receptor: a hypothalamic function in the control of energy homeostasis	FASEB JOURNAL			English	Article									Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Leibowitz, SF (corresponding author), Rockefeller Univ, Box 278,1230 York Ave, New York, NY 10021 USA.								0	33	35	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1329	1331		10.1096/fj.00-0530fje	http://dx.doi.org/10.1096/fj.00-0530fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344130				2022-12-28	WOS:000168655200052
J	Klocke, R; Bartels, T; Jennings, G; Brand, K; Halter, R; Strauss, M; Paul, D				Klocke, R; Bartels, T; Jennings, G; Brand, K; Halter, R; Strauss, M; Paul, D			Lack of p53 accelerates hepatocarcinogenesis in transgenic mice constitutively overexpressing c-myc in the liver	FASEB JOURNAL			English	Article						p53; hepatocellular carcinoma; c-myc; apoptosis; cell proliferation	GROWTH-FACTOR-ALPHA; HEPATOCELLULAR-CARCINOMA; IN-VIVO; P53-DEPENDENT APOPTOSIS; TUMOR PROGRESSION; DNA-BINDING; CELL-LINES; MOUSE; MUTATION; GENE	The role of the tumor suppressor function of p53 in the process of hepatocellular carcinoma (HCC) development is still enigmatic in view of uncertainties with respect to the phenotype of most p53 mutations found in human HCCs. We therefore analyzed the effect of the p53 knockout (p53KO) genotype, which imparts a clear-cut loss of function, on hepatocarcinogenesis in livers of transgenic mice prone to develop this tumor type. Deterministic HCC formation in mice overexpressing transgenes encoding murine c-myc, or c-myc plus the secretable human epidermal growth factor (EGF) analogue IgEGF, in the liver was accelerated in the p53KO background as indicated by enhanced relative liver weights and reduced survival times of mice. In contrast, HCC formation was not affected by lack of p53 in IgEGF transgenics. Because p53KO mice are not HCC prone, lack of p53 contributed to hepatocarcinogenesis during progression provided that c-myc was overexpressed in the liver. Thus, deterministic HCC development occurs not simply because of the accumulation of genetic changes in individual hepatocytes; the order in which these changes occur also determines the propensity for liver neoplasia. Enhanced proliferation of hepatocytes was accompanied by markedly reduced p21. levels in tumorous livers of c-myc/IgEGF/p53KO mice. Concomitantly with unaltered p53-independent apoptotic activities, it caused enhanced hyperplasia and accelerated HCC development in livers enlarged fivefold, which killed the mice at 1.9 months of age.	Fraunhofer Inst Toxicol & Aerosol Res, Dept Cell Biol, D-30625 Hannover, Germany; Free Univ Berlin, Inst Vet Pathol, D-14163 Berlin, Germany; HepaVec AG Gentherapie, D-13125 Berlin, Germany; Humboldt Univ, Max Delbruck Ctr Mol Med, Mol Cell Biol Grp, D-13122 Berlin, Germany	Fraunhofer Gesellschaft; Free University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	Klocke, R (corresponding author), Ingenium Pharmaceut AG, Fraunhoferstr 13, D-82152 Martinsried, Germany.	rainer.klocke@ingenium-ag.com	Jennings, Garry/B-3914-2009					Baxi MK, 1996, VIRUS RES, V40, P33, DOI 10.1016/0168-1702(95)01255-9; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Donehower LA, 1996, BBA-REV CANCER, V1242, P171, DOI 10.1016/0304-419X(95)00013-6; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMENCO L, 1995, HEPATOLOGY, V22, P1279, DOI 10.1016/0270-9139(95)90640-1; ELSON A, 1995, ONCOGENE, V11, P181; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Feitelson MA, 1997, AM J PATHOL, V150, P1141; FRITH CH, 1979, J ENVIRON PATHOL TOX, V3, P329; FRITH CH, 1994, PATHOLOGY TUMORS LAB, V2, P223; GAN FY, 1993, J HISTOCHEM CYTOCHEM, V41, P1185, DOI 10.1177/41.8.7687263; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Ghebranious N, 1998, HEPATOLOGY, V27, P967, DOI 10.1002/hep.510270411; GHEBRANIOUS N, 1995, MOL CARCINOGEN, V13, P104, DOI 10.1002/mc.2940130207; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HOWES KA, 1994, GENE DEV, V8, P1738; Hui AM, 1997, HEPATOLOGY, V25, P575, DOI 10.1002/hep.510250314; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; KEMP CJ, 1995, MOL CARCINOGEN, V12, P132, DOI 10.1002/mc.2940120304; KOOPMAN P, 1989, GENE DEV, V3, P16, DOI 10.1101/gad.3.1.16; KRESS S, 1992, MOL CARCINOGEN, V6, P148, DOI 10.1002/mc.2940060210; Kubicka S, 1997, HEPATOLOGY, V25, P867, DOI 10.1002/hep.510250414; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIYASHITA T, 1995, CELL, V80, P293; NISHIDA N, 1993, CANCER RES, V53, P368; PONCHEL F, 1994, CANCER RES, V54, P2064; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; SCHAFF Z, 1994, HUM PATHOL, V25, P644, DOI 10.1016/0046-8177(94)90296-8; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TANAKA S, 1993, CANCER RES, V53, P2884; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; TONJES RR, 1995, ONCOGENE, V10, P765; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Ulrich RG, 1998, CELL BIOCHEM FUNCT, V16, P77; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	41	8	9	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1404	+		10.1096/fj.00-0487fje	http://dx.doi.org/10.1096/fj.00-0487fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387238				2022-12-28	WOS:000173705800030
J	Giri, S; Jatana, M; Rattan, R; Won, JS; Singh, I; Singh, AK				Giri, S; Jatana, M; Rattan, R; Won, JS; Singh, I; Singh, AK			Galactosylsphingosine (psychosine)-induced expression of cytokine-mediated inducible nitric oxide synthases via AP-1 and C/EBP: implications for Krabbe disease	FASEB JOURNAL			English	Article						cerebroside; GLD; iNOS; oligodendrocytes; beta-galactosidase	GLOBOID-CELL LEUKODYSTROPHY; NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; TWITCHER MOUSE; PSYCHOSINE GALACTOSYLSPHINGOSINE; TRANSCRIPTION FACTORS; GENE-EXPRESSION; SPINAL-CORD; ACCUMULATION; BETA	Globoid cell leukodystrophy (Krabbe disease) is characterized by the accumulation of a toxic metabolite, psychosine (galactosylsphingosine), which is a substrate for the deficient enzyme (galactocerebroside beta-galactosidase). This study underscores the possible role of psychosine in the effect of inducible nitric oxide synthase (iNOS) -derived NO in the pathophysiology of this demyelinating disease. For the first time, we provide evidence of the expression of iNOS in CNS of Krabbe patient and show that the iNOS-expressing cells in the CNS were astrocytes. Psychosine potentiated the LPS-induced production of proinflammatory cytokines (IL-1beta, IL-6, and TNF-alpha) in primary rat astrocytes and regulated the cytokine-mediated production of NO in C6 glioma and primary rat astrocyte. Psychosine induced cytokine-mediated nuclear translocation of AP-1 and C/EBP by potentiating the expression of Fra-1 and C/EBP-delta proteins. This suggests that psychosine maintained or sustained the cytokine-primed expression of iNOS by further potentiating the nuclear translocation of AP-1 and C/EBP without modulating the cytokine-mediated transcription activity of NF-kappaB. This study hypothesizes that accumulated psychosine leads to production of cytokines and iNOS expression. The ensuing excessive production of NO and ONOO- may play a role in pathogenesis of Krabbe disease.	Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; Ralph Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Singh, AK (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 316 Clin Sci Bldg, Charleston, SC 29425 USA.	singhi@musc.edu	Singh, Ashok/HGF-2506-2022	Won, Jeseong/0000-0003-2408-0386	NINDS NIH HHS [NS-34741, NS-22576, NS 37766, NS-40810] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022576, R01NS040810, R01NS034741, R37NS022576, R01NS037766] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; ANDREWS J M, 1970, Experimental Neurology, V29, P483, DOI 10.1016/0014-4886(70)90075-0; AUSTIN J, 1970, ARCH NEUROL-CHICAGO, V23, P502, DOI 10.1001/archneur.1970.00480300024003; AUSTIN JH, 1963, BRAIN LIPIDS LIPOPRO, P120; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Cardinaux JR, 2000, GLIA, V29, P91, DOI 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.0.CO;2-I; Chao CC, 1996, GLIA, V16, P276, DOI 10.1002/(SICI)1098-1136(199603)16:3<276::AID-GLIA10>3.0.CO;2-X; COSTANTI.E, 1972, LIPIDS, V7, P656, DOI 10.1007/BF02533072; Cross AH, 1996, J NEUROIMMUNOL, V71, P145, DOI 10.1016/S0165-5728(96)00147-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eberhardt W, 1996, BIOCHEM BIOPH RES CO, V223, P752, DOI 10.1006/bbrc.1996.0968; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; Guan ZH, 1999, J BIOL CHEM, V274, P36200, DOI 10.1074/jbc.274.51.36200; Gupta AK, 1999, AM J PHYSIOL-RENAL, V276, pF599, DOI 10.1152/ajprenal.1999.276.4.F599; Hu JG, 1998, BRAIN RES, V785, P195, DOI 10.1016/S0006-8993(97)01318-8; IDA H, 1990, BRAIN DEV-JPN, V12, P412, DOI 10.1016/S0387-7604(12)80074-X; IGISU H, 1984, SCIENCE, V224, P753, DOI 10.1126/science.6719111; IGISU H, 1986, BIOCHEM BIOPH RES CO, V137, P323, DOI 10.1016/0006-291X(86)91213-1; JACOBS JM, 1982, J NEUROL SCI, V55, P285, DOI 10.1016/0022-510X(82)90127-7; KOBAYASHI T, 1985, J BIOL CHEM, V260, P4982; KOBAYASHI T, 1987, BIOCHEM BIOPH RES CO, V144, P41, DOI 10.1016/S0006-291X(87)80472-2; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; Krabbe K, 1916, BRAIN, V39, P74, DOI 10.1093/brain/39.1-2.74; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LeVine SM, 1997, J NEUROIMMUNOL, V73, P47, DOI 10.1016/S0165-5728(96)00166-X; Luzi P, 1996, ANN NEUROL, V40, P116, DOI 10.1002/ana.410400119; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Merrill JE, 1999, NEUROPATH APPL NEURO, V25, P435; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Merrill JE, 1997, METAB BRAIN DIS, V12, P97, DOI 10.1023/B:MEBR.0000007105.13587.ba; MITROVIC B, 1995, NEUROSCIENCE, V65, P531, DOI 10.1016/0306-4522(94)00491-M; MIYATAKE T, 1972, BIOCHEM BIOPH RES CO, V48, P538, DOI 10.1016/0006-291X(72)90381-6; MORELL P, 1969, BIOCHEMISTRY-US, V8, P506, DOI 10.1021/bi00830a008; OKUDA Y, 1995, J NEUROIMMUNOL, V62, P103, DOI 10.1016/0165-5728(95)00114-H; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; Pahan K, 1998, J BIOL CHEM, V273, P12219, DOI 10.1074/jbc.273.20.12219; Pedchenko TV, 1999, EXP NEUROL, V158, P459, DOI 10.1006/exnr.1999.7125; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; SHINODA H, 1987, J NEUROCHEM, V49, P92, DOI 10.1111/j.1471-4159.1987.tb03399.x; Smith KJ, 1999, BRAIN PATHOL, V9, P69; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUGAMA S, 1990, PEDIATR RES, V28, P473, DOI 10.1203/00006450-199011000-00011; SUZUKI K, 1970, P NATL ACAD SCI USA, V66, P302, DOI 10.1073/pnas.66.2.302; Suzuki K, 1998, NEUROCHEM RES, V23, P251, DOI 10.1023/A:1022436928925; SUZUKI K, 1976, CURRENT TRENDS SPHIN, V50, P99; SUZUKI K, 1995, METABOLIC MOL BASES, V2, P2671; SVENNERHOLM L, 1980, J LIPID RES, V21, P53; SVENNERHOLM L, 1963, BRAIN LIPIDS LIPOPRO, P104; SWEET H, 1986, MOUSE NEWSLETTER, V75, P30; TAKAHASHI H, 1984, ACTA NEUROPATHOL, V62, P298, DOI 10.1007/BF00687612; TAKAHASHI H, 1983, ACTA NEUROPATHOL, V59, P159, DOI 10.1007/BF00703199; TANAKA K, 1993, J NEUROPATH EXP NEUR, V52, P490, DOI 10.1097/00005072-199309000-00007; TANAKA K, 1989, BRAIN RES, V482, P347, DOI 10.1016/0006-8993(89)91198-0; TANAKA K, 1988, BRAIN RES, V454, P340, DOI 10.1016/0006-8993(88)90835-9; TANIIKE M, 1995, J NEUROSCI RES, V40, P325, DOI 10.1002/jnr.490400306; Taniike M, 1999, J NEUROPATH EXP NEUR, V58, P644, DOI 10.1097/00005072-199906000-00009; Torreilles F, 1999, BRAIN RES REV, V30, P153, DOI 10.1016/S0165-0173(99)00014-4; Vodovotz Y, 1996, J EXP MED, V184, P1425, DOI 10.1084/jem.184.4.1425; Wu YP, 2001, J NEUROPATH EXP NEUR, V60, P1062, DOI 10.1093/jnen/60.11.1062; ZLOTOGORA J, 1990, AM J HUM GENET, V47, P37	62	90	91	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7							UNSP 0892-6638/02/0016-0661	10.1096/fj.01-0798com	http://dx.doi.org/10.1096/fj.01-0798com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	11978730				2022-12-28	WOS:000175973900020
J	Hunter, RB; Stevenson, EJ; Koncarevic, A; Mitchell-Felton, H; Essig, DA; Kandarian, SC				Hunter, RB; Stevenson, EJ; Koncarevic, A; Mitchell-Felton, H; Essig, DA; Kandarian, SC			Activation of an alternative NF-kappa B pathway in skeletal muscle during disuse atrophy	FASEB JOURNAL			English	Article						unloading; cytokine; Bcl-2 protein; NF-kappaB p50; NF-kappaB p65; Bcl-3 protein	TUMOR-NECROSIS-FACTOR; UBIQUITIN-PROTEASOME PATHWAY; HEME OXYGENASE-1 GENE; TRANSCRIPTION FACTORS; ENDOPLASMIC-RETICULUM; ONCOPROTEIN BCL-3; P50 HOMODIMERS; BREAST-CANCER; FACTOR-ALPHA; PROTEIN LOSS	Although cytokine-induced nuclear factor kappaB (NF-kappaB) pathways are involved in muscle wasting subsequent to disease, their potential role in disuse muscle atrophy has not been characterized. Seven days of hind limb unloading led to a 10-fold activation of an NF-kappaB-dependent reporter in rat soleus muscle but not the atrophy-resistant extensor digitorum longus muscle. Nuclear levels of p50 were markedly up-regulated, c-Rel was moderately up-regulated, Rel B was down-regulated, and p52 and p65 were unchanged in unloaded solei. The nuclear IkappaB protein Bcl-3 was increased. There was increased binding to an NF-kappaB consensus oligonucleotide, and this complex bound antibodies to p50, c-Rel, and Bcl-3 but not other NF-kappaB family members. Tumor necrosis factor alpha (TNF-alpha) and TNF receptor-associated factor 2 protein were moderately down-regulated. There was no difference in p38, c-Jun NH2-terminal kinase or Akt activity, nor were activator protein 1 or nuclear factor of activated T cell-dependent reporters activated. Thus, whereas several NF-kappaB family members are up-regulated, the prototypical markers of cytokine-induced activation of NF-kappaB seen with disease-related wasting are not evident during disuse atrophy. Levels of an anti-apoptotic NF-kappaB target, Bcl-2, were increased fourfold whereas proapoptotic proteins Bax and Bak decreased. The evidence presented here suggests that disuse muscle atrophy is associated with activation of an alternative NF-kappaB pathway that involves the activation of p50 but not p65.	Boston Univ, Dept Hlth Sci, Boston, MA 02215 USA; Geneva Coll, Dept Biol, Beaver Falls, PA USA	Boston University	Kandarian, SC (corresponding author), Boston Univ, Dept Hlth Sci, 635 Commonwealth Ave,Room 443, Boston, MA 02215 USA.	skandar@bu.edu			NIAMS NIH HHS [AR41705] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Allen DL, 1997, AM J PHYSIOL-CELL PH, V273, pC579, DOI 10.1152/ajpcell.1997.273.2.C579; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baghdiguian S, 2001, J MOL MED, V79, P254, DOI 10.1007/s001090100225; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bergman MR, 1999, AM J PHYSIOL-HEART C, V277, pH543, DOI 10.1152/ajpheart.1999.277.2.H543; Blough E, 1999, BIOTECHNIQUES, V26, P202, DOI 10.2144/99262bm05; BOOTH F, 1996, EXERCISE REGULATION, P1075; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Canicio J, 2001, J BIOL CHEM, V276, P20228, DOI 10.1074/jbc.M100718200; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; DAVIS HL, 1993, HUM GENE THER, V4, P151, DOI 10.1089/hum.1993.4.2-151; De Rossi M, 2000, INT IMMUNOL, V12, P1329, DOI 10.1093/intimm/12.9.1329; Demartino GN, 1998, EXERCISE SPORT SCI R, V26, P219; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; ESPAT NJ, 1994, SURG ONCOL, V3, P255, DOI 10.1016/0960-7404(94)90027-2; Frenette J, 2000, AM J PATHOL, V156, P2103, DOI 10.1016/S0002-9440(10)65081-X; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Hunter RB, 2001, AM J PHYSIOL-CELL PH, V281, pC1285, DOI 10.1152/ajpcell.2001.281.4.C1285; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawamura I, 1999, GENE THER, V6, P91, DOI 10.1038/sj.gt.3300819; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Lavrovsky Y, 2000, MECH AGEING DEV, V114, P49, DOI 10.1016/S0047-6374(00)00087-7; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Lewis AJ, 1999, CURR OPIN CHEM BIOL, V3, P489, DOI 10.1016/S1367-5931(99)80071-4; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165, DOI 10.1152/ajpregu.2000.279.4.R1165; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P461, DOI 10.1002/(SICI)1097-4644(19981215)71:4<461::AID-JCB1>3.0.CO;2-0; Mitchell-Felton H, 1999, AM J PHYSIOL-CELL PH, V277, pC1269, DOI 10.1152/ajpcell.1999.277.6.C1269; Moldawer LL, 1997, CANCER-AM CANCER SOC, V79, P1828; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; Peters DG, 1999, AM J PHYSIOL-CELL PH, V276, pC1218, DOI 10.1152/ajpcell.1999.276.5.C1218; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Schwoon DR, 1997, EUR ADDICT RES, V3, P11, DOI 10.1159/000259142; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Swoap SJ, 2000, AM J PHYSIOL-CELL PH, V279, pC915, DOI 10.1152/ajpcell.2000.279.4.C915; Taillandier D, 1996, BIOCHEM J, V316, P65, DOI 10.1042/bj3160065; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tamatani M, 2000, J NEUROCHEM, V75, P683, DOI 10.1046/j.1471-4159.2000.0750683.x; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Wilson BE, 1996, MOL CELL BIOL, V16, P5546	64	216	227	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					529	538		10.1096/fj.01-0866com	http://dx.doi.org/10.1096/fj.01-0866com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	11919155				2022-12-28	WOS:000175425900006
J	Tosetti, F; Ferrari, N; De Flora, S; Albini, A				Tosetti, F; Ferrari, N; De Flora, S; Albini, A			'Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents	FASEB JOURNAL			English	Review						antiangiogenesis; chemoprevention; steroids; retinoids; flavonoids; thiols; protease inhibitors; NSAIDs	ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; KINASE SIGNALING PATHWAY; TUMOR-CELL LINES; PROSTATE-SPECIFIC ANTIGEN; GREEN-TEA CONSUMPTION; IN-VITRO ANGIOGENESIS; RETINOID-X-RECEPTOR; BREAST-CANCER; CARCINOMA-CELLS	The potential to block tumor growth by inhibition of the neoangiogenic process represents an intriguing approach to the treatment of solid tumors. The high proliferation rate in the tumor deprived of proper vascularization would be balanced by cell death due to lack of diffusion of nutrients and oxygen. Matrix metalloproteinases (MMPs), angiogenic growth factors, and their receptors are the main targets of an increasing number of clinical trials approved to test the tolerance and therapeutic efficacy of antiangiogenic agents. We observed that a series of substances proposed as possible cancer chemopreventive agents show antiangiogenic properties when tested in in vitro and in vivo angiogenesis models. We demonstrated that N-acetyl- L-cysteine is able to reduce the invasive and metastatic potential of melanoma cells, and to inhibit endothelial cell invasion by direct inhibition of MMP activity. We also showed that epigallocatechin gallate (EGCG), a flavonoid from green tea that possesses chemopreventive activity in experimental and epidemiological studies, is a potent inhibitor of MMP-2 and MMP-9. Angiogenesis has also been demonstrated to be a target for nonsteroidal anti-inflammatory drug chemopreventive activity. Based on these data, we hypothesize that other chemopreventive agents, including natural or synthetic retinoids, steroid hormone antagonists, peroxisome proliferator-activated receptor gamma ligands, vitamin D, and protease inhibitors, might have antiangiogenesis as an important mechanism of action, a novel concept we will term 'angioprevention'. We analyze the mechanisms on how and why chemopreventive agents could exert antiangiogenic effects aimed at controlling tumor growth, and their potential use in the clinic.	Ist Nazl Ric Canc IST, Mol Biol Lab, Ctr Biotecnol Avanzate, I-16132 Genoa, Italy; Univ Genoa, Dept Hlth Sci, Sect Hyg & Prevent Med, Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Genoa	Albini, A (corresponding author), Ist Nazl Ric Canc IST, Mol Biol Lab, Ctr Biotecnol Avanzate, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.	albini@cba.unige.it	Tosetti, Francesca/I-7866-2012; Ferrari, Nicoletta/AAG-6049-2019; Tosetti, Francesca/AAE-5569-2021	Ferrari, Nicoletta/0000-0002-6027-1035; Tosetti, Francesca/0000-0001-8772-4834; Albini, Adriana/0000-0002-9624-5103				Ahn HY, 1999, MOL BIOL CELL, V10, P1093, DOI 10.1091/mbc.10.4.1093; ALBINI A, 1995, INT J CANCER, V61, P121, DOI 10.1002/ijc.2910610121; Armstrong WB, 2000, CLIN CANCER RES, V6, P4684; Banerjee SK, 2000, ANTICANCER RES, V20, P2641; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Bengtson EM, 1999, DRUGS, V58, P57, DOI 10.2165/00003495-199958003-00009; BERGELSON S, 1994, CANCER RES, V54, P36; Bertolini F, 2000, LEUKEMIA, V14, P1477, DOI 10.1038/sj.leu.2401854; Bhatia N, 2001, PROSTATE, V46, P98; Bischoff ED, 1999, J NATL CANCER I, V91, P2118, DOI 10.1093/jnci/91.24.2118; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Bratland A, 2000, CANCER RES, V60, P5578; BRAUNHUT SJ, 1994, J BIOL CHEM, V269, P13472; Brawley OW, 2000, EUR J CANCER, V36, P1312, DOI 10.1016/S0959-8049(00)00105-2; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; Cai T, 1999, LAB INVEST, V79, P1151; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chinery R, 1998, CANCER RES, V58, P2323; Chua CC, 1998, FREE RADICAL BIO MED, V25, P891, DOI 10.1016/S0891-5849(98)00115-4; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; De Flora S, 2001, CARCINOGENESIS, V22, P999, DOI 10.1093/carcin/22.7.999; Decensi A, 2000, EUR J CANCER, V36, P694, DOI 10.1016/S0959-8049(00)00040-X; Diaz BV, 2000, J BIOL CHEM, V275, P642, DOI 10.1074/jbc.275.1.642; Dong ZG, 1997, J BIOL CHEM, V272, P9962; Erdreich-Epstein A, 2000, CANCER RES, V60, P712; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; Folkman J, 2000, JNCI-J NATL CANCER I, V92, P94, DOI 10.1093/jnci/92.2.94; Fortier AH, 1999, J NATL CANCER I, V91, P1635, DOI 10.1093/jnci/91.19.1635; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Gallo O, 1998, J NATL CANCER I, V90, P587, DOI 10.1093/jnci/90.8.587; GAO YT, 1994, JNCI-J NATL CANCER I, V86, P855, DOI 10.1093/jnci/86.11.855; Garbisa S, 1999, NAT MED, V5, P1216, DOI 10.1038/15145; Garbisa S, 2001, CANCER-AM CANCER SOC, V91, P822, DOI 10.1002/1097-0142(20010215)91:4<822::AID-CNCR1070>3.0.CO;2-G; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; Gniadecki R, 1996, J INVEST DERMATOL, V106, P1212, DOI 10.1111/1523-1747.ep12348498; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Gottardis MM, 1996, CANCER RES, V56, P5566; Griffiths K, 1999, EUR UROL, V35, P443, DOI 10.1159/000019877; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Heidtmann HH, 1999, BRIT J CANCER, V81, P1269, DOI 10.1038/sj.bjc.6692167; Henderson BE, 2000, CARCINOGENESIS, V21, P427, DOI 10.1093/carcin/21.3.427; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Huss WJ, 2001, CANCER RES, V61, P2736; Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455; Hyder SM, 2001, INT J CANCER, V92, P469, DOI 10.1002/ijc.1236; Hyder SM, 2000, CANCER RES, V60, P3183; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Iurlaro M, 1998, EUR J CANCER, V34, P570, DOI 10.1016/S0959-8049(97)10082-X; Jankun J, 1997, NATURE, V387, P561, DOI 10.1038/42381; JANSSEN YMW, 1995, CANCER RES, V55, P2085; Jiang C, 2000, BIOCHEM BIOPH RES CO, V276, P371, DOI 10.1006/bbrc.2000.3474; Jones MK, 1999, NAT MED, V5, P1418; Jones MK, 1998, BIOCHEM BIOPH RES CO, V249, P118, DOI 10.1006/bbrc.1998.9095; Joseph IBJK, 1997, CLIN CANCER RES, V3, P2507; Jung YD, 2001, BRIT J CANCER, V84, P844, DOI 10.1054/bjoc.2000.1691; Kamata H, 1996, J BIOL CHEM, V271, P33018, DOI 10.1074/jbc.271.51.33018; Katiyar SK, 1999, CARCINOGENESIS, V20, P2117, DOI 10.1093/carcin/20.11.2117; Kawamori T, 1998, CANCER RES, V58, P409; Kelloff GJ, 2000, J NUTR, V130, p467S, DOI 10.1093/jn/130.2.467S; Kelloff GJ, 2000, ADV CANCER RES, V78, P199; Kennedy AR, 1998, PHARMACOL THERAPEUT, V78, P167, DOI 10.1016/S0163-7258(98)00010-2; Kerbel RS, 2000, EUR J CANCER, V36, P1248, DOI 10.1016/S0959-8049(00)00092-7; Kim H, 1998, AM J CLIN NUTR, V68, p1418S, DOI 10.1093/ajcn/68.6.1418S; Kleinman H K, 2001, Surg Oncol Clin N Am, V10, P329; Kong ANT, 2000, ARCH PHARM RES, V23, P1, DOI 10.1007/BF02976458; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; Lamartiniere CA, 2000, AM J CLIN NUTR, V71, p1705S, DOI 10.1093/ajcn/71.6.1705S; Lansink M, 1998, BLOOD, V92, P927; Lee OH, 2000, BRIT J CANCER, V82, P385; Lewis M, 1999, J CELL BIOCHEM, V72, P373, DOI 10.1002/(SICI)1097-4644(19990301)72:3<373::AID-JCB7>3.0.CO;2-N; Li WQ, 2000, BIOCHEM BIOPH RES CO, V275, P789, DOI 10.1006/bbrc.2000.3385; Liang YC, 1997, J CELL BIOCHEM, V67, P55, DOI 10.1002/(SICI)1097-4644(19971001)67:1<55::AID-JCB6>3.0.CO;2-V; Liberto M, 2000, CANCER LETT, V154, P151, DOI 10.1016/S0304-3835(00)00378-5; Lin JK, 1999, BIOCHEM PHARMACOL, V58, P911, DOI 10.1016/S0006-2952(99)00112-4; Lingen MW, 1996, AM J PATHOL, V149, P247; Lingen MW, 1996, LAB INVEST, V74, P476; Lippman SC, 2000, J NUTR, V130, p479S, DOI 10.1093/jn/130.2.479S; Lippman SM, 1998, JNCI-J NATL CANCER I, V90, P1514, DOI 10.1093/jnci/90.20.1514; Lippman SM, 2000, CLIN CANCER RES, V6, P4599; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; Ludwig MG, 2000, J BIOL CHEM, V275, P39981, DOI 10.1074/jbc.M007529200; MAJEWSKI S, 1995, CANCER LETT, V89, P117, DOI 10.1016/0304-3835(95)90166-3; MAJEWSKI S, 1994, INT J CANCER, V57, P81, DOI 10.1002/ijc.2910570115; Mantell DJ, 2000, CIRC RES, V87, P214, DOI 10.1161/01.RES.87.3.214; Masferrer JL, 2000, CANCER RES, V60, P1306; Masood R, 2000, BLOOD, V96, P3188, DOI 10.1182/blood.V96.9.3188.h8003188_3188_3194; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; MERKE J, 1989, J CLIN INVEST, V83, P1903, DOI 10.1172/JCI114097; Mestre JR, 1997, CANCER RES, V57, P2890; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309; Na SY, 1999, J BIOL CHEM, V274, P7674, DOI 10.1074/jbc.274.12.7674; Nakachi K, 1998, JPN J CANCER RES, V89, P254, DOI 10.1111/j.1349-7006.1998.tb00556.x; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; Nargi Jennifer L., 1999, Neoplasia (New York), V1, P544; Narvaez CJ, 2001, J BIOL CHEM, V276, P9101, DOI 10.1074/jbc.M006876200; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Padro T, 2000, BLOOD, V95, P2637, DOI 10.1182/blood.V95.8.2637.008k07_2637_2644; Pages G, 2000, ANN NY ACAD SCI, V902, P187; Park BH, 2001, CURR OPIN ONCOL, V13, P78, DOI 10.1097/00001622-200101000-00015; PIENTA KJ, 1993, CANCER RES, V53, P224; PIPILISYNETOS E, 1994, BRIT J PHARMACOL, V111, P894, DOI 10.1111/j.1476-5381.1994.tb14822.x; Qadan LR, 2000, ENDOCRINOLOGY, V141, P2567, DOI 10.1210/en.141.7.2567; Rak J, 2000, CANCER RES, V60, P490; Redondo P, 2000, CYTOKINE, V12, P374, DOI 10.1006/cyto.1999.0566; Rioux N, 2000, CARCINOGENESIS, V21, P1745, DOI 10.1093/carcin/21.9.1745; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rudek MA, 2001, J CLIN ONCOL, V19, P584, DOI 10.1200/JCO.2001.19.2.584; Ryter SW, 1998, FREE RADICAL BIO MED, V24, P1520, DOI 10.1016/S0891-5849(97)00461-9; Schoenermark MP, 1999, ANN NY ACAD SCI, V878, P466, DOI 10.1111/j.1749-6632.1999.tb07703.x; Schroen DJ, 1996, GENE EXPRESSION, V6, P197; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shao ZM, 1998, CANCER RES, V58, P4851; SHOKRAVI MT, 1995, INVEST OPHTH VIS SCI, V36, P83; Shono T, 1996, MOL CELL BIOL, V16, P4231; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; Steele VE, 2000, CARCINOGENESIS, V21, P63, DOI 10.1093/carcin/21.1.63; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Stewart RJ, 2001, J UROLOGY, V165, P688, DOI 10.1097/00005392-200102000-00095; Strasly M, 2001, J IMMUNOL, V166, P3890, DOI 10.4049/jimmunol.166.6.3890; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Sun SY, 1999, MOL PHARMACOL, V55, P403; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; THOMPSON EA, 1991, EUR J BIOCHEM, V201, P627, DOI 10.1111/j.1432-1033.1991.tb16323.x; Torrisi R, 2000, Curr Oncol Rep, V2, P263, DOI 10.1007/s11912-000-0077-x; Torrisi R, 2000, INT J CANCER, V87, P601, DOI 10.1002/1097-0215(20000815)87:4<601::AID-IJC22>3.0.CO;2-W; Tsubono Y, 2001, NEW ENGL J MED, V344, P632, DOI 10.1056/NEJM200103013440903; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Uckun FM, 1999, CLIN CANCER RES, V5, P3906; Vaccari M, 2000, ANTICANCER RES, V20, P3059; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; Xiao WH, 1997, J BIOL CHEM, V272, P9742, DOI 10.1074/jbc.272.15.9742; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Yang CS, 2000, J NUTR, V130, p472S, DOI 10.1093/jn/130.2.472S; Yao L, 2000, BLOOD, V96, P1900, DOI 10.1182/blood.V96.5.1900.h8001900_1900_1905; Yeh JRJ, 2000, P NATL ACAD SCI USA, V97, P12782, DOI 10.1073/pnas.97.23.12782; Yen L, 2000, ONCOGENE, V19, P3460, DOI 10.1038/sj.onc.1203685; YU GP, 1995, CANCER CAUSE CONTROL, V6, P532, DOI 10.1007/BF00054162; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951; Zhao JF, 1999, MOL CARCINOGEN, V26, P321, DOI 10.1002/(SICI)1098-2744(199912)26:4<321::AID-MC11>3.3.CO;2-0; Zhou JR, 1998, CANCER RES, V58, P5231	158	275	292	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					2	14		10.1096/fj.01-0300rev	http://dx.doi.org/10.1096/fj.01-0300rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11772931				2022-12-28	WOS:000173656600002
J	Atamna, H; Robinson, C; Ingersoll, R; Elliott, H; Ames, BN				Atamna, H; Robinson, C; Ingersoll, R; Elliott, H; Ames, BN			N-t-butyl hydroxylamine is an antioxidant that reverses age-related changes in mitochondria in vivo and in vitro	FASEB JOURNAL			English	Article						NtBHA; senescence; proteasome; growth factors	FLOW CYTOMETRIC ANALYSIS; OLD HUMAN-FIBROBLASTS; ACETYL-L-CARNITINE; OXIDATIVE DAMAGE; CALORIC RESTRICTION; PROTEIN OXIDATION; ACRIDINE-ORANGE; THYROID-HORMONE; RAT HEPATOCYTES; NITRIC-OXIDE	N-t-butyl hydroxylamine (NtBHA) delays senescence-dependent changes in human lung fibroblasts (IMR90) (Atamna et al., J. Biol. Chem. 275, 6741-6748). The current study examines the effect of NtBHA on mitochondria in old and young rats and human primary fibroblasts (IMR90). In NtBHA-treated rats, the age-dependent decline in food consumption and ambulatory activity was reversed without affecting body weight. The respiratory control ratio of mitochondria from liver of old rats improved after feeding NtBHA. These findings suggest that NtBHA improved mitochondrial function in vivo. The age-dependent increase in proteins with thiol-mixed disulfides was significantly lower in old rats treated with NtBHA. NtBHA was effective only in old rats; no significant effect was observed in young rats. In IMR90 cells, NtBHA delayed senescence-associated changes in mitochondria and cellular senescence induced by maintaining the cells under suboptimal levels of growth factors. Proteasomal activity was also higher in cells treated with NtBHA than in untreated cells. NtBHA accumulates in cells 10- to 15-fold the extracellular concentration and is maintained by mitochondrial NADH. NtBHA is an antioxidant that is recycled by mitochondrial electron transport chain and prevents radical-induced toxicity to mitochondria.	Univ Calif Berkeley, CHORI, Dept Mol & Cell Biol, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California Berkeley	Ames, BN (corresponding author), Univ Calif Berkeley, CHORI, Dept Mol & Cell Biol, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	bnames@uclink4.berkeley.edu			NIA NIH HHS [AG17140] Funding Source: Medline; NIEHS NIH HHS [ES01896] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017140] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Atamna H, 2000, J BIOL CHEM, V275, P6741, DOI 10.1074/jbc.275.10.6741; Atamna H, 2000, P NATL ACAD SCI USA, V97, P686, DOI 10.1073/pnas.97.2.686; Barja G, 1998, ANN NY ACAD SCI, V854, P224, DOI 10.1111/j.1749-6632.1998.tb09905.x; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Beckman KB, 1998, ANN NY ACAD SCI, V854, P118, DOI 10.1111/j.1749-6632.1998.tb09897.x; BENEL L, 1989, BASIC APPL HISTOCHEM, V33, P71; BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; CHAMULITRAT W, 1995, FREE RADICAL RES, V23, P1, DOI 10.3109/10715769509064014; CHAMULITRAT W, 1993, J BIOL CHEM, V268, P11520; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; DARZYNKIEWICZ Z, 1981, P NATL ACAD SCI-BIOL, V78, P2383, DOI 10.1073/pnas.78.4.2383; de Grey ADNJ, 2000, ARCH BIOCHEM BIOPHYS, V373, P295, DOI 10.1006/abbi.1999.1509; DEALMEIDA AF, 1989, INT J BIOCHEM, V21, P937, DOI 10.1016/0020-711X(89)90295-4; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; Dikalov SI, 1999, J BIOL CHEM, V274, P9392, DOI 10.1074/jbc.274.14.9392; DJOUADI F, 1994, AM J PHYSIOL, V267, pC245, DOI 10.1152/ajpcell.1994.267.1.C245; DUMAS M, 1995, CR ACAD SCI III-VIE, V318, P191; FEUERS RJ, 1989, MECH AGEING DEV, V48, P179, DOI 10.1016/0047-6374(89)90049-3; FISHER HF, 1985, METHOD ENZYMOL, V113, P16; Gabbita SP, 1997, FREE RADICAL BIO MED, V23, P191, DOI 10.1016/S0891-5849(97)00043-9; GORDON MN, 1988, ENDOCRINOLOGY, V122, P726, DOI 10.1210/endo-122-2-726; Hack V, 1998, BLOOD, V92, P59, DOI 10.1182/blood.V92.1.59.413a05_59_67; Hagen TM, 1998, ANN NY ACAD SCI, V854, P214, DOI 10.1111/j.1749-6632.1998.tb09904.x; Hagen TM, 1999, FASEB J, V13, P411, DOI 10.1096/fasebj.13.2.411; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Hagen TM, 1998, P NATL ACAD SCI USA, V95, P9562, DOI 10.1073/pnas.95.16.9562; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; HARDY L, 1991, BIOCHEM J, V274, P133, DOI 10.1042/bj2740133; Harman D, 1998, ANN NY ACAD SCI, V854, P1, DOI 10.1111/j.1749-6632.1998.tb09886.x; Harman D, 1998, J Int Fed Clin Chem, V10, P24; Kotake Y, 1999, ANTIOXID REDOX SIGN, V1, P481, DOI 10.1089/ars.1999.1.4-481; LAGERCRANTZ C, 1991, FREE RADICAL RES COM, V14, P395, DOI 10.3109/10715769109093428; LEE CY, 1982, METHOD ENZYMOL, V89, P252; LEQUOC D, 1989, ARCH BIOCHEM BIOPHYS, V273, P466, DOI 10.1016/0003-9861(89)90506-7; LIZARD G, 1990, CYTOTECHNOLOGY, V3, P179, DOI 10.1007/BF00143680; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P247, DOI 10.1111/j.1432-1033.1992.tb17044.x; Lykkesfeldt J, 1998, FASEB J, V12, P1183, DOI 10.1096/fasebj.12.12.1183; MARTINEZ AO, 1987, MECH AGEING DEV, V39, P1, DOI 10.1016/0047-6374(87)90081-9; MARTINEZ AO, 1991, GROWTH DEVELOP AGING, V55, P185; Nakahara H, 1998, FREE RADICAL BIO MED, V24, P85, DOI 10.1016/S0891-5849(97)00164-0; NELSON BD, 1995, BBA-MOL BASIS DIS, V1271, P85, DOI 10.1016/0925-4439(95)00014-U; PACKER L, 1994, ANN NY ACAD SCI, V738, P257; PARADIES FMR, 1993, B MOL BIOL MED, V18, P89; Prieur B, 1998, EUR J BIOCHEM, V252, P194, DOI 10.1046/j.1432-1327.1998.2520194.x; Raha S, 2000, FREE RADICAL BIO MED, V29, P170, DOI 10.1016/S0891-5849(00)00338-5; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; Sastre J, 2000, FREE RADICAL RES, V32, P189, DOI 10.1080/10715760000300201; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SHUKLA SP, 1968, EXP GERONTOL, V3, P31, DOI 10.1016/0531-5565(68)90053-3; SIES H, 1977, EUR J BIOCHEM, V72, P301, DOI 10.1111/j.1432-1033.1977.tb11253.x; Sitte N, 2000, FREE RADICAL BIO MED, V28, P701, DOI 10.1016/S0891-5849(99)00279-8; Stadtman ER, 1997, CHEM RES TOXICOL, V10, P485, DOI 10.1021/tx960133r; STIO M, 1994, BIOCHEM CELL BIOL, V72, P58, DOI 10.1139/o94-010; TORII K, 1992, AM J RESP CELL MOL, V6, P88, DOI 10.1165/ajrcmb/6.1.88; TYLER DD, 1992, RESP ENZYME SYSTEMS; WILKINSON RF, 1993, ART SCI TISSUE CULTU, V12, P1; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; WULF JH, 1975, EXP GERONTOL, V10, P101, DOI 10.1016/0531-5565(75)90040-6; Zhou ZX, 2000, J HISTOCHEM CYTOCHEM, V48, P585, DOI 10.1177/002215540004800502	64	41	42	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2196	2204		10.1096/fj.01-0134com	http://dx.doi.org/10.1096/fj.01-0134com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641246				2022-12-28	WOS:000171920400031
J	Chung, JY; Park, JO; Phyu, H; Dong, ZG; Yang, CS				Chung, JY; Park, JO; Phyu, H; Dong, ZG; Yang, CS			Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3,3 '-digallate	FASEB JOURNAL			English	Article						tea polyphenols; MAP kinases; Erk1/2 activity; MEK1/2; Raf-1	ACTIVATOR PROTEIN-1 ACTIVITY; PROLINE-RICH PROTEINS; NITRIC-OXIDE SYNTHASE; I-KAPPA-B; BLACK TEA; GREEN TEA; LUNG TUMORIGENESIS; CANCER CELLS; GROWTH; INDUCTION	Our previous study showed that tea polyphenols inhibited MAP kinase and AP-1 activities in mouse epidermal JB6 cells and the corresponding H-ras-transformed cell line 30.7b Ras 12. The present study investigated the mechanisms of this inhibition. The cells were incubated with (-)-epigallocatechin-3-gallate (EGCG) or theaflavin-3,3'-digallate (TFdiG) (20 muM) for different times, and the cell lysate was analyzed by immunoblotting. EGCG treatment decreased the levels of phospho-Erk1/2 and -MEK1/2 time-dependently (by 60% at 60 min). TFdiG lowered their levels by 38%-50% at 15 min. TFdiG effectively decreased total Raf-1 protein levels, most likely through lysosomal degradation. EGCG did not affect protein levels or the activity of Raf-1 significantly but decreased its association with MEK1 as determined by co-immunoprecipitation. In addition, EGCG and TFdiG (10 muM) inhibited the phosphorylation of Elk-1 by isolated phospho-Erk1/2 in vitro. This inhibition of Erk1/2 activity is Elk-1 concentration-dependent and ATP concentration-independent, which suggests that EGCG and TFdiG interfere with the binding of the protein substrate to the kinase. The presently demonstrated specific mechanisms of inhibition of MAP kinases by EGCG and TFdiG may help us to understand the effects of tea consumption on cancer, inflammatory diseases, and cardiovascular diseases.	Rutgers State Univ, Coll Pharm, Canc Res Lab, Piscataway, NJ 08854 USA; Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	Rutgers State University New Brunswick; University of Minnesota System	Yang, CS (corresponding author), Rutgers State Univ, Coll Pharm, Canc Res Lab, 164 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	csyang@rci.rutgers.edu						ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Balentine DA, 1997, CRIT REV FOOD SCI, V37, P693, DOI 10.1080/10408399709527797; Barthelman M, 1998, CARCINOGENESIS, V19, P2201, DOI 10.1093/carcin/19.12.2201; Baxter NJ, 1997, BIOCHEMISTRY-US, V36, P5566, DOI 10.1021/bi9700328; Blot WJ, 1997, CRIT REV FOOD SCI, V37, P739, DOI 10.1080/10408399709527800; Bushman JL, 1998, NUTR CANCER, V31, P151, DOI 10.1080/01635589809514697; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Charlton AJ, 1996, FEBS LETT, V382, P289, DOI 10.1016/0014-5793(96)00186-X; Chung JY, 1999, CANCER RES, V59, P4610; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Conney AH, 1999, P SOC EXP BIOL MED, V220, P229, DOI 10.1046/j.1525-1373.1999.d01-39.x; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; Cuervo AM, 1998, MOL BIOL CELL, V9, P1995, DOI 10.1091/mbc.9.8.1995; Damert A, 1997, BIOCHEM J, V327, P419, DOI 10.1042/bj3270419; de Martin R, 1999, MUTAT RES-REV MUTAT, V437, P231, DOI 10.1016/S1383-5742(99)00089-7; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DICE JF, 1992, ANN NY ACAD SCI, V674, P58, DOI 10.1111/j.1749-6632.1992.tb27477.x; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Dong ZG, 1997, CANCER RES, V57, P4414; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885; Hibasami H, 1998, INT J MOL MED, V1, P725; Hibasami H, 1998, ONCOL REP, V5, P527; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang MT, 1997, CANCER RES, V57, P2623; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Katiyar SK, 1996, INT J ONCOL, V8, P221; Kohlmeier L, 1997, NUTR CANCER, V27, P1, DOI 10.1080/01635589709514494; Liang YC, 1999, CARCINOGENESIS, V20, P733, DOI 10.1093/carcin/20.4.733; Lin YL, 1999, EUR J PHARMACOL, V367, P379, DOI 10.1016/S0014-2999(98)00953-4; Lin YL, 1997, MOL PHARMACOL, V52, P465, DOI 10.1124/mol.52.3.465; Lu YP, 1997, CARCINOGENESIS, V18, P2163, DOI 10.1093/carcin/18.11.2163; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McCarty MF, 1998, MED HYPOTHESES, V50, P511, DOI 10.1016/S0306-9877(98)90273-0; MEHANSHO H, 1987, ANNU REV NUTR, V7, P423, DOI 10.1146/annurev.nu.07.070187.002231; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MURRAY NJ, 1994, EUR J BIOCHEM, V219, P923, DOI 10.1111/j.1432-1033.1994.tb18574.x; Pan MH, 2000, BIOCHEM PHARMACOL, V59, P357, DOI 10.1016/S0006-2952(99)00335-4; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; SCHULZ B, 1996, CURR TRENDS POLYM SC, V1, P1; Trevisanato SI, 2000, NUTR REV, V58, P1, DOI 10.1111/j.1753-4887.2000.tb01818.x; Valcic S, 1996, ANTI-CANCER DRUG, V7, P461, DOI 10.1097/00001813-199606000-00011; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Yang CS, 2000, J NUTR, V130, p472S, DOI 10.1093/jn/130.2.472S; Yang CS, 1999, P SOC EXP BIOL MED, V220, P213, DOI 10.1046/j.1525-1373.1999.d01-36.x; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038; Yang CS, 2000, J NUTR, V130, P2409, DOI 10.1093/jn/130.10.2409; YANG CS, 1999, CURR PRACT MED, V2, P163; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yang GY, 1997, CANCER RES, V57, P1889; Yang GY, 1997, CARCINOGENESIS, V18, P2361, DOI 10.1093/carcin/18.12.2361	56	143	152	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2022	+		10.1096/fj.01-0031fje	http://dx.doi.org/10.1096/fj.01-0031fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511526				2022-12-28	WOS:000170318500020
J	Miclo, L; Perrin, E; Driou, A; Papadopoulos, V; Boujrad, N; Vanderesse, R; Boudier, JF; Desor, D; Linden, G; Gaillard, JL				Miclo, L; Perrin, E; Driou, A; Papadopoulos, V; Boujrad, N; Vanderesse, R; Boudier, JF; Desor, D; Linden, G; Gaillard, JL			Characterization of alpha-casozepine, a tryptic peptide from bovine alpha(s1)-casein with benzodiazepine-like activity	FASEB JOURNAL			English	Article						milk; casein peptide; anxiolysis; anticonvulsant; diazepam binding inhibitor	ELEVATED PLUS-MAZE; BINDING INHIBITOR RECEPTOR; RAT CEREBRAL-CORTEX; IMMUNOREACTIVE MATERIAL; LIQUID-CHROMATOGRAPHY; ANXIOGENIC ACTION; KINDLED SEIZURES; MILK-PROTEINS; PENTYLENETETRAZOL; DIAZEPAM	Caseins are a known source of biologically active peptides. In this study, we have shown evidence of a novel anxiolytic activity in a tryptic hydrolysate of bovine alpha (s1)-casein. Injection of 3 mg/kg of this hydrolysate significantly reduced the epileptic symptoms caused by pentylenetetrazole in rats. Anxiety reduction was also observed when the hydrolysate was tested in the elevated plus-maze and in the conditioned defensive burying rat models. Peptides isolated from the hydrolysate were examined for their affinity for the gamma -amino-butyric acid (GABA) type A receptor. Only one peptide, named alpha -casozepine, corresponding to the 91-100 fragment from bovine alpha (s1)-casein, expressed affinity for GABA(A) receptor. In vitro, the peptide had 10,000 less affinity for the benzodiazepine site of the GABA(A) than did diazepam. However, in the conditioned defensive burying paradigm it was 10-fold more efficient than diazepam. The difference observed between the in vitro and in vivo activity of alpha -casozepine could not been explained by an action via the peripheral-type benzodiazepine receptor; alpha -casozepine had no affinity for this receptor. The alpha -casozepine amino acid sequence could be related to the carboxyterminal sequence of the polypeptide diazepam binding inhibitor, an endogenous ligand of the central GABA(A) and peripheral-type benzodiazepine receptors.	Univ Nancy 1, Fac Sci, Lab Biosci Aliment, INRA,UA 885, F-54506 Vandoeuvre Les Nancy, France; Georgetown Univ, Med Ctr, Dept Cell Biol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; INPL, ENSIC, Lab Chim Phys Macromol, CNRS,UMR 7568, Nancy, France; Ingredia, Arras, France; Univ Nancy 1, Fac Sci, Lab Aspects Fonct & Dev Comportements, CNRS,URA 1293, F-54506 Vandoeuvre Les Nancy, France; Univ Rennes 1, Endocrinol Mol Reprod UMR CNRS Interact Cellulair, F-35042 Rennes, France	INRAE; Universite de Lorraine; Georgetown University; Georgetown University; Georgetown University; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Universite de Rennes	Miclo, L (corresponding author), Univ Nancy 1, Fac Sci, Lab Biosci Aliment, INRA,UA 885, BP 239, F-54506 Vandoeuvre Les Nancy, France.	Laurent.Miclo@scbiol.uhp-nancy.fr	Papadopoulos, Vassilios/AAI-2613-2019; BOUJRAD, Noureddine/L-1367-2015	Papadopoulos, Vassilios/0000-0002-1183-8568; 				AGUNOD M, 1969, AM J DIG DIS, V14, P400, DOI 10.1007/BF02239360; ANDERSEN KV, 1991, BIOCHEMISTRY-US, V30, P10654, DOI 10.1021/bi00108a008; BIGGIO G, 1990, PHARMACOL THERAPEUT, V48, P121, DOI 10.1016/0163-7258(90)90077-F; BRETT RR, 1990, EUR J PHARMACOL, V178, P135, DOI 10.1016/0014-2999(90)94806-9; BREZINOVA V, 1972, BMJ-BRIT MED J, V2, P431, DOI 10.1136/bmj.2.5811.431; CORDA MG, 1991, PHARMACOL BIOCHEM BE, V40, P329, DOI 10.1016/0091-3057(91)90562-G; Dalvi A, 1999, PHARMACOL BIOCHEM BE, V62, P727, DOI 10.1016/S0091-3057(98)00220-2; DENCKER SJ, 1990, LANCET, V335, P413, DOI 10.1016/0140-6736(90)90246-2; DENCKER SJ, 1992, PSYCHOPHARMACOLOGY, V107, P69, DOI 10.1007/BF02244967; DIAL EJ, 1995, DIGEST DIS SCI, V40, P2295, DOI 10.1007/BF02063227; DIEHL RG, 1984, EPILEPSIA, V25, P506, DOI 10.1111/j.1528-1157.1984.tb03452.x; DOROW R, 1983, LANCET, V2, P98; EIGEL WN, 1984, J DAIRY SCI, V67, P1599, DOI 10.3168/jds.S0022-0302(84)81485-X; Ferrarese C, 1998, EPILEPSY RES, V29, P129, DOI 10.1016/S0920-1211(97)00074-0; FERRERO P, 1984, NEUROPHARMACOLOGY, V23, P1359, DOI 10.1016/0028-3908(84)90061-3; FILE SE, 1982, NEUROPHARMACOLOGY, V21, P1033, DOI 10.1016/0028-3908(82)90118-6; GRAMLICH CA, 1987, PHARMACOL BIOCHEM BE, V26, P159, DOI 10.1016/0091-3057(87)90549-1; GUIDOTTI A, 1983, P NATL ACAD SCI-BIOL, V80, P3531, DOI 10.1073/pnas.80.11.3531; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; KAMINOGAWA S, 1987, J AM OIL CHEM SOC, V64, P1688, DOI 10.1007/BF02542504; Karle J, 1998, J NEUROSCI RES, V54, P863, DOI 10.1002/(SICI)1097-4547(19981215)54:6<863::AID-JNR14>3.0.CO;2-6; KARLER R, 1989, NEUROPHARMACOLOGY, V28, P775, DOI 10.1016/0028-3908(89)90166-4; KOCH G, 1988, REGUL PEPTIDES, V20, P107, DOI 10.1016/0167-0115(88)90044-4; KRUEGER KE, 1990, J BIOL CHEM, V265, P15015; KRUEGER KE, 1991, NEUROPSYCHOPHARMACOL, V4, P237; KUMOSINSKI TF, 1991, J DAIRY SCI, V74, P2889, DOI 10.3168/jds.S0022-0302(91)78470-1; LACOSTE L, 1988, CAN J PHYSIOL PHARM, V66, P1135, DOI 10.1139/y88-186; LAIRD D. A., 1934, Journal of the American Dietetic Association, V10, P89; LAZAROVA-BAKAROVA M, 1990, Acta Physiologica et Pharmacologica Bulgarica, V16, P37; LEBENTHAL E, 1983, J PEDIATR-US, V102, P1, DOI 10.1016/S0022-3476(83)80276-5; LOUKAS S, 1983, BIOCHEMISTRY-US, V22, P4567, DOI 10.1021/bi00288a034; LUDDENS H, 1995, J PSYCHIATR RES, V29, P77, DOI 10.1016/0022-3956(94)00040-X; MEDINA JH, 1988, BIOCHEM BIOPH RES CO, V152, P534, DOI 10.1016/S0006-291X(88)80070-6; MEDINA JH, 1992, MOL NEUROBIOL, V6, P377, DOI 10.1007/BF02757942; Meisel H, 1997, BIOPOLYMERS, V43, P119, DOI [10.1002/(SICI)1097-0282(1997)43:2<119::AID-BIP4>3.0.CO;2-Y, 10.1002/(SICI)1097-0282(1997)43:2&lt;119::AID-BIP4&gt;3.0.CO;2-Y]; MEISEL H, 1986, FEBS LETT, V196, P223, DOI 10.1016/0014-5793(86)80251-4; Meisel H, 1999, ANTON LEEUW INT J G, V76, P207, DOI 10.1023/A:1002063805780; MOSER PC, 1989, PSYCHOPHARMACOLOGY, V99, P48, DOI 10.1007/BF00634451; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NORUSIS MJ, 1994, SPSS ADV STAT 6 1 MA, P117; PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PAPADOPOULOS V, 1992, P NATL ACAD SCI USA, V89, P5113, DOI 10.1073/pnas.89.11.5113; PELISSOLO A, 1995, ENCEPHALE, V21, P133; PELLMAR TC, 1977, SCIENCE, V197, P912, DOI 10.1126/science.887932; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; PERRIN E, 1995, J CHROMATOGR B, V664, P267, DOI 10.1016/0378-4347(94)00400-Y; PINEL JPJ, 1978, J COMP PHYSIOL PSYCH, V92, P708, DOI 10.1037/h0077494; POMES A, 1994, J PHARMACOL EXP THER, V271, P1616; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; ROHMER JG, 1990, BEHAV BRAIN RES, V38, P45, DOI 10.1016/0166-4328(90)90023-8; SANOGO T, 1989, J DAIRY SCI, V72, P2242, DOI 10.3168/jds.S0022-0302(89)79354-1; SCHMIDT J, 1987, BIOMED BIOCHIM ACTA, V46, P267; SVEDBERG J, 1985, PEPTIDES, V6, P825, DOI 10.1016/0196-9781(85)90308-0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TREIT D, 1987, BRAIN RES BULL, V19, P401, DOI 10.1016/0361-9230(87)90143-2; TREIT D, 1981, PHARMACOL BIOCHEM BE, V15, P619, DOI 10.1016/0091-3057(81)90219-7; UMBACH M, 1985, REGUL PEPTIDES, V12, P223, DOI 10.1016/0167-0115(85)90063-1; Walsh LA, 1999, J PHARMACOL EXP THER, V289, P1626; Winer BJ., 1970, STAT PRINCIPLES EXPT, V2nd; YAMAMOTO N, 1994, J DAIRY SCI, V77, P917, DOI 10.3168/jds.S0022-0302(94)77026-0	61	62	66	3	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1780	+		10.1096/fj.00-0685fje	http://dx.doi.org/10.1096/fj.00-0685fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481228				2022-12-28	WOS:000169261200032
J	Pinnix, I; Council, JE; Roseberry, B; Onstead, L; Mallender, W; Sucic, J; Sambamurti, K				Pinnix, I; Council, JE; Roseberry, B; Onstead, L; Mallender, W; Sucic, J; Sambamurti, K			Convertases other than furin cleave beta-secretase to its mature form	FASEB JOURNAL			English	Article						proprotein convertases; memapsin; aspartyl proteases; proprotein convertases; BACE; zymogen activation; amyloid; Alzheimer	AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE; ALZHEIMERS-DISEASE; SITE; PROPROTEIN; PEPTIDE; ENZYME; INHIBITORS; PRESENILIN; MATURATION	An aspartyl protease, Beta-Site APP cleaving enzyme (BACE), was identified as the beta -secretase responsible for generating the Amyloid beta protein that is believed to cause Alzheimer's disease. BACE has a short propeptide domain that is absent in the mature enzyme because of proteolytic cleavage after the sequence RLPR. This sequence is a predicted substrate for proprotein convertases such as furin. To determine the role of furin and other proprotein convertases, we expressed proBACE in a furin-deficient mutant Chinese hamster ovary (CHO-K1) line, RPE. 40. ProBACE signal was higher in RPE. 40 than in the CHO-K1 parent, which confirmed that furin plays a role in propeptide removal. However, two independent approaches showed that proBACE is cleaved to mature BACE in RPE. 40: proBACE was rapidly turned over in RPE. 40 although total BACE was stable, and decanoyl-RVKR-chloromethylketone, an inhibitor of the proprotein convertase family, substantially increased proBACE levels in both RPE 40 and CHO-K1. Transient transfection shows that furin, PACE4, PC5/6, and PC7 mediate BACE cleavage in vivo, at least when overexpressed. RPE. 40 is proficient in BACE activity despite its furin deficiency. Therefore, our finding that proBACE is cleaved in this mutant leaves open the possibility that maturation is an important regulatory step and a therapeutic target.	Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA; Univ Michigan, Dept Biol, Flint, MI 48502 USA	Mayo Clinic; University of Michigan System; University of Michigan; University of Michigan Flint	Sambamurti, K (corresponding author), Mayo Clin, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	samba@mayo.edu	Sambamurti, Kumar/A-1620-2012	Sambamurti, Kumar/0000-0001-9507-9214				Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAI H, 2000, SOC NEUR 30 ANN M NO; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P12450, DOI 10.1021/bi001494f; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; GANDY S, 1994, NEUROBIOL AGING, V15, P253, DOI 10.1016/0197-4580(94)90125-2; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Harlow E., 1988, ANTIBODIES LAB MANUA; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Inocencio NM, 1997, J BIOL CHEM, V272, P1344, DOI 10.1074/jbc.272.2.1344; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; MOEHRING TJ, 1977, CELL, V11, P447, DOI 10.1016/0092-8674(77)90063-0; OHNISHI Y, 1994, J VIROL, V68, P4075, DOI 10.1128/JVI.68.6.4075-4079.1994; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Sambamurti K, 1999, J BIOL CHEM, V274, P26810, DOI 10.1074/jbc.274.38.26810; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Selkoe DJ, 2000, P NATL ACAD SCI USA, V97, P5690, DOI 10.1073/pnas.97.11.5690; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; SPENCE MJ, 1995, SOMAT CELL MOLEC GEN, V21, P1, DOI 10.1007/BF02255818; Sucic JF, 1999, BIOCHEM J, V339, P639, DOI 10.1042/0264-6021:3390639; Sucic JF, 1998, SOMAT CELL MOLEC GEN, V24, P75, DOI 10.1023/B:SCAM.0000007111.46513.70; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	53	26	26	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1810	+		10.1096/fj.00-0891fje	http://dx.doi.org/10.1096/fj.00-0891fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481238	Green Submitted			2022-12-28	WOS:000169261200035
J	Chen, SY; Wilkemeyer, MF; Sulik, KK; Charness, ME				Chen, SY; Wilkemeyer, MF; Sulik, KK; Charness, ME			Octanol antagonism of ethanol teratogenesis	FASEB JOURNAL			English	Article						fetal alcohol syndrome; L1 cell adhesion molecule; alcohol, ethyl; fetal development; apoptosis	FETAL ALCOHOL SYNDROME; CEREBELLAR GRANULE NEURONS; ADHESION MOLECULES L1; CELL-CELL ADHESION; NEURAL CREST CELLS; POTASSIUM CHANNELS; FREE-RADICALS; DEATH; INHIBITION; APOPTOSIS	Alcohol may cause birth defects in part by disrupting the developmentally critical L1 cell adhesion molecule. Because 1-octanol antagonizes ethanol inhibition of L1-mediated cell adhesion, we asked whether 1-octanol also prevents ethanol teratogenicity. L1 was detected in control mouse embryos as early as gestational day 8 (GD8), an early stage of vulnerability to ethanol teratogenesis. Culture of GD8 embryos with ethanol increased apoptotic cell death and decreased numbers of somite pairs. 1-Octanol markedly reduced both ethanol effects. The paradoxical inhibition of ethanol teratogenicity by a longer chain 1-alcohol suggests a strategy for developing compounds that prevent alcohol-related birth defects.	Univ N Carolina, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; VA Boston Healthcare Syst, Neurol Serv, W Roxbury, MA 02132 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Charness, ME (corresponding author), Harvard Med Sch, VA Boston Healthcare Syst, Dept Neurol 127, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.	mcharness@hms.harvard.edu		Charness, Michael/0000-0002-3301-8966				BATTIFORA H, 1995, ADV PATHOL LAB MED, V8, P101; Bearer CF, 1999, J BIOL CHEM, V274, P13264, DOI 10.1074/jbc.274.19.13264; Bhave SV, 1997, J NEUROCHEM, V68, P578, DOI 10.1046/j.1471-4159.1997.68020578.x; Bhave SV, 1999, J NEUROSCI, V19, P3277, DOI 10.1523/jneurosci.19-09-03277.1999; Cartwright MM, 1998, ALCOHOL CLIN EXP RES, V22, P142, DOI 10.1097/00000374-199802000-00019; Cartwright MM, 1995, ALCOHOL CLIN EXP RES, V19, P1454, DOI 10.1111/j.1530-0277.1995.tb01007.x; CHARNESS ME, 1994, J BIOL CHEM, V269, P9304; Chen S, 1999, J NEUROBIOL, V38, P428, DOI 10.1002/(SICI)1097-4695(19990215)38:3<428::AID-NEU10>3.0.CO;2-6; Chen SY, 1996, ALCOHOL CLIN EXP RES, V20, P1071, DOI 10.1111/j.1530-0277.1996.tb01948.x; Chu BS, 1997, ALCOHOL CLIN EXP RES, V21, P1103, DOI 10.1097/00000374-199709000-00025; Cui SJ, 1997, ALCOHOL CLIN EXP RES, V21, P1121, DOI 10.1111/j.1530-0277.1997.tb04262.x; DAVIS WL, 1990, J CRAN GENET DEV BIO, V10, P277; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056; Kamiguchi H, 1998, J NEUROSCI, V18, P3749, DOI 10.1523/jneurosci.18-10-03749.1998; KOTCH LE, 1992, TERATOLOGY, V46, P323, DOI 10.1002/tera.1420460403; KOTCH LE, 1992, AM J MED GENET, V44, P168, DOI 10.1002/ajmg.1320440210; KOTCH LE, 1992, INT J DEV NEUROSCI, V10, P273, DOI 10.1016/0736-5748(92)90016-S; KOTCH LE, 1995, TERATOLOGY, V52, P128, DOI 10.1002/tera.1420520304; Lewohl JM, 1999, NAT NEUROSCI, V2, P1084, DOI 10.1038/16012; Li AE, 1999, CIRC RES, V85, P304, DOI 10.1161/01.RES.85.4.304; Liesi P, 1997, J NEUROSCI RES, V48, P439, DOI 10.1002/(SICI)1097-4547(19970601)48:5<439::AID-JNR5>3.0.CO;2-F; Minami K, 1997, J PHARMACOL EXP THER, V281, P1136; Mitchell JJ, 1999, ALCOHOL, V17, P163, DOI 10.1016/S0741-8329(98)00051-2; MOSCOSO LM, 1995, J COMP NEUROL, V352, P321, DOI 10.1002/cne.903520302; NAKAHIRO M, 1991, J PHARMACOL EXP THER, V259, P235; Ramanathan R, 1996, J CELL BIOL, V133, P381, DOI 10.1083/jcb.133.2.381; REID RA, 1992, J MOL NEUROSCI, V3, P127, DOI 10.1007/BF02919404; SADLER TW, 1979, J EMBRYOL EXP MORPH, V49, P17; SADLER TW, 1984, PHARMACOL REV, V36, P1455; SULIK KK, 1981, SCIENCE, V214, P936, DOI 10.1126/science.6795717; Takeda Y, 1996, J NEUROCHEM, V66, P2338; Vallejo Y, 1997, J BIOL CHEM, V272, P12244, DOI 10.1074/jbc.272.18.12244; WEST JR, 1990, ALCOHOL CLIN EXP RES, V14, P813, DOI 10.1111/j.1530-0277.1990.tb01820.x; Wilkemeyer MF, 1999, ALCOHOL CLIN EXP RES, V23, P1711, DOI 10.1097/00000374-199911000-00002; Wilkemeyer MF, 1998, J NEUROCHEM, V71, P2382; Wilkemeyer WF, 2000, P NATL ACAD SCI USA, V97, P3690, DOI 10.1073/pnas.97.7.3690; Yamamoto Y, 1999, DEV BIOL, V214, P60, DOI 10.1006/dbio.1999.9413; Zhang FX, 1998, J NEUROCHEM, V71, P196, DOI 10.1046/j.1471-4159.1998.71010196.x	41	48	49	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1649	+		10.1096/fj.00-0862fje	http://dx.doi.org/10.1096/fj.00-0862fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427515				2022-12-28	WOS:000173707700011
J	Chu, A; Matusiewicz, N; Stochaj, U				Chu, A; Matusiewicz, N; Stochaj, U			Heat-induced nuclear accumulation of hsc70 proteins is regulated by phosphorylation and inhibited in confluent cells	FASEB JOURNAL			English	Article						nuclear transport; stress; heat shock proteins; protein phosphorylation	HELA-CELLS; IN-VITRO; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; SHOCK PROTEIN-70; IMPORT; KINASE; EXPRESSION; HEAT-SHOCK-PROTEIN-70; TRANSLOCATION	Stress affects the general organization of cells and, in particular, the subcellular localization of molecules. Proteins of the hsp70/hsc70 family relocate to nuclei in response to heat shock, when classical nuclear protein import is inhibited. We have now further characterized the effect of stress on hsc70 protein localization in HeLa cells. Heat-induced nuclear concentration of hsc70 proteins depends on cell density, and low-density cultures efficiently imported hsc70 proteins into nuclei when exposed to heat. However, high-density cultures failed to accumulate hsc70 proteins in nuclei during heat shock. In low-density cultures, heat-induced hsc70 nuclear accumulation was insensitive to inhibitors of tyrosine kinases, Ser/Thr protein kinases, and rapamycin, which indicates that activation of mitogen-activated protein kinase family members or p70 S6 kinase is not required for this process. In contrast, inhibitors of Ser/Thr protein phosphatase and Tyr protein phosphatase abolished the nuclear concentration of hsc70 proteins. Likewise, inhibitors of protein phosphatases affected classical nuclear protein import in unstressed cells, but these transport pathways differed drastically in their sensitivities toward inhibitors. Although protein phosphorylation negatively regulates hsc70 nuclear accumulation in response to heat, protein kinase inhibitors were unable to overcome the block of hsc70 nuclear accumulation in high-density cultures, indicating that additional components control hsc70 nuclear transport.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	McGill University	Chu, A (corresponding author), McGill Univ, Dept Physiol, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	achu@med.mcgill.ca; stochaj@med.mcgill.ca	stochaj, ursula/AAC-1865-2021					Barth W, 1999, BIOCHEM CELL BIOL, V77, P355, DOI 10.1139/bcb-77-4-355; BENJAMIN LJ, 1994, BIOL HEAT SHOCK PROT, P533; Bonelli MA, 1999, EXP CELL RES, V252, P20, DOI 10.1006/excr.1999.4614; Chatterjee S, 1998, BIOTECHNIQUES, V24, P668, DOI 10.2144/98244rr04; Chen HC, 1999, KIDNEY INT, V56, P1270, DOI 10.1046/j.1523-1755.1999.00693.x; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; Czubryt MP, 2000, J CELL BIOL, V148, P7, DOI 10.1083/jcb.148.1.7; Dynlacht JR, 1999, J CELL PHYSIOL, V178, P28, DOI 10.1002/(SICI)1097-4652(199901)178:1<28::AID-JCP4>3.3.CO;2-B; Gutsmann-Conrad A, 1998, EXP CELL RES, V241, P404, DOI 10.1006/excr.1998.4069; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Kehlenbach RH, 2000, J BIOL CHEM, V275, P17848, DOI 10.1074/jbc.M001455200; Kim-Kaneyama JR, 2000, J BIOL CHEM, V275, P20685, DOI 10.1074/jbc.M908723199; Knowlton AA, 2000, AM J PHYSIOL-HEART C, V278, pH2143, DOI 10.1152/ajpheart.2000.278.6.H2143; Kobayashi S, 1997, J BIOL CHEM, V272, P16262, DOI 10.1074/jbc.272.26.16262; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Lamian V, 1996, EXP CELL RES, V228, P84, DOI 10.1006/excr.1996.0302; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Liu Y, 1996, EMBO J, V15, P6750, DOI 10.1002/j.1460-2075.1996.tb01064.x; Malek AM, 1997, AM J PHYSIOL-CELL PH, V273, pC1764, DOI 10.1152/ajpcell.1997.273.5.C1764; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; Manzerra P, 1996, EXP CELL RES, V229, P35, DOI 10.1006/excr.1996.0341; NERI LM, 1995, EXP CELL RES, V221, P301, DOI 10.1006/excr.1995.1379; NOWAK TS, 1994, BIOL HEAT SHOCK PROT, P553; PAHLAVANI MA, 1995, EXP CELL RES, V218, P310, DOI 10.1006/excr.1995.1160; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Stochaj U, 2000, FASEB J, V14, P2130, DOI 10.1096/fj.99-0751fje; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wang HCR, 2000, J BIOL CHEM, V275, P25850, DOI 10.1074/jbc.M000818200	33	32	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1478	+		10.1096/fj.00-0680fje	http://dx.doi.org/10.1096/fj.00-0680fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387263				2022-12-28	WOS:000173705800004
J	Hansel, A; Kuschel, L; Hehl, S; Lemke, C; Agricola, HJ; Hoshi, T; Heinemann, SH				Hansel, A; Kuschel, L; Hehl, S; Lemke, C; Agricola, HJ; Hoshi, T; Heinemann, SH			Mitochondrial targeting of the human peptide methionine sulfoxide reductase (MSRA), an enzyme-involved in the repair of oxidized proteins	FASEB JOURNAL			English	Article						methionine oxidation; reactive oxygen species; mitochondria; signal sequence; confocal microscopy; electron microscopy	CATALYTIC MECHANISM; EXPRESSION; IDENTIFICATION; OXIDATION; RESIDUES; GENE; CLONING; IMPORT; CA2+; LOCALIZATION	Peptide methionine sulfoxide reductase (MSRA) catalyzes the reduction of methionine sulfoxide to methionine. This widely expressed enzyme constitutes an important repair mechanism for oxidatively damaged proteins, which accumulate during the manifestation of certain degenerative diseases and aging processes. In addition, it is discussed to be involved in regulatory processes. Here we address the question of how the enzyme's diverse functions are reflected in its subcellular localization. Using fusions of the human version of MSRA with the enhanced green fluorescence protein expressed in various mammalian cell lines, we show a distinct localization at mitochondria. The N-terminal 23 amino acid residues contain the signal for this mitochondrial targeting. Activity tests showed that they are not required for enzyme function. Mitochondrial localization of native MSRA in mouse and rat liver slices was verified with an MSRA-specific antibody by using immunohistochemical methods. The protein was located in the mitochondrial matrix, as demonstrated by using pre-embedding immunostaining and electron microscopy. Mitochondria are the major source of reactive oxygen species (ROS). Therefore, MSRA has to be considered an important means for the general reduction of ROS release from mitochondria.	Univ Jena, Fac Med, D-07747 Jena, Germany; Univ Jena, Inst Anat 1, D-07743 Jena, Germany; Univ Jena, Inst Gen Zool & Anim Physiol, D-07743 Jena, Germany; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; University of Pennsylvania	Heinemann, SH (corresponding author), Univ Jena, Fac Med, Drackendorfer Str 1, D-07747 Jena, Germany.	stefan.h.heinemann@uni-jena.de		Heinemann, Stefan H./0000-0002-4144-0251				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Boschi-Muller S, 2000, J BIOL CHEM, V275, P35908, DOI 10.1074/jbc.M006137200; BROT N, 1983, ARCH BIOCHEM BIOPHYS, V223, P271, DOI 10.1016/0003-9861(83)90592-1; CALDWELL P, 1978, P NATL ACAD SCI USA, V75, P5349, DOI 10.1073/pnas.75.11.5349; Ciorba MA, 1997, P NATL ACAD SCI USA, V94, P9932, DOI 10.1073/pnas.94.18.9932; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Gabbita SP, 1999, J NEUROCHEM, V73, P1660, DOI 10.1046/j.1471-4159.1999.0731660.x; Grimaud R, 2001, J BIOL CHEM, V276, P48915, DOI 10.1074/jbc.M105509200; Hammen PK, 1996, J BIOL CHEM, V271, P21041, DOI 10.1074/jbc.271.35.21041; Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x; Huang WH, 1999, GENE, V233, P233, DOI 10.1016/S0378-1119(99)00131-6; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Kuschel L, 1999, FEBS LETT, V456, P17, DOI 10.1016/S0014-5793(99)00917-5; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lowther WT, 2000, P NATL ACAD SCI USA, V97, P6463, DOI 10.1073/pnas.97.12.6463; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P2095, DOI 10.1073/pnas.93.5.2095; Moskovitz J, 2000, J BIOL CHEM, V275, P14167, DOI 10.1074/jbc.275.19.14167; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P3205, DOI 10.1073/pnas.93.8.3205; Ni L, 1999, J BIOL CHEM, V274, P12685, DOI 10.1074/jbc.274.18.12685; Petropoulos I, 2001, BIOCHEM J, V355, P819, DOI 10.1042/bj3550819; Pfanner N, 2000, CURR BIOL, V10, pR412, DOI 10.1016/S0960-9822(00)00507-8; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Sadanandom A, 2000, PLANT PHYSIOL, V123, P255, DOI 10.1104/pp.123.1.255; Sharov VS, 1999, FEBS LETT, V455, P247, DOI 10.1016/S0014-5793(99)00888-1; Simpson PB, 2000, J BIOENERG BIOMEMBR, V32, P5, DOI 10.1023/A:1005552126516; Smaili SS, 2000, J BIOENERG BIOMEMBR, V32, P35, DOI 10.1023/A:1005508311495; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; Squier TC, 2000, FRONT BIOSCI-LANDMRK, V5, pD504, DOI 10.2741/Squier; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; Taggart C, 2000, J BIOL CHEM, V275, P27258; Yao YH, 1996, BIOCHEMISTRY-US, V35, P2767, DOI 10.1021/bi951712i; Yermolaieva O, 2000, P NATL ACAD SCI USA, V97, P448, DOI 10.1073/pnas.97.1.448	34	92	101	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					911	+		10.1096/fj.01-0737fje	http://dx.doi.org/10.1096/fj.01-0737fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039877				2022-12-28	WOS:000175425900030
J	Gunther, EJ; Belka, GK; Wertheim, GBW; Wang, J; Hartman, JL; Boxer, RB; Chodosh, LA				Gunther, EJ; Belka, GK; Wertheim, GBW; Wang, J; Hartman, JL; Boxer, RB; Chodosh, LA			A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology	FASEB JOURNAL			English	Article						transgenic mice; MMTV; transgene induction	BREAST-CANCER RISK; GENE-EXPRESSION; NEU ONCOGENE; TUMOR VIRUS; HA-RAS; MICE; TUMORIGENESIS; SINGLE; CELLS; TIME	Normal developmental events such as puberty, pregnancy, and parity influence the susceptibility of the mammary gland to tumorigenesis in both humans and rodent model systems. Unfortunately, constitutive transgenic mouse models that rely on mammary- specific promoters to control transgene expression have limited utility for studying the effect of developmental events on breast cancer risk since the hormonal signals governing these events also markedly influence transgene expression levels. A novel transgenic mouse system is described that uses the MMTV-LTR to drive expression of the reverse tetracycline-dependent transactivator rtTA. Transgenic mice expressing rtTA in the mammary epithelium were crossed with reporter lines bearing tet operator- controlled transgenes. We tested the ability to spatially, temporally, and quantitatively control reporter gene expression after administration of doxycycline to bi-transgenic mice. Transgene expression using this system can be rapidly induced and deinduced, is highly mammary specific, can be reproducibly titrated over a wide range of expression levels, and is essentially undetectable in the uninduced state. Homogeneous transgene expression throughout the mammary epithelium can be achieved. This system permits transgene expression to be restricted to any desired stage of postnatal mammary gland development. We have developed a mammary- specific, doxycycline- inducible transgenic mouse model for studying the effect of mammary gland development on transgene- mediated phenotypes. Unlike other mammary- specific, transgenic systems that have been described, this system combines spatially homogeneous transgene expression in the mammary epithelium during puberty, pregnancy, lactation, and involution with the use of an orally administered, inexpensive, and widely available inducing agent. This system offers new opportunities for the transgenic analysis of mammary gland biology in vivo.	Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Chodosh, LA (corresponding author), Univ Penn, Sch Med, Dept Canc Biol, 612 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	chodosh@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [P01CA077596, K08CA079682, R01CA092190, R01CA078410, P30CA016520, R01CA083849] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA77596, K08 CA79682, CA92190, CA83849, CA78410, CA16520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanese C, 2000, FASEB J, V14, P877, DOI 10.1096/fasebj.14.7.877; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Gardner HP, 2000, DEVELOPMENT, V127, P4493; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOULD MN, 1995, SEMIN CANCER BIOL, V6, P147, DOI 10.1006/scbi.1995.0023; Hennighausen L, 1995, J CELL BIOCHEM, V59, P463, DOI 10.1002/jcb.240590407; Hennighausen L, 1999, NAT BIOTECHNOL, V17, P1062, DOI 10.1038/15046; HENNIGHAUSEN LG, 1982, EUR J BIOCHEM, V125, P131, DOI 10.1111/j.1432-1033.1982.tb06660.x; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209; MARCHANT J, 1955, J PATHOL BACTERIOL, V70, P415, DOI 10.1002/path.1700700218; Medina D, 1999, J NATL CANCER I, V91, P967, DOI 10.1093/jnci/91.11.967; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUNOZ B, 1989, MOL CELL ENDOCRINOL, V62, P23, DOI 10.1016/0303-7207(89)90109-3; RAMIREZ MI, 1994, MOL CELL BIOL, V14, P2809, DOI 10.1128/MCB.14.4.2809; ROSS SR, 1990, MOL CELL BIOL, V10, P5822, DOI 10.1128/MCB.10.11.5822; Rossant J, 1999, GENE DEV, V13, P142, DOI 10.1101/gad.13.2.142; RUSSO J, 1990, LAB INVEST, V62, P244; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TOKUNAGA M, 1994, RADIAT RES, V138, P209, DOI 10.2307/3578591; Utomo ARH, 1999, NAT BIOTECHNOL, V17, P1091, DOI 10.1038/15073; VARLEY JM, 1987, ONCOGENE, V1, P423; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511	31	160	162	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0283	10.1096/fj.01-0551com	http://dx.doi.org/10.1096/fj.01-0551com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874978				2022-12-28	WOS:000174755900021
J	Malcangio, M; Getting, S; Grist, J; Cunningham, JR; Bradbury, EJ; Issa, PC; Lever, IJ; Pezet, S; Perretti, M				Malcangio, M; Getting, S; Grist, J; Cunningham, JR; Bradbury, EJ; Issa, PC; Lever, IJ; Pezet, S; Perretti, M			A novel control mechanism based on GDNF modulation of somatostatin release from sensory neurones	FASEB JOURNAL			English	Article						substance P; evoked release; spinal cord; thermal hypersensitivity; inflammation	RAT SPINAL-CORD; DORSAL-HORN NEURONS; SUBSTANCE-P; NEUROTROPHIC FACTOR; RECEPTOR; NEUROPEPTIDES; HYPERALGESIA; ACTIVATION; IMMUNOREACTIVITY; INVOLVEMENT	Small-diameter sensory neurones found in the rat dorsal root ganglia (DRG) include cells sensitive to glial cell line-derived neurotrophic factor (GDNF), which express the inhibitory peptide somatostatin (SOM). Here we addressed the functional relationship between GDNF and sensory neurone-derived SOM. Topical application of GDNF through the rat isolated dorsal horn of the spinal cord promoted activity-induced release of SOM from central terminals of sensory neurones. Once released by sensory neurones, SOM is known to act, at least in part, by opposing the action of Substance P (SP) in neurogenic inflammation. Therefore, we evaluated GDNF ability to modulate two well-documented effects of peripherally and centrally administered SP. Local application of GDNF in the mouse air pouch reduced SP-induced leukocyte migration. This effect of GDNF was mimicked by the SOM analog octreotide (OCT) and required intact SOM neuronal pools. Intrathecal injection of GDNF activated rat lumbar dorsal horn neurones and inhibited intrathecal SP-induced thermal hypersensitivity. This effect of GDNF was reversed by the SOM antagonist c-SOM and mimicked by OCT. In conclusion we propose GDNF regulation of neuronal SOM release as a novel mechanism that, if explored, may lead to new therapeutic strategies based on local release of somatostatin.	Kings Coll London, Guys Kings & St Thomas Sch Biomed Sci, Ctr Res Neurosci, London WC2R 2LS, England; St Thomas Hosp, Rayne Inst, Vis & Ophthalmol Res Grp, London SE1 7EH, England; William Harvey Res Inst, London, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; Queen Mary University London	Malcangio, M (corresponding author), KCL, Ctr Neurosci, Hodgkin Bldg,Guys Campus,London Bridge, London SE1 1UL, England.	Marzia.Malcangio@kcl.ac.uk	Issa, Peter Charbel/E-8935-2018; Issa, Peter Charbel/F-9603-2011; PEZET, sophie/AAR-1239-2021	Issa, Peter Charbel/0000-0002-0351-6673; PEZET, sophie/0000-0002-3305-3315; Bradbury, Elizabeth/0000-0003-4252-0234; Malcangio, Marzia/0000-0003-4296-5727				ALVAREZ FJ, 1990, NEUROSCIENCE, V38, P343, DOI 10.1016/0306-4522(90)90033-Z; Bennett DLH, 1998, J NEUROSCI, V18, P3059; Boucher TJ, 2000, SCIENCE, V290, P124, DOI 10.1126/science.290.5489.124; Carlton SM, 2001, PAIN, V90, P233, DOI 10.1016/S0304-3959(00)00407-3; CECCATELLI S, 1987, PEPTIDES, V8, P371, DOI 10.1016/0196-9781(87)90114-8; CHAPMAN V, 1992, NEUROPEPTIDES, V23, P147, DOI 10.1016/0143-4179(92)90115-D; CHRUBASIK J, 1984, LANCET, V2, P1208; EDWARDS JCW, 1981, J PATHOL, V134, P147, DOI 10.1002/path.1711340205; GREEN PG, 1992, NEUROSCIENCE, V50, P745, DOI 10.1016/0306-4522(92)90461-A; GRIFFITHS EC, 1977, ACTA ENDOCRINOL-COP, V85, P1; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HARTUNG HP, 1986, J IMMUNOL, V136, P3856; Helyes Z, 2000, NEUROSCI LETT, V278, P185, DOI 10.1016/S0304-3940(99)00936-2; HELYES Z, 2000, BRIT J PHARMACOL, V134, P1571; Heppelmann B, 1997, PAIN, V73, P377, DOI 10.1016/S0304-3959(97)00124-3; HOKFELT T, 1976, NEUROSCIENCE, V1, P131, DOI 10.1016/0306-4522(76)90008-7; Holzer P, 1998, GEN PHARMACOL, V30, P5, DOI 10.1016/S0306-3623(97)00078-5; Ibanez CF, 1998, TRENDS NEUROSCI, V21, P438, DOI 10.1016/S0166-2236(98)01266-1; Issa PC, 2001, J NEUROCHEM, V78, P221, DOI 10.1046/j.1471-4159.2001.00430.x; Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040; KARALIS K, 1994, J CLIN INVEST, V93, P2000, DOI 10.1172/JCI117193; KOLASINSKI SL, 1992, ARTHRITIS RHEUM, V35, P369, DOI 10.1002/art.1780350402; Lever IJ, 2001, J NEUROSCI, V21, P4469, DOI 10.1523/JNEUROSCI.21-12-04469.2001; MALCANGIO M, 1993, J PHARMACOL EXP THER, V266, P1490; Malcangio M, 1997, EUR J NEUROSCI, V9, P1101, DOI 10.1111/j.1460-9568.1997.tb01462.x; Malcangio M, 2000, EUR J NEUROSCI, V12, P397, DOI 10.1046/j.1460-9568.2000.00946.x; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; MANCUSO F, 1995, J IMMUNOL, V155, P377; MORTON CR, 1988, NEUROPEPTIDES, V12, P189, DOI 10.1016/0143-4179(88)90054-6; MURASE K, 1982, BRAIN RES, V234, P170, DOI 10.1016/0006-8993(82)90483-8; Nicole O, 2001, J NEUROSCI, V21, P3024, DOI 10.1523/JNEUROSCI.21-09-03024.2001; Olson L, 1997, TRENDS NEUROSCI, V20, P277, DOI 10.1016/S0166-2236(97)01098-9; Paice JA, 1996, NEUROSURGERY, V38, P203, DOI 10.1097/00006123-199601000-00047; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PAYAN DG, 1986, J BIOL CHEM, V261, P14321; PERRETTI M, 1993, IMMUNOLOGY, V80, P73; Perretti M, 1996, BRIT J PHARMACOL, V117, P1145, DOI 10.1111/j.1476-5381.1996.tb16709.x; PROUDLOCK F, 1993, J COMP NEUROL, V327, P289, DOI 10.1002/cne.903270210; Ren K, 1996, BRIT J PHARMACOL, V117, P196, DOI 10.1111/j.1476-5381.1996.tb15174.x; SANDKUHLER J, 1990, NEUROSCIENCE, V34, P565, DOI 10.1016/0306-4522(90)90165-Z; Schinder AF, 2000, TRENDS NEUROSCI, V23, P639, DOI 10.1016/S0166-2236(00)01672-6; Schindler M, 1998, BRAIN RES, V798, P25, DOI 10.1016/S0006-8993(98)00361-8; Schulz S, 1998, EUR J NEUROSCI, V10, P3700, DOI 10.1046/j.1460-9568.1998.00386.x; Sluka KA, 1997, BRIT J PHARMACOL, V120, P1263, DOI 10.1038/sj.bjp.0701044; Szolcsanyi J, 1998, BRIT J PHARMACOL, V123, P936, DOI 10.1038/sj.bjp.0701685; Todd AJ, 1998, NEUROSCIENCE, V85, P459, DOI 10.1016/S0306-4522(97)00669-6; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TUCHSCHERER MM, 1989, J NEUROSCI, V9, P195; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; Widenfalk J, 2001, J NEUROSCI, V21, P3457, DOI 10.1523/JNEUROSCI.21-10-03457.2001; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619	52	18	21	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3					730	+		10.1096/fj.01-0971fje	http://dx.doi.org/10.1096/fj.01-0971fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11978739				2022-12-28	WOS:000174755900016
J	Devy, L; Blacher, S; Grignet-Debrus, C; Bajou, K; Masson, R; Gerard, RD; Gils, A; Carmeliet, G; Carmeliet, P; Declerck, PJ; Noel, A; Foidart, JM				Devy, L; Blacher, S; Grignet-Debrus, C; Bajou, K; Masson, R; Gerard, RD; Gils, A; Carmeliet, G; Carmeliet, P; Declerck, PJ; Noel, A; Foidart, JM			The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent	FASEB JOURNAL			English	Article						angiogenesis; cell migration; proteolysis; serine protease; PAI-1	ENDOTHELIAL-CELLS; UROKINASE RECEPTOR; ANGIOGENESIS INVITRO; BREAST-CANCER; GROWTH-FACTOR; MOUSE MODEL; MICE; PAI-1; GENE; METASTASIS	Plasminogen activator inhibitor 1 (PAI-1) is believed to control proteolytic activity and cell migration during angiogenesis. We previously demonstrated in vivo that this inhibitor is necessary for optimal tumor invasion and vascularization. We also showed that PAI-1 angiogenic activity is associated with its control of plasminogen activation but not with the regulation of cell-matrix interaction. To dissect the role of the various components of the plasminogen activation system during angiogenesis, we have adapted the aortic ring assay to use vessels from gene-inactivated mice. The single deficiency of tPA, uPA, or uPAR, as well as combined deficiencies of uPA and tPA, did not dramatically affect microvessel formation. Deficiency of plasminogen delayed microvessel outgrowth. Lack of PAI-1 completely abolished angiogenesis, demonstrating its importance in the control of plasmin-mediated proteolysis. Microvessel outgrowth from PAI-1(-/-) aortic rings could be restored by adding exogenous PAI-1 (wild-type serum or purified recombinant PAI-1). Addition of recombinant PAI-1 led to a bell-shaped angiogenic response clearly showing that PAI-1 is proangiogenic at physiological concentrations and antiangiogenic at higher levels. Using specific PAI-1 mutants, we could demonstrate that PAI-1 promotes angiogenesis at physiological (nanomolar) concentrations through its antiproteolytic activity rather than by interacting with vitronectin.	Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX USA; Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Expt Med & Endocrinol LEGENDO, B-3000 Louvain, Belgium; Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium	University of Liege; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; KU Leuven; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven	Noel, A (corresponding author), Univ Liege, Lab Tumor & Dev Biol, Tour Pathol B23,Sart Tilman, B-4000 Liege, Belgium.	agnes.noel@ulg.ac.be	Declerck, Paul J/A-2330-2017; Carmeliet, Peter/AAQ-5140-2020	Declerck, Paul J/0000-0003-1259-9105; Carmeliet, Peter/0000-0001-7961-1821; Bajou, Khalid/0000-0002-5529-9228; Noel, Agnes/0000-0002-7670-6179				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BEHRINGER RR, 1993, DEVELOPMENT, V117, P823; Blacher Silvia, 2001, Angiogenesis, V4, P133, DOI 10.1023/A:1012251229631; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; Carmeliet P, 1998, THROMB RES, V91, P255, DOI 10.1016/S0049-3848(98)00122-4; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1999, CURR TOP MICROBIOL, V237, P133; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; COLMAN RW, 1969, BIOCHEM BIOPH RES CO, V35, P273, DOI 10.1016/0006-291X(69)90278-2; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Eitzman DT, 1996, BLOOD, V87, P4718; Foekens JA, 2000, CANCER RES, V60, P636; GERARD RD, 1995, DNA CLONING PRACTICA, P285; Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d; Gutierrez LS, 2000, CANCER RES, V60, P5839; Harbeck N, 2000, INT J BIOL MARKER, V15, P79, DOI 10.1177/172460080001500115; Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com; LIU GH, 1995, INT J CANCER, V60, P501, DOI 10.1002/ijc.2910600413; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; MILES LA, 1983, THROMB RES, V29, P407, DOI 10.1016/0049-3848(83)90244-X; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; NICOSIA RF, 1990, LAB INVEST, V63, P115; NICOSIA RF, 1982, IN VITRO CELL DEV B, V18, P538; PEPPER MS, 1992, J CELL PHYSIOL, V153, P129, DOI 10.1002/jcp.1041530117; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Ploplis VA, 1998, BLOOD, V91, P2005, DOI 10.1182/blood.V91.6.2005.2005_2005_2009; SHUBEITA HE, 1990, J BIOL CHEM, V265, P18379; Soff GA, 1995, J CLIN INVEST, V96, P2593, DOI 10.1172/JCI118323; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; TSUBOI R, 1990, INT J CANCER, V46, P56, DOI 10.1002/ijc.2910460112; Tsuchiya H, 1997, ANTICANCER RES, V17, P313; Vleugels N, 2000, BBA-PROTEIN STRUCT M, V1476, P20, DOI 10.1016/S0167-4838(99)00224-1; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521	38	236	244	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2							UNSP 0892-6638/02/0016-0147	10.1096/fj.01-0552com	http://dx.doi.org/10.1096/fj.01-0552com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11818362				2022-12-28	WOS:000174203700019
J	Ojcius, DM; Delarbre, C; Kourilsky, P; Gachelin, G				Ojcius, DM; Delarbre, C; Kourilsky, P; Gachelin, G			MHC and MHC-related proteins as pleiotropic signal molecules	FASEB JOURNAL			English	Article						signal transduction; homeostasis; protein-protein interaction; MHC class I	CLASS-I MHC; CRYSTAL-STRUCTURE; NKG2D RECEPTOR; T-CELLS; EXPRESSION; LIGANDS; CNS	Class I molecules of the major histocompatibility complex (MHC) have been studied primarily for their role in presenting peptide antigens to conventional T lymphocytes. An increasing body of evidence suggests that MHC and newly characterized MHC-related molecules have a much more varied function in the body. Many of these molecules are involved in pleiotropic interactions with other proteins, which initiate signal transduction cascades and contribute to cellular and tissue homeostasis.	Inst Pasteur, INSERM, U277, F-75724 Paris 15, France; Univ Paris 07, Inst Pasteur, Unite Biol Mol Gene, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	Gachelin, G (corresponding author), Inst Pasteur, Unite Biol Mol Gene, 25 Rue Dr Roux, F-75015 Paris, France.	ggachel@pasteur.fr						Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Corriveau RA, 1998, NEURON, V21, P505, DOI 10.1016/S0896-6273(00)80562-0; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; Crowley MP, 2000, SCIENCE, V287, P314, DOI 10.1126/science.287.5451.314; Das H, 2001, IMMUNITY, V15, P83, DOI 10.1016/S1074-7613(01)00168-6; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Diefenbach A, 2001, NATURE, V413, P165, DOI 10.1038/35093109; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; Huh GS, 2000, SCIENCE, V290, P2155, DOI 10.1126/science.290.5499.2155; Lauvau G, 2001, J EXP MED, V193, pF35, DOI 10.1084/jem.193.10.F35; Li PW, 1999, IMMUNITY, V10, P577, DOI 10.1016/S1074-7613(00)80057-6; Park SH, 2001, J EXP MED, V193, P893, DOI 10.1084/jem.193.8.893; Ronet C, 2001, J IMMUNOL, V166, P1755, DOI 10.4049/jimmunol.166.3.1755; Sanchez LM, 1999, SCIENCE, V283, P1914, DOI 10.1126/science.283.5409.1914; Ugolini S, 2001, NAT IMMUNOL, V2, P198, DOI 10.1038/85246; Wingren C, 2000, SCIENCE, V287, P310, DOI 10.1126/science.287.5451.310	17	13	14	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					202	206		10.1096/fj.01-0758com	http://dx.doi.org/10.1096/fj.01-0758com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11818368				2022-12-28	WOS:000174203700025
J	Jones, AK; Bentley, GN; Parra, WGO; Agnew, A				Jones, AK; Bentley, GN; Parra, WGO; Agnew, A			Molecular characterization of an acetylcholinesterase implicated in the regulation of glucose scavenging by the parasite Schistosoma	FASEB JOURNAL			English	Article						GPI-anchor; glucose transport; acetylcholine receptor	NONNEURONAL SECRETED ACETYLCHOLINESTERASE; IN-VITRO EXPRESSION; ENCODING ACETYLCHOLINESTERASE; SUBSTRATE-SPECIFICITY; TORPEDO-CALIFORNICA; BINDING; CLONING; SITE; IDENTIFICATION; SEQUENCE	Acetylcholinesterase (AChE) present on the surface of the trematode blood fluke Schistosoma has been implicated in the regulation of glucose scavenging from the host blood. Determination of the molecular structure and functional characteristics of this molecule is a crucial first step in understanding the novel function for AChE and in evaluating the potential of schistosome AChE as a target of new parasite control methods. We have determined the primary structure of acetylcholinesterase from Schistosoma haematobium. Immunolocalization studies confirmed that the enzyme was present on the parasite surface as well as in the muscle. The derived amino acid sequence possesses features common to acetylcholinesterases: the catalytic triad, six cysteines that form three intramolecular disulphide bonds, and aromatic residues lining the catalytic gorge. An unusual feature is that the fully processed native enzyme exists as a glycoinositol phospholipid (GPI)-anchored dimer, but the sequence of the C-terminus does not conform to the current consensus for GPI modification. The enzyme expressed in Xenopus oocytes showed conventional substrate specificity and sensitivity to established inhibitors of AChE, although it is relatively insensitive to the peripheral site inhibitor propidium iodide. Distinctions between host and parasite AChEs will allow the rational design of schistosome-specific drugs and vaccines.	Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Agnew, A (corresponding author), Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England.	a.m.agnew@leeds.ac.uk		Jones, Andrew/0000-0002-7835-0890				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARPAGAUS M, 1994, J BIOL CHEM, V269, P9957; BARAK D, 1995, BIOCHEMISTRY-US, V34, P15444, DOI 10.1021/bi00047a008; Bucht C, 1996, BBA-PROTEIN STRUCT M, V1292, P223, DOI 10.1016/0167-4838(95)00205-7; CAMACHO M, 1994, PARASITOLOGY, V108, P153, DOI 10.1017/S0031182000068244; Camacho M, 1996, PARASITOLOGY, V112, P199, DOI 10.1017/S0031182000084766; Camacho M, 1995, EXP PARASITOL, V81, P584, DOI 10.1006/expr.1995.1152; CAMACHO M, 1995, MOL BIOCHEM PARASIT, V71, P127, DOI 10.1016/0166-6851(94)00039-P; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Combes D, 2000, J MOL BIOL, V300, P727, DOI 10.1006/jmbi.2000.3917; Cousin X, 1996, J BIOL CHEM, V271, P15099, DOI 10.1074/jbc.271.25.15099; Eisenhaber B, 1998, PROTEIN ENG, V11, P1155, DOI 10.1093/protein/11.12.1155; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; ESPINOZA B, 1991, EUR J BIOCHEM, V195, P863, DOI 10.1111/j.1432-1033.1991.tb15776.x; FOURNIER D, 1989, J MOL BIOL, V210, P15, DOI 10.1016/0022-2836(89)90287-8; Fujii T, 1995, NEUROSCI LETT, V201, P207, DOI 10.1016/0304-3940(95)12180-3; FUNKEL Y, 1980, AM J TROP MED HYG, V29, P426; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; HAAS R, 1988, BIOCHEMISTRY-US, V27, P6453, DOI 10.1021/bi00417a038; Hussein AS, 1999, J BIOL CHEM, V274, P9312, DOI 10.1074/jbc.274.14.9312; Hussein AS, 2000, EUR J BIOCHEM, V267, P2276, DOI 10.1046/j.1432-1327.2000.01232.x; KAWASHIMA K, 1993, BIOGENIC AMINES, V9, P251; Kohler P, 2001, INT J PARASITOL, V31, P336, DOI 10.1016/S0020-7519(01)00131-X; KREIENKAMP HJ, 1991, P NATL ACAD SCI USA, V88, P6117, DOI 10.1073/pnas.88.14.6117; Massoulie J, 1998, J PHYSIOLOGY-PARIS, V92, P183, DOI 10.1016/S0928-4257(98)80007-7; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; McClellan JS, 1998, EUR J BIOCHEM, V258, P419, DOI 10.1046/j.1432-1327.1998.2580419.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; PAX RA, 1984, EXP PARASITOL, V58, P314, DOI 10.1016/0014-4894(84)90048-1; SASTRY BVR, 1978, PHARMACOL REV, V30, P65; SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; Simon S, 1999, J BIOL CHEM, V274, P27740, DOI 10.1074/jbc.274.39.27740; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; Szegletes T, 1999, BIOCHEMISTRY-US, V38, P122, DOI 10.1021/bi9813577; Talesa V, 1999, J NEUROCHEM, V72, P1250, DOI 10.1046/j.1471-4159.1999.0721250.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003	42	30	32	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					441	+		10.1096/fj.01-0683fje	http://dx.doi.org/10.1096/fj.01-0683fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11821256				2022-12-28	WOS:000173656600012
J	Joussen, AM; Poulaki, V; Mitsiades, N; Kirchhof, B; Koizumi, K; Dohmen, S; Adamis, AP				Joussen, AM; Poulaki, V; Mitsiades, N; Kirchhof, B; Koizumi, K; Dohmen, S; Adamis, AP			Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression	FASEB JOURNAL			English	Article						cyclooxygenase; nitric oxide; NF-kappa B; Erk kinase	NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; CELL-ADHESION MOLECULE-1; BLOOD-RETINAL BARRIER; SMOOTH-MUSCLE-CELLS; RHEUMATOID-ARTHRITIS; ICAM-1 EXPRESSION; GENE-EXPRESSION; IN-VIVO	Leukocyte adhesion to the diabetic retinal vasculature results in blood-retinal barrier breakdown, capillary nonperfusion, and endothelial cell injury and death. Intercellular adhesion molecule-1 (ICAM-1) and the leukocyte integrin CD18 are required for these processes. Diabetes was induced in Long Evans rats, resulting in a two- to threefold increase in retinal leukocyte adhesion. Following one week of diabetes, neutrophil CD11a, CD11b, and CD18 expression was increased significantly, as were retinal ICAM-1 levels. Animals were treated with aspirin, a cyclooxygenase 2 (COX-2) inhibitor (meloxicam), or a soluble tumor necrosis factor alpha (TNF-alpha) receptor/Fc construct (TNFR-Fc, etanercept). High-dose aspirin, etanercept, and high-dose meloxicam each reduced leukocyte adhesion and suppressed blood-retinal barrier breakdown. High-dose aspirin also reduced the expression of CD11a, CD11b, and CD18, whereas meloxicam and etanercept did not. High-dose aspirin, etanercept, and high-dose meloxicam each reduced retinal ICAM-1 expression. Aspirin and meloxicam both lowered retinal TNF-alpha levels. Notably, aspirin, meloxicam, and etanercept did not change retinal vascular endothelial growth factor levels. High-dose aspirin, etanercept and high-dose meloxicam, each suppressed the retinal expression of eNOS and the DNA-binding capacity of retinal nuclear factor-kappaB. High-dose aspirin also suppressed Erk kinase activity, which is involved in CD18 up-regulation. Taken together, these data identify COX-2 and TNF-alpha as operative in the early signature pathologies of diabetic retinopathy, a newly recognized inflammatory disease.	Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Res Lab, Boston, MA 02114 USA; Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med ZMMK, D-50931 Cologne, Germany; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; University of Cologne; University of Cologne; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Adamis, AP (corresponding author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Res Lab, 324 Cambridge St, Boston, MA 02114 USA.	tony_adamis@meei.harvard.edu	Joussen, Antonia/AAA-6901-2022					ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Amore Alessandro, 2000, Journal of the American Society of Nephrology, V11, p634A; Amrani Y, 1999, J IMMUNOL, V163, P2128; [Anonymous], 1991, OPHTHALMOLOGY, V98, P741; ARIASNEGRETE S, 1995, BIOCHEM BIOPH RES CO, V208, P582, DOI 10.1006/bbrc.1995.1378; AUTIERI MV, 1995, BIOCHEM BIOPH RES CO, V213, P827, DOI 10.1006/bbrc.1995.2204; Barner A, 1996, SCAND J RHEUMATOL, P29, DOI 10.3109/03009749609097228; Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; Carmo A, 2000, NITRIC OXIDE-BIOL CH, V4, P590, DOI 10.1006/niox.2000.0312; Carteron NL, 2000, MOL MED TODAY, V6, P315, DOI 10.1016/S1357-4310(00)01757-3; Chen TT, 1999, MAR BIOTECHNOL, V1, P1; CHEW EY, 1995, ARCH OPHTHALMOL-CHIC, V113, P52, DOI 10.1001/archopht.1995.01100010054020; Clancy R, 2000, J IMMUNOL, V165, P1582, DOI 10.4049/jimmunol.165.3.1582; COLLINS T, 1993, LAB INVEST, V68, P499; DAMAD GD, 1982, DIABETES METAB, V8, P307; DiRosa M, 1996, PROSTAG LEUKOTR ESS, V54, P229, DOI 10.1016/S0952-3278(96)90053-8; Dumont I, 1999, J PHARMACOL EXP THER, V291, P627; FERRIS FL, 1992, JAMA-J AM MED ASSOC, V268, P1292; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Hatano E, 2001, GASTROENTEROLOGY, V120, P1251, DOI 10.1053/gast.2001.23239; Hawrami K, 1996, HUM IMMUNOL, V46, P49, DOI 10.1016/0198-8859(95)00177-8; Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1; JOUSSEN AM, 2002, IN PRESS AM J PATHOL; Kacimi R, 1998, CIRC RES, V82, P576, DOI 10.1161/01.RES.82.5.576; KHOSLA PK, 1982, DIABETOLOGIA, V23, P104, DOI 10.1007/BF01271169; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LEE SE, 2001, J BIOL CHEM, V23; Lim JW, 2001, LAB INVEST, V81, P349, DOI 10.1038/labinvest.3780243; Limb GA, 1996, BRIT J OPHTHALMOL, V80, P168, DOI 10.1136/bjo.80.2.168; Limb GA, 1999, CLIN EXP IMMUNOL, V118, P213; Limb GA, 1999, CLIN EXP IMMUNOL, V115, P409; Liu SF, 1999, CIRCULATION, V100, P1330, DOI 10.1161/01.CIR.100.12.1330; Lu M, 1999, INVEST OPHTH VIS SCI, V40, P1808; Luong BT, 2000, ANN PHARMACOTHER, V34, P743; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; McCormack K, 1998, J RHEUMATOL, V25, P2279; MCLEOD DS, 1995, AM J PATHOL, V147, P642; Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836; Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4; Mohamed AK, 1999, BIOFACTORS, V10, P157, DOI 10.1002/biof.5520100211; Moreland LW, 2000, J RHEUMATOL, V27, P601; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; MOYNAGH PN, 1994, J IMMUNOL, V153, P2681; Murata T, 1996, LAB INVEST, V74, P819; Najarian T, 2000, CIRC RES, V87, P1149, DOI 10.1161/01.RES.87.12.1149; Niederberger E, 2001, FASEB J, V15, P1622, DOI 10.1096/fj.00-0716fje; Pairet M, 1996, FUND CLIN PHARMACOL, V10, P1, DOI 10.1111/j.1472-8206.1996.tb00144.x; Penglis PS, 2000, J IMMUNOL, V165, P1605, DOI 10.4049/jimmunol.165.3.1605; Pierce JW, 1996, J IMMUNOL, V156, P3961; Pillinger MH, 1998, P NATL ACAD SCI USA, V95, P14540, DOI 10.1073/pnas.95.24.14540; POWELL EDU, 1964, LANCET, V2, P17; Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Safieh-Garabedian B, 2000, NEUROPHARMACOLOGY, V39, P1653, DOI 10.1016/S0028-3908(99)00247-6; SCHRODER S, 1991, AM J PATHOL, V139, P81; Shi XL, 1999, MOL CELL BIOCHEM, V199, P93, DOI 10.1023/A:1006934612368; SPRANGER J, 1995, MED KLIN, V90, P134; Tummala PE, 2000, J MOL CELL CARDIOL, V32, P1499, DOI 10.1006/jmcc.2000.1183; Valen G, 2000, CARDIOVASC RES, V47, P49, DOI 10.1016/S0008-6363(00)00071-7; Van Assche G, 2000, EXPERT OPIN INV DRUG, V9, P103; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wang WH, 2000, J BIOL CHEM, V275, P16899, DOI 10.1074/jbc.M000301200; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; WILLIAMS B, 1993, J CLIN INVEST, V92, P2889, DOI 10.1172/JCI116911; Wright PS, 1999, J CELL PHYSIOL, V180, P381, DOI 10.1002/(SICI)1097-4652(199909)180:3<381::AID-JCP9>3.0.CO;2-F; Xu QW, 2001, INVEST OPHTH VIS SCI, V42, P789; Yerneni KKV, 1999, DIABETES, V48, P855, DOI 10.2337/diabetes.48.4.855; Zouki C, 2001, FASEB J, V15, P25	72	437	480	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					438	+		10.1096/fj.01-0707fje	http://dx.doi.org/10.1096/fj.01-0707fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11821258				2022-12-28	WOS:000173656600014
J	Heller-Stilb, B; van Roeyen, C; Rascher, K; Hartwig, HG; Huth, A; Seeliger, MW; Warskulat, U; Haussinger, D				Heller-Stilb, B; van Roeyen, C; Rascher, K; Hartwig, HG; Huth, A; Seeliger, MW; Warskulat, U; Haussinger, D			Disruption of the taurine transporter gene (taut) leads to retinal degeneration in mice	FASEB JOURNAL			English	Article						knockout mice; compatible organic osmolytes; retinitis pigmentosa	RETINITIS-PIGMENTOSA; PLASMA TAURINE; CELL-DEATH; IN-SITU; MOUSE; CLONING; LOCALIZATION; HYPOTAURINE; DEFICIENCY; EXPRESSION	Taurine is involved in cell volume homeostasis, antioxidant defense, protein stabilization, and stress responses. High levels of intracellular taurine are maintained by a Na+-dependent taurine transporter (TAUT) in the plasma membrane. In view of the immunomodulatory and cytoprotective effects of taurine, a mouse model with a disrupted gene coding for the taurine transporter (taut-/- mice) was generated. These mice show markedly decreased taurine levels in a variety of tissues, a reduced fertility, and loss of vision due to severe retinal degeneration. In particular, the retinal involvement identifies the taurine transporter as an important factor for the development and maintenance of normal retinal functions and morphology.	Univ Dusseldorf, Dept Gastroenterol Hepatol & Infectiol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Anat, D-4000 Dusseldorf, Germany; Univ Tubingen, Dept Ophthalmol, Retinal Electrodiagnost Res Grp, D-72074 Tubingen, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Haussinger, D (corresponding author), Univ Dusseldorf, Dept Gastroenterol Hepatol & Infectiol, Moorenstr 5, D-40225 Dusseldorf, Germany.	haeussin@uni-duesseldorf.de						ALVAREZ JG, 1983, BIOL REPROD, V29, P548, DOI 10.1095/biolreprod29.3.548; BENINI G, 1988, OPHTHALMOLOGICA, V197, P130, DOI 10.1159/000309933; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; CHAPMAN RA, 1993, CARDIOVASC RES, V27, P358, DOI 10.1093/cvr/27.3.358; COCKER SE, 1987, EXP EYE RES, V45, P977, DOI 10.1016/S0014-4835(87)80111-2; Devreker F, 1999, HUM REPROD, V14, P2350, DOI 10.1093/humrep/14.9.2350; Dumoulin JCM, 1997, BIOL REPROD, V56, P739, DOI 10.1095/biolreprod56.3.739; DUMOULIN JCM, 1992, HUM REPROD, V7, P403, DOI 10.1093/oxfordjournals.humrep.a137658; Gal A, 1997, PROG RETIN EYE RES, V16, P51, DOI 10.1016/S1350-9462(96)00021-3; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEGGEL HS, 1985, NEW ENGL J MED, V312, P142, DOI 10.1056/NEJM198501173120302; GREEN TR, 1991, BIOCHIM BIOPHYS ACTA, V1073, P91, DOI 10.1016/0304-4165(91)90187-L; HAYES KC, 1975, SCIENCE, V188, P949, DOI 10.1126/science.1138364; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; HUXTABLE RJ, 1982, J NUTR, V112, P1003, DOI 10.1093/jn/112.5.1003; Jaissle GB, 2001, INVEST OPHTH VIS SCI, V42, P506; Komarov AM, 1998, CLIN BIOCHEM, V31, P107, DOI 10.1016/S0009-9120(97)00168-9; KONTRO P, 1984, ACTA PHYSIOL SCAND, P71; Kurz AK, 1998, HEPATOLOGY, V28, P774, DOI 10.1002/hep.510280326; KWON HM, 1995, CURR OPIN CELL BIOL, V7, P465, DOI 10.1016/0955-0674(95)80002-6; LAKE N, 1987, EXP EYE RES, V44, P331, DOI 10.1016/S0014-4835(87)80169-0; LAKE N, 1982, NEUROCHEM RES, V7, P1385, DOI 10.1007/BF00966067; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lima L, 1999, NEUROCHEM RES, V24, P1333, DOI 10.1023/A:1027376511473; LIU QR, 1992, P NATL ACAD SCI USA, V89, P12145, DOI 10.1073/pnas.89.24.12145; LOMBARDINI JB, 1991, BRAIN RES REV, V16, P151, DOI 10.1016/0165-0173(91)90003-Q; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; PARK E, 1995, J IMMUNOL, V154, P4778; PASANTESMORALES H, 1986, EXP EYE RES, V43, P55, DOI 10.1016/S0014-4835(86)80045-8; RAMAMOORTHY S, 1994, BIOCHEM J, V300, P893, DOI 10.1042/bj3000893; Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3; SCHLOSS P, 1994, CURR OPIN CELL BIOL, V6, P595, DOI 10.1016/0955-0674(94)90081-7; SMITH KE, 1992, MOL PHARMACOL, V42, P563; Stapleton PP, 1998, JPEN-PARENTER ENTER, V22, P42, DOI 10.1177/014860719802200142; TIMBRELL JA, 1995, GEN PHARMACOL-VASC S, V26, P453, DOI 10.1016/0306-3623(94)00203-Y; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; UMA SM, 1983, BIOCHEM MED METAB B, V30, P49, DOI 10.1016/0006-2944(83)90007-8; Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0; VELAZQUEZ A, 1986, LIFE SCI, V38, P991, DOI 10.1016/0024-3205(86)90232-8; Vinnakota S, 1997, J NEUROCHEM, V69, P2238; vom Dahl S, 2000, AMINO ACIDS, V19, P585, DOI 10.1007/s007260070008; Warskulat U, 1997, BIOCHEM J, V321, P683, DOI 10.1042/bj3210683; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; Wettstein M, 1997, HEPATOLOGY, V26, P1560; WONG P, 1994, BIOCHEM CELL BIOL, V72, P489, DOI 10.1139/o94-066; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	46	178	184	2	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2001	15	14					231	+		10.1096/fj.01-0691fje	http://dx.doi.org/10.1096/fj.01-0691fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11772953				2022-12-28	WOS:000172964800002
J	Light, PE; Kanji, HD; Fox, JEM; French, RJ				Light, PE; Kanji, HD; Fox, JEM; French, RJ			Distinct myoprotective roles of cardiac sarcolemmal and mitochondrial K-ATP channels during metabolic inhibition and recovery	FASEB JOURNAL			English	Article						ischemic preconditioning; protein kinase C; adenosine	SENSITIVE POTASSIUM CHANNELS; PROTEIN-KINASE-C; ADENOSINE; MECHANISMS; PROTECTION; RECEPTOR; STRESS; CARDIOPROTECTION; EFFECTORS; TRIGGERS	The protective roles of sarcolemmal (sarc) and mitochondrial (mito) K-ATP channels are unclear despite their apparent importance to ischemic preconditioning. We examined these roles by monitoring intracellular calcium ([Ca](int)), using fura-2 and fluo-3, in enzymatically isolated rat right ventricular myocytes. Myocyte mortality, estimated using a trypan blue assay, changed approximately in parallel with changes in [Ca](int). Chemically induced hypoxia (CIH), induced by application of cyanide and 2-deoxy-glucose, caused a steady rise in [Ca](int). Calcium increased more rapidly on 'reoxygenation' by return to control solutions. The protein kinase C (PKC) activator PMA abolished both phases of calcium increase. The mitoK(ATP) channel-selective blocker 5-hydroxydecanoate partially prevented the PMA-induced protection during CIH, but not during reoxygenation. In contrast, HMR 1098, a sarcK(ATP) channel-selective blocker, abolished protection only during the reoxygenation. Adenosine (A(1)) receptor activation prevented or reduced increases in [Ca](int) and improved cell viability via a PKC and mito/sarcK(ATP) channel-dependent mechanism. PKC-dependent protection against cytoplasmic calcium increases was also observed in a human cell line (tsA201) transiently expressing sarcK(ATP) channels. Protection was abolished only during the reoxygenation phase by the amino acid substitution (T180A) in the pore-forming Kir6.2 subunit, a mutation previously shown to prevent PKC-dependent modulation. Our data suggest that sarc and mitoK(ATP) channel populations play distinct protective roles, triggered by PKC and/or adenosine, during chemically induced hypoxia/reoxygenation.	Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB, Canada	University of Alberta; University of Calgary	Light, PE (corresponding author), Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada.	peter.light@ualberta.ca						Blondeau N, 2000, NEUROSCIENCE, V100, P465, DOI 10.1016/S0306-4522(00)00304-3; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; COATES J, 1994, GEN PHARMACOL, V25, P387, DOI 10.1016/0306-3623(94)90185-6; Cohen MV, 2000, ANNU REV PHYSIOL, V62, P79, DOI 10.1146/annurev.physiol.62.1.79; D'hahan N, 1999, P NATL ACAD SCI USA, V96, P12162, DOI 10.1073/pnas.96.21.12162; Diaz RJ, 1999, CIRC RES, V84, P763; Downey JM, 1997, ADV EXP MED BIOL, V430, P39; Gross GJ, 2000, CIRC RES, V87, P431; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; Holmuhamedov EL, 1999, J PHYSIOL-LONDON, V519, P347, DOI 10.1111/j.1469-7793.1999.0347m.x; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Jovanovic N, 1999, FASEB J, V13, P923, DOI 10.1096/fasebj.13.8.923; LAWSON CS, 1993, CARDIOVASC RES, V27, P542, DOI 10.1093/cvr/27.4.542; Light P, 1998, J MEMBRANE BIOL, V162, P217; Light PE, 2000, P NATL ACAD SCI USA, V97, P9058, DOI 10.1073/pnas.160068997; Light PE, 1996, CIRC RES, V79, P399, DOI 10.1161/01.RES.79.3.399; Light PE, 1999, CAN J CARDIOL, V15, P1123; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; Liu YG, 1996, CIRC RES, V78, P443, DOI 10.1161/01.RES.78.3.443; Liu YG, 1999, ANN NY ACAD SCI, V874, P27, DOI 10.1111/j.1749-6632.1999.tb09222.x; LOHSE MJ, 1988, N-S ARCH PHARMACOL, V337, P687; Miura T, 1999, CLIN EXP PHARMACOL P, V26, P92, DOI 10.1046/j.1440-1681.1999.03003.x; Nakano A, 2000, PHARMACOL THERAPEUT, V86, P263, DOI 10.1016/S0163-7258(00)00058-9; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; O'Rourke B, 2000, CIRC RES, V87, P845, DOI 10.1161/01.RES.87.10.845; Pain T, 2000, CIRC RES, V87, P460; PARRATT JR, 1994, TRENDS PHARMACOL SCI, V15, P19, DOI 10.1016/0165-6147(94)90129-5; Piper HM, 1999, ANN THORAC SURG, V68, P1913, DOI 10.1016/S0003-4975(99)01025-5; Sanada S, 2001, AM J PHYSIOL-HEART C, V280, pH256, DOI 10.1152/ajpheart.2001.280.1.H256; Sato T, 2000, CIRCULATION, V102, P800, DOI 10.1161/01.CIR.102.7.800; Schwarz ER, 1997, CURR OPIN CARDIOL, V12, P475, DOI 10.1097/00001573-199712050-00007; Toyoda Y, 2000, CIRCULATION, V102, P326; Toyoda Y, 2000, AM J PHYSIOL-HEART C, V279, pH2694, DOI 10.1152/ajpheart.2000.279.6.H2694; Wirth KJ, 2000, N-S ARCH PHARMACOL, V361, P155, DOI 10.1007/s002109900166; Wu S, 1999, CIRC RES, V84, P1388; YarovYarovoy V, 1997, BBA-BIOENERGETICS, V1321, P128, DOI 10.1016/S0005-2728(97)00051-0	38	85	88	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					2586	2594		10.1096/fj.01-0188com	http://dx.doi.org/10.1096/fj.01-0188com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726534				2022-12-28	WOS:000172964800028
J	Meydani, SN; Erickson, KL				Meydani, SN; Erickson, KL			Nutrients as regulators of immune function: Introduction	FASEB JOURNAL			English	Editorial Material							VITAMIN-E SUPPLEMENTATION; ELDERLY SUBJECTS		Tufts Univ, USDA, Human Nutr Res Ctr Aging, Natl Immunol Lab, Boston, MA 02111 USA; Univ Calif Davis, Sch Med, Dept Cell Biol & Human Anat, Davis, CA 95616 USA	Tufts University; United States Department of Agriculture (USDA); University of California System; University of California Davis	Meydani, SN (corresponding author), Tufts Univ, USDA, Human Nutr Res Ctr Aging, Natl Immunol Lab, 711 Washington St, Boston, MA 02111 USA.	smeydani@hnrc.tufts.edu						BECK MA, 1995, NAT MED, V1, P433, DOI 10.1038/nm0595-433; BEISEL WR, 1992, J NUTR, V122, P591, DOI 10.1093/jn/122.suppl_3.591; CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C; Hayek MG, 1997, J INFECT DIS, V176, P273, DOI 10.1086/517265; Meydani M, 1998, NUTR REV, V56, pS177; Meydani SN, 1997, JAMA-J AM MED ASSOC, V277, P1380, DOI 10.1001/jama.277.17.1380; MEYDANI SN, 1998, NUTR REV ILSI, V56	7	4	4	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2001	15	14					2555	2555		10.1096/fj.01-0477com	http://dx.doi.org/10.1096/fj.01-0477com			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	506HT	11726529				2022-12-28	WOS:000172964800023
J	Kroncke, KD				Kroncke, KD			Cysteine-Zn(2+) complexes: unique molecular switches for inducible nitric oxide synthase-derived NO	FASEB JOURNAL			English	Article						chaperone; cysteine switch; metalloproteinase; nitric oxide; transcription; zinc	FINGER TRANSCRIPTION FACTORS; ZINC-SULFUR CLUSTERS; CHAPERONE; METALLOTHIONEIN; INHIBITION; RELEASE; DOMAIN; DNAJ; MECHANISM; BINDING	Nitric oxide (NO) in the low nanomolar range acts as a transcellular messenger molecule to initiate regulatory and physiological responses in nearby target cells via binding to the soluble guanylate cyclase heme moiety. Higher NO concentrations, as synthesized by the inducible NO synthase (iNOS) during inflammatory processes, show additional effects: NO may react with O(2), yielding nitrogen oxides like N(2)O(3) that are able to nitrosate thiols. A variety of proteins involved in very different functions of the cell contain cysteine-Zn(2+) complexes. Effects of NO on different proteins containing cysteine-Zn(2+) domains and playing essential roles during transcription, protein folding, and proteolysis are discussed. It is suggested that iNOS-derived NO acts as a signal molecule targeting cysteine-Zn(2+) linkages, thus enabling cells to react toward nitrosative stress.	Univ Dusseldorf, Dept Med, MED, Res Grp Immunobiol 23 12, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Kroncke, KD (corresponding author), Univ Dusseldorf, Dept Med, MED, Res Grp Immunobiol 23 12, Moorenstr 5, D-40225 Dusseldorf, Germany.	kroencke@uni-duessel-dorf.de						Aravindakumar CT, 1999, BIOCHEM J, V344, P253, DOI 10.1042/0264-6021:3440253; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; Barbirz S, 2000, J BIOL CHEM, V275, P18759, DOI 10.1074/jbc.M001089200; Berendji D, 1999, MOL MED, V5, P721, DOI 10.1007/BF03402096; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Gergel D, 1996, BIOCHEMISTRY-US, V35, P16186, DOI 10.1021/bi962043r; Graumann J, 2001, STRUCTURE, V9, P377, DOI 10.1016/S0969-2126(01)00599-8; Grishin NV, 2001, NUCLEIC ACIDS RES, V29, P1703, DOI 10.1093/nar/29.8.1703; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Kim SJ, 2001, NAT STRUCT BIOL, V8, P459, DOI 10.1038/87639; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Kroncke KD, 2000, FASEB J, V14, P166; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; Kroncke KD, 2001, NITRIC OXIDE-BIOL CH, V5, P289, DOI 10.1006/niox.2001.0354; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; KRONCKE KD, 1998, BIOL CHEM, V379, pS92; Liu SX, 2001, BIOCHEM J, V354, P397, DOI 10.1042/0264-6021:3540397; Maeda H, 1998, BIOL CHEM, V379, P193, DOI 10.1515/bchm.1998.379.2.193; Martinez-Yamout M, 2000, J MOL BIOL, V300, P805, DOI 10.1006/jmbi.2000.3923; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Montoliu C, 2000, J NEUROCHEM, V75, P266, DOI 10.1046/j.1471-4159.2000.0750266.x; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wang SB, 1999, J BIOL CHEM, V274, P33190, DOI 10.1074/jbc.274.47.33190; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Zhang ZL, 2000, J BIOL CHEM, V275, P15839, DOI 10.1074/jbc.M000604200	27	29	30	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2503	2507		10.1096/fj.01-0240hyp	http://dx.doi.org/10.1096/fj.01-0240hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689476				2022-12-28	WOS:000172420500021
J	Lee, NS; Sun, BH; Williamson, R; Gunkel, N; Salvaterra, PM; Rossi, JJ				Lee, NS; Sun, BH; Williamson, R; Gunkel, N; Salvaterra, PM; Rossi, JJ			Functional colocalization of ribozymes and target mRNAs in Drosophila oocytes	FASEB JOURNAL			English	Article						3 ' UTR; RNA localization; hammerhead ribozyme; Drosophila bicoid and oskar mRNAs	MESSENGER-RNA LOCALIZATION; DOUBLE-STRANDED-RNA; ANTEROPOSTERIOR POLARITY; THERAPEUTIC AGENTS; DEPENDENT MANNER; CELL-EXTRACTS; BICOID RNA; PROTEIN; OSKAR; ACTIN	The effectiveness of catalytic RNAs (ribozymes) should be increased when they are colocalized to the same intracellular compartment as their RNA targets. We colocalized ribozymes with their mRNA targets in an animal model by using the discrete RNA localization signals present in the 3' untranslated regions (UTRs) of Drosophila bicoid and oskar mRNAs. These signals have been fused to a lacZ mRNA target and hammerhead ribozymes targeted against lacZ. Ribozyme efficacy was first assessed by an oligodeoxyribonucleotide-based assay to identify the most accessible sites for ribozyme interaction on native lacZ transcripts in ovary extracts. The most accessible sequence was used for the design and in vivo testing of a hammerhead ribozyme. When the ribozyme and target with synonymous 3' UTRs were expressed in the same ovaries, colocalization could be indirectly demonstrated by in situ hybridization. Colocalized ribozyme and target mRNAs resulted in a two- to threefold enhancement of ribozyme function compared with noncolocalized transcripts. This study provides the first demonstration of functional ribozyme target colocalization in an animal model.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Biol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Neurosci, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA; Aventis Crop Sci, Forsch Biochem, D-65926 Frankfurt, Germany	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Rossi, JJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Biol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	jrossi@coh.org	Gunkel, Nikolas/AAR-8220-2021		NIAID NIH HHS [AI46030, AI29329] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029329, R01AI029329, P01AI046030] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; BURGIN KE, 1990, J NEUROSCI, V10, P1788; Caplen NJ, 2000, GENE, V252, P95, DOI 10.1016/S0378-1119(00)00224-9; CHRISTOFFERSEN RE, 1995, J MED CHEM, V38, P2023, DOI 10.1021/jm00012a001; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; Gunkel N, 1998, GENE DEV, V12, P1652, DOI 10.1101/gad.12.11.1652; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HILL MA, 1993, J CELL BIOL, V122, P825, DOI 10.1083/jcb.122.4.825; JEFFERY WR, 1983, DEV BIOL, V99, P408, DOI 10.1016/0012-1606(83)90290-7; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; Kim-Ha Jeongsil, 1993, Development (Cambridge), V119, P169; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; Lee NS, 1999, RNA, V5, P1200, DOI 10.1017/S1355838299990246; LIEBHABER SA, 1992, J MOL BIOL, V226, P609, DOI 10.1016/0022-2836(92)90619-U; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; RONGO C, 1995, DEVELOPMENT, V121, P2737; ROSSI JJ, 1982, J BIOL CHEM, V257, P9226; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; Scherr M, 2000, NUCLEIC ACIDS RES, V28, P2455, DOI 10.1093/nar/28.13.2455; Scherr M, 2000, MOL THER, V2, P26, DOI 10.1006/mthe.2000.0091; Scherr M, 1998, NUCLEIC ACIDS RES, V26, P5079, DOI 10.1093/nar/26.22.5079; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TIEDGE H, 1991, P NATL ACAD SCI USA, V88, P2093, DOI 10.1073/pnas.88.6.2093; UHLENBECK OC, 1995, NAT STRUCT BIOL, V2, P610, DOI 10.1038/nsb0895-610; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; Wilhelm JE, 2000, J CELL BIOL, V148, P427, DOI 10.1083/jcb.148.3.427	45	6	10	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2001	15	13					2390	2400		10.1096/fj.01-0116com	http://dx.doi.org/10.1096/fj.01-0116com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689464				2022-12-28	WOS:000172420500009
J	Pober, JS; Neuhauser, CS; Pober, JM				Pober, JS; Neuhauser, CS; Pober, JM			Obstacles facing translational research in academic medical centers	FASEB JOURNAL			English	Article						clinical and basic science research interdisciplinary; interdepartmental; collaboration	PATIENT-ORIENTED RESEARCH; PHYSICIAN-SCIENTIST; ATHEROSCLEROSIS; DISEASE; ANGIOGENESIS; INFLAMMATION; MECHANISMS; THERAPY; INJURY; MOUSE	Over the last quarter of the 20th century, there has been a boom in biomedical research discoveries that, for the most part, has not been successfully exploited for improving medical therapy or diagnosis. This lack of success is surprising because there is a broad consensus within academic medical centers (AMCs) that a primary mission is to move scientific discoveries into meaningful clinical outcomes, and there are numerous opportunities for doing so. We illustrate the latter point with 10 clinical opportunities for translating scientific discoveries from our field of vascular biology and transplantation. We attribute the limited success of translation to various factors, chief of which is that translation is rarely straightforward and requires continuing research in both the clinic and the laboratory. Translational research is hindered by insufficient targeted resources, a shortage of qualified investigators, an academic culture that hinders collaboration between clinical and laboratory-based investigators, a traditional structure of the AMC that favors departmental efforts over interdisciplinary programs, an increasing regulatory burden, and a lack of specific mechanisms within the AMC for facilitating solutions to these problems. We offer several suggestions to reduce these impediments.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol & Transplantat, New Haven, CT 06536 USA; Haverford Coll, Dept Mol Cellular & Dev Biol, Haverford, PA 19041 USA	Yale University; Haverford College	Pober, JS (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol & Transplantat, 295 Congress Ave,BCMM 454, New Haven, CT 06536 USA.	jordan.pober@yale.edu						*AM CANC SOC BURR, 2000, ROL PRIV SECT TRAIN; *ASS AM MED COLL, 2000, BREAK SCI BOTTL CLIN; Breslow JL, 1997, NAT MED, V3, P600, DOI 10.1038/nm0697-600; Brown MS, 1999, ANN NY ACAD SCI, V882, P247, DOI 10.1111/j.1749-6632.1999.tb08555.x; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; Collen D, 1997, THROMB HAEMOSTASIS, V78, P742; COLVIN RB, 1991, TRANSPL P, V23, P2052; *CTR SCI REV, 2000, NEW CSR; *CTR SCI REV, 2000, REC CHANG NIHS CTR S; Dauphinee D, 2000, ACAD MED, V75, P881, DOI 10.1097/00001888-200009000-00008; Feinstein AR, 1999, AM J MED, V107, P461, DOI 10.1016/S0002-9343(99)00264-8; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Freireich EJ, 1997, CLIN CANCER RES, V3, P2711; Gelijns AC, 1998, NEW ENGL J MED, V339, P693, DOI 10.1056/NEJM199809033391010; Goldstein JL, 1997, J CLIN INVEST, V99, P2803, DOI 10.1172/JCI119470; Goldstein JL, 2001, SCIENCE, V292, P1310, DOI 10.1126/science.1061815; *H HUGH MED I, 2001, HHMI ANN NAT COMP AP; Harris CE, 2001, ISSUES LAW MED, V16, P213; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1370, DOI 10.1056/NEJM199411173312010; Libby P, 2000, AM J CARDIOL, V86, p3J; Libby P, 2001, IMMUNITY, V14, P387, DOI 10.1016/S1074-7613(01)00119-4; Logan JS, 2000, CURR OPIN IMMUNOL, V12, P563, DOI 10.1016/S0952-7915(00)00139-4; Los M, 2001, SEMIN ONCOL, V28, P93, DOI 10.1016/S0093-7754(01)90047-8; Ludewig B, 2000, P NATL ACAD SCI USA, V97, P12752, DOI 10.1073/pnas.220427097; Marwick C, 2001, J NATL CANCER I, V93, P13, DOI 10.1093/jnci/93.1.13; Minna JD, 1996, NAT MED, V2, P974, DOI 10.1038/nm0996-974; *NAT I ALL INF DIS, 1998, NIAID EXP PAN IMM TO; *NIH, 1997, NIH DIR PAN CLIN RES; Rauch U, 2001, ANN INTERN MED, V134, P224, DOI 10.7326/0003-4819-134-3-200102060-00014; Rosenberg LE, 1999, J CLIN INVEST, V103, P1621, DOI 10.1172/JCI7304; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rustgi AK, 1999, GASTROENTEROLOGY, V116, P1285, DOI 10.1016/S0016-5085(99)70488-9; Salgado JCGV, 2000, ACTA CHIR BELG, V100, P268; Schwartz S, 1997, NATO ADV SCI I D-BEH, V87, P89; Shalala D, 2000, NEW ENGL J MED, V343, P808, DOI 10.1056/NEJM200009143431112; Shaywitz DA, 2000, AM J MED, V109, P136, DOI 10.1016/S0002-9343(00)00452-6; SHAYWITZ DA, 2000, BOSTON GLOBE, pD2; Stock UA, 2001, ANNU REV MED, V52, P443, DOI 10.1146/annurev.med.52.1.443; *TASK FORC FUT CLI, COMM REP FUT CLIN SC; TOOKE JE, 1995, DIABETES, V44, P721, DOI 10.2337/diabetes.44.7.721; Ward MR, 2000, CIRCULATION, V102, P1186, DOI 10.1161/01.CIR.102.10.1186; Williams GH, 1997, JAMA-J AM MED ASSOC, V278, P227, DOI 10.1001/jama.278.3.227	43	94	99	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2303	2313		10.1096/fj.01-0540lsf	http://dx.doi.org/10.1096/fj.01-0540lsf			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689456				2022-12-28	WOS:000172420500001
J	Ramamurthy, B; Hook, P; Jones, AD; Larsson, L				Ramamurthy, B; Hook, P; Jones, AD; Larsson, L			Changes in myosin structure and function in response to glycation	FASEB JOURNAL			English	Article						skeletal muscle; myosin; glucose; soleus muscle; MALDI; mass spectrometry	SKELETAL-MUSCLE-FIBERS; UNLOADED SHORTENING VELOCITY; VITRO MOTILITY ASSAY; ALKALI LIGHT-CHAIN; IN-VITRO; HEAVY-CHAIN; NONENZYMATIC GLYCOSYLATION; ISOFORM COMPOSITION; CONTRACTILE PROPERTIES; MYOFIBRILLAR PROTEINS	Nonenzymatic glycosylation (glycation) is recognized as an important post-translational modification underlying alterations of structure and function of extracellular proteins. The effect of glycation on intracellular proteins is, on the other hand, less well known despite the vital importance of intracellular proteins for cell, tissue, and organ function. The aim of this study was to explore the effects of glycation on the structure and function of skeletal muscle myosin. Myosin was incubated for up to 30 min with glucose and subsequently tested for structural and functional modifications by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry and a single-fiber in vitro motility assay, respectively. MALDI spectra revealed glycation-related structural alterations as evidenced by the disappearance of specific Lys-C proteolysis products and the appearance of higher mass peaks that are attributed to cross-linking by glucose. This change was paralleled by a significant reduction in the in vitro motility speed, suggesting a structure-related decline in myosin mechanics in response to glucose exposure. Further evidence that early glycation products form in the regulatory regions of the myosin molecule is derived from the fact that there is complete reversal of motility speed after reaction with the Schiff base-cleaving agent hydroxylamine hydrochloride. Thus, glycation of skeletal muscle myosin has a significant effect on both the structural and functional properties of the protein, a finding that is important in understanding the mechanisms underlying the impairment in muscle function associated with aging and diabetes.	Penn State Univ, Noll Physiol Res Ctr 111, University Pk, PA 16802 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Karolinska Institutet	Larsson, L (corresponding author), Penn State Univ, Noll Physiol Res Ctr 111, University Pk, PA 16802 USA.	lg15@psu.edu	Larsson, Lars/AAY-1347-2021; Jones, Arthur D/C-2670-2013	Larsson, Lars/0000-0003-3722-035X; Jones, A. Daniel/0000-0002-7408-6690	NCRR NIH HHS [RR11318] Funding Source: Medline; NIAMS NIH HHS [AR45627] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045627] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Avigad G, 1996, BIOCHEM MOL BIOL INT, V40, P273; Balagopal P, 1997, AM J PHYSIOL-ENDOC M, V273, pE790, DOI 10.1152/ajpendo.1997.273.4.E790; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BOTTINELLI R, 1994, J PHYSIOL-LONDON, V478, P341, DOI 10.1113/jphysiol.1994.sp020254; BROWN MR, 1992, BIOCHEM CELL BIOL, V70, P617, DOI 10.1139/o92-095; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; Degens H, 1998, ACTA PHYSIOL SCAND, V163, P33, DOI 10.1046/j.1365-201x.1998.00329.x; ELSALEH SC, 1984, J BIOL CHEM, V259, P1014; ELSALEH SC, 1986, J BIOL CHEM, V261, P4646; Frontera WR, 1997, MUSCLE NERVE, V20, P948, DOI 10.1002/(SICI)1097-4598(199708)20:8<948::AID-MUS3>3.0.CO;2-6; GREASER ML, 1988, J PHYSIOL-LONDON, V406, P85, DOI 10.1113/jphysiol.1988.sp017370; Hook P, 1999, J PHYSIOL-LONDON, V520, P463, DOI 10.1111/j.1469-7793.1999.00463.x; Hook P, 2001, AM J PHYSIOL-CELL PH, V280, pC782, DOI 10.1152/ajpcell.2001.280.4.C782; Hook P, 2000, J MUSCLE RES CELL M, V21, P357, DOI 10.1023/A:1005614212575; Kay J, 1978, BIOCHEM SOC T, V6, P789, DOI 10.1042/bst0060789; KRAFT R, 1989, NUCLEIC ACIDS RES, V17, P7529, DOI 10.1093/nar/17.18.7529; Lal GBS, 1996, MOL CELL BIOCHEM, V154, P95; Lapolla A, 2000, MASS SPECTROM REV, V19, P279; LARSSON L, 1993, J PHYSIOL-LONDON, V472, P595, DOI 10.1113/jphysiol.1993.sp019964; Larsson L, 1997, AM J PHYSIOL-CELL PH, V272, pC638, DOI 10.1152/ajpcell.1997.272.2.C638; Larsson L, 1999, ITAL J NEUROL SCI, V20, P413; Li XP, 1996, AM J PHYSIOL-CELL PH, V270, pC352, DOI 10.1152/ajpcell.1996.270.1.C352; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOORADIAN AD, 1991, J AM GERIATR SOC, V39, P717, DOI 10.1111/j.1532-5415.1991.tb03628.x; Nicolau DV, 1999, BIOPHYS J, V77, P1126, DOI 10.1016/S0006-3495(99)76963-8; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Patterson MF, 2000, PFLUG ARCH EUR J PHY, V439, P845, DOI 10.1007/s004240051013; Ramamurthy B, 2000, J AGING PHYS ACTIV, V8, P289; Ramamurthy B, 1999, FASEB J, V13, pA413; Reggiani C, 1997, J PHYSIOL-LONDON, V502, P449, DOI 10.1111/j.1469-7793.1997.449bk.x; Shrager JB, 2000, J MUSCLE RES CELL M, V21, P345, DOI 10.1023/A:1005635030494; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; Svensson C, 1997, J CELL BIOCHEM, V67, P241, DOI 10.1002/(SICI)1097-4644(19971101)67:2<241::AID-JCB9>3.0.CO;2-X; SWEENEY HL, 1988, J BIOL CHEM, V263, P9034; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; SYROVY I, 1992, GEN PHYSIOL BIOPHYS, V11, P301; SYROVY I, 1993, INT J BIOCHEM, V25, P941, DOI 10.1016/0020-711X(93)90251-9; Thompson LV, 1999, J APPL PHYSIOL, V86, P881, DOI 10.1152/jappl.1999.86.3.881; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WATANABE H, 1992, BIOSCI BIOTECH BIOCH, V56, P1109, DOI 10.1271/bbb.56.1109; Yu FS, 1998, PFLUG ARCH EUR J PHY, V437, P21, DOI 10.1007/s004240050741; YUDKIN JS, 1988, DIABETIC MED, V5, P338, DOI 10.1111/j.1464-5491.1988.tb01001.x	45	104	108	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2001	15	13					2415	2422		10.1096/fj.01-0183com	http://dx.doi.org/10.1096/fj.01-0183com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	496WR	11689466				2022-12-28	WOS:000172420500011
J	La, M; D'Amico, M; Bandiera, S; Di Filippo, C; Oliani, SM; Gavins, FNE; Flower, RJ; Perretti, M				La, M; D'Amico, M; Bandiera, S; Di Filippo, C; Oliani, SM; Gavins, FNE; Flower, RJ; Perretti, M			Annexin 1 peptides protect against experimental myocardial ischemia-reperfusion: analysis of their mechanism of action	FASEB JOURNAL			English	Article						lipocortin 1; receptor; neutrophil; FPR; fMLP	LIPOCORTIN 1; NITRIC-OXIDE; CLINICAL-IMPLICATIONS; NEUTROPHIL DEPLETION; MONOCLONAL-ANTIBODY; BINDING PROTEINS; HUMAN-LEUKOCYTES; INFARCT SIZE; IN-VIVO; INJURY	Myocardial reperfusion injury is associated with the infiltration of blood-borne polymorphonuclear leukocytes. We have previous described the protection afforded by annexin 1 (ANXA1) in an experimental model of rat myocardial ischemia-reperfusion (IR) injury. We examined the 1) amino acid region of ANXA1 that retained the protective effect in a model of rat heart IR; 2) changes in endogenous ANXA1 in relation to the IR induced damage and after pharmacological modulation; and 3) potential involvement of the formyl peptide receptor (FPR) in the protective action displayed by ANXA1 peptides. Administration of peptide Ac2-26 at 0, 30, and 60 min postreperfusion produced a significant protection against IR injury, and this was associated with reduced myeloperoxidase activity and IL-1 beta levels in the infarcted heart. Western blotting and electron microscopy analyses showed that IR heart had increased ANXA1 expression in the injured tissue, associated mainly with the infiltrated leukocytes. Finally, an antagonist to the FPR receptor selectively inhibited the protective action of peptide ANXA1 and its derived peptides against IR injury. Altogether, these data provide further insight into the protective effect of ANXA1 and its mimetics and a rationale for a clinical use for drugs developed from this line of research.	Univ London St Bartholomews Hosp Med Coll, Coll Med, William Harvey Res Inst, Dept Biochem Pharmacol, London EC1M 6BQ, England; Univ Naples 2, Dept Expt Med, Sect Pharmacol L Donatelli, I-80138 Naples, Italy; UNESP, IBILCE, Dept Biol, Sao Jose Do Rio Preto, SP, Brazil	University of London; Queen Mary University London; Universita della Campania Vanvitelli; Universidade Estadual Paulista	La, M (corresponding author), Univ London St Bartholomews Hosp Med Coll, Coll Med, William Harvey Res Inst, Dept Biochem Pharmacol, Charterhouse Sq, London EC1M 6BQ, England.	m.la@mds.qmw.ac.uk	Gavins, Felicity N. E./AAU-6010-2020; Oliani, Sonia Maria/E-3476-2012	Gavins, Felicity N. E./0000-0001-7008-5423; Oliani, Sonia Maria/0000-0003-0918-2130; d'amico, michele/0000-0002-6899-0595				ABOUMOHAMED G, 1995, J PHARMACOL EXP THER, V275, P584; Ambrosio G, 1999, AM HEART J, V138, pS69, DOI 10.1016/S0002-8703(99)70323-6; BALLER D, 1981, BASIC RES CARDIOL, V76, P163, DOI 10.1007/BF01907955; Becker EL, 1998, CELL TISSUE RES, V292, P129, DOI 10.1007/s004410051042; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIRINO G, 1989, P NATL ACAD SCI USA, V86, P3428, DOI 10.1073/pnas.86.9.3428; Cuzzocrea S, 1997, J IMMUNOL, V159, P5089; D'Amico M, 2000, FASEB J, V14, P1867; Dreier R, 1998, HISTOCHEM CELL BIOL, V110, P137, DOI 10.1007/s004180050275; Euzger HS, 1999, MEDIAT INFLAMM, V8, P53, DOI 10.1080/09629359990720; Getting SJ, 1997, BRIT J PHARMACOL, V120, P1075, DOI 10.1038/sj.bjp.0701029; Goulding NJ, 1996, BIOCHEM J, V316, P593, DOI 10.1042/bj3160593; HANSEN PR, 1995, CIRCULATION, V91, P1872, DOI 10.1161/01.CIR.91.6.1872; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; KLONER RA, 1991, CIRCULATION, V84, P1758, DOI 10.1161/01.CIR.84.4.1758; KUBES P, 1995, J CLIN INVEST, V95, P2510, DOI 10.1172/JCI117952; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; LITT MR, 1989, CIRCULATION, V80, P1816, DOI 10.1161/01.CIR.80.6.1816; Ma XL, 1999, P NATL ACAD SCI USA, V96, P14617, DOI 10.1073/pnas.96.25.14617; McCafferty DM, 2000, EUR J IMMUNOL, V30, P2362, DOI 10.1002/1521-4141(2000)30:8<2362::AID-IMMU2362>3.0.CO;2-F; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Oliani SM, 2001, AM J PATHOL, V158, P603, DOI 10.1016/S0002-9440(10)64002-3; PEPINSKY RB, 1990, FEBS LETT, V261, P247, DOI 10.1016/0014-5793(90)80564-Y; PERRETTI M, 1993, BIOCHEM BIOPH RES CO, V192, P345, DOI 10.1006/bbrc.1993.1421; Perretti M, 2001, AM J PATHOL, V158, P1969, DOI 10.1016/S0002-9440(10)64667-6; PERRETTI M, 1995, BIOCHEM PHARMACOL, V50, P1037, DOI 10.1016/0006-2952(95)00238-U; PERRETTI M, 1993, J IMMUNOL, V151, P4306; Perretti M, 1997, TRENDS PHARMACOL SCI, V18, P418; PERRETTI M, 1995, AGENT ACTION SUPPL, V46, P131; PERRETTI M, 1993, J IMMUNOL, V150, P992; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Perretti M, 2000, CELL BIOL INT, V24, P163, DOI 10.1006/cbir.1999.0468; Poon BY, 2001, J CELL BIOL, V152, P857, DOI 10.1083/jcb.152.5.857; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; Schioth HB, 1997, NEUROPEPTIDES, V31, P565, DOI 10.1016/S0143-4179(97)90002-0; SMITH SF, 1990, ENVIRON HEALTH PERSP, V85, P135, DOI 10.2307/3430676; Solito E, 2000, J IMMUNOL, V165, P1573, DOI 10.4049/jimmunol.165.3.1573; Srikrishna G, 2001, J IMMUNOL, V166, P4678, DOI 10.4049/jimmunol.166.7.4678; Strausbaugh HJ, 2001, J IMMUNOL, V166, P6294, DOI 10.4049/jimmunol.166.10.6294; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; VERGNOLLE N, 1995, EUR J BIOCHEM, V232, P603, DOI 10.1111/j.1432-1033.1995.603zz.x; Vermeiren GLJ, 2000, RESUSCITATION, V45, P35, DOI 10.1016/S0300-9572(00)00168-4; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; Yang YH, 1998, CLIN EXP IMMUNOL, V111, P117; Zhao ZQ, 1997, J LEUKOCYTE BIOL, V62, P292, DOI 10.1002/jlb.62.3.292; Zouki C, 2000, FASEB J, V14, P572, DOI 10.1096/fasebj.14.3.572	50	106	116	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2247	2256		10.1096/fj.01-0196com	http://dx.doi.org/10.1096/fj.01-0196com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641252				2022-12-28	WOS:000171920400037
J	Thompson, RB				Thompson, RB			Foundations for blockbuster drugs in federally sponsored research	FASEB JOURNAL			English	Article						cholesterol; research funding; statins; HMG CoA reductase; mevastatin	COMBINATORIAL TECHNOLOGIES; REDUCTASE; DISCOVERY; COENZYME; ML-236A	'Blockbuster' drugs, which are widely prescribed and improve the health of millions, often originate in fundamental laboratory research. An important example of such drugs are the cholesterol-lowering drugs called 'statins', including Zocor, Pravachol, and Lipitor, which millions of people take in the U.S. every year. This short paper outlines the direct and indirect contributions of federally sponsored research to the development of these important drugs.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Thompson, RB (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	rthompso@umaryland.edu						ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; Anitschkow N., 1913, ZENTRALBL ALLG PATHO, V24, P1; BLOCH K, 1965, SCIENCE, V150, P19, DOI 10.1126/science.150.3692.19; BOOTS MR, 1973, J PHARM SCI, V62, P952, DOI 10.1002/jps.2600620620; BOOTS SG, 1971, J PHARM SCI, V60, P614, DOI 10.1002/jps.2600600425; BROWN AG, 1976, J CHEM SOC PERK T 1, P1165, DOI 10.1039/p19760001165; DURR IF, 1960, J BIOL CHEM, V235, P2572; ENDO A, 1976, FEBS LETT, V72, P323, DOI 10.1016/0014-5793(76)80996-9; ENDO A, 1976, J ANTIBIOT, V29, P1346, DOI 10.7164/antibiotics.29.1346; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GORDON EM, 1994, J MED CHEM, V37, P1385, DOI 10.1021/jm00036a001; Istvan ES, 2000, EMBO J, V19, P819, DOI 10.1093/emboj/19.5.819; KANNEL WB, 1961, ANN INTERN MED, V55, P33, DOI 10.7326/0003-4819-55-1-33; *MERCK, 1998, ANN REP SHAR; *NHLBI, 1999, FACT BOOK; PEDERSEN TR, 1994, LANCET, V344, P1383; TAPOLCZAY D, 2000, DRUG DISCOVERY, V5, P44; Windaus A, 1910, H-S Z PHYSIOL CHEM, V67, P174, DOI 10.1515/bchm2.1910.67.2.174	18	101	101	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2001	15	10					1671	1676		10.1096/fj.01-0024lsf	http://dx.doi.org/10.1096/fj.01-0024lsf			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11481212				2022-12-28	WOS:000170809900001
J	Garcia-Martinez, C; Sibille, B; Solanes, G; Darimont, C; Mace, K; Villarroya, F; Gomez-Foix, AM				Garcia-Martinez, C; Sibille, B; Solanes, G; Darimont, C; Mace, K; Villarroya, F; Gomez-Foix, AM			Overexpression of UCP3 in cultured human muscle lowers mitochondrial membrane potential, raises ATP/ADP ratio, and favors fatty acid versus glucose oxidation	FASEB JOURNAL			English	Article						oleate; glycolytic rate; nutrient oxidation; glycolysis	UNCOUPLING PROTEIN-3 GENE; BROWN ADIPOSE-TISSUE; SKELETAL-MUSCLE; EXPRESSION; HEPATOCYTES; OBESITY; 2,4-DINITROPHENOL; THERMOGENESIS; ACTIVATION; TRANSPORT	The skeletal muscle mitochondrial uncoupling protein-3 (UCP3) promotes substrate oxidation, but direct evidence for its metabolic role is lacking. Here, we show that UCP3 overexpression in cultured human muscle cells decreased mitochondrial membrane potential (Delta Psim). Despite this, the ATP content was not significantly decreased compared with control cells, whereas ADP content was reduced and thus the ATP/ADP ratio raised. This finding was in contrast with the effect caused by the chemical protonophoric uncoupler, CCCP, which lowered Delta Psim, ATP, and the ATP/ADP ratio. UCP3-overexpression enhanced oxidation of oleate, regardless of the presence of glucose, whereas etomoxir, which blocks fatty acid entry to mitochondria, suppressed the UCP3 effect. Glucose oxidation was stimulated in UCP3-overexpressing cells, but this effect was inhibited by oleate. UCP3 caused weak increase of both 2-Deoxyglucose uptake and glycolytic rate, which differed from the marked stimulation by CCCP. We concluded that UCP3 promoted nutrient oxidation by lowering Delta Psim and enhanced fatty acid-dependent inhibition of glucose oxidation. Unlike the uncoupler CCCP, however, UCP3 raised the ATP/ADP ratio and modestly increased glucose uptake and glycolysis. We propose that this differential effect provides a biological significance to UCP3, which is up-regulated in metabolic stress situations where it could be involved in nutrient partitioning.	Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Nestle Res Ctr, CH-1000 Lausanne, Switzerland; Univ Lyon 1, Lab Physiol & Regulat Energet Cellulaires & Mol, F-69622 Villeurbanne, France	University of Barcelona; Nestle SA; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Gomez-Foix, AM (corresponding author), Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, Marti & Franques 1, E-08028 Barcelona, Spain.	anamaria@sun.bq.ub.es	Sibille, Brigitte/Q-8240-2016; Martinez, Celia Garcia/G-9536-2017; Villarroya, Francesc/K-4357-2014	Sibille, Brigitte/0000-0001-6806-0454; Martinez, Celia Garcia/0000-0002-5267-0191; Villarroya, Francesc/0000-0003-1266-9142				Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Askanas V, 1992, HDB CLIN NEUROL, P85; Bao S, 1998, DIABETES, V47, P1935, DOI 10.2337/diabetes.47.12.1935; Baque S, 1998, DIABETES, V47, P1185, DOI 10.2337/diabetes.47.8.1185; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; Brand MD, 1999, INT J OBESITY, V23, pS4, DOI 10.1038/sj.ijo.0800936; Brun S, 1999, FEBS LETT, V453, P205, DOI 10.1016/S0014-5793(99)00722-X; Brun S, 1999, DIABETES, V48, P1217, DOI 10.2337/diabetes.48.6.1217; Carmona MC, 1998, BIOCHEM BIOPH RES CO, V243, P224, DOI 10.1006/bbrc.1998.8088; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Krook A, 1998, DIABETES, V47, P1528, DOI 10.2337/diabetes.47.9.1528; LEVERVE XM, 1994, EUR J BIOCHEM, V224, P967, DOI 10.1111/j.1432-1033.1994.00967.x; MA SW, 1986, CAN J PHYSL PHARM, V9, P1252; Matthias A, 2000, J BIOL CHEM, V275, P25073, DOI 10.1074/jbc.M000547200; MUOIO DM, 2000, KEYST S MOL CONTR AD, P143; Otabe S, 2000, DIABETOLOGIA, V43, P245, DOI 10.1007/s001250050037; Otabe S, 1999, DIABETES, V48, P206; Pierrat B, 2000, EUR J BIOCHEM, V267, P2680, DOI 10.1046/j.1432-1327.2000.01285.x; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; RIGOULET M, 1989, BIOCHIM BIOPHYS ACTA, V975, P325, DOI 10.1016/S0005-2728(89)80339-1; Samec S, 1999, PFLUG ARCH EUR J PHY, V438, P452, DOI 10.1007/s004240051061; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; SIBILLE B, 1995, EUR J BIOCHEM, V231, P498, DOI 10.1111/j.1432-1033.1995.tb20724.x; Solanes G, 2000, FASEB J, V14, P2141; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Wang MY, 1999, DIABETES, V48, P1020, DOI 10.2337/diabetes.48.5.1020; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; WINTER CG, 1994, ARCH BIOCHEM BIOPHYS, V314, P17, DOI 10.1006/abbi.1994.1406	38	85	90	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2033	+		10.1096/fj.00-0828fje	http://dx.doi.org/10.1096/fj.00-0828fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511517				2022-12-28	WOS:000170318500012
J	Dobashi, H; Sato, M; Tanaka, T; Tokuda, M; Ishida, T				Dobashi, H; Sato, M; Tanaka, T; Tokuda, M; Ishida, T			Growth hormone restores glucocorticoid-induced T cell suppression	FASEB JOURNAL			English	Article						growth hormone; T lymphocytes; glucocorticoid; apoptosis	FACTOR-I; BINDING-PROTEIN; GENE-EXPRESSION; IMMUNE FUNCTION; RAT-TISSUES; RECEPTOR; APOPTOSIS; PROLIFERATION; CHILDREN; THERAPY	Growth hormone (GH) is a potent anabolic hormone, and its clinical use has been extended to the improvement of metabolic imbalance in many disease,s including autoimmune disorders treated with glucocorticoids (GCs). GH has, however, a potential action on the immune system, and this might be a demerit in GH therapy for those diseases. We report here the anti-GC effects of GH on T lymphocytes. Human peripheral T lymphocytes (HPTLs) expressed GH receptor mRNA. GH stimulated tyrosine phosphorylation of cellular proteins, including JAK2 and STAT5b in HPTLs. GH and IGF-I alleviated dexamethasone (Dex)-induced suppression of [H-3] thymidine incorporation into HPTLs. GH alleviated Dex-induced apoptosis in CD4(+) (positive) HPTLs. GH increased Bcl-2 expression in CD4(+) HPTLs but not in CD8(+) HPTLs. In vivo, GH raised the CD4/8 ratio of T lymphocytes in rats chronically administered with Dex. These findings indicate that GH may inhibit GC-induced apoptosis predominantly in CD4(+) T lymphocytes and present important implications of GH therapy, especially for autoimmune disorders treated with GCs.	Kagawa Med Univ, Dept Internal Med 1, Sch Med, Miki, Kagawa 7610793, Japan; Kagawa Med Univ, Dept Environm Hlth Sci, Miki, Kagawa 7610793, Japan	Kagawa University; Kagawa University	Dobashi, H (corresponding author), Kagawa Med Univ, Dept Internal Med 1, Sch Med, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	hdobashi@kms.ac.jp		DOBASHI, HIROAKI/0000-0003-2944-5583				Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; Auernhammer CJ, 1995, EUR J ENDOCRINOL, V133, P635, DOI 10.1530/eje.0.1330635; BOZZOLA M, 1990, J PEDIATR-US, V117, P596, DOI 10.1016/S0022-3476(05)80697-3; Bresson JL, 1999, ENDOCRINOLOGY, V140, P3203, DOI 10.1210/en.140.7.3203; Clark R, 1997, ENDOCR REV, V18, P157, DOI 10.1210/er.18.2.157; FINE RN, 1991, PEDIATR NEPHROL, V5, P477, DOI 10.1007/BF01453685; FRANCO P, 1990, ACTA ENDOCRINOL-COP, V123, P339, DOI 10.1530/acta.0.1230339; GEFFNER ME, 1990, J CLIN ENDOCR METAB, V71, P464, DOI 10.1210/jcem-71-2-464; GELATO MC, 1993, TRENDS ENDOCRIN MET, V4, P106, DOI 10.1016/1043-2760(93)90088-V; Haeffner A, 1999, EUR J IMMUNOL, V29, P334, DOI 10.1002/(SICI)1521-4141(199901)29:01<334::AID-IMMU334>3.0.CO;2-S; HAYASHIDA T, 1957, J EXP MED, V105, P93, DOI 10.1084/jem.105.2.93; Karlsson H, 1999, MOL CELL ENDOCRINOL, V154, P37, DOI 10.1016/S0303-7207(99)00101-X; KOOIJMAN R, 1995, EUR J IMMUNOL, V25, P931, DOI 10.1002/eji.1830250411; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Lee PDK, 1996, J CLIN ENDOCR METAB, V81, P2968, DOI 10.1210/jc.81.8.2968; LeRoith D, 1996, ENDOCRINOLOGY, V137, P1071, DOI 10.1210/en.137.3.1071; LESNIAK MA, 1973, NATURE-NEW BIOL, V241, P20, DOI 10.1038/newbio241020a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Loke KY, 1997, J PEDIATR-US, V130, P793, DOI 10.1016/S0022-3476(97)80023-6; MATSUBARA S, 1995, ENDOCRINOLOGY, V136, P4147, DOI 10.1210/en.136.9.4147; MEMON SA, 1995, J IMMUNOL, V155, P4644; MERCOLA KE, 1981, BLOOD, V58, P337; RAPAPORT R, 1995, J CLIN ENDOCR METAB, V80, P2612, DOI 10.1210/jc.80.9.2612; RIVKEES SA, 1994, J PEDIATR-US, V125, P322, DOI 10.1016/S0022-3476(94)70219-5; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; Sabharwal P, 1996, J CLIN ENDOCR METAB, V81, P2663, DOI 10.1210/jc.81.7.2663; TIMSIT J, 1992, J CLIN ENDOCR METAB, V75, P183, DOI 10.1210/jc.75.1.183; TONSHOFF B, 1991, PEDIATR NEPHROL, V5, P454; Touati G, 1998, J CLIN ENDOCR METAB, V83, P403, DOI 10.1210/jc.83.2.403; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WADA Y, 1995, ENDOCRINOLOGY, V136, P3936, DOI 10.1210/en.136.9.3936; WIT JM, 1993, HORM RES, V39, P107, DOI 10.1159/000182708; Xu BXC, 1996, J BIOL CHEM, V271, P19768, DOI 10.1074/jbc.271.33.19768; Yap HK, 1998, PEDIATR NEPHROL, V12, P133, DOI 10.1007/s004670050421; Yokote R, 1998, PEPTIDES, V19, P15, DOI 10.1016/S0196-9781(97)00263-5; YOSHIDA A, 1992, ACTA ENDOCRINOL-COP, V126, P524, DOI 10.1530/acta.0.1260524	36	21	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1861	+		10.1096/fj.00-0702fje	http://dx.doi.org/10.1096/fj.00-0702fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11481255				2022-12-28	WOS:000169261200013
J	Zocchi, E; Podesta, M; Pitto, A; Usai, C; Bruzzone, S; Franco, L; Guida, L; Bacigalupo, A; De Flora, A				Zocchi, E; Podesta, M; Pitto, A; Usai, C; Bruzzone, S; Franco, L; Guida, L; Bacigalupo, A; De Flora, A			Stroma-generated cyclic ADP-ribose stimulates the expansion of early human hemopoietic progenitors by a paracrine interaction	FASEB JOURNAL			English	Article						paracrine communication; NAD(+); CD38	HUMAN MARROW CULTURES; CALCIUM-CONCENTRATION; LIMITING DILUTION; STEM-CELLS; HUMAN CD38; MECHANISMS; EXPRESSION; MICROENVIRONMENT; GLYCOPROTEIN; SECRETION	Both mammalian ectoenzymes CD38 and BST-1, which convert NAD+ into the potent intracellular calcium regulator cyclic ADP-ribose (cADPR), are expressed in the bone marrow microenvironment. Therefore, we investigated the effect of extracellular cADPR on human long-term culture-initiating cells (LTC-IC), the most immature hemopoietic progenitors (HP). A threefold expansion of LTC-IC was elicited by exposure of cord blood mononuclear cells for 24 h either to micromolar concentrations of exogenously added cADPR or to the nanomolar concentrations of cADPR that are produced by CD38-transfected murine stromal cell lines cocultured with the HP. The latter effect was due to connexin 43-mediated release of NAD(+) from feeder cells and to subsequent CD38-catalyzed generation of cADPR at their outer surface. The increased [Ca2+](i) induced in the feeder cells by autocrinally generated cADPR, however, increased production of interferon gamma, a potent hemopoiesis-inhibiting cytokine. Thus, long-term culture (5 wk) of HP over undiluted CD38(+) feeders decreased LTC-IC output by 90%, whereas a fivefold increase was observed when HP were cultured over a mixed CD38(+/-) feeder (1:10), whose ecto-ADP-ribosyl cyclase activity was as low as that expressed by native human stroma. These results demonstrate a new paracrine role for cADPR in the regulation of human hemopoiesis.	Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy; San Martino Hosp, Dept Hematol, Genoa, Italy; CNR, Inst Cybernet & Biophys, Genoa, Italy; G Gaslini Inst Children, Genoa, Italy	University of Genoa; University of Genoa; IRCCS AOU San Martino IST; Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR); University of Genoa; IRCCS Istituto Giannina Gaslini	Zocchi, E (corresponding author), Univ Genoa, Dept Expt Med, Biochem Sect, Viale Benedetto XV-1, I-16132 Genoa, Italy.	toninodf@unige.it	Bruzzone, Santina/A-4264-2015; Podestà, Marina/K-3875-2016	Bruzzone, Santina/0000-0003-2034-3716; Podestà, Marina/0000-0002-6755-613X; Usai, Cesare/0000-0001-8863-7759				Ausiello CM, 1996, CELL IMMUNOL, V173, P192, DOI 10.1006/cimm.1996.0267; BACIGALUPO A, 1991, EXP HEMATOL, V19, P829; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruzzone S, 2001, FASEB J, V15, P10; Cancelas JA, 2000, BLOOD, V96, P498; EAVES CJ, 1991, BLOOD, V78, P110; Eaves CJ, 1991, J TISSUE CULTURE MET, V13, P55; Emerson SG, 1996, BLOOD, V87, P3082, DOI 10.1182/blood.V87.8.3082.bloodjournal8783082; Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365-2141.2000.01986.x; Franco L, 2001, AM J PHYSIOL-LUNG C, V280, pL98; Franco L, 1998, FASEB J, V12, P1507; Graeff RM, 1997, METHOD ENZYMOL, V280, P230; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KAISHO T, 1994, P NATL ACAD SCI USA, V91, P5325, DOI 10.1073/pnas.91.12.5325; Kojima S, 1998, INT J HEMATOL, V68, P19; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; Masuda W, 1997, FEBS LETT, V405, P104, DOI 10.1016/S0014-5793(97)00168-3; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Montecino-Rodriguez E, 2000, BLOOD, V96, P917, DOI 10.1182/blood.V96.3.917.015k45_917_924; Podesta M, 2000, FASEB J, V14, P680, DOI 10.1096/fasebj.14.5.680; PORTER EH, 1963, BRIT J CANCER, V17, P583, DOI 10.1038/bjc.1963.78; ROSENDAAL M, 1994, J CELL SCI, V107, P29; Selleri C, 1996, BLOOD, V87, P4149, DOI 10.1182/blood.V87.10.4149.bloodjournal87104149; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; SUTHERLAND HJ, 1991, BLOOD, V78, P666, DOI 10.1182/blood.V78.3.666.bloodjournal783666; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TASWELL C, 1981, J IMMUNOL, V126, P1614; VANDERSLUIJS JP, 1990, EXP HEMATOL, V18, P893; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; Wineman J, 1996, BLOOD, V87, P4082, DOI 10.1182/blood.V87.10.4082.bloodjournal87104082; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; Young NS, 2000, SEMIN HEMATOL, V37, P3, DOI 10.1016/S0037-1963(00)90026-X; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9; Zocchi E, 1999, FASEB J, V13, P273, DOI 10.1096/fasebj.13.2.273; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017	39	24	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1610	+		10.1096/fj.00-0803fje	http://dx.doi.org/10.1096/fj.00-0803fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427502				2022-12-28	WOS:000173707700017
J	Hampson, L; El Hady, ESA; Moore, JV; Kitchener, H; Hampson, IN				Hampson, L; El Hady, ESA; Moore, JV; Kitchener, H; Hampson, IN			The HPV16 E6 and E7 proteins and the radiation resistance of cervical carcinoma	FASEB JOURNAL			English	Article						HPV; ERCC1; cervical carcinoma	HUMAN-PAPILLOMAVIRUS TYPE-16; NUCLEOTIDE EXCISION-REPAIR; CELL-LINES; IONIZING-RADIATION; TUMOR-CELLS; INTRINSIC RADIOSENSITIVITY; P53 FUNCTION; HPV-16 E6; EXPRESSION; CANCER	Using a murine transplantation model, we have investigated the function of the HPV16 E6 and E7 proteins in the development of radiation resistance in advanced cervical carcinoma. Constitutive high-level expression of the HPV16 E6 oncogene in HPV negative human C33A cervical carcinoma cells was shown to induce rapid onset and radiation resistance in transplanted tumors when compared with tumors derived from E7 or vector transfected cells. The radiation-resistant, E6 tumor phenotype was not due solely to increased hypoxia, because all E6 tumors were shown to be uniformly hypoxic, and artificial induction of hypoxia, in E7 and control tumors, failed to produce the same degree of radiobiological resistance. Differential screening of a 1.2-k human cancer cDNA array indicated that E6 tumors had up-regulated expression of the DNA nucleotide excision repair gene excision repair cross-complementation enzyme 1 (ERCC1). High-level expression of ERCC1 mRNA and protein was found to be restricted to radiation-resistant E6 tumors. In vitro maintenance of E6 and control vector-expressing cells under anoxic conditions showed that ERCC1 expression was induced preferentially in E6-expressing cells. These data indicate that the HPV16 E6 protein may influence the response to therapy of cervical carcinoma by inappropriate activation of DNA repair mechanisms.	Univ Manchester, St Marys Hosp, Acad Unit Obstet & Gynaecol, Manchester M13 0JH, Lancs, England; Christie Hosp, Paterson Inst Canc Res, Dept Laser Oncol, Manchester M20 4BX, Lancs, England	University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Hampson, IN (corresponding author), Univ Manchester, St Marys Hosp, Acad Unit Obstet & Gynaecol, Manchester M13 0JH, Lancs, England.	mdsisinh@fs1.scg.man.ac.uk	Hampson, Lynne/E-1583-2011	Abdel-Hady, EL-SAID/0000-0001-5010-1449; Hampson, Lynne/0000-0002-0656-0127				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; Britten RA, 2000, INT J CANCER, V89, P453, DOI 10.1002/1097-0215(20000920)89:5<453::AID-IJC9>3.3.CO;2-5; Carlomagno F, 2000, INT J CANCER, V85, P845, DOI 10.1002/(SICI)1097-0215(20000315)85:6<845::AID-IJC18>3.3.CO;2-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DeWeese TL, 1997, INT J RADIAT ONCOL, V37, P145, DOI 10.1016/S0360-3016(96)00448-8; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; Herring CJ, 1998, BRIT J CANCER, V78, P1128, DOI 10.1038/bjc.1998.641; Huang H, 1996, INT J RADIAT BIOL, V70, P151, DOI 10.1080/095530096145148; Lawrence S, 2000, EMBED SYST PROGRAM, V13, P55; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MONGE RM, 1993, RADIOTHER ONCOL, V28, P127, DOI 10.1016/0167-8140(93)90004-R; Murray D, 1996, MUTAT RES-DNA REPAIR, V364, P217, DOI 10.1016/S0921-8777(96)00036-5; Murray D, 1996, INT J RADIAT BIOL, V69, P319, DOI 10.1080/095530096145878; Mythily DV, 1999, J GEN VIROL, V80, P1707, DOI 10.1099/0022-1317-80-7-1707; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Santin AD, 1998, CANCER-AM CANCER SOC, V83, P2346, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2346::AID-CNCR14>3.0.CO;2-G; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; STEWART FA, 1989, INT J RADIAT ONCOL, V16, P1195, DOI 10.1016/0360-3016(89)90282-4; TSANG NM, 1995, ONCOGENE, V10, P2403; Tseng CJ, 1999, J CLIN ONCOL, V17, P1391, DOI 10.1200/JCO.1999.17.5.1391; UNGER ER, 1995, J INFECT DIS, V172, P1184, DOI 10.1093/infdis/172.5.1184; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Weeda G, 1997, CURR BIOL, V7, P427, DOI 10.1016/S0960-9822(06)00190-4; WEST CML, 1993, BRIT J CANCER, V68, P819, DOI 10.1038/bjc.1993.434; Yang LY, 2000, CLIN CANCER RES, V6, P773; Yu YJ, 1997, ONCOGENE, V14, P1661, DOI 10.1038/sj.onc.1201026; ZURHAUSEN H, 1996, BIOCHIM BIOPHYS ACTA, V1288, pPF55	35	53	57	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1445	+		10.1096/fj.00-0728fje	http://dx.doi.org/10.1096/fj.00-0728fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387252				2022-12-28	WOS:000173705800017
J	Pooga, M; Kut, C; Kihlmark, M; Hallbrink, M; Fernaeus, S; Raid, R; Land, T; Hallberg, E; Bartfai, T; Langel, U				Pooga, M; Kut, C; Kihlmark, M; Hallbrink, M; Fernaeus, S; Raid, R; Land, T; Hallberg, E; Bartfai, T; Langel, U			Cellular translocation of proteins by transportan	FASEB JOURNAL			English	Article						peptide-mediated transport; cell-penetrating peptides; drug delivery; transport vectors; protein transduction	GREEN FLUORESCENT PROTEIN; IN-VIVO; INTRACELLULAR DELIVERY; TRANSDUCTION; PEPTIDES; CELLS; REAGENTS; DNA	Proteins with molecular masses ranging from 30 kDa. (green fluorescent protein, GFP) to 150 kDa (monoclonal and polyclonal antibodies) were coupled to the cellular translocating peptide transportan. We studied the ability of the resulting protein-peptide constructs to penetrate into Bowes melanoma, BRL, and COS-7 cells. After 0.5-3 h incubation with recombinant GFP coupled to transportan, most of the GFP fluorescence was found in intracellular membranes of BRL and COS-7 cells, which suggests that transportan could internalize covalently linked proteins of about 30 kDa in a folded state. Transportan could internalize covalently coupled molecules of even larger size; that is, avidin and antibodies, (up to 150 kDa). The covalent bond between the transport peptide and its cargo is not obligatory because streptavidin was translocated into the cells within 15 min as a noncovalent complex with biotinylated transportan. Inside the cells, the delivered streptavidin was first located mainly in close proximity to the plasma membrane and was later distributed to the perinuclear region. Most of the internalized streptavidin was confined to vesicular structures, but a significant fraction of the protein was distributed in the cytoplasm. Our data suggest that transportan can deliver proteins and other hydrophilic macromolecules into intact mammalian cells, and this finding demonstrates good potential as powerful cellular delivery vector for scientific and therapeutic purposes.	Scripps Res Inst, Dept Neuropharmacol, Harold L Dorris Neurol Res Ctr, La Jolla, CA 92037 USA; Univ Stockholm, Arrhenius Lab, Dept Neurochem & Neurotoxicol, S-10691 Stockholm, Sweden; Estonian Bioctr, EE-51010 Tartu, Estonia; Sodertorns Hogskola Univ Coll, Sect Nat Sci, S-14104 Huddinge, Sweden; Univ Stockholm, Arrhenius Lab, Dept Biochem, S-10691 Stockholm, Sweden; Univ Tartu, Inst Zool & Hydrobiol, EE-51014 Tartu, Estonia	Scripps Research Institute; Stockholm University; Estonian Biocentre; Sodertorn University; Stockholm University; University of Tartu	Langel, U (corresponding author), Scripps Res Inst, Dept Neuropharmacol, Harold L Dorris Neurol Res Ctr, 10550 N Torrey Pines Rd,Mail SR-307, La Jolla, CA 92037 USA.	ulangel@scripps.edu	Pooga, Margus/A-8575-2011	Pooga, Margus/0000-0003-4532-4087; Hallberg, Einar/0000-0003-2092-457X				ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Kato D, 1998, FEBS LETT, V427, P203, DOI 10.1016/S0014-5793(98)00426-8; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Niemeyer CM, 1999, NUCLEIC ACIDS RES, V27, P4553, DOI 10.1093/nar/27.23.4553; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PEETERS JM, 1989, J IMMUNOL METHODS, V120, P133, DOI 10.1016/0022-1759(89)90298-6; Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440; Pooga M, 1998, FASEB J, V12, P67, DOI 10.1096/fasebj.12.1.67; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509	21	149	162	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1451	+		10.1096/fj.00-0780fje	http://dx.doi.org/10.1096/fj.00-0780fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387254				2022-12-28	WOS:000173705800015
J	Ullrich, O; Diestel, A; Bechmann, I; Homberg, M; Grune, T; Hass, R; Nitsch, R				Ullrich, O; Diestel, A; Bechmann, I; Homberg, M; Grune, T; Hass, R; Nitsch, R			Turnover of oxidatively damaged nuclear proteins in BV-2 microglial cells is linked to their activation state by poly(ADP-ribose)polymerase	FASEB JOURNAL			English	Article						oxidative stress; proteasome; protein degradation; tumor necrosis factor-alpha; antioxidative protection	ADHESION MOLECULE EXPRESSION; ADP-RIBOSE-POLYMERASE; OXIDIZED PROTEINS; INTERFERON-GAMMA; ASTROCYTES; PROTEASOME; 20S; DIFFERENTIATION; DEGRADATION; MODULATION	During neuroinflammation, activated microglial cells migrate to the sites of neuronal injury, phagocytose neighboring cells, and produce large amounts of oxygen free radicals, which might contribute to severe cell damage and death. It is interesting that microglial cells have withstood this cytotoxic action of free radicals, which indicates that there is an intracellular mechanism that apparently enables microglial cells to cope with such oxidative challenges. In this study, we investigated the capability of BV-2 murine microglial cells to cope with oxidatively damaged proteins by the proteasomal proteolytic system. To induce a highly activated state, we used the proinflammatory cytokine tumor necrosis factor-alpha, which acts as a priming signal for microglial superoxide radical production. We showed that activation of the nuclear enzyme poly(ADPribose)polymerase (PARP) enabled activated microglial cells to resist oxidative damage by an up-regulation of the nuclear proteasome. Activated microglial cells revealed an efficient recognition and degradation of oxidatively damaged proteins during an enhanced endogenous protein turnover. The impairment of PARP function by inhibitor or antisense experiments resulted in an accumulation of damaged proteins and subsequently cell death. In contrast, this was not the case in resting microglial cells. These findings demonstrate the crucial role of the PARP in microglial cell survival during activation and renders it a potential anti-inflammatory target.	Humboldt Univ, Fac Med Charite, Dept Cell & Neurobiol, Inst Anat, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Neurosci Res Ctr, D-10098 Berlin, Germany; Hannover Med Sch, Oststadtkrankenhaus, Clin Obstet & Gynecol OE 6410, Dept Biochem & Tumor Biol, D-30659 Hannover, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School	Ullrich, O (corresponding author), Humboldt Univ, Fac Med Charite, Inst Anat, Dept Cell & Neurobiol, Philippstr 12, D-10115 Berlin, Germany.	oliver.ullrich@charite.de	Nitsch, Robert/AAI-9129-2021; Hass, Ralf/F-3197-2012	Hass, Ralf/0000-0002-2481-7547; Gimsa, Ulrike/0000-0003-2248-5793; Grune, Tilman/0000-0003-4775-9973				AKIYAMA H, 1993, ACTA NEUROPATHOL, V85, P628, DOI 10.1007/BF00334673; Bechmann I, 1997, GLIA, V20, P145, DOI 10.1002/(SICI)1098-1136(199706)20:2<145::AID-GLIA6>3.0.CO;2-8; Bhatia M, 1996, CELL GROWTH DIFFER, V7, P91; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; CANTONI O, 1989, BIOCHIM BIOPHYS ACTA, V1014, P1, DOI 10.1016/0167-4889(89)90234-6; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; EMIG S, 1995, J BIOL CHEM, V270, P13787, DOI 10.1074/jbc.270.23.13787; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; Grune T, 1997, BIOFACTORS, V6, P165, DOI 10.1002/biof.5520060210; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; Hailer NP, 1997, HIPPOCAMPUS, V7, P341, DOI 10.1002/(SICI)1098-1063(1997)7:3<341::AID-HIPO8>3.0.CO;2-N; Heppner FL, 1998, GLIA, V22, P180, DOI 10.1002/(SICI)1098-1136(199802)22:2<180::AID-GLIA9>3.0.CO;2-B; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HU SX, 1995, GLIA, V13, P45, DOI 10.1002/glia.440130106; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KIRSTEN E, 1991, EXP CELL RES, V194, P1, DOI 10.1016/0014-4827(91)90122-B; Kleczkowska HE, 1996, MUTAT RES-FUND MOL M, V358, P215, DOI 10.1016/S0027-5107(96)00123-6; KREUTZBERG GW, 1995, ARZNEIMITTEL-FORSCH, V45-1, P357; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LEE SC, 1993, J IMMUNOL, V150, P594; Leist P, 1996, FREE RADICAL BIO MED, V21, P297, DOI 10.1016/0891-5849(96)00045-7; Lindenau J, 1998, GLIA, V24, P252, DOI 10.1002/(SICI)1098-1136(199810)24:2<252::AID-GLIA10>3.0.CO;2-Z; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; Mayer-Kuckuk P, 1999, BIOCHEM BIOPH RES CO, V259, P576, DOI 10.1006/bbrc.1999.0824; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4589; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; NIETOSAMPEDRO M, 1985, BRAIN RES, V343, P320, DOI 10.1016/0006-8993(85)90750-4; NITSCH R, 1993, HIPPOCAMPUS, V3, P247; Noack H, 1998, GLIA, V23, P285, DOI 10.1002/(SICI)1098-1136(199808)23:4<285::AID-GLIA1>3.0.CO;2-2; Paris D, 2000, NEUROSCI LETT, V278, P5, DOI 10.1016/S0304-3940(99)00901-5; PERRY VH, 1993, GLIA, V7, P60, DOI 10.1002/glia.440070111; Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V377, P65, DOI 10.1006/abbi.2000.1717; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Schubert P, 1998, ALZ DIS ASSOC DIS, V12, pS21; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; Stohwasser R, 2000, GLIA, V29, P355, DOI 10.1002/(SICI)1098-1136(20000215)29:4<355::AID-GLIA6>3.0.CO;2-4; Sugaya K, 1997, NEUROREPORT, V8, P2241, DOI 10.1097/00001756-199707070-00030; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; TOMODA T, 1992, BIOCHIM BIOPHYS ACTA, V1135, P79, DOI 10.1016/0167-4889(92)90169-C; Ullrich O, 2000, FREE RADICAL BIO MED, V29, P995, DOI 10.1016/S0891-5849(00)00399-3; Ullrich O, 1999, ARCH BIOCHEM BIOPHYS, V362, P211, DOI 10.1006/abbi.1998.1031; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZIELASEK J, 1993, NEUROSCI LETT, V153, P136, DOI 10.1016/0304-3940(93)90306-6; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	51	102	103	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1460	+		10.1096/fj.00-0540fje	http://dx.doi.org/10.1096/fj.00-0540fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11292676				2022-12-28	WOS:000173705800009
J	Plat, J; Mensink, RP				Plat, J; Mensink, RP			Increased intestinal ABCA1 expression contributes to the decrease in cholesterol absorption after plant stanol consumption	FASEB JOURNAL			English	Article						sitostanol; intestine; LXR; cholesterol transport	BETA-SITOSTEROL; METABOLISM; STEROL; MARGARINES; PATHWAY; MICE; ACCUMULATION; MUTATIONS; EFFLUX	The hypocholesterolemic effect of plant stanols is explained by a decreased intestinal cholesterol absorption due to a competition between plant stanols and cholesterol for incorporation into mixed micelles. Earlier we had suggested that plant stanols have a so far unknown action inside the enterocytes. The recent discovery of the involvement of ATP binding cassette (ABC) transporters in cholesterol absorption was a lead to further explore the hypocholesterolemic mechanism of plant stanols. We found that mixed micelles enriched with sitostanol or with cholesterol plus sitostanol were potent inducers of ABCA1 expression in caco-2 cells, an accepted model to study human intestinal lipoprotein metabolism. Based on these findings, we now hypothesize that plant stanols- and possibly plant sterols-increase ABCA1-mediated cholesterol efflux back into the intestinal lumen. We further hypothesize that intracellular levels of plant stanols are monitored by the same sensors (SREBP-2 and LXR) as those that monitor cholesterol. Consequently, increased plant stanol levels within the enterocyte activate cholesterol efflux through ABCA1- but not SREBP-2-mediated endogenous cholesterol synthesis even if intracellular cholesterol concentrations are lowered through consumption of plant stanols. If our hypothesis is correct, then the LXR pathway may be a target for dietary regulation of intestinal lipid metabolism.	Maastricht Univ, Dept Human Biol, NL-6200 MD Maastricht, Netherlands	Maastricht University	Plat, J (corresponding author), Maastricht Univ, Dept Human Biol, POB 616, NL-6200 MD Maastricht, Netherlands.	J.Plat@HB.UNIMAAS.NL						Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7; Costet P, 2000, J BIOL CHEM, V275, P28240; Dean M, 2001, J LIPID RES, V42, P1007; Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250; Field FJ, 1997, J LIPID RES, V38, P348; FIELD FJ, 1983, J LIPID RES, V24, P409; IKEDA I, 1989, J NUTR SCI VITAMINOL, V35, P361, DOI 10.3177/jnsv.35.361; IKEDA I, 1988, J LIPID RES, V29, P1573; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Law M, 2000, BMJ-BRIT MED J, V320, P861, DOI 10.1136/bmj.320.7238.861; Le Lay S, 2001, J BIOL CHEM, V276, P16904, DOI 10.1074/jbc.M010955200; Lee MH, 2001, CURR OPIN LIPIDOL, V12, P141, DOI 10.1097/00041433-200104000-00007; LEVY E, 1995, FASEB J, V9, P626, DOI 10.1096/fasebj.9.8.7768354; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PETERSON DW, 1951, P SOC EXP BIOL MED, V78, P143, DOI 10.3181/00379727-78-19002; Plat J, 2000, EUR J CLIN NUTR, V54, P671, DOI 10.1038/sj.ejcn.1601071; Plat J, 2001, METABOLISM, V50, P520, DOI 10.1053/meta.2001.22509; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sierksma A, 1999, BRIT J NUTR, V82, P273, DOI 10.1017/S0007114599001476; SYLVEN C, 1970, SCAND J GASTROENTERO, V5, P57; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Weststrate JA, 1998, EUR J CLIN NUTR, V52, P334, DOI 10.1038/sj.ejcn.1600559	29	176	187	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1248	10.1096/fj.01-0718hyp	http://dx.doi.org/10.1096/fj.01-0718hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	11772951				2022-12-28	WOS:000177814000034
